ecNumber	organism	activatingCompound	inhibitors	literature	ligandStructureId	commentary
1.1.1.100	Synechococcus elongatus PCC 7942	more		701783		variation of the buffer molarity between 25 mM and 200 mM or addition of NaCl up to 500 mM has no significant effect on enzyme activity
1.1.1.100	Plasmodium falciparum	more		706639		affinity of acyl-carrier protein for FabG is increased by 3fold in the presence of 1 M urea
1.1.1.100	Escherichia coli		(E)-1-(4-methylpiperidin-1-yl)-3-phenylprop-2-en-1-one	703163	96400	80% residual activity
1.1.1.100	Escherichia coli		(E)-2-nitrophenyl cinnamate	703163	53976	
1.1.1.100	Escherichia coli		(E)-3-phenoxybenzyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	703163	92483	61% residual activity
1.1.1.100	Escherichia coli		(E)-4-cyanophenyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	703163	53975	
1.1.1.100	Escherichia coli		(E)-benzyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	703163	96399	71% residual activity
1.1.1.100	Escherichia coli		(E)-phenyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	703163	53974	69% residual activity
1.1.1.100	Escherichia coli		1,2,3,4,6-penta-O-galloyl-beta-D-glucose	685704	8498	mixed type of inhibition. IC50 value 0.9 microgramm per ml, Ki value 0.21 microgramm per ml
1.1.1.100	Pseudomonas aeruginosa		1,2,3,4,6-penta-O-galloyl-beta-D-glucose	685704	8498	minimal inhibitory concentration 0.125 mg/ml
1.1.1.100	Staphylococcus epidermidis		1,2,3,4,6-penta-O-galloyl-beta-D-glucose	685704	8498	minimal inhibitory concentration 0.25 mg/ml
1.1.1.100	Plasmodium falciparum		3-hydroxybutyryl-CoA	667520	1615	competitive product inhibition
1.1.1.100	Mycobacterium tuberculosis		3-hydroxybutyryl-CoA	667708	1615	noncompetitive product inhibition pattern
1.1.1.100	Plasmodium falciparum K1		4-acetoxyanthecotulide	689435	25288	most active linear sesquiterpene lactone from Anthemis auriculata against FabG
1.1.1.100	Plasmodium falciparum K1		4-hydroxyanthecotulide	689435	25287	linear sesquiterpene lactone from Anthemis auriculata
1.1.1.100	Lactococcus lactis		Acyl carrier protein	654725	454	beta-ketobutyryl-CoA reductase activity of FabG1 is inhibited, activity of FabG2 is unaffected
1.1.1.100	Plasmodium falciparum		acyl-carrier protein	703630	454	inhibition of wild-type with increasing concentrations
1.1.1.100	Plasmodium falciparum K1		anthecotulide	689435	16943	linear sesquiterpene lactone from Anthemis auriculata
1.1.1.100	Plasmodium falciparum		Bithionol	667520	1974	over 75% inhibition at 0.02 mM, IC50: 0.010 mM
1.1.1.100	Plasmodium falciparum		bromochlorophen	667520	39754	an anthelmintic agent, over 75% inhibition at 0.02 mM, IC50: 0.0154 mM
1.1.1.100	Escherichia coli		chlorogenic acid	669013	488	IC50: 0.881-0.948 mM
1.1.1.100	Plasmodium falciparum		di-resorcinol sulfide	667520	39753	over 75% inhibition at 0.02 mM, IC50: 0.0038 mM
1.1.1.100	Streptococcus pneumoniae		DL-3-hydroxybutyryl-CoA	667646	1615	competitive product inhibition
1.1.1.100	Escherichia coli		epigallocatechin gallate	704337	936	
1.1.1.100	Plasmodium falciparum		Guanidinium chloride	706639	804	FabG is fully unfolded at 4 M, approximately 90% of the enzyme activity can be recovered on dialyzing the denaturant. In presence of NADPH, there is no stabilization of FabG in case of equilibrium unfolding with guanidinium chloride
1.1.1.100	Plasmodium falciparum		Hexachlorophene	667520	1545	an anthelmintic and antimicrobial agent, over 75% inhibition at 0.02 mM, IC50: 0.002 mM
1.1.1.100	synthetic construct		kaempferol	704843	341	
1.1.1.100	Spinacia oleracea		more	285668		not: N-ethylmaleimide, arsenite
1.1.1.100	Plasmodium falciparum		more	667520		no inhibition by triclosan
1.1.1.100	Escherichia coli		more	703163		cinnamic acid derivatives can be accommodated in the substrate-binding region of the active site, above the nicotinamide moiety of the NADPH cofactor
1.1.1.100	Pseudomonas aeruginosa		more	704843		FabG is inhibited by extract of galangal (rhizome of Alpinia officinarum). Minimum inhibitory concentration is above 1.28 mM
1.1.1.100	Staphylococcus aureus		more	704843		FabG is inhibited by extract of galangal (rhizome of Alpinia officinarum). Minimum inhibitory concentration is 0.32-0.64 mM
1.1.1.100	Streptococcus pneumoniae		more	704843		FabG is inhibited by extract of galangal (rhizome of Alpinia officinarum). Minimum inhibitory concentration is 0.01-0.02 mM
1.1.1.100	Streptococcus sp.		more	704843		FabG is inhibited by extract of galangal (rhizome of Alpinia officinarum). Minimum inhibitory concentration is 0.025-0.05 mM
1.1.1.100	synthetic construct		more	704843		FabG is inhibited by extract of galangal (rhizome of Alpinia officinarum), strongest inhibition with 40% ethanol extract of galangal. Inhibition is consisted of both reversible and irreversible inhibition. Inhibits FabG in a competitive pattern against NADPH, irreversible inhibition presents two phases (slow and fast one)
1.1.1.100	Acinetobacter calcoaceticus		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Enterobacter aerogenes		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Enterobacter cloacae		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Enterococcus sp.		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Escherichia coli		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge; inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge. Leaf extracts of Acer saccharum and Acer truncatum Bunge display time-dependent irreversible inhibition of FabG, whereas leaf extracts of Acer platanoides, Acer campestre and Acer rubrum show reversible inhibition
1.1.1.100	Klebsiella pneumoniae		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Proteus vulgaris		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge. Is inhibited by the leaf extracts from all five kinds of maples more effectively than are other Gram-negative bacteria strains
1.1.1.100	Pseudomonas aeruginosa		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Salmonella enterica subsp. enterica serovar Typhi		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge. Is inhibited by the leaf extracts from all five kinds of maples more effectively than are other Gram-negative bacteria strains
1.1.1.100	Salmonella enterica subsp. enterica serovar Typhimurium		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Serratia marcescens		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Shigella dysenteriae		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge. Is inhibited by the leaf extracts from all five kinds of maples more effectively than are other Gram-negative bacteria strains
1.1.1.100	Shigella flexneri		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Shigella sonnei		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Staphylococcus aureus		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge
1.1.1.100	Staphylococcus epidermidis		more	706142		inhibition by leaf extracts from Acer platanoides, Acer campestre, Acer rubrum, Acer saccharum and Acer truncatum Bunge, except strain 04-5
1.1.1.100	Escherichia coli		N-(1,3-dioxoisoindolin-2-yl)-2-oxo-2H-chromene-3-carboxamide	703163	53977	69% residual activity
1.1.1.100	Streptococcus pneumoniae		NADP+	667646	6	competitive product inhibition
1.1.1.100	Mycobacterium tuberculosis		NADP+	667708	6	noncompetitive product inhibition pattern
1.1.1.100	Escherichia coli		NADP+	669013	6	competitive product inhibition
1.1.1.100	Spinacia oleracea		p-chloromercuribenzoate	285668	40	
1.1.1.100	Persea americana		Phenylglyoxal	285674	258	with NADPH 45% remaining activity, without total loss of activity
1.1.1.100	Cuphea lanceolata		Phenylglyoxal	285679	258	
1.1.1.100	synthetic construct		quercetin	704843	131	
1.1.1.100	Escherichia coli		quercetin	706142	131	
1.1.1.100	Arabidopsis thaliana		RNAi	700827		suppresses KCR activity, which results in a reduction of cuticular wax load and affects very-long-chain fatty acid composition of sphingolipids, seed triacylglycerols, and root glycerolipids. RNAi-suppressed Arabidopsis KCR1 plants display fused vegetative and reproductive organs, an abnormal root morphology and have abnormal trichome and epidermal cell morphology
1.1.1.100	Acinetobacter calcoaceticus		Tannic acid	706142	782	
1.1.1.100	Enterobacter aerogenes		Tannic acid	706142	782	
1.1.1.100	Enterobacter cloacae		Tannic acid	706142	782	
1.1.1.100	Enterococcus sp.		Tannic acid	706142	782	
1.1.1.100	Escherichia coli		Tannic acid	706142	782	; strongest inhibition on FabG, shows time-dependent irreversible inhibition
1.1.1.100	Klebsiella pneumoniae		Tannic acid	706142	782	
1.1.1.100	Proteus vulgaris		Tannic acid	706142	782	
1.1.1.100	Pseudomonas aeruginosa		Tannic acid	706142	782	
1.1.1.100	Salmonella enterica subsp. enterica serovar Typhi		Tannic acid	706142	782	
1.1.1.100	Salmonella enterica subsp. enterica serovar Typhimurium		Tannic acid	706142	782	
1.1.1.100	Serratia marcescens		Tannic acid	706142	782	
1.1.1.100	Shigella dysenteriae		Tannic acid	706142	782	
1.1.1.100	Shigella flexneri		Tannic acid	706142	782	
1.1.1.100	Shigella sonnei		Tannic acid	706142	782	
1.1.1.100	Staphylococcus aureus		Tannic acid	706142	782	displays very strong inhibition
1.1.1.100	Staphylococcus epidermidis		Tannic acid	706142	782	displays very strong inhibition
1.1.1.100	Plasmodium falciparum		Urea	706639	110	FabG is fully unfolded at 6 M, approximately 90% of the enzyme activity can be recovered on dialyzing the denaturant. Two states in the reversible unfolding process of FabG in presence of NADPH, one is an activity-enhanced state and the other, an inactive state in case of equilibrium unfolding with urea
2.3.1.1	Homo sapiens	arginine		486061	117	
2.3.1.1	Rattus norvegicus	arginine		486061	117	0.02 mM, 4.2fold activation
2.3.1.1	Rattus norvegicus	arginine		486062	117	
2.3.1.1	Rattus norvegicus	arginine		486065	117	0.1 mM, 2fold activation at pH 7.2, 8fold activation at pH 8.2; rapid rate of synthesis of acetyl glutamate requires a concentration of arginine of about 0.025 mM and either relatively high glutamate concentrations or relatively high pH
2.3.1.1	Rattus norvegicus	arginine		486068	117	1 mM, 2-6fold activation in mitochondria, 1.6fold activation of partially purified enzyme
2.3.1.1	Rattus norvegicus	arginine		486071	117	5.1fold activiation of matrix enzyme
2.3.1.1	Mus musculus	arginine		486078	117	activation is high if the enzyme is purified from fed mice and low if purified from fasted mice, thiol/disulfide interchange may be responsible for arginine sensitivity
2.3.1.1	Mus musculus	arginine		486080	117	1 mM, 2-6fold activation of recombinant enzyme
2.3.1.1	Mus musculus	arginine		685805	117	
2.3.1.1	Xenopus laevis	arginine		685805	117	
2.3.1.1	Xenopus (Silurana) tropicalis	arginine		685805	117	
2.3.1.1	Rattus norvegicus	Cationic polypeptides		486061		4fold activation
2.3.1.1	Rattus norvegicus	culpein		486071		
2.3.1.1	Homo sapiens	L-arginine		661264	117	
2.3.1.1	Rattus norvegicus	L-Argininic acid		486071	6181	activates to a lesser extent than L-arginine
2.3.1.1	Saccharomyces cerevisiae	more		390290, 486081		enzyme must interact stoichoimetrically in vivo with acetylglutamate kinase to be active
2.3.1.1	Homo sapiens	more		661264		dilution of the purified recombinant enzyme results in an increase in activity
2.3.1.1	Rattus norvegicus	Polyarginine		486071	5500	
2.3.1.1	Rattus norvegicus	polylysine		486071	1883	
2.3.1.1	Rattus norvegicus	salmin		486071		
2.3.1.1	Rattus norvegicus	Triton X-100		486061	57	0.1%, 4fold activation
2.3.1.1	Pseudomonas aeruginosa		1,3-Diaminopropane	486069	580	10 mM, 88% inhibition in the presence of 0.5 mM N-acetyl-L-glutamate
2.3.1.1	Rattus norvegicus		5,5'-dithiobis(2-nitrobenzoate)	486062	196	strong inhibition
2.3.1.1	Mycobacterium tuberculosis		acetyl-CoA	662031	27	substrate inhibition
2.3.1.1	Pseudomonas aeruginosa		acetyl-CoA	703712	27	
2.3.1.1	Rattus norvegicus		AgNO3	486062	307	0.1 mM, 70-90% inhibition
2.3.1.1	Homo sapiens		Arg	676019	117	activates
2.3.1.1	Mus musculus		Arg	676019	117	activates
2.3.1.1	Escherichia coli		arginine	486063, 486066	117	0.02 mM, 50% inhibition; L-arginine
2.3.1.1	Neurospora crassa		arginine	486067	117	feed back inhibition, 0.16 mM, 50% inhibition; L-arginine
2.3.1.1	Pseudomonas aeruginosa		arginine	486069	117	0.2 mM, 73% inhibition, 97% inhibition in the presence of 0.5 mM N-acetyl-L-glutamate
2.3.1.1	Chlorella vulgaris		arginine	486074	117	
2.3.1.1	Arabidopsis thaliana		arginine	685805	117	
2.3.1.1	Danio rerio		arginine	685805	117	
2.3.1.1	Escherichia coli		arginine	685805	117	
2.3.1.1	Maricaulis maris		arginine	685805	117	
2.3.1.1	Pseudomonas aeruginosa		arginine	685805	117	the arginine binding site is localized in the kinase domain. Arginine is an allosteric inhibitor of microbial NAGS as part of feedback regulation of arginine biosynthesis, arginine is also an inhibitor of plant NAGS, a partial inhibitor of fish NAGS, but an allosteric activator of mammalian NAGS
2.3.1.1	Takifugu rubripes		arginine	685805	117	
2.3.1.1	Xanthomonas campestris		arginine	685805	117	
2.3.1.1	Pseudomonas aeruginosa		arginine	703696	117	10 mM, 90% inhibition for wild-type enzyme and mutations affecting the putative arginine site, about 70-80% inhibition for mutations affecting the GCN5-related N-acetyltransferase domain, 98% inhibition for mutant E352D
2.3.1.1	Pseudomonas aeruginosa		arginine	703712	117	
2.3.1.1	Rattus norvegicus		BaCl2	486062	968	1 mM, 30-50% inhibition
2.3.1.1	Rattus norvegicus		CaCl2	486062	193	1 mM, 30-50% inhibition
2.3.1.1	Pseudomonas aeruginosa		cadaverine	486069	444	10 mM, 80% inhibition in the presence of 0.5 mM N-acetyl-L-glutamate
2.3.1.1	Escherichia coli		Cd2+	486063	48	0.1 mM, 94% inhibition
2.3.1.1	Rattus norvegicus		CoCl2	486062	347	0.1 mM, 30-50% inhibition
2.3.1.1	Rattus norvegicus		coenzyme A	486061	10	1 mM, 20% inhibition
2.3.1.1	Rattus norvegicus		coenzyme A	486062	10	
2.3.1.1	Escherichia coli		coenzyme A	486061, 486063	10	2.5 mM, 50% inhibition
2.3.1.1	Neurospora crassa		coenzyme A	486067	10	1 mM, 30% inhibition
2.3.1.1	Rattus norvegicus		Cu2+	486062	28	CuSO4, 0.1 mM, 70-90% inhibition
2.3.1.1	Escherichia coli		Cu2+	486063	28	0.1 mM, 68% inhibition
2.3.1.1	Rattus norvegicus		EDTA	486062	223	weak inhibition
2.3.1.1	Rattus norvegicus		FeCl3	486062	566	0.1 mM, 30-50% inhibition
2.3.1.1	Rattus norvegicus		FeSO4	486062	531	0.1 mM, 30-50% inhibition
2.3.1.1	Rattus norvegicus		Hg2+	486062	31	Hg(CHCOO)2, 0.1 mM, 70-90% inhibition
2.3.1.1	Escherichia coli		Hg2+	486063	31	0.1 mM; 50% inhibition
2.3.1.1	Rattus norvegicus		High ionic strength	486061		
2.3.1.1	Escherichia coli		High ionic strength	486061, 486063		
2.3.1.1	Rattus norvegicus		isobutylmethylxanthine	719937	875	and other oxypurines containing a 2,6-dione group interfere with the binding of glutamate to the active site of N-acetylglutamate synthetase, thereby decreasing synthesis of N-acetylglutamate, resulting in reduction of citrulline and urea synthesis. Isobutylmethylxanthine significantly increases the apparent Km for glutamate and decreases velocity of N-acetylglutamate synthetase, with little effect on carbamoylphosphate synthase-1. Inhibition is reversed by supplementation with N-carbamylglutamate
2.3.1.1	Rattus norvegicus		K2SO4	486062	1867	
2.3.1.1	Rattus norvegicus		KCl	486062	74	100 mM, 30% inhibition, 200 mM, 50% inhibition
2.3.1.1	Escherichia coli		KCl	486063	74	100 mM, 36% inhibition after 1 h, 300 mM, 74% inhibition after 1 h, 500 mM, 87% inhibition after 1 h
2.3.1.1	Rattus norvegicus		L-alpha-Acetoxylglutamate	486062	64723	2 mM, 17% inhibition
2.3.1.1	Pseudomonas aeruginosa		L-arginine	661651	117	0.1 mM, 50% inhibition
2.3.1.1	Mycobacterium tuberculosis		L-arginine	662031	117	feedback inhibition, regulatory function, 50% inhibition at 0.026 mM, complete inhibition at 0.5 mM, negatively cooperative binding
2.3.1.1	Neisseria gonorrhoeae		L-arginine	704614	117	
2.3.1.1	Homo sapiens		L-arginine	720845	117	allosteric inhibition
2.3.1.1	Maricaulis maris		L-arginine	720845	117	allosteric inhibition
2.3.1.1	Escherichia coli		L-citrulline	486063	730	10 mM, 75% inhibition
2.3.1.1	Pseudomonas aeruginosa		L-glutamate	703712	38	
2.3.1.1	Mycobacterium tuberculosis		L-glutamine	662031	96	substrate inhibition
2.3.1.1	Escherichia coli		L-Indospicine	486066	29438	0.2 mM; 50% inhibition
2.3.1.1	Rattus norvegicus		MgCl2	486062	176	1 mM, 30-50% inhibition
2.3.1.1	Rattus norvegicus		MnCl2	486062	262	0.1 mM, 30-50% inhibition
2.3.1.1	Pseudomonas aeruginosa		more	661651		not inhibitory: N-acetyl-L-ornithine, L-ornithine, L-citrulline
2.3.1.1	Mycobacterium tuberculosis		more	662031		no inhibition by other proteinogenic L-amino acids
2.3.1.1	Rattus norvegicus		N-acetyl-D-glutamate	486062	29530	2 mM, 30% inhibition
2.3.1.1	Rattus norvegicus		N-acetyl-DL-alpha-aminoadipate	486062	62998	2 mM, 78% inhibition
2.3.1.1	Rattus norvegicus		N-acetyl-L-aspartate	486062	1675	2 mM, 25% inhibition
2.3.1.1	Homo sapiens		N-acetyl-L-glutamate	486073	450	
2.3.1.1	Rattus norvegicus		N-acetyl-L-glutamine	486062	3576	2 mM, 46% inhibition
2.3.1.1	Escherichia coli		N-acetylglutamate	486061	450	
2.3.1.1	Rattus norvegicus		N-acetylglutamate	486061	450	2 mM, 88% inhibition
2.3.1.1	Rattus norvegicus		N-acetylglutamate	486062	450	
2.3.1.1	Escherichia coli		N-acetylglutamate	486063	450	25 mM, 50% inhibition
2.3.1.1	Rattus norvegicus		N-benzoyl-L-glutamate	486062	4883	2 mM, 29% inhibition
2.3.1.1	Rattus norvegicus		N-Butyryl-L-glutamate	486062	8788	2 mM, 19% inhibition
2.3.1.1	Rattus norvegicus		N-carbamoyl-L-glutamate	486062	29553	2 mM, 31% inhibition
2.3.1.1	Escherichia coli		N-ethylmaleimide	486063	46	
2.3.1.1	Rattus norvegicus		N-propionyl-L-glutamate	486062	20503	2 mM, 63% inhibition
2.3.1.1	Xanthomonas campestris		NaCl	672793	39	200 mM NaCl inhibits the activity by about 22%
2.3.1.1	Rattus norvegicus		Ni(NO3)2	486062	65168	0.1 mM, 30-50% inhibition
2.3.1.1	Escherichia coli		O-(L-Norvalyl-5)-isourea	486066	65180	0.02 mM, 50% inhibition
2.3.1.1	Neurospora crassa		oxaloacetate	486067	53	1 mM, 68% inhibition
2.3.1.1	Escherichia coli		p-chloromercuribenzoate	486063	40	
2.3.1.1	Rattus norvegicus		p-hydroxymercuribenzoate	486062	92	strong inhibition
2.3.1.1	Escherichia coli		p-hydroxymercuribenzoate	486063	92	
2.3.1.1	Rattus norvegicus		Pb(NO3)2	486062	3833	0.1 mM, 70-90% inhibition
2.3.1.1	Pseudomonas aeruginosa		Polyamines	486069		
2.3.1.1	Rattus norvegicus		potassium phosphate	486062	1140	
2.3.1.1	Rattus norvegicus		propionyl-CoA	486061	297	
2.3.1.1	Pseudomonas aeruginosa		putrescine	486069	144	10 mM, 74% inhibition in the presence of 0.5 mM N-acetyl-L-glutamate
2.3.1.1	Xanthomonas campestris		Sodium acetate	672793	1341	100 mM NaCl inhibits the activity by about 22%
2.3.1.1	Pseudomonas aeruginosa		spermidine	486069	140	1 mM, 78% inhibition in the presence of 0.5 mM N-acetyl-L-glutamate
2.3.1.1	Pseudomonas aeruginosa		spermine	486069	177	1 mM, 88% inhibition in the presence of 0.5 mM N-acetyl-L-glutamate
2.3.1.1	Rattus norvegicus		succinate	486062	54	2 mM, 21% inhibition
2.3.1.1	Rattus norvegicus		Uric acid	719937	570	significantly increases the apparent Km for glutamate and decreases velocity of N-acetylglutamate synthetase, with little effect on carbamoylphosphate synthase-1. Inhibition is reversed by supplementation with N-carbamylglutamate
2.3.1.1	Rattus norvegicus		xanthine	719937	208	significantly increases the apparent Km for glutamate and decreases velocity of N-acetylglutamate synthetase, with little effect on carbamoylphosphate synthase-1. Inhibition is reversed by supplementation with N-carbamylglutamate
2.3.1.1	Rattus norvegicus		Zn2+	486062	19	ZnCl2, 0.1 mM, 70-90% inhibition
2.3.1.1	Escherichia coli		Zn2+	486063	19	0.1 mM, 43% inhibition
3.5.99.6	Musca domestica	2-deoxyglucose 6-phosphate		648219	1578	activates
3.5.99.6	Musca domestica	6-phosphogluconate		648219	327	activates
3.5.99.6	Musca domestica	D-glucose 6-phosphate		648219	99	activates
3.5.99.6	Drosophila virilis	D-glucose 6-phosphate		648222	99	activates
3.5.99.6	Musca domestica	D-mannose 6-phosphate		648219	564	
3.5.99.6	Escherichia coli	more		648227		enzyme contains 5 half-cystines per monomer, the sulfhydryls are not essential for catalysis or allosteric behavior of the enzyme
3.5.99.6	Escherichia coli	more		648230		each subunit has for Cys residues located at positions 118, 219, 228 and 239, Cys118 and Cys239 form a pair of vicinal thiols
3.5.99.6	Canis lupus familiaris	more		671576		no effect by glucose 6-phosphate
3.5.99.6	Homo sapiens	N-acetylgalactosamine		648232	820	
3.5.99.6	Sus scrofa	N-Acetylgalactosamine 6-phosphate		648215	20841	activates
3.5.99.6	Homo sapiens	N-acetylglucosamine		648232	257	
3.5.99.6	Escherichia coli	N-acetylglucosamine 6-phosphate		648215	830	activates; increases reaction velocity when D-glucosamine 6-phosphate is present at levels below that required for saturation
3.5.99.6	Sus scrofa	N-acetylglucosamine 6-phosphate		648215	830	activates
3.5.99.6	Proteus vulgaris	N-acetylglucosamine 6-phosphate		648216	830	activates in both directions
3.5.99.6	Musca domestica	N-acetylglucosamine 6-phosphate		648219	830	activates
3.5.99.6	Escherichia coli	N-acetylglucosamine 6-phosphate		648220	830	activates
3.5.99.6	Bos taurus	N-acetylglucosamine 6-phosphate		648236	830	activates enzyme by increasing its kcat without any change in the Km values for D-glucosamine 6-phosphate
3.5.99.6	Escherichia coli	N-acetylglucosamine 6-phosphate		648226, 648237, 648238, 648240, 648243	830	
3.5.99.6	Canis lupus familiaris	N-acetylglucosamine 6-phosphate		671576	830	the cooperativity of the reaction is completely abolished by saturating concentrations of GlcNAcGP, this allosteric modulator activated the reaction with a typical K-effect, overview
3.5.99.6	Aspergillus niger	N-acetylglucosamine 6-phosphate		684638	830	activator of the enzyme in amination direction, leads to about 30% increased activity at 0.07-0.14 mM, overview
3.5.99.6	Homo sapiens	N-acetylglucosamine 6-phosphate		718986	830	GlcNAc6P, allosteric site ligand, behaving as a V activator and a K inhibitor: in the absence of GlcNAc6P, the apparent kcat of the enzyme is so low, that GlcNAc6P behaves as an essential activator. Additionally, substrate inhibition, dependent on GlcNAc6P concentration, is observed, Monod allosteric model with some additional postulates, overview. The ligand binds to either enzyme conformational state, but with higher affinity for the R form
3.5.99.6	Escherichia coli	N-acetylglucosamine-6-phosphate		712289	830	allosteric activator of NagB
3.5.99.6	Homo sapiens	PCMB		648217	40	inhibits at high concentrations, activates at low concentrations
3.5.99.6	Homo sapiens	UDP-N-acetylglucosamine		648232	120	slight activation at 0.00167-0.167 mM, slight inhibition at 1.67 mM
3.5.99.6	Escherichia coli		2,5-anhydro mannitol 6-phosphate	648239	33680	
3.5.99.6	Giardia intestinalis		2-deoxy-2-amino-D-glucitol 6-phosphate	648228	3035	
3.5.99.6	Bos taurus		2-deoxy-2-amino-D-glucitol 6-phosphate	648236	3035	
3.5.99.6	Escherichia coli		2-deoxy-2-amino-D-glucitol 6-phosphate	648221, 648239, 648244, 667624, 667638	3035	
3.5.99.6	Canis lupus familiaris		2-deoxy-2-amino-D-glucitol 6-phosphate	671576	3035	
3.5.99.6	Escherichia coli		5,5'-dithiobis(2-nitrobenzoate)	648227	196	
3.5.99.6	Homo sapiens		Cd2+	648217	48	
3.5.99.6	Homo sapiens		Cu2+	648232	28	
3.5.99.6	Homo sapiens		cysteine	648217	70	
3.5.99.6	Homo sapiens		D-fructose 1,6-diphosphate	648232	100	
3.5.99.6	Homo sapiens		D-fructose 6-phosphate	648232	82	
3.5.99.6	Escherichia coli		D-fructose 6-phosphate	648239	82	
3.5.99.6	Escherichia coli		D-fructose oxime 6-phosphate	648239	33902	
3.5.99.6	Bacillus subtilis		D-Glucosamine 6-phosphate	669338	417	substrate inhibition
3.5.99.6	Homo sapiens		D-glucose 6-phosphate	648232	99	
3.5.99.6	Escherichia coli		diethyl dicarbonate	648239	265	complete inactivation, 2-deoxy-2-amino-D-glucitol 6-phosphate protects
3.5.99.6	Homo sapiens		diphosphate	648217	13	
3.5.99.6	Homo sapiens		EDTA	648217	223	
3.5.99.6	Homo sapiens		EDTA	648232	223	no inhibition
3.5.99.6	Candida albicans		Fluorescamine	648224	29339	
3.5.99.6	Escherichia coli		more	648239		not: alpha and beta O-methyl glycoside of D-fructose 6-phosphate
3.5.99.6	Canis lupus familiaris		more	671576		no effect by glucose 6-phosphate
3.5.99.6	Homo sapiens		N-acetylglucosamine 6-phosphate	648232	830	
3.5.99.6	Bacillus subtilis		N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid	648234	5493	
3.5.99.6	Homo sapiens		Ni2+	648232	36	
3.5.99.6	Homo sapiens		PCMB	648217	40	inhibits at high concentrations, activates at low concentrations
3.5.99.6	Rattus norvegicus		PCMB	648223	40	protection by 0.3 mM glucosamine 6-phosphate, no protection by 0.3 mM N-acetylglucosamine 6-phosphate
3.5.99.6	Candida albicans		PCMB	648224	40	
3.5.99.6	Musca domestica		phosphate	648219	12	slight inhibition
3.5.99.6	Homo sapiens		UDP-N-acetylglucosamine	648232	120	slight inhibition at 1.67 mM, slight activation at 0.00167-0.167 mM
3.5.99.6	Homo sapiens		Zn2+	648232	19	
3.5.99.6	Escherichia coli		Zn2+	648233	19	tightly bound and slow partial inhibitor
2.7.1.25	Penicillium chrysogenum	ammonium sulfate		641223	334	high salt activates at high adenosine 5'-phosphosulfate concentrations but inhibits at low adenosine 5'-phosphosulfate concentrations
2.7.1.25	Escherichia coli	ascorbate		641217	88	activation
2.7.1.25	Chlamydomonas reinhardtii	dithioerythritol		641213	475	2 mM, 200% activation
2.7.1.25	Rattus norvegicus	dithiothreitol		641205	42	activation
2.7.1.25	Chlamydomonas reinhardtii	dithiothreitol		641213	42	2 mM, 200% activation; activation
2.7.1.25	Escherichia coli	dithiothreitol		641217	42	activation
2.7.1.25	Saccharomyces cerevisiae	dithiothreitol		641217	42	activation
2.7.1.25	Arabidopsis thaliana	dithiothreitol		641230	42	activity declines rapidly in the absence of dithiothreitol
2.7.1.25	Homo sapiens	dithiothreitol		661125	42	
2.7.1.25	Escherichia coli	glutathione		641217	41	reduced glutathione increases the activity significantly
2.7.1.25	Saccharomyces cerevisiae	glutathione		641217	41	reduced glutathione increases the activity significantly
2.7.1.25	Arabidopsis thaliana	High ionic strength		641230		maximal activity at a high concentration of buffer-salts either alone or plus dithiothreitol and thioredoxin 1 from Escherichia coli
2.7.1.25	Escherichia coli	L-cysteine		641217	70	activation
2.7.1.25	Chlamydomonas reinhardtii	more		641213		not activated by 2-mercaptoethanol
2.7.1.25	Escherichia coli	more		641217		not activated by 2-mercaptoethanol
2.7.1.25	Saccharomyces cerevisiae	more		641217		not activated by 2-mercaptoethanol; not activated by L-cysteine and ascorbate
2.7.1.25	Chlamydomonas reinhardtii	Na2SO3		641213	2592	5 mM, 200% activation
2.7.1.25	Escherichia coli	thioredoxin		641217	115	activation in the presence of dithiothreitol
2.7.1.25	Saccharomyces cerevisiae	thioredoxin		641217	115	activation in the presence of dithiothreitol
2.7.1.25	Arabidopsis thaliana	thioredoxin		641230	115	essential for activity
2.7.1.25	Chlamydomonas reinhardtii	Thioredoxin f		641214		from spinach, 0.002 mg, 3fold activation in the presence of saturating concentrations of thiols
2.7.1.25	Penicillium chrysogenum		2'-Phosphoadenosine 5'-phosphosulfate	641207	62885	
2.7.1.25	Penicillium chrysogenum		2,4,6-Trinitrobenzene sulfonate	641209	2353	in the presence or absence of ATP-sulfurylase
2.7.1.25	Escherichia coli		2,4,6-Trinitrobenzene sulfonate	641217	2353	0.05 mM, complete inhibition
2.7.1.25	Saccharomyces cerevisiae		2,4,6-Trinitrobenzene sulfonate	641217	2353	0.05 mM, 28% inhibition
2.7.1.25	Escherichia coli		2,6-dichlorophenol indophenol	641217	152	0.05 mM, complete inhibition
2.7.1.25	Saccharomyces cerevisiae		2,6-dichlorophenol indophenol	641217	152	0.05 mM, complete inhibition
2.7.1.25	Penicillium chrysogenum		3'-phosphoadenosine 5'-phosphosulfate	641207	106	product inhibition
2.7.1.25	Chlamydomonas reinhardtii		4-Aminophenylacetate	641213	28912	0.008 mM, 50% inhibition
2.7.1.25	Rattus norvegicus		adenosine 5'-phosphosulfate	641205	354	potent substrate inhibition, ATP reverses
2.7.1.25	Penicillium chrysogenum		adenosine 5'-phosphosulfate	641207	354	kinetics
2.7.1.25	Pyropia yezoensis		adenosine 5'-phosphosulfate	641211	354	
2.7.1.25	Chlamydomonas reinhardtii		adenosine 5'-phosphosulfate	641212	354	substrate inhibition above 0.03-0.04 mM
2.7.1.25	Escherichia coli		adenosine 5'-phosphosulfate	641215	354	
2.7.1.25	Arabidopsis thaliana		adenosine 5'-phosphosulfate	641222	354	substrate inhibition above 0.01 mM
2.7.1.25	Penicillium chrysogenum		adenosine 5'-phosphosulfate	641226	354	
2.7.1.25	Arabidopsis thaliana		adenosine 5'-phosphosulfate	641230	354	uncompetitive inhibition above 0.001 mM
2.7.1.25	Penicillium chrysogenum		adenosine 5'-phosphosulfate	641233	354	adenosine 5'-phosphosulfate can bind to E-MgADP forming a catalytically inactive E-MgADP-APS ternary complex
2.7.1.25	Homo sapiens		adenosine 5'-phosphosulfate	661125	354	substrate inhibition
2.7.1.25	Homo sapiens		adenosine 5'-phosphosulfate	674838	354	acts as a strong uncompetitive inhibitor of the APS kinase reaction
2.7.1.25	Arabidopsis thaliana		adenosine 5'-phosphosulfate	722775, 722817, 723657	354	
2.7.1.25	Synechocystis sp.		adenosine 5'-phosphosulfate	723657	354	
2.7.1.25	Homo sapiens		adenylyl sulfate	674838	354	adenylyl sulfate acts as a strong uncompetitive inhibitor of the APS kinase reaction
2.7.1.25	Escherichia coli		ADP	641215	8	free form, reverse reaction, weak
2.7.1.25	Penicillium chrysogenum		ammonium sulfate	641223	334	high salt inhibits at low adenosine 5'-phosphosulfate concentrations, but activates at high adenosine 5'-phosphosulfate concentrations
2.7.1.25	Chlamydomonas reinhardtii		AMP	641213	9	
2.7.1.25	Penicillium chrysogenum		ATP	641207	7	inhibition by free ATP, i.e. in excess of total Mg2+
2.7.1.25	Chlamydomonas reinhardtii		ATP	641212	7	in the absence of ATP regenerating system, substrate inhibition above 0.6 mM, in the presence of ATP regenerating system, substrate inhibition above 0.2 mM
2.7.1.25	Escherichia coli		ATP	641215	7	free form, weak inhibition; MgATP2-: product inhibition, reverse reaction
2.7.1.25	Chlamydomonas reinhardtii		Bromosuccinimide	641213	6131	strong inhibition
2.7.1.25	Escherichia coli		Bromosuccinimide	641217	6131	0.05 mM, complete inhibition
2.7.1.25	Saccharomyces cerevisiae		Bromosuccinimide	641217	6131	0.05 mM, complete inhibition
2.7.1.25	Escherichia coli		Cd2+	641215	48	in excess
2.7.1.25	Chlamydomonas reinhardtii		CMP	641213	94	
2.7.1.25	Chlamydomonas reinhardtii		Co2+	641213	21	2 mM, 63% inhibition
2.7.1.25	Escherichia coli		Co2+	641215	21	in excess, activating below
2.7.1.25	Chlamydomonas reinhardtii		Cu2+	641213	28	2 mM, 90% inhibition
2.7.1.25	Escherichia coli		dehydroascorbate	641217	362	
2.7.1.25	Saccharomyces cerevisiae		dehydroascorbate	641217	362	
2.7.1.25	Penicillium chrysogenum		diethyldicarbonate	641209	265	in the presence or absence of ATP-sulfurylase
2.7.1.25	Escherichia coli		EDTA	641215	223	
2.7.1.25	Arabidopsis thaliana		EDTA	641230	223	complete inhibition
2.7.1.25	Escherichia coli		FAD	641217	14	
2.7.1.25	Saccharomyces cerevisiae		FAD	641217	14	
2.7.1.25	Escherichia coli		ferricyanide	641217	126	0.05 mM, complete inhibition
2.7.1.25	Chlamydomonas reinhardtii		GMP	641213	150	
2.7.1.25	Rattus norvegicus		iodoacetamide	641205	63	strong inhibition, dithiothreitol partially protects
2.7.1.25	Escherichia coli		Mercuriphenylacetate	641217	1830	0.05 mM, complete inhibition
2.7.1.25	Saccharomyces cerevisiae		Mercuriphenylacetate	641217	1830	0.05 mM, complete inhibition
2.7.1.25	Escherichia coli		Mn2+	641215	26	in excess, activating below
2.7.1.25	Escherichia coli		more	641215		not inhibited by Mg2+
2.7.1.25	Escherichia coli		more	641217		
2.7.1.25	Saccharomyces cerevisiae		more	641217		not inhibited by ferricyanide
2.7.1.25	Geobacillus stearothermophilus		more	641221		not inhibited by adenosine 5'-phosphosulfate
2.7.1.25	Saccharomyces cerevisiae		more	641221		
2.7.1.25	Chlamydomonas reinhardtii		N-ethylmaleimide	641213	46	0.02 mM, 50% inhibition
2.7.1.25	Homo sapiens		NaClO3	641229	30348	6.57 mM, 50% inhibition of brain PAPSS activity, 3.26 mM, 50% inhibition of liver PAPSS
2.7.1.25	Escherichia coli		oxidized glutathione	641217	283	thioredoxin reverses inactivation
2.7.1.25	Chlamydomonas reinhardtii		p-chloromercuribenzoate	641213	40	0.005 mM, 50% inhibition
2.7.1.25	Escherichia coli		reduced glutathion	641217		
2.7.1.25	Saccharomyces cerevisiae		reduced glutathion	641217		
2.7.1.25	Chlamydomonas reinhardtii		UMP	641213	127	
2.7.1.23	Methanocaldococcus jannaschii	5'-AMP		680634	9	1.56fold activation at 3.0 mM
2.7.1.23	Avena sativa	adenine		641203	136	5 mM, activity of both isoenzymes is modestly enhanced
2.7.1.23	Avena sativa	AMP		641203	9	5 mM, activity of both isoenzymes is modestly enhanced
2.7.1.23	Arabidopsis thaliana	Ca2+		660240	18	
2.7.1.23	Avena sativa	Caffeine		641203	695	5 mM, activity of both isoenzymes is modestly enhanced
2.7.1.23	Pisum sativum	Calmodulin		641190	119	CaM-2 isoform is a significantly more efficient activator of NAD kinase compared with the CaM-4 and CaM-6 isoforma
2.7.1.23	Euglena gracilis	Calmodulin		641192	119	independent on calmodulin
2.7.1.23	Pisum sativum	Calmodulin		641196	119	the enzyme can be activated by soybean CaM-1, but not by the divergent soybean CaM isoform CaM-4
2.7.1.23	Phaseolus acutifolius	Calmodulin		641197	119	five forms of NAD+ kinase: 1. a solvent Ca2+ sensitive form, 2. and 3. two Ca2+-calmodulin independent forms, one solvent and one membranal, 4. and 5. two Ca2+-calmodulin dependent forms, one solvent and one membranal. In dry seeds the membranal-Ca2+-calmodulin-dependent form represents 100% of the total pelletable activity; in dry seeds the membranal-Ca2+-calmodulin-dependent form represents 30% of the total pelletable activity
2.7.1.23	Phaseolus vulgaris	Calmodulin		641197	119	five forms of NAD+ kinase: 1. a solvent Ca2+ sensitive form, 2. and 3. two Ca2+-calmodulin independent forms, one solvent and one membranal, 4. and 5. two Ca2+-calmodulin dependent forms, one solvent and one membranal. In dry seeds the membranal-Ca2+-calmodulin-dependent form represents 100% of the total pelletable activity
2.7.1.23	Avena sativa	Calmodulin		641198	119	the Ca2+-calmodulin-dependent NAD+ kinase isoforms, amongst which is the isoform bound to mitochondrial membranes play an important role at the end of sensu stricto germination and during the following growth of Avena sativa
2.7.1.23	Solanum pimpinellifolium	Calmodulin		641199	119	two peaks of calmodulin-dependent NAD+ kinase activity occur at times when the cells are not actively dividing: the first one, a few hours after medium inoculation and the second one, at the end of the exponential growth phase
2.7.1.23	Pisum sativum	Calmodulin		641200	119	Ca2+-calmodulin-dependent enzyme. Half-saturating concentration of calmodulin is 19 ng
2.7.1.23	Homo sapiens	Calmodulin		641201	119	calmodulin-dependent enzyme is stimulated 3.5fold by addition of calmodulin in presence of Ca2+
2.7.1.23	Avena sativa	Calmodulin		641203	119	a 410000 Da Ca2+-calmodulin-independent isoform and a 63000 Da Ca2+-calmodulin-dependent isoform
2.7.1.23	Arabidopsis thaliana	Calmodulin		660240	119	; calmodulin-dependent isoform, full activation in presence of Ca2+
2.7.1.23	Pisum sativum	Calmodulin		663065	119	presence of bovine calmodulin, 100% activity, Nicotiana tabacum calmodulin 1, 207% activity, Nicotiana tabacum calmodulin 3, 235% activity, Nicotiana tabacum calmodulin 1, 9% activity
2.7.1.23	Pisum sativum	Calmodulin		682340	119	activates
2.7.1.23	Homo sapiens	Calmodulin		691390	119	Ca2+/calmodulin regulates NAD kinase activity. Ca2+/calmodulin has no detectable effect on recombinant human NAD kinase
2.7.1.23	Avena sativa	D-ribose 5-phosphate		641203	165	5 mM, activity of both isoenzymes is modestly enhanced
2.7.1.23	Arabidopsis thaliana	H2O2		691390	20	upregulates NADK1 by 3fold after treatment of plant cells with 5 mM
2.7.1.23	Avena sativa	imidazole		641203	390	5 mM, activity of both isoenzymes is modestly enhanced
2.7.1.23	Arabidopsis thaliana	more		691390		irradiation upregulates NADK1 by 8fold. NADK1 is Ca2+/calmodulin-independent, and not activated by Ca2+/calmodulin; NADK2 is Ca2+/calmodulin-independent, and not activated by Ca2+/calmodulin, although recombinant NADK2, which has a calmodulin-binding motif in its N-terminal, is able to bind to calmodulin; NADK3 is Ca2+/calmodulin-independent, and not activated by Ca2+/calmodulin
2.7.1.23	Micrococcus flavus	more		691390		is not regulated by NADH
2.7.1.23	Homo sapiens	more		693013		overexpression of NADK results in an almost 200fold increase of both the mRNA level, the protein amount and the catalytic activity
2.7.1.23	Avena sativa	nicotinic acid		641203	787	5 mM, activity of both isoenzymes is modestly enhanced
2.7.1.23	Avena sativa	Pyridine		641203	1509	5 mM, activity of both isoenzymes is modestly enhanced
2.7.1.23	Bacillus subtilis	quinolinic acid		641186	1319	allosteric activator
2.7.1.23	Pisum sativum		(2S,3R)-5-hydroxy-6,8,10-trimethoxy-2,3-dimethyl-2,3-dihydro-4H-naphtho-(2,3-b)-pyran-4-one	661914	82243	phytotoxin from Guanomyces polythrix, 50% inhibition at 0.0243 mM
2.7.1.23	Pisum sativum		(2S,3R)-5-hydroxy-6,8-dimethoxy-2,3-dimethyl-2,3-dihydro-4H-naphtho-(2,3-b)-pyran-4-one	661914	82242	phytotoxin from Guanomyces polythrix, 50% inhibition at 0.0422 mM
2.7.1.23	Pisum sativum		(2S,3S)-5-hydroxy-6,8,10-trimethoxy-2,3-dimethyl-4H-2,3-dihydronaphtho-(2,3-b)-pyran-4-one	661914	82241	phytotoxin from Guanomyces polythrix, 50% inhibition at 0.022 mM
2.7.1.23	Pisum sativum		(2S,3S)-5-hydroxy-6,8-dimethoxy-2,3-dimethyl-4H-2,3-dihydronaphtho-(2,3-b)-pyran-4-one	661914	82240	phytotoxin from Guanomyces polythrix, 50% inhibition at 0.0401 mM
2.7.1.23	Azotobacter vinelandii		2'-AMP	641177	621	2 mM, 25% inhibition
2.7.1.23	Listeria monocytogenes		2-([6-amino-9-[(2R,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxytetrahydrofuran-2-yl]-9H-purin-8-yl]sulfanyl)-N-[[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl]acetamide	723781	61766	
2.7.1.23	Strongylocentrotus purpuratus		3',5'-cAMP	641180	233	3.5 mM, 20% inhibition
2.7.1.23	Azotobacter vinelandii		3'-AMP	641177	529	2 mM, 20% inhibition
2.7.1.23	Columba sp.		3-(bromoacetyl)pyridine	641202	73688	
2.7.1.23	Homo sapiens		3-acetyl-pyridine adenine dinucleotide	641193	706	1 mM, 30% inhibition
2.7.1.23	Azotobacter vinelandii		3-acetylpyridine-adenine-dinucleotide (oxidized form)	641177	73693	0.5 mM, 10% inhibition
2.7.1.23	Homo sapiens		3-aldehyde-pyridine adenine dinucleotide	641193	73694	1 mM, 32% inhibition
2.7.1.23	Azotobacter vinelandii		5'-AMP	641177	9	2 mM, 15% inhibition
2.7.1.23	Listeria monocytogenes		5'-thioacetyladenosine	693014	48831	
2.7.1.23	Euglena gracilis		5,5'-dithiobis(2-nitrobenzoate)	641192	196	0.5 mM, 62% inhibition of isoenzyme 1 and 33% inhibition of isoenzyme 2
2.7.1.23	Pisum sativum		5-hydroxy-6,8-dimethoxy-2,3-dimethyl-4H-naphtho-(2,3-b)-pyran-4-one	661914	82244	phytotoxin from Guanomyces polythrix, 50% inhibition at 0.0171 mM
2.7.1.23	Strongylocentrotus purpuratus		adenosine diphosphoribose	641180	337	3.5 mM, 31% inhibition
2.7.1.23	Azotobacter vinelandii		ADP	641177	8	2 mM, 15% inhibition
2.7.1.23	Strongylocentrotus purpuratus		ADP	641180	8	3.5 mM, 63% inhibition
2.7.1.23	Azotobacter vinelandii		ADP	641184	8	inhibits NADP+ formation by NAD+ kinase
2.7.1.23	Avena sativa		ADP	641203	8	5 mM, 4% inhibition of the 410000 Da isoform, 25% inhibition of the 63000 Da isoform
2.7.1.23	Methanocaldococcus jannaschii		ADP	680634	8	3 mM, 29% inhibition
2.7.1.23	Strongylocentrotus purpuratus		AMP	641180	9	3.5 mM, 29% inhibition
2.7.1.23	Arabidopsis thaliana		Ca2+	660240	18	12% inhibition at 0.2 mM, 50% inhibition at 2 mM
2.7.1.23	Corynebacterium glutamicum		Ca2+	721366	18	ATP-dependent activity is reduced to 72% in the presence of 20 mM Ca2+
2.7.1.23	Azotobacter vinelandii		CH3HgBr	641177	20464	0.1 mM, 63% inhibition
2.7.1.23	Avena sativa		chlorpromazin	641203	585	5 mM, 11% inhibition of the 410000 Da isoform, 80% inhibition of the 63000 Da isoform
2.7.1.23	Strongylocentrotus purpuratus		citrate	641180	125	3.5 mM, 55% inhibition
2.7.1.23	Pisum sativum		citrinin	661914	36968	phytotoxin from Guanomyces polythrix, 50% inhibition above 0.120 mM
2.7.1.23	Azotobacter vinelandii		deaminopyridinealdehyde adenine dinucleotide	641177	3529	0.5 mM, 10% inhibition
2.7.1.23	Listeria monocytogenes		di-(5'-thioadenosine)	693014	48832	
2.7.1.23	Avena sativa		diphosphate	641203	13	5 mM, 46% inhibition of the 410000 Da isoform, 69% inhibition of the 63000 Da isoform
2.7.1.23	Euglena gracilis		dithiothreitol	641192	42	0.1 mM, 81% inhibition, irreversible for isoenzyme 1 and reversible for isoenzyme 2
2.7.1.23	Azotobacter vinelandii		DTNB	641177	196	0.1 mM, 74% inhibition
2.7.1.23	Avena sativa		EGTA	641203	157	5 mM, 20% inhibition of the 410000 Da isoform, 85% inhibition of the 63000 Da isoform
2.7.1.23	Pisum sativum		ergosta-4,6,8(14),22-tetraen-3-one	661914	80694	phytotoxin from Guanomyces polythrix, 50% inhibition at 0.090 mM
2.7.1.23	Azotobacter vinelandii		Hg(CH3COO)2	641177	4427	0.1 mM, complete inhibition
2.7.1.23	Bacillus subtilis		HgCl2	641186	104	1 mM, 75% inhibition
2.7.1.23	Escherichia coli		HgCl2	641189	104	0.25 mM, 65% inhibition
2.7.1.23	Sphingomonas sp.		HgCl2	663300	104	1 mM, 6% residual activity
2.7.1.23	Avena sativa		iodoacetic acid	641203	87	1 mM, 56% inhibition of the 63000 Da isoform, no inhibition of the 410000 Da isoform
2.7.1.23	Corynebacterium glutamicum		KCl	721366	74	200 mM KCl decreases the polyphosphate-dependent activity to 75%
2.7.1.23	Strongylocentrotus purpuratus		Mn2+	641180	26	above 1 mM
2.7.1.23	Euglena gracilis		more	641192		no inhibition by 2-mercaptoethanol, isoenzyme 1 and 2
2.7.1.23	Sphingomonas sp.		more	663300		not inhibitory: NADH
2.7.1.23	Saccharomyces cerevisiae		more	691390		utr1 shows slow growth in a low-iron medium
2.7.1.23	Homo sapiens		more	723167		not inhibited by NADP+
2.7.1.23	Corynebacterium glutamicum		NaCl	721366	39	200 mM NaCl decreases the polyphosphate-dependent activity to 75%
2.7.1.23	Azotobacter vinelandii		NAD+	641184	4	inhibits exchange reaction between ADP and ATP
2.7.1.23	Azotobacter vinelandii		NADH	641177	3	0.1 mM, 20% inhibition
2.7.1.23	Strongylocentrotus purpuratus		NADH	641179, 641180	3	
2.7.1.23	Escherichia coli		NADH	641189	3	0.01 mM, 61% inhibition
2.7.1.23	Pisum sativum		NADH	641200	3	
2.7.1.23	Mycobacterium tuberculosis		NADH	661147	3	0.4 mM, 43% residual activity
2.7.1.23	Salmonella enterica		NADH	682536	3	allosterically inhibited
2.7.1.23	Escherichia coli		NADH	691390	3	
2.7.1.23	Salmonella enterica		NADH	691390	3	
2.7.1.23	Homo sapiens		NADH	693013	3	may become inhibitory at very high concentrations (mM)
2.7.1.23	Corynebacterium glutamicum		NADH	721366, 722144	3	
2.7.1.23	Corynebacterium glutamicum subsp. lactofermentum		NADH	722144	3	
2.7.1.23	Homo sapiens		NADH	723167	3	40% residual activity at 0.5 mM
2.7.1.23	Homo sapiens		NADH	723257	3	34% residual activity at 0.5 mM NADH
2.7.1.23	Listeria monocytogenes		NADP	693014	6	
2.7.1.23	Bacillus licheniformis		NADP+	641183	6	0.1-0.2 mM, marked inhibition
2.7.1.23	Bacillus subtilis		NADP+	641186	6	0.05 mM, 75% inhibition
2.7.1.23	Escherichia coli		NADP+	641189	6	0.1 mM, 21% inhibition
2.7.1.23	Mycobacterium tuberculosis		NADP+	661147	6	0.4 mM, 22% residual activity
2.7.1.23	Sphingomonas sp.		NADP+	663300	6	0.1 mM, 38% residual activity
2.7.1.23	Methanocaldococcus jannaschii		NADP+	680634	6	0.3 mM, complete inhibition
2.7.1.23	Corynebacterium glutamicum		NADP+	721366, 722144	6	
2.7.1.23	Corynebacterium glutamicum subsp. lactofermentum		NADP+	722144	6	
2.7.1.23	Homo sapiens		NADP+	723257	6	58% residual activity at 0.5 mM NADP+
2.7.1.23	Strongylocentrotus purpuratus		NADPH	641179, 641180	5	
2.7.1.23	Escherichia coli		NADPH	641189	5	0.01 mM, 76% inhibition
2.7.1.23	Pisum sativum		NADPH	641200	5	
2.7.1.23	Mycobacterium tuberculosis		NADPH	661147	5	0.4 mM, 50% residual activity
2.7.1.23	Sphingomonas sp.		NADPH	663300	5	0.1 mM, 67% residual activity
2.7.1.23	Methanocaldococcus jannaschii		NADPH	680634	5	0.3 mM, 18% inhibition
2.7.1.23	Salmonella enterica		NADPH	682536	5	allosterically inhibited
2.7.1.23	Escherichia coli		NADPH	691390	5	
2.7.1.23	Homo sapiens		NADPH	691390	5	; 
2.7.1.23	Salmonella enterica		NADPH	691390	5	
2.7.1.23	Corynebacterium glutamicum		NADPH	722144	5	
2.7.1.23	Corynebacterium glutamicum subsp. lactofermentum		NADPH	722144	5	
2.7.1.23	Homo sapiens		NADPH	723167	5	66% residual activity at 0.5 mM
2.7.1.23	Homo sapiens		NADPH	723257	5	17% residual activity at 0.5 mM NADPH
2.7.1.23	Avena sativa		NEM	641203	46	1 mM, 92% inhibition of the 63000 Da isoform, 34% inhibition of the 410000 Da isoform
2.7.1.23	Corynebacterium glutamicum		Ni2+	721366	36	ATP-dependent activity is reduced to 60% or 7% in the presence of 5 or 20 mM Ni2+
2.7.1.23	Homo sapiens		nicotinamide guanine dinucleotide	641193	1939	1 mM, 23% inhibition
2.7.1.23	Homo sapiens		nicotinamide hypoxanthine dinucleotide	641193	1551	1 mM, 24% inhibition
2.7.1.23	Azotobacter vinelandii		nicotinamide mononucleotide	641177	623	2 mM, 15% inhibition
2.7.1.23	Homo sapiens		nicotinic acid adenine dinucleotide phosphate	641193	109326	1 mM, 37% inhibition
2.7.1.23	Azotobacter vinelandii		PCMB	641177	40	0.01 mM, 79% inhibition, NAD+ and ATP protect from inactivation
2.7.1.23	Bacillus licheniformis		PCMB	641183	40	0.02 mM, 35% inhibition
2.7.1.23	Escherichia coli		PCMB	641189	40	0.25 mM, 67% inhibition
2.7.1.23	Euglena gracilis		PCMB	641192	40	0.5 mM, 74% inhibition of isoenzyme 1, 23% inhibition of isoenzyme 2
2.7.1.23	Strongylocentrotus purpuratus		phosphoenolpyruvate	641180	47	3.5 mM, 20% inhibition
2.7.1.23	Strongylocentrotus purpuratus		pyruvate	641180	29	3.5 mM, 10% inhibition
2.7.1.23	Avena sativa		R24571	641203	2569	1 mM, 46% inhibition of the 410000 Da isoform, 89% inhibition of the 63000 da isoform
2.7.1.23	Pisum sativum		rubrofusarin B	661914	80693	phytotoxin from Guanomyces polythrix, 50% inhibition at 0.0133 mM
2.7.1.23	Homo sapiens		shRNA	693013		shRNA1-NADK exhibits a notably higher efficiency compared with a shRNA2-NADK construct. About 70% decrease of both NADK expression, activity, and the NADPH concentration, accompanied by increased sensitivity toward H2O2
2.7.1.23	Pisum sativum		Trifluoperazine	641200	751	
2.7.1.23	Homo sapiens		Trifluoperazine	641201	751	inhibits stimulation by calmodulin
2.7.1.23	Avena sativa		Trifluoperazine	641203	751	2 mM, 8% inhibition of the 410000 da isoform, 83% inhibition of the 63000 Da isoform
2.7.1.23	Arabidopsis thaliana		Trifluoperazine	660240	751	; calmodulin-dependent isoform, 50% inhibition at 0.057 mM, isoforms NADK1, NADK2, no effect
2.7.1.23	Pisum sativum		W-7	641200	4442	
6.3.4.4	Aspergillus nidulans	AMP		692460	9	ASS expression is induced by AMP
6.3.4.4	Plasmodium falciparum	D-fructose 1,6 bisphosphate		714324	100	binds to the Asp loop and induces a conformation that facilitates aspartate binding to the enzyme active site
6.3.4.4	Plasmodium falciparum	D-fructose 1,6-diphosphate		662801	100	activates
6.3.4.4	Aspergillus nidulans	NH4+		692460	50	ASS expression is induced rather than repressed by NH4
6.3.4.4	Ocimum basilicum		(+)-Hydantocidin	1551	62517	
6.3.4.4	Leishmania donovani		(NH4)2SO4	1541	334	25 mM
6.3.4.4	Leishmania donovani		2'-GMP	1541	3749	
6.3.4.4	Abutilon theophrasti		2,4-dihydro-4-(beta-D-ribofuranosyl)-1,2,4(3H)-triazol-3-one	652965	5702	
6.3.4.4	Alopecurus myosuroides		2,4-dihydro-4-(beta-D-ribofuranosyl)-1,2,4(3H)-triazol-3-one	652965	5702	
6.3.4.4	Amaranthus retroflexus		2,4-dihydro-4-(beta-D-ribofuranosyl)-1,2,4(3H)-triazol-3-one	652965	5702	
6.3.4.4	Arabidopsis thaliana		2,4-dihydro-4-(beta-D-ribofuranosyl)-1,2,4(3H)-triazol-3-one	652965	5702	
6.3.4.4	Avena fatua		2,4-dihydro-4-(beta-D-ribofuranosyl)-1,2,4(3H)-triazol-3-one	652965	5702	
6.3.4.4	Echinochloa crus-galli		2,4-dihydro-4-(beta-D-ribofuranosyl)-1,2,4(3H)-triazol-3-one	652965	5702	
6.3.4.4	Helianthus annuus		2,4-dihydro-4-(beta-D-ribofuranosyl)-1,2,4(3H)-triazol-3-one	652965	5702	
6.3.4.4	Ipomoea hederacea		2,4-dihydro-4-(beta-D-ribofuranosyl)-1,2,4(3H)-triazol-3-one	652965	5702	
6.3.4.4	Setaria faberi		2,4-dihydro-4-(beta-D-ribofuranosyl)-1,2,4(3H)-triazol-3-one	652965	5702	
6.3.4.4	Azotobacter vinelandii		2-mercaptosuccinate	1544	4441	
6.3.4.4	Oryctolagus cuniculus		3',5'-cyclic GMP	1547	292	
6.3.4.4	Homo sapiens		3',5'-cyclic GMP	1548	292	
6.3.4.4	Leishmania donovani		3'-GMP	1541	2641	
6.3.4.4	Azotobacter vinelandii		4-Oxo-2-aminopentanoic acid	1538	5377	i.e. 2-oxonorvaline, poor
6.3.4.4	Oryctolagus cuniculus		5,5'-dithiobis(2-nitrobenzoate)	1549	196	
6.3.4.4	Saccharomyces cerevisiae		5-amino-4-(N-succinocarboxamide)imidazole ribonucleotide	650258	10915	
6.3.4.4	Saccharomyces cerevisiae		5-amino-4-carbamoyl-imidazole ribonucleotide	650258	77504	
6.3.4.4	Escherichia coli		6-(4-bromo-2,3-dioxobutyl)thioadenosine 5'-monophosphate	649897	35672	
6.3.4.4	Homo sapiens		6-mercaptopurine ribonucleotide	1548	13256	
6.3.4.4	Escherichia coli		6-mercaptopurine riboside 5'-phosphate	1537	13256	
6.3.4.4	Leishmania donovani		6-Thio-GMP	1541	7110	
6.3.4.4	Oryctolagus cuniculus		6-Thio-GMP	1547	7110	
6.3.4.4	Oryctolagus cuniculus		6-thio-IMP	1547	6108	
6.3.4.4	Leishmania donovani		8-Aza-7-deaza-GMP	1541	29068	
6.3.4.4	Oryctolagus cuniculus		8-Aza-7-deaza-GMP	1547	29068	competitive with respect to GTP
6.3.4.4	Leishmania donovani		8-aza-GMP	1541	10463	
6.3.4.4	Oryctolagus cuniculus		8-aza-GMP	1547	10463	competitive with respect to GTP
6.3.4.4	Oryctolagus cuniculus		8-Aza-IMP	1547	29069	
6.3.4.4	Leishmania donovani		acyclo-GMP	1541	150	
6.3.4.4	Homo sapiens		adenosine 3',5'-AMP	1548	1321	
6.3.4.4	Escherichia coli		adenylosuccinate	1537	113171	
6.3.4.4	Homo sapiens		adenylosuccinate	1537	113171	
6.3.4.4	Rattus norvegicus		adenylosuccinate	1537, 1546	113171	
6.3.4.4	Homo sapiens		adenylosuccinate	1548	113171	competitive with respect to IMP
6.3.4.4	Oryctolagus cuniculus		adenylosuccinate	1537, 1549	113171	
6.3.4.4	Saccharomyces cerevisiae		adenylosuccinate	649670	113171	
6.3.4.4	Mus musculus		adenylosuccinate	652317	113171	feedback inhibition
6.3.4.4	Mus musculus		adenylosuccinate	652500	113171	
6.3.4.4	Plasmodium falciparum		adenylosuccinate	662801	113171	competitive versus IMP, non-competitive versus GTP and aspartate
6.3.4.4	Methanocaldococcus jannaschii		adenylosuccinate	726945	113171	competitive inhibitor of IMP, noncompetitive inhibitor of GTP and aspartate
6.3.4.4	Rattus norvegicus		ADP	1539	8	
6.3.4.4	Homo sapiens		ADP	1548	8	
6.3.4.4	Oryctolagus cuniculus		allopurinol nucleotide	1547	8324	
6.3.4.4	Azotobacter vinelandii		AMP	1544	9	
6.3.4.4	Rattus norvegicus		AMP	1539, 1545	9	
6.3.4.4	Homo sapiens		AMP	1548	9	competitive with respect to IMP
6.3.4.4	Oryctolagus cuniculus		AMP	1543, 1549	9	
6.3.4.4	Schizosaccharomyces pombe		AMP	1550	9	
6.3.4.4	Saccharomyces cerevisiae		AMP	649670	9	
6.3.4.4	Mus musculus		AMP	652317	9	feedback inhibition
6.3.4.4	Mus musculus		AMP	652500	9	inhibits the acidic isozyme competitively, weak inhibition of the basic isozyme noncompetitively
6.3.4.4	Plasmodium falciparum		AMP	662801	9	competitive versus IMP, non-competitive versus GTP and non-competitive versus aspartate
6.3.4.4	Methanocaldococcus jannaschii		AMP	726945	9	competitive with respect to IMP and noncompetitive with GTP and aspartate
6.3.4.4	Leishmania donovani		arabinosyl-GMP	1541	23544	
6.3.4.4	Oryctolagus cuniculus		arabinosyl-GMP	1547	23544	beta-D-arabinosyl-GMP, competitive with respect to GTP
6.3.4.4	Rattus norvegicus		argininosuccinate	1546	1106	
6.3.4.4	Oryctolagus cuniculus		argininosuccinate	1549	1106	
6.3.4.4	Oryctolagus cuniculus		arsenate	1549	222	
6.3.4.4	Saccharomyces cerevisiae		aspartate analogs	650258	77505	
6.3.4.4	Saccharomyces cerevisiae		ATP	649670	7	
6.3.4.4	Escherichia coli		beta,gamma-5'-Guanylylmethylene diphosphate	1537	13746	
6.3.4.4	Rattus norvegicus		Ca2+	1539	18	in presence of Mg2+
6.3.4.4	Rattus norvegicus		Carbamoylphosphate	1546	368	
6.3.4.4	Rattus norvegicus		Cd2+	1539	48	in presence of Mg2+
6.3.4.4	Homo sapiens		CDP	1548	188	
6.3.4.4	Azotobacter vinelandii		Cl-	1544	134	
6.3.4.4	Saccharomyces cerevisiae		Cl-	649670	134	weak inhibitor
6.3.4.4	Azotobacter vinelandii		Cl3CCO2-	1544	7422	
6.3.4.4	Homo sapiens		CMP	1548	94	
6.3.4.4	Rattus norvegicus		Cu2+	1539	28	in presence of Mg2+
6.3.4.4	Plasmodium falciparum		Cu2+	727078	28	complete loss in activity within 4 h at 0.5 mM
6.3.4.4	Azotobacter vinelandii		cyanoalanine	1538	2822	poor
6.3.4.4	Leishmania donovani		cyclic GMP	1541	292	
6.3.4.4	Azotobacter vinelandii		cysteine	1538	70	poor
6.3.4.4	Azotobacter vinelandii		cysteine sulfonate	1538	2703	poor
6.3.4.4	Methanocaldococcus jannaschii		D-fructose 1,6 bisphosphate	726945	100	competitive with IMP and noncompetitive against GTP
6.3.4.4	Mus musculus		D-fructose 1,6-bisphosphate	652500	100	inhibits both isozymes competitively
6.3.4.4	Homo sapiens		dAMP	1548	575	
6.3.4.4	Homo sapiens		dCMP	1548	376	
6.3.4.4	Homo sapiens		dGDP	1548	863	
6.3.4.4	Leishmania donovani		dGMP	1541	587	2'-dGMP
6.3.4.4	Oryctolagus cuniculus		dGMP	1547	587	2'-dGMP
6.3.4.4	Homo sapiens		dGMP	1548	587	
6.3.4.4	Rattus norvegicus		dGTP	1539	194	
6.3.4.4	Dictyostelium discoideum		Formycin B monophosphate	1536	63750	
6.3.4.4	Rattus norvegicus		fructose 1,6-diphosphate	1537	100	basic type M isozym more strongly inhibited than acidic type L isozym
6.3.4.4	Oryctolagus cuniculus		fructose 1,6-diphosphate	1537, 1543	100	
6.3.4.4	Azotobacter vinelandii		fumarate	1544	156	
6.3.4.4	Escherichia coli		fumarate	652356	156	
6.3.4.4	Homo sapiens		GDP	1537	49	
6.3.4.4	Rattus norvegicus		GDP	1537, 1539	49	
6.3.4.4	Homo sapiens		GDP	1548	49	competitive with respect to GTP
6.3.4.4	Oryctolagus cuniculus		GDP	1537, 1543, 1549	49	
6.3.4.4	Escherichia coli		GDP	1537, 1557	49	
6.3.4.4	Mus musculus		GDP	652500	49	
6.3.4.4	Plasmodium falciparum		GDP	662801	49	uncompetitive versus IMP, competitive versus GTP and non-competitive versus aspartate
6.3.4.4	Methanocaldococcus jannaschii		GDP	726945	49	competitive inhibitor of GTP, noncompetitive inhibitor with IMP and aspartate
6.3.4.4	Leishmania donovani		GMP	1541	150	and analogs
6.3.4.4	Rattus norvegicus		GMP	1539, 1545	150	
6.3.4.4	Oryctolagus cuniculus		GMP	1547	150	
6.3.4.4	Homo sapiens		GMP	1548	150	competitive with respect to GTP
6.3.4.4	Schizosaccharomyces pombe		GMP	1550	150	
6.3.4.4	Saccharomyces cerevisiae		GMP	649670	150	potent inhibitor, competitive inhibition towards IMP
6.3.4.4	Mus musculus		GMP	652500	150	
6.3.4.4	Plasmodium falciparum		GMP	662801	150	uncompetitive versus IMP, competitive versus GTP and non-competitive versus aspartate
6.3.4.4	Methanocaldococcus jannaschii		GMP	726945	150	competitive with respect to GTP and noncompetitive with IMP and aspartate
6.3.4.4	Rattus norvegicus		guanosine	1539	256	
6.3.4.4	Dictyostelium discoideum		guanosine 5'-(beta,gamma-imino)triphosphate	1536	2383	
6.3.4.4	Escherichia coli		guanosine 5'-diphosphate	651925	49	
6.3.4.4	Escherichia coli		Guanosine 5'-diphosphate-3'-diphosphate	1542	2614	competitive with respect to GTP and noncompetitive with respect to L-Asp and IMP
6.3.4.4	Escherichia coli		Guanosine 5'-O-[S-(4-bromo-2,3-dioxobutyl)thio]phosphate	1555	64618	
6.3.4.4	Dictyostelium discoideum		Hadacidin	1536	2290	5 mM, 100% inhibition
6.3.4.4	Azotobacter vinelandii		Hadacidin	1537	2290	
6.3.4.4	Rattus norvegicus		Hadacidin	1537, 1539	2290	
6.3.4.4	Homo sapiens		Hadacidin	649264	2290	
6.3.4.4	Plasmodium falciparum		Hadacidin	652929	2290	
6.3.4.4	Plasmodium falciparum		Hadacidin	662801	2290	uncompetitive versus IMP and GTP, competitive versus aspartate
6.3.4.4	Escherichia coli		Hadacidin	1537, 1557, 1558, 649264, 649423, 651925, 652347, 672068	2290	
6.3.4.4	Mus musculus		Hadacidin	652317, 672068	2290	
6.3.4.4	Azotobacter vinelandii		HCO2-	1544	114	
6.3.4.4	Rattus norvegicus		Hg2+	1539	31	reversed by addition of DTT
6.3.4.4	Azotobacter vinelandii		homocysteine	1538	260	poor
6.3.4.4	Arabidopsis thaliana		Hydantocidin 5'-phosphate	1571	29401	
6.3.4.4	Zea mays		Hydantocidin 5'-phosphate	1571	29401	
6.3.4.4	Saccharomyces cerevisiae		hydroxylamine	650258	80	
6.3.4.4	Azotobacter vinelandii		I-	1544	422	
6.3.4.4	Rattus norvegicus		IDP	1539	372	
6.3.4.4	Homo sapiens		IDP	1548	372	
6.3.4.4	Escherichia coli		IMP	1557	206	
6.3.4.4	Mus musculus		IMP	652500	206	competitive inhibition of the acidic isozyme, noncompetitive of the basic isozyme
6.3.4.4	Methanocaldococcus jannaschii		IMP	726945	206	inhibits the enzyme activity at subsaturating GTP concentrations
6.3.4.4	Leishmania donovani		KCl	1541	74	75 mM
6.3.4.4	Azotobacter vinelandii		Maleate	1544	474	
6.3.4.4	Escherichia coli		Maleate	652356	474	
6.3.4.4	Azotobacter vinelandii		methionine sulfone	1538	6196	poor
6.3.4.4	Rattus norvegicus		Mn2+	1539	26	in presence of Mg2+
6.3.4.4	Azotobacter vinelandii		more	1537		overview
6.3.4.4	Bacillus subtilis		more	1537		overview
6.3.4.4	Escherichia coli		more	1537		overview
6.3.4.4	Gallus gallus		more	1537		overview
6.3.4.4	Homo sapiens		more	1537		overview
6.3.4.4	Leishmania donovani		more	1537		overview
6.3.4.4	Oryctolagus cuniculus		more	1537		overview
6.3.4.4	Rattus norvegicus		more	1537		overview
6.3.4.4	Schizosaccharomyces pombe		more	1537		overview
6.3.4.4	Sus scrofa		more	1537		overview
6.3.4.4	Triticum aestivum		more	1537		overview
6.3.4.4	Trypanosoma cruzi		more	1537		overview
6.3.4.4	Escherichia coli		more	1557		hydantocidin 5'-phosphate, GDP, HPO42-, and Mg2+ may represent a set of synergistic inhibitors even more effective than the combination of IMP, GDP, NO3-, and Mg2+
6.3.4.4	Saccharomyces cerevisiae		more	649670		negligible inhibition by adenine nucleotides
6.3.4.4	Escherichia coli		more	689055		GMP is not a strong inhibitor of AMPsS at physiological concentrations
6.3.4.4	Plasmodium falciparum		more	727078		not inhibited Mn2+
6.3.4.4	Dictyostelium discoideum		N-(Thiocarboxy)-L-aspartic anhydride	1536	64957	5 mM, 27.5% inhibition
6.3.4.4	Arabidopsis thaliana		N-Acetyl-5'-phosphohydantocidin	1571	29524	
6.3.4.4	Zea mays		N-Acetyl-5'-phosphohydantocidin	1571	29524	
6.3.4.4	Dictyostelium discoideum		N-Acetyl-N-hydroxyglycine	1536	64992	5 mM, 72.9% inhibition
6.3.4.4	Dictyostelium discoideum		N-acetylglycine	1536	3577	5 mM, 51.2% inhibition
6.3.4.4	Dictyostelium discoideum		N-benzoylglycine	1536	913	5 mM, 6% inhibition
6.3.4.4	Methanocaldococcus jannaschii		N-formyl-N-hydroxyglycine	726945		i.e. hadacidin. competitive inhibitor of aspartate, showed uncompetitive inhibition with IMP and GTP
6.3.4.4	Dictyostelium discoideum		N-Formylglycine	1536	29561	5 mM, 61.1% inhibition
6.3.4.4	Azotobacter vinelandii		N-Hydroxyaspartate	1538	65048	poor
6.3.4.4	Dictyostelium discoideum		N-Hydroxyglycine	1536	29568	5 mM, 49.3% inhibition
6.3.4.4	Azotobacter vinelandii		N-methylaspartate	1538	21834	poor
6.3.4.4	Azotobacter vinelandii		NO2-	1544	155	
6.3.4.4	Azotobacter vinelandii		NO3-	1544	263	
6.3.4.4	Escherichia coli		NO3-	1557	263	
6.3.4.4	Rattus norvegicus		Nucleotides	1537		acidic type L isozyme more strongly inhibited than basic type M isozyme
6.3.4.4	Saccharomyces cerevisiae		oligonucleotides	1570	1365	inhibition by single-stranded autonomously replicating sequences, highly specific inhibition by a 44-base DNA oligonucleotide carrying the autonomously replicating sequences core consensus sequence
6.3.4.4	Azotobacter vinelandii		oxaloacetate	1544	53	
6.3.4.4	Rattus norvegicus		Pb2+	1539	132	in presence of Mg2+
6.3.4.4	Rattus norvegicus		PCMB	1539, 1546	40	
6.3.4.4	Escherichia coli		Phenylglyoxal	1560	258	GTP or IMP partially protect
6.3.4.4	Azotobacter vinelandii		phosphate	1544	12	
6.3.4.4	Rattus norvegicus		phosphate	1546	12	
6.3.4.4	Oryctolagus cuniculus		phosphate	1549	12	
6.3.4.4	Plasmodium falciparum		phosphate	714324	12	competitive with aspartate
6.3.4.4	Methanocaldococcus jannaschii		phosphate	726945	12	potent inhibitor, biphasic inhibition, competitive with IMP and noncompetitive with GTP
6.3.4.4	Leishmania donovani		phosphoenolpyruvate	1541	47	
6.3.4.4	Azotobacter vinelandii		SCN-	1544	790	i.e. thiocyanate
6.3.4.4	Azotobacter vinelandii		SO32-	1544	86	
6.3.4.4	Rattus norvegicus		SO42-	1546	148	
6.3.4.4	Oryctolagus cuniculus		SO42-	1549	148	
6.3.4.4	Azotobacter vinelandii		succinate	1537, 1544	54	
6.3.4.4	Rattus norvegicus		succinate	1537, 1546	54	
6.3.4.4	Homo sapiens		succinate	1537, 1548	54	
6.3.4.4	Escherichia coli		succinate	649423	54	poor inhibitor
6.3.4.4	Escherichia coli		succinate	1537, 652356	54	
6.3.4.4	Homo sapiens		TDP	1548	449	
6.3.4.4	Homo sapiens		TMP	1548	518	
6.3.4.4	Homo sapiens		UDP	1548	24	
6.3.4.4	Homo sapiens		UMP	1548	127	
6.3.4.4	Rattus norvegicus		XMP	1539	772	
6.3.4.4	Oryctolagus cuniculus		XMP	1547	772	
6.3.4.4	Homo sapiens		XMP	1548	772	competitive with respect to IMP
6.3.4.4	Rattus norvegicus		Zn2+	1539	19	in presence of Mg2+
3.2.2.9	Arabidopsis thaliana	5'-methylthioadenosine		716534	335	enzyme activity is induced by 5'-methylthioadenosine
3.2.2.9	Escherichia coli		(+/-)-cis-1-[(9-deazaadenin-9-yl)methyl]-4-ethyl-3-hydroxypyrrolidine	715849	111972	
3.2.2.9	Escherichia coli		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(1H-1,2,3-triazol-4-yl)pyrrolidine	715849	111968	
3.2.2.9	Escherichia coli		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(penta-3-yl)pyrrolidine	715849	111963	
3.2.2.9	Escherichia coli		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-isobutylpyrrolidine	715849	111962	
3.2.2.9	Escherichia coli		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-phenylpyrrolidine	715849	112559	
3.2.2.9	Escherichia coli		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-vinylpyrrolidine	715849	112560	
3.2.2.9	Escherichia coli		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-4-ethynyl-3-hydroxypyrrolidine	715849	111967	
3.2.2.9	Escherichia coli		(+/-)-trans-4-(1-benzyl-1H-1,2,3-triazol-4-yl)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111969	
3.2.2.9	Escherichia coli		(+/-)-trans-4-(cyclohexylmethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111965	
3.2.2.9	Escherichia coli		(+/-)-trans-4-allyl-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111966	
3.2.2.9	Escherichia coli		(+/-)-trans-4-butyl-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111961	
3.2.2.9	Escherichia coli		(+/-)-trans-4-cyclopentyl-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	112558	
3.2.2.9	Escherichia coli		(+/-)-trans-4-cyclopropyl-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111964	
3.2.2.9	Escherichia coli		(+/-)-trans-4-[3-(benzylthio)propyl]-1-[(9-deazaadenin-9-yl)-methyl]-3-hydroxypyrrolidine	715849	111970	
3.2.2.9	Escherichia coli		(+/-)trans-1-[(9-deazaadenin-9-yl)methyl]-4-ethyl-3-hydroxypyrrolidine	715849	111971	
3.2.2.9	Escherichia coli		(1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-(3-methylphenylthio)-D-ribitol	669334	23873	
3.2.2.9	Escherichia coli		(1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-(4-methylphenylthio)-D-ribitol	669334	23872	
3.2.2.9	Escherichia coli		(1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol	727159	37178	
3.2.2.9	Neisseria meningitidis		(1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol	727159	37178	
3.2.2.9	Escherichia coli		(1S)-5-(4-chlorophenylthio)-1-(9-deaza-adenin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol	669334	23871	
3.2.2.9	Escherichia coli		(2R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-(methylsulfanyl)propan-1-ol	727159	111510	
3.2.2.9	Neisseria meningitidis		(2R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-(methylsulfanyl)propan-1-ol	727159	111510	
3.2.2.9	Escherichia coli		(2R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-[(hydroxymethyl)sulfanyl]propan-1-ol	727159	111288	
3.2.2.9	Escherichia coli		(2R,3R)-2-([[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl](methyl)amino]methyl)-4-(methylsulfanyl)butane-1,3-diol	727159	111299	
3.2.2.9	Neisseria meningitidis		(2R,3R)-2-([[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl](methyl)amino]methyl)-4-(methylsulfanyl)butane-1,3-diol	727159	111299	
3.2.2.9	Escherichia coli		(2R,3R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111293	
3.2.2.9	Neisseria meningitidis		(2R,3R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111293	
3.2.2.9	Escherichia coli		(2R,3S)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111291	
3.2.2.9	Neisseria meningitidis		(2R,3S)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111291	
3.2.2.9	Escherichia coli		(2R,3S)-4-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl](methyl)amino]-3-[(methylsulfanyl)methyl]butane-1,2-diol	727159	111298	
3.2.2.9	Neisseria meningitidis		(2R,3S)-4-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl](methyl)amino]-3-[(methylsulfanyl)methyl]butane-1,2-diol	727159	111298	
3.2.2.9	Escherichia coli		(2S)-1-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-(methylsulfanyl)propan-2-ol	727159	111296	
3.2.2.9	Neisseria meningitidis		(2S)-1-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-(methylsulfanyl)propan-2-ol	727159	111296	
3.2.2.9	Escherichia coli		(2S)-2-[[(1S)-1-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-2-hydroxyethyl]amino]-3-(methylsulfanyl)propan-1-ol	727159	111301	
3.2.2.9	Neisseria meningitidis		(2S)-2-[[(1S)-1-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-2-hydroxyethyl]amino]-3-(methylsulfanyl)propan-1-ol	727159	111301	
3.2.2.9	Escherichia coli		(2S)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-[(hydroxymethyl)sulfanyl]propan-1-ol	727159	111289	
3.2.2.9	Escherichia coli		(2S,3R)-1-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl](methyl)amino]-4-(methylsulfanyl)butane-2,3-diol	727159	111312	
3.2.2.9	Neisseria meningitidis		(2S,3R)-1-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl](methyl)amino]-4-(methylsulfanyl)butane-2,3-diol	727159	111312	
3.2.2.9	Escherichia coli		(2S,3R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111292	
3.2.2.9	Neisseria meningitidis		(2S,3R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111292	
3.2.2.9	Escherichia coli		(2S,3R)-N-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-3,4-dihydroxy-2-[(methylsulfanyl)methyl]butan-1-aminium trifluoroacetate	727159	111297	
3.2.2.9	Neisseria meningitidis		(2S,3R)-N-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-3,4-dihydroxy-2-[(methylsulfanyl)methyl]butan-1-aminium trifluoroacetate	727159	111297	
3.2.2.9	Escherichia coli		(2S,3S)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111294	
3.2.2.9	Neisseria meningitidis		(2S,3S)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111294	
3.2.2.9	Escherichia coli		(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine	669334	2436	
3.2.2.9	Escherichia coli		(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-4-ethyl-3-hydroxypyrrolidine	715849	111971	
3.2.2.9	Escherichia coli		(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]3-hydroxy-4-methylthiomethylpyrrolidine	727159	113052	
3.2.2.9	Neisseria meningitidis		(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]3-hydroxy-4-methylthiomethylpyrrolidine	727159	113052	
3.2.2.9	Escherichia coli		(3R,4S)-4-(1-butylthiomethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxypyrrolidine	727674	41502	
3.2.2.9	Escherichia coli		(3R,4S)-4-(4-chlorophenyl-thiomethyl)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	669334	3968	potential antibiotic to interfere with the metabolic pathways involved in methylation, polyamine biosynthesis, methionine recycling, and quorum sensing pathways
3.2.2.9	Escherichia coli		(3R,4S)-4-(benzylthiomethyl)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	669334		
3.2.2.9	Borrelia burgdorferi		(3R,4S)-4-(benzylthiomethyl)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	698517		complete inhibition at 0.1 mM
3.2.2.9	Escherichia coli		(3R,4S)-4-butyl-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111961	
3.2.2.9	Escherichia coli		(3R,4S)-butylthio-5'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin	715849	6906	
3.2.2.9	Escherichia coli		(3R,4S)-ethylthio-5'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin	715849	111769	
3.2.2.9	Escherichia coli		(3R,4S)-methylthio-5'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin	715849	2436	
3.2.2.9	Escherichia coli		(5'R)-cycloMethylthioadenosine	171858		competitive inhibition
3.2.2.9	Escherichia coli		(p-bromophenyl)thioadenosine	171857	68395	
3.2.2.9	Escherichia coli		(p-fluorophenyl)thioadenosine	171857	68396	
3.2.2.9	Escherichia coli		2',3'-didehydromethylthioadenosine	171858	68461	competitive inhibition
3.2.2.9	Escherichia coli		2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-2-[(methylsulfanyl)methyl]propane-1,3-diol	727159	111295	
3.2.2.9	Neisseria meningitidis		2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-2-[(methylsulfanyl)methyl]propane-1,3-diol	727159	111295	
3.2.2.9	Escherichia coli		2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-(methylsulfanyl)propan-1-ol	727159	111290	
3.2.2.9	Neisseria meningitidis		2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-(methylsulfanyl)propan-1-ol	727159	111290	
3.2.2.9	Escherichia coli		3'-deoxy-methylthioadenosine	171858	68511	competitive inhibition
3.2.2.9	Escherichia coli		4-chlorophenylthio-4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin-A	678158	3968	
3.2.2.9	Streptococcus pneumoniae		4-chlorophenylthio-4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin-A	678158	3968	
3.2.2.9	Escherichia coli		5'-(4-aminophenyl)thioadenosine	171857		
3.2.2.9	Escherichia coli		5'-(4-bromophenyl)thioadenosine	171857		moderate inhibitor
3.2.2.9	Escherichia coli		5'-(4-chlorophenyl)thioadenosine	171857		
3.2.2.9	Escherichia coli		5'-(4-fluorophenyl)thioadenosine	171857		moderate inhibitor
3.2.2.9	Escherichia coli		5'-(4-iodophenyl)thioadenosine	171857		
3.2.2.9	Escherichia coli		5'-(4-nitrophenyl)thioadenosine	171857		most potent inhibitor
3.2.2.9	Escherichia coli		5'-(p-nitrophenyl)thioadenosine	171857	9868	most potent inhibitor
3.2.2.9	Vibrio cholerae		5'-butylthio-DADMe-ImmucillinA	700355	6906	potent MTAN inhibitor, disrupting autoinducer production in a dose-dependent manner without affecting growth. Despite having a 3fold lower affinity with purified MTAN, 5'-butylthio-DADMe-ImmucillinA inhibits cellular MTAN activity 5fold better than its methylthio- and ethylthio-counterparts, significant diffusion barrier
3.2.2.9	Escherichia coli		5'-butylthioadenosine	171857	23242	
3.2.2.9	Escherichia coli		5'-Chloroadenosine	171857	10438	
3.2.2.9	Escherichia coli		5'-Chloroformycin	171854	7097	; powerful inhibitor
3.2.2.9	Escherichia coli		5'-Chloroformycin	171857	7097	competitive inhibition
3.2.2.9	Escherichia coli		5'-dimethylthioadenosine	171857	12784	
3.2.2.9	Vibrio cholerae		5'-ethylthio-DADMe-ImmucillinA	700355	111769	potent MTAN inhibitor, disrupting autoinducer production in a dose-dependent manner without affecting growth
3.2.2.9	Escherichia coli		5'-Ethylthioadenosine	171851	3126	competitive inhibition
3.2.2.9	Escherichia coli		5'-Ethylthioadenosine	171857	3126	
3.2.2.9	Escherichia coli		5'-isobutylthio-3-deaza-adenosine	171854	68570	poor inhibitor
3.2.2.9	Escherichia coli		5'-isobutylthioadenosine	171857	7098	
3.2.2.9	Escherichia coli		5'-Isobutylthioinosine	171854	28963	
3.2.2.9	Escherichia coli		5'-Isopropylthioadenosine	171857	28964	
3.2.2.9	Escherichia coli		5'-Methylselenoadenosine	171857	63548	
3.2.2.9	Escherichia coli		5'-methylthio-3-deaza-adenosine	171854	113051	poor inhibitor
3.2.2.9	Vibrio cholerae		5'-methylthio-DADMe-ImmucillinA	700355	2436	potent MTAN inhibitor, disrupting autoinducer production in a dose-dependent manner without affecting growth
3.2.2.9	Escherichia coli		5'-methylthioadenosine	171857	335	
3.2.2.9	Escherichia coli		5'-Methylthioformycin	171854	28965	; powerful inhibitor
3.2.2.9	Escherichia coli		5'-Methylthioformycin	171857	28965	competitive inhibition
3.2.2.9	Escherichia coli		5'-methylthioinosine	171857	6097	
3.2.2.9	Escherichia coli		5'-methylthiotubercidin	171854	3249	; powerful inhibitor
3.2.2.9	Escherichia coli		5'-methylthiotubercidin	171857, 656196	3249	
3.2.2.9	Escherichia coli		5'-n-butylthioinosine	171854	68572	
3.2.2.9	Escherichia coli		5'-n-Propylthioadenosine	171851	13228	competitive inhibition
3.2.2.9	Borrelia burgdorferi		5'-p-aminophenylthioadenosine	698517	9817	Pfs protein shows 45% relative activity in the presence of 0.1 mM 5'-p-aminophenylthioadenosine, Bgp protein shows 20% relative activity in the presence of 0.1 mM 5'-p-aminophenylthioadenosine
3.2.2.9	Borrelia burgdorferi		5'-p-nitrophenylthioadenosine	698517	9868	
3.2.2.9	Borrelia burgdorferi		5'-p-nitrophenythioadenosine	698517	9868	Pfs protein shows 0.6% relative activity in the presence of 0.1 mM 5'-p-aminophenylthioadenosine, Bgp protein shows 5% relative activity in the presence of 0.1 mM 5'-p-aminophenylthioadenosine
3.2.2.9	Escherichia coli		5'-phenylthioadenosine	171857	13893	; moderate inhibitor
3.2.2.9	Escherichia coli		5'-propylthioadenosine	171857	13228	
3.2.2.9	Escherichia coli		5'-purinothioadenosine	171857		
3.2.2.9	Escherichia coli		adenine	171854	136	poor inhibitor
3.2.2.9	Escherichia coli		adenine	171851, 171857	136	
3.2.2.9	Escherichia coli		adenine	171859	136	recombinant MTA/SAH'ase (rMTAN)
3.2.2.9	Escherichia coli		adenosine	171857	116	
3.2.2.9	Vibrio cholerae		benzylthio-immucillin A	700355	52224	
3.2.2.9	Vibrio cholerae		butylthio-4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin-A	700355	111768	picomolar inhibitor of MTAN
3.2.2.9	Escherichia coli		carbocyclic 5'-methylthioadenosine	171857		
3.2.2.9	Vibrio cholerae		ethylthio-4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin-A	700355	4685	picomolar inhibitor of MTAN
3.2.2.9	Vibrio cholerae		ethylthio-immucillin A	700355	6752	
3.2.2.9	Escherichia coli		ethylthio-immucillin-A	678158	6752	
3.2.2.9	Streptococcus pneumoniae		ethylthio-immucillin-A	678158	6752	
3.2.2.9	Escherichia coli		Formycin A	171857, 656196	1462	
3.2.2.9	Borrelia burgdorferi		Formycin A	698517	1462	complete inhibition at 0.1 mM
3.2.2.9	Escherichia coli		methylthio-4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin-A	678158	2436	
3.2.2.9	Streptococcus pneumoniae		methylthio-4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin-A	678158	2436	
3.2.2.9	Vibrio cholerae		methylthio-4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin-A	700355	2436	picomolar inhibitor of MTAN
3.2.2.9	Staphylococcus aureus		methylthio-DADMe-immucillin-A	727044		i.e. (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol
3.2.2.9	Vibrio cholerae		methylthio-immucillin A	700355	6749	
3.2.2.9	Escherichia coli		methylthio-immucillin-A	678158	6749	weak
3.2.2.9	Streptococcus pneumoniae		methylthio-immucillin-A	678158	6749	weak
3.2.2.9	Escherichia coli		more	171854		not inhibited by 5'-methylthioinosine, S-inosyl-L-homocysteine, S-guanosyl-L-homocysteine, S-N6-methyl-3-deaza-adenosyl-L-homocysteine, S-adenosyl-L-homocysteine dialdehyde, acyclic adenosyl-L-homocysteine, S-cytidylhomocysteine, hypoxanthine, guanine, and AMP
3.2.2.9	Escherichia coli		more	171857		not inhibited by 5-methylthioribose, 5-trifluoromethylthioribose, 5-(4-iodophenyl)thioribose, adenosine, erythro-9-(2-hydroxy-3-nonyl)adenine, and inosine
3.2.2.9	Escherichia coli		more	667625		the transition state structure of the enzyme predictes that transition state analogue inhibitors resembling 5'-methylthioadenosine with riboxacarbenium features in the ribosyl group and elevated pKa values in the leaving group adenine analogue would be powerful inhibitors
3.2.2.9	Vibrio cholerae		p-chlorophenylthio-immucillin A	700355	52225	
3.2.2.9	Escherichia coli		p-tolylthio-immucillin-A	678158	6751	
3.2.2.9	Streptococcus pneumoniae		p-tolylthio-immucillin-A	678158	6751	
3.2.2.9	Escherichia coli		phenylthio-immucillin-A	678158	6750	
3.2.2.9	Streptococcus pneumoniae		phenylthio-immucillin-A	678158	6750	
3.2.2.9	Escherichia coli		S-8-aza-adenosyl-L-homocysteine	171854	8469	powerful inhibitor
3.2.2.9	Escherichia coli		S-8-aza-adenosylhomocysteine	171854	8469	
3.2.2.9	Escherichia coli		S-adenosyl-L-homocysteine	171857	34	; moderate inhibitor
3.2.2.9	Escherichia coli		S-adenosyl-L-homocysteine sulfoxide	171854	6228	poor inhibitor
3.2.2.9	Escherichia coli		S-adenosylhomocysteine	171851	34	competitive inhibition
3.2.2.9	Escherichia coli		S-Formycinylhomocysteine	171854		; powerful inhibitor
3.2.2.9	Escherichia coli		S-Formycinylhomocysteine	171857		competitive inhibition
3.2.2.9	Escherichia coli		S-N6-dimethyl-3-deaza-adenosyl-L-homocysteine	171854	29717	poor inhibitor
3.2.2.9	Escherichia coli		S-Tubercidinylhomocysteine	171854	10675	; powerful inhibitor
3.2.2.9	Escherichia coli		sinefungin	171854	535	poor inhibitor
3.2.2.9	Helicobacter pylori		Tris	716856	272	weak inhibitor; weak inhibitor, about 20% residual activity at 250 mM
2.3.1.46	Escherichia coli		D-methionine	487045	743	slight feed-back inhibition
2.3.1.46	Salmonella enterica subsp. enterica serovar Typhimurium		D-methionine	487045	743	slight feed-back inhibition
2.3.1.46	Escherichia coli		diethyldicarbonate	672232	265	inactivation, pH dependence, overview
2.3.1.46	Escherichia coli		Hydroxyethylclavam	487044	64660	oxygen analogue beta-lactam antibiotic
2.3.1.46	Escherichia coli		iodoacetamide	487046	63	inhibition is pH-dependent
2.3.1.46	Escherichia coli		iodoacetamide	672232	63	inactivation, pH dependence, overview
2.3.1.46	Escherichia coli		L-methionine	487044, 487045	83	feed-back inhibition
2.3.1.46	Salmonella enterica subsp. enterica serovar Typhimurium		L-methionine	487045	83	feed-back inhibition
2.3.1.46	Escherichia coli		L-methionine	671413	83	feedback inhibition
2.3.1.46	Escherichia coli		more	487044		overview, competitive antagonism of peptides against enzyme inhibition by valclavam; overview, inhibition of several fungi and procaryotes by valclavam
2.3.1.46	Escherichia coli		S-adenosyl-L-methionine	487044	22	feed-back inhibition
2.3.1.46	Escherichia coli		S-adenosyl-L-methionine	671413	22	feedback inhibition
2.3.1.46	Escherichia coli		Valclavam	487044	20644	oxygen analogue beta-lactam antibiotic, complete inhibition at 0.2 mM
2.6.1.62	Mycobacterium tuberculosis		(R)-8-amino-7-oxononanoate	702483		binds both to the pyridoxal 5'-phosphate form and to the pyridoxamine 5'-phosphate form by forming specific hydrogen bonds with residue T309 and the phosphate group of the cofactor
2.6.1.62	Mycobacterium tuberculosis		(R)-8-amino-7-oxononanoic acid	702483	3994	potent inhibitor
2.6.1.62	Mycobacterium tuberculosis		3-(4-aminocyclopent-2-en-1-yl)propan-1-ol	728182	110553	
2.6.1.62	Mycobacterium tuberculosis		3-(cis-4-aminocyclohexa-2,5-dien-1-yl)propan-1-ol	673564	40736	suicide substrate, compound at 0.1 mg/l completely inhibits the growth of an Escherichia coli C268bioA mutant strain transformed with a plasmid expressing the Myobaterium tuberculosis bioA gene, coding for diaminopelargonic acid aminotransferase; suicide substrate, irreversible inhibition
2.6.1.62	Escherichia coli		7-amino-8-oxononanoate	637092	10459	2 mM
2.6.1.62	Escherichia coli		7-amino-8-oxononanoate	637094	10459	
2.6.1.62	Corynebacterium glutamicum		7-Keto-8-aminopelargonic acid	637090	1131	substrate inhibition above 0.1 mM
2.6.1.62	Corynebacterium glutamicum		7-Keto-8-aminopelargonic acid	637092	1131	
2.6.1.62	Escherichia coli		7-Keto-8-aminopelargonic acid	637092, 637094	1131	competitive with adenosyl-L-methionine
2.6.1.62	Escherichia coli		7-Keto-8-aminopelargonic acid	637090, 637095	1131	
2.6.1.62	Escherichia coli		8-Amino-7-oxononanoate	661047	1131	
2.6.1.62	Bacillus subtilis		8-Amino-7-oxononanoate	661370	1131	substrate inhibition above 0.08 mM
2.6.1.62	Mycobacterium tuberculosis		8-Amino-7-oxononanoate	673564	1131	; substrate inhibition
2.6.1.62	Mycobacterium tuberculosis		8-amino-7-oxooctanoate	702483	12762	potent inhibitor
2.6.1.62	Mycobacterium tuberculosis		8-amino-7-oxooctanoic acid	702483	12762	achiral analog of 8-amino-7-oxononanoate
2.6.1.62	Mycobacterium tuberculosis		8-amino-7-oxopelargonic acid	721279		; 
2.6.1.62	Escherichia coli		adenine	637092	136	8 mM
2.6.1.62	Escherichia coli		adenosine	637092	116	5 mM
2.6.1.62	Escherichia coli		adenosine	637094	116	
2.6.1.62	Mycobacterium tuberculosis		amiclenomycin	661047	11717	and analogues
2.6.1.62	Escherichia coli		amiclenomycin	663002	11717	
2.6.1.62	Mycobacterium tuberculosis		amiclenomycin	673564	11717	suicide substrate; suicide substrate, irreversible inhibition
2.6.1.62	Corynebacterium glutamicum		As5+	1335, 637090	29158	
2.6.1.62	Corynebacterium glutamicum		Ca2+	637090	18	
2.6.1.62	Escherichia coli		cis-amiclenomycin	661047	11717	and analogues, overview, irreversible inactivation, kinact. 0.4 min-1, little or no inhibition by the trans-compound, overview
2.6.1.62	Corynebacterium glutamicum		Co2+	1335	21	
2.6.1.62	Corynebacterium glutamicum		Co2+	637090	21	94% inhibition at 1 mM
2.6.1.62	Corynebacterium glutamicum		D-cycloserine	637090	689	
2.6.1.62	Corynebacterium glutamicum		DL-Penicillamine	637090	1829	
2.6.1.62	Corynebacterium glutamicum		HgCl2	1335	104	
2.6.1.62	Corynebacterium glutamicum		HgCl2	637090	104	100% inhibition at 1 mM
2.6.1.62	Corynebacterium glutamicum		hydroxylamine	1335	80	
2.6.1.62	Corynebacterium glutamicum		hydroxylamine	637090	80	100% inhibition at 1 mM
2.6.1.62	Corynebacterium glutamicum		iodoacetate	1335, 637090	87	
2.6.1.62	Corynebacterium glutamicum		Isoniazid	1335	674	
2.6.1.62	Corynebacterium glutamicum		Isoniazid	637090	674	94% inhibition at 1 mM
2.6.1.62	Corynebacterium glutamicum		KCN	637090	149	
2.6.1.62	Escherichia coli		more	660565		no inhibition by the (R,S)-diastereomer of S-adenosyl-L-methionine
2.6.1.62	Corynebacterium glutamicum		p-chloromercuribenzoate	1335	40	
2.6.1.62	Corynebacterium glutamicum		p-chloromercuribenzoate	637090	40	100% inhibition at 1 mM
2.6.1.62	Corynebacterium glutamicum		Pb2+	637090	132	
2.6.1.62	Corynebacterium glutamicum		phenylhydrazine	1335	333	
2.6.1.62	Corynebacterium glutamicum		phenylhydrazine	637090	333	100% inhibition at 1 mM
2.6.1.62	Escherichia coli		S-Adenosyl-L-(2-hydroxy-4-methylthio)butyric acid	637092	29725	2.5 mM
2.6.1.62	Escherichia coli		S-Adenosyl-L-(2-hydroxy-4-methylthio)butyric acid	637094	29725	
2.6.1.62	Escherichia coli		S-adenosyl-L-ethionine	637092	2861	2 mM
2.6.1.62	Escherichia coli		S-adenosyl-L-ethionine	637094	2861	
2.6.1.62	Escherichia coli		S-adenosyl-L-homocysteine	637092	34	5 mM
2.6.1.62	Escherichia coli		S-Inosyl-L-(2-hydroxy-4-methylthio)butyric acid	637092	30440	2 mM
2.6.1.62	Corynebacterium glutamicum		Semicarbazide	1335	322	
2.6.1.62	Corynebacterium glutamicum		Semicarbazide	637090	322	100% inhibition at 1 mM
2.3.1.47	Kocuria rosea	biotin		487051	135	stimulates
2.3.1.47	Pseudomonas fluorescens	biotin		487051	135	stimulates
2.3.1.47	Escherichia coli		(R)-8-amino-7-oxononanoic acid	702483	3994	no inhibition up to 15 microM with 94.6% ee (S)-enantiomer as substrate, beyond that strong inhibitor of both enzyme forms, binding to active site
2.3.1.47	Mycobacterium tuberculosis		(R)-8-amino-7-oxononanoic acid	702483	3994	no inhibition up to 15 microM with 94.6% ee (S)-enantiomer as substrate, beyond that strong inhibitor of both enzyme forms, binding to active site
2.3.1.47	Lysinibacillus sphaericus		1,10-phenanthroline	487052	58	to some extent
2.3.1.47	Arabidopsis thaliana		2,3-dichloronaphthalene-1,4-dione	719203	8828	
2.3.1.47	Arabidopsis thaliana		2-(furan-2-yl)-1H-benzimidazole	719203	61119	
2.3.1.47	Lysinibacillus sphaericus		2-amino-3-hydroxy-2-methylnonadioic acid	487054	32606	competitive, transition state analogue
2.3.1.47	Arabidopsis thaliana		2-[(1,1,2,2-tetrachloroethyl)sulfanyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione	719203	61138	
2.3.1.47	Arabidopsis thaliana		2-[(trichloromethyl)sulfanyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione	719203	20250	
2.3.1.47	Arabidopsis thaliana		4-(1H-inden-3-yl)naphthalene-1,2-dione	719203	61116	
2.3.1.47	Lysinibacillus sphaericus		4-carboxybutyl(1-amino-1-carboxyethyl)phosphonate	487054	32637	competitive, transition state analogue
2.3.1.47	Arabidopsis thaliana		5,10-dioxo-5,10-dihydronaphtho[2,3-b][1,4]dithiine-2,3-dicarbonitrile	719203	61141	
2.3.1.47	Arabidopsis thaliana		5,8-dihydronaphthalene-1,4-dione	719203	61117	
2.3.1.47	Arabidopsis thaliana		5,8-dihydroxynaphthalene-1,4-dione	719203	4032	
2.3.1.47	Arabidopsis thaliana		5-hydroxy-2-methylnaphthalene-1,4-dione	719203	1882	
2.3.1.47	Arabidopsis thaliana		5-hydroxynaphthalene-1,4-dione	719203	1018	
2.3.1.47	Lysinibacillus sphaericus		8-amino-7-oxo-8-phosphonononanoic acid	487054	32687	strong inhibition
2.3.1.47	Escherichia coli		8-Amino-7-oxononanoate	487047	1131	product inhibition in vivo
2.3.1.47	Mycobacterium tuberculosis		8-amino-7-oxooctanoic acid	702483	12762	achiral analog of substrate, strong inhibitor of both enzyme forms, binding to active site
2.3.1.47	Lysinibacillus sphaericus		Ag+	487052	71	
2.3.1.47	Bacillus subtilis		biotin	487051	135	
2.3.1.47	Lysinibacillus sphaericus		biotin	487051	135	
2.3.1.47	Lysinibacillus sphaericus		Cd2+	487052	48	weak
2.3.1.47	Lysinibacillus sphaericus		citrate	487052	125	to some extent
2.3.1.47	Lysinibacillus sphaericus		Co2+	487052	21	
2.3.1.47	Lysinibacillus sphaericus		Cu2+	487052	28	
2.3.1.47	Pseudomonas fluorescens		D-alanine	487051	151	
2.3.1.47	Lysinibacillus sphaericus		D-alanine	487051, 487052	151	
2.3.1.47	Lysinibacillus sphaericus		D-alanine	487054	151	competitive; Schiff base formation between D- or L-alanine and pyridoxal-5'-phophate in the active site
2.3.1.47	Lysinibacillus sphaericus		D-cycloserine	487052	689	
2.3.1.47	Lysinibacillus sphaericus		D-histidine	487051	2201	
2.3.1.47	Mycobacterium tuberculosis		D-KAPA	674626	1131	product inhibition
2.3.1.47	Lysinibacillus sphaericus		D-penicillamine	487052	1979	L-enantiomer not as effective
2.3.1.47	Alcaligenes faecalis		D/L-histidine	487051	4409	
2.3.1.47	Bacillus subtilis		D/L-histidine	487051	4409	
2.3.1.47	Citrobacter freundii		D/L-histidine	487051	4409	
2.3.1.47	Enterobacter aerogenes		D/L-histidine	487051	4409	
2.3.1.47	Enterobacter cloacae		D/L-histidine	487051	4409	
2.3.1.47	Erwinia aroidea		D/L-histidine	487051	4409	
2.3.1.47	Escherichia coli		D/L-histidine	487051	4409	
2.3.1.47	Kocuria rosea		D/L-histidine	487051	4409	
2.3.1.47	Pseudomonas fluorescens		D/L-histidine	487051	4409	
2.3.1.47	Lysinibacillus sphaericus		D/L-histidine	487051, 487052	4409	
2.3.1.47	Lysinibacillus sphaericus		diisopropyl fluorophosphate	487052	216	to some extent
2.3.1.47	Pseudomonas fluorescens		glycine	487051	68	
2.3.1.47	Lysinibacillus sphaericus		glycine	487051, 487052	68	
2.3.1.47	Lysinibacillus sphaericus		hydroxylamine	487052	80	
2.3.1.47	Lysinibacillus sphaericus		isoniazide	487052	674	to some extent
2.3.1.47	Escherichia coli		L-cysteine	487047, 487051	70	
2.3.1.47	Lysinibacillus sphaericus		L-cysteine	487051	70	
2.3.1.47	Pseudomonas fluorescens		L-cysteine	487051	70	
2.3.1.47	Lysinibacillus sphaericus		L-cysteine	487052	70	strong
2.3.1.47	Lysinibacillus sphaericus		L-histidine	487051	296	
2.3.1.47	Pseudomonas fluorescens		L-serine	487051	89	
2.3.1.47	Lysinibacillus sphaericus		L-serine	487051, 487052	89	
2.3.1.47	Arabidopsis thaliana		methyl 3-(5,6-dioxo-5,6-dihydronaphthalen-2-yl)propanoate	719203	61135	
2.3.1.47	Arabidopsis thaliana		methyl 3-[8-(1H-inden-3-yl)-5,6-dioxo-5,6-dihydronaphthalen-2-yl]propanoate	719203	61115	
2.3.1.47	Arabidopsis thaliana		methyl 3-[8-[(4-fluorophenyl)amino]-5,6-dioxo-5,6-dihydronaphthalen-2-yl]propanoate	719203	61137	
2.3.1.47	Arabidopsis thaliana		methyl 3-[8-[(4-methylphenyl)amino]-5,6-dioxo-5,6-dihydronaphthalen-2-yl]propanoate	719203	61136	
2.3.1.47	Lysinibacillus sphaericus		more	487052		no inhibition by HgCl2, EDTA, 2,2'-dipyridyl, oxalate, KCN, various amino acids
2.3.1.47	Lysinibacillus sphaericus		more	487054		inhibition mechanism; no inhibition by 8-amino-7-oxo-8-phosphonononanoic acid
2.3.1.47	Escherichia coli		more	487058		concentration above 10 mM of Ca2+, Mg2+, and Mn2+ cause slow precipitation of the enzyme
2.3.1.47	Mycobacterium tuberculosis		more	674626		no inhibition by D-alanine
2.3.1.47	Arabidopsis thaliana		N-[dichloro(fluoro)-l4-sulfanyl]-N',N'-dimethyl-N-phenylsulfuric diamide	719203	61139	
2.3.1.47	Arabidopsis thaliana		N-[dichloro(fluoromethyl)-lambda4-sulfanyl]-N',N'-dimethyl-N-(4-methylphenyl)sulfuric diamide	719203	61140	
2.3.1.47	Arabidopsis thaliana		naphthalene-1,2-dione	719203	1415	
2.3.1.47	Lysinibacillus sphaericus		Ni2+	487052	36	
2.3.1.47	Lysinibacillus sphaericus		phenylhydrazine	487052	333	
2.3.1.47	Lysinibacillus sphaericus		pyridoxal 5'-phosphate	487051	30	high concentrations
2.3.1.47	Pseudomonas fluorescens		Pyruvic acid	487051	29	
2.3.1.47	Lysinibacillus sphaericus		Semicarbazide	487052	322	
2.3.1.47	Escherichia coli		trifluoroalanine	676274	8342	binding structure, irreversible suicide inhibition of the enzyme, involves decarboxylative defluorination of the inhibitor-PLP aldimine followed by attack of the conjugated imine by the amino group of the active site lysine to afford a covalently bound difluorinated intermediate, which can subsequently undergo further HF losses and hydrolysis to afford a 2-(pyridoximine phosphate) acetoyl protein adduct
2.3.1.47	Arabidopsis thaliana		triphenyltin acetate	720623		herbicidal activity (foliar treatment) under greenhouse conditions
2.3.1.47	Lysinibacillus sphaericus		Zn2+	487052	19	weak
4.1.1.11	Escherichia coli	acetyl-CoA		726873	27	acetyl-CoA is required for activation
4.1.1.11	Escherichia coli	more		726592		role for Thr57 in the activation of the enzyme, while neither Tyr58 nor Tyr22 is required for the activation reaction, overview
4.1.1.11	Salmonella enterica	more		728234		no activation with the CoA-binding-deficient PanMG76L variant
4.1.1.11	Corynebacterium glutamicum	more		728327		the enzyme does not require activation by an endogenous PanM-like protein, incontrast to other species like Escherichia coli or Salmonella enterica
4.1.1.11	Salmonella enterica	PanM		728234		Salmonella enterica PanM, formerly YhhK, a Gcn5-like N-acetyltransferase, is necessary for pro-PanD maturation, both in vitro and in vivo. PanM-dependent pro-PanD maturation does not involve an acetyl transfer event. CoA binding to PanM is needed for in vivo activity, disruption of CoA binding prevents PanM from interacting with PanD. PanM lacks acetyltransferase activity but functions instead as an acetyl-coenzyme A (CoA) sensor, overview
4.1.1.11	Escherichia coli	PanZ		726873		analysis of the protein complex between Escherichia coli PanD and PanZ in vitro using isothermal titration calorimetry and mass spectrometry and thereby determine the stoichiometry and affinity of the components of this protein complex, high affinity 4:4 heterooctameric complex, overview. Non-covalent interaction between the acetyl group of acetyl-CoA and the PanD zymogen may be required to induce activation
4.1.1.11	Escherichia coli	PanZ		728266		PanD is activated by the putative acetyltransferase YhhK, termed PanZ. Activation of PanD both in vivo and in vitro is PanZ-dependent. PanZ binds to PanD. Gene panZ is conserved only in Escherichia coli-related enterobacterial species including Shigella, Salmonella, Klebsiella and Yersinia
4.1.1.11	Escherichia coli	Pyruvoyl group		3947, 3948	6287	1 mol of pyruvate is covalently bound per mol of enzyme
4.1.1.11	Escherichia coli	Pyruvoyl group		3949	6287	catalytic pyruvoyl groups at three active sites and an ester at the fourth. The ester is an intermediate in the autocatalytic self-processing leading to formation of the pyruvoyl group
4.1.1.11	Escherichia coli	Pyruvoyl group		3950	6287	contains 3 pyruvoyl groups per tetrameric enzyme
4.1.1.11	Escherichia coli	Pyruvoyl group		714741	6287	
4.1.1.11	Mycobacterium tuberculosis	Pyruvoyl group		714741	6287	
4.1.1.11	Salmonella enterica	YhhK		728327		or PanM, the protein interacts directly with PanD, such interactions accelerate pro-PanD maturation, analysis by yeast two hybrid system. One PanM monomer (14.5 kDa) interacts with one PanD tetramer (55.6 kDa)
4.1.1.11	Mycobacterium tuberculosis		(2S,3R,4S,5S)-2,3,4,6-tetrahydroxy-5-mercaptohexanal	728571, 728583		ZINC03871163
4.1.1.11	Mycobacterium tuberculosis		(2S,3S,4R,5R)tetrahydro-2H-pyran2,3,4,5-tetraol	728571		ZINC03606295
4.1.1.11	Mycobacterium tuberculosis		(2S,3S,4R,5S)2,5bis(hydroxymethyl)tetrahydrofuran-2,3,4-triol	728571		ZINC03830875
4.1.1.11	Mycobacterium tuberculosis		(2S,3S,4S,5R)-2(hydroxymethyl) tetrahydro-2H-pyran-2,3,4,5-tetraol	728571		ZINC03830878
4.1.1.11	Mycobacterium tuberculosis		(S)-5-acetoxy-4-methylpentanoat	728571		ZINC02036492
4.1.1.11	Mycobacterium tuberculosis		(S)-thiazolidin-3-ium-4-carboxylate	728571		ZINC00967474
4.1.1.11	Mycobacterium tuberculosis		1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one	728571		ZINC05177572
4.1.1.11	Mycobacterium tuberculosis		2,4-dihydroxypyrimidine-5-carboxylate	728583		ZINC00901606, moderate inhibition
4.1.1.11	Escherichia coli		2-(difluoromethyl)-L-aspartic acid	714741	112563	
4.1.1.11	Mycobacterium tuberculosis		2-(difluoromethyl)-L-aspartic acid	714741	112563	
4.1.1.11	Mycobacterium tuberculosis		3-amino-4-(propylamino)cyclobutane-1 2-dione	728571		LIGAND10436
4.1.1.11	Escherichia coli		beta-hydroxy-DL-Asp	3947, 3948	30090	
4.1.1.11	Escherichia coli		CuCl	3947, 3948	4403	10 mM, 88% inhibition
4.1.1.11	Escherichia coli		D-Ser	3947, 3948	401	
4.1.1.11	Mycobacterium tuberculosis		D-tagatose	728583	1621	ZINC03830878, weak inhibition
4.1.1.11	Mycobacterium tuberculosis		D-Tartrate	728583	3375	ZINC00895296, strong inhibition
4.1.1.11	Mycobacterium tuberculosis		DL-threo-beta-hydroxyaspartate	728583	6391	strong inhibition
4.1.1.11	Escherichia coli		hydroxylamine	3947, 3948	80	
4.1.1.11	Escherichia coli		KCl	3947, 3948	74	200 mM, 63% inhibition
4.1.1.11	Corynebacterium glutamicum		L-aspartate	727235	91	substrate inhibition
4.1.1.11	Escherichia coli		L-cysteic acid	3947, 3948	2703	
4.1.1.11	Mycobacterium tuberculosis		L-cysteic acid	728583	2703	strong inhibition
4.1.1.11	Escherichia coli		L-Glu	3947, 3948	38	
4.1.1.11	Mycobacterium tuberculosis		L-glutamate	728583	38	strong inhibition
4.1.1.11	Escherichia coli		L-Ser	3947, 3948	89	
4.1.1.11	Mycobacterium tuberculosis		L-serine	728583	89	weak inhibition
4.1.1.11	Mycobacterium tuberculosis		L-Tartrate	728583	1389	ZINC00895301, strong inhibition
4.1.1.11	Escherichia coli		more	714741		not inhibited by (2R,3R)-3-fluoroaspartic acid and (2R,3S)-3-fluoroaspartic acid
4.1.1.11	Mycobacterium tuberculosis		more	714741		not inhibited by (2R,3R)-3-fluoroaspartic acid and (2R,3S)-3-fluoroaspartic acid
4.1.1.11	Mycobacterium tuberculosis		more	728571		potential inhibitor molecule docking using the enzyme's crystal structure, overview
4.1.1.11	Mycobacterium tuberculosis		more	728583		no inhibition by D-serine, (4S)-1,3-thiazolidin-3-ium-4-carboxylate, alpha-D-arabinopyranose, and 1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one
4.1.1.11	Escherichia coli		NaBH4	3947, 3948	507	
4.1.1.11	Escherichia coli		oxaloacetate	3947, 3948	53	
4.1.1.11	Mycobacterium tuberculosis		oxaloacetate	728583	53	very strong inhibition
4.1.1.11	Escherichia coli		phenylhydrazine	3947, 3948	333	
4.1.1.11	Escherichia coli		succinate	3947, 3948	54	
4.1.1.11	Mycobacterium tuberculosis		succinate	728583	54	moderate inhibition
3.1.3.7	Schizosaccharomyces pombe	K+		651657	37	
3.1.3.7	Chlorella pyrenoidosa		5'-AMP	81102	9	
3.1.3.7	Chlorella pyrenoidosa		adenosine 5'-phosphosulfate	81102	354	slight
3.1.3.7	Chlorella pyrenoidosa		adenosine-3',5'-bisphosphate	81102	64	inhibition at high concentration
3.1.3.7	Zea mays		Ca2+	652120	18	; 
3.1.3.7	Saccharomyces cerevisiae		Ca2+	730884	18	competitive to Mg2+. Inhibition by Ca2+can be prevented by addition of Mg2+
3.1.3.7	Chlorella pyrenoidosa		Ca2+	81102	18	in presence of Mg2+
3.1.3.7	Oryza sativa		Ca2+	81105	18	
3.1.3.7	Chlorella pyrenoidosa		dithiothreitol	81102	42	slight
3.1.3.7	Homo sapiens		inositol 1,4-bisphosphate	81106	2842	
3.1.3.7	Mus musculus		inositol 1,4-bisphosphate	81106	2842	
3.1.3.7	Zea mays		K+	652120	37	
3.1.3.7	Homo sapiens		Li+	651264	142	
3.1.3.7	Schizosaccharomyces pombe		Li+	651657	142	
3.1.3.7	Zea mays		Li+	652120	142	; 
3.1.3.7	Saccharomyces cerevisiae		Li+	652888	142	mechanism of lithium inhibition
3.1.3.7	Arthrospira platensis		Li+	677661	142	
3.1.3.7	Debaryomyces hansenii		Li+	677833	142	
3.1.3.7	Mus musculus		Li+	694864	142	inhibited by lithium in vitro
3.1.3.7	Arabidopsis thaliana		Li+	81104	142	
3.1.3.7	Oryza sativa		Li+	81105	142	
3.1.3.7	Mus musculus		Li+	81106	142	
3.1.3.7	Saccharomyces cerevisiae		Li+	81108	142	
3.1.3.7	Solanum lycopersicum		Li+	81108	142	
3.1.3.7	Escherichia coli		LiCl	677696	654	
3.1.3.7	Escherichia coli		Mg2+	677696	25	activity is decreased to approximately 70% in the presence of 10 mM MgCl2
3.1.3.7	Schizosaccharomyces pombe		Na+	651657	55	
3.1.3.7	Zea mays		Na+	652120	55	
3.1.3.7	Arthrospira platensis		Na+	677661	55	
3.1.3.7	Debaryomyces hansenii		Na+	677833	55	
3.1.3.7	Chlorella pyrenoidosa		Na+	81102	55	slight
3.1.3.7	Arabidopsis thaliana		Na+	81104	55	
3.1.3.7	Oryza sativa		Na+	81105	55	
3.1.3.7	Saccharomyces cerevisiae		Na+	652888, 81108	55	
2.8.1.6	Escherichia coli	amino acid		645585	3318	one of the amino acids: Asn, Asp, Gln or Ser
2.8.1.6	Escherichia coli	asparagine		645594	231	required
2.8.1.6	Arabidopsis thaliana	D-fructose 1,6-bisphosphate		645610	100	enhances biotin formation
2.8.1.6	Lysinibacillus sphaericus	dithiothreitol		645582	42	
2.8.1.6	Escherichia coli	dithiothreitol		645593	42	potential sulfur donor
2.8.1.6	Escherichia coli	dithiothreitol		645595	42	
2.8.1.6	Escherichia coli	dithiothreitol		645609	42	10fold stimulation of cysteine desulfurase activity of the enzyme at 20 mM
2.8.1.6	Arabidopsis thaliana	dithiothreitol		645610	42	required
2.8.1.6	Escherichia coli	dithiothreitol		645613	42	required for formation of mixed [Fe-S] cluster state
2.8.1.6	Escherichia coli	Flavodoxin		645599		
2.8.1.6	Escherichia coli	flavodoxin reductase		645595		omission results in a 100fold decrease in activity
2.8.1.6	Escherichia coli	flavodoxin reductase		645599		
2.8.1.6	Escherichia coli	fructose 1,6-diphosphate		645593	100	
2.8.1.6	Lysinibacillus sphaericus	L-cysteine		645582	70	
2.8.1.6	Escherichia coli	L-cysteine		645585	70	required as sulfur donor
2.8.1.6	Escherichia coli	L-cysteine		645593, 645594	70	required
2.8.1.6	Escherichia coli	L-cysteine		645609	70	increases biotin production
2.8.1.6	Arabidopsis thaliana	L-cysteine		645610	70	highly stimulates
2.8.1.6	Escherichia coli	MioC		645599		essential, may function as an electron transport protein
2.8.1.6	Escherichia coli	more		645593		a labile low-molecular-weight product of the 7,8-diaminoperlargonic acid aminotransferase reaction stimulates by 3fold
2.8.1.6	Arabidopsis thaliana	more		645610		one or more unidentified factors from mitochoncrial matrix of pea and potato and from mitochondrial membranes of pea, in addition to the purified enzyme, are obligatory for the conversion of dithiobiotin to biotin in plants
2.8.1.6	Escherichia coli	NifS		645614		a member of the Nif protein family stimulates biotin production
2.8.1.6	Escherichia coli	NifU		645614		a member of the Nif protein family stimulates biotin production
2.8.1.6	Escherichia coli	Pyridine nucleotide		645585		required, NADPH being most effective
2.8.1.6	Escherichia coli	pyridoxal 5'-phosphate		645609	30	required for cysteine desulfurase activity of the enzyme
2.8.1.6	Lysinibacillus sphaericus	S-adenosyl-L-methionine		645582	22	absolute requirement as electron source
2.8.1.6	Lysinibacillus sphaericus	S-adenosyl-L-methionine		645583, 645588, 645589	22	
2.8.1.6	Escherichia coli	S-adenosyl-L-methionine		645594	22	two molecules of S-adenosyl-L-methionine are used to synthesize one molecule of biotin, one from dethiobiotin to the intermediate, and a second from the intermediate to biotin
2.8.1.6	Bacillus subtilis	S-adenosyl-L-methionine		645605	22	required
2.8.1.6	Escherichia coli	S-adenosyl-L-methionine		645583, 645585, 645593, 645595, 645605	22	required
2.8.1.6	Escherichia coli	S-adenosyl-L-methionine		645608	22	one molecule S-adenosyl-L-methionine is required to form one molecule of biotin
2.8.1.6	Arabidopsis thaliana	S-adenosyl-L-methionine		645610	22	required
2.8.1.6	Escherichia coli	S-adenosyl-L-methionine		645597, 645598, 645612	22	
2.8.1.6	Escherichia coli	thiamine diphosphate-dependent protein		645585		required
2.8.1.6	Escherichia coli		5'-deoxyadenosine	645608	734	strong inhibitor, reversible, 90% inhibition upon addition of 1 equivalent of 5'-deoxyadenosine with regard to the enzyme
2.8.1.6	Arabidopsis thaliana		acidomycin	645610	20792	structural analog of biotin, complete inhibition at 0.4 mM, 50% inhibition at 0.035 mM
2.8.1.6	Lysinibacillus sphaericus		Cd2+	1333	48	1 mM, almost complete inhibition
2.8.1.6	Lysinibacillus sphaericus		Co2+	1333	21	1 mM, almost complete inhibition
2.8.1.6	Lysinibacillus sphaericus		Cu2+	1333	28	1 mM, almost complete inhibition
2.8.1.6	Lysinibacillus sphaericus		Fe2+	645582	23	above 1 mM
2.8.1.6	Lysinibacillus sphaericus		Hg2+	1333	31	1 mM, almost complete inhibition
2.8.1.6	Escherichia coli		methionine and 5'-deoxyadenosine	724296		modest inhibitor
2.8.1.6	Escherichia coli		more	661113		not inhibitory: pyridoxal 5-phosphate, deoxyadenosine
2.8.1.6	Escherichia coli		more	724296		5'-methylthioadenosine is not an inhibitor. Neither biotin nor iminobiotin is a significant inhibitor
2.8.1.6	Escherichia coli		NaBH4	645609	507	decreases cysteine desulfurase and biotin synthase activity
2.8.1.6	Escherichia coli		S-adenosyl-L-homocysteine	724296	34	potent inhibitor
2.8.1.6	Escherichia coli		sinefungin	724296	535	
2.8.1.6	Lysinibacillus sphaericus		Zn2+	1333	19	1 mM, almost complete inhibition
2.1.2.2	Gallus gallus	glycine		485713	68	stimulatory effect
2.1.2.2	Gallus gallus	histidine		485713	296	stimulatory effect
2.1.2.2	Gallus gallus	NH4+		485716	50	activity enhanced by
2.1.2.2	Gallus gallus	tryptophan		485713	113	stimulatory effect
2.1.2.2	Homo sapiens		(6R)-5,10-dideazatetrahydrofolate	485737	4259	lometrexol
2.1.2.2	Homo sapiens		(6R)-dideazatetrahydrofolate diglutamate	485737	32561	LY235340
2.1.2.2	Mus musculus		(6R)-dideazatetrahydrofolate diglutamate	485737	32561	LY235340
2.1.2.2	Homo sapiens		(6R)-dideazatetrahydrofolate pentaglutamate	485737	32562	LY235542
2.1.2.2	Mus musculus		(6R)-dideazatetrahydrofolate pentaglutamate	485737	32562	LY235542
2.1.2.2	Homo sapiens		(6R)-dideazatetrahydrofolate tetraglutamate	485737	32563	LY266978
2.1.2.2	Mus musculus		(6R)-dideazatetrahydrofolate tetraglutamate	485737	32563	LY266978
2.1.2.2	Homo sapiens		(6R)-dideazatetrahydrofolate triglutamate	485737	32564	LY235337
2.1.2.2	Mus musculus		(6R)-dideazatetrahydrofolate triglutamate	485737	32564	LY235337
2.1.2.2	Homo sapiens		(6S)-dideazatetrahydrofolate	485737	32565	LY243246
2.1.2.2	Mus musculus		(6S)-dideazatetrahydrofolate	485737	32565	LY243246
2.1.2.2	Escherichia coli		(6S)-N10-formyltetrahydrofolate	485718	72285	
2.1.2.2	Homo sapiens		(alpha,beta)-hydroxyacetamide ribonucleotide	485734	72288	
2.1.2.2	Homo sapiens		(S)-2-(((4R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylthio)butyl)benzamido)pentanedioic acid	688291	108753	
2.1.2.2	Homo sapiens		(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic acid	688291	6782	
2.1.2.2	Homo sapiens		(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl)benzamido)pentanedioic acid	688291	6783	
2.1.2.2	Homo sapiens		(S)-2-(4-(2-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)propyl)-1,3-dithian-2-yl)benzamido)pentanedioic acid	688291	9554	
2.1.2.2	Homo sapiens		10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid	658000	37102	specifically inhibits recombinant GAR Tfase, inactive against other folate-dependent enzymes, potent inhibitor of tumor cell proliferation
2.1.2.2	Drosophila melanogaster		10-Acetyl-5,8-dideazafolate	485725	13137	
2.1.2.2	Mus musculus		10-Acetyl-5,8-dideazafolate	485725	13137	
2.1.2.2	Homo sapiens		10-Acetyl-5,8-dideazafolate	485725, 485734	13137	
2.1.2.2	Homo sapiens		10-CF3CO-DDACTHF	672526, 688291	5140	
2.1.2.2	Mus musculus		10-formyl-5,8-dideazafolic acid hexaglutamate	485731	72355	
2.1.2.2	Homo sapiens		10-formyl-DDACTHF	672526, 688291	15939	
2.1.2.2	Homo sapiens		10-methanesulfonyl-5-DACTHF	672526	41432	
2.1.2.2	Homo sapiens		10-methanesulfonyl-DDACTHF	672526	40737	
2.1.2.2	Homo sapiens		10-methylthio-DDACTHF	672526, 688291	15940	
2.1.2.2	Escherichia coli		10-trifluoroacetyl-DDACTHF	672527	5140	
2.1.2.2	Homo sapiens		10-trifluoroacetyl-DDACTHF	672527	5140	
2.1.2.2	Homo sapiens		2',3'-dideoxy-2',3'-didehydro-carbocyclic glycinamide ribonucleotide	485735	72370	
2.1.2.2	Homo sapiens		2',3'-dideoxy-carbocyclic glycinamide ribonucleotide	485735	72371	
2.1.2.2	Homo sapiens		2',5'-furan-dideazatetrahydrofolate	485737	32595	LY222306
2.1.2.2	Mus musculus		2',5'-furan-dideazatetrahydrofolate	485737	32595	LY222306
2.1.2.2	Homo sapiens		2',5'-thiophene dideazatetrahydrofolate	485731	8786	LY309887, diastereomer B
2.1.2.2	Mus musculus		2',5'-thiophene dideazatetrahydrofolate	485731	8786	LY309887, diastereomer B
2.1.2.2	Homo sapiens		2',5'-thiophene dideazatetrahydrofolate	485737	8786	LY309886, diastereomer A; LY309887, diastereomer B
2.1.2.2	Mus musculus		2',5'-thiophene dideazatetrahydrofolate	485737	8786	LY309886, diastereomer A; LY309887, diastereomer B
2.1.2.2	Mus musculus		2-deaminodideazatetrahydrofolate	485731	72411	
2.1.2.2	Escherichia coli		4-carbamoyl-2-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid	672527	24283	
2.1.2.2	Homo sapiens		4-carbamoyl-2-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid	672527	24283	
2.1.2.2	Escherichia coli		4-carbamoyl-4-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid	672527	24284	
2.1.2.2	Homo sapiens		4-carbamoyl-4-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid	672527	24284	
2.1.2.2	Homo sapiens		5'-phosphonate carbocyclic glycinamide ribonucleotide	485735	72534	
2.1.2.2	Homo sapiens		5,10-dideaza-5,6,7,8-tetrahydrofolate	485715	7613	
2.1.2.2	Escherichia coli		5,10-dideaza-5,6,7,8-tetrahydrofolate	485715, 485719	7613	
2.1.2.2	Homo sapiens		5,10-dideaza-5,6,7,8-tetrahydrofolic acid	688291	7613	
2.1.2.2	Mus musculus		5,10-dideazafolic acid	485725	72535	
2.1.2.2	Escherichia coli		5,10-dideazatetrahydrofolate	485715, 485719, 485731, 485735	3415	
2.1.2.2	Homo sapiens		5,10-dideazatetrahydrofolate	485715, 485731, 485735, 485737	3415	
2.1.2.2	Mus musculus		5,10-dideazatetrahydrofolate	485715, 485719, 485731, 485737	3415	
2.1.2.2	Escherichia coli		5,8-Dideazafolate	485720, 485731	8296	
2.1.2.2	Mus musculus		5,8-dideazafolate hexaglutamate	485731	72540	
2.1.2.2	Mus musculus		5,8-dideazapteroyl hexaglutamate	485731	72541	
2.1.2.2	Mus musculus		5-deazatetrahydrofolate	485731	11121	
2.1.2.2	Homo sapiens		AG2034	688291	90088	
2.1.2.2	Homo sapiens		AG2037	688291	90089	
2.1.2.2	Mus musculus		alpha,beta-hydroxyacetamideribonucleotide	485725	72288	
2.1.2.2	Mus musculus		alpha,beta-N-(hydroxyacetyl)-D-ribofuranosylamine	485725	72709	
2.1.2.2	Escherichia coli		beta-thioglycinamide dideazafolate	485718	72771	
2.1.2.2	Gallus gallus		Cu2+	485713	28	
2.1.2.2	Escherichia coli		DDACTHF	672526, 672527	3265	
2.1.2.2	Homo sapiens		DDACTHF	672526, 672527, 688291	3265	
2.1.2.2	Escherichia coli		dideazafolate	485718	8296	
2.1.2.2	Mus musculus		dideazatetrahydrofolate	485731	72840	
2.1.2.2	Mus musculus		dideazatetrahydrofolate hexaglutamate	485731	72841	
2.1.2.2	Mus musculus		homo-dideazatetrahydrofolate	485731	72917	
2.1.2.2	Gallus gallus		L-(+)-10-Formyltetrahydrofolate	485714	2297	excellent competitive inhibitor
2.1.2.2	Homo sapiens		LY231514	658380	873	antitumor activity may result from simultaneous and multiple inhibition of several key folate-requiring enzymes via its polyglutamated metabolites
2.1.2.2	Homo sapiens		LY231514 monoglutamate	658380	873	
2.1.2.2	Homo sapiens		LY231514 pentaglutamate	658380	37103	
2.1.2.2	Homo sapiens		LY309887	688291	7882	
2.1.2.2	Escherichia coli		more	672526		10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF and 10-methylthio-DDACTHF shows KI-values above 0.1 mM
2.1.2.2	Escherichia coli		more	672528		no inhibition by N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid
2.1.2.2	Homo sapiens		N-(4-[3-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-propyl]benzoyl)-L-glutamic acid	705032	18112	dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase, resulting in potent growth inhibition of human tumor cells KB and IGROV1 that express folate receptors
2.1.2.2	Mus musculus		N-(4-[3-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-propyl]benzoyl)-L-glutamic acid	705032	18112	dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase
2.1.2.2	Homo sapiens		N-(4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-butyl]benzoyl)-L-glutamic acid	705032	18113	dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase, resulting in potent growth inhibition of human tumor cells KB and IGROV1 that express folate receptors
2.1.2.2	Mus musculus		N-(4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-butyl]benzoyl)-L-glutamic acid	705032	18113	dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase
2.1.2.2	Homo sapiens		N-(4-[5-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-pentyl]benzoyl)-L-glutamic acid	705032	18114	dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase, resulting in potent growth inhibition of human tumor cells KB and IGROV1 that express folate receptors
2.1.2.2	Mus musculus		N-(4-[5-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-pentyl]benzoyl)-L-glutamic acid	705032	18114	dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase
2.1.2.2	Homo sapiens		N-(4-[6-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-hexyl]benzoyl)-L-glutamic acid	705032	18115	dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase, resulting in potent growth inhibition of human tumor cells KB and IGROV1 that express folate receptors
2.1.2.2	Mus musculus		N-(4-[6-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-hexyl]benzoyl)-L-glutamic acid	705032	18115	dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase
2.1.2.2	Homo sapiens		N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamyl-gamma-glutamyl-gamma-glutamylglutamic acid	702155	9950	
2.1.2.2	Homo sapiens		N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamylglutamic acid	702155	9949	
2.1.2.2	Homo sapiens		N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)glutamic acid	702155	213	
2.1.2.2	Homo sapiens		N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl]phenyl]carbonyl)glutamic acid	688291	6777	
2.1.2.2	Homo sapiens		N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl]phenyl]carbonyl)glutamic acid	688291	6776	
2.1.2.2	Homo sapiens		N-([4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]phenyl]carbonyl)glutamic acid	688291	6775	
2.1.2.2	Homo sapiens		N-([4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]phenyl]carbonyl)glutamic acid	688289	16894	
2.1.2.2	Mus musculus		N-([4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]phenyl]carbonyl)glutamic acid	688289	16894	
2.1.2.2	Homo sapiens		N-([4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]phenyl]carbonyl)glutamic acid	688289	16895	
2.1.2.2	Mus musculus		N-([4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]phenyl]carbonyl)glutamic acid	688289	16895	
2.1.2.2	Homo sapiens		N-([5-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2,3-dihydrothiophen-2-yl]carbonyl)-4-methylideneglutamic acid	702155	5263	
2.1.2.2	Homo sapiens		N-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5264	
2.1.2.2	Homo sapiens		N-[4-[2-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5266	
2.1.2.2	Homo sapiens		N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2-fluorobenzoyl]-4-methylideneglutamic acid	702155	5265	
2.1.2.2	Homo sapiens		N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5928	
2.1.2.2	Homo sapiens		N-[4-[2-(2-amino-4-methylquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5262	
2.1.2.2	Mus musculus		N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid	688289	4259	
2.1.2.2	Homo sapiens		N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid	688289, 688291	4259	
2.1.2.2	Mus musculus		N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid	688289	25321	
2.1.2.2	Homo sapiens		N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid	672528	41431	effective inhibitor
2.1.2.2	Mus musculus		N-[4-[5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)pentyl]benzoyl]-L-glutamic acid	688289	25322	
2.1.2.2	Mus musculus		N-[4-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexyl]benzoyl]-L-glutamic acid	688289	25323	
2.1.2.2	Homo sapiens		N-{4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl}-L-glutamic acid	688289	25321	
2.1.2.2	Homo sapiens		N-{4-[5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)pentyl]benzoyl}-L-glutamic acid	688289	25322	
2.1.2.2	Homo sapiens		N-{4-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexyl]benzoyl}-L-glutamic acid	688289	25323	
2.1.2.2	Escherichia coli		N10-(Bromoacetyl)-5,8-dideazafolate	485718	65101	
2.1.2.2	Escherichia coli		N10-formyl-2,4-diaminodideazafolate	485718	1373	
2.1.2.2	Homo sapiens		pemetrexed	688289	873	
2.1.2.2	Mus musculus		pemetrexed	688289	873	
4.1.3.40	Escherichia coli		3-carboxymethylaminomethyl-4-hydroxybenzoate	650373	14679	
4.1.3.40	Escherichia coli		4-hydroxybenzaldehyde	650373	571	
4.1.3.40	Escherichia coli		4-hydroxybenzoate	650373	311	product inhibition
4.1.3.40	Mycobacterium tuberculosis		4-hydroxybenzoate	665681	311	strong product inhibition
4.1.3.40	Escherichia coli		vanillate	650373, 663775	1395	
2.3.3.1	Rattus norvegicus	aldosterone		488073	2030	
2.3.3.1	Nitrobacter winogradskyi		2-oxoglutarate	488052	32	no inhibition
2.3.3.1	Rattus norvegicus		amphetamine	689831	3544	valproate reverses and lithium prevents the enzyme inhibition
2.3.3.1	Solanum lycopersicum		ATP	286663	7	
2.3.3.1	Nitrobacter winogradskyi		ATP	488052	7	no inhibition
2.3.3.1	Yarrowia lipolytica		ATP	488055	7	noncompetitive against acetyl-CoA
2.3.3.1	Yarrowia lipolytica		citrate	488055	125	
2.3.3.1	Nitrobacter winogradskyi		CuSO4	488052	228	
2.3.3.1	Rattus norvegicus		D-serine	702966	401	
2.3.3.1	Nitrobacter winogradskyi		HgCl2	488052	104	
2.3.3.1	Solanum lycopersicum		NADH	286663	3	no effect
2.3.3.1	Nitrobacter winogradskyi		NADH	488052	3	no effect
2.3.3.1	Rattus norvegicus		Ouabain	720443	683	activity was inhibited immediately after the administration of ouabain in the prefrontal cortex at the doses of 0.01 mM and 0.1 mM
2.3.3.1	Nitrobacter winogradskyi		SDS	488052	118	strong inhibition
6.3.4.2	Escherichia coli	2'-deoxy-GTP		674909	194	0 mM guanosine, kact: 1.5/sec, KA: 0.21 mM, Ki: 0.36 mM; the GTP analogue is capable of activating Gln-dependent CTP formation
6.3.4.2	Mus musculus	2-mercaptoethanol		648987	59	required for optimal activity, above 50 mM increase activity to 221%
6.3.4.2	Saccharomyces cerevisiae	2-mercaptoethanol		648999	59	stimulates
6.3.4.2	Escherichia coli	6-thio-GTP		674909	12548	the GTP analogue is capable of activating Gln-dependent CTP formation
6.3.4.2	Escherichia coli	6-thioguanosine 5'-triphosphate		674909	12118	0 mM guanosine, kact: 8.5/sec, KA: 0.035 mM, Ki: 0.27 mM
6.3.4.2	Mus musculus	dithiothreitol		648987	42	required for optimal activity, above 50 mM increase activity to 223% mM
6.3.4.2	Mus musculus	GDP		648982	49	slight activation
6.3.4.2	Mus musculus	GMP		648982	150	slight activation
6.3.4.2	Escherichia coli	GTP		648962	35	required as an allosteric effector to promote glutamine hydrolysis
6.3.4.2	Escherichia coli	GTP		648963	35	required as allosteric effector to promote reaction with glutamine as substrate, GTP functions by stabilizing the protein conformation that binds the tetrahedral intermediate(s) formed during glutamine hydrolysis
6.3.4.2	Lactococcus lactis	GTP		648964	35	the binding of GTP to the allosteric site promotes coordination of the phosphorylation of UTP and hydrolysis of glutamine for optimal efficiency in CTP synthesis rather than just acting to increase the rate of glutamine hydrolysis itself
6.3.4.2	Mus musculus	GTP		648982	35	activates glutamine reaction, no activation of ammonia reaction
6.3.4.2	Mus musculus	GTP		648985	35	essential activator when glutamine is the nitrogen source
6.3.4.2	Mus musculus	GTP		648987	35	not essential, but acts as activator on the glutamine reaction, optimal activation at 1 mM
6.3.4.2	Lactococcus lactis	GTP		660794	35	stimulates reaction with ATP, UTP and Gln
6.3.4.2	Escherichia coli	GTP		661241	35	activates enzyme-catalyzed glutamine hydrolysis
6.3.4.2	Lactococcus lactis	GTP		661713	35	allosteric activator
6.3.4.2	Escherichia coli	GTP		674909	35	0.1 mM guanosine, kact: 10.3/sec, KA: 0.088 mM, Ki: 0.22 mM; 0.2 mM guanosine, kact: 8.2/sec, KA: 0.078 mM, Ki: 0.12 mM; 0 mM guanosine, kact: 10.6/sec, KA: 0.081 mM, Ki: 0.28 mM; allosteric effector, structural requirements for activation are stringent, but requirements for inhibition are lax. GTP promotes Gln hydrolysis but inhibits Gln-dependent CTP formation at concentrations of over 0.15 mM
6.3.4.2	Escherichia coli	GTP		690817	35	required, activates
6.3.4.2	Homo sapiens	GTP		694484	35	
6.3.4.2	Escherichia coli	GTP		702613	35	GTP acts a positive allosteric effector for Gln-dependent CTP formation. However, at concentrations exceeding 0.15 mM, GTP inhibits Gln-dependent CTP formation. Moreover, GTP is an inhibitor of NH3-dependent CTP formation at all concentrations
6.3.4.2	Trypanosoma brucei	GTP		727139	35	activates glutamine-dependent CTP formation at concentrations below 0.2 mM
6.3.4.2	Escherichia coli	guanosine 5'-tetraphosphate		674909	1332	0 mM guanosine, kact: 4/sec, KA: 0.19 mM, Ki: 0.5 mM; the GTP analogue is capable of activating Gln-dependent CTP formation
6.3.4.2	Escherichia coli	ITP		674909	203	0 mM guanosine, kact: 5.2/sec, KA: 2.9 mM, Ki: 4.5 mM; the GTP analogue is capable of activating Gln-dependent CTP formation
6.3.4.2	Escherichia coli	more		674909		activation potency in descending order: GTP = 6-thio-GTP, ITP = guanosine 5'-tetraphosphate, O6-methyl-GTP, 2'-deoxy-GTP, no activation with guanosine, GMP, GDP, 2',3'-dideoxy-GTP, acycloguanosine, and acycloguanosine monophosphate, indicating that the 5'-triphosphate, 2'-OH, and 3'-OH are required for full activation, binding structures and kinetics, overview
6.3.4.2	Escherichia coli	more		690817		binding of the substrates ATP and UTP, or the product CTP, promotes oligomerization of CTPS from inactive dimers to active tetramers, Gly142 is critical for nucleotide-dependent oligomerization of CTPS to active tetramers
6.3.4.2	Saccharomyces cerevisiae	more		694934		the URA7-encoded enzyme is phosphorylated by protein kinases A and C at Ser424, and these phosphorylations stimulate CTP synthetase activity and increase cellular CTP levels and the utilization of the Kennedy pathway
6.3.4.2	Escherichia coli	O-methylguanosine 5'-triphosphate		674909	12119	0 mM guanosine, kact: 2.8/sec, KA: 0.13 mM, Ki: 0.29 mM
6.3.4.2	Escherichia coli	O6-methyl-GTP		674909	25770	the GTP analogue is capable of activating Gln-dependent CTP formation
6.3.4.2	Escherichia coli		1,3,7,9-tetramethyluric	702613	27034	
6.3.4.2	Escherichia coli		1,3,7-trimethyluric acid	702613	27033	
6.3.4.2	Escherichia coli		1,3-dimethyluric acid	702613	27031	pH-dependent inhibition, overview
6.3.4.2	Escherichia coli		1,7-dimethyluric acid	702613	27032	pH-dependent inhibition, overview
6.3.4.2	Escherichia coli		1-methyluric acid	702613	13135	
6.3.4.2	Escherichia coli		2',3'-dialdehyde adenosine 5'-triphosphate	672395	9333	irreversible inhibitor of CTPS
6.3.4.2	Escherichia coli		2'-deoxy-GTP	674909	194	no guanosine, kact: 1.5/sec, KA: 0.21 mM, Ki: 0.36 mM; the GTP analogue is capable of inhibiting Gln-dependent CTP formation at over 0.15 mM
6.3.4.2	Escherichia coli		2'-deoxy-guanosine	674909	419	
6.3.4.2	Escherichia coli		2,6-diaminopurine riboside	674909	8830	
6.3.4.2	Escherichia coli		2-aminopurine riboside	674909	5824	
6.3.4.2	Escherichia coli		2-Thiocytidine 5'-triphosphate	648986	19973	
6.3.4.2	Escherichia coli		2-thiouridine 5'-triphosphate	648986, 648993	8633	
6.3.4.2	Escherichia coli		3'-deoxy-guanosine	674909	24354	
6.3.4.2	Escherichia coli		3,7-dimethyluric acid	702613	15230	
6.3.4.2	Bos taurus		3-Deazauridine 5'-triphosphate	648988	63310	
6.3.4.2	Escherichia coli		4-thiouridine 5'-triphosphate	648986, 648993	33741	
6.3.4.2	Escherichia coli		5-bromoUTP	648986, 648993	8299	
6.3.4.2	Trypanosoma brucei		6-diazo-5-oxo-L-norleucine	648972	666	reduces the parasite CTP level even further and inhibits trypanosome proliferation in vitro and in Trypanosoma brucei-infected mice
6.3.4.2	Escherichia coli		6-diazo-5-oxo-L-norleucine	648981	666	
6.3.4.2	Escherichia coli		6-thio-GTP	674909	12548	the GTP analogue is capable of inhibiting Gln-dependent CTP formation at over 0.15 mM
6.3.4.2	Escherichia coli		6-Thioguanine	674909	951	
6.3.4.2	Escherichia coli		6-thioguanosine	674909	6378	
6.3.4.2	Escherichia coli		6-thioguanosine 5'-triphosphate	674909	12118	no guanosine, kact: 8.5/sec, KA: 0.035 mM, Ki: 0.27 mM
6.3.4.2	Escherichia coli		7-deazaguanosine	674909	86514	
6.3.4.2	Escherichia coli		8-oxoguanosine	674909	16141	
6.3.4.2	Escherichia coli		8-oxoguanosine 5'-triphosphate	674909	24352	
6.3.4.2	Trypanosoma brucei		acivicin	674786	2029	irreversible inhibition by the glutamine analogue acivin. The acivicin inhibition of Trypanosoma brucei CTPS is more pronounced when the enzyme is preincubated with the drug in the presence of nucleotide substrates than in the absence of substrates
6.3.4.2	Escherichia coli		acycloguanosine	674909	2196	
6.3.4.2	Escherichia coli		acycloguanosine monophosphate	674909	8513	
6.3.4.2	Escherichia coli		adenine	702613	136	
6.3.4.2	Escherichia coli		adenosine	674909	116	
6.3.4.2	Lactococcus lactis		adenosine 5'-[beta,gamma-imido]triphosphate	648964	2889	poor inhibitor compared to ATPgammaS
6.3.4.2	Mus musculus		adenylyl-iminodiphosphate	648985	2969	competitive with ATP
6.3.4.2	Trypanosoma brucei		alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid	648972	35673	reduces the parasite CTP level even further and inhibits trypanosome proliferation in vitro and in Trypanosoma brucei-infected mice
6.3.4.2	Lactococcus lactis		ATPgammaS	648964	1380	
6.3.4.2	Escherichia coli		Caffeine	702613	695	
6.3.4.2	Trypanosoma brucei		Caffeine	727139	695	
6.3.4.2	Escherichia coli		Co2+	649002	21	above 2 mM
6.3.4.2	Saccharomyces cerevisiae		CTP	648973	56	IC50: 0.3 mM
6.3.4.2	Saccharomyces cerevisiae		CTP	648976	56	product inhibition of wild-type enzyme, mutant E161K is less sensitive to CTP product inhibition
6.3.4.2	Lactococcus lactis		CTP	648977	56	cooperative inhibition
6.3.4.2	Saccharomyces cerevisiae		CTP	648978	56	IC50: 0.32 mM
6.3.4.2	Mus musculus		CTP	648982	56	mixed inhibition
6.3.4.2	Escherichia coli		CTP	648986	56	
6.3.4.2	Saccharomyces cerevisiae		CTP	648994	56	IC50 for the native enzyme: 0.12 in presence of 0.5 mM ATP, 0.22 mM in presence of 1 mM ATP. IC50 for the phosphorylated enzyme: 0.21 mM in presence of 0.5 mM ATP, 0.31 mM in presence of 1 mM ATP
6.3.4.2	Saccharomyces cerevisiae		CTP	648999	56	allosteric inhibition
6.3.4.2	Chlamydia trachomatis		CTP	649000	56	feedback inhibitor; IC50: 0.05 mM
6.3.4.2	Escherichia coli		CTP	649000	56	IC50: 0.15 mM
6.3.4.2	Mus musculus		CTP	649001	56	the enzyme from T lymphoblast S49 cells is refractory to complete inhibition by CTP
6.3.4.2	Saccharomyces cerevisiae		CTP	694934	56	allosteric regulation, product inhibition
6.3.4.2	Homo sapiens		CTP	715549	56	; 
6.3.4.2	Escherichia coli		Cu2+	649002	28	inhibition is not reversed by EDTA, in presence of dithiothreitol inhibition at concentrations below 0.2 mM
6.3.4.2	Homo sapiens		cyclopentenyl cytosine	648967	33894	the inhibitor has a cytostatic effect on lymphoblasts of children with acute lymphocytic leukemia
6.3.4.2	Homo sapiens		cyclopentenyl cytosine	694484	33894	a highly specific inhibitor of CTPS1, in vivo inhibition leads to alterations in the cell nuclei and microtubule network, overview
6.3.4.2	Mus musculus		cyclopentylcytosine triphosphate	648998	75375	
6.3.4.2	Escherichia coli		D,L-2-amino-4-phosphonobutyrate	648963	13355	
6.3.4.2	Lactococcus lactis		dCTP	648977	161	very weak inhibitor
6.3.4.2	Escherichia coli		DELTA1-Pyrroline-5-carboxylate	648963	1456	weak
6.3.4.2	Escherichia coli		dideoxy-GTP	674909	11817	
6.3.4.2	Lactococcus lactis		DL-DELTA1-pyrroline 5-carboxylate	660794	1456	0.125 mM, complete inhibition of ammonium chloride-dependent CTP synthesis
6.3.4.2	Escherichia coli		GDP	674909	49	
6.3.4.2	Lactococcus lactis		Gln	660794	96	inhibition of hydroxylamine-dependent N4-OH CTP synthesis in presence of GTP
6.3.4.2	Escherichia coli		glutamate gamma-semialdehyde	648963	6182	potent linear mixed-type inhibitor, competitive with respect to ammonia, no inhibition of the mutant enzyme C379A
6.3.4.2	Escherichia coli		GMP	674909	150	
6.3.4.2	Lactococcus lactis		GTP	660794	35	inhibition of N4-OH-CTP synthesis
6.3.4.2	Escherichia coli		GTP	661241	35	inhibition of glutamine-dependent CTP formation above 0.15 mM, inhibition of glutamine-dependent CTP formation in a concentration-dependent manner
6.3.4.2	Escherichia coli		GTP	674909	35	0.1 mM guanosine, kact: 10.3/sec, KA: 0.088 mM, Ki: 0.22 mM; 0.2 mM guanosine, kact: 8.2/sec, KA: 0.078 mM, Ki: 0.12 mM; allosteric effector, structural requirements for activation are stringent, but requirements for inhibition are lax. GTP promotes Gln hydrolysis but inhibits Gln-dependent CTP formation at concentrations of over 0.15 mM; no guanosine, kact: 10.6/sec, KA: 0.081 mM, Ki: 0.28 mM
6.3.4.2	Escherichia coli		GTP	702613	35	GTP acts a positive allosteric effector for Gln-dependent CTP formation. However, at concentrations exceeding 0.15 mM, GTP inhibits Gln-dependent CTP formation. Moreover, GTP is an inhibitor of NH3-dependent CTP formation at all concentrations
6.3.4.2	Trypanosoma brucei		GTP	727139	35	inhibits glutamine-dependent CTP formation at concentrations above 0.2 mM
6.3.4.2	Escherichia coli		guanosine	674909	256	
6.3.4.2	Trypanosoma brucei		guanosine	727139	256	
6.3.4.2	Escherichia coli		guanosine 5'-tetraphosphate	674909	1332	; no guanosine, kact: 4/sec, KA: 0.19 mM, Ki: 0.5 mM; the GTP analogue is capable of inhibiting Gln-dependent CTP formation at over 0.15 mM
6.3.4.2	Saccharomyces cerevisiae		HgCl2	648999	104	
6.3.4.2	Escherichia coli		Inosine	674909	154	
6.3.4.2	Escherichia coli		ITP	674909	203	no guanosine, kact: 5.2/sec, KA: 2.9 mM, Ki: 4.5 mM; the GTP analogue is capable of inhibiting Gln-dependent CTP formation at over 0.15 mM
6.3.4.2	Escherichia coli		L-2-pyrrolidone 5-carboxylate	648963	784	weak competitive inhibition of the reaction with ammonia as substrate, no significant inhibition with glutamine as substrate
6.3.4.2	Escherichia coli		Mn2+	649002	26	above 2 mM
6.3.4.2	Escherichia coli		more	648963		enzyme loses activity at ionic strengths higher than 0.4 M
6.3.4.2	Escherichia coli		more	674909		GTP analogues inhibite NH3-and Gln-dependent CTP-formation, often in a cooperative manner, to a similar extent as they activate it with IC50 values of 0.2-0.5 mM, the inhibition appears to be due solely to the purine base, binding structures and kinetics, overview. Inhibitor structure-activity study, overview
6.3.4.2	Escherichia coli		more	677028		incubation of EcCTPS modified by CysNO and HcyNO with 5 mM DTT for 30 min at 37&deg;C reveals that 88% and 97%, respectively, of the original activity can be recovered; it is shown that in the presence of 1 mM Gln, S-nitroso-L-cysteine reduces the enzymatic activity by 88% and by 32% in the presence of 10 mM Gln. Similar studies with S-nitroso-L-homocysteine result in reduction of the activity by 43% and 19%, respectively. The results suggest that the substrate Gln competitively protects the active site of EcCTPS from the modification with S-nitroso-L-cysteine and S-nitroso-L-homocysteine.; no inhibition by S-nitrosoglutathione presumably due to its inability to enter the actve site of the enzyme
6.3.4.2	Escherichia coli		more	702613		inhibition by xanthine and derivatives, no inhibition by allantoin, an intact purine ring with anionic character favors inhibition. In general, methylation of the purine does not significantly affect inhibition
6.3.4.2	Escherichia coli		N-methylguanosine	674909	24353	
6.3.4.2	Saccharomyces cerevisiae		NEM	648999	46	
6.3.4.2	Lactococcus lactis		NH4Cl	648968	282	substrate inhibition , a significant part of the inhibition can be shown to be due to the increase in ionic strength with increasing substrate concentrations
6.3.4.2	Escherichia coli		Ni2+	649002	36	in presence of dithiothreitol inhibition at concentrations below 0.2 mM
6.3.4.2	Escherichia coli		O-methylguanosine	674909	7910	
6.3.4.2	Escherichia coli		O-methylguanosine 5'-triphosphate	674909	12119	no guanosine, kact: 2.8/sec, KA: 0.13 mM, Ki: 0.29 mM
6.3.4.2	Escherichia coli		O6-methyl-GTP	674909	25770	the GTP analogue is capable of inhibiting Gln-dependent CTP formation at over 0.15 mM
6.3.4.2	Saccharomyces cerevisiae		p-chloromercuribenzenesulfonic acid	648999	1069	
6.3.4.2	Escherichia coli		paraxanthine	702613	2781	pH-dependent inhibition, overview
6.3.4.2	Mus musculus		PCMB	648987	40	0.01 mM, 50% inhibition
6.3.4.2	Escherichia coli		pyrrole-2-carboxylate	648963	3361	weak competitive inhibition of the reaction with ammonia as substrate, no significant inhibition with glutamine as substrate
6.3.4.2	Escherichia coli		S-nitroso-L-cysteine	677028	5700	specific irreversible inhibitor,inhibits the activity by 94%
6.3.4.2	Escherichia coli		S-nitroso-L-homocysteine	677028	6628	specific irreversible inhibitor, inhibits the activity by 90%
6.3.4.2	Escherichia coli		s4UTP	648986, 648993	14515	
6.3.4.2	Escherichia coli		SO42-	648963	148	
6.3.4.2	Escherichia coli		Theobromine	702613	1996	
6.3.4.2	Escherichia coli		theophylline	702613	926	pH-dependent inhibition, overview
6.3.4.2	Escherichia coli		Uracil	702613	287	
6.3.4.2	Escherichia coli		uracil-4-acetic acid	702613	27035	
6.3.4.2	Escherichia coli		Uric acid	702613	570	pH-dependent inhibition, overview
6.3.4.2	Trypanosoma brucei		Uric acid	727139	570	
6.3.4.2	Escherichia coli		uridine	702613	227	
6.3.4.2	Mus musculus		UTP	648985	61	competitive with ATP
6.3.4.2	Escherichia coli		xanthine	702613	208	; pH-dependent inhibition, overview
6.3.4.2	Escherichia coli		Xanthosine	674909	927	
6.3.4.2	Escherichia coli		Zn2+	649002	19	inhibition is reversed by EDTA, in presence of dithiothreitol inhibition at concentrations below 0.2 mM
2.7.4.25	Escherichia coli K-12		more	645154		TMP, Ant-dCMP, 5-methyl-CMP, AMP, dAMP, GMP, and dGMP are no inhibitors of the enzyme
4.1.1.20	Escherichia coli	2,3-Dimercaptopropan-1-ol		4110	1854	activates
4.1.1.20	Lysinibacillus sphaericus	2,3-Dimercaptopropan-1-ol		4115	1854	activates
4.1.1.20	Escherichia coli	D-Lysine		4127	1155	activates
4.1.1.20	Lysinibacillus sphaericus	dithiothreitol		4115	42	activates
4.1.1.20	Bacillus subtilis	EDTA		4111	223	activates
4.1.1.20	Methanocaldococcus jannaschii		1,5-Diaminopentane	653897	444	
4.1.1.20	Methanocaldococcus jannaschii		1,6-diaminohexane	653897	1148	
4.1.1.20	Methanocaldococcus jannaschii		1,7-Diaminoheptane	653897	1455	
4.1.1.20	Escherichia coli		2,3-Diaminopropionic acid	4110	8502	
4.1.1.20	Methanocaldococcus jannaschii		Adipic acid	653897	1281	
4.1.1.20	Vicia faba		Aminooxyacetate	4112	1037	
4.1.1.20	Methanocaldococcus jannaschii		azelaic acid	653897	2371	
4.1.1.20	Methanocaldococcus jannaschii		caproic acid	653897	813	
4.1.1.20	Lysinibacillus sphaericus		D,L-alpha-aminoheptanedioate	4115	20331	
4.1.1.20	Bacillus subtilis		D-Lysine	4111	1155	
4.1.1.20	Escherichia coli		D-Lysine	4127	1155	not
4.1.1.20	Mycobacterium tuberculosis		D-Lysine	714346	1155	; a small amount of decarboxlation occurs
4.1.1.20	Lysinibacillus sphaericus		diaminoheptanedioic acid	4123	20976	analogs
4.1.1.20	Escherichia coli		glutamic acid	4110	38	
4.1.1.20	Mycobacterium tuberculosis		L,L-2,6-diaminoheptanedioate	714346	2991	no detectable amounts of decarboxylation products
4.1.1.20	Bacillus subtilis		L-2,4-diaminobutyrate	4111	1868	
4.1.1.20	Lysinibacillus sphaericus		L-2,4-diaminobutyrate	4115	1868	
4.1.1.20	Escherichia coli		L-cystine	4110	923	
4.1.1.20	Lysinibacillus sphaericus		L-cystine	4115	923	
4.1.1.20	Escherichia coli		L-lysine	4110	128	
4.1.1.20	Bacillus subtilis		L-lysine	4111	128	involved in sequential feedback inhibition, pH-dependent
4.1.1.20	Lysinibacillus sphaericus		L-lysine	4115	128	
4.1.1.20	Methanothermobacter thermautotrophicus		L-lysine	4120	128	
4.1.1.20	Escherichia coli		L-lysine	4127	128	reversed by diaminoheptanedioate addition
4.1.1.20	Mycobacterium tuberculosis		L-lysine	714346	128	; no detectable amounts of decarboxylation products
4.1.1.20	Bacillus subtilis		L-ornithine	4111	172	
4.1.1.20	Bacillus subtilis		L-S-aminoethylcysteine	4111	1512	
4.1.1.20	Mycobacterium tuberculosis		LL-2,6-Diaminoheptanedioate	714346	2991	
4.1.1.20	Landoltia punctata		mercuribenzoic acid	4109	554	
4.1.1.20	Landoltia punctata		meso-2,6-diaminoheptanedioate	4109	1057	substrate inhibition
4.1.1.20	Lysinibacillus sphaericus		more	4123		various substrate analogs
4.1.1.20	Triticum sp.		more	4123		various substrate analogs
4.1.1.20	Bacillus subtilis		n-butylamine	4111	1044	
4.1.1.20	Lysinibacillus sphaericus		N-Hydroxydiaminoheptanedioate	4123	21349	Ki: 0.91 mM
4.1.1.20	Triticum sp.		N-Hydroxydiaminoheptanedioate	4123	21349	Ki: 0.71 mM
4.1.1.20	Vicia faba		NH2OH	4112	80	
4.1.1.20	Landoltia punctata		p-chloromercuribenzoate	4109	40	
4.1.1.20	Escherichia coli		Penicillamine	4110	1829	no effect at 10fold pyridoxal phosphate concentration
5.1.1.7	Bacillus megaterium	more		2054		no pyridoxal phosphate requirement
5.1.1.7	Escherichia coli	more		2054		no pyridoxal phosphate requirement
5.1.1.7	Bacillus megaterium	more		2136		pyridoxal phosphate does not stimulate
5.1.1.7	Escherichia coli	more		2140		no pyridoxal phosphate requirement; one, but not both, of the proton acceptor sites is a thiol
5.1.1.7	Bacillus megaterium	thiol compound		2136	752	2,3-dimercaptopropan-1-ol is most effective; required for activity
5.1.1.7	Escherichia coli	thiol compound		2155	752	required for activity
5.1.1.7	Haemophilus influenzae		(2-(4-amino-4-carboxybutyl) aziridine-2-carboxylic acid)	671810	28688	AziDAP
5.1.1.7	Mycobacterium tuberculosis		1,2-benzisothiazolidine 3-one	692384	92769	30 nM, complete inhibition
5.1.1.7	Arabidopsis thaliana		2-(4-amino-4-carboxybutyl)-aziridine-2-carboxylate	693680	86495	substrate mimic, irreversible inhibition
5.1.1.7	Escherichia coli		2-(4-amino-4-carboxybutyl)aziridine-2-carboxylic acid	2146, 2155	28688	irreversible
5.1.1.7	Mycobacterium tuberculosis		2-nitro-5-thiocyanatobenzoate	692384	7067	30 nM, complete inhibition
5.1.1.7	Escherichia coli		3-Chlorodiaminopimelate	2144	63304	the inhibitor is converted to a tight-binding transition state analog at the active site of this enzyme
5.1.1.7	Escherichia coli		3-Fluoro analogs of diaminopimelate	2148		potent competitive inhibitors
5.1.1.7	Escherichia coli		4-Oxo-1,2,3,4-tetrahydro-pyridine-2,6-dicarboxylic acid	653403	76424	very poor inhibitor
5.1.1.7	Mycobacterium tuberculosis		5,5'-dithiobis(2-nitrobenzoic acid)	692384	196	30 nM, complete inhibition
5.1.1.7	Kitasatospora setae		acetone	728008	286	inactivation by 50% acetone
5.1.1.7	Escherichia coli		dilithium (2Z,6S)-2,6-diamino-4-oxohept-2-enedioate	653403	34285	competitive, IC50: 0.5 mM
5.1.1.7	Haemophilus influenzae		DL-aziridino analogues of diaminoheptanedioate	676873	28688	DL-aziridino diaminopimelic acid, irreversible inhibitor
5.1.1.7	Haemophilus influenzae		DL-aziridino-diaminopimelate	704812	96806	product-like inhibitor, inhibitor mimics the natural substrate, the methylene carbon of the aziridine ring of the 2 diastereomeric inhibitors is covalently bonded to the sulfur atom of Cys73 or Cys217 after the nucleophilic attack of the sulfur on the aziridine ring that irreversibly inhibits the enzyme
5.1.1.7	Bacillus megaterium		hydroxylamine	2054	80	no inhibition
5.1.1.7	Escherichia coli		hydroxylamine	2054	80	no inhibition
5.1.1.7	Escherichia coli		hydroxylamine	2140	80	; no inhibition
5.1.1.7	Escherichia coli		iodoacetamide	2140	63	half-life for inactivation with 0.25 mM iodoacetamide is 9.6 min
5.1.1.7	Escherichia coli		iodoacetamide	2155	63	
5.1.1.7	Escherichia coli		Isoniazid	2054	674	
5.1.1.7	Escherichia coli		Lanthionine isomers	2145		
5.1.1.7	Escherichia coli		Lanthionine sulfone	2145	64767	
5.1.1.7	Escherichia coli		Lanthionine sulfoxide	2145	64768	
5.1.1.7	Haemophilus influenzae		LL-aziridino analogues of diaminoheptanedioate	676873	86495	LL-aziridino diaminopimelic acid, irreversible inhibitor
5.1.1.7	Haemophilus influenzae		LL-aziridino-diaminopimelate	704812	96805	reactant-like inhibitor, inhibitor mimics the natural substrate, the methylene carbon of the aziridine ring of the 2 diastereomeric inhibitors is covalently bonded to the sulfur atom of Cys73 or Cys217 after the nucleophilic attack of the sulfur on the aziridine ring that irreversibly inhibits the enzyme
5.1.1.7	Escherichia coli		Mercurials	2054		
5.1.1.7	Bacillus megaterium		more	2054		no inhibition by deoxypyridioxine
5.1.1.7	Escherichia coli		more	2054		
5.1.1.7	Escherichia coli		more	2149		none of the following compounds shows significant inhibition: (2S)-2-amino-3-(4-carboxyimidazol-1-yl)propanoic acid, (2S,5'R)-2-amino-3-(3-carboxy-2-isoxazolin-5-yl)propanoic acid and its 5'S diastereomer, 2-isoxazoline-3-carboxylic acid, and 2-isoxazoline-3,5-dicarboxylic acid
5.1.1.7	Escherichia coli		N-Aminodiaminopimelate	2145	67196	
5.1.1.7	Escherichia coli		N-Hydroxydiaminopimelate	2145	21349	
5.1.1.7	Escherichia coli		Phosphonate analogs of diaminopimelate	2150		
5.1.1.7	Bacillus megaterium		Semicarbazide	2054	322	no inhibition
5.1.1.7	Escherichia coli		Semicarbazide	2054	322	
4.1.99.12	Meyerozyma guilliermondii		EDTA	674401	223	complete inhibition, reversible by Mg2+
4.1.99.12	Bacillus subtilis		EDTA	675226	223	
4.1.99.12	Escherichia coli K-12		EDTA	675800	223	complete inhibition
6.3.3.3	Pseudomonas graveolens		1,10-phenanthroline	1335	58	
6.3.3.3	Pseudomonas graveolens		2,2'-dipyridyl	1335	317	
6.3.3.3	Escherichia coli		6-hydroxypyrimidin-4(3H)-one	653958	35671	competitive inhibition
6.3.3.3	Pseudomonas graveolens		7,8-diaminononanoate	1335	2684	competitive to diaminobiotin
6.3.3.3	Escherichia coli		adenine	653958	136	
6.3.3.3	Escherichia coli		ADP	1334	8	competitive to ATP
6.3.3.3	Pseudomonas graveolens		ADP	1335	8	competitive to ATP
6.3.3.3	Escherichia coli		ADP	1338	8	
6.3.3.3	Lysinibacillus sphaericus		Ag+	1333	71	1 mM, 100% inhibition
6.3.3.3	Escherichia coli		AMP	1338	9	
6.3.3.3	Escherichia coli		AMP-PNP	653958	2889	
6.3.3.3	Lysinibacillus sphaericus		Cd2+	1333	48	1 mM, 70% inhibition
6.3.3.3	Lysinibacillus sphaericus		Co2+	1333	21	1 mM, 35% inhibition
6.3.3.3	Lysinibacillus sphaericus		Cu2+	1333	28	1 mM, 100% inhibition
6.3.3.3	Escherichia coli		dethiobiotin	1334	1865	10 mM, 30% inhibition
6.3.3.3	Pseudomonas graveolens		Diaminobiotin	1335	29289	competitive to 7,8-diaminononanoate
6.3.3.3	Pseudomonas graveolens		EDTA	1335	223	
6.3.3.3	Lysinibacillus sphaericus		Hg2+	1333	31	1 mM, 100% inhibition
6.3.3.3	Lysinibacillus sphaericus		Ni2+	1333	36	1 mM, 80% inhibition
4.2.1.9	Spinacia oleracea		2,4,5,6-tetrahydroxyhexanoate	33981	65896	
4.2.1.9	Spinacia oleracea		2,4,5-trihydroxypentanoate	33981	65897	
4.2.1.9	Spinacia oleracea		2,4-dihydroxybutanoate	33981	29898	
4.2.1.9	Aspergillus fumigatus		2-hydroxy-3-methylbutyric acid	730702		
4.2.1.9	Sulfolobus solfataricus		2-mercaptoethanol	680539	59	1 mM, 40% inhibition
4.2.1.9	Escherichia coli		3-(5-nitrofuran-2-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole hydrochloride	33978	67002	
4.2.1.9	Escherichia coli		4,7-dicyanobenzofurazan	33979	66053	bacteriostatic effect due to inactivation of 2,3-dihydroxyisovalerate dehydratase
4.2.1.9	Spinacia oleracea		Ag+	33960	71	
4.2.1.9	Escherichia coli		benzoquinone	33978	270	
4.2.1.9	Sulfolobus solfataricus		Ca2+	680539	18	
4.2.1.9	Sulfolobus solfataricus		Co2+	680539	21	
4.2.1.9	Escherichia coli		Cu2+	33959	28	CuSO4
4.2.1.9	Spinacia oleracea		Cu2+	33960	28	weak
4.2.1.9	Methanococcus aeolicus		Cu2+	33983	28	strong
4.2.1.9	Sulfolobus solfataricus		Cu2+	680539	28	
4.2.1.9	Spinacia oleracea		Cys	33960	70	
4.2.1.9	Escherichia coli		duroquinone	33978	946	
4.2.1.9	Escherichia coli		EDTA	33959	223	
4.2.1.9	Neurospora crassa		EDTA	33963	223	
4.2.1.9	Spinacia oleracea		EDTA	33960, 33963	223	
4.2.1.9	Sulfolobus solfataricus		Fe2+	680539	23	
4.2.1.9	Spinacia oleracea		Hg2+	33960	31	
4.2.1.9	Escherichia coli		hydralazine	33978	2042	
4.2.1.9	Escherichia coli		juglone	33978	1018	
4.2.1.9	Methanococcus aeolicus		KCN	33983	149	
4.2.1.9	Sulfolobus solfataricus		Mg2+	680539	25	
4.2.1.9	Escherichia coli		more	696105		formation of the IlvD-bound DNIC, dinitrosyl-iron complex, and inactivation of the enzyme activity under anaerobic conditions, reaction kinetics of NO and enzyme using diethylamine NONOate as NO donor. GSH fails to prevent the NO-mediated modification of the IlvD [4Fe-4S] cluster regardless of the presence of O2 in the medium, overview
4.2.1.9	Escherichia coli		NaF	33959	209	
4.2.1.9	Spinacia oleracea		NaF	33960, 33963	209	
4.2.1.9	Spinacia oleracea		NEM	33960	46	
4.2.1.9	Escherichia coli		nitric oxide	682577	240	nitric oxide halts bacterial growth via inhibition of the branched-chain amino acid biosynthesis enzyme dihydroxyacid dehydratase
4.2.1.9	Escherichia coli		Nitrofurantoin	33978	1827	
4.2.1.9	Escherichia coli		NO	700277	240	IlvD is completely inactivated in cells by NO with the concomitant formation of the IlvD-bound dinitrosyl iron complex, DNIC. While the IlvD-bound DNIC and other protein-bound DNICs are stable in cells under anaerobic growth conditions, they are efficiently repaired under aerobic growth conditions even without new protein synthesis, L-cysteine plays an important role, overview
4.2.1.9	Mycobacterium tuberculosis		NO	716148	240	inactivation of Rv0189c by NO probably inhibits bacterial growth
4.2.1.9	Sulfolobus solfataricus		p-chloromercuribenzoic acid	680539	40	
4.2.1.9	Sulfolobus solfataricus		p-hydroxymercuribenzoic acid	680539	92	
4.2.1.9	Escherichia coli		paraquat	33978	302	
4.2.1.9	Escherichia coli		PCMB	33959	40	
4.2.1.9	Spinacia oleracea		PCMB	33960, 33963	40	
4.2.1.9	Escherichia coli		Plumbagin	33978	1882	
1.17.1.8	Corynebacterium glutamicum	aspartate-beta-semialdehyde		390613	472	crude extract
1.17.1.8	Bacillus cereus	more		390614		no flavins
1.17.1.8	Bacillus megaterium	more		390614		no flavins
1.17.1.8	Escherichia coli	more		390617, 390618		no flavins
1.17.1.8	Escherichia coli	NADH		696300	3	
1.17.1.8	Escherichia coli	NADPH		696300	5	similar affinity as NADH
1.17.1.8	Corynebacterium glutamicum	pyruvate		390613	29	crude extract
1.17.1.8	Escherichia coli		(4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinate	390620	4325	
1.17.1.8	Lysinibacillus sphaericus		1,10-phenanthroline	390194	58	
1.17.1.8	Bacillus subtilis		1,10-phenanthroline	390615	58	
1.17.1.8	Thermotoga maritima		2,3-dihydrodipicolinate	687457	3192	the enzyme is inhibited by high concentrations of 2,3-dihydrodipicolinate
1.17.1.8	Escherichia coli		2,6-pyridine dicarboxylate	696300	1090	stable analog of the dihydrodipicolinate substrate, the binding affinity is not affected by the presence of NADH or NAD+
1.17.1.8	Mycobacterium tuberculosis		2,6-pyridinedicarboxylate	654674	1090	competitive, binding site structure
1.17.1.8	Mycobacterium tuberculosis		2,6-pyridinedicarboxylic acid	390623	1090	
1.17.1.8	Escherichia coli		2,6-pyridinedicarboxylic acid	390624	1090	dead-end inhibitor
1.17.1.8	Escherichia coli		2,6-pyridinedicarboxylic acid	390623, 390625	1090	
1.17.1.8	Zea mays		2-pyridine carboxylic acid	390612	3360	
1.17.1.8	Escherichia coli		3-acetyl-NAD+	390617	706	
1.17.1.8	Corynebacterium glutamicum		alanine	390613	97	
1.17.1.8	Zea mays		alpha-picolinic acid	390612	3360	higher concentration
1.17.1.8	Escherichia coli		alpha-picolinic acid	390617	3360	
1.17.1.8	Escherichia coli		catechol rhodanine acetic acid	696300	94414	binds to the NADH cofactor site
1.17.1.8	Bacillus subtilis		Cd2+	390615	48	
1.17.1.8	Bacillus subtilis		Cu2+	390615	28	
1.17.1.8	Corynebacterium glutamicum		cysteine	390613	70	
1.17.1.8	Escherichia coli		DELTA3-tetrahydroisophthalic acid	390620	71843	moderate inhibition
1.17.1.8	Staphylococcus aureus		dihydrodipicolinate	721427	3192	the enzyme is inhibited by high concentrations of dihydrodipicolinate when using NADPH as a cofactor, but not with NADH
1.17.1.8	Lysinibacillus sphaericus		dipicolinate	390194	1090	
1.17.1.8	Zea mays		dipicolinate	390612	1090	
1.17.1.8	Bacillus cereus		dipicolinate	390614	1090	non-competitively versus dihydrodipicolinate, competitive versus NADPH
1.17.1.8	Bacillus megaterium		dipicolinate	390614	1090	non-competitively versus dihydrodipicolinate, competitive versus NADPH
1.17.1.8	Bacillus subtilis		dipicolinate	390615	1090	
1.17.1.8	Bacillus subtilis		dipicolinate	390616	1090	non-competitively versus dihydrodipicolinate, competitive versus NADPH; positive cooperativity
1.17.1.8	Escherichia coli		dipicolinate	390617, 390618	1090	
1.17.1.8	Escherichia coli		dipicolinate	390620	1090	reversible, competitive versus substrate (4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinate
1.17.1.8	Bacillus subtilis		Fe3+	390615	66	
1.17.1.8	Zea mays		isocinchomeronic acid	390612	2398	
1.17.1.8	Zea mays		Isophthalic acid	390612	2475	higher concentration
1.17.1.8	Escherichia coli		Isophthalic acid	390617	2475	competitive versus dihydrodipicolinate
1.17.1.8	Escherichia coli		Isophthalic acid	390618	2475	
1.17.1.8	Escherichia coli		Isophthalic acid	390620	2475	reversible, competitive versus substrate 2,3-dihydrodipicolinate
1.17.1.8	Zea mays		L-Pipecolic acid	390612	2477	higher concentration
1.17.1.8	Lysinibacillus sphaericus		more	390194		not inhibited by lysine, methionine and threonine
1.17.1.8	Bacillus cereus		more	390614		no inhibition by lysine and diaminopimelate
1.17.1.8	Bacillus megaterium		more	390614		no inhibition by lysine and diaminopimelate
1.17.1.8	Bacillus subtilis		more	390615		no inhibition by lysine and diaminopimelate
1.17.1.8	Mycobacterium tuberculosis		more	390623		investigation of inhibitory potential of diverse heterocyclic and aromatic compounds, overview
1.17.1.8	Lactobacillus plantarum		more	670165		no regulation of enzyme by amino acids from the aspartate family
1.17.1.8	Lactobacillus plantarum		more	677262		neither repression nor inhibition by the end products of lysine biosynthetic pathway
1.17.1.8	Escherichia coli		NAD+	390617	4	
1.17.1.8	Thermotoga maritima		NADH	687457	3	
1.17.1.8	Zea mays		NADP+	390612	6	
1.17.1.8	Bacillus cereus		NADP+	390614	6	
1.17.1.8	Bacillus megaterium		NADP+	390614	6	
1.17.1.8	Escherichia coli		NADP+	390617	6	
1.17.1.8	Escherichia coli		NADP+	390624	6	product inhibition
1.17.1.8	Escherichia coli		phosphate	390617, 390618	12	
1.17.1.8	Bacillus cereus		pyridine 2,6-dicarboxylic acid	390614	1090	
1.17.1.8	Bacillus megaterium		pyridine 2,6-dicarboxylic acid	390614	1090	
1.17.1.8	Mycobacterium tuberculosis		sulfonamide derivatives	390623	72165	
4.3.3.7	Pisum sativum	(2R,3S,6S)-2,6-diamino-3-hydroxyheptanedioic acid		33915	66924	134% of the activity without
4.3.3.7	Pisum sativum	(2R,6S)-2,6-diamino-2-methyl-3-heptenedioic acid		33915	65720	110% of the activity without
4.3.3.7	Pisum sativum	(2R,6S/S)-2,6-diamino-6-phosphonohexanoic acid		33915	66925	113% of the activity without
4.3.3.7	Bacillus megaterium	2-mercaptoethanol		33908	59	activation
4.3.3.7	Bacillus megaterium	cysteine		33908	70	activation
4.3.3.7	Bacillus subtilis	isocitric acid		33906	242	activation
4.3.3.7	Corynebacterium glutamicum	L-lysine		729062	128	mutagenesis of the lysine binding sites of the Corynebacterium glutamicum enzyme according to the residues in the Escherichia coli enzyme does not conver the expected feedback inhibition but an activation of the nezyme by L-lysine
4.3.3.7	Escherichia coli	L-methionine		702448	83	at 10 mM 112% activity, at 100 mM 111% activity
4.3.3.7	Escherichia coli	meso-diaminopimelate		702448	1057	at 1 mM 108% activity, at 10 mM 122% activity
4.3.3.7	Bacillus anthracis	more		702448		meso-diaminopimelate has no effect
4.3.3.7	Escherichia coli		(1SR,3R,5S)-1-hydroxy-3,5-bis(methoxycarbonyl)thiomorpholin-1-ium	664304	83388	30 mM, 18% inhibition
4.3.3.7	Escherichia coli		(1SS,3R,5S)-1-hydroxy-3,5-bis(methoxycarbonyl)thiomorpholin-1-ium	664304	83387	9 mM, 48% inhibition
4.3.3.7	Escherichia coli		(2E)-4-oxohept-2-enedioic acid	691243	47679	
4.3.3.7	Escherichia coli		(2E,5E)-4-oxohepta-2,5-dienedioic acid	691243	47680	
4.3.3.7	Escherichia coli		(2R,6S)-piperidine-2,6-dicarboxylic acid	664304	9183	IC50: 20 mM, 83% inhibition at 50 mM
4.3.3.7	Escherichia coli		(2R,6S)-piperidine-2,6-dicarboxylic acid	678711	9183	20 mM, 49% inhibition
4.3.3.7	Mycobacterium tuberculosis		(2R,6S)-piperidine-2,6-dicarboxylic acid	678711	9183	20 mM, 43% inhibition; 20 mM, 77% inhibition
4.3.3.7	Staphylococcus aureus		(2R,6S)-piperidine-2,6-dicarboxylic acid	678711	9183	20 mM, 51% inhibition
4.3.3.7	Escherichia coli		(3R,5R)-thiomorpholine-3,5-dicarboxylic acid	664304	83386	50 mM, 32% inhibition
4.3.3.7	Escherichia coli		(3R,5R)-thiomorpholine-3,5-dicarboxylic acid 1,1-dioxide	664304	83390	50 mM, 11% inhibition
4.3.3.7	Escherichia coli		(3R,5S)-thiomorpholine-3,5-dicarboxylic acid 1,1-dioxide	664304	83389	50 mM, 14% inhibition
4.3.3.7	Staphylococcus aureus		(S)-aspartate 4-semialdehyde	693141	472	
4.3.3.7	Agrobacterium tumefaciens		(S)-aspartate-4-semialdehyde	730915		substrate inhibition
4.3.3.7	Escherichia coli		(S)-Lys	663499	128	partial mixed inhibition with respect to pyruvate and partial non-competitive inhibition with resoect to L-aspartate 4-semialdehyde
4.3.3.7	Escherichia coli		(S)-lysine	664072	128	mutant enzymes R138H and R138A show the same IC50 values as the wild-type enzyme, but different partial inhibition patterns
4.3.3.7	Escherichia coli		(S)-lysine	664244	128	partial mixed inhibition with respect to its first substrate, pyruvate
4.3.3.7	Escherichia coli		(S)-lysine	690914	128	partial mixed inhibition with respect to (S)-aspartate 4-semialdehyde, partial non-ncompetitive inhibition with respect to pyruvate in wild-type and in Y107W mutant, Y107W mutant still retains over 25% of uninhibited activity, even at high inhibitor concentrations compared to the wild-type enzyme retaining less than 10% of normal activity
4.3.3.7	Sinorhizobium meliloti		(S)-lysine	690983	128	no significant conformational change between the pyruvate-bound and (S)-lysine-bound enzyme, presence of substrate has substantial effect on the nature of enzyme-inhibitor association, solvent plays a key role in binding of inhibitor
4.3.3.7	Caldanaerobacter subterraneus subsp. tengcongensis		(S)-lysine	692255	128	increasing amounts of (S)-lysine (0-200 mM) added, not inhibited under physiological conditions, binding site of the allosteric inhibitor lysine appears not to be conserved
4.3.3.7	Escherichia coli		(S)-lysine	695011	128	allosteric inhibitor
4.3.3.7	Escherichia coli		(S)-lysine	729062	128	feedback inhibition, feedback inhibition of the Escherichia coli enzyme by lysine is successfully alleviated after substitution of the residues around the inhibitor's binding sites with those of the Corynabacterium glutamicum enzyme
4.3.3.7	Campylobacter jejuni		(S)-lysine	729237	128	feedback inhibition, the tetrameric enzyme has two allosteric sites, each of which binds two molecules of lysine. Lysine binds highly cooperatively, and primarily to the F form of the enzyme during the ping-pong mechanism. (S)-Lysine is an uncompetitive partial inhibitor with respect to its first substrate, pyruvate, and a mixed partial inhibitor with respect to its second substrate, (S)-aspartate-4-semialdehyde
4.3.3.7	Aquifex aeolicus		(S)-lysine	729694	128	feedback inhibitor, docking study with enzyme crystals
4.3.3.7	Agrobacterium tumefaciens		(S)-lysine	730915	128	allosteric feedback inhibition; allosteric feedback inhibition; allosteric feedback inhibition; allosteric feedback inhibition; allosteric feedback inhibition; allosteric feedback inhibition; allosteric feedback inhibition, allosteric site modeling; allosteric feedback inhibition, allosteric site modeling; allosteric feedback inhibition, allosteric site modeling; allosteric feedback inhibition, allosteric site modeling
4.3.3.7	Escherichia coli		2,2'-(2-hydroxy-1,3-phenylene)bis(2-oxoacetic acid)	729385		slow-tight inhibition
4.3.3.7	Escherichia coli		2,2'-benzene-1,3-diylbis(oxoacetic acid)	691294	47891	
4.3.3.7	Escherichia coli		2,2'-benzene-1,3-diylbis(oxoacetic acid)	729385	47891	slow inhibition
4.3.3.7	Escherichia coli		2-fluoropyruvate	33920		
4.3.3.7	Sinorhizobium meliloti		2-oxobutyrate	691786	313	forms a Schiff base with MosA protein, competitive inhibition
4.3.3.7	Escherichia coli		2-oxobutyrate	712704	313	competitive inhibitor of DHDPS
4.3.3.7	Escherichia coli		2-oxoglutarate	712704	32	competitive inhibitor of DHDPS
4.3.3.7	Escherichia coli		2-oxopimelic acid	718827	21889	
4.3.3.7	Escherichia coli		3-Bromopyruvate	33912	1425	
4.3.3.7	Pisum sativum		3-Bromopyruvate	33915	1425	
4.3.3.7	Corynebacterium glutamicum		3-Bromopyruvate	690628	1425	competitive inhibition, pyruvate as varied substrate
4.3.3.7	Pisum sativum		3-bromopyruvate ethyl ester	33915	66013	1.2 mM, 85% inhibition
4.3.3.7	Escherichia coli		3-Fluoropyruvate	712704	2448	competitive inhibitor of DHDPS, and a competitive substrates
4.3.3.7	Escherichia coli		3-hydroxy-2-oxopropanoate	695011	326	time-dependent inhibition, qualitatively followed by mass spectrometry, initial noncovalent adduct formation, followed by the slow formation of the covalent adduct
4.3.3.7	Escherichia coli		3-hydroxypyruvate	712704	326	competitive inhibitor of DHDPS and a competitive substrate
4.3.3.7	Escherichia coli		4-oxo-1,4-dihydropyridine-2,6-dicarboxylic acid	664304	7800	i.e. chelidamic acid, IC50: 22 mM, 99% inhibition at 50 mM, uncompetitive inhibitor with respect to both substrates
4.3.3.7	Escherichia coli		4-oxo-1,4-dihydropyridine-2,6-dicarboxylic acid	678711	7800	
4.3.3.7	Mycobacterium tuberculosis		4-oxo-1,4-dihydropyridine-2,6-dicarboxylic acid	678711	7800	20 mM, 73% inhibition
4.3.3.7	Staphylococcus aureus		4-oxo-1,4-dihydropyridine-2,6-dicarboxylic acid	678711	7800	20 mM, 83% inhibition
4.3.3.7	Escherichia coli		Bromopyruvate	712704	1425	is an irreversible inhibitor of DHDPS
4.3.3.7	Escherichia coli		cis-(1SS,3R5S)-3,5-thiomorpholinedicarboxylic acid, dimethyl ester, 1-oxide	678711	24804	20 mM, 8% inhibition
4.3.3.7	Mycobacterium tuberculosis		cis-(1SS,3R5S)-3,5-thiomorpholinedicarboxylic acid, dimethyl ester, 1-oxide	678711	24804	20 mM, 8% inhibition
4.3.3.7	Staphylococcus aureus		cis-(1SS,3R5S)-3,5-thiomorpholinedicarboxylic acid, dimethyl ester, 1-oxide	678711	24804	20 mM, 10% inhibition
4.3.3.7	Escherichia coli		cis-piperidine-2,6-dicarboxylic acid	33918	9183	and derivatives
4.3.3.7	Agrobacterium tumefaciens		D-Lysine	728891	1155	allosteric inhibitor
4.3.3.7	Escherichia coli		diethyl (2E)-4-oxohept-2-enedioate	691243	48095	
4.3.3.7	Escherichia coli		diethyl (2E,5E)-4-oxohepta-2,5-dienedioate	691243	48096	
4.3.3.7	Escherichia coli		dimethyl (2R,6S)-piperidine-2,6-dicarboxylate	678711	16210	20 mM, 92% inhibition
4.3.3.7	Mycobacterium tuberculosis		dimethyl (2R,6S)-piperidine-2,6-dicarboxylate	678711	16210	20 mM, 24% inhibition; 20 mM, 99% inhibitione
4.3.3.7	Staphylococcus aureus		dimethyl (2R,6S)-piperidine-2,6-dicarboxylate	678711	16210	20 mM, 58% inhibition
4.3.3.7	Escherichia coli		dimethyl (3R,5R)-thiomorpholine-3,5-dicarboxylate	678711	42213	20 mM, 12% inhibition
4.3.3.7	Mycobacterium tuberculosis		dimethyl (3R,5R)-thiomorpholine-3,5-dicarboxylate	678711	42213	20 mM, 19% inhibition
4.3.3.7	Escherichia coli		dimethyl (3R,5R)-thiomorpholine-3,5-dicarboxylate 1,1-dioxide	664304	15572	50 mM, 12% inhibition
4.3.3.7	Escherichia coli		dimethyl (3R,5R)-thiomorpholine-3,5-dicarboxylate 1,1-dioxide	678711	15572	20 mM, 14% inhibition
4.3.3.7	Mycobacterium tuberculosis		dimethyl (3R,5R)-thiomorpholine-3,5-dicarboxylate 1,1-dioxide	678711	15572	20 mM, 6% inhibition; 20 mM, 7% inhibition
4.3.3.7	Mycobacterium tuberculosis		dimethyl (3R,5R)-thiomorpholine-3,5-dicarboxylate 1-oxide	678711	42214	20 mM, 7% inhibition
4.3.3.7	Staphylococcus aureus		dimethyl (3R,5R)-thiomorpholine-3,5-dicarboxylate 1-oxide	678711	42214	20 mM, 7% inhibition
4.3.3.7	Escherichia coli		dimethyl (3R,5S)-thiomorpholine-3,5-dicarboxylate	664304	23659	50 mM, 36% inhibition
4.3.3.7	Escherichia coli		dimethyl (3R,5S)-thiomorpholine-3,5-dicarboxylate	678711	23659	20 mM, 35% inhibition
4.3.3.7	Mycobacterium tuberculosis		dimethyl (3R,5S)-thiomorpholine-3,5-dicarboxylate	678711	23659	20 mM, 23% inhibition
4.3.3.7	Mycobacterium tuberculosis		dimethyl (3R,5S)-thiomorpholine-3,5-dicarboxylate 1,1-dioxide	678711	42215	20 mM, 19% inhibition; 20 mM, 6% inhibition
4.3.3.7	Escherichia coli		dimethyl 2,2'-benzene-1,3-diylbis[(hydroxyimino)ethanoate]	691294	48097	
4.3.3.7	Escherichia coli		dimethyl 4-oxo-1,4-dihydropyridine-2,6-dicarboxylate	678711	15571	
4.3.3.7	Mycobacterium tuberculosis		dimethyl 4-oxo-1,4-dihydropyridine-2,6-dicarboxylate	678711	15571	20 mM, 84% inhibition
4.3.3.7	Staphylococcus aureus		dimethyl 4-oxo-1,4-dihydropyridine-2,6-dicarboxylate	678711	15571	20 mM, 88% inhibition
4.3.3.7	Escherichia coli		dimethyl chelidamate	664304	15571	IC50: 14 mM. 99% inhibition at 50 mM, noncompetitive with respect to both substrates
4.3.3.7	Escherichia coli		dimethyl piperidine-2,6-dicarboxylate	664304	83385	
4.3.3.7	Escherichia coli		dimethyl pyridine-2,6-dicarboxylate	678711	42212	20 mM, 5% inhibition
4.3.3.7	Mycobacterium tuberculosis		dimethyl pyridine-2,6-dicarboxylate	678711	42212	20 mM, 13% inhibition
4.3.3.7	Escherichia coli		dimethyl-(2E,2'E)-2,2'-benzene-1,3-diylbis[(hydroxyimino)ethanoate]	729385		slow inhibition
4.3.3.7	Escherichia coli		dimethyl-2,2'-(2-hydroxy-1,3-phenylene)bis(2-oxoacetate)	729385		slow-tight inhibition
4.3.3.7	Escherichia coli		dipicolinic acid	33912	1090	1.2 mM, 50% inhibition
4.3.3.7	Escherichia coli		dipicolinic acid	33918	1090	1 mM, 50% inhibition
4.3.3.7	Escherichia coli		dipicolinic acid	664304	1090	IC50: 20 mM, competitive inhibitor
4.3.3.7	Escherichia coli		dipicolinic acid	33920, 718827	1090	
4.3.3.7	Escherichia coli		dipicolinic acid di-imidate	33918	67121	
4.3.3.7	Escherichia coli		dipicolinic acid N-oxide	33918	30162	0.8 mM 50% inhibition
4.3.3.7	Triticum aestivum		DL-diaminopimelic acid	33902	20976	slightly inhibitory
4.3.3.7	Bacillus subtilis		DL-diaminopimelic acid	33906	20976	
4.3.3.7	Pisum sativum		DL-diaminopimelic acid	33915	20976	1.2 mM, 91% inhibition
4.3.3.7	Bacillus subtilis		glyoxylic acid	33906	95	
4.3.3.7	Spinacia oleracea		Isoleucine	33903	266	5 mM, significant inhibition
4.3.3.7	Geobacillus stearothermophilus		Isoleucine	33914	266	not inhibitory
4.3.3.7	Triticum aestivum		KCl	33902	74	1 M, 35% inactivation, 2 M, 55% inactivation
4.3.3.7	Pisum sativum		L-alpha-(2-aminoethoxyvinyl)-glycine	33915	1584	1.2 mM, 100% inhibition
4.3.3.7	Triticum aestivum		L-arginine	33902	117	slightly inhibitory
4.3.3.7	Pisum sativum		L-arginine	33903	117	
4.3.3.7	Spinacia oleracea		L-arginine	33903	117	5 mM, significant inhibition
4.3.3.7	Spinacia oleracea		L-arginine	33904	117	
4.3.3.7	Triticum aestivum		L-arginine	33904	117	1 mM, 69% inhibition
4.3.3.7	Pisum sativum		L-arginine	33915	117	1.2 mM, 62% inhibition
4.3.3.7	Corynebacterium glutamicum		L-aspartate	690628	91	competitive inhibition, L-aspartate 4-semialdehyde as varied substrate
4.3.3.7	Corynebacterium glutamicum		L-aspartate 4-semialdehyde	690628	472	uncompetitive inhibition by high concentrations of, no overcome by increasing pyruvate concentrations from 5 to 15 mM
4.3.3.7	Neisseria meningitidis		L-aspartate 4-semialdehyde	702445	472	is subject to substrate inhibition by high concentrations
4.3.3.7	Bacillus anthracis		L-aspartate 4-semialdehyde	702448	472	DHDPS is subject to substrate inhibition by L-aspartate 4-semialdehyde
4.3.3.7	Escherichia coli		L-aspartate 4-semialdehyde	702484	472	competitive inhibition at high substrate concentrations
4.3.3.7	Triticum aestivum		L-homoserine	33904	294	1 mM, 13% inhibition
4.3.3.7	Spinacia oleracea		L-lysine	33903	128	0.1 mM, complete inhibition, I0.5: 0.02 mM
4.3.3.7	Spinacia oleracea		L-lysine	33904	128	
4.3.3.7	Triticum aestivum		L-lysine	33902, 33904	128	
4.3.3.7	Bacillus subtilis		L-lysine	33906	128	no inhibition
4.3.3.7	Escherichia coli		L-lysine	33907	128	Ki: 0.21 mM
4.3.3.7	Bacillus megaterium		L-lysine	33908	128	no inhibition
4.3.3.7	Zea mays		L-lysine	33904, 33911	128	
4.3.3.7	Escherichia coli		L-lysine	33912	128	1 mM, 50% inhibition
4.3.3.7	Geobacillus stearothermophilus		L-lysine	33914	128	no inhibition
4.3.3.7	Nicotiana sylvestris		L-lysine	33921	128	discussion of plant inhibition versus bacterial inhibition
4.3.3.7	Methanothermobacter thermautotrophicus		L-lysine	4120	128	
4.3.3.7	Corynebacterium glutamicum		L-lysine	690628	128	lack of feedback inhibition, not regulated under normal physiological conditions
4.3.3.7	Staphylococcus aureus		L-lysine	692356	128	poor feedback inhibition by
4.3.3.7	Escherichia coli		L-lysine	33920, 701934, 702036, 702445	128	
4.3.3.7	Neisseria meningitidis		L-lysine	702445	128	is significantly more sensitive to feedback inhibition than Escherichia coli DHDPS
4.3.3.7	Escherichia coli		L-lysine	702448	128	at 1 mM 23% residual activity, at 100 mM 13% residual activity
4.3.3.7	Escherichia coli		L-lysine	702479	128	no difference in its sensitivity or behaviour with respect to L-lysine when compared to the wild-type
4.3.3.7	Escherichia coli		L-lysine	702484	128	binding interaction of L-lysine is characterised as a cooperative event in which an entropic pre-organisation step precedes a secondary enthalpic association. This allosteric association is of a mixed competitive nature in which heterotropic ligand cooperativity is observed to subtly influence the binding events
4.3.3.7	Escherichia coli		L-lysine	713953	128	inhibition of the tetrameric wild-type enzyme, but not of the disrupted minimeric mutant enzyme. Allosteric binding by two molecules of (S)-lysine at the DHDPS tight-dimer interface cleft has been observed to operate via a cooperative mechanism and to result in incomplete partial mixed inhibition, inhibition kinetics, overview
4.3.3.7	Pseudomonas aeruginosa		L-lysine	715195	128	binds at three sites to the enzyme, binding structure, overview
4.3.3.7	Escherichia coli		L-lysine	718827	128	natural feedback inhibitor
4.3.3.7	Medicago truncatula		L-lysine	730623	128	feedback inhibition
4.3.3.7	Vitis vinifera		L-lysine	730624	128	feedback inhibition, binding of lysine to the allosteric cleft of the enzyme, cooperative binding, structural mechanism for allosteric inhibition, overview. With respect to L-aspartate-4-semialdehyde, lysine is a noncompetitive inhibitor
4.3.3.7	Bacillus anthracis		L-methionine	702448	83	at 10 or 100 mM 80% residual activity
4.3.3.7	Bacillus anthracis		L-threonine	702448	220	at 100 mM 40% residual activity
4.3.3.7	Escherichia coli		L-threonine	702448	220	at 100 mM 23% residual activity, at 100 mM 33% residual activity
4.3.3.7	Zea mays		Lys	682458	128	strong inhibition
4.3.3.7	Escherichia coli		lysine	702489	128	inhibition of wild-type DHDPS by lysine with respect to pyruvate is partial and uncompetitive, and partial non-competitive with respect to L-aspartate 4-semialdehyde. Ethanolamine, n-butylamine, 1-amino-2-propanol, 3-amino-1-propanol, iso-butylamine and Tris-HCl cannot rescue activity
4.3.3.7	Zea mays		lysine ethyl ester	33911	13411	
4.3.3.7	Bacillus subtilis		more	33906		not inhibitory: ATP, ADP, AMP, citric acid, L-malic acid, 2-oxoglutaric acid, fumaric acid, succinic acid, L-glutamic acid, L-threonine
4.3.3.7	Bacillus megaterium		more	33908		not inhibitory: iodoacetate, iodoacetamide, p-chloromercuribenzoate
4.3.3.7	Geobacillus stearothermophilus		more	33914		not inhibitory: L-Thr, L-Met
4.3.3.7	Escherichia coli		more	649771		no inhibition by (S)-aspartate 4-semialdehyde, but inhibition occurs by a derivative that is built of the compounbd in the enzyme preparation by ozonolysis
4.3.3.7	Escherichia coli		more	664304		no inhibition by dipicolinic acid methyl ester, (3R,5S)-thiomorpholine-3,5-dicarboxylic acid compound 20b, (3R,5R)-thiomorpholine-3,5-dicarboxylic acid, compound 23, compound 24b, dimethyl (3R,5S)thiomorpholine-3,5-dicarboxylate 1,1-dioxide
4.3.3.7	Thermotoga maritima		more	678046		not inhibited by (S)-lysine, suggesting that feedback control of the lysine biosynthetic pathway evolves later in the bacterial lineage
4.3.3.7	Escherichia coli		more	691243		inhibition studies by using 4-oxo-heptenedioic acid analogues, determination of second-order rate constants of inactivation, substrate co-incubation studies show that the inhibitors act at the active-site, interaction analyzed by mass spectrometry, sites of enzyme alkylation determined
4.3.3.7	Escherichia coli		more	691294		new constrained inhibitors of DHDPS identified and tested, time-dependent inhibition and substrate protection, dimethyl 2,2'-benzene-1,3-diylbis[(hydroxyimino)ethanoate] discovered as a relatively potent inhibitor of DHDPS enzyme, validates constrained acyclic-intermediate model as a potential inhibitor lead, modifications of the aromatic ring are possible and may result in improvements in activity
4.3.3.7	Staphylococcus aureus		more	693141		insensitivity to lysine inhibition
4.3.3.7	Escherichia coli		more	702445		no substrate inhibition by (S)-aspartate 4-semialdehyde
4.3.3.7	Bacillus anthracis		more	702448		is not inhibited by 1-100 mM L-lysine or L-isoleucine
4.3.3.7	Escherichia coli		more	702448		1-100 mM L-isoleucine has no effect
4.3.3.7	Thermotoga maritima		more	702484		is insensitive to L-lysine inhibition, produces no binding isotherm upon L-lysine addition in either the absence or presence of pyruvate
4.3.3.7	Escherichia coli		more	712704		the substrate specificity of the enzyme, two pyruvate analogues, previously classified as weak competitive inhibitors, are turned over productively by DHDPS, NMR spectroscopy, overview
4.3.3.7	Corynebacterium glutamicum		more	729062		no feedback inhibition by L-lysine
4.3.3.7	Escherichia coli		more	729385		1,3-phenylene bis(ketoacid) derivatives as enzyme inhibitors, overview. Ketoacid derivatives act as slow and slow-tight binding inhibitors with either an encounter complex or a condensation product for the slow and slow-tight binding inhibitors, respectively, modeling, overview. No or poor inhibition by dimethyl 2,2'-benzene-1,3-diylbis(oxoacetate), (2E,2'E)-2,2'-benzene-1,3-diylbis[(hydroxyimino)ethanoic acid], and dimethyl-2,2'-(2-methoxy-1,3-phenylene)bis(2-oxoacetate)
4.3.3.7	Escherichia coli		NaBH4	702484	507	NaBH4 reduction of the pyruvyl-Schiff-base intermediate results in enzyme inactivation
4.3.3.7	Corynebacterium glutamicum		oxaloacetate	690628	53	non-competitive inhibition, pyruvate as varied substrate
4.3.3.7	Zea mays		PMSF	33911	218	
4.3.3.7	Escherichia coli		pyridine-2,6-dicarboxylic acid	678711	1090	
4.3.3.7	Mycobacterium tuberculosis		pyridine-2,6-dicarboxylic acid	678711	1090	20 mM, 75% inhibition; 20 mM, 80% inhibition
4.3.3.7	Staphylococcus aureus		pyridine-2,6-dicarboxylic acid	678711	1090	20 mM, 67% inhibition
4.3.3.7	Agrobacterium tumefaciens		pyruvate	730915	29	substrate inhibition
4.3.3.7	Triticum aestivum		S-(2-aminoethyl)-L-cysteine	33902	1512	
4.3.3.7	Pisum sativum		S-(2-aminoethyl)-L-cysteine	33903	1512	
4.3.3.7	Spinacia oleracea		S-(2-aminoethyl)-L-cysteine	33903	1512	I0.5: 0.4 mM
4.3.3.7	Zea mays		S-(2-aminoethyl)-L-cysteine	33911	1512	
4.3.3.7	Escherichia coli		S-(2-aminoethyl)-L-cysteine	33912	1512	4.6 mM, 50% inhibition
4.3.3.7	Escherichia coli		Sodium borohydride	702489	507	wild-type DHDPS is inactivated when incubated with pyruvate, whereas incubation with L-aspartate 4-semialdehyde has no effect
4.3.3.7	Escherichia coli		Succinate-semialdehyde	718827	440	reversible inhibitor which is competitive with respect to L-aspartate-4-semialdehyde and uncompetitive with respect to pyruvate
4.3.3.7	Escherichia coli		Succinic semialdehyde	33920	440	
4.3.3.7	Corynebacterium glutamicum		Succinic semialdehyde	690628	440	uncompetitive inhibition, L-aspartate 4-semialdehyde as varied substrate
4.3.3.7	Triticum aestivum		threo-4-hydroxy-L-lysine	33902	20995	
4.3.3.7	Zea mays		threo-4-hydroxy-L-lysine	33911	20995	
4.3.3.7	Escherichia coli		trans-(1SS,3R5S)-3,5-thiomorpholinedicarboxylic acid, dimethyl ester, 1-oxide	678711	16211	20 mM, 20% inhibition
4.3.3.7	Mycobacterium tuberculosis		trans-(1SS,3R5S)-3,5-thiomorpholinedicarboxylic acid, dimethyl ester, 1-oxide	678711	16211	20 mM, 14% inhibition; 20 mM, 22% inhibition
4.3.3.7	Staphylococcus aureus		trans-(1SS,3R5S)-3,5-thiomorpholinedicarboxylic acid, dimethyl ester, 1-oxide	678711	16211	20 mM, 12% inhibition
6.3.2.12	Plasmodium falciparum		2-[[(4-[[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino]phenyl)(hydroxy)phosphoryl]methyl]pentanedioic acid	705610	8145	; selective for dihydrofolate synthase activity
6.3.2.12	Plasmodium falciparum		2-[[[(3S)-3-[(4-[[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino]benzoyl)amino]-3-carboxypropyl](hydroxy)phosphoryl]methyl]pentanedioic acid	705610	12806	
6.3.2.12	Neisseria gonorrhoeae		7,8-dihydrofolate	1007	173	noncompetitive with respect to dihydropteroate, competitive with respect to L-Glu
6.3.2.12	Escherichia coli		7,8-dihydrofolate	1018	173	
6.3.2.12	Pisum sativum		ADP	1012	8	
6.3.2.12	Serratia indica		ADP	1016	8	
6.3.2.12	Neisseria gonorrhoeae		Dihydro-10-carbonylfolic acid	1011	14308	
6.3.2.12	Neisseria gonorrhoeae		Dihydro-10-carbonylpteroic acid	1011	64408	
6.3.2.12	Neisseria gonorrhoeae		Dihydro-10-thiofolic acid	1011	66352	
6.3.2.12	Neisseria gonorrhoeae		Dihydro-10-thiopteroic acid	1011	20318	
6.3.2.12	Escherichia coli		Dihydro-10-thiopteroic acid	1013, 1017	20318	
6.3.2.12	Neisseria gonorrhoeae		Dihydrofolate derivatives	1011		
6.3.2.12	Neisseria gonorrhoeae		dihydrofolic acid	1011	173	
6.3.2.12	Escherichia coli		dihydrofolic acid	1013, 1017	173	
6.3.2.12	Serratia indica		Dihydrohomopteroic acid	1015	13349	
6.3.2.12	Escherichia coli		Dihydrohomopteroic acid	1013, 1017, 1018	13349	
6.3.2.12	Neisseria gonorrhoeae		Dihydroisopteroic acid	1011	20319	
6.3.2.12	Escherichia coli		Dihydroisopteroic acid	1013, 1017	20319	
6.3.2.12	Neisseria gonorrhoeae		Dihydromonopteroic acid	1011		
6.3.2.12	Escherichia coli		Dihydropterin-sulfonamides	1014		
6.3.2.12	Neisseria gonorrhoeae		Dihydropteroate derivatives	1011		
6.3.2.12	Corynebacterium sp.		more	1005		5,6,7,8-tetrahydrofolate does not significantly inhibit
6.3.2.12	Escherichia coli		more	1010		no inhibition by 10N-formyltetrahydropteroyldiglutamate
6.3.2.12	Escherichia coli		more	662362		in Escherichia coli, the addition of L-glutamate to dihydropteroate (dihydrofolate synthetase activity) and the subsequent additions of L-glutamate to tetrahydrofolate (folylpolyglutamate synthetase (FPGS) activity) are catalyzed by the same enzyme, FolC. The presence of a folate binding site in Escherichia coli FolC, which is different from the one seen in folylpolyglutamate synthetases, provides avenues for the design of specific inhibitors of this enzyme in antimicrobial therapy
6.3.2.12	Plasmodium falciparum		more	705610		not inhibitory: methotrexate
6.3.2.12	Neisseria gonorrhoeae		p-hydroxymercuribenzoate	1007	92	
6.3.2.12	Corynebacterium sp.		pABA	1008	905	
6.3.2.12	Neisseria gonorrhoeae		PCMB	1007	40	
6.3.2.12	Serratia indica		PCMB	1016	40	
6.3.2.12	Serratia indica		Tetrahydrohomopteroate	1015	65564	
2.7.1.39	Rhodospirillum rubrum	L-Cys		641464	70	slight activation
2.7.1.39	Hordeum vulgare	NH4+		641460	50	monovalent cation required, K+ or NH4+
2.7.1.39	Pisum sativum	NH4+		641461	50	100 mM NH4Cl results in 35% of the activation compared to 100 mM K+
2.7.1.39	Escherichia coli	NH4+		641465	50	30% of the activity obtained with 0.5 M K+
2.7.1.39	Brevibacterium flavum	NH4+		641466	50	not essential, but stimulates
2.7.1.39	Schizosaccharomyces pombe		(2Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide	722043	6699	
2.7.1.39	Escherichia coli		(4R)-4-hydroxypentan-2-one	641471	91688	
2.7.1.39	Escherichia coli		(p-hydroxyphenyl)-glyoxal	641471	20867	
2.7.1.39	Escherichia coli		1,2-amino-5-hydroxyvalerate	641471		substrate inhibition
2.7.1.39	Schizosaccharomyces pombe		1-(naphthalen-2-yl)prop-2-en-1-one	722043	61772	
2.7.1.39	Schizosaccharomyces pombe		2-(2-methylpropyl)-6,7,8,9-tetrahydro-4H,5H-cyclohepta[4,5]thieno[2,3-d][1,3]oxazin-4-one	722043	61775	
2.7.1.39	Schizosaccharomyces pombe		2-(3,4-dihydroxyphenyl)-3,6,7-trihydroxy-2,3-dihydro-4H-chromen-4-one	722043	61773	
2.7.1.39	Escherichia coli		2-amino-3-(phosphonoethyl)thiopropionate	641471	33093	
2.7.1.39	Escherichia coli		2-Amino-5-phosphonovalerate	641471	28699	
2.7.1.39	Escherichia coli		2-amino-5-phosphovalerate	641471	33095	
2.7.1.39	Escherichia coli		2-chloro-L-alanine	641470	28728	
2.7.1.39	Schizosaccharomyces pombe		3-methyl-1-phenyl-6-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-4-ol	722043	62038	
2.7.1.39	Schizosaccharomyces pombe		4-hydroxy-3-[(4-hydroxy-2-oxo-3,8a-dihydro-2H-chromen-3-yl)methyl]-2H-chromen-2-one	722043	61774	
2.7.1.39	Escherichia coli		5'-adenylylimidodiphosphate	641463	2969	
2.7.1.39	Pisum sativum		6-hydroxy-DL-Lys	641461	73884	5 mM, 92% inhibition
2.7.1.39	Escherichia coli		alpha-amino-beta-hydroxy valeric acid	641465	31826	
2.7.1.39	Escherichia coli		diethyl dicarbonate	641473	265	
2.7.1.39	Escherichia coli		L-2-aminobutyrate	641470	1112	
2.7.1.39	Escherichia coli		L-2-aminobutyric acid	641465	1302	40 mM, 50% inhibition
2.7.1.39	Escherichia coli		L-alpha-aminobutyric acid	641463	1302	
2.7.1.39	Pisum sativum		L-Arg	641461	117	10 mM, 13% inhibition
2.7.1.39	Rhodospirillum rubrum		L-aspartate	641464	91	slight
2.7.1.39	Escherichia coli		L-aspartate semialdehyde	641463	472	mixed inhibition versus L-homoserine and ATP
2.7.1.39	Pisum sativum		L-Cys	641461	70	10 mM, 25% inhibition
2.7.1.39	Escherichia coli		L-Cys	641470, 641471	70	
2.7.1.39	Escherichia coli		L-Glutamic acid	641471	38	
2.7.1.39	Escherichia coli		L-homocysteine	641470	260	
2.7.1.39	Escherichia coli		L-homoserine	641463	294	above 0.75 mM
2.7.1.39	Saccharomyces cerevisiae		L-homoserine	641468	294	
2.7.1.39	Escherichia coli		L-homoserine	641471	294	
2.7.1.39	Escherichia coli		L-homoserine	641473	294	substrate inhibition
2.7.1.39	Escherichia coli		L-homoserine alpha-methyl ester	641471	11179	substrate inhibition
2.7.1.39	Escherichia coli		L-homoserine ethyl ester	641471	8849	unlike the wild-type enzyme the mutant enzyme H202L is inhibited
2.7.1.39	Escherichia coli		L-homoserine isopropyl ester	641471	14375	unlike the wild-type enzyme the mutant enzyme H202L is inhibited
2.7.1.39	Escherichia coli		L-homoserine n-propyl ester	641471	14376	unlike the wild-type enzyme the mutant enzyme H202L is inhibited
2.7.1.39	Pisum sativum		L-Ile	641461	266	7.5 mM, 90% inhibition
2.7.1.39	Raphanus sativus		L-Ile	641462	266	no inhibition with the D-isomer
2.7.1.39	Escherichia coli		L-Ile	641470	266	
2.7.1.39	Pisum sativum		L-Leu	641461	121	10 mM, 20% inhibition
2.7.1.39	Pisum sativum		L-Lys	641461	128	10 mM, 35% inhibition
2.7.1.39	Pisum sativum		L-Met	641461	83	10 mM, 17% inhibition
2.7.1.39	Escherichia coli		L-Met	641470	83	
2.7.1.39	Escherichia coli		L-norvaline	641471	559	
2.7.1.39	Pisum sativum		L-Orn	641461	172	10 mM, 64% inhibition
2.7.1.39	Pisum sativum		L-Ser	641461	89	10 mM, 10% inhibition
2.7.1.39	Escherichia coli		L-Ser	641470	89	
2.7.1.39	Pisum sativum		L-Thr	641461	220	10 mM, 18% inhibition
2.7.1.39	Raphanus sativus		L-Thr	641462	220	
2.7.1.39	Escherichia coli		L-Thr	641465	220	
2.7.1.39	Brevibacterium flavum		L-Thr	641466	220	8.1 mM, 50% inhibition
2.7.1.39	Saccharomyces cerevisiae		L-Thr	641468	220	half-maximal inhibition at 10 mM
2.7.1.39	Escherichia coli		L-Thr	641470	220	competitive to the substrate L-homoserine
2.7.1.39	Escherichia coli		L-Thr	641471	220	substrate inhibition
2.7.1.39	Pisum sativum		L-Val	641461	217	16 mM, 86% inhibition
2.7.1.39	Escherichia coli		L-Val	641470	217	
2.7.1.39	Hordeum vulgare		more	641460		no feedback inhibition by Thr, Met or Ile
2.7.1.39	Pisum sativum		O-Phospho-DL-homoserine	641461	29628	10 mM, 91% inhibition
2.7.1.39	Escherichia coli		O-phospho-L-serine	641471	899	
2.7.1.39	Brevibacterium flavum		phosphohomoserine	641466	2593	inhibits phosphorylation of L-homoserine
2.7.1.39	Escherichia coli		pyridoxal 5'-phosphate	641473	30	
2.7.1.39	Pisum sativum		S-adenosyl-L-methionine	641461	22	10 mM, 92% inhibition
2.7.1.39	Raphanus sativus		S-adenosyl-L-methionine	641462	22	
2.7.1.39	Triticum aestivum		S-adenosyl-L-methionine	641467	22	10 mM, 26% inhibition
3.5.2.3	Crithidia fasciculata	Dimethylsulfoxide		246644	702	increases the catalytic efficiency on the ring cyclization reaction, but not on the ring hydrolysis
3.5.2.3	Plasmodium berghei	Dimethylsulfoxide		246644	702	increases the catalytic efficiency on the ring cyclization reaction, but not on the ring hydrolysis
3.5.2.3	Pseudomonas oryzihabitans	more		712312		following pyrimidine limitation of orotidine 5'-monophosphate decarboxylase mutant strain cells, dihydroorotase and dihydroorotate dehydrogenase activities double while aspartate transcarbamoylase and orotate phosphoribosyltransferase activities are slightly elevated compared to their activities in the mutant strain cells grown on excess uracil
3.5.2.3	Escherichia coli		(S)-1,2,3,6-tetrahydro-6-oxopyridine-2-carboxylic acid	667912	40253	competitive inhibitor versus dihydroorotate and thio-dihydroorotate
3.5.2.3	Simian virus 40		1,10-phenanthroline	246629	58	
3.5.2.3	Cricetinae		2-oxo-1,2,3,6-tetrahydropyrimidine-4,6-dicarboxylate	172162, 246646	7826	
3.5.2.3	Escherichia coli		2-oxo-1,2,3,6-tetrahydropyrimidine-4,6-dicarboxylate	688362	7826	
3.5.2.3	Bacillus caldolyticus		2-oxo-1,2,3,6-tetrahydropyrimidine-4,6-dicarboxylic acid	667738	7826	at 37&deg;C or 60&deg;c the enzyme binds 2-oxo-1,2,3,6-tetrahydropyrimidine-4,6-dicarboxylic acid only slightly more strongly than DHO; competitive inhibitor
3.5.2.3	Cricetinae		2-oxo-1,2,3,6-tetrahydropyrimidine-4,6-dicarboxylic acid	667738	7826	at 37&deg;C or 60&deg;C the enzyme binds 2-oxo-1,2,3,6-tetrahydropyrimidine-4,6-dicarboxylic acid more tightly than DHO
3.5.2.3	Mesocricetus auratus		2-oxo-1,2,3,6-tetrahydropyrimidine-4,6-dicarboxylic acid	667738	7826	competitive inhibitor
3.5.2.3	Escherichia coli		4(R)-hydroxy-6-oxo-piperidine-2(S)-carboxylic acid	667912	40252	competitive inhibitor versus dihydroorotate and thio-dihydroorotate
3.5.2.3	Escherichia coli		4(S)-hydroxy-6-oxo-piperidine-2(S)-carboxylic acid	667912	40251	competitive inhibitor versus dihydroorotate and thio-dihydroorotate
3.5.2.3	Escherichia coli		4,6-dioxo-piperidine-2-(S)-carboxylic acid	667912	7825	most active competitive inhibitor versus dihydroorotate and thio-dihydroorotate
3.5.2.3	Plasmodium berghei		5-aminoorotate	246645	5618	
3.5.2.3	Mesocricetus auratus		5-aminoorotate	650954	5618	1 mM, 90% inhibition
3.5.2.3	Plasmodium falciparum		5-aminoorotate	684892	5618	
3.5.2.3	Rattus norvegicus		5-aminoorotic acid	697580	5618	
3.5.2.3	Plasmodium berghei		5-bromoorotate	246645	5620	
3.5.2.3	Plasmodium falciparum		5-bromoorotate	684892	5620	
3.5.2.3	Plasmodium berghei		5-Fluoroorotate	246645	2276	
3.5.2.3	Plasmodium falciparum		5-Fluoroorotate	684892	2276	
3.5.2.3	Escherichia coli		5-Fluoroorotate	684208, 688362	2276	
3.5.2.3	Plasmodium berghei		5-iodoorotate	246645	6376	
3.5.2.3	Plasmodium falciparum		5-iodoorotate	684892	6376	
3.5.2.3	Plasmodium berghei		5-Methylorotate	246645	4373	
3.5.2.3	Plasmodium falciparum		5-Methylorotate	684892	4373	
3.5.2.3	Simian virus 40		8-hydroxyquinoline	246629	276	
3.5.2.3	Rattus norvegicus		Ag2+	246642	798	0.2 mM, 63% inhibition
3.5.2.3	Rattus norvegicus		Cd2+	246642	48	0.2 mM, 12% inhibition
3.5.2.3	Klebsiella pneumoniae		Cd2+	713469	48	
3.5.2.3	Cricetinae		cis-2-oxohexahydropyrimidine-4,6-dicarboxylate	246646	70223	
3.5.2.3	Plasmodium falciparum		Co2+	684892	21	
3.5.2.3	Klebsiella pneumoniae		Co2+	713469	21	
3.5.2.3	Rattus norvegicus		Cu2+	246642	28	0.2 mM, 33% inhibition
3.5.2.3	Homo sapiens		Desferrioxamine	670430	3329	hypoxia causes a decrease in carbamoyl phosphate synthetase-aspartate carbamoyltransferase-dihydroorotase expression incubated under desferrioxamine-induced HIF-1alpha accumulation detected in A293T, IMR32, colo320DM and HeLa cell lines
3.5.2.3	Plasmodium falciparum		diethyl dicarbonate	684892	265	strong inhibition at 1 mM, activity is restored more than 95% when the enzyme is preincubated with both 1 mM diethyl dicarbonate and 5 mM L-carbamoyl-L-aspartate
3.5.2.3	Clostridium oroticum		diethyldicarbonate	246631	265	
3.5.2.3	Crithidia fasciculata		diethyldicarbonate	246644	265	
3.5.2.3	Plasmodium berghei		diethyldicarbonate	246644	265	
3.5.2.3	Simian virus 40		EDTA	246629	223	
3.5.2.3	Clostridium oroticum		EDTA	246631, 246632, 246633	223	
3.5.2.3	Mesocricetus auratus		Furosemide	650954	1172	1 mM, 80% inhibition
3.5.2.3	Rattus norvegicus		Hg2+	246642	31	0.2 mM, 87% inhibition
3.5.2.3	Cricetinae		L-6-thiodihydroorotate	172162, 246646	31891	
3.5.2.3	Klebsiella pneumoniae		Mn2+	713469	26	
3.5.2.3	Mesocricetus auratus		more	650954		not inhibitory: 4-chlorobenzenesulfonamide
3.5.2.3	Homo sapiens		more	670430		hypoxia causes a decrease in carbamoyl phosphate synthetase-aspartate carbamoyltransferase-dihydroorotase expression detected in A293T, IMR32, HeLa cell lines and human endometiral stromal cells
3.5.2.3	Plasmodium falciparum		more	684892		EDTA and 1,10-phenanthroline have no effect on the enzyme activity; L-carbamoyl-L-aspartate and L-dihydroorotate have no inhibitory effect on the enzyme at the pH 7.4
3.5.2.3	Pseudomonas putida		N-carbamoylamino acids	246647	68903	competitive inhibition
3.5.2.3	Clostridium oroticum		N-formylaspartate	246632	3163	competitive inhibitor
3.5.2.3	Klebsiella pneumoniae		Ni2+	713469	36	
3.5.2.3	Plasmodium berghei		Orotate	246645	373	
3.5.2.3	Pseudomonas putida		Orotate	246647	373	noncompetitive inhibition
3.5.2.3	Plasmodium falciparum		Orotate	684892	373	
3.5.2.3	Clostridium oroticum		phosphate	246641	12	300 mM caused 84% inhibition
3.5.2.3	Klebsiella pneumoniae		phosphate	713469	12	
3.5.2.3	Pseudomonas putida		sulfhydryl reagents	246647	752	
3.5.2.3	Cricetinae		trans-2-oxohexahydropyrimidine-4,6-dicarboxylate	246646	70954	
3.5.2.3	Rattus norvegicus		Zn2+	246642	19	0.2 mM, 18% inhibition
3.5.2.3	Plasmodium falciparum		Zn2+	684892	19	complete inhibition
3.5.2.3	Klebsiella pneumoniae		Zn2+	713469	19	
3.5.4.26	Escherichia coli	EDTA		246736	223	
2.5.1.15	Bacillus anthracis	Sulfadiazine		691070	2226	reaction rate increased by sulfadiazine sodium salt, sulfamethoxazole, sulfamethazole, sulfanilamide, sulfathiazole sodium salt in presence of both substrates
2.5.1.15	Bacillus anthracis	sulfamethoxazole		691070	1556	reaction rate increased by sulfadiazine sodium salt, sulfamethoxazole, sulfamethazole, sulfanilamide, sulfathiazole sodium salt in presence of both substrates
2.5.1.15	Bacillus anthracis	sulfanilamide		691070	833	reaction rate increased by sulfadiazine sodium salt, sulfamethoxazole, sulfamethazole, sulfanilamide, sulfathiazole sodium salt in presence of both substrates
2.5.1.15	Bacillus anthracis	sulfathiazole		691070	2304	reaction rate increased by sulfadiazine sodium salt, sulfamethoxazole, sulfamethazole, sulfanilamide, sulfathiazole sodium salt in presence of both substrates
2.5.1.15	Bacillus anthracis		(7-amino-1-methyl-4,5-dioxo-1,4,5,6-tetrahydropyrimido[4,5-c]pyridazin-3-yl)acetic acid	722063	102426	
2.5.1.15	Bacillus anthracis		(7-amino-4,5-dioxo-1,4,5,6-tetrahydropyrimido[4,5-c]pyridazin-3-yl)acetic acid	722063	102430	
2.5.1.15	Francisella tularensis		2-(7-amino-1-methyl-4,5-dioxo-1,4,5,6-tetrahydorpyrimido[4,5-c]pyridazin-3-yl)propanoic acid	723522		binding structure, interactions with the DHPS module and the HPPK module, modeling, ovverview
2.5.1.15	Bacillus anthracis		2-(7-amino-1-methyl-4,5-dioxo-1,4,5,6-tetrahydropyrimido[4,5-c]pyridazin-3-yl)propanoic acid	722063	26869	
2.5.1.15	Bacillus anthracis		2-(7-amino-4,5-dioxo-1,4,5,6-tetrahydropyrimido[4,5-c]pyridazin-3-yl)propanoic acid	722063	102429	
2.5.1.15	Plasmodium chabaudi		2-amino-4-hydroxy-6-hydroxymethyl-dihydropteridine	639668	4789	
2.5.1.15	Bacillus anthracis		3-(7-amino-1-methyl-4,5-dioxo-1,4,5,6-tetrahydropyrimido[4,5-c]pyridazin-3-yl)butanoic acid	722063	102427	
2.5.1.15	Bacillus anthracis		3-(7-amino-1-methyl-4,5-dioxo-1,4,5,6-tetrahydropyrimido[4,5-c]pyridazin-3-yl)propanoic acid	722063	102428	
2.5.1.15	Bacillus anthracis		3-(7-amino-4,5-dioxo-1,4,5,6-tetrahydropyrimido[4,5-c]pyridazin-3-yl)propanoic acid	722063	102431	
2.5.1.15	Plasmodium berghei		4,4-Diaminodiphenyl sulfone	639667	2628	
2.5.1.15	Bacillus anthracis		5-nitro-6-methylamino-isocytosine	663405		
2.5.1.15	Bacillus anthracis		6-hydroxymethylpterin monophosphate	691070	48828	6HMP, competitive inhibitor, 6-hydroxymethyl-7,8-dihydropterin diphosphate analogue
2.5.1.15	Escherichia coli		7,8-Dihydropteroic acid	639665, 639666	1459	
2.5.1.15	Pisum sativum		7,8-Dihydropteroic acid	639674, 639684	1459	
2.5.1.15	Bacillus anthracis		7-amino-1-methyl-4,5-dioxo-1,4,5,6-tetrahydropyrimido[4,5-c]pyridazine-3-carboxylic acid	722063	102425	
2.5.1.15	Plasmodium falciparum		7-amino-3-(1-carboxyethyl)-1-methyl-pyrimido (4,5-c)-pyridazine-4,5(1H,6H)-dione	704962	26869	
2.5.1.15	Pneumocystis jirovecii		7-amino-3-(1-carboxyethyl)-1-methyl-pyrimido (4,5-c)-pyridazine-4,5(1H,6H)-dione	704962, 705059	26869	
2.5.1.15	Plasmodium vivax		cycloguanil	671272	1838	
2.5.1.15	Mycobacterium tuberculosis		dapson	691734	2628	KD: 0.2 microM according to molecular modelling
2.5.1.15	Mycobacterium tuberculosis		dapsone	639680	2628	
2.5.1.15	Mycobacterium leprae		dapsone	639681	2628	; 
2.5.1.15	Plasmodium falciparum		dapsone	661908	2628	effective against wild-type enzyme and mutants A437G/K540E and A437G. Ineffective against mutants A437G/A581G, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Plasmodium falciparum		dapsone	639673, 662800	2628	
2.5.1.15	Saccharomyces cerevisiae		dapsone	671307	2628	
2.5.1.15	Pneumocystis jirovecii		dapsone	671366	2628	
2.5.1.15	Mycobacterium leprae		dapsone	639680, 673141	2628	
2.5.1.15	Streptococcus pneumoniae		dihydrofolate	639679	173	
2.5.1.15	Pisum sativum		dihydrofolate monoglutamate	639684	173	
2.5.1.15	Streptococcus pneumoniae		folate	639679	1001	
2.5.1.15	Plasmodium falciparum		Guanidine HCl	662800	804	0.25 M, 50% inhibition
2.5.1.15	Plasmodium falciparum		KCl	662800	74	above 0.4 M
2.5.1.15	Bacillus anthracis		more	691070		no inhibition by sulfadiazine sodium salt, sulfamethoxazole, sulfamethazole, sulfanilamide, sulfathiazole sodium salt in presence of both substrates
2.5.1.15	Bacillus anthracis		more	721829		compounds 4-([(2-amino-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-6-yl)-(2-phosphono-ethyl)-amino]-methyl)-benzoic acid and 4-([(2-amino-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-6-yl)-(3-phosphono-propyl)-amino]-methyl)-benzoic acid are inactive in inhibition of DHPS, sp2 centers are required at the pterin 5-6 positions for inhibition
2.5.1.15	Bacillus anthracis		more	722063		a series of 4,5-dioxo-1,4,5,6-tetrahydropyrimido[4,5-c]pyridazines are designed to improve binding affinity as dihydropteroate synthase inhibitors, overview. The N-methyl ring substitution is removed to improve binding within the pterin pocket, and the length of the side chain carboxylic acid is optimized to fully engage the diphosphate binding site. Evaluation by evaluated an enzyme activity assay, X-ray crystallography, isothermal calorimetry, and surface plasmon resonance to obtain a comprehensive understanding of the binding interactions from structural, kinetic, and thermodynamic perspectives
2.5.1.15	Francisella tularensis		more	723522		simultaneously targeting of the two modules of the bifunctional enzyme with pterin binding inhibitors
2.5.1.15	Bacillus anthracis		more	723771		structural, computational and mutagenesis studies on the catalytic and resistance mechanisms of DHPS with sulfonamide antibiotics, overview
2.5.1.15	Yersinia pestis		more	723771		structural, computational and mutagenesis studies on the catalytic and resistance mechanisms of DHPS with sulfonamide antibiotics, overview
2.5.1.15	Plasmodium falciparum		NaCl	662800	39	above 0.2 M
2.5.1.15	Plasmodium chabaudi		p-Aminobenzoate	639668	905	
2.5.1.15	Lactobacillus plantarum		p-Aminobenzoylglutamate	1022	7909	weak
2.5.1.15	Mycobacterium leprae		p-Aminosalicylate	639680	3530	
2.5.1.15	Mycobacterium tuberculosis		p-Aminosalicylate	639680	3530	
2.5.1.15	Plasmodium chabaudi		p-Aminosalicylic acid	639668	3530	
2.5.1.15	Plasmodium falciparum		p-Aminosalicylic acid	662800	3530	
2.5.1.15	Escherichia coli		phosphanilic acid	660716	37633	28% inhibition at 2.0 mM, complete inhibition at 20 mM
2.5.1.15	Pseudomonas aeruginosa		phosphanilic acid	660716	37633	22% inhibition at 2.0 mM, 84% inhibition at 20 mM
2.5.1.15	Bacillus anthracis		potassium 4-([(2-amino-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-6-yl)-(2-phosphonoethyl)-amino]-methyl)-benzoate	721829		the oxidized analogue shows significant DHPS inhibition and significant antimicrobial activity
2.5.1.15	Bacillus anthracis		potassium 4-([(2-amino-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-6-yl)-(3-phosphonopropyl)-amino]-methyl)-benzoate	721829		the oxidized analogue shows significant DHPS inhibition and significant antimicrobial activity
2.5.1.15	Mycobacterium tuberculosis		Pteroic acid	691734	10662	PTA, product analog, binds pterin- and 4-aminobenzoate-binding regions
2.5.1.15	Plasmodium vivax		pyrimethamine	671272	613	
2.5.1.15	Plasmodium falciparum		pyrimethamine	639683, 671349	613	
2.5.1.15	Plasmodium falciparum		sulfacetamide	661908	15357	effective against wild-type enzyme and mutant enzymes A437G/K540E, A437G, A437G/A581G, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Plasmodium falciparum		sulfacetamide	662800	15357	
2.5.1.15	Pneumocystis jirovecii		sulfacetamide	671366	15357	
2.5.1.15	Plasmodium falciparum		sulfachloropyridazine	661908	5115	effective against wild-type enzyme and mutant enzymes A437G/K540E, A437G, A437G/A581G, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Plasmodium falciparum		sulfachloropyridazine	662800	5115	
2.5.1.15	Saccharomyces cerevisiae		sulfachloropyridazine	671307	5115	
2.5.1.15	Pneumocystis jirovecii		sulfachlorpyridazine	671366	5115	
2.5.1.15	Plasmodium berghei		Sulfadiazine	639667	2226	
2.5.1.15	Escherichia coli		Sulfadiazine	660716	2226	0.2 mM, complete inhibition
2.5.1.15	Pseudomonas aeruginosa		Sulfadiazine	660716	2226	0.2 mM, complete inhibition
2.5.1.15	Plasmodium falciparum		Sulfadiazine	662800	2226	
2.5.1.15	Pneumocystis jirovecii		Sulfadiazine	671366	2226	
2.5.1.15	Plasmodium falciparum		sulfadimethoxine	661908	15355	effective against wild-type enzyme and mutant A437G. Ineffective against mutants A437G/A581G, A437G/K540E, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Plasmodium falciparum		sulfadimethoxine	662800	15355	
2.5.1.15	Pneumocystis jirovecii		sulfadimethoxine	671366	15355	
2.5.1.15	Plasmodium falciparum		sulfadoxine	661908	5682	effective against wild-type enzyme. Ineffective against mutants A437G, A437G/A581G, A437G/K540E, S436F/A437G/A613S and S436F/A437G/A613T. IC50 for wild-type enzyme: 0.071 mg/ml, IC50 for mutant enzyme A437G: 0.203 mg/ml, IC50 for mutant enzyme A437G/K540E: 0.423 mg/ml, IC50 for mutant enzyme A437G/A581G: 0.775 mg/ml, IC50 for mutant enzymes S436F/A437G/A613S and S436F/A437G/A613T is above 1 mg/ml
2.5.1.15	Pneumocystis jirovecii		sulfadoxine	671366	5682	
2.5.1.15	Plasmodium falciparum		sulfadoxine	639673, 639683, 662800, 672544	5682	
2.5.1.15	Plasmodium falciparum		sulfadoxine-pyrimethamine	671349	86344	
2.5.1.15	Plasmodium chabaudi		Sulfaguanidine	639668, 639670	13527	
2.5.1.15	Plasmodium falciparum		sulfamerazine	661908	10685	effective against wild-type enzyme and mutants A437G/K540E and A437G. Ineffective against mutants A437G/A581G, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Plasmodium falciparum		sulfamerazine	662800	10685	
2.5.1.15	Pneumocystis jirovecii		sulfamerazine	671366	10685	
2.5.1.15	Escherichia coli		sulfamethoxazole	1014	1556	competitive to 4-aminobenzoate
2.5.1.15	Streptococcus pneumoniae		sulfamethoxazole	639679	1556	
2.5.1.15	Mycobacterium leprae		sulfamethoxazole	639680	1556	
2.5.1.15	Mycobacterium tuberculosis		sulfamethoxazole	639680	1556	
2.5.1.15	Plasmodium falciparum		sulfamethoxazole	661908	1556	effective against wild-type enzyme and mutant A437G. Ineffective against mutants A437G/A581G, A437G/K540E, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Plasmodium falciparum		sulfamethoxazole	639673, 662800	1556	
2.5.1.15	Saccharomyces cerevisiae		sulfamethoxazole	671307	1556	
2.5.1.15	Pneumocystis jirovecii		sulfamethoxazole	671366	1556	
2.5.1.15	Streptococcus pneumoniae		sulfamethoxazole	690820	1556	a sulfonamide, KD = 2.3 +/-0.1 microM as revealed by fluorescence spectroscopy
2.5.1.15	Mycobacterium leprae		sulfamethoxypyridazine	639680	7540	
2.5.1.15	Mycobacterium tuberculosis		sulfamethoxypyridazine	639680	7540	
2.5.1.15	Plasmodium falciparum		sulfamethoxypyridazine	662800	7540	
2.5.1.15	Pneumocystis jirovecii		sulfamethoxypyridazine	671366	7540	
2.5.1.15	Plasmodium falciparum		sulfamoxisole	661908		effective against wild-type enzyme and mutant enzymes A437G/K540E, A437G, S436F/A437G/A613S and S436F/A437G/A613T. Ineffective against A437G/A581G
2.5.1.15	Plasmodium falciparum		sulfamoxole	662800	23456	
2.5.1.15	Pneumocystis jirovecii		sulfamoxole	671366	23456	
2.5.1.15	Escherichia coli		sulfanilamide	1014	833	
2.5.1.15	Plasmodium chabaudi		sulfanilamide	639668, 639670	833	
2.5.1.15	Streptococcus pneumoniae		sulfanilamide	639679	833	
2.5.1.15	Plasmodium falciparum		sulfanilamide	661908	833	effective against wild-type enzyme and mutants A437G/K540E and A437G. Ineffective against mutants A437G/A581G, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Plasmodium falciparum		sulfanilamide	662800	833	
2.5.1.15	Pneumocystis jirovecii		sulfanilamide	671366	833	
2.5.1.15	Plasmodium chabaudi		Sulfanilic acid	639668	7260	
2.5.1.15	Plasmodium falciparum		sulfapyridine	662800	8478	
2.5.1.15	Pneumocystis jirovecii		sulfapyridine	671366	8478	
2.5.1.15	Plasmodium falciparum		sulfaquinoxaline	661908	15356	effective against wild-type enzyme and mutant A437G. Ineffective against mutants A437G/A581G, A437G/K540E, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Plasmodium falciparum		sulfaquinoxaline	662800	15356	
2.5.1.15	Pneumocystis jirovecii		sulfaquinoxaline	671366	15356	
2.5.1.15	Streptococcus pneumoniae		sulfaquinoxazoline	639679		
2.5.1.15	Plasmodium chabaudi		sulfathiazole	639668, 639670	2304	competitive to 4-aminobenzoate
2.5.1.15	Plasmodium falciparum		sulfathiazole	639673	2304	competitive to 4-aminobenzoate
2.5.1.15	Escherichia coli		sulfathiazole	1014, 639666, 639676	2304	competitive to 4-aminobenzoate
2.5.1.15	Campylobacter jejuni		sulfathiazole	639678	2304	competitive to 4-aminobenzoate
2.5.1.15	Streptococcus pneumoniae		sulfathiazole	639682	2304	competitive to 4-aminobenzoate
2.5.1.15	Plasmodium falciparum		sulfathiazole	661908	2304	effective against wild-type enzyme and mutants A437G/K540E and A437G. Ineffective against mutants A437G/A581G, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Plasmodium falciparum		sulfathiazole	662800	2304	
2.5.1.15	Pneumocystis jirovecii		sulfathiazole	671366	2304	
2.5.1.15	Plasmodium falciparum		sulfisoxazole	661908	7772	effective against wild-type enzyme and mutant A437G. Ineffective against mutants A437G/A581G, A437G/K540E, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Plasmodium falciparum		sulfisoxazole	662800	7772	
2.5.1.15	Pneumocystis jirovecii		sulfisoxazole	671366	7772	
2.5.1.15	Escherichia coli		sulfonamide	1014, 639666	4706	competitive to 4-aminobenzoate
2.5.1.15	Plasmodium chabaudi		sulfonamide	639668, 639670	4706	competitive to 4-aminobenzoate
2.5.1.15	Bacillus anthracis		Sulfonamides	721829	29765	act as competitive inhibitors with respect to the 4-amino benzoic acid substrate within the DHPS enzyme active site. The 4-amino benzoic acid/sulfonamide binding site is formed close to the protein surface by flexible protein loops facilitating rapid development of sulfonamide resistance. Study of inhibitors designed to target the conserved central pterin binding site within DHPS, molecular dynamics simulation and molecular modeling, overview. Design and synthesis of transition state analogues with ability to mimic the intermediate transient carbocation by the incorporation of a basic amine at the 6-position of the pterin ring
2.5.1.15	Plasmodium falciparum		sulfpyridine	661908		effective against wild-type enzyme. Ineffective against mutants A437G, A437G/A581G, A437G/K540E, S436F/A437G/A613S and S436F/A437G/A613T
2.5.1.15	Pisum sativum		tetrahydrofolate monoglutamate	639684	74786	
2.5.1.15	Pneumocystis jirovecii		trimethoprim-sulfamethoxazole	675117	86345	
2.5.1.15	Mycobacterium tuberculosis		Trp-Lys	691734	92431	WK, highly potent with KD: 0.23 nM according to structure-based molecular modelling and docking, overlaps with pterin monophosphate and pteroic acid binding regions, highly selective for microbial DHPS compared to human pterin and folate-binding enzymes (dihydrofolate reductase, thymidylate synthase)
2.5.1.15	Plasmodium falciparum		Urea	662800	110	0.9 M, 50% inhibition
2.5.1.15	Plasmodium vivax		WR99210	671272	1910	
4.2.1.10	Helicobacter pylori		(1R,2R,4S,5R)-1,4,5-trihydroxy-2-(4-methoxybenzyl)-3-oxocyclohexanecarboxylic acid	703225	18162	
4.2.1.10	Mycobacterium tuberculosis		(1R,2R,4S,5R)-1,4,5-trihydroxy-2-(4-methoxybenzyl)-3-oxocyclohexanecarboxylic acid	703225	18162	
4.2.1.10	Helicobacter pylori		(1R,2R,4S,5R)-1,4,5-trihydroxy-2-(4-methylbenzyl)-3-oxocyclohexanecarboxylic acid	703225	18163	
4.2.1.10	Mycobacterium tuberculosis		(1R,2R,4S,5R)-1,4,5-trihydroxy-2-(4-methylbenzyl)-3-oxocyclohexanecarboxylic acid	703225	18163	
4.2.1.10	Helicobacter pylori		(1R,2R,4S,5R)-1,4,5-trihydroxy-3-oxo-2-(prop-2-en-1-yl)cyclohexanecarboxylic acid	703225	18164	
4.2.1.10	Mycobacterium tuberculosis		(1R,2R,4S,5R)-1,4,5-trihydroxy-3-oxo-2-(prop-2-en-1-yl)cyclohexanecarboxylic acid	703225	18164	
4.2.1.10	Helicobacter pylori		(1R,2R,4S,5R)-1,4,5-trihydroxy-3-oxo-2-propylcyclohexanecarboxylic acid	703225	18165	
4.2.1.10	Mycobacterium tuberculosis		(1R,2R,4S,5R)-1,4,5-trihydroxy-3-oxo-2-propylcyclohexanecarboxylic acid	703225	18165	
4.2.1.10	Helicobacter pylori		(1R,2R,4S,5R)-2-(1-benzothiophen-5-yl)-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18166	
4.2.1.10	Mycobacterium tuberculosis		(1R,2R,4S,5R)-2-(1-benzothiophen-5-yl)-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18166	
4.2.1.10	Helicobacter pylori		(1R,2R,4S,5R)-2-benzyl-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18167	
4.2.1.10	Mycobacterium tuberculosis		(1R,2R,4S,5R)-2-benzyl-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18167	
4.2.1.10	Helicobacter pylori		(1R,2R,4S,5R)-2-[difluoro(pentafluorophenyl)methyl]-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18168	
4.2.1.10	Mycobacterium tuberculosis		(1R,2R,4S,5R)-2-[difluoro(pentafluorophenyl)methyl]-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18168	
4.2.1.10	Helicobacter pylori		(1R,2S,4S,5R)-1,4,5-trihydroxy-2-(4-methoxybenzyl)-3-oxocyclohexanecarboxylic acid	703225	18169	
4.2.1.10	Mycobacterium tuberculosis		(1R,2S,4S,5R)-1,4,5-trihydroxy-2-(4-methoxybenzyl)-3-oxocyclohexanecarboxylic acid	703225	18169	
4.2.1.10	Helicobacter pylori		(1R,2S,4S,5R)-1,4,5-trihydroxy-2-(4-methylbenzyl)-3-oxocyclohexanecarboxylic acid	703225	18170	
4.2.1.10	Mycobacterium tuberculosis		(1R,2S,4S,5R)-1,4,5-trihydroxy-2-(4-methylbenzyl)-3-oxocyclohexanecarboxylic acid	703225	18170	
4.2.1.10	Helicobacter pylori		(1R,2S,4S,5R)-1,4,5-trihydroxy-3-oxo-2-(prop-2-en-1-yl)cyclohexanecarboxylic acid	703225	18171	
4.2.1.10	Mycobacterium tuberculosis		(1R,2S,4S,5R)-1,4,5-trihydroxy-3-oxo-2-(prop-2-en-1-yl)cyclohexanecarboxylic acid	703225	18171	
4.2.1.10	Helicobacter pylori		(1R,2S,4S,5R)-2-(1-benzothiophen-5-yl)-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18172	
4.2.1.10	Mycobacterium tuberculosis		(1R,2S,4S,5R)-2-(1-benzothiophen-5-yl)-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18172	
4.2.1.10	Helicobacter pylori		(1R,2S,4S,5R)-2-benzyl-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18173	
4.2.1.10	Mycobacterium tuberculosis		(1R,2S,4S,5R)-2-benzyl-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18173	
4.2.1.10	Helicobacter pylori		(1R,2S,4S,5R)-2-[difluoro(pentafluorophenyl)methyl]-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18174	
4.2.1.10	Mycobacterium tuberculosis		(1R,2S,4S,5R)-2-[difluoro(pentafluorophenyl)methyl]-1,4,5-trihydroxy-3-oxocyclohexanecarboxylic acid	703225	18174	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(3,5-difluoro)phenylcyclohex-5-en-1-carboxylic acid	665979	38730	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(3-carboxylic)phenylcyclohex-5-en-1-carboxylic acid	665979	38729	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(3-fluoro)phenylcyclo-hex-5-en-1-carboxylic acid	665979	38726	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(3-hydroxy)phenylcyclohex-5-en-1-carboxylic acid	665979	38728	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(3-nitro)phenylcyclohex-5-en-1-carboxylic acid	665979	12497	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(3-trifluoromethyl)phenylcyclohex-5-en-1-carboxylic acid	665979	38727	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(4-fluoro)phenylcyclo-hex-5-en-1-carboxylic acid	665979	38724	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(4-trifluoromethyl)phenylcyclohex-5-en-1-carboxylic acid	665979	38725	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(furan-3-yl)phenylcyclohex-5-en-1-carboxylic acid	665979	38733	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(pyridine-3-yl)cyclohex-5-en-1-carboxylic acid	665979	38732	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-(thiophen-3-yl)phenyl-cyclohex-5-en-1-carboxylic acid	665979	38731	
4.2.1.10	Mycobacterium tuberculosis		(1R,3R,4R)-1,3,4-trihydroxy-5-phenylcyclohex-5-en-1-carboxylic acid	665979	38723	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-2-cyclohexene-1-carboxylic acid	691819	6593	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(1-phenyl-1H-1,2,3-triazol-4-yl)cyclohex-2-ene-1-carboxylic acid	716099	10211	competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-(1-phenyl-1H-1,2,3-triazol-4-yl)cyclohex-2-ene-1-carboxylic acid	716099	10211	competitive inhibitor
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-(1-phenyl-1H-1,2,3-triazol-4-yl)cyclohex-2-ene-1-carboxylic acid	716099	10211	competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(1H-1,2,3-triazol-4-yl)cyclohex-2-en-1-carboxylic acid	691819	49501	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(2-hydroxy)ethylcyclohex-2-ene-1-carboxylic acid	730168		
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-(2-hydroxy)ethylcyclohex-2-ene-1-carboxylic acid	730168		
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(2-nitrophenyl)cyclohex-2-ene-1-carboxylic acid	691819	48257	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(2-nitrothien-3-yl)cyclohex-2-en-1-carboxylic acid	691819	49502	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(3-bromothien-2-yl)cyclohex-2-en-1-carboxylic acid	691819	49504	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(3-hydroxyphenyl)cyclohex-2-ene-1-carboxylic acid	691819	38728	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(3-nitrophenyl)cyclohex-2-ene-1-carboxylic acid	691819	12497	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(3-nitrophenyl)cyclohex-2-ene-1-carboxylic acid	714752	12497	a competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-(3-nitrophenyl)cyclohex-2-ene-1-carboxylic acid	714752	12497	a competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(3-nitrothien-2-yl)cyclohex-2-en-1-carboxylic acid	691819	49505	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(3-phenoxyphenyl)cyclohex-2-ene-1-carboxylic acid	705060	12728	competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(3-phenoxyphenyl)cyclohex-2-ene-1-carboxylic acid	714752	12728	a competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-(3-phenoxyphenyl)cyclohex-2-ene-1-carboxylic acid	714752	12728	a competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(4-nitrophenyl)cyclohex-2-ene-1-carboxylic acid	691819	48258	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(phenylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10203	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-(phenylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10203	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-(phenylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10203	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(pyridin-3-ylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10207	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-(pyridin-3-ylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10207	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-(pyridin-3-ylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10207	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(quinolin-3-ylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10210	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-(quinolin-3-ylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10210	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-(quinolin-3-ylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10210	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(thien-2-yl)cyclohex-2-en-1-carboxylic acid	691819	9930	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(thiophen-2-yl)cyclohex-2-ene-1-carboxylic acid	705060	9930	competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(thiophen-2-yl)cyclohex-2-ene-1-carboxylic acid	714752	9930	a competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-(thiophen-2-yl)cyclohex-2-ene-1-carboxylic acid	714752	9930	a competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-(thiophen-2-ylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10208	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-(thiophen-2-ylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10208	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-(thiophen-2-ylethynyl)cyclohex-2-ene-1-carboxylic acid	714751	10208	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-hydroxymethylcyclohex-2-en-1-carboxylic acid	730168		
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-hydroxymethylcyclohex-2-en-1-carboxylic acid	730168		
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-naphthalen-2-ylcyclohex-2-ene-1-carboxylic acid	691819	48259	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-phenylcyclohex-2-ene-1-carboxylic acid	691819	38723	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-pyridin-3-ylcyclohex-2-ene-1-carboxylic acid	691819	38732	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-thiophen-3-ylcyclohex-2-ene-1-carboxylic acid	691819	48260	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[(1E)-3-phenoxyprop-1-en-1-yl]cyclohex-2-ene-1-carboxylic acid	714752	28033	a competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[(1E)-3-phenoxyprop-1-en-1-yl]cyclohex-2-ene-1-carboxylic acid	714752	28033	a competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[(1R)-1-chloro-2-phenyl]-ethylcyclohex-2-en-1-carboxylic acid	730168		
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[(1R)-1-chloro-2-phenyl]-ethylcyclohex-2-en-1-carboxylic acid	730168		
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[(1R)-1-hydroxy-2-phenylethyl]cyclohex-2-en-1-carboxylic acid	730168		
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[(1R)-1-hydroxy-2-phenylethyl]cyclohex-2-en-1-carboxylic acid	730168		
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[(1S)-1-chloro-2-phenyl]-ethylcyclohex-2-en-1-carboxylic acid	730168		
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[(1S)-1-chloro-2-phenyl]-ethylcyclohex-2-en-1-carboxylic acid	730168		
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[(1S)-1-hydroxy-2-phenylethyl]cyclohex-2-en-1-carboxylic acid	730168		
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[(1S)-1-hydroxy-2-phenylethyl]cyclohex-2-en-1-carboxylic acid	730168		
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[(3-nitrophenyl)ethynyl]cyclohex-2-ene-1-carboxylic acid	714751	10205	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[(3-nitrophenyl)ethynyl]cyclohex-2-ene-1-carboxylic acid	714751	10205	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-[(3-nitrophenyl)ethynyl]cyclohex-2-ene-1-carboxylic acid	714751	10205	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(2-hydroxyphenyl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10215	competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(2-hydroxyphenyl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10215	competitive inhibitor
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(2-hydroxyphenyl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10215	competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(3-nitrophenyl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10213	competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(3-nitrophenyl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10213	competitive inhibitor
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(3-nitrophenyl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10213	competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(pyridin-3-yl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10216	competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(pyridin-3-yl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10216	competitive inhibitor
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(pyridin-3-yl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10216	competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(thiophen-2-ylmethyl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10218	competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(thiophen-2-ylmethyl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10218	competitive inhibitor
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-[1-(thiophen-2-ylmethyl)-1H-1,2,3-triazol-4-yl]cyclohex-2-ene-1-carboxylic acid	716099	10218	competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[3-(phenylsulfanyl)phenyl]cyclohex-2-ene-1-carboxylic acid	714752	28035	a competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[3-(phenylsulfanyl)phenyl]cyclohex-2-ene-1-carboxylic acid	714752	28035	a competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[3-(trifluoromethyl)phenyl]cyclohex-2-ene-1-carboxylic acid	691819	38727	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[3-phenoxy-prop-(E)-enyl]-cyclohex-2-enecarboxylic acid	714105	28033	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[4-(trifluoromethyl)phenyl]cyclohex-2-ene-1-carboxylic acid	691819	38725	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-1,4,5-trihydroxy-3-[[3-(trifluoromethyl)phenyl]ethynyl]cyclohex-2-ene-1-carboxylic acid	714751	10206	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxy-3-[[3-(trifluoromethyl)phenyl]ethynyl]cyclohex-2-ene-1-carboxylic acid	714751	10206	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxy-3-[[3-(trifluoromethyl)phenyl]ethynyl]cyclohex-2-ene-1-carboxylic acid	714751	10206	
4.2.1.10	Aspergillus nidulans		(1R,4R,5R)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	666281	6593	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	666281	6593	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhimurium		(1R,4R,5R)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	666281	6593	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	666281	6593	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-(1,3-benzothiazol-2-ylethynyl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	714751	10209	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-3-(1,3-benzothiazol-2-ylethynyl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	714751	10209	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-3-(1,3-benzothiazol-2-ylethynyl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	714751	10209	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-(1-benzofuran-5-yl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	691819	48261	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-(1-benzofuran-6-yl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	691819	48262	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-(1-benzothiophen-5-yl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	691819	48263	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-(1-benzothiophen-6-yl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	691819	48264	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-3-(2-carboxy-vinyl)-1,4,5-trihydroxy-cyclohex-2-enecarboxylic acid	679231	16655	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-3-(2-carboxy-vinyl)-1,4,5-trihydroxy-cyclohex-2-enecarboxylic acid	679231	16655	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-(3,5-difluorophenyl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	691819	38730	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-(3-carbonitrilethien-2-yl)-1,4,5-trihydroxycyclohex-2-en-1-carboxylic acid	691819	49506	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-(3-fluorophenyl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	691819	38726	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-(4-fluorophenyl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	691819	38724	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-(furan-2-yl)-1,4,5-trihydroxycyclohex-2-en-1-carboxylic acid	691819	49503	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-3-(tert-butylcarbamoyl)-1,4,5-trihydroxycyclohex-2-enecarboxylic acid	679231	9440	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-3-(tert-butylcarbamoyl)-1,4,5-trihydroxycyclohex-2-enecarboxylic acid	679231, 714105	9440	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-furan-3-yl-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	691819	48265	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-[(4-fluorophenyl)ethynyl]-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	714751	10204	
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-3-[(4-fluorophenyl)ethynyl]-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	714751	10204	
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-3-[(4-fluorophenyl)ethynyl]-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	714751	10204	
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-[1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl]-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	716099	10212	competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-3-[1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl]-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	716099	10212	competitive inhibitor
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-3-[1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl]-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	716099	10212	competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4R,5R)-3-[1-(furan-2-ylmethyl)-1H-1,2,3-triazol-4-yl]-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	716099	10217	competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4R,5R)-3-[1-(furan-2-ylmethyl)-1H-1,2,3-triazol-4-yl]-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	716099	10217	competitive inhibitor
4.2.1.10	Streptomyces coelicolor		(1R,4R,5R)-3-[1-(furan-2-ylmethyl)-1H-1,2,3-triazol-4-yl]-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	716099	10217	competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4S,5R)-1,3,4,5-tetrahydroxycyclohex-2-ene-1-carboxylate	705060	96050	
4.2.1.10	Helicobacter pylori		(1R,4S,5R)-1,4,5-trihydroxy-3-(naphthalen-2-ylmethoxy)cyclohex-2-ene-1-carboxylic acid	730168		competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4S,5R)-1,4,5-trihydroxy-3-(naphthalen-2-ylmethoxy)cyclohex-2-ene-1-carboxylic acid	730168		competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4S,5R)-1,4,5-trihydroxy-3-[(1E)-3-phenoxyprop-1-en-1-yl]cyclohex-2-ene-1-carboxylic acid	714105	59978	
4.2.1.10	Helicobacter pylori		(1R,4S,5R)-1,4,5-trihydroxy-3-[(5-methyl-1-benzothiophen-2-yl)methoxy]cyclohex-2-ene-1-carboxylic acid	730168		competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4S,5R)-1,4,5-trihydroxy-3-[(5-methyl-1-benzothiophen-2-yl)methoxy]cyclohex-2-ene-1-carboxylic acid	730168		competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4S,5R)-3,3-difluoro-1,4,5-trihydroxycyclohexane-1-carboxylic acid	666521	9181	inhibitor is selective for the type II dehydroquinase over the type I dehydroquinase
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		(1R,4S,5R)-3,3-difluoro-1,4,5-trihydroxycyclohexane-1-carboxylic acid	666521	9181	
4.2.1.10	Streptomyces coelicolor		(1R,4S,5R)-3,3-difluoro-1,4,5-trihydroxycyclohexane-1-carboxylic acid	666521	9181	inhibitor is selective for the type II dehydroquinase over the type I dehydroquinase
4.2.1.10	Helicobacter pylori		(1R,4S,5R)-3-(1-benzothiophen-2-ylmethoxy)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	714752	28034	a competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4S,5R)-3-(1-benzothiophen-2-ylmethoxy)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	714752	28034	a competitive inhibitor
4.2.1.10	Helicobacter pylori		(1R,4S,5R)-3-(1-benzothiophen-2-ylmethoxy)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	730168	28034	competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4S,5R)-3-(1-benzothiophen-2-ylmethoxy)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylic acid	730168	28034	competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(1R,4S,5R)-3-fluoro-1,4,5-trihydroxy-2-cyclohexene-1-carboxylic acid	666521	9180	inhibitor is selective for the type II dehydroquinase over the type I dehydroquinase
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		(1R,4S,5R)-3-fluoro-1,4,5-trihydroxy-2-cyclohexene-1-carboxylic acid	666521	9180	
4.2.1.10	Streptomyces coelicolor		(1R,4S,5R)-3-fluoro-1,4,5-trihydroxy-2-cyclohexene-1-carboxylic acid	666521	9180	inhibitor is selective for the type II dehydroquinase over the type I dehydroquinase
4.2.1.10	Streptomyces coelicolor		(1S,3R,4R)-1,3,4-trihydroxy-5-cyclohexene-1-carboxylic acid	653401		
4.2.1.10	Aspergillus nidulans		(1S,3R,4R)-1,3,4-trihydroxy-5-methylenecyclohexanecarboxylic acid	666281	9179	
4.2.1.10	Mycobacterium tuberculosis		(1S,3R,4R)-1,3,4-trihydroxy-5-methylenecyclohexanecarboxylic acid	666281	9179	
4.2.1.10	Streptomyces coelicolor		(1S,3R,4R)-1,3,4-trihydroxy-5-methylenecyclohexanecarboxylic acid	666281	9179	
4.2.1.10	Aspergillus nidulans		(1S,3R,4R)-1,3,4-trihydroxycyclohexanecarboxylic acid	666281	6594	
4.2.1.10	Mycobacterium tuberculosis		(1S,3R,4R)-1,3,4-trihydroxycyclohexanecarboxylic acid	666281	6594	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhimurium		(1S,3R,4R)-1,3,4-trihydroxycyclohexanecarboxylic acid	666281	6594	
4.2.1.10	Streptomyces coelicolor		(1S,3R,4R)-1,3,4-trihydroxycyclohexanecarboxylic acid	666281	6594	
4.2.1.10	Aspergillus nidulans		(1S,3R,4R,5E)-1,3,4-trihydroxy-5-(methylimino)cyclohexanecarboxylic acid	666281	9178	
4.2.1.10	Mycobacterium tuberculosis		(1S,3R,4R,5E)-1,3,4-trihydroxy-5-(methylimino)cyclohexanecarboxylic acid	666281	9178	
4.2.1.10	Streptomyces coelicolor		(1S,3R,4R,5E)-1,3,4-trihydroxy-5-(methylimino)cyclohexanecarboxylic acid	666281	9178	
4.2.1.10	Mycobacterium tuberculosis		(1S,4R,5R)-3-(3-benzoylphenyl)-1,4,5-trihydroxycyclohex-2-enecarboxylic acid	714105	112598	
4.2.1.10	Helicobacter pylori		(2R)-2-p-methoxybenzyl-3-dehydroquinic acid	714749	18162	a reversible, competitive inhibitor of DHQ2
4.2.1.10	Mycobacterium tuberculosis		(2R)-2-p-methoxybenzyl-3-dehydroquinic acid	714749	18162	a reversible, competitive inhibitor of DHQ2, pH not specified in the publication, temperature not specified in the publication
4.2.1.10	Helicobacter pylori		(2R)-2-p-methylbenzyl-3-dehydroquinic acid	714749	18163	a reversible, competitive inhibitor of DHQ2
4.2.1.10	Mycobacterium tuberculosis		(2R)-2-p-methylbenzyl-3-dehydroquinic acid	714749	18163	a reversible, competitive inhibitor of DHQ2, pH not specified in the publication, temperature not specified in the publication
4.2.1.10	Helicobacter pylori		(2R)-2-pentafluoro-benzyl-3-dehydroquinic acid	714749	111979	a reversible, competitive inhibitor of DHQ2
4.2.1.10	Mycobacterium tuberculosis		(2R)-2-pentafluoro-benzyl-3-dehydroquinic acid	714749	111979	a reversible, competitive inhibitor of DHQ2, pH not specified in the publication, temperature not specified in the publication
4.2.1.10	Mycobacterium tuberculosis		(3R,5R,6R)-3,5,6-trihydroxycyclohex-1-ene-1,3-dicarboxylic acid	679231	7936	
4.2.1.10	Streptomyces coelicolor		(3R,5R,6R)-3,5,6-trihydroxycyclohex-1-ene-1,3-dicarboxylic acid	679231	7936	
4.2.1.10	Helicobacter pylori		(3R,5R,6R)-3,5,6-trihydroxycyclohex-1-ene-1,3-dicarboxylic acid	714752	7936	a competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(3R,5R,6R)-3,5,6-trihydroxycyclohex-1-ene-1,3-dicarboxylic acid	714752	7936	a competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		(3R,5R,6R)-3-carbamoyl-3,5,6-trihydroxycyclohex-1-enecarboxylic acid	679231	16654	
4.2.1.10	Streptomyces coelicolor		(3R,5R,6R)-3-carbamoyl-3,5,6-trihydroxycyclohex-1-enecarboxylic acid	679231	16654	
4.2.1.10	Helicobacter pylori		(4R,6R,7S)-2-(1-cyclopropylethyl)-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10201	
4.2.1.10	Mycobacterium tuberculosis		(4R,6R,7S)-2-(1-cyclopropylethyl)-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10201	
4.2.1.10	Streptomyces coelicolor		(4R,6R,7S)-2-(1-cyclopropylethyl)-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10201	
4.2.1.10	Helicobacter pylori		(4R,6R,7S)-2-ethenyl-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10195	
4.2.1.10	Mycobacterium tuberculosis		(4R,6R,7S)-2-ethenyl-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10195	
4.2.1.10	Streptomyces coelicolor		(4R,6R,7S)-2-ethenyl-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10195	
4.2.1.10	Helicobacter pylori		(4R,6R,7S)-2-ethyl-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10196	
4.2.1.10	Mycobacterium tuberculosis		(4R,6R,7S)-2-ethyl-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10196	
4.2.1.10	Streptomyces coelicolor		(4R,6R,7S)-2-ethyl-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10196	
4.2.1.10	Helicobacter pylori		(4R,6R,7S)-2-[(1E)-2-cyclopropylprop-1-en-1-yl]-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10198	
4.2.1.10	Mycobacterium tuberculosis		(4R,6R,7S)-2-[(1E)-2-cyclopropylprop-1-en-1-yl]-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10198	
4.2.1.10	Streptomyces coelicolor		(4R,6R,7S)-2-[(1E)-2-cyclopropylprop-1-en-1-yl]-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10198	
4.2.1.10	Helicobacter pylori		(4R,6R,7S)-4,6,7-trihydroxy-2-(2-hydroxyethyl)-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10200	
4.2.1.10	Mycobacterium tuberculosis		(4R,6R,7S)-4,6,7-trihydroxy-2-(2-hydroxyethyl)-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10200	
4.2.1.10	Streptomyces coelicolor		(4R,6R,7S)-4,6,7-trihydroxy-2-(2-hydroxyethyl)-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10200	
4.2.1.10	Helicobacter pylori		(4R,6R,7S)-4,6,7-trihydroxy-2-(prop-2-en-1-yl)-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10199	
4.2.1.10	Mycobacterium tuberculosis		(4R,6R,7S)-4,6,7-trihydroxy-2-(prop-2-en-1-yl)-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10199	
4.2.1.10	Streptomyces coelicolor		(4R,6R,7S)-4,6,7-trihydroxy-2-(prop-2-en-1-yl)-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10199	
4.2.1.10	Helicobacter pylori		(4R,6R,7S)-4,6,7-trihydroxy-2-(propan-2-yl)-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10202	
4.2.1.10	Mycobacterium tuberculosis		(4R,6R,7S)-4,6,7-trihydroxy-2-(propan-2-yl)-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10202	
4.2.1.10	Streptomyces coelicolor		(4R,6R,7S)-4,6,7-trihydroxy-2-(propan-2-yl)-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10202	
4.2.1.10	Helicobacter pylori		(4R,6R,7S)-4,6,7-trihydroxy-2-methyl-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10194	
4.2.1.10	Mycobacterium tuberculosis		(4R,6R,7S)-4,6,7-trihydroxy-2-methyl-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10194	
4.2.1.10	Streptomyces coelicolor		(4R,6R,7S)-4,6,7-trihydroxy-2-methyl-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10194	
4.2.1.10	Helicobacter pylori		(4R,6R,7S)-4,6,7-trihydroxy-2-[(1Z)-prop-1-en-1-yl]-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10197	
4.2.1.10	Mycobacterium tuberculosis		(4R,6R,7S)-4,6,7-trihydroxy-2-[(1Z)-prop-1-en-1-yl]-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10197	
4.2.1.10	Streptomyces coelicolor		(4R,6R,7S)-4,6,7-trihydroxy-2-[(1Z)-prop-1-en-1-yl]-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10197	
4.2.1.10	Helicobacter pylori		(4R,6R,7S)-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10193	
4.2.1.10	Mycobacterium tuberculosis		(4R,6R,7S)-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10193	
4.2.1.10	Streptomyces coelicolor		(4R,6R,7S)-4,6,7-trihydroxy-4,5,6,7-tetrahydro-1-benzothiophene-4-carboxylic acid	714752	10193	
4.2.1.10	Aspergillus nidulans		1,3,4-trihydroxy-5-hydroxyiminocyclohexanecarboxylic acid	5484	13556	
4.2.1.10	Mycobacterium tuberculosis		1,3,4-trihydroxy-5-hydroxyiminocyclohexanecarboxylic acid	5484	13556	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		1,3,4-trihydroxy-5-hydroxyiminocyclohexanecarboxylic acid	5484	13556	poor inhibition
4.2.1.10	Streptomyces coelicolor		1,3,4-trihydroxy-5-hydroxyiminocyclohexanecarboxylic acid	5484	13556	
4.2.1.10	Aspergillus nidulans		1,3,4-trihydroxy-5-oxocyclohexanecarboxylic acid	5484	13557	
4.2.1.10	Mycobacterium tuberculosis		1,3,4-trihydroxy-5-oxocyclohexanecarboxylic acid	5484	13557	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		1,3,4-trihydroxy-5-oxocyclohexanecarboxylic acid	5484	13557	poor inhibition
4.2.1.10	Streptomyces coelicolor		1,3,4-trihydroxy-5-oxocyclohexanecarboxylic acid	5484	13557	
4.2.1.10	Aspergillus nidulans		1,3,4-trihydroxycyclohexanecarboxylic acid	5484	13558	
4.2.1.10	Mycobacterium tuberculosis		1,3,4-trihydroxycyclohexanecarboxylic acid	5484	13558	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		1,3,4-trihydroxycyclohexanecarboxylic acid	5484	13558	poor inhibition
4.2.1.10	Streptomyces coelicolor		1,3,4-trihydroxycyclohexanecarboxylic acid	5484	13558	
4.2.1.10	Aspergillus nidulans		1,4,5-trihydroxycyclohex-2-enecarboxylic acid	5484	13559	
4.2.1.10	Mycobacterium tuberculosis		1,4,5-trihydroxycyclohex-2-enecarboxylic acid	5484	13559	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		1,4,5-trihydroxycyclohex-2-enecarboxylic acid	5484	13559	poor inhibition
4.2.1.10	Streptomyces coelicolor		1,4,5-trihydroxycyclohex-2-enecarboxylic acid	5484	13559	
4.2.1.10	Helicobacter pylori		2,3-anhydroquinate	665986	700	
4.2.1.10	Mycobacterium tuberculosis		2,3-anhydroquinate	714105	700	mimics the flattened enol/enolate reaction intermediate and serves as an anchor molecule for four of the inhibitors investigated, overview. Structure of MtDHQase in complex with a 2,3-anhydroquinate moiety attached to a biaryl group shows that this group extends to an active-site subpocket inducing significant structural rearrangement
4.2.1.10	Aspergillus nidulans		2,3-anhydroquinic acid	5484	6593	
4.2.1.10	Mycobacterium tuberculosis		2,3-anhydroquinic acid	5484	6593	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		2,3-anhydroquinic acid	5484	6593	poor inhibition
4.2.1.10	Streptomyces coelicolor		2,3-anhydroquinic acid	5484	6593	
4.2.1.10	Peptoclostridium difficile		2,5-dichloro-N-(4-phenyl-1,3-thiazol-2-yl)benzenesulfonamide	730780		
4.2.1.10	Peptoclostridium difficile		2,5-dichloro-N-(6-methoxy-1,3-benzothiazol-2-yl)benzenesulfonamide	730780		
4.2.1.10	Peptoclostridium difficile		2-[(4,5,6,7-tetrahydro-1-benzothiophen-3-ylcarbonyl)amino]benzoic acid	730780		
4.2.1.10	Aspergillus nidulans		3-deoxyquinic acid	5484	6594	
4.2.1.10	Mycobacterium tuberculosis		3-deoxyquinic acid	5484	6594	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		3-deoxyquinic acid	5484	6594	poor inhibition
4.2.1.10	Streptomyces coelicolor		3-deoxyquinic acid	5484	6594	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		3-hydroxy-cyclohex-1-ene-1,3-dicarboxylic acid	679231	16656	
4.2.1.10	Streptomyces coelicolor		3-hydroxy-cyclohex-1-ene-1,3-dicarboxylic acid	679231	16656	
4.2.1.10	Helicobacter pylori		3-[(3R,5R,6R)-3-carboxy-3,5,6-trihydroxycyclohex-1-en-1-yl]benzoic acid	691819	38729	
4.2.1.10	Helicobacter pylori		3-[4-[(3R,5R,6R)-3-carboxy-3,5,6-trihydroxycyclohex-1-en-1-yl]-1H-1,2,3-triazol-1-yl]benzoic acid	716099	10214	competitive inhibitor
4.2.1.10	Mycobacterium tuberculosis		3-[4-[(3R,5R,6R)-3-carboxy-3,5,6-trihydroxycyclohex-1-en-1-yl]-1H-1,2,3-triazol-1-yl]benzoic acid	716099	10214	competitive inhibitor
4.2.1.10	Streptomyces coelicolor		3-[4-[(3R,5R,6R)-3-carboxy-3,5,6-trihydroxycyclohex-1-en-1-yl]-1H-1,2,3-triazol-1-yl]benzoic acid	716099	10214	competitive inhibitor
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		4-hydroxy-2-hydroxymethyl-4-methyl-pent-2-enedioic acid	679231	16657	
4.2.1.10	Streptomyces coelicolor		4-hydroxy-2-hydroxymethyl-4-methyl-pent-2-enedioic acid	679231	16657	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		4-hydroxy-4-methyl-pent-2-enedioic acid	679231	16658	
4.2.1.10	Streptomyces coelicolor		4-hydroxy-4-methyl-pent-2-enedioic acid	679231	16658	
4.2.1.10	Escherichia coli		acetate	5473, 5474	44	
4.2.1.10	Helicobacter pylori		benzo[b]thiophen-5-yl-3-dehydroquinic acid	714749	111980	a reversible, competitive inhibitor of DHQ2
4.2.1.10	Mycobacterium tuberculosis		benzo[b]thiophen-5-yl-3-dehydroquinic acid	714749	111980	a reversible, competitive inhibitor of DHQ2, pH not specified in the publication, temperature not specified in the publication
4.2.1.10	Helicobacter pylori		carbaphosphonate	690739	49500	
4.2.1.10	Helicobacter pylori		citrate	665986	125	
4.2.1.10	Mycobacterium tuberculosis		citrazinic acid	714105	32587	a planar analogue of the reaction product, complex structure, overview
4.2.1.10	Escherichia coli		Cl-	5473, 5474	134	
4.2.1.10	Streptomyces coelicolor		Cl-	5480	134	no significant effect
4.2.1.10	Escherichia coli		Cu2+	5463	28	partial
4.2.1.10	Escherichia coli		D-(+)-tartrate	5473	3375	
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		diethyl dicarbonate	5479	265	
4.2.1.10	Aspergillus nidulans		diethyl dicarbonate	5483	265	
4.2.1.10	Escherichia coli		diethyl dicarbonate	5483	265	
4.2.1.10	Spinacia oleracea		EDTA	5488	223	
4.2.1.10	Escherichia coli		Fe2+	5463	23	partial
4.2.1.10	Neurospora crassa		guanidine hydrochloride	5465	804	55 C, irreversible inactivation
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		guanidine hydrochloride	5479	804	
4.2.1.10	Helicobacter pylori		HTS 11955	690739	15278	
4.2.1.10	Escherichia coli		hydroxylamine	5463	80	partial
4.2.1.10	Escherichia coli		iodoacetamide	5463	63	partial
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhimurium		more	666281		Ki-values for (1S,3R,4R,5E)-1,3,4-trihydroxy-5-(methylimino)cyclohexanecarboxylic acid and (1S,3R,4R)-1,3,4-trihydroxy-5-methylenecyclohexanecarboxylic acid are above 25 mM
4.2.1.10	Mycobacterium tuberculosis		more	679232		the in silico design, synthesis, and biological evaluation of ten potent type II dehydroquinase inhibitors are described. These compounds contain an anhydroquinate core, incorporated as a mimic of the enolate reaction intermediate. This substructure is attached by a variety of linking units to a terminal phenyl group that binds in an adjacent pocket. Inhibitors are synthesised from (-)-quinic acid using palladium-catalysed Stille and carboamidation chemistry. Several inhibitors exhibited nanomolar inhibition constants
4.2.1.10	Streptomyces coelicolor		more	679232		the in silico design, synthesis, and biological evaluation of ten potent type II dehydroquinase inhibitors are described. These compounds contain an anhydroquinate core, incorporated as a mimic of the enolate reaction intermediate. This substructure is attached by a variety of linking units to a terminal phenyl group that binds in an adjacent pocket. Inhibitors are synthesised from (-)-quinic acid using palladium-catalysed Stille and carboamidation chemistry. Several inhibitors exhibited nanomolar inhibition constants
4.2.1.10	Mycobacterium tuberculosis		more	679233		nanomolar competitive inhibitors
4.2.1.10	Streptomyces coelicolor		more	679233		nanomolar competitive inhibitors
4.2.1.10	Nicotiana tabacum		more	681134		RNA interference of NtDHD/SHD-1 strongly inhibits DHD/SHD activity in transgenic tobacco plants
4.2.1.10	Mycobacterium tuberculosis		more	714105		active-site binding of inhibitors, structure, overview
4.2.1.10	Helicobacter pylori		more	714749		binding mechanism of (2R)-2-benzyl-3-dehydroquinic acids, molecular dynamics simulations, overview
4.2.1.10	Mycobacterium tuberculosis		more	714749		binding mechanism of (2R)-2-benzyl-3-dehydroquinic acids, molecular dynamics simulations, overview
4.2.1.10	Helicobacter pylori		more	714751		development of a range of ene-yne-based inhibitors, active site docking study using enzyme structure PDB ID 2WKS, overview
4.2.1.10	Mycobacterium tuberculosis		more	714751		development of a range of ene-yne-based inhibitors, overview
4.2.1.10	Streptomyces coelicolor		more	714751		development of a range of ene-yne-based inhibitors, active site docking study using enzyme structure PDB ID 1GU1, overview
4.2.1.10	Helicobacter pylori		more	714752		inhibitor design and synthesis, binding structure and inhibition mechanism, overview
4.2.1.10	Mycobacterium tuberculosis		more	714752		inhibitor design and synthesis, binding structure and inhibition mechanism, overview
4.2.1.10	Streptomyces coelicolor		more	714752		inhibitor design and synthesis, binding structure and inhibition mechanism, overview
4.2.1.10	Helicobacter pylori		N-tetrazol-5-yl-9-oxo-9H-xanthene-2-sulfonamide	665986	38722	
4.2.1.10	Escherichia coli		NaBH4	5473	507	irreversible inactivation in presence of 3-dehydroquinate
4.2.1.10	Salmonella enterica subsp. enterica serovar Typhi		NaBH4	5479	507	irreversible inactivation in presence of 3-dehydroquinate
4.2.1.10	Pisum sativum		NaBH4	5482	507	
4.2.1.10	Amycolatopsis methanolica		NaBH4	5486	507	
4.2.1.10	Streptomyces coelicolor		phosphate	651312	12	
4.2.1.10	Helicobacter pylori		RH00573	690739	23369	
4.2.1.10	Neurospora crassa		SDS	5465	118	55 C, irreversible inactivation
4.2.1.10	Helicobacter pylori		sodium (1R,4S,5R)-1,4,5-trihydroxy-3-(5-methylbenzo[b]-thiophen-2-yl)methoxycyclohex-2-en-1-carboxylate	705060	54755	
4.2.1.10	Helicobacter pylori		sodium (1R,4S,5R)-1,4,5-trihydroxy-3-(benzo[b]thiophen-2-yl)methoxycyclohex-2-en-1-carboxylate	705060	54754	
4.2.1.10	Helicobacter pylori		sodium (1R,4S,5R)-1,4,5-trihydroxy-3-(thien-2-yl)methoxycyclohex-2-en-1-carboxylate	705060	54752	
4.2.1.10	Helicobacter pylori		sodium (1R,4S,5R)-1,4,5-trihydroxy-3-[(benzo[b]thiophen-5-yl)methoxy]cyclohex-2-en-1-carboxylate	705060	54753	
4.2.1.10	Escherichia coli		succinate	5473, 5474	54	
4.2.1.10	Streptomyces coelicolor		sulfate	651312	148	
4.2.1.10	Escherichia coli		Zn2+	5463	19	partial
2.7.4.9	Acetabularia acetabulum	more		645197		freezing at -70&deg;C and then thawing results in an increase in activity
2.7.4.9	Mycobacterium tuberculosis		(+/-)(Z)-5-acetamido-1-(4-(thymin-1-yl)but-2-enyl)-5,6-dihydro-1H-imidazo[4,5,1-ij]quinolin-2(4H)-one	722186		
2.7.4.9	Mycobacterium tuberculosis		(+/-)(Z)-5-amino-1-(4-(thymin-1-yl)but-2-enyl)-5,6-dihydro-1H-imidazo[4,5,1-ij]quinolin-2(4H)-one	722186		
2.7.4.9	Staphylococcus aureus		(3-chlorophenoxy)-4-((R)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)propyl)benzoic acid	722918	112003	
2.7.4.9	Streptococcus pneumoniae		(3-chlorophenoxy)-4-((R)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)propyl)benzoic acid	722918	112003	
2.7.4.9	Staphylococcus aureus		(3-chlorophenoxy)-4-((S)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)propyl)benzoic acid	722918	112004	
2.7.4.9	Streptococcus pneumoniae		(3-chlorophenoxy)-4-((S)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)propyl)benzoic acid	722918	112004	
2.7.4.9	Homo sapiens		(3E)-4-[4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]but-3-enoic acid	691226	17059	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		(3E)-4-[4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]but-3-enoic acid	691226	17059	comparison with inhibition of human enzyme
2.7.4.9	Vaccinia virus		(E)-5-(2-bromovinyl)-deoxyuridine	706485	4975	
2.7.4.9	Saccharomyces cerevisiae		(NH4)2SO4	645191	334	0.35 M, 50% inhibition
2.7.4.9	Staphylococcus aureus		(R)-1-(1-(3-(3,4-dichlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	112000	
2.7.4.9	Streptococcus pneumoniae		(R)-1-(1-(3-(3,4-dichlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	112000	
2.7.4.9	Staphylococcus aureus		(R)-1-(1-(3-(4-chlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111998	
2.7.4.9	Streptococcus pneumoniae		(R)-1-(1-(3-(4-chlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111998	
2.7.4.9	Staphylococcus aureus		(S)-1-(1-(3-(3,4-dichlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111999	
2.7.4.9	Streptococcus pneumoniae		(S)-1-(1-(3-(3,4-dichlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111999	
2.7.4.9	Staphylococcus aureus		(S)-1-(1-(3-(3,5-dichlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111996	
2.7.4.9	Streptococcus pneumoniae		(S)-1-(1-(3-(3,5-dichlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111996	
2.7.4.9	Staphylococcus aureus		(S)-1-(1-(3-(3-bromophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111993	
2.7.4.9	Streptococcus pneumoniae		(S)-1-(1-(3-(3-bromophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111993	
2.7.4.9	Staphylococcus aureus		(S)-1-(1-(3-(3-chloro-4-methylphenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111994	
2.7.4.9	Streptococcus pneumoniae		(S)-1-(1-(3-(3-chloro-4-methylphenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111994	
2.7.4.9	Staphylococcus aureus		(S)-1-(1-(3-(3-chloro-5-fluorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111995	
2.7.4.9	Streptococcus pneumoniae		(S)-1-(1-(3-(3-chloro-5-fluorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111995	
2.7.4.9	Staphylococcus aureus		(S)-1-(1-(3-(3-chlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111992	
2.7.4.9	Streptococcus pneumoniae		(S)-1-(1-(3-(3-chlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111992	
2.7.4.9	Staphylococcus aureus		(S)-1-(1-(3-(3-fluorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111991	
2.7.4.9	Streptococcus pneumoniae		(S)-1-(1-(3-(3-fluorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111991	
2.7.4.9	Staphylococcus aureus		(S)-1-(1-(3-(4-chlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111997	
2.7.4.9	Streptococcus pneumoniae		(S)-1-(1-(3-(4-chlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111997	
2.7.4.9	Staphylococcus aureus		(S)-2-(3-bromophenoxy)-4-((3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)benzoic acid	722918	112098	
2.7.4.9	Streptococcus pneumoniae		(S)-2-(3-bromophenoxy)-4-((3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)benzoic acid	722918	112098	
2.7.4.9	Staphylococcus aureus		(S)-2-(3-fluorophenoxy)-4-((3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)benzoic acid	722918		
2.7.4.9	Streptococcus pneumoniae		(S)-2-(3-fluorophenoxy)-4-((3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)benzoic acid	722918		
2.7.4.9	Staphylococcus aureus		(S)-4-((3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-piperidin-1-yl)methyl)-2-(m-tolyloxy)benzoic acid	722918	112099	
2.7.4.9	Streptococcus pneumoniae		(S)-4-((3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-piperidin-1-yl)methyl)-2-(m-tolyloxy)benzoic acid	722918	112099	
2.7.4.9	Staphylococcus aureus		(S)-5-methyl-1-(1-(3-(m-tolyloxy)benzyl)piperidin-3-yl)-pyrimidine-2,4(1H,3H)-dione	722918	111990	
2.7.4.9	Streptococcus pneumoniae		(S)-5-methyl-1-(1-(3-(m-tolyloxy)benzyl)piperidin-3-yl)-pyrimidine-2,4(1H,3H)-dione	722918	111990	
2.7.4.9	Mycobacterium tuberculosis		(Z)-1-(4-(thymin-1-yl)but-2-enyl)-1H-benzo[c,d]indol-2(1H)one	691813	47744	
2.7.4.9	Mycobacterium tuberculosis		(Z)-1-(4-(thymin-1-yl)but-2-enyl)-5,6-dihydro-1H-imidazo[4,5,1-ij]quinolin-2(4H)-one	722186		
2.7.4.9	Mycobacterium tuberculosis		(Z)-2-(4-(5-bromouracil-1-yl)but-2-enyl)-1H-benzo[d,e] isoquinoline-1,3(2H)-dione	691813	47745	
2.7.4.9	Mycobacterium tuberculosis		(Z)-2-(4-(thymin-1-yl)but-2-enyl)-1H-benzo[d,e]isoquinoline-1,3(2H)-dione	691813	47746	
2.7.4.9	Mycobacterium tuberculosis		(Z)-2-(4-(thymin-1-yl)but-2-enyl)-2,3-dihydro-1H-benzo-[d,e]isoquinolin-1-one	691813	47747	
2.7.4.9	Mycobacterium tuberculosis		(Z)-2-(4-(thymin-1-yl)but-2-enyl)-2H-naphtho[1,8 cd]isothiazole-1,1-dioxide	691813	47748	
2.7.4.9	Mycobacterium tuberculosis		(Z)-2-(4-(thymin-1-yl)but-2-enyl)-6-nitrobenzo[c,d]indol-2(1H)one	691813	47749	
2.7.4.9	Mycobacterium tuberculosis		(Z)-8-acetamido-1-(4-(thymin-1-yl)but-2-enyl)-5,6-dihydro-1H-imidazo[4,5,1-ij]quinolin-2(4H)-one	722186		
2.7.4.9	Mycobacterium tuberculosis		(Z)-8-amino-1-(4-(thymin-1-yl)but-2-enyl)-5,6-dihydro-1H-imidazo[4,5,1-ij]quinolin-2(4H)-one	722186		
2.7.4.9	Mycobacterium tuberculosis		1,3-bis[[(2S,3R,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]methyl]urea	704800	95997	
2.7.4.9	Homo sapiens		1,3-bis[[(2S,3R,5R)-2-methyl-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]methyl]urea	662597	24192	
2.7.4.9	Mycobacterium tuberculosis		1,3-bis[[(2S,3R,5R)-2-methyl-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]methyl]urea	662597	24192	
2.7.4.9	Mycobacterium tuberculosis		1-(((2R,3S,5S)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)methyl)-3-(((2S,3R,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)methyl)urea	721834	61942	
2.7.4.9	Mycobacterium tuberculosis		1-((2R,4S,5R)-4-hydroxy-5-(2-(methylsulfonyl)ethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	721846		
2.7.4.9	Mycobacterium tuberculosis		1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-hydroxytetrahydrofuran-2-yl)-5-(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione	721846		
2.7.4.9	Mycobacterium tuberculosis		1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-hydroxytetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	721846		
2.7.4.9	Staphylococcus aureus		1-(1-(3-(4-chlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111988	
2.7.4.9	Streptococcus pneumoniae		1-(1-(3-(4-chlorophenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111988	
2.7.4.9	Staphylococcus aureus		1-(1-(3-(4-methoxyphenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111989	
2.7.4.9	Streptococcus pneumoniae		1-(1-(3-(4-methoxyphenoxy)benzyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	722918	111989	
2.7.4.9	Pseudomonas aeruginosa		1-(3,4-dichlorophenyl)-3-[[(2R,3R,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea	722925	102524	
2.7.4.9	Homo sapiens		1-(3,4-dichlorophenyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea	693534	5926	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		1-(3,4-dichlorophenyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea	693534	5926	comparison with inhibition of human enzyme
2.7.4.9	Mycobacterium tuberculosis		1-(3,4-dichlorophenyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea	704800	5926	
2.7.4.9	Mycobacterium tuberculosis		1-(3,4-dichlorophenyl)-3-[[(2S,3R,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]methyl]thiourea	693534	48963	comparison with inhibition of human enzyme
2.7.4.9	Mycobacterium bovis		1-(3-amino-3-deoxy-2-O,3-N-(thiocarbonyl)-beta-D-ribofuranosyl)thymine	673092	41639	IC99: 500 microg/ml
2.7.4.9	Mycobacterium bovis		1-(3-aminomethyl-3,5-dideoxy-2-O,6-N-(thiocarbonyl)-beta-D-ribofuranosyl)thymine	673092	41638	IC99: 100 microg/ml
2.7.4.9	Homo sapiens		1-(3-chloro-4-trifluoromethylphenyl)-3-[[(2S,3R,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]methyl]thiourea	693534	17278	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		1-(3-chloro-4-trifluoromethylphenyl)-3-[[(2S,3R,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]methyl]thiourea	693534	17278	comparison with inhibition of human enzyme
2.7.4.9	Mycobacterium tuberculosis		1-(4-benzyloxyphenyl)-3-[[(2S,3R,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]methyl]thiourea	693534	48964	comparison with inhibition of human enzyme
2.7.4.9	Mycobacterium tuberculosis		1-(4-bromobenzyl)-5-methylpyrimidine-2,4(1H,3H)-dione	691226	47778	comparison with inhibition of human enzyme
2.7.4.9	Homo sapiens		1-(4-chlorophenyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea	693534	12517	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		1-(4-chlorophenyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea	693534	12517	comparison with inhibition of human enzyme
2.7.4.9	Mycobacterium tuberculosis		1-(4-chlorophenyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea	704800	12517	
2.7.4.9	Mycobacterium tuberculosis		1-(4-chlorophenyl)-3-[[(2S,3R,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]methyl]thiourea	693534	48962	comparison with inhibition of human enzyme
2.7.4.9	Pseudomonas aeruginosa		1-methyl-6-(pyridin-3-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Pseudomonas aeruginosa		1-methyl-6-(pyridin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Pseudomonas aeruginosa		1-methyl-6-(pyrimidin-5-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Pseudomonas aeruginosa		1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Plasmodium falciparum		1-[(1R,2R,3S,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]-5-methylpyrimidine-2,4(1H,3H)-dione	723332	28360	
2.7.4.9	Anaplasma marginale		1-[(1R,2R,4R,5S)-4-(hydroxymethyl)-6-oxabicyclo[3.1.0]hex-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	705992	12726	
2.7.4.9	Plasmodium falciparum		1-[(1R,2R,4R,5S)-4-(hydroxymethyl)-6-oxabicyclo[3.1.0]hex-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	705992, 723332	12726	
2.7.4.9	Plasmodium falciparum		1-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]-5-methylpyrimidine-2,4(1H,3H)-dione	723332	61939	
2.7.4.9	Plasmodium falciparum		1-[(1R,3S,4R)-3-hydroxy-4-(hydroxymethyl)cyclopentyl]-5-methylpyrimidine-2,4(1H,3H)-dione	723332	28362	
2.7.4.9	Plasmodium falciparum		1-[(1R,4S)-4-(hydroxymethyl)cyclopent-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	723332	28359	
2.7.4.9	Plasmodium falciparum		1-[(1S,3R)-3-(hydroxymethyl)cyclopentyl]-5-methylpyrimidine-2,4(1H,3H)-dione	723332	28361	
2.7.4.9	Mycobacterium tuberculosis		1-[(2S,4S,5R)-5-(aminomethyl)-4-hydroxytetrahydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	704800	96015	
2.7.4.9	Mycobacterium tuberculosis		1-[(2S,4S,5R)-5-(azidomethyl)-4-hydroxytetrahydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	704800	96014	
2.7.4.9	Mycobacterium tuberculosis		1-[(2Z)-(4-(5-bromouracil-1-yl)but-2-enyl)]-5,6-dihydro-1H,4H-1,2,5-thiadiazolo[4,3,2-ij]quinolin-2,2-dioxide	722186		
2.7.4.9	Mycobacterium tuberculosis		1-[(2Z)-4-(1,1-dioxido-2H-naphtho[1,8-cd][1,2]thiazol-2-yl)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	722186	47748	
2.7.4.9	Homo sapiens		1-[(4aR,5S,7R,7aR)-5-(hydroxymethyl)-2-oxohexahydro-2H-furo[3,4-e][1,3]oxazin-7-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	662597	15941	
2.7.4.9	Mycobacterium tuberculosis		1-[(4aR,5S,7R,7aR)-5-(hydroxymethyl)-2-oxohexahydro-2H-furo[3,4-e][1,3]oxazin-7-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	662597	15941	
2.7.4.9	Homo sapiens		1-[(4aR,5S,7R,7aR)-5-(hydroxymethyl)-2-thioxohexahydro-2H-furo[3,4-e][1,3]oxazin-7-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	662597	9293	
2.7.4.9	Mycobacterium tuberculosis		1-[(4aR,5S,7R,7aR)-5-(hydroxymethyl)-2-thioxohexahydro-2H-furo[3,4-e][1,3]oxazin-7-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	662597, 721846	9293	
2.7.4.9	Pseudomonas aeruginosa		1-[(4aR,5S,7R,7aS)-5-(hydroxymethyl)-2-thioxohexahydro-2H-furo[3,4-e][1,3]oxazin-7-yl]-5-methylpyrimidine-2,4(1H,3H)-dione	722925	102523	
2.7.4.9	Mycobacterium tuberculosis		1-[(Z)-(4-(thymin-1-yl)but-2-enyl)]-5,6-dihydro-1H,4H-1,2,5-thiadiazolo[4,3,2-ij]quinolin-2,2-dioxide	722186		
2.7.4.9	Mycobacterium tuberculosis		1-[2-ammonio-3-(4-hydroxyphenyl)propanoyl]-N-[1-(4-hydroxyphenyl)-3-oxoniopropan-2-yl]prolinamide	723007	102516	
2.7.4.9	Mycobacterium tuberculosis		1-[2-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy]ethyl]-3-phenylthiourea	704800	96012	
2.7.4.9	Mycobacterium tuberculosis		1-[3-aminomethyl-3,5-dideoxy-2-O,6-N-(thiocarbonyl)-beta-D-ribofuranosyl]thymine	673092	41638	
2.7.4.9	Mycobacterium tuberculosis		1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[2-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy]ethyl]thiourea	704800	96013	
2.7.4.9	Homo sapiens		1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea	693534	5927	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea	693534	5927	comparison with inhibition of human enzyme
2.7.4.9	Mycobacterium tuberculosis		1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea	704800	5927	
2.7.4.9	Mycobacterium tuberculosis		1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]urea	704800	96010	
2.7.4.9	Mycobacterium tuberculosis		1-[5-([[4-chloro-3-(trifluoromethyl)phenyl]carbamothioyl]amino)-2,5-dideoxy-a-D-erythro-pentofuranosyl]-5-methyl-4-thioxo-3,4-dihydropyrimidin-2(1H)-one	721846	61940	
2.7.4.9	Mycobacterium tuberculosis		1-[N-[2-ammonio-3-(1H-indol-3-yl)propanoyl]tyrosyl]pyrrolidine-2-carboxylate	723007	102514	
2.7.4.9	Mycobacterium tuberculosis		1-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]-3-(4-methoxyphenyl)thiourea	704800	95999	
2.7.4.9	Mycobacterium tuberculosis		1-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]-3-(4-methylphenyl)thiourea	704800	96000	
2.7.4.9	Mycobacterium tuberculosis		1-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]-3-phenylthiourea	704800	12723	
2.7.4.9	Mycobacterium tuberculosis		1-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]-3-pyridin-3-ylthiourea	704800	96002	
2.7.4.9	Mycobacterium tuberculosis		1-[[(2S,3R,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]methyl]-3-phenylthiourea	704800	95998	
2.7.4.9	Bacillus anthracis		2',3'-dideoxy-2',3'-didehydrothymidine	695005	5681	poor inhibitor
2.7.4.9	Mycobacterium tuberculosis		2',5'-dideoxy-5'-(4-phenyl-1H-1,2,3-triazol-1-yl)-3,4-dihydrothymidine	721834	61947	
2.7.4.9	Mycobacterium tuberculosis		2',5'-dideoxy-5'-([[3-(trifluoromethyl)phenyl]carbamoyl]amino)-3,4-dihydrothymidine	721834	61944	
2.7.4.9	Mycobacterium tuberculosis		2',5'-difluoro-3'-azidomethylthymidine	662597	37719	
2.7.4.9	Mycobacterium tuberculosis		2'-chlorothymidine 5'-monophosphate	662597	41647	
2.7.4.9	Mycobacterium tuberculosis		2'-deoxy-5-(hydroxymethyl)uridine	662987	32771	
2.7.4.9	Mycobacterium tuberculosis		2'-deoxy-5-(trifluoromethyl)uridine	662987	86461	
2.7.4.9	Mycobacterium tuberculosis		2'-deoxy-5-ethyluridine	662987	28652	
2.7.4.9	Mycobacterium tuberculosis		2'-deoxy-5-fluorouridine	662987	2364	
2.7.4.9	Mycobacterium tuberculosis		2'-deoxy-5-hydroxyuridine	662987	24143	
2.7.4.9	Mycobacterium tuberculosis		2'-deoxyuridine	662987	812	
2.7.4.9	Mycobacterium tuberculosis		2'-fluorothymidine 5'-monophosphate	662597	41646	
2.7.4.9	Mycobacterium tuberculosis		2-((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)-N-methylethanesulfonamide	721846		
2.7.4.9	Pseudomonas aeruginosa		2-(3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-benzamido)acetic acid	722925		
2.7.4.9	Pseudomonas aeruginosa		2-(3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-benzamido)ethanesulfonic acid	722925		
2.7.4.9	Pseudomonas aeruginosa		2-(3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-benzamido)propanoic acid	722925		
2.7.4.9	Pseudomonas aeruginosa		2-(3-(1-N-ethyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-benzamido)-4-phenylbutanoic acid	722925		
2.7.4.9	Pseudomonas aeruginosa		2-(3-(3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamido)propyl)benzoic acid	722925		
2.7.4.9	Staphylococcus aureus		2-(3-bromophenoxy)-4-((R)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)hexyl)benzoic acid	722918	112011	
2.7.4.9	Streptococcus pneumoniae		2-(3-bromophenoxy)-4-((R)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)hexyl)benzoic acid	722918	112011	
2.7.4.9	Staphylococcus aureus		2-(3-bromophenoxy)-4-((R)-3-ethyl-3-methyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)pentyl)benzoic acid	722918	112012	
2.7.4.9	Streptococcus pneumoniae		2-(3-bromophenoxy)-4-((R)-3-ethyl-3-methyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)pentyl)benzoic acid	722918	112012	
2.7.4.9	Staphylococcus aureus		2-(3-bromophenoxy)-4-((S)-3,3-dimethyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)butyl)benzoic acid	722918	111985	
2.7.4.9	Streptococcus pneumoniae		2-(3-bromophenoxy)-4-((S)-3,3-dimethyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)butyl)benzoic acid	722918	111985	
2.7.4.9	Staphylococcus aureus		2-(3-bromophenoxy)-4-(R)-(2-(1-adamantane)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)ethyl)benzoic acid	722918	112016	
2.7.4.9	Streptococcus pneumoniae		2-(3-bromophenoxy)-4-(R)-(2-(1-adamantane)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)ethyl)benzoic acid	722918	112016	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((R)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)-2-(tetrahydro-2H-pyran-4-yl)ethyl)benzoic acid	722918	112015	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((R)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)-2-(tetrahydro-2H-pyran-4-yl)ethyl)benzoic acid	722918	112015	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((R)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)ethyl)benzoic acid	722918	112001	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((R)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)ethyl)benzoic acid	722918	112001	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((R)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1-(2H)-yl)piperidin-1-yl)butyl)benzoic acid	722918	112005	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((R)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1-(2H)-yl)piperidin-1-yl)butyl)benzoic acid	722918	112005	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((R)-2-cyclohexyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)ethyl)benzoic acid	722918	112014	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((R)-2-cyclohexyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)ethyl)benzoic acid	722918	112014	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((R)-3,3-dimethyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)hexyl)benzoic acid	722918	112013	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((R)-3,3-dimethyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)hexyl)benzoic acid	722918	112013	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((R)-3,3-dimethyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)pentyl)benzoic acid	722918	112009	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((R)-3,3-dimethyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)pentyl)benzoic acid	722918	112009	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((R)-3-ethyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)pentyl)benzoic acid	722918	112010	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((R)-3-ethyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)pentyl)benzoic acid	722918	112010	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((R)-3-methyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)butyl)benzoic acid	722918	112007	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((R)-3-methyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)butyl)benzoic acid	722918	112007	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((S)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)butyl)benzoic acid	722918	112006	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((S)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)butyl)benzoic acid	722918	112006	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((S)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)ethyl)benzoic acid	722918	112002	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((S)-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)ethyl)benzoic acid	722918	112002	
2.7.4.9	Staphylococcus aureus		2-(3-chlorophenoxy)-4-((S)-3-methyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)butyl)benzoic acid	722918	112008	
2.7.4.9	Streptococcus pneumoniae		2-(3-chlorophenoxy)-4-((S)-3-methyl-1-((S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)butyl)benzoic acid	722918	112008	
2.7.4.9	Mycobacterium tuberculosis		2-([1-[2-ammonio-3-(1H-indol-3-yl)propanoyl]prolyl]amino)-3-(1H-indol-3-yl)propanoate	723007	102515	
2.7.4.9	Mycobacterium tuberculosis		2-([1-[2-ammonio-3-(1H-indol-3-yl)propanoyl]prolyl]amino)-3-(4-methylphenyl)propanoate	723007	102513	
2.7.4.9	Mycobacterium tuberculosis		2-([1-[2-ammonio-3-(1H-indol-3-yl)propanoyl]prolyl]amino)-3-hydroxypropanoate	723007	102519	
2.7.4.9	Mycobacterium tuberculosis		2-([1-[2-ammonio-3-(1H-indol-3-yl)propanoyl]prolyl]amino)pentanedioate	723007	102509	
2.7.4.9	Mycobacterium tuberculosis		2-([1-[2-ammonio-3-(4-hydroxyphenyl)propanoyl]prolyl]amino)-3-(1H-indol-3-yl)propanoate	723007	102517	
2.7.4.9	Mycobacterium tuberculosis		2-([N-[2-ammonio-3-(1H-indol-3-yl)propanoyl]tyrosyl]amino)-3-(4-hydroxyphenyl)propanoate	723007	102512	
2.7.4.9	Mycobacterium tuberculosis		2-([N-[2-ammonio-3-(1H-indol-3-yl)propanoyl]tyrosyl]amino)-3-hydroxybutanoate	723007	102520	
2.7.4.9	Mycobacterium tuberculosis		2-([N-[2-ammonio-3-(1H-indol-3-yl)propanoyl]tyrosyl]amino)-3-hydroxypropanoate	723007	102518	
2.7.4.9	Mycobacterium tuberculosis		2-([N-[2-ammonio-3-(1H-indol-3-yl)propanoyl]tyrosyl]amino)-4-carboxybutanoate	723007	102508	
2.7.4.9	Mycobacterium tuberculosis		2-([N-[2-ammonio-3-(1H-indol-3-yl)propanoyl]tyrosyl]amino)butanedioate	723007	102507	
2.7.4.9	Pseudomonas aeruginosa		2-benzyl-3-(3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]-pyridin-6-yl)benzamido)propanoic acid	722925		
2.7.4.9	Mus musculus		2-mercaptoethanol	645188	59	0.4 mM
2.7.4.9	Mycobacterium tuberculosis		2-[(4aS,5R,7R,7aR)-5-[5-(hydroxymethyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]-2,2-dioxidooctahydrocyclopenta[c][1,2,6]thiadiazin-7-yl]-N-methylethanesulfonamide	721846	61941	
2.7.4.9	Mycobacterium tuberculosis		2-[([1-[2-ammonio-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]methyl)amino]butanedioate	723007	61938	
2.7.4.9	Mycobacterium tuberculosis		2-[([1-[2-ammonio-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]acetyl)amino]-3-hydroxybutanoate	723007	102521	
2.7.4.9	Mycobacterium tuberculosis		2-[([1-[2-ammonio-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]acetyl)amino]-3-hydroxypropanoate	723007	102522	
2.7.4.9	Mycobacterium tuberculosis		3',5'-diazido-2',3',5'-trideoxy-3,4-dihydrothymidine	721834	61946	
2.7.4.9	Mycobacterium tuberculosis		3'-(4-chlorophenyl-1,2,3-triazol-1-yl)-3'-deoxy-4-thio-beta-D-thymidine	721834		
2.7.4.9	Mycobacterium tuberculosis		3'-(4-chlorophenyl-1,2,3-triazol-1-yl)-3'-deoxy-alpha-D-thymidine	721834		
2.7.4.9	Mycobacterium tuberculosis		3'-(aminomethyl)-2'-chloro-3'-deoxythymidine	662597	37716	
2.7.4.9	Homo sapiens		3'-(aminomethyl)-3'-deoxythymidine	662597	15370	
2.7.4.9	Mycobacterium tuberculosis		3'-(aminomethyl)-3'-deoxythymidine	662597	15370	
2.7.4.9	Mycobacterium tuberculosis		3'-(azidomethyl)-2'-chloro-3'-deoxythymidine	662597	37717	
2.7.4.9	Mycobacterium tuberculosis		3'-(azidomethyl)-3'-deoxy-2'-fluorothymidine	662597	37718	
2.7.4.9	Homo sapiens		3'-(azidomethyl)-3'-deoxy-alpha-D-ribosyl-thymine	662597	40739	
2.7.4.9	Mycobacterium tuberculosis		3'-(azidomethyl)-3'-deoxy-alpha-D-ribosyl-thymine	662597	40739	
2.7.4.9	Homo sapiens		3'-(azidomethyl)-3'-deoxythymidine	662597	15369	
2.7.4.9	Mycobacterium tuberculosis		3'-(azidomethyl)-3'-deoxythymidine	662597	15369	
2.7.4.9	Mycobacterium tuberculosis		3'-([[(4-chlorophenyl)carbamothioyl]amino]methyl)-3'-deoxythymidine	704800	12717	
2.7.4.9	Mycobacterium tuberculosis		3'-azedo-deoxythymidine	723007		
2.7.4.9	Mycobacterium tuberculosis		3'-azido-2',3'-dideoxyuridine	662987	41641	
2.7.4.9	Mycobacterium tuberculosis		3'-azido-3'-deoxy-4-thio-beta-D-thymidine	721834		
2.7.4.9	Mycobacterium tuberculosis		3'-azido-3'-deoxy-alpha-D-thymidine	721834		
2.7.4.9	Pseudomonas aeruginosa		3'-azido-3'-deoxy-thymidine-5'-monophosphate	722925	3036	
2.7.4.9	Mycobacterium tuberculosis		3'-azido-3'-deoxythymidine	661170, 662597, 662987	896	
2.7.4.9	Mycobacterium tuberculosis		3'-azido-3'-deoxythymidine 5'-monophosphate	645207	3036	potent competitive inhibitor
2.7.4.9	Mycobacterium tuberculosis		3'-azido-3'-deoxythymidine 5'-monophosphate	661170	3036	
2.7.4.9	Mycobacterium tuberculosis		3'-azido-3'-deoxythymidine 5'-monophosphate	662169	3036	potential inhibitor
2.7.4.9	Mycobacterium tuberculosis		3'-azido-3'-deoxythymidine 5'-monophosphate	662597	3036	potential inhibitor of the bacterial enzyme, not inhibitory in human
2.7.4.9	Mycobacterium tuberculosis		3'-azido-3'-deoxythymidine 5'-phosphate	662597	11203	
2.7.4.9	Mycobacterium tuberculosis		3'-azido-3'-deoxythymidine monophosphate	645207	11203	
2.7.4.9	Mycobacterium tuberculosis		3'-azido-5-bromo-2',3'-dideoxyuridine	662987	41643	
2.7.4.9	Mycobacterium tuberculosis		3'-azido-5-chloro-2',3'-dideoxyuridine	662987	41642	
2.7.4.9	Bacillus anthracis		3'-azidothymidine	695005	22030	poor inhibitor
2.7.4.9	Mycobacterium tuberculosis		3'-deoxy-3'-([[(3,4-dichlorophenyl)carbamothioyl]amino]methyl)thymidine	704800	12720	
2.7.4.9	Mycobacterium tuberculosis		3'-deoxy-3'-([[(4-methoxyphenyl)carbamothioyl]amino]methyl)thymidine	704800	12718	
2.7.4.9	Mycobacterium tuberculosis		3'-deoxy-3'-([[(4-methylphenyl)carbamothioyl]amino]methyl)thymidine	704800	12719	
2.7.4.9	Mycobacterium tuberculosis		3'-Deoxythymidine	723007	5386	
2.7.4.9	Mycobacterium tuberculosis		3'-deoxythymidine 5'-monophosphate	662597	33070	
2.7.4.9	Mycobacterium tuberculosis		3'-[([[4-(benzyloxy)phenyl]carbamothioyl]amino)methyl]-3'-deoxythymidine	704800	12721	
2.7.4.9	Mycobacterium tuberculosis		3'-[([[4-chloro-3-(trifluoromethyl)phenyl]carbamothioyl]amino)methyl]-2',3'-dideoxy-3,4-dihydrothymidine	721834	12722	
2.7.4.9	Mycobacterium tuberculosis		3'-[([[4-chloro-3-(trifluoromethyl)phenyl]carbamothioyl]amino)methyl]-3'-deoxythymidine	704800	12722	
2.7.4.9	Mycobacterium tuberculosis		3-((2R,3S,5R)-3-hydroxy-5-(5-(hydroxymethyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)propanenitrile	721846		
2.7.4.9	Mycobacterium tuberculosis		3-((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)propanenitrile	721846		
2.7.4.9	Pseudomonas aeruginosa		3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-benzenesulfonamide	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-benzonitrile	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-(pyridin-4-yl)ethyl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3-(4-(trifluoromethyl)phenyl)propyl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3-(pyridin-3-yl)propyl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3-morpholinopropyl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3-phenylpropyl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-N-(pyridin-2-ylmethyl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-N-phenethylbenzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-benzamido)propanoic acid	722925		
2.7.4.9	Pseudomonas aeruginosa		3-(3-(3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamido)propyl)benzoic acid	722925		
2.7.4.9	Mycobacterium tuberculosis		3-([1-[2-ammonio-3-(4-hydroxyphenyl)propanoyl]prolyl]amino)-4-oxoniobutanoate	723007	102510	
2.7.4.9	Staphylococcus aureus		4-((3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-piperidin-1-yl)methyl)-2-(3-(trifluoromethyl)phenoxy)benzoic acid	722918	112100	
2.7.4.9	Streptococcus pneumoniae		4-((3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-piperidin-1-yl)methyl)-2-(3-(trifluoromethyl)phenoxy)benzoic acid	722918	112100	
2.7.4.9	Pseudomonas aeruginosa		4-(1-methyl -2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		4-(3-(3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamido)propyl)benzoic acid	722925		
2.7.4.9	Mycobacterium tuberculosis		4-([1-[2-ammonio-3-(4-hydroxyphenyl)propanoyl]prolyl]amino)-5-oxoniopentanoate	723007	102511	
2.7.4.9	Homo sapiens		4-[4-[(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]butanamide	691226	25530	not inhibitory up to 2 mM, inhibitory to Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		4-[4-[(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]butanamide	691226	25530	comparison with inhibition of human enzyme
2.7.4.9	Homo sapiens		4-[4-[(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]butanoic acid	691226	17070	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		4-[4-[(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]butanoic acid	691226	17070	comparison with inhibition of human enzyme
2.7.4.9	Homo sapiens		4-[4-[(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]butanamide	691226	25531	not inhibitory up to 2 mM, inhibitory to Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		4-[4-[(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]butanamide	691226	25531	comparison with inhibition of human enzyme
2.7.4.9	Homo sapiens		4-[4-[(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]butanoic acid	691226	17071	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		4-[4-[(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]butanoic acid	691226	17071	comparison with inhibition of human enzyme
2.7.4.9	Mycobacterium tuberculosis		4-[4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]butanoic acid	691226	48000	comparison with inhibition of human enzyme
2.7.4.9	Mycobacterium tuberculosis		5'-(4-benzyl-1H-1,2,3-triazol-1-yl)-2',5'-dideoxy-3,4-dihydrothymidine	721834	61949	
2.7.4.9	Mycobacterium tuberculosis		5'-(4-chlorophenyl-1,2,3-triazol-1-yl)-5'-deoxy-alpha-D-thymidine	721834		
2.7.4.9	Mycobacterium tuberculosis		5'-(4-chlorophenyl-1,2,3-triazol-1-yl)-5'-deoxy-beta-D-thymidine	721834		
2.7.4.9	Mycobacterium tuberculosis		5'-([[4-chloro-3-(trifluoromethyl)benzyl]carbamothioyl]amino)-5'-deoxythymidine	704800	96006	
2.7.4.9	Mycobacterium tuberculosis		5'-([[4-chloro-3-(trifluoromethyl)phenyl]carbamothioyl]amino)-2',5'-dideoxy-3,4-dihydro-alpha-thymidine	721834	61943	
2.7.4.9	Mycobacterium tuberculosis		5'-([[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl]amino)-2',5'-dideoxy-3,4-dihydrothymidine	721834	61945	
2.7.4.9	Mycobacterium tuberculosis		5'-amino-5'-deoxythymidine	662987	5820	
2.7.4.9	Mus musculus		5'-aminodeoxythymidine	645196	33742	
2.7.4.9	Mycobacterium tuberculosis		5'-azido-2',5'-dideoxy-3,4-dihydrothymidine	721834	24334	
2.7.4.9	Mycobacterium tuberculosis		5'-azido-5'-deoxythymidine	662987	24334	
2.7.4.9	Mus musculus		5'-carboxyldeoxythymidine	645196	33743	
2.7.4.9	Mus musculus		5'-chlorodeoxythymidine	645196	12136	
2.7.4.9	Mycobacterium tuberculosis		5'-deoxy-5'-(methylamino)thymidine	662987	41644	
2.7.4.9	Mycobacterium tuberculosis		5'-deoxy-5'-([[2-(3,4-dichlorophenyl)ethyl]carbamothioyl]amino)thymidine	704800	96008	
2.7.4.9	Mycobacterium tuberculosis		5'-deoxy-5'-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamothioyl)amino]thymidine	704800	12724	
2.7.4.9	Bacillus anthracis		5'-deoxy-5'-[2-(methylsulfonyl)benzenesulfonylamido]thymidine	694480	92104	91% inhibition
2.7.4.9	Bacillus anthracis		5'-deoxy-5'-[4-(4-fluorophenyl)-(1,2,3)triazol-1-yl]thymidine	694480	92105	87% inhibition of enzyme activity, inhibition of Bacillus anthracis Sterne growth
2.7.4.9	Bacillus anthracis		5'-deoxy-5'-[4-(methylsulfonyl)benzenesulfonylamido]thymidine	694480	92106	94% inhibition
2.7.4.9	Mycobacterium tuberculosis		5'-deoxy-5'-[[(2-phenylethyl)carbamothioyl]amino]thymidine	704800	96007	
2.7.4.9	Mycobacterium tuberculosis		5'-deoxy-5'-[[(3,4-dichlorophenyl)carbamoyl]amino]thymidine	704800	96009	
2.7.4.9	Mycobacterium tuberculosis		5'-deoxy-5'-[[(4-morpholin-4-ylphenyl)carbamothioyl]amino]thymidine	704800	96001	
2.7.4.9	Mycobacterium tuberculosis		5'-deoxy-5'-[[(diphenylmethyl)carbamothioyl]amino]thymidine	704800	12725	
2.7.4.9	Mycobacterium tuberculosis		5'-deoxy-5'-[[(phenylcarbonyl)carbamothioyl]amino]thymidine	704800	96005	
2.7.4.9	Bacillus anthracis		5'-deoxy-5'-[[2-(methylthio)anilinothiocarbonyl]amino]thymidine	694480	92103	84% inhibition
2.7.4.9	Bacillus anthracis		5'-deoxy-5'-[[3-(methylthio)anilinothiocarbonyl]amino]thymidine	694480	92103	69% inhibition of enzyme activity, inhibition of Bacillus anthracis Sterne growth
2.7.4.9	Mycobacterium tuberculosis		5'-Deoxythymidine	662987	4810	
2.7.4.9	Mus musculus		5'-iododeoxythymidine	645196	16085	
2.7.4.9	Mycobacterium tuberculosis		5'-O-methylthymidine	662987	41645	
2.7.4.9	Mycobacterium tuberculosis		5'-[(benzylcarbamothioyl)amino]-5'-deoxythymidine	704800	96004	
2.7.4.9	Mycobacterium tuberculosis		5'-[([[9-(2-carboxyphenyl)-3-oxo-2,3-dihydro-1H-xanthen-6-yl]oxy]carbamothioyl)amino]-5'-deoxythymidine	704800	96003	
2.7.4.9	Mycobacterium tuberculosis		5'-[4-(4-chlorophenyl)-1H-1,2,3-triazol-1-yl]-2',5'-dideoxy-3,4-dihydrothymidine	721834	61948	
2.7.4.9	Mycobacterium tuberculosis		5'-[5-(2-aminobenzyl)-1H-1,2,3-triazol-1-yl]-2',5'-dideoxy-3,4-dihydrothymidine	721834	61951	
2.7.4.9	Mycobacterium tuberculosis		5'-[5-amino-4-[4-chloro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-1-yl]-2',5'-dideoxy-3,4-dihydrothymidine	721834	61950	
2.7.4.9	Homo sapiens		5,5'-dithio-bis(2-nitrobenzoic acid)	701680	196	general thymidylate kinase inhibitor
2.7.4.9	Mycobacterium tuberculosis		5-(5'-amino-5'-deoxy-beta-D-thymidin-5'-N-yl)-1-(4-chloro-3-trifluoromethylphenyl)-tetrazole	721834		
2.7.4.9	Homo sapiens		5-bromo-2'-deoxyuridine	661477	2363	
2.7.4.9	Mycobacterium tuberculosis		5-bromo-2'-deoxyuridine	661477	2363	potential inhibitor with high selectivity between bacterial and human enzyme
2.7.4.9	Mycobacterium tuberculosis		5-bromo-2'-deoxyuridine	662987	2363	
2.7.4.9	Vaccinia virus		5-bromo-deoxyuridine	706485	2363	
2.7.4.9	Homo sapiens		5-chloro-2'-deoxyuridine	661477	7530	
2.7.4.9	Mycobacterium tuberculosis		5-chloro-2'-deoxyuridine	661477	7530	potential inhibitor with high selectivity between bacterial and human enzyme
2.7.4.9	Mycobacterium tuberculosis		5-chloro-2'-deoxyuridine	662987	7530	
2.7.4.9	Vaccinia virus		5-chloro-deoxyuridine	706485	7530	
2.7.4.9	Homo sapiens		5-fluoro-2'-deoxyuridine	661477	2364	not inhibitory at 4 mM
2.7.4.9	Mycobacterium tuberculosis		5-fluoro-2'-deoxyuridine	661477	2364	potential inhibitor with high selectivity between bacterial and human enzyme
2.7.4.9	Vaccinia virus		5-fluoro-deoxyuridine	706485	2364	
2.7.4.9	Bacillus anthracis		5-fluorodeoxyuridine	695005	2364	poor inhibitor
2.7.4.9	Mycobacterium tuberculosis		5-hydroxymethyl-dUMP	721846	21482	
2.7.4.9	Homo sapiens		5-iodo-2'-deoxyuridine	661477	4146	
2.7.4.9	Mycobacterium tuberculosis		5-iodo-2'-deoxyuridine	661477	4146	potential inhibitor with high selectivity between bacterial and human enzyme
2.7.4.9	Mycobacterium tuberculosis		5-iodo-2'-deoxyuridine	662987	4146	
2.7.4.9	Escherichia coli		5-iodo-2'-dUMP	645198	13238	
2.7.4.9	Human herpesvirus 1		5-iodo-5'-fluoro-2',5'-dideoxyuridine	645192	22188	
2.7.4.9	Vaccinia virus		5-iodo-deoxyuridine	706485	5403	
2.7.4.9	Saccharomyces cerevisiae		5-iodo-dUMP	645191	13238	2.5 mM, 30% inhibition
2.7.4.9	Human herpesvirus 1		5-iodo-dUMP	645192	13238	competitive versus both thymidylate and thymidine
2.7.4.9	Mycobacterium tuberculosis		5-methyl iso-dCMP	645207	33751	competitive
2.7.4.9	Staphylococcus aureus		5-methyl-1-(1-(3-(3-(trifluoromethyl)phenoxy)benzyl)piperidin-3-yl)pyrimidine-2,4(1H,3H)-dione	722918	111986	
2.7.4.9	Streptococcus pneumoniae		5-methyl-1-(1-(3-(3-(trifluoromethyl)phenoxy)benzyl)piperidin-3-yl)pyrimidine-2,4(1H,3H)-dione	722918	111986	
2.7.4.9	Mycobacterium tuberculosis		5-methyl-1-[(2Z)-4-(2-oxobenzo[cd]indol-1(2H)-yl)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione	722186	47744	
2.7.4.9	Staphylococcus aureus		5-methyl-1-[1-(3-phenoxybenzyl)piperidin-3-yl]pyrimidine-2,4(1H,3H)-dione	722918	111810	
2.7.4.9	Streptococcus pneumoniae		5-methyl-1-[1-(3-phenoxybenzyl)piperidin-3-yl]pyrimidine-2,4(1H,3H)-dione	722918	111810	
2.7.4.9	Staphylococcus aureus		5-methyl-1-[1-[3-(4-methylphenoxy)benzyl]piperidin-3-yl]-pyrimidine-2,4(1H,3H)-dione	722918	111987	
2.7.4.9	Streptococcus pneumoniae		5-methyl-1-[1-[3-(4-methylphenoxy)benzyl]piperidin-3-yl]-pyrimidine-2,4(1H,3H)-dione	722918	111987	
2.7.4.9	Mycobacterium tuberculosis		5-[(E)-2-bromoethenyl]-2'-deoxyuridine	662987	41640	
2.7.4.9	Mycobacterium tuberculosis		5-[4-[(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]pentanoic acid	691226	48018	comparison with inhibition of human enzyme
2.7.4.9	Homo sapiens		5-[4-[(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]pentanoic acid	691226	17079	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		5-[4-[(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]pentanoic acid	691226	17079	comparison with inhibition of human enzyme
2.7.4.9	Pseudomonas aeruginosa		6-(3-(aminomethyl)phenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Pseudomonas aeruginosa		6-(3-(hydroxymethyl)phenyl)-1-methyl-1H-imidazo[4,5-b]-pyridin-2(3H)-one	722925		
2.7.4.9	Pseudomonas aeruginosa		6-(3-acetylphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Pseudomonas aeruginosa		6-(3-aminophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Pseudomonas aeruginosa		6-(3-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Pseudomonas aeruginosa		6-(3-hydroxyphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Pseudomonas aeruginosa		6-(4-(aminomethyl)phenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Pseudomonas aeruginosa		6-(4-hydroxyphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one	722925		
2.7.4.9	Mycobacterium tuberculosis		6-[4-[(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]hexanamide	691226	48061	comparison with inhibition of human enzyme
2.7.4.9	Mycobacterium tuberculosis		6-[4-[(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]hexanamide	691226	48062	comparison with inhibition of human enzyme
2.7.4.9	Mycobacterium tuberculosis		6-[4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]phenyl]hexanamide	691226	48063	comparison with inhibition of human enzyme
2.7.4.9	Mus musculus		ADP	645188	8	100 nM, 64% inhibition
2.7.4.9	Homo sapiens		ADP	645189	8	0.5 mM, 33% inhibition
2.7.4.9	Saccharomyces cerevisiae		ADP	645191	8	2.5 mM, 24% inhibition
2.7.4.9	Human herpesvirus 1		ADP	645192	8	ADP*Mg2+ product inhibition, competitive versus MgATP2-, noncompetitive versus thymidylate
2.7.4.9	Homo sapiens		ADP	645193	8	
2.7.4.9	Gallus gallus		ADP	645194	8	25% inhibition
2.7.4.9	Mus musculus		ADP	645196	8	
2.7.4.9	Streptococcus pneumoniae		ADP	645203	8	ADP[beta-S]
2.7.4.9	Mycobacterium tuberculosis		azido-TMP	662169		
2.7.4.9	Mus musculus		Ca2+	645188	18	
2.7.4.9	Mus musculus		CH2ATP	645188	2691	100 nM, 23% inhibition
2.7.4.9	Strongylocentrotus intermedius		Cu2+	645205	28	
2.7.4.9	Bacillus anthracis		D-2'-fluoroarabinosyl-5-methyldeoxyuridine	695005	25630	poor inhibitor; strong
2.7.4.9	Mus musculus		dADP	645188	589	100 nM, 57% inhibition
2.7.4.9	Homo sapiens		dADP	645189	589	0.5 mM, 34% inhibition
2.7.4.9	Saccharomyces cerevisiae		dADP	645191	589	2.5 mM, 23% inhibition
2.7.4.9	Homo sapiens		dADP	645193	589	
2.7.4.9	Plasmodium falciparum		dAMP	692915	575	5 mM, about 15% inhibition
2.7.4.9	Mus musculus		dATP	645188	133	100 nM, 15% inhibition
2.7.4.9	Gallus gallus		dATP	645194	133	0.4 mM, 12% inhibition, adult liver
2.7.4.9	Escherichia coli		dCTP	645198	161	
2.7.4.9	Pseudomonas aeruginosa		deoxy-fluorothymidine	722925		
2.7.4.9	Mycobacterium tuberculosis		deoxythymidine	661170	153	
2.7.4.9	Homo sapiens		deoxythymidine	661477	153	
2.7.4.9	Mycobacterium tuberculosis		deoxythymidine	661477	153	potential inhibitor with high selectivity between bacterial and human enzyme
2.7.4.9	Bacillus anthracis		deoxythymidine	695005	153	poor inhibitor
2.7.4.9	Vaccinia virus		deoxythymidine	706485	153	
2.7.4.9	Vaccinia virus		deoxyuridine	706485	812	
2.7.4.9	Homo sapiens		dGDP	645189	863	0.5 mM, 23% inhibition
2.7.4.9	Mycobacterium tuberculosis		dGMP	661477	587	competitive
2.7.4.9	Mus musculus		dGTP	645188	194	100 nM, 12% inhibition
2.7.4.9	Mus musculus		dTDP	645188	449	100 nM, 39% inhibition
2.7.4.9	Homo sapiens		dTDP	645189	449	0.5 mM, 91% inhibition
2.7.4.9	Saccharomyces cerevisiae		dTDP	645191	449	2.5 mM, 75% inhibition
2.7.4.9	Human herpesvirus 1		dTDP	645192	449	product inhibition, competitive versus MgATP2-
2.7.4.9	Homo sapiens		dTDP	645193	449	
2.7.4.9	Gallus gallus		dTDP	645194	449	0.4 mM, 48% inhibition
2.7.4.9	Streptococcus pneumoniae		dTDP	645203	449	
2.7.4.9	Streptococcus pneumoniae		dTMP	645203	518	
2.7.4.9	Homo sapiens		dTMP	662597	518	
2.7.4.9	Mycobacterium tuberculosis		dTMP	662597	518	
2.7.4.9	Pseudomonas aeruginosa		dTMP	722925	518	
2.7.4.9	Saccharomyces cerevisiae		dTTP	645191	137	2.5 mM, 17% inhibition
2.7.4.9	Human herpesvirus 1		dTTP	645192	137	competitive versus both thymidine and thymidylate
2.7.4.9	Homo sapiens		dTTP	645193	137	
2.7.4.9	Gallus gallus		dTTP	645194	137	0.4 mM, 43% inhibition
2.7.4.9	Mus musculus		dTTP	645196	137	potent feedback inhibitor of dTMP
2.7.4.9	Acetabularia acetabulum		dTTP	645197	137	
2.7.4.9	Escherichia coli		dTTP	645198	137	
2.7.4.9	Homo sapiens		dUDP	645189	1330	0.5 mM, 42% inhibition
2.7.4.9	Saccharomyces cerevisiae		dUDP	645191	1330	2.5 mM, 15% inhibition
2.7.4.9	Saccharomyces cerevisiae		dUMP	645191	496	2.5 mM, 19% inhibition
2.7.4.9	Escherichia coli		dUMP	645198	496	
2.7.4.9	Plasmodium falciparum		dUMP	692915	496	5 mM, about 15% inhibition
2.7.4.9	Plasmodium falciparum		EDTA	692915	223	4 mM, 80% loss of activity
2.7.4.9	Strongylocentrotus intermedius		Fe2+	645205	23	
2.7.4.9	Mus musculus		GDP	645188	49	100 nM, 21% inhibition
2.7.4.9	Saccharomyces cerevisiae		KCl	645191	74	0.5 M, 10% inhibition
2.7.4.9	Pseudomonas aeruginosa		methyl 2-(3-(3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]-pyridin-6-yl)benzamido)propyl)benzoate	722925		
2.7.4.9	Human herpesvirus 1		MgADP-	645192	639	
2.7.4.9	Mus musculus		Mn2+	645188	26	slight inhibition
2.7.4.9	Mycobacterium tuberculosis		more	662169		several different TMP analogues tested and found to be inhibitory
2.7.4.9	Homo sapiens		more	662597		3-azido-3-deoxythymidine monophosphate is not inhibitory, various thymine derivatives tested and found to inhibit activity to different extents
2.7.4.9	Mycobacterium tuberculosis		more	662597		3'-(aminomethyl)-3'-deoxy-2'-fluorothymidine is not inhibitory at 1 mM; 3-azido-3-deoxythymidine monophosphate is not inhibitory, various thymine derivatives tested and found to inhibit activity to different extents
2.7.4.9	Homo sapiens		more	691813		acyclic nucleoside analogues (Z)-2-(4-(thymin-1-yl)but-2-enyl)-1H-benzo[d,e]isoquinoline-1,3(2H)-dione and (Z)-2-(4-(thymin-1-yl)but-2-enyl)-2,3-dihydro-1H-benzo-[d,e]isoquinolin-1-one are not inhibitory up to 0.02 mM
2.7.4.9	Plasmodium falciparum		more	692915		not inhibitory: 2-mercaptoethanol up to 5 mM, AMP, CMP, dCMP, GMP and dGMP and
2.7.4.9	Mycobacterium tuberculosis		more	721834		not inhibited by N-(5'-deoxy-4-thio-alpha-D-thymidin-5'-yl)-N'-phenylthiourea
2.7.4.9	Mycobacterium tuberculosis		more	721846		not inhibited by 3-((2R,3S,5R)-3-hydroxy-5-(5-(hydroxymethyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)propanenitrile and 1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-hydroxytetrahydrofuran-2-yl)-5-(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione
2.7.4.9	Pseudomonas aeruginosa		N,N-dimethyl-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]-pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-((1H-benzo[d]imidazol-2-yl)methyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(2-(1H-benzo[d]imidazol-2-yl)ethyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(2-(1H-imidazol-5-yl)ethyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(2-amino-2-oxoethyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(2-aminoethyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo-[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(2-hydroxyethyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo-[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Homo sapiens		N-(3,4-dichlorophenyl)-N'-(5'-deoxy-alpha-D-thymidin-5'-yl)-urea	693534	17100	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		N-(3,4-dichlorophenyl)-N'-(5'-deoxy-alpha-D-thymidin-5'-yl)-urea	693534	17100	comparison with inhibition of human enzyme
2.7.4.9	Pseudomonas aeruginosa		N-(3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)phenyl)acetamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(3-(1H-imidazol-4-yl)propyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(3-(1H-indol-3-yl)propyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(3-(3-(aminomethyl)phenyl)propyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(3-(4-(aminomethyl)phenyl)propyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(3-(4-fluorophenyl)propyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-(3-cyclopentylpropyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Mycobacterium tuberculosis		N-(5'-deoxy-4-thio-alpha-D-thymidin-5'-yl)-N'-(3-trifluoromethyl-4-chlorophenyl)thiourea	721834		
2.7.4.9	Homo sapiens		N-(5'-deoxy-alpha-D-thymidin-5'-yl)-N'-(3,4-dichlorophenylethyl)thiourea	693534	17101	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		N-(5'-deoxy-alpha-D-thymidin-5'-yl)-N'-(3,4-dichlorophenylethyl)thiourea	693534	17101	comparison with inhibition of human enzyme
2.7.4.9	Homo sapiens		N-(5'-deoxy-alpha-D-thymidin-5'-yl)-N'-(3-trifluoromethyl-4-chlorobenzyl)thiourea	693534	17102	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		N-(5'-deoxy-alpha-D-thymidin-5'-yl)-N'-(3-trifluoromethyl-4-chlorobenzyl)thiourea	693534	17102	comparison with inhibition of human enzyme
2.7.4.9	Homo sapiens		N-(5'-deoxy-alpha-D-thymidin-5'-yl)-N'-(4-chloro-3-(trifluoromethyl)phenylethyl)urea	693534	17103	comparison with inhibition of Mycobacterium tuberculosis enzyme
2.7.4.9	Mycobacterium tuberculosis		N-(5'-deoxy-alpha-D-thymidin-5'-yl)-N'-(4-chloro-3-(trifluoromethyl)phenylethyl)urea	693534	17103	comparison with inhibition of human enzyme
2.7.4.9	Pseudomonas aeruginosa		N-(cyanomethyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo-[4,5-b]pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-benzyl-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]-pyridin-6-yl)benzamide	722925		
2.7.4.9	Pseudomonas aeruginosa		N-methyl-3-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]-pyridin-6-yl)benzamide	722925		
2.7.4.9	Mycobacterium tuberculosis		N-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]benzamide	704800	96011	
2.7.4.9	Escherichia coli		NaCl	645198	39	0.1 M, 25% inhibition
2.7.4.9	Escherichia coli		NH4Cl	645198	282	0.4 M, 75% inhibition
2.7.4.9	Mycobacterium tuberculosis		P1,P5-di(adenosine-5')pentaphosphate	662169	1594	potential inhibitor
2.7.4.9	Pseudomonas aeruginosa		P1-(5'-adenosyl)-P5-(5'-thymidyl)pentaphosphate	722925		
2.7.4.9	Homo sapiens		P1-(adenosine 5')-P4-(thymidine 5')-tetraphosphate	641085	22151	
2.7.4.9	Homo sapiens		P1-(adenosine 5')-P5-(thymidine 5')-pentaphosphate	641085	22152	
2.7.4.9	Homo sapiens		P1-(Adenosine 5')-P6-(thymidine 5')-hexaphosphate	641085	20532	
2.7.4.9	Mus musculus		TDP	645196	449	
2.7.4.9	Pseudomonas aeruginosa		thiourea-alpha-TM	722925		
2.7.4.9	Saccharomyces cerevisiae		thymidine	645191	153	2.5 mM, 40% inhibition
2.7.4.9	Homo sapiens		thymidine	645193	153	0.77 mM, 27% inhibition
2.7.4.9	Mus musculus		thymidine	645196	153	
2.7.4.9	Homo sapiens		thymidine	662597	153	
2.7.4.9	Mycobacterium tuberculosis		thymidine	662597, 662987, 691813	153	
2.7.4.9	Staphylococcus aureus		TK-666	722918	111985	i.e. 2-(3-bromophenoxy)-4-((R)-3,3-dimethyl-1-((S)-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1-(2H)-yl)piperidin-1-yl)butyl)benzoic acid
2.7.4.9	Streptococcus pneumoniae		TK-666	722918	111985	i.e. 2-(3-bromophenoxy)-4-((R)-3,3-dimethyl-1-((S)-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1-(2H)-yl)piperidin-1-yl)butyl)benzoic acid
2.7.4.9	Plasmodium falciparum		UMP	692915	127	5 mM, about 15% inhibition
2.7.4.9	Strongylocentrotus intermedius		Zn2+	645205	19	
2.7.4.9	Plasmodium falciparum		[(1S,4R)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)cyclopent-2-en-1-yl]methyl acetate	723332	28358	
1.1.1.267	Picea abies	chitosan		689559	851	induces expression; induces expression
1.1.1.267	Camptotheca acuminata	methyl jasmonate		688641	1845	strong induction, reaching the highest level after 24 h of the treatment, and gradually decreasing thereafter
1.1.1.267	Picea abies	methyl jasmonate		689559	1845	induces expression; induces expression
1.1.1.267	Arabidopsis thaliana	more		676579		the enzyme is inducible by light
1.1.1.267	Hevea brasiliensis	more		699265		transcript accumulation of DXR gene is regulated by mechanical wounding and fungal elicitors. Expression of the DXR gene in rubber trees is not induced by light
1.1.1.267	Salvia miltiorrhiza	salicylic acid		695411	508	strongly induces DXR in leaves, reaches the highest level after 48 h of the treatment, and gradually decreases after. Is induced by salicylic acid at least at transcriptional level
1.1.1.267	Escherichia coli		(2R,3R)-2,3,4-trihydroxybutyl dihydrogen phosphate	675580	39699	IC50: 0.310 mM
1.1.1.267	Escherichia coli		(2R,3R)-4-amino-2,3-dihydroxybutyl dihydrogen phosphate	675580	39700	very weak inhibitor, IC50: 5 mM, above
1.1.1.267	Escherichia coli		(2R,3S)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl dihydrogen phosphate	675580	39697	very weak inhibitor, IC50: 5 mM, above
1.1.1.267	Escherichia coli		(2R,3S)-4-amino-2,3-dihydroxy-4-oxobutyl dihydrogen phosphate	675580	39698	IC50: 0.253 mM
1.1.1.267	Escherichia coli		(2S,3R)-2,3-dihydroxy-4-phosphonooxybutyric acid	675580	41314	IC50: 0.551 mM
1.1.1.267	Synechocystis sp.		(2S,3R)-dihydroxybutyramide 4-phosphate	654973	39698	50% inhibition at 0.09 mM
1.1.1.267	Escherichia coli		(2S,3R)-methyl 2,3-dihydroxy-4-phosphonooxybutyrate	675580	41315	IC50: 1.024 mM
1.1.1.267	Escherichia coli		(3-(hydroxy[(pentafluorophenyl)carbonyl]amino)propyl)phosphonic acid	684769	45954	
1.1.1.267	Mycobacterium tuberculosis		(3-(N-hydroxyacetamido)-1-phenyl)propylphosphonic acid	725663	10331	92% inhibition at 0.1 mM
1.1.1.267	Escherichia coli		(3-[hydroxy(5-oxohexanoyl)amino]propyl)phosphonic acid	684769	45955	
1.1.1.267	Escherichia coli		(3-[hydroxy(6-phenylhexanoyl)amino]propyl)phosphonic acid	684769	45956	
1.1.1.267	Escherichia coli		(3-[hydroxy(hexadecanoyl)amino]propyl)phosphonic acid	684769	45957	
1.1.1.267	Synechocystis sp.		(3S)-hydroxypentan-2-one 5-phosphate	654973	79766	50% inhibition at 0.03 mM
1.1.1.267	Escherichia coli		(3S,4R)-3,4-dihydroxy-4-methyl-5-oxohexylphosphonic acid	697249	52037	
1.1.1.267	Escherichia coli		(4-[[3-(hydroxymethyl)phenyl]amino]-4-oxobutyl)phosphonic acid	724558	62202	26.8% inhibition
1.1.1.267	Plasmodium falciparum		(4-[[3-(hydroxymethyl)phenyl]amino]-4-oxobutyl)phosphonic acid	724558	62202	
1.1.1.267	Synechocystis sp.		(4S)-hydroxypentan-2-one 5-phosphate	654973	79765	50% inhibition at 0.15 mM
1.1.1.267	Toxoplasma gondii		(pyridin-2-ylmethyl)phosphonic acid	724543	62203	
1.1.1.267	Escherichia coli		1,1,1-trifluoro-1-deoxy-D-xylulose 5-phosphoric acid	675577	41311	i.e. CF3-DXP, very low inhibition
1.1.1.267	Escherichia coli		1,1-difluoro-1-deoxy-D-xylulose 5-phosphoric acid	675577	41312	i.e. CF2-DXP, very low inhibition
1.1.1.267	Escherichia coli		1,2-dideoxy-D-hexulose 6-phosphate	675577	41313	i.e. Et-DXP, very low inhibition
1.1.1.267	Synechocystis sp.		1,2-dideoxy-D-threo-3-hexulose 6-phosphate	654973	9025	50% inhibition at 0.63 mM
1.1.1.267	Synechocystis sp.		1,2-dideoxy-D-threo-3-hexulose 6-phosphate	671590	9025	weak, competitive inhibition, a highly conserved tryptophan residue in the flexible loop is blocked by the substrate analog
1.1.1.267	Mycobacterium tuberculosis		1-deoxy-D-xylulose 5-phosphate	674260	959	substrate inhibition
1.1.1.267	Synechocystis sp.		1-deoxy-L-ribulose 5-phosphate	654973	79764	50% inhibition at 0.18 mM
1.1.1.267	Bacillus anthracis		1-hydroxy-5-phenylpyridin-2(1H)-one	712689	8183	minimal inhibitory concentration for growth 0.02 mM
1.1.1.267	Escherichia coli		1-hydroxy-5-phenylpyridin-2(1H)-one	712689	8183	minimal inhibitory concentration for growth 0.1 mM
1.1.1.267	Micrococcus luteus		1-hydroxy-5-phenylpyridin-2(1H)-one	712689	8183	minimal inhibitory concentration for growth 0.1 mM
1.1.1.267	Pseudomonas aeruginosa		1-hydroxy-5-phenylpyridin-2(1H)-one	712689	8183	minimal inhibitory concentration for growth 0.05 mM
1.1.1.267	Toxoplasma gondii		1-hydroxy-5-phenylpyridin-2(1H)-one	724543	8183	
1.1.1.267	Escherichia coli		3-(hydroxy([(2-phenylbutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17925	
1.1.1.267	Plasmodium falciparum		3-(hydroxy([(2-phenylbutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17925	
1.1.1.267	Escherichia coli		3-(hydroxy([(3-methylbutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17924	
1.1.1.267	Plasmodium falciparum		3-(hydroxy([(3-methylbutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17924	
1.1.1.267	Escherichia coli		3-(hydroxy([(4-phenoxybutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17930	
1.1.1.267	Plasmodium falciparum		3-(hydroxy([(4-phenoxybutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17930	
1.1.1.267	Escherichia coli		3-(hydroxy([(4-phenylbutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17926	
1.1.1.267	Plasmodium falciparum		3-(hydroxy([(4-phenylbutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17926	
1.1.1.267	Mycobacterium tuberculosis		3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid	725663	62189	
1.1.1.267	Mycobacterium tuberculosis		3-(N-hydroxyformamido)-1-(2-bromophenyl)propylphosphonic acid	725663	62191	93% inhibition at 0.1 mM
1.1.1.267	Mycobacterium tuberculosis		3-(N-hydroxyformamido)-1-(3,4-dichlorophenyl)propylphosphonic acid	725663	62187	
1.1.1.267	Escherichia coli		3-([(1H-indol-3-yl)acetyl]amino)propylphosphonic acid	697249	52040	
1.1.1.267	Escherichia coli		3-([2-(methoxycarbonyl)benzoyl]amino)propylphosphonic acid	697249	52041	
1.1.1.267	Escherichia coli		3-([3-(1H-indol-3-yl)propanoyl]amino)propylphosphonic acid	697249	52039	
1.1.1.267	Escherichia coli		3-([4-(1H-indol-3-yl)butanoyl]amino)propylphosphonic acid	697249	52038	
1.1.1.267	Escherichia coli		3-fluoro-1-deoxy-D-xylulose-5-phosphate	656890	36418	noncompetitive
1.1.1.267	Escherichia coli		3-[(([(3,4-dimethoxyphenyl)acetyl]amino)acetyl)(hydroxy)amino]propylphosphonic acid	697249	17928	
1.1.1.267	Plasmodium falciparum		3-[(([(3,4-dimethoxyphenyl)acetyl]amino)acetyl)(hydroxy)amino]propylphosphonic acid	697249	17928	
1.1.1.267	Escherichia coli		3-[(2-hydroxybenzoyl)amino]propylphosphonic acid	697249	52042	
1.1.1.267	Escherichia coli		3-[(3,4-diethoxybenzoyl)amino]propylphosphonic acid	697249	52043	
1.1.1.267	Escherichia coli		3-[(3,4-dimethoxybenzoyl)amino]propylphosphonic acid	697249	52046	
1.1.1.267	Escherichia coli		3-[(4-methylpentanoyl)amino]propylphosphonic acid	697249	52044	
1.1.1.267	Escherichia coli		3-[(4-phenoxybenzoyl)amino]propylphosphonic acid	697249	52045	
1.1.1.267	Escherichia coli		3-[([(cyclopropylcarbonyl)amino]acetyl)(hydroxy)amino]propylphosphonic acid	697249	17927	
1.1.1.267	Plasmodium falciparum		3-[([(cyclopropylcarbonyl)amino]acetyl)(hydroxy)amino]propylphosphonic acid	697249	17927	
1.1.1.267	Escherichia coli		3-[hydroxy(([3-(trifluoromethoxy)benzoyl]amino)acetyl)amino]propylphosphonic acid	697249	17929	
1.1.1.267	Plasmodium falciparum		3-[hydroxy(([3-(trifluoromethoxy)benzoyl]amino)acetyl)amino]propylphosphonic acid	697249	17929	
1.1.1.267	Escherichia coli		3-[hydroxy(([4-(1H-indol-3-yl)butanoyl]amino)acetyl)amino]propylphosphonic acid	697249	17923	
1.1.1.267	Plasmodium falciparum		3-[hydroxy(([4-(1H-indol-3-yl)butanoyl]amino)acetyl)amino]propylphosphonic acid	697249	17923	
1.1.1.267	Synechocystis sp.		4-(N-formyl-N-hydroxy-amino)-butyric acid	672538	41307	
1.1.1.267	Bacillus anthracis		4-benzylbenzene-1,2-diol	712689	12913	minimal inhibitory concentration for growth 0.2 mM
1.1.1.267	Escherichia coli		4-benzylbenzene-1,2-diol	712689	12913	minimal inhibitory concentration for growth 1 mM
1.1.1.267	Micrococcus luteus		4-benzylbenzene-1,2-diol	712689	12913	minimal inhibitory concentration for growth 0.2 mM
1.1.1.267	Pseudomonas aeruginosa		4-benzylbenzene-1,2-diol	712689	12913	minimal inhibitory concentration for growth 0.2 mM
1.1.1.267	Escherichia coli		4-fluoro-1-deoxy-D-xylulose-5-phosphate	656890	36419	noncompetitive
1.1.1.267	Escherichia coli		Arbutus andrachne plant extract	689434		
1.1.1.267	Bacillus anthracis		biphenyl-3,4-diol	712689	10055	minimal inhibitory concentration for growth 0.2 mM
1.1.1.267	Escherichia coli		biphenyl-3,4-diol	712689	10055	minimal inhibitory concentration for growth 0.5 mM
1.1.1.267	Micrococcus luteus		biphenyl-3,4-diol	712689	10055	minimal inhibitory concentration for growth 0.2 mM
1.1.1.267	Pseudomonas aeruginosa		biphenyl-3,4-diol	712689	10055	minimal inhibitory concentration for growth 0.2 mM
1.1.1.267	Escherichia coli		Cercis siliquastrum leaf extract	689434		high inhibitory activity
1.1.1.267	Plasmodium falciparum		Chloroquine	684379	1087	
1.1.1.267	Escherichia coli		Cu2+	286427	28	
1.1.1.267	Mycobacterium tuberculosis		diethyl (1-(3,4-dichlorophenyl)-3-(N-hydroxyacetamido)propyl)phosphonate	725663		
1.1.1.267	Mycobacterium tuberculosis		diethyl (1-(3,4-dichlorophenyl)-3-(N-hydroxyformamido)propyl)phosphonate	725663	62186	
1.1.1.267	Escherichia coli		diethyl (2-[[3-(hydroxymethyl)phenyl]amino]-2-oxoethyl)phosphonate	724558	62198	40.4% inhibition
1.1.1.267	Plasmodium falciparum		diethyl (2-[[3-(hydroxymethyl)phenyl]amino]-2-oxoethyl)phosphonate	724558	62198	
1.1.1.267	Escherichia coli		diethyl (3-[[3-(hydroxymethyl)phenyl]amino]-3-oxopropyl)phosphonate	724558	102999	17.9% inhibition
1.1.1.267	Escherichia coli		diethyl [2-[(3-bromophenyl)amino]-2-oxoethyl]phosphonate	724558	103003	21.4% inhibition
1.1.1.267	Escherichia coli		diethyl [2-[(3-cyanophenyl)amino]-2-oxoethyl]phosphonate	724558	62197	11.9% inhibition
1.1.1.267	Plasmodium falciparum		diethyl [2-[(3-cyanophenyl)amino]-2-oxoethyl]phosphonate	724558	62197	
1.1.1.267	Escherichia coli		diethyl [2-[(3-hydroxyphenyl)amino]-2-oxoethyl]phosphonate	724558	62196	24.4% inhibition
1.1.1.267	Plasmodium falciparum		diethyl [2-[(3-hydroxyphenyl)amino]-2-oxoethyl]phosphonate	724558	62196	
1.1.1.267	Escherichia coli		diethyl [2-[(3-methoxyphenyl)amino]-2-oxoethyl]phosphonate	724558	103001	11% inhibition
1.1.1.267	Escherichia coli		diethyl [3-[(3-hydroxyphenyl)amino]-3-oxopropyl]phosphonate	724558	103000	33.5% inhibition
1.1.1.267	Escherichia coli		diethyl [3-[(3-methoxyphenyl)amino]-3-oxopropyl]phosphonate	724558	103002	14.1% inhibition
1.1.1.267	Zymomonas mobilis		EDTA	286424	223	
1.1.1.267	Escherichia coli		EDTA	286427	223	
1.1.1.267	Mycobacterium tuberculosis		EDTA	674260	223	complete inhibition at 5 mM
1.1.1.267	Plectranthus barbatus		EDTA	676660	223	
1.1.1.267	Mycobacterium tuberculosis		ethyl hydrogen [1-(3,4-dichlorophenyl)-3-[formyl(hydroxy)amino]propyl]phosphonate	725663	62188	
1.1.1.267	Mycobacterium tuberculosis		ethyl hydrogen [3-[acetyl(hydroxy)amino]-1-(3,4-dichlorophenyl)propyl]phosphonate	725663	62190	
1.1.1.267	Mycobacterium tuberculosis		ethyl hydrogen [3-[acetyl(hydroxy)amino]-1-[2-(pyridin-3-yl)phenyl]propyl]phosphonate	725663	102993	20% inhibition at 0.1 mM
1.1.1.267	Zymomonas mobilis		Fe2+	286424	23	
1.1.1.267	Escherichia coli		Fe2+	286427	23	
1.1.1.267	Synechocystis sp.		fosfoxacin	672538	41305	phosphate analogue of fosmidomycin
1.1.1.267	Zymomonas mobilis		fosmidomycin	286424	1029	
1.1.1.267	Pseudomonas aeruginosa		fosmidomycin	286425	1029	
1.1.1.267	Escherichia coli		fosmidomycin	655787	1029	50% inhibition at 0.0035 mM
1.1.1.267	Escherichia coli		fosmidomycin	656553	1029	model for tight-binding mode of inhibition
1.1.1.267	Synechocystis sp.		fosmidomycin	672396, 672538	1029	
1.1.1.267	Escherichia coli		fosmidomycin	673073	1029	acts by binding strongly to DXR as a slow tight-binding inhibitor, inhibitor-enzyme interaction and structure analysis for design of inhibitors, possibly mimics a transition state in the reaction coordinate of the substrate, the initial rapid equilibrium is subject to negative cooperativity, overview
1.1.1.267	Arabidopsis thaliana		fosmidomycin	673562	1029	
1.1.1.267	Mycobacterium tuberculosis		fosmidomycin	674260	1029	IC50: 310 nM for the forward reaction, 0.0027 mM for the reverse reaction, Gram positive bacteria, including Mycobacterium tuberculosis, are resistant against the antibiotic fosmidomycin, which is an inhibitor of the enzyme from most gram-negative bacteria and other organisms
1.1.1.267	Plasmodium falciparum		fosmidomycin	675038	1029	a natural antibiotic from Streptomyces lavendulae, a specific, mixed type inhibitor, the N-formyl-N-hydroxy amino headgroup of fosmidomycin coordinates Mg2+ ion forming an octahedral complex with active site residues Asp157, Glu159, and Glu241 and a critical binding site water molecule, residue His219 is essential for placing fosmidomycin in the active site for optimal catalysis, mechanism, overview, NADPH has a vital role in tight binding of the inhibitor within the enzyme active site
1.1.1.267	Escherichia coli		fosmidomycin	675580	1029	a phosphonic metabolite from Streptomyces rubellomurinus
1.1.1.267	Plectranthus barbatus		fosmidomycin	676660	1029	IC50: 450 nM, recombinant enzyme, inhibition of growth and forskolin production in vivo
1.1.1.267	Plasmodium falciparum		fosmidomycin	684379	1029	analysis of parasite growth in infected cultured erythrocytes. 50% growth inhibition at about 301 nM
1.1.1.267	Hevea brasiliensis		fosmidomycin	700838	1029	
1.1.1.267	Thermotoga maritima		fosmidomycin	712892	1029	
1.1.1.267	Francisella tularensis		fosmidomycin	713353	1029	
1.1.1.267	Escherichia coli		fosmidomycin	286428, 675577, 684210, 684769, 697249, 697335, 723812	1029	
1.1.1.267	Plasmodium falciparum		fosmidomycin	697249, 723812	1029	
1.1.1.267	Toxoplasma gondii		fosmidomycin	724543	1029	potent inhibitor but with very short half-life in plasma and low oral availability
1.1.1.267	Escherichia coli		fosmidomycin	724558	1029	a natural product isolated from Streptomyces lavendulae
1.1.1.267	Plasmodium falciparum		fosmidomycin	724558	1029	a natural product isolated from Streptomyces lavendulae
1.1.1.267	Mycobacterium tuberculosis		fosmidomycin	671075, 687567, 725564, 725663	1029	
1.1.1.267	Escherichia coli		fosmidomycin analogues	673073		synthesis, stereochemistry, and analysis of inhibitory potency of several fosmidomycin analogues, overview
1.1.1.267	Escherichia coli		FR 900098	673073	3266	N-acetyl analogue of fosmidomycin
1.1.1.267	Pseudomonas aeruginosa		FR-900098	286425	3266	
1.1.1.267	Escherichia coli		FR-900098	697249	3266	fosmidomycin homologue
1.1.1.267	Plasmodium falciparum		FR-900098	697249	3266	fosmidomycin homologue
1.1.1.267	Synechocystis sp.		FR900098	672538	3266	N-acetyl analogue of fosmidomycin
1.1.1.267	Plasmodium falciparum		FR900098	675038	3266	
1.1.1.267	Escherichia coli		FR900098	675577	3266	specific inhibition
1.1.1.267	Plasmodium falciparum		FR900098	684379	3266	analysis of parasite growth in infected cultured erythrocytes. 50% growth inhibition at about 118 nM
1.1.1.267	Escherichia coli		FR900098	684769	3266	N-acetyl homologue of fosmidomycin
1.1.1.267	Escherichia coli		FR900098	697335	3266	fosmidomycin homologue
1.1.1.267	Toxoplasma gondii		FR900098	724543	3266	
1.1.1.267	Escherichia coli		FR900098	724558	3266	an acetyl analogue of fosmidomycin
1.1.1.267	Plasmodium falciparum		FR900098	724558	3266	an acetyl analogue of fosmidomycin
1.1.1.267	Mycobacterium tuberculosis		FR900098	725663	3266	
1.1.1.267	Escherichia coli		Geranium molle plant extract	689434		
1.1.1.267	Escherichia coli		Helianthemum ventosum plant extract	689434		
1.1.1.267	Escherichia coli		Helianthemum vesicarium plant extract	689434		
1.1.1.267	Salvia miltiorrhiza		methyl jasmonate	695411	1845	
1.1.1.267	Escherichia coli		more	672040		1,1,1-trifluoro-1-deoxy-D-xylulose 5-phosphoric acid, 1,1-difluoro-1-deoxy-D-xylulose 5-phosphoric acid, and 1,2-dideoxy-D-hexulose 6-phosphate are poor inhibitors, most likely because of the increase in steric bulk at C1
1.1.1.267	Mycobacterium tuberculosis		more	674260		no substrate inhibition by 2-C-methyl-D-erythritol 4-phosphate, NADPH or NADP+
1.1.1.267	Plasmodium falciparum		more	675038		design and development of inhibitors, structure and docking modeling, overview
1.1.1.267	Escherichia coli		more	675577		inhibitor design and synthesis, overview
1.1.1.267	Escherichia coli		more	697335		neither the sulfone (N-hydroxy-N-[3-(alkylsulfonyl)propyl]acetamides) nor the sulfonamide derivatives (N-hydroxy-N-(3-sulfamoylpropyl) acetamide and N-hydroxy-N-(3-(N-alkylsulfamoyl)propyl)acetamide) of FR900098 display any significant inhibitory activity against DXR at a concentration of 0.03 mM. Importance of the negative charge for the binding of fosmidomycin-like inhibitors to DXR. Uncharged molecules are virtually inactive whereas derivatives that possess only one instead of two negative charges are markedly less active. It is possible to regain some of the activity that is lost by the reduction of the charge by occupation of hitherto unexploited areas of the enzyme
1.1.1.267	Plasmodium falciparum		more	723812		pyridine-containing fosmidomycin derivative inhibitor design and development using quantitative structure?activity relationship and crystallographic studies, synthesis, overview
1.1.1.267	Toxoplasma gondii		more	724543		inhibitor design and synthesis, structure-activity relationship profile for the inhibition of TgDXR, overview
1.1.1.267	Escherichia coli		more	724558		inhibitory potencies of a series of aryl- and heteroarylcarbamoylphosphonic acids, their diethyl esters and disodium salts as analogues of the potent DXR inhibitor fosmidomycin, effects of the carboxamide N-substituents and the length of the methylene linker, in silico docking studies, saturation transfer difference NMR spectroscopy and enzyme inhibition assays, overview. Molecular modelling and simulated docking studies. No or poor inhibition by diethyl (4-[[3-(hydroxymethyl)phenyl]amino]-4-oxobutyl)phosphonate, diethyl [5-[(3-hydroxyphenyl)amino]-5-oxopentyl]phosphonate, [3-[(3-hydroxyphenyl)amino]-3-oxopropyl]phosphonic acid, [5-[(3-bromophenyl)amino]-5-oxopentyl]phosphonic acid, diethyl [5-[(3-methoxyphenyl)amino]-5-oxopentyl]phosphonate, [4-[(3-methoxyphenyl)amino]-4-oxobutyl]phosphonic acid, [5-[(3-methoxyphenyl)amino]-5-oxopentyl]phosphonic acid, diethyl [4-[(3-bromophenyl)amino]-4-oxobutyl]phosphonate, [4-[(3-bromophenyl)amino]-4-oxobutyl]phosphonic acid, and [5-[(3-bromophenyl)amino]-5-oxopentyl]phosphonic acid
1.1.1.267	Plasmodium falciparum		more	724558		inhibitory potencies of a series of aryl- and heteroarylcarbamoylphosphonic acids, their diethyl esters and disodium salts as analogues of the potent DXR inhibitor fosmidomycin, effects of the carboxamide N-substituents and the length of the methylene linker, in silico docking studies, saturation transfer difference NMR spectroscopy and enzyme inhibition assays, overview. Molecular modelling and simulated docking studies. No or poor inhibition by diethyl [3-[(3-hydroxyphenyl)amino]-3-oxopropyl]phosphonate, diethyl [2-[(3-methoxyphenyl)amino]-2-oxoethyl]phosphonate, diethyl [3-[(3-methoxyphenyl)amino]-3-oxopropyl]phosphonate, diethyl [2-[(3-bromophenyl)amino]-2-oxoethyl]phosphonate, diethyl (3-[[3-(hydroxymethyl)phenyl]amino]-3-oxopropyl)phosphonate, [4-[(3-methoxyphenyl)amino]-4-oxobutyl]phosphonic acid, and [2-[(3-cyanophenyl)amino]-2-oxoethyl]phosphonic acid
1.1.1.267	Mycobacterium tuberculosis		more	725564		development and evaluation of a high-throughput screening spectrometric assay, measuring Dxr activity of Dxr coupled with 1-deoxy-D-xylulose-5-phosphate synthase, Dxs, activity, for simultaneous selection of inhibitors of the enzyme, overview
1.1.1.267	Mycobacterium tuberculosis		more	725663		design, synthesis, and X-ray crystallographic studies of alpha-aryl 3,4-dichlorophenyl-substituted fosmidomycin analogues as enzyme inhibitors. The introduction of a 3,4-dichlorophenyl group in the Calpha-position relative to the phosphonate group produces analogues that have a higher in vitro antimalarial activity than fosmidomycin
1.1.1.267	Mycobacterium tuberculosis		N-hydroxy-N-[2-(3-hydroxy-3-oxido-3,4-dihydro-1H-2,3-benzoxaphosphinin-4-yl)ethyl]acetamide	725663	102996	12% inhibition at 0.1 mM
1.1.1.267	Synechocystis sp.		NaCl	654877	39	100 mM, 87% residual activity
1.1.1.267	Mycobacterium tuberculosis		NADP+	724346	6	product inhibition
1.1.1.267	Zymomonas mobilis		Ni2+	286424	36	
1.1.1.267	synthetic construct		phosphate mono-((2S,3S)-3-fluoromethyl-2,4-dihydroxy-3-methyl-butyl) ester	696620	94364	is a weak competitive inhibitor of DXR, most likely due to the steric hindrance caused by the substitution of a fluoromethylgroup for a hydroxyl group. Is not an irreversible inactivator (suicide inhibitor) for DXR, fails to act as a mechanism-based inactivator if the retroaldol/aldol mechanism is operative
1.1.1.267	Synechocystis sp.		phosphoric acid mono-[2-(N-acetyl-N-hydroxy-amino)-ethyl]-ester	672538	41306	
1.1.1.267	Plasmodium falciparum		pyrimethamine	684379	613	
1.1.1.267	Escherichia coli		Sarcopoterium spinosum plant extract	689434		
1.1.1.267	Synechocystis sp.		sulfamic acid 2-(N-formyl-N-hydroxy-amino)-ethyl ester	672538	41308	
1.1.1.267	Zymomonas mobilis		Zn2+	286424	19	
1.1.1.267	Escherichia coli		[(1-isoquinolinylamino)methylene]-1,1-bisphosphonate	655787	79763	50% inhibition at 0.004 mM
1.1.1.267	Toxoplasma gondii		[(5-phenylpyridin-2-yl)methyl]phosphonic acid	724543	62204	
1.1.1.267	Toxoplasma gondii		[1-(3,4-dichlorophenyl)-3-[formyl(hydroxy)amino]propyl]phosphonic acid	724543	62187	
1.1.1.267	Plasmodium falciparum		[2-[(3-bromophenyl)amino]-2-oxoethyl]phosphonic acid	724558	102997	
1.1.1.267	Escherichia coli		[2-[(3-cyanophenyl)amino]-2-oxoethyl]phosphonic acid	724558	103005	20.0% inhibition
1.1.1.267	Escherichia coli		[2-[(3-hydroxyphenyl)amino]-2-oxoethyl]phosphonic acid	724558	62199	43.9% inhibition
1.1.1.267	Plasmodium falciparum		[2-[(3-hydroxyphenyl)amino]-2-oxoethyl]phosphonic acid	724558	62199	
1.1.1.267	Escherichia coli		[2-[(3-methoxyphenyl)amino]-2-oxoethyl]phosphonic acid	724558	62201	17.8% inhibition
1.1.1.267	Plasmodium falciparum		[2-[(3-methoxyphenyl)amino]-2-oxoethyl]phosphonic acid	724558	62201	
1.1.1.267	Escherichia coli		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid 3-methylbutyl ester	697335	52051	
1.1.1.267	Escherichia coli		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid mono(2-naphthalen-1-yl-ethyl) ester	697335	52054	
1.1.1.267	Escherichia coli		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid mono(2-naphthalen-2-yl-ethyl) ester	697335	52053	
1.1.1.267	Escherichia coli		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid mono-n-butyl ester	697335	52050	
1.1.1.267	Escherichia coli		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid mono-n-propyl ester	697335	52049	
1.1.1.267	Escherichia coli		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid monomethyl ester	697335	52047	
1.1.1.267	Escherichia coli		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid monophenethyl ester	697335	52052	
1.1.1.267	Escherichia coli		[3-(acetyl(hydroxy)amino)propyl]phosphonic monoethyl ester	697335	52048	
1.1.1.267	Synechocystis sp.		[3-(N-acetyl-N-methyl-amino)propyl]-phosphonic acid	672538	41310	
1.1.1.267	Synechocystis sp.		[3-(N-formyl-N-methyl-amino)-propyl]-phosphonic acid	672538	41309	
1.1.1.267	Mycobacterium tuberculosis		[3-[acetyl(hydroxy)amino]-1-(2-bromophenyl)propyl]phosphonic acid	725663	62192	38% inhibition at 0.1 mM
1.1.1.267	Mycobacterium tuberculosis		[3-[acetyl(hydroxy)amino]-1-(2-cyanophenyl)propyl]phosphonic acid	725663	102991	30% inhibition at 0.1 mM
1.1.1.267	Mycobacterium tuberculosis		[3-[acetyl(hydroxy)amino]-1-(2-methylphenyl)propyl]phosphonic acid	725663	62194	55% inhibition at 0.1 mM
1.1.1.267	Toxoplasma gondii		[3-[acetyl(hydroxy)amino]-1-(3,4-dichlorophenyl)propyl]phosphonic acid	724543	62189	
1.1.1.267	Escherichia coli		[3-[acetyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid	723812	7036	
1.1.1.267	Plasmodium falciparum		[3-[acetyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid	723812	7036	
1.1.1.267	Toxoplasma gondii		[3-[acetyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid	724543	7036	
1.1.1.267	Escherichia coli		[3-[acetyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid	723812	7037	
1.1.1.267	Plasmodium falciparum		[3-[acetyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid	723812	7037	
1.1.1.267	Toxoplasma gondii		[3-[acetyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid	724543	7037	
1.1.1.267	Escherichia coli		[3-[acetyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid	723812	10331	
1.1.1.267	Plasmodium falciparum		[3-[acetyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid	723812	10331	
1.1.1.267	Mycobacterium tuberculosis		[3-[acetyl(hydroxy)amino]-1-[2-(2-hydroxyethyl)phenyl]propyl]phosphonic acid	725663	62195	35% inhibition at 0.1 mM
1.1.1.267	Mycobacterium tuberculosis		[3-[acetyl(hydroxy)amino]-1-[2-(hydroxymethyl)phenyl]propyl]phosphonic acid	725663	62193	36% inhibition at 0.1 mM
1.1.1.267	Mycobacterium tuberculosis		[3-[acetyl(hydroxy)amino]-1-[2-(methoxymethyl)phenyl]propyl]phosphonic acid	725663	102995	30% inhibition at 0.1 mM
1.1.1.267	Mycobacterium tuberculosis		[3-[acetyl(hydroxy)amino]-1-[2-(pyridin-3-yl)phenyl]propyl]phosphonic acid	725663	102992	20% inhibition at 0.1 mM
1.1.1.267	Mycobacterium tuberculosis		[3-[acetyl(hydroxy)amino]-1-[2-(thiophen-2-yl)phenyl]propyl]phosphonic acid	725663	102994	30% inhibition at 0.1 mM
1.1.1.267	Escherichia coli		[3-[formyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid	723812	7034	
1.1.1.267	Plasmodium falciparum		[3-[formyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid	723812	7034	
1.1.1.267	Toxoplasma gondii		[3-[formyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid	724543	7034	
1.1.1.267	Escherichia coli		[3-[formyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid	723812	7035	
1.1.1.267	Plasmodium falciparum		[3-[formyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid	723812	7035	
1.1.1.267	Toxoplasma gondii		[3-[formyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid	724543	7035	
1.1.1.267	Escherichia coli		[3-[formyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid	723812	19743	
1.1.1.267	Plasmodium falciparum		[3-[formyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid	723812	19743	
1.1.1.267	Synechocystis sp.		[4-(hydroxyamino)-4-oxobutyl]phosphonic acid	672538	39701	
1.1.1.267	Plasmodium falciparum		[4-[(3-bromophenyl)amino]-4-oxobutyl]phosphonic acid	724558	102998	
1.1.1.267	Escherichia coli		[4-[(3-hydroxyphenyl)amino]-4-oxobutyl]phosphonic acid	724558	62200	49.2% inhibition
1.1.1.267	Plasmodium falciparum		[4-[(3-hydroxyphenyl)amino]-4-oxobutyl]phosphonic acid	724558	62200	
1.1.1.267	Escherichia coli		[5-[(3-bromophenyl)amino]-5-oxopentyl]phosphonic acid	724558	103004	26.8% inhibition
1.1.1.267	Escherichia coli		[[(5-chloro-2-pyridinyl)amino]methylene]-1,1-bisphosphonate	655787	47758	50% inhibition at 0.007 mM
2.2.1.7	Oryza sativa	more		672737		UV-irradiation of etiolated rice induces the expression of gene dxs3 up to 9fold compared to the unirradiated control, while etiolation itself has no effect on the expression level
2.2.1.7	Ginkgo biloba	more		676738		the enzyme expression is induced by elicitors including methyl jasmonate, ceric ammonium sulfate, arachidonic acid, and acetyl salicylic acid
2.2.1.7	Rhodobacter capsulatus		2,3-diphospho-D-glyceric acid	657953	5373	0.1 mM, 50% inhibition
2.2.1.7	Populus tremula x Populus alba		2-fluoropyruvate	720633		competitive, 0.1 mM, up to 57% inhibition
2.2.1.7	Mycobacterium tuberculosis		2-methyl-3,5-diphenyl-6-propylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51634	
2.2.1.7	Mycobacterium tuberculosis		2-methyl-3,5-diphenylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51628	
2.2.1.7	Mycobacterium tuberculosis		2-methyl-5-naphthalen-2-yl-3-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51633	
2.2.1.7	Mycobacterium tuberculosis		3,5-bis(4-methoxyphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51623	
2.2.1.7	Mycobacterium tuberculosis		3,5-diphenyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51616	
2.2.1.7	Mycobacterium tuberculosis		3-(4-bromophenyl)-5-(2-methoxyphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51627	
2.2.1.7	Mycobacterium tuberculosis		3-(4-bromophenyl)-5-methyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51619	
2.2.1.7	Mycobacterium tuberculosis		3-(4-chlorophenyl)-2-ethyl-5-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51635	
2.2.1.7	Mycobacterium tuberculosis		3-(4-chlorophenyl)-2-methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51624	
2.2.1.7	Mycobacterium tuberculosis		3-(4-chlorophenyl)-2-methyl-5-[[(1-phenyl-1H-tetrazol-5-yl)sulfanyl]methyl]pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51629	
2.2.1.7	Mycobacterium tuberculosis		3-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51625	
2.2.1.7	Mycobacterium tuberculosis		3-(4-chlorophenyl)-5-(methoxymethyl)-2-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51632	
2.2.1.7	Mycobacterium tuberculosis		3-(4-chlorophenyl)-5-(methoxymethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51611	
2.2.1.7	Mycobacterium tuberculosis		3-(4-chlorophenyl)-5-methyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51620	
2.2.1.7	Mycobacterium tuberculosis		3-(4-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51612	
2.2.1.7	Mycobacterium tuberculosis		3-(4-chlorophenyl)-5-[[(4-chlorophenyl)sulfanyl]methyl]-2-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51630	
2.2.1.7	Mycobacterium tuberculosis		3-(4-fluorophenyl)-5-(4-methoxyphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51626	
2.2.1.7	Mycobacterium tuberculosis		3-(4-methoxyphenyl)-2-methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51622	
2.2.1.7	Mycobacterium tuberculosis		3-(4-methoxyphenyl)-5-phenyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	26101	
2.2.1.7	Plasmodium vivax		3-Fluoropyruvate	719510	2448	competitive with respect to pyruvate
2.2.1.7	Mycobacterium tuberculosis		5-(chloromethyl)-3-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51614	
2.2.1.7	Mycobacterium tuberculosis		5-benzyl-3-(4-chlorophenyl)-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51617	
2.2.1.7	Mycobacterium tuberculosis		5-benzyl-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51610	
2.2.1.7	Mycobacterium tuberculosis		5-benzyl-3-phenyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51615	
2.2.1.7	Mycobacterium tuberculosis		5-[[(4-chlorophenyl)sulfanyl]methyl]-2-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51631	
2.2.1.7	Mycobacterium tuberculosis		6-benzyl-3-(4-chlorophenyl)-5-methyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	702548	51621	
2.2.1.7	Rhodobacter capsulatus		beta-fluoropyruvate	657953	2448	dead-end inhibitor for pyruvate
2.2.1.7	Rhodobacter capsulatus		beta-Glycerophosphate	657953	1810	0.3 mM, 40% inhibition
2.2.1.7	Rhodobacter capsulatus		D-3-Phosphoglyceric acid	657953	181	0.16 mM, 23% inhibition
2.2.1.7	Escherichia coli		D-glyceraldehyde	719975	520	competitive inhibition with respect to pyruvate
2.2.1.7	Escherichia coli		D-glyceraldehyde 3-phosphate	719975	139	substrate inhibition
2.2.1.7	Rhodobacter capsulatus		DL-alpha-glycerophosphate	657953		0.29 mM, 50% inhibition
2.2.1.7	Streptomyces sp.		EDTA	395812	223	recombinant protein
2.2.1.7	Plasmodium vivax		EDTA	719510	223	completely active after dialysis against EDTA. Incubation of the enzyme with saturated ammonium sulfate and 5.0mM EDTA at pH 3.5 leads to the complete loss of DXScc activity, with only a 25% recovery of activity upon the addition of Mg(II)
2.2.1.7	Mycobacterium tuberculosis		ethyl (5-methyl-7-oxo-3-phenyl-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)acetate	702548	51613	
2.2.1.7	Pseudomonas aeruginosa		Fluoropyruvate	286425	2448	recombinant protein, 50% inhibition at 0.4 mM, fluoropyruvate is supposed to bind covalently to the active site
2.2.1.7	Mycobacterium tuberculosis		methyl [3-(4-bromophenyl)-7-oxo-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-5-yl]acetate	702548	51618	
2.2.1.7	Zea mays		more	720127		protein is feedback regulated in response to the inhibition of the pathway flow; protein is feedback regulated in response to the inhibition of the pathway flow
2.2.1.7	Rhodobacter capsulatus		phosphonoacetohydroxamate	657953	10808	0.1 mM, 25% inhibition
2.2.1.7	Rhodobacter capsulatus		phosphonopropionohydroxamate	657953	80843	0.1 mM, 10% inhibition
2.2.1.7	Escherichia coli		pyruvate	719975	29	substrate inhibition
4.2.1.11	Oryctolagus cuniculus	ARP		697260		the 26-amino-acid-long acetylcholinesterase C-terminal peptide ARP elevates activity of enolase in dose-dependent manner: 200 nM ARP by 7.1%, 600 nM ARP by 12.5%
4.2.1.11	Geobacillus kaustophilus	HCO3-		678268	175	Km about 50% increased in presence of sodium bicarbonate, crystallized enzyme structure complexed with HCO3- in its activated form
4.2.1.11	Solanum tuberosum	more		33599		-SH groups required for activity
4.2.1.11	Solanum tuberosum	more		33619		
4.2.1.11	Spinacia oleracea	more		33619		contains 23 half-cystines per mol of subunit
4.2.1.11	Streptococcus ratti	phosphate		33630	12	slight stimulation without F-
4.2.1.11	Trypanosoma brucei		2-fluoro-2-phosphonoacetohydroxamate	679787	45313	competitive inhibitor
4.2.1.11	Sus scrofa		2-phosphoglycerate	33602	606	substrate inhibition
4.2.1.11	Ricinus communis		2-phosphoglycerate	33620	606	competitive
4.2.1.11	Streptococcus ratti		2-phosphoglycerate	33630	606	competitive
4.2.1.11	Mus musculus		2-phosphoglycerate	678431	606	presence of 0.8 mM 2-phosphoglycerate abolished the binding of beta,beta-enolase to tubulin, kinetics shown
4.2.1.11	Salmonella enterica		3-aminoenolpyruvate phosphate	729342		
4.2.1.11	Saccharomyces cerevisiae		3-hydroxy-2-nitro-1-phosphonopropane	650084	77167	
4.2.1.11	Saccharomyces cerevisiae		3-hydroxypropionic acid phosphate	33599	63354	
4.2.1.11	Homo sapiens		4-hydroxy-2-nonenal	716843	1076	
4.2.1.11	Sus scrofa		4-hydroxy-2-nonenal	716843	1076	
4.2.1.11	Homo sapiens		acrolein	716843	908	
4.2.1.11	Sus scrofa		acrolein	716843	908	
4.2.1.11	Macaca mulatta		Ca2+	33601	18	
4.2.1.11	Pyrococcus furiosus		citrate	721409	125	competitive
4.2.1.11	Brucella abortus		Cr2+	716180	701	leads to complete inhibition at 10 mM
4.2.1.11	Brucella abortus		Cu2+	716180	28	leads to complete inhibition at 10 mM
4.2.1.11	Bacillus megaterium		cumene hydroperoxide	678997	653	1% residual activity after treatment with 17 mM cumene hydroperoxide at 50&deg;C and pH 7 for 2 h
4.2.1.11	Saccharomyces cerevisiae		D-2,3-dihydroxyisobutyric acid 2-phosphate	33599	67101	
4.2.1.11	Saccharomyces cerevisiae		D-erythro-2,3-dihydroxybutyric acid 2-phosphate	33599	66299	
4.2.1.11	Saccharomyces cerevisiae		D-erythro-2,3-dihydroxybutyric acid 3-phosphate	33599	1904	
4.2.1.11	Bos taurus		D-glycerate-2-phosphate	3235	783	mixed-type inhibition in the binding of D-glycerate-2-phosphate and D-phosphoglycerate mutase to the D-glycerate-2-phosphate binding site on the enolase in absence of D-glycerate-2,3-diphosphate, inhibition is almost fully reverted by D-glycerate-2,3-diphosphate
4.2.1.11	Saccharomyces cerevisiae		D-glyceric acid 3-phosphate	33599	181	
4.2.1.11	Saccharomyces cerevisiae		D-lactic acid phosphate	33599	56262	
4.2.1.11	Salmonella enterica		D-tartronate semialdehyde phosphate	729342	97389	
4.2.1.11	Leishmania mexicana		diphosphate	679699	13	inhibits natural enolase and recombinant protein
4.2.1.11	Bacillus megaterium		EDTA	33609	223	
4.2.1.11	Pyrococcus furiosus		EDTA	721409	223	1 mM
4.2.1.11	Saccharomyces cerevisiae		F-	33599	158	
4.2.1.11	Escherichia coli		F-	33600, 33605	158	
4.2.1.11	Oncorhynchus keta		F-	33606	158	
4.2.1.11	Oncorhynchus kisutch		F-	33606	158	
4.2.1.11	Oncorhynchus mykiss		F-	33606	158	
4.2.1.11	Bacillus megaterium		F-	33609	158	
4.2.1.11	Spinacia oleracea		F-	33619	158	
4.2.1.11	Ricinus communis		F-	33620	158	
4.2.1.11	Peptoclostridium difficile		F-	33627	158	in presence of phosphate, competitive
4.2.1.11	Streptococcus ratti		F-	33630	158	
4.2.1.11	Streptococcus mutans		F-	33632	158	noncompetitive inhibition below 10 mM, competitive above 10 mM
4.2.1.11	Streptococcus mutans		F-	33635	158	quasi-irreverible inhibition above 0.01 mM
4.2.1.11	Thermotoga maritima		F-	33637	158	in absence of phosphate noncompetitive inhibition up to 10 mM F-, competitive inhibition in presence of 0.5 mM phosphate
4.2.1.11	Candida albicans		F-	650872	158	noncompetitive in the presence of phosphate, competitive in the absence of phosphate
4.2.1.11	Homo sapiens		F-	664141	158	
4.2.1.11	Leuconostoc mesenteroides		F-	679893	158	non-competitive inhibition without phosphate and in presence of 1 mM phosphate, competitive inhibition in presence of 20 mM phosphate
4.2.1.11	Homo sapiens		fluoride	701578	158	the inhibitory effect of fluoride alone is noncompetitive, but it is competitive in the presence of a low phosphate level
4.2.1.11	Klebsiella pneumoniae		fluoride	701578	158	the inhibitory effect of fluoride alone is noncompetitive, but it is competitive in the presence of a low phosphate level
4.2.1.11	Brucella abortus		Hg2+	716180	31	leads to complete inhibition at 10 mM
4.2.1.11	Bacillus megaterium		hydrogen peroxide	678997	20	inhibitory at 0.25%, at pH 7
4.2.1.11	Trypanosoma brucei		iodoacetamide	652923	63	binds to cysteine residues
4.2.1.11	Plasmodium falciparum		KBr	679767	1987	monomeric form
4.2.1.11	Plasmodium falciparum		KCl	679767	74	monomeric form
4.2.1.11	Sus scrofa		Li+	33638	142	noncompetitive with either 2-phosphoglycerate or Mg2+
4.2.1.11	Sus scrofa		Li+	33639	142	liver enzyme is severely inhibited, muscle enzyme is moderately inhibited
4.2.1.11	Oryctolagus cuniculus		Li+	33641	142	
4.2.1.11	Homo sapiens		methylglyoxal	704848	277	incubation of0.015 mM enzyme with 2 mM, 3.1 mM and 4.34 mM methylglyoxal in 100 mM phosphate buffer pH 7.4 for 3 h causes the loss a 32%, 55% and 82% of initial specific activity, respectively. Inhibition of enolase by methylglyoxal and formation of enolase-derived glycation products arises more effectively in slight alkaline conditions and in the presence of inorganic phosphate
4.2.1.11	Homo sapiens		methylglyoxal	716843	277	
4.2.1.11	Sus scrofa		methylglyoxal	716843	277	
4.2.1.11	Saccharomyces cerevisiae		Mg2+	653043	25	inhibitor above 1 mM, N207A, H159A, H159N and H159F mutants are stimulated at this concentration
4.2.1.11	Plasmodium falciparum		Mg2+	664835	25	inhibitory at higher concentrations
4.2.1.11	Homo sapiens		Mg2+	666023	25	at high concentrations
4.2.1.11	Leishmania mexicana		Mg2+	679699	25	above 2 mM
4.2.1.11	Homo sapiens		Mg2+	701578	25	inhibitory in excess
4.2.1.11	Klebsiella pneumoniae		Mg2+	701578	25	inhibitory in excess
4.2.1.11	Homo sapiens		Mg2+	703739	25	Mg2+ is inhibitory at 30 mM to the physiological reaction, but not to the reaction with D-tartronate semialdehyde phosphate
4.2.1.11	Saccharomyces cerevisiae		Mg2+	703739	25	Mg2+ is inhibitory at 30 mM to the physiological reaction, but not to the reaction with D-tartronate semialdehyde phosphate
4.2.1.11	Saccharomyces cerevisiae		Mg2+	731032	25	inhibitory at higher concentrations
4.2.1.11	Homo sapiens		Mn2+	701578	26	inhibitory in excess
4.2.1.11	Klebsiella pneumoniae		Mn2+	701578	26	inhibitory in excess
4.2.1.11	Streptococcus ratti		monofluorophosphate	33630	66560	
4.2.1.11	Saccharomyces cerevisiae		more	33599		no inhibition by SH-reagents
4.2.1.11	Solanum tuberosum		more	33599		
4.2.1.11	Bacillus megaterium		more	33609		no inhibition by NEM and iodoacetate
4.2.1.11	Streptococcus mutans		more	33632		inhibition of enolase by fluoride in combination with phosphate can influence glycolysis and so reduce acid production of even growth rate, thereby leading to potential anticariogenic effects
4.2.1.11	Leuconostoc mesenteroides		more	679893		recombinant enolase inhibits activity of purified dextransucrase
4.2.1.11	Leishmania mexicana		more	682238		antibodies against enolase inhibits up to 60% of plasminogen binding
4.2.1.11	Homo sapiens		more	716843		the muscle-specific enolase is used as a model enzyme for inhibition analysis by acrolein, 4-hydroxy-2-nonenal, and trans-2-nonenal, incubation for 1-24 h at 25&deg;C, 37&deg;C, and 45&deg;C, overview. The compounds show inhibition effectivity in the following descending order: inhibition degree of enolase activity occurred in following order: 4-hydroxy-2-nonenal, acrolein, methylglyoxal, trans-2-nonenal, overview
4.2.1.11	Sus scrofa		more	716843		the muscle-specific enolase is used as a model enzyme for inhibition analysis by acrolein, 4-hydroxy-2-nonenal, and trans-2-nonenal, incubation for 1-24 h at 25&deg;C, 37&deg;C, and 45&deg;C, overview. The compounds show inhibition effectivity in the following descending order: inhibition degree of enolase activity occurred in following order: 4-hydroxy-2-nonenal, acrolein, methylglyoxal, trans-2-nonenal, overview
4.2.1.11	Plasmodium falciparum		Na+	664835	55	50% inhibition around 0.3-0.4 M
4.2.1.11	Streptococcus mutans		Na2PO3F	33632	67205	
4.2.1.11	Plasmodium falciparum		NaCl	679767	39	inhibits dimeric and monomeric forms of the enzyme, inhibition stronger for the monomeric form
4.2.1.11	Oryctolagus cuniculus		NaClO4	650303	6206	inactivation is due to dissociation of the enolase into inactive monomers, 2-phospho-D-glycerate prevents this inactivation
4.2.1.11	Oryctolagus cuniculus		NaClO4	650385	6206	E414L mutant is more sensitive to inactivation than the wild-type enzyme
4.2.1.11	Streptococcus pyogenes		NaClO4	706454	6206	enolase at 19.4 mM after incubation in 0.2 M NaClO4, has 32% of its original activity and is 21% octameric. Following a 24 h dialysis against buffer, the protein is 77% octameric and has 74% of its original activity
4.2.1.11	Homo sapiens		p19ras	703010		when full-length p19ras and C-terminal region are bound to NSE, it inhibits the enzymatic activity of NSE, p19ras interacts with enolase alpha and represses its enzymatic activity in vitro
4.2.1.11	Bacillus megaterium		peracetic acid	678997	3245	1% residual activity after treatment with 4 mM peracetic acid at 25&deg;C and pH 7 for 15 min
4.2.1.11	Saccharomyces cerevisiae		phosphate	33599	12	
4.2.1.11	Macaca mulatta		phosphate	33601	12	
4.2.1.11	Cyprinus carpio		phosphate	33631	12	competitive inhibition at 2-4 mM phosphate with respect to 2-phosphoglycerate becomes noncompetitive in presence of 20-40 mM phosphate
4.2.1.11	Oryctolagus cuniculus		phosphate	33631	12	competitive inhibition at 2-4 mM phosphate with respect to 2-phosphoglycerate becomes noncompetitive in presence of 20-40 mM phosphate
4.2.1.11	Pagrus major		phosphate	33631	12	competitive inhibition at 2-4 mM phosphate with respect to 2-phosphoglycerate becomes noncompetitive in presence of 20-40 mM phosphate
4.2.1.11	Scomber japonicus		phosphate	33631	12	competitive inhibition at 2-4 mM phosphate with respect to 2-phosphoglycerate becomes noncompetitive in presence of 20-40 mM phosphate
4.2.1.11	Thermotoga maritima		phosphate	33637	12	
4.2.1.11	Homo sapiens		phosphate	701578	12	at a high phosphate concentration, noncompetitive inhibition is found and at a lower concentration competitive inhibition
4.2.1.11	Klebsiella pneumoniae		phosphate	701578	12	at a high phosphate concentration, noncompetitive inhibition is found and at a lower concentration competitive inhibition
4.2.1.11	Saccharomyces cerevisiae		phosphate	706611	12	competitive inhibitor of enolase
4.2.1.11	Saccharomyces cerevisiae		phosphonoacetohydroxamate	33603	10808	
4.2.1.11	Trypanosoma brucei		phosphonoacetohydroxamate	679787	10808	retains open tunnel from catalytic site to protein surface, offers possibilities for drug development
4.2.1.11	Saccharomyces cerevisiae		phosphonoacetohydroxamate	680369	10808	preference for formation of hybrid Zn2+/Mn2+ complexes with enolase, in vitro activity of the complexed enolase in presence of phosphonoacetohydroxamate investigated by crystallography and electron paramagnetic resonance spectroscopy
4.2.1.11	Homo sapiens		PO43-	664141	684	mimics the phosphate group of substrate
4.2.1.11	Trypanosoma brucei		SO42-	679787	148	induces a complete closure of catalytic site loops
4.2.1.11	Bacillus megaterium		tert-butyl hydroperoxide	678997	511	1% residual activity after treatment with 290 mM tert-butyl hydroperoxide at 50&deg;C and pH 7 for 3 h
4.2.1.11	Homo sapiens		trans-2-nonenal	716843	1739	
4.2.1.11	Sus scrofa		trans-2-nonenal	716843	1739	
4.2.1.11	Homo sapiens		Zn2+	701578	19	inhibitory in excess
4.2.1.11	Klebsiella pneumoniae		Zn2+	701578	19	inhibitory in excess
3.1.2.20	Cavia porcellus	1-acyl-sn-glycero-3-phosphocholine		646126	560	0.5 mM stimulates acylation 3-9fold
3.1.2.20	Rattus norvegicus	3-hydroxybutyrate		80783	2001	stimulates the mitochondrial-matrix enzyme activity
3.1.2.20	Rattus norvegicus	3-thia fatty acids		646190		i.e. tetradecylthioacetic acid and 3-dithiacarboxylic acid; stimulates palmitoyl-CoA, tetradecylthioacetyl-CoA and tetradecylthiopropionyl-CoA hydrolase activities in cytosol, mitochondrion and peroxisome, overview
3.1.2.20	Rattus norvegicus	3-thiadicarboxylic acid		646170	21042	
3.1.2.20	Pseudomonas aeruginosa	acetone		646130	286	
3.1.2.20	Rattus norvegicus	Acetylsalicylic acid		646138	1667	
3.1.2.20	Homo sapiens	ACTH		646188		
3.1.2.20	Rattus norvegicus	ADP		80783	8	stimulates the microsomal activity
3.1.2.20	Rattus norvegicus	ATP		80783	7	stimulates the microsomal activity
3.1.2.20	Spinacia oleracea	Bovine serum albumin		646136		
3.1.2.20	Rattus norvegicus	Bovine serum albumin		646140		
3.1.2.20	Homo sapiens	Bovine serum albumin		646142		
3.1.2.20	Rattus norvegicus	Bovine serum albumin		646141, 646165		a small amount activates the hydrolase
3.1.2.20	Euglena gracilis	Bovine serum albumin		646179		activation; effect of stimulation increases as chain-length increases up to C-12 and decreases progressively as chain-length increases beyond C-12, inhibitory with octadecanoyl-CoA as substrate
3.1.2.20	Sus scrofa	Bovine serum albumin		646180		activation; only with long-chain acyl-CoA as substrate
3.1.2.20	Rattus norvegicus	citrate		80783	125	
3.1.2.20	Rattus norvegicus	Clofibrate		646144	970	2-3fold enhancement of activity
3.1.2.20	Rattus norvegicus	Clofibrate		646151	970	
3.1.2.20	Bumilleriopsis filiformis	Clofibrate		646156	970	
3.1.2.20	Eremosphaera viridis	Clofibrate		646156	970	
3.1.2.20	Mougeotia scalaris	Clofibrate		646156	970	
3.1.2.20	Rattus norvegicus	Clofibrate		646175	970	stimulates; stimulates
3.1.2.20	Rattus norvegicus	Clofibrate		646187	970	hypolipidemic drug; stimulates
3.1.2.20	Mus musculus	Clofibrate		646197	970	isozymes CTE-I and MTE-I are induced, induction is completely dependent on PPARalpha
3.1.2.20	Mus musculus	Clofibrate		646203	970	isozymes CTE-I and MTE-I are induced, induction is completely dependent on PPARalpha; peroxisome proliferator
3.1.2.20	Rattus norvegicus	cyanide		80783	112	
3.1.2.20	Rattus norvegicus	cysteine		80783	70	
3.1.2.20	Rattus norvegicus	di(2-ethylhexyl)phthalate		646115	1949	induces the mitochondrial enzyme by 10fold
3.1.2.20	Rattus norvegicus	di(2-ethylhexyl)phthalate		646163	1949	; induction in liver, slightly in kidney; strong induction in liver, moderately in kidney
3.1.2.20	Rattus norvegicus	di(2-ethylhexyl)phthalate		646138, 646164, 646172, 646175	1949	
3.1.2.20	Rattus norvegicus	di(2-ethylhexyl)phthalate		646187	1949	a plastisizer; stimulates
3.1.2.20	Mus musculus	di(2-ethylhexyl)phthalate		646203	1949	induction of enzyme expression; peroxisome proliferator
3.1.2.20	Rattus norvegicus	dithiothreitol		80783	42	stimulation of the microsomal enzyme
3.1.2.20	Rattus norvegicus	dithiothreitol		646129, 80791	42	
3.1.2.20	Rattus norvegicus	EDTA		80783	223	stimulates the activity of the mitochondrial enzyme above 2 mM
3.1.2.20	Mycobacterium phlei	Elongation factor		646122		chain elongation
3.1.2.20	Pseudomonas aeruginosa	ethanol		646130	65	
3.1.2.20	Rattus norvegicus	ethyl p-chlorophenoxyisobutyrate		646138	970	
3.1.2.20	Rattus norvegicus	FAD		80783	14	stimulates the activity of the mitochondrial-matrix enzyme up to 0.4 mM
3.1.2.20	Rattus norvegicus	fish oil		646155		partially hydrogenated, hydrolase activity reaches maximum after administration of the dietary oil for 6.5 days
3.1.2.20	Rattus norvegicus	FMN		80783	52	stimulates the microsomal activity
3.1.2.20	Rattus norvegicus	fumarate		80783	156	stimulates the microsomal activity
3.1.2.20	Euglena gracilis	hexadecanol		646179	1042	activation, only with acyl-CoA of more than C-8 as substrates
3.1.2.20	Rattus norvegicus	isopropyl thiogalactoside		646161	3077	
3.1.2.20	Streptomyces coelicolor	isopropyl-thio-beta-D-galactoside		695787		inducer
3.1.2.20	Rattus norvegicus	isoproterenol		646182	1261	stimulates enzyme expression, can be blocked by specific beta-adrenoreceptor antagonists, e.g. actinomycin D
3.1.2.20	Rattus norvegicus	L-carnitine		80791	284	activates at low concentrations
3.1.2.20	Homo sapiens	linoleic acid		646194	357	both conjugated and gamma-linoleic acid, increase activity
3.1.2.20	Rattus norvegicus	Lipids		646141		activate
3.1.2.20	Rattus norvegicus	lysophosphatidylcholine		171023	560	
3.1.2.20	Rattus norvegicus	lysophosphatidylethanolamine		171023	2608	
3.1.2.20	Rattus norvegicus	malate		80783	246	stimulates the mitochondrial-matrix enzyme activity
3.1.2.20	Bumilleriopsis filiformis	monoethylhexylphthalate		646156	8608	
3.1.2.20	Eremosphaera viridis	monoethylhexylphthalate		646156	8608	
3.1.2.20	Mougeotia scalaris	monoethylhexylphthalate		646156	8608	
3.1.2.20	Rattus norvegicus	more		646112		cold acclimation induces enzyme activity
3.1.2.20	Rattus norvegicus	more		646190		no stimulation by tetradecylthiopropionate
3.1.2.20	Homo sapiens	more		646194		no stimulation of activity by docosahexaenoic and eisosapentaenoic acids
3.1.2.20	Streptomyces sp.	more		695756		overexpression of FscTE under the strong constitutive ermE*p promoter in the wild-type strain, does not suppress FR-008/candicidin formation
3.1.2.20	Escherichia coli K-12	more		696310		EntH active site consists of Gln48, Gly55, Glu63, Thr64, Ser67, Met68, and Gly82
3.1.2.20	Pseudomonas aeruginosa PAO1	more		697481		PA5185 contains Asp26
3.1.2.20	Amycolatopsis mediterranei	more		698975		movement of a helical lid controls access of substrates to the active site of RifR. The active site of RifR is a classic catalytic triad comprising residues Ser94, Asp200, and His228
3.1.2.20	Rattus norvegicus	NAD+		80783	4	stimulates the microsomal activity
3.1.2.20	Rattus norvegicus	niadenate		646151	31008	
3.1.2.20	Rattus norvegicus	nicotinic acid		646151	787	
3.1.2.20	Rattus norvegicus	nicotinic acid		80783	787	stimulates the microsomal activity
3.1.2.20	Saccharomyces cerevisiae	oleate		646193	320	induces enzyme expression in peroxisomes
3.1.2.20	Rattus norvegicus	Phenobarbital		646144	1115	2-3fold enhancement of activity
3.1.2.20	Rattus norvegicus	phosphatidylcholine		171023	190	
3.1.2.20	Rattus norvegicus	phosphatidylethanolamine		171023	427	
3.1.2.20	Mus musculus	PPARalpha		646197		gene expression inducing and regulatory role, mediates the stimulation by clofibrate; i.e. peroxisome proliferator-activated receptor alpha; internal receptor protein essential for effect of stimulating compounds
3.1.2.20	Mus musculus	PPARalpha		646200		i.e. peroxisome proliferator-activated receptor alpha; internal receptor protein essential for effect of stimulating compounds
3.1.2.20	Rattus norvegicus	riboflavin		80783	298	
3.1.2.20	Rattus norvegicus	succinate		80783	54	stimulates the mitochondrial-matrix enzyme activity
3.1.2.20	Euglena gracilis	Tetradecanol		646179	3595	activation, only with acyl-CoA of more than C-8 as substrates
3.1.2.20	Rattus norvegicus	tetradecylthioacetic acid		646170	21245	
3.1.2.20	Rattus norvegicus	tiadenol		646144	13872	produces a 7-9fold increase of the total activity
3.1.2.20	Rattus norvegicus	tiadenol		646151	13872	
3.1.2.20	Rattus norvegicus	Triton X-100		646128	57	prevents inhibition together with serum albumin
3.1.2.20	Rattus norvegicus	Triton X-100		646129, 646141	57	
3.1.2.20	Rattus norvegicus	Triton X-100		646162	57	0.005% slightly stimulates the activity
3.1.2.20	Candida rugosa	Triton X-100		646168	57	slightly stimulates at low concentrations
3.1.2.20	Euglena gracilis	Triton X-100		646179	57	activation, 0.005%, dodecanoyl-CoA as substrate
3.1.2.20	Rattus norvegicus	Triton X-35		646141		
3.1.2.20	Rattus norvegicus	Triton X-405		646141	10892	
3.1.2.20	Rattus norvegicus		1-acyl-sn-glycerol-3-phosphocholine	646165	560	competitive inhibition at low concentration of palmitoyl-CoA
3.1.2.20	Anas platyrhynchos		1-ethyl-3-(3-dimethylaminopropyl)carbodiimide	646181	2269	23% inhibition at 10 mM
3.1.2.20	Oryctolagus cuniculus		13-hydroperoxyoctadecadienoic acid	646192	33674	only the mitochondrial enzyme form is inhibited, not the cytosolic one
3.1.2.20	Escherichia coli		2,2-dinitrofluorobenzene	646120		inhibits very slowly
3.1.2.20	Rattus norvegicus		2,2-dinitrofluorobenzene	646137		
3.1.2.20	Rattus norvegicus		2,4-dichlorophenoxyacetate	646173	3519	reduced activity in microsomes and mitochondria
3.1.2.20	Rattus norvegicus		3-dithiacarboxylic acid	646190		palmitoyl-CoA hydrolase activity, L-fraction and peroxisomes, especially of 3-thia fatty acids treated rats
3.1.2.20	Mycobacterium smegmatis		3-O-methylmannose polysaccharide	646139		
3.1.2.20	Rattus norvegicus		4-chloromercuribenzoate	715623	40	inhibitor of acyl-CoA thioesterase 2
3.1.2.20	Escherichia coli		4-hydroxyphenacyl-CoA	690932	3675	
3.1.2.20	Haemophilus influenzae		4-hydroxyphenacyl-CoA	690932	3675	
3.1.2.20	Rattus norvegicus		4-Pentenoate	646173	13225	reduced activity in microsomes
3.1.2.20	Rattus norvegicus		5,5'-dithiobis(2-nitrobenzoate)	646131, 646137	196	
3.1.2.20	Mycobacterium smegmatis		6-O-methylglucose polysaccharide	646139		
3.1.2.20	Rattus norvegicus		Acetyl salicylate	646173	1667	reduced activity in microsomes
3.1.2.20	Rattus norvegicus		acetyl-CoA	646129	27	
3.1.2.20	Bos taurus		acetyl-CoA	646153	27	
3.1.2.20	Arabidopsis thaliana		acyl-CoA	646195	409	e.g. lauroyl-CoA, at 0.005 mM, can be overcome by addition of bovine serum albumin or alpha-casein
3.1.2.20	Mus musculus		acyl-CoA	646200	409	substrate inhibition at concentrations higher than 0.005-0.01 mM of acyl-CoA longer than C10, BSA protects
3.1.2.20	Sus scrofa		ADP	646180	8	
3.1.2.20	Rattus norvegicus		ADP	80783	8	inhibits the mitochondrial-matrix enzyme
3.1.2.20	Rattus norvegicus		Albumin	646115		
3.1.2.20	Sus scrofa		AMP	646180	9	acetyl-CoA as substrate
3.1.2.20	Rattus norvegicus		ATP	646164	7	inhibits ACH1 but not ACH2
3.1.2.20	Sus scrofa		ATP	646180	7	competitive to acetyl-CoA
3.1.2.20	Rattus norvegicus		ATP	80783	7	inhibits the mitochondrial-matrix enzyme
3.1.2.20	Rattus norvegicus		beta-hydroxybutyrate	80783	2001	moderately inhibits the microsomal enzyme activity
3.1.2.20	Rattus norvegicus		bezafibrate	646164, 646171	4119	
3.1.2.20	Rattus norvegicus		bis-(4-nitrophenyl) phosphate	646150, 80787	715	
3.1.2.20	Cavia porcellus		Bovine serum albumin	646126		
3.1.2.20	Pseudomonas aeruginosa		Bovine serum albumin	646130		
3.1.2.20	Rattus norvegicus		Bovine serum albumin	646125, 646135, 646138, 646161		
3.1.2.20	Rattus norvegicus		Bovine serum albumin	646141, 646165		a high amount inhibits the hydrolase
3.1.2.20	Euglena gracilis		Bovine serum albumin	646179		octadecanoyl-CoA as substrate, stimulates with C-6 to C-12 CoA as substrates
3.1.2.20	Spinacia oleracea		Ca2+	646136	18	10 mM inhibits the enzyme by 30-35%
3.1.2.20	Mycobacterium smegmatis		Ca2+	646143	18	
3.1.2.20	Pisum sativum		Ca2+	646147	18	
3.1.2.20	Bos taurus		Ca2+	646153	18	weakly inhibitory
3.1.2.20	Rattus norvegicus		Ca2+	646164	18	inhibits ACH1, but ACH 2 just at higher concentrations
3.1.2.20	Rattus norvegicus		Ca2+	646165	18	50% inhibition at 1.6 mM
3.1.2.20	Bos taurus		Ca2+	646167	18	
3.1.2.20	Oryctolagus cuniculus		Ca2+	646149, 646167	18	
3.1.2.20	Rattus norvegicus		Ca2+	646125, 646150, 646167	18	
3.1.2.20	Rattus norvegicus		Ca2+	80783	18	inhibits the microsomal enzyme
3.1.2.20	Rattus norvegicus		cardiolipin	171023	652	
3.1.2.20	Sus scrofa		citrate	646180	125	
3.1.2.20	Rattus norvegicus		Clofibrate	646164, 646171	970	
3.1.2.20	Rattus norvegicus		Clofibrate	646173	970	reduced activity of the mitochondrial enzyme
3.1.2.20	Rattus norvegicus		Co2+	80783	21	slightly inhibits the mitochondrial enzyme
3.1.2.20	Escherichia coli		CoA	690932	10	strong feedback inhibitor, product inhibition
3.1.2.20	Haemophilus influenzae		CoA	690932	10	strong feedback inhibitor, product inhibition
3.1.2.20	Sus scrofa		CoA-S-S-CoA	646180	3797	competitive to acetyl-CoA; i.e. oxidized CoA, additive with NADH, kinetics
3.1.2.20	Sus scrofa		CoASH	646180	10	product inhibition, acetyl-CoA as substrate, kinetics
3.1.2.20	Arabidopsis thaliana		CoASH	646195	10	feedback inhibition of recombinant enzyme at concentrations above 0.1 mM
3.1.2.20	Saccharomyces cerevisiae		CoASH	665707	10	IC50: 0.03 mM
3.1.2.20	Sus scrofa		Cu2+	646180	28	
3.1.2.20	Rattus norvegicus		Cu2+	80783	28	
3.1.2.20	Rattus norvegicus		D-carnitine	80791	2461	inhibits at concentrations over 6 mM
3.1.2.20	Homo sapiens		desulfoCoA	707486	1063	
3.1.2.20	Alcaligenes faecalis		diethyl dicarbonate	679739	265	1 mM, complete inhibition
3.1.2.20	Gallus gallus		diethyldicarbonate	646160	265	
3.1.2.20	Rattus norvegicus		diethyldicarbonate	646161	265	
3.1.2.20	Rattus norvegicus		diethyldicarbonate	646165	265	inactivation
3.1.2.20	Escherichia coli		diethyldicarbonate	646178	265	hydroxylamine reverses
3.1.2.20	Euglena gracilis		diethyldicarbonate	646179	265	hydroxylamine reverses
3.1.2.20	Sus scrofa		diethyldicarbonate	646180	265	
3.1.2.20	Anas platyrhynchos		diethyldicarbonate	646181	265	95% inhibition at 2 mM
3.1.2.20	Escherichia coli		diisopropylfluorophosphate	646119	216	at 0.01 mM inhibition of 95% after 40 min.
3.1.2.20	Escherichia coli		diisopropylfluorophosphate	646123	216	1 mM DFP at 40 min at 25&deg;C produces a 95% inhibition at palmityl thioesterase I
3.1.2.20	Mycobacterium smegmatis		diisopropylfluorophosphate	646143	216	1 mM inhibits activity completely
3.1.2.20	Rhodobacter sphaeroides		diisopropylfluorophosphate	646145	216	0.01 mM inhibits
3.1.2.20	Candida rugosa		diisopropylfluorophosphate	646168	216	
3.1.2.20	Rhodobacter sphaeroides		diisopropylfluorophosphate	646176	216	no inhibition
3.1.2.20	Euglena gracilis		diisopropylfluorophosphate	646179	216	
3.1.2.20	Sus scrofa		diisopropylfluorophosphate	646180	216	
3.1.2.20	Anas platyrhynchos		diisopropylfluorophosphate	646181	216	94% inhibition at 5 mM, maximal inhibition
3.1.2.20	Rhodotorula aurantiaca		diisopropylfluorophosphate	646199	216	complete inhibition
3.1.2.20	Alcaligenes faecalis		dimethyl (2-hydroxy-5-nitrobenzyl) sulfonium bromide	679739	63085	1 mM, 11% inhibition
3.1.2.20	Alcaligenes faecalis		dithiothreitol	679739	42	1 mM, 20% inhibition
3.1.2.20	Euglena gracilis		Dodecanoyl-CoA	646179	577	substrate inhibition
3.1.2.20	Arabidopsis thaliana		DTNB	646195	196	above 0.3 mM
3.1.2.20	Rattus norvegicus		EDTA	80783	223	inhibits the activity of the mitochondrial enzyme at concentrations of 0.5 mM
3.1.2.20	Rattus norvegicus		ethanol	646134	65	
3.1.2.20	Rattus norvegicus		F-	80783	158	
3.1.2.20	Rattus norvegicus		FAD	80783	14	slightly inhibits the microsomal enzyme
3.1.2.20	Rattus norvegicus		FMN	80783	52	inhibits the mitochondrial-matrix enzyme activity
3.1.2.20	Rattus norvegicus		fumarate	80783	156	inhibits the mitochondrial-matrix enzyme activity
3.1.2.20	Rattus norvegicus		gemfibrozil	646171	4121	
3.1.2.20	Sus scrofa		GTP	646180	35	acetyl-CoA as substrate
3.1.2.20	Sus scrofa		hexadecanoyl-CoA	646180	122	substrate inhibition
3.1.2.20	Escherichia coli		hexyl-CoA	690932	17315	
3.1.2.20	Haemophilus influenzae		hexyl-CoA	690932	17315	
3.1.2.20	Rattus norvegicus		Hg2+	646131	31	
3.1.2.20	Rattus norvegicus		HPO42-	646150	2041	
3.1.2.20	Escherichia coli		IAA	646178	2122	
3.1.2.20	Rattus norvegicus		Ibuprofen	646173	1233	reduced activity in microsomes and mitochondria
3.1.2.20	Escherichia coli		iodoacetamide	646120	63	
3.1.2.20	Gallus gallus		iodoacetamide	646160	63	
3.1.2.20	Rattus norvegicus		KCl	646129	74	
3.1.2.20	Rattus norvegicus		KCl	646141	74	inhibits at high concentrations
3.1.2.20	Rattus norvegicus		KCl	80783	74	inhibits the mitochondrial enzyme above 125 mM
3.1.2.20	Rattus norvegicus		L-carnitine	80791	284	inhibits at concentrations over 6 mM
3.1.2.20	Oryctolagus cuniculus		L-palmitoyl carnitine	646149	4866	competitively inhibits at 0.02-04 mM
3.1.2.20	Rattus norvegicus		L-palmitoyl carnitine	646165	4866	competitive to acyl-CoA
3.1.2.20	Rattus norvegicus		lysophosphatidic acid	171023	848	
3.1.2.20	Bos taurus		lysophosphatidylcholine	646153	560	strongly inhibitory
3.1.2.20	Rattus norvegicus		lysophosphatidylcholine	646165	560	
3.1.2.20	Bos taurus		lysophosphatidylethanolamine	646153	2608	weakly inhibitory
3.1.2.20	Bos taurus		lysophosphatidylinositol	646153	4109	strong inhibition
3.1.2.20	Rattus norvegicus		lysophosphatidylinositol	646165	4109	
3.1.2.20	Bos taurus		Lysophosphatidylserine	646153	4112	weakly inhibitory
3.1.2.20	Sus scrofa		malate	646180	246	weak
3.1.2.20	Rattus norvegicus		methyl methanethiosulfonate	646165	1724	slight inhibition
3.1.2.20	Escherichia coli		methylene blue	646120	426	photooxidation
3.1.2.20	Rattus norvegicus		Mg2+	646129	25	0.5 mM gives 40% inhibition
3.1.2.20	Pseudomonas aeruginosa		Mg2+	646130	25	
3.1.2.20	Spinacia oleracea		Mg2+	646136	25	10 mM inhibits the enzyme by 30-35%
3.1.2.20	Mycobacterium smegmatis		Mg2+	646143	25	
3.1.2.20	Bos taurus		Mg2+	646153	25	weak inhibition
3.1.2.20	Rattus norvegicus		Mg2+	646164	25	inhibits ACH1, but ACH2 just at higher concentrations
3.1.2.20	Rattus norvegicus		Mg2+	646165	25	50% inhibition at 1.6 mM
3.1.2.20	Bos taurus		Mg2+	646167	25	
3.1.2.20	Rattus norvegicus		Mg2+	646125, 646131, 646150, 646167	25	
3.1.2.20	Candida rugosa		Mg2+	646168	25	
3.1.2.20	Rattus norvegicus		Mg2+	80783	25	inhibits the microsomal enzyme, at higher concentrations also the mitochondrial enzyme
3.1.2.20	Rattus norvegicus		Mn2+	646129	26	0.2 mM gives 60% inhibition
3.1.2.20	Bos taurus		Mn2+	646153	26	weakly inhibitory
3.1.2.20	Rattus norvegicus		Mn2+	646164	26	inhibits ACH1, but ACH2 just at higher concentrations
3.1.2.20	Bos taurus		Mn2+	646167	26	
3.1.2.20	Sus scrofa		Mn2+	646167, 646180	26	
3.1.2.20	Rattus norvegicus		Mn2+	646128, 646167, 80783, 80791	26	
3.1.2.20	Gallus gallus		more	646160		
3.1.2.20	Rattus norvegicus		more	646165		no inhibition by NEM, iodoacetamide, L-carnitine
3.1.2.20	Escherichia coli		more	646178		no inhibition by iodoacetate
3.1.2.20	Euglena gracilis		more	646179		no inhibition by NEM
3.1.2.20	Sus scrofa		more	646180		no inhibition by EDTA, Mg2+, Fe2+, NAD+, NADP+, NADPH, glutamate, 2-oxoglutarate, pyruvate, alanine, asparagine, succinate; no inhibition by NEM
3.1.2.20	Homo sapiens		more	683004		no inhibition by acetyl-CoA, diisopropyl fluorophosphate and bis(p-nitrophenyl)phosphate
3.1.2.20	Alcaligenes faecalis		N-bromosuccinimide	679739	185	1 mM, complete inhibition
3.1.2.20	Rattus norvegicus		N-ethylmaleimide	646129	46	0.001 mM gives 50% inhibition
3.1.2.20	Rattus norvegicus		N-ethylmaleimide	646137	46	
3.1.2.20	Rattus norvegicus		NaCl	646129	39	
3.1.2.20	Rattus norvegicus		NaCl	646141	39	inhibits at high concentrations
3.1.2.20	Rattus norvegicus		NAD+	80783	4	inhibits the mitochondrial-matrix enzyme
3.1.2.20	Rattus norvegicus		NADH	646112	3	no inhibition
3.1.2.20	Sus scrofa		NADH	646180	3	additive with oxidized CoA, noncompetitive
3.1.2.20	Homo sapiens		Nafamostat	683004	7603	competitive inhibition of palmitoyl-CoA hydrolytic activity
3.1.2.20	Homo sapiens		NGDA	646188	34079	isozymes CTE-I and MTE-I
3.1.2.20	Sus scrofa		Ni2+	646180	36	
3.1.2.20	Rattus norvegicus		nicotinic acid	80783	787	inhibits the mitochondrial-matrix enzyme activity
3.1.2.20	Rattus norvegicus		NO3-	80783	263	
3.1.2.20	Rattus norvegicus		nordihydroguaiaretic acid	715623	721	inhibitor of acyl-CoA thioesterase 2
3.1.2.20	Euglena gracilis		O,O-Diethyl-O-(2,4,5-trichlorophenyl)-phosphate	646179	29620	
3.1.2.20	Euglena gracilis		O,O-Diethyl-O-(3,5,6-trichloro-2-pyridyl)-phosphate	646179	2923	
3.1.2.20	Euglena gracilis		O,O-diethyl-O-(3,5,6-trichloro-2-pyridyl)-phosphorothionate	646179	1343	i.e. Chloropyrifos
3.1.2.20	Euglena gracilis		O,O-Dimethyl-O-(2,4,5-trichloro-1-phenyl)-phosphate	646179	29621	
3.1.2.20	Euglena gracilis		O,O-Dimethyl-O-(3,5,6-trichloro-2-pyridyl)-phosphate	646179	14649	i.e. Fospirate
3.1.2.20	Rattus norvegicus		octylglucoside	646165	1726	50% inhibition at 0.3%
3.1.2.20	Rattus norvegicus		octylglycoside	646165		
3.1.2.20	Pseudomonas aeruginosa		oleic acid	646130	320	
3.1.2.20	Spinacia oleracea		oleic acid	646136	320	1 mM inhibits by 90%
3.1.2.20	Alcaligenes faecalis		p-chloromercuribenzoate	679739	40	1 mM, 12% inhibition
3.1.2.20	Homo sapiens		p-chloromercuribenzoic acid	646166	40	
3.1.2.20	Rattus norvegicus		p-chloromercuribenzoic acid	646162, 646164, 646167	40	
3.1.2.20	Candida rugosa		p-chloromercuribenzoic acid	646168	40	
3.1.2.20	Rattus norvegicus		p-hydroxymercuribenzoate	646129	92	0.005 mM gives 50% inhibition
3.1.2.20	Rattus norvegicus		p-hydroxymercuribenzoate	646131, 646137, 646161, 646165	92	
3.1.2.20	Euglena gracilis		p-hydroxymercuribenzoate	646179	92	weak inhibition
3.1.2.20	Anas platyrhynchos		p-hydroxymercuribenzoate	646181	92	99% inhibition at 0.1 mM
3.1.2.20	Spinacia oleracea		palmitic acid	646136	431	1 mM inhibits by 30%
3.1.2.20	Homo sapiens		palmitoyl-CoA	683004	122	0.1 mM, 67% inhibition of nafamostat
3.1.2.20	Mycobacterium smegmatis		Papain	646143		
3.1.2.20	Rattus norvegicus		Pb2+	80783	132	slightly inhibits the mitochondrial enzyme
3.1.2.20	Homo sapiens		phenylacetylmethyl-CoA	707486	56458	
3.1.2.20	Homo sapiens		phenylmethylsulfonyl fluoride	683004	218	0.1 mM, 43% inhibition of nafamostat hydrolysis
3.1.2.20	Alcaligenes faecalis		picrylsulfonic acid	679739	2353	1 mM, 11% inhibition
3.1.2.20	Escherichia coli		PMSF	646123	218	less effective than DFP, produces a 27% loss of activity under similar conditions
3.1.2.20	Rattus norvegicus		PMSF	646165	218	no inhibition
3.1.2.20	Sus scrofa		PMSF	646180	218	no inhibition
3.1.2.20	Anas platyrhynchos		PMSF	646181	218	96% inhibition at 1 mM
3.1.2.20	Pseudomonas aeruginosa		SDS	646130	118	
3.1.2.20	Mycobacterium smegmatis		SDS	646143	118	
3.1.2.20	Rattus norvegicus		SDS	646165	118	50% inhibition at 0.035%
3.1.2.20	Rattus norvegicus		SO42-	80783	148	
3.1.2.20	Rattus norvegicus		Sodium deoxycholate	646128	453	
3.1.2.20	Bos taurus		Sodium deoxycholate	646153	453	
3.1.2.20	Rattus norvegicus		Sodium deoxycholate	646165	453	50% inhibition at 0.04%
3.1.2.20	Euglena gracilis		tetradecanoyl-CoA	646179	382	substrate inhibition
3.1.2.20	Pseudomonas aeruginosa		Triton X-100	646130	57	
3.1.2.20	Mycobacterium smegmatis		Triton X-100	646143	57	
3.1.2.20	Bos taurus		Triton X-100	646153	57	
3.1.2.20	Rattus norvegicus		Triton X-100	646162	57	0.05-.0025% inhibits the activity
3.1.2.20	Rattus norvegicus		Triton X-100	646165	57	50% inhibition at 0.01%
3.1.2.20	Candida rugosa		Triton X-100	646168	57	
3.1.2.20	Rattus norvegicus		Triton X-100	646138, 646141, 80783	57	
3.1.2.20	Rattus norvegicus		Triton X-35	646141		
3.1.2.20	Rattus norvegicus		Triton X-405	646141	10892	
3.1.2.20	Mycobacterium smegmatis		Trypsin	646143		
3.1.2.20	Homo sapiens		undecan-2-one-CoA	707486	27287	
3.1.2.20	Spinacia oleracea		unsaturated fatty acids	646136		
3.1.2.20	Rattus norvegicus		Valproate	646173	1777	reduced activity in microsomes and mitochondria
3.1.2.20	Sus scrofa		Zn2+	646180	19	
3.1.2.20	Rattus norvegicus		Zn2+	80783	19	
4.99.1.1	Saccharomyces cerevisiae	ascorbate		729863	88	optimum activity at 6 mM ascorbate
4.99.1.1	Sus scrofa	ascorbate		729863	88	optimum activity at 6 mM ascorbate
4.99.1.1	Thermus thermophilus	ascorbate		729863	88	optimum activity at 6 mM ascorbate
4.99.1.1	Chironomus sp.	Cu2+		666325	28	0.1 mM, causes 4fold increase in activity
4.99.1.1	Saccharomyces cerevisiae	L-cysteine		729863	70	optimum activity at 6 mM L-cysteine
4.99.1.1	Sus scrofa	L-cysteine		729863	70	optimum activity at 6 mM L-cysteine
4.99.1.1	Thermus thermophilus	L-cysteine		729863	70	optimum activity at 6 mM L-cysteine
4.99.1.1	Homo sapiens	more		678251		recombinant ferrochelatase exhibits iron removal activity when added together with purified recombinant b5 reductase
4.99.1.1	Mus musculus	more		678251		b5 reductase required for the full enzyme activity
4.99.1.1	Saccharomyces cerevisiae	NaCl		729863	39	optimum activity at 100 mM NaCl
4.99.1.1	Sus scrofa	NaCl		729863	39	optimum activity at 100 mM NaCl
4.99.1.1	Thermus thermophilus	NaCl		729863	39	optimum activity at 100 mM NaCl
4.99.1.1	Rattus norvegicus		2,2'-dipyridyl	34964	317	
4.99.1.1	Rhodobacter sphaeroides		Cd2+	34934	48	
4.99.1.1	Homo sapiens		Cd2+	34968	48	
4.99.1.1	Mus musculus		Cd2+	34968, 650802	48	
4.99.1.1	Homo sapiens		Cd2+	705158	48	the crystallographic data indicate that the inhibition of ferrochelatase by Cd2+ occurs because the metallated product is poorly released from the enzyme and is not due to a selection mechanism that occurs prior to chelation
4.99.1.1	Novispirillum itersonii		Co2+	34940	21	
4.99.1.1	Rattus norvegicus		Co2+	34943	21	
4.99.1.1	Gallus gallus		Co2+	34950	21	
4.99.1.1	Mus musculus		Co2+	715572	21	substrate inhibition occurs when assayed in the absence of metal ion-complexing buffer components
4.99.1.1	Rattus norvegicus		Cu2+	34943	28	
4.99.1.1	Rhodobacter sphaeroides		Cu2+	34944	28	
4.99.1.1	Mus musculus		Cu2+	715572	28	substrate inhibition occurs when assayed in the absence of metal ion-complexing buffer components
4.99.1.1	Homo sapiens		deferoxamine	703094	15206	
4.99.1.1	Homo sapiens		deuteroporphyrin IX	704589	4213	
4.99.1.1	Novispirillum itersonii		Divalent cations	34940		
4.99.1.1	Saccharomyces cerevisiae		Fe2+	34946	23	Zn2+-chelatase activity
4.99.1.1	Novispirillum itersonii		heme	34940	45	
4.99.1.1	Bos taurus		heme	34948	45	
4.99.1.1	Rhodobacter sphaeroides		Hemin	34944	45	
4.99.1.1	Rhodobacter sphaeroides		Hg2+	34944	31	
4.99.1.1	Bos taurus		Hg2+	34948	31	
4.99.1.1	Gallus gallus		Hg2+	34950	31	
4.99.1.1	Homo sapiens		Hg2+	34968	31	
4.99.1.1	Mus musculus		Hg2+	34968, 650802	31	
4.99.1.1	Homo sapiens		Hg2+	705158	31	the crystallographic data indicate that the inhibition of ferrochelatase by Hg2+ occurs because the metallated product is poorly released from the enzyme and is not due to a selection mechanism that occurs prior to chelation
4.99.1.1	Homo sapiens		iodacetic acid	34970	87	
4.99.1.1	Rattus norvegicus		iodoacetamide	34943	63	
4.99.1.1	Rhodobacter sphaeroides		iodoacetamide	34944	63	
4.99.1.1	Gallus gallus		iodoacetamide	34950	63	
4.99.1.1	Mus musculus		metalloporphyrin	650802		containing Fe2+, Co2+, Zn2+, Sn2+
4.99.1.1	Hordeum vulgare		Metalloporphyrins	34937		
4.99.1.1	Chironomus sp.		Mg2+	666325	25	0.1 mM, reduces the enzymatic activity by more than 60%
4.99.1.1	Rhodobacter sphaeroides		Mg2+-protoporphyrin	34934	8579	
4.99.1.1	Rattus norvegicus		Mn2+	34943	26	
4.99.1.1	Bos taurus		Mn2+	34948, 34954	26	
4.99.1.1	Gallus gallus		Mn2+	34950, 34954	26	
4.99.1.1	Mus musculus		Mn2+	34968, 650802	26	
4.99.1.1	Chironomus sp.		Mn2+	666325	26	0.1 mM, reduces the enzymatic activity by more than 60%
4.99.1.1	Homo sapiens		Mn2+	34968, 703094	26	
4.99.1.1	Homo sapiens		Mn2+	705158	26	the crystallographic data indicate that the inhibition of ferrochelatase by Mn2+ because the metallated product is poorly released from the enzyme and is not due to a selection mechanism that occurs prior to chelation
4.99.1.1	Rhodobacter sphaeroides		monobromobimane	34952	29503	
4.99.1.1	Rhodobacter sphaeroides		more	34953		
4.99.1.1	Bos taurus		more	34954		
4.99.1.1	Gallus gallus		more	34954		
4.99.1.1	Saccharomyces cerevisiae		more	665534		unknown mitochondrial compound with a molecular mass greater than 10 kD, reversible inhibition
4.99.1.1	Homo sapiens		more	704589		no inhibition by deuteroporphyrin
4.99.1.1	Homo sapiens		more	705158		the inhibitory metals Hg, Cd, and Mn all serve as substrates for the enzyme in that they are inserted into the porphyrin macrocycle. The crystallographic data indicate that the inhibition of ferrochelatase by these metals occurs because the metallated product is poorly released from the enzyme and is not due to a selection mechanism that occurs prior to chelation
4.99.1.1	Homo sapiens		more	706101		siRNA-mediated knockdown of ferrochelatase suppresses heme synthesis and significantly increases intracellular protoporphyrin IX (PpIX) accumulation, this improves the phototoxicity of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines
4.99.1.1	Rattus norvegicus		more	729207		no Ni2+ substrate inhibition of ferrochelatase is observed
4.99.1.1	Synechocystis sp.		more	730722		the presence of pigments results in lower enzyme activity
4.99.1.1	Mus musculus		N-alkylated porphyrins	34951		investigation of structural requirements
4.99.1.1	Homo sapiens		N-alkylated porphyrins	34968		
4.99.1.1	Mus musculus		N-alkylated porphyrins	34968		
4.99.1.1	Gallus gallus		N-ethylmaleimide	34950	46	
4.99.1.1	Rhodobacter sphaeroides		N-ethylmaleimide	34944, 34952	46	
4.99.1.1	Homo sapiens		N-ethylmaleimide	34970	46	
4.99.1.1	Bacillus subtilis		N-methyl mesoporphyrin	666052	23665	transition-state inhibitor
4.99.1.1	Rattus norvegicus		N-methylmesoporphyrin	34964		
4.99.1.1	Bacillus subtilis		N-methylmesoporphyrin	652813, 730229		
4.99.1.1	Rhodobacter sphaeroides		N-Methylprotoporphyrin	34952	4932	
4.99.1.1	Bos taurus		N-Methylprotoporphyrin	34948, 34954	4932	
4.99.1.1	Gallus gallus		N-Methylprotoporphyrin	34954	4932	
4.99.1.1	Pisum sativum		N-Methylprotoporphyrin	649728	4932	50% inhibition at 1 nM
4.99.1.1	Cucumis sativus		N-Methylprotoporphyrin	653461	4932	50% inhibition at 4 nM
4.99.1.1	Mus musculus		N-Methylprotoporphyrin	678038	4932	binds to wild-type ferrochelatase and P255R mutant via a two-step pathway with a kinetically significant intermediate, firstly formation of an initial complex, which subsequently is rearranged into a more stable complex, secondly slow conformational change of the inhibitorprotein complex
4.99.1.1	Synechocystis sp.		N-methylprotoporphyrin IX	665650	83408	
4.99.1.1	Mus musculus		Ni2+	715572	36	substrate inhibition occurs when assayed in the absence of metal ion-complexing buffer components
4.99.1.1	Rattus norvegicus		O2	34945	11	
4.99.1.1	Homo sapiens		p-chloromercuribenzoate	34970	40	
4.99.1.1	Novispirillum itersonii		Pb2+	34940	132	
4.99.1.1	Rattus norvegicus		Pb2+	34943	132	
4.99.1.1	Rhodobacter sphaeroides		Pb2+	34944	132	
4.99.1.1	Bos taurus		Pb2+	34948	132	
4.99.1.1	Gallus gallus		Pb2+	34950	132	
4.99.1.1	Mus musculus		Pb2+	34968, 650802	132	
4.99.1.1	Chironomus sp.		Pb2+	666325	132	0.1 mM, reduces the enzymatic activity by more than 60%
4.99.1.1	Homo sapiens		Pb2+	34968, 34970, 681453	132	
4.99.1.1	Homo sapiens		porphyrin	704589	3838	high porphyrin concentrations noticeably increase the extent of zinc inhibition
4.99.1.1	Mus musculus		porphyrin isomer	650802		competitive
4.99.1.1	Bos taurus		Porphyrins	34954	5501	2,4 position substitution
4.99.1.1	Gallus gallus		Porphyrins	34954	5501	2,4 position substitution
4.99.1.1	Rhodobacter sphaeroides		protohaem	34934		
4.99.1.1	Novispirillum itersonii		sulfhydryl reagents	34940	752	
4.99.1.1	Rattus norvegicus		sulfhydryl reagents	34943	752	
4.99.1.1	Rattus norvegicus		Zn2+	34943	19	
4.99.1.1	Saccharomyces cerevisiae		Zn2+	34946	19	iron-chelatase activity
4.99.1.1	Chironomus sp.		Zn2+	666325	19	0.1 mM, inhibits over 90% of the enzyme activity
4.99.1.1	Homo sapiens		Zn2+	704589	19	uncompetitive substrate inhibitor, zinc inhibition is enhanced by increasing porphyrin concentration, zinc inhibits by binding to an enzyme-product complex and is likely to be the second substrate in an ordered mechanism, this inhibition is not observed in the presence of higher concentrations of the detergent cholate, and it is likely that increasing detergent concentrations also increases KM for deuteroporphyrin Ix as substrate and so reduces the concentration of enzymeproduct species for the inhibitor to bind
4.99.1.1	Mus musculus		Zn2+	715572	19	substrate inhibition occurs when assayed in the absence of metal ion-complexing buffer components
2.3.1.157	Mycobacterium tuberculosis	more		701468		MtGlmU has acetyltransferase activity in the absence of reducing agent and in the presence of a thiolreactive reagent (N-ethylmaleimide)
2.3.1.157	Escherichia coli		(1R,2R)-2-[[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10263	
2.3.1.157	Haemophilus influenzae		(1R,2R)-2-[[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10263	
2.3.1.157	Streptococcus pneumoniae		(1R,2R)-2-[[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10263	
2.3.1.157	Escherichia coli		(1R,2R)-2-[[4-hydroxy-2-methoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	111799	
2.3.1.157	Haemophilus influenzae		(1R,2R)-2-[[4-hydroxy-2-methoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	111799	
2.3.1.157	Streptococcus pneumoniae		(1R,2R)-2-[[4-hydroxy-2-methoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	111799	
2.3.1.157	Escherichia coli		(1R,2R)-2-[[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10262	
2.3.1.157	Haemophilus influenzae		(1R,2R)-2-[[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10262	
2.3.1.157	Streptococcus pneumoniae		(1R,2R)-2-[[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10262	
2.3.1.157	Escherichia coli		(1R,2R)-2-[[5-(acridin-10(9H)-ylsulfonyl)-4-hydroxy-2-methoxyphenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10269	
2.3.1.157	Haemophilus influenzae		(1R,2R)-2-[[5-(acridin-10(9H)-ylsulfonyl)-4-hydroxy-2-methoxyphenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10269	
2.3.1.157	Streptococcus pneumoniae		(1R,2R)-2-[[5-(acridin-10(9H)-ylsulfonyl)-4-hydroxy-2-methoxyphenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10269	
2.3.1.157	Escherichia coli		(2E)-4-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobut-2-enoic acid	719064	6990	
2.3.1.157	Haemophilus influenzae		(2E)-4-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobut-2-enoic acid	719064	6990	
2.3.1.157	Staphylococcus aureus		(2E)-4-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobut-2-enoic acid	719064	6990	
2.3.1.157	Streptococcus pneumoniae		(2E)-4-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobut-2-enoic acid	719064	6990	
2.3.1.157	Escherichia coli		1-(2-[[([5-[(3-carboxypropanoyl)amino]-2,4-dimethoxyphenyl]sulfonyl)amino]methyl]phenyl)piperidine-4-carboxylic acid	719064	7018	
2.3.1.157	Haemophilus influenzae		1-(2-[[([5-[(3-carboxypropanoyl)amino]-2,4-dimethoxyphenyl]sulfonyl)amino]methyl]phenyl)piperidine-4-carboxylic acid	719064	7018	
2.3.1.157	Staphylococcus aureus		1-(2-[[([5-[(3-carboxypropanoyl)amino]-2,4-dimethoxyphenyl]sulfonyl)amino]methyl]phenyl)piperidine-4-carboxylic acid	719064	7018	
2.3.1.157	Streptococcus pneumoniae		1-(2-[[([5-[(3-carboxypropanoyl)amino]-2,4-dimethoxyphenyl]sulfonyl)amino]methyl]phenyl)piperidine-4-carboxylic acid	719064	7018	
2.3.1.157	Escherichia coli		2'-[[([5-[(3-carboxypropanoyl)amino]-2,4-dimethoxyphenyl]sulfonyl)amino]methyl]biphenyl-4-carboxylic acid	719064	8211	
2.3.1.157	Haemophilus influenzae		2'-[[([5-[(3-carboxypropanoyl)amino]-2,4-dimethoxyphenyl]sulfonyl)amino]methyl]biphenyl-4-carboxylic acid	719064	8211	
2.3.1.157	Staphylococcus aureus		2'-[[([5-[(3-carboxypropanoyl)amino]-2,4-dimethoxyphenyl]sulfonyl)amino]methyl]biphenyl-4-carboxylic acid	719064	8211	
2.3.1.157	Streptococcus pneumoniae		2'-[[([5-[(3-carboxypropanoyl)amino]-2,4-dimethoxyphenyl]sulfonyl)amino]methyl]biphenyl-4-carboxylic acid	719064	8211	
2.3.1.157	Escherichia coli		2-(2-cyanopyridin-4-yl)-N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]acetamide	719070	10267	
2.3.1.157	Haemophilus influenzae		2-(2-cyanopyridin-4-yl)-N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]acetamide	719070	10267	
2.3.1.157	Streptococcus pneumoniae		2-(2-cyanopyridin-4-yl)-N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]acetamide	719070	10267	
2.3.1.157	Escherichia coli		2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethyl acetate	719064	6989	
2.3.1.157	Haemophilus influenzae		2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethyl acetate	719064	6989	
2.3.1.157	Staphylococcus aureus		2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethyl acetate	719064	6989	
2.3.1.157	Streptococcus pneumoniae		2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethyl acetate	719064	6989	
2.3.1.157	Mycobacterium tuberculosis		2-amino-2,3-dideoxy-3-fluoro-alpha-D-glucopyranosyl phosphate	719224	19567	
2.3.1.157	Escherichia coli		2-Nitro-5-thiocyanobenzoic acid	288685, 288686	7067	
2.3.1.157	Escherichia coli		4-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobutanoic acid	719064	6991	
2.3.1.157	Haemophilus influenzae		4-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobutanoic acid	719064	6991	
2.3.1.157	Staphylococcus aureus		4-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobutanoic acid	719064	6991	
2.3.1.157	Streptococcus pneumoniae		4-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobutanoic acid	719064	6991	
2.3.1.157	Escherichia coli		4-([2,4-dimethoxy-5-[naphthalen-2-yl(phenyl)sulfamoyl]phenyl]amino)-4-oxobutanoic acid	719070	10258	
2.3.1.157	Haemophilus influenzae		4-([2,4-dimethoxy-5-[naphthalen-2-yl(phenyl)sulfamoyl]phenyl]amino)-4-oxobutanoic acid	719070	10258	
2.3.1.157	Streptococcus pneumoniae		4-([2,4-dimethoxy-5-[naphthalen-2-yl(phenyl)sulfamoyl]phenyl]amino)-4-oxobutanoic acid	719070	10258	
2.3.1.157	Escherichia coli		4-([4-hydroxy-2-methoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobutanoic acid	719986	6985	
2.3.1.157	Haemophilus influenzae		4-([4-hydroxy-2-methoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobutanoic acid	719986	6985	
2.3.1.157	Staphylococcus aureus		4-([4-hydroxy-2-methoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobutanoic acid	719986	6985	
2.3.1.157	Streptococcus pneumoniae		4-([4-hydroxy-2-methoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobutanoic acid	719986	6985	
2.3.1.157	Escherichia coli		4-([5-[(4-aminophenyl)(phenyl)sulfamoyl]-2,4-dimethoxyphenyl]amino)-4-oxobutanoic acid	719070, 719986	3740	
2.3.1.157	Haemophilus influenzae		4-([5-[(4-aminophenyl)(phenyl)sulfamoyl]-2,4-dimethoxyphenyl]amino)-4-oxobutanoic acid	719070, 719986	3740	
2.3.1.157	Staphylococcus aureus		4-([5-[(4-aminophenyl)(phenyl)sulfamoyl]-2,4-dimethoxyphenyl]amino)-4-oxobutanoic acid	719986	3740	
2.3.1.157	Streptococcus pneumoniae		4-([5-[(4-aminophenyl)(phenyl)sulfamoyl]-2,4-dimethoxyphenyl]amino)-4-oxobutanoic acid	719070, 719986	3740	
2.3.1.157	Escherichia coli		4-([5-[bis(4-methylphenyl)sulfamoyl]-2,4-dimethoxyphenyl]amino)-4-oxobutanoic acid	719070	10257	
2.3.1.157	Haemophilus influenzae		4-([5-[bis(4-methylphenyl)sulfamoyl]-2,4-dimethoxyphenyl]amino)-4-oxobutanoic acid	719070	10257	
2.3.1.157	Streptococcus pneumoniae		4-([5-[bis(4-methylphenyl)sulfamoyl]-2,4-dimethoxyphenyl]amino)-4-oxobutanoic acid	719070	10257	
2.3.1.157	Escherichia coli		4-[(2,4-dimethoxy-5-[[2-(piperidin-1-yl)benzyl]sulfamoyl]phenyl)amino]-4-oxobutanoic acid	719064	7015	
2.3.1.157	Haemophilus influenzae		4-[(2,4-dimethoxy-5-[[2-(piperidin-1-yl)benzyl]sulfamoyl]phenyl)amino]-4-oxobutanoic acid	719064	7015	
2.3.1.157	Staphylococcus aureus		4-[(2,4-dimethoxy-5-[[2-(piperidin-1-yl)benzyl]sulfamoyl]phenyl)amino]-4-oxobutanoic acid	719064	7015	
2.3.1.157	Streptococcus pneumoniae		4-[(2,4-dimethoxy-5-[[2-(piperidin-1-yl)benzyl]sulfamoyl]phenyl)amino]-4-oxobutanoic acid	719064	7015	
2.3.1.157	Escherichia coli		4-[(5-[[2-(4-[[(carboxyacetyl)oxy]methyl]piperidin-1-yl)benzyl]sulfamoyl]-2,4-dimethoxyphenyl)amino]-4-oxobutanoic acid	719064	7017	
2.3.1.157	Haemophilus influenzae		4-[(5-[[2-(4-[[(carboxyacetyl)oxy]methyl]piperidin-1-yl)benzyl]sulfamoyl]-2,4-dimethoxyphenyl)amino]-4-oxobutanoic acid	719064	7017	
2.3.1.157	Staphylococcus aureus		4-[(5-[[2-(4-[[(carboxyacetyl)oxy]methyl]piperidin-1-yl)benzyl]sulfamoyl]-2,4-dimethoxyphenyl)amino]-4-oxobutanoic acid	719064	7017	
2.3.1.157	Streptococcus pneumoniae		4-[(5-[[2-(4-[[(carboxyacetyl)oxy]methyl]piperidin-1-yl)benzyl]sulfamoyl]-2,4-dimethoxyphenyl)amino]-4-oxobutanoic acid	719064	7017	
2.3.1.157	Escherichia coli		4-[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethoxy]benzoic acid	719064	6994	
2.3.1.157	Haemophilus influenzae		4-[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethoxy]benzoic acid	719064	6994	
2.3.1.157	Staphylococcus aureus		4-[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethoxy]benzoic acid	719064	6994	
2.3.1.157	Streptococcus pneumoniae		4-[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethoxy]benzoic acid	719064	6994	
2.3.1.157	Escherichia coli		4-[[2,4-dimethoxy-5-(10H-phenothiazin-10-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070	10259	
2.3.1.157	Haemophilus influenzae		4-[[2,4-dimethoxy-5-(10H-phenothiazin-10-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070	10259	
2.3.1.157	Streptococcus pneumoniae		4-[[2,4-dimethoxy-5-(10H-phenothiazin-10-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070	10259	
2.3.1.157	Haemophilus influenzae		4-[[2,4-dimethoxy-5-(10H-phenoxazin-10-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070	3503	
2.3.1.157	Escherichia coli		4-[[2,4-dimethoxy-5-(10H-phenoxazin-10-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070, 719986	3503	
2.3.1.157	Haemophilus influenzae		4-[[2,4-dimethoxy-5-(10H-phenoxazin-10-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719986	3503	substrate inhibition, competitive versus N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]acetamide
2.3.1.157	Staphylococcus aureus		4-[[2,4-dimethoxy-5-(10H-phenoxazin-10-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719986	3503	
2.3.1.157	Streptococcus pneumoniae		4-[[2,4-dimethoxy-5-(10H-phenoxazin-10-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070, 719986	3503	
2.3.1.157	Escherichia coli		4-[[4-hydroxy-2-methoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070	10268	
2.3.1.157	Haemophilus influenzae		4-[[4-hydroxy-2-methoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070	10268	
2.3.1.157	Streptococcus pneumoniae		4-[[4-hydroxy-2-methoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070	10268	
2.3.1.157	Escherichia coli		4-[[5-(dibenzo[b,f][1,4]oxazepin-10(11H)-ylsulfonyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719070	10260	
2.3.1.157	Haemophilus influenzae		4-[[5-(dibenzo[b,f][1,4]oxazepin-10(11H)-ylsulfonyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719070	10260	
2.3.1.157	Streptococcus pneumoniae		4-[[5-(dibenzo[b,f][1,4]oxazepin-10(11H)-ylsulfonyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719070	10260	
2.3.1.157	Escherichia coli		4-[[5-(diphenylsulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719070	10256	
2.3.1.157	Haemophilus influenzae		4-[[5-(diphenylsulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719070	10256	pH and temperature not specified in the publication
2.3.1.157	Streptococcus pneumoniae		4-[[5-(diphenylsulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719070	10256	pH and temperature not specified in the publication
2.3.1.157	Escherichia coli		4-[[5-([2-[4-(carboxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719064	7019	
2.3.1.157	Haemophilus influenzae		4-[[5-([2-[4-(carboxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719064	7019	
2.3.1.157	Staphylococcus aureus		4-[[5-([2-[4-(carboxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719064	7019	
2.3.1.157	Streptococcus pneumoniae		4-[[5-([2-[4-(carboxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719064	7019	
2.3.1.157	Escherichia coli		4-[[5-([2-[4-(hydroxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719064	7016	
2.3.1.157	Haemophilus influenzae		4-[[5-([2-[4-(hydroxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719064	7016	
2.3.1.157	Staphylococcus aureus		4-[[5-([2-[4-(hydroxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719064	7016	
2.3.1.157	Streptococcus pneumoniae		4-[[5-([2-[4-(hydroxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719064	7016	
2.3.1.157	Haemophilus influenzae		alpha-D-glucosamine 1-phosphate	719986	2321	substrate inhibition, competitive versus N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]acetamide
2.3.1.157	Sulfolobus tokodaii		Ca2+	725249	18	2 mM, inhibits D-glucosamine-1-phosphate N-acetyltransferase activity
2.3.1.157	Sulfolobus tokodaii		Co2+	725249	21	2 mM, inhibits D-glucosamine-1-phosphate N-acetyltransferase activity
2.3.1.157	Escherichia coli		DTNB	288685, 288686	196	
2.3.1.157	Escherichia coli		iodoacetamide	288686	63	
2.3.1.157	Escherichia coli		methyl 2-[([[5-(acetylamino)-2,4-dimethoxyphenyl]sulfonyl]amino)methyl]benzoate	719064	7012	
2.3.1.157	Haemophilus influenzae		methyl 2-[([[5-(acetylamino)-2,4-dimethoxyphenyl]sulfonyl]amino)methyl]benzoate	719064	7012	
2.3.1.157	Staphylococcus aureus		methyl 2-[([[5-(acetylamino)-2,4-dimethoxyphenyl]sulfonyl]amino)methyl]benzoate	719064	7012	
2.3.1.157	Streptococcus pneumoniae		methyl 2-[([[5-(acetylamino)-2,4-dimethoxyphenyl]sulfonyl]amino)methyl]benzoate	719064	7012	
2.3.1.157	Sulfolobus tokodaii		Mg2+	725249	25	2 mM, inhibits D-glucosamine-1-phosphate N-acetyltransferase activity
2.3.1.157	Sulfolobus tokodaii		Mn2+	725249	26	2 mM, inhibits D-glucosamine-1-phosphate N-acetyltransferase activity
2.3.1.157	Escherichia coli		more	719064		high throughput inhibitor screening for inhibition of the acetyltransferase domain of GlmU by a arylsulfonamide series
2.3.1.157	Haemophilus influenzae		more	719064		high throughput inhibitor screening for inhibition of the acetyltransferase domain of GlmU by a arylsulfonamide series
2.3.1.157	Staphylococcus aureus		more	719064		high throughput inhibitor screening for inhibition of the acetyltransferase domain of GlmU by a arylsulfonamide series
2.3.1.157	Streptococcus pneumoniae		more	719064		high throughput inhibitor screening for inhibition of the acetyltransferase domain of GlmU by a arylsulfonamide series
2.3.1.157	Escherichia coli		more	719070		inhibitor synthesis and inhibition potencies, overview
2.3.1.157	Haemophilus influenzae		more	719070		inhibitor synthesis and inhibition potencies, MIC values, overview
2.3.1.157	Streptococcus pneumoniae		more	719070		inhibitor synthesis and inhibition potencies, MIC values, overview; inhibitor synthesis and inhibition potencies, overview
2.3.1.157	Mycobacterium tuberculosis		more	719224		inhibitor synthesis, detailed overview. No inhibition of GlmU by methyl 2-amino-2-deoxyl-alpha-D-glucopyranoside 6-phosphate, methyl 2-amino-2-deoxyl-beta-D-glucopyranoside 6-phosphate, and 2-azido-2-deoxy-alpha-D-glucopyranosyl phosphate even at high concentrations
2.3.1.157	Escherichia coli		more	719986		inhibitor design from enzyme structure, analysis of antimicrobial compounds mediating their growth inhibitory effects specifically via GlmU, antimicrobial properties of sulfonamide inhibitors of GlmU acetyl transferase, overview
2.3.1.157	Haemophilus influenzae		more	719986		inhibitor design from enzyme structure, analysis of antimicrobial compounds mediating their growth inhibitory effects specifically via GlmU, antimicrobial properties of sulfonamide inhibitors of GlmU acetyl transferase, overview
2.3.1.157	Staphylococcus aureus		more	719986		inhibitor design from enzyme structure, analysis of antimicrobial compounds mediating their growth inhibitory effects specifically via GlmU, antimicrobial properties of sulfonamide inhibitors of GlmU acetyl transferase, overview
2.3.1.157	Streptococcus pneumoniae		more	719986		inhibitor design from enzyme structure, analysis of antimicrobial compounds mediating their growth inhibitory effects specifically via GlmU, antimicrobial properties of sulfonamide inhibitors of GlmU acetyl transferase, overview
2.3.1.157	Mycobacterium tuberculosis		more	720872		modelling of competitive and uncompetitive inhibition of Rxn-1 by substrates/products, overview
2.3.1.157	Escherichia coli		N-(2,4-dimethoxy-5-[[2-(piperidin-1-yl)benzyl]sulfamoyl]phenyl)acetamide	719064	7013	
2.3.1.157	Haemophilus influenzae		N-(2,4-dimethoxy-5-[[2-(piperidin-1-yl)benzyl]sulfamoyl]phenyl)acetamide	719064	7013	
2.3.1.157	Staphylococcus aureus		N-(2,4-dimethoxy-5-[[2-(piperidin-1-yl)benzyl]sulfamoyl]phenyl)acetamide	719064	7013	
2.3.1.157	Streptococcus pneumoniae		N-(2,4-dimethoxy-5-[[2-(piperidin-1-yl)benzyl]sulfamoyl]phenyl)acetamide	719064	7013	
2.3.1.157	Escherichia coli		N-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]carbamothioyl)glycine	719064	6987	
2.3.1.157	Haemophilus influenzae		N-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]carbamothioyl)glycine	719064	6987	
2.3.1.157	Staphylococcus aureus		N-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]carbamothioyl)glycine	719064	6987	
2.3.1.157	Streptococcus pneumoniae		N-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]carbamothioyl)glycine	719064	6987	
2.3.1.157	Escherichia coli		N-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]carbamoyl)glycine	719064	6988	
2.3.1.157	Haemophilus influenzae		N-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]carbamoyl)glycine	719064	6988	
2.3.1.157	Staphylococcus aureus		N-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]carbamoyl)glycine	719064	6988	
2.3.1.157	Streptococcus pneumoniae		N-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]carbamoyl)glycine	719064	6988	
2.3.1.157	Escherichia coli		N-acetylglucosamine-1-phosphate	288685	1096	acetyltransferase activity inhibited by its reaction product
2.3.1.157	Escherichia coli		N-ethylmaleimide	288686	46	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]-2-(2-fluoropyridin-4-yl)acetamide	719070	10265	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]-2-(2-fluoropyridin-4-yl)acetamide	719070	10265	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]-2-(2-fluoropyridin-4-yl)acetamide	719070	10265	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]-3-(2H-tetrazol-5-yl)propanamide	719070	10261	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]-3-(2H-tetrazol-5-yl)propanamide	719070	10261	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]-3-(2H-tetrazol-5-yl)propanamide	719070	10261	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-(phenylsulfamoyl)phenyl]acetamide	719064	6997	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-(phenylsulfamoyl)phenyl]acetamide	719064	6997	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-(phenylsulfamoyl)phenyl]acetamide	719064	6997	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-(phenylsulfamoyl)phenyl]acetamide	719064	6997	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-(piperidin-1-ylsulfonyl)phenyl]acetamide	719064	7002	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-(piperidin-1-ylsulfonyl)phenyl]acetamide	719064	7002	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-(piperidin-1-ylsulfonyl)phenyl]acetamide	719064	7002	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-(piperidin-1-ylsulfonyl)phenyl]acetamide	719064	7002	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[(2-methoxybenzyl)sulfamoyl]phenyl]acetamide	719064	7009	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[(2-methoxybenzyl)sulfamoyl]phenyl]acetamide	719064	7009	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[(2-methoxybenzyl)sulfamoyl]phenyl]acetamide	719064	7009	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[(2-methoxybenzyl)sulfamoyl]phenyl]acetamide	719064	7009	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[(2-methyl-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl]acetamide	719064	6986	the inhibitor binds at the C-terminal domain of GlmU engaging the A, B and C subunits of the trimer
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[(2-methyl-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl]acetamide	719064	6986	the inhibitor binds at the C-terminal domain of GlmU engaging the A, B and C subunits of the trimer
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[(2-methyl-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl]acetamide	719064	6986	the inhibitor binds at the C-terminal domain of GlmU engaging the A, B and C subunits of the trimer
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[(2-methyl-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl]acetamide	719064	6986	the inhibitor binds at the C-terminal domain of GlmU engaging the A, B and C subunits of the trimer
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]-2-(pyridin-4-ylsulfanyl)acetamide	719064	6993	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]-2-(pyridin-4-ylsulfanyl)acetamide	719064	6993	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]-2-(pyridin-4-ylsulfanyl)acetamide	719064	6993	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]-2-(pyridin-4-ylsulfanyl)acetamide	719064	6993	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]acetamide	719064, 719986	3291	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]acetamide	719064, 719986	3291	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]acetamide	719064, 719986	3291	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]acetamide	719064, 719986	3291	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]benzamide	719064	6996	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]benzamide	719064	6996	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]benzamide	719064	6996	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]benzamide	719064	6996	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]methanesulfonamide	719064	6995	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]methanesulfonamide	719064	6995	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]methanesulfonamide	719064	6995	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]methanesulfonamide	719064	6995	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[(2-methylpyrrolidin-1-yl)sulfonyl]phenyl]acetamide	719064	7001	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[(2-methylpyrrolidin-1-yl)sulfonyl]phenyl]acetamide	719064	7001	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[(2-methylpyrrolidin-1-yl)sulfonyl]phenyl]acetamide	719064	7001	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[(2-methylpyrrolidin-1-yl)sulfonyl]phenyl]acetamide	719064	7001	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[(3-methylphenyl)sulfamoyl]phenyl]acetamide	719064	7007	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[(3-methylphenyl)sulfamoyl]phenyl]acetamide	719064	7007	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[(3-methylphenyl)sulfamoyl]phenyl]acetamide	719064	7007	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[(3-methylphenyl)sulfamoyl]phenyl]acetamide	719064	7007	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[(4-methylphenyl)sulfamoyl]phenyl]acetamide	719064	7008	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[(4-methylphenyl)sulfamoyl]phenyl]acetamide	719064	7008	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[(4-methylphenyl)sulfamoyl]phenyl]acetamide	719064	7008	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[(4-methylphenyl)sulfamoyl]phenyl]acetamide	719064	7008	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[methyl(phenyl)sulfamoyl]phenyl]acetamide	719064, 719986	3292	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[methyl(phenyl)sulfamoyl]phenyl]acetamide	719064, 719986	3292	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[methyl(phenyl)sulfamoyl]phenyl]acetamide	719064, 719986	3292	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[methyl(phenyl)sulfamoyl]phenyl]acetamide	719064, 719986	3292	
2.3.1.157	Escherichia coli		N-[2,4-dimethoxy-5-[phenyl(propan-2-yl)sulfamoyl]phenyl]acetamide	719064	6998	
2.3.1.157	Haemophilus influenzae		N-[2,4-dimethoxy-5-[phenyl(propan-2-yl)sulfamoyl]phenyl]acetamide	719064	6998	
2.3.1.157	Staphylococcus aureus		N-[2,4-dimethoxy-5-[phenyl(propan-2-yl)sulfamoyl]phenyl]acetamide	719064	6998	
2.3.1.157	Streptococcus pneumoniae		N-[2,4-dimethoxy-5-[phenyl(propan-2-yl)sulfamoyl]phenyl]acetamide	719064	6998	
2.3.1.157	Escherichia coli		N-[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]-2-(2-fluoropyridin-4-yl)acetamide	719070	10266	
2.3.1.157	Haemophilus influenzae		N-[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]-2-(2-fluoropyridin-4-yl)acetamide	719070	10266	
2.3.1.157	Streptococcus pneumoniae		N-[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]-2-(2-fluoropyridin-4-yl)acetamide	719070	10266	
2.3.1.157	Escherichia coli		N-[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]-2-(pyridin-4-yl)acetamide	719070	10264	
2.3.1.157	Haemophilus influenzae		N-[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]-2-(pyridin-4-yl)acetamide	719070	10264	
2.3.1.157	Streptococcus pneumoniae		N-[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]-2-(pyridin-4-yl)acetamide	719070	10264	
2.3.1.157	Escherichia coli		N-[5-(dimethylsulfamoyl)-2,4-dimethoxyphenyl]acetamide	719064	7003	
2.3.1.157	Haemophilus influenzae		N-[5-(dimethylsulfamoyl)-2,4-dimethoxyphenyl]acetamide	719064	7003	
2.3.1.157	Staphylococcus aureus		N-[5-(dimethylsulfamoyl)-2,4-dimethoxyphenyl]acetamide	719064	7003	
2.3.1.157	Streptococcus pneumoniae		N-[5-(dimethylsulfamoyl)-2,4-dimethoxyphenyl]acetamide	719064	7003	
2.3.1.157	Escherichia coli		N-[5-([2-[4-(hydroxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]acetamide	719064	7014	
2.3.1.157	Haemophilus influenzae		N-[5-([2-[4-(hydroxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]acetamide	719064	7014	
2.3.1.157	Staphylococcus aureus		N-[5-([2-[4-(hydroxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]acetamide	719064	7014	
2.3.1.157	Streptococcus pneumoniae		N-[5-([2-[4-(hydroxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]acetamide	719064	7014	
2.3.1.157	Escherichia coli		N-[5-[(1,3-benzodioxol-5-ylmethyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7010	
2.3.1.157	Haemophilus influenzae		N-[5-[(1,3-benzodioxol-5-ylmethyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7010	
2.3.1.157	Staphylococcus aureus		N-[5-[(1,3-benzodioxol-5-ylmethyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7010	
2.3.1.157	Streptococcus pneumoniae		N-[5-[(1,3-benzodioxol-5-ylmethyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7010	
2.3.1.157	Escherichia coli		N-[5-[(2-bromobenzyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7011	
2.3.1.157	Haemophilus influenzae		N-[5-[(2-bromobenzyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7011	
2.3.1.157	Staphylococcus aureus		N-[5-[(2-bromobenzyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7011	
2.3.1.157	Streptococcus pneumoniae		N-[5-[(2-bromobenzyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7011	
2.3.1.157	Escherichia coli		N-[5-[(2-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7006	
2.3.1.157	Haemophilus influenzae		N-[5-[(2-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7006	
2.3.1.157	Staphylococcus aureus		N-[5-[(2-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7006	
2.3.1.157	Streptococcus pneumoniae		N-[5-[(2-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7006	
2.3.1.157	Escherichia coli		N-[5-[(3-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7005	
2.3.1.157	Haemophilus influenzae		N-[5-[(3-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7005	
2.3.1.157	Staphylococcus aureus		N-[5-[(3-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7005	
2.3.1.157	Streptococcus pneumoniae		N-[5-[(3-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7005	
2.3.1.157	Escherichia coli		N-[5-[(4-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7004	
2.3.1.157	Haemophilus influenzae		N-[5-[(4-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7004	
2.3.1.157	Staphylococcus aureus		N-[5-[(4-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7004	
2.3.1.157	Streptococcus pneumoniae		N-[5-[(4-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7004	
2.3.1.157	Escherichia coli		N-[5-[butyl(propan-2-yl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7000	
2.3.1.157	Haemophilus influenzae		N-[5-[butyl(propan-2-yl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7000	
2.3.1.157	Staphylococcus aureus		N-[5-[butyl(propan-2-yl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7000	
2.3.1.157	Streptococcus pneumoniae		N-[5-[butyl(propan-2-yl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7000	
2.3.1.157	Escherichia coli		N-[5-[ethyl(2-methylphenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	6999	
2.3.1.157	Haemophilus influenzae		N-[5-[ethyl(2-methylphenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	6999	
2.3.1.157	Staphylococcus aureus		N-[5-[ethyl(2-methylphenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	6999	
2.3.1.157	Streptococcus pneumoniae		N-[5-[ethyl(2-methylphenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	6999	
2.3.1.157	Escherichia coli		p-hydroxymercuribenzoate	288686	92	
2.3.1.157	Escherichia coli		UDP-MurNAc	288685	1441	1 mM, relative enzyme activity 2%
2.3.1.157	Sulfolobus tokodaii		Zn2+	725249	19	2 mM, inhibits D-glucosamine-1-phosphate N-acetyltransferase activity
2.3.1.157	Escherichia coli		[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethoxy]acetic acid	719064	8210	
2.3.1.157	Haemophilus influenzae		[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethoxy]acetic acid	719064	8210	
2.3.1.157	Staphylococcus aureus		[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethoxy]acetic acid	719064	8210	
2.3.1.157	Streptococcus pneumoniae		[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethoxy]acetic acid	719064	8210	
2.3.1.157	Escherichia coli		[[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethyl]sulfanyl]acetic acid	719064	6992	
2.3.1.157	Haemophilus influenzae		[[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethyl]sulfanyl]acetic acid	719064	6992	
2.3.1.157	Staphylococcus aureus		[[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethyl]sulfanyl]acetic acid	719064	6992	
2.3.1.157	Streptococcus pneumoniae		[[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethyl]sulfanyl]acetic acid	719064	6992	
1.1.1.94	Escherichia coli		(NH4)2SO4	287523	334	100 mM, 68% inhibition, 10 mM, 8% inhibition
1.1.1.94	Escherichia coli		2',5'-ADP	669177	1457	
1.1.1.94	Escherichia coli		3,4-dihydroxybutyl 1-phosphonate	669177	84692	competitive versus dihydroxyacetone phosphate, binding to a regulatory site
1.1.1.94	Oryctolagus cuniculus		adenosine	287524	116	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		Adenosine diphosphate	287524	8	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		adenosine diphosphoribose	287524	337	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		adenylic acid	287524	9	competitive vs. NAD+
1.1.1.94	Escherichia coli		ADP	669177	8	
1.1.1.94	Escherichia coli		ADP-ribose	669177	337	
1.1.1.94	Escherichia coli		AMP	669177	9	
1.1.1.94	Escherichia coli		ATP	669177	7	
1.1.1.94	Escherichia coli		dihydroxyacetone phosphate	669175	241	noncompetitive versus NADP+
1.1.1.94	Escherichia coli		DL-glycerol 3-phosphate	287523	352	0.05 mM, 26% inhibition
1.1.1.94	Escherichia coli		ethylene glycol phosphate	669177	28739	binding to the active site
1.1.1.94	Escherichia coli		glyceraldehyde-3-phosphate	689802	473	competitive inhibitor
1.1.1.94	Escherichia coli		glyceric acid 2-phosphate	689802	783	competitive inhibitor
1.1.1.94	Escherichia coli		glycerol 3-phosphate	287523	352	50% inhibition with 0.035 mM, sigmoid inhibition curve, competitive inhibition vs. glycerone phosphate, uncompetitive vs. NADPH
1.1.1.94	Escherichia coli		K2PO4-	287523	70513	100 mM, 95% inhibition, 10 mM, 27% inhibition
1.1.1.94	Escherichia coli		K2SO4	287523	1867	100 mM, 60% inhibition
1.1.1.94	Escherichia coli		KCl	287523	74	100 mM, 47% inhibition
1.1.1.94	Oryctolagus cuniculus		N1-butylnicotinamide chloride	287524	21638	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-decylnicotinamide chloride	287524	39761	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-dodecylnicotinamide chloride	287524	70712	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-ethylnicotinamide chloride	287524	39758	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-heptylnicotinamide chloride	287524	21639	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-hexylnicotinamide chloride	287524	21640	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-methylnicotinamide chloride	287524	14331	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-nonylnicotinamide chloride	287524	39760	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-octylnicotinamide chloride	287524	21641	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-pentylnicotinamide chloride	287524	21642	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-propylnicotinamide chloride	287524	39759	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-undecylnicotinamide chloride	287524	39762	competitive vs. NAD+
1.1.1.94	Escherichia coli		Na2PO4-	287523	2591	100 mM, 92% inhibition, 10 mM, 27% inhibition
1.1.1.94	Escherichia coli		Na2SO4	287523	590	100 mM, 63% inhibition
1.1.1.94	Escherichia coli		NaCl	287523	39	100 mM, 47% inhibition
1.1.1.94	Escherichia coli		NAD+	669177	4	
1.1.1.94	Escherichia coli		NADP+	669175	6	competitive versus NADPH
1.1.1.94	Escherichia coli		NADP+	669177	6	
1.1.1.94	Escherichia coli		NADPH	669175	5	competitive versus NADP+
1.1.1.94	Escherichia coli		NH4Cl	287523	282	100 mM, 37% inhibition
1.1.1.94	Escherichia coli		NMN	669177	623	
1.1.1.94	Escherichia coli		palmitoyl-CoA	287523	122	0.0015 mM, 52% inhibition
1.1.1.94	Escherichia coli		phosphoenolpyruvate	689802	47	competitive inhibitor
1.1.1.94	Escherichia coli K-12		sn-glycerol-3-phosphate	669174	352	the wild-type enzyme is feedback inhibited
1.1.1.94	Escherichia coli		sn-glycerol-3-phosphate	669175	352	product inhibition at an allosteric, regulatory site, competitive versus dihydroxyacetone phosphate, noncompetitive versus NADPH, the wild-type enzyme is feedback inhibited
1.1.1.94	Escherichia coli		sn-glycerol-3-phosphate	669177	352	the wild-type enzyme is feedback regulated, competitive versus dihydroxyacetone phosphate, binding to a regulatory site
1.1.1.94	Escherichia coli		(NH4)2SO4	287523	334	100 mM, 68% inhibition, 10 mM, 8% inhibition
1.1.1.94	Escherichia coli		2',5'-ADP	669177	1457	
1.1.1.94	Escherichia coli		3,4-dihydroxybutyl 1-phosphonate	669177	84692	competitive versus dihydroxyacetone phosphate, binding to a regulatory site
1.1.1.94	Oryctolagus cuniculus		adenosine	287524	116	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		Adenosine diphosphate	287524	8	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		adenosine diphosphoribose	287524	337	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		adenylic acid	287524	9	competitive vs. NAD+
1.1.1.94	Escherichia coli		ADP	669177	8	
1.1.1.94	Escherichia coli		ADP-ribose	669177	337	
1.1.1.94	Escherichia coli		AMP	669177	9	
1.1.1.94	Escherichia coli		ATP	669177	7	
1.1.1.94	Escherichia coli		dihydroxyacetone phosphate	669175	241	noncompetitive versus NADP+
1.1.1.94	Escherichia coli		DL-glycerol 3-phosphate	287523	352	0.05 mM, 26% inhibition
1.1.1.94	Escherichia coli		ethylene glycol phosphate	669177	28739	binding to the active site
1.1.1.94	Escherichia coli		glyceraldehyde-3-phosphate	689802	473	competitive inhibitor
1.1.1.94	Escherichia coli		glyceric acid 2-phosphate	689802	783	competitive inhibitor
1.1.1.94	Escherichia coli		glycerol 3-phosphate	287523	352	50% inhibition with 0.035 mM, sigmoid inhibition curve, competitive inhibition vs. glycerone phosphate, uncompetitive vs. NADPH
1.1.1.94	Escherichia coli		K2PO4-	287523	70513	100 mM, 95% inhibition, 10 mM, 27% inhibition
1.1.1.94	Escherichia coli		K2SO4	287523	1867	100 mM, 60% inhibition
1.1.1.94	Escherichia coli		KCl	287523	74	100 mM, 47% inhibition
1.1.1.94	Oryctolagus cuniculus		N1-butylnicotinamide chloride	287524	21638	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-decylnicotinamide chloride	287524	39761	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-dodecylnicotinamide chloride	287524	70712	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-ethylnicotinamide chloride	287524	39758	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-heptylnicotinamide chloride	287524	21639	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-hexylnicotinamide chloride	287524	21640	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-methylnicotinamide chloride	287524	14331	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-nonylnicotinamide chloride	287524	39760	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-octylnicotinamide chloride	287524	21641	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-pentylnicotinamide chloride	287524	21642	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-propylnicotinamide chloride	287524	39759	competitive vs. NAD+
1.1.1.94	Oryctolagus cuniculus		N1-undecylnicotinamide chloride	287524	39762	competitive vs. NAD+
1.1.1.94	Escherichia coli		Na2PO4-	287523	2591	100 mM, 92% inhibition, 10 mM, 27% inhibition
1.1.1.94	Escherichia coli		Na2SO4	287523	590	100 mM, 63% inhibition
1.1.1.94	Escherichia coli		NaCl	287523	39	100 mM, 47% inhibition
1.1.1.94	Escherichia coli		NAD+	669177	4	
1.1.1.94	Escherichia coli		NADP+	669175	6	competitive versus NADPH
1.1.1.94	Escherichia coli		NADP+	669177	6	
1.1.1.94	Escherichia coli		NADPH	669175	5	competitive versus NADP+
1.1.1.94	Escherichia coli		NH4Cl	287523	282	100 mM, 37% inhibition
1.1.1.94	Escherichia coli		NMN	669177	623	
1.1.1.94	Escherichia coli		palmitoyl-CoA	287523	122	0.0015 mM, 52% inhibition
1.1.1.94	Escherichia coli		phosphoenolpyruvate	689802	47	competitive inhibitor
1.1.1.94	Escherichia coli K-12		sn-glycerol-3-phosphate	669174	352	the wild-type enzyme is feedback inhibited
1.1.1.94	Escherichia coli		sn-glycerol-3-phosphate	669175	352	product inhibition at an allosteric, regulatory site, competitive versus dihydroxyacetone phosphate, noncompetitive versus NADPH, the wild-type enzyme is feedback inhibited
1.1.1.94	Escherichia coli		sn-glycerol-3-phosphate	669177	352	the wild-type enzyme is feedback regulated, competitive versus dihydroxyacetone phosphate, binding to a regulatory site
1.2.1.41	Halobacillus halophilus	more		692834		cellular mRNA levels are increased up to 90fold in the presence of glutamate. A minimal concentration of 0.2 M glutamate already stimulates proA gene expression
1.2.1.41	Rattus norvegicus	phosphate		390302	12	100 mM
1.2.1.41	Escherichia coli		3-(Phosphonoacetylamido)-L-alanine	390307	28827	competitive with respect to DL-pyrroline-5-carboxylic acid, non-competitive with respect to NADP+ and phosphate
1.2.1.41	Escherichia coli		Ba2+	390308	105	50% inhibition at 1 mM
1.2.1.41	Escherichia coli		Co2+	390308	21	50% inhibition at 2.5 mM
1.2.1.41	Escherichia coli		Cu2+	390308	28	75% inhibition at 0.1 mM
1.2.1.41	Homo sapiens		Disulfiram	689379	758	0.01 mM
1.2.1.41	Escherichia coli		iodoacetamide	390308	63	40% inhibition at 1 mM
1.2.1.41	Escherichia coli		iodoacetate	390308	87	15% inhibition at 1 mM
1.2.1.41	Pseudomonas aeruginosa		L-proline	390308	215	25% inhibition at 50 mM
1.2.1.41	Solanum lycopersicum		L-proline	390314	215	50% inhibition at 0.07 mM
1.2.1.41	Escherichia coli		NADPH	390307	5	competitive with respect to all three substrates
1.2.1.41	Escherichia coli		Ni2+	390308	36	100% inhibition at 0.1 mM
1.2.1.41	Escherichia coli		p-chloromercuribenzoate	390308	40	100% inhibition at 1 mM
5.3.1.6	Bacillus caldolyticus	2-mercaptoethanol		2783, 2787	59	stimulates
5.3.1.6	Thiobacillus thioparus	2-mercaptoethanol		2783, 2787	59	stimulates
5.3.1.6	Bacillus caldolyticus	EDTA		2783, 2787	223	stimulates
5.3.1.6	Thiobacillus thioparus	EDTA		2783, 2787	223	stimulates
5.3.1.6	Cyberlindnera jadinii		3'-AMP	2782, 2784	529	
5.3.1.6	Cyberlindnera jadinii		3'-CMP	2782	1482	
5.3.1.6	Cyberlindnera jadinii		3'-GMP	2782	2641	
5.3.1.6	Cyberlindnera jadinii		3'-UMP	2782	1698	
5.3.1.6	Pisum sativum		3-phosphoglycerate	2792	174	
5.3.1.6	Spinacia oleracea		4-deoxy-4-phosphonomethyl-D-erythronate	663425	37745	stable and potent competitive inhibitor
5.3.1.6	Spinacia oleracea		4-phospho-D-erythronamide	663426	6542	competitive
5.3.1.6	Mycobacterium tuberculosis		4-phospho-D-erythronate	662445	1904	
5.3.1.6	Trypanosoma cruzi		4-phospho-D-erythronate	678047	1904	
5.3.1.6	Trypanosoma cruzi		4-phospho-D-erythronhydrazide	678047	16665	
5.3.1.6	Spinacia oleracea		4-phospho-D-erythronohydrazide	663426	37746	competitive
5.3.1.6	Trypanosoma cruzi		4-phospho-D-erythronohydroxamic acid	678047	4200	competitive
5.3.1.6	Spinacia oleracea		4-phosphoerythronate	2786	1904	strong competitive
5.3.1.6	Spinacia oleracea		4-phosphono-D-erythronate	663426	1904	
5.3.1.6	Mycobacterium tuberculosis		4-phosphono-D-erythronohydroxamate	662445	4200	
5.3.1.6	Spinacia oleracea		4-phosphono-D-erythronohydroxamic acid	663426	4200	competitive
5.3.1.6	Cyberlindnera jadinii		5'-AMP	2782	9	competitive
5.3.1.6	Cyberlindnera jadinii		5'-AMP	2784	9	
5.3.1.6	Cyberlindnera jadinii		5'-CMP	2782	94	
5.3.1.6	Cyberlindnera jadinii		5'-GMP	2782	150	
5.3.1.6	Cyberlindnera jadinii		5'-UMP	2782	127	
5.3.1.6	Mycobacterium tuberculosis		5-deoxy-5-phospho-D-ribonohydroxamate	693661	5838	
5.3.1.6	Mycobacterium tuberculosis		5-deoxy-5-phospho-D-ribonohydroxamic acid	663427	15393	competitive and selective inhibitor of type B ribose-5-phosphate isomerase from Mycobacterium tuberculosis
5.3.1.6	Spinacia oleracea		5-deoxy-5-phospho-D-ribonohydroxamic acid	663427	15393	weak
5.3.1.6	Escherichia coli		5-phospho-D-ribonamide	703070	8142	
5.3.1.6	Mycobacterium tuberculosis		5-phospho-D-ribonamide	703070	8142	
5.3.1.6	Escherichia coli		5-phospho-D-ribonate	703070	4616	competitive inhibitor of a Rpi, displays specific inhibition of Mycobacterium tuberculosis RpiB versus Escherichia coli RpiB, inhibition kinetics, overview
5.3.1.6	Mycobacterium tuberculosis		5-phospho-D-ribonate	703070	4616	very strong competitive inhibitor of a Rpi, specific inhibition of Mycobacterium tuberculosis RpiB versus Escherichia coli RpiB, inhibition kinetics, overview
5.3.1.6	Trypanosoma cruzi		5-phospho-D-ribonohydroxamic acid	678047	5838	
5.3.1.6	Escherichia coli		5-phospho-D-ribonohydroxamic acid	703070	5838	
5.3.1.6	Mycobacterium tuberculosis		5-phospho-D-ribonohydroxamic acid	703070	5838	
5.3.1.6	Cyberlindnera jadinii		6-phosphogluconate	2782	327	competitive
5.3.1.6	Bacillus caldolyticus		6-phosphogluconate	2783	327	temperature-dependent inhibition
5.3.1.6	Thiobacillus thioparus		6-phosphogluconate	2783	327	temperature-dependent inhibition
5.3.1.6	Bacillus caldolyticus		6-phosphogluconate	2787	327	
5.3.1.6	Escherichia coli		6-phosphogluconate	2787	327	
5.3.1.6	Thiobacillus thioparus		6-phosphogluconate	2787	327	
5.3.1.6	Pisum sativum		6-phosphogluconate	2792	327	noncompetitive
5.3.1.6	Bacillus caldolyticus		Ag+	2783	71	1 mM
5.3.1.6	Thiobacillus thioparus		Ag+	2783	71	1 mM
5.3.1.6	Bacillus caldolyticus		AMP	2783	9	temperature-dependent inhibition
5.3.1.6	Thiobacillus thioparus		AMP	2783	9	temperature-dependent inhibition
5.3.1.6	Bacillus caldolyticus		AMP	2787	9	
5.3.1.6	Escherichia coli		AMP	2787	9	
5.3.1.6	Rhodospirillum rubrum		AMP	2787	9	10 mM
5.3.1.6	Thiobacillus thioparus		AMP	2787	9	
5.3.1.6	Spinacia oleracea		arabinose 5-phosphate	649425	447	
5.3.1.6	Escherichia coli		arabinose 5-phosphate	653911	447	
5.3.1.6	Vibrio vulnificus		arabinose 5-phosphate	705731	447	RpiA binds arabinose 5-phosphate located at the opening of the active site, the sugar ring of the inhibitor interacts with the Asp4, Lys7, Ser30, Asp118, and Lys121 residues, the phosphate group of arabinose 5-phosphate interacts with two water molecules, W51 and W82, binding mode of inhibitor, overview
5.3.1.6	Rhodospirillum rubrum		citrate	2787	125	10 mM
5.3.1.6	Bacillus caldolyticus		Co2+	2783	21	1 mM
5.3.1.6	Thiobacillus thioparus		Co2+	2783	21	1 mM
5.3.1.6	Spinacia oleracea		D-5-Phosphoribonic acid	2786	4616	
5.3.1.6	Mycobacterium tuberculosis		D-Allose 6-phosphate	693661	6139	
5.3.1.6	Trypanosoma cruzi		D-Allose 6-phosphate	714990	6139	weak competitive inhibitor
5.3.1.6	Mycobacterium tuberculosis		D-allulose 6-phosphate	693661	25747	
5.3.1.6	Spinacia oleracea		D-arabinose 5-phosphate	649425	447	effective
5.3.1.6	Thermus thermophilus		D-arabinose 5-phosphate	652484	447	
5.3.1.6	Cyberlindnera jadinii		EDTA	2782, 2784	223	
5.3.1.6	Pisum sativum		erythrose 4-phosphate	2792	1137	competitive
5.3.1.6	Escherichia coli		fructose 6-phosphate	2787	82	
5.3.1.6	Pisum sativum		glyceraldehyde 3-phosphate	2792	473	competitive
5.3.1.6	Cyberlindnera jadinii		Hg2+	2784	31	
5.3.1.6	Cyberlindnera jadinii		iodoacetamide	2776	63	
5.3.1.6	Bos taurus		iodoacetamide	2778	63	
5.3.1.6	Trypanosoma cruzi		iodoacetamide	678047	63	5 mM, complete inhibition
5.3.1.6	Escherichia coli		iodoacetate	2779	87	1.25 mM, 100% loss of ribosephosphate isomerase B, no effect on ribosephosphate isomerase A
5.3.1.6	Mycobacterium tuberculosis		iodoacetate	652933	87	
5.3.1.6	Coccidioides immitis		iodoacetic acid	727257	87	suicide inhibitor
5.3.1.6	Bacillus caldolyticus		Mg2+	2783	25	0.01 M
5.3.1.6	Thiobacillus thioparus		Mg2+	2783	25	0.01 M
5.3.1.6	Pisum sativum		Mg2+	2792	25	MgCl2, noncompetitive
5.3.1.6	Cyberlindnera jadinii		Mn2+	2784	26	slight inhibition of enzyme form I and II, strong inhibition of enzyme form III
5.3.1.6	Ruminiclostridium thermocellum		more	678884		EDTA is not inhibitory
5.3.1.6	Escherichia coli		more	703070		substrate-derived enzyme inhibitor design and synthesis of analogues of the 6-carbon high-energy intermediate postulated for the D-allose 6-phosphate to D-allulose 6-phosphate isomerization reaction, overview
5.3.1.6	Mycobacterium tuberculosis		more	703070		substrate-derived enzyme inhibitor design and synthesis of analogues of the 6-carbon high-energy intermediate postulated for the D-allose 6-phosphate to D-allulose 6-phosphate isomerization reaction, overview
5.3.1.6	Peptoclostridium difficile		more	727222		enzyme is not affected by metal ions and not inhibited by EDTA
5.3.1.6	Escherichia coli		N-(5-phospho-D-ribonoyl)-gamma-aminobutanoate	703070	12799	
5.3.1.6	Mycobacterium tuberculosis		N-(5-phospho-D-ribonoyl)-gamma-aminobutanoate	703070	12799	
5.3.1.6	Escherichia coli		N-(5-phospho-D-ribonoyl)-glycine	703070	12798	poor inhibition with substrate D-ribose 5-phosphate, no inhibition with substrate D-allose 5-phosphate
5.3.1.6	Mycobacterium tuberculosis		N-(5-phospho-D-ribonoyl)-glycine	703070	12798	
5.3.1.6	Escherichia coli		N-(5-phospho-D-ribonoyl)-hydrazine	703070	18365	
5.3.1.6	Mycobacterium tuberculosis		N-(5-phospho-D-ribonoyl)-hydrazine	703070	18365	
5.3.1.6	Escherichia coli		N-(5-phospho-D-ribonoyl)-methylamine	703070	8143	
5.3.1.6	Mycobacterium tuberculosis		N-(5-phospho-D-ribonoyl)-methylamine	703070	8143	
5.3.1.6	Rhodospirillum rubrum		NAD+	2787	4	10 mM
5.3.1.6	Cyberlindnera jadinii		NEM	2776	46	
5.3.1.6	Bos taurus		NEM	2778	46	
5.3.1.6	Bos taurus		Organic mercurials	2780		
5.3.1.6	Cyberlindnera jadinii		Organic mercurials	2781		
5.3.1.6	Cyberlindnera jadinii		PCMB	2776	40	
5.3.1.6	Bos taurus		PCMB	2778	40	
5.3.1.6	Bacillus caldolyticus		Phenylmercuriacetate	2783	1830	reversible by 0.02-10 mM 2-mercaptoethanol, and by 10 mM Cys
5.3.1.6	Thiobacillus thioparus		Phenylmercuriacetate	2783	1830	reversible by 0.02-10 mM 2-mercaptoethanol, and by 10 mM Cys
5.3.1.6	Spinacia oleracea		phosphate	649425	12	competitive
5.3.1.6	Mycobacterium tuberculosis		phosphate	652933	12	weak
5.3.1.6	Escherichia coli		phosphate	653911	12	
5.3.1.6	Rhodospirillum rubrum		ribulose diphosphate	2787	407	1.0 mM, strong
5.3.1.6	Pisum sativum		sedoheptulose bisphosphate	2792	686	competitive
5.3.1.6	Bacillus caldolyticus		Sodium mersalyl	2783	4903	reversible by 2-mercaptoethanol, 0.02-10 mM, and by Cys, 10 mM
5.3.1.6	Thiobacillus thioparus		Sodium mersalyl	2783	4903	reversible by 2-mercaptoethanol, 0.02-10 mM, and by Cys, 10 mM
5.3.1.6	Cyberlindnera jadinii		Sodium salt of 2-(ethylmercurimercapto)-benzoxazole-5-carboxylic acid	2776	30449	
5.3.1.6	Bos taurus		Sodium salt of 2-(ethylmercurimercapto)-benzoxazole-5-carboxylic acid	2778	30449	
5.3.1.6	Bos taurus		sulfhydryl reagents	2780	752	
5.3.1.6	Cyberlindnera jadinii		sulfhydryl reagents	2781	752	
5.3.1.6	Spinacia oleracea		Xylulose 5-phosphate	649425	524	
5.3.1.6	Bacillus caldolyticus		Zn2+	2783	19	0.01 M
5.3.1.6	Thiobacillus thioparus		Zn2+	2783	19	0.01 M
1.1.1.49	Homo sapiens	5-(3alpha,12alpha-dihydroxy-5-beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide		688050	11448	weak activation
1.1.1.49	Homo sapiens	5-(3alpha,acetoxy-5-beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide		688050	77183	activates
1.1.1.49	Homo sapiens	6-Aminohexanoic acid		696962	1969	marginally increases the refolding yield in the presence of Arg, and it is unable to replace Arg in promoting a high refolding yield
1.1.1.49	Homo sapiens	acetazolamide		688050	225	activates
1.1.1.49	Arabidopsis thaliana	anhydrotetracyclin		697951		induces expression of mature G6PDH1
1.1.1.49	Rattus norvegicus	artesunate		695426	12625	induces a 25fold increase in glucose-6-phosphate dehydrogenase activity while there is no significant reduction in the red blood cell count. Critical role for glucose-6-phosphate dehydrogenase in the prevention of oxidative stress and lysis of red blood cells in artesunate-treated rats
1.1.1.49	Homo sapiens	butanol		696962	456	marginally increases the refolding yield in the presence of Arg, and it is unable to replace Arg in promoting a high refolding yield
1.1.1.49	Homo sapiens	cyclophilin A		696962		facilitates refolding, the yield, at about 82%, is about 12% higher than without cyclophilin A. Even with 0.0004 mM cyclophilin A in the standard refolding buffer, maximal recovery takes about 7 days
1.1.1.49	Homo sapiens	dithiothreitol		696962	42	dithiothreitol has major positive influence on refolding
1.1.1.49	Azotobacter vinelandii	glucosamine 6-phosphate		287003	417	
1.1.1.49	Homo sapiens	glycerol		696962	129	marginally increases the refolding yield in the presence of Arg, and it is unable to replace Arg in promoting a high refolding yield
1.1.1.49	Brugia malayi	guanosine hydrochloride		723340		the enzyme shows a sharp loss in activity above 0.75 M, but is activated by low concentrations of 0.2 M of GdmCl
1.1.1.49	Phragmites australis	H2O2		700844	20	H2O2, produced under salt stress, induces increased G6PDH activity and the enzymes of glutathione cycle, which concomitantly results in an increased reduced glutathione contents
1.1.1.49	Homo sapiens	Insulin		696152		stimulates, in pregnant women with types 1 diabetes insulin effect on the enzyme activity is lower than in the control. In the group of pregnant women with type 2 diabetes and gestational diabetes the effect of insulin is decreased as compared to control
1.1.1.49	Homo sapiens	insulin-like growth factor 1		696152		stimulates, in pregnant women with types 1 diabetes effect of insulin-like growth factor 1 is absent. In the group of pregnant women with type 2 diabetes and gestational diabetes the effect of insulin-like growth factor 1 is decreased as compared to control
1.1.1.49	Homo sapiens	L-Arg		696962	117	L-Arg has major positive influence on refolding. L-Arg is the key player in the refolding of human G6PD, preventing the aggregation of folding intermediate
1.1.1.49	Homo sapiens	metamizol		656387	9030	activation of mutant enzymes 1 and 2
1.1.1.49	Solanum tuberosum	more		657060		light and metabolizable sugars induce the cytosolic isozyme by increased de novo protein synthesis, while the plastidic isozymes are unaffected
1.1.1.49	Homo sapiens	more		696962		temperature and protein concentration have positive influence on refolding. Refolding at 25&deg;C is relatively slow, taking about one week to reach the maximum activity. Final refolding yield at pH 7.5 is about 69%, similar to 71% at pH 8.0, and only slightly higher than 65% at pH 8.5. At 30&deg;C, refolding is faster in the early stages than at 25&deg;C, but the highest activities, achieved after 4-5 days, are 49% at pH 7.5, 53% at pH 8.0, and 48% at pH 8.5, respectively, considerably lower than at 25&deg;C. Correct refolding is severely suppressed at 37&deg;C, with the highest recovery yield at 13%. Recovery yields are 54%, 70%, 56%, and 33% for protein concentrations at 5 microg/ml, 10 microg/ml, 20 microg/ml and 50 microg/ml, respectively
1.1.1.49	Arabidopsis thaliana	more		697951		oxidative activation is strictly dependent on plastidial thioredoxins that show differential efficiencies. Trx f1 regulates G6PDH1 activity as efficiently as Trx m1 or m4. Trx x is a very poor regulator of G6PDH activity. Trx y1 is inefficient as inhibitor but it shows high efficiency in activation. G6PDH activity can be recovered by transferring from light to dark, reversibility of inactivation certifying redox modulation of the enzyme. In the dark, reactivation can be enhanced by the addition of oxidants, such as oxidized dithiothreitol and H2O2
1.1.1.49	Nicotiana tabacum	more		701015		after pathogen infection with Phytophthora nicotianae, G6PDH activity rises 2 to 3fold in leaves of a resistant, but not of a susceptible, tobacco cultivar
1.1.1.49	Arabidopsis thaliana	more		701432		activity of G6PDH increases rapidly just after the inoculation of 10-day-old cells into fresh medium; activity of G6PDH increases rapidly just after the inoculation of 10-day-old cells into fresh medium; activity of G6PDH increases rapidly just after the inoculation of 10-day-old cells into fresh medium; activity of G6PDH increases rapidly just after the inoculation of 10-day-old cells into fresh medium; activity of G6PDH increases rapidly just after the inoculation of 10-day-old cells into fresh medium; activity of G6PDH increases rapidly just after the inoculation of 10-day-old cells into fresh medium
1.1.1.49	Brugia malayi	N-ethylmaleimide		723340	46	blocking the SH group leads to activation of rBmG6PD activity
1.1.1.49	Solanum tuberosum	paraquat		657060	302	activates plastidic isozymes by 10fold by direct action on the enzyme, no activation of the cytosolic isozyme
1.1.1.49	Homo sapiens	PEG 3350		696962		marginally increases the refolding yield in the presence of Arg, and it is unable to replace Arg in promoting a high refolding yield
1.1.1.49	Homo sapiens	relaxin		696152		stimulates, in pregnant women with types 1 diabetes effect of relaxin is absent. In the group of pregnant women with type 2 diabetes and gestational diabetes the effect of relaxin is somewhat higher as compared to control
1.1.1.49	Fragaria x ananassa	S-methyl 1,2,3-benzothiadiazole-7-carbothioate		704148	8155	treatment of fruits
1.1.1.49	Escherichia coli	spermidine		722577	140	activation constant: 0.2 mM
1.1.1.49	Homo sapiens	streptomycin		656387	1731	activation of mutant enzymes 1 and 2
1.1.1.49	Arabidopsis thaliana	Sucrose		700801	51	in wild-type seedlings G6PD5 and G6PD6 show small (1.7- and 2fold, respectively) but significant induction by sucrose
1.1.1.49	Homo sapiens	trehalose		696962	484	marginally increases the refolding yield in the presence of Arg, and it is unable to replace Arg in promoting a high refolding yield
1.1.1.49	Rattus norvegicus	vitamin E		675105	4043	in concert with nicotine the enzyme from testis brain and liver is inhibited, while the enzyme from muscle and stomach is activated by 36% and 20%, respectively, overview
1.1.1.49	Saccharomyces cerevisiae		(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate	685541	3505	
1.1.1.49	Saccharomyces cerevisiae		(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate	685541	936	
1.1.1.49	Saccharomyces cerevisiae		(2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate	685541	11781	
1.1.1.49	Saccharomyces cerevisiae		(2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate	685541	25088	
1.1.1.49	Plasmodium falciparum		(4Z)-4-(3-bromobenzylidene)-1-(4-methylphenyl)pyrazolidine-3,5-dione	730067	113720	
1.1.1.49	Plasmodium falciparum		(5Z)-1-(4-bromophenyl)-5-[[5-(2-nitrophenyl)furan-2-yl]methylidene]pyrimidine-2,4,6(1H,3H,5H)-trione	730067	113724	
1.1.1.49	Plasmodium falciparum		(5Z)-1-(4-ethoxyphenyl)-5-[[5-(2-nitrophenyl)furan-2-yl]methylidene]pyrimidine-2,4,6(1H,3H,5H)-trione	730067	113726	
1.1.1.49	Plasmodium falciparum		(5Z)-5-[[5-(2-methyl-4-nitrophenyl)furan-2-yl]methylidene]-1-(3-methylphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione	730067	113723	reversible, non-competitive inhibition versus NADP+, mixed-type versus D-glucose 6-phosphate
1.1.1.49	Cryptococcus neoformans		2'-phosphoadenosine 5'-diphosphoribose	287008	7434	
1.1.1.49	Homo sapiens		2,3-diphosphoglycerate	287016	557	
1.1.1.49	Plasmodium falciparum		2-[(5Z)-5-(4-hydroxy-3-methoxybenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]-3-phenylpropanoate	730067	113721	
1.1.1.49	Plasmodium falciparum		2-[(E)-(4-nitrocyclohexa-2,4-dien-1-yl)(2-phenylhydrazinylidene)methyl]benzene-1,4-diol	730067	113727	non-competitive inhibition versus NADP+, non-competitive or mixed-type versus D-glucose 6-phosphate
1.1.1.49	Plasmodium falciparum		2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-5-methyl-4-(3,4,5-trimethoxybenzyl)-2,4-dihydro-3H-pyrazol-3-one	730067	113725	irreversible, non-competitive inhibition versus NADP+, mixed-type versus D-glucose 6-phosphate
1.1.1.49	Solanum tuberosum		3-(3,4-dichlorophenyl)-1,1'-dimethyl urea	657060	13353	cytosolic isozyme, inhibition by uncoupling of photosynthetic electron transport
1.1.1.49	Plasmodium falciparum		3-(4-hydroxyphenyl)-2-(pyridin-3-yl)quinazolin-4(3H)-one	730067	113729	irreversible, non-competitive inhibition versus NADP+, mixed-type versus D-glucose 6-phosphate
1.1.1.49	Plasmodium falciparum		3-(5-bromopyridin-2-yl)-2-(pyridin-3-yl)quinazolin-4(3H)-one	730067	113728	irreversible, non-competitive inhibition versus NADP+, mixed-type versus D-glucose 6-phosphate
1.1.1.49	Plasmodium falciparum		3-(5-[(E)-[2-(5-nitropyridin-2-yl)hydrazinylidene]methyl]furan-2-yl)benzoic acid	730067	113722	
1.1.1.49	Plasmodium falciparum		4-fluoro-N-(4-hydroxynaphthalen-1-yl)benzenesulfonamide	730067	113730	
1.1.1.49	Plasmodium falciparum		4-methyl-3-(propan-2-yloxy)-6H-benzo[c]chromen-6-one	730067	113731	non-competitive inhibition versus NADP+, mixed-type versus D-glucose 6-phosphate
1.1.1.49	Homo sapiens		5-(3alpha,7alpha,12alpha-triacetoxy-5-beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide	688050	6479	weak inhibition
1.1.1.49	Homo sapiens		5-(3alpha,7alpha,12alpha-trihydroxy-5-beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide	688050	6478	weak inhibition
1.1.1.49	Plasmodium falciparum		5-[[5-(4-methoxy-2-nitrophenyl)furan-2-yl]methylidene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione	730067		reversible, competitive inhibition versus NADP+, mixed-type versus D-glucose 6-phosphate
1.1.1.49	Trypanosoma cruzi		5alpha-androstan-16-alpha-bromo-3beta-ol-17-one	711462	58969	in vitro cell viability assays shows a LD50 of 20 microM for Trypanosoma cruzi epimastigotes
1.1.1.49	Trypanosoma cruzi		5alpha-Androstan-3beta-ol-17-one	711462	3309	uncompetitive inhibitor
1.1.1.49	Trypanosoma cruzi		5alpha-androsten-16-alpha-bromo-3beta-ol-17-one	711462	58380	potent inhibitor, in vitro cell viability assays shows a LD50 of 12 microM for Trypanosoma cruzi epimastigotes
1.1.1.49	Saccharomyces cerevisiae		6-amino-NAD+	697523	94365	irreversibly inhibits G6PD
1.1.1.49	Saccharomyces cerevisiae		6-amino-NADP+	697523	94366	irreversibly inhibits G6PD
1.1.1.49	Taenia crassiceps		6-phosphogluconate	689323	327	
1.1.1.49	Pseudomonas fluorescens		acetyl-CoA	286985	27	
1.1.1.49	Brugia malayi		adenosine 5' [beta,gamma-amido] triphosphate	723340		
1.1.1.49	Brugia malayi		adenosine 5' [beta-thio] diphosphate	723340		
1.1.1.49	Brugia malayi		adenosine 5' [gamma-thio] triphosphate	723340	1380	
1.1.1.49	Pseudomonas fluorescens		ADP	286985	8	
1.1.1.49	Zea mays		ADP	286996	8	
1.1.1.49	Cryptococcus neoformans		ADP	287008	8	
1.1.1.49	Rattus norvegicus		ADP	287014	8	
1.1.1.49	Aspergillus aculeatus		ADP	674379	8	
1.1.1.49	Brugia malayi		ADP	723340	8	15% inhibition at 2 mM
1.1.1.49	Ovis aries		amikacin	656382	1053	in vitro, noncompetitive
1.1.1.49	Oncorhynchus mykiss		ammonia	673169	16	inhibition in vitro and in vivo at sublethal concentration of 0.0022-0.0055 mM, IC50: 0.0187 mM
1.1.1.49	Chalcalburnus tarischii		amoxicillin	688131	1323	
1.1.1.49	Pseudomonas fluorescens		AMP	286985	9	
1.1.1.49	Candida boidinii		AMP	286987	9	
1.1.1.49	Cryptococcus neoformans		AMP	287008	9	only 2'-AMP
1.1.1.49	Brugia malayi		AMP	723340	9	5% inhibition at 2 mM
1.1.1.49	Pseudomonas sp.		ATP	286819	7	
1.1.1.49	Cyberlindnera jadinii		ATP	286983	7	
1.1.1.49	Pseudomonas fluorescens		ATP	286985	7	
1.1.1.49	Anabaena sp.		ATP	286986	7	
1.1.1.49	Zea mays		ATP	286996	7	
1.1.1.49	Candida maltosa		ATP	286997	7	
1.1.1.49	Schizosaccharomyces pombe		ATP	287006	7	
1.1.1.49	Rattus norvegicus		ATP	287014	7	
1.1.1.49	Homo sapiens		ATP	287017	7	
1.1.1.49	Sus scrofa		ATP	287017	7	
1.1.1.49	Thermotoga maritima		ATP	655612	7	15% inhibition at 2.5 mM, 24% inhibition at 10 mM
1.1.1.49	Meleagris gallopavo		ATP	655712	7	weak, noncompetitive inhibition
1.1.1.49	Aspergillus aculeatus		ATP	674379	7	
1.1.1.49	Deinococcus radiophilus		ATP	688308	7	2.0 mM, 65% inhibition, G6PDH-2; G6PDH-1
1.1.1.49	Escherichia coli		ATP	722473	7	10 mM, 50-75% inhibition, assay without MgCl2
1.1.1.49	Brugia malayi		ATP	723340	7	31% inhibition at 5 mM, non-competitive inhibition with respect to D-glucose 6-phosphate
1.1.1.49	Deinococcus radiophilus		beta-naphthoquinone-4-sulfonic acid	688308	23270	1 mM, 68% inhibition, G6PDH-1; 1 mM, 81% inhibition, G6PDH-2
1.1.1.49	Lactobacillus buchneri		Blue dextran	286988		
1.1.1.49	Lactobacillus buchneri		Cd2+	286988	48	
1.1.1.49	Aspergillus parasiticus		Cd2+	286995	48	
1.1.1.49	Cryptococcus neoformans		Cd2+	287008	48	
1.1.1.49	Deinococcus radiophilus		Cd2+	688308	48	1 mM, 53% inhibition, G6PDH-1
1.1.1.49	Escherichia coli		Cd2+	722473	48	1 mM, 83% inhibition
1.1.1.49	Oncorhynchus mykiss		Cd2+	723747	48	noncompetitive inhibition
1.1.1.49	Gallus gallus		ceftriaxone	695960	2504	strongly inhibits
1.1.1.49	Homo sapiens		Chymotrypsin	696447		
1.1.1.49	Chalcalburnus tarischii		Ciprofloxacin	688131	932	
1.1.1.49	Aspergillus parasiticus		Co2+	286995	21	
1.1.1.49	Aspergillus aculeatus		Co2+	674379	21	competitive, 60% inhibition at 0.01 mM
1.1.1.49	Escherichia coli		Co2+	722473	21	1 mM, 56% inhibition
1.1.1.49	Pseudomonas fluorescens		CoA	286985	10	
1.1.1.49	Lactobacillus buchneri		Cu2+	286988	28	
1.1.1.49	Deinococcus radiophilus		Cu2+	688308	28	1 mM, 24% inhibition, G6PDH-1; 1 mM, 78% inhibition, G6PDH-2
1.1.1.49	Escherichia coli		Cu2+	722473	28	1 mM, complete inhibition
1.1.1.49	Brugia malayi		Cu2+	723340	28	
1.1.1.49	Oncorhynchus mykiss		Cu2+	723747	28	noncompetitive inhibition
1.1.1.49	Bacillus megaterium		cumene hydroperoxide	678997	653	1% residual activity after treatment with 17 mM cumene hydroperoxide at 50&deg;C and pH 7 for 2 h
1.1.1.49	Solanum tuberosum		cycloheximide	657060	1283	
1.1.1.49	Oncorhynchus mykiss		cypermethrin	700590	2907	inhibits G6PD in vitro
1.1.1.49	Trypanosoma cruzi		D-glucose 6-phosphate	711462	99	
1.1.1.49	Trypanosoma cruzi		dehydroandrosterone	711462	239	uncompetitive inhibitor
1.1.1.49	Trypanosoma brucei		dehydroepiandrosterone	696748	239	uncompetitively inhibits bloodstream form cells
1.1.1.49	Homo sapiens		dehydroepiandrosterone	697523	239	non-competitively inhibits
1.1.1.49	Oncorhynchus mykiss		deltamethrin	700590	4212	inhibits G6PD both in vivo and in vitro, significantly inhibits activity after the 48th hour. Among pesticides, it is the most effective one, which is widely used both at homes and in agricultural fields. Deltamethrin inhibits the enzyme at very low doses, particularly in in vivo conditions, indicating that fish in natural and cultural environments are susceptible to this pesticide and that deltamethrin contaminations can be cause high mortality in fish population, which may lead to the increase in food insufficiency for increasing populations and cause disruption of ecological balance. Thus, usage of deltamethrin must be well controlled
1.1.1.49	Pisum sativum		DTT	660941	42	1 mM, 2 h, 20% loss of activity in the first 15 min and then the enzyme activity remains steady throughout the incubation
1.1.1.49	Koliella antarctica		DTT	722212	42	
1.1.1.49	Homo sapiens		EDTA	287017	223	slightly
1.1.1.49	Sus scrofa		EDTA	287017	223	slightly
1.1.1.49	Deinococcus radiophilus		EDTA	688308	223	5 mM, 85% inhibition, G6PDH-1; 5 mM, 97% inhibition, G6PDH-2
1.1.1.49	Trypanosoma brucei		epiandrosterone	696748	3332	uncompetitively inhibits bloodstream form cells
1.1.1.49	Homo sapiens		epiandrosterone	697523	3332	non-competitively inhibits
1.1.1.49	Bos taurus		Estrogen	286980	2234	
1.1.1.49	Oncorhynchus mykiss		Fe2+	723747	23	strong competitive inhibition
1.1.1.49	Aspergillus aculeatus		fructose 6-phosphate	674379	82	
1.1.1.49	Ovis aries		gentamicin sulfate	656382	11667	in vitro, noncompetitive
1.1.1.49	Taenia crassiceps		glucosamine 6-phosphate	689323	417	parabolic inhibition
1.1.1.49	Nicotiana tabacum		glucosamine 6-phosphate	701015	417	competitive G6PDH inhibitor
1.1.1.49	Bos taurus		glucose	287011	33	at concentration above 10 mM
1.1.1.49	Homo sapiens		glucose	711960	33	high glucose level of 25 mM leads to a decrease in G6PD activity and protein level in islets
1.1.1.49	Candida boidinii		glyceraldehyde 3-phosphate	286987	473	
1.1.1.49	Candida maltosa		glyoxylate	286997	95	
1.1.1.49	Pseudomonas fluorescens		GTP	286985	35	
1.1.1.49	Candida boidinii		GTP	286987	35	
1.1.1.49	Schizosaccharomyces pombe		GTP	287006	35	
1.1.1.49	Homo sapiens		guanidinium hydrochloride	696447	804	denatures
1.1.1.49	Homo sapiens		guanidinium hydrochloride	696962	804	in the presence of 4 M, after 2 hours all secondary structure is lost
1.1.1.49	Brugia malayi		guanosine hydrochloride	723340		the enzyme shows a sharp loss in activity above 0.75 M, but is activated by low concentrations of 0.2 M of GdmCl
1.1.1.49	Lactobacillus buchneri		Hg2+	286988	31	
1.1.1.49	Deinococcus radiophilus		Hg2+	688308	31	1 mM, 47% inhibition, G6PDH-2; 1 mM, 84% inhibition, G6PDH-1
1.1.1.49	Escherichia coli		Hg2+	722473	31	1 mM, complete inhibition
1.1.1.49	Oncorhynchus mykiss		Hg2+	723747	31	noncompetitive inhibition
1.1.1.49	Bacillus megaterium		hydrogen peroxide	678997	20	inhibitory at 0.25%, at pH 7
1.1.1.49	Candida maltosa		Isocitrate	286997	242	
1.1.1.49	Pseudomonas fluorescens		ITP	286985	203	
1.1.1.49	Brugia malayi		K+	723340	37	
1.1.1.49	Chalcalburnus tarischii		KMnO4	688131	1546	
1.1.1.49	Brugia malayi		Li+	723340	142	
1.1.1.49	Gallus gallus		lidocaine	695960	6432	strongly inhibits
1.1.1.49	Oncorhynchus mykiss		marcaine	675104	14465	noncompetitive
1.1.1.49	Gallus gallus		meloksikam	695960	3654	strongly inhibits
1.1.1.49	Homo sapiens		metamizol	656387	9030	inhibition of wild-type and mutant enzyme 3
1.1.1.49	Oncorhynchus mykiss		metamizol	675104	9030	competitive
1.1.1.49	Gallus gallus		metamizol	695960	9030	strongly inhibits
1.1.1.49	Oncorhynchus mykiss		MgSO4	675104	914	competitive
1.1.1.49	Escherichia coli		Mn2+	722473	26	1 mM, 56% inhibition
1.1.1.49	Solanum tuberosum		more	657060		the cytosolic isoyzme is not affected by osmotic change, phosphate sequestration, or ocidative stress
1.1.1.49	Petroselinum crispum		more	657147		effects of streptomycin sulfate and tetracyclin antibiotics
1.1.1.49	Aspergillus aculeatus		more	674379		product and dead-end inhibition studies, overview, no inhibition by AMP
1.1.1.49	Bacillus megaterium		more	677998		not inhibited by ATP, phosphate, or Mg2+
1.1.1.49	Leishmania mexicana		more	696748		is not inhibited by dehydroepiandrosterone and epiandrosterone
1.1.1.49	Homo sapiens		more	697523		hyperaldosteronism downregulates G6PD and whereby decreases GSH levels and conversely increases oxidative stress, which evokes endothelial-derived NO and impairs vascular function
1.1.1.49	Rattus norvegicus		more	697523		inhibition of G6PD protects rat hearts from ischemia-reperfusion injury induced by oxidative stress
1.1.1.49	Arabidopsis thaliana		more	697951		Trx f1 regulates G6PDH1 activity as efficiently as Trx m1 or m4. Trx x is a very poor regulator of G6PDH activity. Trx y1 is inefficient as inhibitor but it shows high efficiency in activation. Upon illumination, a strong and fast reductive inhibition of G6PDH1 activity dependent on the presence of all the components of the Fd/Trx system
1.1.1.49	Arabidopsis thaliana		more	701432		during 7 days of phosphate starvation, G6PD5 is continuously expressed throughout phosphate-starvation; during 7 days of phosphate starvation, transcript levels are reduced; during 7 days of phosphate starvation, transcript levels are reduced; during 7 days of phosphate starvation, transcript levels are reduced; during 7 days of phosphate starvation, transcript levels are reduced; during 7 days of phosphate starvation, transcript levels are reduced
1.1.1.49	Homo sapiens		more	711728		fluoride-containing bioactive glasses as used in tissue engineering as well as bone repair, inhibit the pentose phosphate oxidative pathway and the glucose 6-phosphate dehydrogenase activity. The effects are ascribable to the fluoride content/release of glass powders, they are mimicked by NaF solutions and are prevented by radical scavengers dimethyl sulfoxide and tempol, by superoxide dismutase, and by glutathione, but not by apocynin
1.1.1.49	Homo sapiens		more	713131		non-radioactive Tl+, Fe3+ and Cu2+ do not influence the enzyme in vitro
1.1.1.49	Escherichia coli		more	722580		NADH: no inhibition at up to 0.5 mM
1.1.1.49	Plasmodium falciparum		more	730067		high-throughput screening for small-molecule inhibitors of the enzyme from Plasmodium falciparum, inhibitor evaluation, structure-activity relationship analysis, overview
1.1.1.49	Plasmodium falciparum		N-(4-hydroxynaphthalen-1-yl)-2,5-dimethylbenzenesulfonamide	730067		
1.1.1.49	Brugia malayi		Na+	723340	55	
1.1.1.49	Pseudomonas sp.		NADH	286819	3	
1.1.1.49	Pseudomonas fluorescens		NADH	286985	3	
1.1.1.49	Meleagris gallopavo		NADH	655712	3	noncompetitive
1.1.1.49	Escherichia coli		NADH	722577	3	allosteric inhibition, inhibition is not reversed by NAD+, AMP, or spermidine
1.1.1.49	Schizosaccharomyces pombe		NADP+	287006	6	at high concentration, dead-end ternary complexes are formed
1.1.1.49	Homo sapiens		NADP+	287016	6	at concentrations above 0.3 mM
1.1.1.49	Homo sapiens		NADP+	287017	6	
1.1.1.49	Aspergillus aculeatus		NADP+	674379	6	substrate inhibition
1.1.1.49	Cyberlindnera jadinii		NADPH	286983	5	
1.1.1.49	Pseudomonas fluorescens		NADPH	286985	5	
1.1.1.49	Anabaena sp.		NADPH	286986	5	
1.1.1.49	Candida boidinii		NADPH	286987	5	
1.1.1.49	Pisum sativum		NADPH	286998	5	
1.1.1.49	Agaricus bisporus		NADPH	286999	5	
1.1.1.49	Schizosaccharomyces pombe		NADPH	287006	5	
1.1.1.49	Cryptococcus neoformans		NADPH	287008	5	
1.1.1.49	Rattus norvegicus		NADPH	287010	5	liver enzyme is more sensitive to inhibition than kidney enzyme
1.1.1.49	Dictyostelium discoideum		NADPH	287013	5	
1.1.1.49	Mus musculus		NADPH	287015	5	inhibition patterns of substrates and product
1.1.1.49	Homo sapiens		NADPH	287016	5	NADPH binding is important for physiological regulation of pentose phosphate pathway
1.1.1.49	Homo sapiens		NADPH	287017	5	
1.1.1.49	Sus scrofa		NADPH	287017	5	
1.1.1.49	Thermotoga maritima		NADPH	655612	5	competitive
1.1.1.49	Meleagris gallopavo		NADPH	655712	5	competitive
1.1.1.49	Canis lupus familiaris		NADPH	655736	5	has a regulatory role in pentaose phosphate pathway
1.1.1.49	Hordeum vulgare		NADPH	657133	5	slight inhibition
1.1.1.49	Aspergillus aculeatus		NADPH	674379	5	product inhibition
1.1.1.49	Taenia crassiceps		NADPH	689323	5	
1.1.1.49	Arabidopsis thaliana		NADPH	701015	5	
1.1.1.49	Nicotiana tabacum		NADPH	701015	5	
1.1.1.49	Escherichia coli		NADPH	722244	5	product inhibition with NADP+ or D-glucose 6-phosphate as the varying substrate
1.1.1.49	Escherichia coli		NADPH	722473	5	
1.1.1.49	Escherichia coli		NADPH	722577	5	when NADP+ is the varied substrate, NADPH NADPH is a competitive inhibitor both in the presence and absence of Mg2+, linear competitive inhibition. When glucose 6-phosphate is the varied substrate NADPH causes linear noncompetitive inhibition
1.1.1.49	Brugia malayi		NADPH	723340	5	competitive inhibition with respect to NADP+ and D-glucose 6-phosphate
1.1.1.49	Homo sapiens		netilmicin	656387	1899	inhibition of wild-type and mutant enzymes 1-3
1.1.1.49	Rattus norvegicus		Nicotine	675105	1876	inhibits the enzyme from lung, testis, kidney, stomach, and brain, in concert with vitamin E the enzyme from testis brain and liver is inhibited, tissue-specific inhibition of 12.5-48%, overview, nicotine has no effect on enzyme from muscle, heart, and liver
1.1.1.49	Chalcalburnus tarischii		nidazole	688131	3688	
1.1.1.49	Deinococcus radiophilus		oleic acid	688308	320	G6PDH-1 is more susceptible to oleic acid than G6PDH-2
1.1.1.49	Bos taurus		p-chloromercuribenzoate	286980	40	
1.1.1.49	Rattus norvegicus		p-chloromercuribenzoate	287014	40	can be reversed 100% by dithiothreitol, partially by glutathione
1.1.1.49	Rattus norvegicus		p-chloromercuribenzoate	655495	40	
1.1.1.49	Agaricus bisporus		palmitoyl-CoA	286999	122	
1.1.1.49	Azotobacter vinelandii		palmitoyl-CoA	287003	122	non-competitive
1.1.1.49	Homo sapiens		palmitoyl-CoA	287017	122	leads to dissociation of active tetramers to inactive dimers
1.1.1.49	Sus scrofa		palmitoyl-CoA	287017	122	leads to dissociation of active tetramers to inactive dimers
1.1.1.49	Oncorhynchus mykiss		Pb2+	723747	132	noncompetitive inhibition
1.1.1.49	Ovis aries		penicillin G potassium	656382	36420	in vitro, noncompetitive
1.1.1.49	Oncorhynchus mykiss		pental sodium	675104	41316	noncompetitive
1.1.1.49	Bacillus megaterium		peracetic acid	678997	3245	1% residual activity after treatment with 4 mM peracetic acid at 25&deg;C and pH 7 for 15 min
1.1.1.49	Cyberlindnera jadinii		phosphate	286983	12	
1.1.1.49	Brugia malayi		phosphoenol pyruvate	723340	47	25% inhibition at 10 mM
1.1.1.49	Pseudomonas fluorescens		phosphoenolpyruvate	286985	47	
1.1.1.49	Thermotoga maritima		phosphoenolpyruvate	655612	47	13% inhibition at 2.5 mM, 31% inhibition at 10 mM
1.1.1.49	Aspergillus aculeatus		phosphoenolpyruvate	674379	47	
1.1.1.49	Gallus gallus		prilocaine	695960	52063	strongly inhibits
1.1.1.49	Bos taurus		progesterone	286980	249	
1.1.1.49	Oncorhynchus mykiss		propoxur	700590	2233	inhibits G6PD in vitro
1.1.1.49	Cyberlindnera jadinii		pyridoxal 5'-phosphate	286976, 286983	30	
1.1.1.49	Mus musculus		quartz	697311		24 h incubation with quartz particles (80 microg/cm(2)) inhibits G6PD activity by 70%. Inhibition is fully prevented by glutathione. Silica exerts on G6PD an oxidative damage
1.1.1.49	Anabaena sp.		Ribulose 1,5-diphosphate	286986	407	
1.1.1.49	Trypanosoma brucei		RNAi	696748		mediates reduction of the G6PDH level in bloodstream form cells
1.1.1.49	Nicotiana tabacum		RNAi	701015		suppression of endogenous cytosolic G6PDH isoforms result in highly uniform defense responses and also enhanced drought tolerance and flowering
1.1.1.49	Homo sapiens		sodium ceftizoxime	656387	79776	inhibition of wild-type and mutant enzymes 1-3
1.1.1.49	Homo sapiens		sodium cefuroxime	656387	79777	inhibition of wild-type and mutant enzymes 1-3
1.1.1.49	Homo sapiens		streptomycin	656387	1731	inhibition of wild-type and mutant enzyme 3
1.1.1.49	Chalcalburnus tarischii		sulfanilacetamide	688131	15357	
1.1.1.49	Chalcalburnus tarischii		sulfanilamide	688131	833	
1.1.1.49	Brugia malayi		suramin	723340	568	77% inhibition at 0.05 mM
1.1.1.49	Bacillus megaterium		tert-butyl hydroperoxide	678997	511	1% residual activity after treatment with 290 mM tert-butyl hydroperoxide at 50&deg;C and pH 7 for 3 h
1.1.1.49	Koliella antarctica		Thioredoxin f	722212		from chloroplasts
1.1.1.49	Homo sapiens		Tl+	713131	2066	201Tl solution and radiation exposure has inhibitory effects on the enzyme activity both in vivo and in vitro
1.1.1.49	Oncorhynchus mykiss		Urea	673169	110	inhibition in vitro and in vivo at sublethal concentration of 0.02-0.05 mM, IC50: 0.0238 mM
1.1.1.49	Oncorhynchus mykiss		Vancomycin	675104	1560	competitive
1.1.1.49	Chalcalburnus tarischii		Vancomycin	688131	1560	
1.1.1.49	Rattus norvegicus		vitamin E	675105	4043	in concert with nicotine the enzyme from testis brain and liver is inhibited, while the enzyme from muscle and stomach is activated, overview
1.1.1.49	Lactobacillus buchneri		Zn2+	286988	19	
1.1.1.49	Aspergillus parasiticus		Zn2+	286995	19	
1.1.1.49	Cryptococcus neoformans		Zn2+	287008	19	
1.1.1.49	Homo sapiens		Zn2+	287017	19	
1.1.1.49	Sus scrofa		Zn2+	287017	19	
1.1.1.49	Aspergillus aculeatus		Zn2+	674379	19	competitive, 40% inhibition at 0.01 mM
1.1.1.49	Deinococcus radiophilus		Zn2+	688308	19	1 mM, 83% inhibition, G6PDH-2; 1 mM, 94% inhibition, G6PDH-1
1.1.1.49	Oncorhynchus mykiss		Zn2+	723747	19	noncompetitive inhibition
1.2.1.12	Bos taurus	2,3-Dimercaptopropanol		287979	1854	poor activation
1.2.1.12	Haloarcula vallismortis	2-mercaptoethanol		287907	59	maximal activation at 5 mM, dependent on sulfhydryl compound
1.2.1.12	Bos taurus	2-mercaptoethanol		287979	59	10 mM, 2fold activation of the oxidation of D-glyceraldehyde 3-phosphate
1.2.1.12	Thermus thermophilus	acetone		287938	286	activates
1.2.1.12	Bos taurus	Cys		287979	70	10 mM, 2.8fold activation of the oxidation of D-glyceraldehyde 3-phosphate
1.2.1.12	Bos taurus	dithioerythritol		287979	475	10 mM, 2fold activation of the oxidation of D-glyceraldehyde 3-phosphate
1.2.1.12	Trypanosoma cruzi	DMSO		684403	702	activity is increased about 2fold in the presence of 5% DMSO (v/v)
1.2.1.12	Homo sapiens	Doxorubicin		699592	662	treatment results in increased nuclear localization of expressed wild-type GAPDH, where it protects telomeres against rapid degradation, concomitant with increased resistance to the growth-inhibitory effects of the drug
1.2.1.12	Bos taurus	EDTA		287979	223	poor activation
1.2.1.12	Thermus thermophilus	ethanol		287938, 287968	65	30% v/v, 5fold activation
1.2.1.12	Homo sapiens	Ferric protoporphyrin IX		685025	32370	145% increase of activity at 0.04 mM ferric protoporphyrin IX after 30 min exposure to stauroporin
1.2.1.12	Homo sapiens	gemcitabine		699592	1407	treatment results in increased nuclear localization of expressed wild-type GAPDH, where it protects telomeres against rapid degradation, concomitant with increased resistance to the growth-inhibitory effects of the drug
1.2.1.12	Haloarcula vallismortis	GSH		287907	41	dependent on sulfhydryl compound
1.2.1.12	Bos taurus	GSH		287979	41	poor activation
1.2.1.12	Homo sapiens	H2O2		685025	20	186% increase of activity at 1 mM H2O2
1.2.1.12	Homo sapiens	H2O2		695602	20	subapoptotic doses lead to strong hyperactivation, related to mild oxidative stress. U937 cells hyperactivate glyceraldehyde 3-phosphate dehydrogenase with the same timing observed for glyceraldehyde 3-phosphate dehydrogenase alterations from apoptogenic doses of H2O2
1.2.1.12	Trypanosoma cruzi	methanol		684403	78	activity is increased about 6fold in the presence of 5% methanol (v/v)
1.2.1.12	Bacillus cereus	more		287974		enzyme contains 8 SH groups per tetramer of which 4 are highly reactive and essential for activity
1.2.1.12	Homo sapiens	more		684972		human TATA-binding protein-associated factor II 68-TEC fusion protein-dependent transcription is enhanced by GAPDH
1.2.1.12	Homo sapiens	more		687584		GAPDH functions as a coactivator with high selectivity for androgen receptor and enhances androgen receptor transactivation independent of its glycolytic activity
1.2.1.12	Homo sapiens	more		697687		20% increase of GADPH expression 3 h post concentric exercise
1.2.1.12	Entamoeba histolytica	NAD+		686607	4	highest activity in the presence of 0.2 mM NAD+ at 30&deg;C
1.2.1.12	Pseudomonas aeruginosa	NADPH		287919	5	slight activation
1.2.1.12	Thermus thermophilus	propan-1-ol		287968	536	activates
1.2.1.12	Thermus thermophilus	propan-2-ol		287968	551	activates
1.2.1.12	Thermus thermophilus	tetrabutylammonium chloride		287968	70928	50% activation
1.2.1.12	Homo sapiens	Triton X-100		685025	57	
1.2.1.12	Trypanosoma cruzi		(8E,11E)-C15:2-anacardic acid	696747	52070	
1.2.1.12	Trypanosoma cruzi		(8E,11E,14E)-C15:3-anacardic acid	696747	52069	
1.2.1.12	Trypanosoma cruzi		(E)-2-hydroxy-6-(pentadec-8-en-1-yl)benzoic acid	696747	26091	
1.2.1.12	Oryctolagus cuniculus		(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide	687602	75415	treatment with (E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide between 0.001 and 1 mM induces the oligomerization of GAPDH, dithiothreitol reduces (E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide-induced aggregation in a concentration-dependent manner
1.2.1.12	Haloarcula vallismortis		(NH4)2SO4	287907	334	
1.2.1.12	Homo sapiens		1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene	687602	9320	
1.2.1.12	Oryctolagus cuniculus		1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene	687602	9320	
1.2.1.12	Leishmania mexicana		2'-deoxy-2'-[(quinolin-7-ylcarbonyl)amino]adenosine	687934	90249	
1.2.1.12	Glycine max		2,3-diphosphoglycerate	287920	557	
1.2.1.12	Homo sapiens		2,3-diphosphoglycerate	287945	557	
1.2.1.12	Leishmania mexicana		2-(6-amino-2-methyl-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol	687934	90180	
1.2.1.12	Trypanosoma cruzi		2-(dodec-1-en-1-yl)-6-hydroxybenzoic acid	696735		inhibition is not reversed or prevented by addition of Triton X-100. Noncompetitive with respect to both substrate and cofactor
1.2.1.12	Leishmania mexicana		2-(hydroxymethyl)-5-[6-[(2-methylphenyl)amino]-9H-purin-9-yl]tetrahydrofuran-3,4-diol	687934	90110	
1.2.1.12	Leishmania mexicana		2-(hydroxymethyl)-5-[6-[(3-methylbutyl)amino]-9H-purin-9-yl]tetrahydrofuran-3,4-diol	687934	90095	
1.2.1.12	Leishmania mexicana		2-(hydroxymethyl)-5-[6-[(3-methylphenyl)amino]-9H-purin-9-yl]tetrahydrofuran-3,4-diol	687934	90092	
1.2.1.12	Leishmania mexicana		2-methyl-9H-purin-6-amine	687934	33216	
1.2.1.12	Trypanosoma cruzi		2-pentadecyl-6-hydroxybenzoic acid	696735		inhibition is not reversed or prevented by addition of Triton X-100. Noncompetitive with respect to both substrate and cofactor
1.2.1.12	Leishmania mexicana		2-[6-amino-8-(pyrimidin-2-ylsulfanyl)-9H-purin-9-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol	687934	90124	
1.2.1.12	Leishmania mexicana		2-[9-(2-deoxy-2-[[(2,4-dimethoxyphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-yl]-2,3-dihydroisoquinoline	687934	90122	
1.2.1.12	Entamoeba histolytica		3',4',5',5,7-pentamethoxyflavone	686053	90770	
1.2.1.12	Entamoeba histolytica		3',4'-methylenedioxy-5,6,7-trimethoxyflavone	686053	90771	
1.2.1.12	Apis mellifera		3',5'-AMP	287971	233	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-2-oxo-2H-chromen-6-ylacetate	686053	90773	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-2-oxo-2H-chromen-7-ylacetate	686053	90774	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-2-oxo-2H-chromen-8-ylacetate	686053	90775	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-2H-chromen-2-one	686053	90776	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-6-hydroxy-2H-chromen-2-one	686053	90777	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-6-nitro-2H-chromen-2-one	686053	90772	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-6-[[(1E)-1H-indol-3-ylmethylene]amino]-2H-chromen-2-one	686053	90784	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-6-[[(1E)-1H-pyrrol-2-ylmethylene]amino]-2H-chromen-2-one	686053	90781	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-6-[[(1E)-2-furylmethylene]amino]-2H-chromen-2-one	686053	90782	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-6-[[(1E)-pyridin-2-ylmethylene]amino]-2H-chromen-2-one	686053	90785	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-6-[[(1E)-thien-2-ylmethylene]amino]-2H-chromen-2-one	686053	90783	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-7-hydroxy-2H-chromen-2-one	686053	90778	
1.2.1.12	Entamoeba histolytica		3-(1,3-benzodioxol-5-yl)-8-hydroxy-2H-chromen-2-one	686053	90779	
1.2.1.12	Trypanosoma cruzi		3-(4-nitrophenoxycarboxyl)-3-ethylene propyl dihydroxyphosphonate	726108		
1.2.1.12	Geobacillus stearothermophilus		3-(chloroacetyl)-pyridine adenine dinculeotide	287909	63302	
1.2.1.12	Mus musculus		3-morpholino-sydnonimine	287982	5566	the NO-generating compound inactivates by induction of a covalent binding of NAD+ to the enzyme. The superoxide anion released by 3-morpholino-sydnonimine potentiates the inactivation
1.2.1.12	Pisum sativum		3-phospho-D-glyceroyl phosphate	287936	462	
1.2.1.12	Leishmania mexicana		5'-deoxy-5'-[(diphenylacetyl)amino]adenosine	687934	90153	
1.2.1.12	Leishmania mexicana		5'-deoxy-5'-[[(4'-ethylbiphenyl-4-yl)carbonyl]amino]adenosine	687934	90151	
1.2.1.12	Entamoeba histolytica		6-amino-3-(1,3-benzodioxol-5-yl)-2H-chromen-2-one	686053	90780	
1.2.1.12	Pseudomonas aeruginosa		6-phosphogluconate	287919	327	
1.2.1.12	Leishmania mexicana		9-(2-aminoethyl)-8-thiophen-2-yl-9H-purin-6-amine	687934	90453	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(2,4-dichlorophenyl)carbonyl]amino]pentofuranosyl)-N-(3-hydroxynaphthalen-1-yl)-9H-purin-6-amine	687934	90454	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(2,4-dichlorophenyl)carbonyl]amino]pentofuranosyl)-N-naphthalen-1-yl-9H-purin-6-amine	687934	90455	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(2,4-dichlorophenyl)carbonyl]amino]pentofuranosyl)-N-naphthalen-2-yl-9H-purin-6-amine	687934	90484	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(2,4-dihydroxyphenyl)carbonyl]amino]pentofuranosyl)-N-naphthalen-1-yl-9H-purin-6-amine	687934	90564	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(2,4-dimethoxyphenyl)carbonyl]amino]pentofuranosyl)-N-(3-hydroxynaphthalen-1-yl)-9H-purin-6-amine	687934	90471	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(2,4-dimethoxyphenyl)carbonyl]amino]pentofuranosyl)-N-naphthalen-1-yl-9H-purin-6-amine	687934	90538	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(2,4-dimethoxyphenyl)carbonyl]amino]pentofuranosyl)-N-naphthalen-2-yl-9H-purin-6-amine	687934	90539	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(2-hydroxy-3-methoxyphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90540	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3,4-dihydroxyphenyl)carbonyl]amino]pentofuranosyl)-N-(naphthalen-1-ylmethyl)-9H-purin-6-amine	687934	90541	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3,4-dimethoxyphenyl)carbonyl]amino]pentofuranosyl)-N-(naphthalen-1-ylmethyl)-9H-purin-6-amine	687934	90542	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3,5-dihydroxyphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90543	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3,5-dimethoxyphenyl)carbonyl]amino]pentofuranosyl)-N-(2-methylphenyl)-9H-purin-6-amine	687934	90544	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3,5-dimethoxyphenyl)carbonyl]amino]pentofuranosyl)-N-(3-methylphenyl)-9H-purin-6-amine	687934	90545	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3,5-dimethoxyphenyl)carbonyl]amino]pentofuranosyl)-N-phenyl-9H-purin-6-amine	687934	90547	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3,5-dimethoxyphenyl)carbonyl]amino]pentofuranosyl)-N-[(3-methoxynaphthalen-1-yl)methyl]-9H-purin-6-amine	687934	90546	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3-ethoxyphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90561	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3-hydroxy-4-methoxyphenyl)carbonyl]amino]pentofuranosyl)-N-naphthalen-1-yl-9H-purin-6-amine	687934	90549	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3-hydroxyphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90537	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3-hydroxyphenyl)carbonyl]amino]pentofuranosyl)-N-(naphthalen-1-ylmethyl)-9H-purin-6-amine	687934	90551	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3-hydroxyphenyl)carbonyl]amino]pentofuranosyl)-N-naphthalen-1-yl-9H-purin-6-amine	687934	90552	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3-methoxyphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90553	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3-methoxyphenyl)carbonyl]amino]pentofuranosyl)-N-(2-methoxyphenyl)-9H-purin-6-amine	687934	90554	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3-methoxyphenyl)carbonyl]amino]pentofuranosyl)-N-phenyl-9H-purin-6-amine	687934	90556	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(3-methoxyphenyl)carbonyl]amino]pentofuranosyl)-N-[(7-methylnaphthalen-1-yl)methyl]-9H-purin-6-amine	687934	90555	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(4-heptylphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90557	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(4-hydroxy-3-methoxyphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90558	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(4-hydroxy-3-methoxyphenyl)carbonyl]amino]pentofuranosyl)-N-naphthalen-1-yl-9H-purin-6-amine	687934	90559	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(4-methoxyphenyl)carbonyl]amino]pentofuranosyl)-N-(1-phenylethyl)-9H-purin-6-amine	687934	90560	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(4-methoxyphenyl)carbonyl]amino]pentofuranosyl)-N-(2,5-dimethylphenyl)-9H-purin-6-amine	687934	90534	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(4-methoxyphenyl)carbonyl]amino]pentofuranosyl)-N-(3,4-dimethylphenyl)-9H-purin-6-amine	687934	90550	
1.2.1.12	Leishmania mexicana		9-(2-deoxy-2-[[(4-methoxyphenyl)carbonyl]amino]pentofuranosyl)-N-(3-hydroxynaphthalen-1-yl)-9H-purin-6-amine	687934	90548	
1.2.1.12	Leishmania mexicana		9-(2-[[(4-chlorophenyl)carbonyl]amino]-2-deoxypentofuranosyl)-N-(3-hydroxynaphthalen-1-yl)-9H-purin-6-amine	687934	90450	
1.2.1.12	Leishmania mexicana		9-(2-[[(4-chlorophenyl)carbonyl]amino]-2-deoxypentofuranosyl)-N-(naphthalen-1-ylmethyl)-9H-purin-6-amine	687934	90451	
1.2.1.12	Leishmania mexicana		9-(2-[[(4-chlorophenyl)carbonyl]amino]-2-deoxypentofuranosyl)-N-naphthalen-1-yl-9H-purin-6-amine	687934	90452	
1.2.1.12	Leishmania mexicana		9-[2-(benzylamino)ethyl]-8-thiophen-2-yl-9H-purin-6-amine	687934	90529	
1.2.1.12	Leishmania mexicana		9-[2-([[2,4-bis(acetyloxy)phenyl]carbonyl]amino)-2-deoxypentofuranosyl]-N-naphthalen-1-yl-9H-purin-6-amine	687934	90524	
1.2.1.12	Leishmania mexicana		9-[2-([[3,4-bis(acetyloxy)phenyl]carbonyl]amino)-2-deoxypentofuranosyl]-N-naphthalen-1-yl-9H-purin-6-amine	687934	90525	
1.2.1.12	Leishmania mexicana		9-[2-([[3-(acetyloxy)phenyl]carbonyl]amino)-2-deoxypentofuranosyl]-N-(naphthalen-1-ylmethyl)-9H-purin-6-amine	687934	90526	
1.2.1.12	Leishmania mexicana		9-[2-([[3-(acetyloxy)phenyl]carbonyl]amino)-2-deoxypentofuranosyl]-N-naphthalen-1-yl-9H-purin-6-amine	687934	90527	
1.2.1.12	Leishmania mexicana		9-[2-([[4-(acetyloxy)-3-methoxyphenyl]carbonyl]amino)-2-deoxypentofuranosyl]-N-(naphthalen-1-ylmethyl)-9H-purin-6-amine	687934	90528	
1.2.1.12	Leishmania mexicana		9-[2-deoxy-2-([[4-(dimethylamino)phenyl]carbonyl]amino)pentofuranosyl]-N-naphthalen-1-yl-9H-purin-6-amine	687934	90530	
1.2.1.12	Leishmania mexicana		9-[2-deoxy-2-[(phenylcarbonyl)amino]pentofuranosyl]-8-thiophen-2-yl-9H-purin-6-amine	687934	90531	
1.2.1.12	Homo sapiens		acetylleucine chloromethyl ketone	654926	36430	binds to GAPDH to modulate the conformation of the enzyme, the modified enzyme is susceptible to chymotrypsin-like protease activity, cleavage at TRp195-Arg196; irreversible inhibition, enzyme modified by acetylleucine chloromethyl ketone is deduced to be digested at the peptide bond Trp196-Arg196
1.2.1.12	Apis mellifera		ADP	287971	8	
1.2.1.12	Escherichia coli		ADP	287977	8	inhibition of esterase activity with p-nitrophenyl acetate
1.2.1.12	Homo sapiens		ADP	657393	8	moderately inhibits arsenate reductase activity
1.2.1.12	Rattus norvegicus		ADP	657393	8	moderately inhibits arsenate reductase activity
1.2.1.12	Panulirus versicolor		ADP-ribose	654051	337	coenzyme analogue with a non-cooperative behaviour of binding, is a potent competitive inhibitor
1.2.1.12	Oryctolagus cuniculus		Agaricic acid	287900	8321	0.14 mM, 50% inhibition in absence of NAD+. 2 mM, 35% loss of activity in presence of 0.017 mM NAD+
1.2.1.12	Trypanosoma brucei		Agaricic acid	287900	8321	glyoxysomal enzyme: 0.2 mM, 60% loss of activity. Cytosolic enzyme: 2 mM, less than 20% loss of activity
1.2.1.12	Rattus norvegicus		alpha-chlorohydrin	698925	10417	the contraceptive activity of alpha-chlorohydrin and its apparent specificity for the sperm isoform in vivo are likely to be due to differences in metabolism to 3-chlorolactaldehyde in spermatozoa and somatic cells
1.2.1.12	Pseudomonas aeruginosa		AMP	287919	9	
1.2.1.12	Glycine max		AMP	287920	9	
1.2.1.12	Apis mellifera		AMP	287971	9	
1.2.1.12	Escherichia coli		AMP	287977	9	inhibition of esterase activity with p-nitrophenyl acetate
1.2.1.12	Dissostichus mawsoni		AMP	287978	9	18 mM, only 5% loss of activity
1.2.1.12	Saccharomyces cerevisiae		anti-TLAb serum	287899		
1.2.1.12	Pseudomonas aeruginosa		ATP	287919	7	
1.2.1.12	Homo sapiens		ATP	287945	7	noncompetitive inhibitor
1.2.1.12	Sus scrofa		ATP	287966	7	at 0&deg;C, loss of activity. Some of the lost activity is regained upon warming to room temperature
1.2.1.12	Apis mellifera		ATP	287971	7	
1.2.1.12	Euglena gracilis		ATP	287973	7	10 mM, 50% inhibition
1.2.1.12	Escherichia coli		ATP	287977	7	inhibition of esterase activity with p-nitrophenyl acetate
1.2.1.12	Dissostichus mawsoni		ATP	287978	7	1 mM, 25% loss of activity
1.2.1.12	Homo sapiens		ATP	657393	7	moderately inhibits arsenate reductase activity
1.2.1.12	Rattus norvegicus		ATP	657393	7	moderately inhibits arsenate reductase activity
1.2.1.12	Homo sapiens		ATP	696174	7	inhibition is less pronounced for enzyme from sarcoma tissue as compared to normal muscle tissue
1.2.1.12	Leishmania donovani		benzyl carbazate	725568		
1.2.1.12	Neisseria meningitidis		beta-mercaptoethanol	688953	59	strong inhibition at 10 mM
1.2.1.12	Euglena gracilis		cAMP	287973	233	
1.2.1.12	Camelus dromedarius		Cd2+	684127	48	strong inhibition
1.2.1.12	Thermus thermophilus		CdCl2	287938, 287968	707	
1.2.1.12	Pleurodeles waltl		CdCl2	655270	707	20 mM, about 30% inhibition. 10 mM, 70% inhibition
1.2.1.12	Xenopus laevis		CdCl2	655270	707	20 mM, about 65% inhibition
1.2.1.12	Homo sapiens		CGP-3466	671070	86260	deprenyl-related compound that inhibits the pro-apoptotic activity of GAPDH
1.2.1.12	Entamoeba histolytica		chalepin	686053	46997	
1.2.1.12	Entamoeba histolytica		chalepin	687842	46997	natural inhibitor of GAPDH
1.2.1.12	Haloarcula vallismortis		Cu2+	287907	28	1 mM CuCl2, complete inhibition
1.2.1.12	Thermus thermophilus		Cu2+	287938, 287968	28	
1.2.1.12	Bacillus cereus		Cu2+	287974	28	
1.2.1.12	Camelus dromedarius		Cu2+	684127	28	
1.2.1.12	Arabidopsis thaliana		CuCl2	673587	295	1 mM
1.2.1.12	Pleurodeles waltl		CuSO4	655270	228	0.001 mM, 90% inhibition within 2 min
1.2.1.12	Xenopus laevis		CuSO4	655270	228	0.001 mM, 70% inhibition in 2 min
1.2.1.12	Pisum sativum		D-glyceraldehyde 3-phosphate	287936	139	substrate inhibition
1.2.1.12	Homo sapiens		D-glyceraldehyde 3-phosphate	287945	139	substrate inhibition
1.2.1.12	Dissostichus mawsoni		D-glyceraldehyde 3-phosphate	287978	139	substrate inhibition
1.2.1.12	Homo sapiens		demethylasterriquinone B1	688250	90786	binding of demethylasterriquinone B1 toGAPDH could disrupt phosphatase acting upon phosphatidylinositol lipids and thereby potentiate insulin signaling via the phosphatidylinositol-3-kinase pathway
1.2.1.12	Arabidopsis thaliana		Diamide	673587	1817	1 mM
1.2.1.12	Homo sapiens		diepoxybutane	686080	70338	incubation of GAPDH with bis-electrophiles results in inhibition of its catalytic activity, but only at high concentrations of diepoxybutane
1.2.1.12	Arabidopsis thaliana		dithiothreitol	663144	42	DTT
1.2.1.12	Neisseria meningitidis		dithiothreitol	688953	42	strong inhibition at 2 mM
1.2.1.12	Oryctolagus cuniculus		Fe2+	686849	23	in the absence of quercetin, GAPDH can be oxidized by ferrous ions due to the formation of reactive oxygen species according to the following series of reactions
1.2.1.12	Plasmodium falciparum		ferriprotoporphorin IX	677046	12096	
1.2.1.12	Plasmodium falciparum		ferriprotoporphyrin IX	671063	12096	
1.2.1.12	Homo sapiens		ferriprotoporphyrin IX	673629	12096	enzyme is partially inactivated through oxidation of critical thiols
1.2.1.12	Homo sapiens		FK506-binding protein 36	698989		i.e. FKBP36. The interaction between FKBP36 and GAPDH directly inhibits the catalytic activity of GAPDH. FKBP36 expression causes a significant reduction of the GAPDH level and activity in COS-7 cells. GAPDH is depleted by FKBP36 expression, particularly in the cytosolic fraction
1.2.1.12	Oryctolagus cuniculus		FK506-binding protein 36	698989		i.e. FKBP36, forms complexes with glyceraldehyde-3-phosphate dehydrogenase and Hsp90. Both proteins bind independently to different sites of the FKBP36 tetratricopeptide repeat domain. The interaction between FKBP36 and GAPDH directly inhibits the catalytic activity of GAPDH
1.2.1.12	Oryctolagus cuniculus		fumarate	686305	156	approximately 20% of GAPDH activity is lost by incubation with 0.5 mM fumarate for 24 h, and 100% activity is lost in incubations with 500 mM fumarate at 24 h, NADH in the presence or absence of D-glyceraldehyde 3-phosphate significantly accelerates the inactivation of GAPDH by fumarate
1.2.1.12	Rattus norvegicus		fumarate	686305	156	inactivation of GAPDH by fumarate in vitro correlates with formation of S-(2-succinyl)cysteine, in diabetic compared with control rats fumarate and S-(2-succinyl)cysteine concentration increase approximately 5fold, accompanied by an about 25% decrease in GAPDH specific activity
1.2.1.12	Arabidopsis thaliana		glutathione	673587	41	5 mM oxidized glutathione, GSSG, formation of mixed disulfide between glutathione and A4-GAPDH results in the inhibition of enzyme activity
1.2.1.12	Spinacia oleracea		glutathione	673587	41	formation of mixed disulfide between glutathione and GAPDH results in the inhibition of enzyme activity
1.2.1.12	Arabidopsis thaliana		glutathione	689409	41	inactivation with 10 mM glutathione is reversible upon addition of 20 mM dithiothreitol
1.2.1.12	Oryctolagus cuniculus		glutathione	689409	41	inactivation with 10 mM glutathione is reversible upon addition of 20 mM dithiothreitol
1.2.1.12	Saccharomyces cerevisiae		glutathione	689409	41	inactivation with 10 mM glutathione is reversible upon addition of 20 mM dithiothreitol
1.2.1.12	Spinacia oleracea		glutathione	689409	41	inactivation with 10 mM glutathione is reversible upon addition of 20 mM dithiothreitol
1.2.1.12	Trypanosoma brucei		gossypol	287900	1358	
1.2.1.12	Trypanosoma cruzi		guajaverin	696747	44979	molecular docking studies. Guajaverin is stabilized by five hydrogen bonds with the amino acids Ser165, Thr226, Arg249, Ser134, and Glu336
1.2.1.12	Arabidopsis thaliana		H2O2	663144	20	
1.2.1.12	Arabidopsis thaliana		H2O2	673587	20	1 mM
1.2.1.12	Spinacia oleracea		H2O2	673587	20	
1.2.1.12	Oryctolagus cuniculus		H2O2	686849	20	GAPDH is oxidized by H2O2 which is likely formed due to the spontaneous dismutation of the superoxide anion that is formed during the autooxidation of quercetin that can result in the oxidation of SH-groups of GAPDH
1.2.1.12	Oryctolagus cuniculus		H2O2	672402, 687602	20	
1.2.1.12	Homo sapiens		H2O2	673629, 687602, 688661	20	
1.2.1.12	Arabidopsis thaliana		H2O2	726233	20	isoform GAPC1 is irreversibly inhibited in a time- and concentration-dependent manner
1.2.1.12	Camelus dromedarius		Hg2+	684127	31	strong inhibition
1.2.1.12	Haloarcula vallismortis		HgCl2	287907	104	1 mM, complete inhibition
1.2.1.12	Thermus thermophilus		HgCl2	287938, 287968	104	
1.2.1.12	Leishmania donovani		hydrazine	725568	552	
1.2.1.12	Tetrahymena pyriformis		hydrogen peroxide	688066	20	maximum inhibition is observed at concentrations of 0.2 mM
1.2.1.12	Haloarcula vallismortis		iodoacetamide	287907	63	5 mM, complete inhibition
1.2.1.12	Thermus thermophilus		iodoacetamide	287938	63	
1.2.1.12	Thermus thermophilus		iodoacetamide	287968	63	0.5 mM, 9% inhibition
1.2.1.12	Homo sapiens		iodoacetamide	686080	63	
1.2.1.12	Thermus thermophilus		iodoacetate	287938	87	
1.2.1.12	Homo sapiens		iodoacetate	287950	87	
1.2.1.12	Thermus thermophilus		iodoacetate	287968	87	0.2 mM, 67% inhibition
1.2.1.12	Apis mellifera		iodoacetate	287971	87	
1.2.1.12	Euglena gracilis		iodoacetate	287973	87	
1.2.1.12	Bacillus cereus		iodoacetate	287974	87	
1.2.1.12	Escherichia coli		iodoacetate	287977	87	
1.2.1.12	Lactococcus lactis		iodoacetate	712937	87	
1.2.1.12	Vigna radiata var. radiata		K+	287949	37	0.2-1.0 M
1.2.1.12	Camelus dromedarius		K+	684127	37	
1.2.1.12	Trichoderma koningii		Koningic acid	287908	10598	irreversible inhibition, GAPDH I : 50% inhibition by 1 mM, no effect at 0.1 mM. GAPDH II: 50% inhibition by 0.01 mM. Under conditions of koningic acid production the koningic-acid-resistant isoenzyme GAPDH I is produced. In peptone-rich medium where non koningic acid is produced the koningic-acid-sensitive isoenzyme GAPDH II is produced in addition to GAPDH 1
1.2.1.12	Homo sapiens		Koningic acid	657393	10598	inhibits arsenate reductase activity and activity with D-glyceraldehyde 3-phosphate, phosphate and NAD+
1.2.1.12	Rattus norvegicus		Koningic acid	657393	10598	inhibits arsenate reductase activity and activity with D-glyceraldehyde 3-phosphate, phosphate and NAD+
1.2.1.12	Trypanosoma cruzi		mangiferin	696747	26025	
1.2.1.12	Camelus dromedarius		Mn2+	684127	26	
1.2.1.12	Oryctolagus cuniculus		monoclonal antibody 8B7	695902		antibody is specific for glyceraldehyde 3-phosphate dehydrogenase. In lysates of Sf21 cells, the antibody inhibits protein translation, possibly due to inhibition of the binding of glyceraldehyde 3-phosphate dehydrogenase to mRNA and tRNA
1.2.1.12	Geobacillus stearothermophilus		more	672306		the produced type I antibody induces a time-dependent decrease in the activity by 80-90% of the active holoenzyme and 25% of the apoenzyme
1.2.1.12	Homo sapiens		more	673629		inhibited by binding to the cell membrane
1.2.1.12	Lactococcus lactis ssp. cremoris		more	674222		the NADH/NAD+ ratio is shown to modulate the in vivo activity; the wild type GADPH is strongly inhibited in vitro by decreased pH values
1.2.1.12	Homo sapiens		more	685025		stauroporine does not inhibit stimulation of G3PD activity
1.2.1.12	Mus musculus		more	685334		not inhibited by thiorphan and lipopolysaccharide
1.2.1.12	Oryctolagus cuniculus		more	685334		not inhibited by thiorphan and lipopolysaccharide
1.2.1.12	Rattus norvegicus		more	685334		not inhibited by thiorphan and lipopolysaccharide
1.2.1.12	Homo sapiens		more	686080		not inhibited by DMSO, dibromomethane and 1,2-dibromoethane
1.2.1.12	Oryctolagus cuniculus		more	686305		succinate has no effect on enzyme activity
1.2.1.12	Tetrahymena pyriformis		more	688066		H2O2 does not significantly alter GAPDH-specific activity levels in cell free extracts
1.2.1.12	Neisseria meningitidis		more	688953		NADH, glucose-1-phosphate, AMP, ADP, ATP, and fructose-6-phosphate do not affect kinetic properties of GAPN and no change in cofactor preference from NAD+ to NADP+ in the presence of these metabolic intermediates is detected
1.2.1.12	Homo sapiens		more	712640		anti-GAPDH immunoglobulin G in the cerebrospinal fluid of patients with multiple sclerosis inhibits GAPDH glycolytic activity (38% or 58% inhibition after incubation of GAPDH with 0.002 or 0.004 mg, respectively)
1.2.1.12	Lactococcus lactis		more	712937		no inhibition by D-glucose 6-phosphate, D-fructose 6-phosphate, D-fructose 1,6-bisphosphate, dihydroxyacetone phosphate, phosphoenolpyruvate, pyruvate
1.2.1.12	Oryctolagus cuniculus		more	724398		not inhibited by ((R)-mandelyl)-(S)-cysteine
1.2.1.12	Synechococcus elongatus		more	726498		the C-terminus of CP12 is inserted into the active-site region of glyceraldehyde-3-phosphate dehydrogenase, resulting in competitive inhibition of the enzyme
1.2.1.12	Leishmania mexicana		N-(1,2,3,4-tetrahydronaphthalen-1-yl)adenosine	687934	90520	
1.2.1.12	Leishmania mexicana		N-(2-[[2-(hydroxymethyl)phenyl]sulfanyl]phenyl)adenosine	687934	90512	
1.2.1.12	Leishmania mexicana		N-(3-acetylnaphthalen-1-yl)-9-(2-deoxy-2-[[(2,4-dichlorophenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90509	
1.2.1.12	Leishmania mexicana		N-(3-acetylnaphthalen-1-yl)-9-(2-deoxy-2-[[(4-methoxyphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90510	
1.2.1.12	Leishmania mexicana		N-(4-acetylnaphthalen-1-yl)-9-(2-deoxy-2-[[(4-methoxyphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90378	
1.2.1.12	Leishmania mexicana		N-(4-acetylnaphthalen-1-yl)-9-[2-deoxy-2-([[4-(methylamino)phenyl]carbonyl]amino)pentofuranosyl]-9H-purin-6-amine	687934	90379	
1.2.1.12	Leishmania mexicana		N-(diphenylmethyl)adenosine	687934	90384	
1.2.1.12	Leishmania mexicana		N-(naphthalen-2-ylmethyl)-9-pentofuranosyl-9H-purin-6-amine	687934	90385	
1.2.1.12	Oryctolagus cuniculus		N-(phenoxyacetyl)-L-cysteine	724398		65% inhibition at 0.56 mM
1.2.1.12	Oryctolagus cuniculus		N-(phenylacetyl)-glutathione	724398		45% inhibition at 0.56 mM
1.2.1.12	Homo sapiens		N-acetylcysteine	685025	1771	5 mM N-acetylcysteine significantly reduces G3PD activation induced by both H2O2 and ferric protoporphyrin IX
1.2.1.12	Leishmania mexicana		N-benzyl-9-(2-deoxy-2-[[(4-methoxyphenyl)carbonyl]amino]pentofuranosyl)-9H-purin-6-amine	687934	90350	
1.2.1.12	Leishmania mexicana		N-cycloheptyladenosine	687934	90352	
1.2.1.12	Oryctolagus cuniculus		N-ethylmaleimide	686305	46	1 mM completely inactivates the enzyme in 10 min
1.2.1.12	Leishmania mexicana		N-[2-(6-amino-8-bromo-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl]benzamide	687934	90392	
1.2.1.12	Leishmania mexicana		N-[2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl]-1H-benzimidazole-5-carboxamide	687934	90393	
1.2.1.12	Leishmania mexicana		N-[2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl]-3,4,5-trihydroxybenzamide	687934	90394	
1.2.1.12	Leishmania mexicana		N-[2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl]benzamide	687934	90395	
1.2.1.12	Leishmania mexicana		N-[2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl]thiophene-2-carboxamide	687934	90396	
1.2.1.12	Leishmania mexicana		N-[2-(6-amino-9H-purin-9-yl)cyclopentyl]-3-bromobenzamide	687934	90397	
1.2.1.12	Leishmania mexicana		N-[2-(6-amino-9H-purin-9-yl)ethyl]-4-methylbenzamide	687934	90398	
1.2.1.12	Vigna radiata var. radiata		Na+	287949	55	120 mM almost complete inhibition. Cys, GSH and deproteinated crude extract protect against inhibition
1.2.1.12	Thermus thermophilus		Na2S4O6	287938		
1.2.1.12	Thermus thermophilus		Na2S4O6	287968		0.1 mM, complete inhibition
1.2.1.12	Bacillus cereus		Na2S4O6	287974		
1.2.1.12	Geobacillus stearothermophilus		NAD+	287909	4	competitive against NADH
1.2.1.12	Homo sapiens		NAD+	287932	4	competitive against NADH
1.2.1.12	Pisum sativum		NAD+	287936	4	substrate inhibition
1.2.1.12	Sus scrofa		NAD+	287966	4	
1.2.1.12	Pseudomonas aeruginosa		NADH	287919	3	
1.2.1.12	Glycine max		NADH	287920	3	competitive with respect to NAD+ and phosphate
1.2.1.12	Homo sapiens		NADH	287932	3	competitive against NAD+
1.2.1.12	Pisum sativum		NADH	287936	3	competitive with NAD+ and with D-glyceraldehyde 3-phosphate
1.2.1.12	Homo sapiens		NADH	287945	3	
1.2.1.12	Geobacillus stearothermophilus		NADH	287970	3	
1.2.1.12	Homo sapiens		NADH	657393	3	strongly inhibits arsenate reductase activity
1.2.1.12	Rattus norvegicus		NADH	657393	3	strongly inhibits arsenate reductase activity
1.2.1.12	Lactococcus lactis		NADH	712937	3	competitive
1.2.1.12	Neisseria meningitidis		NADP+	688953	6	75% inhibition in the presence of 2 mM NADP+
1.2.1.12	Neisseria meningitidis		NADPH	688953	5	
1.2.1.12	Apis mellifera		NEM	287971	46	
1.2.1.12	Euglena gracilis		NEM	287973	46	1 mM, complete inhibition
1.2.1.12	Bacillus cereus		NEM	287974	46	
1.2.1.12	Thermus thermophilus		NiCl2	287968	598	
1.2.1.12	Arabidopsis thaliana		nitric oxide	726233	240	isoform GAPC1 is irreversibly inhibited in a time- and concentration-dependent manner
1.2.1.12	Tetrahymena pyriformis		nitrogen oxide	688066	240	
1.2.1.12	Mus musculus		NO	287982	240	inactivation by induction of a covalent binding of NAD+ to the enzyme
1.2.1.12	Tetrahymena pyriformis		NO	688066	240	diminishes GAPDH specific activity by 10%-20%
1.2.1.12	Homo sapiens		NO3-	287945	263	uncompetitive inhibitor with NAD+, dead end inhibitor
1.2.1.12	Arabidopsis thaliana		oxidized glutathione	689409	283	inactivation, at least partially reversible upon addition of dithiothreitol. Both residues C155 and C159 are found glutathionylated; inactivation, at least partially reversible upon addition of dithiothreitol. Both residues C155 and C159 are found glutathionylated
1.2.1.12	Oryctolagus cuniculus		oxidized glutathione	689409	283	inactivation, at least partially reversible upon addition of dithiothreitol
1.2.1.12	Spinacia oleracea		oxidized glutathione	689409	283	inactivation, at least partially reversible upon addition of dithiothreitol
1.2.1.12	Geobacillus stearothermophilus		p-hydroxymercuribenzoate	287970	92	
1.2.1.12	Haloarcula vallismortis		PCMB	287907	40	5 mM, complete inhibition
1.2.1.12	Euglena gracilis		PCMB	287973	40	1 mM, complete inhibition, partially reversed by dithiothreitol; 1 mM, inhibition is partially reversed by dithiothreitol
1.2.1.12	Bos taurus		PCMB	287979	40	
1.2.1.12	Geobacillus stearothermophilus		pentalenolactone	287900	4456	reversible
1.2.1.12	Trypanosoma brucei		pentalenolactone	287900	4456	most potent inhibitor; reversible
1.2.1.12	Haloarcula vallismortis		pentalenolactone	287907	4456	insensitive to
1.2.1.12	Streptomyces arenae		pentalenolactone	287930	4456	pentalenolactone-sensitive enzyme is strongly inhibited, pentalenolactone-insensitive enzyme is not inhibited
1.2.1.12	Oryctolagus cuniculus		pentalenolactone	287900, 288344	4456	irreversible
1.2.1.12	Saccharomyces cerevisiae		pentalenolactone	288344	4456	
1.2.1.12	Spinacia oleracea		pentalenolactone	288344	4456	irreversible
1.2.1.12	Pisum sativum		phosphate	287936	12	substrate inhibition
1.2.1.12	Mus musculus		pyridoxal 5'-phosphate	287957	30	inactivation with pseudo-first-order kinetics
1.2.1.12	Oryctolagus cuniculus		pyridoxal 5'-phosphate	287957	30	
1.2.1.12	Trypanosoma cruzi		quercetin	696747	131	molecular docking studies. Quercetin is stabilized by two hydrogen bonds with the amino acids Ala198 and Pro253
1.2.1.12	Rattus norvegicus		S-(2-succinyl)cysteine	695595	94410	chemical modification by S-(2-succinyl)cysteine causes irreversible inactivation of glyceraldehyde-3-phosphate dehydrogenase in vitro. In diabetic rats, succination of GAPDH is increased in muscle, and the extent of succination correlates strongly with the decrease in specific activity of the enzyme
1.2.1.12	Arabidopsis thaliana		S-nitrosoglutathione	689409	753	inactivation, at least partially reversible upon addition of dithiothreitol. Both residues C155 and C159 are found nitrosylated; inactivation, at least partially reversible upon addition of dithiothreitol. Both residues C155 and C159 are found nitrosylated; inactivation with 0.5 mM S-nitrosoglutathione is reversible upon addition of 20 mM dithiothreitol
1.2.1.12	Oryctolagus cuniculus		S-nitrosoglutathione	689409	753	inactivation, at least partially reversible upon addition of dithiothreitol; inactivation with 0.5 mM S-nitrosoglutathione is reversible upon addition of 20 mM dithiothreitol
1.2.1.12	Saccharomyces cerevisiae		S-nitrosoglutathione	689409	753	inactivation with 0.5 mM S-nitrosoglutathione is reversible upon addition of 20 mM dithiothreitol
1.2.1.12	Spinacia oleracea		S-nitrosoglutathione	689409	753	inactivation, at least partially reversible upon addition of dithiothreitol; inactivation with 0.5 mM S-nitrosoglutathione is reversible upon addition of 20 mM dithiothreitol
1.2.1.12	Oryctolagus cuniculus		sodium nitroprusside	287981	1122	inhibition in presence of NAD+ is due primarily to active-site nitrosylation, covalent binding of NAD+ through a NO-dependent thiol intermediate
1.2.1.12	Mus musculus		sodium nitroprusside	287982	1122	the NO-generating compound inactivates by induction of a covalent binding of NAD+ to the enzyme
1.2.1.12	Tetrahymena pyriformis		sodium nitroprusside	688066	1122	maximum inhibition is observed at concentrations of 0.2 mM
1.2.1.12	Thermus thermophilus		Sodium tetrathionate	287938	4469	
1.2.1.12	Bacillus cereus		Sodium tetrathionate	287974	4469	
1.2.1.12	Trypanosoma brucei		suramin	287900	568	cyosolic enzyme: competitive with NAD+. Effect on Km-value and maximal veocity of glyoxysomal enzyme
1.2.1.12	Trypanosoma cruzi		tiliroside	696747	25259	molecular docking studies. Tiliroside is stabilized by four hydrogen bonds with the amino acids Cys166, Ser134, and Ser110
1.2.1.12	Mus musculus		Trinitrobenzenesulfonic acid	287957	2353	inactivation with pseudo-first-order kinetics. D-glyceraldehyde-3-phosphate, NAD+, NADH and 3-phospho-D-glyceroyl phosphate almost completely protect from inactivation
1.2.1.12	Oryctolagus cuniculus		Trinitrobenzenesulfonic acid	287957	2353	
1.2.1.12	Leishmania donovani		vetrazine	725568		
1.2.1.12	Camelus dromedarius		Zn2+	684127	19	
1.2.1.12	Pleurodeles waltl		ZnSO4	655270	404	20 mM, 70% inhibition
1.2.1.12	Xenopus laevis		ZnSO4	655270	404	20 mM, 50% inhibition
2.7.7.3	Rattus norvegicus	cysteine		643174	70	
2.7.7.3	Sus scrofa	cysteine		643174	70	activation, in vitro
2.7.7.3	Rattus norvegicus	cysteine		643176	70	requirement
2.7.7.3	Rattus norvegicus	deoxycholate		643176	369	stimulation at 0.01%, inactivation at 0.2%
2.7.7.3	Rattus norvegicus		3'-Dephospho-CoA	643180	1349	
2.7.7.3	Mycobacterium tuberculosis		adenosine-5'-[(alpha,beta)-methyleno]triphosphate	722971		
2.7.7.3	Escherichia coli		CoA	674344	10	
2.7.7.3	Arabidopsis thaliana		CoA	694729	10	
2.7.7.3	Mycobacterium tuberculosis		coenzyme A	721210	10	
2.7.7.3	Helicobacter pylori		coenzyme A	721491	10	feedback inhibition
2.7.7.3	Rattus norvegicus		deoxycholate	643176	369	inactivation at 0.2%, activation at 0.01%
2.7.7.3	Escherichia coli		dephospho-CoA	674344	1349	
2.7.7.3	Escherichia coli		diphosphate	674344	13	
2.7.7.3	Escherichia coli		more	674344		no inhibition is observed with AMPCPP, ATP-gamma-S, ADPPNP, or ADP at concentrations up to 1 mM and although no inhibition is observed with acetyl-CoA, desulfo-CoA, and palmitoyl-CoA at concentrations up to 500 mM
2.7.7.3	Enterococcus faecalis		pantetheine	723189	1632	potent inhibitor
2.7.7.3	Escherichia coli		phosphopantetheine	674344	966	
2.7.7.3	Escherichia coli		PTX040334	643184	21987	IC50: 0.03 mM
2.7.7.3	Sus scrofa		PTX040334	643184	21987	no inhibition
2.7.7.3	Escherichia coli		PTX042695	643184	21986	IC50: 0.000006 mM
2.7.7.3	Sus scrofa		PTX042695	643184	21986	no inhibition
1.5.1.5	Saccharomyces cerevisiae	2,3-Dimercaptopropanol		392313	1854	the most effective thiol
1.5.1.5	Saccharomyces cerevisiae	2-mercaptoethanol		392313	59	
1.5.1.5	Saccharomyces cerevisiae	cysteine		392313	70	
1.5.1.5	Saccharomyces cerevisiae	formaldehyde		392313	124	maximal activity at 0.3 mM
1.5.1.5	Saccharomyces cerevisiae	glutathione		392313	41	
1.5.1.5	Photobacterium phosphoreum	phosphate		209738	12	effect on the NAD+-dependent dehydrogenase activity
1.5.1.5	Leishmania major		(2S)-2-[[4-[(6aR)-3-amino-1,9-dioxo-5,6,6a,7-tetrahydro-4H-imidazol[3,4-f]pteridin-8-yl]benzoyl]amino]pentanedioate	700281	12669	
1.5.1.5	Leishmania major		(2S)-2-[[4-[(6aR)-3-amino-1,9-dioxo-5,6,6a,7-tetrahydro-4H-imidazol[3,4-f]pteridin-8-yl]benzoyl]amino]pentanedioic acid	700281	12669	5,10-formyltetrahydrofolate substrate analogue inhibits dehydrogenase activity
1.5.1.5	Leishmania major		(2S)-2-[[4-[(6aR)-3-amino-1,9-dioxo-5,6,6a,7-tetrahydro-4H-imidazo[3,4-f]pteridin-8-yl]benzoyl]amino]pentanedioic acid	700281		competitive substrate analogue
1.5.1.5	Pisum sativum		2,2'-dipyridyl	392326	317	
1.5.1.5	Leishmania major		2,4-diamino-6-(3,4-dichlorophenoxy)-quinazoline	700281	12628	
1.5.1.5	Leishmania major		2,4-diamino-6-benzyl-5-(3-phenylpropyl)-pyrimidine	700281	12629	
1.5.1.5	Escherichia coli		ATP	392307, 392308	7	
1.5.1.5	Clostridium cylindrosporum		ATP	392310	7	
1.5.1.5	Salmonella enterica subsp. enterica serovar Typhimurium		ATP	392312	7	
1.5.1.5	Saccharomyces cerevisiae		Borate	392313	1054	inhibition reversible by potassium
1.5.1.5	Saccharomyces cerevisiae		Ca2+	1505, 392313	18	
1.5.1.5	Bos taurus		Ca2+	392316	18	
1.5.1.5	Pisum sativum		dihydropteroylmonoglutamate	209737	1001	competitive inhibition
1.5.1.5	Pisum sativum		dihydropteroylpentaglutamate	209737	21680	competitive inhibition
1.5.1.5	Sus scrofa		folic acid	209726	1001	
1.5.1.5	Sus scrofa		folic acid	209727	1001	competitive against methylenetetrahydrofolate
1.5.1.5	Saccharomyces cerevisiae		formaldehyde	392313	124	50% inhibition at 2.5 mM
1.5.1.5	Bos taurus		formaldehyde	392316	124	above 0.4 mM
1.5.1.5	Escherichia coli		GTP	392307, 392308	35	
1.5.1.5	Salmonella enterica subsp. enterica serovar Typhimurium		GTP	392312	35	
1.5.1.5	Enterococcus faecium		Guanine	392306	179	48% inhibition
1.5.1.5	Pisum sativum		iodoacetate	392326	87	
1.5.1.5	Enterococcus faecium		Iodosobenzoate	392306	2732	
1.5.1.5	Salmonella enterica subsp. enterica serovar Typhimurium		ITP	392312	203	
1.5.1.5	Leishmania major		LY354899	720406		i.e. 5,6,7,8-tetrahydro N5,N10-carbonylfolic acid
1.5.1.5	Leishmania major		methotrexate	700281	213	
1.5.1.5	Enterococcus faecium		Mg2+	392306	25	inhibition of 5%
1.5.1.5	Saccharomyces cerevisiae		Mg2+	1505, 392313	25	
1.5.1.5	Bos taurus		Mg2+	392316	25	
1.5.1.5	Leishmania major		more	700281		no inhibition by pteridine analogues, such as methotrexate, or by hydrophobic diamino-quinazoline, -pyrimidine or -pteridine analogues, such as 2,4-diamino-6-(3,4-dichlorophenoxy)-quinazoline, or 2,4-diamino-6-benzyl-5-(3-phenylpropyl)-pyrimidine, or 2,4-diamino-6,7-diisopropylpteridine
1.5.1.5	Enterococcus faecium		N-ethylmaleimide	392306	46	
1.5.1.5	Bos taurus		N-ethylmaleimide	392316	46	
1.5.1.5	Escherichia coli		N10-formyltetrahydrofolate	392307, 392308	2297	
1.5.1.5	Sus scrofa		NAD+	209727	4	
1.5.1.5	Moorella thermoacetica		NAD+	392311	4	
1.5.1.5	Sus scrofa		NADPH	209726	5	against NADP+ and methylentetrahydrofolate
1.5.1.5	Sus scrofa		NADPH	209727	5	
1.5.1.5	Homo sapiens		NADPH	392331	5	
1.5.1.5	Pisum sativum		o-phenanthroline	392326	58	
1.5.1.5	Enterococcus faecium		p-chloromercuribenzoate	392306	40	
1.5.1.5	Saccharomyces cerevisiae		p-chloromercuribenzoate	392313	40	
1.5.1.5	Bos taurus		p-chloromercuribenzoate	392316	40	inhibition reversible by dimercaptopropanol
1.5.1.5	Bos taurus		phenacyl bromide	392316	70835	
1.5.1.5	Homo sapiens		phosphate	701402	12	competitive inhibitor against NADP+
1.5.1.5	Photobacterium phosphoreum		potassium phosphate	209738	1140	effect on NADP+-dependent dehydrogenase activity
1.5.1.5	Photobacterium phosphoreum		potassium sulfate	209738	1867	effect on NADP+-dependent dehydrogenase activity
1.5.1.5	Pisum sativum		pteroylglutamate	209737	1001	competitive inhibition
1.5.1.5	Pisum sativum		pteroylglutamates	209737	1001	
1.5.1.5	Sus scrofa		pteroylglutamates	392321	1001	containing 1 to 7 glutamyl residues
2.1.2.1	Corynebacterium glutamicum	5,6,7,8-tetrahydrofolate		671499	184	control of SHMT activity by the availability of 5,6,7,8-tetrahydrofolate
2.1.2.1	Escherichia coli	L-serine		718984	89	stabilizes the dimeric form of the enzyme
2.1.2.1	Macaca radiata	more		441403		in the presence of 1mM dithiothreitol + 1mM pyridoxal 5-phosphate + 20 mM EDTA: 29fold increase in the specific activity
2.1.2.1	Danio rerio	more		676954		higher concentrations of IPTG, increased induction temperature and/or prolonged induction time increase the ratio of insoluble and soluble SHMT-1
2.1.2.1	Homo sapiens	more		720054		recombinant dominant negative SHMT1, DN2-SHMT1, localizes with lamin B1 and enhances SHMT1 activity for de novo thymidylate biosynthesis
2.1.2.1	Corynebacterium glutamicum	pyridoxal 5'-phosphate		671499	30	
2.1.2.1	Homo sapiens	pyridoxal 5'-phosphate		671589	30	
2.1.2.1	Oryctolagus cuniculus	pyridoxal 5'-phosphate		671589	30	
2.1.2.1	Trichomonas vaginalis	pyridoxal phosphate		673412	30	
2.1.2.1	Oryctolagus cuniculus		1,10-phenanthroline	441401	58	
2.1.2.1	Hyphomicrobium methylovorum		1,10-phenanthroline	441410	58	
2.1.2.1	Plasmodium falciparum		1843U89	705603	25505	
2.1.2.1	Hyphomicrobium methylovorum		2,2'-dipyridyl	441410	317	
2.1.2.1	Euglena gracilis		2-aminoalanine	441409	32170	
2.1.2.1	Oryctolagus cuniculus		2-aminoisobutyrate	441400	1376	
2.1.2.1	Euglena gracilis		2-mercaptopropionic acid	441409	8256	
2.1.2.1	Saccharomyces cerevisiae		4-chloro-L-threonine	441427	3227	
2.1.2.1	Cricetulus griseus		4-chloro-L-threonine	441434	3227	
2.1.2.1	Escherichia coli		4-chloro-L-threonine	441427, 441434	3227	
2.1.2.1	Homo sapiens		4-chloro-L-threonine	441427, 441434	3227	
2.1.2.1	Neurospora crassa		4-chloro-L-threonine	441434	3227	
2.1.2.1	Oryctolagus cuniculus		4-chloro-L-threonine	441427, 441434	3227	
2.1.2.1	Ovis aries		4-chloro-L-threonine	441427, 441434	3227	
2.1.2.1	Pisum sativum		4-chloro-L-threonine	441427, 441434	3227	
2.1.2.1	Rattus norvegicus		4-chloro-L-threonine	441434	3227	
2.1.2.1	Vigna radiata		4-chloro-L-threonine	441434	3227	
2.1.2.1	Glycine max		5,10-methenyltetrahydrofolate	441407	825	
2.1.2.1	Glycine max		5,10-methylene-5,6,7,8-tetrahydrofolic acid	441407	2508	
2.1.2.1	Hyphomicrobium methylovorum		5,5-dithiobis(2-nitrobenzoic acid)	441410	196	
2.1.2.1	Escherichia coli		5,5-dithiobis(2-nitrobenzoic acid)	441412	196	
2.1.2.1	Arabidopsis thaliana		5-formyltetrahydrofolate	662384	1207	can inhibit SHMT in vivo and thereby influence glycine pool size, can accumulate glycine in both wild-type and 5-CHO-THF cycloligase mutant
2.1.2.1	Escherichia coli		5-formyltetrahydrofolate monoglutamate	441418	32280	
2.1.2.1	Oryctolagus cuniculus		5-formyltetrahydrofolate monoglutamate	441418	32280	
2.1.2.1	Glycine max		5-methyl-5,6,7,8-tetrahydrofolate	441407	1036	
2.1.2.1	Escherichia coli		5-methyltetrahydrofolate monoglutamate	441418	14207	
2.1.2.1	Oryctolagus cuniculus		5-methyltetrahydrofolate monoglutamate	441418	14207	
2.1.2.1	Escherichia coli		5-Methyltetrahydrofolate triglutamate	441418	20101	
2.1.2.1	Oryctolagus cuniculus		5-Methyltetrahydrofolate triglutamate	441418	20101	
2.1.2.1	Hyphomicrobium methylovorum		Ag+	441410	71	strong
2.1.2.1	Plasmodium falciparum		AG331	705603	54035	
2.1.2.1	Plasmodium falciparum		AG337	705603	5883	
2.1.2.1	Oryctolagus cuniculus		allothreonine	441400	2124	
2.1.2.1	Oryctolagus cuniculus		aminoisobutyrate	441400	23530	
2.1.2.1	Macaca radiata		aminopterin	441403	769	
2.1.2.1	Vigna radiata		aminopterin	441408	769	
2.1.2.1	Oryctolagus cuniculus		Antibodies to cytosolic enzyme	441394		
2.1.2.1	Oryctolagus cuniculus		Antibodies to mitochondrial enzyme	441394		no inhibition of cytosolic enzyme
2.1.2.1	Rattus norvegicus		beta-Alanine	441398	411	weak
2.1.2.1	Euglena gracilis		beta-Alanine	441437	411	
2.1.2.1	Rattus norvegicus		beta-Aminoalanine	441398	411	
2.1.2.1	Hyphomicrobium methylovorum		beta-chloroalanine	441411	1230	suicide substrate
2.1.2.1	Escherichia coli		beta-trifluoroallothreonine	441427		
2.1.2.1	Homo sapiens		beta-trifluoroallothreonine	441427		
2.1.2.1	Oryctolagus cuniculus		beta-trifluoroallothreonine	441427		
2.1.2.1	Pisum sativum		beta-trifluoroallothreonine	441427		
2.1.2.1	Saccharomyces cerevisiae		beta-trifluoroallothreonine	441427		
2.1.2.1	Escherichia coli		beta-trifluorothreonine	441427		
2.1.2.1	Homo sapiens		beta-trifluorothreonine	441427		
2.1.2.1	Oryctolagus cuniculus		beta-trifluorothreonine	441427		
2.1.2.1	Ovis aries		beta-trifluorothreonine	441427		
2.1.2.1	Pisum sativum		beta-trifluorothreonine	441427		
2.1.2.1	Saccharomyces cerevisiae		beta-trifluorothreonine	441427		
2.1.2.1	Oryctolagus cuniculus		Bromopyruvate	441402	1425	irreversible inactivation, substrates partially protect
2.1.2.1	Oryctolagus cuniculus		Bromopyruvate	441419	1425	only cytoplasmac not mitochondrial enzyme
2.1.2.1	Spinacia oleracea		carboxymethoxylamine	441391	1037	strong
2.1.2.1	Oryctolagus cuniculus		Chloroacetaldehyde	441402	1812	irreversible inactivation, substrates partially protect
2.1.2.1	Oryctolagus cuniculus		Chloroacetaldehyde	441419	1812	only cytoplasmic not mitochondrial enzyme
2.1.2.1	Ovis aries		Cibacron blue F3GA	441393	2974	complete inhibition, NAD(H) protects, reversible by tetrahydrofolate
2.1.2.1	Macaca radiata		Cibacron blue F3GA	441404	2974	reversible by dialysis
2.1.2.1	Hyphomicrobium methylovorum		Cu2+	441410	28	strong
2.1.2.1	Rattus norvegicus		D-alanine	441399	151	inactivates enzyme by converting the enzyme bound pyridoxal 5'-phosphate to pyridoxamine phosphate in a transamination reaction
2.1.2.1	Bos taurus		D-alanine	441420	151	
2.1.2.1	Cricetulus griseus		D-alanine	441420	151	
2.1.2.1	Oryctolagus cuniculus		D-alanine	441400, 441420	151	
2.1.2.1	Escherichia coli		D-alanine	441412, 441424	151	inactivates enzyme by converting the enzyme bound pyridoxal 5'-phosphate to pyridoxamine phosphate in a transamination reaction
2.1.2.1	Ovis aries		D-alanine	441420, 441425	151	
2.1.2.1	Bos taurus		D-beta-Fluoroalanine	441420	10524	
2.1.2.1	Cricetulus griseus		D-beta-Fluoroalanine	441420	10524	
2.1.2.1	Oryctolagus cuniculus		D-beta-Fluoroalanine	441420	10524	
2.1.2.1	Ovis aries		D-beta-Fluoroalanine	441420	10524	
2.1.2.1	Macaca radiata		D-cycloserine	441403	689	
2.1.2.1	Vigna radiata		D-cycloserine	441408	689	
2.1.2.1	Hyphomicrobium methylovorum		D-cycloserine	441410, 441411	689	
2.1.2.1	Ovis aries		D-cycloserine	441416	689	interaction extreme rapidly and irreversible
2.1.2.1	Bos taurus		D-cycloserine	441420	689	
2.1.2.1	Cricetulus griseus		D-cycloserine	441420	689	
2.1.2.1	Oryctolagus cuniculus		D-cycloserine	441420, 441427	689	
2.1.2.1	Ovis aries		D-cycloserine	441393, 441420, 441427	689	
2.1.2.1	Leishmania major		D-cycloserine	675874	689	overexpression of SHMT-S increases resistance in a rich folate containing medium
2.1.2.1	Plasmodium falciparum		D1694	705603	2263	
2.1.2.1	Macaca radiata		Dichloromethotrexate	441403	13346	
2.1.2.1	Vigna radiata		Dichloromethotrexate	441408	13346	
2.1.2.1	Macaca radiata		dihydrofolate	441403	173	
2.1.2.1	Oryctolagus cuniculus		DL-2-methylserine	441401	13575	
2.1.2.1	Vigna radiata		DL-2-methylserine	441408	13575	
2.1.2.1	Oryctolagus cuniculus		DL-allothreonine	441400	6158	
2.1.2.1	Vigna radiata		DL-O-Methylserine	441408	8447	
2.1.2.1	Oryctolagus cuniculus		EDTA	441401	223	weak
2.1.2.1	Oryctolagus cuniculus		Glycidaldehyde	441415	29375	directed to C1-binding-site
2.1.2.1	Oryctolagus cuniculus		Glycidaldehyde	441419	29375	only cytoplasmic enzyme
2.1.2.1	Rattus norvegicus		glycine	441398	68	
2.1.2.1	Oryctolagus cuniculus		glycine	441400	68	
2.1.2.1	Macaca radiata		glycine	441403	68	
2.1.2.1	Glycine max		glycine	441407	68	
2.1.2.1	Vigna radiata		glycine	441408	68	
2.1.2.1	Euglena gracilis		glycine	441409, 441437	68	
2.1.2.1	Plasmodium falciparum		glycine	705602	68	glycine inhibits His6-tagged SHMT competitively with respect to serine and non-competitively with respect to tetrahydrofolate
2.1.2.1	Plasmodium falciparum		GR1	705603	54034	
2.1.2.1	Leishmania donovani		guanidine hydrochloride	676982	804	86% loss of activity at 0.25 M
2.1.2.1	Hyphomicrobium methylovorum		Hg2+	441410	31	strong
2.1.2.1	Oryctolagus cuniculus		hydrazine	441401	552	
2.1.2.1	Oryctolagus cuniculus		iodoacetamide	441402	63	irreversible inactivation, substrates partially protect
2.1.2.1	Oryctolagus cuniculus		iodoacetamide	441419	63	only cytoplasmic not mitochondrial enzyme
2.1.2.1	Glycine max		KCl	441407	74	
2.1.2.1	Hyphomicrobium methylovorum		KCl	441410	74	
2.1.2.1	Hyphomicrobium methylovorum		KCN	441410	149	
2.1.2.1	Rattus norvegicus		L-alanine	441398	97	
2.1.2.1	Euglena gracilis		L-alanine	441409, 441437	97	
2.1.2.1	Euglena gracilis		L-alpha,beta-diaminopropionic acid	441437	6178	
2.1.2.1	Rattus norvegicus		L-amino acids	441398	2739	weak, e.g. L-aspartic acid, ornithine, lysine, methionine, phenylalanine, homoserine, threonine, 4-aminobutyric acid
2.1.2.1	Euglena gracilis		L-amino acids	441409, 441437	2739	
2.1.2.1	Oryctolagus cuniculus		L-cysteine	441394	70	
2.1.2.1	Rattus norvegicus		L-cysteine	441398	70	mitochondrial enzyme
2.1.2.1	Sulfolobus solfataricus		L-cysteine	441422	70	
2.1.2.1	Euglena gracilis		L-cysteine	441409, 441437	70	
2.1.2.1	Saccharomyces cerevisiae		L-methionine	441420	83	
2.1.2.1	Euglena gracilis		L-methionine	441437	83	not
2.1.2.1	Homo sapiens		L-mimosine	674506	2046	inhibits SHMT1 transcription by chelating zinc, eliminates the metal regulatory element- and Sp1-binding activity in nuclear extracts from MCF-7 cells, but not in nuclear extracts from the mimosine-resistant cell line, MCF-7/2a
2.1.2.1	Oryctolagus cuniculus		L-serine	441394	89	competitive to glycine
2.1.2.1	Rattus norvegicus		L-serine	441398	89	strong
2.1.2.1	Oryctolagus cuniculus		L-serine	441400	89	
2.1.2.1	Mus musculus		L-serine	441405	89	
2.1.2.1	Euglena gracilis		L-serine	441409, 441437	89	
2.1.2.1	Oryctolagus cuniculus		L-threonine	441400	220	
2.1.2.1	Danio rerio		leucovorin	686353	12430	leucovorin (N5-CHO-THF) exhibits a differential inhibition pattern: it significantly inhibits the aldol cleavage of serine catalyzed by zebrafish cytosolic SHMT but it inhibits to a lesser extent the reaction catalyzed by the mitochondrial isozyme. Approximately 70% and 30% inhibition are observed for zebrafish cytosolic- and zebrafish mitochondrial SHMT activities, respectively, in the presence of 70 mM leucovorin. An even larger difference between both isoenzymes is observed when the inhibition is assayed in the presence of 50 mM serine; leucovorin (N5-CHO-THF) exhibits a differential inhibition pattern: it significantly inhibits the aldol cleavage of serine catalyzed by zebrafish cytosolic SHMT but it inhibits to a lesser extent the reaction catalyzed by the mitochondrial isozyme. Approximately 70% and 30% inhibition are observed for zebrafish cytosolic- and zebrafish mitochondrial SHMT activities, respectively, in the presence of 70 mM leucovorin. An even larger difference between both isoenzymes is observed when the inhibition is assayed in the presence of 50 mM serine
2.1.2.1	Hyphomicrobium methylovorum		LiCl	441410	654	
2.1.2.1	Macaca radiata		methotrexate	441403	213	
2.1.2.1	Vigna radiata		methotrexate	441408	213	
2.1.2.1	Plasmodium falciparum		methotrexate	705603	213	
2.1.2.1	Escherichia coli		methyl methanethiosulfonate	441412	1724	
2.1.2.1	Bos taurus		methyl methanethiosulfonate	441420	1724	
2.1.2.1	Cricetulus griseus		methyl methanethiosulfonate	441420	1724	
2.1.2.1	Oryctolagus cuniculus		methyl methanethiosulfonate	441420	1724	
2.1.2.1	Ovis aries		methyl methanethiosulfonate	441420	1724	
2.1.2.1	Rattus norvegicus		more	441398		not: mercaptopropionic acid, mercaptoethanolamine; not: valine, leucine, glutamic acid, 3-hydroxybutyric acid
2.1.2.1	Oryctolagus cuniculus		more	441401		not: iodoacetate; not: NaN3, mono- or divalent cations, 2-mercaptoethanol, DTT; not: purine nucleoside mono-, di- and triphosphates
2.1.2.1	Oryctolagus cuniculus		more	441402		not: chloroacetamide; not: iodoacetate
2.1.2.1	Macaca radiata		more	441403		inhibition kinetics
2.1.2.1	Glycine max		more	441407		not: methionine, S-adenosyl-L-methionine, XMP, IMP, phosphoglycerate
2.1.2.1	Euglena gracilis		more	441409		not: ethanolamine, ethylenediamine; not: valine, leucine, glutamic acid, 3-hydroxybutyric acid
2.1.2.1	Hyphomicrobium methylovorum		more	441410		not: EDTA
2.1.2.1	Escherichia coli		more	441412		not: iodoacetate
2.1.2.1	Saccharomyces cerevisiae		more	441413		not: EDTA; not: purine nucleoside mono-, di- and triphosphates
2.1.2.1	Ovis aries		more	441416		inhibition kinetics
2.1.2.1	Escherichia coli		more	441418		
2.1.2.1	Oryctolagus cuniculus		more	441415, 441418		inhibition kinetics
2.1.2.1	Oryctolagus cuniculus		more	441419		not: N-/O-chloroacetyl and N-/O-bromoacetyl derivatives of glycine and L-serine
2.1.2.1	Euglena gracilis		more	441437		not: valine, leucine, glutamic acid, 3-hydroxybutyric acid
2.1.2.1	Homo sapiens		more	674993		prototypes with negative total charge have greater affinity for Plasmodium falciparum SHMT than for human SHMT
2.1.2.1	Plasmodium falciparum		more	674993		in order to act as selective ligands for the active site, the tails of the 5-formyl-6-hydrofolic acid analogues as potential selective inhibitors should be short to avoid the repulsive interactions with residues Lys138, Lys139 and Lys140 of the active site of SHMT, the tails may be longer, but in that case they must possess both negative and positive charges at the right positions, in order to explore their interactions with Lys138, Lys139, Lys140 and Glu137, prototypes with negative total charge have greater affinity for Plasmodium falciparum SHMT than for human SHMT
2.1.2.1	Arabidopsis thaliana		more	718775		model of uncompetitive substrate inhibition using tetrahydropteroylglutamates with different numbers of glutamate residues, overview
2.1.2.1	Oryctolagus cuniculus		N-ethylmaleimide	441401	46	
2.1.2.1	Glycine max		NaCl	441407	39	
2.1.2.1	Hyphomicrobium methylovorum		NaCl	441410	39	
2.1.2.1	Aphanothece halophytica		NaCl	719529	39	60% inhibition at 100 mM, restored to 66-71% activity in presence of 50 mM glycine betaine
2.1.2.1	Sulfolobus solfataricus		NaCNBH3	441422		
2.1.2.1	Ovis aries		NAD+	441393	4	negative effector
2.1.2.1	Hyphomicrobium methylovorum		NaF	441410	209	
2.1.2.1	Oryctolagus cuniculus		NH2OH	441401	80	weak
2.1.2.1	Hyphomicrobium methylovorum		NH2OH	441410	80	
2.1.2.1	Vigna radiata		O-phosphoserine	441408	899	
2.1.2.1	Hyphomicrobium methylovorum		Pb2+	441410	132	strong
2.1.2.1	Oryctolagus cuniculus		PCMB	441401	40	
2.1.2.1	Hyphomicrobium methylovorum		PCMB	441410	40	strong
2.1.2.1	Hyphomicrobium methylovorum		Penicillamine	441410	1829	
2.1.2.1	Plasmodium falciparum		permetrexed	705603	6905	
2.1.2.1	Hyphomicrobium methylovorum		phenylhydrazine	441410	333	partially reversible by pyridoxal 5'-phosphate
2.1.2.1	Plasmodium falciparum		pyrimethamine	705603	613	
2.1.2.1	Saccharomyces cerevisiae		S-adenosyl-L-methionine	441420	22	
2.1.2.1	Hyphomicrobium methylovorum		Semicarbazide	441410	322	
2.1.2.1	Hyphomicrobium methylovorum		Sodium borohydride	441410	507	
2.1.2.1	Escherichia coli		substituted hydroxylamine derivates	441427		
2.1.2.1	Homo sapiens		substituted hydroxylamine derivates	441427		
2.1.2.1	Oryctolagus cuniculus		substituted hydroxylamine derivates	441427		
2.1.2.1	Ovis aries		substituted hydroxylamine derivates	441427		
2.1.2.1	Pisum sativum		substituted hydroxylamine derivates	441427		
2.1.2.1	Saccharomyces cerevisiae		substituted hydroxylamine derivates	441427		
2.1.2.1	Escherichia coli		sulfonyl fluoride triazine derivates	441427	8781	
2.1.2.1	Homo sapiens		sulfonyl fluoride triazine derivates	441427	8781	
2.1.2.1	Oryctolagus cuniculus		sulfonyl fluoride triazine derivates	441427	8781	
2.1.2.1	Ovis aries		sulfonyl fluoride triazine derivates	441427	8781	
2.1.2.1	Pisum sativum		sulfonyl fluoride triazine derivates	441427	8781	
2.1.2.1	Saccharomyces cerevisiae		sulfonyl fluoride triazine derivates	441427	8781	
2.1.2.1	Leishmania donovani		tetrahydrofolate	676982	184	inhibitory at non-saturating concentration of serine, at concentrations above 1.5 mM
2.1.2.1	Methanosarcina barkeri		tetrahydrofolate	726831	184	at concentrations above 0.015 mM, substrate inhibition is observed
2.1.2.1	Macaca radiata		Tetrahydrofolate derivatives	441403		
2.1.2.1	Mus musculus		Tetrahydrofolate derivatives	441405		
2.1.2.1	Glycine max		Tetrahydrofolate derivatives	441407		
2.1.2.1	Bos taurus		Tetrahydrofolate derivatives	441420		
2.1.2.1	Cricetulus griseus		Tetrahydrofolate derivatives	441420		
2.1.2.1	Oryctolagus cuniculus		Tetrahydrofolate derivatives	441420		
2.1.2.1	Ovis aries		Tetrahydrofolate derivatives	441420		
2.1.2.1	Arabidopsis thaliana		tetrahydropteroylglutamate	718775	184	
2.1.2.1	Escherichia coli		Thiosemicarbazide	441427	2487	
2.1.2.1	Homo sapiens		Thiosemicarbazide	441427	2487	
2.1.2.1	Oryctolagus cuniculus		Thiosemicarbazide	441427	2487	
2.1.2.1	Pisum sativum		Thiosemicarbazide	441427	2487	
2.1.2.1	Saccharomyces cerevisiae		Thiosemicarbazide	441427	2487	
2.1.2.1	Leishmania major		Thiosemicarbazide	675874	2487	poorly active against promastigotes, but SHMT-S transfectants can provide a small but significant resistance
2.1.2.1	Leishmania donovani		Urea	676982	110	81% loss of activity at 1M
2.1.2.1	Escherichia coli		Urea	703674	110	in 1 M urea, almost all the cofactor is bound to the enzyme as internal aldimine, indicating that the loss of activity does not result from the denaturation of the active site, these observations suggest that urea might act as an enzyme inhibitor
2.1.2.1	Plasmodium falciparum		WR99210	705603	1910	
2.7.4.8	Mus musculus	more		642684		no activation by EDTA
2.7.4.8	Rattus norvegicus	more		642686		no activation by 1,4-dithiothreitol or 2-mercaptoethanol
2.7.4.8	Homo sapiens		5,5'-dithiobis(2-nitrobenzoate)	642688	196	
2.7.4.8	Rattus norvegicus		5,5'-dithiobis(2-nitrobenzoate)	642686, 642688	196	
2.7.4.8	Rattus norvegicus		6-Selenoguanosine 5'-phosphate	642695	63708	GMP-phosphorylation, pI 4.9-isozyme, competitive with respect to GMP
2.7.4.8	Rattus norvegicus		6-Thioguanosine 5'-phosphate	642686	20126	dGMP-phosphorylation; not thiodeoxyguanosine derivative
2.7.4.8	Rattus norvegicus		6-Thioguanosine 5'-phosphate	642695	20126	GMP-phosphorylation, pI 4.9-isozyme, competitive with respect to GMP
2.7.4.8	Rattus norvegicus		8-azaguanosine 5'-monophosphate	642686	10463	(d)GMP-phosphorylation
2.7.4.8	Rattus norvegicus		8-bromoguanosine 5'-monophosphate	642686	29072	(d)GMP-phosphorylation
2.7.4.8	Homo sapiens		9-(1,3-dihydroxy-2-propylmethyl)guanine 5'-monophosphate	642698	11162	
2.7.4.8	Homo sapiens		9-(2-hydroxyethoxymethyl)guanine 5'-monophosphate	642698	8513	
2.7.4.8	Sus scrofa		9-(6,6-difluoro-6-phosphonohexyl)guanine	642697		competitive with respect to GMP, non-competitive with respect to ATP
2.7.4.8	Sus scrofa		9-(6-phosphonohexyl)guanine	642697		competitive with respect to GMP, non-competitive with respect to ATP
2.7.4.8	Plasmodium falciparum		AMP	700079	9	10-15% inhibition at 5 mM
2.7.4.8	Escherichia coli		Ap5G	672440	24119	Ap5G locks an incompletely closed conformation of the enzyme, in which the adenine moiety is located outside its expected binding site. Instead, it binds at a subunit interface that is unique to the bacterial enzyme, which is in equilibrium between a dimeric and an hexameric form in solution.
2.7.4.8	Mus musculus		ATP	642684	7	
2.7.4.8	Helianthus tuberosus		ATP	642694	7	free form, substrate inhibition, competitive toward MgATP2-
2.7.4.8	Bos taurus		Ca2+	642561	18	in the presence of Mg2+
2.7.4.8	Plasmodium falciparum		CMP	700079	94	10-15% inhibition at 5 mM
2.7.4.8	Rattus norvegicus		Cs+	642686	478	strong
2.7.4.8	Plasmodium falciparum		dAMP	700079	575	10-15% inhibition at 5 mM
2.7.4.8	Plasmodium falciparum		dCMP	700079	376	10-15% inhibition at 5 mM
2.7.4.8	Bos taurus		dGMP	642685	587	competitive inhibitor to GMP
2.7.4.8	Plasmodium falciparum		dGMP	700079	587	competitive versus GMP and mixed-type versus ATP
2.7.4.8	Mus musculus		EDTA	642684	223	
2.7.4.8	Plasmodium falciparum		EDTA	700079	223	85% inhibition at 3 mM
2.7.4.8	Helianthus tuberosus		GDP	642694	49	GMP-phosphorylation
2.7.4.8	Saccharomyces cerevisiae		GDP	642701	49	
2.7.4.8	Bos taurus		GMP	642685	150	competitive inhibitor to dGMP
2.7.4.8	Saccharomyces cerevisiae		GMP	642701	150	non competitive with respect to MgATP2- because of the formation of an abortive complex guanylate kinase-MgATP2-GMP
2.7.4.8	Saccharomyces cerevisiae		GMP	642702	150	
2.7.4.8	Helianthus tuberosus		GTP	642694	35	GMP-phosphorylation
2.7.4.8	Rattus norvegicus		indol-3-acetic acid	642686	2122	GMP + ATP protect
2.7.4.8	Helianthus tuberosus		K+	642694	37	weak
2.7.4.8	Bos taurus		Li+	642685	142	
2.7.4.8	Rattus norvegicus		Li+	642685	142	
2.7.4.8	Rattus norvegicus		Li+	642686	142	strong
2.7.4.8	Saccharomyces cerevisiae		MgADP-	642701	639	
2.7.4.8	Saccharomyces cerevisiae		MgATP2-	642701, 642702	102	
2.7.4.8	Rattus norvegicus		more	642686		GMP-phosphorylation is less sensitive to metal ions than dGMP-phosphorylation; minimal inactivation by iodoacetate and iodoacetamide not affected by the presence or absence of KCl; no inhibition by 2-mercaptoethanol, 1,4-dithiothreitol
2.7.4.8	Homo sapiens		more	642688		no inhibition by 2-mercaptoethanol, 1,4-dithiothreitol; no inhibition by guanosine, AMP, CMP, UMP, XMP, 6-thioinosine 5'-phosphate
2.7.4.8	Rattus norvegicus		more	642688		no inhibition by 2-mercaptoethanol, 1,4-dithiothreitol; no inhibition by guanosine, AMP, CMP, UMP, XMP, 6-thioinosine 5'-phosphate
2.7.4.8	Sus scrofa		more	642688		no inhibition by 2-mercaptoethanol, 1,4-dithiothreitol; no inhibition by guanosine, AMP, CMP, UMP, XMP, 6-thioinosine 5'-phosphate
2.7.4.8	Helianthus tuberosus		more	642694		guanylic nucleotides strongly inhibit, compete with GMP
2.7.4.8	Sus scrofa		more	642697		no inhibition by 9-(5-phosphonopentyl)guanine (i.e. isosteric analogue of acyclovir 5'-monophosphate)
2.7.4.8	Plasmodium falciparum		more	700079		no inhibition by TMP and by 2-mercaptoethanol up to 5 mM
2.7.4.8	Homo sapiens		N-ethylmaleimide	642688	46	
2.7.4.8	Rattus norvegicus		N-ethylmaleimide	642686, 642688	46	
2.7.4.8	Homo sapiens		p-chloromercuribenzoic acid	642688	40	1,4-dithiothreitol reverses
2.7.4.8	Rattus norvegicus		p-chloromercuribenzoic acid	642688	40	1,4-dithiothreitol reverses
2.7.4.8	Sus scrofa		p-chloromercuribenzoic acid	642688	40	1,4-dithiothreitol reverses
2.7.4.8	Mus musculus		p-hydroxymercuribenzoate	642684	92	no effect at 0.25 mM, 30% activity at 2.5 mM
2.7.4.8	Homo sapiens		p-hydroxymercuribenzoate	642688	92	
2.7.4.8	Rattus norvegicus		p-hydroxymercuribenzoate	642686, 642688	92	
2.7.4.8	Helianthus tuberosus		phosphate	642694	12	weak
2.7.4.8	Plasmodium falciparum		UMP	700079	127	10-15% inhibition at 5 mM
2.7.2.11	Triticum aestivum	L-Pro		642205	215	at low temperatures the inhibition switches over into allosteric activation and the biosynthesis of proline is started
2.7.2.11	Saccharomyces cerevisiae	more		677691		GK activity requires gamma-glutamyl phosphate reductase
2.7.2.11	Spinacia oleracea	more		682460		significant increase of the glutamate kinase activity in the spinach biomass growing on sewage sludge treatment
2.7.2.11	Pseudomonas aeruginosa		5-oxo-L-Pro	642203	784	12 mM, 10% inhibition
2.7.2.11	Escherichia coli		5-oxoproline	681421	784	AAK domain has a crater on the beta sheet C-edge that hosts the active centre and binds 5-oxoproline
2.7.2.11	Escherichia coli		ADP	642200	8	
2.7.2.11	Pseudomonas aeruginosa		ADP	642203	8	
2.7.2.11	Thermotoga maritima		ADP	722207	8	
2.7.2.11	Spinacia oleracea		As2+	682460	88174	applied into soil strongly decreases activity by 87.7%
2.7.2.11	Pseudomonas aeruginosa		Cd2+	642203	48	0.1 mM, complete inhibition
2.7.2.11	Spinacia oleracea		Cd2+	682460	48	applied into soil strongly decreases activity
2.7.2.11	Spinacia oleracea		Cd2+	692057	48	increased content in soil decreases enzyme activity
2.7.2.11	Thermotoga maritima		cis-4-hydroxy-L-proline	722207	12151	
2.7.2.11	Pseudomonas aeruginosa		DL-3,4-Didehydroproline	642203	64435	9 mM, 50% inhibition
2.7.2.11	Pseudomonas aeruginosa		Hg2+	642203	31	0.1 mM, complete inhibition
2.7.2.11	Pseudomonas aeruginosa		iodoacetamide	642203	63	0.125 mM, 60% inhibition. Preincubation with 0.25 mM dithiothreitol for 5 min partially protects
2.7.2.11	Pseudomonas aeruginosa		L-azetidine-2-carboxylic acid	642203	5471	3 mM, 50% inhibition
2.7.2.11	Pseudomonas aeruginosa		L-methionine-DL-sulphoximine	642203	1989	competitive with L-glutamate
2.7.2.11	Pseudomonas aeruginosa		L-Orn	642203	172	12 mM, 10% inhibition
2.7.2.11	Pseudomonas aeruginosa		L-Pro	642203	215	enzyme from strain PAO1: 5 mM, 50% inhibition, complete inhibition at 30 mM, noncompetitive. Strain PAO 879, a proline-auxotroph mutant lacks a proline-inhibitable gamma-glutamyl kinase
2.7.2.11	Triticum aestivum		L-Pro	642205	215	IC50: 0.08 mM, at room temperature. At low temperatures the inhibition switches over into allosteric activation and the biosynthesis of proline is started
2.7.2.11	Triticum aestivum		L-Pro	642206	215	feedback-inhibition
2.7.2.11	Solanum lycopersicum		L-Pro	642208	215	
2.7.2.11	Bacillus subtilis		L-proline	673741	215	completely inhibits the activity of wild-type gamma-glutamyl kinase/gamma-glutamyl phosphate reductase at concentrations greater than 0.1mM, and inhibits it by 30% at 0.01mM
2.7.2.11	Saccharomyces cerevisiae		L-proline	677691	215	GK activity is subject to feedback inhibition by proline
2.7.2.11	Escherichia coli		L-proline	681421	215	AAK domain is responsible for inhibition
2.7.2.11	Spinacia oleracea		L-proline	682460	215	free proline decreases activity, allosteric regulation
2.7.2.11	Chlamydomonas reinhardtii		L-proline	722836	215	results indicate that the sensitivity of Chlamydomonas glutamte kinase to feedback inhibition by L-proline is much lower than that of similar microbial glutamte kinase
2.7.2.11	Escherichia coli		L-proline	679845, 722974	215	
2.7.2.11	Pseudomonas aeruginosa		L-Thioproline	642203	10694	12 mM, 10% inhibition
2.7.2.11	Thermotoga maritima		methyl L-proline	722207		
2.7.2.11	Pseudomonas aeruginosa		Mg2+	642203	25	above 20 mM
2.7.2.11	Pseudomonas aeruginosa		Mn2+	642203	26	above 20 mM
2.7.2.11	Saccharomyces cerevisiae		more	677691		no significant differences in growth between mutant yeast cells on SD agar medium with heat shock (50&deg;C, 3 to 5 h), ethanol (16 to20%), and sorbitol (2.0 to 2.5 M) stresses, although the proline-accumulating cells are more resistant to these stresses than cells expressing wild-type GK
2.7.2.11	Pseudomonas aeruginosa		NEM	642203	46	0.125 mM, complete inhibition. Preincubation with 0.25 mM dithiothreitol for 5 min partially protects
2.7.2.11	Pseudomonas aeruginosa		PCMB	642203	40	0.125 mM, complete inhibition. Preincubation with 0.25 mM dithiothreitol for 5 min partially protects
2.7.2.11	Pseudomonas aeruginosa		phosphate	642203	12	
2.7.2.11	Thermotoga maritima		trans-4-hydroxy-L-proline	722207	4507	
2.7.2.11	Spinacia oleracea		Zn2+	682460	19	applied into soil strongly decreases activity
2.7.2.11	Spinacia oleracea		Zn2+	692057	19	increased content in soil decreases enzyme activity
1.4.1.4	Aspergillus niger	3,5-pyrazoledicarboxylate		675825	41285	activates at lower 2-oxoglutarate concentration
1.4.1.4	Aspergillus niger	3,5-pyridinedicarboxylate		675825	13504	activates at lower 2-oxoglutarate concentration
1.4.1.4	Aeropyrum pernix K1	acetonitrile		391642	754	activates
1.4.1.4	Dictyostelium discoideum	ADP		391663	8	at 1 mM, 11% activation
1.4.1.4	Proteus inconstans	ADP		391680	8	at 0.3 mM 40% activation
1.4.1.4	Escherichia coli	AMP		391685	9	slight activation up to 1 mM
1.4.1.4	Salmonella enterica subsp. enterica serovar Typhimurium	AMP		391689	9	slight activation up to 1 mM
1.4.1.4	Proteus inconstans	ATP		391680	7	at 0.3 mM, 60% activation of reductive amination
1.4.1.4	Escherichia coli	ATP		391685	7	at 2 mM, 50% activation
1.4.1.4	Salmonella enterica subsp. enterica serovar Typhimurium	ATP		391689	7	at 0.8 M, 68% activation
1.4.1.4	Aspergillus terreus	ATP		700335	7	30% stimulation in the presence of 2 mM Mg2+
1.4.1.4	Thermococcus sp.	CaCl2		391661	193	at 5 mM, 135% activation, oxidative deamination
1.4.1.4	Synechocystis sp.	CaCl2		391673	193	at 20 mM, 25% and 108% activation of reductive amination and oxidative deamination respectively
1.4.1.4	Aspergillus niger	DL-2-hydroxyglutarate		675825	4350	activates at lower 2-oxoglutarate concentration
1.4.1.4	Aeropyrum pernix K1	ethanol		391642	65	activates up to 40% v/v
1.4.1.4	Trichomonas vaginalis	GDP		391669	49	at 1 mM five-fold Michaelis Menten constant of 2-oxoglutarate
1.4.1.4	Aspergillus terreus	GDP		700335	49	30% stimulation in the presence of 2 mM Mg2+
1.4.1.4	Aspergillus niger	Glutarate		675825	451	activates at lower 2-oxoglutarate concentration
1.4.1.4	Dictyostelium discoideum	GTP		391663	35	at 0.083 mM 22% activation
1.4.1.4	Aspergillus terreus	GTP		700335	35	30% stimulation in the presence of 2 mM Mg2+
1.4.1.4	Trichomonas vaginalis	IDP		391669	372	at 1 mM five-fold Michaelis Menten constant of 2-oxoglutarate
1.4.1.4	Aspergillus niger	Itaconate		675825	1466	activates even in the presence of 10 mM 2-oxoglutarate
1.4.1.4	Archaeoglobus fulgidus	K2HPO4		391640	1216	at 0.15 M three to fourfold stimulation of activity
1.4.1.4	Aeropyrum pernix K1	K2SO4		391644	1867	280-300% activity at 150-200 mM
1.4.1.4	Aeropyrum pernix K1	K3PO4		391644	1140	less effective than K2SO4 and Na3PO4
1.4.1.4	Aeropyrum pernix K1	KCl		391644	74	170-200% activity at 50-100 mM
1.4.1.4	Archaeoglobus fulgidus	KCl		391640, 391648	74	at 0.2 M three to fourfold stimulation of activity
1.4.1.4	Haloferax mediterranei	KCl		391650	74	optimal activity at 1-1.5 M
1.4.1.4	Pyrococcus furiosus	KCl		391660	74	at concentrations below 2 mM
1.4.1.4	Pyrococcus woesei	KCl		391660	74	at concentrations below 1 mM
1.4.1.4	Trypanosoma cruzi	KCl		391683	74	up to 50mM
1.4.1.4	Aeropyrum pernix K1	methanol		391642	78	activates
1.4.1.4	Thermococcus sp.	MgCl2		391661	176	at 5 mM, 104% activity, oxidative deamination
1.4.1.4	Thermococcus sp.	MnCl2		391661	262	at 5 mM, 250% activity, oxidative deamination
1.4.1.4	Lactococcus lactis	more		671447		exhibits 2.5-fold-higher GDH activity than cells are grown in milk, instead of glucose
1.4.1.4	Aeropyrum pernix K1	Na2SO4		391644	590	less effective than K2SO4 and Na3PO4
1.4.1.4	Aeropyrum pernix K1	Na3PO4		391644	2140	280-300% activity at 150-200 mM
1.4.1.4	Aeropyrum pernix K1	NaCl		391644	39	170-200% activity at 50-100 mM
1.4.1.4	Archaeoglobus fulgidus	NaCl		391640, 391648	39	at 0.2 M three to fourfold stimulation of activity
1.4.1.4	Haloferax mediterranei	NaCl		391650	39	optimal activity at 1-1.5 M
1.4.1.4	Trypanosoma cruzi	NaCl		391683	39	up to 50 mM
1.4.1.4	Aspergillus niger	oxalylglycine		675825	1691	activates at lower 2-oxoglutarate concentration
1.4.1.4	Saccharomyces cerevisiae	potassium phosphate		391684	1140	up to 0.1 M oxidative deamination
1.4.1.4	Escherichia coli	UTP		391675	61	activates up to 70%
1.4.1.4	Mycobacterium smegmatis	Zn2+		391679	19	activates up to 0.1 mM
1.4.1.4	Aspergillus niger		2,4-Pyridinedicarboxylate	675825	1196	
1.4.1.4	Aspergillus niger		2,4-Pyridinedicarboxylate	697654	1196	inhibits less efficiently
1.4.1.4	Aspergillus terreus		2,4-Pyridinedicarboxylate	700335	1196	weak inhibitor
1.4.1.4	Aspergillus niger		2-Methyleneglutarate	675825, 697654	2956	
1.4.1.4	Aspergillus terreus		2-Methyleneglutarate	700335	2956	weak inhibitor
1.4.1.4	Trichomonas vaginalis		2-oxoglutarate	391669	32	competitive inhibitor of the deamination
1.4.1.4	Aspergillus niger		2-oxoglutarate	675825	32	shows allosteric properties and a sigmoid response (nH=2.5) towards 2-oxoglutarate saturation
1.4.1.4	Pyrococcus furiosus		2-oxoglutarate	722160	32	substrate inhibition above 2.0 mM
1.4.1.4	Bacillus sp.		4-chloromercuribenzoate	391651	40	at 1 mM, 86% inhibition
1.4.1.4	Streptomyces fradiae		4-chloromercuribenzoate	391666	40	at 0.01 mM, 35% inhibition
1.4.1.4	Mycobacterium smegmatis		4-chloromercuribenzoate	391679	40	at 1 mM and 10 mM, 30% inhibition and 100% inhibition
1.4.1.4	Agaricus bisporus		ADP	391655	8	at 4 mM slight inhibitory
1.4.1.4	Streptomyces fradiae		ADP	391666	8	at 1 mM, 57% inhibition for oxidative deamination and 23% inhibition for reductive amination respectively
1.4.1.4	Proteus inconstans		ADP	391680	8	at 0.3 mM, 22% inhibition of oxidative deamination
1.4.1.4	Bacillus sp.		Ag2+	391651	798	at 1 mM, 60% inhibition
1.4.1.4	Klebsiella pneumoniae		AgNO3	656309	307	1 mM, 30&deg;C, complete loss of aminating activity
1.4.1.4	Pyrococcus furiosus		AlCl3	391660	1328	at 1 mM, 30% inhibition
1.4.1.4	Pyrococcus woesei		AlCl3	391660	1328	at 1 mM, 21% inhibition
1.4.1.4	Klebsiella pneumoniae		AlCl3	656309	1328	1 mM, 30&deg;C, 23% loss of aminating activity
1.4.1.4	Dictyostelium discoideum		AMP	391663	9	slight inhibitory
1.4.1.4	Streptomyces fradiae		AMP	391666	9	slight inhibitory
1.4.1.4	Proteus inconstans		AMP	391680	9	at 0.3 mM 33% inhibition of oxidative deamination
1.4.1.4	Escherichia coli		AMP	391685	9	inhibitory at higher concentrations than 1 mM
1.4.1.4	Agaricus bisporus		ATP	391655	7	at 4 mM slight inhibitory
1.4.1.4	Klebsiella pneumoniae		BaCl2	656309	968	1 mM, 30&deg;C, 15% loss of aminating activity
1.4.1.4	Plasmodium falciparum		Bithionol	725918	1974	; 
1.4.1.4	Escherichia coli		Ca2+	391662	18	at 1 mM 27% inhibition
1.4.1.4	Klebsiella pneumoniae		CaCl2	656309	193	1 mM, 30&deg;C, 11% loss of aminating activity
1.4.1.4	Klebsiella pneumoniae		CH2ICOOH	656309	87	1 mM, 30&deg;C, 15% loss of aminating activity
1.4.1.4	Aspergillus niger		dimethyl ester of isophthalic acid	697654	94419	dimethyl ester of isophthalate (DMIP), but not isophthalate, inhibits Aspergillus niger growth on agar as well as in liquid culture. This is ascribed to the inability of isophthalate to enter fungal mycelia. Dimethyl ester of isophthalic acid is hydrolysed intracellularly to isophthalate. Subsequent to DMIP addition, intracellular isophthalate can be demonstrated. Addition of NH4+ to DMIP-treated Aspergillus niger mycelia results in intensive vacuolation, retraction of cytoplasm and autolysis
1.4.1.4	Klebsiella pneumoniae		FeSO3(NH4)2SO4	656309	79850	1 mM, 30&deg;C, 14% loss of aminating activity
1.4.1.4	Bacillus fastidiosus		fumarate	391665	156	at 5 mM 20% inhibition
1.4.1.4	Nitrobacter hamburgensis		fumarate	391672	156	at 20 mM 30% inhibition
1.4.1.4	Trichomonas vaginalis		glutamate	391669	38	competitive inhibitor of the amination reaction
1.4.1.4	Phormidium laminosum		Glutaric acid	391668	451	at 20 mM, 25% inhibition
1.4.1.4	Nitrobacter hamburgensis		glyoxylate	391672	95	at 20 mM, 30% inhibition
1.4.1.4	Aeropyrum pernix K1		guanidine hydrochloride	391642	804	complete loss of activity
1.4.1.4	Escherichia coli		guanidine hydrochloride	391686	804	complete loss of activity
1.4.1.4	Plasmodium falciparum		GW5074	725918	10294	; 
1.4.1.4	Plasmodium falciparum		Hexachlorophene	725918	1545	15% inhibition at 0.016 mM; 80% inhibition at 0.016 mM
1.4.1.4	Bryopsis maxima		Hg2+	391649	31	at 1 mM, 100% activity loss
1.4.1.4	Bacillus sp.		Hg2+	391651	31	at 1 mM, 70% inhibition
1.4.1.4	Thermococcus profundus		Hg2+	391654	31	at 0.1 mM, complete activity loss
1.4.1.4	Mycobacterium smegmatis		Hg2+	391679	31	at 1 mM, 10% inhibition
1.4.1.4	Proteus inconstans		Hg2+	391680	31	at 1 mM, 100% activity loss
1.4.1.4	Pyrococcus furiosus		HgCl2	391660	104	at 1 mM, 64% inhibition
1.4.1.4	Pyrococcus woesei		HgCl2	391660	104	at 1 mM, 45% inhibition
1.4.1.4	Thermococcus sp.		HgCl2	391661	104	at 1 mM, no activity, oxidative deamination
1.4.1.4	Streptomyces fradiae		HgCl2	391666	104	at 0.01 mM, 27% inhibition
1.4.1.4	Klebsiella pneumoniae		HgCl2	656309	104	1 mM, 30&deg;C, 48% loss of aminating activity
1.4.1.4	Halobacterium salinarum		hydroxylamine	391664	80	competitive inhibitor with ammonia and uncompetitive inhibitor with both 2-oxoglutarate and NADPH
1.4.1.4	Proteus inconstans		iodoacetamide	391680	63	at 4 mM, complete inactivation
1.4.1.4	Aspergillus niger		Isophthalate	675825	2475	
1.4.1.4	Aspergillus niger		Isophthalate	697654	2475	potent in vitro inhibitor
1.4.1.4	Acinetobacter lwoffii		Isophthalate	700045	2475	
1.4.1.4	Pseudomonas aeruginosa		Isophthalate	700045	2475	
1.4.1.4	Aspergillus terreus		Isophthalate	700335	2475	weak inhibitor
1.4.1.4	Acinetobacter lwoffii		Isophthalate	712309	2475	a competitive inhibitor of glutamate dehydrogenase, is involved in C and N metabolism
1.4.1.4	Pseudomonas aeruginosa		Isophthalate	712309	2475	a competitive inhibitor of glutamate dehydrogenase, is involved in C and N metabolism
1.4.1.4	Benjaminiella poitrasii		Isophthalic acid	696792	2475	
1.4.1.4	Trypanosoma cruzi		KCl	391683	74	more than 50 mM
1.4.1.4	Debaryomyces hansenii		KCl	655305	74	500 mM, 80-90% inhibition, by high ionic strength
1.4.1.4	Thermococcus waiotapuensis		KCl	727455	74	1 M, 30% loss of activity
1.4.1.4	Pyrococcus furiosus		L-glutamate	722160	38	substrate inhibition above 15 mM
1.4.1.4	Phormidium laminosum		L-Glutamic acid	391668	38	at 20 mM 25% inhibition
1.4.1.4	Escherichia coli		L-homoserine	391686	294	competitive inhibitor with respect to both ammonia and glutamine
1.4.1.4	Phormidium laminosum		L-tryptophan	391668	113	at 20 mM, 15% inhibition
1.4.1.4	Bacillus fastidiosus		malate	391665	246	at 5 mM, 20% inhibition
1.4.1.4	Nitrobacter hamburgensis		malate	391672	246	at 20 mM, 30% inhibition
1.4.1.4	Bryopsis maxima		Mg2+	391649	25	at 1 mM, 16% activity loss
1.4.1.4	Bryopsis maxima		Mn2+	391649	26	at 1 mM, 19% activity loss
1.4.1.4	Pyrococcus furiosus		MnCl2	391660	262	at 1 mM, 63% inhibition
1.4.1.4	Pyrococcus woesei		MnCl2	391660	262	at 1 mM, 20% inhibition
1.4.1.4	Aspergillus niger		more	675825		not inhibited by D-glutamate, L-glutamine or DL-2-hydroxyglutarate
1.4.1.4	Escherichia coli		more	686805		2-oxoglutarate and NH3 show substrate inhibition
1.4.1.4	Pyrococcus furiosus		more	722160		no effect: EDTA, o-phenanthroline, sodium azide, 8-hydroxyquinoline in the concentration raneg of 1-10 mM
1.4.1.4	Plasmodium falciparum		more	725918		inhibitors hexachlorophene, GW5074, and bithionol are more effective on PfGDH2 than on PfGDH1; inhibitors hexachlorophene, GW5074, and bithionol are more effective on PfGDH2 than on PfGDH1
1.4.1.4	Proteus inconstans		N-ethylmaleimide	391680	46	at 0.8 mM, 44% inhibition
1.4.1.4	Trypanosoma cruzi		NaCl	391683	39	more than 50 mM
1.4.1.4	Debaryomyces hansenii		NaCl	655305	39	50 mM, 50% inhibition. 100 mM, about 60% inhibition. 500 mM, about 90% inhibition by high ionic strength
1.4.1.4	Aspergillus niger		NADP+	675825	6	inhibits at higher 2-oxoglutarate levels
1.4.1.4	Aspergillus niger		NH4+	675825	50	
1.4.1.4	Aspergillus terreus		NH4+	700335	50	inhibits the oxidative deamination activity as a product, inhibition is non-competitive with respect to L-glutamate
1.4.1.4	Klebsiella pneumoniae		nitrogen assimilation control protein	674258		represses the transcription of the gene gdhA
1.4.1.4	Archaeoglobus fulgidus		O2	391648	11	inactivation
1.4.1.4	Agaricus bisporus		oxaloacetate	391655	53	at 20 mM slight inhibitory
1.4.1.4	Nitrobacter hamburgensis		oxaloacetate	391672	53	at 20 mM, 60% inhibition
1.4.1.4	Proteus inconstans		p-Chloromercuriphenyl sulfonate	391680	1069	inactivetes, can be reversed by addition of cysteine
1.4.1.4	Dictyostelium discoideum		p-hydroxymercuribenzoic acid	391663	92	at 0.08 mM, 50% inhibition
1.4.1.4	Salmonella enterica subsp. enterica serovar Typhimurium		p-hydroxymercuribenzoic acid	391688	92	at 10 mM, 90% inhibition after 40 min
1.4.1.4	Pyrococcus furiosus		Pb(CH3COO)2	391660	2058	at 1 mM, 59% inhibition
1.4.1.4	Pyrococcus woesei		Pb(CH3COO)2	391660	2058	at 1 mM, 64% inhibition
1.4.1.4	Saccharomyces cerevisiae		potassium phosphate	391684	1140	over 0.1 M at oxidative deamination
1.4.1.4	Pyrococcus furiosus		pyridoxal 5'-phosphate	391660	30	at 1 mM, 35% inhibition
1.4.1.4	Pyrococcus woesei		pyridoxal 5'-phosphate	391660	30	at 1 mM, 45% inhibition
1.4.1.4	Escherichia coli		pyridoxal 5'-phosphate	391667	30	at 10 mM, 90% inhibition, complete protection when 16.8 mM 2-oxoglutarate and 1.68 mM NADP+ are added
1.4.1.4	Agaricus bisporus		pyruvate	391655	29	at 10 mM slight inhibitory
1.4.1.4	Salmonella enterica subsp. enterica serovar Typhimurium		sodium dodecylsulfate	391688	118	at 0.7% w/v after 1 h 5% activity
1.4.1.4	Halobacterium salinarum		succinate	391664	54	competitive inhibitor with 2 oxoglutarate, uncompetitive with NADPH and non-competitive with ammonia
1.4.1.4	Agaricus bisporus		Urea	391655	110	at 0&deg;C 1 h at 2 M 65% inhibition
1.4.1.4	Pyrococcus furiosus		Urea	391660	110	inactivation with 2 mM urea
1.4.1.4	Pyrococcus woesei		Urea	391660	110	fully active at 20&deg;C in 8 mM urea
1.4.1.4	Phormidium laminosum		Urea	391668	110	no activity at 6 mM
1.4.1.4	Escherichia coli		Urea	391685	110	at 8 M stable for 10 min
1.4.1.4	Bryopsis maxima		Zn2+	391649	19	at 1 mM, 64% activity loss
1.4.1.4	Escherichia coli		Zn2+	391662	19	at 1 mM, 40% inhibition
1.4.1.4	Mycobacterium smegmatis		Zn2+	391679	19	over 0.1 mM
2.4.2.14	Escherichia coli	Mg-phosphoribosyldiphosphate		489747		no glutamine-binding site in the absence of Mg-phosphoribosyldiphosphate
2.4.2.14	Homo sapiens	Mg-phosphoribosyldiphosphate		489752		
2.4.2.14	Glycine max	Mg-phosphoribosyldiphosphate		489760		requirement, phosphoribosyldiphosphate-Mg3- is the reactive molecular species of phosphoribosyldiphosphate, Km-value: 0.62 mM
2.4.2.14	Columba livia	more		489756		complex allosteric enzyme whose activity is regulated by a series of conformational changes induced by a number of ligands
2.4.2.14	Gallus gallus	more		489762		
2.4.2.14	Escherichia coli	phosphoribosyl-5-phosphate		489747	147	3-4fold activation of glutaminase activity in the presence of phosphate or diphosphate
2.4.2.14	Escherichia coli		1-alpha-diphosphoryl-2-alpha,3-alpha-dihydroxy-4-beta-cyclopentane-methanol-5-phosphate	489766	21880	competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate in wild-type and P410W mutant, competition for the amidotransferase C site
2.4.2.14	Escherichia coli		2-amino-4-oxo-5-chloropentanoate	489747	63007	approx. 80% inactivation of NH3-dependent activity after 30 min
2.4.2.14	Artemia sp.		5',5'-P1,P4-diguanosine tetraphosphate	489750	3582	IC50: 0.4 mM, 2 mM, approx. 80% inhibition
2.4.2.14	Escherichia coli		5'-p-fluorosulfonylbenzoyladenosine	489763	5401	inactivation follows pseudo-first order kinetic, AMP, GMP and 5-phospho-alpha-D-ribose 1-diphosphate protect
2.4.2.14	Escherichia coli		6-diazo-5-oxo-L-norleucine	489747	666	approx. 98% inactivation of amidotransferase activity after 30 min
2.4.2.14	Homo sapiens		6-diazo-5-oxo-L-norleucine	489758	666	competitive vs. glutamine, inactivation half-life: 11 min
2.4.2.14	Homo sapiens		6-iodopurine	489757	21303	5 mM, 39% inhibition
2.4.2.14	Homo sapiens		6-mercaptopurine ribonucleotide	489757	13256	5 mM, 64% inhibition
2.4.2.14	Arabidopsis thaliana		adenine nucleotide	694707	9	maximal inhibition by combination of adenine nucleotides (in total 10 mM), inhibitory effect of single nucleotides (5 mM) increases in the order AMP, ATP, ADP
2.4.2.14	Columba livia		ADP	489745	8	
2.4.2.14	Escherichia coli		ADP	489747	8	
2.4.2.14	Artemia sp.		ADP	489750	8	1 mM, approx. 95% inhibition
2.4.2.14	Homo sapiens		ADP	489757	8	5 mM, 40% inhibition
2.4.2.14	Bacillus subtilis		ADP	489769	8	50% inhibition of wild-type, S283A, K305Q, R307Q and S347A mutant enzyme at 4.7 mM, 24 mM, 31 mM, 28 mM and 8.1 mM respectively
2.4.2.14	Aquifex aeolicus		ADP	489772	8	4.1 mM, 50% inhibition
2.4.2.14	Homo sapiens		allopurinol ribonucleotide	489757	8324	5 mM, 68% inhibition
2.4.2.14	Columba livia		AMP	489745	9	
2.4.2.14	Rattus norvegicus		AMP	489745	9	
2.4.2.14	Escherichia coli		AMP	489747	9	approx. 10 mM, complete inhibition, sigmoidal inhibition curve, competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate, GMP and AMP together have a synergistic effect on inhibition
2.4.2.14	Artemia sp.		AMP	489750	9	1 mM, approx. 40% inhibition
2.4.2.14	Rattus norvegicus		AMP	489751	9	no inhibition in the presence of 5-phospho-alpha-D-ribose 1-diphosphate at high concentrations
2.4.2.14	Homo sapiens		AMP	489752	9	1.8 mM, 50% inhibition
2.4.2.14	Homo sapiens		AMP	489757	9	5 mM, 76% inhibition, noncompetive vs. glutamine
2.4.2.14	Homo sapiens		AMP	489758	9	5 mM, 79% and 24% inhibition of aminotransferase and amidotransferase activity at 1 mM 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.14	Glycine max		AMP	489760	9	competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.14	Schizosaccharomyces pombe		AMP	489761	9	2.7 mM and 1.2 mM, 50% inhibition of stable and unstable enzyme preparation respectively
2.4.2.14	Gallus gallus		AMP	489762	9	5 mM, 50% inhibition
2.4.2.14	Escherichia coli		AMP	489763	9	4.7 mM, 50% inhibition
2.4.2.14	Mus musculus		AMP	489768	9	competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate, noncompetitive vs. glutamine
2.4.2.14	Bacillus subtilis		AMP	489769	9	50% inhibition of wild-type, S283A, K305Q, R307Q and S347A mutant enzyme at 0.9 mM, 6.1 mM, 2.5 mM, 2.6 mM and 1.5 mM respectively
2.4.2.14	Aquifex aeolicus		AMP	489772	9	6.12 mM, 50% inhibition
2.4.2.14	Columba livia		ATP	489745	7	
2.4.2.14	Homo sapiens		ATP	489757	7	5 mM, 21% inhibition
2.4.2.14	Eremothecium gossypii		ATP	657611	7	10 mM, 10% residual activity
2.4.2.14	Homo sapiens		azaserine	489758	1381	competitive vs. glutamine, inactivation half-life: 12 min
2.4.2.14	Homo sapiens		CMP	489757	94	5 mM, 22% inhibition
2.4.2.14	Arabidopsis thaliana		DAS734	694707	8031	phenyltriazole acetic acid herbicide, [5-(4-chlorophenyl)-1-isopropyl-1H-[1,2,4]triazol-3-yl]-acetic acid, inhibits Arabidopsis root growth by 50% at 200 nM, phytotoxicity can be alleviated by addition of adenine, no inhibitory effect on Escherichia coli; phenyltriazole acetic acid herbicide, [5-(4-chlorophenyl)-1-isopropyl-1H-[1,2,4]triazol-3-yl]-acetic acid, non-competitive with respect to L-glutamine with slow, tight-binding behavior, inhibits Arabidopsis root growth by 50% at 200 nM, phytotoxicity can be alleviated by addition of adenine, no inhibitory effect on Escherichia coli
2.4.2.14	Homo sapiens		dCMP	489757	376	5 mM, 26% inhibition
2.4.2.14	Glycine max		diphosphate	489760	13	uncompetitive vs. 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.14	Columba livia		GDP	489745	49	
2.4.2.14	Escherichia coli		GDP	489747	49	
2.4.2.14	Artemia sp.		GDP	489750	49	1 mM, approx. 75% inhibition
2.4.2.14	Homo sapiens		GDP	489757	49	5 mM, 40% inhibition
2.4.2.14	Aquifex aeolicus		GDP	489772	49	8.5 mM, 50% inhibition
2.4.2.14	Glycine max		glutamate	489760	38	competitive vs. glutamate
2.4.2.14	Columba livia		GMP	489745	150	
2.4.2.14	Rattus norvegicus		GMP	489745	150	
2.4.2.14	Escherichia coli		GMP	489747	150	approx. 2.5 mM, complete inhibition, highly sigmoidal inhibition curve, competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate, GMP and AMP together have an synergistic effect on inhibition
2.4.2.14	Artemia sp.		GMP	489750	150	1 mM, approx. 60% inhibition
2.4.2.14	Rattus norvegicus		GMP	489751	150	no inhibition in the presence of 5-phospho-alpha-D-ribose 1-diphosphate at high concentrations
2.4.2.14	Homo sapiens		GMP	489752	150	0.5 mM; 50% inhibition
2.4.2.14	Homo sapiens		GMP	489757	150	0.5 mM; 5 mM, 70% inhibition
2.4.2.14	Homo sapiens		GMP	489758	150	0.5 mM; 5 mM, 56% and 12% inhibition of aminotransferase and amidotransferase activity at 1 mM 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.14	Glycine max		GMP	489760	150	
2.4.2.14	Schizosaccharomyces pombe		GMP	489761	150	0.44 mM and 0.25 mM, 50% inhibition of stable and unstable enzyme preparation respectively
2.4.2.14	Gallus gallus		GMP	489762	150	2 mM, 50% inhibition
2.4.2.14	Escherichia coli		GMP	489763	150	1.2-1.4 mM, 50% inhibition
2.4.2.14	Bacillus subtilis		GMP	489769	150	50% inhibition of wild-type, S283A, K305Q, R307Q and S347A mutant enzyme at 9.4 mM, 6.6 mM, 50 mM, 50 mM and 145 mM respectively
2.4.2.14	Aquifex aeolicus		GMP	489772	150	IC50: 7.9 mM
2.4.2.14	Escherichia coli		GTP	489747	35	5 mM, 79% inhibition
2.4.2.14	Homo sapiens		GTP	489757	35	5 mM, 13% inhibition
2.4.2.14	Eremothecium gossypii		GTP	657611	35	10 mM, 10% residual activity
2.4.2.14	Homo sapiens		IDP	489757	372	5 mM, 29% inhibition
2.4.2.14	Columba livia		IMP	489745	206	
2.4.2.14	Escherichia coli		IMP	489747	206	5 mM, 86% inhibition
2.4.2.14	Homo sapiens		IMP	489757	206	5 mM, 41% inhibition
2.4.2.14	Glycine max		IMP	489760	206	
2.4.2.14	Bacillus subtilis		IMP	489769	206	50% inhibition of wild-type and S347A mutant enzyme at 26 mM and 41 mM respectively
2.4.2.14	Escherichia coli		iodoacetamide	489747	63	approx. 60% inactivation of amidotransferase activity after 30 min, very weak inactivation of NH3-dependent activity
2.4.2.14	Homo sapiens		methyl-dCMP	489757	13241	5 mM, 47% inhibition
2.4.2.14	Columba livia		more	489745		not inhibited by ribose 5-phosphate, purine ribonucleosides or bases, 2'- or 3'-phosphate or deoxyribose phosphate analogues or by pyrimidine ribonucleotides
2.4.2.14	Escherichia coli		more	489763		synergistic inhibition of glutaminase activity by AMP plus GMP and N3-AMP plus GMP
2.4.2.14	Escherichia coli		more	489765		synergistic inhibition by AMP and GMP, binding of GMP to an allosteric i.e. A site and AMP to a proximal catalytic i. e. C site are necessary for synergistic inhibition
2.4.2.14	Bacillus subtilis		more	489769		strong synergistic inhibition with ADP and GMP
2.4.2.14	Arabidopsis thaliana		more	694707		minimal inhibition by inosine monophosphate (IMP) and guanosine monophosphate (GMP)
2.4.2.14	Escherichia coli		N3-AMP	489763	20138	1.2-1.4 mM, 50% inhibition, AMP and GMP protect
2.4.2.14	Homo sapiens		NH3	489758	16	inhibition of amidotransferase activity
2.4.2.14	Glycine max		NH4+	489760	50	competitive vs. glutamine
2.4.2.14	Homo sapiens		OMP	489757	65209	5 mM, 25% inhibition
2.4.2.14	Escherichia coli		p-mercuribenzoate	489747	554	0.001 mM, complete inhibition
2.4.2.14	Homo sapiens		phosphate	489757	12	competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.14	Gallus gallus		phosphate	489762	12	20 mM, 50% inhibition
2.4.2.14	Mus musculus		piritrexim	489768	3911	noncompetitive vs. 5-phospho-alpha-D-ribose 1-diphosphate, binds with positive cooperativity at 2 allosteric sites of an inactive dimer
2.4.2.14	Arabidopsis thaliana		purine nucleotide	694707		allosteric feedback inhibition by end products of the purine biosynthesis pathway, act on the PRPP domain
2.4.2.14	Homo sapiens		TMP	489757	518	5 mM, 42% inhibition
2.4.2.14	Homo sapiens		TTP	489757	137	5 mM, 12% inhibition
2.4.2.14	Homo sapiens		UDP	489757	24	5 mM, 19% inhibition
2.4.2.14	Homo sapiens		UMP	489757	127	5 mM, 25% inhibition
2.4.2.14	Homo sapiens		UTP	489757	61	5 mM, 16% inhibition
2.4.2.14	Homo sapiens		XDP	489757	2869	5 mM, 27% inhibition
2.4.2.14	Escherichia coli		XMP	489747	772	51% inhibition; 5 mM
2.4.2.14	Homo sapiens		XMP	489757	772	5 mM, 41% inhibition
2.4.2.14	Glycine max		XMP	489760	772	competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.14	Homo sapiens		XTP	489757	1442	5 mM, 44% inhibition
5.1.1.3	Lactobacillus fermentum	more		2054		
5.1.1.3	Lactobacillus plantarum	more		2054, 2097		not stimulated by the addition of pyridoxal 5'-phosphate
5.1.1.3	Lactobacillus brevis	more		2103		cofactor-independent enzyme
5.1.1.3	Lactobacillus fermentum	more		2104		cofactor-independent enzyme
5.1.1.3	Pediococcus pentosaceus	more		2078, 2107		pyridoxal phosphate-independent enzyme
5.1.1.3	Bacillus subtilis	more		2108		cofactor-independent enzyme
5.1.1.3	Aquifex pyrophilus	more		652768		the pressure does not affect catalysis after substrate binding
5.1.1.3	Enterococcus faecalis	more		676152		in contrast to Escherichia coli no activation by UDP-MurNAc-Ala, the product of the preceding enzyme in the peptidoglycan biosynthetic pathway
5.1.1.3	Enterococcus faecium	more		676152		in contrast to Escherichia coli no activation by UDP-MurNAc-Ala, the product of the preceding enzyme in the peptidoglycan biosynthetic pathway
5.1.1.3	Helicobacter pylori	more		676152		in contrast to Escherichia coli no activation by UDP-MurNAc-Ala, the product of the preceding enzyme in the peptidoglycan biosynthetic pathway
5.1.1.3	Staphylococcus aureus	more		676152		in contrast to Escherichia coli no activation by UDP-MurNAc-Ala, the product of the preceding enzyme in the peptidoglycan biosynthetic pathway
5.1.1.3	Escherichia coli	UDP-MurNAc-Ala		676152	86554	strong activation by UDP-MurNAc-Ala, the product of the preceding enzyme in the peptidoglycan biosynthetic pathway
5.1.1.3	Escherichia coli	UDP-N-acetylmuramyl-L-Ala		2102, 2113	3004	absolutely required
5.1.1.3	Escherichia coli	UDP-N-acetylmuramyl-L-Ala		2111, 2115	3004	activator
5.1.1.3	Streptococcus pneumoniae		(2R,4R)-2-amino-4-(2-benzo[b]furyl)methyl pentanedioic acid	652738	77362	IC50: 0.1 mg/l, minimum inhibitor concentration: 0.24 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4R)-2-amino-4-(2-benzo[b]thiazolyl)methyl pentanedioic acid	652738	77363	IC50: 0.38 mg/l, minimum inhibitor concentration: 0.24 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4R)-2-amino-4-(2-benzo[b]thienyl)methyl pentanedioic acid	652738	77360	IC50: 0.036 mg/l, minimum inhibitor concentration: 0.24 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4R)-2-amino-4-(2-indolyl)methyl pentanedioic acid	652738	77364	IC50: 9.8 mg/l, minimum inhibitor concentration: 62.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4R)-2-amino-4-(2-thienyl)methyl pentanedioic acid	652738	77366	IC50: 0.1 mg/l, minimum inhibitor concentration: above 1.0 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4R)-2-amino-4-[(3-chloro)-2-benzo[b]thienyl]methyl pentanedioic acid	652738	77365	IC50: 0.01 mg/l, minimum inhibitor concentration: 0.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(2-bromo)benzyl pentanedioic acid	652738	77332	IC50: 6.3 mg/l, minimum inhibitor concentration: 31.3 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(2-chloro)benzyl pentanedioic acid	652738	77331	IC50: 7.1 mg/l, minimum inhibitor concentration: 3.9 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(2-naphthyl)methyl pentanedioic acid	652738	8922	IC50: 0.1 mg/l, minimum inhibitor concentration: 0.25 mg/l
5.1.1.3	Bacillus anthracis		(2R,4S)-2-amino-4-(2-naphthyl)methyl pentanedioic acid	675451	8922	D-glutamate analog, good competitive inhibitor for RacE1; D-glutamate analog, only weak inhibitor of RacE2, but a potent competitive inhibitor for mutant V149A
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3,4,5-trimethoxy)benzyl pentanedioic acid	652738	77346	IC50: 81 mg/l, minimum inhibitor concentration: above 250 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3,5-dichloro)benzyl pentanedioic acid	652738	77345	IC50: 3.0 mg/l, minimum inhibitor concentration: 3.9 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3-benzo[b]thienyl)methyl pentanedioic acid	652738	77361	IC50: 1.7 mg/l, minimum inhibitor concentration: 7.8 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3-bromo)benzyl pentanedioic acid	652738	77334	IC50: 0.13 mg/l, minimum inhibitor concentration: 0.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3-chloro)benzyl pentanedioic acid	652738	77333	IC50: 3.4 mg/l, minimum inhibitor concentration: 1.0 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3-cyclohexyl)propyl pentanedioic acid	652738	77350	IC50: 0.6 mg/l, MIC: 2.0 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3-methoxy)benzyl pentanedioic acid	652738	77335	IC50: 0.2 mg/l, minimum inhibitor concentration: 0.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3-nitro)benzyl pentanedioic acid	652738	77336	IC50: 5.2 mg/l, minimum inhibitor concentration: 2.0 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3-phenyl)benzyl pentanedioic acid	652738	77337	IC50: 0.7 mg/l, minimum inhibitor concentration: 0.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3-phenyl)propargyl pentanedioic acid	652738	77352	IC50: 0.37 mg/l, minimum inhibitor concentration: 2.0 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3-phenyl)propyl pentanedioic acid	652738	77349	IC50: 0.5 mg/l, minimum inhibitor concentration: 3.9 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(3-trifluoromethyl)benzyl pentanedioic acid	652738	77338	IC50: 0.8 mg/l, minimum inhibitor concentration: 0.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(4-chloro)benzyl pentanedioic acid	652738	77339	IC50: 0.3 mg/l, minimum inhibitor concentration: 0.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(4-methoxy)benzyl pentanedioic acid	652738	77342	IC50: 0.1 mg/l, minimum inhibitor concentration: 0.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(4-nitro)benzyl pentanedioic acid	652738	77340	IC50: 5.2 mg/l, minimum inhibitor concentration: 2.0 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(4-phenyl)benzyl pentanedioic acid	652738	77343	IC50: 0.078 mg/l, minimum inhibitor concentration: 1.0 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(4-tert-butyl)benzyl pentanedioic acid	652738	77344	IC50: 0.6 mg/l, minimum inhibitor concentration: 1.0 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(4-trifluoromethyl)benzyl pentanedioic acid	652738	77341	IC50: 0.8 mg/l, minimum inhibitor concentration: 7.8 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(5-phenyl-2E,4E-pentadienyl)pentanedioic acid	652738	77348	IC50: 9.1 mg/l, minimum inhibitor concentration: 3.9 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-(prop-2-ynyl) pentanedioic acid	652738	77351	IC50: 5.5 mg/l, MIC: 31.3 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-[3-(2-benzo[b]thienyl)]benzyl pentanedioic acid	652738	77354	IC50: 0.3 mg/l, minimum inhibitor concentration: 0.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-[3-(2-furyl)]benzyl pentanedioic acid	652738	77353	IC50: 0.5 mg/l, minimum inhibitor concentration: 0.24 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-[4-(2-benzo[b]thienyl)]benzyl pentanedioic acid	652738	77356	IC50: 0.65 mg/l, minimum inhibitor concentration: 3.9 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-[4-(2-naphthyl)]benzyl pentanedioic acid	652738	77357	IC50: 0.42 mg/l, minimum inhibitor concentration: 7.8 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-[4-(3-thienyl)]benzyl pentanedioic acid	652738	77355	IC50: 0.32 mg/l, minimum inhibitor concentration: 0.24 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-[4-(n-benzenesulfonylamino)]benzyl pentanedioic acid	652738	77358	IC50: 10.2 mg/l, minimum inhibitor concentration: above 250 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S)-2-amino-4-[4-(N-phenylaminocarbonyl)amino]-benzyl pentanedioic acid	652738	77359	IC50: 0.49 mg/l, minimum inhibitor concentration: 15.6 mg/l
5.1.1.3	Streptococcus pneumoniae		(2R,4S,E)-2-amino-4-(3-phenylprop-2-enyl) pentanedioic acid	652738	12115	IC50: 0.1 mg/l, minimum inhibitor concentration: 0.4 mg/l
5.1.1.3	Bacillus anthracis		(2R,4S,E)-2-amino-4-(3-phenylprop-2-enyl)pentanedioic acid	675451	12115	D-glutamate analog, good competitive inhibitor for RacE1; D-glutamate analog, only weak inhibitor of RacE2, but a potent competitive inhibitor for mutant V149A
5.1.1.3	Streptococcus pneumoniae		(2R,4S,E)-2-amino-4-[3-(2-naphthyl)prop-2-enyl]pentanedioic acid	652738	77347	IC50: 0.5 mg/l, minimum inhibitor concentration: 0.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2S,4R)-2-amino-4-benzyl pentanedioic acid	652738	77329	IC50: 0.3 mg/l, minimum inhibitor concentration: 0.5 mg/l
5.1.1.3	Streptococcus pneumoniae		(2S,4S)-2-amino-4-(1-naphthyl)methyl pentanedioic acid	652738	77330	IC50: 5.6 mg/l, minimum inhibitor concentration: 3.9 mg/l
5.1.1.3	Bacillus anthracis		(4R,2S)-2-cinnamyl-4-amino-5-hydroxypentanoic acid	675451	12116	D-glutamate analog, good competitive inhibitor for RacE1; D-glutamate analog, only weak inhibitor of RacE2, but a potent competitive inhibitor for mutant V149A
5.1.1.3	Enterococcus faecalis		(R,S)-1-hydroxy-1-oxo-4-amino-4-carboxyphosphorinane	727152	110237	
5.1.1.3	Enterococcus faecalis		(R,S)-4-amino-4-carboxy-1,1-dioxotetrahydro-thiopyran	727152	110238	
5.1.1.3	Enterococcus faecalis		1,1-dioxo-tetrahydrothiopyran-4-one	727152	110249	
5.1.1.3	Enterococcus faecalis		1-hydroxyphosphinan-4-one 1-oxide	727152	110385	
5.1.1.3	Lactobacillus sp.		2-(2-Carboxyethyl)aziridine-2-carboxylic acid	2105	62970	i.e. aziridino-glutamate, inactivates glutamate racemase by alkylating an active site Cys residue
5.1.1.3	Enterococcus faecalis		2-(butylsulfanyl)-8-(4-fluorobenzyl)-4-(methylamino)-5,8-dihydropteridine-6,7-dione	691310	17064	comparison with effect on enzyme from Staphylococcus aureus
5.1.1.3	Staphylococcus aureus		2-(butylsulfanyl)-8-(4-fluorobenzyl)-4-(methylamino)-5,8-dihydropteridine-6,7-dione	691310	17064	comparison with effect on enzyme from Enterococcus faecalis
5.1.1.3	Enterococcus faecalis		2-(butylsulfanyl)-9-(2-methoxy-5-nitrobenzyl)-9H-purin-6-amine	691292	12485	comparison with effect on Enterococcus faecium and Staphylococcus aureus
5.1.1.3	Enterococcus faecium		2-(butylsulfanyl)-9-(2-methoxy-5-nitrobenzyl)-9H-purin-6-amine	691292	12485	comparison with effect on Enterococcus faecalis and Staphylococcus aureus
5.1.1.3	Helicobacter pylori		2-(butylsulfanyl)-9-(2-methoxy-5-nitrobenzyl)-9H-purin-6-amine	691296	12485	analysis of mouse and human internal clearance
5.1.1.3	Enterococcus faecalis		2-(butylsulfanyl)-9-(3-chloro-2,6-difluorobenzyl)-9H-purin-6-amine	691292	17065	comparison with effect on Enterococcus faecium and Staphylococcus aureus
5.1.1.3	Enterococcus faecium		2-(butylsulfanyl)-9-(3-chloro-2,6-difluorobenzyl)-9H-purin-6-amine	691292	17065	comparison with effect on Enterococcus faecalis and Staphylococcus aureus
5.1.1.3	Enterococcus faecalis		2-(butylsulfanyl)-9-(4-nitrophenyl)-9H-purin-6-amine	691310	9586	comparison with effect on enzyme from Staphylococcus aureus
5.1.1.3	Enterococcus faecium		2-(butylsulfanyl)-9-(4-nitrophenyl)-9H-purin-6-amine	691310	9586	comparison with effect on enzyme from Enterococcus faecalis and Staphylococcus aureus
5.1.1.3	Staphylococcus aureus		2-(butylsulfanyl)-9-(4-nitrophenyl)-9H-purin-6-amine	691310	9586	comparison with effect on enzyme from Enterococcus faecalis
5.1.1.3	Enterococcus faecalis		2-amino-4-phosphonobutanoic acid	727152	13355	
5.1.1.3	Enterococcus faecalis		2-butoxy-9-(3-chloro-2,6-difluorobenzyl)-N-(pyridin-3-ylmethyl)-9H-purin-6-amine	691292	9589	comparison with effect on Enterococcus faecium and Staphylococcus aureus
5.1.1.3	Enterococcus faecium		2-butoxy-9-(3-chloro-2,6-difluorobenzyl)-N-(pyridin-3-ylmethyl)-9H-purin-6-amine	691292	9589	comparison with effect on Enterococcus faecalis and Staphylococcus aureus
5.1.1.3	Helicobacter pylori		2-butoxy-9-(3-chloro-2,6-difluorobenzyl)-N-(pyridin-3-ylmethyl)-9H-purin-6-amine	691296	9589	
5.1.1.3	Bacillus subtilis		2-hydroxy-3,4,5-trioxocyclopent-1-en-1-olate	713607, 723810	19275	
5.1.1.3	Bacillus subtilis		2-nitro-5-thiocyanatobenzoate	2108	7067	0.2 mM
5.1.1.3	Pediococcus pentosaceus		2-Nitro-5-thiocyanobenzoate	2098	7067	
5.1.1.3	Pediococcus pentosaceus		2-Nitro-5-thiocyanobenzoate	2120	7067	complete inactivation at 0.1 mM
5.1.1.3	Helicobacter pylori		2-[(5-chloro-1-methyl-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	691296	47896	analysis of mouse and human internal clearance
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-5,7-bis(cyclopropylmethyl)-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110490	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-5-cyclopropyl-7-(cyclopropylmethyl)-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110491	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110492	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110493	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-3-(1-methyl-1H-imidazol-5-yl)-5-(pent-4-yn-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110494	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-3-(1-methyl-1H-imidazol-5-yl)-5-(prop-2-en-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110495	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-3-(1-methyl-1H-imidazol-5-yl)-5-(prop-2-yn-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110496	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-3-(1-methyl-1H-imidazol-5-yl)-5-(propan-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110497	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-3-(1-methyl-1H-imidazol-5-yl)-5-[4-(morpholin-4-yl)but-2-yn-1-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110498	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-(3-hydroxyprop-2-yn-1-yl)-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110499	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-ethyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110500	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-1,2,4-triazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110501	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144		
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110502	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-1H-pyrazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110503	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110504	
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	691296	47898	analysis of mouse and human internal clearance
5.1.1.3	Helicobacter pylori		2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	47898	
5.1.1.3	Helicobacter pylori		2-[2-[(6-chloroquinolin-4-yl)methyl]-5,7-bis(cyclopropylmethyl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-carbonitrile	727144	110513	
5.1.1.3	Helicobacter pylori		2-[2-[(6-chloroquinolin-4-yl)methyl]-5-cyclopropyl-7-(cyclopropylmethyl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-carbonitrile	727144	110514	
5.1.1.3	Helicobacter pylori		2-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-5-(prop-2-en-1-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-carbonitrile	727144	110515	
5.1.1.3	Helicobacter pylori		2-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-5-(prop-2-yn-1-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-carbonitrile	727144	110516	
5.1.1.3	Helicobacter pylori		2-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-ethyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-carbonitrile	727144	110517	
5.1.1.3	Helicobacter pylori		2-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-carbonitrile	727144		
5.1.1.3	Helicobacter pylori		3-(2-amino-4-methyl-1,3-thiazol-5-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110547	
5.1.1.3	Helicobacter pylori		3-(2-amino-5-methyl-1,3-thiazol-4-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110548	
5.1.1.3	Helicobacter pylori		3-(3-chlorothiophen-2-yl)-5-(furan-2-yl)-N-methyl-3H-pyrido[2,3-e][1,4]diazepin-2-amine	691326	47927	uncompetitive, inhibitor with improved solubility and reduced plasma protein binding, binds at the enzyme dimer interface
5.1.1.3	Helicobacter pylori		3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144		
5.1.1.3	Lactobacillus fermentum		3-hydroxypropyl FAD	2096	66973	
5.1.1.3	Bacillus subtilis		3-sulfobenzoic acid	704192	54772	structural analogue of dipicolinate dianion
5.1.1.3	Enterococcus faecalis		4-amino-2-(butylsulfanyl)-8-(2,6-difluorobenzyl)-5,8-dihydropteridine-6,7-dione	691310	17072	comparison with effect on enzyme from Staphylococcus aureus
5.1.1.3	Staphylococcus aureus		4-amino-2-(butylsulfanyl)-8-(2,6-difluorobenzyl)-5,8-dihydropteridine-6,7-dione	691310	17072	comparison with effect on enzyme from Enterococcus faecalis
5.1.1.3	Enterococcus faecalis		4-amino-2-(butylsulfanyl)-8-(3,4-dichlorobenzyl)-5,8-dihydropteridine-6,7-dione	691310	17073	comparison with effect on enzyme from Staphylococcus aureus
5.1.1.3	Staphylococcus aureus		4-amino-2-(butylsulfanyl)-8-(3,4-dichlorobenzyl)-5,8-dihydropteridine-6,7-dione	691310	17073	comparison with effect on enzyme from Enterococcus faecalis
5.1.1.3	Enterococcus faecalis		4-amino-2-(butylsulfanyl)-8-(4-fluorobenzyl)-5,8-dihydropteridine-6,7-dione	691310	17074	comparison with effect on enzyme from Staphylococcus aureus
5.1.1.3	Staphylococcus aureus		4-amino-2-(butylsulfanyl)-8-(4-fluorobenzyl)-5,8-dihydropteridine-6,7-dione	691310	17074	comparison with effect on enzyme from Enterococcus faecalis
5.1.1.3	Enterococcus faecalis		4-amino-8-benzyl-2-(benzylsulfanyl)-5,8-dihydropteridine-6,7-dione	691310	17075	comparison with effect on enzyme from Staphylococcus aureus
5.1.1.3	Staphylococcus aureus		4-amino-8-benzyl-2-(benzylsulfanyl)-5,8-dihydropteridine-6,7-dione	691310	17075	comparison with effect on enzyme from Enterococcus faecalis
5.1.1.3	Enterococcus faecalis		4-amino-8-benzyl-2-(butylsulfanyl)-5,8-dihydropteridine-6,7-dione	691310	17076	comparison with effect on enzyme from Staphylococcus aureus
5.1.1.3	Staphylococcus aureus		4-amino-8-benzyl-2-(butylsulfanyl)-5,8-dihydropteridine-6,7-dione	691310	17076	comparison with effect on enzyme from Enterococcus faecalis
5.1.1.3	Enterococcus faecalis		4-amino-8-benzyl-2-(cyclopentylsulfanyl)-5,8-dihydropteridine-6,7-dione	691310	17077	comparison with effect on enzyme from Staphylococcus aureus
5.1.1.3	Staphylococcus aureus		4-amino-8-benzyl-2-(cyclopentylsulfanyl)-5,8-dihydropteridine-6,7-dione	691310	17077	comparison with effect on enzyme from Enterococcus faecalis
5.1.1.3	Bacillus subtilis		4-chlorobenzene-1,2,3-triol	713607, 723810	113271	noncompetitive inhibition
5.1.1.3	Lactobacillus fermentum		4-Hydroxypropyl FAD	2096	66988	
5.1.1.3	Helicobacter pylori		4-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-methylfuran-2-carbonitrile	727144	110670	
5.1.1.3	Pediococcus pentosaceus		5,5'-dithiobis(2-nitrobenzoate)	2098	196	
5.1.1.3	Lactobacillus fermentum		5,5'-dithiobis(2-nitrobenzoate)	2104	196	
5.1.1.3	Helicobacter pylori		5-(but-2-yn-1-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	110711	
5.1.1.3	Helicobacter pylori		5-(furan-2-yl)-N-methyl-3-(thiophen-2-yl)-3H-pyrido[2,3-e][1,4]diazepin-2-amine	691326	48012	uncompetitive, inhibitor with improved solubility and reduced plasma protein binding, binds at the enzyme dimer interface
5.1.1.3	Helicobacter pylori		5-methyl-7-(2-methylpropyl)-2-(naphthalen-1-ylmethyl)-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	727144	40738	
5.1.1.3	Helicobacter pylori		5-methyl-7-(2-methylpropyl)-2-(naphthalen-1-ylmethyl)-3-pyridin-4-yl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	676152	40738	a pyrazolopyrimidinedione analogue identified by a high-throughput screen demonstrates inhibition with excellent selectivity for MurI of Helicobacter pylori, it is time-independent, fully-reversible and insensitive to changes in enzyme or detergent concentration
5.1.1.3	Helicobacter pylori		5-methyl-7-(2-methylpropyl)-2-(naphthalen-1-ylmethyl)-3-pyridin-4-yl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione	701737	40738	pyrazolopyrimidinedione inhibits growth of Helicobacter pylori specifically, inhibition of enzyme results in inhibition of peptidoglycan biosynthesis, minimum inhibitory concentration in wild-type strains SS1 and ARHp80 is 4 microg/ml
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloro-1,2-dihydroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	701737	96027	pyrazolopyrimidinedione inhibits growth of Helicobacter pylori specifically, inhibition of enzyme results in inhibition of peptidoglycan biosynthesis, minimum inhibitory concentration in wild-type strains SS1 and ARHp80 is 1 and 0.5 microg/ml
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-5,7-bis(cyclopropylmethyl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110734	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-5-(cyanomethyl)-7-(cyclopropylmethyl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110735	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-5-cyclopropyl-7-(cyclopropylmethyl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110736	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-5-methyl-7-(2-methylpropyl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110737	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-5-(prop-2-en-1-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110738	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-5-(prop-2-yn-1-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110739	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-5-(propan-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110740	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-5-[2-(1H-1,2,3-triazol-1-yl)ethyl]-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110741	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-5-[2-(1H-pyrazol-1-yl)ethyl]-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110742	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-5-[4-(1H-1,2,4-triazol-1-yl)but-2-yn-1-yl]-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110743	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-5-[4-(1H-pyrazol-1-yl)but-2-yn-1-yl]-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110744	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-(2-hydroxyethyl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110745	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-(4-hydroxybut-2-yn-1-yl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110746	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-ethyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110747	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	107485	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-4-methylfuran-2-carbonitrile	727144	110748	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-[4-(1H-imidazol-1-yl)but-2-yn-1-yl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110749	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-[4-(morpholin-4-yl)but-2-yn-1-yl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110750	
5.1.1.3	Helicobacter pylori		5-[2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-[5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl]-1H-pyrrole-3-sulfonamide	691296	49539	analysis of mouse and human internal clearance
5.1.1.3	Helicobacter pylori		5-[5-(but-2-yn-1-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110753	
5.1.1.3	Helicobacter pylori		5-[5-(but-3-yn-2-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile	727144	110754	
5.1.1.3	Helicobacter pylori		5-[7-(cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide	701737	96026	pyrazolopyrimidinedione inhibits growth of Helicobacter pylori specifically, inhibition of enzyme results in inhibition of peptidoglycan biosynthesis, minimum inhibitory concentration in wild-type strains SS1 and ARHp80 is 16 microg/ml
5.1.1.3	Helicobacter pylori		6-chloro-4-([7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl)isoquinoline-3-carbonitrile	701737	96025	pyrazolopyrimidinedione inhibits growth of Helicobacter pylori specifically, inhibition of enzyme results in inhibition of peptidoglycan biosynthesis, minimum inhibitory concentration in wild-type strains SS1 and ARHp80 is 16 and 8 microg/ml
5.1.1.3	Helicobacter pylori		6-chloro-4-[[3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-7-(cyclopropylmethyl)-4,6-dioxo-5-prop-2-yn-1-yl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl]isoquinoline-3-carbonitrile	701737	96024	pyrazolopyrimidinedione inhibits growth of Helicobacter pylori specifically, inhibition of enzyme results in inhibition of peptidoglycan biosynthesis, minimum inhibitory concentration in wild-type strains SS1 and ARHp80 is 2 and 1 microg/ml
5.1.1.3	Enterococcus faecalis		9-(2,6-difluoro-3-methylbenzyl)-2-[(1,1,1,2,2-pentafluoropentan-3-yl)oxy]-9H-purin-6-amine	691292	17080	comparison with effect on Enterococcus faecium and Staphylococcus aureus
5.1.1.3	Enterococcus faecium		9-(2,6-difluoro-3-methylbenzyl)-2-[(1,1,1,2,2-pentafluoropentan-3-yl)oxy]-9H-purin-6-amine	691292	17080	comparison with effect on Enterococcus faecalis and Staphylococcus aureus
5.1.1.3	Bacillus subtilis		benzene-1,3-disulfonate	713607, 723810	113196	
5.1.1.3	Enterococcus faecalis		bis(2-carboxyethyl)-phosphinic acid	727152	110869	
5.1.1.3	Aquifex pyrophilus		D-Gln	653305	1586	competitive
5.1.1.3	Helicobacter pylori		D-glutamate	676152	293	MurI of Helicobacter pylori is strongly inhibited by D-glutamate
5.1.1.3	Lactobacillus fermentum		D-N-Hydroxyglutamate	2099	66306	the compound acts as alternate substrate and is converted into 2-oxoglutarate and NH4+. Km: 0.057 mM, turnover number: 1080 min-1. An imine intermediate is likely the species causing the inhibition
5.1.1.3	Bacillus subtilis		dipicolinate dianion	704192	1090	DPA
5.1.1.3	Bacillus anthracis		dipicolinic acid	716017	1090	allosteric inhibitor of both Bacillus anthracis glutamate racemase isozymes which exhibits low micromolar inhibition with clear noncompetitive behavior
5.1.1.3	Helicobacter pylori		exiguaquinol	694524	25547	pentacyclic hydroquinone from Neopetrosia exigua, protein-ligand modeling
5.1.1.3	Lactobacillus fermentum		FAD	2054	14	and analogs
5.1.1.3	Lactobacillus fermentum		FAD	2096	14	
5.1.1.3	Lactobacillus fermentum		FMN	2054, 2096	52	
5.1.1.3	Streptococcus pyogenes		gamma-2-naphthylmethyl-D-glutamate	675453	86494	potent competitive inhibitor that induces a disorder in one of the loops near the active site
5.1.1.3	Pediococcus pentosaceus		Hemin	2106	45	
5.1.1.3	Lactobacillus fermentum		hydroxylamine	2054	80	different experimentators found inhibition or no inhibition
5.1.1.3	Lactobacillus fermentum		hydroxylamine	2096	80	
5.1.1.3	Lactobacillus plantarum		hydroxylamine	2054, 2095, 2097	80	
5.1.1.3	Pediococcus pentosaceus		hydroxylamine	2098	80	no inactivation
5.1.1.3	Pediococcus pentosaceus		iodoacetamide	2120	63	
5.1.1.3	Pediococcus pentosaceus		L-alpha-Aminohexanedioate	2120	1333	
5.1.1.3	Lactobacillus fermentum		L-N-Hydroxyglutamate	2099	66507	weak
5.1.1.3	Pediococcus pentosaceus		L-serine-O-sulfate	2100	3159	suicide substrate. The glutamate racemase catalyzes alpha,beta-elimination of L-serine O-sulfate to produce a pyruvate concomitantly with an irreversible inactivation of the enzyme
5.1.1.3	Pediococcus pentosaceus		more	2098		no inactivation by carbonyl reagents such as hydroxylamine and NaBH4
5.1.1.3	Lactobacillus brevis		more	2103		insensitive to carbonyl reagents such as hydroxylamine, phenylhydrazine, or NaBH4
5.1.1.3	Aquifex pyrophilus		more	652768		the pressure does not affect catalysis after substrate binding
5.1.1.3	Enterococcus faecalis		more	676152		in contrast to MurI of Helicobacter pylori no inhibition by D-glutamate
5.1.1.3	Enterococcus faecium		more	676152		in contrast to MurI of Helicobacter pylori no inhibition by D-glutamate
5.1.1.3	Escherichia coli		more	676152		in contrast to MurI of Helicobacter pylori no inhibition by D-glutamate
5.1.1.3	Staphylococcus aureus		more	676152		in contrast to MurI of Helicobacter pylori no inhibition by D-glutamate
5.1.1.3	Fusobacterium nucleatum subsp. nucleatum		more	701927		although Tris-HCl isthe buffer most commonly employed when assaying glutamate racemases from various microbial sources, FnGR is slightly inhibited in this buffer, kcat values are reduced 14% and 25% in the L-D and D-L reaction directions at pH 8.0, respectively relative to the corresponding values observed using the phosphate assay buffer
5.1.1.3	Helicobacter pylori		more	727144		design of inhibitors of glutamate racemase as selective antibacterial agents, incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailabilty, structure-activity relationships, MIC values with wild-type Helicobacter pylori strain 055 and mutant strain hefC-, overview. Substituents on the inhibitor scaffold are varied to optimize target potency, antibacterial activity, and in vivo pharmacokinetic stability
5.1.1.3	Enterococcus faecalis		more	727152		substrate-product analogue inhibitor synthesis and evaluation, overview
5.1.1.3	Helicobacter pylori		N,8-dimethyl-5-phenyl-3-(thiophen-2-yl)-3H-pyrido[2,3-e][1,4]diazepin-2-amine	691326	48155	uncompetitive, inhibitor with improved solubility and reduced plasma protein binding, binds at the enzyme dimer interface
5.1.1.3	Helicobacter pylori		N-methyl-3,5-di(thiophen-2-yl)-3H-pyrido[2,3-e][1,4]diazepin-2-amine	691326	48214	uncompetitive, inhibitor with improved solubility and reduced plasma protein binding, binds at the enzyme dimer interface
5.1.1.3	Helicobacter pylori		N-methyl-5-(1H-pyrrol-3-yl)-3-(thiophen-2-yl)-3H-pyrido[2,3-e][1,4]diazepin-2-amine	691326	48215	uncompetitive, inhibitor with improved solubility and reduced plasma protein binding, binds at the enzyme dimer interface
5.1.1.3	Helicobacter pylori		N-methyl-5-phenyl-3-(thiophen-2-yl)-3H-pyrido[2,3-e][1,4]diazepin-2-amine	691326	48216	uncompetitive, inhibitor with improved solubility and reduced plasma protein binding, binds at the enzyme dimer interface
5.1.1.3	Pediococcus pentosaceus		p-chloromercuribenzoate	2098	40	
5.1.1.3	Lactobacillus fermentum		riboflavin	2054	298	slight inhibition, restoration by FAD
5.1.1.3	Helicobacter pylori		tetracycline	701737	2065	inhibition of enzyme results in inhibition of peptidoglycan biosynthesis, minimum inhibitory concentration in wild-type strains SS1 and ARHp80 is 0.25 and 0.13 microg/ml
5.1.1.3	Pediococcus pentosaceus		Thiol-blocking reagents	2107		DL-Glu protects from inactivation
5.1.1.3	Pediococcus pentosaceus		Thiol-blocking reagents	2120		
5.1.1.3	Helicobacter pylori		[2-[(6-chloro-1,2-dihydroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-3-(1-methyl-1H-imidazol-5-yl)-4,6-dioxo-2,4,6,7-tetrahydro-5H-pyrazolo[3,4-d]pyrimidin-5-yl]acetonitrile	701737	96028	pyrazolopyrimidinedione inhibits growth of Helicobacter pylori specifically, inhibition of enzyme results in inhibition of peptidoglycan biosynthesis, minimum inhibitory concentration in wild-type strains SS1 and ARHp80 is 2 and 1 microg/ml
1.2.1.70	Arabidopsis thaliana	cycloheximide		694706	1283	
1.2.1.70	Prosthecochloris vibrioformis	glutamate-1-semialdehyde aminotransferase		674242		2.5fold activity in presence of glutamate-1-semialdehyde aminotransferase
1.2.1.70	Chlamydomonas reinhardtii	glutamate-1-semialdehyde aminotransferase		674450		2.5fold activity in presence of glutamate-1-semialdehyde aminotransferase
1.2.1.70	Acidithiobacillus ferrooxidans	heme		676889	45	under high heme requirement for respiration levels of GluTR increase
1.2.1.70	Arabidopsis thaliana	more		694706		is induced in photosynthetic tissues by oxidative stresses such as wounding
1.2.1.70	Arabidopsis thaliana	Ozone		694706	4893	induces expression in photosynthetic tissues
1.2.1.70	Arabidopsis thaliana	puromycin		694706	533	
1.2.1.70	Escherichia coli		1,10-phenanthroline	656104	58	5 mM, 25% inhibition
1.2.1.70	Escherichia coli		2,2'-dipyridyl	656104	317	5 mM, 20% inhibition
1.2.1.70	Arabidopsis thaliana		2,4-diphenyl-6-styryl-1-p-tolyl-pyridinium boron tetrafluoride	654329	36309	IC50: 0.01 mM
1.2.1.70	Arabidopsis thaliana		4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol	654329	721	IC50: 0.055 mM
1.2.1.70	Methanopyrus kandleri		5,5'-dithiobis(2-nitrobenzoic acid)	655972	196	1.0 mM, 90% inhibition
1.2.1.70	Escherichia coli		5,5'-dithiobis(2-nitrobenzoic acid)	656104	196	1 mM, 80% inhibition
1.2.1.70	Methanopyrus kandleri		5,5'-dithiobis-(2-nitrobenzoic acid)	654558	196	
1.2.1.70	Arabidopsis thaliana		5,6-dichloro-1,3-benzodioxol-2-one	654329	36308	IC50: 0.055 mM
1.2.1.70	Hordeum vulgare		Cd2+	655401	48	1 mM Cd(Ac)2, 92% inhibition
1.2.1.70	Hordeum vulgare		Co2+	655401	21	10 mM CoCl2, 78% inhibition
1.2.1.70	Escherichia coli		Co2+	656104	21	
1.2.1.70	Hordeum vulgare		Cu2+	655401	28	1 mM CuCl2, 84% inhibition
1.2.1.70	Escherichia coli		EDTA	656104	223	10 mM, 55% inhibition
1.2.1.70	Escherichia coli		EGTA	656104	157	10 mM, 35% inhibition
1.2.1.70	Hordeum vulgare		Fe2+	655401	23	5 mM FeSO4, 66% inhibition
1.2.1.70	Hordeum vulgare		Fe3+	655401	66	10 mM FeCl3, 80% inhibition
1.2.1.70	Hordeum vulgare		glutamate 1-semialdehyde	655401	3853	0.2 mM, 50% inhibition
1.2.1.70	Methanopyrus kandleri		glutamate-1-semialdehyde	655972	3853	1.0 mM, 50% inhibition
1.2.1.70	Methanopyrus kandleri		glutamycin	654558	23065	competitive
1.2.1.70	Methanopyrus kandleri		glutamycin	655972	23065	2.5 mM, 75% inhibition
1.2.1.70	Escherichia coli		glutamycin	656104	23065	3 mM, 90% inhibition
1.2.1.70	Hordeum vulgare		heme	655401	45	0.004 mM, 50% inhibition
1.2.1.70	Synechocystis sp.		heme	655964	45	0.05 mM, 50% inhibition
1.2.1.70	Methanopyrus kandleri		heme	655972	45	0.007 mM, 70% inhibition
1.2.1.70	Hordeum vulgare		heme	656936	45	0.002 mM, 63% inhibition of non-truncated enzyme
1.2.1.70	Chlamydomonas reinhardtii		heme	676535	45	80% inhibition at 0.005 mM
1.2.1.70	Acidithiobacillus ferrooxidans		heme	676889	45	when intracellular heme is in excess, the cells respond by a dramatic decrease of the level of GluTR
1.2.1.70	Hordeum vulgare		Hemin	657174	45	50% inhibition at 0.0015 mM
1.2.1.70	Methanopyrus kandleri		iodoacetamide	655972	63	0.01 mM, 30% inhibition, 0.1 mM, complete inhibition
1.2.1.70	Escherichia coli		iodoacetamide	656104	63	0.1 mM, complete inhibition
1.2.1.70	Methanopyrus kandleri		N-tosyl-L-phenylalaninechloromethyl ketone	655972	3579	0.1 mM, 90% inhibition, 1.0 mM, complete inhibition
1.2.1.70	Escherichia coli		Ni2+	656104	36	
1.2.1.70	Methanopyrus kandleri		PbCl2	655972	2059	0.1 mM, 60% inhibition, 1.0 mM, complete inhibition
1.2.1.70	Methanopyrus kandleri		PtCl4	655972	36432	0.1 mM, 55% inhibition, 1.0 mM, 90% inhibition
1.2.1.70	Escherichia coli		PtCl4	656104	36432	1 mM, 90% inhibition
1.2.1.70	Hordeum vulgare		Zn2+	655401	19	2.5 mM, ZnSO4, 94% inhibition
1.2.1.70	Methanopyrus kandleri		ZnCl2	655972	236	0.2 mM, 45% inhibition, 5.0 mM, 90% inhibition
6.1.1.17	Saccharomyces cerevisiae	Arc1p		658101		protein from Aspergillus fumigatus, Accession code Q4QTS4, mediates stimulation of tRNA glutamylation
6.1.1.17	Saccharomyces cerevisiae	Arc1p		671048		accessory protein Arc1p, structure of the interacting domains, crystals structure determination and analysis at 1.9 A resolution, phasing, model building, and refinement of Arc1p, unusual noncrystallographic symmetry in the structure of Arc1p, overview
6.1.1.17	Saccharomyces cerevisiae	Arc1p		676213		accessory protein Arc1p, SwissProt ID P46672
6.1.1.17	Saccharomyces cerevisiae	Arc1p-N		676213		residues 1-122 of Arc1p, recombinantly expressed, the GluRS-NArc1p-N complex represents an unusual mode of interaction
6.1.1.17	Escherichia coli	Bovine serum albumin		215		optimal activity at 0.25 mg/ml
6.1.1.17	Saccharomyces cerevisiae	Cytoplasmic protein Arc1p		207		forms a complex with glutamyl-tRNA synthetase, facilitates the delivery of tRNA molecules to the Arc1p-associated aminoacyl-tRNA synthetase
6.1.1.17	Plasmodium falciparum	Diphosphatase		727963		the addition of diphosphatase dramatically stimulates the reaction rate
6.1.1.17	Acidithiobacillus ferrooxidans	more		676889		under high heme requirement for respiration increased levels of GluRS occur
6.1.1.17	Thermus thermophilus	tRNA		677157	309	GluRS is one of the aminoacyl-tRNA synthetases that require the cognate tRNA for specific amino acid recognition and activation, tRNA serves as the enzyme activator in the first step, and as the substrate in the second step of aminoacylation, overview, On the other hand, the main chain of the glutamate is immature glutamate-binding site in the absence of tRNA
6.1.1.17	Helicobacter pylori		(1R,2R)-1-(4-methylsulfonylphenyl)-2-(L-methionylsulfone-amido)-1,3-propanediol	714451	59220	
6.1.1.17	Helicobacter pylori		(1R,2R)-1-(4-nitrophenyl)-2-(L-ethionyl-sulfoneamido)-1,3-propanediol	714451	59498	competitive inhibition with respect to Asp-tRNAAsn
6.1.1.17	Helicobacter pylori		(1R,2R)-1-phenyl-2-(L-methionyl-sulfone-amido)-1,3-propanediol	714451	59221	
6.1.1.17	Helicobacter pylori		(1R,2S)-1-(4-nitrophenyl)-2-(L-methionyl-sulfoneamido)-1,3-propanediol	714451	59222	
6.1.1.17	Helicobacter pylori		(1S,2R)-1-(4-nitrophenyl)-2-(L-methionyl-sulfoneamido)-1,3-propanediol	714451	59219	
6.1.1.17	Helicobacter pylori		(1S,2S)-1-(4-nitrophenyl)-2-(L-methionyl-sulfone-amido)-1,3-propanediol	714451	59223	
6.1.1.17	Escherichia coli		1,10-phenanthroline	210	58	ATP protects the enzyme against zinc removal
6.1.1.17	Escherichia coli		5'-O-(N'-(L-pyroglutamyl)-sulfamoyl)adenosine	659591	37224	weak
6.1.1.17	Escherichia coli		5'-O-(N-(L-glutamyl)-sulfamoyl)adenosine	659591	15237	potent competitive with respect to glutamic acid
6.1.1.17	Mus musculus		5'-O-(N-(L-glutamyl)-sulfamoyl)adenosine	659591	15237	potent competitive with respect to glutamic acid
6.1.1.17	Plasmodium falciparum		5'-O-[N-(Lglutamyl)sulfamoyl]adenosine	727963		competitive inhibitor with respect to L-glutamate
6.1.1.17	Acidithiobacillus ferrooxidans		amino levulinic acid	676889	1052	indirect inhibition, growth of Acidithiobacillus ferrooxidans in aminolevulic acid inhibits the activity of GluRS1, the reduced activity of GluRS1 is the result of an interaction of the enzyme with heme or any other intermediate tetrrapyrrole, amino levulic acid added to the reaction mixture has no effect in the activity of GluRSs
6.1.1.17	Helicobacter pylori		Chloramphenicol	714451	742	
6.1.1.17	Mycobacterium tuberculosis		diphosphate	703636	13	competitive to ATP and L-glutamate, uncompetitive to tRNAGlu
6.1.1.17	Plasmodium falciparum		diphosphate	727963	13	
6.1.1.17	Vigna radiata var. radiata		erythro-4-Hydroxy-DL-glutamic acid	214	66384	glutamate transfer to tRNA
6.1.1.17	Vigna radiata var. radiata		erythro-Methyl-L-glutamic acid	214		glutamate transfer to tRNA
6.1.1.17	Bacillus subtilis		gamma-Globulin	221		
6.1.1.17	Escherichia coli		Glu-AMS	672564	15237	
6.1.1.17	Escherichia coli		glutaminyl-beta-ketophosphonate-adenosine	672564	16129	i.e. Gln-KPA, competitive inhibition, non-cognate, binds at one site on the monomeric enzyme
6.1.1.17	Thermus thermophilus		glutamol-AMP	651000	8928	competitive inhibition
6.1.1.17	Mycobacterium tuberculosis		glutamol-AMP	703636	8928	noncompetitive to ATP and L-glutamate
6.1.1.17	Escherichia coli		glutamyl adenylate	650511	35644	
6.1.1.17	Escherichia coli		glutamyl cytidylate	650511	35647	weak inhibition
6.1.1.17	Escherichia coli		glutamyl dihydrocytidylate	650511	35648	very weak inhibition
6.1.1.17	Escherichia coli		glutamyl N6-benzoyladenylate	650511	35645	
6.1.1.17	Escherichia coli		glutamyl uridylate	650511	35646	very weak inhibition
6.1.1.17	Escherichia coli		glutamyl-beta-ketophosphonate-adenosine	672564	16128	i.e. Glu-KPA, selective, competitive inhibition of GluRS, binds at one site on the monomeric enzyme
6.1.1.17	Acidithiobacillus ferrooxidans		H2O2	714031	20	GluRS1 activity is reversibly inactivated upon oxidation by hydrogen peroxide, the enzyme loses 90% activity after 10 min at 0.3 mM H2O2. tRNAGlu is able to protect GluRS1 against oxidative inactivation by hemin plus hydrogen peroxide. GluRS1 is the main enzyme responsible for supplying Glu-tRNAGlu for heme biosynthesis. Partial recovery of the enzymatic activity by treatment with DTT or 2-mercaptoethanol
6.1.1.17	Chlamydomonas reinhardtii		heme	208	45	
6.1.1.17	Acidithiobacillus ferrooxidans		heme	676889	45	indirect mechanism, when intracellular heme is in excess, the cells respond by a dramatic decrease of GluRS activity, heme or any other precursor tetrapyrrole is the intracellular effector that triggers this regulatory mechanism
6.1.1.17	Acidithiobacillus ferrooxidans		Hemin	676889	45	recombinant GluRS1 enzyme is inhibited in vitro by hemin, but NADPH restores its activity, GluRS2 is also inhibited by hemin to a similar extent as GluRS1
6.1.1.17	Acidithiobacillus ferrooxidans		Hemin	714031	45	GluRS1 activity is reversibly inactivated upon oxidation by hemin. tRNAGlu is able to protect GluRS1 against oxidative inactivation by hemin plus hydrogen peroxide
6.1.1.17	Vigna radiata var. radiata		KCl	214	74	100 mM, 15% inhibition of ATP-diphosphate exchange, 500 mM, 62% inhibition
6.1.1.17	Thermus thermophilus		KCl	225	74	aminoacylation
6.1.1.17	Vigna radiata var. radiata		LiCl	214	654	100 mM, 22% inhibition of ATP-diphosphate exchange, 500 mM, 73% inhibition
6.1.1.17	Streptococcus pneumoniae		more	675229		rGtS and anti-rGtS antiserum significantly inhibits the adhesion of 3 pairs of encapsulated and unencapsulated strains of Streptococcus pneumoniae to human epithelial A549 cells
6.1.1.17	Escherichia coli		more	677107		ERS aminoacylation of tRNAGlu is inhibited by the tRNA fragments, RNA-protein interactions, ERS binding of minihelixGlu and fragments ASLGlu and ASLGlu-s2U34, overview
6.1.1.17	Escherichia coli		N6-Benzoyl-L-glutamyl AMP	201	65141	specific for glutamyl-tRNA synthetase, does not inhibit glutaminyl-tRNA synthetase
6.1.1.17	Vigna radiata var. radiata		NaCl	214	39	100 mM, 40% inhibition of ATP-diphosphate exchange, 500 mM, 91% inhibition
6.1.1.17	Vigna radiata var. radiata		NH4Cl	214	282	100 mM, 31% inhibition of ATP-diphosphate exchange, 500 mM, 82% inhibition of ATP-diphosphate exchange
6.1.1.17	Escherichia coli		p-hydroxymercuribenzoate	216	92	
6.1.1.17	Caesalpinia bondue		threo-4-Hydroxy-L-glutamic acid	214	30462	glutamate transfer to tRNA
6.1.1.17	Vigna radiata var. radiata		threo-4-Hydroxy-L-glutamic acid	214	30462	glutamate transfer to tRNA
6.1.1.17	Caesalpinia bondue		threo-4-Methyl-D-glutamic acid	214	30463	glutamate transfer to tRNA
6.1.1.17	Vigna radiata var. radiata		threo-4-Methyl-D-glutamic acid	214	30463	glutamate transfer to tRNA
2.7.1.30	Bos taurus	1,3-butanediol		641299	1576	activates
2.7.1.30	Bos taurus	1,3-Propanediol		641299	2097	activates
2.7.1.30	Bos taurus	1,4-Butanediol		641299	3108	activates
2.7.1.30	Bos taurus	1-butanol		641299	456	activates
2.7.1.30	Bos taurus	1-Chloro-2-propanol		641299	19891	activates
2.7.1.30	Bos taurus	1-propanol		641299	536	activates
2.7.1.30	Candida mycoderma	1-propanol		641304	536	inhibits
2.7.1.30	Bos taurus	2,3-Butanediol		641299	1484	activates
2.7.1.30	Bos taurus	2-butanol		641299	857	activates
2.7.1.30	Bos taurus	2-Chloroethanol		641299	4347	activates
2.7.1.30	Bos taurus	2-methyl-1-propanol		641299	2384	activates
2.7.1.30	Bos taurus	2-Methyl-2-propanol		641299	1647	activates
2.7.1.30	Bos taurus	2-Pentanol		641299	1710	activates
2.7.1.30	Bos taurus	2-propanol		641299	551	activates
2.7.1.30	Candida mycoderma	2-propanol		641304	551	inhibits
2.7.1.30	Bos taurus	3-methyl-1-butanol		641299	2556	activates
2.7.1.30	Bos taurus	Cyclohexanol		641299	688	activates
2.7.1.30	Bos taurus	Ethanediol methyl ether		641299	10401	activates
2.7.1.30	Bos taurus	ethanol		641299	65	activates
2.7.1.30	Bos taurus	methanol		641299	78	activates
2.7.1.30	Rattus norvegicus	rosiglitazone		681755	2423	rosiglitazone treatment markebly increases glycerol kinase mRNA expression in both the mesenteric and epididymal adipose tissues (1085.9% and 523.8% of the abundance in Long-Evans Tokushima Otsuka rats, respectively). The magnitude of glycerol kinase induced by rosiglitazone is significantly greater in the mesenteric fat than in the epididymal fat.
2.7.1.30	Debaryomyces hansenii		(NH4)2SO4	641307	334	
2.7.1.30	Bos taurus		1,2-Propanediol	641299	679	
2.7.1.30	Bos taurus		1-Pentanol	641299	874	
2.7.1.30	Bos taurus		3-Chloro-1,2-propanediol	641299	10417	
2.7.1.30	Candida mycoderma		3-Deoxy-sn-glycerol	641304	7338	
2.7.1.30	Rattus norvegicus		ADP	641287	8	
2.7.1.30	Trypanosoma brucei		ADP	641288	8	weak, competitive to ATP, uncompetitive to glycerol
2.7.1.30	Culex quinquefasciatus		ADP	641291	8	
2.7.1.30	Gallus gallus		ADP	641287, 641292	8	
2.7.1.30	Escherichia coli		ADP	641287, 641294	8	
2.7.1.30	Debaryomyces hansenii		ADP	641307	8	product inhibition
2.7.1.30	Pediococcus pentosaceus		ADP	641323	8	
2.7.1.30	Saccharomyces cerevisiae		AMP	641287	9	
2.7.1.30	Culex quinquefasciatus		AMP	641291	9	
2.7.1.30	Debaryomyces hansenii		AMP	641307	9	
2.7.1.30	Escherichia coli		ATP	722712	7	substrate inhibition
2.7.1.30	Candida mycoderma		Butane-1,3-diol	641304	1576	D- and L-configuration
2.7.1.30	Candida mycoderma		CrATP	641305	13749	coordination complex of Cr3+ and ATP, dead-end inhibitor
2.7.1.30	Escherichia coli		cytosolic subunit of the glucose-specific phosphotransferase system	722712		allosteric inhibition
2.7.1.30	Escherichia coli		D-fructose 1,6-bisphosphate	701931	100	
2.7.1.30	Escherichia coli		D-fructose-1,6-bisphosphate	722712	100	allosteric inhibition
2.7.1.30	Escherichia coli		DTNB	641298	196	inactivation reversed by dithiothreitol
2.7.1.30	Candida mycoderma		Erythritol	641304	1717	
2.7.1.30	Bos taurus		Ethanediol	641299	1064	
2.7.1.30	Candida mycoderma		Ethanediol	641304	1064	
2.7.1.30	Candida mycoderma		ethanol	641304	65	
2.7.1.30	Enterococcus casseliflavus		fructose 1,6-bisphosphate	661122	100	
2.7.1.30	Escherichia coli		fructose 1,6-bisphosphate	661122	100	
2.7.1.30	Candida mycoderma		fructose 1,6-diphosphate	641287	100	not
2.7.1.30	Microsporum gypseum		fructose 1,6-diphosphate	641289	100	
2.7.1.30	Epidermophyton floccosum		fructose 1,6-diphosphate	641290	100	not
2.7.1.30	Debaryomyces hansenii		fructose 1,6-diphosphate	641307	100	weak inhibition
2.7.1.30	Neurospora crassa		fructose 1,6-diphosphate	641287, 641308	100	not
2.7.1.30	Escherichia coli		fructose 1,6-diphosphate	641287, 641294, 641295, 641309	100	
2.7.1.30	Geobacillus stearothermophilus		fructose 1,6-diphosphate	641309	100	
2.7.1.30	Escherichia coli		fructose 1,6-diphosphate	641311	100	normal enzyme is inhibited, genetically altered enzyme not, inhibition is reduced by high pH, high ionic strength or 0.2 M guanidine HCl
2.7.1.30	Haemophilus influenzae		fructose 1,6-diphosphate	641321	100	inhibition is associated with oligomerization
2.7.1.30	Escherichia coli		fructose 1,6-diphosphate	641326	100	mechanism
2.7.1.30	Epidermophyton floccosum		glucose	641289	33	not
2.7.1.30	Microsporum gypseum		glucose	641289	33	not
2.7.1.30	Epidermophyton floccosum		glucose	641290	33	
2.7.1.30	Gallus gallus		glucose	641292	33	
2.7.1.30	Avena sativa		glucose	641296	33	not
2.7.1.30	Cucumis sativus		glucose	641296	33	not
2.7.1.30	Phaseolus vulgaris		glucose	641296	33	not
2.7.1.30	Pisum sativum		glucose	641296	33	not
2.7.1.30	Vicia faba		glucose	641296	33	not
2.7.1.30	Vigna radiata var. radiata		glucose	641296	33	not
2.7.1.30	Zea mays		glucose	641296	33	not
2.7.1.30	Microsporum gypseum		glucose 6-phosphate	641289	99	
2.7.1.30	Epidermophyton floccosum		glucose 6-phosphate	641290	99	not
2.7.1.30	Avena sativa		glucose 6-phosphate	641296	99	not
2.7.1.30	Cucumis sativus		glucose 6-phosphate	641296	99	not
2.7.1.30	Phaseolus vulgaris		glucose 6-phosphate	641296	99	not
2.7.1.30	Pisum sativum		glucose 6-phosphate	641296	99	not
2.7.1.30	Vicia faba		glucose 6-phosphate	641296	99	not
2.7.1.30	Vigna radiata var. radiata		glucose 6-phosphate	641296	99	not
2.7.1.30	Zea mays		glucose 6-phosphate	641296	99	not
2.7.1.30	Escherichia coli		glucose-specific phosphocarrier protein of the phosphoenolpyruvate:glucose phosphotransferase system	701931		
2.7.1.30	Escherichia coli		glucose-specific phosphocarrier protein of the phosphoenolpyruvate:glucose phosphotransferase system (IIA(Glc))	701908		allosteric inhibitor
2.7.1.30	Trypanosoma brucei		glycerol	723070	129	inhibitor of the glycerol kinase reverse reaction
2.7.1.30	Trypanosoma congolense		glycerol	723070	129	inhibitor of the glycerol kinase reverse reaction
2.7.1.30	Trypanosoma vivax		glycerol	723070	129	inhibitor of the glycerol kinase reverse reaction
2.7.1.30	Bacillus subtilis		glycerol 3-phosphate	641287	352	
2.7.1.30	Bombus sp.		glycerol 3-phosphate	641287	352	
2.7.1.30	Bos taurus		glycerol 3-phosphate	641287	352	
2.7.1.30	Candida mycoderma		glycerol 3-phosphate	641287	352	
2.7.1.30	Cavia porcellus		glycerol 3-phosphate	641287	352	
2.7.1.30	Clostridium novyi		glycerol 3-phosphate	641287	352	
2.7.1.30	Columba sp.		glycerol 3-phosphate	641287	352	
2.7.1.30	Cyberlindnera jadinii		glycerol 3-phosphate	641287	352	
2.7.1.30	Enterobacter aerogenes		glycerol 3-phosphate	641287	352	
2.7.1.30	Enterococcus faecalis		glycerol 3-phosphate	641287	352	
2.7.1.30	Escherichia coli		glycerol 3-phosphate	641287	352	
2.7.1.30	Felis catus		glycerol 3-phosphate	641287	352	
2.7.1.30	Geotrichum candidum		glycerol 3-phosphate	641287	352	
2.7.1.30	Gluconobacter oxydans		glycerol 3-phosphate	641287	352	
2.7.1.30	Halobacterium salinarum		glycerol 3-phosphate	641287	352	
2.7.1.30	Homo sapiens		glycerol 3-phosphate	641287	352	
2.7.1.30	Locusta sp.		glycerol 3-phosphate	641287	352	
2.7.1.30	Mesocricetus auratus		glycerol 3-phosphate	641287	352	
2.7.1.30	Mus musculus		glycerol 3-phosphate	641287	352	
2.7.1.30	Mycobacterium butyricum		glycerol 3-phosphate	641287	352	
2.7.1.30	Mycobacterium smegmatis		glycerol 3-phosphate	641287	352	
2.7.1.30	Mycobacterium sp.		glycerol 3-phosphate	641287	352	
2.7.1.30	Mycobacterium tuberculosis		glycerol 3-phosphate	641287	352	
2.7.1.30	Neurospora crassa		glycerol 3-phosphate	641287	352	
2.7.1.30	Nocardia asteroides		glycerol 3-phosphate	641287	352	
2.7.1.30	Oryctolagus cuniculus		glycerol 3-phosphate	641287	352	
2.7.1.30	Pseudomonas aeruginosa		glycerol 3-phosphate	641287	352	
2.7.1.30	Rattus norvegicus		glycerol 3-phosphate	641287	352	competitive to glycerol
2.7.1.30	Saccharomyces cerevisiae		glycerol 3-phosphate	641287	352	
2.7.1.30	Shigella sonnei		glycerol 3-phosphate	641287	352	
2.7.1.30	Staphylococcus aureus		glycerol 3-phosphate	641287	352	
2.7.1.30	trout		glycerol 3-phosphate	641287	352	
2.7.1.30	Wickerhamomyces anomalus		glycerol 3-phosphate	641287	352	
2.7.1.30	Trypanosoma brucei		glycerol 3-phosphate	641288	352	up to 10 mM, no product inhibition of the forward reaction
2.7.1.30	Epidermophyton floccosum		glycerol 3-phosphate	641290	352	
2.7.1.30	Cucumis sativus		glycerol 3-phosphate	641296	352	not
2.7.1.30	Pediococcus pentosaceus		glycerol 3-phosphate	641323	352	competitive to glycerol
2.7.1.30	Thermus thermophilus		HgCl2	641325	104	
2.7.1.30	Candida mycoderma		iodoacetamide	641286, 641287	63	
2.7.1.30	Rattus norvegicus		iodoacetamide	641287	63	
2.7.1.30	Escherichia coli		iodoacetate	641287	87	
2.7.1.30	Candida mycoderma		L(+)-Butane-2,3-diol	641304	2874	
2.7.1.30	Escherichia coli		L-alpha-glycerophosphate	641295	2845	no inhibition up to 3 mM in presence of 0.1 M glycerol
2.7.1.30	Candida mycoderma		L-Threitol	641304	3817	
2.7.1.30	Thermus thermophilus		Mn2+	641325	26	
2.7.1.30	Haemophilus influenzae		more	641321		not: IIAGlc
2.7.1.30	Escherichia coli		more	661122		regulation of activity by allosteric inhibition through complex formation with enzyme IIAGlc
2.7.1.30	Plasmodium falciparum		more	705779		not regulated by fructose-1,6-bisphosphate
2.7.1.30	Rattus norvegicus		N-ethylmaleimide	641287	46	
2.7.1.30	Culex quinquefasciatus		N-ethylmaleimide	641291	46	
2.7.1.30	Escherichia coli		N-ethylmaleimide	641287, 641297	46	
2.7.1.30	Escherichia coli		N-ethylmaleimide	641298	46	protection by: glycerol propane-1,2-diol, ATP, ADP, AMP, cAMP, no protection by: Mg2+, fructose 1,6-bisphosphate, propane-1,3-diol
2.7.1.30	Debaryomyces hansenii		Na2SO4	641307	590	
2.7.1.30	Debaryomyces hansenii		NaCl	641307	39	
2.7.1.30	Candida mycoderma		p-chloromercuribenzoate	641286, 641287	40	
2.7.1.30	Rattus norvegicus		p-chloromercuribenzoate	641287	40	
2.7.1.30	Culex quinquefasciatus		p-chloromercuribenzoate	641291	40	glutathione protects
2.7.1.30	Thermus thermophilus		p-chloromercuribenzoate	641325	40	
2.7.1.30	Escherichia coli		p-Hydroxymercuriphenylsulfonate	641287, 641294	3353	
2.7.1.30	Escherichia coli		phosphocarrier protein IIAGlc	685101		the unphosphorylated form of the phosphocarrier protein IIAGlc is an allosteric inhibitor of Escherichia coli glycerol kinase
2.7.1.30	Geobacillus stearothermophilus		Procion Blue MX-3G	641301	66716	5 mM, inactivates after a period of increased activity
2.7.1.30	Bos taurus		propan-1-ol	641299	536	activates
2.7.1.30	Candida mycoderma		propan-1-ol	641304	536	
2.7.1.30	Bos taurus		propan-2-ol	641299	551	activates
2.7.1.30	Candida mycoderma		propan-2-ol	641304	551	
2.7.1.30	Candida mycoderma		Salyrganic acid	641286	65470	
6.3.5.2	Mus musculus	DTT		1359, 1363	42	stimulates
6.3.5.2	Escherichia coli	more		1380		the total number of sulfhydryl groups is approximately 22 per dimer
6.3.5.2	Pyrococcus horikoshii	more		705173		all substrates of PH-ATPPase, Mg2+, ATP and XMP, except for ammonia, are required to stabilize the active complex of PH-ATPPase and PH-GATase subunits
6.3.5.2	Rattus norvegicus	reduced sulfhydryl compounds		1354	752	e.g. dithiothreitol, required
6.3.5.2	Escherichia coli		(5R)-acivicin	650087	35674	
6.3.5.2	Escherichia coli		(alpha-S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid	650087	35673	trivial name acivicin
6.3.5.2	Escherichia coli		1,N6-Ethenoadenosine	1362	17043	
6.3.5.2	Mus musculus		1,N6-Ethenoadenosine 5'-triphosphate	1359	8238	
6.3.5.2	Escherichia coli		1-methyladenosine	1362	7054	
6.3.5.2	Escherichia coli		1-Ribosyl-4,6-dihydroxypyrazolo[3,4-d]-pyrimidine 5'-phosphate	1364	28614	
6.3.5.2	Escherichia coli		1-Ribosyl-4-hydroxy-6-aminopyrazolo[3,4-d]pyrimidine 5'-phosphate	1364	29068	
6.3.5.2	Escherichia coli		2'-deoxyadenosine	1362	304	
6.3.5.2	Escherichia coli		2,6-Diaminopurine ribonucleoside	1362	8830	
6.3.5.2	Escherichia coli		2-Amino-6-methylthiopurine ribonucleoside	1362	63011	
6.3.5.2	Homo sapiens		2-chloroadenosine	1372	2807	
6.3.5.2	Escherichia coli		2-fluoroadenosine	1362	3754	
6.3.5.2	Escherichia coli		2-fluoroinosine 5'-monophosphate	649891	21290	50% inhibition above 2 mM
6.3.5.2	Mus musculus		2-mercaptoethanol	1359, 1363	59	
6.3.5.2	Homo sapiens		3'-dAMP	1372	4353	
6.3.5.2	Escherichia coli		3'-deoxyadenosine	1362	1579	
6.3.5.2	Escherichia coli		5'-Azido-5'-deoxyadenosine	1362	63541	
6.3.5.2	Mus musculus		5'-deoxyadenosine	1361	734	
6.3.5.2	Homo sapiens		5'-deoxyadenosine	1372	734	
6.3.5.2	Escherichia coli		5'-Thioethyl-5'-deoxyadenosine	1362	3126	
6.3.5.2	Escherichia coli		6-Amino-9-D-psicofuranosylpurine	1360	13251	i.e. psicofuranine, irreversible inhibition, dependent on presence of XMP and diphosphate
6.3.5.2	Homo sapiens		6-Amino-9-D-psicofuranosylpurine	1372, 1374	13251	
6.3.5.2	Bacillus subtilis		6-Amino-9-D-psicofuranosylpurine	1379	13251	strong inhibition of wild type enzyme, mutant enzyme GP-1 with decreased inhibition, complete loss of inhibition of mutant enzyme MG-1
6.3.5.2	Escherichia coli		6-Chloropurine ribonucleoside	1362	4379	
6.3.5.2	Escherichia coli		6-diazo-5-oxo-L-norleucine	1365	666	irreversible inhibition is dependent on presence of XMP, ATP and Mg2+
6.3.5.2	Escherichia coli		6-diazo-5-oxo-L-norleucine	1380	666	irreversible inhibition of Gln-dependent activity
6.3.5.2	Escherichia coli		6-diazo-5-oxo-L-norleucine	1381	666	inhibition of Gln-dependent activity and NH4+-dependent activity
6.3.5.2	Escherichia coli		6-diazo-5-oxo-L-norleucine	1382	666	Gln-dependent activity is more sensitive than NH4+-dependent activity; inhibition of Gln-dependent activity and NH4+-dependent activity
6.3.5.2	Escherichia coli		6-diazo-5-oxo-L-norleucine	1360, 650087	666	
6.3.5.2	Plasmodium falciparum		6-diazo-5-oxo-L-norleucine	727469	666	irreversible inhibitor
6.3.5.2	Escherichia coli		6-Methylmercaptopurine ribonucleoside	1362	4036	
6.3.5.2	Escherichia coli		6-Methylpurine ribonucleoside	1362	25372	
6.3.5.2	Escherichia coli		6-Methylpurine ribonucleotide	1362	63700	
6.3.5.2	Escherichia coli		6-Thio-GMP	649891	7110	
6.3.5.2	Escherichia coli		6-ThioGMP	1364	7110	
6.3.5.2	Plasmodium falciparum		6-Thioguanine	671905	951	0.5 mM, 27% inhibition
6.3.5.2	Mus musculus		6-thioXMP	1359, 1363	10457	
6.3.5.2	Escherichia coli		6-thioXMP	1364	10457	
6.3.5.2	Escherichia coli		8-aza-GMP	649891	10463	
6.3.5.2	Escherichia coli		8-azaadenosine	1362	6109	
6.3.5.2	Escherichia coli		8-azaGMP	1364	10463	
6.3.5.2	Plasmodium falciparum		8-Azaguanine	671905	1540	0.5 mM, 40% inhibition
6.3.5.2	Escherichia coli		8-Bromoadenosine	1362	6111	
6.3.5.2	Homo sapiens		acivicin	1373	2029	selectively abolishes glutaminase activity and Gln-dependent synthetase activity. No effect on NH4+-dependent synthetase activity
6.3.5.2	Plasmodium falciparum		acivicin	727469	2029	irreversible inhibitor
6.3.5.2	Mus musculus		Adenine 9-beta-D-arabinofuranoside 5'-triphosphate	1359	6116	
6.3.5.2	Escherichia coli		adenine arabinoside	1362	8319	
6.3.5.2	Escherichia coli		adenosine	1362	116	
6.3.5.2	Bacillus subtilis		adenosine	1379	116	strong inhibition of wild type enzyme, mutant GP-1 with decreased inhibition, complete loss of inhibition in mutant MG-1
6.3.5.2	Plasmodium falciparum		adenosine	671905	116	0.5 mM, 37% inhibition
6.3.5.2	Plasmodium falciparum		adenosine 5'-(beta,gamma-imido)triphosphate	671905	2889	non-competitive versus XMP, competitive versus ATP
6.3.5.2	Escherichia coli		ADP	1362	8	
6.3.5.2	Rattus norvegicus		AMP	1354	9	
6.3.5.2	Homo sapiens		AMP	1372	9	poor product inhibitor, competitive towards ATP
6.3.5.2	Plasmodium falciparum		AMP	671905	9	0.5 mM, 22% inhibitiion; 0.5 mM, 22% inhibition
6.3.5.2	Plasmodium falciparum		AMP-PNP	671905	2889	potent inhibitor, competitive and non-competitive inhibitor with respect to ATP and XMP
6.3.5.2	Pigeon		ATP	1383	7	above 5 mM
6.3.5.2	Mycobacterium tuberculosis		ATP	726806	7	substrate inhibition
6.3.5.2	Homo sapiens		ATPgammaS	1372	1380	
6.3.5.2	Escherichia coli		azaserine	1375	1381	
6.3.5.2	Homo sapiens		beta,gamma-Imidoadenosine 5-triphosphate	1372	2889	
6.3.5.2	Mus musculus		Bredinin 5'-phosphate	1387	11930	
6.3.5.2	Escherichia coli		Bromopyruvate	1380	1425	
6.3.5.2	Rattus norvegicus		cAMP	1354	233	
6.3.5.2	Rattus norvegicus		cGMP	1354	292	
6.3.5.2	Rattus norvegicus		CMP	1354	94	
6.3.5.2	Mus musculus		CTP	1359	56	
6.3.5.2	Escherichia coli		Decoyinine	1362	6147	
6.3.5.2	Homo sapiens		Decoyinine	1372	6147	uncompetitive towards Gln and XMP and noncompetitive towards ATP
6.3.5.2	Homo sapiens		Decoyinine	1374	6147	
6.3.5.2	Bacillus subtilis		Decoyinine	1379	6147	strong inhibition of wild type enzyme, and mutant enzyme GP-1, complete loss of inhibition in mutant MG-1
6.3.5.2	Mus musculus		diphosphate	1359	13	
6.3.5.2	Mus musculus		diphosphate	1361	13	competitive with respect to ATP
6.3.5.2	Escherichia coli		diphosphate	1362	13	competitive with respect to ATP; kinetic parameters for the two progressively formed inhibitory complexes
6.3.5.2	Homo sapiens		diphosphate	1372, 1373	13	
6.3.5.2	Plasmodium falciparum		diphosphate	671905	13	non-competitive versus XMP, competitive versus ATP, non-competitive versus L-Gln; potent inhibitor, competitive and non-competitive inhibition with respect to ATP and XMP
6.3.5.2	Escherichia coli		DTNB	1380	196	
6.3.5.2	Plasmodium falciparum		GDP	671905	49	0.5 mM, 42% inhibition
6.3.5.2	Escherichia coli		Glucofuranosyladenine	1362	64563	
6.3.5.2	Homo sapiens		glutamic acid-gamma-methyl ester	1372	11793	competitive towards Gln
6.3.5.2	Rattus norvegicus		GMP	1354	150	
6.3.5.2	Homo sapiens		GMP	1372	150	
6.3.5.2	Escherichia coli		GMP	649891	150	0.33 mM, 50% inhibition
6.3.5.2	Plasmodium falciparum		GMP	671905	150	competitive versus XMP, uncompetitive versus ATP, non-competitive versus L-Gln; potent inhibitor, competitive and uncompetitive inhibition with respect to XMP and ATP
6.3.5.2	Plasmodium falciparum		GTP	671905	35	0.5 mM, 40% inhibition
6.3.5.2	Escherichia coli		guanidine hydrochloride	1360	804	
6.3.5.2	Plasmodium falciparum		guanosine	671905	256	0.5 mM, 50% inhibition
6.3.5.2	Mus musculus		hydroxylamine	1363	80	
6.3.5.2	Plasmodium falciparum		IMP	671905	206	0.5 mM, 10% inhibition
6.3.5.2	Escherichia coli		iodoacetamide	1381	63	inhibition of Gln-dependent activity, no inhibition of NH4+-dependent activity
6.3.5.2	Plasmodium falciparum		K+	671905	37	
6.3.5.2	Escherichia coli		Kinetin ribonucleoside	1362	64713	
6.3.5.2	Escherichia coli		L-2-Amino-4-oxo-5-chloropentanoic acid	1381	4073	inhibition of Gln-dependent activity and NH4+-dependent activity
6.3.5.2	Plasmodium falciparum		Li+	671905	142	
6.3.5.2	Plasmodium falciparum		more	671905		not inhibitory at 0.5 mM: hypoxanthine, chloroadenosine, xanthosine, inosine, decoyinine
6.3.5.2	Escherichia coli		mycophenolate	1362	470	
6.3.5.2	Escherichia coli		N2-hydroxyguanosine 5'-monophosphate	649891	35675	0.0003-0.0005 mM, 50% inhibition
6.3.5.2	Escherichia coli		N6,N6-Dimethyladenosine	1362	63683	
6.3.5.2	Escherichia coli		N6-Allyladenosine	1362	65140	
6.3.5.2	Escherichia coli		N6-Benzyladenosine	1362	20509	
6.3.5.2	Escherichia coli		N6-Hydroxyaminopurine ribonucleoside	1362	65145	
6.3.5.2	Escherichia coli		N6-isopentenyladenosine	1362	4888	
6.3.5.2	Escherichia coli		N6-methyladenosine	1362	4448	
6.3.5.2	Plasmodium falciparum		Na+	671905	55	25% loss of activity at 24 mM, 90% loss of activity at 200 mM
6.3.5.2	Escherichia coli		Nucleodide inhibitors	1362		overview
6.3.5.2	Escherichia coli		oxanosine	649891	35676	
6.3.5.2	Mus musculus		p-chloromercuribenzoate	1359, 1363	40	
6.3.5.2	Escherichia coli		p-chloromercuribenzoate	1380	40	
6.3.5.2	Pigeon		p-chloromercuribenzoate	1383	40	
6.3.5.2	Plasmodium falciparum		phosphate	671905	12	
6.3.5.2	Plasmodium falciparum		Psicofuranine	655513	13502	
6.3.5.2	Plasmodium falciparum		Psicofuranine	671905	13502	0.5 mM, 25% inhibition
6.3.5.2	Escherichia coli		tubercidin	1362	2600	
6.3.5.2	Escherichia coli		XMP	727023	772	substrate inhibition above 0.2 mM
6.3.5.2	Escherichia coli		Zeatin ribonucleoside	1362	65699	
1.1.1.44	Rattus norvegicus	17beta-estradiol		655737	602	administration causes an increase in liver enzyme, but not in white adipose tissue enzyme, activity and mRNA level in female and male rats
1.1.1.44	Nicotiana tabacum	2,3-diphosphoglycerate		286866	557	activates both isoenzymes up to 200% of their original activity
1.1.1.44	Homo sapiens	5-(3alpha-acetoxy-5-beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide		688050	77183	activates
1.1.1.44	Homo sapiens	5-(3alpha-hydroxy-5-beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide		688050	16956	activates
1.1.1.44	Ovis aries	6-phosphogluconate		286903	327	bona fide allosteric activator
1.1.1.44	Brevibacterium flavum	ADP		286885	8	
1.1.1.44	Phormidium sp.	AMP		286882	9	1 mM, relative activity 105%
1.1.1.44	Brevibacterium flavum	ATP		286885	7	
1.1.1.44	Brevibacterium flavum	D-Fructose 1-phosphate		286885	544	
1.1.1.44	Cyberlindnera jadinii	D-fructose 6-phosphate		286893	82	slight activation
1.1.1.44	Enterococcus faecalis	D-gluconate		286885	562	induced by
1.1.1.44	Corynebacterium glutamicum	gluconate		696574	562	6-phosphogluconate dehydrogenase, although constituvely expressed, shows a 3-fold higher specific level in gluconate grown cells than those grown in fructose under similar conditions
1.1.1.44	Dictyostelium discoideum	glycylglycine		286825	771	
1.1.1.44	Brevibacterium flavum	L-aspartate		286885	91	
1.1.1.44	Brevibacterium flavum	L-histidine		286885	296	
1.1.1.44	Brevibacterium flavum	L-tryptophan		286885	113	
1.1.1.44	Rattus norvegicus	metimazole		657143	79923	in vitro activation
1.1.1.44	Oryza sativa	more		656766		the enzyme is upregulated during salt stress
1.1.1.44	Azospirillum brasilense	more		700784		external gluconate has no effect on the activity of 6-phosphogluconate dehydrogenase
1.1.1.44	Mus musculus		(-)-catechin gallate	685541	11781	NADP+-competitive inhibitor of glucose-6-phosphate dehydrogenase
1.1.1.44	Mus musculus		(-)-epicatechin gallate	685541	3505	
1.1.1.44	Mus musculus		(-)-epigallocatechin	685541	1645	NADP+-competitive inhibitor of glucose-6-phosphate dehydrogenase
1.1.1.44	Mus musculus		(-)-epigallocatechin gallate	685541	936	NADP+-competitive inhibitor of glucose-6-phosphate dehydrogenase
1.1.1.44	Mus musculus		(-)-gallocatechin gallate	685541	7880	NADP+-competitive inhibitor of glucose-6-phosphate dehydrogenase
1.1.1.44	Trypanosoma brucei		(2E)-2-cyano-3-(5-nitrofuran-2-yl)prop-2-enoic acid	711463	58334	
1.1.1.44	Leishmania donovani		(2R)-(2-hydroxy-3-phosphonooxypropane-1-sulfinyl)acetic acid	656470	7720	compound shows in vitro antiparasitic activity
1.1.1.44	Ovis aries		(2R)-(2-hydroxy-3-phosphonooxypropane-1-sulfinyl)acetic acid	656470	7720	
1.1.1.44	Plasmodium falciparum		(2R)-(2-hydroxy-3-phosphonooxypropane-1-sulfinyl)acetic acid	656470	7720	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		(2R)-(2-hydroxy-3-phosphonooxypropane-1-sulfinyl)acetic acid	656470	7720	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		(2R)-(2-hydroxy-3-phosphonooxypropane-1-sulfinyl)acetic acid	656470	7720	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		(2R)-[3-(bis(benzyloxy)phosphoryloxy)-2-(tetrahydropyran-2-yloxy)propane-1-sulfinyl]acetic acid	656470	23058	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		(2R)-[3-(bis(benzyloxy)phosphoryloxy)-2-(tetrahydropyran-2-yloxy)propane-1-sulfinyl]acetic acid	656470	23058	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		(2R)-[3-(bis(benzyloxy)phosphoryloxy)-2-(tetrahydropyran-2-yloxy)propane-1-sulfinyl]acetic acid	656470	23058	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		(2R,3R)-2,3,4,N-tetrahydroxybutyramide	656470	6761	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		(2R,3R)-2,3,4,N-tetrahydroxybutyramide	656470	6761	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		(2R,3R)-2,3,4,N-tetrahydroxybutyramide	656470	6761	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		(2R,3R)-2,3,4,N-tetrahydroxybutyramide	656470	6761	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		(3aR,6aR)-2,2-dimethyldihydrofuro[3,4-d][1,3]dioxol-4-one	656470	15060	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		(3aR,6aR)-2,2-dimethyldihydrofuro[3,4-d][1,3]dioxol-4-one	656470	15060	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		(3aR,6aR)-2,2-dimethyldihydrofuro[3,4-d][1,3]dioxol-4-one	656470	15060	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		(3aR,6aR)-2,2-dimethyldihydrofuro[3,4-d][1,3]dioxol-4-one	656470	15060	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		(3R,4R)-3,4-di(tetrahydro-2H-pyranyloxy)tetrahydro-2-furanone	656470	15058	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		(3R,4R)-3,4-di(tetrahydro-2H-pyranyloxy)tetrahydro-2-furanone	656470	15058	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		(3R,4R)-3,4-di(tetrahydro-2H-pyranyloxy)tetrahydro-2-furanone	656470	15058	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		(3R,4R)-3,4-di(tetrahydro-2H-pyranyloxy)tetrahydro-2-furanone	656470	15058	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		(4R,5R)-5-hydroxymethyl-2,2-dimethyl-[1,3]dioxolane-4-carboxylic acid benzyloxyamide	656470	15061	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		(4R,5R)-5-hydroxymethyl-2,2-dimethyl-[1,3]dioxolane-4-carboxylic acid benzyloxyamide	656470	15061	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		(4R,5R)-5-hydroxymethyl-2,2-dimethyl-[1,3]dioxolane-4-carboxylic acid benzyloxyamide	656470	15061	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		(4R,5R)-5-hydroxymethyl-2,2-dimethyl-[1,3]dioxolane-4-carboxylic acid benzyloxyamide	656470	15061	compound shows in vitro antiparasitic activity
1.1.1.44	Homo sapiens		(4S)-trans-4-ethylammonio-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide	688050	25281	i.e. dorzolamide, competitive
1.1.1.44	Cyberlindnera jadinii		(5-(dimethylamine)naphthalin-1-sulfonylchloride)	286853	20297	dansyl chloride, DNSCl, rapid inactivation at pH 7.5, 95% inhibition at pH 6.2
1.1.1.44	Ovis aries		1,5-diphospho-D-ribulose	654952	15050	
1.1.1.44	Trypanosoma brucei		1,5-diphospho-D-ribulose	654952	15050	
1.1.1.44	Ovis aries		1,5-diphospho-ribitol	654952	15049	
1.1.1.44	Trypanosoma brucei		1,5-diphospho-ribitol	654952	15049	
1.1.1.44	Ovis aries		2'-AMP	286830, 286840	621	
1.1.1.44	Trypanosoma brucei		2-deoxy-6-phosphono-D-gluconate	654952	4615	
1.1.1.44	Leishmania donovani		2-deoxy-6-phosphono-D-gluconate	656470	4615	compound shows in vitro antiparasitic activity
1.1.1.44	Ovis aries		2-deoxy-6-phosphono-D-gluconate	654952, 656470	4615	
1.1.1.44	Plasmodium falciparum		2-deoxy-6-phosphono-D-gluconate	656470	4615	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		2-deoxy-6-phosphono-D-gluconate	656470	4615	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		2-deoxy-6-phosphono-D-gluconate	656470	4615	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		2-methyl-5-nitrofuran-3-carboxylic acid	711463	58328	
1.1.1.44	Ovis aries		3'-AMP	286830, 286840	529	
1.1.1.44	Trypanosoma brucei		3,3',4,4'-tetramethyl-1H,1'H-2,2'-bipyrrole-5,5'-dicarboxylic acid	711463	58331	
1.1.1.44	Trypanosoma brucei		3-methyl-4-oxo-4,7-dihydro-5H-thiopyrano[3,4-b]furan-2-carboxylic acid	711463	58330	
1.1.1.44	Trypanosoma brucei		3-Oxo-2-deoxy-6-phosphogluconate	286903	8676	competitive inhibitor
1.1.1.44	Trypanosoma brucei		4,5-dichloro-1H-pyrrole-2-carboxylic acid	711463	58335	
1.1.1.44	Leishmania donovani		4,N-dihydroxy(2R,3R)-2,3-bis(tetrahydropyran-2-yloxy)butyramide	656470	15059	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		4,N-dihydroxy(2R,3R)-2,3-bis(tetrahydropyran-2-yloxy)butyramide	656470	15059	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		4,N-dihydroxy(2R,3R)-2,3-bis(tetrahydropyran-2-yloxy)butyramide	656470	15059	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		4,N-dihydroxy(2R,3R)-2,3-bis(tetrahydropyran-2-yloxy)butyramide	656470	15059	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		4-chloro-1H-pyrrole-2-carboxylic acid	711463	58327	
1.1.1.44	Leishmania donovani		4-phospho-D-erythronamide	656470	6542	compound shows in vitro antiparasitic activity
1.1.1.44	Ovis aries		4-phospho-D-erythronamide	656470	6542	
1.1.1.44	Plasmodium falciparum		4-phospho-D-erythronamide	656470	6542	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		4-phospho-D-erythronamide	656470	6542	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		4-phospho-D-erythronamide	656470	6542	compound shows in vitro antiparasitic activity
1.1.1.44	Ovis aries		4-phospho-D-erythronate	654952	1904	bio-isosteric analogue
1.1.1.44	Trypanosoma brucei		4-phospho-D-erythronate	654952	1904	bio-isosteric analogue
1.1.1.44	Leishmania donovani		4-phospho-D-erythronate	656470	1904	compound shows in vitro antiparasitic activity
1.1.1.44	Ovis aries		4-phospho-D-erythronate	656470	1904	
1.1.1.44	Plasmodium falciparum		4-phospho-D-erythronate	656470	1904	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		4-phospho-D-erythronate	656470	1904	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		4-phospho-D-erythronate	656470	1904	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		4-phospho-D-erythronate	686656	1904	mimics the transition state of dehydrogenation. The inhibitor forces the catalytic lysine 185 into the protonated state
1.1.1.44	Leishmania donovani		4-phospho-D-erythronohydroxamic acid	656470	4200	compound shows low in vitro antiparasitic activity
1.1.1.44	Ovis aries		4-phospho-D-erythronohydroxamic acid	656470	4200	
1.1.1.44	Plasmodium falciparum		4-phospho-D-erythronohydroxamic acid	656470	4200	compound shows low in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		4-phospho-D-erythronohydroxamic acid	656470	4200	compound shows low in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		4-phospho-D-erythronohydroxamic acid	656470	4200	compound shows low in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		4-phospho-D-erythronohydroxamic acid	686094	4200	conversion of the 6-PGDH inhibitor into prodrugs to increase its activity against the Trypanosoma brucei by enhancing uptake by passive permeation across the plasma membrane. Production of five different phosphate-masking groups (phosphoramidate, bis-S-acyl thioethyl esters, bis-pivaloxymethyl, cycloSaligenyl and phenyl, S-acyl thioethyl mixed phosphate esters). Prodrugs are studied for stability and activity against the intact parasites. Most prodrugs cause inhibition of the growth of the parasites. The activity of the prodrugs against the parasites appears to be related to their stability in aqueous buffer
1.1.1.44	Lactococcus lactis		4-phospho-D-erythronohydroxamic acid	686656	4200	
1.1.1.44	Ovis aries		4-phospho-D-erythrose	654952	416	bio-isosteric analogue
1.1.1.44	Trypanosoma brucei		4-phospho-D-erythrose	654952	416	bio-isosteric analogue
1.1.1.44	Trypanosoma brucei		4H-thieno[3,2-b]pyrrole-5-carboxylic acid	711463	9509	
1.1.1.44	Cyberlindnera jadinii		5,5'-dithiobis(2-nitrobenzoic acid)	286856	196	DTNB
1.1.1.44	Geobacillus stearothermophilus		5,5'-dithiobis(2-nitrobenzoic acid)	286836, 286874	196	Ellman's reagent
1.1.1.44	Enterococcus faecalis		5,5'-dithiobis(2-nitrobenzoic acid)	286846, 286851, 286882	196	
1.1.1.44	Escherichia coli		5,5'-dithiobis(2-nitrobenzoic acid)	286851, 286874, 286882	196	
1.1.1.44	Geobacillus stearothermophilus		5,5'-dithiobis(2-nitrobenzoic acid)	286851, 286882	196	
1.1.1.44	Phormidium sp.		5,5'-dithiobis(2-nitrobenzoic acid)	286882	196	
1.1.1.44	Cyberlindnera jadinii		5,5'-dithiobis(2-nitrobenzoic acid)	286833, 286836, 286846, 286851, 286873, 286874, 286882, 286883	196	
1.1.1.44	Ovis aries		5,5'-dithiobis(2-nitrobenzoic acid)	286833, 286883	196	
1.1.1.44	Ovis aries		5,6-dideoxy-6-phosphono-D-arabino-hexonate	654952	15046	
1.1.1.44	Trypanosoma brucei		5,6-dideoxy-6-phosphono-D-arabino-hexonate	654952	15046	
1.1.1.44	Homo sapiens		5-(3,7,12-trioxo-5-beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide	688050	77186	weak inhibition
1.1.1.44	Homo sapiens		5-(3alpha,7alpha,12alpha-triacetoxy-5-beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide	688050	6479	competitive
1.1.1.44	Homo sapiens		5-(3alpha,7alpha,12alpha-trihydroxy-5-beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide	688050	6478	competitive
1.1.1.44	Trypanosoma brucei		5-(ethoxycarbonyl)-3,4-dimethyl-1H-pyrrole-2-carboxylic acid	711463	58326	
1.1.1.44	Ovis aries		5-deoxy-5-phosphonoD-arabinonate	654952	15051	
1.1.1.44	Trypanosoma brucei		5-deoxy-5-phosphonoD-arabinonate	654952	15051	
1.1.1.44	Ovis aries		5-phospho-D-arabinonamide	654952	15047	
1.1.1.44	Trypanosoma brucei		5-phospho-D-arabinonamide	654952	15047	
1.1.1.44	Ovis aries		5-phospho-D-arabinonate	654952	5054	
1.1.1.44	Trypanosoma brucei		5-phospho-D-arabinonate	654952	5054	
1.1.1.44	Ovis aries		5-phospho-D-arabinonhydrazide	654952	6541	
1.1.1.44	Trypanosoma brucei		5-phospho-D-arabinonhydrazide	654952	6541	
1.1.1.44	Ovis aries		5-phospho-D-arabinono-1,4-lactone	654952	15048	
1.1.1.44	Trypanosoma brucei		5-phospho-D-arabinono-1,4-lactone	654952	15048	
1.1.1.44	Ovis aries		5-phospho-D-arabinonohydroxamic acid	654952	3681	
1.1.1.44	Trypanosoma brucei		5-phospho-D-arabinonohydroxamic acid	654952	3681	
1.1.1.44	Ovis aries		5-phospho-D-arabinose	654952	447	
1.1.1.44	Trypanosoma brucei		5-phospho-D-arabinose	654952	447	
1.1.1.44	Ovis aries		5-phospho-D-ribonate	654952	4616	
1.1.1.44	Trypanosoma brucei		5-phospho-D-ribonate	654952	4616	
1.1.1.44	Trypanosoma brucei		5-phospho-D-ribonate	686656	4616	substrate analogue
1.1.1.44	Ovis aries		6-deoxy-6-phosphono-D-gluconate	654952	15045	
1.1.1.44	Trypanosoma brucei		6-deoxy-6-phosphono-D-gluconate	654952	15045	
1.1.1.44	Nicotiana tabacum		6-methoxy-7-hydroxycoumarin	286866	1025	scopolin
1.1.1.44	Cyberlindnera jadinii		6-phospho-D-allonate	286893	70266	
1.1.1.44	Ovis aries		6-phospho-D-galactonate	654952	15044	
1.1.1.44	Trypanosoma brucei		6-phospho-D-galactonate	654952	15044	
1.1.1.44	Ovis aries		6-phosphono-D-mannonate	654952	15043	competitive
1.1.1.44	Trypanosoma brucei		6-phosphono-D-mannonate	654952	15043	competitive
1.1.1.44	Geobacillus stearothermophilus		7-Chloro-4-nitrobenzo-2-oxa-1,3-diazole	286874	2816	NBD-Cl
1.1.1.44	Leishmania donovani		acetic acid (1R,2R)-2-acetoxy-1-(acetylbenzyloxyaminocarbonyl)-3-(bis(benzyloxy)phosphoryloxy)propyl ester	656470	7721	compound shows in vitro antiparasitic activity
1.1.1.44	Ovis aries		acetic acid (1R,2R)-2-acetoxy-1-(acetylbenzyloxyaminocarbonyl)-3-(bis(benzyloxy)phosphoryloxy)propyl ester	656470	7721	
1.1.1.44	Plasmodium falciparum		acetic acid (1R,2R)-2-acetoxy-1-(acetylbenzyloxyaminocarbonyl)-3-(bis(benzyloxy)phosphoryloxy)propyl ester	656470	7721	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		acetic acid (1R,2R)-2-acetoxy-1-(acetylbenzyloxyaminocarbonyl)-3-(bis(benzyloxy)phosphoryloxy)propyl ester	656470	7721	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		acetic acid (1R,2R)-2-acetoxy-1-(acetylbenzyloxyaminocarbonyl)-3-(bis(benzyloxy)phosphoryloxy)propyl ester	656470	7721	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		acetic acid (1R,2R)-2-acetoxy-1-benzyloxycarbamoyl-3-(bis(benzyloxy)phosphoryloxy)propyl ester	656470	15064	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		acetic acid (1R,2R)-2-acetoxy-1-benzyloxycarbamoyl-3-(bis(benzyloxy)phosphoryloxy)propyl ester	656470	15064	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		acetic acid (1R,2R)-2-acetoxy-1-benzyloxycarbamoyl-3-(bis(benzyloxy)phosphoryloxy)propyl ester	656470	15064	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		acetic acid (1R,2R)-2-acetoxy-1-benzyloxycarbamoyl-3-(bis(benzyloxy)phosphoryloxy)propyl ester	656470	15064	compound shows in vitro antiparasitic activity
1.1.1.44	Ovis aries		acetic acid (2R,1R)-2-acetoxy-1-hydroxycarbamoyl-3-phosphonooxypropyl ester	656470	9028	
1.1.1.44	Plasmodium falciparum		acetic acid (2R,1R)-2-acetoxy-1-hydroxycarbamoyl-3-phosphonooxypropyl ester	656470	9028	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		acetic acid (2R,1R)-2-acetoxy-1-hydroxycarbamoyl-3-phosphonooxypropyl ester	656470	9028	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		acetic acid (2R,1R)-2-acetoxy-1-hydroxycarbamoyl-3-phosphonooxypropyl ester	656470	9028	compound shows in vitro antiparasitic activity
1.1.1.44	Brevibacterium flavum		acetyl-CoA	286885	27	
1.1.1.44	Ovis aries		adenosine	286830	116	
1.1.1.44	Ovis aries		ADP	286830	8	
1.1.1.44	Phormidium sp.		ADP	286882	8	
1.1.1.44	Rattus norvegicus		ADP	286826, 286882	8	
1.1.1.44	Homo sapiens		amikacin	656386	1053	in vitro inhibition
1.1.1.44	Rattus norvegicus		amikacin sulfate	657143	79773	in vitro and in vivo inhibition
1.1.1.44	Homo sapiens		amoxicillin	688036	1323	competitive
1.1.1.44	Rattus norvegicus		AMP	286826	9	
1.1.1.44	Homo sapiens		ampicillin	656386	171	in vitro inhibition
1.1.1.44	Rattus norvegicus		ampicillin	657143	171	in vitro inhibition
1.1.1.44	Cyberlindnera jadinii		arsenate	286854	222	
1.1.1.44	Phormidium sp.		ATP	286882	7	
1.1.1.44	Methylobacillus flagellatus		ATP	286888	7	
1.1.1.44	Arthrobacter globiformis		ATP	286889	7	
1.1.1.44	Corynebacterium glutamicum		ATP	286904	7	
1.1.1.44	Escherichia coli		ATP	286861, 286882, 286904	7	
1.1.1.44	Candida boidinii		ATP	286904, 286987	7	
1.1.1.44	Ovis aries		ATP	286830, 286840, 286904, 286987	7	
1.1.1.44	Cyberlindnera jadinii		Butan-2,3-dione	286854	603	
1.1.1.44	Nicotiana tabacum		caffeic acid	286866	355	
1.1.1.44	Enterococcus faecalis		Cd2+	286845, 286882	48	
1.1.1.44	Phormidium sp.		Cd2+	286882	48	
1.1.1.44	Ovis aries		CDP	286830, 286840	188	
1.1.1.44	Homo sapiens		cefepime	656386	739	in vitro inhibition
1.1.1.44	Rattus norvegicus		cefepime	656386	739	in vitro and in vivo inhibition, noncompetitive
1.1.1.44	Homo sapiens		ceftazidim	656386	79774	in vitro inhibition
1.1.1.44	Homo sapiens		Chloramphenicol	656386	742	in vitro inhibition
1.1.1.44	Nicotiana tabacum		chlorogenic acid	286866	488	
1.1.1.44	Cyberlindnera jadinii		chromate	286854	2200	
1.1.1.44	Homo sapiens		Ciprofloxacin	656386	932	in vitro inhibition
1.1.1.44	Oryctolagus cuniculus		citrate	286849	125	
1.1.1.44	Ovis aries		citrate	286830, 286840, 286849	125	
1.1.1.44	Homo sapiens		clindamycin	688036	4669	competitive
1.1.1.44	Ovis aries		CMP	286830, 286840	94	
1.1.1.44	Sus scrofa		CO2	286850	17	
1.1.1.44	Arthrobacter globiformis		Co2+	286889	21	
1.1.1.44	Ovis aries		CTP	286830, 286840	56	
1.1.1.44	Enterococcus faecalis		Cu2+	286845, 286882	28	
1.1.1.44	Phormidium sp.		Cu2+	286882	28	
1.1.1.44	Cyberlindnera jadinii		D-2-deoxyglucose	286835, 286883	443	
1.1.1.44	Ovis aries		D-2-deoxyglucose	286883	443	
1.1.1.44	Cyberlindnera jadinii		D-5-phosphoarabonate	286893	70265	
1.1.1.44	Cyberlindnera jadinii		D-5-phosphoribonate	286893	4616	
1.1.1.44	Brevibacterium flavum		D-5-phosphoribosyl-1-diphosphate	286885	147	
1.1.1.44	Catharanthus roseus		D-5-phosphoribosyl-1-diphosphate	286891	147	
1.1.1.44	Cyberlindnera jadinii		D-6-phosphogluconate	286894	327	competitive substrate inhibition at pH 7
1.1.1.44	Homo sapiens		D-6-sulfogluconate	286881	21534	
1.1.1.44	Cyberlindnera jadinii		D-6-sulfogluconate	286881, 286893	21534	
1.1.1.44	Cyberlindnera jadinii		D-ATP-ribose	286892	70066	
1.1.1.44	Beta vulgaris		D-erythrose 4-phosphate	286896	416	
1.1.1.44	Brevibacterium flavum		D-erythrose 4-phosphate	286885, 286904	416	
1.1.1.44	Corynebacterium glutamicum		D-erythrose 4-phosphate	286904	416	
1.1.1.44	Neurospora crassa		D-fructose 1,6-diphosphate	286831, 286846, 286851, 286882	100	
1.1.1.44	Phormidium sp.		D-fructose 1,6-diphosphate	286882	100	
1.1.1.44	Enterococcus faecalis		D-fructose 1,6-diphosphate	286845, 286846, 286851, 286882, 286885	100	
1.1.1.44	Beta vulgaris		D-fructose 1,6-diphosphate	286896	100	
1.1.1.44	Brevibacterium flavum		D-fructose 1,6-diphosphate	286885, 286904	100	
1.1.1.44	Corynebacterium glutamicum		D-fructose 1,6-diphosphate	286904	100	
1.1.1.44	Escherichia coli		D-fructose 1,6-diphosphate	286851, 286861, 286882, 286904	100	
1.1.1.44	Gluconobacter oxydans		D-fructose 1,6-diphosphate	286904	100	
1.1.1.44	Pseudomonas sp.		D-fructose 1,6-diphosphate	286904	100	
1.1.1.44	Candida boidinii		D-fructose 1,6-diphosphate	286904, 286987	100	
1.1.1.44	Ovis aries		D-fructose 1,6-diphosphate	286827, 286830, 286831, 286837, 286840, 286844, 286904, 286987	100	
1.1.1.44	Ovis aries		D-Fructose 1-phosphate	286830, 286840	544	
1.1.1.44	Ricinus communis		D-fructose 2,6-bisphosphate	286877	573	
1.1.1.44	Ovis aries		D-fructose 6-phosphate	286830, 286840	82	
1.1.1.44	Phormidium sp.		D-fructose 6-phosphate	286882	82	
1.1.1.44	Nicotiana tabacum		D-Glucose 1,6-bisphosphate	286866, 286877	1231	
1.1.1.44	Rattus norvegicus		D-Glucose 1,6-bisphosphate	286863, 286877	1231	
1.1.1.44	Ricinus communis		D-Glucose 1,6-bisphosphate	286877	1231	
1.1.1.44	Ovis aries		D-glucose 6-phosphate	286830, 286840	99	
1.1.1.44	Brevibacterium flavum		D-glyceraldehyde 3-phosphate	286885, 286904	139	
1.1.1.44	Corynebacterium glutamicum		D-glyceraldehyde 3-phosphate	286904	139	
1.1.1.44	Homo sapiens		D-phosphate	286837		competitive inhibitor of the substrates
1.1.1.44	Neurospora crassa		D-phosphate	286843		
1.1.1.44	Ovis aries		D-phosphate	286830, 286837, 286840, 286862		
1.1.1.44	Phormidium sp.		D-ribulose 5-phosphate	286882	371	
1.1.1.44	Beta vulgaris		D-ribulose 5-phosphate	286896	371	
1.1.1.44	Cyberlindnera jadinii		D-ribulose 5-phosphate	286882, 286893, 286901	371	
1.1.1.44	Schizosaccharomyces pombe		D-ribulose 5-phosphate	286901	371	
1.1.1.44	Brevibacterium flavum		D-ribulose 5-phosphate	286885, 286904	371	
1.1.1.44	Corynebacterium glutamicum		D-ribulose 5-phosphate	286904	371	
1.1.1.44	Candida boidinii		D-ribulose 5-phosphate	286904, 286987	371	
1.1.1.44	Brevibacterium flavum		D-xylulose 5-phosphate	286885	524	
1.1.1.44	Cyberlindnera jadinii		diethyldicarbonate	286873	265	
1.1.1.44	Oryctolagus cuniculus		diphosphate	286849	13	
1.1.1.44	Ovis aries		diphosphate	286830, 286840, 286849	13	
1.1.1.44	Nicotiana tabacum		esculetin	286866	1157	
1.1.1.44	Nicotiana tabacum		esculin	286866	2380	
1.1.1.44	Arthrobacter globiformis		Fe2+	286889	23	
1.1.1.44	Nicotiana tabacum		ferulic acid	286866	378	
1.1.1.44	Ovis aries		GDP	286830, 286840	49	
1.1.1.44	Homo sapiens		gentamicin sulfate	656386	11667	in vitro inhibition
1.1.1.44	Ovis aries		GMP	286830, 286840	150	
1.1.1.44	Ovis aries		GTP	286830, 286840	35	
1.1.1.44	Cyberlindnera jadinii		hexachloroplatinate	286854	70486	
1.1.1.44	Geobacillus stearothermophilus		Hg2+	286836, 286882	31	
1.1.1.44	Phormidium sp.		Hg2+	286882	31	HgCl2
1.1.1.44	Ovis aries		IDP	286830, 286840	372	
1.1.1.44	Homo sapiens		Imipenem	688036	323	noncompetitive
1.1.1.44	Ovis aries		IMP	286830, 286840	206	
1.1.1.44	Homo sapiens		iodoacetamide	286834	63	
1.1.1.44	Neurospora crassa		iodoacetamide	286831, 286843	63	
1.1.1.44	Geobacillus stearothermophilus		iodoacetamide	286834, 286874	63	
1.1.1.44	Homo sapiens		isepamycin	656386	32773	in vitro inhibition
1.1.1.44	Ovis aries		ITP	286830, 286840	203	
1.1.1.44	Homo sapiens		levofloxacin	656386	7544	in vitro inhibition
1.1.1.44	Homo sapiens		lornoxicam	688036	4258	noncompetitive
1.1.1.44	Homo sapiens		metronidazole	688036	3688	noncompetitive
1.1.1.44	Sus scrofa		Mg2+	286850	25	acts as an inhibitor above 20 mM
1.1.1.44	Cyberlindnera jadinii		molybdate	286854	424	
1.1.1.44	Nicotiana tabacum		more	654929		infection with potato virus Y increases the enzyme activity but decreases the 6-phosphono-D-gluconate content, maximal decrease of 30-50% at period of the highest virus replication
1.1.1.44	Rattus norvegicus		more	655737		ovariectomized rats show a decrease in mRNA level and enzyme activity in the liver, but not in white adipose tissue, which can be restored by 17beta-estradiol administration
1.1.1.44	Homo sapiens		more	656386		no inhibition by cefozin, decefin, streptomycin, combisid, and meronem
1.1.1.44	Leishmania donovani		more	656470		IC50 for antiparasitic activity of inhibitors, overview
1.1.1.44	Ovis aries		more	656470		no inhibition by [3-(bis(benzyloxy)phosphoryloxy)-(2R)-2-hydroxypropane-1-sulfinyl]acetic acid, [(2R)-2-acetoxy-3-(bis(benzyloxy)phosphoryloxy)-propane-1-sulfinyl]acetic acid benzyl ester, (2R)-[3-(bis(benzyloxy)phosphoryloxy)-2-(tetrahydropyran-2-yloxy)propane-1-sulfinyl]acetic acid, and acetic acid (1R,2R)-2-acetoxy-1-benzyloxycarbamoyl-3-(bis(benzyloxy)phosphoryloxy)propyl ester
1.1.1.44	Plasmodium falciparum		more	656470		IC50 for antiparasitic activity of inhibitors, overview
1.1.1.44	Trypanosoma brucei		more	656470		IC50 values for antiparasitic activity of inhibitors, overview
1.1.1.44	Trypanosoma cruzi		more	656470		IC50 values for antiparasitic activity of inhibitors, overview
1.1.1.44	Mus musculus		more	685541		not inhibited by ungallated catechins like (-)-epigallocatechin, (-)-gallocatechin, (-)-epicatechin, (-)-catechin, and dehydroepiandrosterone
1.1.1.44	Arabidopsis thaliana		more	701432		the activityand transcript level of 6PGDH decreases to 67% of its initial activity after 7 days of phosphate starvation
1.1.1.44	Phormidium sp.		N-ethylmaleimide	286882	46	
1.1.1.44	Arthrobacter globiformis		NADH	286889	3	
1.1.1.44	Cyberlindnera jadinii		NADP+	286869, 286884	6	
1.1.1.44	Ovis aries		NADP+	286884	6	
1.1.1.44	Homo sapiens		NADPH	286837	5	product inhibition
1.1.1.44	Sus scrofa		NADPH	286850	5	
1.1.1.44	Geobacillus stearothermophilus		NADPH	286851, 286882	5	
1.1.1.44	Phormidium sp.		NADPH	286882	5	
1.1.1.44	Methylobacillus flagellatus		NADPH	286888	5	
1.1.1.44	Arthrobacter globiformis		NADPH	286889	5	
1.1.1.44	Catharanthus roseus		NADPH	286891	5	
1.1.1.44	Cyberlindnera jadinii		NADPH	286892	5	noncompetitive inhibition versus 6-phosphogluconate
1.1.1.44	Rattus norvegicus		NADPH	286827, 286850, 286882, 286892	5	
1.1.1.44	Homo sapiens		NADPH	286881, 286895	5	competitive inhibition
1.1.1.44	Rattus norvegicus		NADPH	286895	5	competitive inhibition
1.1.1.44	Dicentrarchus labrax		NADPH	286887, 286901	5	
1.1.1.44	Neurospora crassa		NADPH	286831, 286843, 286851, 286882, 286901	5	
1.1.1.44	Schizosaccharomyces pombe		NADPH	286901	5	competitive inhibition
1.1.1.44	Homo sapiens		NADPH	286850, 286892, 286903	5	
1.1.1.44	Trypanosoma brucei		NADPH	286903	5	
1.1.1.44	Brevibacterium flavum		NADPH	286885, 286904	5	
1.1.1.44	Candida boidinii		NADPH	286904	5	
1.1.1.44	Corynebacterium glutamicum		NADPH	286904	5	
1.1.1.44	Escherichia coli		NADPH	286851, 286882, 286904	5	
1.1.1.44	Candida boidinii		NADPH	286987	5	competitive inhibition
1.1.1.44	Ovis aries		NADPH	667652	5	competitive inhibition versus NADP+ with 6-phospho-D-gluconate equal to its Km and at a saturating concentration
1.1.1.44	Ovis aries		NADPH	667707	5	saturating concentration at pH 7.5
1.1.1.44	Rattus norvegicus		NADPH	670806	5	complete inhibition
1.1.1.44	Cyberlindnera jadinii		NADPH	712444	5	6-phosphogluconate modulates 6PGDH activity. In the forward reaction, it suppresses inhibition by NADP and decreases inhibition by NADPH by increasing the Kd of the reduced coenzyme 6fold it increases the rate of decarboxylation of the 3-keto intermediate , whereas in the reverse reaction, it decreases the Km and removes the slow step
1.1.1.44	Rattus norvegicus		netilmicin	656386	1899	
1.1.1.44	Homo sapiens		netilmicin sulfate	656386	23059	in vitro inhibition
1.1.1.44	Rattus norvegicus		netilmicin sulfate	656386	23059	in vitro and in vivo inhibition, competitive
1.1.1.44	Rattus norvegicus		netilmicin sulfate	657143	23059	in vitro and in vivo inhibition
1.1.1.44	Arthrobacter globiformis		Ni2+	286889	36	
1.1.1.44	Ovis aries		Nicotinamide	286830	232	
1.1.1.44	Homo sapiens		ofloxacin	656386	22587	in vitro inhibition
1.1.1.44	Homo sapiens		ornidazole	688036	9537	noncompetitive
1.1.1.44	Ovis aries		oxalate	286830	166	
1.1.1.44	Brevibacterium flavum		oxaloacetate	286885, 286904	53	
1.1.1.44	Corynebacterium glutamicum		oxaloacetate	286904	53	
1.1.1.44	Ovis aries		oxaloacetate	286830, 286840, 286904	53	
1.1.1.44	Enterococcus faecalis		p-chloromercuribenzoate	286845, 286851, 286882	40	
1.1.1.44	Escherichia coli		p-chloromercuribenzoate	286851, 286882	40	
1.1.1.44	Geobacillus stearothermophilus		p-chloromercuribenzoate	286836, 286851, 286882	40	
1.1.1.44	Phormidium sp.		p-chloromercuribenzoate	286882	40	
1.1.1.44	Nicotiana tabacum		p-coumaric acid	286866	900	
1.1.1.44	Enterococcus faecalis		p-hydroxymercuribenzoate	286846	92	
1.1.1.44	Geobacillus stearothermophilus		p-hydroxymercuribenzoate	286874	92	
1.1.1.44	Ovis aries		p-hydroxymercuribenzoate	286833, 286883	92	
1.1.1.44	Homo sapiens		penicillin G	656386	163	in vitro inhibition
1.1.1.44	Cyberlindnera jadinii		perchlorate	286854	2035	
1.1.1.44	Cyberlindnera jadinii		Periodate	286854, 286873	5499	
1.1.1.44	Cyberlindnera jadinii		Permanganate	286854	13437	
1.1.1.44	Dicentrarchus labrax		phosphoenolpyruvate	286887	47	
1.1.1.44	Leishmania donovani		phosphoric acid dibenzyl ester (2R,3R)-3-benzyloxycarbamoyl-2,3-dihydroxypropyl ester	656470	15063	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		phosphoric acid dibenzyl ester (2R,3R)-3-benzyloxycarbamoyl-2,3-dihydroxypropyl ester	656470	15063	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		phosphoric acid dibenzyl ester (2R,3R)-3-benzyloxycarbamoyl-2,3-dihydroxypropyl ester	656470	15063	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		phosphoric acid dibenzyl ester (2R,3R)-3-benzyloxycarbamoyl-2,3-dihydroxypropyl ester	656470	15063	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		phosphoric acid dibenzyl ester (4R,5R)-5-benzyloxycarbamoyl-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester	656470	15062	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		phosphoric acid dibenzyl ester (4R,5R)-5-benzyloxycarbamoyl-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester	656470	15062	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		phosphoric acid dibenzyl ester (4R,5R)-5-benzyloxycarbamoyl-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester	656470	15062	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		phosphoric acid dibenzyl ester (4R,5R)-5-benzyloxycarbamoyl-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester	656470	15062	compound shows in vitro antiparasitic activity
1.1.1.44	Ovis aries		phosphoric acid mono-[(4R,5R)-5-carbamoyl-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl] ester	656470	9029	
1.1.1.44	Plasmodium falciparum		phosphoric acid mono-[(4R,5R)-5-carbamoyl-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl] ester	656470	9029	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		phosphoric acid mono-[(4R,5R)-5-carbamoyl-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl] ester	656470	9029	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		phosphoric acid mono-[(4R,5R)-5-carbamoyl-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl] ester	656470	9029	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		phosphoric acid mono-[(5R,4R)-5-hydroxycarbamoyl-2,2-dimethyl[1,3]dioxolan-4-ylmethyl] ester	656470	7722	compound shows low in vitro antiparasitic activity
1.1.1.44	Ovis aries		phosphoric acid mono-[(5R,4R)-5-hydroxycarbamoyl-2,2-dimethyl[1,3]dioxolan-4-ylmethyl] ester	656470	7722	
1.1.1.44	Plasmodium falciparum		phosphoric acid mono-[(5R,4R)-5-hydroxycarbamoyl-2,2-dimethyl[1,3]dioxolan-4-ylmethyl] ester	656470	7722	compound shows low in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		phosphoric acid mono-[(5R,4R)-5-hydroxycarbamoyl-2,2-dimethyl[1,3]dioxolan-4-ylmethyl] ester	656470	7722	compound shows low in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		phosphoric acid mono-[(5R,4R)-5-hydroxycarbamoyl-2,2-dimethyl[1,3]dioxolan-4-ylmethyl] ester	656470	7722	compound shows low in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		potassium 3,4-dioxo-3,4-dihydronaphthalene-1-sulfonate	711463	58333	
1.1.1.44	Neurospora crassa		pyridoxal 5'-phosphate	286831	30	photooxidation
1.1.1.44	Cyberlindnera jadinii		pyridoxal 5'-phosphate	286831, 286854	30	photooxidation
1.1.1.44	Cyberlindnera jadinii		pyridoxal 5'-phosphate	286873	30	
1.1.1.44	Escherichia coli		Rose bengal	286851	1008	photooxidation
1.1.1.44	Geobacillus stearothermophilus		Rose bengal	286851	1008	photooxidation
1.1.1.44	Neurospora crassa		Rose bengal	286831, 286851	1008	photooxidation
1.1.1.44	Escherichia coli		Rose bengal	286882	1008	
1.1.1.44	Geobacillus stearothermophilus		Rose bengal	286882	1008	
1.1.1.44	Neurospora crassa		Rose bengal	286882	1008	
1.1.1.44	Phormidium sp.		Rose bengal	286882	1008	
1.1.1.44	Nicotiana tabacum		scopoletin	286866	1025	
1.1.1.44	Trypanosoma brucei		sodium (4E)-4-(hydroxyimino)-3-oxo-1,2,3,4-tetrahydronaphthalene-1-sulfonate	711463	58329	
1.1.1.44	Ovis aries		sulfate	286830	148	
1.1.1.44	Cyberlindnera jadinii		sulfate	286854	148	
1.1.1.44	Ovis aries		TDP	286830, 286840	449	
1.1.1.44	Homo sapiens		teicoplanin	656386	23060	in vitro inhibition
1.1.1.44	Cyberlindnera jadinii		Tetranitromethane	286824	1100	irreversible loss of catalytic activity
1.1.1.44	Ovis aries		TMP	286830, 286840	518	
1.1.1.44	Ovis aries		TTP	286830, 286840	137	
1.1.1.44	Cyberlindnera jadinii		tungstate	286854	1475	
1.1.1.44	Ovis aries		UDP	286830, 286840	24	
1.1.1.44	Ovis aries		UMP	286830, 286840	127	
1.1.1.44	Candida boidinii		UTP	286987	61	
1.1.1.44	Ovis aries		UTP	286830, 286840, 286987	61	
1.1.1.44	Homo sapiens		Vancomycin	688036	1560	competitive
1.1.1.44	Enterococcus faecalis		Zn2+	286845, 286882	19	
1.1.1.44	Phormidium sp.		Zn2+	286882	19	
1.1.1.44	Arthrobacter globiformis		Zn2+	286889	19	
1.1.1.44	Leishmania donovani		[(2R)-2,3-dihydroxypropylsulfanyl]acetic acid benzyl ester	656470	15053	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		[(2R)-2,3-dihydroxypropylsulfanyl]acetic acid benzyl ester	656470	15053	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		[(2R)-2,3-dihydroxypropylsulfanyl]acetic acid benzyl ester	656470	15053	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		[(2R)-2,3-dihydroxypropylsulfanyl]acetic acid benzyl ester	656470	15053	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		[(2R)-2-acetoxy-3-(bis(benzyloxy)phosphoryloxy)-propane-1-sulfinyl]acetic acid benzyl ester	656470	15057	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		[(2R)-2-acetoxy-3-(bis(benzyloxy)phosphoryloxy)-propane-1-sulfinyl]acetic acid benzyl ester	656470	15057	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		[(2R)-2-acetoxy-3-(bis(benzyloxy)phosphoryloxy)-propane-1-sulfinyl]acetic acid benzyl ester	656470	15057	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		[(2R)-2-acetoxy-3-(bis(benzyloxy)phosphoryloxy)-propane-1-sulfinyl]acetic acid benzyl ester	656470	15057	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		[(2R)-2-acetoxy-3-(bis(benzyloxy)phosphoryloxy)-propylsulfanyl]acetic acid	656470	15055	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		[(2R)-2-acetoxy-3-(bis(benzyloxy)phosphoryloxy)-propylsulfanyl]acetic acid	656470	15055	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		[(2R)-2-acetoxy-3-(bis(benzyloxy)phosphoryloxy)-propylsulfanyl]acetic acid	656470	15055	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		[(2R)-2-acetoxy-3-(bis(benzyloxy)phosphoryloxy)-propylsulfanyl]acetic acid	656470	15055	compound shows in vitro antiparasitic activity
1.1.1.44	Ovis aries		[(2R)-2-acetoxy-3-phosphonooxypropane-1-sulfinyl]acetic acid	656470	9027	
1.1.1.44	Plasmodium falciparum		[(2R)-2-acetoxy-3-phosphonooxypropane-1-sulfinyl]acetic acid	656470	9027	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		[(2R)-2-acetoxy-3-phosphonooxypropane-1-sulfinyl]acetic acid	656470	9027	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		[(2R)-2-acetoxy-3-phosphonooxypropane-1-sulfinyl]acetic acid	656470	9027	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		[(4R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethylsulfanyl]acetic acid benzyl ester	656470	15052	compound shows low in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		[(4R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethylsulfanyl]acetic acid benzyl ester	656470	15052	compound shows low in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		[(4R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethylsulfanyl]acetic acid benzyl ester	656470	15052	compound shows low in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		[(4R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethylsulfanyl]acetic acid benzyl ester	656470	15052	compound shows low in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		[(5-nitrofuran-2-yl)methylidene]propanedioic acid	711463	58332	
1.1.1.44	Leishmania donovani		[3-(bis(benzyloxy)phosphoryloxy)-(2R)-2-hydroxypropane-1-sulfinyl]acetic acid	656470	15056	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		[3-(bis(benzyloxy)phosphoryloxy)-(2R)-2-hydroxypropane-1-sulfinyl]acetic acid	656470	15056	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		[3-(bis(benzyloxy)phosphoryloxy)-(2R)-2-hydroxypropane-1-sulfinyl]acetic acid	656470	15056	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		[3-(bis(benzyloxy)phosphoryloxy)-(2R)-2-hydroxypropane-1-sulfinyl]acetic acid	656470	15056	compound shows in vitro antiparasitic activity
1.1.1.44	Leishmania donovani		[3-(bis(benzyloxy)phosphoryloxy)-(2R)-2-hydroxypropane-1-sulfinyl]acetic acid benzyl ester	656470	15054	compound shows in vitro antiparasitic activity
1.1.1.44	Plasmodium falciparum		[3-(bis(benzyloxy)phosphoryloxy)-(2R)-2-hydroxypropane-1-sulfinyl]acetic acid benzyl ester	656470	15054	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma brucei		[3-(bis(benzyloxy)phosphoryloxy)-(2R)-2-hydroxypropane-1-sulfinyl]acetic acid benzyl ester	656470	15054	compound shows in vitro antiparasitic activity
1.1.1.44	Trypanosoma cruzi		[3-(bis(benzyloxy)phosphoryloxy)-(2R)-2-hydroxypropane-1-sulfinyl]acetic acid benzyl ester	656470	15054	compound shows in vitro antiparasitic activity
3.5.4.16	Rattus norvegicus	17beta-estradiol		670416	602	can regulate GTPCH gene expression via transcriptional mechanisms
3.5.4.16	Homo sapiens	H2O2		699378	20	0.1 mM H2O2 is the optimum concentration for the activation of GTPCHI
3.5.4.16	Homo sapiens	interferon-gamma		701141		GCH1 expression is strongly induced by a mixture of interleukin-1beta, tissue necrosis factor-alpha, and interferon-gamma released by microglia under brain-damaging conditions
3.5.4.16	Homo sapiens	Interleukin-1beta		701141		GCH1 expression is strongly induced by a mixture of interleukin-1beta, tissue necrosis factor-alpha, and interferon-gamma released by microglia under brain-damaging conditions
3.5.4.16	Rattus norvegicus	L-phenylalanine		656261	98	stimulates the enzyme via mediation of GFRP which forms a complex with the enzyme
3.5.4.16	Rattus norvegicus	L-phenylalanine		657188	98	feed-forward stimulation at subsaturating concentration of GTP mediated by GTP cyclohydrolase I feedback regulatory protein, i.e. GFRP, in complex with the enzyme, binding site structure
3.5.4.16	Rattus norvegicus	L-phenylalanine		657288	98	feed-forward stimulation at subsaturating concentration of GTP mediated by GTP cyclohydrolase I feedback regulatory protein, i.e. GFRP
3.5.4.16	Homo sapiens	L-phenylalanine		699378	98	feedback regulation via L-phenylalanine
3.5.4.16	Mus musculus	lipolysaccharide		667769		commercially isolated from Escherichia coli serotype 026:B6, activates and upregulates the enzyme in adipose tissue, but in cultured 3T3-L1 adipocytes lipolysaccharide addition only increases the enzyme expression level in presence of TNFalpha and interferon gamma, overview
3.5.4.16	Rattus norvegicus	more		667025		lipopolysaccharide application by injection increases enzyme expression in kidney, but not in liver and lung
3.5.4.16	Rattus norvegicus	more		670416		estrogen-triggered activation of GTP cyclohydrolase 1 gene expression, time course in transfected cells and mechanism, overview
3.5.4.16	Rattus norvegicus	more		684313		GTP-CH 1 mRNA and protein expression is unaltered by renal ischemia-reperfusion
3.5.4.16	Drosophila melanogaster	more		698830		GTP cyclohydrolase I is activated by phosphorylation with protein kinase C or A
3.5.4.16	Mus musculus	more		698891		GTPCH expression is regulated by inflammatory stimuli, in association with reduced expression of GTP cyclohydrolase feedback regulatory protein
3.5.4.16	Mus musculus	more		701372		reduction in GTP-CH1 regulatory protein expression following proinflammatory stimulation is necessary for optimal GTP-CH1 activity
3.5.4.16	Homo sapiens	more		719308		S81 phosphorylation enhances GTPCH-1 enzyme activity
3.5.4.16	Homo sapiens	tissue necrosis factor-alpha		701141		GCH1 expression is strongly induced by a mixture of interleukin-1beta, tissue necrosis factor-alpha, and interferon-gamma released by microglia under brain-damaging conditions
3.5.4.16	Rattus norvegicus		(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin	657188	221	i.e. BH4, feedback inhibition mediated by GTP cyclohydrolase I feedback regulatory protein, i.e. GFRP, in complex with the enzyme, binding site structure
3.5.4.16	Rattus norvegicus		(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin	657288	221	i.e. BH4, feedback inhibition mediated by GTP cyclohydrolase I feedback regulatory protein, i.e. GFRP, inhibition is enhaced by dGTP
3.5.4.16	Rattus norvegicus		2,4-Diamino-6-hydroxypyrimidine	209556	10385	direct inhibitition at higher concentrations
3.5.4.16	Rattus norvegicus		2,4-Diamino-6-hydroxypyrimidine	669268	10385	DAHP, the inhibition mechanism involves the GTP cyclohydrolase I feedback regulatory protein GFRP, overview, the inhibition is fully reversible by L-phenylalanine
3.5.4.16	Bos taurus		2,4-Diamino-6-hydroxypyrimidine	698205	10385	
3.5.4.16	Mus musculus		2,4-Diamino-6-hydroxypyrimidine	698205	10385	
3.5.4.16	Methanocaldococcus jannaschii		7-methyl-GTP	685163	7112	36% inhibition at 2 mM GMP
3.5.4.16	Homo sapiens		8-Aminoguanosine triphosphate	209543	63749	
3.5.4.16	Escherichia coli		8-Azaguanine	670924	1540	43% inhibition at 2.9 mM
3.5.4.16	Escherichia coli		8-ethoxycarbonyl-7-deazaguanine	670924	84910	78% inhibition at 2.9 mM
3.5.4.16	Escherichia coli		8-methyl-7-deazaguanine	670924	84908	94% inhibition at 2.9 mM
3.5.4.16	Thermus thermophilus		8-oxo-dGTP	669149	1687	competitive inhibition
3.5.4.16	Thermus thermophilus		8-oxo-GTP	669149	5623	competitive inhibition, binds tightly to the enzyme with higher affinity than GTP, structure and binding network, overview
3.5.4.16	Escherichia coli		8-trifluoromethyl-7-deazaguanine	670924	84909	17% inhibition at 2.9 mM
3.5.4.16	Escherichia coli		ADP	209546	8	competitive inhibitor
3.5.4.16	Serratia indica		Al3+	209551	229	
3.5.4.16	Escherichia coli		ascorbate	209553	88	
3.5.4.16	Drosophila melanogaster		ATP	209544, 209546	7	
3.5.4.16	Escherichia coli		ATP	209546	7	competitive inhibitor
3.5.4.16	Escherichia coli		ATP	209541, 209549	7	
3.5.4.16	Serratia indica		ATP	209546, 209551	7	
3.5.4.16	Thermus thermophilus		ATP	669149	7	competitive inhibition
3.5.4.16	Drosophila melanogaster		Ca2+	209544, 209546	18	
3.5.4.16	Geobacillus stearothermophilus		Ca2+	209546, 209548	18	
3.5.4.16	Streptomyces tubercidicus		Ca2+	209561	18	
3.5.4.16	Bacillus subtilis		Ca2+	712290	18	no activity detected regardless of metal concentration
3.5.4.16	Mus musculus		caveolin-1	698211		overexpression of caveolin-1 inhibits GTPCH I activity
3.5.4.16	Geobacillus stearothermophilus		Cd2+	209548	48	
3.5.4.16	Serratia indica		Cd2+	209550, 209551	48	
3.5.4.16	Mus musculus		Cd2+	209559	48	
3.5.4.16	Bacillus subtilis		Cd2+	712290	48	no activity detected regardless of metal concentration
3.5.4.16	Streptomyces tubercidicus		Co2+	209561	21	
3.5.4.16	Homo sapiens		Co2+	655489	21	inhibition by elimination of the required metal-free GTP when present at high concentration with respect to the GTP concentration, overview
3.5.4.16	Bacillus subtilis		Co2+	712290	21	24% residual activity at 0.1 mM
3.5.4.16	Bacillus subtilis		Co3+	712290	21	no activity detected regardless of metal concentration
3.5.4.16	Streptomyces tubercidicus		CTP	209561	56	
3.5.4.16	Gallus gallus		Cu2+	209546	28	
3.5.4.16	Rattus norvegicus		Cu2+	209545, 209546	28	
3.5.4.16	Geobacillus stearothermophilus		Cu2+	209545, 209546, 209548	28	
3.5.4.16	Serratia indica		Cu2+	209545, 209546, 209550	28	
3.5.4.16	Escherichia coli		Cu2+	209545, 209546, 209553	28	
3.5.4.16	Mus musculus		Cu2+	209559	28	
3.5.4.16	Streptomyces tubercidicus		Cu2+	209561	28	
3.5.4.16	Bacillus subtilis		Cu2+	712290	28	no activity detected regardless of metal concentration
3.5.4.16	Drosophila melanogaster		DAHP	687523	3060	non-competitive inhibitor
3.5.4.16	Drosophila melanogaster		dGTP	209546	194	
3.5.4.16	Escherichia coli		dGTP	209546	194	competitive inhibitor
3.5.4.16	Escherichia coli		dGTP	209549	194	
3.5.4.16	Thermus thermophilus		dGTP	669149	194	competitive inhibition
3.5.4.16	Methanocaldococcus jannaschii		dGTP	685163	194	28% inhibition at 2 mM GMP
3.5.4.16	Rattus norvegicus		dihydrobiopterin	656261	1041	induction of feedback inhibition, binding site structure
3.5.4.16	Drosophila melanogaster		Divalent cations	209544		
3.5.4.16	Bacillus subtilis		EDTA	712290	223	no activity of GCYH-IB is observed in the presence of EDTA
3.5.4.16	Methanocaldococcus jannaschii		fapy-GMP	685163	47274	1 mM results in a 5fold reduction in activity
3.5.4.16	Escherichia coli		Fe2+	209553	23	
3.5.4.16	Streptomyces tubercidicus		Fe2+	209561	23	
3.5.4.16	Bacillus subtilis		Fe2+	712290	23	75% residual activity at 1 mM
3.5.4.16	Serratia indica		Fe3+	209545	66	
3.5.4.16	Bacillus subtilis		Fe3+	712290	66	no activity detected regardless of metal concentration
3.5.4.16	Drosophila melanogaster		GDP	209546	49	
3.5.4.16	Serratia indica		GDP	209546, 209551	49	
3.5.4.16	Streptomyces tubercidicus		GDP	209561	49	
3.5.4.16	Streptomyces tubercidicus		GMP	209561	150	
3.5.4.16	Methanocaldococcus jannaschii		GMP	685163	150	43% inhibition at 2 mM GMP
3.5.4.16	Drosophila melanogaster		GTP	209544	35	substrate inhibition above 0.2 mM
3.5.4.16	Rattus norvegicus		GTP	209545	35	substrate inhibition above 0.2 mM
3.5.4.16	Solanum lycopersicum		GTP	660407	35	substrate inhibition above 0.1 mM
3.5.4.16	Homo sapiens		GTP cyclohydrolase feedback regulatory protein	719308		i.e. GFRP, GTP cyclohydrolase I, GTPCH-1, undergoes negative feedback regulation by its endproduct tetrahydrobiopterin via interaction with the GTP cyclohydrolase feedback regulatory protein, GFRP. GFRP binding increased the apparent Km of GTPCH-1, which also contributes to inhibition and increases the cooperativity of substrate binding in the wild-type but not the S81D mutant. GFRP both inhibits and stimulates GTPCH-1 activity in vitro depending on interactions with either tetrahydrobiopterin or phenylalanine. GTPCH-1 phosphorylation reduces its binding to GFRP
3.5.4.16	Rattus norvegicus		GTP cyclohydrolase I feedback regulatory protein GFRP	669268		natural inhibitor, inhibition mechanism, in vitro inhibition together with 2,4-diamino-6-hydroxypyrimidine, the inhibition is fully reversible by L-phenylalanine, regulatory function in physiological feedback inhibition, overview
3.5.4.16	Rattus norvegicus		GTPCH feedback regulatory protein	719914		GFRP, the allosteric regulatory protein GFRP triggers a noncompetitive attenuation of GTPCH activity, an allosteric effector is unnecessary for GFRP to influence GTPCH activity. GFRP-mediated allosteric regulation by small molecule effectors is indistinguishable for truncated mutant DELTA45-GTPCH and wild-type GTPCH
3.5.4.16	Escherichia coli		guanosine 5'-tetraphosphate	209546, 209549	1332	
3.5.4.16	Homo sapiens		H2O2	699378	20	more than 0.3 mM H2O2 result in a decrease in activity of GTPCHI, the function of the GTP cyclohydrolase I/GTP cyclohydrolase I feedback regulatory protein complex is not affected by H2O2
3.5.4.16	Gallus gallus		Hg2+	209546	31	
3.5.4.16	Geobacillus stearothermophilus		Hg2+	209545, 209546, 209548	31	
3.5.4.16	Serratia indica		Hg2+	209545, 209546, 209550, 209551	31	
3.5.4.16	Escherichia coli		Hg2+	209545, 209546, 209553	31	
3.5.4.16	Mus musculus		Hg2+	209559	31	
3.5.4.16	Drosophila melanogaster		ITP	209544	203	
3.5.4.16	Streptomyces tubercidicus		K+	209561	37	
3.5.4.16	Drosophila melanogaster		KCl	209544	74	
3.5.4.16	Homo sapiens		L-erythro-5,6,7,8-tetrahydrobiopterin	209543	221	
3.5.4.16	Rattus norvegicus		L-erythro-5,6,7,8-tetrahydrobiopterin	209556	221	indirect inhibition of 2,4-diamino-6-hydroxypyrimidine at lower concentrations with the help of feedback regulatory protein
3.5.4.16	Rattus norvegicus		L-erythro-5,6,7,8-tetrahydrobiopterin	209557, 209558	221	L-phenylalanine reverses inhibition; with help of feedback regulatory protein
3.5.4.16	Escherichia coli		L-erythro-5,6,7,8-tetrahydrobiopterin	209566	221	UTP reduces inhibition
3.5.4.16	Homo sapiens		L-erythro-7,8-dihydrobiopterin	209543	1041	
3.5.4.16	Homo sapiens		L-Sepiapterin	209543	1099	
3.5.4.16	Drosophila melanogaster		Mg2+	209544, 209546	25	
3.5.4.16	Lactobacillus plantarum		Mg2+	209545, 209546	25	
3.5.4.16	Rattus norvegicus		Mg2+	209545, 209546	25	
3.5.4.16	Mus musculus		Mg2+	209559	25	
3.5.4.16	Streptomyces tubercidicus		Mg2+	209561	25	
3.5.4.16	Bacillus subtilis		Mg2+	209564	25	
3.5.4.16	Homo sapiens		Mg2+	655489	25	inhibition by elimination of the required metal-free GTP when present at high concentration with respect to the GTP concentration, formation of Mg-GTP, overview
3.5.4.16	Bacillus subtilis		Mg2+	712290	25	43% residual activity at 0.1 mM
3.5.4.16	Drosophila melanogaster		Mn2+	209544	26	
3.5.4.16	Escherichia coli		Mn2+	209553	26	
3.5.4.16	Streptomyces tubercidicus		Mn2+	209561	26	
3.5.4.16	Homo sapiens		Mn2+	655489	26	inhibition by elimination of the required metal-free GTP when present at high concentration with respect to the GTP concentration, overview
3.5.4.16	Homo sapiens		more	655489		no inhibition by EGTA
3.5.4.16	Escherichia coli		more	670924		synthesis and inhibitory potential of 7-deazaguanine derivatives on GTPCH I, inhibitory mechanism, overview
3.5.4.16	Methanocaldococcus jannaschii		more	685163		Mn2+ enzyme is not inactivated by exposure to oxygen
3.5.4.16	Mus musculus		more	701372		GTP-CH1 activity can be inhibited by tetrahydrobiopterin through its protein-protein interactions with GTP-CH1 regulatory protein
3.5.4.16	Ovis aries		more	718553		asymmetric dimethylarginine, ADMA, decreases GCH1 protein, but not mRNA concentrations, in pulmonary arterial endothelial cells because of the ubiquitination and proteasome-dependent degradation of GCH1. Overexpression of CHIP potentiates, whereas a CHIP U-box domain mutant attenuates, ADMA-induced GCH1 degradation and reductions in cellular BH4 concentrations. L-Arginine acts antagonistic and restores the activities
3.5.4.16	Rattus norvegicus		more	719914		the N-terminal peptide of mammalian GTP cyclohydrolase I is an autoinhibitory control element and contributes to binding the allosteric regulatory protein GFRP. The autoinhibitory peptide provides a molecular mechanism for physiological up-regulation of GTPCH activity
3.5.4.16	Bos taurus		N-acetyl-serotonin	698205	1097	
3.5.4.16	Mus musculus		N-acetyl-serotonin	698205	1097	
3.5.4.16	Streptomyces tubercidicus		Na+	209561	55	
3.5.4.16	Drosophila melanogaster		NaCl	209544	39	
3.5.4.16	Streptomyces tubercidicus		Ni2+	209561	36	
3.5.4.16	Bacillus subtilis		Ni2+	712290	36	9.8% residual activity at 0.1 mM
3.5.4.16	Methanocaldococcus jannaschii		oxygen	685163	11	
3.5.4.16	Serratia indica		p-chloromercuribenzoate	209551	40	
3.5.4.16	Geobacillus stearothermophilus		Pb2+	209548	132	
3.5.4.16	Escherichia coli		PO43-	209546	684	uncompetitive inhibitor
3.5.4.16	Escherichia coli		PO43-	209545, 209549	684	
3.5.4.16	Geobacillus stearothermophilus		Sn2+	209548	346	
3.5.4.16	Mus musculus		Sn2+	209559	346	
3.5.4.16	Serratia indica		SO42-	209551	148	
3.5.4.16	Geobacillus stearothermophilus		Sr2+	209548	289	
3.5.4.16	Rattus norvegicus		streptozotocin	698049	3664	the expression of GCH-I is decreased by streptozotocin treatment (60 mg/kg iv, 7 weeks)
3.5.4.16	Escherichia coli		tetrahydrobiopterin	654607	221	feedback inhibition
3.5.4.16	Rattus norvegicus		tetrahydrobiopterin	656261	221	induction of feedback inhibition of the enzyme via mediation of GFRP which forms a complex with the enzyme, binding site structure
3.5.4.16	Rattus norvegicus		tetrahydrobiopterin	656492	221	the cofactor required for hydroxylation of aromatic amino acids regulates its own synthesis through feedback inhibition of the enzyme mediated by the regulatory subunit called GTP cyclohydrolase I feedback regulatory protein, i.e. GFRP
3.5.4.16	Drosophila melanogaster		tetrahydrobiopterin	698830	221	
3.5.4.16	Homo sapiens		tetrahydrobiopterin	719308	221	GTP cyclohydrolase I, GTPCH-1, undergoes negative feedback regulation by its endproduct tetrahydrobiopterin via interaction with the GTP cyclohydrolase feedback regulatory protein, GFRP
3.5.4.16	Rattus norvegicus		tetrahydrobiopterin	719914	221	BH4, can limit its own synthesis by triggering decameric GTPCH to assemble in an inhibitory complex with two GTPCH feedback regulatory protein, GFRP, pentamers
3.5.4.16	Escherichia coli		TTP	209546	137	competitive inhibitor
3.5.4.16	Escherichia coli		UTP	209541	61	
3.5.4.16	Escherichia coli		UTP	209546	61	competitive inhibitor
3.5.4.16	Streptomyces tubercidicus		UTP	209561	61	
3.5.4.16	Bacillus subtilis		UTP	209564	61	
3.5.4.16	Drosophila melanogaster		Zn2+	209546	19	
3.5.4.16	Serratia indica		Zn2+	209545, 209546, 209551	19	
3.5.4.16	Mus musculus		Zn2+	209559	19	
3.5.4.16	Homo sapiens		Zn2+	655489	19	inhibition by elimination of the required metal-free GTP when present at high concentration with respect to the GTP concentration, overview
3.5.4.16	Bacillus subtilis		Zn2+	712290	19	14% residual activity at 0.05 mM
3.5.4.25	Meyerozyma guilliermondii		Cu2+	209545	28	
3.5.4.25	Meyerozyma guilliermondii		diphosphate	209545	13	
3.5.4.25	Escherichia coli		diphosphate	246729	13	0.1 mM
3.5.4.25	Escherichia coli		diphosphate	209545, 246730	13	
3.5.4.25	Escherichia coli		diphosphate	246732	13	competitive inhibitor
3.5.4.25	Escherichia coli		diphosphate	656006	13	competitive
3.5.4.25	Bacillus subtilis		EDTA	675226	223	
3.5.4.25	Meyerozyma guilliermondii		phosphate	209545	12	
3.5.4.25	Escherichia coli		phosphate	656006	12	partial uncompetitive at low concentration, competitive at concentrations above 6 mM
3.5.4.25	Meyerozyma guilliermondii		Zn2+	209545	19	
1.1.1.23	Mycobacterium tuberculosis	EDTA		721426	223	118% activity at 0.1 mM, 135% at 1 mM, slightly inhibitory above 10 mM
1.1.1.23	Brucella suis		(2S)-2-amino-3-(1H-imidazol-4-yl)-N'-(naphthalen-2-ylsulfonyl)propanehydrazide	688045	45944	
1.1.1.23	Brucella suis		(2S)-2-amino-3-(1H-imidazol-4-yl)-N'-[(4-methylphenyl)sulfonyl]propanehydrazide	688045	45945	
1.1.1.23	Brucella suis		(2S)-2-amino-N'-(biphenyl-4-ylsulfonyl)-3-(1H-imidazol-4-yl)propanehydrazide	688045	45946	
1.1.1.23	Brucella suis		(2S)-2-amino-N'-[(4-bromophenyl)sulfonyl]-3-(1H-imidazol-4-yl)propanehydrazide	688045	45947	
1.1.1.23	Brucella sp.		(3S)-3-amino-1-(2,3,4,5,6-pentafluorophenyloxy)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride	723090	61578	
1.1.1.23	Brucella sp.		(3S)-3-amino-1-(2,3,4,5,6-pentafluorophenylthio)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride	723090	61571	
1.1.1.23	Brucella sp.		(3S)-3-amino-1-(4-bromophenoxy)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride	723090	61577	
1.1.1.23	Brucella sp.		(3S)-3-amino-1-(4-bromophenylthio)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride	723090	61570	
1.1.1.23	Brucella sp.		(3S)-3-amino-1-(4-fluorophenoxy)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride	723090	61575	
1.1.1.23	Brucella sp.		(3S)-3-amino-1-(4-fluorophenylthio)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride	723090	61568	
1.1.1.23	Brucella sp.		(3S)-3-amino-1-hydroxy-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride	723090	61572	
1.1.1.23	Brucella sp.		(3S)-3-amino-1-thio-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride	723090	61565	
1.1.1.23	Brucella suis		(3S)-3-amino-1-[4-(benzyloxy)phenyl]-4-(1H-imidazol-4-yl)butan-2-one	723322	46964	
1.1.1.23	Brucella suis		(3S)-3-amino-1-[4-(biphenyl-4-ylethynyl)phenyl]-4-(1H-imidazol-4-yl)butan-2-one	723322	102356	
1.1.1.23	Brucella suis		(3S)-3-amino-1-[4-(biphenyl-4-ylmethoxy)phenyl]-4-(1H-imidazol-4-yl)butan-2-one	723322	102354	
1.1.1.23	Brucella suis		(3S)-3-amino-1-[4-[(4-bromobenzyl)oxy]phenyl]-4-(1H-imidazol-4-yl)butan-2-one	723322	102353	
1.1.1.23	Brucella suis		(3S)-3-amino-1-[4-[(4-butylbenzyl)oxy]phenyl]-4-(1H-imidazol-4-yl)butan-2-one	723322	61551	50% inhibition of pathogen growth in minimal medium at 0.5 mM
1.1.1.23	Brucella suis		(3S)-3-amino-1-[4-[(4-tert-butylphenyl)ethynyl]phenyl]-4-(1H-imidazol-4-yl)butan-2-one	723322	61563	30% inhibition of pathogen growth in minimal medium at 0.5 mM
1.1.1.23	Brucella suis		(3S)-3-amino-1-[4-[(E)-2-(biphenyl-4-yl)ethenyl]phenyl]-4-(1H-imidazol-4-yl)butan-2-one	723322	102355	
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(4-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]phenyl)butan-2-one	723322	61560	
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(4-[[4-(naphthalen-2-yl)benzyl]oxy]phenyl)butan-2-one	723322	61555	complete inhibition of pathogen growth in minimal medium at 0.5 mM
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(4-[[4-(trifluoromethyl)benzyl]oxy]phenyl)butan-2-one	723322	61553	70% inhibition of pathogen growth in minimal medium at 0.5 mM
1.1.1.23	Brucella sp.		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(naphthalen-2-yloxy)butan-2-one dihydrochloride	723090	61576	
1.1.1.23	Brucella sp.		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(naphthalen-2-ylthio)butan-2-one dihydrochloride	723090	61569	
1.1.1.23	Brucella sp.		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(p-tolyloxy)butan-2-one dihydrochloride	723090	61574	
1.1.1.23	Brucella sp.		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(phenyloxy)butan-2-one dihydrochloride	723090	61573	
1.1.1.23	Brucella sp.		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(phenylthio)butan-2-one dihydrochloride	723090	61566	
1.1.1.23	Brucella sp.		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(tolylthio)butan-2-one dihydrochloride	723090	61567	
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-(2-phenylethyl)phenyl]butan-2-one	723322	61556	
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-(phenylethynyl)phenyl]butan-2-one	723322	61561	complete inhibition of pathogen growth in minimal medium at 0.5 mM
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(1E)-3-phenylprop-1-en-1-yl]phenyl]butan-2-one	723322	61557	
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(4-methoxybenzyl)oxy]phenyl]butan-2-one	723322	61552	30% inhibition of pathogen growth in minimal medium at 0.5 mM
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(4-methylbenzyl)oxy]phenyl]butan-2-one	723322	61550	30% inhibition of pathogen growth in minimal medium at 0.5 mM
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(4-methylphenyl)ethynyl]phenyl]butan-2-one	723322	61562	
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(4-pentylphenyl)ethynyl]phenyl]butan-2-one	723322	61564	30% inhibition of pathogen growth in minimal medium at 0.5 mM
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(4-phenoxybenzyl)oxy]phenyl]butan-2-one	723322	61554	70% inhibition of pathogen growth in minimal medium at 0.5 mM
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(E)-2-(4-methylphenyl)ethenyl]phenyl]butan-2-one	723322	61559	complete inhibition of pathogen growth in minimal medium at 0.5 mM
1.1.1.23	Brucella suis		(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(E)-2-phenylethenyl]phenyl]butan-2-one	723322	61558	
1.1.1.23	Geotrichum candidum		(7R)-1,3-diiodo-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylic acid	697254	51259	weaker inhibitor
1.1.1.23	Brucella suis		(S)-3-amino-1-(4-(benzyloxy)phenyl)-4-(1H-imidazol-4-yl)butan-2-one	688045	46964	
1.1.1.23	Brucella suis		(S)-3-amino-1-(4-bromophenyl)-4-(1H-imidazol-4-yl)butan-2-one	684485	25094	growth of cells is inhibited in minimal medium, multiplication of cells in human macrophages is totally abolished. No biological effect in rich medium
1.1.1.23	Brucella suis		(S)-3-amino-1-(4-bromophenyl)-4-(1H-imidazol-4-yl)butan-2-one	688045	25094	
1.1.1.23	Brucella suis		(S)-3-amino-1-(4-chlorophenyl)-4-(1H-imidazol-4-yl)butan-2-one	684485	25095	growth of cells is inhibited in minimal medium, multiplication of cells in human macrophages is totally abolished. No biological effect in rich medium
1.1.1.23	Brucella suis		(S)-3-amino-1-(4-chlorophenyl)-4-(1H-imidazol-4-yl)butan-2-one	688045	25095	
1.1.1.23	Brucella suis		(S)-3-amino-1-(4-fluorophenyl)-4-(1H-imidazol-4-yl)butan-2-one	688045	46000	
1.1.1.23	Brucella suis		(S)-3-amino-4-(1H-imidazol-4-yl)-1-(4-phenoxyphenyl)butan-2-one	688045	46001	
1.1.1.23	Brucella suis		(S)-3-amino-4-(1H-imidazol-4-yl)-1-(naphthalen-2-yl)butan-2-one	684485	25096	growth of cells is inhibited in minimal medium, multiplication of cells in human macrophages is totally abolished. No biological effect in rich medium
1.1.1.23	Brucella suis		(S)-3-amino-4-(1H-imidazol-4-yl)-1-(naphthalen-2-yl)butan-2-one	688045	25096	
1.1.1.23	Brucella suis		(S)-3-amino-4-(1H-imidazol-4-yl)-1-p-tolylbutan-2-one	688045	46002	
1.1.1.23	Mycobacterium tuberculosis		1,10-phenanthroline	721426	58	54% inhibition at 1 mM, 96% at 5 mM
1.1.1.23	Geotrichum candidum		1,3-diiodo-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylic acid	711417	58352	
1.1.1.23	Geotrichum candidum		3-(1H-imidazol-4-yl)propanoic acid	711417	58353	
1.1.1.23	Geotrichum candidum		5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylic acid	711417	58354	i.e. RJ-278
1.1.1.23	Geotrichum candidum		7,8-dihydroimidazo[1,5-c]pyrimidin-5(6H)-one	697254	17543	most active inhibitor
1.1.1.23	Geotrichum candidum		7,8-dihydroimidazo[1,5-c]pyrimidin-5(6H)-one	711417	17543	
1.1.1.23	Salmonella enterica subsp. enterica serovar Typhimurium		7-chloro-4-nitro-2,1,3-benzoxadiazole	286330	2816	0.1 mM, pseudo first order inactivation, binds to Cys-116 in active site
1.1.1.23	Brassica oleracea		Ba2+	286329	105	0.5 mM, 35% inhibition
1.1.1.23	Arthrobacter histidinolovorans		Borate	286340	1054	10 mM, 90% inhibition
1.1.1.23	Brassica oleracea		Ca2+	286327	18	
1.1.1.23	Brassica oleracea		Ca2+	286329	18	0.5 mM, 64% inhibition
1.1.1.23	Salmonella enterica subsp. enterica serovar Typhimurium		Cd2+	286339	48	0.1 mM, 33% inhibition
1.1.1.23	Brassica oleracea		Cu2+	286327	28	
1.1.1.23	Brassica oleracea		Cu2+	286329	28	0.5 mM, 76% inhibition
1.1.1.23	Arthrobacter histidinolovorans		EDTA	286340	223	30 mM, 50% inhibition at pH 7.5
1.1.1.23	Mycobacterium tuberculosis		EDTA	721426	223	118% activity at 0.1 mM, 135% at 1 mM, slightly inhibitory above 10 mM
1.1.1.23	Escherichia coli		HgCl2	286332	104	0.5 mM, 100% inhibition, 0.05 mM 79% inhibition
1.1.1.23	Salmonella enterica subsp. enterica serovar Typhimurium		HgCl2	286339	104	0.1 mM, 80% inhibition, pH 9.4
1.1.1.23	Salmonella enterica subsp. enterica serovar Typhimurium		histamine	286330	498	competitive inhibition
1.1.1.23	Salmonella enterica subsp. enterica serovar Typhimurium		imidazole	286330	390	competitive inhibition
1.1.1.23	Geotrichum candidum		imidazole-4-carboxylic acid	697254	52036	most active inhibitor
1.1.1.23	Geotrichum candidum		methyl (7R)-1-chloro-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylate	697254	51260	weaker inhibitor
1.1.1.23	Geotrichum candidum		methyl 1-chloro-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylate	711417	58355	
1.1.1.23	Geotrichum candidum		methyl 1-methyl-N-(phenoxycarbonyl)histidinate	711417	58350	
1.1.1.23	Geotrichum candidum		methyl 3-(1H-imidazol-4-yl)propanoate	697254, 711417	17542	
1.1.1.23	Geotrichum candidum		methyl N-(ethoxycarbonyl)-1-methyl-L-histidinate	697254	51258	
1.1.1.23	Geotrichum candidum		methyl N-(methoxycarbonyl)-3-methyl-L-histidinate	697254	51257	
1.1.1.23	Geotrichum candidum		methyl N-(methoxycarbonyl)histidinate	711417	58351	
1.1.1.23	Brassica oleracea		Mg2+	286327	25	
1.1.1.23	Brassica oleracea		Mg2+	286329	25	0.5 mM, 46% inhibition
1.1.1.23	Geotrichum candidum		more	697254		5% dimethyl sulfoxide or methyl N-[(trifluoromethoxy)carbonyl]-L-histidinate trifluoroacetate fails to exert any growth inhibitory activity
1.1.1.23	Geotrichum candidum		more	711417		screening of substrate analog inhibitors of histidinol dehydrogenase, and docking analysis of these antifungal agents, overview
1.1.1.23	Brucella sp.		more	723090		synthesis and evaluation of alpha-O-arylketones and alpha-S-arylketones derived from histidine
1.1.1.23	Brucella suis		more	723322		design, synthesis and evaluation of 19 potential HDH inhibitors, molecular modeling and docking study, overview
1.1.1.23	Salmonella enterica subsp. enterica serovar Typhimurium		N-(4-dimethylamino-3,5-dinitrophenyl)-maleimide	286333	31425	75% inhibition with one equivalent per subunit
1.1.1.23	Salmonella enterica subsp. enterica serovar Typhimurium		N-(4-dimethylamino-3,5-dinitrophenyl)-maleimide	286336	31425	
1.1.1.23	Brassica oleracea		Ni2+	286329	36	0.5 mM, 54% inhibition
1.1.1.23	Salmonella enterica subsp. enterica serovar Typhimurium		p-chloromercuribenzoate	286333	40	75% inhibition with two equivalents per subunit
1.1.1.23	Salmonella enterica subsp. enterica serovar Typhimurium		p-chloromercuribenzoate	286339	40	2.5 mM, 60% inhibition
1.1.1.23	Arthrobacter histidinolovorans		p-chloromercuribenzoate	286340	40	0.02 mM, 50% inhibition
1.1.1.23	Salmonella enterica subsp. enterica serovar Typhimurium		pyridoxal 5'-phosphate	286334	30	100 mM, 62.5% inhibition, concentration dependent, almost completely reversible
1.1.1.23	Escherichia coli		Urea	286332	110	2.2 mM, 50% inhibition, reversible
1.1.1.23	Brassica oleracea		Zn2+	286327	19	
1.1.1.23	Brassica oleracea		Zn2+	286329	19	0.5 mM, 66% inhibition
2.5.1.61	Arabidopsis thaliana		2-bromoporphobilinogen	489952	66953	
2.5.1.61	Homo sapiens		2-methylopsopyrroledicarboxylic acid	5883	65971	
2.5.1.61	Rattus norvegicus		5,5'-dithiobis(2-nitrobenzoic acid)	489953	196	5 mM, pH 8.0, 50% inhibition
2.5.1.61	Arabidopsis thaliana		Ag2+	489952	798	1 mM AgCl2, 90% inhibition
2.5.1.61	Rattus norvegicus		Al3+	489934	229	
2.5.1.61	Rhodobacter sphaeroides		aniline	489923	547	
2.5.1.61	Rattus norvegicus		Ba2+	489934	105	
2.5.1.61	Rhodobacter sphaeroides		Ca2+	489922	18	CaCl2
2.5.1.61	Rhodobacter sphaeroides		Ca2+	489923	18	
2.5.1.61	Homo sapiens		Ca2+	489926	18	0.1 mM CaCl2, 80% inhibition
2.5.1.61	Pisum sativum		Ca2+	489946	18	CaCl2, weak
2.5.1.61	Homo sapiens		Ca2+	5883	18	25 mM CaCl2, 90% inhibition
2.5.1.61	Rattus norvegicus		Cd2+	489934	48	strong
2.5.1.61	Arabidopsis thaliana		Cd2+	489952	48	0.1 mM CdCl2, 55% inhibition
2.5.1.61	Homo sapiens		Cd2+	5883	48	12 mM, complete inhibition
2.5.1.61	Rattus norvegicus		Co2+	489934	21	
2.5.1.61	Pisum sativum		Co2+	489946	21	CoCl2, strong
2.5.1.61	Arabidopsis thaliana		Co2+	489952	21	0.1 mM CoCl2, 95% inhibition
2.5.1.61	Homo sapiens		Coproporphyrinogen	489948	10802	
2.5.1.61	Rattus norvegicus		Cr3+	489934	701	strong
2.5.1.61	Homo sapiens		Cu2+	489926	28	1 mM CuSO4, 87% inhibition
2.5.1.61	Rattus norvegicus		Cu2+	489934	28	strong
2.5.1.61	Arabidopsis thaliana		Cu2+	489952	28	1 mM CuSO4, 66% inhibition
2.5.1.61	Rhodobacter sphaeroides		Fe2+	489922	23	0.1 mM FeSO4
2.5.1.61	Homo sapiens		Fe2+	489926	23	1 mM FeSO4, 58% inhibition
2.5.1.61	Pisum sativum		Fe2+	489946	23	FeSO4, strong
2.5.1.61	Rhodobacter sphaeroides		Fe3+	489922	66	0.1 mM FeCl3
2.5.1.61	Homo sapiens		Fe3+	489926	66	1 mM FeCl3, 62% inhibition
2.5.1.61	Rattus norvegicus		Fe3+	489934	66	strong
2.5.1.61	Homo sapiens		glycerol	5883	129	15% inhibits 40% of enzyme activity
2.5.1.61	Rhodobacter sphaeroides		Hg2+	489922	31	HgCl2, strong
2.5.1.61	Homo sapiens		Hg2+	489926	31	0.0004 mM HgCl2, 80% inhibition
2.5.1.61	Triticum aestivum		Hg2+	489930	31	inhibition by mercury derivates of porphobilinogen, i.e. PBG-Hg, and opsopyrroledicarboxylic acid, i.e. OPD-Hg, is enhanced by porphobilinogen; opsopyrroledicarboxylic acid enhances inhibition by HgCl2
2.5.1.61	Rattus norvegicus		Hg2+	489934	31	strong
2.5.1.61	Arabidopsis thaliana		Hg2+	489952	31	0.1 mm HgCl2, 76% inhibition
2.5.1.61	Rhodobacter sphaeroides		hydrazine	489923	552	
2.5.1.61	Rhodobacter sphaeroides		hydroxylamine	489923	80	
2.5.1.61	Arabidopsis thaliana		hydroxylamine	489952	80	
2.5.1.61	Rhodobacter sphaeroides		Iodine	489922	1215	
2.5.1.61	Homo sapiens		isoporphobilinogen	5883	66480	
2.5.1.61	Arabidopsis thaliana		K+	489952	37	at high concentrations
2.5.1.61	Rhodobacter sphaeroides		methoxyamine	489923	4929	
2.5.1.61	Rhodobacter sphaeroides		methylamine	489923	279	
2.5.1.61	Rhodobacter sphaeroides		Mg2+	489922	25	MgCl2
2.5.1.61	Rhodobacter sphaeroides		Mg2+	489923	25	
2.5.1.61	Homo sapiens		Mg2+	489926	25	50 mM MgCl2, 55% inhibition
2.5.1.61	Rattus norvegicus		Mg2+	489934	25	
2.5.1.61	Pisum sativum		Mg2+	489946	25	MgCl2, weak
2.5.1.61	Homo sapiens		Mg2+	5883	25	25 mM, 90% inhibition
2.5.1.61	Rhodobacter sphaeroides		Mn2+	489922	26	MnCl2
2.5.1.61	Rattus norvegicus		Mn2+	489934	26	
2.5.1.61	Pisum sativum		Mn2+	489946	26	MnCl2; strong inhibition at submillimolar concentrations
2.5.1.61	Rhodobacter sphaeroides		more	489923		mechanism of inhibition
2.5.1.61	Triticum aestivum		more	489923		
2.5.1.61	Triticum aestivum		more	489930		effects of sulfhydryl reagents
2.5.1.61	Arabidopsis thaliana		more	489952		
2.5.1.61	Rattus norvegicus		more	489934, 489953		
2.5.1.61	Homo sapiens		N-ethylmaleimide	489926	46	1 mM 38% inhibition
2.5.1.61	Chlorella regularis		N-ethylmaleimide	489929	46	1 mM, 59% inhibition
2.5.1.61	Rhodobacter sphaeroides		N-ethylmaleimide	489922, 489929	46	
2.5.1.61	Triticum aestivum		N-ethylmaleimide	489929, 489930	46	
2.5.1.61	Rattus norvegicus		N-ethylmaleimide	489953	46	5 mM, pH 8.0, 70% inhibition
2.5.1.61	Homo sapiens		N-ethylmaleimide	5883	46	
2.5.1.61	Rattus norvegicus		Na+	489934	55	
2.5.1.61	Pisum sativum		Na+	489946	55	NaCl greater than 300 mM
2.5.1.61	Arabidopsis thaliana		Na+	489952	55	at high concentrations
2.5.1.61	Escherichia coli		NaBH4	489944	507	partially inactivates
2.5.1.61	Rhodobacter sphaeroides		NH4+	489923	50	
2.5.1.61	Rattus norvegicus		NH4+	489938	50	
2.5.1.61	Pisum sativum		NH4+	489946	50	
2.5.1.61	Arabidopsis thaliana		NH4+	489952	50	
2.5.1.61	Rattus norvegicus		Ni2+	489934	36	
2.5.1.61	Rhodobacter sphaeroides		opsopyrroledicarboxylic acid	489923	20863	1 mM, 40% inhibition
2.5.1.61	Triticum aestivum		opsopyrroledicarboxylic acid	489923	20863	
2.5.1.61	Triticum aestivum		opsopyrroledicarboxylic acid	489930	20863	i.e. OPD, competitive
2.5.1.61	Rhodobacter sphaeroides		p-chloromercuribenzoate	489922	40	strong
2.5.1.61	Homo sapiens		p-chloromercuribenzoate	489926	40	0.002 mM, 74% inhibition
2.5.1.61	Chlorella regularis		p-chloromercuribenzoate	489929	40	0.025 mM, 62% inhibition
2.5.1.61	Rhodobacter sphaeroides		p-chloromercuribenzoate	489929	40	
2.5.1.61	Triticum aestivum		p-hydroxymercuribenzoate	489930	92	i.e. PHMB, inhibition is enhanced by porphobilinogen
2.5.1.61	Homo sapiens		p-hydroxymercuribenzoate	5883	92	
2.5.1.61	Rattus norvegicus		Pb2+	489934	132	strong
2.5.1.61	Homo sapiens		PbNO3	489926		0.005 mM, 35% inhibition
2.5.1.61	Rattus norvegicus		protoporphyrin IX	489953	685	enzyme activity decreases with increasing concentrations, reaching a 33% inhibition at the vivo concentration of porphyrin, 0.00185 mM, and 0.014 mM porphobilinogen
2.5.1.61	Homo sapiens		protoporphyrinogen	489948	545	inhibits both erythroid and lymphoblast forms of the enzyme
2.5.1.61	Escherichia coli		pyridoxal 5'-phosphate	489944	30	partially inactivates
2.5.1.61	Rattus norvegicus		UO22+	489934	13549	
2.5.1.61	Rattus norvegicus		VO2+	489934	7274	
2.5.1.61	Rattus norvegicus		Zn2+	489934	19	strong
2.5.1.61	Pisum sativum		Zn2+	489946	19	ZnCl2, strong
2.5.1.61	Arabidopsis thaliana		Zn2+	489952	19	1 mM ZnCl2, 78% inhibition
2.7.6.3	Arabidopsis thaliana	more		674784		expression of cytHPPK/DHPS mRNA is induced by salt stress
2.7.6.3	Plasmodium chabaudi		2-Amino-4-hydroxy-6-carboxydihydropteridine	639668	29908	competitive with 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine
2.7.6.3	Escherichia coli		2-amino-6-[(2-[4-[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-ylmethylsulfanyl]-piperidin-1-yl]-ethylamino)-methyl]-3H-pteridin-4-one	721840		
2.7.6.3	Escherichia coli		2-amino-6-[(2-[4-[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-ylmethylsulfanyl]-piperidin-1-yl]-ethylamino)-methyl]-7,7-dimethyl-7,8-dihydro-3H-pteridin-4-one	721840		
2.7.6.3	Escherichia coli		2-amino-7,7-dimethyl-4-oxo-3,4,7,8-tetrahydro-pteridine-6-carboxylic acid (2-[4-[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethylsulfanyl]-piperidin-1-yl]-ethyl)-amide	721840		
2.7.6.3	Escherichia coli		2-amino-7,7-dimethyl-4-oxo-3,4,7,8-tetrahydropteridine-6-carboxylic acid (2-[2-[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethanesulfonyl]-ethylcarbamoyl]-ethyl)-amide	721839		about 45% residual activity at 0.01 mM, about 30% residual activity at 0.02 mM, about 15% residual activity at 0.05 mM, almost complete inhibition at 0.1 mM
2.7.6.3	Escherichia coli		5'-S-[1-(2-{[(2-amino-7,7-dimethyl-4-oxo-3,4,7,8-tetrahydropteridin-6-yl)carbonyl]amino}ethyl)piperidin-4-yl]-5'-thioadenosine	721839		
2.7.6.3	Escherichia coli		6-hydroxymethyl-7,7-dimethyl-7,8-dihydropterin	721840		
2.7.6.3	Pisum sativum		6-hydroxymethyl-7,8-dihydropterin diphosphate	639684	3235	competitive inhibitor of ATP, mixed type inhibitor of 6-hydroxymethyl-7,8-dihydropteridine
2.7.6.3	Escherichia coli		6-hydroxymethyl-7-methyl-7-phenethyl-7,8-dihydropterin	721840		
2.7.6.3	Escherichia coli		alpha,beta-methyleneadenosine triphosphate	642759	4820	competitive with respect to ATP
2.7.6.3	Pisum sativum		AMP	639684	9	poor inhibitor
2.7.6.3	Saccharomyces cerevisiae		dapsone	671307	2628	
2.7.6.3	Plasmodium falciparum		Guanidine-HCl	662800	804	0.25 M, 50% inhibitioin
2.7.6.3	Plasmodium falciparum		KCl	662800	74	activation at 0.4 M, inhibition at higher concentration
2.7.6.3	Plasmodium falciparum		NaCl	662800	39	activation at 0.2 M, inhibition at higher concentration
2.7.6.3	Escherichia coli		P1-(6-hydroxymethylpterin)-P2-(5'-adenosyl)diphosphate	721840		
2.7.6.3	Escherichia coli		P1-(6-hydroxymethylpterin)-P3-(5'-adenosyl)triphosphate	721840		
2.7.6.3	Escherichia coli		P1-(6-hydroxymethylpterin)-P4-(5'-adenosyl)tetraphosphate	721839, 721840		
2.7.6.3	Saccharomyces cerevisiae		sulfachloropyridazine	671307	5115	
2.7.6.3	Plasmodium falciparum		sulfadoxine	662800	5682	competitive, moderately potent
2.7.6.3	Saccharomyces cerevisiae		sulfamethoxazole	671307	1556	
2.7.6.3	Plasmodium falciparum		sulfathiazole	662800	2304	competitive
2.7.6.3	Plasmodium falciparum		Urea	662800	110	0.9 M, 50% inhibition
2.6.1.16	Rattus norvegicus	chondroitin sulfate B		639907	6135	
2.6.1.16	Mus musculus	Desferrioxamine		674058	3329	0.2 mM; activation of gene expression via iron chelation
2.6.1.16	Saccharomyces cerevisiae	dithiothreitol		639921	42	1 mM, activates 1.8fold
2.6.1.16	Rattus norvegicus	more		639908		small acidic compound devoid of SH groups thermolabile at 100&deg;C dialyzable, not precipitable with HClO4 easily separated from proteins in a Sephadex G-25 column
2.6.1.16	Saccharomyces cerevisiae	more		674422		requires methionine aminopeptidase activity for proper function
2.6.1.16	Mus musculus	Picolinic acid		674058	3360	2 mM; activation of gene expression via iron chelation
2.6.1.16	Saccharomyces cerevisiae		(2S)-2-amino-3-(([(2R,3R)-3-benzoyloxiran-2-yl]carbonyl)amino)propanoic acid	722052		
2.6.1.16	Saccharomyces cerevisiae		(2S)-2-amino-3-([(2E)-4-oxo-4-phenylbut-2-enoyl]amino)propanoic acid	722052		
2.6.1.16	Saccharomyces cerevisiae		(2S)-2-amino-3-([(2E)-4-oxopent-2-enoyl]amino)propanoic acid	722052		
2.6.1.16	Saccharomyces cerevisiae		(2S)-3-(([(2R,3R)-3-acetyloxiran-2-yl]carbonyl)amino)-2-aminopropanoic acid	722052		
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		1,1'-dithiodiformamidine	639910	11149	irreversible inhibition
2.6.1.16	Arthrobacter aurescens		1,1'-dithiodiformamidine	639911	11149	irreversible inhibition
2.6.1.16	Bacillus thuringiensis		1,1'-dithiodiformamidine	639911	11149	irreversible inhibition
2.6.1.16	Escherichia coli		1,1'-dithiodiformamidine	639911	11149	irreversible inhibition
2.6.1.16	Pseudomonas aeruginosa		1,1'-dithiodiformamidine	639911	11149	irreversible inhibition
2.6.1.16	Escherichia coli		1,2-anhydrohexitol 6-phosphate	639929	73421	mixture of the four diastereoisomers. Irreversible inactivation. D-fructose 6-phosphate and 2-amino-2-deoxyglucitol protect, L-glutamine does not
2.6.1.16	Candida albicans		2-amino-2-deoxy-D-glucitol 6-phosphate	671089	3035	
2.6.1.16	Escherichia coli		2-amino-2-deoxy-D-glucitol 6-phosphate	684404	3035	
2.6.1.16	Homo sapiens		2-amino-2-deoxy-D-glucitol-6-phosphate	671032	3035	inhibitor of the sugar isomerising domain
2.6.1.16	Candida albicans		2-amino-2-deoxy-D-glucitol-6-phosphate	671603	3035	
2.6.1.16	Escherichia coli		2-amino-2-deoxy-D-glucitol-6-phosphate	672619	3035	IC50: 0.056 mM
2.6.1.16	Volvariella volvacea		2-amino-2-deoxy-D-glucitol-6-phosphate	706608	3035	
2.6.1.16	Candida albicans		2-amino-2-deoxy-D-glucitol-6-phosphate dimethyl ester	671603	41555	
2.6.1.16	Escherichia coli		2-amino-2-deoxy-D-mannitol 6-phosphate	684404	16666	
2.6.1.16	Homo sapiens		2-amino-2-deoxy-D-mannitol-6-phosphate	671032	16666	exhibits stronger affinity for the sugar-binding site of GlcN-6-P synthase than 2-amino-2-deoxy-D-glucitol-6-phosphate
2.6.1.16	Candida albicans		2-amino-2-deoxy-D-mannitol-6-phosphate	671603	16666	
2.6.1.16	Escherichia coli		2-Amino-2-deoxyglucitol 6-phosphate	639926, 639927	3035	competitive with respect to D-fructose 6-phosphate
2.6.1.16	Rattus norvegicus		4,4'-dithiodipyridine	639931	4618	inactivation reversed by dithiothreitol. Competitive with respect to L-glutamine. Non-competitive with respect to D-fructose 6-phosphate
2.6.1.16	Escherichia coli		4-(furan-2-ylcarbonyl)-3-hydroxy-5-(4-phenoxyphenyl)-1-(pyridin-3-ylmethyl)-1,5-dihydro-2H-pyrrol-2-one	672619	85830	20% inhibition at 0.1 mM
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		4-Glutamylhydroxamate	639910	30560	
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		5,5'-dithionitrobenzoic acid	639910		irreversible inhibition
2.6.1.16	Arthrobacter aurescens		5,5'-dithionitrobenzoic acid	639911		irreversible inhibition
2.6.1.16	Bacillus thuringiensis		5,5'-dithionitrobenzoic acid	639911		irreversible inhibition
2.6.1.16	Escherichia coli		5,5'-dithionitrobenzoic acid	639911		irreversible inhibition
2.6.1.16	Pseudomonas aeruginosa		5,5'-dithionitrobenzoic acid	639911		irreversible inhibition
2.6.1.16	Rattus norvegicus		5,5'-dithionitrobenzoic acid	639931		inactivation reversed by dithiothreitol
2.6.1.16	Candida albicans		5-phospho-D-arabinoamide	671603	15047	
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		6,6'-Dithiodinicotinic acid	639910	6260	irreversible inhibition
2.6.1.16	Arthrobacter aurescens		6,6'-Dithiodinicotinic acid	639911	6260	irreversible inhibition
2.6.1.16	Bacillus thuringiensis		6,6'-Dithiodinicotinic acid	639911	6260	irreversible inhibition
2.6.1.16	Escherichia coli		6,6'-Dithiodinicotinic acid	639911	6260	irreversible inhibition
2.6.1.16	Pseudomonas aeruginosa		6,6'-Dithiodinicotinic acid	639911	6260	irreversible inhibition
2.6.1.16	Escherichia coli		6,7-bis(2-methoxyphenyl)-10-methyl-1,4,7,12-tetrahydro-6H-chromeno[4,3-d][1,2,4]triazolo[1,5-a]pyrimidine	672619	85831	70% inhibition at 0.1 mM
2.6.1.16	Neurospora crassa		6-diazo-5-oxo-L-norleucine	639904	666	
2.6.1.16	Bos taurus		6-diazo-5-oxo-L-norleucine	639906	666	competitive with respect to L-glutamine
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		6-diazo-5-oxo-L-norleucine	639910	666	
2.6.1.16	Bos taurus		6-diazo-5-oxo-L-norleucine	639920	666	
2.6.1.16	Rattus norvegicus		6-diazo-5-oxo-L-norleucine	639904, 639919, 639931	666	
2.6.1.16	Homo sapiens		6-diazo-5-oxo-L-norleucine	671032	666	inhibitor of the glutamine binding site
2.6.1.16	Escherichia coli		6-diazo-5-oxo-L-norleucine	674745	666	2 mM
2.6.1.16	Escherichia coli		6-diazo-5-oxo-L-norleucine	639904, 639917, 639922, 677033	666	
2.6.1.16	Escherichia coli		Aaptamine	672619	24148	IC50: 0.12 mM
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		albizziin	639910	7122	
2.6.1.16	Escherichia coli		amitrole	672619	1350	IC50: 0.1 mM
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		anticapsin	639910	3785	
2.6.1.16	Arthrobacter aurescens		anticapsin	639911	3785	L-glutamine protects, irreversible inhibition
2.6.1.16	Bacillus thuringiensis		anticapsin	639911	3785	L-glutamine protects, irreversible inhibition
2.6.1.16	Escherichia coli		anticapsin	639911	3785	L-glutamine protects, irreversible inhibition
2.6.1.16	Pseudomonas aeruginosa		anticapsin	639911	3785	L-glutamine protects, irreversible inhibition
2.6.1.16	Bacteria		anticapsin	661954	3785	competitive
2.6.1.16	Homo sapiens		anticapsin	671032	3785	inhibitor of the glutamine binding site
2.6.1.16	Homo sapiens		arabinose oxime 5-phosphate	671032	86372	inhibitor of the sugar isomerising domain
2.6.1.16	Escherichia coli		azaserine	639904	1381	weak
2.6.1.16	Neurospora crassa		azaserine	639904	1381	
2.6.1.16	Rattus norvegicus		azaserine	639904	1381	weak
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		azaserine	639910	1381	
2.6.1.16	Escherichia coli		D-glucitol 6-phosphate	639929	4838	competitive with respect to D-fructose 6-phosphate
2.6.1.16	Escherichia coli		D-Glucosamine 6-phosphate	689045	417	negative feedback-regulation at post-transcriptional level. The biological function of small RNA GlmZ is to positively control the enzyme's mRNA in response to D-glucosamine 6-phosphate concentrations. YhbJ, a gene of the rpoN operon, negatively regulates GlmZ
2.6.1.16	Escherichia coli		D-Glucosamine-6-phosphate	672444	417	1 mM, about 50% loss of activity
2.6.1.16	Rattus norvegicus		dihydroxyacetone	639912	509	weak
2.6.1.16	Rattus norvegicus		dihydroxyacetone phosphate	639912	241	weak
2.6.1.16	Escherichia coli		DL-delta-1-pyrroline-5-carboxylate	639926	1456	competitive with respect to L-glutamine
2.6.1.16	Escherichia coli		ethyl 2-[2-(3-bromophenyl)-3-[(4-fluorophenyl)carbonyl]-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrol 1-yl]-4-methyl-1,3-thiazole-5-carboxylate	672619	86374	70% inhibition at 0.1 mM
2.6.1.16	Escherichia coli		ethyl 2-[3-[(4-fluorophenyl)carbonyl]-4-hydroxy-2-(4-methoxyphenyl)-5-oxo-2,5-dihydro-1H pyrrol-1-yl]-4-methyl-1,3-thiazole-5-carboxylate	672619	86375	70% inhibition at 0.1 mM
2.6.1.16	Rattus norvegicus		fructose 1,6-diphosphate	639912	100	weak
2.6.1.16	Rattus norvegicus		glyceraldehyde 3-phosphate	639912	473	50% inhibition at 0.2 mM
2.6.1.16	Rattus norvegicus		glycolaldehyde	639912	497	weak
2.6.1.16	Rattus norvegicus		Glyoxal	639912	1091	50% inhibition at 0.03 mM
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		iodoacetamide	639910	63	irreversible inhibition
2.6.1.16	Arthrobacter aurescens		iodoacetamide	639911	63	irreversible inhibition
2.6.1.16	Bacillus thuringiensis		iodoacetamide	639911	63	irreversible inhibition
2.6.1.16	Escherichia coli		iodoacetamide	639911	63	irreversible inhibition
2.6.1.16	Pseudomonas aeruginosa		iodoacetamide	639911	63	irreversible inhibition
2.6.1.16	Escherichia coli		iodoacetamide	639922	63	
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		iodoacetate	639910	87	
2.6.1.16	Bacillus pumilus		L-2,3-diaminopropanoic acid	639916	6178	
2.6.1.16	Candida albicans		L-2,3-diaminopropanoic acid	639916	6178	
2.6.1.16	Escherichia coli		L-2,3-diaminopropanoic acid	639916	6178	
2.6.1.16	Rattus norvegicus		L-alpha-glycerophosphate	639912	2845	weak
2.6.1.16	Saccharomyces cerevisiae		Mercuric chloride	639921	3822	84% inhibition at 1 mM
2.6.1.16	Rattus norvegicus		methylglyoxal	639912	277	50% inhibition at 0.01 mM, non competitive
2.6.1.16	Rattus norvegicus		methylglyoxal	639924	277	inhibits preincubated enzyme less profoundly than the untreated enzyme
2.6.1.16	Escherichia coli		more	672619		no inhibition by 0.1 mM c3, 4, 6, 9, 12, 13
2.6.1.16	Candida albicans		N-acetyl-2-amino-2-deoxy-D-glucitol-6-phosphate	671603	41554	
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		N-ethylmaleimide	639910	46	irreversible inhibition
2.6.1.16	Arthrobacter aurescens		N-ethylmaleimide	639911	46	irreversible inhibition
2.6.1.16	Bacillus thuringiensis		N-ethylmaleimide	639911	46	irreversible inhibition
2.6.1.16	Escherichia coli		N-ethylmaleimide	639911	46	irreversible inhibition
2.6.1.16	Pseudomonas aeruginosa		N-ethylmaleimide	639911	46	irreversible inhibition
2.6.1.16	Saccharomyces cerevisiae		N-ethylmaleimide	639921	46	78% inhibition at1 mM
2.6.1.16	Escherichia coli		N-iodoacetylglucosamine 6-phosphate	639927	74529	D-fructose 6-phosphate protects
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid	639910	5493	L-glutamine and some analogs protect
2.6.1.16	Escherichia coli		N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid	639917	5493	
2.6.1.16	Homo sapiens		N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid	671032	5493	acts as active-site-directed inactivator blocking the N-terminal, glutamine-binding domain of the enzyme; inhibitor of the glutamine binding site
2.6.1.16	Volvariella volvacea		N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid	706608	5493	
2.6.1.16	Bacillus pumilus		N3-bromoacetyl-L-2,3-diaminopropanoic acid	639916	11183	competitive with respect to L-glutamine
2.6.1.16	Candida albicans		N3-bromoacetyl-L-2,3-diaminopropanoic acid	639916	11183	competitive with respect to L-glutamine
2.6.1.16	Escherichia coli		N3-bromoacetyl-L-2,3-diaminopropanoic acid	639916	11183	competitive with respect to L-glutamine
2.6.1.16	Homo sapiens		N3-bromoacetyl-L-2,3-diaminopropanoic acid	671032	11183	inhibitor of the glutamine binding site
2.6.1.16	Bacillus pumilus		N3-chloroacetyl-L-2,3-diaminopropanoic acid	639916	14382	competitive with respect to L-glutamine
2.6.1.16	Candida albicans		N3-chloroacetyl-L-2,3-diaminopropanoic acid	639916	14382	competitive with respect to L-glutamine
2.6.1.16	Escherichia coli		N3-chloroacetyl-L-2,3-diaminopropanoic acid	639916	14382	competitive with respect to L-glutamine
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		N3-fumaramoyl-L-2,3-diaminopropanoic acid	639910	22124	
2.6.1.16	Escherichia coli		N3-fumaramoyl-L-2,3-diaminopropanoic acid	639917	22124	
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		N3-Fumaroyl-L-2,3-diaminopropanoic acid	639910	6017	
2.6.1.16	Escherichia coli		N3-Fumaroyl-L-2,3-diaminopropanoic acid	639917	6017	
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		N3-Fumaroylcarboxyamido-L-2,3-diaminopropionic acid	639909		competitive with L-glutamine
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		N3-Fumaroylcarboxyamido-L-2,3-diaminopropionic acid	639910		
2.6.1.16	Bacillus pumilus		N3-iodoacetyl-L-2,3-diaminopropanoic acid	639916	14383	competitive with respect to L-glutamine
2.6.1.16	Candida albicans		N3-iodoacetyl-L-2,3-diaminopropanoic acid	639916	14383	competitive with respect to L-glutamine
2.6.1.16	Escherichia coli		N3-iodoacetyl-L-2,3-diaminopropanoic acid	639916	14383	competitive with respect to L-glutamine
2.6.1.16	Homo sapiens		N3-L-trans-epoxysuccinamoyl-L-2,3-diaminopropanoic acid	671032	86373	inhibitor of the glutamine binding site
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		N4-(4-Methoxyfumaroyl)-L-2,4-diaminobutanoic acid	639910	65115	
2.6.1.16	Mus musculus		p-chloromercuribenzoate	639915	40	
2.6.1.16	Saccharomyces cerevisiae		p-chloromercuribenzoate	639921	40	84% inhibition at 0.1 mM
2.6.1.16	Salmonella enterica subsp. enterica serovar Typhimurium		p-hydroxymercuribenzoate	639910	92	
2.6.1.16	Rattus norvegicus		pyridoxamine-5'-phosphate	639905	539	
2.6.1.16	Rattus norvegicus		Tolbutamide	639907	6243	80% inhibition at 2 mg/ml
2.6.1.16	Mus musculus		UDP-glucose	639915	60	
2.6.1.16	Saccharomyces cerevisiae		UDP-N-acetyl-alpha-D-glucosamine	722052	120	
2.6.1.16	Bos taurus		UDP-N-acetylglucosamine	639906	120	competitive with respect to D-fructose 6-phosphate, non-competitive with respect to L-glutamine
2.6.1.16	Mus musculus		UDP-N-acetylglucosamine	639915	120	weak
2.6.1.16	Bos taurus		UDP-N-acetylglucosamine	639920	120	partial
2.6.1.16	Saccharomyces cerevisiae		UDP-N-acetylglucosamine	639921	120	40% inhibition at 1 mM
2.6.1.16	Vigna radiata var. radiata		UDP-N-acetylglucosamine	639923	120	competitive inhibitor with respect to D-fructose 6-phosphate
2.6.1.16	Homo sapiens		UDP-N-acetylglucosamine	639925	120	feed-back inhibition
2.6.1.16	Rattus norvegicus		UDP-N-acetylglucosamine	639931	120	
2.6.1.16	Candida albicans		uridine 5'-diphospho-N-acetyl-D-glucosamine	723015	120	
2.6.1.16	Volvariella volvacea		uridine 5'-diphospho-N-acetylglucosamine	706608	120	
2.7.7.38	Escherichia coli	GSH		645226	41	
2.7.7.38	Escherichia coli		(1R,4S,5R)-3-[2-[(S)-1-((S)-1-carboxy-ethylcarbamoyl)-ethylamino]-ethyl]-4,5-dihydroxy-cyclohexanecarboxylic acid	661340	80704	
2.7.7.38	Escherichia coli		2,6-Anhydro-3-deoxy-D-glycero-D-talo-octanoate	645229	8504	2-deoxy KDO analog
2.7.7.38	Salmonella enterica subsp. enterica serovar Typhimurium		2,6-Anhydro-3-deoxy-D-glycero-D-talo-octanoate	645229	8504	2-deoxy KDO analog
2.7.7.38	Escherichia coli		2,6-Anhydro-3-deoxy-D-glycero-D-talo-octanoate	645238	8504	
2.7.7.38	Salmonella enterica subsp. enterica serovar Typhimurium		2,6-Anhydro-3-deoxy-D-glycero-D-talo-octanoate	645238	8504	
2.7.7.38	Escherichia coli		diphosphate	645227	13	weak inhibition
2.7.7.38	Escherichia coli		Hg2+	645227	31	strong inhibition
2.7.7.38	Escherichia coli		more	645227		no inhibition by CDP, CMP, 3-deoxy-manno-octulosonate 8-phosphate, N-acetylneuraminate
2.7.7.38	Escherichia coli		more	645229		no inhibition with 3-deoxy-D-manno-octulosonate analog 2,6-anhydro-3-deoxy-D-glycero-D-galacto-octanoate
2.7.7.38	Salmonella enterica subsp. enterica serovar Typhimurium		more	645229		no inhibition with 3-deoxy-D-manno-octulosonate analog 2,6-anhydro-3-deoxy-D-glycero-D-galacto-octanoate
1.1.1.42	Sus scrofa	acetic acid		656180	44	mutant Y140T, 106fold activation compared to the wild-type enzyme
1.1.1.42	Mus musculus	ADP		656247	8	
1.1.1.42	Spirodela polyrhiza	cis-aconitate		656616	933	isozyme ICDH2, not isozyme ICDH1
1.1.1.42	Spirodela polyrhiza	citrate		656616	125	isozymes ICDH2 and ICDH1
1.1.1.42	Sus scrofa	ethylamine		656180	565	mutant K212Q, 4fold activation compared to the wild-type enzyme
1.1.1.42	Pisum sativum	glutamate		654914	38	
1.1.1.42	Zea mays	glutamate		654914	38	
1.1.1.42	Spirodela polyrhiza	glutamate		656616	38	160% stimulation of isozyme ICDH1 at 0.3 mM
1.1.1.42	Spirodela polyrhiza	Isocitrate		656616	242	isozymes ICDH2 and ICDH1
1.1.1.42	Saccharomyces cerevisiae	more		654367		isozyme IDP3 is inducible by fatty acids, isozyme IDP2 by non-fermentable carbon sources, expression of isozyme IDP1 is constitutive
1.1.1.42	Pisum sativum	more		654843		the mitochondrial isozyme is light-inducible, while the cytosolic one is not
1.1.1.42	Pisum sativum	more		654914		enzyme is not affected by gamma-aminobutyric acid and succinate
1.1.1.42	Zea mays	more		654914		enzyme is not affected by gamma-aminobutyric acid and succinate
1.1.1.42	Plasmodium falciparum	more		655456		applied oxidative stress leads to upregulation of enzyme expression in erythrocytic stages
1.1.1.42	Saccharomyces cerevisiae	more		656233		glucose induces epression of isozyme IDP1, glycerol induces epression of isozymes IDP1 and IDP2, fatty acids induce epression of isozymes IDP1, IDP2, and IDP3
1.1.1.42	Spirodela polyrhiza	more		656616		no effect by trans-aconitate on isozyme ICDH2
1.1.1.42	Mycobacterium tuberculosis	NaCl		668080	39	isoform ICD-2, increase in activity in up to 200 mM NaCl. Isoform ICD-1, no influence of NaCl. Above 200 mM, NaCl is inhibitory
1.1.1.42	Pisum sativum	paraquat		670638	302	administration at 0.01 mM to roots results in remarkable induction of enzyme gene expression and dramatic increase of gene activity
1.1.1.42	Sus scrofa	Phenol		656180	219	mutant Y140T, 88fold activation compared to the wild-type enzyme
1.1.1.42	Pisum sativum	succinic acid		654914	54	
1.1.1.42	Zea mays	succinic acid		654914	54	
1.1.1.42	Homo sapiens		2',5'-ADP	286786	1457	
1.1.1.42	Chlamydomonas reinhardtii		2,3-Butanedione	286806	603	
1.1.1.42	Mycobacterium phlei		2-mercaptoethanol	286795	59	
1.1.1.42	Acinetobacter calcoaceticus		2-oxoglutarate	286781	32	substrate inhibition
1.1.1.42	Bombyx mori		2-oxoglutarate	286784	32	substrate inhibition
1.1.1.42	Homo sapiens		2-oxoglutarate	286786	32	substrate inhibition
1.1.1.42	Aspergillus niger		2-oxoglutarate	286793	32	substrate inhibition
1.1.1.42	Phormidium laminosum		2-oxoglutarate	286799	32	substrate inhibition
1.1.1.42	Synechocystis sp.		2-oxoglutarate	286803	32	non-competitive inhibitor
1.1.1.42	Pinus spp.		2-oxoglutarate	286805	32	inhibition by chelating Mg2+
1.1.1.42	Pisum sativum		2-oxoglutarate	654843	32	
1.1.1.42	Fomitopsis palustris		2-oxoglutarate	655035	32	92% inhibition at 5 mM
1.1.1.42	Saccharopolyspora erythraea		2-oxoglutarate	655094	32	60% inhibition at 1 mM
1.1.1.42	Spirodela polyrhiza		2-oxoglutarate	656616	32	isozymes ICDH2 and ICDH1, isozyme ICDH2 is more sensitive to negative feedback inhibition by 2-oxoglutarate
1.1.1.42	Chlorobium limicola		2-oxoglutarate	656740	32	50% inhibition of the forward reaction at 1.5 mM, 99% inhibition at 15 mM
1.1.1.42	Rhodopseudomonas palustris		2-oxoglutarate	656740	32	50% inhibition of the forward reaction at 1.5 mM, 95% inhibition at 15 mM
1.1.1.42	Rattus norvegicus		2-oxoglutarate	670236	32	; 
1.1.1.42	Mycobacterium tuberculosis		2-oxoglutarate	721687	32	noncompetitive versus NADP+
1.1.1.42	Arabidopsis thaliana		3-morpholinosydnonimine	721779	5566	44% inhibition at 5 mM of leaf and root enzymes
1.1.1.42	Bacillus sp.		3-phosphoglycerate	286796	174	
1.1.1.42	Homo sapiens		4-hydroxynonenal	655663	1076	50% inhibition at 37&deg;C, after 1 h at 0.5 mM, lipid peroxidation product, enzyme becomes susceptible to oxidative damage leading to structural alterations, carbonylation
1.1.1.42	Homo sapiens		5'-ADP	286786	8	
1.1.1.42	Phormidium laminosum		5'-ADP	286799	8	
1.1.1.42	Synechocystis sp.		5'-ADP	286803	8	non-competitive inhibitor
1.1.1.42	Pinus spp.		5'-ADP	286805	8	inhibition by chelating Mg2+
1.1.1.42	Bombyx mori		adenosine-3',5'-cyclic monophosphate	286784	233	
1.1.1.42	Fomitopsis palustris		ADP	655035	8	15% inhibition at 2 mM
1.1.1.42	Saccharopolyspora erythraea		ADP	655094	8	20% inhibition at 1 mM
1.1.1.42	Sus scrofa		Ag+	286749	71	decarboxylation of isocitrate and oxalosuccinate
1.1.1.42	Bombyx mori		Ag+	286784	71	decarboxylation of isocitrate and oxalosuccinate
1.1.1.42	Acinetobacter calcoaceticus		ATP	286781	7	
1.1.1.42	Homo sapiens		ATP	286786	7	
1.1.1.42	Aspergillus niger		ATP	286793	7	
1.1.1.42	Bacillus sp.		ATP	286796	7	
1.1.1.42	Phormidium laminosum		ATP	286799	7	
1.1.1.42	Pinus spp.		ATP	286805	7	inhibition by chelating Mg2+
1.1.1.42	Fomitopsis palustris		ATP	655035	7	10% inhibition at 2 mM
1.1.1.42	Saccharopolyspora erythraea		ATP	655094	7	50% inhibition at 1 mM
1.1.1.42	Fomitopsis palustris		Ca2+	655035	18	in presence of 5 mM Mg2+ 6% of maximal activity is remaining
1.1.1.42	Streptomyces lividans		Ca2+	696488	18	4.94% relative activity at 2 mM
1.1.1.42	Streptomyces diastaticus		Ca2+	723151	18	
1.1.1.42	Microcystis aeruginosa		Ca2+	723152	18	
1.1.1.42	Fomitopsis palustris		Cd2+	655035	48	complete inhibition at 5 mM in presence of 5 mM Mg2+
1.1.1.42	Mus musculus		Cd2+	670334	48	coadministration with oxalomalate results in inhibition of enzyme and glutaredoxin and enhanced susceptibility to apoptosis
1.1.1.42	Sus scrofa		Cd2+	670334	48	binds to C379 of enzyme, resulting in loss of activity and structural alterations. Loss of glutaredoxin activity in cells treated with Cd2+ is more pronounced when cells are transfected with enzyme antisense cDNA
1.1.1.42	Homo sapiens		Cd2+	711158	48	inhibits the purified enzyme and the enzyme in cells, NADP+ does not protect. No inhibition of IDPc mutant S269S. DNA fragmentation is enhanced in IDPc siRNA-transfected HEK293 cells compared to control cells upon exposure to cadmium
1.1.1.42	Bacillus sp.		cis-aconitate	286796	933	
1.1.1.42	Fomitopsis palustris		cis-aconitate	655035	933	35% inhibition at 5 mM
1.1.1.42	Spirodela polyrhiza		cis-aconitate	656616	933	isozyme ICDH1, not isozyme ICDH2
1.1.1.42	Bombyx mori		citrate	286784	125	
1.1.1.42	Homo sapiens		citrate	286786	125	
1.1.1.42	Aspergillus niger		citrate	286793	125	
1.1.1.42	Fomitopsis palustris		citrate	655035	125	30% inhibition at 1 mM and 5 mM
1.1.1.42	Rattus norvegicus		citrate	670236	125	; 
1.1.1.42	Saccharopolyspora erythraea		Citric acid	655094	125	50% inhibition at 1 mM
1.1.1.42	Fomitopsis palustris		Co2+	655035	21	92% inhibition in presence of 5 mM Mg2+
1.1.1.42	Streptomyces lividans		Co2+	696488	21	46.47% relative activity at 2 mM
1.1.1.42	Streptomyces diastaticus		Co2+	723151	21	
1.1.1.42	Microcystis aeruginosa		Co2+	723152	21	
1.1.1.42	Sus scrofa		Cu2+	286749	28	
1.1.1.42	Bacillus sp.		Cu2+	286796	28	
1.1.1.42	Fomitopsis palustris		Cu2+	655035	28	enzyme is completely inhibited at 5 mM in presence of 5 mM Mg2+, organism is a copper-tolerant basidiomycete
1.1.1.42	Streptomyces lividans		Cu2+	696488	28	complete inhibition at 2 mM
1.1.1.42	Streptomyces diastaticus		Cu2+	723151	28	complete inhibition
1.1.1.42	Microcystis aeruginosa		Cu2+	723152	28	complete inhibition
1.1.1.42	Escherichia coli		desferroxamine	698056	3329	
1.1.1.42	Rattus norvegicus		desferroxamine	698056	3329	
1.1.1.42	Homo sapiens		Diamide	698059	1817	
1.1.1.42	Escherichia coli		Diethylenetriaminepentaacetic acid	698056	10742	
1.1.1.42	Rattus norvegicus		Diethylenetriaminepentaacetic acid	698056	10742	
1.1.1.42	Sus scrofa		Diphenylchloroarsine	286749	64422	
1.1.1.42	Mycobacterium phlei		dithiothreitol	286795	42	
1.1.1.42	Streptomyces lividans		EDTA	696488	223	complete inhibition at 2 mM
1.1.1.42	Streptomyces diastaticus		EDTA	723151	223	
1.1.1.42	Rattus norvegicus		Fe2+	670236	23	; the inhibitory effect of the Fe2+ and H2O2 mixture associated with the generation of hydroxyl radicals is lower in enzyme from ischemic heart compared to enzyme from normoxic heart
1.1.1.42	Spirodela polyrhiza		glutamate	656616	38	80% inhibition of isozyme ICDH2 at 2 mM
1.1.1.42	Mycobacterium phlei		glutathione	286795	41	
1.1.1.42	Sus scrofa		glutathione	669307	41	oxidized glutathione leads to enzyme inactivation with simultaneous formation of a mixed disulfide between glutathione and the cysteine residues of enzyme. Enzymical reactivation by glutaredoxin2 in presence of reduced glutathione
1.1.1.42	Rattus norvegicus		glutathione	670236	41	; 
1.1.1.42	Homo sapiens		glutathione disulfide	698059	283	incubation with 5 mM glutathione disulfide for 30 min completely eliminates activity
1.1.1.42	Bacillus sp.		glyceraldehyde-3-phosphate	286796	473	
1.1.1.42	Saccharopolyspora erythraea		glyoxalate	655094	95	20% inhibition at 1 mM, presence of 1 mM oxaloacetate results in 50% inhibition
1.1.1.42	Bacillus subtilis		glyoxylate	286779	95	plus oxaloacetate
1.1.1.42	Chlamydomonas reinhardtii		glyoxylate	286779	95	plus oxaloacetate
1.1.1.42	Thermus aquaticus		glyoxylate	286779	95	plus oxaloacetate
1.1.1.42	Thermus thermophilus		glyoxylate	286780	95	plus oxaloacetate
1.1.1.42	Acinetobacter calcoaceticus		glyoxylate	286781	95	plus oxaloacetate
1.1.1.42	Vibrio sp.		glyoxylate	286787	95	plus oxaloacetate
1.1.1.42	Bos taurus		glyoxylate	286788	95	plus oxaloacetate
1.1.1.42	Aspergillus niger		glyoxylate	286793	95	plus oxaloacetate
1.1.1.42	Mycobacterium phlei		glyoxylate	286795	95	plus oxaloacetate
1.1.1.42	Fomitopsis palustris		glyoxylate	655035	95	18% inhibition at 5 mM, mixed type inhibition together with oxaloacetate, completely at 5 mM each
1.1.1.42	Corynebacterium glutamicum		glyoxylate	721162	95	
1.1.1.42	Arabidopsis thaliana		GSH	721779	41	inhibits the leaf enzyme by 40% at 5 mM, but not the root enzyme
1.1.1.42	Saccharopolyspora erythraea		GTP	655094	35	10% inhibition at 1 mM
1.1.1.42	Rattus norvegicus		H2O2	670236	20	; the inhibitory effect of the Fe2+ and H2O2 mixture associated with the generation of hydroxyl radicals is lower in enzyme from ischemic heart compared to enzyme from normoxic heart
1.1.1.42	Arabidopsis thaliana		H2O2	721779	20	affects the root enzyme slightly but not the enzyme from leaves
1.1.1.42	Mycobacterium phlei		Hg2+	286795	31	
1.1.1.42	Bacillus sp.		Hg2+	286796	31	
1.1.1.42	Homo sapiens		HOCl	686899	5657	i.e. hypochlorous acid, the HOCl-mediated damage to NADP+-dependent isocitrate dehydrogenase mayesult in perturbation of the cellular antioxidant defense mechanism and subsequently lead to a pro-oxidant condition
1.1.1.42	Mus musculus		HOCl	686899	5657	i.e. hypochlorous acid
1.1.1.42	Sus scrofa		Isocitrate	286749	242	competitive inhibition of decarboxylation of oxalosuccinate
1.1.1.42	Pisum sativum		Isocitrate	654843	242	reverse reaction
1.1.1.42	Chlorobium limicola		Isocitrate	656740	242	50% inhibition of the reverse reaction at 0.1 mM, 97% inhibition at 1.2 mM
1.1.1.42	Rhodopseudomonas palustris		Isocitrate	656740	242	70% inhibition of the reverse reaction at 0.1 mM, 99% inhibition at 1.2 mM
1.1.1.42	Fomitopsis palustris		Itaconate	655035	1466	18% inhibition at 5 mM
1.1.1.42	Streptomyces lividans		K+	696488	37	3.53% relative activity at 2 mM
1.1.1.42	Streptomyces diastaticus		K+	723151	37	
1.1.1.42	Microcystis aeruginosa		K+	723152	37	slight inhibition
1.1.1.42	Microcystis aeruginosa		Li+	723152	142	slight inhibition
1.1.1.42	Homo sapiens		lipid hydroperoxide	655663	29472	50% inhibition at 37&deg;C, after 1 h at 0.05 mM, lipid peroxidation product, enzyme becomes susceptible to oxidative damage leading to structural alterations, carbonylation
1.1.1.42	Mycobacterium tuberculosis		malate	721687	246	noncompetitive versus NADP+ and isocitrate
1.1.1.42	Bombyx mori		Maleate	286784	474	
1.1.1.42	Homo sapiens		malondialdehyde	655663	2389	50% inhibition at 37&deg;C, after 1 h at 5 mM, lipid peroxidation product, enzyme becomes susceptible to oxidative damage leading to structural alterations, carbonylation
1.1.1.42	Escherichia coli		manganese(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin	698056	52062	a superoxide dismutase mimic, ICD is inactivated by superoxide, but the inactivated enzyme is replaced by de novo protein synthesis
1.1.1.42	Rattus norvegicus		manganese(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin	698056	52062	a superoxide dismutase mimic
1.1.1.42	Bombyx mori		monoiodoacetate	286784	87	
1.1.1.42	Mycobacterium phlei		monoiodoacetate	286795	87	
1.1.1.42	Saccharomyces cerevisiae		more	654652		activity is not affected by the nonspecific binding of the mitochondrial isozyme, not the cytosolic one, to 5'-untranslated regions of yeast mitochondrial mRNAs
1.1.1.42	Pisum sativum		more	654843		poor inhibition of the forward reaction by 2-oxoglutarate, no inhibition by CO2
1.1.1.42	Pisum sativum		more	654914		enzyme is not affected by gamma-aminobutyric acid and succinate
1.1.1.42	Zea mays		more	654914		enzyme is not affected by gamma-aminobutyric acid and succinate
1.1.1.42	Fomitopsis palustris		more	655035		AMP is a no inhibitor, no inhibition by glutamate, pyruvate and succinate
1.1.1.42	Saccharopolyspora erythraea		more	655094		no inhibition by phosphoenolpyruvate, fructose 1,6-bisphosphate, and pyruvate
1.1.1.42	Chlorobium limicola		more	655430		no inhibition of carboxylation by citrate, pyruvate, succinate, fumarate, malate, glyoxylate, ATP, and ADP
1.1.1.42	Chlorobium limicola		more	656740		no inhibition by glyoxylate
1.1.1.42	Rhodopseudomonas palustris		more	656740		no inhibition by glyoxylate
1.1.1.42	Mus musculus		more	695502		ischemia-reperfusion significantly reduces IDPc expression and activity
1.1.1.42	Homo sapiens		more	698058		transfection of HeLa cells with an IDPc small interfering RNA decreases activity of IDPc by 80%, enhancing the susceptibility of staurosporine-induced apoptosis reflected by DNA fragmentation, cellular redox status and the modulation of apoptotic marker proteins
1.1.1.42	Homo sapiens		more	698059		5 mM glutathione does not noticeably inhibit IDPc activity
1.1.1.42	Homo sapiens		more	713508		tumor-derived mutant IDH1 dominantly inhibits the wild-type IDH1 by forming a catalytically inactive heterodimer, resulting in a decrease of cellular 2-oxoglutarate
1.1.1.42	Mycobacterium tuberculosis		more	721687		product inhibition patterns for ICDH-1, overview
1.1.1.42	Bacillus sp.		N-ethylmaleimide	286796	46	
1.1.1.42	Streptomyces lividans		Na+	696488	55	4.67% relative activity at 2 mM
1.1.1.42	Streptomyces diastaticus		Na+	723151	55	
1.1.1.42	Microcystis aeruginosa		Na+	723152	55	slight inhibition
1.1.1.42	Mycobacterium tuberculosis		NaCl	668080	39	isoform ICD-2, increase in activity in up to 200 mM NaCl. Isoform ICD-1, no influence of NaCl. Above 200 mM, NaCl is inhibitory
1.1.1.42	Sus scrofa		NAD+	654341	4	
1.1.1.42	Pisum sativum		NADH	654843	3	noncompetitive
1.1.1.42	Pisum sativum		NADP+	654843	6	reverse reaction
1.1.1.42	Chlorobium limicola		NADP+	656740	6	37% inhibition of the reverse reaction at 4.0 mM
1.1.1.42	Rhodopseudomonas palustris		NADP+	656740	6	35% inhibition of the reverse reaction at 4.0 mM
1.1.1.42	Aspergillus niger		NADPH	286793	5	
1.1.1.42	Bacillus sp.		NADPH	286796	5	
1.1.1.42	Phormidium laminosum		NADPH	286799	5	
1.1.1.42	Synechocystis sp.		NADPH	286803	5	competitive inhibitor
1.1.1.42	Sus scrofa		NADPH	654649	5	
1.1.1.42	Pisum sativum		NADPH	654843	5	forward reaction
1.1.1.42	Chlorobium limicola		NADPH	656740	5	42% inhibition of the forward reaction at 0.5 mM
1.1.1.42	Rhodopseudomonas palustris		NADPH	656740	5	66% inhibition of the forward reaction at 0.5 mM
1.1.1.42	Mycobacterium tuberculosis		NADPH	668080	5	isoform ICD-2, competitive inhibition
1.1.1.42	Mycobacterium tuberculosis		NADPH	721687	5	product inhibition competitive versus NADP+ and noncompetitive versus isocitrate
1.1.1.42	Chlorobium limicola		NaHCO3	656740	2129	28% inhibition of the forward reaction at 10 mM
1.1.1.42	Rhodopseudomonas palustris		NaHCO3	656740	2129	9% inhibition of the forward reaction at 10 mM
1.1.1.42	Microcystis aeruginosa		Ni2+	723152	36	
1.1.1.42	Homo sapiens		nicotinamide mononucleotide	286786	623	
1.1.1.42	Fomitopsis palustris		oxalate	655035	166	18% inhibition at 5 mM
1.1.1.42	Acinetobacter calcoaceticus		oxaloacetate	286781	53	
1.1.1.42	Bombyx mori		oxaloacetate	286784	53	
1.1.1.42	Bacillus sp.		oxaloacetate	286796	53	
1.1.1.42	Fomitopsis palustris		oxaloacetate	655035	53	41% inhibition at 5 mM, mixed type inhibition together with glyoxylate, completely at 5 mM each
1.1.1.42	Saccharopolyspora erythraea		oxaloacetate	655094	53	25% inhibition at 1 mM, presence of 1 mM glyoxalate results in 50% inhibition
1.1.1.42	Chlorobium limicola		oxaloacetate	655430	53	competitive, inhibits the reverse reaction, over 50% inhibition at 1 mM, synergistically with glyoxylate
1.1.1.42	Chlorobium limicola		oxaloacetate	656740	53	18.6% inhibition at 2.5 mM
1.1.1.42	Rhodopseudomonas palustris		oxaloacetate	656740	53	15.5% inhibition at 2.5 mM
1.1.1.42	Corynebacterium glutamicum		oxaloacetate	721162	53	
1.1.1.42	Chlamydomonas reinhardtii		Oxalomalate	286779	5495	
1.1.1.42	Mycobacterium phlei		Oxalomalate	286795	5495	
1.1.1.42	Mus musculus		Oxalomalate	670334	5495	competitive, coadministration with CD2+ results in inhibition of enzyme and glutaredoxin and enhanced susceptibility to apoptosis
1.1.1.42	Sus scrofa		oxalylglycine	286797	1691	
1.1.1.42	Sus scrofa		p-chloromercuribenzoate	286749	40	
1.1.1.42	Bombyx mori		p-chloromercuribenzoate	286784	40	
1.1.1.42	Bos taurus		p-chloromercuribenzoate	286788	40	
1.1.1.42	Mycobacterium phlei		p-chloromercuribenzoate	286795	40	
1.1.1.42	Bacillus sp.		p-chloromercuribenzoate	286796	40	
1.1.1.42	Thermoleophilum minutum		p-chloromercuribenzoate	286809	40	
1.1.1.42	Sus scrofa		p-hydroxymercuribenzoate	286749	92	decarboxylation of isocitrate and oxalosuccinate
1.1.1.42	Homo sapiens		peroxynitrite	685421	925	ethanol toxicity is mediated by peroxynitrite and the peroxynitrite-mediated damage to NADP+-dependent isocitrate dehydrogenase and superoxide dismutase may be resulting in the perturbation of the cellular antioxidant defense systems and subsequently lead to a pro-oxidant condition
1.1.1.42	Arabidopsis thaliana		peroxynitrite	721779	925	
1.1.1.42	Sus scrofa		Phenarsazines	286749	66692	
1.1.1.42	Chlamydomonas reinhardtii		Phenylglyoxal	286806	258	
1.1.1.42	Sus scrofa		Phenylmercuric nitrate	286749	6216	
1.1.1.42	Bacillus sp.		phosphoenolpyruvate	286796	47	
1.1.1.42	Escherichia coli		phosphoenolpyruvate	680481	47	allosteric inhibition. Phosphoenolpyruvate enhances the uncompetitive inhibition of isocitrate lyase by increasing isocitrate, which protects isocitrate dehydrogenase from the inhibition, and contributes to the control through the tricarboxylic acid cycle and glyoxylate shunt
1.1.1.42	Homo sapiens		propanetricarboxylate	286786	6244	
1.1.1.42	Chlamydomonas reinhardtii		pyridoxal 5'-phosphate	286806	30	
1.1.1.42	Microcystis aeruginosa		Rb+	723152	400	slight inhibition
1.1.1.42	Arabidopsis thaliana		S-nitrosoglutathione	721779	753	; 70.5% inhibtion at 5 mM of the leaf enzyme, 37.3% of the root enzyme
1.1.1.42	Homo sapiens		Selenite	712077	1438	inactivates IDPm
1.1.1.42	Spirodela polyrhiza		succinate	656616	54	isozymes ICDH2 and ICDH1
1.1.1.42	Homo sapiens		Threo-L-Isocitrate	286786	28478	
1.1.1.42	Spirodela polyrhiza		trans-aconitate	656616	2067	isozyme ICDH1, not isozyme ICDH2
1.1.1.42	Acinetobacter calcoaceticus		Urea	286781	110	low molecular weight form
1.1.1.42	Bombyx mori		Zn2+	286784	19	
1.1.1.42	Fomitopsis palustris		Zn2+	655035	19	complete inhibition at 5 mM in presence of 5 mM Mg2+
1.1.1.42	Streptomyces lividans		Zn2+	696488	19	1.85% relative activity at 2 mM
1.1.1.42	Streptomyces diastaticus		Zn2+	723151	19	
1.1.1.42	Microcystis aeruginosa		Zn2+	723152	19	strong inhibition
4.1.1.48	Mycobacterium bovis BCG		ATB107	692324	13335	1-azabicyclo[2.2.2]octan-3-one[4-(phenylamino)-6-(1-piperidinyl)-1,3,5-triazin-2-yl]hydrazone, 0.1 microg/ml minimum inhibitory concentration, potent competitive inhibitor of the substrate 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose-5-phosphate
4.1.1.48	Mycobacterium tuberculosis		ATB107	692324	13335	1-azabicyclo[2.2.2]octan-3-one[4-(phenylamino)-6-(1-piperidinyl)-1,3,5-triazin-2-yl]hydrazone, 0.1 microg/ml minimum inhibitory concentration, potent competitive inhibitor of the substrate 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose-5-phosphate
4.1.1.48	Mycobacterium tuberculosis H37Ra		ATB107	692324	13335	1-azabicyclo[2.2.2]octan-3-one[4-(phenylamino)-6-(1-piperidinyl)-1,3,5-triazin-2-yl]hydrazone, 0.1 microg/ml minimum inhibitory concentration, potent competitive inhibitor of the substrate 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose-5-phosphate
4.1.1.48	Mycobacterium tuberculosis		ATB107	715893	13335	potent inhibitor
4.1.1.48	Mycobacterium tuberculosis		geomycine	678351	10642	0.5 mg/ml
4.1.1.48	Mycobacterium tuberculosis		H2O2	678351	20	0.001% H2O2 inactivates the enzyme almost completely
4.1.1.48	Mycobacterium tuberculosis		kanamycin	678351	634	0.5 mg/ml
4.1.1.48	Mycobacterium tuberculosis		L-tryptophan	692324	113	tryptophan at high concentrations has definite inhibitory activity against Mycobacterium tuberculosis but does not antagonize the activity of ATB107
4.1.1.48	Mycobacterium tuberculosis		methanol	678351	78	enzyme activity is gradually lost in the presence of increasing concentrations of methanol and completely lost at 65%
4.1.1.48	Mycobacterium tuberculosis		more	692324		inhibitory effect of ATB107 can not be reversed by the addition of tryptophan
4.1.1.48	Mycobacterium tuberculosis H37Ra		more	692324		inhibitory effect of ATB107 can not be reversed by the addition of tryptophan
4.1.1.48	Thermotoga maritima		phosphate	648890	12	
4.1.1.48	Escherichia coli		Reduced 1-[2-carboxyphenyl)amino]-1-deoxyribulose 5-phosphate	4611		
4.1.1.48	Mycobacterium tuberculosis		streptomycin	678351	1731	0.5 mg/ml
4.1.1.48	Mycobacterium tuberculosis H37Ra		tryptophan	692324	113	tryptophan at high concentrations has definite inhibitory activity against Mycobacterium tuberculosis but does not antagonize the activity of ATB107
1.1.1.205	Schizosaccharomyces pombe	ATP		347930	7	30% activation at 0.8 mM
1.1.1.205	Homo sapiens	ATP		669476	7	allosteric activator of the enzyme
1.1.1.205	Enterobacter aerogenes	Bovine serum albumin		347908		final concentration of 0.05% stimulates 50%
1.1.1.205	Bacillus anthracis	Cs+		724347	478	36% of the activity with K+
1.1.1.205	Enterobacter aerogenes	cysteine		347944	70	cysteine or glutathione required
1.1.1.205	Bacillus anthracis	dimethyl sulfoxide		724347	702	up to 15-20% increase IMP dehydrogenase activity
1.1.1.205	Enterobacter aerogenes	glutathione		347908	41	level for maximum activity: 2-4 mM
1.1.1.205	Bacillus subtilis	glutathione		347922	41	removal of glutathione from the reaction mixture causes 35% loss of acitivity
1.1.1.205	Enterobacter aerogenes	glutathione		347944	41	cysteine or glutathione required
1.1.1.205	Escherichia coli	glutathione		347934, 347946	41	
1.1.1.205	Cryptosporidium parvum	K+		724327	37	the K+ dependence of kcat value derives from the rate of flap closure, which increases by more than 65fold in the presence of K+. When K+ is replaced with a dummy ion, the residues of the K+ binding site relax into ordered secondary structure, creating a barrier to conformational exchange. K+ mobilizes these residues by providing alternate interactions for the main chain carbonyls. So K+ changes the shape of the energy well, shrinking the reaction coordinate by shifting the closed conformation toward the open state
1.1.1.205	Bacillus anthracis	K+		724347	37	optimal activation at 100-150 mM K+
1.1.1.205	Bacillus anthracis	Li+		724347	142	less than 1% of the activity with K+
1.1.1.205	Vigna unguiculata	more		347936		the enzyme is not affected by allantoin, allantoic acid, uric acid, inosine, xanthosine, and xanthosine 5'-phosphate
1.1.1.205	Saccharomyces cerevisiae	more		701583		genes IMD2, IMD3 and IMD4 support growth in the absence of guanine
1.1.1.205	Bacillus anthracis	more		724347		strict requirement for a monovalent cation
1.1.1.205	Homo sapiens	mycophenolate mofetil		703272	8727	median IMPDH activity in erythrocytes is 1.73times higher in mycophenolate mofetil positive than in mycophenolate mofetil negative kidney transplant recipients. Predose IMPDH activity in erythrocytes is induced slowly by mycophenolate mofetil therapy and is dependent on mycophenolic acid, phenolic and acyl glucuronides in stable kidney transplant recipients
1.1.1.205	Bacillus anthracis	Na+		724347	55	less than 1% of the activity with K+
1.1.1.205	Bacillus anthracis	NH4+		724347	50	77% of the activity with K+
1.1.1.205	Enterobacter aerogenes	Reducing agent		347935		effectiveness decreases in the order: dithiothreitol, mercaptoethanol, cyanide, ascorbate
1.1.1.205	Vigna unguiculata	Sulfhydryl-reducing agents		347936		required for maximal activity
1.1.1.205	Homo sapiens		(2-[acetyl[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]amino]ethyl)phosphonic acid	667980	39539	isozyme IMPDH II IC50: 785 nM
1.1.1.205	Homo sapiens		(2-[formyl[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]amino]ethyl)phosphonic acid	667980	39540	isozyme IMPDH II IC50: 749 nM
1.1.1.205	Homo sapiens		(2-[[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](methyl)amino]ethyl)phosphonic acid	667980	39545	isozyme IMPDH II IC50: above 0.001 mM
1.1.1.205	Homo sapiens		(2-[[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](methylsulfonyl)amino]ethyl)phosphonic acid	667980	39541	isozyme IMPDH II IC50: 498 nM
1.1.1.205	Homo sapiens		(2-[[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](sulfamoyl)amino]ethyl)phosphonic acid	667980	39546	isozyme IMPDH II IC50: 93 nM
1.1.1.205	Homo sapiens		(2-[[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]amino]ethyl)phosphonic acid	667980	39538	isozyme IMPDH II IC50: 499 nM
1.1.1.205	Homo sapiens		(2-[[(2E)-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](methyl)amino]ethyl)phosphonic acid	667980	39552	isozyme IMPDH II IC50: 132 nM
1.1.1.205	Homo sapiens		(2-[[(2E)-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](methylsulfonyl)amino]ethyl)phosphonic acid	667980	39550	isozyme IMPDH II IC50: 68 nM
1.1.1.205	Homo sapiens		(2-[[(2E)-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](sulfamoyl)amino]ethyl)phosphonic acid	667980	39551	isozyme IMPDH II IC50: 24 nM
1.1.1.205	Homo sapiens		(2-[[(2E)-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]amino]ethyl)phosphonic acid	667980	39549	isozyme IMPDH II IC50: 13 nM
1.1.1.205	Homo sapiens		(2E)-3-furan-2-yl-N-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]prop-2-enamide	667935	11929	isozyme IMPDH II IC50: 28 nM
1.1.1.205	Homo sapiens		(2E)-3-furan-2-yl-N-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]prop-2-enamide	703193	11929	; 
1.1.1.205	Homo sapiens		(2E)-3-furan-2-yl-N-[4-(4-methyl-1,3-oxazol-5-yl)phenyl]prop-2-enamide	667935	39586	isozyme IMPDH II IC50: 0.002 mM
1.1.1.205	Cryptosporidium parvum		(2S)-2-[(1-naphthyl)amino]-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide	725678	62157	competitive versus NAD+
1.1.1.205	Cryptosporidium parvum		(2S)-2-[(3,4-dichlorophenyl)amino]-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide	725678	62156	competitive versus NAD+, displays excellent IMPDH inhibitory activity and moderate stability in mouse liver microsomes
1.1.1.205	Homo sapiens		(4E)-6-(4,6-dihydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid	711473	18896	derivative of mycophenolic acid. IC50 value for K562 cells proliferation 8.2 microM; derivative of mycophenolic acid. IC50 value for K562 cells proliferation 8.2 microM
1.1.1.205	Homo sapiens		(4E)-6-[4-(acetyloxy)-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoic acid	711473	18897	derivative of mycophenolic acid. IC50 value for K562 cells proliferation 0.59 microM; derivative of mycophenolic acid. IC50 value for K562 cells proliferation 0.59 microM
1.1.1.205	Homo sapiens		(4E)-N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide	711473	18899	derivative of mycophenolic acid. IC50 value for K562 cells proliferation 2.1 microM; derivative of mycophenolic acid. IC50 value for K562 cells proliferation 2.1 microM
1.1.1.205	Homo sapiens		(5E)-N-hydroxy-7-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-5-methylhept-5-enamide	688266	25092	comparison with inhibition of histone deacetylase and K562 cell proliferation
1.1.1.205	Homo sapiens		([[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]oxy]methyl)phosphonic acid	667980	39534	isozyme IMPDH II IC50: 246 nM
1.1.1.205	Homo sapiens		([[(2E)-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]oxy]methyl)phosphonic acid	667980	39548	isozyme IMPDH II IC50: 23 nM
1.1.1.205	Homo sapiens		1,4-dimethyl-6-nitro-2H-cyclopenta[d]pyridazine	703193	26085	; 
1.1.1.205	Homo sapiens		1-(2,2-dimethylpropanoyl)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-1'H-spiro[pyrrolidine-3,2'-quinazolin]-4'(3'H)-one	667965	39644	IC50: 0.094 mM, isozyme IMPDH II
1.1.1.205	Cryptosporidium parvum		1-(2-[3-[(1E)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)-3-quinolin-7-ylurea	725673	62159	displays high potency against Cryptosporidium parvum IMPDH, more than 1000fold selectivity versus human IMPDH type 2 and good stability in mouse liver microsomes
1.1.1.205	Homo sapiens		1-(3-methylphenyl)-3-[4-(1,3-oxazol-5-yl)phenyl]urea	667935	39582	isozyme IMPDH II IC50: 640 nM
1.1.1.205	Cryptosporidium parvum		1-(4-chloro-5-nitrocyclohexa-1,5-dien-1-yl)-3-(2-[3-[(1E)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)urea	725673		displays high potency against Cryptosporidium parvum IMPDH, more than 1000fold selectivity versus human IMPDH type 2 and good stability in mouse liver microsomes
1.1.1.205	Homo sapiens		1-(benzyloxy)-3-(3-pyridin-4-yl-1H-indol-6-yl)urea	703193	26084	; 
1.1.1.205	Homo sapiens		1-methyl-6-[(5-phenyl-1,3-oxazol-2-yl)amino]-1H-indole-3-carbonitrile	703193	26083	; 
1.1.1.205	Homo sapiens		1-phenylsulfonylindol-3-yl boronic acid	667976	84618	
1.1.1.205	Homo sapiens		1-tert-butyl 5-methyl (3R,5R)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1,5-dicarboxylate	667965	39655	IC50: 35 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		1-tert-butyl 5-methyl (3R,5S)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1,5-dicarboxylate	667965	39654	IC50: 948 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		1-tert-butyl 5-methyl (3S,5R)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1,5-dicarboxylate	667965	39653	IC50: 35 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		1-tert-butyl 5-methyl (3S,5S)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1,5-dicarboxylate	667965	84516	26% inhibition at 10 micromol, isozyme IMPDH II
1.1.1.205	Cryptosporidium parvum		1-[2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]-3-quinolin-7-ylurea	725673	62158	displays high potency against Cryptosporidium parvum IMPDH, more than 1000fold selectivity versus human IMPDH type 2 and good stability in mouse liver microsomes
1.1.1.205	Homo sapiens		1-[3-chloro-4-(1,3-oxazol-5-yl)phenyl]-3-(3-methylphenyl)urea	667935	39581	isozyme IMPDH II IC50: 43 nM
1.1.1.205	Homo sapiens		1-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-3-(3-methylphenyl)urea	667935	39553	isozyme IMPDH II IC50: 19 nM
1.1.1.205	Homo sapiens		1-[4-(4-methyl-1,3-oxazol-5-yl)phenyl]-3-(3-methylphenyl)urea	667935	39583	isozyme IMPDH II IC50: 500 nM
1.1.1.205	Homo sapiens		14,16-dihydroxy-3,8-dimethyl-3,4,5,6,9,10-hexahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione	711475	12912	inhibition of leukemia K562 cells proliferation, IC50 of 71.3 microM
1.1.1.205	Cryptosporidium parvum		1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate	703193	5912	binds in the nicotinamide subsite and does not interact with ADP
1.1.1.205	Borrelia burgdorferi		1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate	711735	5912	
1.1.1.205	Escherichia coli		1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate	711735	5912	not inhibitory to wild-type
1.1.1.205	Helicobacter pylori		1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate	711735	5912	
1.1.1.205	Streptococcus pyogenes		1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate	711735	5912	
1.1.1.205	Bacillus subtilis		2'-Deoxy-ATP	347922	133	18% inhibition at 0.5 mM
1.1.1.205	Bacillus subtilis		2'-deoxy-GDP	347922	863	12% inhibition at 0.5 mM
1.1.1.205	Bacillus subtilis		2'-deoxy-GTP	347922	194	21% inhibition at 0.5 mM
1.1.1.205	Homo sapiens		2'-methylthiazole-4-carboxamide adenine dinucleotide	667921	23865	noncompetitive inhibition, less cytotoxic against K562 tumor cells
1.1.1.205	Homo sapiens		2-(1,3-oxazol-5-yl)-5-[(5-phenyl-1,3-oxazol-2-yl)amino]phenol	667935	39560	isozyme IMPDH II IC50: 0.0016 mM
1.1.1.205	Homo sapiens		2-(1-benzothiophen-3-yl)-6-methoxy-5-(1,3-oxazol-5-yl)-1H-indole-3-carbaldehyde	703193	26076	; 
1.1.1.205	Homo sapiens		2-(dimethylamino)-7-methoxy-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one	667938	39785	isozyme IMPDH II IC50: 200 nM
1.1.1.205	Homo sapiens		2-amino-oxazole-cyanoindoles	667938		
1.1.1.205	Homo sapiens		2-benzyl-7-methoxy-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one	667938	39783	isozyme IMPDH II IC50: 180 nM
1.1.1.205	Cricetulus griseus		2-beta-D-ribofuranosylthiazole-4-carboxamide	347910	1402	NSC 286193, RTC
1.1.1.205	Cricetulus griseus		2-beta-D-ribofuranosylthiazole-4-carboxamide 5'-phosphate	347910	2264	RTC monophosphate
1.1.1.205	Homo sapiens		2-cyano-1-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-3-phenylguanidine	667935	39554	isozyme IMPDH II IC50: 240 nM
1.1.1.205	Homo sapiens		2-ethyl-9-[5-O-[hydroxy(2-[hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl]ethyl)phosphoryl]-beta-L-ribofuranosyl]-9H-purin-6-amine	711475	19170	inhibition of leukemia K562 cells proliferation, IC50 of 4.0 microM; inhibition of leukemia K562 cells proliferation, IC50 of 4.0 microM
1.1.1.205	Homo sapiens		2-furan-3-yl-7-methoxy-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one	667938	39773	isozyme IMPDH II IC50: 32 nM
1.1.1.205	Homo sapiens		2-hydroxy-N-[2-(2-[[3-methoxy-4-(1,3-oxazol-4-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methylacetamide	667935	39596	isozyme IMPDH II IC50: 41 nM
1.1.1.205	Rattus norvegicus		2-mercaptoethanol	347940	59	inhibits above 2 mM
1.1.1.205	Homo sapiens		2-methyl-3-(pyrid-4-yl)indole	667976	39772	IC50: 343 nM
1.1.1.205	Homo sapiens		2-tert-butyl-7-methoxy-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one	667938	39782	isozyme IMPDH II IC50: 0.01 mM
1.1.1.205	Cryptosporidium parvum		2-[(3,4-dichlorophenyl)amino]-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide	725678		racemic variant, competitive versus NAD+. Compound displays good antiparasitic activity in a Toxoplasma gondii strain that relies on Cryptosporidium parvum IMPDH, EC50 20 nM. No toxicity is observed against four mammalian cells lines
1.1.1.205	Cryptosporidium parvum		2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide	703193	5911	antagonizes ADP binding
1.1.1.205	Borrelia burgdorferi		2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide	711735	5911	
1.1.1.205	Escherichia coli		2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide	711735	5911	not inhibitory to wild-type
1.1.1.205	Helicobacter pylori		2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide	711735	5911	
1.1.1.205	Streptococcus pyogenes		2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide	711735	5911	
1.1.1.205	Escherichia coli		2-[2-(Z)-fluorovinyl]-inosine 5'-phosphate	703193	53985	is a time-dependent inactivator
1.1.1.205	Homo sapiens		2-[methyl[2-(2-[[3-(1,3-oxazol-5-yl)-1H-indol-6-yl]amino]-1,3-oxazol-5-yl)phenyl]amino]-2-oxoethyl acetate	703193	26082	; 
1.1.1.205	Homo sapiens		2264A	703193	26839	inhibits lymphocyte proliferation; inhibits lymphocyte proliferation
1.1.1.205	Homo sapiens		2264B	703193	53981	inhibits lymphocyte proliferation; inhibits lymphocyte proliferation
1.1.1.205	Homo sapiens		3'-methylthiazole-4-carboxamide adenine dinucleotide	667921	23866	noncompetitive inhibition, less cytotoxic against K562 tumor cells
1.1.1.205	Borrelia burgdorferi		3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate	711735	6928	
1.1.1.205	Escherichia coli		3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate	711735	6928	not inhibitory to wild-type
1.1.1.205	Helicobacter pylori		3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate	711735	6928	
1.1.1.205	Streptococcus pyogenes		3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate	711735	6928	
1.1.1.205	Homo sapiens		3-(pyrid-4-yl)indole	667976	39771	
1.1.1.205	Homo sapiens		3-carbamoylindole	667976	84617	
1.1.1.205	Homo sapiens		3-cyanoindole	667976	39770	inhibits isozyme IMPDH II at 0.03 mM
1.1.1.205	Homo sapiens		3-cyanoindole-based inhibitors	667937		synthesis and initial structureactivity relationships of 3-cyanoindole-based inhibitors with isozyme IMPDH II, IC50: 33-420 nM, comparison to other inhibitor structural classes, overview
1.1.1.205	Homo sapiens		3-formyl-1-methylindole	667976	84619	
1.1.1.205	Homo sapiens		3-formylindole	667976	3157	
1.1.1.205	Homo sapiens		3-hydrogenkwadaphnin	703193	53980	; 
1.1.1.205	Homo sapiens		3-hydroxy-N-methyl-N-[2-(2-[[3-methyl-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]propanamide	667935	39569	isozyme IMPDH II IC50: 100 nM
1.1.1.205	Homo sapiens		3-hydroxy-N-[2-(2-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methylpropanamide	667935	39567	isozyme IMPDH II IC50: 21 nM
1.1.1.205	Homo sapiens		3-methoxy-4-(oxazol-5-yl)aniline	667976	84620	
1.1.1.205	Homo sapiens		3-phenyl quinolone derivatives	667938		several, isozyme IMPDH II IC50: 5-160 nM, overview
1.1.1.205	Homo sapiens		4-pyridylindole	667976	39771	IC50: 0.00115 mM
1.1.1.205	Bacillus anthracis		4-[(1R)-1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]ethoxy]quinoline 1-oxide	724347	19741	
1.1.1.205	Campylobacter jejuni		4-[(1R)-1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]ethoxy]quinoline 1-oxide	724347	19741	
1.1.1.205	Homo sapiens		4-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]amino]-6-phenyl-1,3,5-triazin-2-ol	703193	26077	; 
1.1.1.205	Enterobacter aerogenes		5'-thio-IMP	347928	69875	competitive inhibitor
1.1.1.205	Escherichia coli		5,5'-dithiobis(2-nitrobenzoate)	347929	196	
1.1.1.205	Homo sapiens		5-bromoisoquinolin-6-amine	703193	26089	; 
1.1.1.205	Homo sapiens		5-chloro-1,4-dimethyl-2H-cyclopenta[d]pyridazine-6-carbonitrile	703193	26086	; 
1.1.1.205	Cryptosporidium parvum		6,6'-oxydi(1,4-dihydroquinoxaline-2,3-dione)	703193	94274	binds in the nicotinamide subsite and does not interact with ADP
1.1.1.205	Homo sapiens		6-((E)-4-(((1-(50-deoxy-adenosin-50-yl)-1H-1,2,3-triazol-4-yl)-methyl)amino)-3-methylbut-2-en-1-yl)-7-hydroxy-5-methoxy-4-methylisobenzofuran-1(3H)-one	712703	18900	; 
1.1.1.205	Homo sapiens		6-((E)-4-(4-(adenosin-50-yl)methyl-1H-1,2,3-triazol-1-yl)-3-methylbut-2-en-1-yl)-7-hydroxy-5-methoxy-4-methylisobenzofuran-1(3H)-one	712703	10118	; 
1.1.1.205	Mycobacterium tuberculosis		6-((E)-4-(4-(adenosin-50-yl)methyl-1H-1,2,3-triazol-1-yl)-3-methylbut-2-en-1-yl)-7-hydroxy-5-methoxy-4-methylisobenzofuran-1(3H)-one	712703	10118	uncompetitive versus IMP
1.1.1.205	Enterobacter aerogenes		6-Chloro-9-beta-D-ribofuranosylpurine 5 '-phosphate	347923	12759	50% inactivation after 90 min at 0.00012 mM Cl-IMP
1.1.1.205	Escherichia coli		6-Chloro-9-beta-D-ribofuranosylpurine 5 '-phosphate	347929	12759	covalent modification of the enzyme, total inactivation after 15 min at 0.01 mg/ml Cl-IMP, activity can be restored with 2-mercaptoethanol
1.1.1.205	Rattus norvegicus		6-Chloro-9-beta-D-ribofuranosylpurine 5 '-phosphate	347937	12759	
1.1.1.205	Sus scrofa		6-Chloro-9-beta-D-ribofuranosylpurine 5 '-phosphate	347947	12759	acts at the IMP binding site
1.1.1.205	Escherichia coli		6-chloroinosine 5'-phosphate	701583	12759	
1.1.1.205	Homo sapiens		6-chloroinosine 5'-phosphate	701583	12759	
1.1.1.205	Homo sapiens		6-chloroinosine 5'-phosphate	703193	12759	; 
1.1.1.205	Streptococcus pyogenes		6-Chloropurine	347959	2028	irreversible inhibitor
1.1.1.205	Enterobacter aerogenes		6-Chloropurine ribonucleoside 5'-phosphate	347908	12759	inosine 5'-phosphate and guanosine 5'-phosphate retard inactivation
1.1.1.205	Enterobacter aerogenes		6-Chloropurine ribonucleoside 5'-phosphate	347923	12759	
1.1.1.205	Enterobacter aerogenes		6-Cl-IMP	703193	12759	
1.1.1.205	Homo sapiens		6-mercaptopurine ribonucleotide	347931	13256	
1.1.1.205	Rattus norvegicus		6-thio-IMP	347940	6108	
1.1.1.205	Homo sapiens		6-thioguanosine	690045	6378	expression of isoform IMPDH2 increases modestly in response to 6-thioguanosine exposure. However, the basal enzyme activity decreases when the cells are exposed to a proliferation-blocking 6-thioguanosine concentration
1.1.1.205	Enterobacter aerogenes		6-thioinosine 5'-phosphate	347908	13256	complete inactivation after 10 min preincubation at a concentration of 0.001 mM; in absence of glutathione
1.1.1.205	Enterobacter aerogenes		6-thioinosine 5'-phosphate	347928	13256	in absence of glutathione
1.1.1.205	Homo sapiens		7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-1'H-spiro[cyclopentane-1,2'-quinazolin]-4'(3'H)-one	667965	39639	IC50: 328 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-1-(piperidin-1-ylcarbonyl)-1'H-spiro[pyrrolidine-3,2'-quinazolin]-4'(3'H)-one	667965	39650	IC50: 0.068 mM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-2,3,5,6-tetrahydro-1'H-spiro[pyran-4,2'-quinazolin]-4'(3'H)-one	667965	39640	IC50: 526 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-N-phenyl-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide	667965	39646	IC50: 0.393 mM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4,6-dihydro-1'H-spiro[cyclopenta[b]thiophene-5,2'-quinazolin]-4'(3'H)-one	667965	39641	IC50: 96 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7'-methoxy-3'-methyl-N,N-bis(1-methylethyl)-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide	667965	39651	IC50: 0.071 mM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7'-methoxy-N,3'-dimethyl-6'-(1,3-oxazol-5-yl)-4'-oxo-N-phenyl-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide	667965	39647	IC50: 0.064 mM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7-hydroxy-5-methoxy-4-methyl-6-(3-methylbut-2-en-1-yl)-2-benzofuran-1(3H)-one	667980	39543	isozyme IMPDH II IC50: 254 nM
1.1.1.205	Homo sapiens		7-hydroxy-5-methoxy-6-[(2E)-4-methoxy-3-methylbut-2-en-1-yl]-4-methyl-2-benzofuran-1(3H)-one	667980	39544	isozyme IMPDH II IC50: 273 nM
1.1.1.205	Homo sapiens		7-methoxy-2,2,3-trimethyl-6-(1,3-oxazol-5-yl)-2,3-dihydroquinazolin-4(1H)-one	667965	39636	IC50: 192 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7-methoxy-2,2-dimethyl-6-(1,3-oxazol-5-yl)-3-(2-pyridin-4-ylethyl)-2,3-dihydroquinazolin-4(1H)-one	667965	39637	IC50: 300 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7-methoxy-2,3-dimethyl-6-(1,3-oxazol-5-yl)-2-[(E)-2-phenylethenyl]-2,3-dihydroquinazolin-4(1H)-one	667965	39638	IC50: 49 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7-methoxy-2-(3-methylphenyl)-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one	703193	26079	; 
1.1.1.205	Homo sapiens		7-methoxy-2-(methylamino)-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one	667938	39784	isozyme IMPDH II IC50: 220 nM
1.1.1.205	Homo sapiens		7-methoxy-2-methyl-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one	667938	39781	isozyme IMPDH II IC50: 110 nM
1.1.1.205	Homo sapiens		7-methoxy-3-methyl-6-(1,3-oxazol-5-yl)-2-phenylquinolin-4(1H)-one	667938	39786	isozyme IMPDH II IC50: 65 nM
1.1.1.205	Homo sapiens		7-methoxy-3-methyl-6-(1,3-oxazol-5-yl)quinazoline-2,4(1H,3H)-dione	667965	39635	IC50: 104 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-4-yl)-2-phenylquinolin-4(1H)-one	667935	39598	isozyme IMPDH II IC50: 210 nM
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)-2-(1,3-thiazol-4-yl)quinolin-4(1H)-one	667938	39776	isozyme IMPDH II IC50: 34 nM
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)-2-phenoxyquinolin-4(1H)-one	667935	39558	isozyme IMPDH II IC50: 8 nM
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)-2-phenylquinolin-4(1H)-one	667938	23864	isozyme IMPDH II IC50: 8 nM
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)-2-pyridin-2-ylquinolin-4(1H)-one	667938	39777	isozyme IMPDH II IC50: 43 nM
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)-2-pyridin-3-ylquinolin-4(1H)-one	667938	39778	isozyme IMPDH II IC50: 70 nM
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)-2-pyridin-4-ylquinolin-4(1H)-one	667938	39779	isozyme IMPDH II IC50: 46 nM
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)-2-thiophen-2-ylquinolin-4(1H)-one	667938	39775	isozyme IMPDH II IC50: 63 nM
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)-2-thiophen-3-ylquinolin-4(1H)-one	667938	39774	isozyme IMPDH II IC50: 9 nM
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one	667966	39769	IC50: 303 nM
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)-3-(2-pyridin-4-ylethyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one	703193	26080	; 
1.1.1.205	Homo sapiens		7-methoxy-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one	667938	39780	isozyme IMPDH II IC50: 300 nM
1.1.1.205	Homo sapiens		9-(5-deoxy-5-([(([2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]sulfonyl)methyl)sulfonyl]amino)-b-L-ribofuranosyl)-2-ethyl-9H-purin-6-amine	685555	25278	
1.1.1.205	Homo sapiens		9-(5-deoxy-5-([(([2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]sulfonyl)methyl)sulfonyl]amino)-b-L-ribofuranosyl)-2-ethynyl-9H-purin-6-amine	685555	25277	
1.1.1.205	Homo sapiens		9-(5-deoxy-5-([(([2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]sulfonyl)methyl)sulfonyl]amino)-b-L-ribofuranosyl)-2-phenyl-9H-purin-6-amine	685555	25276	
1.1.1.205	Homo sapiens		9-(5-deoxy-5-([(([2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]sulfonyl)methyl)sulfonyl]amino)-b-L-ribofuranosyl)-9H-purin-6-amine	685555	25275	
1.1.1.205	Homo sapiens		9-(5-O-[hydroxy[([hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl]oxy)methyl]phosphoryl]-beta-L-ribofuranosyl)-9H-purin-6-amine	711475	19169	inhibition of leukemia K562 cells proliferation, IC50 of 71.3 microM
1.1.1.205	Homo sapiens		9-(5-O-[hydroxy[([hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl]oxy)methyl]phosphoryl]-beta-L-ribofuranosyl)-9H-purin-6-amine	712703	19169	homology modeling; homology modeling
1.1.1.205	Escherichia coli		ADP	347946	8	
1.1.1.205	Candida albicans		ADP	669310	8	multiple inhibition with tiazofurin, competitive versus NAD+
1.1.1.205	Cryptosporidium parvum		ADP	703193	8	
1.1.1.205	Homo sapiens		ADP	703193	8	; 
1.1.1.205	Tritrichomonas suis		ADP	703193	8	binds in the adenosine portion, tiazofurin and ADP are strongly synergistic inhibitors, a conformational change occurs upon the binding of one inhibitor that increases the affinity of the second inhibitor
1.1.1.205	Tritrichomonas suis		ADP	711219	8	
1.1.1.205	Homo sapiens		allopurinol ribonucleotide	347931	8324	
1.1.1.205	Homo sapiens		AMP	347931	9	
1.1.1.205	Vigna unguiculata		AMP	347936	9	; competitive
1.1.1.205	Rattus norvegicus		AMP	347937, 347940	9	
1.1.1.205	Mus musculus		AMP	347945	9	20% inhibition at high concentrations
1.1.1.205	Escherichia coli		AMP	347946	9	
1.1.1.205	Sus scrofa		AMP	347947	9	
1.1.1.205	Bacillus subtilis		ATP	347922	7	at high concentration of IMP and KCl
1.1.1.205	Schizosaccharomyces pombe		ATP	347930	7	0.8 mM, not
1.1.1.205	Escherichia coli		ATP	347946	7	
1.1.1.205	Homo sapiens		AVN944	703193	18263	induces caspase-independent apoptosis in multiple myeloma cell lines and displays antiproliferative activity against both androgen-dependent and androgen-independent prostate cancer cell lines; induces caspase-independent apoptosis in multiple myeloma cell lines and displays antiproliferative activity against both androgen-dependent and androgen-independent prostate cancer cell lines
1.1.1.205	Homo sapiens		benzamide riboside	347960	8702	NAD+ binding site inhibitor
1.1.1.205	Homo sapiens		benzamide riboside	670128	8702	
1.1.1.205	Homo sapiens		benzamide riboside	703193	8702	displays skeletal muscle toxicity in preclinical trials, which limits its utility; displays skeletal muscle toxicity in preclinical trials, which limits its utility
1.1.1.205	Homo sapiens		benzamide riboside	705494	8702	inhibitory activity is higher than tiazofurin and lower than selenazofurin; inhibitory activity is higher than tiazofurin and lower than selenazofurin
1.1.1.205	Homo sapiens		beta-difluoromethylene-tiazofurin	703193	53983	; 
1.1.1.205	Homo sapiens		beta-methylene thiazole 4-carboxamide adenine dinucleotide	668351	39634	i.e. beta-Me-TAD or CH2-TAD
1.1.1.205	Tritrichomonas suis		beta-methylene thiazole 4-carboxamide adenine dinucleotide	668351	39634	i.e. beta-Me-TAD
1.1.1.205	Homo sapiens		beta-methylene-TAD	667921	53982	noncompetitive inhibition
1.1.1.205	Tritrichomonas suis		beta-methylene-thiazole-4-carboxamide adenine dinucleotide	667573	39634	i.e. beta-Me-TAD, enzyme binding structure analysis, the enzyme active site loop is ordered in this complex, and the catalytic Cys319 is 3.6 A from IMP, in the same plane as the hypoxanthine ring, the active site loop forms hydrogen bonds to the carboxamide of beta-Me-TAD, overview
1.1.1.205	Tritrichomonas suis		beta-methylene-thiazole-4-carboxyamide-adenine dinucleotide	705494	4752	
1.1.1.205	Homo sapiens		beta-methylene-tiazofurin	703193	53982	; 
1.1.1.205	Homo sapiens		blastadin 11	703193	53979	; 
1.1.1.205	Homo sapiens		BMS-337197	667937	6625	isozyme IMPDH II IC50: 16 nM
1.1.1.205	Homo sapiens		BMS-337197	667938	6625	i.e. BMS-337197
1.1.1.205	Homo sapiens		BMS-337197	667966	6625	
1.1.1.205	Homo sapiens		BMS-337197	667976	6625	IC50: 0.0082 mM
1.1.1.205	Mus musculus		BMS-337197	705494	6625	is a potent IMPDH inhibitor, shows in vivo activity for inhibition of antibody production in mice
1.1.1.205	Rattus norvegicus		BMS-337197	705494	6625	is a potent IMPDH inhibitor, shows in vivo activity for inhibition of antibody production in the adjuvant-induced arthritis model in rats
1.1.1.205	Chlorocebus aethiops		Bredinin	347917	29206	
1.1.1.205	Homo sapiens		C2-mycophenolic adenine dinucleotide	669807	23863	methylenephosphophosphonate analogue of mycophenolic adenine dinucleotide
1.1.1.205	Homo sapiens		C2-mycophenolic adenine dinucleotide	701583	23863	
1.1.1.205	Homo sapiens		C4-mycophenolic adenine dinucleotide	669807	39766	methylenephosphophosphonate analogue of mycophenolic adenine dinucleotide
1.1.1.205	Mus musculus		Ca2+	347945	18	29% inactivation in the presence of 0.1M K+
1.1.1.205	Escherichia coli		Ca2+	701583	18	competitive inhibition with respect to both K+ and NAD+
1.1.1.205	Toxoplasma gondii		CH2-SAD	667219	39633	i.e. 4-carboxamido-2-beta-D-ribofuranosylselenazolyl adenosine methylenediphosphonic acid, an adenine dinucleotide analogue nonhydrolyzable beta-methylene derivative
1.1.1.205	Toxoplasma gondii		CH2-TAD	667219	39634	i.e. 4-carboxamido-2-beta-D-ribofuranosylthiazolyl adenosine methylenediphosphonic acid, an adenine dinucleotide analogue nonhydrolyzable beta-methylene derivative
1.1.1.205	Mus musculus		chlorogenic acid	711518	488	0.1 mM, 30% inhibition
1.1.1.205	Schizosaccharomyces pombe		CMP	347930	94	25% inhibition at 0.6 mM
1.1.1.205	Homo sapiens		curcumin	711518	561	significantly reduces the level of GTP and reduces the rate of cell growth
1.1.1.205	Mus musculus		curcumin	711518	561	0.1 mM, 68% inhibition, both competitive and uncompetitive
1.1.1.205	Homo sapiens		dimethyl (2-[[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]amino]ethyl)phosphonate	667980	39542	isozyme IMPDH II IC50: above 0.001 mM
1.1.1.205	Homo sapiens		dimethyl [(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]phosphonate	667980	39533	isozyme IMPDH II IC50: 289 nM
1.1.1.205	Rattus norvegicus		dithioerythrol	347940	70336	inhibits above 1 mM
1.1.1.205	Escherichia coli		EAD	703193	53984	
1.1.1.205	Escherichia coli		EICARMP	703193	12760	
1.1.1.205	Homo sapiens		EICARMP	703193	12760	; 
1.1.1.205	Mus musculus		eicosadienoic acid	685417	4594	competitive to inosine 5'-phosphate
1.1.1.205	Homo sapiens		eicosadienoic acid	703193	4594	competitive inhibitor versus IMPDH; competitive inhibitor versus IMPDH
1.1.1.205	Mus musculus		Ellagic acid	711518	971	0.1 mM, 27% inhibition
1.1.1.205	Mus musculus		epigallocatechin gallate	711518	936	0.1 mM, 47% inhibition
1.1.1.205	Homo sapiens		ethyl 7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxylate	667965	39643	IC50: 0.08 mM, isozyme IMPDH II
1.1.1.205	Homo sapiens		ethyl 9-oxo-9,10-dihydroacridine-1-carboxylate	703193	26087	; 
1.1.1.205	Bacillus cereus		Fe3+	347958	66	11% inhibition at 1 nM
1.1.1.205	Homo sapiens		FFAD	703193	18266	; 
1.1.1.205	Schizosaccharomyces pombe		GDP	347930	49	45% inhibition at 0.6 mM
1.1.1.205	Escherichia coli		GDP	347946	49	
1.1.1.205	Enterobacter aerogenes		glutathione	347908	41	above 4 mM
1.1.1.205	Enterobacter aerogenes		GMP	347908	150	competitive with respect to IMP
1.1.1.205	Escherichia coli		GMP	347909	150	competitive with respect to IMP and non competitive with respect to NAD+
1.1.1.205	Salmonella enterica subsp. enterica serovar Typhimurium		GMP	347921	150	feedback inhibitor; feed-back inhibitor eliciting 'allosteric' kinetics of the enzyme, determination of the GMP binding site
1.1.1.205	Bacillus subtilis		GMP	347922	150	competitive, 58% inhibition at 0.5 mM
1.1.1.205	Enterobacter aerogenes		GMP	347924	150	competitive with respect to IMP, non competitive with respect to NAD+ and K+
1.1.1.205	Schizosaccharomyces pombe		GMP	347930	150	55% inhibition at 0.6 mM
1.1.1.205	Homo sapiens		GMP	347931	150	
1.1.1.205	Vigna unguiculata		GMP	347936	150	; competitive
1.1.1.205	Rattus norvegicus		GMP	347937	150	
1.1.1.205	Escherichia coli		GMP	347938	150	competitive with respect to IMP
1.1.1.205	Rattus norvegicus		GMP	347940	150	competitive with respect to IMP
1.1.1.205	Escherichia coli		GMP	347941	150	; weak and competitive inhibition, strong binding, dissociation by 3 M urea
1.1.1.205	Escherichia coli		GMP	347939, 347946	150	
1.1.1.205	Sus scrofa		GMP	347947	150	
1.1.1.205	Borrelia burgdorferi		GMP	347955	150	competitive with respect to IMP
1.1.1.205	Leishmania donovani		GMP	688888	150	
1.1.1.205	Schizosaccharomyces pombe		GTP	347930	35	45% inhibition at 0.6 mM
1.1.1.205	Escherichia coli		GTP	347946	35	
1.1.1.205	Homo sapiens		halicyclamine A	703193	53978	; 
1.1.1.205	Homo sapiens		helenalin	703193	23267	; 
1.1.1.205	Pisum sativum		HgCl2	347943	104	complete inactivation at 0.5 mM
1.1.1.205	Escherichia coli		imidazo[4,5-e][1,4]diazapine	701583	8129	
1.1.1.205	Homo sapiens		imidazo[4,5-e][1,4]diazapine	701583	8129	
1.1.1.205	Escherichia coli		imidazo[4,5-e][1,4]diazapine	703193	8129	fat base nucleotide, inosine 5'-phosphate but not NAD+ protects against inhibition
1.1.1.205	Homo sapiens		imidazo[4,5-e][1,4]diazapine	703193	8129	fat base nucleotide, inosine 5'-phosphate but not NAD+ protects against inhibition; fat base nucleotide, inosine 5'-phosphate but not NAD+ protects against inhibition
1.1.1.205	Enterobacter aerogenes		Inosine	347920	154	very weak, non-competitive
1.1.1.205	Enterobacter aerogenes		Inosine 5'-methylphosphonate	347920	64685	very weak, non-competitive
1.1.1.205	Toxoplasma gondii		inosine 5'-phosphate	667219	206	
1.1.1.205	Enterobacter aerogenes		Inosine 5'-phosphite	347920	64686	very weak, non-competitive
1.1.1.205	Enterobacter aerogenes		Inosine 5'-phosphofluoridate	347920	64687	very weak, non-competitive
1.1.1.205	Escherichia coli		iodoacetamide	347929	63	
1.1.1.205	Escherichia coli		iodoacetate	347929	87	
1.1.1.205	Pisum sativum		iodoacetate	347943	87	98% inhibition at 10 mM
1.1.1.205	Enterobacter aerogenes		K+	347908	37	above 0.1 M
1.1.1.205	Enterobacter aerogenes		Li+	347924	142	competitive to K+
1.1.1.205	Mus musculus		Li+	347945	142	inhibits stimulatory effect of K+
1.1.1.205	Escherichia coli		Li+	701583	142	competitive inhibition with respect to both K+ and NAD+
1.1.1.205	Borrelia burgdorferi		Li+	703193	142	
1.1.1.205	Escherichia coli		Li+	703193	142	
1.1.1.205	Mus musculus		linoleic acid	685417	357	
1.1.1.205	Homo sapiens		linoleic acid	703193	357	; 
1.1.1.205	Homo sapiens		merimepodib	703193	5088	has immunosuppressive activity; has immunosuppressive activity
1.1.1.205	Homo sapiens		methyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate	711473	18898	derivative of mycophenolic acid. IC50 value for K562 cells proliferation 0.73 microM; derivative of mycophenolic acid. IC50 value for K562 cells proliferation 0.73 microM
1.1.1.205	Cryptosporidium parvum		methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate	703193	5910	antagonizes ADP binding
1.1.1.205	Borrelia burgdorferi		methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate	711735	5910	
1.1.1.205	Escherichia coli		methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate	711735	5910	not inhibitory to wild-type
1.1.1.205	Helicobacter pylori		methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate	711735	5910	
1.1.1.205	Streptococcus pyogenes		methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate	711735	5910	
1.1.1.205	Escherichia coli		methyl methanethiosulfonate	347929	1724	
1.1.1.205	Vigna unguiculata		Mg2+	347936	25	inhibits K+ activation
1.1.1.205	Mus musculus		Mg2+	347945	25	inhibits K+ activation
1.1.1.205	Escherichia coli		Mg2+	347946	25	inhibits K+ activation
1.1.1.205	Escherichia coli		Mg2+	701583	25	competitive inhibition with respect to both K+ and NAD+
1.1.1.205	Streptococcus pyogenes		mizobirine 5'-monophosphate	347959	11930	
1.1.1.205	Homo sapiens		mizoribine	669807	3450	
1.1.1.205	Candida albicans		mizoribine	703193	3450	
1.1.1.205	Eimeria tenella		mizoribine	703193	3450	
1.1.1.205	Escherichia coli		mizoribine	703193	3450	
1.1.1.205	Homo sapiens		mizoribine	703193	3450	; 
1.1.1.205	Leishmania donovani		mizoribine	703193	3450	
1.1.1.205	Plasmodium falciparum		mizoribine	703193	3450	
1.1.1.205	Staphylococcus aureus		mizoribine	703193	3450	
1.1.1.205	Tritrichomonas suis		mizoribine	703193	3450	
1.1.1.205	Trypanosoma brucei		mizoribine	703193	3450	
1.1.1.205	Trypanosoma brucei		mizoribine 5'-monophosphate	726097	11930	
1.1.1.205	Tritrichomonas suis		mizoribine 5'-phosphate	668351	11930	complexes the enzyme
1.1.1.205	Candida albicans		mizoribine 5'-phosphate	669310	11930	competitive versus NAD+, slow tight-binding, the mutant A251T is 20fold more sesitive
1.1.1.205	Candida albicans		mizoribine monophosphate	701583	5261	
1.1.1.205	Cryptosporidium parvum		mizoribine monophosphate	701583	5261	
1.1.1.205	Escherichia coli		mizoribine monophosphate	701583	5261	
1.1.1.205	Homo sapiens		mizoribine monophosphate	701583	5261	
1.1.1.205	Streptococcus pyogenes		mizoribine monophosphate	701583	5261	
1.1.1.205	Escherichia coli		more	347911		dinucleotide analogs of NAD
1.1.1.205	Rattus norvegicus		more	347915		inhibition by products and antimetabolites
1.1.1.205	Bacillus subtilis		more	347922		
1.1.1.205	Enterobacter aerogenes		more	347923		
1.1.1.205	Homo sapiens		more	347931		inhibition by purine and pyrimidine compounds
1.1.1.205	Vigna unguiculata		more	347936		the enzyme is not affected by allantoin, allantoic acid, uric acid, inosine, xanthosine, and xanthosine 5'-phosphate
1.1.1.205	Mus musculus		more	347945		
1.1.1.205	Homo sapiens		more	347950		mycophenolic acid and it's nuclear variants
1.1.1.205	Homo sapiens		more	347960		
1.1.1.205	Tritrichomonas suis		more	347960		
1.1.1.205	Borrelia burgdorferi		more	347961		overview
1.1.1.205	Eimeria tenella		more	347961		overview
1.1.1.205	Escherichia coli		more	347961		overview
1.1.1.205	Homo sapiens		more	347961		overview
1.1.1.205	Rattus norvegicus		more	347961		overview
1.1.1.205	Tritrichomonas suis		more	347961		overview
1.1.1.205	Homo sapiens		more	347964		6-ethoxycarbonyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0.]hexane-2,4-diones inhibit type II enzyme
1.1.1.205	Toxoplasma gondii		more	667219		no inhibition by tiazofurin and seleno-thiazofurin
1.1.1.205	Escherichia coli		more	667473		no enzyme inhibition by nucleic acids
1.1.1.205	Homo sapiens		more	667473		no enzyme inhibition by nucleic acids
1.1.1.205	Tritrichomonas suis		more	667473		no enzyme inhibition by nucleic acids
1.1.1.205	Tritrichomonas suis		more	667573		structural basis of the drug selectivity, overview
1.1.1.205	Homo sapiens		more	667935		determination and analysis of structure-activity relationships of the different inhibitor molecules, overview
1.1.1.205	Homo sapiens		more	667938		development and synthesis of inhibitors, determination and analysis of structure-activity relationships of the different inhibitor molecules with isozyme IMPDH II, overview
1.1.1.205	Homo sapiens		more	667976		optimization of nitrile containing drugs, such as VX-148, by combining them with an oxazole moiety which is very reactive in inhibition, overview
1.1.1.205	Homo sapiens		more	667980		synthesis, inhibitory potency, and structure-activity relationship of enzyme with phosphonic acid-containing analogues of mycophenolic acid inhibitors, IC50 values, overview
1.1.1.205	Homo sapiens		more	668351		the enzyme is resistant to mizoribine 5'-phosphate due to its open dehydrogenase conformation in opposite to the bacterial enzyme which has a closed hydrolase conformation
1.1.1.205	Homo sapiens		more	669807		inhibitor development and synthesis, overview
1.1.1.205	Homo sapiens		more	670128		inhibition of the enzyme in K562 cells sensitizes the before resistant cells to methotrexate
1.1.1.205	Homo sapiens		more	684706		retinal isoforms do not bind significant fractions of a random pool of oligonucleotides
1.1.1.205	Mus musculus		more	685417		not inhibitory: linoelaidic acid, methyl linoleate, cis-9-octadecen-1-ol
1.1.1.205	Homo sapiens		more	703193		IMPDH2 interacts with protein kinase B/Akt via its plekstrin homology domain, the resulting phosphorylation reduces activity
1.1.1.205	Tritrichomonas suis		more	703193		becomes resistant to IMPDH inhibitors by rearranging its purine salvage pathways to rely on xanthine instead of hypoxanthine
1.1.1.205	Homo sapiens		more	703271		mycophenolic acid-phenyl-glucuronide has no effect
1.1.1.205	Homo sapiens		more	704732		involvement of three conserved water molecules (W(L), W(M), and W(C)) in the recognition of catalytic residues (R 322, D 364, and N 303) to inhibitor
1.1.1.205	Cryptosporidium parvum		more	705042		1,2,3-triazole containing ether IMPDH inhibitors, small alkyl group on the alpha-position of the ether is required, with the (R)-enantiomer significantly more active than the (S)-enantiomer. Electron-withdrawing groups in the 3- and/or 4-positions of the pendent phenyl ring are best, and conversion of the quinoline containing inhibitors to quinoline-N-oxides retains inhibitory activity both in the presence and absence of bovine serum albumin
1.1.1.205	Homo sapiens		more	706817		IMPDH activity decreases more than 10% with increasing contamination by erythrocytes due to increasing AMP and protein content. Storage of lithium heparin blood samples at room temperature for 24 hours before peripheral blood mononuclear cell isolation does not lead to any significant changes in the IMPDH activity, when the activity is normalized to the AMP concentration
1.1.1.205	Homo sapiens		more	711473		synthesis of mycophenolic acid derivatives as inhibitors. Functional groups at C5, C7, and C6' positions in mycophenolic acid are important for inhibitory activity against IMPDH. It is difficult to improve specificity against IMPDH II by modification of 5-, 7-, and 6'-group. Demethylation of 5-OMe results in increasing hydrophilicity, and lowering cell permeability. Ester bonds of protective groups at C7 and C6' positions are hydrolyzed to give mycophenolic acid in cultures, the effects of a tubulin-specific histone deacetylase inhibitor on proliferation and differentiation are weaker than its inhibitory activity against IMPDH; synthesis of mycophenolic acid derivatives as inhibitors. Functional groups at C5, C7, and C6' positions in mycophenolic acid are important for inhibitory activity against IMPDH. It is difficult to improve specificity against IMPDH II by modification of 5-, 7-, and 6'-group. Demethylation of 5-OMe results in increasing hydrophilicity, and lowering cell permeability. Ester bonds of protective groups at C7 and C6' positions are hydrolyzed to give mycophenolic acid in cultures, the effects of a tubulin-specific histone deacetylase inhibitor on proliferation and differentiation are weaker than its inhibitory activity against IMPDH
1.1.1.205	Mus musculus		more	711518		not inhibitory: resveratrol, genistein, eugenol, gingerol, naringenin, naringin, caffeic acid, morin, kaempferol, hesperidin, rosmarinic acid
1.1.1.205	Helicobacter pylori		more	711735		compounds are not inhibitory to Escherichia coli, Tritrichomonas foetus, and Leishmania donovani IMPDH. Susceptible enzymes are defined by structural motif A165/Y358, Cryptosporidium parvum numbering
1.1.1.205	Homo sapiens		more	712578		tacrolimus, cyclosporine and prednisolone do not affect IMPDH activity
1.1.1.205	Homo sapiens		mycophenolate mofetil	347960	8727	NAD+ binding site inhibitor
1.1.1.205	Mus musculus		mycophenolate mofetil	702061	8727	prodrug of mycophenolic acid, treatment of diet-induced obese mice with mycophenolate mofetil for 28 days does not affect food intake or lean body mass but reduces body fat content (by 36%), adipocyte size and number and the appearance of hepatic steatosis
1.1.1.205	Homo sapiens		mycophenolate mofetil	706817	8727	
1.1.1.205	Homo sapiens		mycophenolic 2-ethyladenosin-5'-yl-difluoromethylenebis(phosphonate)	711475	18895	potent, sub-micromolar inhibitor of leukemia K562 cells proliferation, IC50 of 0.45 microM; potent, sub-micromolar inhibitor of leukemia K562 cells proliferation, IC50 of 0.45 microM
1.1.1.205	Homo sapiens		mycophenolic 2-ethyladenosin-5'-yl-methylenebis(phosphonate)	711475	18894	inhibition of leukemia K562 cells proliferation, IC50 of 1.0 microM; inhibition of leukemia K562 cells proliferation, IC50 of 1.0 microM
1.1.1.205	Eimeria tenella		Mycophenolic acid	347913	470	50% inhibition at 0.0003 mM, reversible by guanine
1.1.1.205	Mus musculus		Mycophenolic acid	347914	470	mixed type inhibition
1.1.1.205	Rattus norvegicus		Mycophenolic acid	347940	470	
1.1.1.205	Homo sapiens		Mycophenolic acid	347952	470	50% inhibition at 0.00025 mM, human plasma or serum reduces the inhibition
1.1.1.205	Homo sapiens		Mycophenolic acid	347953	470	mutants have increased Ki for MPA
1.1.1.205	Cricetulus griseus		Mycophenolic acid	347954	470	uncompetitive
1.1.1.205	Borrelia burgdorferi		Mycophenolic acid	347955	470	uncompetitive with respect to IMP and NAD+
1.1.1.205	Homo sapiens		Mycophenolic acid	347956	470	type II enzme is 4.8fold more sensitive than type I
1.1.1.205	Pneumocystis carinii		Mycophenolic acid	347957	470	50% inhibition at 0.024 mM
1.1.1.205	Toxoplasma gondii		Mycophenolic acid	667219	470	uncompetitive to NAD+
1.1.1.205	Tritrichomonas suis		Mycophenolic acid	667573	470	i.e. MPA, slight inhibition, microbial IMPDHs differ from mammalian enzymes in their lower affinity for inhibitors such as mycophenolic acid and thiazole-4-carboxamide adenine dinucleotide, part of this resistance is determined by the coupling between nicotinamide and adenosine subsites in the NAD+ binding site that is postulated to involve an active site flap
1.1.1.205	Homo sapiens		Mycophenolic acid	667935	470	key binding interactions for the benzofuranone residue mycophenolic acid and the N-[3-methoxy-4-(5-oxazolyl)phenyl] fragment of VX-497, the benzofuranone ring mycophenolic acid binds in a spatially restricted region of the NAD+ binding site packing with the hypoxanthine ring xanthosine 5'-phosphate, the carbonyl oxygen and hydroxy residues are involved in a hydrogen bond array that involves Gly326, Thr333 and Gln441, the appending methyl substituent of the benzofuranone system, resides in a small hydrophobic pocket defined by the planes of Asn303 amide and Arg322 guanidine, the phenyl oxazole moiety of VX-497 binds in the same region as the benzofuranone ring of mycophenolic acid, forming hydrogen bonds between the oxazole nitrogen and oxygen with Gly326 and possibly Thr333, respectively, the methoxy residue binds in the same pocket as the benzofuranone methyl in mycophenolic acid
1.1.1.205	Homo sapiens		Mycophenolic acid	667937	470	isozyme IMPDH II IC50: 15 nM
1.1.1.205	Homo sapiens		Mycophenolic acid	667938	470	potent, uncompetitive, reversible, inhibits both isozymes, prodrug is mycophenolate mofetil, isozyme IMPDH II IC50: 14 nM
1.1.1.205	Homo sapiens		Mycophenolic acid	667976	470	potent, uncompetitive, reversible, inhibits both isozymes, prodrug is mycophenolate mofetil
1.1.1.205	Homo sapiens		Mycophenolic acid	667980	470	isozyme IMPDH II IC50: 11 nM, potent, uncompetitive inhibition, immunosuppressive drug, prodrug is mycophenolate mofetil
1.1.1.205	Homo sapiens		Mycophenolic acid	668295	470	enzyme inhibition by mycophenolic acid impairs maturation and function of dendritic cells
1.1.1.205	Homo sapiens		Mycophenolic acid	668351	470	traps the reaction intermediate E-XMP, the human enzyme is sensitive to the inhibtior due to its open dehydrogenase conformation
1.1.1.205	Candida albicans		Mycophenolic acid	669310	470	inhibition of the wild-type enzyme uncompetitively versus NAD+, the mutant A251T enzyme is 4fold more resistant to mycophenolic acid
1.1.1.205	Homo sapiens		Mycophenolic acid	669476	470	uncompetitive inhibition, the interaction with the enzyme, inducing striking conformational changes and aggregation, is regulated by GTP, GTP reverses the enzyme aggregation by inhibitor mycophenolic acid, the inhibitor is part of an immunosuppressive drug
1.1.1.205	Homo sapiens		Mycophenolic acid	669800	470	IC50: 99.2 nM with umbilical vein endothelial cells, 128 nM with Jurkat cells, inhibits the enzyme in vivo and in vitro, mycophenolic acid inhibits tumor-associated angiogenesis and is used as clinical drug in immunosuppression
1.1.1.205	Homo sapiens		Mycophenolic acid	670881	470	exerts immunosuppression through inhibition of the enzyme in lymphocytes, inhibitory potency in vivo, overview, prodrug is mycophenolate mofetil
1.1.1.205	Homo sapiens		Mycophenolic acid	688266	470	comparison with inhibition of histone deacetylase and K562 cell proliferation
1.1.1.205	Homo sapiens		Mycophenolic acid	690045	470	biphasic concentration-dependent influence on inosine 5'-phosphate dehydrogenase basal activity. At concentrations around or below IC50 value, mycophenolic acid increases the basal enzymic activity, associated with elevated expression of isoform IMPDH2. Despite increased expression, the basal enzyme activity decreases following exposure to high mycophenolic acid concentrations
1.1.1.205	Borrelia burgdorferi		Mycophenolic acid	701583	470	
1.1.1.205	Cryptosporidium parvum		Mycophenolic acid	701583	470	
1.1.1.205	Saccharomyces cerevisiae		Mycophenolic acid	701583	470	IMD2 imparts mycophenolic acid resistance due to A253S as a critical amino acid substitution
1.1.1.205	Streptococcus pyogenes		Mycophenolic acid	347959, 701583	470	
1.1.1.205	Mus musculus		Mycophenolic acid	702061	470	in 3T3-L1 preadipocytes inhibition of IMPDH with mycophenolic acid reduces intracellular GTP levels by 60% (p &lt;0.05) and blocks adipogenesis. Co-treatment with guanosine restores GTP levels and adipogenesis
1.1.1.205	Candida albicans		Mycophenolic acid	701583, 703193	470	
1.1.1.205	Eimeria tenella		Mycophenolic acid	703193	470	
1.1.1.205	Plasmodium falciparum		Mycophenolic acid	703193	470	
1.1.1.205	Staphylococcus aureus		Mycophenolic acid	703193	470	
1.1.1.205	Homo sapiens		Mycophenolic acid	703271	470	uncompetitive inhibition
1.1.1.205	Homo sapiens		Mycophenolic acid	703272	470	IMPDH activity in erythrocytes is inhibited at the peak plasma concentration of mycophenolic acid in initial kidney transplant recipients. Reduction does not coincide with the peak of the plasma concentration of phenolic and acyl glucuronides of mycophenolic acid
1.1.1.205	Cricetulus griseus		Mycophenolic acid	701583, 705494	470	
1.1.1.205	Escherichia coli		Mycophenolic acid	705494	470	
1.1.1.205	Homo sapiens		Mycophenolic acid	705494	470	is a uncompetitive inhibitor of IMPDH with respect to both inosine 5'-phosphate and NAD+, inhibits IMPDH by trapping the covalent intermediate. It it is easily converted to mycophenolic acid-7-O-glucuronide, which limits the inhibitory efficacy and higher doses are therefore needed in order to maintain appropriate therapeutic levels; is a uncompetitive inhibitor of IMPDH with respect to both inosine 5'-phosphate and NAD+, inhibits IMPDH by trapping the covalent intermediate. It it is easily converted to mycophenolic acid-7-O-glucuronide, which limits the inhibitory efficacy and higher doses are therefore needed in order to maintain appropriate therapeutic levels
1.1.1.205	Leishmania donovani		Mycophenolic acid	347904, 688888, 703193, 705494	470	
1.1.1.205	Tritrichomonas suis		Mycophenolic acid	347962, 701583, 703193, 705494	470	
1.1.1.205	Homo sapiens		Mycophenolic acid	706815	470	new enzymatic mycophenolic acid assay, cross-reactivity by mycophenolic acid-acyl-glucuronide is less than 5%, thus interference is expected to be clinically irrelevant
1.1.1.205	Homo sapiens		Mycophenolic acid	347931, 347962, 667965, 667966, 669807, 670128, 685555, 689355, 701583, 706090, 706817	470	
1.1.1.205	Cryptococcus gattii		Mycophenolic acid	710737	470	subtype MMRL2651 of Cryptococcus gattii is naturally resistant to inhibition by mycophenolic acid
1.1.1.205	Cryptococcus neoformans		Mycophenolic acid	710737	470	
1.1.1.205	Homo sapiens		Mycophenolic acid	703193, 711473	470	; 
1.1.1.205	Homo sapiens		Mycophenolic acid	711475	470	inhibition of leukemia K562 cells proliferation, IC50 of 7.7 microM; inhibition of leukemia K562 cells proliferation, IC50 of 7.7 microM
1.1.1.205	Bacillus anthracis		Mycophenolic acid	724347	470	noncompetitive with regard to inosine monophosphate and NAD+
1.1.1.205	Babesia gibsoni		Mycophenolic acid	726095	470	inhibitory to enzyme, also inhibits growth of Babesia gibsoni cells. The treated parasite cultures have predominantly single Babesia cells as opposed to untreated cells that have both single and dividing forms as observed on day two
1.1.1.205	Trypanosoma brucei		Mycophenolic acid	703193, 726097	470	
1.1.1.205	Homo sapiens		mycophenolic acid glucuronide	347952	70594	80% inhibition at 0.2 mM, human plasma or serum reduces the inhibition
1.1.1.205	Homo sapiens		mycophenolic acid-acyl-glucuronide	703271	11225	uncompetitive inhibition, is a weaker inhibitor of IMPDH II than mycophenolic acid. When coincubated with mycophenolic acid, mycophenolic acid-acyl-glucuronide activity is negligible at pharmacological concentrations
1.1.1.205	Homo sapiens		mycophenolic acid-acyl-glucuronide	706815	11225	cross-reactivity by mycophenolic acid is less than 5%, thus interference is expected to be clinically irrelevant
1.1.1.205	Homo sapiens		mycophenolic adenine dinucleotide	669807	84616	
1.1.1.205	Homo sapiens		mycophenolic hydroxamic acid	688266	18899	comparison with inhibition of histone deacetylase and K562 cell proliferation
1.1.1.205	Homo sapiens		N,7'-dimethoxy-N,3'-dimethyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide	667965	39652	IC50: 0.079 mM, isozyme IMPDH II
1.1.1.205	Homo sapiens		N,N-diethyl-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide	667965	39649	IC50: 0.045 mM, isozyme IMPDH II
1.1.1.205	Cryptosporidium parvum		N-(2,3-dichlorophenyl)-2-[2-(1,3-thiazol-2-yl)-1H-benzimidazol-1-yl]acetamide	712245	58396	poor inhibition of human IMPDH2
1.1.1.205	Homo sapiens		N-(2,4-difluorophenyl)-7'-methoxy-N,3'-dimethyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide	667965	39648	IC50: 0.051 mM, isozyme IMPDH II
1.1.1.205	Cryptosporidium parvum		N-(4-bromophenyl)-2-[2-(1,3-thiazol-2-yl)-1H-benzimidazol-1-yl]acetamide	712245	58395	crystallization data. Poor inhibition of human IMPDH2
1.1.1.205	Cryptosporidium parvum		N-(4-chlorophenyl)-2-phenoxypropanamide	703193	94272	antagonizes ADP binding
1.1.1.205	Cryptosporidium parvum		N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide	703193	5909	binds in the nicotinamide subsite and does not interact with ADP
1.1.1.205	Borrelia burgdorferi		N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide	711735	5909	
1.1.1.205	Escherichia coli		N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide	711735	5909	not inhibitory to wild-type
1.1.1.205	Helicobacter pylori		N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide	711735	5909	
1.1.1.205	Streptococcus pyogenes		N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide	711735	5909	
1.1.1.205	Cryptosporidium parvum		N-(4-methoxyphenyl)-2-naphthalen-1-ylacetamide	703193	94273	binds in the nicotinamide subsite and does not interact with ADP
1.1.1.205	Cryptosporidium parvum		N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide	703193	5908	binds in the nicotinamide subsite and does not interact with ADP
1.1.1.205	Borrelia burgdorferi		N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide	711735	5908	
1.1.1.205	Escherichia coli		N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide	711735	5908	not inhibitory to wild-type
1.1.1.205	Helicobacter pylori		N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide	711735	5908	
1.1.1.205	Streptococcus pyogenes		N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide	711735	5908	
1.1.1.205	Homo sapiens		N-(5-phenyl-1,3-oxazol-2-yl)isoquinolin-6-amine	703193	26090	; 
1.1.1.205	Cryptosporidium parvum		N-(naphthalen-2-yl)-2-[2-(1,3-thiazol-2-yl)-1H-benzimidazol-1-yl]acetamide	712245	58397	poor inhibition of human IMPDH2
1.1.1.205	Cryptosporidium parvum		N-(naphthalen-2-yl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide	712245	58394	poor inhibition of human IMPDH2
1.1.1.205	Bacillus anthracis		N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide	724347	19742	
1.1.1.205	Campylobacter jejuni		N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide	724347	19742	
1.1.1.205	Borrelia burgdorferi		N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-5,6-dihydro-1H-benzimidazol-1-yl]acetamide	711735	8182	
1.1.1.205	Escherichia coli		N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-5,6-dihydro-1H-benzimidazol-1-yl]acetamide	711735	8182	not inhibitory to wild-type
1.1.1.205	Helicobacter pylori		N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-5,6-dihydro-1H-benzimidazol-1-yl]acetamide	711735	8182	
1.1.1.205	Streptococcus pyogenes		N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-5,6-dihydro-1H-benzimidazol-1-yl]acetamide	711735	8182	
1.1.1.205	Homo sapiens		N-ethyl-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide	667965	39645	IC50: 0.119 mM, isozyme IMPDH II
1.1.1.205	Bacillus subtilis		N-ethylmaleimide	347942	46	100% inhibition at 1 mM
1.1.1.205	Homo sapiens		N-hydroxy-N'-[3-methoxy-4-(1,3-oxazol-2-yl)phenyl]octanediamide	688266	25169	comparison with inhibition of histone deacetylase and K562 cell proliferation
1.1.1.205	Homo sapiens		N-methyl-N'-[4-(1,3-oxazol-5-yl)phenyl]-6-phenyl-1,3,5-triazine-2,4-diamine	667935	39580	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Homo sapiens		N-methyl-N'-[4-(4-methyl-1,3-oxazol-5-yl)phenyl]-6-phenyl-1,3,5-triazine-2,4-diamine	667935	39584	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Homo sapiens		N-methyl-N-[2-(2-[[3-methyl-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-3-morpholin-4-ylpropanamide	667935	39568	isozyme IMPDH II IC50: 45 nM
1.1.1.205	Homo sapiens		N-tert-butyl-N'-[3-chloro-4-(1,3-oxazol-5-yl)phenyl]ethanediamide	667935	39576	isozyme IMPDH II IC50: 55 nM
1.1.1.205	Homo sapiens		N-tert-butyl-N'-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]ethanediamide	667935	39555	isozyme IMPDH II IC50: 10 nM
1.1.1.205	Homo sapiens		N-tert-butyl-N'-[4-(1,3-oxazol-5-yl)phenyl]ethanediamide	667935	39578	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Homo sapiens		N-tert-butyl-N'-[4-(4-methyl-1,3-oxazol-5-yl)phenyl]ethanediamide	667935	39585	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Cryptosporidium parvum		N-[(Z)-(pyridin-3-ylimino)methyl]-2,3-dihydro-1,4-benzodioxine-2-carboxamide	703193	94275	
1.1.1.205	Homo sapiens		N-[1-[6-(4-ethylpiperazin-1-yl)pyridin-3-yl]-1-methylethyl]-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide	703193	26088	; 
1.1.1.205	Homo sapiens		N-[2-(2-[[3-(chloromethyl)-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-3-morpholin-4-ylpropanamide	667935	39570	isozyme IMPDH II IC50: 47 nM
1.1.1.205	Homo sapiens		N-[2-(2-[[3-bromo-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-3-hydroxy-N-methylpropanamide	667935	39573	isozyme IMPDH II IC50: 28 nM
1.1.1.205	Homo sapiens		N-[2-(2-[[3-bromo-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-3-morpholin-4-ylpropanamide	667935	39572	isozyme IMPDH II IC50: 21 nM
1.1.1.205	Homo sapiens		N-[2-(2-[[3-chloro-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-3-hydroxy-N-methylpropanamide	667935	39571	isozyme IMPDH II IC50: 48 nM
1.1.1.205	Homo sapiens		N-[2-(2-[[3-ethyl-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-3-hydroxy-N-methylpropanamide	667935	39575	isozyme IMPDH II IC50: 310 nM
1.1.1.205	Homo sapiens		N-[2-(2-[[3-ethyl-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-3-morpholin-4-ylpropanamide	667935	39574	isozyme IMPDH II IC50: 21 nM
1.1.1.205	Homo sapiens		N-[2-(2-[[3-methoxy-4-(1,3-oxazol-4-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-2-morpholin-4-ylacetamide	667935	39595	isozyme IMPDH II IC50: 91 nM
1.1.1.205	Homo sapiens		N-[2-(2-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-2-morpholin-4-ylacetamide	703193	6625	; 
1.1.1.205	Homo sapiens		N-[2-(2-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-3-morpholin-4-ylpropanamide	667935	39566	isozyme IMPDH II IC50: 16 nM
1.1.1.205	Homo sapiens		N-[2-(hydroxymethyl)cyclopentyl]-N'-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]propanediamide	703193	26078	; 
1.1.1.205	Homo sapiens		N-[2-chloro-3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39564	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Homo sapiens		N-[2-chloro-5-methoxy-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39565	isozyme IMPDH II IC50: 0.0016 mM
1.1.1.205	Homo sapiens		N-[2-fluoro-5-methoxy-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39563	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Homo sapiens		N-[3-bromo-4-(1,3-oxazol-5-yl)phenyl]-N'-tert-butylethanediamide	667935	39577	isozyme IMPDH II IC50: 50 nM
1.1.1.205	Homo sapiens		N-[3-chloro-4-(1,3-oxazol-4-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39594	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Homo sapiens		N-[3-chloro-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39562	isozyme IMPDH II IC50: 88 nM
1.1.1.205	Homo sapiens		N-[3-chloro-4-(1,3-oxazol-5-yl)phenyl]-N'-methyl-6-phenyl-1,3,5-triazine-2,4-diamine	667935	39579	isozyme IMPDH II IC50: 340 nM
1.1.1.205	Homo sapiens		N-[3-ethoxy-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39561	isozyme IMPDH II IC50: 0.010 mM
1.1.1.205	Homo sapiens		N-[3-methoxy-4-(1,3-oxazol-2-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39599	isozyme IMPDH II IC50: 190 nM
1.1.1.205	Homo sapiens		N-[3-methoxy-4-(1,3-oxazol-4-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39592	isozyme IMPDH II IC50: 57 nM
1.1.1.205	Homo sapiens		N-[3-methoxy-4-(1,3-oxazol-4-yl)phenyl]-N'-methyl-6-phenyl-1,3,5-triazine-2,4-diamine	667935	39597	isozyme IMPDH II IC50: 0.0016 mM
1.1.1.205	Homo sapiens		N-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39556	isozyme IMPDH II IC50: 20 nM
1.1.1.205	Homo sapiens		N-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-N'-methyl-6-phenyl-1,3,5-triazine-2,4-diamine	667935	39557	isozyme IMPDH II IC50: 76 nM
1.1.1.205	Homo sapiens		N-[3-methoxy-4-(1H-1,2,4-triazol-1-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39600	isozyme IMPDH II IC50: 410 nM
1.1.1.205	Homo sapiens		N-[3-methoxy-4-(2-methyl-1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39589	isozyme IMPDH II IC50: 0.002 mM
1.1.1.205	Homo sapiens		N-[3-methoxy-4-(4-methyl-1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39588	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Homo sapiens		N-[3-methyl-4-(1,3-oxazol-4-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39593	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Homo sapiens		N-[4-(1,3-oxazol-4-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39591	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Homo sapiens		N-[4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39559	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Homo sapiens		N-[4-(2,4-dimethyl-1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39590	isozyme IMPDH II IC50: 0.002 mM
1.1.1.205	Homo sapiens		N-[4-(4-methyl-1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine	667935	39587	isozyme IMPDH II IC50: 0.005 mM
1.1.1.205	Cryptosporidium parvum		N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide	724539	62155	noncompetitive with respect to NAD+, displays submicromolar activity in a Toxoplasma gondii model of Cryptosporidium parvum infection and displays good stability in mouse liver microsome. No antiparasitic activity is observed in mouse with once per day oral dosing of 250 mg/kg for 7 days
1.1.1.205	Escherichia coli		Na+	701583	55	competitive inhibition with respect to both K+ and NAD+
1.1.1.205	Borrelia burgdorferi		Na+	703193	55	
1.1.1.205	Escherichia coli		Na+	703193	55	
1.1.1.205	Rattus norvegicus		NAD+	347915	4	substrate inhibition at high concentration
1.1.1.205	Rattus norvegicus		NAD+	347932	4	50% inhibition at 0.62 mM
1.1.1.205	Rattus norvegicus		NAD+	347937, 347940	4	
1.1.1.205	Mus musculus		NAD+	347945	4	substrate inhibition at high concentration
1.1.1.205	Sus scrofa		NAD+	347947	4	44% inhibition at 1.5 M
1.1.1.205	Borrelia burgdorferi		NAD+	347955	4	substrate inhibition at high concentration
1.1.1.205	Toxoplasma gondii		NAD+	667219	4	
1.1.1.205	Homo sapiens		NAD+	684706	4	at high concentration, inhibition of canonical isoform. No inhibition of retinal-specific isoforms
1.1.1.205	Candida albicans		NAD+	701583	4	
1.1.1.205	Homo sapiens		NAD+	667508, 701583	4	
1.1.1.205	Tritrichomonas suis		NAD+	667573, 705494	4	
1.1.1.205	Homo sapiens		NAD+	712703	4	; 
1.1.1.205	Mycobacterium tuberculosis		NAD+	712703	4	
1.1.1.205	Cryptosporidium parvum		NAD+	724327	4	
1.1.1.205	Bacillus anthracis		NAD+	724347	4	
1.1.1.205	Trypanosoma brucei		NAD+	726097	4	substrate inhibition
1.1.1.205	Eimeria tenella		NADH	347913	3	
1.1.1.205	Homo sapiens		NADH	347916	3	; mixed inhibition type versus inosine 5'-phosphate and NAD+
1.1.1.205	Rattus norvegicus		NADH	347916	3	; uncompetitive versus inosine 5'-phosphate and mixed inhibition type versus NAD+
1.1.1.205	Enterobacter aerogenes		NADH	347923	3	non competitive
1.1.1.205	Enterobacter aerogenes		NADH	347924	3	poor inhibitor, product inhibition, non competitive
1.1.1.205	Vigna unguiculata		NADH	347936	3	
1.1.1.205	Rattus norvegicus		NADH	347915, 347940	3	
1.1.1.205	Mus musculus		NADH	347945	3	non competitive with respect to NAD+
1.1.1.205	Homo sapiens		NADH	347951	3	non competitive with respect to K+, IMP and NAD
1.1.1.205	Homo sapiens		NADH	347918, 347956	3	
1.1.1.205	Rattus norvegicus		NADPH	347940	5	50% inhibition at 0.14 mM
1.1.1.205	Sus scrofa		NH4+	347947	50	25% inhibition at 2.12 M
1.1.1.205	Enterobacter aerogenes		nicotinic acid	347924	787	inhibitory analog of NAD+, non-competitive with respect to IMP and K+
1.1.1.205	Rattus norvegicus		p-chloromercuribenzoate	347937	40	inhibition can be restored by addition of DTT
1.1.1.205	Bacillus subtilis		p-chloromercuribenzoate	347942	40	100% inhibition at 0.021 mM
1.1.1.205	Escherichia coli		p-chloromercuribenzoate	347946	40	
1.1.1.205	Pisum sativum		p-hydroxymercuribenzoate	347943	92	97% inactivation at 1 mM
1.1.1.205	Homo sapiens		P1-(7-hydroxy-6-(ethyl-2-yl)-5-methoxy-4-methylphthalan-1-one)methylenephospho-P2-(adenosin-5'-yl)phosphonate	669807	39768	
1.1.1.205	Homo sapiens		P1-(adenosine-5'-yl)methylenephospho-P2-(7-hydroxy-6-(ethyl-2-yl)-5-methoxy-4-methylphthalan-1-one)phosphonate	669807	39767	
1.1.1.205	Borrelia burgdorferi		P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate	701583	4752	
1.1.1.205	Cryptosporidium parvum		P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate	701583	4752	
1.1.1.205	Escherichia coli		P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate	701583	4752	
1.1.1.205	Homo sapiens		P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate	701583	4752	
1.1.1.205	Tritrichomonas suis		P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate	701583	4752	
1.1.1.205	Homo sapiens		P1-(tiazofurin-5'-yl)-P2-(2-aminoadenosin-5'-yl) diphosphate	688258	25174	comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
1.1.1.205	Homo sapiens		P1-(tiazofurin-5'-yl)-P2-(2-ethyladenosin-5'-yl) diphosphate	688258	25175	comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
1.1.1.205	Homo sapiens		P1-(tiazofurin-5'-yl)-P2-(2-ethynyladenosin-5'-yl) diphosphate	688258	25176	comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
1.1.1.205	Homo sapiens		P1-(tiazofurin-5'-yl)-P2-(2-iodoadenosin-5'-yl) diphosphate	688258	25177	comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
1.1.1.205	Homo sapiens		P1-(tiazofurin-5'-yl)-P2-(2-phenyladenosin-5'-yl) diphosphate	688258	25178	comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
1.1.1.205	Homo sapiens		P1-(tiazofurin-5'-yl)-P2-(adenosin-5'-yl) diphosphate	688258	25179	comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
1.1.1.205	Homo sapiens		P1-[7-hydroxy-6-(hydroxyethyl)-5-methoxy-4-methylphthtalan-1-one-2-yl]-P2-(2-ethyladenosin-5'-yl)methylenebis(phosphonate)	685555, 688258	12385	
1.1.1.205	Homo sapiens		P1-[7-hydroxy-6-(hydroxyethyl)-5-methoxy-4-methylphthtalan-1-one-2-yl]-P2-(2-phenyladenosin-5'-yl)methylenebis(phosphonate)	685555	25180	
1.1.1.205	Homo sapiens		P1-[7-hydroxy-6-(hydroxyethyl)-5-methoxy-4-methylphthtalan-1-one-2-yl]-P2-(adenosin-5'-yl)methylenebis(phosphonate)	685555	25181	
1.1.1.205	Homo sapiens		pellynic acid	703193	26840	; 
1.1.1.205	Homo sapiens		phenyl N'-cyano-N-(3-[cyano[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamimidamido]benzyl)imidocarbamate	703193	26075	; 
1.1.1.205	Enterobacter aerogenes		phosphate	347920	12	mixed inhibition kinetics
1.1.1.205	Homo sapiens		quinazolinedione derivatives	667966		several derivatives, synthesis and inhibitory values, overview
1.1.1.205	Homo sapiens		quinazolinethione derivatives	667966		several derivatives, synthesis and inhibitory values, overview
1.1.1.205	Parainfluenza virus		ribavirin	347917	991	potent competitive inhibition, shows anti-viral activity in vivo, detailed overview
1.1.1.205	Vaccinia virus		ribavirin	347917	991	potent competitive inhibition, shows anti-viral activity in vivo, detailed overview
1.1.1.205	Homo sapiens		ribavirin	669807	991	
1.1.1.205	Homo sapiens		ribavirin	703193	991	; 
1.1.1.205	Tritrichomonas suis		ribavirin	703193	991	
1.1.1.205	Rattus norvegicus		ribavirin 5'-monophosphate	347915	3985	
1.1.1.205	Chlorocebus aethiops		ribavirin 5'-monophosphate	347917	3985	
1.1.1.205	Homo sapiens		ribavirin 5'-monophosphate	347918	3985	competitive with respect to IMP
1.1.1.205	Streptococcus pyogenes		ribavirin 5'-monophosphate	347959	3985	
1.1.1.205	Trypanosoma brucei		ribavirin 5'-monophosphate	726097	3985	
1.1.1.205	Homo sapiens		ribavirin 5'-phosphate	668351	3985	
1.1.1.205	Tritrichomonas suis		ribavirin 5'-phosphate	668351	3985	
1.1.1.205	Cryptosporidium parvum		ribavirin monophosphate	701583	3985	
1.1.1.205	Homo sapiens		ribavirin monophosphate	701583	3985	
1.1.1.205	Streptococcus pyogenes		ribavirin monophosphate	701583	3985	
1.1.1.205	Tritrichomonas suis		ribavirin monophosphate	701583	3985	
1.1.1.205	Homo sapiens		ribavirin monophosphate	705494	3985	; 
1.1.1.205	Mycobacterium tuberculosis		ribavirin monophosphate	705494	3985	
1.1.1.205	Enterobacter aerogenes		ribose 5-phosphate	347920	165	non-competitive
1.1.1.205	Toxoplasma gondii		SAD	667219	39632	i.e. selenazole-4-carboxamido adenine diphosphonic acid, an adenine dinucleotide analogue
1.1.1.205	Chlorocebus aethiops		Selenazofurin	347917	5510	inhibition (in vivo) by the NAD analog formed intracellularly
1.1.1.205	Parainfluenza virus		Selenazofurin	347917	5510	potent competitive inhibition, shows anti-viral activity in vivo, detailed overview, a complete reversal of the antiviral activity of selenazofurin was obtained by addition of guanosine and selenazofurin at varying concentrations
1.1.1.205	Vaccinia virus		Selenazofurin	347917	5510	potent competitive inhibition, shows anti-viral activity in vivo, detailed overview
1.1.1.205	Homo sapiens		Selenazofurin	703193, 705494	5510	; 
1.1.1.205	Homo sapiens		selenazole adenine dinucleotide	701583	96401	
1.1.1.205	Homo sapiens		selenazole-4-carboxyamide-adenine dinucleotide	705494	53986	; 
1.1.1.205	Mus musculus		Sesquiterpene lactones	347914		a class of anti-neoplastic drugs, overview
1.1.1.205	Homo sapiens		SFAD	703193	18265	; 
1.1.1.205	Toxoplasma gondii		TAD	667219	1595	i.e. thiazole-4-carboxamide adenine dinucleotide, an adenine dinucleotide analogue
1.1.1.205	Homo sapiens		tert-butyl 7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxylate	667965	39642	IC50: 104 nM, isozyme IMPDH II
1.1.1.205	Homo sapiens		tert-butyl methyl (1S,4S)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1'H-spiro[cyclopentane-1,2'-quinazoline]-3,4-dicarboxylate	703193	26081	; 
1.1.1.205	Homo sapiens		TFAD	703193	18264	; 
1.1.1.205	Homo sapiens		thiazofurin-5'-yl-2-ethyladenosin-5'-yl-difluromethylene bis(phosphonate)	711475	18893	inhibition of leukemia K562 cells proliferation, IC50 of 4.7 microM; inhibition of leukemia K562 cells proliferation, IC50 of 4.7 microM
1.1.1.205	Homo sapiens		thiazole-4-carboxamide 2-ethyladenine dinucleotide	711475	18892	; 
1.1.1.205	Cricetulus griseus		thiazole-4-carboxamide adenine dinucleotide	347910	1595	inhibition is strong and not reversible by NAD+; thiazole-4-carboxamide adenine dinucleotide acts non competitive
1.1.1.205	Escherichia coli		thiazole-4-carboxamide adenine dinucleotide	347911	1595	reversible inhibition
1.1.1.205	Rattus norvegicus		thiazole-4-carboxamide adenine dinucleotide	347915	1595	
1.1.1.205	Homo sapiens		thiazole-4-carboxamide adenine dinucleotide	347916	1595	; i.e. TAD, mixed inhibition type versus inosine 5'-phosphate and NAD+
1.1.1.205	Rattus norvegicus		thiazole-4-carboxamide adenine dinucleotide	347916	1595	; i.e. TAD, uncompetitive versus inosine 5'-phosphate and mixed inhibition type versus NAD+
1.1.1.205	Chlorocebus aethiops		thiazole-4-carboxamide adenine dinucleotide	347917	1595	
1.1.1.205	Homo sapiens		thiazole-4-carboxamide adenine dinucleotide	347918	1595	inhibitory mechanism
1.1.1.205	Borrelia burgdorferi		thiazole-4-carboxamide adenine dinucleotide	347955	1595	uncompetitive with respect to IMP and NAD
1.1.1.205	Tritrichomonas suis		thiazole-4-carboxamide adenine dinucleotide	667573	1595	i.e. TAD, slight inhibition, microbial IMPDHs differ from mammalian enzymes in their lower affinity for inhibitors such as mycophenolic acid and thiazole-4-carboxamide adenine dinucleotide, part of this resistance is determined by the coupling between nicotinamide and adenosine subsites in the NAD+ binding site that is postulated to involve an active site flap
1.1.1.205	Homo sapiens		thiazole-4-carboxamide adenine dinucleotide	667921	1595	i.e. TAD, synthesis, noncompetitive inhibition, conformational analysis, and biological activity of inhibitor analogues, overview, TAD binds to the NAD+ binding site with out isozyme specificity, mechanism and molecular modeling using the enzyme crystal structure, overview, cytotoxic against K562 tumor cells
1.1.1.205	Homo sapiens		thiazole-4-carboxamide adenine dinucleotide	711475	1595	inhibition of leukemia K562 cells proliferation, IC50 of 3.7 microM; inhibition of leukemia K562 cells proliferation, IC50 of 3.7 microM
1.1.1.205	Escherichia coli		tiazofurin	347911	1402	
1.1.1.205	Homo sapiens		tiazofurin	347912	1402	decrease of cell growth
1.1.1.205	Homo sapiens		tiazofurin	347916	1402	i.e. 2-beta-D-ribofuranosyl-thiazole-4-carboxamide, overview: clinical and molecular impact of inhibition; the drug is tested in clinical use to treat acute myelocytic leukemia, AML, detailed overview, tiazofurin treatment may result in induced differentiation of leukemic leukocytes in patients, incubation of K-562 cells with tiazofurin produces inhibition of IMP DH and decreases GTP concentration, these biochemical alterations are followed by a decrease in the expression of as proto-oncogene which is followed by induced differentiation of these cells, biochemical mechanism, overview
1.1.1.205	Rattus norvegicus		tiazofurin	347916	1402	inhibits cell proliferation of hepatoma cells, overview
1.1.1.205	Chlorocebus aethiops		tiazofurin	347917	1402	
1.1.1.205	Parainfluenza virus		tiazofurin	347917	1402	
1.1.1.205	Vaccinia virus		tiazofurin	347917	1402	
1.1.1.205	Homo sapiens		tiazofurin	667921	1402	noncompetitive inhibition, cytotoxic against K562 tumor cells
1.1.1.205	Candida albicans		tiazofurin	669310	1402	multiple inhibition with ADP, noncompetitive versus NAD+
1.1.1.205	Homo sapiens		tiazofurin	347918, 669807, 670128	1402	
1.1.1.205	Cryptosporidium parvum		tiazofurin	703193	1402	
1.1.1.205	Tritrichomonas suis		tiazofurin	703193	1402	binds in the nicotinamide portion of the dinucleotide site, tiazofurin and ADP are strongly synergistic inhibitors, a conformational change occurs upon the binding of one inhibitor that increases the affinity of the second inhibitor
1.1.1.205	Homo sapiens		tiazofurin	703193, 705494	1402	; 
1.1.1.205	Tritrichomonas suis		tiazofurin	711219	1402	
1.1.1.205	Schizosaccharomyces pombe		TMP	347930	518	25% inhibition at 0.6 mM
1.1.1.205	Schizosaccharomyces pombe		UMP	347930	127	25% inhibition at 0.6 mM
1.1.1.205	Enterobacter aerogenes		Urea	347935	110	inactive at 3 M but regains activity after dialysis
1.1.1.205	Homo sapiens		VX-148	667937	5128	isozyme IMPDH II IC50: 6 nM
1.1.1.205	Homo sapiens		VX-148	667966, 667976	5128	
1.1.1.205	Homo sapiens		VX-148	703193	5128	has immunosuppressive activity; has immunosuppressive activity
1.1.1.205	Homo sapiens		VX-148	705494	5128	; 
1.1.1.205	Homo sapiens		VX-497	667935	5088	key binding interactions for the benzofuranone residue mycophenolic acid and the N-[3-methoxy-4-(5-oxazolyl)phenyl] fragment of VX-497, the benzofuranone ring mycophenolic acid binds in a spatially restricted region of the NAD+ binding site packing with the hypoxanthine ring xanthosine 5'-phosphate, the carbonyl oxygen and hydroxy residues are involved in a hydrogen bond array that involves Gly326, Thr333 and Gln441, the appending methyl substituent of the benzofuranone system, resides in a small hydrophobic pocket defined by the planes of Asn303 amide and Arg322 guanidine, the phenyl oxazole moiety of VX-497 binds in the same region as the benzofuranone ring of mycophenolic acid, forming hydrogen bonds between the oxazole nitrogen and oxygen with Gly326 and possibly Thr333, respectively, the methoxy residue binds in the same pocket as the benzofuranone methyl in mycophenolic acid
1.1.1.205	Homo sapiens		VX-497	667937	5088	isozyme IMPDH II IC50: 11 nM
1.1.1.205	Homo sapiens		VX-497	667965, 667966, 667976	5088	
1.1.1.205	Homo sapiens		VX-497	705494	5088	; 
1.1.1.205	Mus musculus		xanthosine 5'-phosphate	347914	772	competitive inhibition
1.1.1.205	Rattus norvegicus		xanthosine 5'-phosphate	347915	772	competitive inhibition
1.1.1.205	Homo sapiens		xanthosine 5'-phosphate	347916	772	; competitive versus inosine 5'-phosphate but noncompetitive versus NAD+
1.1.1.205	Rattus norvegicus		xanthosine 5'-phosphate	347916	772	; competitive versus inosine 5'-phosphate but noncompetitive versus NAD+
1.1.1.205	Bacillus subtilis		xanthosine 5'-phosphate	347922	772	39% competitive, inhibition at 0.5 mM
1.1.1.205	Enterobacter aerogenes		xanthosine 5'-phosphate	347923	772	non-competitive with respect to NAD
1.1.1.205	Enterobacter aerogenes		xanthosine 5'-phosphate	347924	772	competitive with respect to IMP, non competitive with respect to NAD and K+
1.1.1.205	Enterobacter aerogenes		xanthosine 5'-phosphate	347928	772	product inhibitor
1.1.1.205	Rattus norvegicus		xanthosine 5'-phosphate	347932, 347937, 347940	772	
1.1.1.205	Mus musculus		xanthosine 5'-phosphate	347945	772	competitive with respect to IMP
1.1.1.205	Escherichia coli		xanthosine 5'-phosphate	347946	772	
1.1.1.205	Sus scrofa		xanthosine 5'-phosphate	347947	772	
1.1.1.205	Homo sapiens		xanthosine 5'-phosphate	347931, 347951	772	competitive with respect to IMP
1.1.1.205	Borrelia burgdorferi		xanthosine 5'-phosphate	347955	772	competitive with respect to IMP
1.1.1.205	Homo sapiens		xanthosine 5'-phosphate	347918, 347956	772	
1.1.1.205	Bacillus anthracis		xanthosine 5'-phosphate	724347	772	competitive with regard to inosine monophosphate
1.1.1.205	Leishmania donovani		XMP	688888	772	
1.1.1.205	Bacillus cereus		Zn2+	347958	19	complete inhibition at 1 nM
1.1.1.205	Homo sapiens		[(1E,3E)-5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-methylpenta-1,3-dien-1-yl]phosphonic acid	667980	39531	isozyme IMPDH II IC50: 506 nM
1.1.1.205	Homo sapiens		[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]phosphonic acid	667980	39536	isozyme IMPDH II IC50: 168 nM
1.1.1.205	Homo sapiens		[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]phosphoramidic acid	667980	39537	isozyme IMPDH II IC50: above 0.001 mM
1.1.1.205	Homo sapiens		[(3E)-5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-methylpent-3-en-1-yl]phosphonic acid	667980	39535	isozyme IMPDH II IC50: 96 nM
1.1.1.205	Homo sapiens		[(3E)-5-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-methylpent-3-en-1-yl]phosphonic acid	667980	39547	isozyme IMPDH II IC50: 20 nM
1.1.1.205	Homo sapiens		[(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-en-1-yl]phosphonic acid	667980	39532	isozyme IMPDH II IC50: 86 nM
1.1.1.85	Thermus thermophilus	DTT		685090	42	
1.1.1.85	Thermus thermophilus		(2S,3S)-3-methylmercaptomalate	711444		strong competitive inhibitor
1.1.1.85	Thermus thermophilus		1,2-Cyclohexanediamine-N,N,N',N'-tetraacetate	639131	62616	
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		Ba2+	639148, 639151	105	
1.1.1.85	Bacillus coagulans		Ca2+	639143	18	0.5 mM, 32% inhibition
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		Ca2+	639148, 639151	18	
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		Co2+	639148	21	above 0.5 mM
1.1.1.85	Bacillus coagulans		Cu2+	639143	28	0.5 mM, 77% inhibition
1.1.1.85	Saccharomyces cerevisiae		Cu2+	639134, 639147	28	
1.1.1.85	Bacillus coagulans		Fe2+	639143	23	0.5 mM, 41% inhibition
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		iodoacetamide	639148, 639150	63	50 mM, slight inhibition
1.1.1.85	Acidithiobacillus ferrooxidans		iodoacetamide	639163	63	5 mM, 50% inhibition
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		iodoacetate	639148, 639150	87	50 mM, slight inhibition
1.1.1.85	Acidithiobacillus ferrooxidans		iodoacetate	639163	87	5 mM, 50% inhibition
1.1.1.85	Thermus thermophilus		Isocitrate	639155	242	
1.1.1.85	Bacillus coagulans		K+	639143	37	250 mM KCl, 23% inhibition
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		K+	639148, 639150	37	above 1 M, slight inhibition
1.1.1.85	Acidithiobacillus ferrooxidans		leucine	639132	121	
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		Li+	639148	142	
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		Mn2+	639148	26	above 0.5 mM
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		N-ethylmaleimide	639148, 639150	46	
1.1.1.85	Bacillus coagulans		NaCl	639143	39	250 mM, 48% inhibition
1.1.1.85	Thermus thermophilus		NADH	639155	3	NADH always produces competitive inhibition patterns with respect to NAD and noncompetitive inhibition patterns with respect to the substrates
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		NEM	639148	46	5 mM, 50% inhibition, not reversed by 2-mercaptoethanol
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		NEM	639150	46	
1.1.1.85	Acidithiobacillus ferrooxidans		NEM	639163	46	5 mM, 50% inhibition
1.1.1.85	Saccharomyces cerevisiae		Ni2+	639134, 639147	36	
1.1.1.85	Mycobacterium tuberculosis		O-isobutenyloxalylhydroxamate	656556	79778	O-isobutenyloxalylhydroxamate binds to the active site of enzyme in a mode similar to the substrate isopropylmalate
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		p-hydroxymercuribenzoate	639148	92	pH 9.0, 2 mM, complete inhibition, reversed by 2-mercaptoethanol
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		p-hydroxymercuribenzoate	639150	92	
1.1.1.85	Bacillus coagulans		PCMB	639143	40	0.2 mM, 90% inhibition
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		PCMB	639148, 639150	40	
1.1.1.85	Acidithiobacillus ferrooxidans		PCMB	639163	40	5 mM, 50% inhibition
1.1.1.85	Thermus thermophilus		Tartrate	639155	614	
1.1.1.85	Salmonella enterica subsp. enterica serovar Typhimurium		Zn2+	639151	19	
2.4.2.10	Vigna mungo	dithiothreitol		489725	42	stimulating
2.4.2.10	Toxoplasma gondii		1-deazaorotic acid	489727	32587	
2.4.2.10	Mycobacterium tuberculosis		2,6-dihydroxypyridine-4-carboxylic acid	722193		competitive to orotate, uncompetitive to 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.10	Mycobacterium tuberculosis		3-(2-hydroxybenzylidene)-2,6-dioxo-1,2,3,6-tetrahydropyridine-4-carboxylic acid	722193		competitive to orotate, uncompetitive to 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.10	Mycobacterium tuberculosis		3-benzylidene-2,6-dioxo-1,2,3,6-tetrahydropyridine-4-carboxylic acid	722193		competitive to orotate, uncompetitive to 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.10	Plasmodium falciparum		5-aminoorotate	659903	5618	50% inhibition at 0.01 mM
2.4.2.10	Toxoplasma gondii		5-azaorotic acid	489727	4167	
2.4.2.10	Plasmodium falciparum		5-bromoorotate	659903	5620	
2.4.2.10	Mus musculus		5-Bromouracil	489712	1806	
2.4.2.10	Mus musculus		5-Chlorouracil	489712	4370	
2.4.2.10	Mus musculus		5-Fluoroorotate	489712	2276	at 0.05 M
2.4.2.10	Plasmodium falciparum		5-Fluoroorotate	659903	2276	50% inhibition at 2-10 nM
2.4.2.10	Plasmodium falciparum		5-fluorouracil	659903	651	50% inhibition at 0.005-0.01 mM
2.4.2.10	Plasmodium falciparum		5-iodoorotate	659903	6376	
2.4.2.10	Plasmodium falciparum		5-Methylorotate	659903	4373	50% inhibition at 0.001 mM
2.4.2.10	Saccharomyces cerevisiae		5-phospho-alpha-D-ribose 1-diphosphate	489718	147	phosphorolysis, product inhibition, kinetics
2.4.2.10	Salmonella enterica subsp. enterica serovar Typhimurium		5-phospho-alpha-D-ribose 1-diphosphate	489723	147	phosphorolysis, product inhibition, kinetics
2.4.2.10	Plasmodium falciparum		5-phospho-alpha-D-ribose 1-diphosphate	659903	147	product inhibition, competitive to diphosphate, competitive to orotidine 5'-phosphate
2.4.2.10	Mycobacterium tuberculosis		6-hydroxy-5-((2-hydroxyethylamino)methyl)-2-oxo-1,2-dihydropyridine-4-carboxylic acid	722193		competitive to orotate, uncompetitive to 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.10	Mus musculus		adenine	489712	136	
2.4.2.10	Escherichia coli		adenine	489719	136	not inhibitory
2.4.2.10	Mus musculus		adenosine	489712	116	
2.4.2.10	Escherichia coli		adenosine	489719	116	not inhibitory
2.4.2.10	Mus musculus		ADP	489712	8	
2.4.2.10	Escherichia coli		ADP	489719	8	not inhibitory
2.4.2.10	Mus musculus		allopurinol	489712	643	
2.4.2.10	Mus musculus		AMP	489712	9	
2.4.2.10	Escherichia coli		AMP	489719	9	not inhibitory
2.4.2.10	Saccharomyces cerevisiae		anthranilate	489718	394	weak
2.4.2.10	Saccharomyces cerevisiae		arabinose 5-phosphate	489718	447	at higher concentrations
2.4.2.10	Mus musculus		ATP	489712	7	
2.4.2.10	Escherichia coli		ATP	489719	7	not inhibitory
2.4.2.10	Mus musculus		Azauracil	489712	3774	
2.4.2.10	Mus musculus		Azauridine	489712	29163	
2.4.2.10	Mus musculus		Barbituric acid	489712	3788	
2.4.2.10	Saccharomyces cerevisiae		Co2+	489716	21	inhibits Mg2+-activation
2.4.2.10	Mus musculus		cytosine	489712	406	
2.4.2.10	Mus musculus		dihydroorotate	489712	709	10 mM
2.4.2.10	Mus musculus		diphosphate	489712	13	
2.4.2.10	Saccharomyces cerevisiae		diphosphate	489718	13	product inhibition, kinetics
2.4.2.10	Salmonella enterica subsp. enterica serovar Typhimurium		diphosphate	489723	13	product inhibition, kinetics
2.4.2.10	Plasmodium falciparum		diphosphate	659903	13	product inhibition, noncompetitive to orotate, competitive to 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.10	Mycobacterium tuberculosis		diphosphate	723161	13	product inhibition
2.4.2.10	Mus musculus		dUMP	489712	496	
2.4.2.10	Saccharomyces cerevisiae		EDTA	489715	223	5 mM, complete inhibition
2.4.2.10	Vigna mungo		EDTA	489725	223	
2.4.2.10	Saccharomyces cerevisiae		erythrose 4-phosphate	489718	1137	at higher concentrations
2.4.2.10	Saccharomyces cerevisiae		fructose 1-phosphate	489718	544	at higher concentrations
2.4.2.10	Saccharomyces cerevisiae		fructose 6-phosphate	489718	82	at higher concentrations
2.4.2.10	Mus musculus		GMP	489712	150	
2.4.2.10	Escherichia coli		HgCl2	489719	104	slight inhibition of mutant, not wild-type
2.4.2.10	Mus musculus		IMP	489712	206	
2.4.2.10	Escherichia coli		iodoacetamide	489719	63	slight inhibition of mutant, not wild-type
2.4.2.10	Mus musculus		more	489712		not inhibitory: CMP, TMP, 6-aza-UMP or 5-bromo-UMP
2.4.2.10	Homo sapiens		more	489721		no inhibition by SH-group reagents
2.4.2.10	Plasmodium falciparum		more	489721		no inhibition by SH-group reagents
2.4.2.10	Toxoplasma gondii		more	489727		structural features of pyrimidine nucleobase inhibitors
2.4.2.10	Escherichia coli		NEM	489719	46	slight inhibition of mutant, not wild-type
2.4.2.10	Saccharomyces cerevisiae		nicotinate	489718	787	weak
2.4.2.10	Saccharomyces cerevisiae		Orotate	489718	373	phosphorolysis, product inhibition, kinetics
2.4.2.10	Salmonella enterica subsp. enterica serovar Typhimurium		Orotate	489723	373	phosphorolysis, product inhibition, kinetics
2.4.2.10	Rhizobium leguminosarum		Orotate	489733	373	above 0.4 mM
2.4.2.10	Plasmodium falciparum		Orotate	659903	373	product inhibition, noncompetitive to diphosphate, competitive to orotidine 5'-phosphate
2.4.2.10	Pseudomonas putida		Orotic acid	678999	373	when grown on glucose as carbon source, supplementation with orotic acid significantly decreases orotate phosphoribosyltransferase and orotidine 5'-monophoshate decarboxylase activities. In a strain deficient for dihydroorotase activity, orotic acid induces both phosphoribosyltransferase and orotidine 5'-monophoshate decarboxylase activites
2.4.2.10	Mus musculus		Orotidine	489712	2998	10 mM
2.4.2.10	Plasmodium falciparum		orotidine 5'-phosphate	659903	599	product inhibition, competitive to 5-phospho-alpha-D-ribose 1-diphosphate, competitive to orotate
2.4.2.10	Mycobacterium tuberculosis		orotidine 5'-phosphate	723161	599	product inhibition
2.4.2.10	Saccharomyces cerevisiae		orotidylate	489715	599	
2.4.2.10	Saccharomyces cerevisiae		orotidylate	489718	599	product inhibition, kinetics
2.4.2.10	Salmonella enterica subsp. enterica serovar Typhimurium		orotidylate	489723	599	product inhibition, kinetics
2.4.2.10	Mus musculus		Oxipurinol	489712	4634	
2.4.2.10	Homo sapiens		p-nitrophenyl beta-D-ribose	704190	12135	
2.4.2.10	Plasmodium falciparum		p-nitrophenyl beta-D-ribose	704190	12135	
2.4.2.10	Homo sapiens		p-nitrophenyl beta-D-ribose 5'-phosphate	704190	18304	competitive inhibitor against orotidine 5'-phosphate
2.4.2.10	Plasmodium falciparum		p-nitrophenyl beta-D-ribose 5'-phosphate	704190	18304	competitive inhibitor against orotidine 5'-phosphate
2.4.2.10	Escherichia coli		PCMB	489719	40	reversible by DTT
2.4.2.10	Homo sapiens		PCMB	489721	40	0.01 mM, complete inhibition
2.4.2.10	Mus musculus		phosphate	489712	12	
2.4.2.10	Saccharomyces cerevisiae		phosphate	489718	12	at higher concentrations
2.4.2.10	Plasmodium falciparum		pyrazofurin	659903	5106	50% inhibition at 0.006-0.024 mM
2.4.2.10	Mus musculus		ribose 5-phosphate	489712	165	not inhibitory
2.4.2.10	Saccharomyces cerevisiae		ribose 5-phosphate	489718	165	at higher concentrations
2.4.2.10	Homo sapiens		sulfate	721644	148	competitive to diphosphate
2.4.2.10	Plasmodium falciparum		sulfate	721644	148	competitive to diphosphate
2.4.2.10	Mus musculus		UDP	489712	24	
2.4.2.10	Vigna mungo		UDP	489725	24	
2.4.2.10	Mus musculus		UMP	489712	127	1 mM, not 0.1 mM
2.4.2.10	Vigna mungo		UMP	489725	127	
2.4.2.10	Mus musculus		Uracil	489712	287	
2.4.2.10	Toxoplasma gondii		Uracil	489727	287	
2.4.2.10	Plasmodium falciparum		Uracil	659903	287	
2.4.2.10	Mus musculus		uridine	489712	227	
2.4.2.10	Mus musculus		UTP	489712	61	
2.4.2.10	Escherichia coli		UTP	489719	61	not inhibitory
2.4.2.10	Vigna mungo		xanthosine-5'-phosphate	489725	772	
2.4.2.10	Escherichia coli		Zn2+	489719	19	
3.1.3.45	Escherichia coli		Ca2+	646344, 652389	18	
3.1.3.45	Escherichia coli		Cd2+	646344, 652389	48	
3.1.3.45	Escherichia coli		Cl-	646344	134	
3.1.3.45	Escherichia coli		Cu2+	646344, 652389	28	
3.1.3.45	Escherichia coli		EDTA	646344	223	
3.1.3.45	Escherichia coli		Hg2+	646344, 652389	31	
2.5.1.55	Escherichia coli	EDTA		637416	223	1 mM, 40% stimulation
2.5.1.55	Escherichia coli	EDTA		659404	223	
2.5.1.55	Gram-negative bacteria		(Z,E)-D-Glucophosphoenolpyruvate	637411	65798	and its carboxylic ester derivatives
2.5.1.55	Chlamydia psittaci		1,10-phenanthroline	637414	58	
2.5.1.55	Helicobacter pylori		1,10-phenanthroline	637414	58	
2.5.1.55	Escherichia coli		1,10-phenanthroline	637416	58	
2.5.1.55	Helicobacter pylori		1,10-phenanthroline	637416	58	IC50: 0.0293 mM
2.5.1.55	Aquifex aeolicus		1,10-phenanthroline	637414, 637422	58	
2.5.1.55	Aquifex pyrophilus		1,10-phenanthroline	658666	58	
2.5.1.55	Aquifex pyrophilus		1,10-phenanthroline	659404	58	inhibits wild-type enzyme, no inhibition of mutant enzyme C11N
2.5.1.55	Acidithiobacillus ferrooxidans		1-carboxyheptane-1,7-diyl bis(phosphate)	721820	19631	
2.5.1.55	Neisseria meningitidis		1-carboxyheptane-1,7-diyl bis(phosphate)	721820	19631	
2.5.1.55	Escherichia coli		2,6-Anhydro-3-deoxy-2beta-phosphonylmethyl-8-phosphate-D-glycero-D-talo-octonate	637408	29902	most potent inhibitor
2.5.1.55	Helicobacter pylori		2,6-pyridine dicarboxylic acid	637416	1090	IC50: 0.0422
2.5.1.55	Aquifex aeolicus		2-dehydro-3-deoxy-D-octonate 8-phosphate	658098	7077	mutant enzyme R106G is more severely inhibited than wild-type enzyme
2.5.1.55	Escherichia coli		2-Deoxy-2-fluoro-D-arabinoate-5-phosphate	637397	66955	
2.5.1.55	Escherichia coli		Bromopyruvate	637403	1425	phosphoenolpyruvate, but not arabinose-5-phosphate protects
2.5.1.55	Escherichia coli		Cd2+	637395	48	
2.5.1.55	Escherichia coli		Cd2+	637397	48	1 mM
2.5.1.55	Aquifex aeolicus		Cd2+	637422	48	10 mM
2.5.1.55	Neisseria meningitidis		Cd2+	709520	48	inhibition of metal-independent wild type and mutant enzymes D247E, P249A at 2 microM and above, inhibition of mutant 247E/P249A at 8 microM and above
2.5.1.55	Pseudomonas aeruginosa		Co2+	637394	21	1 mM, 22% inhibition
2.5.1.55	Acinetobacter calcoaceticus		Co2+	637410	21	
2.5.1.55	Pseudomonas aeruginosa		Cu2+	637394	28	1 mM, 80% inhibition
2.5.1.55	Escherichia coli		Cu2+	637397	28	1 mM
2.5.1.55	Escherichia coli		Cu2+	637395, 637416	28	
2.5.1.55	Helicobacter pylori		Cu2+	637416	28	activity is enhanced below 0.001 mM, inhibitory at higher concentrations
2.5.1.55	Aquifex aeolicus		Cu2+	637422	28	10 mM
2.5.1.55	Neisseria meningitidis		Cu2+	709520	28	slight reduction of wild type enzyme activity
2.5.1.55	Aquifex aeolicus		D-arabinose 5-phosphate	658098	447	mutant enzyme R106G is less severely inhibited than wild-type enzyme
2.5.1.55	Escherichia coli		D-ribose 5-phosphate	637395	165	weak, competitive
2.5.1.55	Escherichia coli		D-ribose 5-phosphate	637397	165	
2.5.1.55	Chlamydia psittaci		dipicolinic acid	637414	1090	
2.5.1.55	Pseudomonas aeruginosa		EDTA	637394	223	
2.5.1.55	Aquifex aeolicus		EDTA	637414	223	
2.5.1.55	Chlamydia psittaci		EDTA	637414	223	
2.5.1.55	Helicobacter pylori		EDTA	637414	223	
2.5.1.55	Escherichia coli		EDTA	637416	223	
2.5.1.55	Helicobacter pylori		EDTA	637416	223	IC50: 0.212 mM
2.5.1.55	Neisseria gonorrhoeae		EDTA	637418	223	no inhibition
2.5.1.55	Aquifex aeolicus		EDTA	637422	223	reactivation by divalent metal ions
2.5.1.55	Aquifex pyrophilus		EDTA	658666	223	
2.5.1.55	Aquifex pyrophilus		EDTA	659404	223	inhibits wild-type enzyme, no inhibition of mutant enzyme C11N
2.5.1.55	Pseudomonas aeruginosa		Fe2+	637394	23	1 mM, 30% inhibition
2.5.1.55	Neisseria meningitidis		Fe2+	709520	23	inhibitory for N23C, N23C/C246S/P249A, N23C/C246S/D247E/P249A
2.5.1.55	Escherichia coli		Hg2+	637395	31	reversed by dithiothreitol
2.5.1.55	Escherichia coli		Hg2+	637397	31	1 mM
2.5.1.55	Pseudomonas aeruginosa		Mn2+	637394	26	1 mM, 40% inhibition
2.5.1.55	Acinetobacter calcoaceticus		Mn2+	637410	26	
2.5.1.55	Aquifex aeolicus		Mn2+	637422	26	10 mM
2.5.1.55	Neisseria meningitidis		Mn2+	709520	26	15% reduced activity above 200 microM for mutant N23C/D247E/P249A
2.5.1.55	Pseudomonas aeruginosa		phosphate	637394	12	
2.5.1.55	Escherichia coli		phosphate	637397	12	
2.5.1.55	Aquifex aeolicus		phosphate	658098	12	mutant enzyme R106G is more severely inhibited than wild-type enzyme
2.5.1.55	Pseudomonas aeruginosa		Zn2+	637394	19	1 mM, 34% inhibition
2.5.1.55	Escherichia coli		Zn2+	637397	19	1 mM
2.5.1.55	Escherichia coli		Zn2+	637395, 637416	19	
2.5.1.55	Helicobacter pylori		Zn2+	637416	19	mild inhibitor at higher concentrations
2.5.1.55	Aquifex aeolicus		Zn2+	637422	19	10 mM
2.5.1.55	Neisseria meningitidis		Zn2+	709520	19	inhibitory for all cloned enzymes
2.4.1.182	Escherichia coli	more		638252, 638255, 638256		no requirement for detergent
2.4.1.182	Escherichia coli	Triton X-100		702266	57	between 0 and 0.5 mM Triton X-100 increases the apparent specific activity 5fold
2.4.1.182	Escherichia coli		octyl-beta-D-glucoside	638252	1726	
3.5.1.16	Escherichia coli	glutathione		171960	41	
3.5.1.16	Escherichia coli	phosphate		171964	12	
3.5.1.16	Escherichia coli		1,10-phenanthroline	171964	58	zinc-specific chelator
3.5.1.16	Bacillus subtilis		3-(ethylamino)piperidin-2-one	710829	109522	
3.5.1.16	Escherichia coli		acetate	171964	44	product inhibition
3.5.1.16	Escherichia coli		Cu2+	171960	28	
3.5.1.16	Escherichia coli		EDTA	171960, 171964	223	
3.5.1.16	Bacillus subtilis		more	710829		synthesis and inhibitory potencies of a series of Nalpha-acyl/alkyl and Nalpha-alkoxycarbonyl derivatives of D- and L-ornithinie, overview. Minimal inhibitory concentrations of inhibitors in bacteria growth inhibition studies, overview
3.5.1.16	Bacillus subtilis		N2-(2,2-dimethylpropanoyl)-L-ornithine	710829	31835	
3.5.1.16	Bacillus subtilis		N2-(2-methylpropanoyl)-L-ornithine	710829	109516	
3.5.1.16	Bacillus subtilis		N2-(ethoxycarbonyl)-L-ornithine	710829	31837	weak inhibition
3.5.1.16	Bacillus subtilis		N2-(methoxycarbonyl)-L-ornithine	710829	31836	
3.5.1.16	Bacillus subtilis		N2-(propoxycarbonyl)-L-ornithine	710829	31840	
3.5.1.16	Bacillus subtilis		N2-(tert-butoxycarbonyl)-L-ornithine	710829	31841	
3.5.1.16	Bacillus subtilis		N2-(trifluoroacetyl)-L-ornithine	710829	109517	weak inhibition
3.5.1.16	Bacillus subtilis		N2-acetyl-D-ornithine	710829	29594	weak inhibition
3.5.1.16	Bacillus subtilis		N2-butanoyl-L-ornithine	710829	65108	
3.5.1.16	Bacillus subtilis		N2-chloroacetyl-L-ornithine	710829	109518	
3.5.1.16	Bacillus subtilis		N2-dichloroacetyl-L-ornithine	710829	109519	
3.5.1.16	Bacillus subtilis		N2-ethyl-L-ornithine	710829	109523	
3.5.1.16	Bacillus subtilis		N2-propanoyl-L-ornithine	710829	65110	
3.5.1.16	Bacillus subtilis		N2-trichloroacetyl-D-ornithine	710829	109521	
3.5.1.16	Bacillus subtilis		N2-trichloroacetyl-L-ornithine	710829	109520	
3.5.1.16	Bacillus subtilis		N2-[(propan-2-yloxy)carbonyl]-L-ornithine	710829	31839	
3.5.1.16	Bacillus subtilis		N2-[[(2-methylpentan-2-yl)oxy]carbonyl]-L-ornithine	710829	31838	
3.5.1.16	Escherichia coli		NaF	171964	209	linear uncompetitive inhibition
3.5.1.16	Escherichia coli		Ni2+	171960	36	
3.5.1.16	Escherichia coli		ornithine	171964	172	product inhibition
3.5.1.16	Escherichia coli		p-chloromercuribenzoate	171960	40	
3.5.1.16	Escherichia coli		Zn2+	171960	19	
3.5.1.16	Escherichia coli		[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]leucine	687815	16724	bestatin, competitive inhibitor
1.1.1.40	Ricinus communis	acetyl carnitine		654369	2563	19% activation at 5 mM
1.1.1.40	Ricinus communis	acetyl-CoA		286742	27	activates
1.1.1.40	Ricinus communis	acetyl-CoA		654369	27	24% activation at 0.005 mM
1.1.1.40	Populus trichocarpa	acetyl-CoA		723150	27	PtNADP-ME1, PtNADP-ME3, and PtNADP-ME4 are activated
1.1.1.40	Nicotiana tabacum	aspartate		689506	91	2fold activation of isozyme NADP-ME1
1.1.1.40	Arabidopsis thaliana	aspartate		689565	91	isozyme NADP-ME2 activity is highly stimulated at both low and high concentrations of 0.5 mM and 2 mM, respectively
1.1.1.40	Ricinus communis	ATP		654369	7	18% activation at 5 mM
1.1.1.40	Ricinus communis	citrate		654369	125	22% activation at 5 mM
1.1.1.40	Zea mays	citrate		656619	125	activation is increased by light exposure
1.1.1.40	Ricinus communis	CoA		286742	10	activates
1.1.1.40	Ricinus communis	CoA		654369	10	29% activation at 0.005 mM
1.1.1.40	Nicotiana tabacum	CoA		689506	10	slight activation of isozyme NADP-ME2
1.1.1.40	Arabidopsis thaliana	CoA		689565	10	activates isozyme NADP-ME2
1.1.1.40	Populus trichocarpa	D-glucose 6-phosphate		723150	99	activates PtNADP-ME3 and PtNADP-ME4
1.1.1.40	Homo sapiens	fumarate		286734	156	increases activity of the mitochondrial enzyme at low malate concentrations, no effect on the activity of the cytosolic enzyme
1.1.1.40	Solanum lycopersicum	fumarate		286737	156	slight activation at low concentration
1.1.1.40	Arabidopsis thaliana	fumarate		689565	156	isozyme NADP-ME2 activity is highly stimulated at both low and high concentrations of 0.5 mM and 2 mM, respectively, twofold activation of at 0.5 mM
1.1.1.40	Arabidopsis thaliana	fumarate		697911	156	about 4fold increase of activity in the presence of 7.5 mM fumarate
1.1.1.40	Zea mays	fumarate		700772	156	when assayed at malate concentrations of 0.2 mM, fumarate activates the enzyme by 80% over the control activity
1.1.1.40	Arabidopsis thaliana	fumarate		723442	156	fumarate activates the NADP-ME2 forward reaction by about 15fold at 0.05 mM NADP+, but only at about 1.5fold at 0.35 mM NADP+. The trans configuration of fumarate is crucial for the activating effect
1.1.1.40	Trypanosoma brucei	L-aspartate		712042	91	the cytosolic isozyme is 50% activated by L-aspartate
1.1.1.40	Trypanosoma cruzi	L-aspartate		712042	91	10fold activation; the cytosolic isozyme is over 10fold activated by L-aspartate
1.1.1.40	Ricinus communis	L-glutamate		654369	38	15% activation at 5 mM
1.1.1.40	Ricinus communis	malonyl-CoA		654369	72	15% activation at 0.005 mM
1.1.1.40	Sulfolobus solfataricus	methanol		724897	78	activation is reversible and inversely related to the temperature
1.1.1.40	Trichomonas vaginalis	more		655672		enzyme activity is not affected by oxaloacetate, fumarate, succinate, AMP, and NH4+
1.1.1.40	Zea mays	more		656619		activation by light with 30% increased Vmax, activation by light is reduced by addition of dithiols
1.1.1.40	Aptenia cordifolia	more		657103		glutamate is a poor activator
1.1.1.40	Oryza sativa	more		685731		the enzyme is induced by salt stress, NADP-ME activities in seedlings, leaves, and roots increase in response to NaCl
1.1.1.40	Hydrilla verticillata	more		689392		isozyme Hvme3 is not affected by light; the plastidic isozyme Hvme1 may perform housekeeping functions, but is upregulated as the photosynthetic decarboxylase
1.1.1.40	Nicotiana tabacum	more		689506		no activation of isozyme NADP-ME2 by aspartate
1.1.1.40	Oryza sativa	more		689557		expression of NADP-ME2 in roots is induced by stress from carbonates, NaHCO3 and Na2CO3, NaCl, and environmental pH changes in leaves and roots of seedlings, overview
1.1.1.40	Zea mays	more		700772		after PEG 6000 treatment, the levels of cytosolic NADP-ME transcripts are enhanced by approximately 2.5times
1.1.1.40	Triticum aestivum	more		721778		activity of the NADP-ME is mostly enhanced under various stresses
1.1.1.40	Pseudomonas aeruginosa	NH4+		286716	50	activates
1.1.1.40	Corynebacterium glutamicum	NH4+		286739	50	activates
1.1.1.40	Ricinus communis	palmitoyl-CoA		286742	122	activates
1.1.1.40	Ricinus communis	palmitoyl-CoA		654369	122	69% activation at 0.005 mM
1.1.1.40	Homo sapiens	succinate		286734	54	increases activity of the mitochondrial enzyme at low malate concentrations, no effect on the activity of the cytosolic enzyme
1.1.1.40	Solanum lycopersicum	succinate		286737	54	slight activation up to 10 mM
1.1.1.40	Ricinus communis	succinate		286742	54	activates
1.1.1.40	Ricinus communis	succinate		654369	54	65% activation at 5 mM
1.1.1.40	Zea mays	succinate		656619	54	activation is increased by light exposure
1.1.1.40	Arabidopsis thaliana	succinate		689565	54	isozyme NADP-ME2 activity is highly stimulated at both low and high concentrations of 0.5 mM and 2 mM, respectively, partial activation of isozyme NADP-ME1 at 2 mM
1.1.1.40	Arabidopsis thaliana	succinate		697911	54	about 3fold increase of activity in the presence of 7.5 mM fumarate
1.1.1.40	Zea mays	succinate		700772	54	when assayed at malate concentrations of 0.2 mM, succinate activates the enzyme by 121% over the control activity, at malate concentration of 1.2 mM, succinate activates the enzyme by 62% over the control activity
1.1.1.40	Arabidopsis thaliana	succinate		723442	54	activates at 10 mM
1.1.1.40	Ricinus communis	UDP		654369	24	10% activation at 5 mM
1.1.1.40	Aptenia cordifolia	UDP-glucose		657103	60	32% activation at 2 mM
1.1.1.40	Homo sapiens		(NH4)2SO4	286740	334	at high concentrations
1.1.1.40	Columba sp.		(S)-malate	685000	180	substrate inhibition
1.1.1.40	Hydrilla verticillata		(S)-malate	689392	180	an increase to malate concentration of 10 mM decreases the specific activity of rHVME1 by almost 50%
1.1.1.40	Zea mays		2'-AMP	654547	621	competitive
1.1.1.40	Pigeon		2,3-Butanedione	286736	603	pseudo-first-order loss of oxidative decarboxylase activity
1.1.1.40	Aptenia cordifolia		2-Ketoglutarate	657103	32	34% inhibition at 2 mM
1.1.1.40	Rattus norvegicus		2-mercaptoethanol	286730	59	inactivation in absence of Mg2+
1.1.1.40	Solanum lycopersicum		2-oxoglutarate	286737	32	strong
1.1.1.40	Zea mays		2-oxoglutarate	687668	32	competitive
1.1.1.40	Arabidopsis thaliana		2-oxoglutarate	723442	32	inhibition of isozyme NADP-ME2
1.1.1.40	Zea mays		5'-AMP	654547	9	competitive
1.1.1.40	Sus scrofa		acetyl-CoA	286725	27	inhibition is much more pronounced in the mitochondrial enzyme than in the cytosolic enzyme and occurs at physiological acetyl-CoA concentrations
1.1.1.40	Nicotiana tabacum		acetyl-CoA	689506	27	40% inhibition of isozyme NADP-ME1 at 2 mM; inhibition of isozyme NADP-ME2
1.1.1.40	Arabidopsis thaliana		acetyl-CoA	689565	27	inhibits isozyme NADP-ME1
1.1.1.40	Arabidopsis thaliana		acetyl-CoA	697911	27	; 
1.1.1.40	Pigeon		adenosine 2'-phosphate	286722	621	
1.1.1.40	Pigeon		ADP	286722	8	
1.1.1.40	Aptenia cordifolia		ADP	657103	8	83% inhibition at 2 mM
1.1.1.40	Ricinus communis		AMP	654369	9	41% inhibition at 5 mM
1.1.1.40	Aptenia cordifolia		AMP	657103	9	75% inhibition at 2 mM
1.1.1.40	Pigeon		arsenite	286722	332	weak
1.1.1.40	Arabidopsis thaliana		aspartate	697911	91	
1.1.1.40	Homo sapiens		ATP	286740, 286741	7	non-competitive versus L-malate
1.1.1.40	Trichomonas vaginalis		ATP	655672	7	27% inhibition at 0.2 mM
1.1.1.40	Aptenia cordifolia		ATP	657103	7	83% inhibition at 2 mM
1.1.1.40	Nicotiana tabacum		ATP	689506	7	20% inhibition of isozyme NADP-ME1 at 2 mM; inhibition of isozyme NADP-ME2
1.1.1.40	Homo sapiens		ATP	697879	7	
1.1.1.40	Arabidopsis thaliana		ATP	697911	7	; 
1.1.1.40	Homo sapiens		ATP	698969	7	weak inhibitor
1.1.1.40	Homo sapiens		ATP	723540	7	10% inhibition of the wild-type enzyme at 3.0 mM in presence of NAD+, no inhibition in presence of NADP+, inhibition of mutant enzymes by ATP inpresence of NAD+ or NADP+
1.1.1.40	Escherichia coli		Ca2+	722940	18	
1.1.1.40	Ricinus communis		cAMP	654369	233	10% inhibition at 5 mM
1.1.1.40	Aptenia cordifolia		citrate	657103	125	competitive, 61% inhibition at 5 mM
1.1.1.40	Zea mays		citrate	687668	125	competitive
1.1.1.40	Populus trichocarpa		Citric acid	723150	125	inhibits all PtNADP-ME activities significantly
1.1.1.40	Ricinus communis		CO2	654369	17	product inhibition, uncompetitive with respect to L-malate and NADP+, 39% inhibition at 25 mM
1.1.1.40	Escherichia coli		Co2+	722940	21	
1.1.1.40	Nicotiana tabacum		CoA	689506	10	30% inhibition of isozyme NADP-ME1 at 2 mM
1.1.1.40	Populus trichocarpa		CoA	723150	10	activities of PtNADP-ME1, PtNADP-ME2 and PtNADPME4 proteins are inhibited
1.1.1.40	Pigeon		Cu2+	286722	28	3 mM, weak
1.1.1.40	Aspergillus niger		Cu2+	655613	28	complete inhibition at 0.1 mM, competitive to Mg2+ and Mn2+, enzyme inhibition leads to reduced lipid biosynthesis and accumulation of citric acid, quantitative overview
1.1.1.40	Escherichia coli		Cu2+	722940	28	strong inhibition
1.1.1.40	Zea mays		Cu2+-ascorbate	655710	79771	rapid inactivation by generation of reactive oxygen species at pH 5.0, Fe2+ can substitute for Cu2+, Cu2+ or ascorbate alone are not effective, azide, 1,4-diazabicyclo-(2.2.2.)octane, histidine and imidazole protect against inhibition, the substrates L-malate and NADP+ and EDTA protect almost completely, loss of activity is accompanied with cleavage of the protein into 4 fragments of 14-55 kDa
1.1.1.40	Zea mays		CuCl2	723390	295	about 40% loss of activity within 60 min
1.1.1.40	Populus trichocarpa		D-fructose	723150	111	PtNADP-ME1
1.1.1.40	Ricinus communis		D-fructose-1,6-bisphosphate	654369	100	13% inhibition at 5 mM
1.1.1.40	Zea mays		D-fructose-1,6-bisphosphate	700772	100	when assayed at malate concentrations of 0.2 mM, D-fructose-1,6-bisphosphate inhibits the enzyme by a 49% over the control activity
1.1.1.40	Nicotiana tabacum		D-glucose 6-phosphate	689506	99	40% inhibition of isozyme NADP-ME1 at 2 mM; inhibition of isozyme NADP-ME2
1.1.1.40	Arabidopsis thaliana		D-Glucose-6-phosphate	697911	99	; 
1.1.1.40	Sinorhizobium meliloti		D-malate	286706	862	
1.1.1.40	Sinorhizobium meliloti		D-Tartrate	286706	3375	
1.1.1.40	Zea mays		Diamide	723390	1817	2 mM, time-dependent decrease in activity reaching about 40% of initial activity after 60 min. In presence of dithiothreitol, a complete recovery is observed after 90 min. Enzyme oxidation decreases the catalytic activity. No severe loss of protein secondary structure takes place after oxidation; about 40% loss of activity within 60 min
1.1.1.40	Pigeon		diphenyliodonium chloride	286722	2796	weak
1.1.1.40	Zea mays		EDTA	286728	223	
1.1.1.40	Aspergillus niger		Fe2+	655613	23	
1.1.1.40	Zea mays		Fe2+-ascorbate	655710	79772	rapid inactivation
1.1.1.40	Solanum lycopersicum		fumarate	286737	156	at high concentration
1.1.1.40	Nicotiana tabacum		fumarate	689506	156	20% inhibition of isozyme NADP-ME1 at 2 mM; inhibition of isozyme NADP-ME2
1.1.1.40	Arabidopsis thaliana		fumarate	689565	156	inhibits isozymes NADP-ME1 , NADP-ME3 and NADP-ME4
1.1.1.40	Arabidopsis thaliana		fumarate	697911	156	
1.1.1.40	Ricinus communis		GDP	654369	49	13% inhibition at 5 mM
1.1.1.40	Corynebacterium glutamicum		glutamate	286739	38	
1.1.1.40	Rattus norvegicus		glutathione	286730	41	strongly inactivates in absence of Mg2+
1.1.1.40	Sinorhizobium meliloti		glyoxylate	286706	95	
1.1.1.40	Zea mays		H2O2	655710	20	83% inhibition at 0.25 mM, 91.1% inhibition at 0.5 mM
1.1.1.40	Pigeon		Hg2+	286722	31	0.0005 mM, almost complete inhibition
1.1.1.40	Pigeon		iodoacetate	286722	87	weak
1.1.1.40	Zea mays		Iodosobenzoate	723390	2732	1 mM, time-dependent decrease in activity reaching about 40% of initial activity after 60 min; about 40% loss of activity within 60 min
1.1.1.40	Aptenia cordifolia		L-aspartate	657103	91	competitive, 94% inhibition at 10 mM
1.1.1.40	Zea mays		L-Malate	656120	180	pH 7.0, high concentration
1.1.1.40	Sinorhizobium meliloti		L-Tartrate	286706	1389	
1.1.1.40	Pigeon		malate	286731	246	substrate inhibition
1.1.1.40	Egeria densa		malate	286732	246	no inhibition at pH 7.0
1.1.1.40	Flaveria floridana		malate	286732	246	no inhibition at pH 7.0
1.1.1.40	Haloxylon persicum		malate	286732	246	inhibition at pH 7.0
1.1.1.40	Mesembryanthemum crystallinum		malate	286732	246	no inhibition at pH 7.0
1.1.1.40	Triticum aestivum		malate	286732	246	no inhibition at pH 7.0
1.1.1.40	Zea mays		malate	286732	246	inhibition at pH 7.0
1.1.1.40	Homo sapiens		malate	286734	246	excess of malate inhibits the oxidative decarboxylation catalyzed by the cytosolic enzyme at pH 7.0, and below, decarboxylation catalyzed by mitochondrial enzyme is unaffected by the substrate
1.1.1.40	Zea mays		malate	687668	246	inhibition at high concentrations at pH 7.0, but not at pH 8.0
1.1.1.40	Nicotiana tabacum		malate	689506	246	inhibition of isozyme NADP-ME1 at pH 7.0
1.1.1.40	Arabidopsis thaliana		Maleate	723442	474	the cis isomer of fumarate, inhibition of isozyme NADP-ME2
1.1.1.40	Sinorhizobium meliloti		malonate	286706	328	
1.1.1.40	Arabidopsis thaliana		malonate	723442	328	inhibition of isozyme NADP-ME2
1.1.1.40	Sus scrofa		malonyl-CoA	286725	72	inhibition of mitochondrial enzyme and cytosolic enzyme to a much lower extent than with acetyl-CoA
1.1.1.40	Sus scrofa		Mg2+	286725	25	mitochondrial enzyme, decarboxylation reaction, above 6 mM
1.1.1.40	Escherichia coli		Mg2+	687388	25	activates at up to 4 mM, inhibition above, probably due to blockage of substrate binding, Km is 0.19 mM
1.1.1.40	Zea mays		more	656619		feedback inhibition is reduced by illumination
1.1.1.40	Aptenia cordifolia		more	657103		glutamine is a poor inhibitor
1.1.1.40	Hydrilla verticillata		more	689392		no substrate inhibition of isozyme Hvme3 at 10 mM L-malate
1.1.1.40	Nicotiana tabacum		more	689506		no inhibition of isozyme NADP-ME2 by aspartate and malate
1.1.1.40	Triticum aestivum		more	697065		the expression levels of isozyme NADP-ME1 in leaves clearly decreases to the lowest point at 6 h following application of abscisic acid (0.2 mM), when treated with 4&deg;C, NaCl, and PEG, NADP-ME1 is down-regulated and low temperature treatment is more distinct; with respect to isozyme NADP-ME2, the expression levels are reduced by abscisic acid and salicylic acid treatments, in the salicylic acid treatment, the expression amounts of NADP-ME2 decrease to least at 3 h treatment, then begin to ascend till 6 h and again start to descend till 24 h treatment
1.1.1.40	Zea mays		more	700772		cytosolic NADP-ME expression in roots decreases with development, decreased levels of expression of cytosolic NADP-ME is observed in roots after incubating in solutions of Na2CO3 at pH 11.0 or NaHCO3 at pH 6.5; cytosolic NADP-ME is not inhibited by high malate concentrations at pH 7.0; NADP-ME is not affected by acetyl-CoA, CoA, pyruvate, L-alanine, alpha-ketoglutarate, glycerol-3-phosphate, 3-phospho-glycerate, and citrate
1.1.1.40	Mnium undulatum		more	713212		keeping plants in CO2-free air suppresses the activities of NADP-ME
1.1.1.40	Pilosella officinarum		more	713212		keeping plants in CO2-free air suppresses the activities of NADP-ME
1.1.1.40	Polytrichum commune		more	713212		keeping plants in CO2-free air suppresses the activities of NADP-ME
1.1.1.40	Polytrichum piliferum		more	713212		keeping plants in CO2-free air suppresses the activities of NADP-ME
1.1.1.40	Zea mays		more	723390		ZmnonC4-NADP-ME activity is not significantly modified by any chemical oxidant in 60 min
1.1.1.40	Arabidopsis thaliana		more	723442		no inhibition of isozyme NADP-ME2 by tartrate
1.1.1.40	Homo sapiens		NaCl	286740	39	at high concentrations
1.1.1.40	Pigeon		NAD+	286722	4	weak
1.1.1.40	Columba sp.		NADP+	685000	6	substrate inhibition
1.1.1.40	Ricinus communis		NADPH	654369	5	product inhibition, competitive with respect to L-malate and NADP+
1.1.1.40	Pigeon		o-Iodosobenzoate	286722	1554	strong
1.1.1.40	Oryctolagus cuniculus		oxalate	286715	166	
1.1.1.40	Ricinus communis		oxalate	654369	166	51% inhibition at 1 mM
1.1.1.40	Zea mays		oxalate	656619	166	inhibition is decreased by light exposure
1.1.1.40	Solanum lycopersicum		oxaloacetate	286737	53	strong
1.1.1.40	Corynebacterium glutamicum		oxaloacetate	286739	53	
1.1.1.40	Aptenia cordifolia		oxaloacetate	657103	53	competitive, 70% inhibition at 2 mM
1.1.1.40	Arabidopsis thaliana		oxaloacetate	697911	53	; 
1.1.1.40	Trypanosoma brucei		oxaloacetate	712042	53	competitive
1.1.1.40	Trypanosoma cruzi		oxaloacetate	712042	53	competitive
1.1.1.40	Nicotiana tabacum		oxaloacetic acid	689506	53	60% inhibition of isozyme NADP-ME1 at 2 mM; inhibition of isozyme NADP-ME2
1.1.1.40	Populus trichocarpa		oxaloacetic acid	723150	53	inhibits all PtNADP-ME activities significantly
1.1.1.40	Pigeon		p-mercuribenzoate	286722	554	strong
1.1.1.40	Pigeon		Phenylglyoxal	286736	258	pseudo-first-order loss of oxidative decarboxylase activity
1.1.1.40	Aptenia cordifolia		phosphate	657103	12	35% inhibition at 5 mM
1.1.1.40	Ricinus communis		phosphoenolpyruvate	654369	47	39% inhibition at 5 mM
1.1.1.40	Aptenia cordifolia		phosphoenolpyruvate	657103	47	competitive, 82% inhibition at 2 mM
1.1.1.40	Cenchrus purpureus		pyruvate	286727	29	competitive
1.1.1.40	Solanum lycopersicum		pyruvate	286737	29	non-competitive inhibition
1.1.1.40	Ricinus communis		pyruvate	654369	29	product inhibition, competitive with respect to L-malate, 16% inhibition at 5 mM
1.1.1.40	Zea mays		pyruvate	656619	29	inhibition is decreased by light exposure
1.1.1.40	Aptenia cordifolia		pyruvate	657103	29	22% inhibition at 2 mM
1.1.1.40	Nicotiana tabacum		pyruvate	689506	29	20% inhibition of isozyme NADP-ME1 at 2 mM; inhibition of isozyme NADP-ME2
1.1.1.40	Mucor circinelloides		sesamol	721393		a specific inhibitor of the enzyme
1.1.1.40	Zea mays		SO32-	286728	86	in decarboxylation of malate: partially competitive with respect to malate, in carboxylation of pyruvate: fully competitive for CO2 or HCO3-
1.1.1.40	Solanum lycopersicum		succinate	286737	54	slight inhibition at high concentrations
1.1.1.40	Aptenia cordifolia		succinate	657103	54	competitive, 28% inhibition at 5 mM
1.1.1.40	Nicotiana tabacum		succinate	689506	54	inhibition of isozyme NADP-ME2
1.1.1.40	Arabidopsis thaliana		succinate	697911	54	
1.1.1.40	Zea mays		sulfite	286728	86	
1.1.1.40	Sinorhizobium meliloti		Tartronate	286706	3003	
1.1.1.40	Homo sapiens		Tartronate	286740	3003	noncompetitive inhibitor with respect to L-malate
1.1.1.40	Columba sp.		Trypsin	685622		digests the mutant enzymes, while the wild-type enzyme is protected in the presence of Mn2+, because a specific cutting site in the Lys352-Gly-Arg354 region is able to generate a unique polypeptide with Mr of 37 kDa, and this polypeptide is resistant to further digestion
1.1.1.40	Columba sp.		Urea	685622	110	inactivation at 3-5 M urea, the pigeon cytosolic NADP+-dependent malic enzyme unfolds and aggregates into various forms with dimers as the basic unit, under the same denaturing conditions but in the presence of 4 mM Mn2+, the enzyme exists exclusively as a molten globule dimer in solution, overview
1.1.1.40	Aspergillus niger		Zn2+	655613	19	
1.1.1.40	Escherichia coli		Zn2+	722940	19	strong inhibition
4.6.1.12	Arabidopsis thaliana		(+)-(S)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6922	
4.6.1.12	Escherichia coli		(+)-(S)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6922	
4.6.1.12	Mycobacterium tuberculosis		(+)-(S)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6922	
4.6.1.12	Plasmodium falciparum		(+)-(S)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6922	
4.6.1.12	Arabidopsis thaliana		(+/-)-(2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-5,7-dimethyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid	708124	5969	
4.6.1.12	Escherichia coli		(+/-)-(2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-5,7-dimethyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid	708124	5969	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-(2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-5,7-dimethyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid	708124	5969	
4.6.1.12	Plasmodium falciparum		(+/-)-(2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-5,7-dimethyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid	708124	5969	
4.6.1.12	Arabidopsis thaliana		(+/-)-(2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid	708124	5965	
4.6.1.12	Escherichia coli		(+/-)-(2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid	708124	5965	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-(2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid	708124	5965	
4.6.1.12	Plasmodium falciparum		(+/-)-(2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid	708124	5965	
4.6.1.12	Arabidopsis thaliana		(+/-)-benzyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5964	
4.6.1.12	Escherichia coli		(+/-)-benzyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5964	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-benzyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5964	
4.6.1.12	Plasmodium falciparum		(+/-)-benzyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5964	
4.6.1.12	Arabidopsis thaliana		(+/-)-benzyl 6-methyl-4-(2-thienyl)-2-thioxo-1,2,3,4-tetra-hydropyrimidine-5-carboxylate	708124	8166	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-benzyl 6-methyl-4-(2-thienyl)-2-thioxo-1,2,3,4-tetra-hydropyrimidine-5-carboxylate	708124	8166	
4.6.1.12	Plasmodium falciparum		(+/-)-benzyl 6-methyl-4-(2-thienyl)-2-thioxo-1,2,3,4-tetra-hydropyrimidine-5-carboxylate	708124	8166	
4.6.1.12	Arabidopsis thaliana		(+/-)-ethyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-5-(4-methoxyphenyl)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5968	
4.6.1.12	Escherichia coli		(+/-)-ethyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-5-(4-methoxyphenyl)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5968	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-ethyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-5-(4-methoxyphenyl)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5968	
4.6.1.12	Plasmodium falciparum		(+/-)-ethyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-5-(4-methoxyphenyl)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5968	
4.6.1.12	Arabidopsis thaliana		(+/-)-ethyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5961	
4.6.1.12	Escherichia coli		(+/-)-ethyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5961	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-ethyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5961	
4.6.1.12	Plasmodium falciparum		(+/-)-ethyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5961	
4.6.1.12	Arabidopsis thaliana		(+/-)-ethyl (2Z)-2-(3,5-difluoro-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6921	
4.6.1.12	Escherichia coli		(+/-)-ethyl (2Z)-2-(3,5-difluoro-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6921	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-ethyl (2Z)-2-(3,5-difluoro-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6921	
4.6.1.12	Plasmodium falciparum		(+/-)-ethyl (2Z)-2-(3,5-difluoro-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6921	
4.6.1.12	Arabidopsis thaliana		(+/-)-ethyl (2Z)-2-(3-bromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5962	
4.6.1.12	Escherichia coli		(+/-)-ethyl (2Z)-2-(3-bromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5962	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-ethyl (2Z)-2-(3-bromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5962	
4.6.1.12	Plasmodium falciparum		(+/-)-ethyl (2Z)-2-(3-bromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5962	
4.6.1.12	Arabidopsis thaliana		(+/-)-ethyl (2Z)-2-(4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5963	
4.6.1.12	Escherichia coli		(+/-)-ethyl (2Z)-2-(4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5963	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-ethyl (2Z)-2-(4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5963	
4.6.1.12	Plasmodium falciparum		(+/-)-ethyl (2Z)-2-(4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5963	
4.6.1.12	Arabidopsis thaliana		(+/-)-ethyl (2Z)-2-(4-methoxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	8167	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-ethyl (2Z)-2-(4-methoxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	8167	
4.6.1.12	Plasmodium falciparum		(+/-)-ethyl (2Z)-2-(4-methoxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	8167	
4.6.1.12	Arabidopsis thaliana		(+/-)-ethyl (2Z)-2-[4-(acetyloxy)-3,5-dibromobenzylidene]-5-(1-benzofuran-2-yl)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo-[3,2-a]pyrimidine-6-carboxylate	708124	6924	
4.6.1.12	Escherichia coli		(+/-)-ethyl (2Z)-2-[4-(acetyloxy)-3,5-dibromobenzylidene]-5-(1-benzofuran-2-yl)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo-[3,2-a]pyrimidine-6-carboxylate	708124	6924	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-ethyl (2Z)-2-[4-(acetyloxy)-3,5-dibromobenzylidene]-5-(1-benzofuran-2-yl)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo-[3,2-a]pyrimidine-6-carboxylate	708124	6924	
4.6.1.12	Plasmodium falciparum		(+/-)-ethyl (2Z)-2-[4-(acetyloxy)-3,5-dibromobenzylidene]-5-(1-benzofuran-2-yl)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo-[3,2-a]pyrimidine-6-carboxylate	708124	6924	
4.6.1.12	Arabidopsis thaliana		(+/-)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5966	
4.6.1.12	Escherichia coli		(+/-)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5966	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5966	
4.6.1.12	Plasmodium falciparum		(+/-)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5966	
4.6.1.12	Arabidopsis thaliana		(+/-)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dichloro-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5967	
4.6.1.12	Escherichia coli		(+/-)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dichloro-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5967	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dichloro-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5967	
4.6.1.12	Plasmodium falciparum		(+/-)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dichloro-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5967	
4.6.1.12	Arabidopsis thaliana		(+/-)-ethyl 4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylate	708124	8165	
4.6.1.12	Mycobacterium tuberculosis		(+/-)-ethyl 4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylate	708124	8165	
4.6.1.12	Plasmodium falciparum		(+/-)-ethyl 4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylate	708124	8165	
4.6.1.12	Arabidopsis thaliana		(-)-(R)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6923	
4.6.1.12	Escherichia coli		(-)-(R)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6923	
4.6.1.12	Mycobacterium tuberculosis		(-)-(R)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6923	
4.6.1.12	Plasmodium falciparum		(-)-(R)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6923	
4.6.1.12	Escherichia coli		2-amino-N-hydroxy-3-(1-H-indol-3-yl)-propionimidic acid	709435	16199	highest affinity of all the ligands examined, due to Zn2+-hydroxamate coordination, KD value of 0.0019 mM
4.6.1.12	Escherichia coli		4-amino-1-(3-O-phosphono-a-D-lyxofuranosyl)pyrimidin-2(1H)-one	709435	99382	
4.6.1.12	Escherichia coli		4-amino-1-[(2S,3aS,4S,6R,6aR)-2-hydroxy-6-(hydroxymethyl)-2-oxidotetrahydrofuro[3,4-d][1,3,2]dioxaphosphol-4-yl]pyrimidin-2(1H)-one	709435	99381	KD value of 20.5 mM
4.6.1.12	Escherichia coli		4-amino-1-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]pyrimidin-2(1H)-one	709435	7305	KD value of 0.925 mM
4.6.1.12	Escherichia coli		5-fluorocytidine	709435	8302	KD value of 2.02 mM
4.6.1.12	Plasmodium falciparum		artesunate	708124	12625	
4.6.1.12	Plasmodium falciparum		Chloroquine	708124	1087	
4.6.1.12	Escherichia coli		Cidofovir	709435	24404	KD value of ca. 40 mM
4.6.1.12	Escherichia coli		Cytosine arabinoside monophosphate	709435	3219	KD value of 18.91 mM
4.6.1.12	Plasmodium falciparum		EDTA	655417	223	5 mM. Activity can be restored by the addition of Mg2+ to a concentration of 10 mM
4.6.1.12	Escherichia coli		more	709435		5-(1,3-benzodioxol-5-ylamino)-5-oxopentanoic acid, 2-[(2,6-diaminopyrimidin-4-yl)sulfanyl]acetamide and 4-(5-amino-1,3,4-oxadiazol-2-yl)-1,2,5-oxadiazol-3-amine are inactive. Activity with compounds 2-amino-N-hydroxy-acetimidic acid, N-hydroxy-nicotinimidic acid, 5-bromo-thiophene-2-sulfonic acid amide, 4-bromobenzenesulfonamide and 4-(4-dimethylamino-phenylazo)-benzenesulfonamide are not measurable
4.6.1.12	Escherichia coli		N-([4-[(4-amino-2-oxopyrimidin-1(2H)-yl)methyl]-1-naphthyl]methyl)-4-chlorobenzamide	680059	42231	1 mM, 52% inhibition
4.6.1.12	Escherichia coli		N-([4-[(4-amino-2-oxopyrimidin-1(2H)-yl)methyl]-1-naphthyl]methyl)benzamide	680059	42230	1 mM, 59% inhibition
4.6.1.12	Escherichia coli		N-[4-[(6-aminopyridin-3-yl)amino]-3-methylbenzyl]-4-(trifluoromethyl)benzamide	680059	42229	1 mM, 60% inhibition
2.7.7.60	Escherichia coli		CTP	661089	56	substrate inhibition
2.5.1.6	Rattus norvegicus	ATP		639068	7	tripolyphosphatase activity stimulated by preincubation with ATP and methionine
2.5.1.6	Leishmania infantum	cycloheximide		686935	1283	cycloheximide inhibition of protein synthesis increases isozyme MAT2 mRNA level in the logarithmic phase only, an indication that the gene is regulated in promastigotes at the posttranscriptional level by protein factors that targets the transcript for degradation
2.5.1.6	Rattus norvegicus	Dimethylsulfoxide		639043, 639044	702	activates isoform from kidney and isoform MAT-III from liver
2.5.1.6	Rattus norvegicus	Dimethylsulfoxide		639054	702	activates alpha and beta isoenzymes from liver
2.5.1.6	Rattus norvegicus	Dimethylsulfoxide		639058	702	activates the beta isozyme from liver 13-15fold; weak activation of the alpha isozyme from liver
2.5.1.6	Rattus norvegicus	dithiothreitol		639054	42	required for alpha and beta isoenzymes activity, not required for gamma enzyme
2.5.1.6	Rattus norvegicus	E2F1		687118		present continually in the MAT2A promoter during liver regeneration
2.5.1.6	Rattus norvegicus	E2F3		687118		present continually in the MAT2A promoter during liver regeneration
2.5.1.6	Rattus norvegicus	E2F4		687118		present continually in the MAT2A promoter during liver regeneration
2.5.1.6	Homo sapiens	Epidermal growth factor		686924	1384	100 ng/ml upregulates MAT2A (but not MAT2beta) expression
2.5.1.6	Mus musculus	Epidermal growth factor		686924	1384	100 ng/ml upregulates MAT2A (but not MAT2beta) expression
2.5.1.6	Rattus norvegicus	forskolin		659509	469	induction of enzyme in organ cell culture
2.5.1.6	Rattus norvegicus	glycerol		639054	129	activates rat liver isoenzymes alpha and beta
2.5.1.6	Homo sapiens	insulin-like growth factor 1		686924		100 ng/ml upregulates MAT2A (but not MAT2beta) expression
2.5.1.6	Mus musculus	insulin-like growth factor 1		686924		100 ng/ml upregulates MAT2A (but not MAT2beta) expression
2.5.1.6	Rattus norvegicus	isoproterenol		659509	1261	induction of enzyme in organ cell culture
2.5.1.6	Rattus norvegicus	L-methionine		686024	83	17% increase is observed at 60 mM L-methionine; 17% increase of activity is observed at 60 mM L-methionine
2.5.1.6	Homo sapiens	leptin		686924		100 ng/ml upregulates MAT2A (but not MAT2beta) expression
2.5.1.6	Mus musculus	leptin		686924		100 ng/ml upregulates MAT2A (but not MAT2beta) expression
2.5.1.6	Homo sapiens	leptin		687010		induces the expression of MAT2A and MAT2beta
2.5.1.6	Saccharomyces cerevisiae	methanol		687859	78	53.26% increased yield of S-adenosyl-L-methionine at 1.0% methanol
2.5.1.6	Rattus norvegicus	methionine		639068	83	stimulation of activity demonstrated in vivo. Tripolyphosphatase activity stimulated by preincubation with ATP and methionine
2.5.1.6	Sulfolobus solfataricus	more		639048		no requirement for reducing agents
2.5.1.6	Rattus norvegicus	more		639068		no effect with ADP and methionine or S-adenosylmethionine
2.5.1.6	Atriplex nummularia	more		660154		salt stress induces the enzyme, differential effects on betaine and lignin biosynthesis, overview; salt stress induces the enzyme, differential effects on betaine and lignin biosynthesis, overview; salt stress induces the enzyme, differential effects on betaine and lignin biosynthesis, overview; salt stress induces the enzyme, differential effects on betaine and lignin biosynthesis, overview
2.5.1.6	Komagataella pastoris	more		673398		methanol induces enzyme expression and S-adenosyl-L-methionine production, while glycerol does not
2.5.1.6	Homo sapiens	more		673793		cell methionine and S-adenosylmethionine contents increase in response to hyperoxia in SAE and A549 cells, enzyme activity increases by 2fold within 5 days, S-adenosylmethionine content by 5fold, overview
2.5.1.6	Mus musculus	more		675572		fasting for 10-16 h increases expression and activity of isozymes MAT I and MAT III, effects on methionine/S-adenosyl-L-methionine metabolism, overview
2.5.1.6	Arabidopsis thaliana	more		676530		lysine enhances methionine content by modulating the expression of S-adenosylmethionine synthase, overview
2.5.1.6	Saccharomyces cerevisiae	more		687859		no significant effect in the presence of n-dodecane
2.5.1.6	Saccharomyces cerevisiae	n-heptane		687859	7183	53.26% increased yield of S-adenosyl-L-methionine at 1.0% n-heptane
2.5.1.6	Rattus norvegicus	norepinephrine		659509	750	induction of enzyme in organ cell culture
2.5.1.6	Rattus norvegicus	S-adenosylmethionine		639043, 639044	22	activation of rat liver MAT-III
2.5.1.6	Sulfolobus solfataricus	S-adenosylmethionine		639048	22	activates the tripolyphosphatase activity of A isoform
2.5.1.6	Rattus norvegicus	S-adenosylmethionine		639053	22	below 0.3 mM activates low-MW isoenzyme
2.5.1.6	Escherichia coli	S-adenosylmethionine		639056	22	enhances tripolyphosphatase activity
2.5.1.6	Leishmania donovani	S-adenosylmethionine		639078	22	nonessential activator of tripolyphosphatase activity in the range of 0.005-0.100 mM
2.5.1.6	Rattus norvegicus	SH-reagents		639042		liver enzyme: requirement, tumor enzyme: no requirement
2.5.1.6	Saccharomyces cerevisiae	sorbitol		687859	513	53.26% increased yield of S-adenosyl-L-methionine at 1.2% sorbitol
2.5.1.6	Rattus norvegicus	Sp1		687118		binding of Sp1 to the MAT2A promoter is essential for the transcriptional up-regulation of the gene
2.5.1.6	Rattus norvegicus	tripolyphosphates		639054	66834	activation or inhibition, depending on isoenzyme, S-adenosylmethionine and tripolyphosphate concentration
2.5.1.6	Homo sapiens	Tumor necrosis factor alpha		686926		induces expression of variant 1 (but not variant 2) MAT2beta
2.5.1.6	Rattus norvegicus		(2S,4S)-amino-4,5-epoxypentanoic acid	659701	80878	
2.5.1.6	Escherichia coli		1-(3-(2-ethoxyphenyl)ureidoacetyl)-4-(2-methyl-5-nitrophenyl)semicarbazide	705048	53381	binding to adenosyl region of the active site
2.5.1.6	Escherichia coli		1-(4-chloro-2-nitrophenyl)-3-(4-sulfamoylphenyl)-urea	705048	53382	binding to adenosyl region of the active site
2.5.1.6	Saccharomyces cerevisiae		1-aminocyclopentanecarboxylic acid	639051	5440	
2.5.1.6	Mycobacterium smegmatis		1-methyluric acid	658351	13135	10 mM, 43.4% inhibition
2.5.1.6	Mycobacterium smegmatis		1-Methylxanthine	658351	3515	10 mM, 35.9% inhibition
2.5.1.6	Mycobacterium smegmatis		2,6-Diaminopurine	658351	1920	10 mM, 29.3% inhibition
2.5.1.6	Mycobacterium smegmatis		2,6-dichloropurine	658351	8831	10 mM, 35.5% inhibition
2.5.1.6	Mycobacterium smegmatis		2-amino-6-carboxyethylmercaptopurine	658351	80876	10 mM, 31.9% inhibition
2.5.1.6	Mycobacterium smegmatis		2-amino-6-chloropurine riboside	658351	21438	10 mM, 17.2% inhibition
2.5.1.6	Mycobacterium smegmatis		2-amino-6-chloropurine-9-acetic acid	658351	80873	10 mM, 23.5% inhibition
2.5.1.6	Mycobacterium smegmatis		2-Aminopurine	658351	4344	10 mM, 11.0% inhibition
2.5.1.6	Mycobacterium smegmatis		2-Hydroxypurine	658351	8254	10 mM, 33.8% inhibition
2.5.1.6	Mycobacterium smegmatis		3,7-dimethyluric acid	658351	15230	10 mM, 27.9% inhibition
2.5.1.6	Rattus norvegicus		3-morpholinosydnoniimide	639064	73731	loss of liver MAT activity in vivo
2.5.1.6	Catharanthus roseus		5-amino-L-norvaline	639063	172	10-25% inhibition with 5 mM; 10-25% inhibition with 5 mM; 10-25% inhibition with 5 mM
2.5.1.6	Crypthecodinium cohnii		5-azacytidine	685831	3768	0.2 mM leads to significant reduction of AdoMetS protein expression
2.5.1.6	Mycobacterium smegmatis		6-benzyloxypurine	658351	80874	10 mM, 17.7% inhibition
2.5.1.6	Mycobacterium smegmatis		6-bromopurine	658351	21301	10 mM, 31.4% inhibition
2.5.1.6	Mycobacterium smegmatis		6-Chloropurine	658351	2028	10 mM, 31.4% inhibition
2.5.1.6	Mycobacterium smegmatis		6-Chloropurine riboside	658351	4379	10 mM, 17.1% inhibition
2.5.1.6	Mycobacterium smegmatis		6-Cyanopurine	658351	29027	10 mM, 24.2% inhibition
2.5.1.6	Mycobacterium smegmatis		6-dimethylallylaminopurine riboside	658351	4888	10 mM, 41.6% inhibition
2.5.1.6	Mycobacterium smegmatis		6-Dimethylaminopurine	658351	10452	10 mM, 28.0% inhibition
2.5.1.6	Mycobacterium smegmatis		6-Mercaptopurine	658351	1019	10 mM, 40.1% inhibition
2.5.1.6	Mycobacterium smegmatis		6-mercaptopurine riboside	658351	4814	10 mM, 30.0% inhibition
2.5.1.6	Mycobacterium smegmatis		6-propoxypurine	658351	80877	10 mM, 27.9% inhibition
2.5.1.6	Mycobacterium smegmatis		7-hydroxypropyl theophylline	658351	80872	10 mM, 16.1% inhibition
2.5.1.6	Mycobacterium smegmatis		7-Methyluric acid	658351	29057	10 mM, 11.4% inhibition
2.5.1.6	Mycobacterium smegmatis		7-methylxanthine	658351	1694	10 mM, 36.3% inhibition
2.5.1.6	Mycobacterium smegmatis		8-aza-2,6-diaminopurine	658351	8795	10 mM, 40.0% inhibition
2.5.1.6	Mycobacterium smegmatis		8-Azaguanine	658351	1540	; 10 mM, 81.7% inhibition
2.5.1.6	Mycobacterium smegmatis		8-chlorotheophylline	658351	11161	10 mM, 7.0% inhibition
2.5.1.6	Escherichia coli		Adenyl-5'-ylimidodiphosphate	639045, 639056	2969	competitive with ATP
2.5.1.6	Catharanthus roseus		ADP	639063	8	35-50% inhibition with 5 mM; 35-50% inhibition with 5 mM; 35-50% inhibition with 5 mM
2.5.1.6	Saccharomyces cerevisiae		Ag+	706910	71	
2.5.1.6	Saccharomyces cerevisiae		alpha,beta-methylene-adenosine tetraphosphate	639050	63903	
2.5.1.6	Saccharomyces cerevisiae		alpha,beta-methylene-ATP	639050	4820	
2.5.1.6	Mycobacterium smegmatis		alpha-methyl-DL-methionine	658351	80870	10 mM, 18.8% inhibition
2.5.1.6	Saccharomyces cerevisiae		AMP	685773	9	causes complete inactivation of the enzyme
2.5.1.6	Homo sapiens		ATP	639052	7	
2.5.1.6	Rattus norvegicus		ATP	639068	7	ATP and methionine act as a switch between two different MAT III isoforms
2.5.1.6	Leishmania infantum		ATP	639075	7	
2.5.1.6	Saccharomyces cerevisiae		ATP	685773	7	causes complete inactivation of the enzyme
2.5.1.6	Mycobacterium smegmatis		Azathioprine	658351	3321	; 10 mM, 75.5% inhibition
2.5.1.6	Saccharomyces cerevisiae		Ba2+	685773	105	70.70% residual activity at 5 mM
2.5.1.6	Rattus norvegicus		bacterial lipopolysaccharide	639064		decreases MAT activity in vivo
2.5.1.6	Rattus norvegicus		bacterial lipopolysaccharide	639073		results in the accumulation of nitrites and nitrates in serum and in the inactivation of MAT I/III
2.5.1.6	Saccharomyces cerevisiae		beta,gamma-methylene-ATP	639050	2691	
2.5.1.6	Saccharomyces cerevisiae		Br-	685773	285	93.33% residual activity at 5 mM
2.5.1.6	Saccharomyces cerevisiae		Ca2+	685773	18	86.36% residual activity at 5 mM
2.5.1.6	Rattus norvegicus		carbon tetrachloride	639073	5673	depletion of glutathione levels reduces MAT I/III activities in vivo
2.5.1.6	Saccharomyces cerevisiae		CH3COO-	685773	44	92.25% residual activity at 5 mM
2.5.1.6	Saccharomyces cerevisiae		Cl-	685773	134	85.27% residual activity at 5 mM
2.5.1.6	Sulfolobus solfataricus		CTP	639048	56	; 20 mM, 37% inhibition, S-adenosylmethionine synthetase B; 20 mM, 40% inhibition, S-adenosylmethionine synthetase A
2.5.1.6	Saccharomyces cerevisiae		CTP	639050	56	
2.5.1.6	Catharanthus roseus		CTP	639063	56	60-70% inhibition with 5 mM; 60-70% inhibition with 5 mM; 60-70% inhibition with 5 mM
2.5.1.6	Saccharomyces cerevisiae		Cu2+	685773	28	25.74% residual activity at 5 mM
2.5.1.6	Rattus norvegicus		Cu2+	686024	28	isozyme subunit MATalpha2 is inhibited by 0.25 mM Cu2+ in the presence or absence of dithiothreitol, strong reduction in MAT2B gene expression induced by Cu2+ (60%), copper effects can only be prevented by buthionine sulfoximine, whereas N-acetylcysteine and neocuproine are ineffective
2.5.1.6	Saccharomyces cerevisiae		Cu2+	706910	28	
2.5.1.6	Trypanosoma brucei brucei		cycloleucine	639046	5440	
2.5.1.6	Sulfolobus solfataricus		cycloleucine	639048	5440	25 mM, 56% inhibition, S-adenosylmethionine synthetase A; inhibits only at sub saturating concentrations of methionine
2.5.1.6	Mycobacterium smegmatis		cycloleucine	658351	5440	10 mM, 25.8% inhibition
2.5.1.6	Cryptosporidium parvum		cycloleucine	658771	5440	competitive
2.5.1.6	Homo sapiens		cycloleucine	681558	5440	1-aminocyclopentane-1-carboxylic acid, specific MAT inhibitor
2.5.1.6	Trypanosoma brucei brucei		D-methionine	639046	743	
2.5.1.6	Saccharomyces cerevisiae		dGTP	639050	194	
2.5.1.6	Escherichia coli		diimidotriphosphate	658062	37196	mechanism
2.5.1.6	Rattus norvegicus		Dimethylsulfoxide	639043, 639044	702	weak inhibition of liver isoenzyme
2.5.1.6	Trypanosoma brucei brucei		Dimethylsulfoxide	639046	702	
2.5.1.6	Homo sapiens		Dimethylsulfoxide	639052	702	
2.5.1.6	Rattus norvegicus		Dimethylsulfoxide	639054	702	slight inhibition of gamma isoenzyme from kidney
2.5.1.6	Rattus norvegicus		Dimethylsulfoxide	639039, 639058	702	
2.5.1.6	Rattus norvegicus		diphosphate	639039	13	individually a weak inhibitor, in combination with phosphate there is a marked synergistic effect
2.5.1.6	Sulfolobus solfataricus		diphosphate	639048	13	; 20 mM, 30% inhibition, S-adenosylmethionine synthetase A; 20 mM, 49% inhibition, S-adenosylmethionine synthetase B
2.5.1.6	Saccharomyces cerevisiae		diphosphate	639050	13	
2.5.1.6	Homo sapiens		diphosphate	639052	13	
2.5.1.6	Rattus norvegicus		diphosphate	639053	13	inhibits high-MW isoenzyme, no effect on low-MW enzyme
2.5.1.6	Escherichia coli		diphosphate	639045, 639056	13	
2.5.1.6	Leishmania infantum		diphosphate	639075	13	inhibition for S-adenosylmethionine and L-methonine
2.5.1.6	Saccharomyces cerevisiae		DL-2-Amino-trans-4-hexenoic acid	639051	64434	
2.5.1.6	Trypanosoma brucei brucei		DL-Ethionine	639046	3803	
2.5.1.6	Saccharomyces cerevisiae		EDTA	706910	223	
2.5.1.6	Homo sapiens		ethanol	681558	65	25 mM ethanol substantially decreases the enzymatic activity of MAT II
2.5.1.6	Catharanthus roseus		Ethionine	639063	3803	32-38% inhibition with 5 mM; 32-38% inhibition with 5 mM; 32-38% inhibition with 5 mM
2.5.1.6	Saccharomyces cerevisiae		F-	685773	158	88.84% residual activity at 5 mM
2.5.1.6	Saccharomyces cerevisiae		Fe2+	685773	23	59.22% residual activity at 5 mM
2.5.1.6	Homo sapiens		Fumarylacetoacetate	639073	10432	reduces MAT I/III activity
2.5.1.6	Saccharomyces cerevisiae		GDP	639050	49	
2.5.1.6	Rattus norvegicus		glycerol	639054	129	inhibits kidney isoenzyme gamma
2.5.1.6	Saccharomyces cerevisiae		GSH	685773	41	causes complete inactivation of the enzyme
2.5.1.6	Sulfolobus solfataricus		GTP	639048	35	; 20 mM, 50% inhibition, S-adenosylmethionine synthetase B; 20 mM, 56% inhibition, S-adenosylmethionine synthetase A
2.5.1.6	Saccharomyces cerevisiae		GTP	639050, 639051	35	
2.5.1.6	Escherichia coli		GTP	639056	35	
2.5.1.6	Catharanthus roseus		GTP	639063	35	not accepted as a substrate but inhibits the reaction in the presence of ATP, 70-80% inhibition with 5 mM; not accepted as a substrate but inhibits the reaction in the presence of ATP, 70-80% inhibition with 5 mM; not accepted as a substrate but inhibits the reaction in the presence of ATP, 70-80% inhibition with 5 mM
2.5.1.6	Methanocaldococcus jannaschii		GTP	639074	35	competitive with respect to ATP and noncompetitive with L-methionine
2.5.1.6	Rattus norvegicus		hydrogen peroxide	639064	20	inactives CHO cells-MAT, prevented by desferoxamine. Time- and dose-dependent inactivation of MAT I/III, activity recovered by addition of glutathione
2.5.1.6	Homo sapiens		hydrogen peroxide	639073	20	reduces MAT I/III activity
2.5.1.6	Rattus norvegicus		hydrogen peroxide	639073	20	
2.5.1.6	Saccharomyces cerevisiae		I-	685773	422	87.91% residual activity at 5 mM
2.5.1.6	Rattus norvegicus		K+	639039	37	above 50 mM
2.5.1.6	Pisum sativum		K+	639040	37	
2.5.1.6	Homo sapiens		K+	639041	37	
2.5.1.6	Rattus norvegicus		K+	639041	37	
2.5.1.6	Saccharomyces cerevisiae		K+	685773	37	85.27% residual activity at 5 mM
2.5.1.6	Saccharomyces cerevisiae		L-2-Amino-4-hexynoic acid	639051	64717	
2.5.1.6	Trypanosoma brucei brucei		L-2-Amino-4-methoxy-cis-but-3-enoic acid	639046	13403	
2.5.1.6	Mus musculus		L-2-Amino-4-methoxy-cis-but-3-enoic acid	639047	13403	
2.5.1.6	Mus musculus		L-2-Amino-4-methylthio-cis-but-3-enoic acid	639047	20425	
2.5.1.6	Rattus norvegicus		L-buthionine-(S,R)-sulfoximine	639064	1541	inhibits glutathione synthesis and this decreases MAT activity in vivo. Prevented by the administration of glutathione-ethyl ester
2.5.1.6	Rattus norvegicus		L-buthionine-(S,R)-sulfoximine	639073	1541	inactivates hepatic MAT, prevented by the administration of glutathione-ethyl ester
2.5.1.6	Mycobacterium smegmatis		L-ethioninamide	658351	80871	10 mM, 23.9% inhibition
2.5.1.6	Methanocaldococcus jannaschii		L-ethionine	639074	1094	competitive with respect to methionine for S-adenosylmethionine formation and noncompetitive with respect to ATP
2.5.1.6	Mycobacterium smegmatis		L-ethionine	658351	1094	10 mM, 20.4% inhibition
2.5.1.6	Crypthecodinium cohnii		L-ethionine	685831	1094	1.2 mM leads to significant reduction of AdoMetS protein expression
2.5.1.6	Homo sapiens		L-methionine	639052	83	
2.5.1.6	Rattus norvegicus		L-methionine	639068	83	ATP and methionine act as a switch between two different MAT III isoforms
2.5.1.6	Rattus norvegicus		L-methionine	686024	83	30% reduction in total activity is detected at 5 mM L-methionine; 30% reduction in total activity is detected at 5 mM L-methionine; 30% reduction in total activity is detected at 5 mM L-methionine
2.5.1.6	Mycobacterium smegmatis		L-methionine methyl ester	658351	7381	10 mM, 17.7% inhibition
2.5.1.6	Mycobacterium smegmatis		L-Methionine sulfone	658351	2213	10 mM, 9.2% inhibition
2.5.1.6	Mycobacterium smegmatis		L-methionine sulfoxide	658351	3340	10 mM, 4.0% inhibition
2.5.1.6	Mycobacterium smegmatis		L-methionine sulfoximine	658351	1989	10 mM, 12.6% inhibition
2.5.1.6	Mycobacterium smegmatis		L-Penicillamine	658351	2386	10 mM, 15.0% inhibition
2.5.1.6	Saccharomyces cerevisiae		Li+	685773	142	81.40% residual activity at 5 mM
2.5.1.6	Streptomyces spectabilis		methanol	684597	78	2.4% methanol depresses methionine adenosyltransferase specific activity, this effect is not observed with 0.8% methanol
2.5.1.6	Mycobacterium smegmatis		methylthio propionaldehyde	658351	28865	10 mM, 18.4% inhibition
2.5.1.6	Mus musculus		methylthioadenosine	686924	335	1 mM downregulates MAT2A expression
2.5.1.6	Homo sapiens		methylthioadenosine	687010	335	lowers expression of MAT2A and MAT2beta
2.5.1.6	Trypanosoma brucei brucei		Mg2+	639046	25	inhibitory above 8.5 mM
2.5.1.6	Trypanosoma brucei brucei		Mn2+	639046	26	inhibition in presence of Mg2+
2.5.1.6	Saccharomyces cerevisiae		Mn2+	685773	26	73.49% residual activity at 5 mM
2.5.1.6	Sulfolobus solfataricus		more	639048		S-adenosyl(5')-3-methylthiopropylamine does not inhibit
2.5.1.6	Homo sapiens		more	639052		overview of the regulatory properties, effect of L-methionine analogues and influence of L-methionine concentration on activating and inhibiting effects, effect of tripolyphosphate and p-hydroxymercuribenzoate
2.5.1.6	Catharanthus roseus		more	639063		addition of reducing agents has no effect; addition of reducing agents has no effect; addition of reducing agents has no effect
2.5.1.6	Rattus norvegicus		more	639064		MAT is inactivated after 6 h of incubation in hypoxia (3% O2) in rat hepatocytes, prevented by NG-monomethyl-L-arginine methyl ester. Hepatic MAT s a sensible target for free radicals in vivo
2.5.1.6	Homo sapiens		more	639073		reactive oxygen and nitrogen species induce the inactivation of MAT I/III
2.5.1.6	Methanocaldococcus jannaschii		more	639074		no inhibition with cycloleucine, L-homocysteine, L-norleucine, L-cis-2-amino-4-methoxy-3-butenoic acid, S-adenosylhomocysteine, 5'-methylthioadenosine, sinefungin
2.5.1.6	Mycobacterium smegmatis		more	658351		not inhibitory: (R)-methioninol, 1,3,7-trimethyluric acid, 6-methylpurine
2.5.1.6	Saccharomyces cerevisiae		more	685773		no effect on activity at 0.1 mM Ni2+
2.5.1.6	Saccharomyces cerevisiae W303		more	689251		overexpression of yeast AdoMet synthase plus cap guanine-N7 methyltransferase affords greater resistance to sinefungin than either enzyme alone
2.5.1.6	Leishmania donovani		N-ethylmaleimide	639078	46	time-dependent inactivation of both MAT activities
2.5.1.6	Trypanosoma brucei brucei		Na+	639046	55	in presence of Mg2+
2.5.1.6	Saccharomyces cerevisiae		Na+	685773	55	80.16% residual activity at 5 mM
2.5.1.6	Rattus norvegicus		nitric oxide	639068	240	two MAT III isoforms, one with low tripolyphosphatase activity that is insensitive to NO and another with high tripolyphosphatase activity that is inhibited by NO
2.5.1.6	Rattus norvegicus		nitric oxide	639073	240	inactivates hepatic MAT
2.5.1.6	Arabidopsis thaliana		nitrosoglutathione	674742	753	reversibly inhibits the isozyme MAT1 via NO binding to Cys114, no inhibition of isozymes MAT2 and MAT3, molecular mechanism for S-nitrosylation of the enzyme
2.5.1.6	Mycobacterium smegmatis		O-methylguanine	658351	80875	10 mM, 60.3% inhibition
2.5.1.6	Homo sapiens		p-chloromercuribenzoate	639052	40	
2.5.1.6	Rattus norvegicus		p-chloromercuribenzoate	639054	40	alpha and beta isoenzymes completely inhibited, gamma isoenzyme slightly inhibited
2.5.1.6	Homo sapiens		p-chloromercuribenzoate	639073	40	reduces MAT I/III activity
2.5.1.6	Rattus norvegicus		phosphate	639039	12	individually a weak inhibitor, in combination with diphosphate there is a synergistic inhibitory effect
2.5.1.6	Sulfolobus solfataricus		phosphate	639048	12	; 10 mM, 19% inhibition, S-adenosylmethionine synthetase B; 10 mM, 45% inhibition, S-adenosylmethionine synthetase A
2.5.1.6	Saccharomyces cerevisiae		phosphate	639050	12	
2.5.1.6	Homo sapiens		phosphate	639052	12	
2.5.1.6	Escherichia coli		phosphate	639045, 639056	12	
2.5.1.6	Methanocaldococcus jannaschii		phosphate	639074	12	competitive toward both ATP and methionine
2.5.1.6	Catharanthus roseus		putrescine	639063	144	15-25% inhibition with 5 mM; 15-25% inhibition with 5 mM; 15-25% inhibition with 5 mM
2.5.1.6	Leishmania infantum		S-adenosyl-L-ethionine	639075	2861	
2.5.1.6	Trypanosoma brucei brucei		S-adenosyl-L-homocysteine	639046	34	
2.5.1.6	Sulfolobus solfataricus		S-adenosyl-L-homocysteine	639048	34	not inhibitory
2.5.1.6	Leishmania infantum		S-adenosyl-L-homocysteine	639075	34	
2.5.1.6	Homo sapiens		S-adenosyl-L-methionine	675169	22	feedback inhibition of isozyme MAT II
2.5.1.6	Pisum sativum		S-adenosylmethionine	639040	22	
2.5.1.6	Rattus norvegicus		S-adenosylmethionine	639043, 639044	22	inhibition of rat kidney enzyme and rat liver MAT-II, weak inhibition of rat liver MAT-I
2.5.1.6	Trypanosoma brucei brucei		S-adenosylmethionine	639046	22	
2.5.1.6	Sulfolobus solfataricus		S-adenosylmethionine	639048	22	inhibits the A form but not the B form; non-competitive, S-adenosylmethionine synthetase A; slight inhibition of S-adenosylmethionine synthetase B
2.5.1.6	Homo sapiens		S-adenosylmethionine	639052	22	non competitive with ATP at low methionine concentration
2.5.1.6	Rattus norvegicus		S-adenosylmethionine	639053	22	above 0.3 mM inhibits both high-MW and low-MW isoenzymes
2.5.1.6	Escherichia coli		S-adenosylmethionine	639045, 639056	22	
2.5.1.6	Methanocaldococcus jannaschii		S-adenosylmethionine	639074	22	noncompetitive inhibitor with respect to ATP and methionine
2.5.1.6	Leishmania infantum		S-adenosylmethionine	639075	22	more than 50% inhibition at 1 mM
2.5.1.6	Leishmania donovani		S-adenosylmethionine	639078	22	non competitive inhibition
2.5.1.6	Mus musculus		S-adenosylmethionine	686924	22	5 mM downregulates MAT2A expression
2.5.1.6	Homo sapiens		S-adenosylmethionine	687010	22	lowers expression of MAT2A and MAT2beta
2.5.1.6	Escherichia coli		S-carbamylcysteine	639045, 639056	32992	competitive with methionine
2.5.1.6	Rattus norvegicus		S-nitrosoglutathione	639068	753	inhibits S-adenosylmethionine sinthetase activity
2.5.1.6	Rattus norvegicus		S-nitrosoglutathione	639073	753	inactivates MATI/III by 70%
2.5.1.6	Rattus norvegicus		S-nitrosoglutathione monoethyl ester	639073	74750	inactivates
2.5.1.6	Rattus norvegicus		S-nitrosylated glutathione	639064	74751	rapid and dose-dependent loss of enzymatic activity of MAT I/III
2.5.1.6	Saccharomyces cerevisiae		S-Trifluoromethyl-L-homocysteine	639051	2790	
2.5.1.6	Trypanosoma brucei brucei		seleno-L-methionine	639046	6233	
2.5.1.6	Rattus norvegicus		SIN-1	639064	74762	rapid and dose-dependent loss of enzymatic activity of MAT I/III
2.5.1.6	Trypanosoma brucei brucei		Sodium diphosphate	639046	1943	
2.5.1.6	Catharanthus roseus		spermidine	639063	140	15-34% inhibition with 5 mM; 15-34% inhibition with 5 mM; 15-34% inhibition with 5 mM
2.5.1.6	Catharanthus roseus		spermine	639063	177	30-40% inhibition with 5 mM; 30-40% inhibition with 5 mM; 30-40% inhibition with 5 mM
2.5.1.6	Sulfolobus solfataricus		Tetrapolyphosphate	639048	2402	; 10 mM, 40% inhibition, S-adenosylmethionine synthetase B; 10 mM, 50% inhibition, S-adenosylmethionine synthetase A
2.5.1.6	Saccharomyces cerevisiae		Tetrapolyphosphate	639050	2402	
2.5.1.6	Escherichia coli		tripolyphosphate	639045	596	
2.5.1.6	Sulfolobus solfataricus		tripolyphosphate	639048	596	1.0 mM, 57% inhibition, S-adenosylmethionine synthetase A; 1.0 mM, 62% inhibition, S-adenosylmethionine synthetase B
2.5.1.6	Saccharomyces cerevisiae		tripolyphosphate	639050	596	
2.5.1.6	Homo sapiens		tripolyphosphate	639052	596	competitive with ATP and non competitive with L-methionine
2.5.1.6	Rattus norvegicus		tripolyphosphate	639054	596	activation or inhibition, depending on isoenzyme, S-adenosylmethionine and tripolyphosphate concentration
2.5.1.6	Escherichia coli		tripolyphosphate	639056	596	competitive with ATP
2.5.1.6	Bos taurus		tripolyphosphate	639057	596	
2.5.1.6	Catharanthus roseus		tripolyphosphate	639063	596	strong inhibitor; strong inhibitor; strong inhibitor
2.5.1.6	Leishmania infantum		tripolyphosphate	639075	596	competitive with ATP; non competitive with L-methionine
2.5.1.6	Saccharomyces cerevisiae		TTP	639050	137	
2.5.1.6	Mycobacterium smegmatis		Uric acid	658351	570	10 mM, 45.6% inhibition
2.5.1.6	Sulfolobus solfataricus		UTP	639048	61	
2.5.1.6	Saccharomyces cerevisiae		UTP	639050	61	
2.5.1.6	Mycobacterium smegmatis		xanthine	658351	208	10 mM, 35.4% inhibition
2.5.1.6	Saccharomyces cerevisiae		Zn2+	685773	19	22.17% residual activity at 5 mM
2.1.1.13	Homo sapiens	aquacob(III)alamin		703638	3558	the addition of 0.05 mM aquacob(III)alamin to the crude extract results in an about 13fold increase in activity which is not greatly affected by the addition of cytochrome P450 reductase or reductase domain of neuronal nitric oxide synthase
2.1.1.13	Rattus norvegicus	cadaverine		441207	444	up to 40% stimulation at 1 mm
2.1.1.13	Escherichia coli	cyanocobalamin		441196	692	supports methyltransferase in extracts of animal tissues and Escherichia coli
2.1.1.13	Homo sapiens	cyanocobalamin		441196	692	supports methyltransferase in extracts of animal tissues and Escherichia coli
2.1.1.13	Rattus norvegicus	cyanocobalamin		441196	692	supports methyltransferase in extracts of animal tissues and Escherichia coli
2.1.1.13	Escherichia coli	K+		441179	37	at 67 mM 1.4 fold activity
2.1.1.13	Escherichia coli	Li+		441179	142	at 67 mM, 1.3fold activity
2.1.1.13	Homo sapiens	methionine synthase reductase		703638		restores the activity of human methionine synthase through reductive methylation of methionine synthase-bound cob(II)alamin. Oxidized methionine synthase reductase does not reactivate methionine synthase, the presence of methionine synthase reductase along with AqCbl or MeCbl causes a dramatic increase in methionine synthase activity (7fold for AqCbl and 20fold for MeCbl) as compared to the cofactor alone
2.1.1.13	Homo sapiens	methylcob(III)alamin		703638	73024	the addition of 0.05 mM methylcob(III)alamin to the crude extract results in an about 6fold increase in activity which is not greatly affected by the addition of cytochrome P450 reductase or reductase domain of neuronal nitric oxide synthase
2.1.1.13	Escherichia coli	Na+		441179	55	at 67 mM 1.5 fold activity
2.1.1.13	Homo sapiens	NADPH		703638	5	reactivation of methionine synthase is dependent on NADPH concentration in a hyperbolic manner with maximum activity at about 0.2 mM
2.1.1.13	Escherichia coli	NH4+		441179	50	at 67 mM 1.5 fold activity
2.1.1.13	Rattus norvegicus	putrescine		441207	144	up to 50% stimulation at 1 mm
2.1.1.13	Escherichia coli	S-adenosyl-L-methionine		659993	22	required
2.1.1.13	Escherichia coli	S-adenosylmethionine		441179	22	at about 0.0001 mM
2.1.1.13	Rattus norvegicus	spermidine		441207	140	up to 2.5 fold stimulation at 1 mm
2.1.1.13	Rattus norvegicus	spermine		441207	177	up to 4 fold stimulation at 1 mm
2.1.1.13	Escherichia coli	TrisHCl		441179	1644	at 67 mM 1.2 fold activity
2.1.1.13	Chlorocebus aethiops	vitamin B12		441212	692	2 to 14 fold stimulation after addition to media due to posttranscriptional regulation
2.1.1.13	Homo sapiens	vitamin B12		441212	692	2 to 14 fold stimulation after addition to media due to posttranscriptional regulation
2.1.1.13	Rattus norvegicus		1-methyl-5-amino-benzimidazole	673596	41393	IC50: more than 0.15 mM
2.1.1.13	Rattus norvegicus		1-methyl-5-nitro-7-methoxybenzimidazole	673596	41396	IC50: 0.15 mM
2.1.1.13	Rattus norvegicus		1-methyl-5-nitro-benzimidazole	673596	41392	IC50: more than 0.15 mM
2.1.1.13	Rattus norvegicus		1-methylbenzimidazole	673596	41389	IC50: more than 0.15 mM
2.1.1.13	Rattus norvegicus		2,1,3-benzothiadiazole	673596	41398	IC50: more than 0.15 mM
2.1.1.13	Rattus norvegicus		2-nitro-1H-benzimidazole	673596	24281	IC50: 0.12 mM
2.1.1.13	Rattus norvegicus		4-amino-2,1,3-benzothiadiazole	673596	41399	IC50: more than 0.15 mM
2.1.1.13	Rattus norvegicus		4-nitro-2,1,3-benzothiadiazole	673596	7688	IC50: 0.08 mM
2.1.1.13	Rattus norvegicus		5-amino-7-methoxy-N1-methylbenzimidazole	673596	41397	IC50: 0.095 mM
2.1.1.13	Rattus norvegicus		5-amino-7-methoxybenzimidazole	673596	41395	IC50: more than 0.15 mM
2.1.1.13	Rattus norvegicus		5-aminobenzimidazole	673596	41390	IC50: more than 0.15 mM
2.1.1.13	Rattus norvegicus		5-methoxybenzimidazole	673596	41391	IC50: more than 0.15 mM
2.1.1.13	Rattus norvegicus		5-nitro-7-methoxybenzimidazole	673596	41394	IC50: 0.1 mM
2.1.1.13	Rattus norvegicus		benzimidazole	673596	1308	IC50: more than 0.15 mM
2.1.1.13	Homo sapiens		ZL-031	684467	46839	i.e. diethyl N-[4-[(2-[2,4-diamino-5-(2,3-dibromopropane)-5,6,7,8-tetrahydropyrido(3,2-d)pyrimidin-6-yl]methyl)amino]3-bromo-benzoyl]L-glutamate
2.1.1.13	Homo sapiens		ZL-033	684467	46629	i.e. N-[4-[(2-[2,4-diamino-5-(2,3-dibromopropane)-5,6,7,8-tetrahydropyrido(3,2-d)pyrimidin-6-yl]methyl)amino]3-bromo-benzoyl]L-glutamic acid
2.1.2.11	Escherichia coli		3-Methyl-2-butanone	485700	7441	5 mM, 27% inhibition
2.1.2.11	Escherichia coli		coenzyme A	485700, 485701	10	above 1 mM
2.1.2.11	Escherichia coli		D-valine	485700	1427	5 mM, 16% inhibition
2.1.2.11	Escherichia coli		formaldehyde	485700	124	0.8 mM, partial inhibition
2.1.2.11	Escherichia coli		formaldehyde	485701	124	0.8 mM, partial inhibition; forward reaction
2.1.2.11	Escherichia coli		Isovalerate	485700	2843	5 mM, 39% inhibition
2.1.2.11	Escherichia coli		L-valine	485700	217	5 mM, 23% inhibition
2.1.2.11	Escherichia coli		more	485700		not inactivated by borohydride reduction in the presence of excess substrates
2.1.2.11	Mycobacterium tuberculosis		more	485710		not inhibited by methylenetetrahydrofolate, i.e. equimolar formaldehyde and tetrahydrofolate, at concentrations up to 2 mM
2.1.2.11	Escherichia coli		Pantoate	485700, 485701	1878	0.05 mM or above
2.1.2.11	Escherichia coli		pantothenate	485700, 485701	1139	0.5 mM or above
2.1.2.11	Escherichia coli		pyruvate	485700	29	5 mM, 38% inhibition
2.1.2.11	Escherichia coli		tetrahydrofolate	485700	184	0.38 mM, partial inhibition
2.1.2.11	Escherichia coli		tetrahydrofolate	485701	184	0.38 mM, partial inhibition; forward reaction
3.5.4.9	Homo sapiens	2',5'-ADP		209736	1457	micromolar concentrations
3.5.4.9	Homo sapiens	2',5'-ADP		654797	1457	stimulates the cyclohydrolase reverse reaction, 2'-phosphate is involved
3.5.4.9	Homo sapiens	2',5'-ADP		701402	1457	analog of NADP+ does not stimulate the reverse cyclohydrolase activity; the analog of NADP+ stimulates the reverse cyclohydrolase activity by more than 2fold
3.5.4.9	Homo sapiens	5'-ADP		701402	8	analog of NADP+ does not stimulate the reverse cyclohydrolase activity
3.5.4.9	Homo sapiens	phosphate		209738	12	
3.5.4.9	Photobacterium phosphoreum	phosphate		209738	12	
3.5.4.9	Homo sapiens		2',5'-ADP	209736	1457	millimolar concentrations
3.5.4.9	Leishmania major		5,6,7,8-tetrahydro-N5,N10-carbonylfolic acid	720406	55532	i.e. LY354899
3.5.4.9	Pisum sativum		aminopterin	209728	769	slightly retards enzyme activity
3.5.4.9	Aedes aegypti		Cu2+	209722	28	
3.5.4.9	Bos taurus		Cu2+	209722	28	
3.5.4.9	Leishmania major		di-2'-deoxyadenosine 5',5''-P1,P5,alpha,beta-methylene-delta,epsilon-methylene-pentaphosphate-gamma-borano	720406	5959	
3.5.4.9	Leishmania major		di-2'-deoxyadenosine 5',5''-P1,P5,alpha,beta-methylene-gamma,delta-methylene-tetraphosphate	720406		
3.5.4.9	Leishmania major		diadenosine 5',5''-P1,P5,alpha,beta-methylene-delta,epsilon-methylene-pentaphosphate-gamma-borano	720406	5958	
3.5.4.9	Pisum sativum		dihydrofolate	209737	173	
3.5.4.9	Aedes aegypti		Fe2+	209722	23	
3.5.4.9	Bos taurus		Fe2+	209722	23	
3.5.4.9	Sus scrofa		folate	209726	1001	competitive inhibition
3.5.4.9	Pisum sativum		folic acid	209737	1001	
3.5.4.9	Pisum sativum		methotrexate	209728	213	slightly retards enzyme activity
3.5.4.9	Aedes aegypti		Mg2+	209722	25	
3.5.4.9	Bos taurus		Mg2+	209722	25	
3.5.4.9	Leishmania donovani		N5,N10-carbonyl tetrahydrofolate	712978	12669	; 
3.5.4.9	Leishmania infantum		N5,N10-carbonyl tetrahydrofolate	712978	12669	
3.5.4.9	Leishmania major		N5,N10-carbonyl tetrahydrofolate	712978	12669	
3.5.4.9	Sus scrofa		NADP+	209736	6	
3.5.4.9	Pisum sativum		NADP+	209737	6	
3.5.4.9	Homo sapiens		NADP+	209736, 701402	6	
3.5.4.9	Aedes aegypti		p-chloromercuribenzoate	209722	40	
3.5.4.9	Leishmania major		P1,P4-bis(5'-adenosyl)-alpha,beta-gamma,delta-bismethylene-tetraphosphate	720406	6006	
3.5.4.9	Pisum sativum		Pyridine nucleotide	209737		
3.5.4.9	Aedes aegypti		suramin	209722	568	
3.5.4.9	Aedes aegypti		Zn2+	209722	19	
3.5.4.9	Bos taurus		Zn2+	209722	19	
4.2.3.4	Thermus thermophilus	NAD+		666871	4	binding on the N-terminal alpha/beta domain
4.2.3.4	Camellia sinensis		(-)-epicatechin gallate	5467	3505	
4.2.3.4	Camellia sinensis		(-)-epigallocatechin gallate	5467	936	
4.2.3.4	Neurospora crassa		1,10-phenanthroline	137628	58	
4.2.3.4	Escherichia coli		3-deoxy-D-arabino-heoptulosonic acid	137635	63315	
4.2.3.4	Escherichia coli		3-deoxy-D-arabino-heptulosonic acid 7-homophosphate	137633		
4.2.3.4	Escherichia coli		3-deoxy-D-arabino-heptulosonic acid 7-phosphonate	137619	3060	
4.2.3.4	Pisum sativum		3-deoxy-D-arabino-heptulosonic acid 7-phosphonate	137620	3060	
4.2.3.4	Escherichia coli		3-deoxy-D-arabino-heptulosonic acid-2-O-methylglycoside 7-phosphate	137635		
4.2.3.4	Escherichia coli		alpha-(2,6-anhydro-3-deoxy-D-arabino-heptulopyranosid)onate 7-phosphate	137619	30590	
4.2.3.4	Pisum sativum		alpha-(2,6-anhydro-3-deoxy-D-arabino-heptulopyranosid)onate 7-phosphate	137620	30590	
4.2.3.4	Escherichia coli		alpha-(2,6-anhydro-3-deoxy-D-arabino-heptulopyranosid)onate 7-phosphonate	137619	67049	
4.2.3.4	Escherichia coli		beta-(2,6-anhydro-3-deoxy-D-arabino-heptulopyranosid)onate 7-phosphate	137619	67070	
4.2.3.4	Neurospora crassa		bistrispropane	137628	27291	
4.2.3.4	Aspergillus nidulans		carabaphosphonate	137643	67076	
4.2.3.4	Helicobacter pylori		CBP	690739	15283	
4.2.3.4	Bacillus subtilis		Cd2+	137636	48	
4.2.3.4	Neurospora crassa		Cu2+	137628	28	
4.2.3.4	Bacillus subtilis		Cu2+	137636	28	
4.2.3.4	Escherichia coli		D-2-cis-hydroquinic acid	137635	67102	
4.2.3.4	Escherichia coli		D-gluco-3-heptulosonate 7-phosphate	137633	67109	
4.2.3.4	Escherichia coli		D-gluco-heptulosonate 7-homophosphonate	137633	67110	
4.2.3.4	Escherichia coli		D-gluco-heptulosonate 7-phosphonate	137633	67111	
4.2.3.4	Aspergillus nidulans		diethyl dicarbonate	137641	265	
4.2.3.4	Neurospora crassa		dithiothreitol	137628	42	
4.2.3.4	Neurospora crassa		EDTA	137628	223	
4.2.3.4	Vigna mungo		EDTA	137632	223	
4.2.3.4	Bacillus subtilis		EDTA	137636	223	
4.2.3.4	Sorghum sp.		EDTA	137637	223	
4.2.3.4	Aspergillus nidulans		EDTA	137641	223	
4.2.3.4	Mycobacterium tuberculosis		EDTA	716188	223	0.1 mM, complete loss of activity. Addition of Co2+, Zn2+ and Ca2+ leads to, respectively, full, 43% and 38% recovery of the enzyme activity
4.2.3.4	Escherichia coli		EDTA	718818	223	treatment of the Co2+-holoenzyme with EDTA in the absence of substrate results in the rapid loss of catalytic activity
4.2.3.4	Pyrococcus furiosus		EDTA	722147	223	inactivates the enzyme, and enzyme activity is restored by several divalent metal ions including (in order of decreasing effectiveness) Cd2+, Co2+, Zn2+, and Mn2+
4.2.3.4	Escherichia coli		EGTA	137623	157	
4.2.3.4	Escherichia coli		epoxyshikimic acid	137635	64477	
4.2.3.4	Neurospora crassa		Fe2+	137628	23	
4.2.3.4	Camellia sinensis		gallic acid	5467	616	
4.2.3.4	Helicobacter pylori		HTS 11955	690739	15278	
4.2.3.4	Neurospora crassa		NADH	137628	3	
4.2.3.4	Bacillus subtilis		NADH	137636	3	
4.2.3.4	Sorghum sp.		NADH	137637	3	
4.2.3.4	Neurospora crassa		Ni2+	137628	36	
4.2.3.4	Helicobacter pylori		RH00573	690739	23369	
4.2.3.4	Escherichia coli		[(1R)-(1alpha,3beta,4alpha ,5beta)]-5-(2-phosphonoethyl)-1,3,4-trihydroxycyclohexane-1-carboxylic acid	718819		
4.2.3.4	Escherichia coli		[(1R)-(1alpha,3beta,4alpha,5beta)]-1,4,5-trihydroxy-3-(phosphonooxy)-cyclohexane-1-carboxylate	718819		
4.2.3.4	Escherichia coli		[(1R)-(1alpha,3beta,4alpha,5beta)]-5-(E)-(2-phosphonoethenyl)-1,3,4-trihydroxycyclohexane-1-carboxylic acid	718819		
4.2.3.4	Escherichia coli		[(1R)-(1alpha,3beta,4alpha,5beta)]-5-(phosphonomethyl)-l,3,4-trihydroxycyclohexane-1-carboxylic acid	718819		slow binding inhibitor
4.2.3.4	Escherichia coli		[(1R)-(1alpha,3beta,4alpha,5beta)]-5-(Z)-(2-phosphonoethenyl)-1,3,4-trihydroxycyclohexane-1-carboxylic acid	718819		
4.2.3.4	Escherichia coli		[(2R)-(2alpha,4beta,5alpha,6beta)]-6-(2-phosphonoethyl)-2,4,5-trihydroxytetrahydropyran-2-carboxylate	718819		
4.2.3.4	Escherichia coli		[(2R)-(2alpha,4beta,5alpha,6beta)]-6-(phosphonomethyl)-2,4,5-trihydroxytetrahydropyran-2-carboxylate	718819		
1.5.1.20	Mus musculus	A23187		687772	2366	treatment of cells results in increase in enzyme mRNA and protein
1.5.1.20	Mus musculus	homocysteine		687772	260	treatment of cells results in increase in enzyme mRNA and protein
1.5.1.20	Mus musculus	inositol-requiring enzyme-1		687772		the induction of MTHFR was also observed after overexpression of inositol-requiring enzyme-1
1.5.1.20	Mus musculus	more		687772		induction of MTHFR is observed after overexpression of inositol-requiring enzyme IRE1 and is inhibited by a dominant-negative mutant of IRE1. Tranfection of c-Jun and its activators LiCl and sodium valproate increase MTHFR expression, whereas inhibitor of c-Jun SP600125 reduces activation; transfection of c-Jun and two activators of c-Jun (LiCl and sodium valproate) increase MTHFR expression, MTHFR mRNA is up-regulated by endoplasmic reticulum stress
1.5.1.20	Arabidopsis sp.	S-adenosylmethionine		437724	22	stimulates
1.5.1.20	Mus musculus	thapsigargin		687772	1652	treatment of cells results in increase in enzyme mRNA and protein
1.5.1.20	Mus musculus	tunicamycin		687772	1243	treatment of cells results in increase in enzyme mRNA and protein
1.5.1.20	Mus musculus	Valproic acid		687925	1777	300 mg/kg treatment increases MTHFR promoter activity 2.5fold and MTHFR mRNA and protein 3.7fold
1.5.1.20	Rattus norvegicus		(+)-5-methyl-5,6,7,8-tetrahydropteroylpentaglutamate	437717	13103	inhibits at high concentrations
1.5.1.20	Sus scrofa		2,4-dihydroxyphenylacetic acid	392150	65904	at 0.01 M
1.5.1.20	Arabidopsis thaliana		5,10-methylenetetrahydrofolate	656085	336	substrate inhibition
1.5.1.20	Saccharomyces cerevisiae		5,10-methylenetetrahydrofolate	656085	336	substrate inhibition
1.5.1.20	Escherichia coli		5,10-methylenetetrahydrofolate	696353	336	
1.5.1.20	Sus scrofa		dicoumarol	392149	608	inhibits menadione reductase activity only
1.5.1.20	Ovis aries		diethyldicarbonate	392154	265	20 mM NADP+ and 20 mM NAD+ partially protected the enzyme against inactivation whereas 20 mM nicotinamide gives complete protection
1.5.1.20	Sus scrofa		dihydrofolate	392152	173	competitive with respect to 5,10-methylenetetrahydrofolate and uncompetitive with respect to NADPH
1.5.1.20	Sus scrofa		dihydrofolate	392155	173	
1.5.1.20	Sus scrofa		dihydropteroylhexaglutamate	392155	21796	
1.5.1.20	Sus scrofa		dihydropteroylpolyglutamate	392152		
1.5.1.20	Sus scrofa		dihydropteroylpolyglutamate	392155		most potent inhibitor is dihydropteroylhexaglutamate
1.5.1.20	Sus scrofa		folylpolyglutamate	392160		overview
1.5.1.20	Escherichia coli		LY309887	672154	7882	i.e. 6R-2,5-thienyl-5,10-dideazatetrahydrofolate monoglutamate
1.5.1.20	Saccharomyces cerevisiae		menadione	437727	212	inhibits enzyme activity in yeast extracts
1.5.1.20	Sus scrofa		Mersalyl	392149	1470	80% inhibition at 1 mM
1.5.1.20	Escherichia coli		methylenetetrahydrofolate	654771	727	
1.5.1.20	Ovis aries		more	392154		residues essential for enzyme activity: arginine, histidine, tryptophan
1.5.1.20	Escherichia coli		more	437715		vitamin B12 and methionine can repress enzyme biosynthesis
1.5.1.20	Arabidopsis sp.		more	437724		not inhibited by S-adenosylmethionine
1.5.1.20	Escherichia coli		more	437724		not inhibited by S-adenosylmethionine
1.5.1.20	Zea mays		more	437724		not inhibited by S-adenosylmethionine
1.5.1.20	Saccharomyces cerevisiae		more	437727		gene contains a putative S-adenosylmethionione binding sequence, that is inhibitory in eukaryotic MTHFR
1.5.1.20	Arabidopsis thaliana		more	656085		no inhibition by S-adenosyl-L-methionine, which is no feed-back regulator of the methyl group biosynthesis pathway in plants
1.5.1.20	Leishmania major		more	674719		not inhibitory: S-adenosyl-L-methionine, no substrate inhibition up to 0.25 mM
1.5.1.20	Homo sapiens		more	685995		inhibiting MTHFR with either antisense or siRNA decreases the viability of methionine-dependent transformed gastric cancer cells
1.5.1.20	Mus musculus		more	687772		inhibited by a dominant-negative mutant of inositol-requiring enzyme-1, a reported inhibitor of c-Jun (SP600125) and a dominant-negative derivative of c-Jun N-terminal kinase-1 reduce MTHFR activation
1.5.1.20	Homo sapiens		N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamyl-gamma-glutamyl-gamma-glutamylglutamic acid	702155	9950	
1.5.1.20	Homo sapiens		N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamylglutamic acid	702155	9949	
1.5.1.20	Homo sapiens		N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)glutamic acid	702155	213	
1.5.1.20	Homo sapiens		N-([5-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2,3-dihydrothiophen-2-yl]carbonyl)-4-methylideneglutamic acid	702155	5263	
1.5.1.20	Ovis aries		N-bromosuccinimide	392154	185	inactivates the enzyme by modification of tryptophan
1.5.1.20	Homo sapiens		N-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5264	
1.5.1.20	Homo sapiens		N-[4-[2-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5266	
1.5.1.20	Homo sapiens		N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2-fluorobenzoyl]-4-methylideneglutamic acid	702155	5265	
1.5.1.20	Homo sapiens		N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5928	
1.5.1.20	Homo sapiens		N-[4-[2-(2-amino-4-methylquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5262	
1.5.1.20	Sus scrofa		NADH	392149	3	substrate inhibition above 1 mM
1.5.1.20	Escherichia coli		NADH	654771	3	
1.5.1.20	Sus scrofa		NADPH	392158	5	100 mM
1.5.1.20	Sus scrofa		p-chloromercuribenzoate	392149	40	60% inhibition of the methylenetetrahydrofolate reductase activity at 0.04 mM, 83% inhibition of the menadione reductase activity at 0.04 mM
1.5.1.20	Ovis aries		Phenylglyoxal	392154	258	
1.5.1.20	Sus scrofa		Polyglutamate analogues	392152, 392158		
1.5.1.20	Saccharomyces cerevisiae		S-adenosyl-L-methionine	656085	22	feed-back regulation of the methyl group biosynthesis pathway in vivo, the chimeric mutant enzyme is insensitive to inhibition by S-adenosyl-L-methionine
1.5.1.20	Homo sapiens		S-adenosyl-L-methionine	676769	22	allosteric inhibition and control of phosphorylation
1.5.1.20	Sus scrofa		S-adenosylmethionine	392149	22	allosteric inhibition; inhibition partially reversed by S-adenosylhomocysteine
1.5.1.20	Sus scrofa		S-adenosylmethionine	392150, 392152, 392155	22	inhibition partially reversed by S-adenosylhomocysteine
1.5.1.20	Sus scrofa		S-adenosylmethionine	392156	22	effect on equilibrium between active and inactive form of enzyme
1.5.1.20	Homo sapiens		S-adenosylmethionine	392157	22	inhibition of the enzyme in crude extracts from fresh liver biopsies, but not after purification from cadaver liver
1.5.1.20	Sus scrofa		S-adenosylmethionine	392158	22	0.05 mM
1.5.1.20	Sus scrofa		S-adenosylmethionine	392160	22	inhibits both the reduction of the enzyme-bound flavin by 5-methyltetrahydrofolate and the reoxidation of reduced enzyme by 5,10-methylenetetrahydrofolate
1.5.1.20	Sus scrofa		S-adenosylmethionine	392164	22	allosteric inhibition
1.5.1.20	Rattus norvegicus		S-adenosylmethionine	437716	22	inhibitory effect at a physiological concentration, dependent on incubation temperature, binds to an allosteric regulatory site different from catalytic site, reversed by S-adenosylhomocysteine; in vivo feedback-inhibition
1.5.1.20	Rattus norvegicus		S-adenosylmethionine	437717	22	in vivo feedback-inhibition
1.5.1.20	Homo sapiens		S-adenosylmethionine	392164, 437721	22	
1.5.1.20	Homo sapiens		S-adenosylmethionine	437725	22	strong, reversible allosteric inhibition, prevented by S-adenosylhomocysteine
1.5.1.20	Sus scrofa		S-adenosylmethionine	726099	22	
1.5.1.20	Homo sapiens		tetrahydrofolate	392157	184	
6.3.4.18	Escherichia coli		1,1'-(imidazolidine-1,3-diyldimethanediyl)bis(1H-indole-2,3-dione)	702643	27029	; class II inhibitor
6.3.4.18	Escherichia coli		1-deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentitol	702643	18430	; noncompetitive, class III inhibitor
6.3.4.18	Escherichia coli		1-[(4-methylpiperazin-1-yl)methyl]-1H-indole-2,3-dione	702643	26694	; class II inhibitor
6.3.4.18	Escherichia coli		2-(2,3-dioxo-2,3-dihydro-1H-indol-1-yl)-N,N-diethylacetamide	702643	18429	; noncompetitive, class II inhibitor
6.3.4.18	Escherichia coli		2-hydroxy-2-[(4-methyl-1,2,5-oxadiazol-3-yl)amino]-1H-indene-1,3(2H)-dione	702643	27025	; class I inhibitor
6.3.4.18	Escherichia coli		5-(trifluoromethoxy)-1H-indole-2,3-dione	702643	26706	; class II inhibitor
6.3.4.18	Escherichia coli		5-bromo-1-(morpholin-4-ylmethyl)-1H-indole-2,3-dione	702643	26707	; class II inhibitor
6.3.4.18	Escherichia coli		5-bromo-1-([3-[(2,3-dioxo-2,3-dihydro-1H-indol-1-yl)methyl]imidazolidin-1-yl]methyl)-1H-indole-2,3-dione	702643		
6.3.4.18	Escherichia coli		5-[(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)carbamoyl]-4-(trifluoromethyl)pyridin-2-olate	702643	96965	class I inhibitor
6.3.4.18	Aspergillus clavatus		ATP	727030	7	substrate inhibition
6.3.4.18	Escherichia coli		ethyl 1-[(2,3-dioxo-2,3-dihydro-1H-indol-1-yl)methyl]piperidine-4-carboxylate	702643	26712	; class II inhibitor
6.3.4.18	Escherichia coli		ethyl 4-(2-[[(4-chlorophenyl)sulfonyl]methyl]-1,3-thiazol-4-yl)-1,2-oxazole-3-carboxylate	702643	27030	
6.3.4.18	Escherichia coli		ethyl 4-(2-[[(4-chlorophenyl)sulfonyl]methyl]-1,3-thiazol-4-yl)-5-methyl-1,2-oxazole-3-carboxylate	702643	53610	; class III inhibitor
6.3.4.18	Escherichia coli		more	702643		high-throughput screening for enzyme inhibitors, identification of inhibitor separated into three classes: class I contains compounds with an indenedione core. Class II contains an indolinedione group, and class III contains compounds that are structurally unrelated to other inhibitors in the group, overview
6.3.4.18	Escherichia coli		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-1,3-dimethyl-1H-pyrazole-5-carboxamide	702643	54916	
6.3.4.18	Escherichia coli		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-1-methyl-1H-pyrazole-5-carboxamide	702643	96964	class I inhibitor
6.3.4.18	Escherichia coli		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-2-methyl-1,3-thiazole-4-carboxamide	702643	27026	; class I inhibitor
6.3.4.18	Escherichia coli		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-4-methoxythiophene-3-carboxamide	702643	27028	; class I inhibitor
6.3.4.18	Escherichia coli		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-6-methoxy-4-(trifluoromethyl)pyridine-3-carboxamide	702643	54917	
6.3.4.18	Escherichia coli		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-9-oxo-9H-fluorene-4-carboxamide	702643	27027	; class I inhibitor
6.3.4.18	Escherichia coli		riboflavin	702643	298	
6.3.1.5	Bacillus subtilis		1-(4-benzyloxyphenoxy)-8-(2-guanidino-2-phenyl-1-ethyloxy)-octane	675318	41743	
6.3.1.5	Bacillus subtilis		1-(4-benzyloxyphenoxy)-8-(2-guanidino-3-phenyl-1-propyloxy)-octane	675318	41741	
6.3.1.5	Bacillus subtilis		1-(4-benzyloxyphenoxy)-8-(2-N,N,N-trimethylammonium-2-phenyl-1-ethyloxy)octane	675318	41739	
6.3.1.5	Bacillus subtilis		1-(4-benzyloxyphenoxy)-8-(2-N,N,N-trimethylammonium-3-phenyl-1-propyloxy)octane	675318	41737	
6.3.1.5	Bacillus subtilis		8-(4-benzyloxyphenoxy)-1-octyl 2-(N,N,N-trimethylammonium)-3-(1H-indol-3-yl)propionate	675318	41735	
6.3.1.5	Bacillus subtilis		8-(4-benzyloxyphenoxy)-1-octyl 2-(N,N,N-trimethylammonium)-3-(4-hydroxyphenyl)propionate	675318	41734	
6.3.1.5	Bacillus subtilis		8-(4-benzyloxyphenoxy)-1-octyl 2-(N,N,N-trimethylammonium)-3-phenylpropionate	675318	24350	
6.3.1.5	Escherichia coli		adenosine	953	116	
6.3.1.5	Bacillus subtilis		ampicillin	675318	171	
6.3.1.5	Bacillus subtilis		Ciprofloxacin	675318	932	
6.3.1.5	Bacillus subtilis		clotrimazole	675318	1133	
6.3.1.5	Escherichia coli		Decoyinine	951, 953	6147	
6.3.1.5	Bacillus subtilis		doxycycline	675318	2336	
6.3.1.5	Bacillus subtilis		Methicillin	675318	1770	
6.3.1.5	Escherichia coli		Mg2+	653053	25	slightly inhibiting above 5 mM
6.3.1.5	Escherichia coli		Mn2+	953	26	can satisfy the metal ion requirement at low concentrations, at high concentrations Mn2+ markedly inhibits
6.3.1.5	Bacillus subtilis		more	675318		clotrimazole does not inhibit in the presence of 0.01% Triton X-100
6.3.1.5	Bacillus subtilis		N-[8-(4-benzyloxyphenoxy)-1-octyl]-2-(N,N,N-trimethylammonium)-2-phenylacetamide	675318	41738	
6.3.1.5	Bacillus subtilis		N-[8-(4-benzyloxyphenoxy)-1-octyl]-2-(N,N,N-trimethylammonium)-3-phenylpropionamide	675318	41736	
6.3.1.5	Bacillus subtilis		N-[8-(4-benzyloxyphenoxy)-1-octyl]-2-guanidino-2-phenylacetamide	675318	41742	
6.3.1.5	Bacillus subtilis		N-[8-(4-benzyloxyphenoxy)-1-octyl]-2-guanidino-3-phenylpropionamide	675318	41740	
6.3.1.5	Escherichia coli		Psicofuranine	951, 953	13502	i.e. 9-D-psicofuranosyl-6-aminopurine, each substrate provides some protection
6.3.1.5	Bacillus subtilis		Rifampin	675318	30429	
6.3.1.5	Mycobacterium tuberculosis		Thrombin	653750		enzyme is highly susceptible too proteolytic cleavage
2.4.2.19	Cupriavidus necator	glycerol		638030	129	glycerol markedly activates enzyme activity at pH 6.1 and pH 6.5, inhibition above pH 7.0, inhibition is strongest at pH 9.0
2.4.2.19	Ricinus communis		2-Hydroxynicotinate	638016	19958	50% at 0.01 M
2.4.2.19	Sus scrofa		2-oxoglutarate	638021	32	1 mM, 60% inhibition
2.4.2.19	Sus scrofa		2-oxoglutarate	638028	32	1 mM, 55% inhibition
2.4.2.19	Homo sapiens		5-phospho-alpha-D-ribose 1-diphosphate	693620	147	substrate inhibition, mixed inhibition (competitive and non-competitive) above 0.3 mM 5-phospho-alpha-D-ribose 1-diphosphate
2.4.2.19	Sus scrofa		5-phosphoribosyl-1-diphosphate	638017	3894	inhibition at alkaline pH and at physiological pH, pH 7.4, but not at an acidic pH, competitive for quinolinate. In presence of 30% glycerol, both the kidney and liver enzyme are inhibited, even at acidic pH
2.4.2.19	Cupriavidus necator		5-phosphoribosyl-1-diphosphate	638030	3894	
2.4.2.19	Salmonella enterica subsp. enterica serovar Typhimurium		5-phosphoribosyl-1-diphosphate	638035	3894	
2.4.2.19	Sus scrofa		acetic acid	638028	44	26% inhibition
2.4.2.19	Sus scrofa		ADP	638015, 638018	8	2 mM, 25% inhibition
2.4.2.19	Cupriavidus necator		ADP	638030	8	1 mM, 12% inhibition
2.4.2.19	Sus scrofa		Ag+	638025	71	1 mM, complete inhibition
2.4.2.19	Lentinula edodes		Al3+	638013	229	
2.4.2.19	Sus scrofa		Al3+	638025	229	1 mM, 82.8% inhibition
2.4.2.19	Sus scrofa		AMP	638018	9	2 mM, 7% inhibition
2.4.2.19	Sus scrofa		aspartic acid	638021	91	1 mM, 23% inhibition
2.4.2.19	Sus scrofa		aspartic acid	638028	91	1 mM, 37% inhibition
2.4.2.19	Sus scrofa		ATP	638015	7	2 mM, 82% inhibition
2.4.2.19	Sus scrofa		ATP	638018	7	2 mM, 82% inhibition; inhibition is removed by raising Mg2+ concentrations
2.4.2.19	Cupriavidus necator		ATP	638030	7	1 mM, 22% inhibition; inhibition is completely recovered by raising Mg2+ concentration
2.4.2.19	Sus scrofa		Ba2+	638025	105	1 mM, 38.1% inhibition
2.4.2.19	Sus scrofa		Ca2+	638025	18	1 mM, 34.9% inhibition
2.4.2.19	Sus scrofa		Cd2+	638025	48	1 mM, 75.5% inhibition
2.4.2.19	Cupriavidus necator		Cd2+	638030	48	
2.4.2.19	Sus scrofa		CDP	638018	188	2 mM, 20% inhibition
2.4.2.19	Cupriavidus necator		CDP	638030	188	1 mM, 13% inhibition
2.4.2.19	Sus scrofa		Citric acid	638021	125	1 mM, 95% inhibition
2.4.2.19	Sus scrofa		Citric acid	638028	125	1 mM, 89% inhibition
2.4.2.19	Lentinula edodes		Cl-	638013	134	
2.4.2.19	Sus scrofa		Co2+	638025	21	1 mM, 65.2% inhibition
2.4.2.19	Cupriavidus necator		Co2+	638030	21	
2.4.2.19	Sus scrofa		Cr3+	638025	701	1 mM, 46.4% inhibition
2.4.2.19	Sus scrofa		CTP	638018	56	2 mM, 77% inhibition
2.4.2.19	Cupriavidus necator		CTP	638030	56	1 mM, 30% inhibition
2.4.2.19	Sus scrofa		Cu2+	638015	28	1 mM, 87% inhibition
2.4.2.19	Sus scrofa		Cu2+	638025	28	1 mM, 86.9% inhibition
2.4.2.19	Cupriavidus necator		Cu2+	638030	28	
2.4.2.19	Escherichia coli		D-fructose-1,6-diphosphate	638020	100	competitive with respect to 5-phosphoribosyl-1-diphosphate and noncompetitive with respect to quinolinate
2.4.2.19	Escherichia coli		diphosphate	638020	13	noncompetitive with respect to both 5-phosphoribosyl-1-diphosphate and quinolinate
2.4.2.19	Sus scrofa		dipicolinic acid	638018	1090	1 mM, 24% inhibition
2.4.2.19	Sus scrofa		dithiobis(2-nitrobenzoic acid)	638018	196	10 mM, 88.7% inhibition
2.4.2.19	Cupriavidus necator		dTDP	638030	449	1 mM, 14% inhibition
2.4.2.19	Cupriavidus necator		dTTP	638030	137	1 mM, 29% inhibition
2.4.2.19	Lentinula edodes		Fe2+	638013	23	
2.4.2.19	Sus scrofa		Fe2+	638015	23	1 mM, 93% inhibition
2.4.2.19	Sus scrofa		Fe2+	638025	23	1 mM, 61.5% inhibition
2.4.2.19	Lentinula edodes		Fe3+	638013	66	
2.4.2.19	Sus scrofa		Fe3+	638025	66	1 mM, 92.9% inhibition
2.4.2.19	Sus scrofa		formic acid	638028	114	1 mM, 54% inhibition
2.4.2.19	Sus scrofa		Fumaric acid	638021	156	1 mM, 72% inhibition
2.4.2.19	Sus scrofa		Fumaric acid	638028	156	1 mM, 67% inhibition
2.4.2.19	Sus scrofa		GDP	638018	49	2 mM, 29% inhibition
2.4.2.19	Sus scrofa		glycerol	638021	129	inhibition increases as the pH raises
2.4.2.19	Cupriavidus necator		glycerol	638030	129	glycerol markedly activates enzyme activity at pH 6.1 and 6.5, inhibition above pH 7.0, inhibition is strongest at pH 9.0
2.4.2.19	Sus scrofa		GTP	638018	35	2 mM, 77% inhibition
2.4.2.19	Cupriavidus necator		GTP	638030	35	1 mM, 17% inhibition
2.4.2.19	Cupriavidus necator		H2PO4-	638029	20399	
2.4.2.19	Sus scrofa		Hg2+	638025	31	1 mM, 99.9% inhibition
2.4.2.19	Cupriavidus necator		Hg2+	638030	31	
2.4.2.19	Sus scrofa		IDP	638018	372	2 mM, 29% inhibition
2.4.2.19	Sus scrofa		IMP	638018	206	2 mM, 6% inhibition
2.4.2.19	Sus scrofa		isocinchomeric acid	638018	2398	1 mM, 15% inhibition
2.4.2.19	Sus scrofa		ITP	638018	203	2 mM, 81% inhibition
2.4.2.19	Cupriavidus necator		ITP	638030	203	1 mM, 24% inhibition
2.4.2.19	Sus scrofa		L-Glutamic acid	638021	38	1 mM, 31% inhibition
2.4.2.19	Sus scrofa		L-Glutamic acid	638028	38	1 mM, 41% inhibition
2.4.2.19	Sus scrofa		L-Malic acid	638021	180	1 mM, 75% inhibition
2.4.2.19	Sus scrofa		L-Malic acid	638028	180	1 mM, 67% inhibition
2.4.2.19	Sus scrofa		Lactic acid	638028	924	1 mM, 29% inhibition
2.4.2.19	Sus scrofa		lutidinic acid	638018	1196	1 mM, 17% inhibition
2.4.2.19	Sus scrofa		Maleic acid	638021	474	1 mM, 34% inhibition
2.4.2.19	Sus scrofa		Maleic acid	638028	474	1 mM, 42% inhibition
2.4.2.19	Ricinus communis		methyl-3-amidopyridine-2-carboxylate	638016	74420	
2.4.2.19	Ricinus communis		methyl-3-cyanopyridine 2-carboxylate	638016	74421	
2.4.2.19	Sus scrofa		Mg2+	638025	25	1 mM, 7.7% inhibition
2.4.2.19	Sus scrofa		Mn2+	638025	26	1 mM, 80.3% inhibition
2.4.2.19	Sus scrofa		Monoiodoacetic acid	638015	87	5 mM, 50% inhibition
2.4.2.19	Sus scrofa		Monoiodoacetic acid	638018	87	50 mM, 99.8% inhibition
2.4.2.19	Vigna radiata var. radiata		more	659608		nicotinic acid and nicotinamide inhibit growth of roots
2.4.2.19	Cupriavidus necator		Na4P2O7	638030	1943	3 mM, complete inhibition
2.4.2.19	Ricinus communis		NAD+	638016	4	19% inhibition at 1 mM, 15% inhibition at 10 mM
2.4.2.19	Sus scrofa		NEM	638018	46	5 mM, 86% inhibition
2.4.2.19	Lentinula edodes		Ni2+	638013	36	
2.4.2.19	Sus scrofa		Ni2+	638025	36	1 mM, 76.5% inhibition
2.4.2.19	Cupriavidus necator		Ni2+	638030	36	
2.4.2.19	Escherichia coli		nicotinate mononucleotide	638020	1045	competitive with respect to 5-phosphoribosyl-1-diphosphate
2.4.2.19	Cupriavidus necator		nicotinate mononucleotide	638030	1045	1 mM, 46% inhibition
2.4.2.19	Salmonella enterica subsp. enterica serovar Typhimurium		nicotinate mononucleotide	638035	1045	
2.4.2.19	Lentinula edodes		NO3-	638013	263	
2.4.2.19	Sus scrofa		oxaloacetic acid	638021	53	1 mM, 56% inhibition
2.4.2.19	Sus scrofa		oxaloacetic acid	638028	53	1 mM, 59% inhibition
2.4.2.19	Sus scrofa		PCMB	638015, 638018	40	0.05 mM, complete inhibition
2.4.2.19	Saccharomyces cerevisiae		Phthalate	702234	2060	
2.4.2.19	Sus scrofa		Phthalic acid	638015, 638018	2060	competitive to quinolinate
2.4.2.19	Escherichia coli		Phthalic acid	638020	2060	dead-end inhibitor, competitive with respect to quinolinate, uncompetitive with respect to 5-phosphoribosyl-1-diphosphate
2.4.2.19	Rattus norvegicus		Phthalic acid	638026	2060	
2.4.2.19	Burkholderia cepacia		Phthalic acid	638033	2060	
2.4.2.19	Salmonella enterica subsp. enterica serovar Typhimurium		Phthalic acid	638035	2060	
2.4.2.19	Ricinus communis		Picolinic acid	638016	3360	
2.4.2.19	Sus scrofa		Sr2+	638025	289	47.6% inhibition
2.4.2.19	Sus scrofa		succinic acid	638021	54	1 mM, 51% inhibition
2.4.2.19	Sus scrofa		succinic acid	638028	54	1 mM, 46% inhibition
2.4.2.19	Bos taurus		Tris	638011	272	
2.4.2.19	Sus scrofa		UDP	638018	24	2 mM, 32% inhibition
2.4.2.19	Sus scrofa		UTP	638018	61	2 mM, 74% inhibition
2.4.2.19	Cupriavidus necator		UTP	638030	61	1 mM, 19% inhibition
2.4.2.19	Lentinula edodes		Zn2+	638013	19	
2.4.2.19	Sus scrofa		Zn2+	638025	19	1 mM, 82.1% inhibition
2.4.2.19	Cupriavidus necator		Zn2+	638030	19	
2.5.1.90	Escherichia coli K-12	Triton X-100		637482	57	addition of 0.1% and 0.5% Triton X-100 activates the enzyme by 3.9- and 4.7fold, respectively
2.5.1.90	Escherichia coli	Triton X-100		707541	57	presence can accelerate the steady-state rate by 3fold
2.5.1.90	Plasmodium falciparum		nerolidol	707424	18610	competitive, 57% inhibition at 50 nM
4.1.1.23	Sulfolobus acidocaldarius	5,5'-dithiobis(2-nitrobenzoate)		651345	196	0.1 mM, 2.2fold stimulation
4.1.1.23	Sulfolobus acidocaldarius	5,5'-dithiobis(2-nitrobenzoic acid)		651345	196	0.1 mM, at 70&deg;C, 2.2fold activation
4.1.1.23	Sulfolobus acidocaldarius	6-Azauracil		651345	3774	1 mM, 1.2fold activation
4.1.1.23	Saccharomyces cerevisiae	HPO32-		727024	66461	decarboxylation of substrate analog 5'-deoxy-5-fluoroorotidine is activated. Decarboxylation of truncated substrate analog 1-(beta-D-erythrofuranosyl)-5-fluoroorotic acid is activated by exogenous phosphite dianion, but the 5-F substituent results in only a 0.8 kcal stabilization of the transition state for the phosphite-activated reaction
4.1.1.23	Sulfolobus acidocaldarius	N-ethylmaleimide		651345	46	10 mM, 18fold stimulation; 10 mM, at 70&deg;C, 17.8fold activation
4.1.1.23	Methanothermobacter thermautotrophicus	orotidine 5'-phosphate		727006	599	the 5'-phosphate group of the substrate activates the enzyme 240000000fold. The binding of orotidine 5'-monophosphate is accompanied by a conformational change of the enzyme from an open, inactive conformation to a closed, active conformation. As the substrate traverses the reaction coordinate to form the stabilized vinyl carbanion/carbene intermediate, interactions that destabilize the carboxylate group of the substrate and stabilize the intermediate are enforced. The activation is equivalently described by an intrinsic binding energy of 11.4 kcal/mol. The residues that directly contact the 5'-phosphate group, participate in a hydrophobic cluster near the base of the active site loop that sequesters the bound substrate from the solvent, or that form hydrogen bonding interactions across the interface between the mobile and fixed half-barrel domains of the (beta/alpha)8-barrel structure. The data support a model in which the intrinsic binding energy provided by the 5'-phosphate group is used to allow interactions both near the N-terminus of the active site loop and across the domain interface that stabilize the complexes of the enzyme in the active closed conformation with the substrate or with the substrate intermediate with the destabilized carboxylate group relative to the complex of the enzyme in the open inactive conformation with the substrate
4.1.1.23	Saccharomyces cerevisiae	phosphite dianion		661941	23516	activates
4.1.1.23	Sulfolobus acidocaldarius	Uracil		651345	287	1 mM, 1.3fold stimulation
4.1.1.23	Homo sapiens		(5-(4-amino-3-oxido-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl)-methyl dihydrogen phosphate	728095	111124	i.e. CMP-N3-oxide
4.1.1.23	Plasmodium falciparum		(5-(4-amino-3-oxido-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl)-methyl dihydrogen phosphate	728095	111124	i.e. CMP-N3-oxide
4.1.1.23	Saccharomyces cerevisiae		1-(5'-phospho-beta-D-ribofuranosyl)barbituric acid	4179	8036	reversible
4.1.1.23	Saccharomyces cerevisiae		1-(5'-phospho-beta-D-ribofuranosyl)barbituric acid	4188	8036	
4.1.1.23	Saccharomyces cerevisiae		1-(5'-phospho-beta-D-ribofuranosyl)barbituric acid	649921	8036	high affinity inhibitor
4.1.1.23	Escherichia coli		1-(5'-phospho-beta-D-ribofuranosyl)barbituric acid	649973	8036	mode of binding
4.1.1.23	Escherichia coli		1-(5'-phospho-beta-D-ribofuranosyl)barbituric acid	652881	8036	
4.1.1.23	Methanothermobacter thermautotrophicus		1-methylorotate	681286	88458	modeling of binding and structure
4.1.1.23	Saccharomyces cerevisiae		1-Ribosyloxipurinol 5'-phosphate	4169	28614	most effective oxipurinol nucleotide inhibitor
4.1.1.23	Saccharomyces cerevisiae		1-Ribosyloxipurinol 5'-phosphate	4182	28614	
4.1.1.23	Homo sapiens		2'-deoxy-2'-fluoro-6-iodo-beta-D-uridine 5'-O-monophosphate	715860	112564	
4.1.1.23	Methanothermobacter thermautotrophicus		2'-deoxy-2'-fluoro-6-iodo-beta-D-uridine 5'-O-monophosphate	715860	112564	
4.1.1.23	Homo sapiens		2'-deoxy-2'-fluoro-6-iodo-UMP	715860	112564	
4.1.1.23	Methanothermobacter thermautotrophicus		2'-deoxy-2'-fluoro-6-iodo-UMP	715860	112564	
4.1.1.23	Homo sapiens		2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl-cytosine	715860	73522	
4.1.1.23	Methanothermobacter thermautotrophicus		2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl-cytosine	715860	73522	
4.1.1.23	Saccharomyces cerevisiae		2'-deoxyuridine 5'-phosphate	650068	496	competitive inhibition, at higher concentrations
4.1.1.23	Saccharomyces cerevisiae		2- thiouridine 5'-phosphate	650513	63167	mixed inhibition
4.1.1.23	Saccharomyces cerevisiae		3-Xanthosine 5'-phosphate	4169	66977	
4.1.1.23	Plasmodium falciparum		4-(2-hydroxy-4-methoxyphenyl)-4-oxobutanoic acid	727794		the inhibitor molecule occupies a part of the active site that overlaps with the phosphate-binding region in the OMP- or UMP-bound complexes. The carboxyl group of the inhibitor causes a dramatic movement of the L1 and L2 loops that play a role in the recognition of the substrate and product molecules
4.1.1.23	Saccharomyces cerevisiae		4-thiouridine 5'-phosphate	650513	22554	competitive inhibition, stronger inhibitor than UMP
4.1.1.23	Saccharomyces cerevisiae		5,5'-dithiobis(2-nitrobenzoate)	4172	196	
4.1.1.23	Saccharomyces cerevisiae		5,6-dihydro-6-sulfonyl-OMP	678241	45266	inhibitor with high affinity for the enzyme
4.1.1.23	Saccharomyces cerevisiae		5,6-dihydro-6-sulfonyl-UMP	678241	45265	inhibitor with high affinity for the enzyme
4.1.1.23	Saccharomyces cerevisiae		5,6-dihydroorotidine 5'-phosphate	649331	77154	
4.1.1.23	Saccharomyces cerevisiae		5-(2-(N-(2-Acetamidoethyl)carbamyl)ethyl)-6-azauridine 5'phosphate	4173	66097	maximal inhibition at pH 8.3
4.1.1.23	Saccharomyces cerevisiae		5-(2-(N-(2-Aminoethyl)carbamyl)ethyl)-6-azauridine 5'-phosphate	4173	66098	
4.1.1.23	Homo sapiens		5-bromo-UMP	695160	6701	
4.1.1.23	Saccharomyces cerevisiae		5-Bromoorotidylate	4185	5620	
4.1.1.23	Saccharomyces cerevisiae		5-Chloroorotidylate	4185	66109	
4.1.1.23	Homo sapiens		5-cyano-2'-deoxy-2'-fluoro-beta-D-uridine 5'-O-monophosphate	715860	111976	
4.1.1.23	Methanothermobacter thermautotrophicus		5-cyano-2'-deoxy-2'-fluoro-beta-D-uridine 5'-O-monophosphate	715860	111976	
4.1.1.23	Helicobacter pylori		5-cyano-UMP	714449	111733	poor inhibition
4.1.1.23	Homo sapiens		5-cyano-UMP	714449	111733	poor inhibition
4.1.1.23	Methanothermobacter thermautotrophicus		5-cyano-UMP	714449	111733	poor inhibition
4.1.1.23	Plasmodium falciparum		5-cyano-UMP	714449	111733	poor inhibition
4.1.1.23	Saccharomyces cerevisiae		5-cyano-UMP	714449	111733	poor inhibition
4.1.1.23	Staphylococcus aureus		5-cyano-UMP	714449	111733	poor inhibition
4.1.1.23	Plasmodium falciparum		5-fluoro-UMP	657769	6101	
4.1.1.23	Homo sapiens		5-fluoro-UMP	695160	6101	
4.1.1.23	Sulfolobus acidocaldarius		5-fluorouracil	651345	651	1 mM, 14% inhibition
4.1.1.23	Homo sapiens		5-iodo-UMP	695160	9331	
4.1.1.23	Saccharomyces cerevisiae		5-phosphoribofuranosylallopurinol	649331	35511	
4.1.1.23	Homo sapiens		6-amido-2'-deoxy-2'-fluoro-beta-D-uridine 5'-O-monophosphate	715860	111975	poor inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		6-amido-2'-deoxy-2'-fluoro-beta-D-uridine 5'-O-monophosphate	715860	111975	poor inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		6-amino-1-methyluracil	681286	88461	modeling of binding and structure
4.1.1.23	Homo sapiens		6-amino-5-fluorouridine	715860	112569	competitive inhibition at submicromolar concentrations
4.1.1.23	Methanothermobacter thermautotrophicus		6-amino-5-fluorouridine	715860	112569	competitive inhibition at submicromolar concentrations
4.1.1.23	Methanothermobacter thermautotrophicus		6-amino-UMP	681286	4276	competitive inhibition
4.1.1.23	Plasmodium falciparum		6-amino-uridine 5'-monophosphate	693558	4276	
4.1.1.23	Bacillus subtilis		6-aminouridine 5'-monophosphate	694055	4276	
4.1.1.23	Escherichia coli		6-aminouridine 5'-monophosphate	694055	4276	
4.1.1.23	Methanococcus thermoautotrophicum		6-aminouridine 5'-monophosphate	694055	4276	
4.1.1.23	Plasmodium vivax		6-aminouridine 5'-monophosphate	694055	4276	
4.1.1.23	Saccharomyces cerevisiae		6-aminouridine 5'-monophosphate	694055	4276	
4.1.1.23	Homo sapiens		6-aminouridine 5'-monophosphate	694055, 694477	4276	
4.1.1.23	Methanothermobacter thermautotrophicus		6-aminouridine 5'-monophosphate	694477	4276	
4.1.1.23	Plasmodium falciparum		6-aminouridine 5'-monophosphate	694055, 694477	4276	
4.1.1.23	Staphylococcus aureus		6-aminouridine 5'-monophosphate	694477	4276	
4.1.1.23	Methanothermobacter thermautotrophicus		6-aminouridine 5'-phosphate	693558	4276	
4.1.1.23	Plasmodium falciparum		6-aza-UMP	657769	2252	
4.1.1.23	Methanothermobacter thermautotrophicus		6-aza-UMP	681286	2252	competitive inhibition
4.1.1.23	Methanothermobacter thermautotrophicus		6-aza-UMP	649128, 692755	2252	
4.1.1.23	Plasmodium falciparum		6-aza-uridine 5'-monophosphate	693558	2252	
4.1.1.23	Methanothermobacter thermautotrophicus		6-Azauracil	650145	3774	competitive inhibitor
4.1.1.23	Homo sapiens		6-azauridine	715860	1583	potent inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		6-azauridine	715860	1583	potent inhibitor
4.1.1.23	Bacillus subtilis		6-azauridine 5'-monophosphate	694055	2252	
4.1.1.23	Escherichia coli		6-azauridine 5'-monophosphate	694055	2252	
4.1.1.23	Homo sapiens		6-azauridine 5'-monophosphate	694055	2252	
4.1.1.23	Methanococcus thermoautotrophicum		6-azauridine 5'-monophosphate	694055	2252	
4.1.1.23	Plasmodium falciparum		6-azauridine 5'-monophosphate	690945, 694055	2252	
4.1.1.23	Plasmodium vivax		6-azauridine 5'-monophosphate	694055	2252	
4.1.1.23	Saccharomyces cerevisiae		6-azauridine 5'-monophosphate	694055	2252	
4.1.1.23	Crithidia luciliae		6-azauridine 5'-phosphate	4177	2252	
4.1.1.23	Mus musculus		6-azauridine 5'-phosphate	4170, 4175, 4183	2252	
4.1.1.23	Saccharomyces cerevisiae		6-azauridine 5'-phosphate	649331, 649921	2252	competitive inhibitor
4.1.1.23	Saccharomyces cerevisiae		6-azauridine 5'-phosphate	650068	2252	competitive inhibition
4.1.1.23	Saccharomyces cerevisiae		6-azauridine 5'-phosphate	4173, 4179, 4185, 4188, 652109	2252	
4.1.1.23	Methanothermobacter thermautotrophicus		6-azauridine 5'-phosphate	653647	2252	mode of binding
4.1.1.23	Methanothermobacter thermautotrophicus		6-azauridine 5'-phosphate	651572, 693558	2252	
4.1.1.23	Homo sapiens		6-azido-2'-deoxy-2'-fluoro-beta-D-uridine 5'-O-monophosphate	715860	112570	
4.1.1.23	Methanothermobacter thermautotrophicus		6-azido-2'-deoxy-2'-fluoro-beta-D-uridine 5'-O-monophosphate	715860	112570	
4.1.1.23	Homo sapiens		6-azido-5-fluorouridine	715860	112568	irreversible inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		6-azido-5-fluorouridine	715860	112568	irreversible inhibitor
4.1.1.23	Homo sapiens		6-azido-UMP	715860	9631	
4.1.1.23	Methanothermobacter thermautotrophicus		6-azido-UMP	715860	9631	
4.1.1.23	Plasmodium falciparum		6-azido-uridine 5'-monophosphate	693558	9631	
4.1.1.23	Homo sapiens		6-azidouridine 5'-monophosphate	694477	9631	
4.1.1.23	Methanothermobacter thermautotrophicus		6-azidouridine 5'-monophosphate	694477	9631	
4.1.1.23	Plasmodium falciparum		6-azidouridine 5'-monophosphate	694477	9631	
4.1.1.23	Staphylococcus aureus		6-azidouridine 5'-monophosphate	694477	9631	
4.1.1.23	Methanothermobacter thermautotrophicus		6-azidouridine 5'-phosphate	693558	9631	
4.1.1.23	Methanothermobacter thermautotrophicus		6-carbamoyl-UMP	715860	77155	
4.1.1.23	Saccharomyces cerevisiae		6-carboxyamidouridine 5'-phosphate	649331	77155	
4.1.1.23	Methanothermobacter thermautotrophicus		6-cyano-1-methyluracil	681286	88460	modeling of binding and structure
4.1.1.23	Homo sapiens		6-cyano-2'-deoxy-2'-fluoro-beta-D-uridine 5'-O-monophosphate	715860	111974	reversible inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		6-cyano-2'-deoxy-2'-fluoro-beta-D-uridine 5'-O-monophosphate	715860	111974	reversible inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		6-cyano-UMP	681286	4275	competitive inhibition
4.1.1.23	Plasmodium falciparum		6-cyano-uridine 5'-monophosphate	693558	4275	
4.1.1.23	Homo sapiens		6-cyanouridine	715860	111973	
4.1.1.23	Methanothermobacter thermautotrophicus		6-cyanouridine	715860	111973	
4.1.1.23	Bacillus subtilis		6-cyanouridine 5'-monophosphate	694055	4275	
4.1.1.23	Escherichia coli		6-cyanouridine 5'-monophosphate	694055	4275	
4.1.1.23	Methanococcus thermoautotrophicum		6-cyanouridine 5'-monophosphate	694055	4275	
4.1.1.23	Plasmodium vivax		6-cyanouridine 5'-monophosphate	694055	4275	
4.1.1.23	Saccharomyces cerevisiae		6-cyanouridine 5'-monophosphate	694055	4275	
4.1.1.23	Homo sapiens		6-cyanouridine 5'-monophosphate	694055, 694477	4275	
4.1.1.23	Methanothermobacter thermautotrophicus		6-cyanouridine 5'-monophosphate	694477	4275	
4.1.1.23	Plasmodium falciparum		6-cyanouridine 5'-monophosphate	694055, 694477	4275	
4.1.1.23	Staphylococcus aureus		6-cyanouridine 5'-monophosphate	694477	4275	
4.1.1.23	Saccharomyces cerevisiae		6-cyanouridine 5'-phosphate	661318	4275	competitive
4.1.1.23	Methanothermobacter thermautotrophicus		6-cyanouridine 5'-phosphate	693558	4275	
4.1.1.23	Saccharomyces cerevisiae		6-hydroxy UMP	661317	82316	inhibits activity with orotidine and orotidine 5'-phosphate, mutant enzyme C155S
4.1.1.23	Methanothermobacter thermautotrophicus		6-hydroxy-1-methyl uracil	681286	88459	modeling of binding and structure
4.1.1.23	Methanothermobacter thermautotrophicus		6-hydroxy-UMP	692755	82316	
4.1.1.23	Homo sapiens		6-hydroxymethyl-UMP	695160	49481	
4.1.1.23	Saccharomyces cerevisiae		6-hydroxyUMP	678582	82316	a transition state analogue inhibitor, binding structure in complex with the enzyme, overview
4.1.1.23	Homo sapiens		6-hydroxyuridine	715860	112565	potent inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		6-hydroxyuridine	715860	112565	potent inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		6-hydroxyuridine 5'-monophosphate	650145	7607	tightly binding competitive inhibitor
4.1.1.23	Saccharomyces cerevisiae		6-hydroxyuridine 5'-phosphate	649331	7607	potent competitive inhibitor
4.1.1.23	Saccharomyces cerevisiae		6-hydroxyuridine 5'-phosphate	650068	7607	mode of binding
4.1.1.23	Saccharomyces cerevisiae		6-hydroxyuridine 5'-phosphate	652109	7607	
4.1.1.23	Homo sapiens		6-iodo-UMP	695160	3081	
4.1.1.23	Homo sapiens		6-iodouridine	715860	112567	
4.1.1.23	Methanothermobacter thermautotrophicus		6-iodouridine	715860	112567	
4.1.1.23	Methanothermobacter thermautotrophicus		6-iodouridine 5'-monophosphate	681320	3081	i.e. 6-iodo-UMP, irreversible inhibition, mass spectral analysis of the enzyme-inhibitor complex, binding to the enzyme is accompanied by loss of two protons and the iodo moiety, covalent bond formation
4.1.1.23	Plasmodium falciparum		6-iodouridine 5'-monophosphate	681320	3081	i.e. 6-iodo-UMP, irreversible inhibition, mass spectral analysis of the enzyme-inhibitor complex, binding to the enzyme is accompanied by loss of two protons and the iodo moiety, covalent bond formation, the inhibitor exhibits potent antiplasmodial activity
4.1.1.23	Bacillus subtilis		6-iodouridine 5'-monophosphate	694055	3081	
4.1.1.23	Escherichia coli		6-iodouridine 5'-monophosphate	694055	3081	
4.1.1.23	Methanococcus thermoautotrophicum		6-iodouridine 5'-monophosphate	694055	3081	
4.1.1.23	Plasmodium vivax		6-iodouridine 5'-monophosphate	694055	3081	
4.1.1.23	Saccharomyces cerevisiae		6-iodouridine 5'-monophosphate	694055	3081	
4.1.1.23	Helicobacter pylori		6-iodouridine 5'-monophosphate	694477	3081	
4.1.1.23	Homo sapiens		6-iodouridine 5'-monophosphate	694055, 694477	3081	
4.1.1.23	Methanothermobacter thermautotrophicus		6-iodouridine 5'-monophosphate	694477	3081	
4.1.1.23	Plasmodium falciparum		6-iodouridine 5'-monophosphate	694055, 694477	3081	
4.1.1.23	Staphylococcus aureus		6-iodouridine 5'-monophosphate	694477	3081	
4.1.1.23	Methanothermobacter thermautotrophicus		6-iodouridine 5'-monophosphate	714720	3081	irreversible inhibitor
4.1.1.23	Plasmodium falciparum		6-methyl-uridine	694477	49482	
4.1.1.23	Plasmodium falciparum		6-methyl-uridine 5'-monophosphate	693558	49480	
4.1.1.23	Methanothermobacter thermautotrophicus		6-methyluridine 5'-phosphate	693558	49480	
4.1.1.23	Homo sapiens		6-thiocarboxamidouridine	715860	112566	potent inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		6-thiocarboxamidouridine	715860	112566	potent inhibitor
4.1.1.23	Bacillus subtilis		6-thiocarboxamidouridine 5'-monophosphate	694055	8037	
4.1.1.23	Escherichia coli		6-thiocarboxamidouridine 5'-monophosphate	694055	8037	
4.1.1.23	Homo sapiens		6-thiocarboxamidouridine 5'-monophosphate	694055	8037	
4.1.1.23	Methanococcus thermoautotrophicum		6-thiocarboxamidouridine 5'-monophosphate	694055	8037	
4.1.1.23	Plasmodium falciparum		6-thiocarboxamidouridine 5'-monophosphate	694055	8037	
4.1.1.23	Plasmodium vivax		6-thiocarboxamidouridine 5'-monophosphate	694055	8037	
4.1.1.23	Saccharomyces cerevisiae		6-thiocarboxamidouridine 5'-monophosphate	694055	8037	
4.1.1.23	Saccharomyces cerevisiae		6-thiocarboxamidouridine 5'-phosphate	649331, 649921	8037	
4.1.1.23	Saccharomyces cerevisiae		6-thiocarboxamidouridine 5'-phosphate	651942	8037	competitive, very strong, reversible inhibition
4.1.1.23	Saccharomyces cerevisiae		7-Ribosyloxipurinol 5'-phosphate	4169	66142	
4.1.1.23	Saccharomyces cerevisiae		8-azaxanthosine 5'-phosphate	649921	20137	
4.1.1.23	Saccharomyces cerevisiae		allopurinol beta-D-riboside 5'-phosphate	649921	35511	
4.1.1.23	Plasmodium falciparum		allopurinol-3-riboside 5'-monophosphate	690945	49483	
4.1.1.23	Homo sapiens		AMP	693556	9	
4.1.1.23	Methanothermobacter thermautotrophicus		AMP	693556	9	
4.1.1.23	Helicobacter pylori		barbiturate ribonucleoside 5'-monophosphate	714449	8036	very potent inhibitor
4.1.1.23	Homo sapiens		barbiturate ribonucleoside 5'-monophosphate	714449	8036	very potent inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		barbiturate ribonucleoside 5'-monophosphate	714449	8036	very potent inhibitor
4.1.1.23	Plasmodium falciparum		barbiturate ribonucleoside 5'-monophosphate	714449	8036	very potent inhibitor
4.1.1.23	Saccharomyces cerevisiae		barbiturate ribonucleoside 5'-monophosphate	714449	8036	very potent inhibitor
4.1.1.23	Staphylococcus aureus		barbiturate ribonucleoside 5'-monophosphate	714449	8036	very potent inhibitor
4.1.1.23	Saccharomyces cerevisiae		Barbituric acid	661317	3788	mutant enzyme C155S
4.1.1.23	Methanothermobacter thermautotrophicus		barbituric acid monophosphate	681286	88457	i.e. 6-hydroxy-UMP
4.1.1.23	Bacillus subtilis		barbituric acid ribonucleoside 5'-monophosphate	694055	8036	
4.1.1.23	Escherichia coli		barbituric acid ribonucleoside 5'-monophosphate	694055	8036	
4.1.1.23	Homo sapiens		barbituric acid ribonucleoside 5'-monophosphate	694055	8036	
4.1.1.23	Methanococcus thermoautotrophicum		barbituric acid ribonucleoside 5'-monophosphate	694055	8036	
4.1.1.23	Plasmodium falciparum		barbituric acid ribonucleoside 5'-monophosphate	694055	8036	
4.1.1.23	Plasmodium vivax		barbituric acid ribonucleoside 5'-monophosphate	694055	8036	
4.1.1.23	Saccharomyces cerevisiae		barbituric acid ribonucleoside 5'-monophosphate	694055	8036	
4.1.1.23	Homo sapiens		beta-D-ribofuranosylbarbiturate 5'-monophosphate	716948	8036	potent inhibitor
4.1.1.23	Homo sapiens		clevudine	715860	33073	
4.1.1.23	Methanothermobacter thermautotrophicus		clevudine	715860	33073	
4.1.1.23	Homo sapiens		CMP	693556	94	
4.1.1.23	Methanothermobacter thermautotrophicus		CMP	693556	94	
4.1.1.23	Homo sapiens		CMP	728095	94	weak inhibitor
4.1.1.23	Plasmodium falciparum		CMP	728095	94	weak inhibitor
4.1.1.23	Homo sapiens		dAMP	693556	575	
4.1.1.23	Methanothermobacter thermautotrophicus		dAMP	693556	575	
4.1.1.23	Sulfolobus acidocaldarius		Dimethylsulfoxide	651345	702	20% v/v, 8% inhibition
4.1.1.23	Sulfolobus acidocaldarius		EDTA	651345	223	10 mM, 6% inhibition; 10 mM, at 70&deg;C, weak inhibition
4.1.1.23	Homo sapiens		gemcitabine	715860	1407	
4.1.1.23	Methanothermobacter thermautotrophicus		gemcitabine	715860	1407	
4.1.1.23	Methanothermobacter thermautotrophicus		GMP	693556	150	
4.1.1.23	Plasmodium falciparum		GMP	693556	150	
4.1.1.23	Methanothermobacter thermautotrophicus		guanidine hydrochloride	650145	804	2 M, denaturates
4.1.1.23	Sulfolobus acidocaldarius		Guanidine-HCl	651345	804	2.0 M, complete inhibition
4.1.1.23	Sulfolobus acidocaldarius		Guanidinium chloride	651345	804	1 M, at 70&deg;C, 81.4% inhibition
4.1.1.23	Saccharomyces cerevisiae		Hg2+	4172	31	
4.1.1.23	Homo sapiens		IMP	693556	206	
4.1.1.23	Methanothermobacter thermautotrophicus		IMP	693556	206	
4.1.1.23	Plasmodium falciparum		IMP	693556	206	
4.1.1.23	Saccharomyces cerevisiae		more	649331		not inhibited by 2-thioorotidine 5'-phosphate
4.1.1.23	Saccharomyces cerevisiae		more	649542		not inhibited by zinc-chelating agents, e.g. EDTA
4.1.1.23	Saccharomyces cerevisiae		more	651942		not inhibited by 6-carboxamidouridine 5-phosphate, recombinant ODCase expressed in Escherichia coli is not inhibited by 1,3-dimercaptopropanol and EDTA
4.1.1.23	Methanothermobacter thermautotrophicus		more	681286		inhibitor synthesis, overview
4.1.1.23	Helicobacter pylori		nifedipine	714449	2644	competitive inhibition
4.1.1.23	Homo sapiens		nifedipine	714449	2644	competitive inhibition
4.1.1.23	Methanothermobacter thermautotrophicus		nifedipine	714449	2644	competitive inhibition
4.1.1.23	Plasmodium falciparum		nifedipine	714449	2644	competitive inhibition
4.1.1.23	Saccharomyces cerevisiae		nifedipine	714449	2644	competitive inhibition
4.1.1.23	Staphylococcus aureus		nifedipine	714449	2644	competitive inhibition
4.1.1.23	Homo sapiens		nifedipine	715860	2644	competitive inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		nifedipine	715860	2644	competitive inhibitor
4.1.1.23	Helicobacter pylori		nimodipine	714449	4938	competitive inhibition
4.1.1.23	Homo sapiens		nimodipine	714449	4938	competitive inhibition
4.1.1.23	Methanothermobacter thermautotrophicus		nimodipine	714449	4938	competitive inhibition
4.1.1.23	Plasmodium falciparum		nimodipine	714449	4938	competitive inhibition
4.1.1.23	Saccharomyces cerevisiae		nimodipine	714449	4938	competitive inhibition
4.1.1.23	Staphylococcus aureus		nimodipine	714449	4938	competitive inhibition
4.1.1.23	Homo sapiens		nimodipine	715860	4938	competitive inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		nimodipine	715860	4938	competitive inhibitor
4.1.1.23	Saccharomyces cerevisiae		Orotate	649331	373	
4.1.1.23	Saccharomyces cerevisiae		Orotidine	661317	2998	mutant enzyme C155S
4.1.1.23	Saccharomyces cerevisiae		Oxipurinol nucleotides	4169		potent, competitive, bimodal. The inhibition of the enzyme by oxipurinol nucleotides is primarily responsible for the increased urinary excretion of orotic acid and orotidine in patients treated with allopurinol
4.1.1.23	Saccharomyces cerevisiae		oxypurinol 5'-phosphate	649921	35510	
4.1.1.23	Saccharomyces cerevisiae		PCMB	4172	40	
4.1.1.23	Saccharomyces cerevisiae		phosphate	4173	12	weak
4.1.1.23	Saccharomyces cerevisiae		phosphate	649331	12	
4.1.1.23	Sulfolobus acidocaldarius		phosphate	651345	12	low activity in phosphate buffers, inhibitory or destabilizing effect
4.1.1.23	Saccharomyces cerevisiae		phosphate	661317	12	competitive, mutant enzyme C155S
4.1.1.23	Homo sapiens		potassium phosphate	4171	1140	
4.1.1.23	Helicobacter pylori		pyrazofurin	714449	5106	also known as pyrazomycin, potent inhibitor
4.1.1.23	Homo sapiens		pyrazofurin	714449	5106	also known as pyrazomycin, potent inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		pyrazofurin	714449	5106	also known as pyrazomycin, potent inhibitor
4.1.1.23	Plasmodium falciparum		pyrazofurin	714449	5106	also known as pyrazomycin, potent inhibitor
4.1.1.23	Saccharomyces cerevisiae		pyrazofurin	714449	5106	also known as pyrazomycin, potent inhibitor
4.1.1.23	Staphylococcus aureus		pyrazofurin	714449	5106	also known as pyrazomycin, potent inhibitor
4.1.1.23	Homo sapiens		pyrazofurin	715860	5106	potent inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		pyrazofurin	715860	5106	potent inhibitor
4.1.1.23	Bacillus subtilis		pyrazofurin 5'-monophosphate	694055	5345	
4.1.1.23	Escherichia coli		pyrazofurin 5'-monophosphate	694055	5345	
4.1.1.23	Homo sapiens		pyrazofurin 5'-monophosphate	694055	5345	
4.1.1.23	Methanococcus thermoautotrophicum		pyrazofurin 5'-monophosphate	694055	5345	
4.1.1.23	Plasmodium falciparum		pyrazofurin 5'-monophosphate	690945, 694055	5345	
4.1.1.23	Plasmodium vivax		pyrazofurin 5'-monophosphate	694055	5345	
4.1.1.23	Saccharomyces cerevisiae		pyrazofurin 5'-monophosphate	694055	5345	
4.1.1.23	Helicobacter pylori		pyrazofurin-5'-monophosphate	714449	5345	slow tight binding inhibitor
4.1.1.23	Homo sapiens		pyrazofurin-5'-monophosphate	714449	5345	slow tight binding inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		pyrazofurin-5'-monophosphate	714449	5345	slow tight binding inhibitor
4.1.1.23	Plasmodium falciparum		pyrazofurin-5'-monophosphate	714449	5345	slow tight binding inhibitor
4.1.1.23	Saccharomyces cerevisiae		pyrazofurin-5'-monophosphate	714449	5345	slow tight binding inhibitor
4.1.1.23	Staphylococcus aureus		pyrazofurin-5'-monophosphate	714449	5345	slow tight binding inhibitor
4.1.1.23	Saccharomyces cerevisiae		ribose	650068	254	weak
4.1.1.23	Saccharomyces cerevisiae		ribose 5'-phosphate	650068	165	
4.1.1.23	Saccharomyces cerevisiae		ribose 5-phosphate	649331	165	competitive inhibitor
4.1.1.23	Saccharomyces cerevisiae		ribose 5-phosphate	649921	165	
4.1.1.23	Sulfolobus acidocaldarius		SDS	651345	118	1%, at 70&deg;C, complete inactivation; 1%, complete inhibition
4.1.1.23	Saccharomyces cerevisiae		thiopurinol 5'-phosphate	649921	35512	
4.1.1.23	Homo sapiens		TMP	693556	518	
4.1.1.23	Methanothermobacter thermautotrophicus		TMP	693556	518	
4.1.1.23	Plasmodium falciparum		TMP	693556	518	
4.1.1.23	Mus musculus		UMP	4170	127	product inhibition
4.1.1.23	Saccharomyces cerevisiae		UMP	4179	127	competitive
4.1.1.23	Mus musculus		UMP	4183	127	
4.1.1.23	Saccharomyces cerevisiae		UMP	649921	127	ineffective inhibitor
4.1.1.23	Escherichia coli		UMP	649973	127	weak inhibitor
4.1.1.23	Saccharomyces cerevisiae		UMP	650068, 650513	127	competitive inhibition
4.1.1.23	Sulfolobus acidocaldarius		UMP	651345	127	1 mM, 19% inhibition; 1 mM, at 70&deg;C, 19% inhibition
4.1.1.23	Saccharomyces cerevisiae		UMP	649331, 652109	127	
4.1.1.23	Methanothermobacter thermautotrophicus		UMP	653647	127	weak inhibition
4.1.1.23	Methanothermobacter thermautotrophicus		UMP	693556	127	
4.1.1.23	Homo sapiens		UMP	693556, 695160, 728095	127	
4.1.1.23	Plasmodium falciparum		UMP	657769, 693556, 728095	127	
4.1.1.23	Treponema denticola		Uracil	679903	287	strong feedback inhibition
4.1.1.23	Homo sapiens		Xanthosine	715860	927	potent inhibitor
4.1.1.23	Methanothermobacter thermautotrophicus		Xanthosine	715860	927	potent inhibitor
4.1.1.23	Bacillus subtilis		xanthosine 5'-monophosphate	694055	772	
4.1.1.23	Escherichia coli		xanthosine 5'-monophosphate	694055	772	
4.1.1.23	Homo sapiens		xanthosine 5'-monophosphate	694055	772	
4.1.1.23	Methanococcus thermoautotrophicum		xanthosine 5'-monophosphate	694055	772	
4.1.1.23	Plasmodium falciparum		xanthosine 5'-monophosphate	690945, 694055	772	
4.1.1.23	Plasmodium vivax		xanthosine 5'-monophosphate	694055	772	
4.1.1.23	Saccharomyces cerevisiae		xanthosine 5'-monophosphate	694055	772	
4.1.1.23	Saccharomyces cerevisiae		xanthosine 5'-phosphate	650068	772	competitive inhibition
4.1.1.23	Saccharomyces cerevisiae		xanthosine 5'-phosphate	649921, 652109	772	
4.1.1.23	Homo sapiens		XMP	693556	772	
4.1.1.23	Methanothermobacter thermautotrophicus		XMP	693556	772	
4.1.1.23	Plasmodium falciparum		XMP	693556	772	
4.2.3.5	Euglena gracilis	light		137663		stimulation
4.2.3.5	Plasmodium falciparum		(3R,4R,5R)-5-(carboxymethoxy)-4-hydroxy-3-phosphonooxycyclohexene-1-carboxylic acid	715196	112602	
4.2.3.5	Plasmodium falciparum		(3R,4S,5R)-4-hydroxy-3-[(2S)-1-hydroxy-1-oxo-2-phosphonooxypropan-2-yl]oxy-5-phosphonooxycyclohexene-1-carboxylic acid	715196	112603	
4.2.3.5	Plasmodium falciparum		(3R,4S,5R)-5-(1-carboxyethoxy)-4-hydroxy-3-phosphonooxycyclohexene-1-carboxylic acid	715196	112604	
4.2.3.5	Plasmodium falciparum		(3R,4S,5R)-5-[(1R)-1-carboxy-1-phosphonoethoxy]-4-hydroxy-3-phosphonooxycyclohexene-1-carboxylic acid	715196	9610	
4.2.3.5	Plasmodium falciparum		(3R,4S,5S,6S)-5-(1-carboxyethenoxy)-6-fluoro-4-hydroxy-3-phosphonooxycyclohexene-1-carboxylic acid	715196	112605	
4.2.3.5	Escherichia coli		(6R)-6-fluoro-5-enoylpyruvylshikimate 3-phosphate	652056	35540	IC50 is 0.0005 mM when the enzyme is preincubated with the inhibitor, the IC50 is 0.25 mM when the enzyme is not preincubated with the inhibitor, inhibition is not absolutely irreversible
4.2.3.5	Neurospora crassa		(6S)-6-fluoro-5-enolpyruvylshikimate 3-phosphate	679365	45320	competitive inhibitor
4.2.3.5	Plasmodium falciparum		2-difluoro-[1-phosphonooxyethoxy]-4-hydroxy-3-phosphonooxycyclohexene-1-carboxylic acid	715196	9609	
4.2.3.5	Escherichia coli		bathophenanthroline	137655	1972	
4.2.3.5	Neurospora crassa		diethyl dicarbonate	652570	265	
4.2.3.5	Neurospora crassa		dioxygen	678265	11	inactivation
4.2.3.5	Escherichia coli		Fe2+	137655	23	
4.2.3.5	Streptococcus pneumoniae		O2	679365	11	activity only in anaerobic conditions
1.5.1.2	Cucurbita maxima	EDTA		392130	223	stimulation of undialyzed enzyme at 30 mM
1.5.1.2	Setaria italica	NaCl		686421	39	a significant increase in the P5C reductase activity is observed with increasing severity of NaCl stress (0-200 mM)
1.5.1.2	Homo sapiens	P53		674605	2133	POX is a p53-induced gene
1.5.1.2	Bos taurus	putrescine		392138	144	11% activation at 5 mM
1.5.1.2	Bos taurus	spermidine		392138	140	10% activation at 1.2 mM
1.5.1.2	Bos taurus	spermine		392138	177	13% activation at 1.2 mM
1.5.1.2	Homo sapiens	troglitazone		674605	2248	is found to activate the POX promoter in colon cancer cells
1.5.1.2	Streptococcus pyogenes		([[3,5-bis(trifluoromethyl)phenyl]amino]methanediyl)bis(phosphonic acid)	723917	110248	71.2% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		2,3-dichlorophenylhydroxymethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(2,3-dichlorophenyl)-1-hydroxyethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(2,3-dichlorophenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(2,6-dichlorophenyl)-1-hydroxyethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(2,6-dichlorophenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(3,5-di(trifluoromethyl)phenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(3,5-dichlorophenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(3,5-dimethylphenyl)-1-hydroxyethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(3,5-dimethylphenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(4-benzylphenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(4-chlorophenyl)-1-hydroxyethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		3,5-di(trifluoromethyl)phenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		3,5-dibromophenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		3,5-difluorophenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		3,5-dimethylphenylhydroxymethylenebisphosphonic acid	725183		
1.5.1.2	Pseudomonas aeruginosa		3-acetylpyridine analogue of NAD+	390310	706	95% inhibition at 2 mM
1.5.1.2	Arabidopsis thaliana		3-carbamoylophenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		3-chlorophenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		4-benzylphenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		4-benzylphenylhydroxymethylenebisphosphonic acid	725183		
1.5.1.2	Saccharomyces cerevisiae		5,5'-dithiobis(2-nitrobenzoate)	392119	196	90% inhibition at 0.012 mM
1.5.1.2	Arabidopsis thaliana		5,6,7,8-tetrahydro-2-naphthylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Rattus norvegicus		ADP	392112	8	
1.5.1.2	Glycine max		ADP	392125	8	1 mM
1.5.1.2	Cucurbita moschata		ADP	392127	8	
1.5.1.2	Bos taurus		ADP	392131	8	
1.5.1.2	Pseudomonas aeruginosa		Ag+	390310	71	inactivation at 0.1 mM
1.5.1.2	Cucurbita moschata		Ag+	392127	71	44% inactivation at 0.7 mM
1.5.1.2	Cucurbita maxima		Ag+	392130	71	65% inactivation at 0.3 mM
1.5.1.2	Bos taurus		Ag+	392131	71	
1.5.1.2	Rattus norvegicus		ATP	392112	7	1 mM
1.5.1.2	Bos taurus		ATP	392117	7	competitive with respect to NADH, 50% inhibition at 0.1 mM
1.5.1.2	Glycine max		ATP	392125	7	reversible with Mg2+
1.5.1.2	Cucurbita maxima		ATP	392130	7	41% inactivation at 1 mM
1.5.1.2	Cucurbita moschata		ATP	392127, 392130	7	
1.5.1.2	Bos taurus		ATP	392131	7	
1.5.1.2	Clostridium sticklandii		ATP	392146	7	70% inhibition at 2 mM
1.5.1.2	Spinacia oleracea		ATP	392148	7	
1.5.1.2	Rattus norvegicus		Cd2+	392112	48	
1.5.1.2	Bos taurus		Cd2+	392131	48	90% inhibition at 3.3 mM
1.5.1.2	Glycine max		CTP	392125	56	91% inactivation at 1 mM reversible with Mg2+
1.5.1.2	Pisum sativum		Cu2+	392107	28	
1.5.1.2	Rattus norvegicus		Cu2+	392112	28	
1.5.1.2	Cucurbita moschata		Cu2+	392127	28	not
1.5.1.2	Bos taurus		Cu2+	392131	28	90% inhibition at 3.3 mM
1.5.1.2	Cucurbita moschata		cysteine	392127	70	77% inactivation at 10 mM
1.5.1.2	Bos taurus		D-allohydroxyproline	392132	32347	competitive inhibition
1.5.1.2	Mycobacterium tuberculosis		deoxycholate	676952	369	
1.5.1.2	Streptococcus pyogenes		EDTA	723922	223	
1.5.1.2	Glycine max		GTP	392125	35	100% inactivation at 10 mM, reversible with Mg2+
1.5.1.2	Mycobacterium tuberculosis		H2O2	676952	20	
1.5.1.2	Pseudomonas aeruginosa		Hg2+	390310	31	75% inactivation at 0.1 mM
1.5.1.2	Rattus norvegicus		Hg2+	392112	31	
1.5.1.2	Glycine max		Hg2+	392125	31	
1.5.1.2	Cucurbita maxima		Hg2+	392130	31	65% inactivation at 0.3 mM
1.5.1.2	Cucurbita moschata		Hg2+	392127, 392130	31	
1.5.1.2	Bos taurus		Hg2+	392131	31	
1.5.1.2	Bos taurus		hydroxylamine	392131	80	
1.5.1.2	Bos taurus		imidazole	392132	390	
1.5.1.2	Arabidopsis thaliana		indan-5-ylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Pseudomonas aeruginosa		iodoacetamide	390310	63	complete inactivation at 1 mM
1.5.1.2	Cucurbita moschata		iodoacetate	392127	87	10% inactivation at 1 mM
1.5.1.2	Chlorella vulgaris var. autotrophica		KCl	392108	74	68% inhibition at 2 M
1.5.1.2	Chloroidium saccharophilum		KCl	392108	74	
1.5.1.2	Pseudomonas aeruginosa		L-2-acetidine-4-carboxylic acid	390310	5471	50% inactivation at 2 mM
1.5.1.2	Bos taurus		L-hydroxyproline	392132	2212	competitive inhibition
1.5.1.2	Neisseria meningitidis		L-proline	675361	215	L-proline inhibits the inverse reaction at a concentration of 10-20 mM
1.5.1.2	Streptococcus pyogenes		L-proline	675361	215	L-proline inhibits the inverse reaction at a concentration of 10-20 mM
1.5.1.2	Mycobacterium tuberculosis		methanol	676952	78	
1.5.1.2	Spinacia oleracea		Mg2+	392148	25	
1.5.1.2	Bos taurus		Mn2+	392131	26	
1.5.1.2	Hordeum vulgare		more	392114		enzyme is not inhibited by the proline-analog L-thiazolidine-4-carboxylic acid
1.5.1.2	Vigna radiata		more	392114		enzyme is not inhibited by the proline-analog L-thiazolidine-4-carboxylic acid
1.5.1.2	Bos taurus		more	392138		
1.5.1.2	Streptococcus pyogenes		more	723922		not inhibited by NADPH
1.5.1.2	Saccharomyces cerevisiae		N-ethylmaleimide	392119	46	90% inhibition at 0.02 mM, inhibition can be prevented by NADH
1.5.1.2	Chlorella vulgaris var. autotrophica		NaCl	392108	39	70% inhibition at 2 M
1.5.1.2	Chloroidium saccharophilum		NaCl	392108	39	
1.5.1.2	Rattus norvegicus		NAD+	392047	4	
1.5.1.2	Bos taurus		NAD+	392131	4	
1.5.1.2	Chlorella vulgaris var. autotrophica		NADH	392108	3	substrate inhibition
1.5.1.2	Chloroidium saccharophilum		NADH	392108	3	substrate inhibition
1.5.1.2	Escherichia coli		NADH	392126	3	above 0.16 mM
1.5.1.2	Streptococcus pyogenes		NADH	723922	3	slight inhibition with 25% reduction of the catalytic rate at 200 mM
1.5.1.2	Rattus norvegicus		NADP+	392112	6	1 mM
1.5.1.2	Glycine max		NADP+	392125	6	
1.5.1.2	Escherichia coli		NADP+	392126	6	
1.5.1.2	Cucurbita maxima		NADP+	392130	6	43% inactivation at 1 mM
1.5.1.2	Escherichia coli		NADPH	392126	5	above 0.13 mM
1.5.1.2	Cucurbita moschata		NaHSO3	392127	1990	88% inactivation at 1 mM
1.5.1.2	Glycine max		NH2OH	392125	80	
1.5.1.2	Cucurbita moschata		NH2OH	392127	80	7% inactivation at 1 mM
1.5.1.2	Cucurbita maxima		NH2OH	392130	80	92% inactivation at 1 mM
1.5.1.2	Cucurbita moschata		NH2OH	392130	80	
1.5.1.2	Pseudomonas aeruginosa		p-chloromercuribenzoate	390310	40	complete inactivation at 1 mM
1.5.1.2	Rattus norvegicus		p-chloromercuribenzoate	392112	40	
1.5.1.2	Glycine max		p-chloromercuribenzoate	392125	40	
1.5.1.2	Escherichia coli		p-chloromercuribenzoate	392126	40	complete inhibition at 0.125 mM, can be prevented by addition of dithiothreitol
1.5.1.2	Cucurbita maxima		p-chloromercuribenzoate	392130	40	not
1.5.1.2	Cucurbita moschata		p-chloromercuribenzoate	392127, 392130	40	not
1.5.1.2	Saccharomyces cerevisiae		p-hydroxymercuribenzoate	392119	92	90% inhibition at 0.008 mM, inhibition can be prevented by addition of excess dithiothreitol
1.5.1.2	Glycine max		phosphate	392125	12	
1.5.1.2	Pseudomonas aeruginosa		proline	390310	215	75% inactivation at 50 mM
1.5.1.2	Chlorella vulgaris var. autotrophica		proline	392108	215	89% inhibition at 2 M
1.5.1.2	Chloroidium saccharophilum		proline	392108	215	
1.5.1.2	Rattus norvegicus		proline	392112	215	5 mM
1.5.1.2	Bos taurus		proline	392117	215	39% inhibition of the NADH dependent activity and 17% of the NADPH dependent activity at 10 mM
1.5.1.2	Glycine max		proline	392125	215	
1.5.1.2	Escherichia coli		proline	392126	215	
1.5.1.2	Cricetulus griseus		proline	392128	215	
1.5.1.2	Homo sapiens		proline	392128	215	competitive inhibition
1.5.1.2	Rattus norvegicus		proline	392047, 392128	215	
1.5.1.2	Cucurbita maxima		proline	392130	215	12% inactivation at 50 mM
1.5.1.2	Cucurbita moschata		proline	392127, 392130	215	
1.5.1.2	Bos taurus		proline	392131	215	
1.5.1.2	Bos taurus		proline	392132	215	competitive inhibition
1.5.1.2	Homo sapiens		proline	675382	215	competitive inhibitor of P5CR NAD(P)H-dependent thioproline dehydrogenase activity
1.5.1.2	Homo sapiens		proline	676969	215	0.1 mM
1.5.1.2	Chlorella vulgaris var. autotrophica		pyrroline-5-carboxylate	392108	1456	substrate inhibition
1.5.1.2	Chloroidium saccharophilum		pyrroline-5-carboxylate	392108	1456	substrate inhibition
1.5.1.2	Mycobacterium tuberculosis		SDS	676952	118	
1.5.1.2	Cucurbita moschata		Sodium bisulfite	392127	1990	
1.5.1.2	Homo sapiens		stearoyl-CoA	675382	438	competitive inhibitor of P5CR NAD(P)H-dependent thioproline dehydrogenase activity
1.5.1.2	Glycine max		thiazolidine-4-carboxylic acid	392125	10694	
1.5.1.2	Bos taurus		thiazolidine-4-carboxylic acid	392131	10694	
1.5.1.2	Escherichia coli		thiazolidine-4-carboxylic acid	392140	10694	42% inhibition at 10 mM, L-isomer
1.5.1.2	Pseudomonas aeruginosa		thio-NAD+	390310	976	65% inactivation at 0.2 mM
1.5.1.2	Pseudomonas aeruginosa		thio-NADP+	390310	1513	65% inactivation at 0.2 mM
1.5.1.2	Cucurbita moschata		Zn2+	392127	19	14% inactivation at 1 mM
1.5.1.2	Bos taurus		Zn2+	392131	19	
1.5.1.2	Streptococcus pyogenes		[[(2,3-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	54895	95.4% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		[[(2,3-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	725183	54895	
1.5.1.2	Streptococcus pyogenes		[[(2,4-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	54896	52% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(2,5-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	111044	63.9% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(2,6-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	54897	96.2% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		[[(2,6-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	725183	54897	
1.5.1.2	Streptococcus pyogenes		[[(3,4-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	111049	92.5% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(3,5-dibromophenyl)amino]methanediyl]bis(phosphonic acid)	723917	111050	98.4% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(3,5-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	134	91.1% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		[[(3,5-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	725183	134	
1.5.1.2	Streptococcus pyogenes		[[(3,5-dimethylphenyl)amino]methanediyl]bis(phosphonic acid)	723917	111051	70.5% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		[[(3,5-dimethylphenyl)amino]methanediyl]bis(phosphonic acid)	725183	111051	
1.5.1.2	Streptococcus pyogenes		[[(3-chlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	111052	71.2% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(4-benzylphenyl)amino]methanediyl]bis(phosphonic acid)	723917	111053	94.5% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(4-chlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	54898	61.5% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		[[(4-chlorophenyl)amino]methanediyl]bis(phosphonic acid)	725183	54898	
6.3.2.1	Fusarium oxysporum	more		653240		PanC expression is induced by alpha-tomatine
6.3.2.1	Escherichia coli		(2RS)-5'-O-(2-hydroxy-4-methoxybutyrylsulfamoyl)adenosine	676279	86509	
6.3.2.1	Escherichia coli		(2RS)-5'-O-(3,3-dimethyl-2-aminobutyrylsulfamoyl)adenosine	676279	16135	
6.3.2.1	Escherichia coli		(2RS)-5'-O-(3,3-dimethyl-2-hydroxy-4-methoxybutyrylsulfamoyl)adenosine	676279	16137	
6.3.2.1	Escherichia coli		(2RS)-5'-O-(3,3-dimethyl-2-hydroxybutyrylsulfamoyl)adenosine	676279	16138	
6.3.2.1	Escherichia coli		(2RS)-5'-O-(3,3-dimethyl-2-oxobutyrylsulfamoyl)adenosine	676279	16136	
6.3.2.1	Escherichia coli		(2RS)-adenosyl-2-hydroxy-3,3-dimethylbuyrate	676279	41753	
6.3.2.1	Escherichia coli		(2RS)-adenosyl-2-hydroxy-4-methoxybutyrate	676279	41751	
6.3.2.1	Escherichia coli		(2RS)-adenosyl-3,3-dimethyl-2-hydroxy-4-methoxybutyrate	676279	41752	
6.3.2.1	Escherichia coli		(2S)-adenosyl-2-L-amino-3,3-dimethylbutanoate	676279	41749	
6.3.2.1	Mycobacterium tuberculosis		(5-(4-fluorophenylsulfonyl)-3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)(phenyl)methanone	727423	110172	77.0% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		(5-(4-nitrophenylsulfonyl)-3-phenyl-4,5,6,7-tetrahydro-1Hpyrazolo[4,3-c]pyridin-1-yl)(phenyl)methanone	727423	110173	39.7% inhibition at 0.1 mM
6.3.2.1	Arabidopsis thaliana		(R)-pantoate	674714	1916	substrate inhibition
6.3.2.1	Escherichia coli		1,10-phenanthroline	977, 978, 979	58	
6.3.2.1	Mycobacterium tuberculosis		1-(4-(1-(cyclohexanecarbonyl)-3-phenyl-6,7-dihydro-1Hpyrazolo[4,3-c]pyridin-5(4H)-ylsulfonyl)phenyl)ethanone	727423	110313	39.2% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-(4-(1-benzoyl-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-ylsulfonyl)phenyl)ethanone	727423	110314	78.5% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-(cyclohexanecarbonyl)-3-phenyl-N-p-tolyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110350	50.5% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-(cyclohexanecarbonyl)-3-phenyl-N-p-tolyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110351	40.8% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-(cyclohexanecarbonyl)-N-(4-ethoxyphenyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110352	48.5% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-(cyclohexanecarbonyl)-N-(4-fluorophenyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110353	49.2% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-(cyclohexanecarbonyl)-N-(4-methoxyphenyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110354	50.6% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-(cyclohexanecarbonyl)-N-(4-methoxyphenyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110355	38.7% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-(cyclohexanecarbonyl)-N-(4-nitrophenyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110356	47.3% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-(cyclohexanecarbonyl)-N-(naphthalen-1-yl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110357	50.9% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-(yclohexanecarbonyl)-N-(4-nitrophenyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110366	50.8% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzofuran-2-carboxylic acid	704206	34606	competitive with respect to both ATP and pantoate
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-3-phenyl-N-p-tolyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110369	23.9% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-3-phenyl-N-p-tolyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110370	49.4% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-(4-bromophenyl)-3-phenyl-6,7-dihydro-1Hpyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110371	60.6% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-(4-chlorophenyl)-3-phenyl-6,7-dihydro-1Hpyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110372	37.7% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-(4-chlorophenyl)-3-phenyl-6,7-dihydro-1Hpyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110373	40.2% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-(4-ethoxyphenyl)-3-phenyl-6,7-dihydro-1Hpyrazolo[4,3-c] pyridine-5(4H)-carboxamide	727423	110374	47.2% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-(4-fluorophenyl)-3-phenyl-6,7-dihydro-1Hpyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110375	43.5% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-(4-methoxyphenyl)-3-phenyl-6,7-dihydro-1Hpyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110376	10.2% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-(4-nitrophenyl)-3-phenyl-6,7-dihydro-1Hpyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110377	95.7% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-(naphthalen-1-yl)-3-phenyl-6,7-dihydro-1Hpyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110378	89.8% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-benzyl-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110379	52.1% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-benzyl-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110380	46.2% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		1-benzoyl-N-isopropyl-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110381	40.9% inhibition at 0.1 mM
6.3.2.1	Escherichia coli		2,3-Diaminopropanoate	978	8502	slight
6.3.2.1	Mycobacterium tuberculosis		2-(5-nitrofuran-2-carboxamido)-6-(4-nitrophenylcarbamothioyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110454	
6.3.2.1	Mycobacterium tuberculosis		2-(5-nitrofuran-2-carboxamido)-6-(4-nitrophenylsulfonyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110455	
6.3.2.1	Escherichia coli		2-hydroxybutanoate	978	2470	slight
6.3.2.1	Escherichia coli		2-Hydroxypropanoate	978	924	slight
6.3.2.1	Mycobacterium tuberculosis		2-methyl-5-methoxyindole	704206	96962	binding mode with the 2-CH3 group facing the pantoate pocket
6.3.2.1	Escherichia coli		3,3-dimethyl-2-oxobutyric acid 5-(6-aminopurin-9-yl)-3,4-dihydroxytetrahydrofuran-2-ylmethyl ester	676279	41750	
6.3.2.1	Mycobacterium tuberculosis		3-(biphenyl-4-yl)-4-cyano-5-(ethylsulfanyl)-1-methyl-1H-pyrrole-2-carboxylic acid	728622	110557	
6.3.2.1	Escherichia coli		3-hydroxybutanoate	978	2001	slight
6.3.2.1	Escherichia coli		3-hydroxypropanoate	978	1223	slight
6.3.2.1	Mycobacterium tuberculosis		4-(2-{3-[(1E,3E)-hexa-1,3,5-trien-1-yl]phenyl}hydrazinyl)-4-oxobutanoic acid	714435	101048	27% inhibition
6.3.2.1	Escherichia coli		4-Amino-3-hydroxybutanoate	977	13210	32% inhibition at 1 mM
6.3.2.1	Escherichia coli		4-Amino-3-hydroxybutanoate	978	13210	
6.3.2.1	Escherichia coli		4-aminobutanoate	977	492	27% inhibition at 1 mM
6.3.2.1	Escherichia coli		4-aminobutanoate	978, 979	492	
6.3.2.1	Mycobacterium tuberculosis		4-cyano-3-(4'-cyanobiphenyl-4-yl)-1-methyl-5-propyl-1H-pyrrole-2-carboxylic acid	728622	110644	
6.3.2.1	Mycobacterium tuberculosis		4-[(4-[[(5-tert-butyl-4,5,6,7-tetrahydro-1,2-benzisoxazol-3-yl)carbonyl]amino]-1H-pyrazol-1-yl)methyl]benzoic acid	693541	47976	0.1 mM, 99% inhibition
6.3.2.1	Escherichia coli		5-Aminopentanoate	978	1967	slight
6.3.2.1	Escherichia coli		5-Aminopentanoate	979	1967	
6.3.2.1	Mycobacterium tuberculosis		5-methoxyindole	704206	16192	competitive with respect to ATP
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxylic acid	693541	92108	0.1 mM, 12% inhibition
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-(1-[4-[(2-phenylethyl)carbamoyl]benzyl]-1H-pyrazol-4-yl)-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48046	0.1 mM, 78% inhibition
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-1H-pyrazol-4-yl-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48054	0.1 mM, 43% inhibition
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide derivatives	693541	92881	silico molecular design, synthesis, and inhibitory activity, overview
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-[1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	92109	0.1 mM, 17% inhibition
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-[1-(2,4-difluorobenzyl)-1H-pyrazol-4-yl]-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48047	0.1 mM, 100% inhibition
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-[1-(2-iodobenzyl)-1H-pyrazol-4-yl]-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48048	0.1 mM, 84% inhibition
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-[1-(2-methylbenzyl)-1H-pyrazol-4-yl]-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48049	0.1 mM, 89% inhibition
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-[1-(4-chlorobenzyl)-1H-pyrazol-4-yl]-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48050	0.1 mM, 98% inhibition
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-[1-(4-fluorobenzyl)-1H-pyrazol-4-yl]-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48051	0.1 mM, 98% inhibition
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-[1-(naphthalen-1-ylmethyl)-1H-pyrazol-4-yl]-4,5,6,7-tetrahydro-1,2-benzoxazole-3-carboxamide	727423	110730	
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-[1-(naphthalen-2-ylmethyl)-1H-pyrazol-4-yl]-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48052	0.1 mM, 97% inhibition
6.3.2.1	Mycobacterium tuberculosis		5-tert-butyl-N-[4-carbamoyl-3-(4-methoxybenzyl)isoxazol-5-yl]-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48053	0.1 mM, 79% inhibition
6.3.2.1	Mycobacterium tuberculosis		6-(4-acetylphenylsulfonyl)-2-(5-nitrofuran-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110767	
6.3.2.1	Mycobacterium tuberculosis		6-(4-acetylphenylsulfonyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110768	
6.3.2.1	Mycobacterium tuberculosis		6-(4-bromophenylsulfonyl)-2-(5-nitrofuran-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110769	
6.3.2.1	Mycobacterium tuberculosis		6-(4-bromophenylsulfonyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110770	
6.3.2.1	Mycobacterium tuberculosis		6-(4-chlorophenylcarbamothioyl)-2-(5-nitrofuran-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110771	
6.3.2.1	Mycobacterium tuberculosis		6-(4-chlorophenylcarbamothioyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110772	
6.3.2.1	Mycobacterium tuberculosis		6-(4-chlorophenylcarbamoyl)-2-(5-nitrofuran-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110773	
6.3.2.1	Mycobacterium tuberculosis		6-(4-chlorophenylcarbamoyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110774	
6.3.2.1	Mycobacterium tuberculosis		6-(4-fluorophenylcarbamothioyl)-2-(5-nitrofuran-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110775	
6.3.2.1	Mycobacterium tuberculosis		6-(4-fluorophenylcarbamothioyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110776	
6.3.2.1	Mycobacterium tuberculosis		6-(4-fluorophenylsulfonyl)-2-(5-nitrofuran-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110777	
6.3.2.1	Mycobacterium tuberculosis		6-(4-fluorophenylsulfonyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110778	
6.3.2.1	Mycobacterium tuberculosis		6-(4-methoxyphenylcarbamoyl)-2-(5-nitrofuran-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110779	
6.3.2.1	Mycobacterium tuberculosis		6-(4-methoxyphenylcarbamoyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110780	
6.3.2.1	Mycobacterium tuberculosis		6-(4-methoxyphenylsulfonyl)-2-(5-nitrofuran-2-arboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169		
6.3.2.1	Mycobacterium tuberculosis		6-(4-methoxyphenylsulfonyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110781	
6.3.2.1	Mycobacterium tuberculosis		6-(4-nitrophenylcarbamothioyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110782	
6.3.2.1	Mycobacterium tuberculosis		6-(4-nitrophenylcarbamoyl)-2-(5-nitrofuran-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110783	
6.3.2.1	Mycobacterium tuberculosis		6-(4-nitrophenylcarbamoyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110784	
6.3.2.1	Mycobacterium tuberculosis		6-(4-nitrophenylsulfonyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110785	
6.3.2.1	Mycobacterium tuberculosis		6-(benzylcarbamothioyl)-2-(5-nitrofuran-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110786	
6.3.2.1	Mycobacterium tuberculosis		6-(benzylcarbamothioyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110787	
6.3.2.1	Mycobacterium tuberculosis		6-(benzylcarbamoyl)-2-(5-nitrofuran-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110788	
6.3.2.1	Mycobacterium tuberculosis		6-(benzylcarbamoyl)-2-(5-nitrothiophene-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide	727169	110789	
6.3.2.1	Escherichia coli		6-Aminohexanoate	978	1969	slight
6.3.2.1	Mycobacterium tuberculosis		actinomycin D	714435, 727423	2109	
6.3.2.1	Escherichia coli		Ag+	977, 978, 979	71	
6.3.2.1	Escherichia coli		AMP	979	9	
6.3.2.1	Escherichia coli		anserine	978	4388	slight
6.3.2.1	Escherichia coli		Asp	979	91	uncompetitive
6.3.2.1	Escherichia coli		aspartate	977	91	24% inhibition at 1 mM
6.3.2.1	Escherichia coli		Ba2+	977, 978	105	
6.3.2.1	Escherichia coli		Ca2+	977, 978, 979	18	
6.3.2.1	Escherichia coli		carnosine	978	2458	slight
6.3.2.1	Escherichia coli		Co2+	977, 978	21	
6.3.2.1	Escherichia coli		Cu2+	977, 978, 979	28	
6.3.2.1	Mycobacterium tuberculosis		cyclohexyl(3-phenyl-5-(thiophen-2-ylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methanone	727423	110875	52.0% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		cyclohexyl(3-phenyl-5-tosyl-4,5,6,7-tetrahydro-1Hpyrazolo[4,3-c]pyridin-1-yl)methanone	727423	110876	41.6% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		cyclohexyl(5-(4-fluorophenylsulfonyl)-3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methanone	727423	110877	46.8% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		cyclohexyl(5-(4-nitrophenylsulfonyl)-3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methanone	727423	110878	50.2% inhibition at 0.1 mM
6.3.2.1	Escherichia coli		cysteine	979	70	weak
6.3.2.1	Escherichia coli		diphosphate	979	13	
6.3.2.1	Escherichia coli		DTT	979	42	weak
6.3.2.1	Escherichia coli		EDTA	977, 978	223	
6.3.2.1	Escherichia coli		EGTA	977, 978	157	
6.3.2.1	Escherichia coli		Fe2+	977	23	slight
6.3.2.1	Escherichia coli		Fe2+	978, 979	23	
6.3.2.1	Escherichia coli		gluconate	977, 978	562	32% inhibition at 1 mM
6.3.2.1	Escherichia coli		glycolate	977, 978	399	30% inhibition at 1 mM
6.3.2.1	Escherichia coli		Hg2+	977, 978, 979	31	
6.3.2.1	Escherichia coli		iodoacetate	978	87	
6.3.2.1	Escherichia coli		iodoacetate	979	87	weak
6.3.2.1	Escherichia coli		L-Ala	978, 979	97	
6.3.2.1	Escherichia coli		L-cysteate	978	2703	
6.3.2.1	Escherichia coli		L-Val	978	217	
6.3.2.1	Escherichia coli		L-Val	979	217	uncompetitive
6.3.2.1	Escherichia coli		Lactate	978	924	
6.3.2.1	Escherichia coli		Li+	979	142	
6.3.2.1	Escherichia coli		mercaptoethanol	979	59	weak
6.3.2.1	Escherichia coli		Mercaptoethanolamine	979	632	weak
6.3.2.1	Escherichia coli		Mercaptopurine	979	1019	weak
6.3.2.1	Mycobacterium tuberculosis		methyl 4-[(4-[[(5-tert-butyl-4,5,6,7-tetrahydro-1,2-benzisoxazol-3-yl)carbonyl]amino]-1H-pyrazol-1-yl)methyl]benzoate	693541	48111	0.1 mM, 100% inhibition
6.3.2.1	Mycobacterium tuberculosis		methyl 5-amino-3-(benzyloxy)-1H-indole-2-carboxylate	727423	110897	
6.3.2.1	Mycobacterium tuberculosis		methyl 6-amino-4-(benzyloxy)-1H-indole-2-carboxylate	714435	59218	69% inhibition
6.3.2.1	Escherichia coli		Methylmalonate	977	1628	38% inhibition at 1 mM
6.3.2.1	Escherichia coli		Mg2+	977	25	inhibition above 10 mM
6.3.2.1	Escherichia coli		Mn2+	977	26	inhibition above 5 mM
6.3.2.1	Mycobacterium tuberculosis		more	727169		development, synthesis and evaluation of tetrahydrothieno[2,3-c]pyridine-3-carboxamide-based inhibitors, computational molecular modeling, overview
6.3.2.1	Mycobacterium tuberculosis		more	727423		synthesis and evaluation of 3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as pantothenate synthetase inhibitors, overview. No inhibition by isoniazid and ethambutol
6.3.2.1	Mycobacterium tuberculosis		more	728622		evaluation of 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as enzyme inhibitors, overview
6.3.2.1	Mycobacterium tuberculosis		N-(1-benzyl-1H-pyrazol-4-yl)-5-tert-butyl-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48134	0.1 mM, 100% inhibition
6.3.2.1	Mycobacterium tuberculosis		N-(2,5-dibromophenyl)-2-hydroxybenzamide	693541	92141	
6.3.2.1	Mycobacterium tuberculosis		N-(4-acetylphenyl)-1-(cyclohexanecarbonyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110923	51.4% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		N-(4-acetylphenyl)-1-benzoyl-3-phenyl-6,7-dihydro-1Hpyrazolo[4,3-c] pyridine-5(4H)-carboxamide	727423	110924	43.7% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		N-(4-bromophenyl)-1-(cyclohexanecarbonyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110927	50.5% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		N-(4-chlorophenyl)-1-(cyclohexanecarbonyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110931	56.3% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		N-(4-chlorophenyl)-1-(cyclohexanecarbonyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110932	54.7% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		N-allyl-1-benzoyl-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110947	41.7% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		N-benzyl-1-(cyclohexanecarbonyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carbothioamide	727423	110948	51.4% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		N-benzyl-1-(cyclohexanecarbonyl)-3-phenyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide	727423	110949	49.1% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		N-[1-(2,4-dichlorobenzyl)-1H-pyrazol-4-yl]-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	92158	0.1 mM, 18% inhibition
6.3.2.1	Mycobacterium tuberculosis		N-[1-(2-bromobenzyl)-1H-pyrazol-4-yl]-5-tert-butyl-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48172	0.1 mM, 94% inhibition
6.3.2.1	Mycobacterium tuberculosis		N-[1-[4-(benzylcarbamoyl)benzyl]-1H-pyrazol-4-yl]-5-tert-butyl-4,5,6,7-tetrahydro-1,2-benzisoxazole-3-carboxamide	693541	48174	0.1 mM, 82% inhibition
6.3.2.1	Mycobacterium tuberculosis		nafronyl oxalate	674945	16134	competitive inhibitor
6.3.2.1	Mycobacterium tuberculosis		nafronyl oxalate	714435, 727423, 728622	16134	
6.3.2.1	Escherichia coli		Ni2+	977, 978	36	slight
6.3.2.1	Escherichia coli		Ni2+	979	36	
6.3.2.1	Mycobacterium tuberculosis		pantothenate	650029	1139	product inhibition
6.3.2.1	Escherichia coli		pantothenic acid	979	1139	
6.3.2.1	Escherichia coli		Pb2+	977	132	slight
6.3.2.1	Escherichia coli		Pb2+	979	132	
6.3.2.1	Escherichia coli		PCMB	979	40	
6.3.2.1	Mycobacterium tuberculosis		phenyl(3-phenyl-5-(thiophen-2-ylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methanone	727423		48.7% inhibition at 0.1 mM
6.3.2.1	Mycobacterium tuberculosis		phenyl(3-phenyl-5-tosyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methanone	727423	111029	9.0% inhibition at 0.1 mM
6.3.2.1	Escherichia coli		Sn2+	977, 978	346	slight
6.3.2.1	Escherichia coli		Sr2+	977, 978	289	slight
6.3.2.1	Escherichia coli		taurine	977	490	52% inhibition at 1 mM
6.3.2.1	Escherichia coli		taurine	978, 979	490	
6.3.2.1	Mycobacterium tuberculosis		tert-butyl 4-[(4-[[(5-tert-butyl-4,5,6,7-tetrahydro-1,2-benzisoxazol-3-yl)carbonyl]amino]-1H-pyrazol-1-yl)methyl]benzoate	693541	48218	0.1 mM, 79% inhibition
6.3.2.1	Escherichia coli		Zn2+	977, 978, 979	19	
6.3.2.1	Mycobacterium tuberculosis		[2-[(1-benzofuran-2-ylsulfonyl)carbamoyl]-5-methyl-1H-inden-1-yl]acetic acid	727423	111036	
1.4.3.5	Oryctolagus cuniculus	2-aminobutanoate		391880	1302	activation
1.4.3.5	Rattus norvegicus	3-Hydroxyanthranilate		391873	1034	145% increase in pyridoxine 5-phosphate oxidase activity, 28% increase in pyridoxamine 5-phosphate oxidase activity
1.4.3.5	Rattus norvegicus	3-hydroxykynurenine		391873	1801	125% increase in pyridoxine 5-phosphate oxidase activity, 20% increase in pyridoxamine 5-phosphate oxidase activity
1.4.3.5	Rattus norvegicus	5-hydroxyindolacetate		391873	13879	125% increase in pyridoxine 5-phosphate oxidase activity, 9% increase in pyridoxamine 5-phosphate oxidase activity
1.4.3.5	Rattus norvegicus	5-hydroxytryptamine		391873	365	20% increase in pyridoxamine 5-phosphate oxidase activity
1.4.3.5	Oryctolagus cuniculus	alanine		391880	97	activation
1.4.3.5	Triticum aestivum	ammonium sulfate		391881	334	short incubation activates isozyme E-II, not E-I
1.4.3.5	Oryctolagus cuniculus	cysteine		391880	70	activation
1.4.3.5	Oryctolagus cuniculus	guanidine hydrochloride		391885	804	500 mM, activation at low concentrations and brief periods of exposure, inactivation at higher concentrations and longer periods of exposure
1.4.3.5	Oryctolagus cuniculus	guanidine hydrochloride urea		391885	39932	both activates and denatures the enzyme
1.4.3.5	Triticum aestivum	more		391897		the enzyme is induced by light without affecting the substrate specificity
1.4.3.5	Oryctolagus cuniculus	Tris		391880	272	activation
1.4.3.5	Rattus norvegicus	tryptamine		391873	310	27% increase in pyridoxamine 5-phosphate oxidase activity
1.4.3.5	Oryctolagus cuniculus	Urea		391885	110	2.0-2.5 M, rapid and reversible activation at low concentrations and brief periods of exposure, inactivation at higher concentrations and longer periods of exposure; both activates and denatures the enzyme, rapid and reversible activation at 2.0-2.5 M urea
1.4.3.5	Oryctolagus cuniculus	valine		391880	217	activation
1.4.3.5	Rattus norvegicus	xanthurenate		391873	3005	21% increase in pyridoxine 5-phosphate oxidase activity
1.4.3.5	Oryctolagus cuniculus		2,3-Butanedione	391870	603	10 mM, complete inhibition after 50 min in borate buffer, inhibition is fully reversible upon removal of borate
1.4.3.5	Oryctolagus cuniculus		2,4-pentandione	391870	2134	0.3 mM, approx. 90% inhibition of holoenzyme
1.4.3.5	Oryctolagus cuniculus		4-chloromercuribenzoate	391880	40	0.1 mM, 90-95% inhibition
1.4.3.5	Oryctolagus cuniculus		4-deoxypyridoxine 5'-phosphate	391880	11700	0.1 mM, 42% inhibition
1.4.3.5	Oryctolagus cuniculus		4-deoxypyridoxine 5'-phosphate	391895	11700	
1.4.3.5	Escherichia coli		4-deoxypyridoxine 5'-phosphate	391903	11700	competitive inhibition
1.4.3.5	Oryctolagus cuniculus		4-Pyridoxic acid phosphate	391880	15075	0.1 mM, 33.5% inhibition
1.4.3.5	Triticum aestivum		ammonium sulfate	391881	334	1.9 M, E II: activation at short incubation time, E I: complete inactivation after 10 h incubation; inactivation of isozyme E-I after 10 h
1.4.3.5	Triticum aestivum		Cd2+	391881	48	0.5 mM, isozyme E I: insensitive, isozyme E II: 44% inhibition; 44% reduced activity of isozyme E-II, no inhibition of isozyme E-I
1.4.3.5	Saccharomyces cerevisiae		Cd2+	391900	48	2.85 mM, 82% inhibition of pyridoxamine 5'-phosphate oxidation, 27% inhibition of pyridoxine oxidation
1.4.3.5	Triticum aestivum		citrate-phosphate buffer	391881		
1.4.3.5	Oryctolagus cuniculus		Cu2+	391880	28	1 mM, 90-95% inhibition
1.4.3.5	Saccharomyces cerevisiae		Cu2+	391900	28	2.85 mM, 38% inhibition of pyridoxamine 5'-phosphate oxidation, 23% inhibition of pyridoxine oxidation
1.4.3.5	Oryctolagus cuniculus		diethyldicarbonate	391884	265	1.2 mM, complete inactivation after 10 min, activity decrease of 60% can be restored by a 20 min incubation with 900 mM hydroxylamine, pyridoxal 5'-phosphate oxime protects from inactivation, inactivation is due to modification of histidine residues
1.4.3.5	Saccharomyces cerevisiae		Fe2+	391900	23	2.85 mM, 44% inhibition of pyridoxamine 5'-phosphate oxidation, 81% inhibition of pyridoxine oxidation
1.4.3.5	Saccharomyces cerevisiae		Fe3+	391900	66	2.85 mM, 26% inhibition of pyridoxamine 5'-phosphate oxidation, 50% inhibition of pyridoxine oxidation
1.4.3.5	Oryctolagus cuniculus		guanidine hydrochloride urea	391885	39932	both activates and denatures the enzyme
1.4.3.5	Oryctolagus cuniculus		Hg2+	391880	31	1 mM, 90-95% inhibition
1.4.3.5	Triticum aestivum		Hg2+	391881	31	0.5 mM, isozyme E I: insensitive, isozyme E II: 54% inhibition; 72% reduced activity of isozyme E-II, no inhibition of isozyme E-I
1.4.3.5	Saccharomyces cerevisiae		Hg2+	391900	31	2.85 mM, 30% inhibition of pyridoxamine 5'-phosphate oxidation, 2% inhibition of pyridoxine oxidation
1.4.3.5	Rattus norvegicus		more	391873		no inhibition by tryptophan metabolites
1.4.3.5	Oryctolagus cuniculus		more	391878		no substrate inhibition with pyridoxamine 5'-phosphate
1.4.3.5	Escherichia coli		more	654870		pyridoxamine 5'-phosphate shows no substrate inhibition
1.4.3.5	Oryctolagus cuniculus		Phenylglyoxal	391870	258	pyridoxal 5'-phosphate protects
1.4.3.5	Sus scrofa		pyridoxal 5'-phosphate	391875	30	
1.4.3.5	Oryctolagus cuniculus		pyridoxal 5'-phosphate	391885	30	potent product inhibition
1.4.3.5	Oryctolagus cuniculus		pyridoxal 5'-phosphate	391887	30	competitive inhibition; competitive product inhibition, overview
1.4.3.5	Rattus norvegicus		pyridoxal 5'-phosphate	391887	30	competitive inhibition
1.4.3.5	Oryctolagus cuniculus		pyridoxal 5'-phosphate	391868, 391880, 391895, 391901	30	
1.4.3.5	Escherichia coli		pyridoxal 5'-phosphate	391903	30	competitive inhibition
1.4.3.5	Escherichia coli		pyridoxal 5'-phosphate	391904, 654870	30	
1.4.3.5	Homo sapiens		pyridoxal 5'-phosphate	391868, 655483, 657296	30	
1.4.3.5	Escherichia coli		pyridoxal 5'-phosphate	724427	30	competitive inhibitor
1.4.3.5	Homo sapiens		pyridoxal 5'-phosphate	724427	30	competitive inhibitor
1.4.3.5	Oryctolagus cuniculus		pyridoxal 5'-phosphate oxime	391895	29704	
1.4.3.5	Sus scrofa		pyridoxaloxime 5'-phosphate	391875	14252	competitive inhibition
1.4.3.5	Oryctolagus cuniculus		pyridoxaloxime 5'-phosphate	391880	14252	0.2 mM, 80% inhibition
1.4.3.5	Oryctolagus cuniculus		pyridoxaloxime 5'-phosphate	391884, 391895	14252	
1.4.3.5	Rattus norvegicus		pyridoxamine 5'-phosphate	391873	539	substrate inhibition above 0.0006 mM
1.4.3.5	Oryctolagus cuniculus		pyridoxine 5'-phosphate	391878	795	substrate inhibition
1.4.3.5	Escherichia coli		pyridoxine 5'-phosphate	654870	795	substrate inhibition
1.4.3.5	Oryctolagus cuniculus		Urea	391885	110	both activates and denatures the enzyme, reversible inactivation above 2.5 M, half-time of inactivation is 46 min at 2 M and 37&deg;C
1.4.3.5	Triticum aestivum		Zn2+	391881	19	0.5 mM, isozyme E I: insensitive, isozyme E II: 54% inhibition; 72% reduced activity of isozyme E-II, no inhibition of isozyme E-I
1.4.3.5	Saccharomyces cerevisiae		Zn2+	391900	19	2.85 mM, 92% inhibition of pyridoxamine 5'-phosphate oxidation, 60% inhibition of pyridoxine oxidation
2.7.1.11	Austromegabalanus psittacus	(NH4)2SO4		673170	334	activates
2.7.1.11	Clostridium pasteurianum	ADP		640421	8	
2.7.1.11	Fasciola hepatica	ADP		640421	8	
2.7.1.11	Rattus norvegicus	ADP		640421	8	
2.7.1.11	Saccharomyces cerevisiae	ADP		640421	8	
2.7.1.11	Lymantria dispar	ADP		640423	8	activation
2.7.1.11	Camelus dromedarius	ADP		640429	8	activation
2.7.1.11	Spinacia oleracea	ADP		640446	8	activation
2.7.1.11	Trypanosoma brucei	ADP		640452	8	1.8 mM, half-maximal activation at fructose 6-phosphate concentrations below 0.5 mM
2.7.1.11	Fasciola hepatica	ADP		640455	8	activation
2.7.1.11	Saccharomyces cerevisiae	ADP		640462	8	activation; slight
2.7.1.11	Lactococcus lactis	ADP		640465	8	activation
2.7.1.11	Aspergillus niger	ADP		640480	8	activation; at high fructose 6-phosphate concentration, inhibits at low fructose 6-phosphate concentration
2.7.1.11	Clostridium pasteurianum	ADP		640485	8	activation; positive effector
2.7.1.11	Oceanimonas doudoroffii	ADP		640495	8	activation; positive effector
2.7.1.11	Thermotoga maritima	ADP		640515	8	
2.7.1.11	Sparus aurata	ADP		672415	8	activates
2.7.1.11	Oryctolagus cuniculus	ADP		702446, 721506	8	
2.7.1.11	Escherichia coli	ADP		722736	8	
2.7.1.11	Homo sapiens	ADP		721506, 722757	8	
2.7.1.11	Methanococcus maripaludis	ADP		727725	8	activates
2.7.1.11	Oryctolagus cuniculus	Aldolase		722869		about 120% activity in the presence of 0.005 mM aldolase
2.7.1.11	Bos taurus	AMP		640421	9	
2.7.1.11	Fasciola hepatica	AMP		640421	9	
2.7.1.11	Rattus norvegicus	AMP		640421	9	
2.7.1.11	Saccharomyces cerevisiae	AMP		640421	9	
2.7.1.11	Lymantria dispar	AMP		640423	9	activation
2.7.1.11	Bos taurus	AMP		640425	9	activation
2.7.1.11	Camelus dromedarius	AMP		640429	9	activation
2.7.1.11	Trypanosoma brucei	AMP		640452	9	0.64 mM, half-maximal activation at fructose 6-phosphate concentrations below 0.5 mM
2.7.1.11	Fasciola hepatica	AMP		640456	9	activation; one of three most potent activators
2.7.1.11	Bombus atratus	AMP		640457	9	activation; synergistic with fructose 2,6-bisphosphate
2.7.1.11	Crassostrea virginica	AMP		640460	9	activation
2.7.1.11	Saccharomyces cerevisiae	AMP		640469	9	activation; positive effector
2.7.1.11	Oncorhynchus mykiss	AMP		640475	9	activation
2.7.1.11	Apis mellifera	AMP		640479	9	activation
2.7.1.11	Calliphoridae	AMP		640479	9	activation
2.7.1.11	Locusta migratoria	AMP		640479	9	activation; concomitant with NH4+ and phosphate
2.7.1.11	Aspergillus niger	AMP		640480	9	activation at low fructose 6-phosphate concentrations, inhibition at high fructose 6-phosphate concentrations
2.7.1.11	Kluyveromyces lactis	AMP		640503	9	2-5 mM, maximal activation at 3 mM ATP
2.7.1.11	Komagataella pastoris	AMP		640514	9	
2.7.1.11	Schizosaccharomyces pombe	AMP		640523	9	activation follows a saturation function, Km: 0.56 mM
2.7.1.11	Aspergillus niger	AMP		671462	9	activates 85000 Da native enzyme form and the 49000 Da shorter fragment
2.7.1.11	Sparus aurata	AMP		672415	9	activates
2.7.1.11	Sus scrofa	AMP		677082	9	activates; at near-physiological substrate concentrations, PFK activity requires activators of which the combination of AMP and fructose 2,6-bisphosphate is most efficient as a result of synergistic effects
2.7.1.11	Oryctolagus cuniculus	AMP		721506	9	
2.7.1.11	Homo sapiens	AMP		721506, 722757	9	
2.7.1.11	Methanococcus maripaludis	AMP		727725	9	activates
2.7.1.11	Oryctolagus cuniculus	Calmodulin		671923	119	clotrimazole-inhibited enzyme can be activated by calmodulin
2.7.1.11	Oryctolagus cuniculus	Calmodulin		702446	119	binding of one calmodulin per monomer promotes the dimerization of the enzyme although maintaining its full catalytic activity, 30 nM calmodulin activates 6-phosphofructo-1-kinase in the presence of its inhibitors citrate and lactate
2.7.1.11	Fasciola hepatica	cAMP		640421	233	
2.7.1.11	Oryctolagus cuniculus	cAMP		640421	233	
2.7.1.11	Rattus norvegicus	cAMP		640421	233	
2.7.1.11	Lymantria dispar	cAMP		640423	233	activation
2.7.1.11	Trypanosoma brucei	cAMP		640452	233	0.4 mM, half-maximal activation at fructose 6-phosphate concentrations below 0.5 mM
2.7.1.11	Fasciola hepatica	cAMP		640455	233	activation
2.7.1.11	Oryctolagus cuniculus	cAMP		640521	233	0.1 mM, approx. 5fold activation
2.7.1.11	Austromegabalanus psittacus	cAMP		673170	233	0.1 mM, activates
2.7.1.11	Fasciola hepatica	cAMP-dependent protein kinase		640455		activation by phosphorylation
2.7.1.11	Fasciola hepatica	cAMP-dependent protein kinase		640456		activation by phosphorylation; kinetics, one of three most potent activators
2.7.1.11	Spinacia oleracea	citrate		640445	125	stimulation, by chelating of free Mg2+
2.7.1.11	Methanococcus maripaludis	citrate		727725	125	activates the enzyme in the absence of phosphate and inhibits the enzyme in the presence of phosphate
2.7.1.11	Spinacia oleracea	Cl-		640445	134	200 mM, 3.1fold activation of cytosolic PFK
2.7.1.11	Bos taurus	D-fructose 1,6-bisphosphate		640425	100	activation
2.7.1.11	Camelus dromedarius	D-fructose 1,6-bisphosphate		640429	100	activation
2.7.1.11	Ascaris suum	D-fructose 1,6-bisphosphate		640454	100	activation
2.7.1.11	Fasciola hepatica	D-fructose 1,6-bisphosphate		640456	100	activation
2.7.1.11	Rana temporaria	D-fructose 1,6-bisphosphate		640476	100	half-maximal activation at 0.0035 mM
2.7.1.11	Locusta migratoria	D-fructose 1,6-bisphosphate		640479	100	activation; activation of flight muscle PFK in the absence of fructose 2,6-bisphosphate
2.7.1.11	Rattus norvegicus	D-fructose 1,6-bisphosphate		640496	100	activation of PFK in INS-1 cell extract
2.7.1.11	Fasciola hepatica	D-fructose 2,6-bisphosphate		640456	573	activation of native and phosphorylated PFK, one of three most potent activators
2.7.1.11	Bombus atratus	D-fructose 2,6-bisphosphate		640457	573	3fold activation in the presence of approx. 0.003 mM, i.e. the physiological fructose 2,6-bisphosphate concentration; synergistic with AMP
2.7.1.11	Saccharomyces cerevisiae	D-fructose 2,6-bisphosphate		640462	573	strong positive allosteric action on PFK
2.7.1.11	Oncorhynchus mykiss	D-fructose 2,6-bisphosphate		640475	573	activation
2.7.1.11	Rana temporaria	D-fructose 2,6-bisphosphate		640476	573	activation
2.7.1.11	Rattus norvegicus	D-fructose 2,6-bisphosphate		640496	573	activation of PFK in INS-1 cell extract
2.7.1.11	Kluyveromyces lactis	D-fructose 2,6-bisphosphate		640503	573	approx. 200-400 mM, maximal activation at 3 mM ATP
2.7.1.11	Mus musculus	D-fructose 2,6-bisphosphate		640504	573	strong stimulation of mammary gland PFK, Kact: 0.00005 mM
2.7.1.11	Rattus norvegicus	D-fructose 2,6-bisphosphate		640504	573	
2.7.1.11	Mus musculus	D-fructose 2,6-bisphosphate		640508	573	
2.7.1.11	Komagataella pastoris	D-fructose 2,6-bisphosphate		640514	573	
2.7.1.11	Oryctolagus cuniculus	D-fructose 2,6-bisphosphate		640521	573	half-maximal activation at 0.0003 mM
2.7.1.11	Schizosaccharomyces pombe	D-fructose 2,6-bisphosphate		640523	573	cooperative activation, Km: 0.00023 mM
2.7.1.11	Austromegabalanus psittacus	D-fructose 2,6-bisphosphate		673170	573	activates at concentrations above 0.002 mM
2.7.1.11	Sus scrofa	D-fructose 2,6-bisphosphate		677082	573	activates
2.7.1.11	Sparus aurata	D-fructose 2,6-bisphosphate		704345	573	converts saturation curves for D-fructose 6-phosphate to hyperbolic and activates PFK synergistically with AMP
2.7.1.11	Aspergillus niger	D-fructose 2,6-bisphosphate		704771	573	the active 49 kDa PFK1 fragment is activated to a higher level by D-fructose 2,6-bisphosphate with respect to the native enzyme, a significant boost in the enzyme activity of the fragment is registered at 1 mM ATP after the introduction of 0.004 mM of D-fructose-2,6-bisphosphate
2.7.1.11	Homo sapiens	D-fructose 2,6-bisphosphate		721541	573	
2.7.1.11	Oryctolagus cuniculus	D-fructose 2,6-bisphosphate		702446, 722978	573	
2.7.1.11	Saccharomyces cerevisiae	D-fructose 2,6-bisphosphate		722978	573	
2.7.1.11	Sparus aurata	D-fructose-1,6-bisphosphate		672415	100	activates synergistically with AMP and ADP
2.7.1.11	Camelus dromedarius	D-Glucose 1,6-bisphosphate		640429	1231	activation
2.7.1.11	Ascaris suum	D-Glucose 1,6-bisphosphate		640454	1231	
2.7.1.11	Fasciola hepatica	D-Glucose 1,6-bisphosphate		640456	1231	activation
2.7.1.11	Ascaris suum	D-Glucose 1,6-bisphosphate		640461	1231	activation only in the presence of AMP
2.7.1.11	Rana temporaria	D-Glucose 1,6-bisphosphate		640476	1231	half-maximal activation at 0.013 mM
2.7.1.11	Homo sapiens	D-Glucose 1,6-bisphosphate		640500	1231	0.02 mM, 474% and 360% activation of M- and L-type PFK, respectively
2.7.1.11	Aspergillus niger	D-glucose 6-phosphate		640480	99	4.8 mM, 1.5fold increase in activity at 2 mM fructose 6-phosphate, 2fold increase at 4 mM fructose 6-phosphate, in vitro
2.7.1.11	Oncorhynchus mykiss	Dimethylsulfoxide		640499	702	20%, 9fold increase in activity, probably due to crowding effect
2.7.1.11	Sus scrofa	fructose 2,6-bisphosphate		677082	573	at near-physiological substrate concentrations, PFK activity requires activators of which the combination of AMP and fructose 2,6-bisphosphate is most efficient as a result of synergistic effects
2.7.1.11	Escherichia coli	GDP		640489	49	activation
2.7.1.11	Geobacillus stearothermophilus	GDP		640498	49	activation at low concetrations, inhibition above 1 mM
2.7.1.11	Escherichia coli	GDP		640490, 722736	49	
2.7.1.11	Methanococcus maripaludis	GDP		727725	49	activates the enzyme in the absence of phosphate and inhibits the enzyme in the presence of phosphate
2.7.1.11	Oryctolagus cuniculus	glutathione		640421	41	activation
2.7.1.11	Oncorhynchus mykiss	glycerol		640499	129	40%, 4fold increase in activity, probably due to crowding effect
2.7.1.11	Spinacia oleracea	HAsO42-		640445	20400	50 mM, 2.9fold activation of cytosolic PFK
2.7.1.11	Spinacia oleracea	HCO3-		640445	175	200 mM, 2.1fold activation of cytosolic PFK
2.7.1.11	Escherichia coli	MgATP2-		722736	102	the apparent Km for MgATP2- is 0.022 mM
2.7.1.11	Vigna mungo	more		640438		not activated by fructose 2,6-bisphosphate
2.7.1.11	Ascaris suum	more		640454		effector studies at near-physiological conditions
2.7.1.11	Mus musculus	more		640459		allosteric enzyme
2.7.1.11	Saccharomyces cerevisiae	more		640469		allosteric enzyme; K-type allosteric enzyme
2.7.1.11	Aspergillus niger	more		640480		not activated by 2-oxoglutarate
2.7.1.11	Escherichia coli	more		640486		
2.7.1.11	Mus musculus	more		640504		ascites tumor PFK is not activated by fructose-1,6-bisphosphate
2.7.1.11	Homo sapiens	more		661508		addition of oestradiol increases enzyme activity in intact cells
2.7.1.11	Dictyostelium discoideum	more		721541		not activated by D-fructose 2,6-bisphosphate
2.7.1.11	Teladorsagia circumcincta	more		722202		D-glucose 1,6-bisphosphate and phosphoenolpyruvate have no effect on activity
2.7.1.11	Oryctolagus cuniculus	more		722869		not influenced by potassium acetate
2.7.1.11	Clostridium pasteurianum	NH4+		640421	50	
2.7.1.11	Escherichia coli	NH4+		640421	50	
2.7.1.11	Rattus norvegicus	NH4+		640421	50	activation of muscle enzyme, inhibitory at high concentrations
2.7.1.11	Saccharomyces cerevisiae	NH4+		640421	50	
2.7.1.11	Cucumis sativus	NH4+		640443	50	40 mM, 50% activation at pH 8.0 and pH 7.2
2.7.1.11	Spinacia oleracea	NH4+		640445	50	cytosolic isozyme is not activated
2.7.1.11	Ascaris suum	NH4+		640454	50	at very low concentration, kinetics, Km-value: 0.56 mM
2.7.1.11	Fasciola hepatica	NH4+		640421, 640455	50	
2.7.1.11	Ascaris suum	NH4+		640461	50	
2.7.1.11	Saccharomyces cerevisiae	NH4+		640462	50	increases maximum activity of PFK and the affinity of PFK to fructose 6-phosphate
2.7.1.11	Bacillus licheniformis	NH4+		640464	50	
2.7.1.11	Lactococcus lactis	NH4+		640465	50	
2.7.1.11	Oryctolagus cuniculus	NH4+		640421, 640467	50	
2.7.1.11	Saccharomyces cerevisiae	NH4+		640469	50	activation at low concentrations
2.7.1.11	Locusta migratoria	NH4+		640479	50	concomitant with AMP and phosphate
2.7.1.11	Aspergillus niger	NH4+		640480	50	NH4+ increases the affinity for fructose 6-phosphate, counteracts the inhibition by ATP
2.7.1.11	Clostridium pasteurianum	NH4+		640485	50	can replace K+; required for activity
2.7.1.11	Escherichia coli	NH4+		640486	50	can replace K+
2.7.1.11	Oceanimonas doudoroffii	NH4+		640495	50	required for activity
2.7.1.11	Aspergillus niger	NH4+		671462	50	activates
2.7.1.11	Spinacia oleracea	NO3-		640445	263	50 mM 1.6fold activation of cytosolic PFK
2.7.1.11	Cucumis sativus	phosphate		640427	12	activation of cytosolic and plastidic isoenzyme
2.7.1.11	Ricinus communis	phosphate		640444	12	1 mM, strong activtion of plastid PFK at pH-values below 7.0; cytosolic isozyme: slight activation
2.7.1.11	Spinacia oleracea	phosphate		640445	12	25 mM, 3.2fold activation of cytosolic PFK
2.7.1.11	Dunaliella marina	phosphate		640447	12	kinetics; the enzyme is both activated and inhibited by phosphate, depending on fructose 6-phosphate/phosphate-ratio
2.7.1.11	Monoraphidium minutum	phosphate		640448	12	25% activation at 5 mM, inhibition above
2.7.1.11	Ascaris suum	phosphate		640454	12	kinetics, Km-value: 1.64 mM
2.7.1.11	Saccharomyces cerevisiae	phosphate		640462	12	synergistic with AMP
2.7.1.11	Apis mellifera	phosphate		640479	12	concomitant with NH4+ and AMP
2.7.1.11	Calliphoridae	phosphate		640479	12	concomitant with NH4+ and AMP
2.7.1.11	Locusta migratoria	phosphate		640479	12	concomitant with NH4+ and AMP
2.7.1.11	Methanococcus maripaludis	phosphate		727725	12	activates
2.7.1.11	Austromegabalanus psittacus	phosphatidylserine		673170	358	
2.7.1.11	Oncorhynchus mykiss	Polyethylene glycol		640499	2061	20%, 8fold increase in activity, probably due to crowding effect
2.7.1.11	Spinacia oleracea	SO42-		640445	148	50 mM, 2.6fold activation of cytosolic PFK
2.7.1.11	Ascaris suum	SO42-		640454	148	kinetics, Km-value: 1.73 mM; stimulation
2.7.1.11	Ascaris suum	SO42-		640461	148	stimulation
2.7.1.11	Oryctolagus cuniculus	Sodium acetate		722869	1341	about 115% activity in the presence of 0.04 mM sodium acetate
2.7.1.11	Oryctolagus cuniculus	trehalose		675940	484	activates
2.7.1.11	Oryctolagus cuniculus		(-)-Hydroxycitrate	640471	13393	
2.7.1.11	Methanococcus maripaludis		(NH4)2SO4	727725	334	inhibits above 50 mM
2.7.1.11	Oryctolagus cuniculus		(S)-hexadecyl-CoA	722699		
2.7.1.11	Musa acuminata		1,3-diphosphoglycerate	640518	1577	0.385 mM and 0.005 mM, 50% inhibition of PFK I and PFK II respectively, phosphate relieves from inhibition
2.7.1.11	Ascaris suum		2',3'-dialdehyde ATP	640506	32981	irreversibly modifies a single lysine residue in the ATP-inhibitory site, thereby locking PFK in a permanantly inhibited state without affecting the integrity of the active site
2.7.1.11	Oryctolagus cuniculus		2,3-diphosphoglycerate	640467	557	
2.7.1.11	Rattus norvegicus		2-oxoglutarate	640421	32	brain PFK, not heart PFK
2.7.1.11	Monoraphidium minutum		2-oxoglutarate	640448	32	2 mM, 92% inhibition
2.7.1.11	Citrus x paradisi		2-oxoglutarate	640507	32	competitive inhibition
2.7.1.11	Cucumis sativus		2-phosphoglycerate	640443	606	2 mM and 3.2 mM, 50% inhibition of cytosolic PFK at pH 8.0 and PH 7.2, respectively, 0.5 mM and 0.4 mM, 50% inhibition of plastid PFK at pH 8.0 and pH 7.2, respectively
2.7.1.11	Spinacia oleracea		2-phosphoglycerate	640445	606	1.3 mM, 50% inhibition of cytosolic PFK, no inhibition in the presence of 5 or 25 mM phosphate
2.7.1.11	Dunaliella marina		2-phosphoglycerate	640447	606	1 mM, complete inhibition, phosphate relieves, kinetics
2.7.1.11	Musa acuminata		2-phosphoglycerate	640518	606	0.032 mM and 0.004 mM, 50% inhibition of PFK I and PFK II respectively, phosphate relieves from inhibition
2.7.1.11	Triticum aestivum		3-phosphoglycerate	640422	174	
2.7.1.11	Ricinus communis		3-phosphoglycerate	640440	174	0.9 mM, 50% inhibition of plastid PFK
2.7.1.11	Cucumis sativus		3-phosphoglycerate	640443	174	
2.7.1.11	Dunaliella marina		3-phosphoglycerate	640447	174	1 mM, complete inhibition, phosphate relieves, 0.5 mM, 50% inhibition, sigmoidal inhibition curve; inhibition kinetics
2.7.1.11	Monoraphidium minutum		3-phosphoglycerate	640448	174	2 mM, 86% inhibition; inhibition kinetics
2.7.1.11	Oryctolagus cuniculus		3-phosphoglycerate	640521	174	1.5-2.0 mM, 50% inhibition
2.7.1.11	Sparus aurata		3-phosphoglycerate	672415	174	mixed inhibition
2.7.1.11	Sparus aurata		3-phosphoglycerate	704345	174	about 70% inhibition at 7 mM
2.7.1.11	Pisum sativum		ADP	640421	8	plant enzymes
2.7.1.11	Zea mays		ADP	640421	8	plant enzymes
2.7.1.11	Triticum aestivum		ADP	640422	8	kinetics
2.7.1.11	Cucumis sativus		ADP	640443	8	most potent inhibitor of cytosolic isozyme, 0.4 mM and 4 mM, 50% inhibition of cytosolic and plastid PFK at pH 8.0
2.7.1.11	Dunaliella marina		ADP	640447	8	
2.7.1.11	Tetrahymena pyriformis		ADP	640450	8	
2.7.1.11	Trypanosoma brucei		ADP	640452	8	kinetics
2.7.1.11	Clostridium pasteurianum		ADP	640421, 640466	8	
2.7.1.11	Aspergillus niger		ADP	640480	8	kinetics
2.7.1.11	Rhodotorula glutinis		ADP	640482	8	
2.7.1.11	Musa acuminata		ADP	640518	8	1.9 mM and 0.0006 mM, 50% inhibition of PFK I and PFK II respectively, phosphate relieves from inhibition
2.7.1.11	Sparus aurata		ADP	704345	8	
2.7.1.11	Homo sapiens		ADP	722757	8	complete inhibition at 4.5 mM ADP, 52.4% residual activity at 2.3 mM ADP
2.7.1.11	Aeropyrum pernix		ADP	727544	8	1 mM, 82% inhibition
2.7.1.11	Oryctolagus cuniculus		Agaric acid	640471	8321	
2.7.1.11	Fasciola hepatica		Aldolase	640456		
2.7.1.11	Ovis aries		Aldolase	640456		
2.7.1.11	Aeropyrum pernix		ammonium sulfate	640513	334	50 mM, 50% inhibition
2.7.1.11	Brassica oleracea var. gemmifera		AMP	640421	9	
2.7.1.11	Daucus carota		AMP	640421	9	weak inhibition
2.7.1.11	Lactobacillus plantarum		AMP	640421	9	weak inhibition
2.7.1.11	Neurospora crassa		AMP	640421	9	weak inhibition
2.7.1.11	Pisum sativum		AMP	640421	9	weak inhibition
2.7.1.11	Zea mays		AMP	640421	9	
2.7.1.11	Trypanosoma brucei		AMP	640452	9	kinetics
2.7.1.11	Lactococcus lactis		AMP	640465	9	5 mM, 80% inhibition
2.7.1.11	Aspergillus niger		AMP	640480	9	at high fructose 6-phosphate concentrations, activates at low fructose 6-phosphate concentrations
2.7.1.11	Amycolatopsis methanolica		AMP	640512	9	1 mM and 4 mM, 20% and 40% inhibition in the presence of 5 mM fructose 6-phosphate and Mg2+
2.7.1.11	Oryctolagus cuniculus		Antibodies against rabbit muscle enzyme	640421		not rabbit erythrocyte, leukocyte or platelet enzyme
2.7.1.11	Oryctolagus cuniculus		Arachidonoyl-CoA	722699	756	
2.7.1.11	Crassostrea virginica		arginine phosphate	640460	2855	
2.7.1.11	Oryctolagus cuniculus		ascorbate	688049	88	inhibition by ascorbate is PFK-1 concentration dependent. Ascorbate does not inhibit above 200 nM PFK-1. It is concluded that ascorbate inhibits PFK-1 dimers (and perhaps monomers) but not PFK-1 tetramers
2.7.1.11	Enterobacter aerogenes		ATP	640421	7	ADP partially reverses inhibition
2.7.1.11	Escherichia coli		ATP	640421	7	
2.7.1.11	Mus musculus		ATP	640421	7	ADP partially reverses inhibition; cAMP partially reverses inhibition; fructose 1,6-bisphosphate partially reverses inhibition; phosphate and AMP partially reverse inhibition
2.7.1.11	Oryctolagus cuniculus		ATP	640421	7	muscle PFK, strong inhibition at pH 7.1, weak inhibition at pH 7.6-8.5, not inhibited at pH 9.0
2.7.1.11	Rattus norvegicus		ATP	640421	7	fructose 1,6-bisphosphate partially reverses inhibition; phosphate and AMP partially reverse inhibition
2.7.1.11	Lymantria dispar		ATP	640423	7	at high concentrations
2.7.1.11	Cucumis sativus		ATP	640427	7	cytosolic isoenzyme is more sensitive to inhibition at pH 8.0 than pH 7.2, Mg2+ alleviates inhibition
2.7.1.11	Cucumis sativus		ATP	640428	7	at high concentrations
2.7.1.11	Camelus dromedarius		ATP	640429	7	
2.7.1.11	Rattus norvegicus		ATP	640431	7	pH-dependent inhibition
2.7.1.11	Chlorella pyrenoidosa		ATP	640432	7	above 0.5 mM
2.7.1.11	Platichthys flesus		ATP	640433	7	cAMP partially reverses inhibition; fructose 6-phosphate partially reverses inhibition; pH-dependent inhibition; phosphate and AMP partially reverse inhibition
2.7.1.11	Solanum lycopersicum		ATP	640436	7	above 1 mM, inhibition is relieved by Mg2+; free form
2.7.1.11	Ricinus communis		ATP	640440	7	inhibition of plastid PFK above 5 mM at pH 8.0 and above 0.5 mM at pH 7.2
2.7.1.11	Cucumis sativus		ATP	640443	7	2 mM, 50% inhibition of cytosolic PFK at pH 8.0, 5 mM, 50% inhibition of plastid PFK at pH 8.0
2.7.1.11	Ricinus communis		ATP	640444	7	substrate inhibition
2.7.1.11	Spinacia oleracea		ATP	640446	7	free form
2.7.1.11	Dunaliella marina		ATP	640447	7	strong inhibition above 1 mM, at 2.5 mM Mg2+
2.7.1.11	Monoraphidium minutum		ATP	640448	7	above 0.2 mM, inhibition is alleviated by Mg2+; free form
2.7.1.11	Tetrahymena pyriformis		ATP	640450	7	
2.7.1.11	Ascaris suum		ATP	640454	7	fructose 6-phosphate partially reverses inhibition
2.7.1.11	Fasciola hepatica		ATP	640455	7	1 mM, almost complete inhibition of native PFK, phosphorylated PFK is less sensitive to inhibition
2.7.1.11	Fasciola hepatica		ATP	640421, 640456	7	
2.7.1.11	Bombus atratus		ATP	640457	7	at high concentrations
2.7.1.11	Mus musculus		ATP	640459	7	ADP partially reverses inhibition; fructose 6-phosphate partially reverses inhibition; phosphate and AMP partially reverse inhibition
2.7.1.11	Ascaris suum		ATP	640461	7	above 0.05 mM, inhibition is more pronounced at pH 6.6 but occurs also at pH 8.0, inhibition is reversed by equivalent amounts of AMP
2.7.1.11	Saccharomyces cerevisiae		ATP	640421, 640462	7	
2.7.1.11	Saccharomyces cerevisiae		ATP	640469	7	NaF and limited proteolysis protect from inhibition
2.7.1.11	Rattus norvegicus		ATP	640473	7	
2.7.1.11	Oncorhynchus mykiss		ATP	640475	7	0.99 mM, 50% inhibition
2.7.1.11	Rana temporaria		ATP	640476	7	7.5 mM, 98% inhibition; fructose 2,6-bisphosphate partially reverses inhibition
2.7.1.11	Trachemys scripta		ATP	640477	7	0.004 mM and 0.003 mM, 50% inhibition at 20&deg;C and 6&deg;C, respectively, normoxic turtles
2.7.1.11	Apis mellifera		ATP	640458, 640479	7	
2.7.1.11	Locusta migratoria		ATP	640479	7	fructose 2,6-bisphosphate partially reverses inhibition; phosphate and AMP partially reverse inhibition
2.7.1.11	Aspergillus niger		ATP	640480	7	synergistic with citrate
2.7.1.11	Enterobacter aerogenes		ATP	640483	7	above 1 mM at 0.33 mM fructose 6-phosphate and 2 mM Mg2+, inhibition at a Mg/ATP ratio below 2; ADP partially reverses inhibition; fructose 6-phosphate partially reverses inhibition; Mg2+ partially reverses inhibition
2.7.1.11	Bos taurus		ATP	640421, 640425, 640487	7	
2.7.1.11	Ovis aries		ATP	640421, 640455, 640456, 640487	7	
2.7.1.11	Sus scrofa		ATP	640487	7	1 mM, 90% inhibition of the activity observed with 0.1 mM ATP
2.7.1.11	Escherichia coli		ATP	640490	7	at alkaline pH; mechanism
2.7.1.11	Oceanimonas doudoroffii		ATP	640495	7	above 0.25 mM in the absence of MgCl2; free form
2.7.1.11	Oncorhynchus mykiss		ATP	640499	7	0.02 mM and 0.94 mM, 50% inhibition at 0.0001 mg/ml and at 0.0006 mg/ml PFK respectively, 3.23 mM, 50% inhibition at 0.0006 mg/ml PFK in the presence of 10% polyethylene glycol
2.7.1.11	Homo sapiens		ATP	640500	7	inhibition of M-type PFK above 0.1 mM
2.7.1.11	Kluyveromyces lactis		ATP	640503	7	in the absence of AMP and fructose 2,6-bisphosphate
2.7.1.11	Ascaris suum		ATP	640506	7	
2.7.1.11	Citrus x paradisi		ATP	640507	7	inhibition above 0.08 mM
2.7.1.11	Mus musculus		ATP	640508	7	
2.7.1.11	Komagataella pastoris		ATP	640514	7	
2.7.1.11	Oryctolagus cuniculus		ATP	640521	7	0.4 mM, 50% inhibition of PFK C
2.7.1.11	Schizosaccharomyces pombe		ATP	640523	7	lower inhibition at pH 6.6 compared to pH 7.2
2.7.1.11	Escherichia coli		ATP	640526	7	inhibition of fructose 1-phosphate phosphorylation above 0.08 mM ATP
2.7.1.11	Sparus aurata		ATP	672415	7	potentiates inhibitory action of citrate
2.7.1.11	Sus scrofa		ATP	677082	7	at physiological concentration; at physiological pH, the enzyme is allosterically inhibited by near-physiological concentrations of its co-substrate ATP, which induces cooperativity, i.e. reduces the affinity for the substrate fructose 6-phosphate. Inhibition by ATP is reinforced by citrate and H+
2.7.1.11	Oryctolagus cuniculus		ATP	702446	7	the inhibition of enzyme activity by ATP (above 1 mM) is abolished in the presence of calmodulin
2.7.1.11	Sparus aurata		ATP	704345	7	complete inhibition at 10 mM
2.7.1.11	Aspergillus niger		ATP	704771	7	in contrast to the native PFK1 enzyme, the 49 kDa PFK1 fragment is highly sensitive to ATP inhibition (5fold lower activity at the 1 mM ATP than at the 0.1 mM concentration)
2.7.1.11	Oryctolagus cuniculus		ATP	640487, 721506	7	
2.7.1.11	Homo sapiens		ATP	640421, 640487, 640488, 721506, 721541	7	
2.7.1.11	Teladorsagia circumcincta		ATP	722202	7	allosteric inhibition by high ATP concentrations. The inhibitory effects of high ATP concentration can be reversed by D-fructose 2,6-bisphosphate and AMP
2.7.1.11	Homo sapiens		ATP	722757	7	millimolar inhibitor
2.7.1.11	Oryctolagus cuniculus		aurintricarboxylic acid	640471	1353	0.0002 mM, 50% inhibition at pH 7.3, reversed by addition of allosteric activators, i.e., fructose 2,6-bisphosphate or AMP, no inhibition at pH 8.0
2.7.1.11	Spinacia oleracea		Ca2+	640446	18	depending upon total Mg2+-concentration, kinetics, cytosolic isozyme
2.7.1.11	Bombus atratus		Ca2+	640457	18	
2.7.1.11	Bacillus licheniformis		Ca2+	640464	18	competitive vs. Mg2+
2.7.1.11	Lactobacillus plantarum		cAMP	640421	233	
2.7.1.11	Rattus norvegicus		cis-aconitate	640421	933	brain, not heart
2.7.1.11	Arthrobacter crystallopoietes		citrate	640421	125	strong inhibition
2.7.1.11	Arthrobacter nicotianae		citrate	640421	125	strong inhibition
2.7.1.11	Bos taurus		citrate	640421	125	strong inhibition
2.7.1.11	Brassica oleracea var. gemmifera		citrate	640421	125	strong inhibition
2.7.1.11	Clostridium pasteurianum		citrate	640421	125	strong inhibition
2.7.1.11	Daucus carota		citrate	640421	125	strong inhibition
2.7.1.11	Dictyostelium discoideum		citrate	640421	125	strong inhibition
2.7.1.11	Enterobacter aerogenes		citrate	640421	125	strong inhibition
2.7.1.11	Escherichia coli		citrate	640421	125	strong inhibition
2.7.1.11	Fasciola hepatica		citrate	640421	125	strong inhibition
2.7.1.11	Gallus gallus		citrate	640421	125	strong inhibition
2.7.1.11	Homo sapiens		citrate	640421	125	strong inhibition
2.7.1.11	Lactobacillus casei		citrate	640421	125	strong inhibition
2.7.1.11	Lactobacillus plantarum		citrate	640421	125	strong inhibition
2.7.1.11	Mus musculus		citrate	640421	125	strong inhibition
2.7.1.11	Neurospora crassa		citrate	640421	125	strong inhibition
2.7.1.11	Oryctolagus cuniculus		citrate	640421	125	strong inhibition
2.7.1.11	Ovis aries		citrate	640421	125	strong inhibition
2.7.1.11	Pisum sativum		citrate	640421	125	strong inhibition
2.7.1.11	Rattus norvegicus		citrate	640421	125	strong inhibition; synergistic with phosphate and AMP
2.7.1.11	Saccharomyces cerevisiae		citrate	640421	125	strong inhibition
2.7.1.11	Thermus thermophilus		citrate	640421	125	strong inhibition
2.7.1.11	Zea mays		citrate	640421	125	strong inhibition
2.7.1.11	Triticum aestivum		citrate	640422	125	
2.7.1.11	Lymantria dispar		citrate	640423	125	weak inhibition
2.7.1.11	Camelus dromedarius		citrate	640429	125	
2.7.1.11	Rattus norvegicus		citrate	640431	125	at pH 7.6, not at pH 8.4
2.7.1.11	Vigna mungo		citrate	640438	125	10 mM, approx. 30% inhibition
2.7.1.11	Musa acuminata		citrate	640442	125	10 mM, 60% inhibition
2.7.1.11	Dunaliella marina		citrate	640447	125	
2.7.1.11	Monoraphidium minutum		citrate	640448	125	2 mM, complete inhibition
2.7.1.11	Trypanosoma brucei		citrate	640452	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Ascaris suum		citrate	640454	125	weak inhibition
2.7.1.11	Fasciola hepatica		citrate	640456	125	strong inhibition; weak inhibition
2.7.1.11	Ovis aries		citrate	640456	125	strong inhibition; weak inhibition
2.7.1.11	Crassostrea virginica		citrate	640460	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Ascaris suum		citrate	640461	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Saccharomyces cerevisiae		citrate	640462	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Escherichia coli		citrate	640463	125	isoenzyme PFK2
2.7.1.11	Bacillus licheniformis		citrate	640464	125	
2.7.1.11	Saccharomyces cerevisiae		citrate	640469	125	
2.7.1.11	Oncorhynchus mykiss		citrate	640475	125	0.12 mM, 50% inhibition
2.7.1.11	Rana temporaria		citrate	640476	125	with glucose 1,6-bisphosphate or fructose 1,6-bisphosphate as activator
2.7.1.11	Trachemys scripta		citrate	640477	125	0.23 and 0.17 mM mM, 50% inhibition at 20&deg; and 6&deg;C, respectively, normoxic turtles, 0.3 mM, 50% inhibition at 20&deg;C and 6&deg;C, anoxic turtles
2.7.1.11	Apis mellifera		citrate	640458, 640479	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Calliphoridae		citrate	640479	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Locusta migratoria		citrate	640479	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Aspergillus niger		citrate	640480	125	strong inhibition; synergistic with ATP; synergistic with NH4+; synergistic with phosphate and AMP
2.7.1.11	Rhodotorula glutinis		citrate	640482	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Enterobacter aerogenes		citrate	640483	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Escherichia coli		citrate	640486	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Homo sapiens		citrate	640488	125	weak inhibition
2.7.1.11	Oceanimonas doudoroffii		citrate	640495	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
2.7.1.11	Rattus norvegicus		citrate	640496	125	inhibition of M- and C-type PFK in pancreatic beta-cells
2.7.1.11	Citrus x paradisi		citrate	640507	125	presence of 12 mM Mg2+ relieves inhibition completely
2.7.1.11	Mus musculus		citrate	640508	125	
2.7.1.11	Oryctolagus cuniculus		citrate	640521	125	50% inhibition below 0.25 mM
2.7.1.11	Aspergillus niger		citrate	671462	125	the native 85000 Da enzyme is moderately inhibited by citrate, the 49000 Da shorter fragment of PFK1 proves to be completely resistant to inhibition by citrate
2.7.1.11	Sparus aurata		citrate	672415	125	
2.7.1.11	Austromegabalanus psittacus		citrate	673170	125	
2.7.1.11	Oryctolagus cuniculus		citrate	702446	125	
2.7.1.11	Sparus aurata		citrate	704345	125	almost complete inhibition at 1 mM citrate in the absence of D-fructose 2,6-bisphosphate
2.7.1.11	Aspergillus niger		citrate	704771	125	when 5 mM of citrate is added a moderate reduction for about 1020% is recorded in the homogenate of TE22 and TE23 strain, while in A158 strain much stronger reduction of PFK1 specific activity, for approximately 40% is observed
2.7.1.11	Teladorsagia circumcincta		citrate	722202	125	mild inhibitory effects, but only at concentrations exceeding 2 mM
2.7.1.11	Methanococcus maripaludis		citrate	727725	125	activates the enzyme in the absence of phosphate and inhibits the enzyme in the presence of phosphate
2.7.1.11	Solanum lycopersicum		Cl-	640437	134	
2.7.1.11	Oryctolagus cuniculus		clotrimazole	671923	1133	clotrimazole alone induces dimerization of the enzyme reducing the population of tetramers, which is not observed when calmodulin is also present. Since PFK dimers are less active than tetramers, this can explain the inhibitory effect of clotrimazole
2.7.1.11	Solanum lycopersicum		CTP	640436	56	free form, Mg2+ relieves
2.7.1.11	Enterobacter aerogenes		CTP	640483	56	
2.7.1.11	Clostridium pasteurianum		Cu2+	640466	28	
2.7.1.11	Thermotoga maritima		Cu2+	640511	28	0.001 mM, 28% inhibition
2.7.1.11	Aeropyrum pernix		Cu2+	727544	28	1 mM, 52.4% inhibition
2.7.1.11	Dictyostelium discoideum		D-fructose 1,6-bisphosphate	640421	100	
2.7.1.11	Triticum aestivum		D-fructose 1,6-bisphosphate	640422	100	product inhibition
2.7.1.11	Apis mellifera		D-fructose 1,6-bisphosphate	640458	100	0.02 mM, 50% inhibition in the presence of physiological concentrations of ATP, AMP, phosphate and fructose 6-phosphate
2.7.1.11	Lactococcus lactis		D-fructose 1,6-bisphosphate	640465	100	5 mM, 25% inhibition
2.7.1.11	Clostridium pasteurianum		D-fructose 1,6-bisphosphate	640421, 640466	100	
2.7.1.11	Apis mellifera		D-fructose 1,6-bisphosphate	640479	100	0.02 mM, 50% inhibition at 100 mM fructose 6-phosphate in the absence of fructose 2,6-bisphosphate, inhibition is reversed by fructose 2,6-bisphosphate
2.7.1.11	Locusta migratoria		D-fructose 1,6-bisphosphate	640479	100	in the absence of fructose 2,6-bisphosphate
2.7.1.11	Arthrobacter crystallopoietes		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Arthrobacter nicotianae		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Bos taurus		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Brassica oleracea var. gemmifera		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Clostridium pasteurianum		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Daucus carota		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Dictyostelium discoideum		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Enterobacter aerogenes		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Escherichia coli		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Fasciola hepatica		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Gallus gallus		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Homo sapiens		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Lactobacillus casei		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Lactobacillus plantarum		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Mus musculus		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Neurospora crassa		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Oryctolagus cuniculus		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Ovis aries		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Pisum sativum		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Rattus norvegicus		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Saccharomyces cerevisiae		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Thermus thermophilus		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Zea mays		D-Fructose 1-phosphate	640421	544	
2.7.1.11	Escherichia coli		D-fructose 6-phosphate	722736	82	inhibition occurs at low concentrations of fructose 6-phosphate
2.7.1.11	Apis mellifera		D-Glucose 1,6-bisphosphate	640458	1231	0.08 mM, 50% inhibition in the presence of physiological concentrations of ATP, AMP, phosphate and fructose 6-phosphate, inhibition is relieved by 50% by 0.008 mM fructose 2,6-bisphosphate
2.7.1.11	Apis mellifera		D-Glucose 1,6-bisphosphate	640479	1231	in the absence of fructose 2,6-bisphosphate
2.7.1.11	Dunaliella marina		D-glucose 6-phosphate	640447	99	weak inhibition
2.7.1.11	Spinacia oleracea		diphosphate	640445	13	
2.7.1.11	Bacillus licheniformis		diphosphate	640464	13	inactivates under assay conditions
2.7.1.11	Thermotoga maritima		diphosphate	640511	13	0.1 mM, 80% inhibition, nucleotide diphosphates, i.e. ADP, GDP or TDP, partially alleviate inhibition
2.7.1.11	Amycolatopsis methanolica		diphosphate	640512	13	1 mM and 4 mM, 20% and 50% inhibition in the presence of 5 mM fructose 6-phosphate and 5 mM Mg2+
2.7.1.11	Aeropyrum pernix		diphosphate	727544	13	1 mM, 21% inhibition
2.7.1.11	Musa acuminata		Dithionitrobenzoic acid	640442	196	0.06 mM, 80% inhibition of PFK III, reversed by 2-mercaptoethanol, dithiothreitol or reduced glutathione
2.7.1.11	Aeropyrum pernix		GDP	727544	49	1 mM, 46% inhibition
2.7.1.11	Methanococcus maripaludis		GDP	727725	49	activates the enzyme in the absence of phosphate and inhibits the enzyme in the presence of phosphate
2.7.1.11	Solanum lycopersicum		GTP	640436	35	free form, Mg2+ relieves
2.7.1.11	Cucumis sativus		GTP	640443	35	plastid, not cytosolic, isozyme
2.7.1.11	Tetrahymena pyriformis		GTP	640450	35	
2.7.1.11	Enterobacter aerogenes		GTP	640483	35	
2.7.1.11	Clostridium pasteurianum		Hg2+	640466	31	
2.7.1.11	Rattus norvegicus		Isocitrate	640421	242	brain, not heart
2.7.1.11	Citrus x paradisi		Isocitrate	640507	242	competitive inhibition
2.7.1.11	Teladorsagia circumcincta		Isocitrate	722202	242	mild inhibitory effects, but only at concentrations exceeding 2 mM
2.7.1.11	Spinacia oleracea		K+	640445	37	
2.7.1.11	Mus musculus		K+	640459	37	at high concentrations, ATP reverses
2.7.1.11	Bos taurus		K+	704850	37	about 30% residual activity of 30 nM PFK-1 in the presence of 0.2 M K+
2.7.1.11	Oryctolagus cuniculus		K+	704850	37	about 30% residual activity of 30 nM PFK-1 in the presence of 0.2 M K+
2.7.1.11	Aeropyrum pernix		KCl	640513	74	100 mM, 50% inhibition
2.7.1.11	Methanococcus maripaludis		KCl	727725	74	inhibits above 50 mM
2.7.1.11	Oryctolagus cuniculus		Lactate	702446	924	
2.7.1.11	Bos taurus		Lactate dehydrogenase	704850		lactate dehydrogenase suspended in 3.2 M ammonium sulfate inhibits 30 nM PFK-1 resulting in a more than 50% inhibition of activity
2.7.1.11	Oryctolagus cuniculus		Lactate dehydrogenase	704850		lactate dehydrogenase suspended in 3.2 M ammonium sulfate inhibits 30 nM PFK-1 resulting in a more than 50% inhibition of activity
2.7.1.11	Lactococcus lactis		Li+	640465	142	weak
2.7.1.11	Oryctolagus cuniculus		Li2CO3	722869		about 75% residual activity at 20 mM, about 40% residual activity at 40 mM, about 10% residual activity at 100 mM, less than 3% residual activity at 200 mM
2.7.1.11	Oryctolagus cuniculus		Li2SO4	722869	3568	about 55% residual activity at 100 mM, about 30% residual activity at 200 mM
2.7.1.11	Oryctolagus cuniculus		linoleoyl-CoA	722699	828	
2.7.1.11	Oryctolagus cuniculus		lithium acetate	722869		about 80% residual activity in the presence of 0.009 mM lithium acetate
2.7.1.11	Rattus norvegicus		malate	640421	246	kidney cortex, brain, not heart
2.7.1.11	Monoraphidium minutum		malate	640448	246	2 mM, 92% inhibition
2.7.1.11	Citrus x paradisi		malate	640507	246	competitive inhibition
2.7.1.11	Teladorsagia circumcincta		malate	722202	246	mild inhibitory effects, but only at concentrations exceeding 2 mM
2.7.1.11	Mus musculus		Maleic anhydride	640421	5476	muscle and heart enzymes, mechanism
2.7.1.11	Oryctolagus cuniculus		Maleic anhydride	640421	5476	muscle and heart enzymes, mechanism
2.7.1.11	Rattus norvegicus		Maleic anhydride	640421	5476	muscle and heart enzymes, mechanism
2.7.1.11	Mus musculus		Mg2+	640421	25	brain enzyme, at high concentrations
2.7.1.11	Oryctolagus cuniculus		Mg2+	640421	25	brain enzyme, at high concentrations
2.7.1.11	Rattus norvegicus		Mg2+	640421	25	brain enzyme, at high concentrations
2.7.1.11	Spinacia oleracea		Mg2+	640446	25	free form, citrate reverses, independent of MgATP-concentration, kinetics, cytosolic isozyme
2.7.1.11	Cucumis sativus		MgATP2-	640427	102	cytosolic isozyme
2.7.1.11	Saccharomyces cerevisiae		MgATP2-	640462	102	
2.7.1.11	Rana temporaria		MgATP2-	640476	102	
2.7.1.11	Geobacillus stearothermophilus		MgATP2-	640484	102	
2.7.1.11	Escherichia coli		MgATP2-	722736	102	inhibition occurs at high concentrations of MgATP2-
2.7.1.11	Arthrobacter crystallopoietes		more	640421		not inhibited by ATP; not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Arthrobacter nicotianae		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Bos taurus		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Brassica oleracea var. gemmifera		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Clostridium pasteurianum		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Daucus carota		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Dictyostelium discoideum		more	640421		not inhibited by ATP; not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Enterobacter aerogenes		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Escherichia coli		more	640421		not inhibited by fructose 1,6-bisphosphate; not inhibited by ITP, fumarate, tricarballylic acid, CoA, acetyl-CoA
2.7.1.11	Fasciola hepatica		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Gallus gallus		more	640421		not inhibited by fructose 1,6-bisphosphate; not inhibited by ITP, fumarate, tricarballylic acid, CoA, acetyl-CoA
2.7.1.11	Homo sapiens		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Lactobacillus casei		more	640421		not inhibited by ATP; not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Lactobacillus plantarum		more	640421		not inhibited by ATP; not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Mus musculus		more	640421		not inhibited by fructose 1,6-bisphosphate; not inhibited by ITP, fumarate, tricarballylic acid, CoA, acetyl-CoA; photooxidation yields a new heart enzyme species that is no longer sensitive to ATP
2.7.1.11	Neurospora crassa		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Oryctolagus cuniculus		more	640421		not inhibited by fructose 1,6-bisphosphate; not inhibited by ITP, fumarate, tricarballylic acid, CoA, acetyl-CoA; photooxidation yields a new heart enzyme species that is no longer sensitive to ATP
2.7.1.11	Ovis aries		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Pisum sativum		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Rattus norvegicus		more	640421		heart enzyme, not inhibited by cis-aconitate, L-isocitrate, alpha-ketoglutarate, succinate, fumarate, malate, tricarnallylic acid, CoASH, or acetyl-CoASH; not inhibited by fructose 1,6-bisphosphate; not inhibited by ITP, fumarate, tricarballylic acid, CoA, acetyl-CoA; photooxidation yields a new heart enzyme species that is no longer sensitive to ATP
2.7.1.11	Saccharomyces cerevisiae		more	640421		not inhibited by fructose 1,6-bisphosphate; not inhibited by GTP; not inhibited by ITP, fumarate, tricarballylic acid, CoA, acetyl-CoA
2.7.1.11	Thermus thermophilus		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Zea mays		more	640421		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Trypanosoma cruzi		more	640430		not inhibited by MgATP2-
2.7.1.11	Rattus norvegicus		more	640431		not inhibited by fructose 6-phosphate
2.7.1.11	Platichthys flesus		more	640433		not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Solanum lycopersicum		more	640436		not inhibited by MgATP2-
2.7.1.11	Musa acuminata		more	640442		not inhibited by AMP; not inhibited by cAMP; not inhibited by phosphate
2.7.1.11	Cucumis sativus		more	640443		cytosolic PFK is not inhibited by GTP; not inhibited by fructose 2,6-bisphosphate
2.7.1.11	Ricinus communis		more	640444		cytosolic PFK is not inhibited by ATP and SO42-
2.7.1.11	Spinacia oleracea		more	640445		not inhibited by 3-phosphoglycerate; not inhibited by fructose 2,6-bisphosphate; not inhibited by Na+
2.7.1.11	Spinacia oleracea		more	640446		not inhibited by cAMP; not inhibited by UDP, UDPglucose
2.7.1.11	Dunaliella marina		more	640447		not inhibited by ADPglucose, dithiothreitol, gluconate 6-phosphate, glucose 1-phosphate; not inhibited by NH4+ and K+
2.7.1.11	Monoraphidium minutum		more	640448		not inhibited by 2-phosphoglycerate; not inhibited by fructose 2,6-bisphosphate; not inhibited by glutamine, glutamate
2.7.1.11	Tetrahymena pyriformis		more	640450		not inhibited by AMP
2.7.1.11	Trypanosoma brucei		more	640452		not inhibited by fructose 1,6-bisphosphate; not inhibited by fructose 2,6-bisphosphate; not inhibited by phosphate
2.7.1.11	Crassostrea virginica		more	640460		not inhibited by ADP; not inhibited by Ca2+; not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Trachemys scripta		more	640477		effect of low temperature or anoxia on inhibition kinetics
2.7.1.11	Aspergillus niger		more	640480		not inhibited by cAMP
2.7.1.11	Rhodotorula glutinis		more	640482		not inhibited by phosphate
2.7.1.11	Enterobacter aerogenes		more	640483		not inhibited by ADP
2.7.1.11	Geobacillus stearothermophilus		more	640484		product inhibition of reverse reaction
2.7.1.11	Clostridium pasteurianum		more	640485		not inhibited by ATP
2.7.1.11	Escherichia coli		more	640486		not inhibited by fructose 1,6-bisphosphate; not inhibited by pyruvate; not inhibited by ribulose 5-phosphate
2.7.1.11	Lactobacillus acidophilus		more	640494		not inhibited by 2-phosphoglycerate; not inhibited by 3-phosphoglycerate; not inhibited by ADP; not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Lactobacillus plantarum		more	640494		not inhibited by 2-phosphoglycerate; not inhibited by 3-phosphoglycerate; not inhibited by ADP; not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Streptococcus thermophilus		more	640494		not inhibited by 2-phosphoglycerate; not inhibited by 3-phosphoglycerate; not inhibited by ADP; not inhibited by fructose 1,6-bisphosphate
2.7.1.11	Oceanimonas doudoroffii		more	640495		not inhibited by AMP; not inhibited by cAMP; not inhibited by phosphate; not inhibited by pyruvate
2.7.1.11	Escherichia coli		more	640526		no substrate inhibition with gamma-thio-ATP
2.7.1.11	Homo sapiens		more	661508		high insulin concentration decreases enzyme activity in intact cells
2.7.1.11	Sparus aurata		more	704345		not inhibited by 6-phosphogluconate and phosphocreatine
2.7.1.11	Aspergillus niger		more	704771		the active 49 kDa PFK1 fragment is not inhibited by citrate
2.7.1.11	Dictyostelium discoideum		more	721541		not inhibited by ATP
2.7.1.11	Oryctolagus cuniculus		more	722699		acetyl-CoA, malonyl-CoA, palmitoylcarnitine, and palmitic acid in the presence of CoASH are without effect on enzyme activity
2.7.1.11	Oryctolagus cuniculus		more	722869		not inhibited by LiCl
2.7.1.11	Lactococcus lactis		Na+	640465	55	weak
2.7.1.11	Bos taurus		Na+	704850	55	about 70% residual activity of 30 nM PFK-1 in the presence of 0.2 M Na+
2.7.1.11	Oryctolagus cuniculus		Na+	704850	55	about 70% residual activity of 30 nM PFK-1 in the presence of 0.2 M Na+
2.7.1.11	Aeropyrum pernix		NaCl	640513	39	1 M, 50% inhibition
2.7.1.11	Oryctolagus cuniculus		NH4+	640421	50	muscle PFK, weak, at high concentrations, activation at very low concentrations
2.7.1.11	Bos taurus		NH4+	704850	50	about 40% residual activity of 30 nM PFK-1 in the presence of 0.2 M NH4+
2.7.1.11	Oryctolagus cuniculus		NH4+	704850	50	about 40% residual activity of 30 nM PFK-1 in the presence of 0.2 M NH4+
2.7.1.11	Clostridium pasteurianum		Ni2+	640466	36	
2.7.1.11	Solanum lycopersicum		NO2-	640437	155	
2.7.1.11	Solanum lycopersicum		NO3-	640437	263	
2.7.1.11	Cucumis sativus		nucleoside triphosphate	640443	1046	
2.7.1.11	Spinacia oleracea		nucleoside triphosphate	640446	1046	free form, pH-dependent
2.7.1.11	Enterobacter aerogenes		nucleoside triphosphate	640483	1046	at a Mg/NTP ratio below 2
2.7.1.11	Oryctolagus cuniculus		oleoyl-CoA	722699	244	
2.7.1.11	Musa acuminata		p-Chloromercurisulfonic acid	640442	1069	0.025 mM, 80% inhibition of PFK III, reversed by 2-mercaptoethanol, dithiothreitol or reduced glutathione
2.7.1.11	Oryctolagus cuniculus		palmitoyl-CoA	722699	122	low micromolar inhibitor, MgAMP and MgADP but not MgATP protect the enzyme against inhibition by palmitoyl-CoA. Acyl-protein thioesterase-1 reverses palmitoyl-CoA-mediated enzyme inhibition
2.7.1.11	Oryctolagus cuniculus		palmitoylcarnitine-CoA	722699		
2.7.1.11	Fasciola hepatica		phosphatase	640456		dephosphorylation inactivates
2.7.1.11	Ovis aries		phosphatase	640456		dephosphorylation inactivates
2.7.1.11	Chlorella pyrenoidosa		phosphate	640432	12	inhibition at 10-100 mM, concentrations at 1- 5 mM relieve the influence of other inhibitors such as phosphoenolpyruvate
2.7.1.11	Vigna mungo		phosphate	640438	12	weak
2.7.1.11	Dunaliella marina		phosphate	640447	12	above 5 mM; kinetics; the enzyme is both activated and inhibited by phosphate, depending on fructose 6-phosphate/phosphate-ratio
2.7.1.11	Lactococcus lactis		phosphate	640465	12	10 mM, 50% inhibition
2.7.1.11	Schizosaccharomyces pombe		phosphate	640523	12	25 mM, 50% and 57% inhibition of PFK-1 at pH 6.6 and pH 7.2, respectively
2.7.1.11	Spinacia oleracea		phosphate	673599	12	slight inhibition; slight inhibition; slight inhibition
2.7.1.11	Mus musculus		phosphoenolpyruvate	640421	47	
2.7.1.11	Triticum aestivum		phosphoenolpyruvate	640422	47	
2.7.1.11	Rattus norvegicus		phosphoenolpyruvate	640431	47	at pH 7.6, not at pH 8.4
2.7.1.11	Chlorella pyrenoidosa		phosphoenolpyruvate	640432	47	0.1 mM, 50% inhibition at low pH; phosphate relieves
2.7.1.11	Platichthys flesus		phosphoenolpyruvate	640433	47	
2.7.1.11	Vigna mungo		phosphoenolpyruvate	640438	47	1 mM, approx. 75% inhibition
2.7.1.11	Ricinus communis		phosphoenolpyruvate	640440	47	0.05 mM, 50% inhibition of plastid PFK
2.7.1.11	Cucumis sativus		phosphoenolpyruvate	640443	47	0.04 mM and 0.05 mM, 50% inhibition of plastid PFK at pH 8.0 and pH 7.2, respectively; most potent inhibitor
2.7.1.11	Spinacia oleracea		phosphoenolpyruvate	640445	47	0.22 mM, 50% inhibition of cytosolic PFK in the presence of 1 mM fructose 6-phosphate, phosphate relives inhibition
2.7.1.11	Dunaliella marina		phosphoenolpyruvate	640447	47	1 mM, complete inhibition, 0.08 mM, 50% inhibition; inhibition kinetic; phosphate relieves
2.7.1.11	Monoraphidium minutum		phosphoenolpyruvate	640448	47	2 mM, complete inhibition; inhibition kinetic
2.7.1.11	Trypanosoma brucei		phosphoenolpyruvate	640452	47	inhibition kinetic
2.7.1.11	Bacillus licheniformis		phosphoenolpyruvate	640464	47	effective inhibition at 0.005-0.02 mM, fructose 6-phosphate relieves inhibition; most potent inhibitor
2.7.1.11	Bacillus sp.		phosphoenolpyruvate	640464	47	most potent inhibitor
2.7.1.11	Lactococcus lactis		phosphoenolpyruvate	640465	47	5 mM; 64% inhibition
2.7.1.11	Oncorhynchus mykiss		phosphoenolpyruvate	640475	47	0.59 mM, 50% inhibition
2.7.1.11	Aspergillus niger		phosphoenolpyruvate	640480	47	
2.7.1.11	Escherichia coli		phosphoenolpyruvate	640486	47	feedback inhibition
2.7.1.11	Oceanimonas doudoroffii		phosphoenolpyruvate	640495	47	
2.7.1.11	Mus musculus		phosphoenolpyruvate	640504	47	inhibition of mammary gland PFK
2.7.1.11	Rattus norvegicus		phosphoenolpyruvate	640421, 640504	47	
2.7.1.11	Thermotoga maritima		phosphoenolpyruvate	640515	47	0.1 mM and 10 mM, allosteric inhibition, almost completely reversed by 2.5 mM ADP
2.7.1.11	Musa acuminata		phosphoenolpyruvate	640518	47	0.0023 mM and 0.0009 mM, 50% inhibition of PFK I and PFK II respectively, phosphate relieves from inhibition
2.7.1.11	Sparus aurata		phosphoenolpyruvate	672415	47	mixed inhibition
2.7.1.11	Sparus aurata		phosphoenolpyruvate	704345	47	about 30% inhibition at 5 mM
2.7.1.11	Escherichia coli		phosphoenolpyruvate	640421, 640463, 722736	47	
2.7.1.11	Ricinus communis		Phosphoglycolate	640440	997	0.25 mM, 50% inhibition of plastid PFK
2.7.1.11	Dunaliella marina		Phosphoglycolate	640447	997	1 mM, complete inhibition, phosphate relieves, kinetics
2.7.1.11	Musa acuminata		Phosphoglycolate	640518	997	0.006 mM and 0.003 mM, 50% inhibition of PFK I and PFK II respectively, phosphate relieves from inhibition
2.7.1.11	Rattus norvegicus		Protein factor	640474		19000 Da protein promotes Zn2+ or Fe2+-dependent dissociation into inactive protomers, maximal inactivation at 0.001-0.02 mM Zn2+, inactivation is abolished at higher Zn2+ concentrations, Ca2+, Mg2+, Mn2+ can substitute for Zn2+ or Fe2+ only at millimolar concentrations, potency in descending order: Mn2+, Mg2+, Ca2+, inactivation can be reversed by the addition of ATP, fructose 1,6-bisphosphate, or fructose 2,6-bisphosphate
2.7.1.11	Mus musculus		pyridoxal 5'-phosphate	640421	30	muscle and heart enzymes, mechanism
2.7.1.11	Oryctolagus cuniculus		pyridoxal 5'-phosphate	640421	30	muscle and heart enzymes, mechanism
2.7.1.11	Rattus norvegicus		pyridoxal 5'-phosphate	640421	30	muscle and heart enzymes, mechanism
2.7.1.11	Solanum lycopersicum		SO42-	640437	148	
2.7.1.11	Cucumis sativus		SO42-	640443	148	20 mM, 50% inhibition of cytosolic and 77% inhibition of plastid PFK at pH 7.2, not at pH 8.0
2.7.1.11	Ricinus communis		SO42-	640444	148	2 mM, 50% inhibition at pH 7.2, 5 mM complete inhibition
2.7.1.11	Clostridium pasteurianum		SO42-	640466	148	
2.7.1.11	Rattus norvegicus		succinate	640421	54	kidney cortex and brain PFK, heart PFk is not inhibited
2.7.1.11	Citrus x paradisi		succinate	640507	54	competitive inhibition
2.7.1.11	Mus musculus		Succinic anhydride	640421	6238	muscle and heart enzymes, mechanism
2.7.1.11	Oryctolagus cuniculus		Succinic anhydride	640421	6238	muscle and heart enzymes, mechanism
2.7.1.11	Rattus norvegicus		Succinic anhydride	640421	6238	muscle and heart enzymes, mechanism
2.7.1.11	Clostridium pasteurianum		Tris-HCl buffer	640466	1644	
2.7.1.11	Solanum lycopersicum		UTP	640436	61	free form, Mg2+ relieves
2.7.1.11	Enterobacter aerogenes		UTP	640483	61	
2.7.1.11	Rattus norvegicus		Zn2+	640474	19	
2.7.1.11	Thermotoga maritima		Zn2+	640511	19	0.001 mM, 28% inhibition
5.4.2.10	Methanococcus maripaludis	D-fructose-1,6-bisphosphate		692855	100	required to activate the enzyme
5.4.2.10	Escherichia coli	D-glucosamine 1,6-diphosphate		210870, 210871	14064	retains the enzyme in an active and phosphorylated form
5.4.2.10	Escherichia coli	D-glucose 1,6-diphosphate		210871	1231	retains the enzyme in an active and phosphorylated form
5.4.2.10	Staphylococcus aureus	D-glucose 1,6-diphosphate		210872	1231	100fold activation
5.4.2.10	Escherichia coli	D-glucose 1,6-diphosphate		210874	1231	20fold activation at 0.7 mM
5.4.2.10	Methanococcus maripaludis	dithiothreitol		692855	42	1 mM, required for maximal activity
5.4.2.10	Methanococcus maripaludis	more		692855		no activity is observed with ATP as an activator
5.4.2.10	Escherichia coli		Ca2+	210870	18	80% reduced activity
5.4.2.10	Escherichia coli		EDTA	210870	223	abolishes autophosphorylation and catalytic activity
5.4.2.10	Escherichia coli		Mn2+	210870	26	80% reduced activity
5.4.2.10	Escherichia coli		Zn2+	210870	19	efficient autophosphorylation, but absence of catalytic activity
1.1.1.95	Sulfolobus tokodaii	(NH4)2SO4		684698	334	enhancing effect on NAD-dependent 3-phospho-D-glycerate oxidation and 3-phosphohydroxypyruvate reduction but inhibitory effect on NADPH-dependent 3-phosphohydroxypyruvate reduction
1.1.1.95	Aphanothece halophytica	CaCl2		687641	193	
1.1.1.95	Glycine max	HPO42-		287540	2041	
1.1.1.95	Sulfolobus tokodaii	K2HPO4		684698	1216	enhancing effect on NAD-dependent 3-phospho-D-glycerate oxidation and 3-phosphohydroxypyruvate reduction but inhibitory effect on NADPH-dependent 3-phosphohydroxypyruvate reduction
1.1.1.95	Aphanothece halophytica	KCl		687641	74	
1.1.1.95	Pisum sativum	L-methionine		287527	83	maximum activation at 10 mM
1.1.1.95	Aphanothece halophytica	MgCl2		687641	176	
1.1.1.95	Aphanothece halophytica	NaCl		687641	39	PGDH activity increase about 1.5-2.3fold upon the increase of salinity from 0.5 to 2.5 M NaCl
1.1.1.95	Glycine max	SO42-		287540	148	
1.1.1.95	Sulfolobus tokodaii		(NH4)2SO4	684698	334	inhibitory effect on NADPH-dependent 3-phosphohydroxypyruvate reduction
1.1.1.95	Escherichia coli		(R)-2-amino-1-propanol	287548	24967	slightly
1.1.1.95	Glycine max		3-phosphoglycerate	287540	174	noncompetitive to phosphohydroxypyruvate
1.1.1.95	Escherichia coli		3-phosphoglycerate	287546	174	
1.1.1.95	Entamoeba histolytica		3-phosphohydroxypyruvate	655484	965	substrate inhibition
1.1.1.95	Sulfolobus tokodaii		3-phosphohydroxypyruvate	684698	965	product inhibition of 3-phospho-D-glycerate oxidation, variable substrate: 3-phospho-D-glycerate, inhibition pattern: competitive; product inhibition of 3-phospho-D-glycerate oxidation, variable substrate: NAD, inhibition pattern: non-competitive
1.1.1.95	Mycobacterium tuberculosis		3-phosphohydroxypyruvate	687625	965	uncompetitive substrate inhibition at high substrate concentration
1.1.1.95	Pisum sativum		ADP	287536	8	free ADP is more effective than the magnesium complex
1.1.1.95	Sulfolobus tokodaii		ADP	684698	8	weak inhibitory effect on 3-phospho-D-glycerate oxidation, remaining activity: 86%
1.1.1.95	Escherichia coli		Ag+	287530	71	inhibition can be overcome by addition of dithiothreitol
1.1.1.95	Escherichia coli		amino acids	287525, 287547, 287548	3318	
1.1.1.95	Sulfolobus tokodaii		AMP	684698	9	weak inhibitory effect on 3-phospho-D-glycerate oxidation, remaining activity: 75%
1.1.1.95	Pisum sativum		ATP	287536	7	free ATP is more effective than the magnesium complex
1.1.1.95	Sulfolobus tokodaii		ATP	684698	7	weak inhibitory effect on 3-phospho-D-glycerate oxidation, remaining activity: 85%
1.1.1.95	Escherichia coli		beta-Alanine	287548	411	slightly
1.1.1.95	Corynebacterium glutamicum		EDTA	660769	223	
1.1.1.95	Pisum sativum		GDP	287536	49	
1.1.1.95	Rattus norvegicus		glycine	287380	68	slightly
1.1.1.95	Escherichia coli		glycine	287546	68	
1.1.1.95	Escherichia coli		glycine	287548	68	mutants show less to no inhibition
1.1.1.95	Pisum sativum		GTP	287536	35	
1.1.1.95	Escherichia coli		hydroxyglutarate	287546	4350	product inhibition of the alpha-ketoglutarate reduction
1.1.1.95	Escherichia coli		iodoacetate	287525	87	
1.1.1.95	Sulfolobus tokodaii		K2HPO4	684698	1216	inhibitory effect on NADPH-dependent 3-phosphohydroxypyruvate reduction. It appears that the phosphate ion PO43- exerts its inhibitory effect by binding to the free enzyme and NADPH-enzyme complex
1.1.1.95	Escherichia coli		L-alanine	287525	97	
1.1.1.95	Escherichia coli		L-alanine	287548	97	native enzyme and mutant H344A
1.1.1.95	Escherichia coli		L-allothreonine	287525	2124	
1.1.1.95	Escherichia coli		L-homoserine	287525	294	
1.1.1.95	Corynebacterium glutamicum		L-Ser	654296	89	mutant enzyme SerADELTA197, a C-terminally truncated mutant enzyme, shows inhibition
1.1.1.95	Escherichia coli		L-Ser	656083	89	binding of the inhibitor to the apoenzyme displays positive cooperativity in the binding of the first two serine molecules and negative cooperativity in the binding of the last two serine molecules. At least two NADH-induced conformational forms of the enzyme bind the inhibitor in the physiological range. Successive binding of NADH to the enzyme results in an increase in the affinity for the first inhibitor ligand bound and a lessening of both the positive and negative cooperativity of inhibitor binding
1.1.1.95	Rattus norvegicus		L-serine	287380	89	non-linear and competitive
1.1.1.95	Escherichia coli		L-serine	287525	89	50% inhibition at 0.005 mM and pH 7.5
1.1.1.95	Escherichia coli		L-serine	287530	89	inhibition of enzyme from E. coli, Salmonella typhimurium and Haemophilus influenzae, not of mammalian enzyme, inhibition in both reaction directions
1.1.1.95	Pisum sativum		L-serine	287527, 287536	89	
1.1.1.95	Bacillus subtilis		L-serine	287537	89	dithiothreitol inhibits enzyme inhibition by serine
1.1.1.95	Glycine max		L-serine	287540	89	not
1.1.1.95	Escherichia coli		L-serine	287546, 287547	89	allosteric inhibition, regulates the pathway of serine biosynthesis by end product inhibition interacting with His344, Asn346 and Asn364
1.1.1.95	Escherichia coli		L-serine	287548	89	50% inhibition at 0.008 mM L-serine; allosteric inhibition, regulates the pathway of serine biosynthesis by end product inhibition interacting with His344, Asn346 and Asn364
1.1.1.95	Escherichia coli		L-serine	287550	89	sigmoidal binding curve with mutant G294V/G336V, mutants with decreased sensitivity to serine
1.1.1.95	Mycobacterium tuberculosis		L-serine	656277	89	I0.5: 0.03 mM. In presence of KCl, the binding and the inhibition of L-serine, are cooperative and in the absence of KCl they are not
1.1.1.95	Corynebacterium glutamicum		L-serine	660769	89	feedback regulation of the wild-type enzyme
1.1.1.95	Escherichia coli		L-serine	663605	89	feedback regulation, positive and negative cooperativity in absence of NADH, positive in presence of NADH, overview
1.1.1.95	Escherichia coli		L-serine	667649	89	the enzyme contains an ACT regulatory domain which binds L-serine for feedback regulation, binding site lies around residues H344-N364
1.1.1.95	Mycobacterium tuberculosis		L-serine	696285	89	
1.1.1.95	Mycobacterium tuberculosis		L-serine	696336	89	two serine molecules bound to the regulatory domain, anion- and serine-binding sites between two adjacent subunits
1.1.1.95	Escherichia coli		L-serine	711203	89	physiological inhibitor, exerts its effect on at least two steps in the kinetic mechanism. There is a small but significant effect on the dissociation constant of NADH, increasing the Kd to 5 and 23 microM from 0.6 and 9 microM, respectively, for the two sets of sites in the enzyme. After the second substrate is added, serine reduces the amplitude of the signal without a significant effect on the observed rate constants for binding. The serine concentration that reduces the amplitude by 50% is equal to the K0.5 for serine inhibition. Serine binding eliminates a conformational change subsequent to substrate binding by formation of a dead-end quaternary complex consisting of enzyme, coenzyme, substrate, and effector. The rate data conform to a model in which serine can bind to two forms of the enzyme with different affinities
1.1.1.95	Escherichia coli		L-serine	287551, 687564, 724307	89	
1.1.1.95	Escherichia coli		L-threonine	287525	220	
1.1.1.95	Escherichia coli		Mercurials	287530		inhibition can be overcome by addition of dithiothreitol
1.1.1.95	Arabidopsis thaliana		more	287549		Ser, Tyr, Val, Gly, Trp, O-acetyl-L-Ser, and Cys have no effect on enzyme activity in both directions
1.1.1.95	Escherichia coli		more	663605		the enzyme contains an ACT domain, which is involved in the allosteric regulation mechanism
1.1.1.95	Sulfolobus tokodaii		more	684698		unlike the Escherichia coli PGDH no inhibition by L-serine
1.1.1.95	Mycobacterium tuberculosis		more	696336		mechanism of substrate inhibition, linked to this pH-dependent depression in activity, overview
1.1.1.95	Homo sapiens		more	698189		substrate inhibition at concentrations above 0.1 mM
1.1.1.95	Homo sapiens		more	701170		HOAX expression downregulates the enzyme by 40%
1.1.1.95	Gallus gallus		N-Butylmaleimide	287541	13451	
1.1.1.95	Escherichia coli		N-ethylmaleimide	287525	46	
1.1.1.95	Gallus gallus		N-ethylmaleimide	287541	46	D-3-phosphoglycerate and AMP protect against inhibition
1.1.1.95	Gallus gallus		N-Heptylmaleimide	287541	20493	
1.1.1.95	Gallus gallus		N-Pentylmaleimide	287541	20502	
1.1.1.95	Gallus gallus		N-Phenylmaleimide	287541	2710	
1.1.1.95	Glycine max		NAD+	287540	4	product inhibition, competitive to NADH
1.1.1.95	Escherichia coli		NADH	287525	3	inhibition of phosphoglycerate oxidation
1.1.1.95	Sulfolobus tokodaii		NADH	684698	3	product inhibition of 3-phospho-D-glycerate oxidation, variable substrate: 3-phospho-D-glycerate, inhibition pattern: non-competitive; product inhibition of 3-phospho-D-glycerate oxidation, variable substrate: NAD, inhibition pattern: competitive
1.1.1.95	Bacillus subtilis		p-chloromercuribenzoate	287537	40	
1.1.1.95	Pisum sativum		p-hydroxymercuribenzoate	287527, 287536	92	
1.1.1.95	Pisum sativum		pyridoxal 5'-phosphate	287542	30	
1.1.1.95	Pisum sativum		pyridoxamine 5'-phosphate	287542	539	
1.1.1.95	Triticum aestivum		sulfhydryl reagents	287529	752	
1.1.1.95	Sulfolobus tokodaii		ZnCl2	684698	236	inhibitory effect on 3-phosphohydroxypyruvate reduction, remaining activity: 29%
5.3.1.9	Pyrococcus furiosus	Zn2+		722445	19	the coordination shell of Zn2+ changes significantly from the initial static crystal conformation to the equilibrated state of the enzyme-D-fructose 6-phosphate complex. Although Zn2+ is not directly involved in the reaction, the metal ion as a structural anchor constructs a hydrogen bond wire to connect the substrate to the outer region, providing a potential channel for hydrogen exchange between the substrate and solvent
5.3.1.9	Saccharomyces cerevisiae		1,5-Anhydroglucitol 6-phosphate	2624	2267	
5.3.1.9	Saccharomyces cerevisiae		2-amino-2-deoxy-D-glucitol 6-phosphate	671603	3035	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		2-amino-2-deoxy-D-glucitol 6-phosphate dimethyl ester	671603	41555	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		2-amino-2-deoxy-D-mannitol 6-phosphate	671603	16666	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		2-Deoxy-D-glucitol 6-phosphate	671603	13170	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		2-deoxyglucose 6-phosphate	2624	1578	
5.3.1.9	Spinacia oleracea		3-phosphoglycerate	2867	174	
5.3.1.9	Saccharomyces cerevisiae		5-deoxy-5-malonate-D-arabinonohydroxamic acid	727158		
5.3.1.9	Saccharomyces cerevisiae		5-phospho-D-arabinoamide	671603	15047	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		5-phospho-D-arabinoate	671603	37747	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		5-phospho-D-arabinohydroxamate	671603	3681	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Geobacillus stearothermophilus		5-phospho-D-arabinonate	652019	5054	
5.3.1.9	Pyrococcus furiosus		5-phospho-D-arabinonate	662637	5054	
5.3.1.9	Pyrococcus furiosus		5-phospho-D-arabinonate	681378	5054	competitive
5.3.1.9	Pyrococcus furiosus		5-phospho-D-arabinonohydroxamate	681378	112108	competitive, stable analogue of putative cis-endiol intermediate
5.3.1.9	Saccharomyces cerevisiae		5-phospho-D-arabinonohydroxamic acid	727158	3681	
5.3.1.9	Pyrobaculum aerophilum		5-phosphoarabinonate	662267	37747	
5.3.1.9	Rattus norvegicus		5-phosphoarabinonhydroxamic acid	706649	3681	
5.3.1.9	Trypanosoma brucei		5-phosphoarabinonhydroxamic acid	706649	3681	competitive inhibition
5.3.1.9	Cassia coluteoides		6-phospho-2-deoxygluconate	2813	4615	glucose 6-phosphate as substrate
5.3.1.9	Saccharomyces cerevisiae		6-phospho-D-gluconate	671603	327	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		6-phospho-D-gluconoamide	671603	45346	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Entamoeba sp.		6-phosphogluconate	2624	327	
5.3.1.9	Cassia coluteoides		6-phosphogluconate	2813	327	glucose 6-phosphate as substrate
5.3.1.9	Homo sapiens		6-phosphogluconate	2624, 2830	327	
5.3.1.9	Pisum sativum		6-phosphogluconate	2624, 2837	327	
5.3.1.9	Escherichia coli		6-phosphogluconate	2624, 2841	327	
5.3.1.9	Dictyostelium discoideum		6-phosphogluconate	2843	327	0.2 mM, 52% inhibition
5.3.1.9	Bacillus caldotenax		6-phosphogluconate	2852	327	
5.3.1.9	Triticum aestivum		6-phosphogluconate	2854	327	competitive
5.3.1.9	Oryctolagus cuniculus		6-phosphogluconate	2624, 2858	327	
5.3.1.9	Saccharomyces cerevisiae		6-phosphogluconate	2624, 2858	327	
5.3.1.9	Trypanosoma brucei		6-phosphogluconate	2858	327	
5.3.1.9	Triticum aestivum		6-phosphogluconate	2853, 2859	327	
5.3.1.9	Geobacillus stearothermophilus		6-phosphogluconate	2836, 2858, 2861	327	
5.3.1.9	Spinacia oleracea		6-phosphogluconate	2867	327	
5.3.1.9	Methanocaldococcus jannaschii		6-phosphogluconate	649517	327	competitive
5.3.1.9	Pyrobaculum aerophilum		6-phosphogluconate	661679	327	
5.3.1.9	Archaeoglobus fulgidus		6-phosphogluconate	662029	327	
5.3.1.9	Methanosarcina mazei		6-phosphogluconate	662029	327	
5.3.1.9	Salmonella enterica		6-phosphogluconate	662029	327	
5.3.1.9	Aeropyrum pernix		6-phosphogluconate	662220	327	
5.3.1.9	Thermoplasma acidophilum		6-phosphogluconate	662220	327	
5.3.1.9	Mycobacterium tuberculosis		6-phosphogluconate	682664	327	pH 7.6, 25&deg;C
5.3.1.9	Cassia coluteoides		6-Phosphomannonate	2813	15043	with glucose 6-phosphate as substrate
5.3.1.9	Trypanosoma brucei		Agaricic acid	2858	8321	
5.3.1.9	Trypanosoma brucei		Agaricic acid	706649	8321	irreversible inhibition
5.3.1.9	Pyrococcus furiosus		Ca2+	701842	18	slight inhibition at 1.5 mM
5.3.1.9	Triticum aestivum		Cd2+	2859	48	
5.3.1.9	Thermococcus litoralis		Cd2+	651319	48	10 mM, 96% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Thermococcus litoralis		Co2+	651319	21	10 mM, 59% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Thermococcus litoralis		Cu2+	651319	28	10 mM, 96% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Thermococcus litoralis		D-fructose 1,6-bisphosphate	651319	100	
5.3.1.9	Pyrococcus furiosus		D-fructose 1,6-bisphosphate	652190	100	; 10 mM, residual activities are 41% and 53% in the direction of fructose 6-phosphate and glucose 6-phosphate formation, respectively
5.3.1.9	Thermococcus litoralis		D-Fructose 1-phosphate	651319	544	
5.3.1.9	Pyrococcus furiosus		D-Fructose 1-phosphate	652190	544	; 2 mM, residual activities are 50% and 69% in the direction of fructose 6-phosphate and glucose 6-phosphate formation, respectively
5.3.1.9	Oryctolagus cuniculus		D-Glucal 6-phosphate	2865	64315	
5.3.1.9	Saccharomyces cerevisiae		D-glucitol 6-phosphate	671603	4838	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Oryctolagus cuniculus		D-gluconate 6-phosphate	650010	327	
5.3.1.9	Thermococcus litoralis		D-gluconate 6-phosphate	651319	327	
5.3.1.9	Thermococcus litoralis		D-mannose 6-phosphate	651319	564	
5.3.1.9	Pyrococcus furiosus		D-mannose 6-phosphate	652190	564	; 1.25 mM, residual activities are 18% and 38% in the direction of fructose 6-phosphate and glucose 6-phosphate formation, respectively
5.3.1.9	Spinacia oleracea		dihydroxyacetone phosphate	2867	241	
5.3.1.9	Thermococcus litoralis		EDTA	651319	223	10 mM, 78% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Archaeoglobus fulgidus		EDTA	662029	223	
5.3.1.9	Methanosarcina mazei		EDTA	662029	223	
5.3.1.9	Salmonella enterica		EDTA	662029	223	
5.3.1.9	Sinorhizobium meliloti		EDTA	662029	223	
5.3.1.9	Pyrococcus furiosus		EDTA	662637	223	complete inhibition
5.3.1.9	Pyrococcus furiosus		EDTA	681378	223	100fold excess, complete loss of activity within 10 min. 93% of activity may be recovered by additon of 1000fold excess of Zn2+
5.3.1.9	Pyrococcus furiosus		EDTA	701842	223	strong inhibition
5.3.1.9	Thermococcus kodakarensis		EDTA	728836	223	the enzyme activity is completely diminished when the enzyme is heated at 70&deg;C in the presence of 10 mM EDTA. Complete restoration of the enzyme activity is observed when the enzyme is incubated at room temperature in the presence of Zn2+
5.3.1.9	Saccharomyces cerevisiae		Erythritol 4-phosphate	2624	66298	
5.3.1.9	Saccharomyces cerevisiae		erythrose 4-phosphate	2624	1137	
5.3.1.9	Cassia coluteoides		erythrose 4-phosphate	2813	1137	glucose 6-phosphate as substrate
5.3.1.9	Lactobacillus casei		erythrose 4-phosphate	2840	1137	activates enzyme form B with ribose 5-phosphate as substrate, inhibits activity of enzyme form A and B with glucose 6-phosphate as substrate, inhibits activity of enzyme form A with glucose 6-phosphate as substrate
5.3.1.9	Dictyostelium discoideum		erythrose 4-phosphate	2843	1137	0.02 mM, 58% inhibition
5.3.1.9	Spinacia oleracea		erythrose 4-phosphate	2867	1137	competitive
5.3.1.9	Methanocaldococcus jannaschii		erythrose 4-phosphate	649517	1137	competitive
5.3.1.9	Methanosarcina mazei		erythrose 4-phosphate	662029	1137	
5.3.1.9	Sinorhizobium meliloti		erythrose 4-phosphate	662029	1137	
5.3.1.9	Aeropyrum pernix		erythrose 4-phosphate	662220	1137	
5.3.1.9	Thermoplasma acidophilum		erythrose 4-phosphate	662220	1137	
5.3.1.9	Pyrobaculum aerophilum		erythrose-4-phosphate	661679	1137	
5.3.1.9	Oryctolagus cuniculus		fructose 1,6-diphosphate	2624	100	
5.3.1.9	Dictyostelium discoideum		fructose 1,6-diphosphate	2843	100	1 mM, 4% inhibition
5.3.1.9	Oryctolagus cuniculus		fructose 1-phosphate	2624	544	
5.3.1.9	Dictyostelium discoideum		fructose 1-phosphate	2843	544	1 mM, 10% inhibition
5.3.1.9	Mycobacterium tuberculosis		gluconate 6-phosphate	660920	327	
5.3.1.9	Spinacia oleracea		glyceraldehyde 3-phosphate	2867	473	
5.3.1.9	Triticum aestivum		Hg2+	2859	31	
5.3.1.9	Homo sapiens		insulin-like growth factor binding protein-3	661423		both glycosylated and unglycosylated, binding and inhibition of enzyme
5.3.1.9	Thermococcus litoralis		K+	651319	37	10 mM, 18% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Saccharomyces cerevisiae		L-Sorbose 6-phosphate	2624	8417	
5.3.1.9	Saccharomyces cerevisiae		L-xylulose 5-phosphate	2624	842	
5.3.1.9	Triticum aestivum		Maleate	2859	474	10 mM, 50% inhibition
5.3.1.9	Lactobacillus casei		Maleic anhydride	2840	5476	
5.3.1.9	Triticum aestivum		malonate	2859	328	10 mM, 15% inhibition
5.3.1.9	Cassia coluteoides		mannitol 1-phosphate	2813	1931	glucose 6-phosphate as substrate
5.3.1.9	Saccharomyces cerevisiae		mannitol 6-phosphate	2624	1931	
5.3.1.9	Saccharomyces cerevisiae		mannose 6-phosphate	2624	564	
5.3.1.9	Triticum aestivum		Mn2+	2859	26	
5.3.1.9	Thermococcus litoralis		Mn2+	651319	26	10 mM, 18% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Dictyostelium discoideum		more	2843		no inhibition by PCMB and iodoacetate
5.3.1.9	Pyrococcus furiosus		more	652190		activity is not affected by addition of 10 mM EDTA. The addition of fructose, glucose, mannose, galactose (10 mM), pyruvate, phosphoenolpyruvate (10 mM), AMP, ADP, or ATP (3.5 mM), does not show any effect on the activity neither in the fructose 6-phosphate formation, nor in the glucose 6-phosphate formation
5.3.1.9	Mycobacterium tuberculosis		more	660920		not inhibitory: EDTA
5.3.1.9	Echinococcus multilocularis		more	704226		screening for thiazolide inhibitors, diverse compounds, mode of action of thiazolides and structure-activity relationship, overview
5.3.1.9	Rattus norvegicus		more	706649		no inhibition by suramin, an anti-trypanosomal drug, and agaricic acid
5.3.1.9	Saccharomyces cerevisiae		N,2,3,4,5-pentahydroxypentanamide	727158	96807	
5.3.1.9	Saccharomyces cerevisiae		N-acetyl-2-amino-2-deoxy-D-glucitol 6-phosphate	671603	41554	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Geobacillus stearothermophilus		N-bromoacetylethanolamine phosphate	652019	77393	
5.3.1.9	Triticum aestivum		Ni2+	2859	36	
5.3.1.9	Thermococcus litoralis		Ni2+	651319	36	10 mM, 84% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Triticum aestivum		oxaloacetate	2859	53	10 mM, 25% inhibition
5.3.1.9	Triticum aestivum		oxoglutarate	2859	32	10 mM, 20% inhibition
5.3.1.9	Geobacillus stearothermophilus		phosphate	2836	12	
5.3.1.9	Spinacia oleracea		phosphate	2867	12	
5.3.1.9	Saccharomyces cerevisiae		ribose 5-phosphate	2624	165	
5.3.1.9	Dictyostelium discoideum		ribose 5-phosphate	2843	165	1 mM, 12% inhibition
5.3.1.9	Triticum aestivum		ribose 5-phosphate	2854, 2859	165	
5.3.1.9	Saccharomyces cerevisiae		ribulose 5-phosphate	2624	371	
5.3.1.9	Dictyostelium discoideum		ribulose 5-phosphate	2843	371	0.5 mM, 48% inhibition
5.3.1.9	Triticum aestivum		ribulose 5-phosphate	2854, 2859	371	
5.3.1.9	Saccharomyces cerevisiae		sedoheptulose 7-phosphate	2624	1242	
5.3.1.9	Dictyostelium discoideum		sedoheptulose 7-phosphate	2843	1242	1 mM, 10% inhibition
5.3.1.9	Saccharomyces cerevisiae		sorbitol 6-phosphate	2624	3327	
5.3.1.9	Archaeoglobus fulgidus		sorbitol-6-phosphate	662029	3327	
5.3.1.9	Methanosarcina mazei		sorbitol-6-phosphate	662029	3327	
5.3.1.9	Salmonella enterica		sorbitol-6-phosphate	662029	3327	
5.3.1.9	Sinorhizobium meliloti		sorbitol-6-phosphate	662029	3327	
5.3.1.9	Triticum aestivum		Sr2+	2859	289	
5.3.1.9	Oryctolagus cuniculus		suramin	2858	568	no inhibition
5.3.1.9	Saccharomyces cerevisiae		suramin	2858	568	
5.3.1.9	Trypanosoma brucei		suramin	2858	568	
5.3.1.9	Trypanosoma brucei		suramin	706649	568	an anti-trypanosomal drug
5.3.1.9	Spinacia oleracea		Zn2+	2844	19	plastid enzyme is completely inhibited by 5 mM, activity of cytosolic isoenzyme is reduced to 49% of untreated control
5.3.1.9	Triticum aestivum		Zn2+	2859	19	
5.3.1.9	Thermococcus litoralis		Zn2+	651319	19	10 mM, 89% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Pyrococcus furiosus	Zn2+		722445	19	the coordination shell of Zn2+ changes significantly from the initial static crystal conformation to the equilibrated state of the enzyme-D-fructose 6-phosphate complex. Although Zn2+ is not directly involved in the reaction, the metal ion as a structural anchor constructs a hydrogen bond wire to connect the substrate to the outer region, providing a potential channel for hydrogen exchange between the substrate and solvent
5.3.1.9	Saccharomyces cerevisiae		1,5-Anhydroglucitol 6-phosphate	2624	2267	
5.3.1.9	Saccharomyces cerevisiae		2-amino-2-deoxy-D-glucitol 6-phosphate	671603	3035	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		2-amino-2-deoxy-D-glucitol 6-phosphate dimethyl ester	671603	41555	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		2-amino-2-deoxy-D-mannitol 6-phosphate	671603	16666	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		2-Deoxy-D-glucitol 6-phosphate	671603	13170	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		2-deoxyglucose 6-phosphate	2624	1578	
5.3.1.9	Spinacia oleracea		3-phosphoglycerate	2867	174	
5.3.1.9	Saccharomyces cerevisiae		5-deoxy-5-malonate-D-arabinonohydroxamic acid	727158		
5.3.1.9	Saccharomyces cerevisiae		5-phospho-D-arabinoamide	671603	15047	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		5-phospho-D-arabinoate	671603	37747	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		5-phospho-D-arabinohydroxamate	671603	3681	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Geobacillus stearothermophilus		5-phospho-D-arabinonate	652019	5054	
5.3.1.9	Pyrococcus furiosus		5-phospho-D-arabinonate	662637	5054	
5.3.1.9	Pyrococcus furiosus		5-phospho-D-arabinonate	681378	5054	competitive
5.3.1.9	Pyrococcus furiosus		5-phospho-D-arabinonohydroxamate	681378	112108	competitive, stable analogue of putative cis-endiol intermediate
5.3.1.9	Saccharomyces cerevisiae		5-phospho-D-arabinonohydroxamic acid	727158	3681	
5.3.1.9	Pyrobaculum aerophilum		5-phosphoarabinonate	662267	37747	
5.3.1.9	Rattus norvegicus		5-phosphoarabinonhydroxamic acid	706649	3681	
5.3.1.9	Trypanosoma brucei		5-phosphoarabinonhydroxamic acid	706649	3681	competitive inhibition
5.3.1.9	Cassia coluteoides		6-phospho-2-deoxygluconate	2813	4615	glucose 6-phosphate as substrate
5.3.1.9	Saccharomyces cerevisiae		6-phospho-D-gluconate	671603	327	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Saccharomyces cerevisiae		6-phospho-D-gluconoamide	671603	45346	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Entamoeba sp.		6-phosphogluconate	2624	327	
5.3.1.9	Cassia coluteoides		6-phosphogluconate	2813	327	glucose 6-phosphate as substrate
5.3.1.9	Homo sapiens		6-phosphogluconate	2624, 2830	327	
5.3.1.9	Pisum sativum		6-phosphogluconate	2624, 2837	327	
5.3.1.9	Escherichia coli		6-phosphogluconate	2624, 2841	327	
5.3.1.9	Dictyostelium discoideum		6-phosphogluconate	2843	327	0.2 mM, 52% inhibition
5.3.1.9	Bacillus caldotenax		6-phosphogluconate	2852	327	
5.3.1.9	Triticum aestivum		6-phosphogluconate	2854	327	competitive
5.3.1.9	Oryctolagus cuniculus		6-phosphogluconate	2624, 2858	327	
5.3.1.9	Saccharomyces cerevisiae		6-phosphogluconate	2624, 2858	327	
5.3.1.9	Trypanosoma brucei		6-phosphogluconate	2858	327	
5.3.1.9	Triticum aestivum		6-phosphogluconate	2853, 2859	327	
5.3.1.9	Geobacillus stearothermophilus		6-phosphogluconate	2836, 2858, 2861	327	
5.3.1.9	Spinacia oleracea		6-phosphogluconate	2867	327	
5.3.1.9	Methanocaldococcus jannaschii		6-phosphogluconate	649517	327	competitive
5.3.1.9	Pyrobaculum aerophilum		6-phosphogluconate	661679	327	
5.3.1.9	Archaeoglobus fulgidus		6-phosphogluconate	662029	327	
5.3.1.9	Methanosarcina mazei		6-phosphogluconate	662029	327	
5.3.1.9	Salmonella enterica		6-phosphogluconate	662029	327	
5.3.1.9	Aeropyrum pernix		6-phosphogluconate	662220	327	
5.3.1.9	Thermoplasma acidophilum		6-phosphogluconate	662220	327	
5.3.1.9	Mycobacterium tuberculosis		6-phosphogluconate	682664	327	pH 7.6, 25&deg;C
5.3.1.9	Cassia coluteoides		6-Phosphomannonate	2813	15043	with glucose 6-phosphate as substrate
5.3.1.9	Trypanosoma brucei		Agaricic acid	2858	8321	
5.3.1.9	Trypanosoma brucei		Agaricic acid	706649	8321	irreversible inhibition
5.3.1.9	Pyrococcus furiosus		Ca2+	701842	18	slight inhibition at 1.5 mM
5.3.1.9	Triticum aestivum		Cd2+	2859	48	
5.3.1.9	Thermococcus litoralis		Cd2+	651319	48	10 mM, 96% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Thermococcus litoralis		Co2+	651319	21	10 mM, 59% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Thermococcus litoralis		Cu2+	651319	28	10 mM, 96% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Thermococcus litoralis		D-fructose 1,6-bisphosphate	651319	100	
5.3.1.9	Pyrococcus furiosus		D-fructose 1,6-bisphosphate	652190	100	; 10 mM, residual activities are 41% and 53% in the direction of fructose 6-phosphate and glucose 6-phosphate formation, respectively
5.3.1.9	Thermococcus litoralis		D-Fructose 1-phosphate	651319	544	
5.3.1.9	Pyrococcus furiosus		D-Fructose 1-phosphate	652190	544	; 2 mM, residual activities are 50% and 69% in the direction of fructose 6-phosphate and glucose 6-phosphate formation, respectively
5.3.1.9	Oryctolagus cuniculus		D-Glucal 6-phosphate	2865	64315	
5.3.1.9	Saccharomyces cerevisiae		D-glucitol 6-phosphate	671603	4838	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Oryctolagus cuniculus		D-gluconate 6-phosphate	650010	327	
5.3.1.9	Thermococcus litoralis		D-gluconate 6-phosphate	651319	327	
5.3.1.9	Thermococcus litoralis		D-mannose 6-phosphate	651319	564	
5.3.1.9	Pyrococcus furiosus		D-mannose 6-phosphate	652190	564	; 1.25 mM, residual activities are 18% and 38% in the direction of fructose 6-phosphate and glucose 6-phosphate formation, respectively
5.3.1.9	Spinacia oleracea		dihydroxyacetone phosphate	2867	241	
5.3.1.9	Thermococcus litoralis		EDTA	651319	223	10 mM, 78% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Archaeoglobus fulgidus		EDTA	662029	223	
5.3.1.9	Methanosarcina mazei		EDTA	662029	223	
5.3.1.9	Salmonella enterica		EDTA	662029	223	
5.3.1.9	Sinorhizobium meliloti		EDTA	662029	223	
5.3.1.9	Pyrococcus furiosus		EDTA	662637	223	complete inhibition
5.3.1.9	Pyrococcus furiosus		EDTA	681378	223	100fold excess, complete loss of activity within 10 min. 93% of activity may be recovered by additon of 1000fold excess of Zn2+
5.3.1.9	Pyrococcus furiosus		EDTA	701842	223	strong inhibition
5.3.1.9	Thermococcus kodakarensis		EDTA	728836	223	the enzyme activity is completely diminished when the enzyme is heated at 70&deg;C in the presence of 10 mM EDTA. Complete restoration of the enzyme activity is observed when the enzyme is incubated at room temperature in the presence of Zn2+
5.3.1.9	Saccharomyces cerevisiae		Erythritol 4-phosphate	2624	66298	
5.3.1.9	Saccharomyces cerevisiae		erythrose 4-phosphate	2624	1137	
5.3.1.9	Cassia coluteoides		erythrose 4-phosphate	2813	1137	glucose 6-phosphate as substrate
5.3.1.9	Lactobacillus casei		erythrose 4-phosphate	2840	1137	activates enzyme form B with ribose 5-phosphate as substrate, inhibits activity of enzyme form A and B with glucose 6-phosphate as substrate, inhibits activity of enzyme form A with glucose 6-phosphate as substrate
5.3.1.9	Dictyostelium discoideum		erythrose 4-phosphate	2843	1137	0.02 mM, 58% inhibition
5.3.1.9	Spinacia oleracea		erythrose 4-phosphate	2867	1137	competitive
5.3.1.9	Methanocaldococcus jannaschii		erythrose 4-phosphate	649517	1137	competitive
5.3.1.9	Methanosarcina mazei		erythrose 4-phosphate	662029	1137	
5.3.1.9	Sinorhizobium meliloti		erythrose 4-phosphate	662029	1137	
5.3.1.9	Aeropyrum pernix		erythrose 4-phosphate	662220	1137	
5.3.1.9	Thermoplasma acidophilum		erythrose 4-phosphate	662220	1137	
5.3.1.9	Pyrobaculum aerophilum		erythrose-4-phosphate	661679	1137	
5.3.1.9	Oryctolagus cuniculus		fructose 1,6-diphosphate	2624	100	
5.3.1.9	Dictyostelium discoideum		fructose 1,6-diphosphate	2843	100	1 mM, 4% inhibition
5.3.1.9	Oryctolagus cuniculus		fructose 1-phosphate	2624	544	
5.3.1.9	Dictyostelium discoideum		fructose 1-phosphate	2843	544	1 mM, 10% inhibition
5.3.1.9	Mycobacterium tuberculosis		gluconate 6-phosphate	660920	327	
5.3.1.9	Spinacia oleracea		glyceraldehyde 3-phosphate	2867	473	
5.3.1.9	Triticum aestivum		Hg2+	2859	31	
5.3.1.9	Homo sapiens		insulin-like growth factor binding protein-3	661423		both glycosylated and unglycosylated, binding and inhibition of enzyme
5.3.1.9	Thermococcus litoralis		K+	651319	37	10 mM, 18% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Saccharomyces cerevisiae		L-Sorbose 6-phosphate	2624	8417	
5.3.1.9	Saccharomyces cerevisiae		L-xylulose 5-phosphate	2624	842	
5.3.1.9	Triticum aestivum		Maleate	2859	474	10 mM, 50% inhibition
5.3.1.9	Lactobacillus casei		Maleic anhydride	2840	5476	
5.3.1.9	Triticum aestivum		malonate	2859	328	10 mM, 15% inhibition
5.3.1.9	Cassia coluteoides		mannitol 1-phosphate	2813	1931	glucose 6-phosphate as substrate
5.3.1.9	Saccharomyces cerevisiae		mannitol 6-phosphate	2624	1931	
5.3.1.9	Saccharomyces cerevisiae		mannose 6-phosphate	2624	564	
5.3.1.9	Triticum aestivum		Mn2+	2859	26	
5.3.1.9	Thermococcus litoralis		Mn2+	651319	26	10 mM, 18% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Dictyostelium discoideum		more	2843		no inhibition by PCMB and iodoacetate
5.3.1.9	Pyrococcus furiosus		more	652190		activity is not affected by addition of 10 mM EDTA. The addition of fructose, glucose, mannose, galactose (10 mM), pyruvate, phosphoenolpyruvate (10 mM), AMP, ADP, or ATP (3.5 mM), does not show any effect on the activity neither in the fructose 6-phosphate formation, nor in the glucose 6-phosphate formation
5.3.1.9	Mycobacterium tuberculosis		more	660920		not inhibitory: EDTA
5.3.1.9	Echinococcus multilocularis		more	704226		screening for thiazolide inhibitors, diverse compounds, mode of action of thiazolides and structure-activity relationship, overview
5.3.1.9	Rattus norvegicus		more	706649		no inhibition by suramin, an anti-trypanosomal drug, and agaricic acid
5.3.1.9	Saccharomyces cerevisiae		N,2,3,4,5-pentahydroxypentanamide	727158	96807	
5.3.1.9	Saccharomyces cerevisiae		N-acetyl-2-amino-2-deoxy-D-glucitol 6-phosphate	671603	41554	comparison with inhibition of Candida albicans D-glucosamine 6-phosphate synthase
5.3.1.9	Geobacillus stearothermophilus		N-bromoacetylethanolamine phosphate	652019	77393	
5.3.1.9	Triticum aestivum		Ni2+	2859	36	
5.3.1.9	Thermococcus litoralis		Ni2+	651319	36	10 mM, 84% inhibition, D-fructose 6-phosphate as substrate
5.3.1.9	Triticum aestivum		oxaloacetate	2859	53	10 mM, 25% inhibition
5.3.1.9	Triticum aestivum		oxoglutarate	2859	32	10 mM, 20% inhibition
5.3.1.9	Geobacillus stearothermophilus		phosphate	2836	12	
5.3.1.9	Spinacia oleracea		phosphate	2867	12	
5.3.1.9	Saccharomyces cerevisiae		ribose 5-phosphate	2624	165	
5.3.1.9	Dictyostelium discoideum		ribose 5-phosphate	2843	165	1 mM, 12% inhibition
5.3.1.9	Triticum aestivum		ribose 5-phosphate	2854, 2859	165	
5.3.1.9	Saccharomyces cerevisiae		ribulose 5-phosphate	2624	371	
5.3.1.9	Dictyostelium discoideum		ribulose 5-phosphate	2843	371	0.5 mM, 48% inhibition
5.3.1.9	Triticum aestivum		ribulose 5-phosphate	2854, 2859	371	
5.3.1.9	Saccharomyces cerevisiae		sedoheptulose 7-phosphate	2624	1242	
5.3.1.9	Dictyostelium discoideum		sedoheptulose 7-phosphate	2843	1242	1 mM, 10% inhibition
5.3.1.9	Saccharomyces cerevisiae		sorbitol 6-phosphate	2624	3327	
5.3.1.9	Archaeoglobus fulgidus		sorbitol-6-phosphate	662029	3327	
5.3.1.9	Methanosarcina mazei		sorbitol-6-phosphate	662029	3327	
5.3.1.9	Salmonella enterica		sorbitol-6-phosphate	662029	3327	
5.3.1.9	Sinorhizobium meliloti		sorbitol-6-phosphate	662029	3327	
5.3.1.9	Triticum aestivum		Sr2+	2859	289	
5.3.1.9	Oryctolagus cuniculus		suramin	2858	568	no inhibition
5.3.1.9	Saccharomyces cerevisiae		suramin	2858	568	
5.3.1.9	Trypanosoma brucei		suramin	2858	568	
5.3.1.9	Trypanosoma brucei		suramin	706649	568	an anti-trypanosomal drug
5.3.1.9	Spinacia oleracea		Zn2+	2844	19	plastid enzyme is completely inhibited by 5 mM, activity of cytosolic isoenzyme is reduced to 49% of untreated control
5.3.1.9	Triticum aestivum		Zn2+	2859	19	
5.3.1.9	Thermococcus litoralis		Zn2+	651319	19	10 mM, 89% inhibition, D-fructose 6-phosphate as substrate
2.7.2.3	Saccharomyces cerevisiae	(NH4)2SO4		642252	334	inhibition at high concentration, acceleration of activity at low concentrations
2.7.2.3	Homo sapiens	1,3-diphosphoglycerate		642275	1577	substrate activation
2.7.2.3	Plasmodium falciparum	acetate		661242	44	as Na or K salt continues to activate at concentrations above 200 mM
2.7.2.3	Saccharomyces cerevisiae	ATP4-		642245	7	binds to the free enzyme as an inhibitor, when binding to the enzyme-MgATP2-(3-phospho-D-glycerate)complex, ATP4- acts as an activator; inhibition at high concentration, acceleration of activity at low concentrations
2.7.2.3	Saccharomyces cerevisiae	ATP4-		642252	7	inhibition at high concentration, acceleration of activity at low concentrations
2.7.2.3	Sus scrofa	more		642289		enzyme is regulated by multivalent anions, overview
2.7.2.3	Mus musculus	more		642304		no effect by glucose 6-phosphate, fructose 6-phosphate, fructose 1,6-phosphate, pyruvate, phosphoenolpyruvate and lactate
2.7.2.3	Trypanosoma brucei	more		681818		in bloodstream forms, after XRNA depletion, abundance of PGKB mRNA increases to about one-third of the PGKC mRNA abundance, with a corresponding decrease in the apparent degradation rate. The degradation of PGKC mRNA is not affected. In procyclic forms, PGKB mRNA is unaffected by XRNA depletion, PGKC mRNA is undetectable, but after XRNA depletion, PGKC mRNA is detectable
2.7.2.3	Homo sapiens	more		682025		hypoxic treatment induces the protein expression of PGK 3fold, induction of HIF-1alpha by addition of 0.5 mM dimethyloxallyl glycine increases PGK expression under normoxic conditions
2.7.2.3	Trypanosoma brucei	SO42-		642237	148	activation with yeast PGK, inhibition with Trypanosomal PGK
2.7.2.3	Saccharomyces cerevisiae	SO42-		642246	148	behaves as an inhibitor at MgATP2- and 3-phospho-D-glycerate concentration below 0.5-1 mM, as an activator at higher substrate concentrations
2.7.2.3	Saccharomyces cerevisiae	Sodium citrate		642252	1730	inhibition at high concentration, acceleration of activity at low concentrations
2.7.2.3	Saccharomyces cerevisiae	Sodium selenate		642252	20587	inhibition at high concentration, acceleration of activity at low concentrations
2.7.2.3	Saccharomyces cerevisiae	Sodium succinate		642252	20588	inhibition at high concentration, acceleration of activity at low concentrations
2.7.2.3	Saccharomyces cerevisiae		(NH4)2SO4	642252	334	inhibition at high concentration, activation at low concentrations
2.7.2.3	Thermus thermophilus		(NH4)2SO4	642266	334	strong
2.7.2.3	Saccharomyces cerevisiae		1,3-bis(difluoro)-1,3-diphospho-2-dihydroxypropane	642283		phosphonate analogues of 1,3-diphosphoglycerate
2.7.2.3	Equus caballus		1,3-bisphosphoglycerate	642252	1577	
2.7.2.3	Saccharomyces cerevisiae		1,3-bisphosphoglycerate	642252	1577	
2.7.2.3	Sus scrofa		1,3-bisphosphoglycerate	642252	1577	
2.7.2.3	Saccharomyces cerevisiae		1,4-bis(difluoro)-1,4-diphospho-diethylether	642283	33053	phosphonate analogues of 1,3-diphosphoglycerate
2.7.2.3	Saccharomyces cerevisiae		1,4-Bisphosphonobutane	642243	28552	
2.7.2.3	Saccharomyces cerevisiae		1,5-Bisphosphonopentane	642243	13125	
2.7.2.3	Sus scrofa		1,5-Bisphosphonopentane	642289	13125	competitive
2.7.2.3	Homo sapiens		1-beta-D-arabinofuranosylcytosine	642306	1495	
2.7.2.3	Homo sapiens		1-beta-D-arabinofuranosylcytosine 5'-diphosphate	642306	74097	
2.7.2.3	Homo sapiens		2',2'-difluorodeoxycytidine	642306	1407	
2.7.2.3	Homo sapiens		2',2'-difluorodeoxycytidine 5'-diphosphate	642306	74100	i.e. gemcitabine
2.7.2.3	Homo sapiens		2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorodeoxycytidine	642306	33069	
2.7.2.3	Homo sapiens		2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorodeoxycytidine 5'-diphosphate	642306	36901	
2.7.2.3	Homo sapiens		2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil	642306	33073	
2.7.2.3	Homo sapiens		2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil 5'-diphosphate	642306	80627	
2.7.2.3	Equus caballus		2,3-diphosphoglycerate	642253	557	competitive to 3-phospho-D-glycerate and MgATP2-
2.7.2.3	Homo sapiens		2,3-diphosphoglycerate	642253	557	competitive to 3-phospho-D-glycerate and MgATP2-
2.7.2.3	Mus musculus		2,3-diphosphoglycerate	642253	557	competitive to 3-phospho-D-glycerate and MgATP2-
2.7.2.3	Oryctolagus cuniculus		2,3-diphosphoglycerate	642253	557	competitive to 3-phospho-D-glycerate and MgATP2-
2.7.2.3	trout		2,3-diphosphoglycerate	642253	557	competitive to 3-phospho-D-glycerate and MgATP2-
2.7.2.3	Thermus thermophilus		2,3-diphosphoglycerate	642266	557	
2.7.2.3	Homo sapiens		2,3-diphosphoglycerate	642275	557	noncompetitive with respect to 1,3-diphosphoglycerate
2.7.2.3	Sus scrofa		2,3-diphosphoglycerate	642289	557	
2.7.2.3	Saccharomyces cerevisiae		2-(p-Sulfophenylazo)-1,8-dihydroxy-3,6-naphthalene disulfonic acid	642249	19940	competitive against MgATP2- and 3-phospho-D-glycerate
2.7.2.3	Saccharomyces cerevisiae		2-Hydroxy-3,5-diiodobenzoate	642248	13890	
2.7.2.3	Saccharomyces cerevisiae		2-Hydroxy-5-iodobenzoate	642248	28738	
2.7.2.3	Saccharomyces cerevisiae		2-Oxo-1,4-bisphosphonobutane	642243	28761	
2.7.2.3	Saccharomyces cerevisiae		2-Oxo-1,5-bisphosphonopentane	642243	28762	
2.7.2.3	Sus scrofa		2-Phosphoglycolate	642289	997	competitive
2.7.2.3	Equus caballus		3-phospho-D-glycerate	642252	181	
2.7.2.3	Saccharomyces cerevisiae		3-phospho-D-glycerate	642252	181	
2.7.2.3	Sus scrofa		3-phospho-D-glycerate	642252	181	
2.7.2.3	Saccharomyces cerevisiae		4-Phosphonobutyronitrile	642243	28953	
2.7.2.3	Fasciola hepatica		5,5'-dithiobis(2-nitrobenzoic acid)	642239	196	reversible
2.7.2.3	Cyprinus carpio		5,5'-dithiobis(2-nitrobenzoic acid)	642251	196	rabbit muscle enzyme
2.7.2.3	Equus caballus		5,5'-dithiobis(2-nitrobenzoic acid)	642251	196	rabbit muscle enzyme
2.7.2.3	Esox sp.		5,5'-dithiobis(2-nitrobenzoic acid)	642251	196	rabbit muscle enzyme
2.7.2.3	Frog		5,5'-dithiobis(2-nitrobenzoic acid)	642251	196	rabbit muscle enzyme
2.7.2.3	Homo sapiens		5,5'-dithiobis(2-nitrobenzoic acid)	642251	196	rabbit muscle enzyme
2.7.2.3	Oryctolagus cuniculus		5,5'-dithiobis(2-nitrobenzoic acid)	642251	196	rabbit muscle enzyme
2.7.2.3	Saccharomyces cerevisiae		5,5'-dithiobis(2-nitrobenzoic acid)	642251	196	rabbit muscle enzyme
2.7.2.3	Sus scrofa		5,5'-dithiobis(2-nitrobenzoic acid)	642251	196	rabbit muscle enzyme
2.7.2.3	Testudinidae		5,5'-dithiobis(2-nitrobenzoic acid)	642251	196	rabbit muscle enzyme
2.7.2.3	Equus caballus		5,5'-dithiobis(2-nitrobenzoic acid)	642253	196	
2.7.2.3	Homo sapiens		5,5'-dithiobis(2-nitrobenzoic acid)	642253	196	
2.7.2.3	Mus musculus		5,5'-dithiobis(2-nitrobenzoic acid)	642253	196	
2.7.2.3	Oryctolagus cuniculus		5,5'-dithiobis(2-nitrobenzoic acid)	642253	196	
2.7.2.3	trout		5,5'-dithiobis(2-nitrobenzoic acid)	642253	196	
2.7.2.3	Saccharomyces cerevisiae		5,5'-dithiobis(2-nitrobenzoic acid)	642254	196	
2.7.2.3	Spinacia oleracea		5,5'-dithiobis(2-nitrobenzoic acid)	642254	196	
2.7.2.3	Hippoglossus stenolepis		5,5'-dithiobis(2-nitrobenzoic acid)	642264	196	
2.7.2.3	Bos taurus		5,5'-dithiobis(2-nitrobenzoic acid)	642270	196	
2.7.2.3	Homo sapiens		5,5'-dithiobis(2-nitrobenzoic acid)	642276	196	complete loss of activity
2.7.2.3	Sus scrofa		5,5'-dithiobis(2-nitrobenzoic acid)	642298	196	nucleotide ligands protect, e.g. MgATP2-, MgADP-, Mg-beta,gamma-methylene-adenosine-5'-triphosphate, Mg-beta,gamma-imido-adenosine-5'-triphosphate
2.7.2.3	Trypanosoma brucei		actinomycin D	681818	2109	blocks transcription
2.7.2.3	Sus scrofa		adenosine	642289	116	
2.7.2.3	Fasciola hepatica		ADP	642239	8	noncompetitive with respect to ATP and 3-phospho-D-glycerate
2.7.2.3	Saccharomyces cerevisiae		ADP	642247	8	
2.7.2.3	Saccharomyces cerevisiae		ADP	642251	8	noncompetitive to ATP and competitive to 3-phospho-D-glycerate
2.7.2.3	Thermus thermophilus		ADP	642266	8	
2.7.2.3	Mus musculus		ADP	642304	8	inhibitory in forward reaction
2.7.2.3	Helianthus annuus		ADP	723369	8	0.1 mM, 63.1% activity; 0.1 mM, 85% activity; 0.1 mM, 86% activity; 1 mM, 31% activity; 1 mM, 32% activity
2.7.2.3	Sulfolobus solfataricus		ADP	724980	8	
2.7.2.3	Saccharomyces cerevisiae		ADP3-	642247	8	competitive to 3-phospho-D-glycerate
2.7.2.3	Saccharomyces cerevisiae		AMP	642168	9	
2.7.2.3	Saccharomyces cerevisiae		AMP	642247	9	above 0.5 mM noncompetitive and below 0.5 mM competitive to 3-phospho-D-glycerate, competitive to MgATP2-
2.7.2.3	Equus caballus		AMP	642253	9	
2.7.2.3	Homo sapiens		AMP	642253	9	
2.7.2.3	Mus musculus		AMP	642253	9	
2.7.2.3	Oryctolagus cuniculus		AMP	642253	9	
2.7.2.3	trout		AMP	642253	9	
2.7.2.3	Homo sapiens		AMP	642275	9	noncompetitive with respect to 1,3-diphosphoglycerate, ADP and Mg2+, inhibition kinetics
2.7.2.3	Helianthus annuus		AMP	723369	9	0.625 mM, 95% activity; 0.625 mM, 98% activity; 10 mM, 40% activity; 10 mM, 44% activity; 10 mM, 50% activity
2.7.2.3	Saccharomyces cerevisiae		AMP2-	642247	9	competitive to MgATP2-, noncompetitive to 3-phospho-D-glycerate
2.7.2.3	Saccharomyces cerevisiae		ATP4-	642245	7	binds to the free enzyme as an inhibitor, when binding to the enzyme-MgATP2-(3-phospho-D-glycerate)complex, ATP4- acts as an activator
2.7.2.3	Equus caballus		ATP4-	642252	7	
2.7.2.3	Saccharomyces cerevisiae		ATP4-	642252	7	inhibition at high concentration, acceleration of activity at low concentrations
2.7.2.3	Sus scrofa		ATP4-	642252	7	
2.7.2.3	Saccharomyces cerevisiae		ATP4-	642259	7	weak
2.7.2.3	Sus scrofa		beta,gamma-imido-adenosine-5'-triphosphate	642298	2889	binding structure; i.e. AMP-PNP, an ATP analogue
2.7.2.3	Sus scrofa		beta,gamma-methylene-adenosine-5'-triphosphate	642298	2691	binding structure; i.e. AMP-PCP, an ATP analogue
2.7.2.3	Homo sapiens		beta-L-2',3'-dideoxy-3'-thiacytidine	642306	11169	
2.7.2.3	Homo sapiens		beta-L-2',3'-dideoxy-3'-thiacytidine diphosphate	642306	33875	
2.7.2.3	Homo sapiens		Ca2+	642276	18	inhibition above 1 mM
2.7.2.3	Homo sapiens		Ca2+	642280	18	partial inhibition in presence of Mg2+
2.7.2.3	Mus musculus		citrate	642304	125	40% inhibition at 50 mM
2.7.2.3	Cyprinus carpio		Co2+	642251	21	CoATP2- is the true substrate
2.7.2.3	Equus caballus		Co2+	642251	21	CoATP2- is the true substrate
2.7.2.3	Esox sp.		Co2+	642251	21	CoATP2- is the true substrate
2.7.2.3	Frog		Co2+	642251	21	CoATP2- is the true substrate
2.7.2.3	Homo sapiens		Co2+	642251	21	CoATP2- is the true substrate
2.7.2.3	Oryctolagus cuniculus		Co2+	642251	21	CoATP2- is the true substrate
2.7.2.3	Saccharomyces cerevisiae		Co2+	642251	21	CoATP2- is the true substrate
2.7.2.3	Sus scrofa		Co2+	642251	21	CoATP2- is the true substrate
2.7.2.3	Testudinidae		Co2+	642251	21	CoATP2- is the true substrate
2.7.2.3	Geobacillus stearothermophilus		Co2+	642257	21	58%
2.7.2.3	Beta vulgaris		Co2+	642271	21	77% of the activity with Mg2+
2.7.2.3	Homo sapiens		Co2+	642276	21	inhibits at high concentrations
2.7.2.3	Saccharomyces cerevisiae		CrATP	642168	13749	
2.7.2.3	Thermus thermophilus		CTP	642266	56	competitive to ATP
2.7.2.3	Homo sapiens		D-2',3'-dideoxycytidine	642306	1743	
2.7.2.3	Homo sapiens		D-MgADP-	684894	47159	competitive inhibitor with respect to MgATP
2.7.2.3	Phaeodactylum tricornutum		Diamide	723744	1817	
2.7.2.3	Homo sapiens		diphosphate	685259	13	
2.7.2.3	Equus caballus		gallic acid	642252	616	
2.7.2.3	Saccharomyces cerevisiae		gallic acid	642252	616	
2.7.2.3	Sus scrofa		gallic acid	642252	616	
2.7.2.3	Phaeodactylum tricornutum		glutathione	723744	41	
2.7.2.3	Sus scrofa		Glycerol 2-phosphate	642289	1810	competitive
2.7.2.3	Helianthus annuus		Glycerol 2-phosphate	723369	1810	10 mM, 97% activity
2.7.2.3	Sus scrofa		glycerol 3-phosphate	642289	352	competitive
2.7.2.3	Helianthus annuus		glycerol 3-phosphate	723369	352	10 mM, 92% activity; 10 mM, 95% activity; 10 mM, 97% activity
2.7.2.3	Equus caballus		GMP	642253	150	
2.7.2.3	Homo sapiens		GMP	642253	150	
2.7.2.3	Mus musculus		GMP	642253	150	
2.7.2.3	Oryctolagus cuniculus		GMP	642253	150	
2.7.2.3	trout		GMP	642253	150	
2.7.2.3	Thermus thermophilus		GTP	642266	35	competitive to ATP
2.7.2.3	Saccharomyces cerevisiae		Guanidinium chloride	642293	804	0.5 M, 30% loss of activity for the mutant P204H, 5% loss of activity for the wild-type, both are unfolded at 1 M
2.7.2.3	Oryctolagus cuniculus		Heavy metal ions	642251		rabbit muscle enzyme
2.7.2.3	Saccharomyces cerevisiae		Hexametaphosphate	642249	4858	competitive against 3-phospho-D-glycerate and noncompetitive against MgATP2-
2.7.2.3	Phaeodactylum tricornutum		hydrogen peroxide	723744	20	
2.7.2.3	Saccharomyces cerevisiae		hydroxyethylidene bisphosphonic acid	642249	22107	competitive against MgATP2- and 3-phospho-D-glycerate
2.7.2.3	Trypanosoma brucei		Ib1	642290		isozymes are differntly sensitive
2.7.2.3	Equus caballus		IMP	642253	206	
2.7.2.3	Homo sapiens		IMP	642253	206	
2.7.2.3	Mus musculus		IMP	642253	206	
2.7.2.3	Oryctolagus cuniculus		IMP	642253	206	
2.7.2.3	trout		IMP	642253	206	
2.7.2.3	Equus caballus		inositol triphosphate	642252	8577	
2.7.2.3	Saccharomyces cerevisiae		inositol triphosphate	642252	8577	
2.7.2.3	Sus scrofa		inositol triphosphate	642252	8577	
2.7.2.3	Fasciola hepatica		iodoacetamide	642239	63	irreversible
2.7.2.3	Sus scrofa		iodoacetamide	642298	63	nucleotide ligands protect, e.g. MgATP2-, MgADP-, Mg-beta,gamma-methylene-adenosine-5'-triphosphate, Mg-beta,gamma-imido-adenosine-5'-triphosphate
2.7.2.3	Mus musculus		iodoacetate	642268	87	
2.7.2.3	Thermus thermophilus		ITP	642266	203	weak competitive inhibitor
2.7.2.3	Methanothermus fervidus		K+	642281	37	activates
2.7.2.3	Pyrococcus woesei		K+	642281	37	activates
2.7.2.3	Saccharomyces cerevisiae		KH2PO4	642252	2123	inhibition at high concentration, activation at low concentrations
2.7.2.3	Plasmodium falciparum		KH2PO4	661242	2123	above 50 mM
2.7.2.3	Homo sapiens		L-2',3'-dideoxycytidine	642306		
2.7.2.3	Homo sapiens		L-MgADP-	684894	47160	competitive inhibitor with respect to MgATP
2.7.2.3	Sus scrofa		Mg-beta,gamma-imido-adenosine-5'-triphosphate	642298	33406	
2.7.2.3	Sus scrofa		Mg-beta,gamma-methylene-adenosine-5'-triphosphate	642298	33407	
2.7.2.3	Homo sapiens		Mg2+	642261	25	inhibition above 50 mM
2.7.2.3	Saccharomyces cerevisiae		MgADP-	642247	639	competitive to 3-phospho-D-glycerate
2.7.2.3	Homo sapiens		MgADP-	642276	639	
2.7.2.3	Sus scrofa		MgADP-	642298	639	
2.7.2.3	Homo sapiens		MgGDP-	642276	30286	
2.7.2.3	Equus caballus		MK-401	642252	20467	
2.7.2.3	Saccharomyces cerevisiae		MK-401	642252	20467	
2.7.2.3	Sus scrofa		MK-401	642252	20467	
2.7.2.3	Homo sapiens		Mn2+	642261	26	inhibition above 50 mM
2.7.2.3	Cyprinus carpio		more	642251		yeast enzyme is insensitive to thiol reagents
2.7.2.3	Equus caballus		more	642251		yeast enzyme is insensitive to thiol reagents
2.7.2.3	Esox sp.		more	642251		yeast enzyme is insensitive to thiol reagents
2.7.2.3	Frog		more	642251		yeast enzyme is insensitive to thiol reagents
2.7.2.3	Homo sapiens		more	642251		yeast enzyme is insensitive to thiol reagents
2.7.2.3	Oryctolagus cuniculus		more	642251		yeast enzyme is insensitive to thiol reagents
2.7.2.3	Saccharomyces cerevisiae		more	642251		yeast enzyme is insensitive to thiol reagents
2.7.2.3	Sus scrofa		more	642251		yeast enzyme is insensitive to thiol reagents
2.7.2.3	Testudinidae		more	642251		yeast enzyme is insensitive to thiol reagents
2.7.2.3	Saccharomyces cerevisiae		more	642259		no inhibition by Hg2+
2.7.2.3	Homo sapiens		more	642283		
2.7.2.3	Saccharomyces cerevisiae		more	642283		inhibitory effect of phosphonate analogues of 1,3-diphosphoglycerate, overview
2.7.2.3	Sus scrofa		more	642289		double-inhibition studies, kinetics, modeling of inhibitor binding, e.g. phosphate; enzyme is regulated by multivalent anions, overview
2.7.2.3	Mus musculus		more	642304		no effect by glucose 6-phosphate, fructose 6-phosphate, fructose 1,6-phosphate, pyruvate, phosphoenolpyruvate and lactate
2.7.2.3	Homo sapiens		more	681295		aromatic bisphosphonate inhibitors
2.7.2.3	Saccharomyces cerevisiae		more	681295		aliphatic bisphosphonate inhibitors
2.7.2.3	Trypanosoma brucei		more	681295		aromatic and aliphatic bisphosphonates
2.7.2.3	Trypanosoma brucei		more	681818		addition of sinefungin prior to actinomycin D is the best protocol for complete and rapid inhibition of mRNA synthesis, thus in bloodstream forms, inhibition of both trans splicing and transcription results in immediate exponential decay of PGKC mRNA with a half-life of 46 min. Inhibition of transcription alone gives non-exponential kinetics and inhibition of splicing alone results in a longer apparent half-life
2.7.2.3	Mus musculus		more	705963		the KH-type splicing regulatory protein, KSRP, serves as a decay-promoting factor for Pgk2 mRNA in male germ cells. KSRP binds to to a 93-nt sequence (the F1 region) of the 3'-UTR of the Pgk2 mRNA and destabilizes Pgk2 mRNA constructs in testis extracts and in transfected cells. Destabilization of Pgk2 mRNA occurs when t-KSRP and the Pgk2 mRNA-stabilizing protein, polypyrimidine tract binding protein 2 (PTBP2), are present together in complexes bound to the 3'-UTR of Pgk2 mRNA
2.7.2.3	Fasciola hepatica		N-ethylmaleimide	642239	46	irreversible
2.7.2.3	Mus musculus		N-ethylmaleimide	642268	46	
2.7.2.3	Saccharomyces cerevisiae		NaCl	642252	39	inhibition at high concentration, acceleration of activity at low concentrations
2.7.2.3	Thermus thermophilus		NaCl	642266	39	weak
2.7.2.3	Plasmodium falciparum		NaH2PO4	661242	2480	above 50 mM
2.7.2.3	Saccharomyces cerevisiae		NaNO2	642252	2714	inhibition at high concentration, activation at low concentrations
2.7.2.3	Saccharomyces cerevisiae		Naphthalene-1,3,6-trisulfonic acid	642249	29601	competitive against 3-phospho-D-glycerate and noncompetitive against MgATP2-, binding structure
2.7.2.3	Cyprinus carpio		nucleoside diphosphates	642251	1114	inhibition of ADP formation in decreasing order: GDP, ADP, IDP
2.7.2.3	Equus caballus		nucleoside diphosphates	642251	1114	inhibition of ADP formation in decreasing order: GDP, ADP, IDP
2.7.2.3	Esox sp.		nucleoside diphosphates	642251	1114	inhibition of ADP formation in decreasing order: GDP, ADP, IDP
2.7.2.3	Frog		nucleoside diphosphates	642251	1114	inhibition of ADP formation in decreasing order: GDP, ADP, IDP
2.7.2.3	Homo sapiens		nucleoside diphosphates	642251	1114	inhibition of ADP formation in decreasing order: GDP, ADP, IDP
2.7.2.3	Oryctolagus cuniculus		nucleoside diphosphates	642251	1114	inhibition of ADP formation in decreasing order: GDP, ADP, IDP
2.7.2.3	Saccharomyces cerevisiae		nucleoside diphosphates	642251	1114	inhibition of ADP formation in decreasing order: GDP, ADP, IDP
2.7.2.3	Sus scrofa		nucleoside diphosphates	642251	1114	inhibition of ADP formation in decreasing order: GDP, ADP, IDP
2.7.2.3	Testudinidae		nucleoside diphosphates	642251	1114	inhibition of ADP formation in decreasing order: GDP, ADP, IDP
2.7.2.3	Geobacillus stearothermophilus		nucleoside diphosphates	642257	1114	purine nucleotide diphosphates
2.7.2.3	Cyprinus carpio		nucleoside monophosphates	642251	2560	
2.7.2.3	Equus caballus		nucleoside monophosphates	642251	2560	
2.7.2.3	Esox sp.		nucleoside monophosphates	642251	2560	
2.7.2.3	Frog		nucleoside monophosphates	642251	2560	
2.7.2.3	Homo sapiens		nucleoside monophosphates	642251	2560	
2.7.2.3	Oryctolagus cuniculus		nucleoside monophosphates	642251	2560	
2.7.2.3	Saccharomyces cerevisiae		nucleoside monophosphates	642251	2560	
2.7.2.3	Sus scrofa		nucleoside monophosphates	642251	2560	
2.7.2.3	Testudinidae		nucleoside monophosphates	642251	2560	
2.7.2.3	Geobacillus stearothermophilus		nucleoside monophosphates	642257	2560	purine nucleotide monophosphates
2.7.2.3	Fasciola hepatica		p-chloromercuribenzoate	642239	40	reversible
2.7.2.3	Cyprinus carpio		p-chloromercuribenzoate	642251	40	
2.7.2.3	Equus caballus		p-chloromercuribenzoate	642251	40	
2.7.2.3	Esox sp.		p-chloromercuribenzoate	642251	40	
2.7.2.3	Frog		p-chloromercuribenzoate	642251	40	
2.7.2.3	Homo sapiens		p-chloromercuribenzoate	642251	40	
2.7.2.3	Oryctolagus cuniculus		p-chloromercuribenzoate	642251	40	rabbit muscle enzyme
2.7.2.3	Saccharomyces cerevisiae		p-chloromercuribenzoate	642251	40	
2.7.2.3	Sus scrofa		p-chloromercuribenzoate	642251	40	
2.7.2.3	Testudinidae		p-chloromercuribenzoate	642251	40	
2.7.2.3	Bos taurus		p-chloromercuribenzoate	642270	40	
2.7.2.3	Nitrosomonas europaea		p-chloromercuribenzoate	642291	40	strong
2.7.2.3	Nitrosomonas sp. K1		p-chloromercuribenzoate	642291	40	strong
2.7.2.3	Equus caballus		phosphate	642252	12	
2.7.2.3	Saccharomyces cerevisiae		phosphate	642252	12	
2.7.2.3	Homo sapiens		phosphate	642261, 642277	12	phosphate buffer
2.7.2.3	Sus scrofa		phosphate	642252, 642289	12	
2.7.2.3	Saccharomyces cerevisiae		salicylate	642248	508	i.e. 2-hydroxybenzoate
2.7.2.3	Nitrosomonas europaea		SDS	642291	118	strong
2.7.2.3	Nitrosomonas sp. K1		SDS	642291	118	strong
2.7.2.3	Homo sapiens		shRNA	682025		knockdown of PGK, followed by a reduced cytotoxicity of beta-L-dioxolane-cytidine approximately 1.4- and 1.8fold under normoxic and hypoxic conditions, respectively
2.7.2.3	Trypanosoma brucei		sinefungin	681818	535	blocks splicing
2.7.2.3	Zymomonas mobilis		SO42-	3241	148	
2.7.2.3	Trypanosoma brucei		SO42-	642237	148	activation with yeast PGK, inhibition with trypanosomal PGK
2.7.2.3	Saccharomyces cerevisiae		SO42-	642246	148	behaves as an inhibitor at MgATP2- and 3-phospho-D-glycerate concentration below 0.5-1 mM, as an activator at higher substrate concentrations
2.7.2.3	Equus caballus		SO42-	642252	148	
2.7.2.3	Saccharomyces cerevisiae		SO42-	642252	148	
2.7.2.3	Sus scrofa		SO42-	642252, 642289	148	
2.7.2.3	Pseudomonas sp.		SO42-	642296	148	above 50 mM
2.7.2.3	Saccharomyces cerevisiae		Sodium citrate	642252	1730	inhibition at high concentration, activation at low concentrations
2.7.2.3	Phaeodactylum tricornutum		sodium nitroprusside	723744	1122	
2.7.2.3	Saccharomyces cerevisiae		Sodium selenate	642252	20587	inhibition at high concentration, activation at low concentrations
2.7.2.3	Saccharomyces cerevisiae		Sodium succinate	642252	20588	inhibition at high concentration, activation at low concentrations
2.7.2.3	Equus caballus		Sulphasalazine	642252	13528	
2.7.2.3	Saccharomyces cerevisiae		Sulphasalazine	642252	13528	
2.7.2.3	Sus scrofa		Sulphasalazine	642252	13528	
2.7.2.3	Saccharomyces cerevisiae		suramin	642249	568	competitive against MgATP2- and 3-phospho-D-glycerate
2.7.2.3	Trypanosoma brucei		suramin	642290	568	isozymes are differently sensitive
2.7.2.3	Plasmodium falciparum		suramin	661242	568	IC50: 0.007 mM
2.7.2.3	Helianthus annuus		UDP	723369	24	10 mM, 94.3% activity; 10 mM, 97% activity
2.7.2.3	Mus musculus		Urea	642268	110	
2.7.2.3	Thermus thermophilus		UTP	642266	61	weak
2.7.2.3	Cyprinus carpio		Zn2+	642251	19	ZnATP2- is an alternative substrate to MgATP2-, free metal ions strongly inhibit
2.7.2.3	Equus caballus		Zn2+	642251	19	ZnATP2- is an alternative substrate to MgATP2-, free metal ions strongly inhibit
2.7.2.3	Esox sp.		Zn2+	642251	19	ZnATP2- is an alternative substrate to MgATP2-, free metal ions strongly inhibit
2.7.2.3	Frog		Zn2+	642251	19	ZnATP2- is an alternative substrate to MgATP2-, free metal ions strongly inhibit
2.7.2.3	Homo sapiens		Zn2+	642251	19	ZnATP2- is an alternative substrate to MgATP2-, free metal ions strongly inhibit
2.7.2.3	Oryctolagus cuniculus		Zn2+	642251	19	ZnATP2- is an alternative substrate to MgATP2-, free metal ions strongly inhibit
2.7.2.3	Saccharomyces cerevisiae		Zn2+	642251	19	ZnATP2- is an alternative substrate to MgATP2-, free metal ions strongly inhibit
2.7.2.3	Sus scrofa		Zn2+	642251	19	ZnATP2- is an alternative substrate to MgATP2-, free metal ions strongly inhibit
2.7.2.3	Testudinidae		Zn2+	642251	19	ZnATP2- is an alternative substrate to MgATP2-, free metal ions strongly inhibit
2.7.2.3	Saccharomyces cerevisiae		Zn2+	642259	19	strong
2.7.2.3	Beta vulgaris		Zn2+	642271	19	
2.7.2.3	Equus caballus		[Co(CN)6]3-	642252	20665	
2.7.2.3	Saccharomyces cerevisiae		[Co(CN)6]3-	642252	20665	
2.7.2.3	Sus scrofa		[Co(CN)6]3-	642252	20665	
2.7.2.3	Equus caballus		[Fe(CN)6]3-	642252	126	
2.7.2.3	Saccharomyces cerevisiae		[Fe(CN)6]3-	642252	126	
2.7.2.3	Sus scrofa		[Fe(CN)6]3-	642252	126	
2.7.2.3	Equus caballus		[Fe(CN)6]4-	642252	251	
2.7.2.3	Saccharomyces cerevisiae		[Fe(CN)6]4-	642252	251	
2.7.2.3	Sus scrofa		[Fe(CN)6]4-	642252	251	
5.3.1.1	Bos taurus	9-methyl-beta-carbolinium ion		662960	82372	1 mM, stimulates
5.3.1.1	Methanococcus maripaludis	dithiothreitol		727725	42	required
5.3.1.1	Gallus gallus	phosphite		727027	943	
5.3.1.1	Trypanosoma brucei subsp. brucei	phosphite		714259, 727027, 727662	943	
5.3.1.1	Trypanosoma cruzi		(1Z,2Z)-N,N'-dihydroxy-4-methylcyclohexa-3,5-diene-1,2-diimine	714899	59388	
5.3.1.1	Trypanosoma cruzi		(2E)-2-[(4-methyl-5-oxido-1,2,5-oxadiazol-3-yl)methylidene]hydrazinecarbothioamide	714899	59384	
5.3.1.1	Trypanosoma cruzi		(2E)-2-[(5-nitrofuran-2-yl)methylidene]hydrazinecarbothioamide	714899	59381	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		(2E)-2-[2-[(3-oxido-2,1,3-benzoxadiazol-5-yl)methoxy]benzylidene]-N-(prop-2-en-1-yl)hydrazinecarbothioamide	714899	59376	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		(2E)-N-(naphthalen-2-yl)-2-[(2E)-3-(5-nitrofuran-2-yl)prop-2-en-1-ylidene]hydrazinecarboxamide	714899	59380	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		(2E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(5-nitrofuran-2-yl)methylidene]hydrazinecarboxamide	714899	59372	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		(4-methyl-1,2,3-thiadiazol-5-yl)methanol	714899	101236	29% inhibition at 0.4 mM
5.3.1.1	Homo sapiens		1,2,4-thiadiazole	714899	113213	59% inhibition at 0.1 mM
5.3.1.1	Trypanosoma cruzi		1,2,4-thiadiazole	714899	113213	
5.3.1.1	Trypanosoma cruzi		1,2,6-thiadiazine	714899	113273	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		1,3,4-oxathiazole	714899	113275	
5.3.1.1	Saccharomyces cerevisiae		1-Chloro-3-hydroxyacetone	2560	37197	
5.3.1.1	Leishmania mexicana		2,2'-methylenebis(1,3-benzothiazole)	678178	24222	irreversible inactivation
5.3.1.1	Trypanosoma brucei		2,2'-methylenebis(1,3-benzothiazole)	678178	24222	irreversible inactivation
5.3.1.1	Trypanosoma cruzi		2,2'-methylenebis(1,3-benzothiazole)	678178	24222	40% inactivation at 0.05 mM, irreversible
5.3.1.1	Saccharomyces cerevisiae		2,4-Dinitrofluorobenzene	2560	2186	no inhibition
5.3.1.1	Oryctolagus cuniculus		2,4-Dinitrofluorobenzene	2561	2186	
5.3.1.1	Trypanosoma cruzi		2,6-dibenzyl-4-[(5-nitrothiophen-2-yl)methylidene]-1,2,6-thiadiazinane-3,5-dione 1,1-dioxide	714899	59373	irreversible inhibitor
5.3.1.1	Bos taurus		2,9-dimethyl-beta-carbolinium ion	662960	82328	
5.3.1.1	Leishmania mexicana		2-(N-formyl-N-hydroxy)-aminoethyl phosphonate	651108	35568	
5.3.1.1	Giardia intestinalis		2-carboxyethyl methanethiosulfonate	694062	92771	modifies four Cys per subunit of dimeric protein and induces 97% of inactivation. Inactivation does not affect secondary structure nor induce dimer dissociation. Cys modification decreases thermal stability of the enzyme
5.3.1.1	Pyrococcus woesei		2-carboxyethylphosphonic acid	649096	14716	
5.3.1.1	Bos taurus		2-methyl-beta-carbolinium ion	662960	82327	
5.3.1.1	Trypanosoma cruzi		2-phenyl-4H-chromen-4-one	714899	1213	
5.3.1.1	Pisum sativum		2-phosphoglycerate	2565	606	
5.3.1.1	Escherichia coli		2-Phosphoglycolate	2586	997	
5.3.1.1	Moritella marina		2-Phosphoglycolate	2586	997	
5.3.1.1	Gallus gallus		2-Phosphoglycolate	661085	997	
5.3.1.1	Giardia intestinalis		2-Phosphoglycolate	663355	997	
5.3.1.1	Saccharomyces cerevisiae		2-Phosphoglycolate	678722	997	strong, competitive. Inhibition results in a large decrease in the unfolding rate constant of the protein. 2-phosphoglycolate shows similar binding affinities in the transition states for the rate-limiting steps of the forward and backward reactions, implicating that both transition states resemble each other in the active site architecture
5.3.1.1	Trypanosoma brucei		2-Phosphoglycolate	650149, 678177, 690232	997	
5.3.1.1	Saccharomyces cerevisiae		2-Phosphoglycolate	714198	997	competitive inhibition
5.3.1.1	Gallus gallus		2-Phosphoglycolate	727027	997	competitive inhibition
5.3.1.1	Trypanosoma brucei subsp. brucei		2-Phosphoglycolate	727027	997	competitive inhibition
5.3.1.1	Pyrococcus woesei		2-phosphoglycolic acid	649096	997	
5.3.1.1	Trypanosoma cruzi		2-[(1E)-2-nitroprop-1-en-1-yl]thiophene	714899	59386	
5.3.1.1	Trypanosoma cruzi		2-[(3-aminophenyl)disulfanyl]aniline	714899	101234	
5.3.1.1	Trypanosoma cruzi		3,5-diphenyl-1,2,4-thiadiazole	714899	59383	74% inhibition at 0.4 mM
5.3.1.1	Trypanosoma cruzi		3-(2-benzothiazolylthio)-1-propanesulfonic acid	662625	82326	binds to the dimer interface of the enzyme and thereby abolishes its function with a high level of selectivity
5.3.1.1	Trypanosoma cruzi		3-(4-methylphenyl)-5-[(4-methylphenyl)sulfonyl]-1,2,4-thiadiazole	714899	59379	
5.3.1.1	Trypanosoma cruzi		3-nitrobiphenyl-4-amine	714899	59389	
5.3.1.1	Sulfolobus solfataricus		3-phospho-D-glycerate	724980	181	
5.3.1.1	Pisum sativum		3-phosphoglycerate	2565	174	
5.3.1.1	Plasmodium falciparum		3-phosphoglycerate	701474	174	binding at the active site with the dimer-interface site showing strong electrostatic anchoring of the phosphate group involving the Arg98 and Lys112 residues of TIM, comparisons of binding structures at the interface, overview
5.3.1.1	Trypanosoma brucei		4,4'-Dithiopyridine	728551	4618	
5.3.1.1	Trypanosoma cruzi		4,4'-Dithiopyridine	728551	4618	
5.3.1.1	Trypanosoma cruzi		4-(4-nitrobenzylidene)-2,6-bis(2-phenylethyl)-1,2,6-thiadiazinane-3,5-dione 1,1-dioxide	714899	59377	irreversible inhibitor, 85% inhibition at 0.4 mM
5.3.1.1	Trypanosoma cruzi		4-[(5-nitrofuran-2-yl)methylidene]-4H-1,2,6-thiadiazine-3,5-diamine 1,1-dioxide	714899	59370	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		4-[(5-nitrothiophen-2-yl)methylidene]-2,6-bis(2-phenylethyl)-1,2,6-thiadiazinane-3,5-dione 1,1-dioxide	714899	59382	irreversible inhibitor
5.3.1.1	Giardia intestinalis		5,5'-dithio-bis(2-nitrobenzoic acid)	694062	196	derivatizes four of the five Cys per subunit of dimeric protein, resulting in inactivation and dissociation of the dimer to stable monomers
5.3.1.1	Rhipicephalus microplus		5,5'-dithio-bis(2-nitrobenzoic acid)	715181	196	about 50% inhibition at about 0.05 mM
5.3.1.1	Saccharomyces cerevisiae		5,5'-dithiobis(2-nitrobenzoate)	2560	196	no inhibition
5.3.1.1	Oryctolagus cuniculus		5,5'-dithiobis(2-nitrobenzoate)	2561	196	
5.3.1.1	Trypanosoma brucei		5,5'-dithiobis(2-nitrobenzoate)	728551	196	
5.3.1.1	Trypanosoma cruzi		5,5'-dithiobis(2-nitrobenzoate)	728551	196	
5.3.1.1	Trypanosoma cruzi		5-[(1E)-2-nitroprop-1-en-1-yl]-1,3-benzodioxole	714899	59387	
5.3.1.1	Leishmania mexicana		6,6'-bi-1,3-benzothiazole-2,2'-diamine	678178	16039	irreversible inactivation. Not inhibitory on human, yeast, chicken, Plasmodium falciparum, and Entamoeba histolytica enzyme
5.3.1.1	Trypanosoma brucei		6,6'-bi-1,3-benzothiazole-2,2'-diamine	678178	16039	irreversible inactivation. Not inhibitory on human, yeast, chicken, Plasmodium falciparum, and Entamoeba histolytica enzyme
5.3.1.1	Trypanosoma cruzi		6,6'-bi-1,3-benzothiazole-2,2'-diamine	678178	16039	91% inactivation at 0.05 mM, irreversible. Not inhibitory on human, yeast, chicken, Plasmodium falciparum, and Entamoeba histolytica enzyme
5.3.1.1	Trypanosoma cruzi		6,6'-bi-1,3-benzothiazole-2,2'-diamine	714899	16039	
5.3.1.1	Pisum sativum		6-phosphogluconate	2565	327	5 mM, 9% inhibition
5.3.1.1	Trypanosoma cruzi		6-[(E)-2-(5-nitrothiophen-2-yl)ethenyl]-2,1,3-benzoxadiazole 1-oxide	714899	59371	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		6-[(E)-2-[(4-fluorophenyl)sulfanyl]ethenyl]-2,1,3-benzoxadiazole 1-oxide	714899	59375	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		8-bromo-5,10-dioxidophenazin-2-yl chloroacetate	714899	59390	50% inhibition at 0.4 mM
5.3.1.1	Saccharomyces cerevisiae		Acetylphosphate	2560	305	competitive
5.3.1.1	Oryctolagus cuniculus		Acetylphosphate	2561	305	
5.3.1.1	Gallus gallus		arsenate	661085	222	
5.3.1.1	Gallus gallus		arsenate	727027	222	competitive inhibition
5.3.1.1	Trypanosoma brucei subsp. brucei		arsenate	727027	222	competitive inhibition
5.3.1.1	Saccharomyces cerevisiae		AsO2-	2560	4824	competitive
5.3.1.1	Oryctolagus cuniculus		AsO2-	2561	4824	
5.3.1.1	Homo sapiens		AsO43-	2562	222	competitive
5.3.1.1	Secale cereale		AsO43-	2570	222	
5.3.1.1	Trypanosoma brucei		AsO43-	2573, 678177, 690232	222	
5.3.1.1	Homo sapiens		ATP	2562	7	
5.3.1.1	Pisum sativum		ATP	2565	7	5 mM, 39% inhibition
5.3.1.1	Bos taurus		ATP	662960	7	
5.3.1.1	Lolium multiflorum		Atrazine	704137	844	a herbicide which interferes with photosynthesis
5.3.1.1	Bartonella henselae		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Caenorhabditis elegans		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Entamoeba histolytica		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Escherichia coli		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Gallus gallus		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Geobacillus stearothermophilus		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Giardia intestinalis		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Helicobacter pylori		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Homo sapiens		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Leishmania mexicana		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Methanocaldococcus jannaschii		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Moritella marina		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Mycobacterium tuberculosis		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Oryctolagus cuniculus		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Plasmodium falciparum		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Pyrococcus woesei		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Saccharomyces cerevisiae		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Tenebrio molitor		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Thermoproteus tenax		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Thermotoga maritima		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Trypanosoma brucei brucei		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Trypanosoma cruzi		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Trypanosoma cruzi		butylbrevifolin carboxylate	702595	54797	
5.3.1.1	Homo sapiens		Chloroacetol phosphate	2562	64226	
5.3.1.1	Pisum sativum		citrate	2565	125	25 mM, 9% inhibition
5.3.1.1	Canis lupus familiaris		cyclo(Gly-Pro-Phe-Val-Phe-PSI[CS-NH]Phe)	2576	13626	no inhibition
5.3.1.1	Escherichia coli		cyclo(Gly-Pro-Phe-Val-Phe-PSI[CS-NH]Phe)	2576	13626	no inhibition
5.3.1.1	Oryctolagus cuniculus		cyclo(Gly-Pro-Phe-Val-Phe-PSI[CS-NH]Phe)	2576	13626	no inhibition
5.3.1.1	Trypanosoma sp.		cyclo(Gly-Pro-Phe-Val-Phe-PSI[CS-NH]Phe)	2576	13626	
5.3.1.1	Canis lupus familiaris		cyclo[Trp-Phe-D-Pro-Phe-Phe-Lys(benzyloxycarbonyl)-]	2582	13627	no inhibition
5.3.1.1	Escherichia coli		cyclo[Trp-Phe-D-Pro-Phe-Phe-Lys(benzyloxycarbonyl)-]	2582	13627	no inhibition
5.3.1.1	Oryctolagus cuniculus		cyclo[Trp-Phe-D-Pro-Phe-Phe-Lys(benzyloxycarbonyl)-]	2582	13627	no inhibition
5.3.1.1	Trypanosoma brucei		cyclo[Trp-Phe-D-Pro-Phe-Phe-Lys(benzyloxycarbonyl)-]	2582	13627	
5.3.1.1	Trypanosoma brucei		cyclo[Trp-Tyr(OSO3Na)-D-Phe-Thr(OSO3Na)-Lys(benzyloxycarbonyl)-]	2582	66283	noncompetitive, reversible
5.3.1.1	Saccharomyces cerevisiae		D-alpha-glycerophosphate	2560	3866	competitive
5.3.1.1	Oryctolagus cuniculus		D-alpha-glycerophosphate	2561	3866	
5.3.1.1	Homo sapiens		D-alpha-glycerophosphate	2562	3866	competitive
5.3.1.1	Oryctolagus cuniculus		D-alpha-glycerophosphate	2563	3866	competitive
5.3.1.1	Oryctolagus cuniculus		D-erythrose 4-phosphate	2561	416	
5.3.1.1	Bartonella henselae		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Caenorhabditis elegans		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Entamoeba histolytica		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Escherichia coli		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Gallus gallus		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Geobacillus stearothermophilus		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Giardia intestinalis		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Helicobacter pylori		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Homo sapiens		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Leishmania mexicana		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Methanocaldococcus jannaschii		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Moritella marina		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Mycobacterium tuberculosis		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Oryctolagus cuniculus		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Plasmodium falciparum		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Pyrococcus woesei		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Saccharomyces cerevisiae		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Tenebrio molitor		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Thermoproteus tenax		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Thermotoga maritima		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Trypanosoma brucei brucei		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Trypanosoma cruzi		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Trypanosoma cruzi		ethyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,2,4-thiadiazole-5-carboxylate	714899	59378	
5.3.1.1	Trypanosoma cruzi		ethyl 3-phenyl-1,2,4-thiadiazole-5-carboxylate	714899	59374	
5.3.1.1	Trypanosoma cruzi		ethylbrevifolin carboxylate	702595	54796	
5.3.1.1	Lolium multiflorum		fluorodifen	704137	6444	a herbicide which interferes with photosynthesis
5.3.1.1	Pisum sativum		fructose 1,6-diphosphate	2565	100	5 mM, 69% inhibition
5.3.1.1	Pisum sativum		fructose 6-phosphate	2565	82	5 mM, 44% inhibition
5.3.1.1	Pisum sativum		glucose 1-phosphate	2565	386	5 mM, 10% inhibition
5.3.1.1	Pisum sativum		glucose 6-phosphate	2565	99	5 mM, 25% inhibition
5.3.1.1	Tenebrio molitor		glycerol 1-phosphate	704030	352	
5.3.1.1	Lolium multiflorum		GSSG	704137	283	oxidized glutathione is a strong inhibitor of the enzyme at low concentrations
5.3.1.1	Chlamydomonas reinhardtii		H2O2	728349	20	the inhibition of the enzyme is negligible when incubated with 0.1 mM H2O2, whereas a 10% inhibition is observed with 1 mM H2O2
5.3.1.1	Oryctolagus cuniculus		iodoacetamide	2561	63	
5.3.1.1	Saccharomyces cerevisiae		iodoacetate	2560	87	no inhibition
5.3.1.1	Oryctolagus cuniculus		iodoacetate	2561	87	
5.3.1.1	Secale cereale		iodoacetate	2570	87	
5.3.1.1	Plasmodium falciparum		KFGNGSYTGEVS	651284	77391	peptide that corresponds to loop 3 of the triosephosphate isomerase, residues 68-79. Efficient inhibitor with the activity falling to about 45% at 1000fold molar excess of the peptide in case of the wild-type enzyme. In the case of either of the mutants, Y74C and Y74G, even at 100fold molar excess of the peptide, only 30% activity can be obtained
5.3.1.1	Plasmodium falciparum		KYGNGSCTGEVS	651284	77392	peptide that is an analog of the peptide that corresponds to loop 3 of the protein, residues 68-79, with the replacement Y74C and F69Y. Inhibits the activity of the mutant enzymes Y74C and Y74G, with about 40% activity remaining in the presence of 1000fold molar excess of the peptide
5.3.1.1	Staphylococcus aureus		mannobiose	705563	1502	
5.3.1.1	Staphylococcus aureus		Mannopentaose	705563	3571	
5.3.1.1	Staphylococcus aureus		Mannotetraose	705563	4439	
5.3.1.1	Staphylococcus aureus		Mannotriose	705563	2993	docking simulation
5.3.1.1	Trypanosoma brucei		methyl methanethiosulfonate	2578	1724	derivatizes Cys14 to a methyl sulfide
5.3.1.1	Gallus gallus		methyl methanethiosulfonate	2584	1724	no inhibition
5.3.1.1	Oryctolagus cuniculus		methyl methanethiosulfonate	2584	1724	
5.3.1.1	Saccharomyces cerevisiae		methyl methanethiosulfonate	2584	1724	no inhibition
5.3.1.1	Schizosaccharomyces pombe		methyl methanethiosulfonate	2584	1724	
5.3.1.1	Leishmania mexicana		methyl methanethiosulfonate	2587	1724	the sensitivity of enzyme from Trypanosoma cruzi is about 40times higher than that of Trypanosoma brucei and 200times higher than that of Leishmania mexicana
5.3.1.1	Trypanosoma brucei		methyl methanethiosulfonate	2587	1724	the sensitivity of enzyme from Trypanosoma cruzi is about 40times higher than that of Trypanosoma brucei and 200times higher than that of Leishmania mexicana
5.3.1.1	Trypanosoma cruzi		methyl methanethiosulfonate	2587	1724	the sensitivity of enzyme from Trypanosoma cruzi is about 40times higher than that of Trypanosoma brucei and 200times higher than that of Leishmania mexicana
5.3.1.1	Giardia intestinalis		methyl methanethiosulfonate	694062	1724	derivatizes three of the five Cys per subunit of dimeric protein and induces 50% of inactivation. Inactivation does not affect secondary structure nor induce dimer dissociation. Cys modification decreases thermal stability of the enzyme
5.3.1.1	Rhipicephalus microplus		methyl methanethiosulfonate	715181	1724	about 50% inhibition at about 0.05 mM
5.3.1.1	Trypanosoma cruzi		methylbrevifolin carboxylate	702595	54795	molecular docking simulations and enzyme binding structure, and inhibition kinetics, overview
5.3.1.1	Entamoeba histolytica		methylmethane thiosulfonate	652896	1724	0.6 mM, 2 h, complete loss of activity, dissociates the dimeric enzyme inducing formation of a compact monomeric state
5.3.1.1	Trypanosoma brucei		methylmethane thiosulfonate	682787	1724	modification at C15 in the dimer interface, inducing abolition of catalysis and structural changes. Susceptibility of Trypanosoma cruzi enzyme to modification of C15 is nearly 100fold higher than susceptibility of C15 of Trypanosoma brucei
5.3.1.1	Trypanosoma cruzi		methylmethane thiosulfonate	682787	1724	modification at C15 in the dimer interface, inducing abolition of catalysis and structural changes. Susceptibility of Trypanosoma cruzi enzyme to modification of C15 is nearly 100fold higher than susceptibility of C15 of Trypanosoma brucei
5.3.1.1	Leishmania donovani		methylmethane thiosulfonate	727428	1724	induces 75% enzyme inactivation within 15 min at 0.25 mM concentration
5.3.1.1	Trypanosoma brucei		methylmethane thiosulfonate	728551	1724	60% residual activity at 0.1 mM
5.3.1.1	Trypanosoma cruzi		methylmethane thiosulfonate	728551	1724	almost complete inhibition at 0.1 mM
5.3.1.1	Plasmodium falciparum		more	651284		ANWKCNGTLE, the peptide that corresponds to loop 1 of triosephosphate isomerase, residues 9-18, shows only negligible inhibition of wild-type enzyme and mutant enzymes Y74G and Y74C, with a fall in the enzymatic activity by only about 20% at 1000fold molar excess of the peptide
5.3.1.1	Homo sapiens		more	693299		in drug-resistant SGC7901 cells induced by vincristine sulfate, triosephosphate isomerase is downregulated.The sensitivity of TPI-SGC7901/VCR cells to adriamycin, vincristine, 5-fluorouracil and cis-dichlorodiamine platinum, as well as the accumulation and retention to adriamycin, are significantly increased when compared to their control cell lines
5.3.1.1	Trypanosoma cruzi		more	702595		brevifolin carboxylate derivatives isolated from Geranium bellum selectively inactivate the enzyme partially, no inhibition by methyl tri-O-methylbrevifolin carboxylate
5.3.1.1	Staphylococcus aureus		more	705563		stronger inhibition by alpha-(1,3)-mannooligosaccharides than with triose, binding constants, overview
5.3.1.1	Mus musculus		more	705903		recombinant expression of Tau in CHO-K1 cells leads to increased protection of TPI against oxidative damage, but also to decreased enzyme activity, with unaltered TPI expression levels
5.3.1.1	Homo sapiens		more	706845		TPI phosphorylation by cyclin A/Cdk2 kinase leads to reduced TPI activity, prevented by treatment with olomoucine, a specific inhibitor of Cdk2
5.3.1.1	Homo sapiens		more	714899		not inhibited by 1,2,6-thiadiazine, phenazine 5,9-dioxide, and 1,3,4-oxathiazole
5.3.1.1	Trypanosoma brucei		N-ethylmaleimide	728551	46	
5.3.1.1	Trypanosoma cruzi		N-ethylmaleimide	728551	46	
5.3.1.1	Trypanosoma cruzi		N-[(2-oxido-4-phenyl-1,2,5-oxadiazol-3-yl)methyl]naphthalen-1-amine	714899	59385	72% inhibition at 0.4 mM
5.3.1.1	Trypanosoma cruzi		N-[(4-methyl-5-oxido-1,2,5-oxadiazol-3-yl)methyl]naphthalen-1-amine	714899	101235	41% inhibition at 0.4 mM
5.3.1.1	Oryctolagus cuniculus		NEM	2561	46	
5.3.1.1	Oryctolagus cuniculus		o-Iodosobenzoate	2561	1554	
5.3.1.1	Oryctolagus cuniculus		p-benzoquinone	2561	270	
5.3.1.1	Secale cereale		p-hydroxymercuribenzoate	2570	92	
5.3.1.1	Trypanosoma brucei		p-hydroxymercuribenzoate	2573	92	
5.3.1.1	Saccharomyces cerevisiae		PCMB	2560	40	no inhibition
5.3.1.1	Oryctolagus cuniculus		PCMB	2561	40	
5.3.1.1	Trypanosoma cruzi		phenazine 5,9-dioxide	714899	113274	84% inhibition at 0.4 mM
5.3.1.1	Saccharomyces cerevisiae		phosphate	2560	12	competitive
5.3.1.1	Oryctolagus cuniculus		phosphate	2561	12	
5.3.1.1	Trypanosoma brucei		phosphate	2573	12	
5.3.1.1	Helicobacter pylori		phosphate	682773	12	competitive, occupies the substrate binding pocket
5.3.1.1	Saccharomyces cerevisiae		phosphoenolpyruvate	2560	47	competitive
5.3.1.1	Oryctolagus cuniculus		phosphoenolpyruvate	2561	47	
5.3.1.1	Pisum sativum		phosphoenolpyruvate	2565	47	
5.3.1.1	Trypanosoma brucei		phosphoenolpyruvate	2573	47	
5.3.1.1	Sulfolobus solfataricus		phosphoenolpyruvate	724980	47	
5.3.1.1	Saccharomyces cerevisiae		Phosphoglycolate	2560	997	competitive
5.3.1.1	Oryctolagus cuniculus		Phosphoglycolate	2561	997	
5.3.1.1	Homo sapiens		Phosphoglycolate	2562	997	competitive
5.3.1.1	Oryctolagus cuniculus		Phosphoglycolate	2563	997	and its corresponding hydroxamate; competitive
5.3.1.1	Homo sapiens		Phosphoglycolate	2567	997	
5.3.1.1	Trypanosoma brucei		Phosphoglycolate	2573	997	2-phosphoglycolate
5.3.1.1	Saccharomyces cerevisiae		Phosphoglycolate	2575	997	
5.3.1.1	Geobacillus stearothermophilus		Phosphoglycolate	2590	997	2-phosphoglycolate
5.3.1.1	Homo sapiens		Phosphoglycolate	2591	997	2-phosphoglycolate
5.3.1.1	Oryctolagus cuniculus		phosphoglycoloaldoxime	661343	37744	
5.3.1.1	Oryctolagus cuniculus		phosphoglycolohydrazide	661343	9123	
5.3.1.1	Saccharomyces cerevisiae		Phosphoglycolohydroxamate	2575	7234	
5.3.1.1	Oryctolagus cuniculus		Phosphoglycolohydroxamate	661343	7234	
5.3.1.1	Leishmania mexicana		Phosphoglycolohydroxamate	706663	7234	the reaction-intermediate analogue binds to the active site with two hydrogen-bonding interactions between PGH and the Glu167 side-chain oxygen atoms
5.3.1.1	Escherichia coli		S-Phenyl-p-toluenethiosulfonate	2584	10773	no inhibition
5.3.1.1	Gallus gallus		S-Phenyl-p-toluenethiosulfonate	2584	10773	
5.3.1.1	Oryctolagus cuniculus		S-Phenyl-p-toluenethiosulfonate	2584	10773	
5.3.1.1	Saccharomyces cerevisiae		S-Phenyl-p-toluenethiosulfonate	2584	10773	no inhibition
5.3.1.1	Schizosaccharomyces pombe		S-Phenyl-p-toluenethiosulfonate	2584	10773	
5.3.1.1	Secale cereale		SO42-	2570	148	CuSO4
5.3.1.1	Trypanosoma brucei		SO42-	2573	148	
5.3.1.1	Pisum sativum		succinate	2565	54	5 mM, 9% inhibition
5.3.1.1	Trypanosoma brucei		suramin	2573	568	
5.3.1.1	Oryctolagus cuniculus		[3-amino-3-(hydroxyimino)propyl]phosphonic acid	661343	37546	
2.7.4.7	Staphylococcus aureus		(6R)-6-[(2E)-4-oxo-6-phenylhex-2-en-1-yl]-5,6-dihydro-2H-pyran-2-one	722048		lactone isolated from Cryptocarya rugulosa, covalent inhibition
2.7.4.7	Staphylococcus aureus		(6R)-6-[(2E)-6-(4-ethynylphenyl)-4-oxohex-2-en-1-yl]-5,6-dihydro-2H-pyran-2-one	722048		derivative of a lactone isolated from Cryptocarya rugulosa, covalent inhibition
2.7.4.7	Staphylococcus aureus		(6S)-6-[(2E)-6-(4-ethynylphenyl)-4-oxohex-2-en-1-yl]tetrahydro-2H-pyran-2-one	722048		derivative of a lactone isolated from Cryptocarya rugulosa, covalent inhibition
2.7.4.7	Saccharomyces cerevisiae		p-hydroxymercuribenzoate	641657	92	1 mM, complete inhibition
2.7.1.33	Spinacia oleracea	Acyl carrier protein		641388	454	PAK II: inhibition, PAK I: stimulation between 0.015-0.035 mM
2.7.1.33	Homo sapiens	cholesterol		722018	169	about 125% activity at 0.1 mM
2.7.1.33	Mus musculus	CoA		641397	10	stimulates
2.7.1.33	Escherichia coli	dithiothreitol		641393	42	activation
2.7.1.33	Homo sapiens	glyburide		722018	9568	; isoform PanK1b is activated by glyburide
2.7.1.33	Rattus norvegicus	more		641392		no activation by L-carnitine
2.7.1.33	Bacillus subtilis	more		662369		enzyme is not affected by CoA or acetyl-CoA
2.7.1.33	Helicobacter pylori	more		662369		enzyme is not affected by CoA or acetyl-CoA
2.7.1.33	Staphylococcus aureus	more		662408		no feedback regulation by CoA or acetyl-CoA
2.7.1.33	Homo sapiens	more		676884		carnitine and octanoylcarnitine do not have any effect on the PanK2 activity
2.7.1.33	Homo sapiens	more		722018		isoform PanK3 is not activated by 1,4-naphthoquinone and phenylmercuric acid
2.7.1.33	Homo sapiens	O-oleoylcarnitine		722018		140% activation at 0.1 mM
2.7.1.33	Homo sapiens	O-palmitoylcarnitine		722018	3832	120% activation at 0.1 mM
2.7.1.33	Homo sapiens	oleoylethanolamide		722018	3350	120% activation at 0.1 mM
2.7.1.33	Homo sapiens	palmitoylcarnitine		676884	3832	activates; the enzymatic activity of PanK2 is stimulated to the highest level by 0.008 mM palmitoylcarnitine
2.7.1.33	Homo sapiens	palmitoylcarnitine		686741	3832	activates
2.7.1.33	Mus musculus	palmitoylcarnitine		686741	3832	activates
2.7.1.33	Homo sapiens	tamoxifen		722018	1221	140% activation at 0.1 mM
2.7.1.33	Homo sapiens		(2R)-2,4-dihydroxy-3,3-dimethyl-N'-phenylbutanohydrazide	660726	15179	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Plasmodium falciparum		(2R)-2,4-dihydroxy-3,3-dimethyl-N'-phenylbutanohydrazide	660726	15179	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Plasmodium falciparum		(2R)-2,4-dihydroxy-3,3-dimethylbutanohydrazide	660726	36994	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Plasmodium falciparum		(2R)-2,4-dihydroxy-N-(2-hydroxyethyl)-3,3-dimethylbutanamide	660726	36992	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Plasmodium falciparum		(2R)-N-(2,3-dihydroxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide	660726	36993	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Homo sapiens		(2R)-N-allyl-2,4-dihydroxy-3,3-dimethylbutanamide	660726	15178	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Plasmodium falciparum		(2R)-N-allyl-2,4-dihydroxy-3,3-dimethylbutanamide	660726	15178	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Escherichia coli		(R)-3-azido-4,4-dimethyl-dihydro-furan-2-one	661331	37661	
2.7.1.33	Staphylococcus aureus		(R)-3-azido-4,4-dimethyl-dihydro-furan-2-one	661331	37661	
2.7.1.33	Aspergillus nidulans		(R)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	15358	80.6% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		(R)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	15358	29.4% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		(R)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	15358	2.7% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		(R)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	15358	78.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		(R)-4-(2-amino-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	37663	11% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		(R)-4-(2-amino-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	37663	13.1% inhibition at 0.1 mM, cell extract
2.7.1.33	Escherichia coli		(R)-4-(2-azido-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	37662	
2.7.1.33	Staphylococcus aureus		(R)-4-(2-azido-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	37662	
2.7.1.33	Escherichia coli		(S)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	24323	12.5% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Staphylococcus aureus		(S)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	24323	54.6% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		(S)-trifluoro-methanesulfonic acid 4,4-dimethyl-2-oxo-tetrahydro-furan-3-yl-ester	661331	37660	
2.7.1.33	Staphylococcus aureus		(S)-trifluoro-methanesulfonic acid 4,4-dimethyl-2-oxo-tetrahydro-furan-3-yl-ester	661331	37660	
2.7.1.33	Mycobacterium tuberculosis		1,4-dioxa-8-azaspiro[4.5]dec-8-yl[2-[(3-fluorophenyl)sulfanyl]pyridin-4-yl]methanone	722830	61769	mixed non-competitive inhibition
2.7.1.33	Homo sapiens		1,4-phenylene-bis(1,2-ethanediyl)bis-isothiourea dihydrobromide	722018		
2.7.1.33	Rattus norvegicus		2'-Ketopantetheine	641387	62879	
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-(2-heptylcarbamoyl-ethyl)-butyramide	661331	6579	10.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-(2-heptylcarbamoyl-ethyl)-butyramide	661331	6579	76.4% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-(2-heptylcarbamoyl-ethyl)-butyramide	661331	6579	89.6% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-(2-heptylcarbamoyl-ethyl)-butyramide	661331	6579	98.2% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-(2-isobutylcarbamoyl-ethyl)-butyramide	661331	15187	46.2% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-(2-isobutylcarbamoyl-ethyl)-butyramide	661331	15187	71.2% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-(2-isobutylcarbamoyl-ethyl)-butyramide	661331	15187	89.9% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-(2-isobutylcarbamoyl-ethyl)-butyramide	661331	15187	97.1% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Plasmodium falciparum		2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide	660726	6578	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide	661331	6578	12.6% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide	661331	6578	72.2% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide	661331	6578	81.4% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide	661331	6578	98.8% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-(2-phenethylcarbamoyl-ethyl)-butyramide	661331	15359	59.5% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-(2-phenethylcarbamoyl-ethyl)-butyramide	661331	15359	57.8% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-(2-phenethylcarbamoyl-ethyl)-butyramide	661331	15359	80.9% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-(2-phenethylcarbamoyl-ethyl)-butyramide	661331	15359	89.5% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Plasmodium falciparum		2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide	660726	9078	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide	661331	9078	51.4% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide	661331	9078	82.5% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide	661331	9078	86.8% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide	661331	9078	99.1% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-(2-[1-methyl-3-phenyl-propylcarbamoyl]-ethyl)-butyramide	661331	15181	40.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-(2-[1-methyl-3-phenyl-propylcarbamoyl]-ethyl)-butyramide	661331	15181	71.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-(2-[1-methyl-3-phenyl-propylcarbamoyl]-ethyl)-butyramide	661331	15181	84.6% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-(2-[1-methyl-3-phenyl-propylcarbamoyl]-ethyl)-butyramide	661331	15181	86.4% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-(2-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-ethyl)-butyramide	661331	15180	35.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-(2-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-ethyl)-butyramide	661331	15180	44.2% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-(2-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-ethyl)-butyramide	661331	15180	70.5% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-(2-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-ethyl)-butyramide	661331	15180	17.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-(2-[3,4,5-trimethoxy-benzylcarbamoyl]-ethyl)-butyramide	661331	15182	28.4% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-(2-[3,4,5-trimethoxy-benzylcarbamoyl]-ethyl)-butyramide	661331	15182	33.4% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-(2-[3,4,5-trimethoxy-benzylcarbamoyl]-ethyl)-butyramide	661331	15182	57.4% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-(2-[3,4,5-trimethoxy-benzylcarbamoyl]-ethyl)-butyramide	661331	15182	8.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-[2-(2,6,6-trimethylbicyclo[3.1.1]hept-3-ylcarbamoyl)-ethyl]-butyramide	661331	15186	71.9% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-[2-(2,6,6-trimethylbicyclo[3.1.1]hept-3-ylcarbamoyl)-ethyl]-butyramide	661331	15186	3.0% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-[2-(2,6,6-trimethylbicyclo[3.1.1]hept-3-ylcarbamoyl)-ethyl]-butyramide	661331	15186	93.3% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-[2-(2,6,6-trimethylbicyclo[3.1.1]hept-3-ylcarbamoyl)-ethyl]-butyramide	661331	15186	76.6% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethoxy-ethylcarbamoyl)-ethyl]-butyramide	661331	15192	41.8% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethoxy-ethylcarbamoyl)-ethyl]-butyramide	661331	15192	28.6% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethoxy-ethylcarbamoyl)-ethyl]-butyramide	661331	15192	68.9% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethoxy-ethylcarbamoyl)-ethyl]-butyramide	661331	15192	95.1% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethylsulfanylethylcarbamoyl)-ethyl]-butyramide	661331	15191	61.0% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethylsulfanylethylcarbamoyl)-ethyl]-butyramide	661331	15191	53.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethylsulfanylethylcarbamoyl)-ethyl]-butyramide	661331	15191	82.9% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethylsulfanylethylcarbamoyl)-ethyl]-butyramide	661331	15191	97.6% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-[2-(2-methylsulfanylethylcarbamoyl)-ethyl]-butyramide	661331	15189	49.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-[2-(2-methylsulfanylethylcarbamoyl)-ethyl]-butyramide	661331	15189	61.9% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-[2-(2-methylsulfanylethylcarbamoyl)-ethyl]-butyramide	661331	15189	85.0% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-[2-(2-methylsulfanylethylcarbamoyl)-ethyl]-butyramide	661331	15189	96.5% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-[2-(2-morpholin-4-yl-ethylcarbamoyl)-ethyl]-butyramide	661331	15184	13.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-[2-(2-morpholin-4-yl-ethylcarbamoyl)-ethyl]-butyramide	661331	15184	10.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-[2-(2-morpholin-4-yl-ethylcarbamoyl)-ethyl]-butyramide	661331	15184	39.1% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-[2-(2-morpholin-4-yl-ethylcarbamoyl)-ethyl]-butyramide	661331	15184	4.2% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-[2-(3,7-dimethylocta-2,6-dienylcarbamoyl)-ethyl]-butyramide	661331	15188	92.2% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-[2-(3,7-dimethylocta-2,6-dienylcarbamoyl)-ethyl]-butyramide	661331	15188	90.6% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-[2-(3,7-dimethylocta-2,6-dienylcarbamoyl)-ethyl]-butyramide	661331	15188	98.9% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-[2-(3,7-dimethylocta-2,6-dienylcarbamoyl)-ethyl]-butyramide	661331	15188	97.2% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Plasmodium falciparum		2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide	660726	9076	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide	661331	9076	62.1% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide	661331	9076	32.3% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide	661331	9076	61.2% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide	661331	9076	96.2% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Plasmodium falciparum		2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide	660726	9077	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide	661331	9077	72.6% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide	661331	9077	54.3% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide	661331	9077	87.2% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide	661331	9077	97.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-[2-(4-methoxy-benzylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15185	54.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-[2-(4-methoxy-benzylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15185	55.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-[2-(4-methoxy-benzylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15185	82.2% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-[2-(4-methoxy-benzylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15185	53.9% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-3,3-dimethyl N-[3-(4-benzyl-piperazin-1-yl)-3-oxo-propyl]-butyramide	661331	15183	15.9% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-3,3-dimethyl N-[3-(4-benzyl-piperazin-1-yl)-3-oxo-propyl]-butyramide	661331	15183	7.3% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-3,3-dimethyl N-[3-(4-benzyl-piperazin-1-yl)-3-oxo-propyl]-butyramide	661331	15183	73.0% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-3,3-dimethyl N-[3-(4-benzyl-piperazin-1-yl)-3-oxo-propyl]-butyramide	661331	15183	9.3% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-N-[2-(2-hydroxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15360	25.9% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-N-[2-(2-hydroxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15360	3.4% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-N-[2-(2-hydroxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15360	56.7% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-N-[2-(2-hydroxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15360	72.2% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-N-[2-(2-methoxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15190	26.8% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-N-[2-(2-methoxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15190	28.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-N-[2-(2-methoxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15190	67.6% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-N-[2-(2-methoxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15190	90.1% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-N-[2-(3-hydroxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15361	i.e. pantothenol, 36.7% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-N-[2-(3-hydroxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15361	i.e. pantothenol, 11.5% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-N-[2-(3-hydroxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15361	i.e. pantothenol, 70.3% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-N-[2-(3-hydroxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15361	i.e. pantothenol, 79.9% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Plasmodium falciparum		2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	660726	9075	competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2.7.1.33	Aspergillus nidulans		2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	9075	52.9% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Escherichia coli		2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	9075	38.6% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mus musculus		2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	9075	64.9% inhibition at 0.1 mM, cell extract
2.7.1.33	Staphylococcus aureus		2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	9075	94.4% inhibition at 0.1 mM, purified enzyme
2.7.1.33	Mycobacterium tuberculosis		2-[2-(1-benzoylpiperidin-4-yl)-5-methyl-1,3-thiazol-4-yl]-N-(4-methylphenyl)acetamide	722830	61768	uncompetitive inhibition
2.7.1.33	Mus musculus		4-(2,4-dihydroxy-3,3-dimethylbutylamido)butyric acid	673027	24323	competitive inhibitor; competitive inhibitor, IC50: 0.05-0.15 mM
2.7.1.33	Thermococcus kodakarensis		4-phosphopantoate	727436	12827	substrate inhibition
2.7.1.33	Bacillus anthracis		5'-deoxy-5'-(4-(beta-D-galactopyranosyloxymethyl)-1,2,3-triazol-1-yl)adenosine	706042	54245	competitive inhibitor with respect to ATP
2.7.1.33	Escherichia coli		acetoacetyl-CoA	641393	167	
2.7.1.33	Brassica napus		acetyl-CoA	641388	27	not
2.7.1.33	Spinacia oleracea		acetyl-CoA	641388	27	not
2.7.1.33	Escherichia coli		acetyl-CoA	641393	27	
2.7.1.33	Rattus norvegicus		acetyl-CoA	641390, 641391, 641394	27	
2.7.1.33	Mus musculus		acetyl-CoA	641397	27	strong
2.7.1.33	Aspergillus nidulans		acetyl-CoA	641402	27	selective and strong, competitive to ATP
2.7.1.33	Mus musculus		acetyl-CoA	662406	27	feedback inhibition, regulatory function, isozyme PanK1beta and isozyme PanK3, strong inhibition of mutant chimera PanK1beta-3-1beta, slight inhibition of mutant chimera PanK3-1beta-3
2.7.1.33	Plasmodium falciparum		acetyl-CoA	674852	27	effective inhibitor
2.7.1.33	Homo sapiens		acetyl-CoA	676884	27	competitive inhibitor of purified PanK2 with respect to ATP; IC50: 60 nM, competitive inhibitor with respect to ATP
2.7.1.33	Homo sapiens		acetyl-CoA	686741	27	
2.7.1.33	Mus musculus		acetyl-CoA	686741	27	
2.7.1.33	Homo sapiens		acetyl-CoA	687612	27	a feedback inhibitor; a feedback inhibitor
2.7.1.33	Homo sapiens		acetyl-CoA	722018	27	complete inhibition of isoform PanK3 at 0.008 mM
2.7.1.33	Brassica napus		Acyl carrier protein	641388	454	
2.7.1.33	Spinacia oleracea		Acyl carrier protein	641388	454	PAK II: inhibition, PAK I: stimulation between 0.015-0.035 mM
2.7.1.33	Rattus norvegicus		acyl-CoA-esters	641390	22067	long-chain acyl-CoAs less efficient than short-chain ester
2.7.1.33	Rattus norvegicus		acyl-CoA-esters	641391	22067	
2.7.1.33	Mus musculus		acyl-CoA-esters	641400	22067	long chain acyl CoA, feed-back inhibition, isoform PanK1alpha
2.7.1.33	Corynebacterium ammoniagenes		ADP	641389	8	not
2.7.1.33	Escherichia coli		ADP	641393	8	
2.7.1.33	Homo sapiens		ADP	722018	8	competitive inhibitor of isoform PanK3 with respect to ATP1 and a mixed-type inhibitor with respect to pantothenate
2.7.1.33	Corynebacterium ammoniagenes		AlCl3	641389	1328	strong
2.7.1.33	Escherichia coli		AMP	641393	9	
2.7.1.33	Rattus norvegicus		Arachidonoyl-CoA	641390	756	
2.7.1.33	Rattus norvegicus		ATP	641391	7	free form
2.7.1.33	Thermococcus kodakarensis		ATP	727436	7	substrate inhibition
2.7.1.33	Corynebacterium ammoniagenes		Ba2+	641389	105	
2.7.1.33	Homo sapiens		chloranil	722018	6398	
2.7.1.33	Rattus norvegicus		citrate	641391	125	
2.7.1.33	Rattus norvegicus		CoA	641387	10	strong
2.7.1.33	Brassica napus		CoA	641388	10	not
2.7.1.33	Spinacia oleracea		CoA	641388	10	not
2.7.1.33	Corynebacterium ammoniagenes		CoA	641389	10	
2.7.1.33	Rattus norvegicus		CoA	641390	10	
2.7.1.33	Rattus norvegicus		CoA	641391	10	not reversible by D-carnitine, acetyl-L-carnitine or other carnitine analogs; reversible by L-carnitine
2.7.1.33	Rattus norvegicus		CoA	641392	10	feed-back inhibition; in vitro; reversible by L-carnitine
2.7.1.33	Escherichia coli		CoA	641393	10	in vitro; in vivo; kinetics
2.7.1.33	Rattus norvegicus		CoA	641394	10	inhibits isoform A stronger than isoform B
2.7.1.33	Mus musculus		CoA	641400	10	feed-back inhibition, isoform PanK1alpha
2.7.1.33	Homo sapiens		CoA	662455	10	feedback inhibition, inhibition kinetics of recombinant isozyme mPanK2
2.7.1.33	Escherichia coli		CoA	671053	10	feedback inhibitor
2.7.1.33	Mycobacterium tuberculosis		CoA	671053	10	feedback inhibitor
2.7.1.33	Plasmodium falciparum		CoA	674852	10	IC50: 0.2 mM
2.7.1.33	Mycobacterium tuberculosis		CoA	677979	10	
2.7.1.33	Escherichia coli		CoA	686816	10	competitive
2.7.1.33	Homo sapiens		CoA esters	662455	409	feedback inhibition, inhibition kinetics of recombinant isozyme mPanK2
2.7.1.33	Escherichia coli		coenzyme A	662251	10	allosteric regulator, feedback inhibition
2.7.1.33	Mus musculus		coenzyme A	662406	10	feedback inhibition, regulatory function, isozyme PanK1beta, slight inhibition of isozyme PanK3
2.7.1.33	Plasmodium falciparum		coenzyme A	674852	10	feedback inhibition regulates pantothenol uptake. Furosemide reduces this inherent feedback inhibition by competing with coenzyme A for binding to pantothenate kinase, thereby increasing pantothenol uptake
2.7.1.33	Corynebacterium ammoniagenes		Cu2+	641389	28	strong
2.7.1.33	Corynebacterium ammoniagenes		D-pantothenate	641389	1139	substrate inhibition, above 0.5 mM
2.7.1.33	Homo sapiens		dehydroisoandrosterone	722018	239	about 30% residual activity at 0.1 mM (isoform PanK3)
2.7.1.33	Homo sapiens		Dehydroisoandrosterone sulfate	722018	3552	; about 8% residual activity at 0.1 mM (isoform PanK3)
2.7.1.33	Corynebacterium ammoniagenes		dephospho-CoA	641389	1349	
2.7.1.33	Rattus norvegicus		dephospho-CoA	641387, 641390, 641391	1349	
2.7.1.33	Escherichia coli		dephospho-CoA	641393	1349	not
2.7.1.33	Rattus norvegicus		diphosphate	641391	13	
2.7.1.33	Corynebacterium ammoniagenes		EDTA	641389	223	
2.7.1.33	Homo sapiens		ephedrine hydrochloride	722018		
2.7.1.33	Homo sapiens		estradiol	722018	602	about 80% residual activity at 0.1 mM (isoform PanK3)
2.7.1.33	Homo sapiens		Estradiol sulfate	722018	13754	about 90% residual activity at 0.1 mM (isoform PanK3)
2.7.1.33	Homo sapiens		Estrone sulfate	722018	2472	about 50% residual activity at 0.1 mM (isoform PanK3)
2.7.1.33	Corynebacterium ammoniagenes		Fe2+	641389	23	strong
2.7.1.33	Homo sapiens		Fusidic acid	722018	2981	
2.7.1.33	Homo sapiens		glipizide	722018		
2.7.1.33	Homo sapiens		glyburide	722018	9568	
2.7.1.33	Homo sapiens		GW5074	722018	10294	
2.7.1.33	Homo sapiens		Hexachlorophene	722018	1545	
2.7.1.33	Corynebacterium ammoniagenes		HgCl2	641389	104	strong
2.7.1.33	Rattus norvegicus		L-Pantothenate	641387	13413	
2.7.1.33	Brassica napus		malonyl-CoA	641388	72	
2.7.1.33	Spinacia oleracea		malonyl-CoA	641388	72	0.075 mM, complete inhibition of PAK I
2.7.1.33	Rattus norvegicus		malonyl-CoA	641390	72	
2.7.1.33	Escherichia coli		malonyl-CoA	641393	72	
2.7.1.33	Mus musculus		malonyl-CoA	662406	72	feedback inhibition, regulatory function, isozyme PanK3, slight inhibition of isozyme PanK1beta
2.7.1.33	Plasmodium falciparum		malonyl-CoA	674852	72	effective inhibitor
2.7.1.33	Homo sapiens		MCC-555	722018		MCC-555 inhibits all three isoforms with a rank order of PanK3 &gt; PanK2 &gt; PanK1b; MCC-555 inhibits all three isoforms with a rank order of PanK3 &gt; PanK2 &gt; PanK1b
2.7.1.33	Spinacia oleracea		more	641388		not inhibitory: 3',5'-ADP; not inhibitory: CoASH, acetyl-CoA
2.7.1.33	Corynebacterium ammoniagenes		more	641389		no inhibition by 2,2'-dipyridyl, Ca2+, Cd2+, 3'-AMP, GTP, GDP, ITP, UTP; not inhibitory: 3',5'-ADP
2.7.1.33	Rattus norvegicus		more	641391		not inhibitory: Mg2+, NADP+; not inhibitory: NAD+
2.7.1.33	Escherichia coli		more	641393		not inhibitory: 3',5'-ADP; not inhibitory: cAMP, NADH, NADPH, CoA:glutathione disulfide; not inhibitory: NAD+
2.7.1.33	Plasmodium falciparum		more	660726		in vivo antiplasmodial activities of the inhibitor molecules, overview
2.7.1.33	Aspergillus nidulans		more	661331		no inhibition by (R)-4-(2-amino-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid and (S)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid, structural features required for enzyme inhibition, overview
2.7.1.33	Escherichia coli		more	661331		structural features required for enzyme inhibition, overview
2.7.1.33	Mus musculus		more	661331		no inhibition by (S)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid, structural features required for enzyme inhibition, overview
2.7.1.33	Staphylococcus aureus		more	661331		no inhibition by (R)-4-(2-amino-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid, structural features required for enzyme inhibition, overview
2.7.1.33	Escherichia coli		more	662251		no inhibition by hopantenate
2.7.1.33	Bacillus subtilis		more	662369		no inhibition by N-pentylpantothenamide, enzyme is not affected by CoA or acetyl-CoA
2.7.1.33	Helicobacter pylori		more	662369		no inhibition by N-pentylpantothenamide, enzyme is not affected by CoA or acetyl-CoA
2.7.1.33	Mus musculus		more	662406		structural determinants for feedback inhibition
2.7.1.33	Staphylococcus aureus		more	662408		no feedback regulation by CoA or acetyl-CoA
2.7.1.33	Homo sapiens		more	662687		feedback inhibition by acyl-CoAs
2.7.1.33	Bacillus anthracis		more	672234		the enzyme is not subject to feedback inhibition by CoASH
2.7.1.33	Thermotoga maritima		more	674291		not inhibited by CoA or its thioesters
2.7.1.33	Escherichia coli		more	686816		inhibition by CoA thioesters
2.7.1.33	Homo sapiens		more	722018		isoform PanK3 is not inhibited by estrone
2.7.1.33	Thermococcus kodakarensis		more	727436		feedback inhibition by CoA/acetyl-CoA and product inhibition by 4'-phosphopantothenate are not observed
2.7.1.33	Aspergillus nidulans		N-heptylpantothenamide	661331	6579	
2.7.1.33	Escherichia coli		N-heptylpantothenamide	662251	6579	competitive to pantothenate
2.7.1.33	Staphylococcus aureus		N-heptylpantothenamide	662408	6579	IC50 is 0.0048 mM, potent growth inhibitory anti-metabolite
2.7.1.33	Aspergillus nidulans		N-pentylpantothenamide	661331	6578	
2.7.1.33	Escherichia coli		N-pentylpantothenamide	662251	6578	competitive to pantothenate
2.7.1.33	Staphylococcus aureus		N-pentylpantothenamide	662408	6578	IC50 is 0.0035 mM, has antimicrobial activity against Staphylococcus aureus
2.7.1.33	Mycobacterium tuberculosis		N-[1-(5-[[2-(4-chlorophenoxy)ethyl]sulfanyl]-4-methyl-4H-1,2,4-triazol-3-yl)ethyl]naphthalene-1-carboxamide	722830	61767	competitive inhibition
2.7.1.33	Corynebacterium ammoniagenes		Na2HAsO4	641389	4449	
2.7.1.33	Corynebacterium ammoniagenes		NH4+	641389	50	
2.7.1.33	Rattus norvegicus		Octanoyl-CoA	641390	324	
2.7.1.33	Rattus norvegicus		oleoyl-CoA	641390	244	
2.7.1.33	Rattus norvegicus		palmitoyl-CoA	641390, 641391	122	
2.7.1.33	Escherichia coli		palmitoyl-CoA	641393	122	
2.7.1.33	Mus musculus		palmitoyl-CoA	662406	122	feedback inhibition, regulatory function, isozyme PanK3, mutant chimera PanK1beta-3-1beta, slight inhibition of mutant chimera PanK3-1beta-3
2.7.1.33	Homo sapiens		palmitoyl-CoA	676884	122	strong inhibitor
2.7.1.33	Corynebacterium ammoniagenes		pantetheine	641389	1632	
2.7.1.33	Rattus norvegicus		pantetheine 4'-phosphate	641387	966	strong
2.7.1.33	Corynebacterium ammoniagenes		pantetheine 4'-phosphate	641389	966	weak
2.7.1.33	Escherichia coli		pantetheine 4'-phosphate	641393	966	not
2.7.1.33	Staphylococcus aureus		pantothenamide, N-substituted	641398		IC50 about 0.0004-0.0016 mM
2.7.1.33	Corynebacterium ammoniagenes		pantothenic acid 4'-phosphate	641389	2943	
2.7.1.33	Plasmodium falciparum		pantothenol	660726	5590	competitive inhibition
2.7.1.33	Rattus norvegicus		pantothenoylcysteine 4'-phosphate	641387	10724	strong
2.7.1.33	Corynebacterium ammoniagenes		pantothenoylcysteine 4'-phosphate	641389	10724	weak
2.7.1.33	Corynebacterium ammoniagenes		pantothenyl alcohol	641389	5590	
2.7.1.33	Corynebacterium ammoniagenes		Pb2+	641389	132	
2.7.1.33	Homo sapiens		pioglitazone hydrochloride	722018		
2.7.1.33	Homo sapiens		pregnenolobe	722018		about 92% residual activity at 0.1 mM (isoform PanK3)
2.7.1.33	Homo sapiens		pregnenolone sulfate	722018	8459	; about 10% residual activity at 0.1 mM (isoform PanK3)
2.7.1.33	Rattus norvegicus		propionyl-CoA	641390	297	
2.7.1.33	Homo sapiens		Psi-rhodomyrtoxin	722018		
2.7.1.33	Homo sapiens		Reactive Blue	722018		
2.7.1.33	Homo sapiens		Ro 41-0960	722018	8780	
2.7.1.33	Homo sapiens		rosiglitazone	722018	2423	
2.7.1.33	Escherichia coli		succinyl-CoA	641393	198	
2.7.1.33	Homo sapiens		tamoxifen	722018	1221	
2.7.1.33	Homo sapiens		tolfenamic acid	722018	12428	
2.7.1.33	Homo sapiens		tyrphostin AG 528	722018		
2.7.1.33	Homo sapiens		tyrphostin AG 808	722018		
2.7.1.33	Homo sapiens		WIN 62577	722018		
2.7.1.33	Mycobacterium tuberculosis		[2-[(3-chlorophenyl)sulfanyl]pyridin-4-yl][4-(hydroxymethyl)piperidin-1-yl]methanone	722830	28339	mixed non-competitive inhibition
2.7.1.33	Mycobacterium tuberculosis		[2-[(3-chlorophenyl)sulfanyl]quinolin-4-yl](piperidin-1-yl)methanone	722830	61770	mixed non-competitive inhibition
2.7.1.33	Mycobacterium tuberculosis		[[2-[[4-(6-methylpyridin-2-yl)piperazin-1-yl]methyl]-4'-(trifluoromethoxy)biphenyl-4-yl]oxy]acetic acid	722830	61771	mixed non-competitive inhibition
4.2.1.24	Rhodobacter capsulatus	2-mercaptoethanol		210707	59	required at very low concentrations of substrate
4.2.1.24	Homo sapiens	glucose		677436	33	incubations of erythrocytes for 24 h with glucose result in an increase of delta-ALA-D activity. Incubations of erythrocytes with 100 to 200 mM glucose for 48 h inhibit delta-ALA-D activity
4.2.1.24	Pseudomonas aeruginosa	NH4+		664001	50	stimulates
4.2.1.24	Bos taurus	thiol		210686	752	20 mM, essential to maintain the enzyme in its reduced state
4.2.1.24	Bos taurus	thiol		210709	752	required
4.2.1.24	Ustilago sphaerogena	thiol		210714	752	required
4.2.1.24	Rattus sp.		(4E)-6-oxodec-4-enedioic acid	691205	92751	
4.2.1.24	Homo sapiens		1,1',1''-[(3-ethoxyprop-1-ene-1,1,2-triyl)triselanyl]tribenzene ethyl 2,3,3-tris(phenylselanyl)prop-2-en-1-yl ether	682908	87726	0.6 mM, 65% inhibition
4.2.1.24	Homo sapiens		1,1',1''-[(3-ethoxyprop-1-ene-1,1,2-triyl)triselanyl]tris(2,4,6-trimethylbenzene) ethyl 2,3,3-tris[(2,4,6-trimethylphenyl)selanyl]prop-2-en-1-yl ether	682908	87728	0.6 mM, 44% inhibition
4.2.1.24	Homo sapiens		1,1',1''-[(3-ethoxyprop-1-ene-1,1,2-triyl)triselanyl]tris(4-chlorobenzene) ethyl 2,3,3-tris[(4-chlorophenyl)selanyl]prop-2-en-1-yl ether	682908	87727	modest inhibition
4.2.1.24	Bos taurus		1,10-phenanthroline	210696	58	
4.2.1.24	Ustilago sphaerogena		1,10-phenanthroline	210714	58	
4.2.1.24	Escherichia coli		1,10-phenanthroline	210734	58	
4.2.1.24	Rattus sp.		1-amino-4-hydroxy-2-butanone	691205	49511	
4.2.1.24	Rattus sp.		1-amino-4-methoxy-2-butanone	691205	49513	
4.2.1.24	Rattus sp.		1-amino-5-hydroxy-2-pentanone	691205	49514	
4.2.1.24	Ustilago sphaerogena		2,2'-Dipyridine	210714	317	
4.2.1.24	Pseudomonas aeruginosa		2,2-difluorosuccinic acid	664001	28659	competitive
4.2.1.24	Homo sapiens		2,3-dimercaptopropane-1-sulfonic acid	651009	22571	1 mM, 0.5 mM ZnCl2 protects but does not reverse inhibition. Dithiothreitol protects inhibition by 1 mM 2,3-dimercaptopropane-1-sulfonic acid in a concentration dependent manner
4.2.1.24	Homo sapiens		2,3-dimercaptopropane-1-sulfonic acid	653997	22571	in presence of Hg2+ or Cd2+ the inhibitory potency increases, no change in inhibitory potency by inclusion of Pb2+, Zn2+ does not modify the inhibitory effect
4.2.1.24	Rattus norvegicus		2,3-dimercaptopropane-1-sulfonic acid	679181	22571	0.1 mM, 20% inhibition, more pronounced inhibition in combination with Cd2+
4.2.1.24	Homo sapiens		2,3-Dimercaptopropanol	651009	1854	cysteine and ZnCl2 protects. Dithiothreitol protects inhibition by 1 mM 2,3-dimercaptopropanol in a concentration dependent manner
4.2.1.24	Bos taurus		2-bromo-3-(imidazol-5-yl)propionic acid	210690	67379	
4.2.1.24	Pisum sativum		3-acetyl-4-oxoheptane-1,7-dioic acid	210729		formation of a Schiff base complex between the inhibitors and the active site Lys
4.2.1.24	Prosthecochloris vibrioformis		4,7-dioxosebacic acid	663503	77308	hanging-drop method, irreversible inhibitor binds by forming Schiff-base linkages with lysines 200 and 253 at the active site. 4,7-dioxosebacic acid is a better inhibitor of the zinc-dependent 5-aminolaevulinic acid dehydratases than of the zinc-independent 5-aminolaevulinic acid dehydratases
4.2.1.24	Escherichia coli		4,7-dioxosebaic acid	652256	77308	
4.2.1.24	Pisum sativum		4-amino-3-oxobutanoate	210729	67408	
4.2.1.24	Rhodobacter sphaeroides		4-nitro-2-butanone	210719	67418	
4.2.1.24	Rattus sp.		4-oxo-pentanenitrile	691205	49512	
4.2.1.24	Rattus sp.		4-oxo-sebacic acid	691205	49509	
4.2.1.24	Escherichia coli		4-oxosebaic acid	652256	49509	active site-directed irreversible inhibitor, less potent than 4,7-dioxosebaic acid
4.2.1.24	Zea mays		5,5'-dithio(bis-2-nitrobenzoic acid)	730630		
4.2.1.24	Homo sapiens		5,5'-dithiobis(2-nitrobenzoic acid)	210688, 210689	196	
4.2.1.24	Pseudomonas aeruginosa		5,5'-iminobis(4-oxopentanoic acid)	678204, 679158	12169	
4.2.1.24	Pseudomonas aeruginosa		5,5'-oxybis(4-oxopentanoic acid)	678204, 679158	12168	
4.2.1.24	Pseudomonas aeruginosa		5,5'-sulfinylbis(4-oxopentanoic acid)	678204, 679158	12171	
4.2.1.24	Pseudomonas aeruginosa		5,5'-sulfonylbis(4-oxopentanoic acid)	678204, 679158	12172	
4.2.1.24	Pseudomonas aeruginosa		5,5'-thiobis(4-oxopentanoic acid)	678204, 679158	12170	
4.2.1.24	Rattus sp.		5-amino-4-oxopentanenitrile	691205	49510	
4.2.1.24	Rattus sp.		5-bromo-levulinic acid	691205	92750	
4.2.1.24	Bos taurus		5-bromolevulinic acid	210686		
4.2.1.24	Bos taurus		5-chlorolevulinic acid	210686	30770	
4.2.1.24	Escherichia coli		5-chlorolevulinic acid	649816	30770	inactivation results fromthe initial formation of a Schiff base with lysine-247, followed by alkylation of lysine-195 by the resulting reactive chloroimide
4.2.1.24	Pseudomonas aeruginosa		5-fluorolevulinic acid	652890	77307	both inhibitor molecules are covalently bound to two conserved, active-site lysine residues, Lys205 and lys260, through Schiff bases
4.2.1.24	Mycobacterium phlei		5-hydroxy-4-oxo-L-norvaline	210713	30771	competitive
4.2.1.24	Rhodobacter sphaeroides		5-hydroxy-4-oxopentanoic acid	210719	30772	
4.2.1.24	Saccharomyces cerevisiae		5-hydroxylaevulinic acid	663501	30772	the competitive inhibitor is bound by a Schiff-base link to one of the invariant active-site lysine residues (Lys263). The inhibitor appears to bind in two well defined conformations
4.2.1.24	Mycobacterium phlei		5-hydroxylevulinate	210713		competitive
4.2.1.24	Pseudomonas aeruginosa		5-hydroxylevulinic acid	678204	30772	
4.2.1.24	Bos taurus		5-iodolevulinic acid	210686		
4.2.1.24	Rhodobacter sphaeroides		5-nitrilo-4-oxopentanoic acid	210719		
4.2.1.24	Rattus sp.		5-oxo-hexanoic acid	691205	13243	
4.2.1.24	Rattus sp.		6-amino-5-oxohexanoic acid	691205	49508	
4.2.1.24	Homo sapiens		7-(3-aminopentan-3-yl)-5-chloroquinolin-8-ol	704601	47306	using in silico screening two hexamer-stabilizing inhibitors of PBGS are identified: N-(3-methoxyphenyl)-1-methyl-6-oxo-2-[(pyridin-2-ylmethyl)sulfanyl]-1,6-dihydropyrimidine-5-carboxamide and 7-(3-aminopentan-3-yl)-5-chloroquinolin-8-ol
4.2.1.24	Ustilago sphaerogena		8-hydroxyquinoline	210714	276	
4.2.1.24	Bos taurus		8-Hydroxyquinoline-5-sulfonic acid	210696	2685	
4.2.1.24	Cucumis sativus		Al2(SO4)3	679525	7120	ALA-D inhibition may be due to the fact that aluminum present in the growth medium can compete with Mg2+ or reduce the expression of ALA-D
4.2.1.24	Bos taurus		Al3+	666966	229	IC50: 0.319 mM, GSH has no protective effect
4.2.1.24	Pseudomonas aeruginosa		alaremycin	701747	27012	porphobilinogen synthase is cocrystallized with the alaremycin. At 1.75 A resolution, the crystal structure reveals that the antibiotic efficiently blocks the active site of porphobilinogen synthase. The antibiotic binds as a reduced derivative of 5-acetamido-4-oxo-5-hexenoic acid. The corresponding methyl group is not coordinated by any amino acid residues of the active site, excluding its functional relevance for alaremycin inhibition. Alaremycin is covalently bound by the catalytically important active-site lysine residue 260 and is tightly coordinated by several active-site amino acids
4.2.1.24	Rattus norvegicus		AlCl3	210716	1328	0.001-0.01 mM AlCl3
4.2.1.24	Mus musculus		alloxan	728984	2687	i.e. 2,4,5,6-tetraoxypyrimidine 5,6-dioxyuracil , 0.00125-0.02 mM alloxan causes a concentration-dependent uncompetitive inhibition. Dithiothreitol (0.7and 1 mM) completely prevents the inhibition induced by 0.01 and 0.02 mM alloxan. Similar protection is obtained in the presence of 2 mMglutathione
4.2.1.24	Rattus norvegicus		alpha-lipoic acid	681018	1501	significant inhibition
4.2.1.24	Zea mays		arsenic acid	666162	222	inhibition of 5-aminolevulinic acid dehydratase activity by arsenic in excised etiolated maize leaf segments during greening. KNO3, chloramphenical, cycloheximide, DTNB and levulinic aciddecrease inhibition. GSH increase inhibition
4.2.1.24	Rattus norvegicus		ascorbic acid	679181	88	0.4 mM, 23% inhibition
4.2.1.24	Bos taurus		bathocuproine disulfonic acid	210696	7131	
4.2.1.24	Ustilago sphaerogena		bathocuproine disulfonic acid	210714	7131	i.e. 2,9-dimethyl-4,7-diphenyl-1,10-phenanthrolinedisulfonate
4.2.1.24	Homo sapiens		bis(4-chlorophenyl)diselenide	730290		
4.2.1.24	Homo sapiens		bis(4-methoxyphenyl)diselenide	730290		
4.2.1.24	Homo sapiens		bis[3-(trifluoromethy)phenyl]diselenide	730290		
4.2.1.24	Spinacia oleracea		Butanedione	210692	603	protection by 5-aminolevulinate
4.2.1.24	Homo sapiens		Carbonate	713748	175	using a carbonate buffer rather than phosphate causes nearly a 90% drop in activity in the developed assay method
4.2.1.24	Bos taurus		Cd2+	210709	48	inhibition at low concentration of substrate and stimulation at high levels of substrate
4.2.1.24	Rattus norvegicus		Cd2+	679181	48	inhibits delta-ALA-D activity. Chelating and antioxidant agents potentiated the inhibition
4.2.1.24	Zea mays		Cd2+	716637	48	enzyme inhibition in excised etiolated leaf segments during greening. Cd2+ inhibits ALAD activity by affecting the ALA bind&shy;ing to the enzyme and/or disrupting thiol interaction. Inhibition of ALAD activity by Cd2+ is decreased in the presence of nitrogenous compounds, glutamine and NH4NO3, overview. Supply of some essential metal ions, such as Mg2+, Zn2+, and Mn2+, also reduces the inhibition of enzyme activity by Cd2+
4.2.1.24	Haloarcula argentinensis		Cd2+	727376	48	0.5 mM, 9% inhibition
4.2.1.24	Mus musculus		Cd2+	729907	48	0.1 mM Cd2+ totally inhibits enzyme activity. Dithiothreitol (0.003 mM) is able to restore the inhibition of enzyme activity caused by Cd2+ (0.02 mM)
4.2.1.24	Pisum sativum		Co2+	210729	21	above 1 mM
4.2.1.24	Streptomyces yokosukanensis		Co2+	694843	21	
4.2.1.24	Haloarcula argentinensis		Co2+	727376	21	0.5 mM, 15% inhibition
4.2.1.24	Neurospora crassa		Coproporphyrinogen III	210697	586	
4.2.1.24	Methanosarcina barkeri		Cu2+	210715	28	
4.2.1.24	Saccharomyces cerevisiae		Cu2+	210725	28	
4.2.1.24	Ustilago sphaerogena		Cuprizone	210714	2826	bis-cyclohexanoneoxaldihydrazone
4.2.1.24	Homo sapiens		D-fructose	664549	111	formation of a Schiff base with the critical lysine residue of the enzyme is involved in inhibition of the enzyme by hexoses and pentoses
4.2.1.24	Homo sapiens		D-glucose	664549	33	formation of a Schiff base with the critical lysine residue of the enzyme is involved in inhibition of the enzyme by hexoses and pentoses
4.2.1.24	Homo sapiens		D-glucose	677436	33	incubations of erythrocytes for 24 h with glucose results in an increase of delta-ALA-D activity. Incubations of erythrocytes with 100 to 200 mM glucose for 48 h inhibit delta-ALA-D activity
4.2.1.24	Escherichia coli		D-glucose	691351	33	
4.2.1.24	Agrobacterium tumefaciens		D-glucose	701765	33	competitive inhibitor for ALA dehydratase
4.2.1.24	Homo sapiens		D-ribose	664549	254	formation of a Schiff base with the critical lysine residue of the enzyme is involved in inhibition of the enzyme by hexoses and pentoses
4.2.1.24	Escherichia coli		D-xylose	691351	109	
4.2.1.24	Rattus norvegicus		diammine(dichloro)platinum	666969	1055	mechanism of inhibition is a direct interaction of the inhibitor with sulfhydryl groups, whereas zinc site appears to be involved with the higher doses only
4.2.1.24	Rattus norvegicus		dibutyl diselenide	664768	9182	IC50: 0.01 mM
4.2.1.24	Rhamdia quelen		dibutyl diselenide	664768	9182	IC50: 0.693 mM, enzyme from liver; IC50: 0.985 mM, enzyme from gill
4.2.1.24	Rattus norvegicus		dicholesteroyl diselenide	695196	49507	significant at 0.1 mM
4.2.1.24	Pseudomonas aeruginosa		diethyl dicarbonate	664001	265	
4.2.1.24	Ustilago sphaerogena		diethyldithiocarbamate	210714	315	
4.2.1.24	Homo sapiens		diphenyl diselenide	653998	3244	dithiothreitol protects
4.2.1.24	Rattus norvegicus		diphenyl diselenide	664768	3244	IC50: 0.007 mM
4.2.1.24	Rhamdia quelen		diphenyl diselenide	664768	3244	IC50: 0.076 mM, enzyme from liver; IC50: 0.274 mM, enzyme from gill
4.2.1.24	Rattus norvegicus		diphenyl diselenide	679181	3244	0.0005 mM, 17% inhibition
4.2.1.24	Mus musculus		diphenyl diselenide	679350	3244	
4.2.1.24	Rattus norvegicus		diphenyl diselenide	682119	3244	significantl inhibition
4.2.1.24	Rattus norvegicus		diphenyl diselenide	695196	3244	significant at 0.001 mM
4.2.1.24	Homo sapiens		diphenyl diselenide	730290	3244	
4.2.1.24	Homo sapiens		diphenyl ditelluride	653998	77309	dithiothreitol protects
4.2.1.24	Bos taurus		DTNB	210686	196	reversible loss of activity
4.2.1.24	Homo sapiens		ebselen	653998	1837	dithiothreitol protects
4.2.1.24	Homo sapiens		EDTA	210688	223	
4.2.1.24	Rhodobacter capsulatus		EDTA	210707	223	no inhibition
4.2.1.24	Bos taurus		EDTA	210686, 210696, 210709	223	
4.2.1.24	Mycobacterium phlei		EDTA	210713	223	
4.2.1.24	Ustilago sphaerogena		EDTA	210714	223	
4.2.1.24	Ictalurus punctatus		EDTA	210726	223	0.1 mM, slight
4.2.1.24	Mus musculus		EDTA	652563	223	5 mM, 90% inhibition
4.2.1.24	Pseudomonas aeruginosa		EDTA	664001	223	activity can be completely restored by addition of Mg2+ or Mn2+. Co2+, Zn2+, and Ni2+ partially restore EDTA-inhibited activity
4.2.1.24	Gammarus pulex		EDTA	679956	223	0.3 mM, 51% inhibition
4.2.1.24	Rattus sp.		EDTA	691205	223	
4.2.1.24	Homo sapiens		Fe2+	210699	23	noncompetitive
4.2.1.24	Streptomyces yokosukanensis		Fe3+	694843	66	
4.2.1.24	Bos taurus		Ga3+	666966	6164	inhibits by competing with Zn2+, IC50: 0.442 mM, GSH has no protective effect, Zn2+ completely recovers inhibition
4.2.1.24	Zea mays		GSH	716637	41	a weak inhibitor
4.2.1.24	Mus musculus		Hg2+	653996	31	inhibits enzyme in vivo at 6 h and 12 h after treatment. Se4+ abolishes the inhibitory effect of Hg2+
4.2.1.24	Homo sapiens		Hg2+	653997	31	inhibitory effect is increased by meso-2,3-dimercaptosuccinic acid, inhibition is prevented by dithiothreitol
4.2.1.24	Zea mays		Hg2+	730630	31	the inhibition caused by 0.37 mM Hg2+ is alleviated by addition of 10 mM KNO3. 10 mM NH4Cl and 5 mM sucrose increase the inhibitory effect of Hg2+ on enzyme activity, while 10 mM levulinic acid and 0.0001 mM 5,5'-dithio(bis-2-nitrobenzoic acid) glutamine and glutathione decrease it
4.2.1.24	Rattus norvegicus		HgCl2	664767	104	pretreatment with a nontoxic dose of Na2SeO3 partially or totally prevents in vivo mercury effects in kidney, including prevention of inhibition of delta-aminolevulinate dehydratase
4.2.1.24	Bos taurus		In3+	666966		inhibits by competing with Zn2+, IC50: 0.298 mM, GSH reduces inhibition, DL-dithiothreitol has modest effect on inhibition, Zn2+ completely recovers inhibition
4.2.1.24	Bos taurus		iodoacetamide	210686	63	irreversible
4.2.1.24	Spinacia oleracea		iodoacetamide	210692	63	insensitive
4.2.1.24	Rhodobacter capsulatus		iodoacetamide	210707	63	
4.2.1.24	Bos taurus		iodoacetamide	210709	63	1 mM, 97% inhibition
4.2.1.24	Bos taurus		iodoacetate	210686	87	irreversible
4.2.1.24	Coturnix japonica		iodoacetate	210710	87	
4.2.1.24	Mycobacterium phlei		K2SO4	210713	1867	slight
4.2.1.24	Ustilago sphaerogena		KCN	210714	149	
4.2.1.24	Prosthecochloris vibrioformis		laevulinic acid	666028	5555	
4.2.1.24	Rhodobacter sphaeroides		levulate	210711	5555	
4.2.1.24	Mycobacterium phlei		levulinic acid	210713	5555	competitive
4.2.1.24	Escherichia coli		levulinic acid	210721	5555	
4.2.1.24	Pseudomonas aeruginosa		levulinic acid	664001	5555	
4.2.1.24	Rattus sp.		levulinic acid	691205	5555	
4.2.1.24	Zea mays		levulinic acid	716637	5555	a weak competitive inhibitor
4.2.1.24	Zea mays		levulinic acid	730630	5555	competitive inhibitor, 8% residual activity at 20 mM
4.2.1.24	Bos taurus		Mercury ions	210686		
4.2.1.24	Homo sapiens		meso-2,3-dimercaptosuccinic acid	651009	22572	4 mM, 1 mM ZnCl2 protects but does not reverse inhibition. Dithiothreitol protects inhibition by 1 mM meso-2,3-dimercaptosuccinic acid in a concentration dependent manner
4.2.1.24	Homo sapiens		meso-2,3-dimercaptosuccinic acid	653997	22572	in presence of Hg2+ or Cd2+ the inhibitory potency increases, Zn2+ does not modify the inhibitory effect
4.2.1.24	Rattus norvegicus		meso-2,3-dimercaptosuccinic acid	679181	22572	0.1 mM, 18% inhibition
4.2.1.24	Escherichia coli		methyl methanethiosulfonate	210734	1724	
4.2.1.24	Streptomyces yokosukanensis		Mg2+	694843	25	
4.2.1.24	Haloarcula argentinensis		Mg2+	727376	25	0.5 mM, 7% inhibition
4.2.1.24	Pisum sativum		Mn2+	210729	26	above 1 mM
4.2.1.24	Streptomyces yokosukanensis		Mn2+	694843	26	
4.2.1.24	Haloarcula argentinensis		Mn2+	727376	26	0.5 mM, 21% inhibition
4.2.1.24	Rhodobacter capsulatus		more	210707		insensitive to inhibition by hemin and protoporphyrin
4.2.1.24	Plasmodium falciparum		more	652563		no inhibition by EDTA even at 25 mM
4.2.1.24	Homo sapiens		more	653998		the enzyme from human erythrocytes is a potential target for organochalcogens
4.2.1.24	Rhodobacter capsulatus		more	664453		no inhibition by 10 mM EDTA or 1,20-phenanthroline
4.2.1.24	Rattus norvegicus		more	682119		no inhibition by dicholesteroyl diselenide
4.2.1.24	Rattus norvegicus		more	716429		in vivo iron reduction in rat blood has a negative correlation with the activity of delta-ALA-D, overview
4.2.1.24	Mus musculus		more	729907		not inhibited by Seleno-furanoside
4.2.1.24	Homo sapiens		N-(3-methoxyphenyl)-1-methyl-6-oxo-2-[(pyridin-2-ylmethyl)sulfanyl]-1,6-dihydropyrimidine-5-carboxamide	704601	47336	using in silico screening two hexamer-stabilizing inhibitors of PBGS are identified: N-(3-methoxyphenyl)-1-methyl-6-oxo-2-[(pyridin-2-ylmethyl)sulfanyl]-1,6-dihydropyrimidine-5-carboxamide and 7-(3-aminopentan-3-yl)-5-chloroquinolin-8-ol
4.2.1.24	Rattus norvegicus		Na2SeO3	664767	6308	inhibits renal and hepatic enzyme
4.2.1.24	Rhodobacter capsulatus		NaCN	210707	678	in presence of the substrate
4.2.1.24	Rhodobacter sphaeroides		NaCN	210711	678	competitive
4.2.1.24	Rhodobacter capsulatus		NEM	210707	46	
4.2.1.24	Bos taurus		NEM	210709	46	1 mM, 85% inhibition
4.2.1.24	Coturnix japonica		NEM	210710	46	
4.2.1.24	Ustilago sphaerogena		Neocuproine	210714	3351	2,9-dimethyl-1,10-phenanthroline
4.2.1.24	Haloarcula argentinensis		Ni2+	727376	36	0.5 mM, 8% inhibition
4.2.1.24	Neurospora crassa		p-hydroxymercuribenzoate	210697	92	
4.2.1.24	Bos taurus		Pb2+	210684	132	does not produce a change in the quarternary structure detectable by small angle X-ray scattering
4.2.1.24	Homo sapiens		Pb2+	210688	132	noncompetitive
4.2.1.24	Homo sapiens		Pb2+	210689	132	
4.2.1.24	Homo sapiens		Pb2+	210698	132	5-aminolevulinate protects
4.2.1.24	Rattus norvegicus		Pb2+	210705	132	reversed by Zn2+
4.2.1.24	Bos taurus		Pb2+	210686, 210709	132	
4.2.1.24	Methanosarcina barkeri		Pb2+	210715	132	
4.2.1.24	Saccharomyces cerevisiae		Pb2+	210725	132	
4.2.1.24	Mus musculus		Pb2+	210727, 679350	132	
4.2.1.24	Streptomyces yokosukanensis		Pb2+	694843	132	
4.2.1.24	Haloarcula argentinensis		Pb2+	727376	132	0.5 mM, 44% inhibition
4.2.1.24	Rhodobacter capsulatus		PCMB	210707	40	
4.2.1.24	Bos taurus		PCMB	210709	40	1 mM, 97% inhibition
4.2.1.24	Coturnix japonica		PCMB	210710	40	
4.2.1.24	Cucumis sativus		phenyl selenoacetylene	653422	11450	IC50: above 0.4 mM
4.2.1.24	Rattus norvegicus		phenyl selenoacetylene	653422	11450	IC50: 0.25 mM
4.2.1.24	Rattus norvegicus		phenyl selenoacetylene	666974	11450	inhibition involves conversion of phenyl selenoacetylene to diphenyl diselenide, that induces oxidation of essential -SH groups of the enzyme. Inhibition is partially prevented by incubation under argon atmosphere and is completely prevented by dithiothreitol
4.2.1.24	Cucumis sativus		phenyl selenoxideacetylene	653422	14712	IC50: 0.1 mM, inhibition is antagonized by dithiothreitol
4.2.1.24	Rattus norvegicus		phenyl selenoxideacetylene	653422	14712	IC50: 0.045 mM, inhibition is antagonized by dithiothreitol
4.2.1.24	Pisum sativum		phosphate	210729	12	competitive against Mg2+
4.2.1.24	Pseudomonas aeruginosa		protoporphyrin IX	664001	685	
4.2.1.24	Rhodobacter sphaeroides		pyridoxal	210711	501	
4.2.1.24	Homo sapiens		pyridoxal 5'-phosphate	210699	30	competitive
4.2.1.24	Rhodobacter sphaeroides		pyridoxal 5'-phosphate	210711	30	30% inhibition at 1 mM, negligible inhibition at 0.05 mM
4.2.1.24	Pseudomonas aeruginosa		pyridoxal phosphate	664001	30	
4.2.1.24	Rhodobacter sphaeroides		pyridoxamine phosphate	210711	539	
4.2.1.24	Rhodobacter sphaeroides		rac-2-hydroxy-4-oxopentanoic acid	210719		
4.2.1.24	Rhodobacter sphaeroides		rac-3-hydroxy-4-oxopentanoic acid	210719		
4.2.1.24	Rattus norvegicus		sodium selenide	664768	7515	IC50: 0.005 mM
4.2.1.24	Rhamdia quelen		sodium selenide	664768	7515	IC50: 0.386 mM, enzyme from gill; IC50: 0.902 mM, enzyme from liver
4.2.1.24	Pseudomonas aeruginosa		succinic acid	664001	54	noncompetitive
4.2.1.24	Pseudomonas aeruginosa		succinic acid monomethyl ester	664001	38735	competitive
4.2.1.24	Pisum sativum		succinylacetone	210729, 210732	7398	
4.2.1.24	Mus musculus		succinylacetone	652563	7398	50% inhibition by 125 nM
4.2.1.24	Plasmodium falciparum		succinylacetone	652563	7398	50% inhibition by 250 nM
4.2.1.24	Toxoplasma gondii		succinylacetone	704678	7398	
4.2.1.24	Bos taurus		Tl3+	666966	38734	inhibits by direct oxidation of essential sulfhydryl groups, IC50: 0.0085 mM, DL-dithiothreitol restores completely enzyme activity inhibited by Tl3+, Zn2+ is unable to change inhibition
4.2.1.24	Homo sapiens		Zn2+	210699	19	activates at 0.1-0.02 mM, inhibits at 1.0 mM
4.2.1.24	Bos taurus		Zn2+	210709	19	
4.2.1.24	Saccharomyces cerevisiae		Zn2+	210725	19	activity is progressively increased with increasing Zn2+ concentrations up to 0.1 mM, inhibition at high concentrations
4.2.1.24	Drosophila melanogaster		Zn2+	652435	19	the inhibitory zinc is located at a subunit interface using Cys219 and His10 as ligands
4.2.1.24	Mus musculus		Zn2+	652563	19	pH 7.5, 50% inhibition at 0.12 mM
4.2.1.24	Plasmodium falciparum		Zn2+	652563	19	at pH 8.5, 50% inhibition by 0.075 mM. At pH 7.5, 50% inhibition by less than 0.02 mM
4.2.1.24	Streptomyces yokosukanensis		Zn2+	694843	19	
4.2.1.24	Homo sapiens		Zn2+	713748	19	exocenous addition of zinc results in a decrease by up to 35% in enzyme activity
1.5.1.2	Cucurbita maxima	EDTA		392130	223	stimulation of undialyzed enzyme at 30 mM
1.5.1.2	Setaria italica	NaCl		686421	39	a significant increase in the P5C reductase activity is observed with increasing severity of NaCl stress (0-200 mM)
1.5.1.2	Homo sapiens	P53		674605	2133	POX is a p53-induced gene
1.5.1.2	Bos taurus	putrescine		392138	144	11% activation at 5 mM
1.5.1.2	Bos taurus	spermidine		392138	140	10% activation at 1.2 mM
1.5.1.2	Bos taurus	spermine		392138	177	13% activation at 1.2 mM
1.5.1.2	Homo sapiens	troglitazone		674605	2248	is found to activate the POX promoter in colon cancer cells
1.5.1.2	Streptococcus pyogenes		([[3,5-bis(trifluoromethyl)phenyl]amino]methanediyl)bis(phosphonic acid)	723917	110248	71.2% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		2,3-dichlorophenylhydroxymethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(2,3-dichlorophenyl)-1-hydroxyethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(2,3-dichlorophenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(2,6-dichlorophenyl)-1-hydroxyethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(2,6-dichlorophenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(3,5-di(trifluoromethyl)phenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(3,5-dichlorophenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(3,5-dimethylphenyl)-1-hydroxyethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(3,5-dimethylphenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(4-benzylphenylamino)ethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		2-(4-chlorophenyl)-1-hydroxyethylidenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		3,5-di(trifluoromethyl)phenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		3,5-dibromophenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		3,5-difluorophenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		3,5-dimethylphenylhydroxymethylenebisphosphonic acid	725183		
1.5.1.2	Pseudomonas aeruginosa		3-acetylpyridine analogue of NAD+	390310	706	95% inhibition at 2 mM
1.5.1.2	Arabidopsis thaliana		3-carbamoylophenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		3-chlorophenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		4-benzylphenylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Arabidopsis thaliana		4-benzylphenylhydroxymethylenebisphosphonic acid	725183		
1.5.1.2	Saccharomyces cerevisiae		5,5'-dithiobis(2-nitrobenzoate)	392119	196	90% inhibition at 0.012 mM
1.5.1.2	Arabidopsis thaliana		5,6,7,8-tetrahydro-2-naphthylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Rattus norvegicus		ADP	392112	8	
1.5.1.2	Glycine max		ADP	392125	8	1 mM
1.5.1.2	Cucurbita moschata		ADP	392127	8	
1.5.1.2	Bos taurus		ADP	392131	8	
1.5.1.2	Pseudomonas aeruginosa		Ag+	390310	71	inactivation at 0.1 mM
1.5.1.2	Cucurbita moschata		Ag+	392127	71	44% inactivation at 0.7 mM
1.5.1.2	Cucurbita maxima		Ag+	392130	71	65% inactivation at 0.3 mM
1.5.1.2	Bos taurus		Ag+	392131	71	
1.5.1.2	Rattus norvegicus		ATP	392112	7	1 mM
1.5.1.2	Bos taurus		ATP	392117	7	competitive with respect to NADH, 50% inhibition at 0.1 mM
1.5.1.2	Glycine max		ATP	392125	7	reversible with Mg2+
1.5.1.2	Cucurbita maxima		ATP	392130	7	41% inactivation at 1 mM
1.5.1.2	Cucurbita moschata		ATP	392127, 392130	7	
1.5.1.2	Bos taurus		ATP	392131	7	
1.5.1.2	Clostridium sticklandii		ATP	392146	7	70% inhibition at 2 mM
1.5.1.2	Spinacia oleracea		ATP	392148	7	
1.5.1.2	Rattus norvegicus		Cd2+	392112	48	
1.5.1.2	Bos taurus		Cd2+	392131	48	90% inhibition at 3.3 mM
1.5.1.2	Glycine max		CTP	392125	56	91% inactivation at 1 mM reversible with Mg2+
1.5.1.2	Pisum sativum		Cu2+	392107	28	
1.5.1.2	Rattus norvegicus		Cu2+	392112	28	
1.5.1.2	Cucurbita moschata		Cu2+	392127	28	not
1.5.1.2	Bos taurus		Cu2+	392131	28	90% inhibition at 3.3 mM
1.5.1.2	Cucurbita moschata		cysteine	392127	70	77% inactivation at 10 mM
1.5.1.2	Bos taurus		D-allohydroxyproline	392132	32347	competitive inhibition
1.5.1.2	Mycobacterium tuberculosis		deoxycholate	676952	369	
1.5.1.2	Streptococcus pyogenes		EDTA	723922	223	
1.5.1.2	Glycine max		GTP	392125	35	100% inactivation at 10 mM, reversible with Mg2+
1.5.1.2	Mycobacterium tuberculosis		H2O2	676952	20	
1.5.1.2	Pseudomonas aeruginosa		Hg2+	390310	31	75% inactivation at 0.1 mM
1.5.1.2	Rattus norvegicus		Hg2+	392112	31	
1.5.1.2	Glycine max		Hg2+	392125	31	
1.5.1.2	Cucurbita maxima		Hg2+	392130	31	65% inactivation at 0.3 mM
1.5.1.2	Cucurbita moschata		Hg2+	392127, 392130	31	
1.5.1.2	Bos taurus		Hg2+	392131	31	
1.5.1.2	Bos taurus		hydroxylamine	392131	80	
1.5.1.2	Bos taurus		imidazole	392132	390	
1.5.1.2	Arabidopsis thaliana		indan-5-ylaminomethylenebisphosphonic acid	725183		
1.5.1.2	Pseudomonas aeruginosa		iodoacetamide	390310	63	complete inactivation at 1 mM
1.5.1.2	Cucurbita moschata		iodoacetate	392127	87	10% inactivation at 1 mM
1.5.1.2	Chlorella vulgaris var. autotrophica		KCl	392108	74	68% inhibition at 2 M
1.5.1.2	Chloroidium saccharophilum		KCl	392108	74	
1.5.1.2	Pseudomonas aeruginosa		L-2-acetidine-4-carboxylic acid	390310	5471	50% inactivation at 2 mM
1.5.1.2	Bos taurus		L-hydroxyproline	392132	2212	competitive inhibition
1.5.1.2	Neisseria meningitidis		L-proline	675361	215	L-proline inhibits the inverse reaction at a concentration of 10-20 mM
1.5.1.2	Streptococcus pyogenes		L-proline	675361	215	L-proline inhibits the inverse reaction at a concentration of 10-20 mM
1.5.1.2	Mycobacterium tuberculosis		methanol	676952	78	
1.5.1.2	Spinacia oleracea		Mg2+	392148	25	
1.5.1.2	Bos taurus		Mn2+	392131	26	
1.5.1.2	Hordeum vulgare		more	392114		enzyme is not inhibited by the proline-analog L-thiazolidine-4-carboxylic acid
1.5.1.2	Vigna radiata		more	392114		enzyme is not inhibited by the proline-analog L-thiazolidine-4-carboxylic acid
1.5.1.2	Bos taurus		more	392138		
1.5.1.2	Streptococcus pyogenes		more	723922		not inhibited by NADPH
1.5.1.2	Saccharomyces cerevisiae		N-ethylmaleimide	392119	46	90% inhibition at 0.02 mM, inhibition can be prevented by NADH
1.5.1.2	Chlorella vulgaris var. autotrophica		NaCl	392108	39	70% inhibition at 2 M
1.5.1.2	Chloroidium saccharophilum		NaCl	392108	39	
1.5.1.2	Rattus norvegicus		NAD+	392047	4	
1.5.1.2	Bos taurus		NAD+	392131	4	
1.5.1.2	Chlorella vulgaris var. autotrophica		NADH	392108	3	substrate inhibition
1.5.1.2	Chloroidium saccharophilum		NADH	392108	3	substrate inhibition
1.5.1.2	Escherichia coli		NADH	392126	3	above 0.16 mM
1.5.1.2	Streptococcus pyogenes		NADH	723922	3	slight inhibition with 25% reduction of the catalytic rate at 200 mM
1.5.1.2	Rattus norvegicus		NADP+	392112	6	1 mM
1.5.1.2	Glycine max		NADP+	392125	6	
1.5.1.2	Escherichia coli		NADP+	392126	6	
1.5.1.2	Cucurbita maxima		NADP+	392130	6	43% inactivation at 1 mM
1.5.1.2	Escherichia coli		NADPH	392126	5	above 0.13 mM
1.5.1.2	Cucurbita moschata		NaHSO3	392127	1990	88% inactivation at 1 mM
1.5.1.2	Glycine max		NH2OH	392125	80	
1.5.1.2	Cucurbita moschata		NH2OH	392127	80	7% inactivation at 1 mM
1.5.1.2	Cucurbita maxima		NH2OH	392130	80	92% inactivation at 1 mM
1.5.1.2	Cucurbita moschata		NH2OH	392130	80	
1.5.1.2	Pseudomonas aeruginosa		p-chloromercuribenzoate	390310	40	complete inactivation at 1 mM
1.5.1.2	Rattus norvegicus		p-chloromercuribenzoate	392112	40	
1.5.1.2	Glycine max		p-chloromercuribenzoate	392125	40	
1.5.1.2	Escherichia coli		p-chloromercuribenzoate	392126	40	complete inhibition at 0.125 mM, can be prevented by addition of dithiothreitol
1.5.1.2	Cucurbita maxima		p-chloromercuribenzoate	392130	40	not
1.5.1.2	Cucurbita moschata		p-chloromercuribenzoate	392127, 392130	40	not
1.5.1.2	Saccharomyces cerevisiae		p-hydroxymercuribenzoate	392119	92	90% inhibition at 0.008 mM, inhibition can be prevented by addition of excess dithiothreitol
1.5.1.2	Glycine max		phosphate	392125	12	
1.5.1.2	Pseudomonas aeruginosa		proline	390310	215	75% inactivation at 50 mM
1.5.1.2	Chlorella vulgaris var. autotrophica		proline	392108	215	89% inhibition at 2 M
1.5.1.2	Chloroidium saccharophilum		proline	392108	215	
1.5.1.2	Rattus norvegicus		proline	392112	215	5 mM
1.5.1.2	Bos taurus		proline	392117	215	39% inhibition of the NADH dependent activity and 17% of the NADPH dependent activity at 10 mM
1.5.1.2	Glycine max		proline	392125	215	
1.5.1.2	Escherichia coli		proline	392126	215	
1.5.1.2	Cricetulus griseus		proline	392128	215	
1.5.1.2	Homo sapiens		proline	392128	215	competitive inhibition
1.5.1.2	Rattus norvegicus		proline	392047, 392128	215	
1.5.1.2	Cucurbita maxima		proline	392130	215	12% inactivation at 50 mM
1.5.1.2	Cucurbita moschata		proline	392127, 392130	215	
1.5.1.2	Bos taurus		proline	392131	215	
1.5.1.2	Bos taurus		proline	392132	215	competitive inhibition
1.5.1.2	Homo sapiens		proline	675382	215	competitive inhibitor of P5CR NAD(P)H-dependent thioproline dehydrogenase activity
1.5.1.2	Homo sapiens		proline	676969	215	0.1 mM
1.5.1.2	Chlorella vulgaris var. autotrophica		pyrroline-5-carboxylate	392108	1456	substrate inhibition
1.5.1.2	Chloroidium saccharophilum		pyrroline-5-carboxylate	392108	1456	substrate inhibition
1.5.1.2	Mycobacterium tuberculosis		SDS	676952	118	
1.5.1.2	Cucurbita moschata		Sodium bisulfite	392127	1990	
1.5.1.2	Homo sapiens		stearoyl-CoA	675382	438	competitive inhibitor of P5CR NAD(P)H-dependent thioproline dehydrogenase activity
1.5.1.2	Glycine max		thiazolidine-4-carboxylic acid	392125	10694	
1.5.1.2	Bos taurus		thiazolidine-4-carboxylic acid	392131	10694	
1.5.1.2	Escherichia coli		thiazolidine-4-carboxylic acid	392140	10694	42% inhibition at 10 mM, L-isomer
1.5.1.2	Pseudomonas aeruginosa		thio-NAD+	390310	976	65% inactivation at 0.2 mM
1.5.1.2	Pseudomonas aeruginosa		thio-NADP+	390310	1513	65% inactivation at 0.2 mM
1.5.1.2	Cucurbita moschata		Zn2+	392127	19	14% inactivation at 1 mM
1.5.1.2	Bos taurus		Zn2+	392131	19	
1.5.1.2	Streptococcus pyogenes		[[(2,3-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	54895	95.4% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		[[(2,3-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	725183	54895	
1.5.1.2	Streptococcus pyogenes		[[(2,4-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	54896	52% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(2,5-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	111044	63.9% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(2,6-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	54897	96.2% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		[[(2,6-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	725183	54897	
1.5.1.2	Streptococcus pyogenes		[[(3,4-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	111049	92.5% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(3,5-dibromophenyl)amino]methanediyl]bis(phosphonic acid)	723917	111050	98.4% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(3,5-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	134	91.1% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		[[(3,5-dichlorophenyl)amino]methanediyl]bis(phosphonic acid)	725183	134	
1.5.1.2	Streptococcus pyogenes		[[(3,5-dimethylphenyl)amino]methanediyl]bis(phosphonic acid)	723917	111051	70.5% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		[[(3,5-dimethylphenyl)amino]methanediyl]bis(phosphonic acid)	725183	111051	
1.5.1.2	Streptococcus pyogenes		[[(3-chlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	111052	71.2% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(4-benzylphenyl)amino]methanediyl]bis(phosphonic acid)	723917	111053	94.5% inhibition at 0.2 mM
1.5.1.2	Streptococcus pyogenes		[[(4-chlorophenyl)amino]methanediyl]bis(phosphonic acid)	723917	54898	61.5% inhibition at 0.2 mM
1.5.1.2	Arabidopsis thaliana		[[(4-chlorophenyl)amino]methanediyl]bis(phosphonic acid)	725183	54898	
4.1.1.36	Equus caballus	2-mercaptoethanol		4408, 4411	59	increases activity
4.1.1.36	Rattus norvegicus	cysteine		4408, 4409	70	
4.1.1.36	Equus caballus	cysteine		4408, 4411	70	increases activity
4.1.1.36	Equus caballus	DTT		4408, 4411	42	increases activity
4.1.1.36	Rattus norvegicus	GSH		4409	41	activates
4.1.1.36	Equus caballus	pyruvate		4411	29	covalently bound, involved in catalytic activity
4.1.1.36	Equus caballus	pyruvate		4414	29	covalently bound through an ester linkage to the enzyme
4.1.1.36	Equus caballus	Urea		4411	110	0.2-0.5 M, increases activity
4.1.1.36	Homo sapiens		4'-phospho-N-(1-mercaptomethyl-cyclopropyl)-pantothenamide	664025	37888	i.e. PPanDELTASH, mechanism-based inhibitor, alkylating C173 residue of enzyme
4.1.1.36	Mycobacterium tuberculosis		4'-phosphopantothenol	677979	24803	
4.1.1.36	Rattus norvegicus		4,4-Bis(dimethylaminodiphenylcarbinol)	4408	63426	
4.1.1.36	Rattus norvegicus		ATP	4407, 4409	7	reversed by equimolar amount of semicarbazide
4.1.1.36	Equus caballus		Diketene	4416	64413	irreversibly inactivated by N-acetoacetylation with diketene following a pseudo-first order kinetics, substrate protects
4.1.1.36	Equus caballus		hydroxylamine	4408, 4411	80	
4.1.1.36	Escherichia coli		hydroxylamine	4415	80	
4.1.1.36	Equus caballus		iodoacetamide	4408, 4411	63	
4.1.1.36	Escherichia coli		KCN	4415	149	
4.1.1.36	Rattus norvegicus		more	4407, 4409		no effect of ADP and AMP
4.1.1.36	Equus caballus		NaBH4	4408, 4411	507	
4.1.1.36	Rattus norvegicus		pantotheine 4-phosphate	4407, 4409	966	competitive product inhibition
4.1.1.36	Equus caballus		phenylhydrazine	4408, 4411	333	
4.1.1.36	Escherichia coli		phenylhydrazine	4415	333	
4.1.1.36	Rattus norvegicus		pyridoxal	4407	501	reversed by equimolar amount of semicarbazide
4.1.1.36	Rattus norvegicus		pyridoxal	4409	501	
4.1.1.36	Escherichia coli		pyridoxal	4415	501	
4.1.1.36	Rattus norvegicus		pyridoxal 5'-phosphate	4407	30	reversed by equimolar amount of semicarbazide
4.1.1.36	Rattus norvegicus		pyridoxal 5'-phosphate	4408, 4409	30	
4.1.1.36	Escherichia coli		pyridoxal 5'-phosphate	4415	30	
4.1.1.36	Rattus norvegicus		UTP	4407	61	reversed by equimolar amount of semicarbazide
4.1.1.36	Rattus norvegicus		UTP	4409	61	
2.7.4.1	Escherichia coli	(NH4)2SO4		645111	334	
2.7.4.1	Escherichia coli	(NH4)2SO4		645115	334	activation, up to 100 mM, inhibition at higher concentrations
2.7.4.1	Salmonella enterica subsp. enterica serovar Minnesota	(NH4)2SO4		645120	334	
2.7.4.1	Escherichia coli	(NH4)2SO4		645125	334	40 mM, approx. 14fold activation of ATP synthesis
2.7.4.1	Corynebacterium glutamicum	(NH4)2SO4		671494	334	optimal at 80 mM
2.7.4.1	Thermosynechococcus elongatus	(NH4)2SO4		674956	334	not activating
2.7.4.1	Dictyostelium discoideum	actin		694850		Dictyostelium discoideum also has an actin-related poly P synthesizing complex, DdPPK2, that is KCl dependent
2.7.4.1	Sinomonas atrocyanea	basic protein		645112		activation; can substitute for histone
2.7.4.1	Alcaligenes faecalis	basic protein		645113		activation
2.7.4.1	Corynebacterium ammoniagenes	basic protein		645113		activation
2.7.4.1	Micrococcus luteus	basic protein		645113		activation
2.7.4.1	Pseudomonas aeruginosa	basic protein		645113		activation
2.7.4.1	Sinomonas atrocyanea	basic protein		645113		activation
2.7.4.1	Escherichia coli	basic protein		645113, 645114		activation
2.7.4.1	Propionibacterium freudenreichii subsp. shermanii	basic protein		645119		activation
2.7.4.1	Sinomonas atrocyanea	Bovine serum albumin		645112		activation, can substitute for histone only in the absence of phosphate
2.7.4.1	Escherichia coli	Bovine serum albumin		645114		activation, can substitute for histone only in the absence of phosphate
2.7.4.1	Sinomonas atrocyanea	casein		645112	595	activation, can substitute for histone only in the absence of phosphate
2.7.4.1	Escherichia coli	casein		645114	595	activation, can substitute for histone only in the absence of phosphate
2.7.4.1	Escherichia coli	diphosphate		645129	13	10 mM, 100% activation of guanosine 5'-tetraphosphate synthesis
2.7.4.1	Escherichia coli	Guanidine HCl		645129	804	5 mM, 20% activation of guanosine 5'-tetraphosphate synthesis
2.7.4.1	Sinomonas atrocyanea	histamine		645113	498	
2.7.4.1	Sinomonas atrocyanea	histone		645112	780	required for activity
2.7.4.1	Escherichia coli	histone		645114	780	maximum activation in the presence of 20 mM phosphate; strong inhibition of reverse reaction
2.7.4.1	Sulfolobus acidocaldarius	more		645121		only active as glycogen-enzyme complex
2.7.4.1	Mycobacterium tuberculosis	more		674956		(NH4)2SO4 is not activating
2.7.4.1	Dictyostelium discoideum	more		694850		polyphosphate or ATP promote oligomerization of the enzyme in vitro, polyphosphate activates about 10fold
2.7.4.1	Sinomonas atrocyanea	phosphate		645112	12	
2.7.4.1	Escherichia coli	phosphate		645114	12	inhibiton above 20 mM; required for activity, only in the presence of histone
2.7.4.1	Propionibacterium freudenreichii subsp. shermanii	phosphate		645118	12	10fold higher rate of polyphosphate synthesis
2.7.4.1	Sinomonas atrocyanea	Polyamine		645113		activation, Arthrobacter atrocyaneus
2.7.4.1	Pseudomonas aeruginosa	Polyphosphate		645131	723	activation of polyphosphate kinase 2
2.7.4.1	Escherichia coli	protamine		645113	978	
2.7.4.1	Sinomonas atrocyanea	protamine		645113	978	
2.7.4.1	Escherichia coli	protamine		645114	978	required for maximal activity
2.7.4.1	Sinomonas atrocyanea	putrescine		645113	144	
2.7.4.1	Sinomonas atrocyanea	spermidine		645113	140	
2.7.4.1	Sinomonas atrocyanea	spermine		645113	177	
2.7.4.1	Escherichia coli	Tetrapolyphosphate		645115	2402	activation, removes lag-phase in synthesis at low ATP-levels, not phosphate, diphosphate or tripolyphosphate
2.7.4.1	Corynebacterium xerosis		(NH4)2SO4	645110	334	40 mM, almost complete inhibition
2.7.4.1	Escherichia coli		(NH4)2SO4	645115	334	activation up to 100 mM; inhibition at higher concentrations; strong inhibition
2.7.4.1	Limnothrix redekei		(NH4)2SO4	645123	334	strong inhibition
2.7.4.1	Corynebacterium xerosis		ADP	645110	8	
2.7.4.1	Escherichia coli		ADP	645111	8	0.08 mM, complete inhibition
2.7.4.1	Sinomonas atrocyanea		ADP	645112	8	4 mM, product inhibition
2.7.4.1	Escherichia coli		ADP	645114	8	0.2 mM, complete inhibition
2.7.4.1	Escherichia coli		ADP	645115	8	50%, 70% and 93% inhibition at 0.08 mM, 0.15 mM and 0.2 mM ADP, respectively
2.7.4.1	Mycobacterium smegmatis		ADP	645117	8	substrate inhibition
2.7.4.1	Salmonella enterica subsp. enterica serovar Minnesota		ADP	645120	8	0.25 mM, approx. 50% inhibition, 1 mM, complete inhibition
2.7.4.1	Sulfolobus acidocaldarius		ADP	645121	8	2 mM, 50% inhibition of glycogen-bound polyphosphate kinase; product inhibition, about 50% inhibition at 2 mM
2.7.4.1	Neisseria gonorrhoeae		ADP	645122	8	
2.7.4.1	Neisseria meningitidis		ADP	645122	8	
2.7.4.1	Limnothrix redekei		ADP	645123	8	competitive inhibition
2.7.4.1	Burkholderia cepacia		ADP	645133	8	0.025 mM, 0.05 mM, 0.1 mM and 0.25 mM, 56%, 68%, 77% and 100% inhibition, respectively of polyphosphate synthesis in crude extracts
2.7.4.1	Mycobacterium tuberculosis		ADP	723523	8	product inhibition
2.7.4.1	Sulfolobus acidocaldarius		ammonium hydrochloride	645121	282	50% inhibition at 200 mM
2.7.4.1	Corynebacterium xerosis		AMP	645110	9	at high concentrations
2.7.4.1	Mycobacterium smegmatis		AMP	645117	9	15% and 70% inhibition of the forward reaction at AMP/ADP ratios of 1 and 10, respectiverly
2.7.4.1	Corynebacterium glutamicum		AMP	671494	9	
2.7.4.1	Sinomonas atrocyanea		ATP	645112	7	free form, above 0.008 mM
2.7.4.1	Mycobacterium smegmatis		ATP	645117	7	substrate inhibition, at high concentrations
2.7.4.1	Sulfolobus acidocaldarius		ATP	645121	7	20% substrate inhibition at 2.4 mM
2.7.4.1	Escherichia coli		Ca2+	645116	18	1 mM, 10% inhibition
2.7.4.1	Escherichia coli		Co2+	645116	21	1 mM, 40% inhibition
2.7.4.1	Escherichia coli		Cu2+	645116	28	0.1 mM, 92% inhibition, 1 mM, complete inhibition
2.7.4.1	Escherichia coli		diphosphate	645111	13	weak inhibition
2.7.4.1	Sinomonas atrocyanea		diphosphate	645112	13	1 mM, complete inhibition
2.7.4.1	Escherichia coli		diphosphate	645114	13	1 mM, complete inhibition
2.7.4.1	Escherichia coli		diphosphate	645129	13	10 mM, 66% inhibition of polyphosphate synthesis, 75% inhibition of GTP synthesis
2.7.4.1	Mycobacterium smegmatis		EDTA	645117	223	10 mM, complete inhibition
2.7.4.1	Escherichia coli		F-	645111	158	5 mM, complete inhibition
2.7.4.1	Sinomonas atrocyanea		F-	645112	158	20 mM, complete inhibition
2.7.4.1	Escherichia coli		F-	645114	158	20 mM, complete inhibition
2.7.4.1	Mycobacterium smegmatis		F-	645117	158	5 mM, 75% inhibition
2.7.4.1	Sulfolobus acidocaldarius		F-	645121	158	2 mM, 25% inhibition of glycogen-bound polyphosphate kinase
2.7.4.1	Saccharomyces cerevisiae		F-	645124	158	10 mM, complete inhibition
2.7.4.1	Escherichia coli		GMP	645129	150	competitive inhibition of polyphosphate 750 and GDP in guanosine 5'-tetraphosphate synthesis
2.7.4.1	Corynebacterium glutamicum		GMP	671494	150	
2.7.4.1	Escherichia coli		Guanidine HCl	645129	804	5 mM, 50% inhibition of polyphosphate synthesis
2.7.4.1	Escherichia coli		histone	645114	780	reverse reaction, strong, activates forward reaction in the presence of phosphate
2.7.4.1	Sulfolobus acidocaldarius		hydrolyzed glycogen	645121		complete inhibition
2.7.4.1	Corynebacterium glutamicum		IMP	671494	206	
2.7.4.1	Escherichia coli		KCl	645114	74	
2.7.4.1	Escherichia coli		KCl	645115	74	50 mM, 50% inhibition
2.7.4.1	Dictyostelium discoideum		KCl	694850	74	inhibits PPK1 80% at 500 mM, but not PPK2
2.7.4.1	Sinomonas atrocyanea		Mg2+	645112	25	free form, above 6 mM, activating below
2.7.4.1	Mycobacterium smegmatis		Mg2+	645117	25	8 mM, complete inhibition
2.7.4.1	Sinomonas atrocyanea		Mn2+	645112	26	free form, above 2 mM, activating below
2.7.4.1	Escherichia coli		Mn2+	645116	26	weak inhibition at 10 mM Mg2+
2.7.4.1	Sinomonas atrocyanea		MnATP2-	645112	1396	at high concentrations, above 0.6 mM, activating below
2.7.4.1	Corynebacterium xerosis		more	645110		not inhibited by NaCl
2.7.4.1	Escherichia coli		more	645111		not inhibited by 2,4-dinitrophenol or potassium arsenate
2.7.4.1	Escherichia coli		more	645114		not inhibited by 3',5'-adenosine monophosphate
2.7.4.1	Sulfolobus acidocaldarius		more	645121		enzymatic hydrolysis of glycogen
2.7.4.1	Limnothrix redekei		more	645123		not inhibited by KCl; not inhibited by NaCl; not inhibited by phosphate; not inhibited by polyphosphate
2.7.4.1	Corynebacterium glutamicum		more	671494		no inhibition by UMP and CMP
2.7.4.1	Glomus sp.		more	701814		not inhibited by bafilomycin A1 or a protonophore
2.7.4.1	Mycobacterium tuberculosis		more	721639		a G9-quadruplex DNA aptamer inhibits isoform PPK2 with an IC50 of 40 nM and exhibits noncompetitive inhibition kinetics
2.7.4.1	Vibrio cholerae		more	721639		a G9-quadruplex DNA aptamer inhibits isoform PPK2 with an IC50 of 105 nM and exhibits noncompetitive inhibition kinetics
2.7.4.1	Escherichia coli		NaCl	645114	39	
2.7.4.1	Sulfolobus acidocaldarius		NH4Cl	645121	282	200 mM, approx. 50% inhibition of glycogen-bound polyphosphate kinase
2.7.4.1	Dictyostelium discoideum		phalloidin	694850	92510	a heptapeptide toxin from the mushroom Amanita phalloides, which binds tightly and specifically to polymerized actin, inhibits DdPPK2 and DdPPK1, the latter by 80% at 10 nM, the molar ratio of phalloidin to DdPPK1 of 10:15 results in complete inhibition of DdPPK1 activity
2.7.4.1	Escherichia coli		phosphate	645114	12	above 20 mM; activates in the presence of histone
2.7.4.1	Mycobacterium smegmatis		phosphate	645117	12	5.5 mM and 11 mM, 33% and 49% inhibition of forward reaction
2.7.4.1	Sulfolobus acidocaldarius		phosphate	645121	12	2 mM, 50% inhibition of glycogen-bound polyphosphate kinase; strong inhbition
2.7.4.1	Sulfolobus acidocaldarius		Polyphosphate	645121	723	substrate inhibition at 2 mM
2.7.4.1	Escherichia coli		Polyphosphate	645129	723	65 residues, competitive inhibition of polyphosphate 750 and GDP in guanosine 5'-tetraphosphate synthesis
2.7.4.1	Sulfolobus acidocaldarius		Sodium fluoride	645121	209	slight inhibition
2.7.4.1	Glomus sp.		vanadate	701814	207	
2.7.4.1	Escherichia coli		Zn2+	645116	19	0.1 mM, 67% inhibition, 1 mM, complete inhibition
1.3.1.12	Escherichia coli	Adamantane 1-acetate		390521	36435	
1.3.1.12	Escherichia coli	Bovine serum albumin		390521		at low concentrations of prephenate
1.3.1.12	Escherichia coli	Bovine serum albumin		390529		formation of an enzyme-albumin complex with MW of 150000
1.3.1.12	Enterobacter aerogenes	Bovine serum albumin		390544		
1.3.1.12	Aquifex aeolicus	Guanidine-HCl		677010	804	activates at low concentrations, at higher concentrations concomitant loss of activity with a multi-state pathway of denaturation
1.3.1.12	Candida maltosa	L-tryptophan		33876	113	
1.3.1.12	Candida maltosa	L-tryptophan analogues		33876		methylated or fluorinated
1.3.1.12	Neurospora sp.	phenylalanine		390543	98	
1.3.1.12	Escherichia coli		2-hydroxyphenylacetate	390524, 654967	4351	
1.3.1.12	Microtetraspora glauca		4-hydroxymercuribenzoate	390511	92	
1.3.1.12	Serpens flexibilis		4-hydroxymercuribenzoate	390548	92	
1.3.1.12	Neisseria gonorrhoeae		4-hydroxyphenylpyruvate	390512	353	
1.3.1.12	Cupriavidus necator		4-hydroxyphenylpyruvate	33883, 390513	353	
1.3.1.12	Escherichia coli		4-hydroxyphenylpyruvate	390529	353	
1.3.1.12	Enterobacter aerogenes		4-hydroxyphenylpyruvate	390544	353	
1.3.1.12	Bacillus subtilis		4-hydroxyphenylpyruvate	390513, 390550	353	
1.3.1.12	Escherichia coli		5,5'-dithiobis(2-nitrobenzoate)	3557, 390522	196	
1.3.1.12	Escherichia coli		5,6-dihydro-5,6-dihydroxychorismate	654967	36438	
1.3.1.12	Escherichia coli		adamantane analogues	390521, 390524, 390555		
1.3.1.12	Escherichia coli		adamantane-1,3-diacetate	654967	36436	
1.3.1.12	Escherichia coli		adamantane-1-acetate	654967	36435	
1.3.1.12	Escherichia coli		adamantane-1-carboxylate	654967	36434	
1.3.1.12	Escherichia coli		adamantane-1-phosphonate	654967	23069	
1.3.1.12	Candida maltosa		alpha-Methyl-D,L-tyrosine	33876	29137	
1.3.1.12	Escherichia coli		AMP	390529	9	
1.3.1.12	Enterobacter aerogenes		AMP	390544	9	
1.3.1.12	Bacillus subtilis		chorismate	390513	182	
1.3.1.12	Escherichia coli		chorismate analogues	390521, 390524, 390555		
1.3.1.12	Escherichia coli		chorismate-5,6-epoxide	654967	36437	
1.3.1.12	Escherichia coli		citrate	390524	125	
1.3.1.12	Aquifex aeolicus		Co2+	677010	21	weakly inhibits
1.3.1.12	Cupriavidus necator		coumaric acid	33883	2460	
1.3.1.12	Cupriavidus necator		Cu2+	3542	28	
1.3.1.12	Bacillus subtilis		D-tyrosine	390550	1232	
1.3.1.12	Escherichia coli		Diethylmalonate	390524	20315	
1.3.1.12	Cupriavidus necator		dihydroxyphenylalanine	33883	275	
1.3.1.12	Cupriavidus necator		Fe2+	3542	23	
1.3.1.12	Cupriavidus necator		Hg2+	3542	31	
1.3.1.12	Escherichia coli		iodoacetamide	3557, 390522	63	
1.3.1.12	Escherichia coli		iodoacetamide	390537	63	modification of only one cysteinyl residue results in the inactivation
1.3.1.12	Enterobacter aerogenes		iodoacetamide	390537, 390542, 390545	63	
1.3.1.12	Escherichia coli		iodoacetate	390522, 390537	87	
1.3.1.12	Enterobacter aerogenes		iodoacetate	390537, 390542	87	
1.3.1.12	Methanohalophilus mahii		KCl	390551	74	
1.3.1.12	Bacillus subtilis		L-phenylalanine	390513, 390550	98	
1.3.1.12	Bacillus subtilis		L-tryptophan	390513, 390550	113	
1.3.1.12	Zymomonas mobilis		L-Tyr	684578	103	L-Tyr inhibits TyrAp activity by 90% at concentrations higher than 0.5 mM
1.3.1.12	Candida maltosa		L-tyrosine	33876	103	
1.3.1.12	Corynebacterium glutamicum		L-tyrosine	33885	103	
1.3.1.12	Microtetraspora glauca		L-tyrosine	390511	103	
1.3.1.12	Neisseria gonorrhoeae		L-tyrosine	390512	103	not inhibiting
1.3.1.12	Cupriavidus necator		L-tyrosine	33883, 390513	103	
1.3.1.12	Acholeplasma laidlawii		L-tyrosine	390517	103	
1.3.1.12	Klebsiella pneumoniae		L-tyrosine	390518	103	
1.3.1.12	Escherichia coli		L-tyrosine	3557, 390518, 390522, 390526, 390539	103	
1.3.1.12	Neurospora sp.		L-tyrosine	390543	103	
1.3.1.12	Pseudomonas aeruginosa		L-tyrosine	390535, 390547	103	
1.3.1.12	Serpens flexibilis		L-tyrosine	390548	103	
1.3.1.12	Azomonas insignis		L-tyrosine	390549	103	
1.3.1.12	Bacillus subtilis		L-tyrosine	390513, 390550	103	
1.3.1.12	Methanohalophilus mahii		L-tyrosine	390551	103	
1.3.1.12	Escherichia coli		L-tyrosine	655472	103	feed-back inhibition of both enzyme activities
1.3.1.12	Escherichia coli		L-tyrosine	671431	103	Tyr263 or residues 354 to 357 of the enzyme are involved in the feedback inhibition
1.3.1.12	Archaeoglobus fulgidus		L-tyrosine	692260	103	0.5 mM, 50% inhibition
1.3.1.12	Streptococcus mutans		L-tyrosine	726409	103	0.1 mM, less than 20% residual activity
1.3.1.12	Escherichia coli		malonate	390524	328	
1.3.1.12	Cupriavidus necator		Mg2+	3542	25	
1.3.1.12	Enterobacter aerogenes		more	390544		substrate analogues
1.3.1.12	Aquifex aeolicus		more	677010		EDTA, MgCl2 and ZnCl2 show no effect on enzyme activity
1.3.1.12	Archaeoglobus fulgidus		more	692260		phenylalanine (up to 5 mM) has no effect. Not inhibited by prephenate or NAD+ at concentrations up to 10 and 2 mM, respectively
1.3.1.12	Soil bacterium		more	723959		not inhibitory: tyrosine
1.3.1.12	Streptococcus mutans		more	726409		not inhibitory: NaCl up to 10 mM, EDTA and dithiothreitol up to 1 mM
1.3.1.12	Escherichia coli		N-benzenesulfonyl-L-phenylalanine	390532		
1.3.1.12	Escherichia coli		N-Benzyloxycarbonyl-L-phenylalanine	390532	6204	
1.3.1.12	Escherichia coli		N-bromosuccinimide	390537	185	
1.3.1.12	Escherichia coli		N-ethylmaleimide	390537	46	
1.3.1.12	Escherichia coli		N-Toluene-p-sulfonyl-L-p-aminophenylalanine	390532	65087	
1.3.1.12	Escherichia coli		N-Toluene-p-sulfonyl-L-phenylalanine	390532	65088	
1.3.1.12	Mycobacterium tuberculosis		NaCl	676965	39	IC50: 0.01 mM
1.3.1.12	Cupriavidus necator		NADH	33883	3	non-competitive inhibition
1.3.1.12	Escherichia coli		NADH	390529	3	
1.3.1.12	Enterobacter aerogenes		NADH	390544	3	
1.3.1.12	Escherichia coli		Tetranitromethane	390537	1100	
1.3.1.12	Escherichia coli		trans-2,3-pleiadanedicarboxylic acid	654967	36019	i.e. diacid, 50% inhibition at 0.25 mM, inhibits competitively the prephenate dehydrogenase activity, but not the chorismate mutase activity of the enzyme
1.3.1.12	Aquifex aeolicus		tyrosine	677010	103	feedback-inhibitor of activity over a wide temperature range, enhances the cooperativity between subunits in the binding of prephenate
1.3.1.12	Aquifex aeolicus		tyrosine	698889	103	binds directly to the active site of the enzyme and not to an allosteric site. Linear competitive inhibition
1.3.1.12	Haemophilus influenzae		tyrosine	710738	103	is bound directly at the catalytic site as a competitive inhibitor
4.2.1.51	Sphingomonas paucimobilis	2-amino-3-phenylpropanol		33879	29907	activation
4.2.1.51	Corynebacterium glutamicum	3-Aminotyrosine		33885	8268	activation
4.2.1.51	Sphingomonas paucimobilis	beta-(4-aminophenyl)-DL-alanine		33879	66222	activation
4.2.1.51	Sphingomonas paucimobilis	beta-(4-aminophenyl)-DL-serine		33879	66223	activation
4.2.1.51	Sphingomonas paucimobilis	beta-(4-fluorophenyl)-DL-alaine		33879	7229	activation
4.2.1.51	Sphingomonas paucimobilis	beta-phenyl-DL-serine		33879	64177	activation
4.2.1.51	Escherichia coli	Bovine serum albumin		33886		activation
4.2.1.51	Sphingomonas paucimobilis	D-tyrosine		33879	1232	activation
4.2.1.51	Corynebacterium glutamicum	D-tyrosine		33885	1232	activation
4.2.1.51	Sphingomonas paucimobilis	DL-tyrosine		33879	4062	activation
4.2.1.51	Haloarcula vallismortis	L-isoleucine		33870	266	allosteric activator
4.2.1.51	Corynebacterium glutamicum	L-isoleucine		33885	266	activation
4.2.1.51	Haloarcula vallismortis	L-leucine		33870	121	activation
4.2.1.51	Bacillus subtilis	L-leucine		33872	121	activation
4.2.1.51	Corynebacterium glutamicum	L-leucine		33885	121	activation
4.2.1.51	Haloarcula vallismortis	L-methionine		33870	83	activation
4.2.1.51	Bacillus subtilis	L-methionine		33872, 33880, 33881	83	activation
4.2.1.51	Corynebacterium glutamicum	L-methionine		33885	83	activation
4.2.1.51	Amycolatopsis methanolica	L-methionine		33898	83	1 mM, 1.6fold activation
4.2.1.51	Mycobacterium tuberculosis	L-Phe		665625	98	allosteric activator, activation above 0.1 mM
4.2.1.51	Mycobacterium tuberculosis	L-Trp		665625	113	allosteric activator, activation above 0.1 mM
4.2.1.51	Candida maltosa	L-tryptophan		33876	113	activation, Ka: 0.56 mM
4.2.1.51	Sphingomonas paucimobilis	L-tryptophan		33879	113	activation
4.2.1.51	Mycobacterium tuberculosis	L-Tyr		665625	103	allosteric activator, activation above 0.1 mM
4.2.1.51	Haloarcula vallismortis	L-tyrosine		33870	103	activation
4.2.1.51	Sphingomonas paucimobilis	L-tyrosine		33879	103	activation
4.2.1.51	Cupriavidus necator	L-tyrosine		33883	103	activation
4.2.1.51	Corynebacterium glutamicum	L-tyrosine		33885	103	1 mM, 6fold activation; activation
4.2.1.51	Pseudomonas sp.	L-tyrosine		33890	103	activation
4.2.1.51	Amycolatopsis methanolica	L-tyrosine		33898	103	Ka: 410 mM
4.2.1.51	Acinetobacter calcoaceticus	L-tyrosine		3566	103	0.1 mM, 24fold activation
4.2.1.51	Archaeoglobus fulgidus	L-tyrosine		692260	103	enzyme activation by 70% at 1 mM
4.2.1.51	Sphingomonas paucimobilis	methyl L-phenylalaninate		33879	2532	activation
4.2.1.51	Sphingomonas paucimobilis	N-acetyl-L-Phe		33879	2051	activation
4.2.1.51	Corynebacterium glutamicum	p-aminophenylalanine		33885	5649	activation
4.2.1.51	Archaeoglobus fulgidus	Tyr		692260	103	1 mM, 70% increase in activity
4.2.1.51	Methanococcus maripaludis	tyrosine		727742	103	
4.2.1.51	Salmonella enterica subsp. enterica serovar Typhimurium		2,4-Dihydroxybenzoate	33888	1417	
4.2.1.51	Candida maltosa		2-methyl-DL-tyrosine	33876	29137	1 mM, 23% inhibition
4.2.1.51	Escherichia coli		3-phenylpropanoate	33886	2450	
4.2.1.51	Corynebacterium glutamicum		4-methyltryptophan	33885	7094	
4.2.1.51	Escherichia coli		5,5'-dithiobis(2-nitrobenzoate)	3574	196	
4.2.1.51	Candida maltosa		5-Fluorotryptophan	33876	6531	
4.2.1.51	Corynebacterium glutamicum		5-Methyltryptophan	33885	4375	
4.2.1.51	Corynebacterium glutamicum		6-Fluorotryptophan	33885	3243	
4.2.1.51	Escherichia coli		alpha-oxo-1-carboxy-4-tetrahydrothiopyranpropanoic acid S-oxide	33891	67058	
4.2.1.51	Escherichia coli		alpha-oxo-1-carboxy-5,6-dihydrothiopyranpropanoic acid S-oxide	33891	67059	
4.2.1.51	Escherichia coli		cis-aconitate	33877	933	
4.2.1.51	Escherichia coli		citrate	33877	125	
4.2.1.51	Cupriavidus necator		Cu2+	3542	28	0.1 mM, 100% inhibition
4.2.1.51	Candida maltosa		D-tryptophan	33876	657	
4.2.1.51	Cupriavidus necator		Fe2+	3542	23	0.1 mM, 85% inhibition
4.2.1.51	Cupriavidus necator		Hg2+	3542	31	0.1 mM, 94% inhibition
4.2.1.51	Escherichia coli		KCl	3543	74	
4.2.1.51	Mycobacterium tuberculosis		L-Phe	665625	98	at concentration up to 0.1 mM
4.2.1.51	Methanocaldococcus jannaschii		L-Phe	678167	98	feedback-inhibition
4.2.1.51	Bacillus subtilis		L-phenylalanine	33872, 33881	98	
4.2.1.51	Cupriavidus necator		L-phenylalanine	33883	98	
4.2.1.51	Corynebacterium glutamicum		L-phenylalanine	33885	98	0.05 mM, 50% inhibition
4.2.1.51	Salmonella enterica subsp. enterica serovar Typhimurium		L-phenylalanine	33889	98	
4.2.1.51	Pseudomonas sp.		L-phenylalanine	33890	98	
4.2.1.51	Amycolatopsis methanolica		L-phenylalanine	33898	98	1 mM, 48% inhibition, Ki: 670 mM
4.2.1.51	Escherichia coli		L-phenylalanine	33886, 3543	98	
4.2.1.51	Acinetobacter calcoaceticus		L-phenylalanine	3566	98	
4.2.1.51	Escherichia coli		L-phenylalanine	3574	98	one phenylalanine-binding site per subunit
4.2.1.51	Corynebacterium glutamicum		L-phenylalanine	649516	98	feedback inhibition, Ser99 is involved, mutants S99M, S99T, S99A, S99C, or S99L are not sensitive to inhibition
4.2.1.51	Escherichia coli		L-phenylalanine	649980	98	feedback inhibition
4.2.1.51	Archaeoglobus fulgidus		L-phenylalanine	692260	98	inhibits activity at 5 microM, competitive inhibition
4.2.1.51	Oryza sativa		L-phenylalanine	694629	98	feedback regulation wild-type, mutant enzyme MTR1 (PDT S298I) shows a reduced feedback sensitivity, resulting in phenylalanine accumulation; inhibits activity of wild-type enzyme, mutant enzyme shows reduced feedback sensitivity, accumulation of L-phenylalanine
4.2.1.51	Escherichia coli		L-phenylalanine	702720	98	feedback inhibition. PDT of Escherichia coli WSH-Z06 is almost completely inhibited by 10 mM L-phenylalanine (92.9% activity loss). PDT of Escherichia coli WSH-Z06 (pAP-B03) exhibits strong resistance to 200 mM L-phenylalanine, manifested by the high residual activities (10 mM L-phenylalanine with only 7.1% loss of activity)
4.2.1.51	Methanococcus maripaludis		L-phenylalanine	727742	98	
4.2.1.51	Mycobacterium tuberculosis		L-Trp	665625	113	at concentration up to 0.1 mM
4.2.1.51	Haloarcula vallismortis		L-tryptophan	33870	113	0.2 mM, 65% inhibition
4.2.1.51	Bacillus subtilis		L-tryptophan	33872	113	
4.2.1.51	Cupriavidus necator		L-tryptophan	33883	113	
4.2.1.51	Corynebacterium glutamicum		L-tryptophan	33885	113	0.1 mM, 100% inhibition
4.2.1.51	Mycobacterium tuberculosis		L-Tyr	665625	103	at concentration up to 0.1 mM
4.2.1.51	Candida maltosa		L-tyrosine	33876	103	1 mM, 66% inhibition
4.2.1.51	Escherichia coli		m-Chlorophenylalanine	33886	22987	
4.2.1.51	Cupriavidus necator		m-Fluorophenylalanine	33883	13431	
4.2.1.51	Escherichia coli		m-Fluorophenylalanine	33886	13431	
4.2.1.51	Acinetobacter calcoaceticus		m-Fluorophenylalanine	3566	13431	
4.2.1.51	Escherichia coli		m-hydroxyphenylalanine	33886	7315	
4.2.1.51	Buchnera aphidicola		more	651653		changes in the ESRP sequence, involved in allosteric binding of phenylalanine, lead to desensitization to inhibition by phenylalanine, permitting the overproduction of the amino aid in vivo
4.2.1.51	Escherichia coli		N-carbobenzoxyphenylalanine	33886		
4.2.1.51	Escherichia coli		N-ethylmaleimide	3574	46	
4.2.1.51	Escherichia coli		NaCl	3543	39	
4.2.1.51	Mycobacterium tuberculosis		NaCl	665625	39	enzyme activity is completely abolished in the presence of 200 mM and higher concentrations of NaCl
4.2.1.51	Cupriavidus necator		Ni2+	3542	36	0.1 mM, 83% inhibition
4.2.1.51	Escherichia coli		o-Chlorophenylalanine	33886	22986	
4.2.1.51	Escherichia coli		o-Fluorophenylalanine	33886	20523	
4.2.1.51	Escherichia coli		o-Hydroxyphenylalanine	33886	30247	
4.2.1.51	Escherichia coli		p-Chlorophenylalanine	33886	6086	
4.2.1.51	Cupriavidus necator		p-Fluorophenylalanine	33883	7229	
4.2.1.51	Escherichia coli		p-Fluorophenylalanine	33886	7229	
4.2.1.51	Acinetobacter calcoaceticus		p-Fluorophenylalanine	3566	7229	
4.2.1.51	Archaeoglobus fulgidus		Phe	692260	98	0.005 mM, 66% inhibition, competitive with prephenate
4.2.1.51	Escherichia coli		tetrathionate	3574	1641	
4.2.1.51	Escherichia coli		trans-aconitate	33877	2067	
4.2.1.51	Cupriavidus necator		Zn2+	3542	19	0.1 mM, 58% inhibition
1.3.3.4	Saccharomyces cerevisiae	cysteine		390982	70	
1.3.3.4	Zea mays	Diamide		654442	1817	activates the N-terminally processed-like enzyme form and processed native form
1.3.3.4	Mus musculus	dicoumarol		390994	608	below 0.015 mM
1.3.3.4	Saccharomyces cerevisiae	dithiothreitol		390982	42	
1.3.3.4	Mus musculus	FAD		390990	14	slight stimulation
1.3.3.4	Spinacia oleracea	FAD		391015	14	
1.3.3.4	Saccharomyces cerevisiae	fatty acid		391001	663	required for full activity
1.3.3.4	Saccharomyces cerevisiae	glutathione		390982	41	
1.3.3.4	Zea mays	H2O2		654442	20	activates the N-terminally processed-like enzyme form and processed native form
1.3.3.4	Bacillus subtilis	imidazole		654950	390	activates recombinant wild-type enzyme and mutant V311M
1.3.3.4	Madracis mirabilis	Irgarol 1051		671629		increases cnidarian PPO
1.3.3.4	Hordeum vulgare	iron-EDTA		390998	71939	in presence of glutathione
1.3.3.4	Hordeum vulgare	Lipids		390998		
1.3.3.4	Bacillus subtilis	n-octylglucopyranoside		391016	72045	1 mM results in maximal activity
1.3.3.4	Hordeum vulgare	oleic acid		390991	320	
1.3.3.4	Bos taurus	oleic acid		390992	320	
1.3.3.4	Bacillus subtilis	Tween 20		654950	428	activates recombinant wild-type enzyme and mutant V311M
1.3.3.4	Mus musculus	Ubiquinone-10		390994	3850	below 0.015 mM
1.3.3.4	Mus musculus	ubiquinone-6		390994	4097	below 0.015 mM
1.3.3.4	Homo sapiens		(2,4-dichlorophenyl)hydrazine	712221	100526	
1.3.3.4	Homo sapiens		(2-bromo-4-fluorophenyl)hydrazine	712221	100528	
1.3.3.4	Homo sapiens		(4-chloro-2-fluorophenyl)hydrazine	712221	100527	
1.3.3.4	Homo sapiens		1-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-4-fluorophenyl)-3-(3-(trifluoromethyl)phenyl)urea	696759	53063	
1.3.3.4	Homo sapiens		1-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-4-fluorophenyl)-3-(4-chlorophenyl)urea	696759	53064	
1.3.3.4	Homo sapiens		1-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-4-fluorophenyl)-3-methylurea	696759	53068	
1.3.3.4	Amaranthus retroflexus		1-(4-chlorophenyl)-3-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]urea	687248	9487	
1.3.3.4	Brassica juncea		1-(4-chlorophenyl)-3-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]urea	687248	9487	
1.3.3.4	Chenopodium album		1-(4-chlorophenyl)-3-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]urea	687248	9487	
1.3.3.4	Digitaria sanguinalis		1-(4-chlorophenyl)-3-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]urea	687248	9487	
1.3.3.4	Echinochloa crus-galli		1-(4-chlorophenyl)-3-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]urea	687248	9487	
1.3.3.4	Setaria viridis		1-(4-chlorophenyl)-3-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]urea	687248	9487	
1.3.3.4	Amaranthus retroflexus		1-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9490	
1.3.3.4	Brassica juncea		1-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9490	
1.3.3.4	Chenopodium album		1-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9490	
1.3.3.4	Digitaria sanguinalis		1-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9490	
1.3.3.4	Echinochloa crus-galli		1-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9490	
1.3.3.4	Setaria viridis		1-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9490	
1.3.3.4	Nicotiana tabacum		1-[2-(allylthio)-6-bromobenzothiazol-5-yl]-3-methyl-4-difluoromethyl-1H-1,2,4-triazol-5(4H)-one	724557	62259	
1.3.3.4	Nicotiana tabacum		1-[2-(allylthio)-6-bromobenzothiazol-5-yl]-3-methyl-4-difluoromethyl-1H-1,2,4-triazol-5(4H)-onesulfentrazone	724557		
1.3.3.4	Nicotiana tabacum		1-[2-(allylthio)-6-chlorobenzothiazol-5-yl]-3-methyl-4-difluoromethyl-1H-1,2,4-triazol-5(4H)-one	724557	62251	
1.3.3.4	Nicotiana tabacum		1-[2-(allylthio)-6-fluorobenzothiazol-5-yl]-3-methyl-4-difluoromethyl-1H-1,2,4-triazol-5(4H)-one	724557	62240	
1.3.3.4	Nicotiana tabacum		1-[2-(butylthio)-6-chlorobenzothiazol-5-yl]-3-methyl-4-difluoromethyl-1H-1,2,4-triazol-5(4H)-one	724557	62252	
1.3.3.4	Nicotiana tabacum		1-[2-(butylthio)-6-fluorobenzothiazol-5-yl]-3-methyl-4-difluoromethyl-1H-1,2,4-triazol-5(4H)-one	724557	62241	
1.3.3.4	Amaranthus retroflexus		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9488	
1.3.3.4	Brassica juncea		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9488	
1.3.3.4	Chenopodium album		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9488	
1.3.3.4	Digitaria sanguinalis		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9488	
1.3.3.4	Echinochloa crus-galli		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9488	
1.3.3.4	Setaria viridis		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9488	
1.3.3.4	Amaranthus retroflexus		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-phenylurea	687248	9489	
1.3.3.4	Brassica juncea		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-phenylurea	687248	9489	
1.3.3.4	Chenopodium album		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-phenylurea	687248	9489	
1.3.3.4	Digitaria sanguinalis		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-phenylurea	687248	9489	
1.3.3.4	Echinochloa crus-galli		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-phenylurea	687248	9489	
1.3.3.4	Setaria viridis		1-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-3-phenylurea	687248	9489	
1.3.3.4	Amaranthus retroflexus		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9491	
1.3.3.4	Brassica juncea		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9491	
1.3.3.4	Chenopodium album		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9491	
1.3.3.4	Digitaria sanguinalis		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9491	
1.3.3.4	Echinochloa crus-galli		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9491	
1.3.3.4	Setaria viridis		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-(4-chlorophenyl)urea	687248	9491	
1.3.3.4	Amaranthus retroflexus		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-phenylurea	687248	9492	
1.3.3.4	Brassica juncea		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-phenylurea	687248	9492	
1.3.3.4	Chenopodium album		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-phenylurea	687248	9492	
1.3.3.4	Digitaria sanguinalis		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-phenylurea	687248	9492	
1.3.3.4	Echinochloa crus-galli		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-phenylurea	687248	9492	
1.3.3.4	Setaria viridis		1-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-3-phenylurea	687248	9492	
1.3.3.4	Amaranthus retroflexus		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-(4-chlorophenyl)urea	687248	9493	
1.3.3.4	Brassica juncea		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-(4-chlorophenyl)urea	687248	9493	
1.3.3.4	Chenopodium album		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-(4-chlorophenyl)urea	687248	9493	
1.3.3.4	Digitaria sanguinalis		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-(4-chlorophenyl)urea	687248	9493	
1.3.3.4	Echinochloa crus-galli		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-(4-chlorophenyl)urea	687248	9493	
1.3.3.4	Setaria viridis		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-(4-chlorophenyl)urea	687248	9493	
1.3.3.4	Amaranthus retroflexus		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9494	
1.3.3.4	Brassica juncea		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9494	
1.3.3.4	Chenopodium album		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9494	
1.3.3.4	Digitaria sanguinalis		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9494	
1.3.3.4	Echinochloa crus-galli		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9494	
1.3.3.4	Setaria viridis		1-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-3-phenylurea	687248	9494	
1.3.3.4	Nicotiana tabacum		1-[6-chloro-2-(methylthio)benzothiazol-5-yl]-3-methyl-4-difluoromethyl-1H-1,2,4-triazol-5(4H)-one	724557	62249	
1.3.3.4	Nicotiana tabacum		1-[6-chloro-2-(propylthio)benzothiazol-5-yl]-3-methyl-4-difluoromethyl-1H-1,2,4-triazol-5(4H)-one	724557	62250	
1.3.3.4	Nicotiana tabacum		1-[6-fluoro-2-(methylthio)benzothiazol-5-yl]-3-methyl-4-difluoromethyl-1H-1,2,4-triazol-5(4H)-one	724557	62238	
1.3.3.4	Nicotiana tabacum		1-[6-fluoro-2-(propylthio)benzothiazol-5-yl]-3-methyl-4-difluoromethyl-1H-1,2,4-triazol-5(4H)-one	724557	62239	
1.3.3.4	Zea mays		2,2'-[[4-(5,7-dimethyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)-5-fluorobenzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698422	26037	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-(5,7-dimethyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)-5-fluorobenzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698439	26037	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-(5,7-dimethyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)-5-fluorobenzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	699636	26037	
1.3.3.4	Zea mays		2,2'-[[4-(5,7-dimethyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)-5-fluorobenzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698422	26036	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-(5,7-dimethyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)-5-fluorobenzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698439	26036	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-(5,7-dimethyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)-5-fluorobenzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	699636	26036	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-(4-oxo-6-prop-2-en-1-yl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698422	26055	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(4-oxo-6-prop-2-en-1-yl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698439	26055	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(4-oxo-6-prop-2-en-1-yl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	699636	26055	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-(4-oxo-6-prop-2-en-1-yl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698422	26054	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(4-oxo-6-prop-2-en-1-yl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698439	26054	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(4-oxo-6-prop-2-en-1-yl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	699636	26054	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-(4-oxo-6-propyl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698422	26057	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(4-oxo-6-propyl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698439	26057	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(4-oxo-6-propyl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	699636	26057	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-(4-oxo-6-propyl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698422	26056	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(4-oxo-6-propyl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698439	26056	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(4-oxo-6-propyl-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	699636	26056	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-(4-oxo-7-prop-2-en-1-yl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698422	26041	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(4-oxo-7-prop-2-en-1-yl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698439	26041	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(4-oxo-7-prop-2-en-1-yl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	699636	26041	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-(4-oxo-7-prop-2-en-1-yl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698422	26040	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(4-oxo-7-prop-2-en-1-yl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698439	26040	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(4-oxo-7-prop-2-en-1-yl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	699636	26040	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-(4-oxo-7-propyl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698422	26043	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(4-oxo-7-propyl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698439	26043	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(4-oxo-7-propyl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	699636	26043	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-(4-oxo-7-propyl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698422	26042	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(4-oxo-7-propyl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698439	26042	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(4-oxo-7-propyl-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	699636	26042	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698422	26032	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698439	26032	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	699636	26032	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698422	26033	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698439	26033	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	699636	26033	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-propylacetamide)	698439	51411	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)benzene-1,2-diyl]bis(oxy)]bis(N-propylacetamide)	699636	51411	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-[7-methyl-4-oxo-5-(trifluoromethyl)-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl]benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698422	26035	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-[7-methyl-4-oxo-5-(trifluoromethyl)-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl]benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	698439	26035	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-[7-methyl-4-oxo-5-(trifluoromethyl)-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl]benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-en-1-ylacetamide)	699636	26035	
1.3.3.4	Zea mays		2,2'-[[4-fluoro-5-[7-methyl-4-oxo-5-(trifluoromethyl)-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl]benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698422	26034	
1.3.3.4	Brassica rapa subsp. campestris		2,2'-[[4-fluoro-5-[7-methyl-4-oxo-5-(trifluoromethyl)-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl]benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	698439	26034	
1.3.3.4	Myxococcus xanthus		2,2'-[[4-fluoro-5-[7-methyl-4-oxo-5-(trifluoromethyl)-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl]benzene-1,2-diyl]bis(oxy)]bis(N-prop-2-yn-1-ylacetamide)	699636	26034	
1.3.3.4	Homo sapiens		2,4-dichloro-N-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-4-fluorophenylcarbamoyl)benzamide	696759	53073	
1.3.3.4	Homo sapiens		2,6-dichloro-N-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-4-fluorophenylcarbamoyl)benzamide	696759	53070	
1.3.3.4	Amaranthus retroflexus		2-(2,4-dichloro-5-propoxyphenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5991	
1.3.3.4	Brassica juncea		2-(2,4-dichloro-5-propoxyphenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5991	
1.3.3.4	Chenopodium album		2-(2,4-dichloro-5-propoxyphenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5991	
1.3.3.4	Digitaria sanguinalis		2-(2,4-dichloro-5-propoxyphenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5991	
1.3.3.4	Echinochloa crus-galli		2-(2,4-dichloro-5-propoxyphenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5991	
1.3.3.4	Eclipta prostrata		2-(2,4-dichloro-5-propoxyphenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5991	
1.3.3.4	Homo sapiens		2-(2,4-dichloro-5-propoxyphenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5991	
1.3.3.4	Setaria viridis		2-(2,4-dichloro-5-propoxyphenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5991	
1.3.3.4	Amaranthus retroflexus		2-(3-amino-4-chlorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5989	
1.3.3.4	Brassica juncea		2-(3-amino-4-chlorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5989	
1.3.3.4	Chenopodium album		2-(3-amino-4-chlorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5989	
1.3.3.4	Digitaria sanguinalis		2-(3-amino-4-chlorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5989	
1.3.3.4	Echinochloa crus-galli		2-(3-amino-4-chlorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5989	
1.3.3.4	Eclipta prostrata		2-(3-amino-4-chlorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5989	
1.3.3.4	Homo sapiens		2-(3-amino-4-chlorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5989	
1.3.3.4	Setaria viridis		2-(3-amino-4-chlorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5989	
1.3.3.4	Brassica rapa subsp. campestris		2-(3-oxo-4-prop-2-yn-1-yl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	698439	94192	
1.3.3.4	Amaranthus retroflexus		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5998	
1.3.3.4	Brassica juncea		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5998	
1.3.3.4	Chenopodium album		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5998	
1.3.3.4	Digitaria sanguinalis		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5998	
1.3.3.4	Echinochloa crus-galli		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5998	
1.3.3.4	Eclipta prostrata		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5998	
1.3.3.4	Homo sapiens		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5998	
1.3.3.4	Setaria viridis		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5998	
1.3.3.4	Amaranthus retroflexus		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5994	
1.3.3.4	Brassica juncea		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5994	
1.3.3.4	Chenopodium album		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5994	
1.3.3.4	Digitaria sanguinalis		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5994	
1.3.3.4	Echinochloa crus-galli		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5994	
1.3.3.4	Eclipta prostrata		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5994	
1.3.3.4	Homo sapiens		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5994	
1.3.3.4	Setaria viridis		2-(4-bromo-2-fluoro-5-hydroxyphenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5994	
1.3.3.4	Amaranthus retroflexus		2-(4-chloro-2-ethoxy-5-nitrophenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5997	
1.3.3.4	Brassica juncea		2-(4-chloro-2-ethoxy-5-nitrophenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5997	
1.3.3.4	Chenopodium album		2-(4-chloro-2-ethoxy-5-nitrophenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5997	
1.3.3.4	Digitaria sanguinalis		2-(4-chloro-2-ethoxy-5-nitrophenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5997	
1.3.3.4	Echinochloa crus-galli		2-(4-chloro-2-ethoxy-5-nitrophenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5997	
1.3.3.4	Eclipta prostrata		2-(4-chloro-2-ethoxy-5-nitrophenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5997	
1.3.3.4	Homo sapiens		2-(4-chloro-2-ethoxy-5-nitrophenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5997	
1.3.3.4	Setaria viridis		2-(4-chloro-2-ethoxy-5-nitrophenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5997	
1.3.3.4	Amaranthus retroflexus		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5983	
1.3.3.4	Brassica juncea		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5983	
1.3.3.4	Chenopodium album		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5983	
1.3.3.4	Digitaria sanguinalis		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5983	
1.3.3.4	Echinochloa crus-galli		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5983	
1.3.3.4	Eclipta prostrata		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5983	
1.3.3.4	Homo sapiens		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5983	
1.3.3.4	Setaria viridis		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5983	
1.3.3.4	Amaranthus retroflexus		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5999	
1.3.3.4	Brassica juncea		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5999	
1.3.3.4	Chenopodium album		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5999	
1.3.3.4	Digitaria sanguinalis		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5999	
1.3.3.4	Echinochloa crus-galli		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5999	
1.3.3.4	Eclipta prostrata		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5999	
1.3.3.4	Homo sapiens		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5999	
1.3.3.4	Setaria viridis		2-(4-chloro-2-fluoro-5-methoxyphenyl)-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5999	
1.3.3.4	Amaranthus retroflexus		2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1H-isoindole-1,3(2H)-dione	711472	5979	
1.3.3.4	Brassica juncea		2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1H-isoindole-1,3(2H)-dione	711472	5979	
1.3.3.4	Chenopodium album		2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1H-isoindole-1,3(2H)-dione	711472	5979	
1.3.3.4	Digitaria sanguinalis		2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1H-isoindole-1,3(2H)-dione	711472	5979	
1.3.3.4	Echinochloa crus-galli		2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1H-isoindole-1,3(2H)-dione	711472	5979	
1.3.3.4	Eclipta prostrata		2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1H-isoindole-1,3(2H)-dione	711472	5979	
1.3.3.4	Homo sapiens		2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1H-isoindole-1,3(2H)-dione	711472	5979	
1.3.3.4	Setaria viridis		2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1H-isoindole-1,3(2H)-dione	711472	5979	
1.3.3.4	Amaranthus retroflexus		2-(4-chloro-2-fluoro-5-propoxy-phenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5992	
1.3.3.4	Brassica juncea		2-(4-chloro-2-fluoro-5-propoxy-phenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5992	
1.3.3.4	Chenopodium album		2-(4-chloro-2-fluoro-5-propoxy-phenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5992	
1.3.3.4	Digitaria sanguinalis		2-(4-chloro-2-fluoro-5-propoxy-phenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5992	
1.3.3.4	Echinochloa crus-galli		2-(4-chloro-2-fluoro-5-propoxy-phenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5992	
1.3.3.4	Eclipta prostrata		2-(4-chloro-2-fluoro-5-propoxy-phenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5992	
1.3.3.4	Homo sapiens		2-(4-chloro-2-fluoro-5-propoxy-phenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5992	
1.3.3.4	Setaria viridis		2-(4-chloro-2-fluoro-5-propoxy-phenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5992	
1.3.3.4	Homo sapiens		2-(4-chloro-2-fluoro-5-[(3-fluorobenzyl)oxy]phenyl)-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472		
1.3.3.4	Amaranthus retroflexus		2-(4-chloro-5-ethoxy-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5990	
1.3.3.4	Brassica juncea		2-(4-chloro-5-ethoxy-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5990	
1.3.3.4	Chenopodium album		2-(4-chloro-5-ethoxy-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5990	
1.3.3.4	Digitaria sanguinalis		2-(4-chloro-5-ethoxy-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5990	
1.3.3.4	Echinochloa crus-galli		2-(4-chloro-5-ethoxy-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5990	
1.3.3.4	Eclipta prostrata		2-(4-chloro-5-ethoxy-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5990	
1.3.3.4	Homo sapiens		2-(4-chloro-5-ethoxy-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5990	
1.3.3.4	Setaria viridis		2-(4-chloro-5-ethoxy-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5990	
1.3.3.4	Homo sapiens		2-(4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl)-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472		
1.3.3.4	Homo sapiens		2-(4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl)-3-ethoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472		
1.3.3.4	Homo sapiens		2-(4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl)-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472		
1.3.3.4	Amaranthus retroflexus		2-(5-allyloxy-4-chloro-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5993	
1.3.3.4	Brassica juncea		2-(5-allyloxy-4-chloro-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5993	
1.3.3.4	Chenopodium album		2-(5-allyloxy-4-chloro-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5993	
1.3.3.4	Digitaria sanguinalis		2-(5-allyloxy-4-chloro-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5993	
1.3.3.4	Echinochloa crus-galli		2-(5-allyloxy-4-chloro-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5993	
1.3.3.4	Eclipta prostrata		2-(5-allyloxy-4-chloro-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5993	
1.3.3.4	Homo sapiens		2-(5-allyloxy-4-chloro-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5993	
1.3.3.4	Setaria viridis		2-(5-allyloxy-4-chloro-2-fluorophenyl)-2,3,4,5,6,7-hexahydro-isoindol-1-one	711472	5993	
1.3.3.4	Homo sapiens		2-(6-(1,3-dioxoisoindolin-2-yl)-7-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)acetonitrile	696759	53052	
1.3.3.4	Homo sapiens		2-(7-fluoro-2-methyl-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-5-methylisoindoline-1,3-dione	696759	53054	
1.3.3.4	Homo sapiens		2-(7-fluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-5-methylisoindoline-1,3-dione	696759	53051	
1.3.3.4	Homo sapiens		2-(7-fluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)isoindoline-1,3-dione	696759	53050	
1.3.3.4	Zea mays		2-chloro-4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)phenyl ethyl carbonate	698422	94188	
1.3.3.4	Homo sapiens		2-chloro-N-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-4-fluorophenylcarbamoyl)-6-fluorobenzamide	696759	53069	
1.3.3.4	Amaranthus retroflexus		2-[2,4-dichloro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5995	
1.3.3.4	Brassica juncea		2-[2,4-dichloro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5995	
1.3.3.4	Chenopodium album		2-[2,4-dichloro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5995	
1.3.3.4	Digitaria sanguinalis		2-[2,4-dichloro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5995	
1.3.3.4	Echinochloa crus-galli		2-[2,4-dichloro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5995	
1.3.3.4	Eclipta prostrata		2-[2,4-dichloro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5995	
1.3.3.4	Homo sapiens		2-[2,4-dichloro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5995	
1.3.3.4	Setaria viridis		2-[2,4-dichloro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5995	
1.3.3.4	Amaranthus retroflexus		2-[2,4-dichloro-5-(prop-2-yn-1-yloxy)phenyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one	687248	9538	azafenidin
1.3.3.4	Brassica juncea		2-[2,4-dichloro-5-(prop-2-yn-1-yloxy)phenyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one	687248	9538	azafenidin
1.3.3.4	Chenopodium album		2-[2,4-dichloro-5-(prop-2-yn-1-yloxy)phenyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one	687248	9538	azafenidin
1.3.3.4	Digitaria sanguinalis		2-[2,4-dichloro-5-(prop-2-yn-1-yloxy)phenyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one	687248	9538	azafenidin
1.3.3.4	Echinochloa crus-galli		2-[2,4-dichloro-5-(prop-2-yn-1-yloxy)phenyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one	687248	9538	azafenidin
1.3.3.4	Setaria viridis		2-[2,4-dichloro-5-(prop-2-yn-1-yloxy)phenyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one	687248	9538	azafenidin
1.3.3.4	Amaranthus retroflexus		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9542	
1.3.3.4	Brassica juncea		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9542	
1.3.3.4	Chenopodium album		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9542	
1.3.3.4	Digitaria sanguinalis		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9542	
1.3.3.4	Echinochloa crus-galli		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9542	
1.3.3.4	Setaria viridis		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9542	
1.3.3.4	Amaranthus retroflexus		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9547	
1.3.3.4	Brassica juncea		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9547	
1.3.3.4	Chenopodium album		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9547	
1.3.3.4	Digitaria sanguinalis		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9547	
1.3.3.4	Echinochloa crus-galli		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9547	
1.3.3.4	Setaria viridis		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9547	
1.3.3.4	Amaranthus retroflexus		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9550	
1.3.3.4	Brassica juncea		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9550	
1.3.3.4	Chenopodium album		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9550	
1.3.3.4	Digitaria sanguinalis		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9550	
1.3.3.4	Echinochloa crus-galli		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9550	
1.3.3.4	Setaria viridis		2-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9550	
1.3.3.4	Amaranthus retroflexus		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9541	
1.3.3.4	Brassica juncea		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9541	
1.3.3.4	Chenopodium album		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9541	
1.3.3.4	Digitaria sanguinalis		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9541	
1.3.3.4	Echinochloa crus-galli		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9541	
1.3.3.4	Setaria viridis		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9541	
1.3.3.4	Amaranthus retroflexus		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9545	
1.3.3.4	Brassica juncea		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9545	
1.3.3.4	Chenopodium album		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9545	
1.3.3.4	Digitaria sanguinalis		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9545	
1.3.3.4	Echinochloa crus-galli		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9545	
1.3.3.4	Setaria viridis		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9545	
1.3.3.4	Amaranthus retroflexus		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9549	
1.3.3.4	Brassica juncea		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9549	
1.3.3.4	Chenopodium album		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9549	
1.3.3.4	Digitaria sanguinalis		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9549	
1.3.3.4	Echinochloa crus-galli		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9549	
1.3.3.4	Setaria viridis		2-[2-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9549	
1.3.3.4	Amaranthus retroflexus		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9543	
1.3.3.4	Brassica juncea		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9543	
1.3.3.4	Chenopodium album		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9543	
1.3.3.4	Digitaria sanguinalis		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9543	
1.3.3.4	Echinochloa crus-galli		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9543	
1.3.3.4	Setaria viridis		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-1H-isoindole-1,3(2H)-dione	687248	9543	
1.3.3.4	Amaranthus retroflexus		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9546	
1.3.3.4	Brassica juncea		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9546	
1.3.3.4	Chenopodium album		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9546	
1.3.3.4	Digitaria sanguinalis		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9546	
1.3.3.4	Echinochloa crus-galli		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9546	
1.3.3.4	Setaria viridis		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9546	
1.3.3.4	Amaranthus retroflexus		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9499	
1.3.3.4	Brassica juncea		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9499	
1.3.3.4	Chenopodium album		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9499	
1.3.3.4	Digitaria sanguinalis		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9499	
1.3.3.4	Echinochloa crus-galli		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9499	
1.3.3.4	Setaria viridis		2-[4-bromo-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-2-fluorophenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9499	
1.3.3.4	Amaranthus retroflexus		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	6000	
1.3.3.4	Brassica juncea		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	6000	
1.3.3.4	Chenopodium album		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	6000	
1.3.3.4	Digitaria sanguinalis		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	6000	
1.3.3.4	Echinochloa crus-galli		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	6000	
1.3.3.4	Eclipta prostrata		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	6000	
1.3.3.4	Homo sapiens		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	6000	
1.3.3.4	Setaria viridis		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	6000	
1.3.3.4	Amaranthus retroflexus		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5996	
1.3.3.4	Brassica juncea		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5996	
1.3.3.4	Chenopodium album		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5996	
1.3.3.4	Digitaria sanguinalis		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5996	
1.3.3.4	Echinochloa crus-galli		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5996	
1.3.3.4	Eclipta prostrata		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5996	
1.3.3.4	Homo sapiens		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5996	
1.3.3.4	Setaria viridis		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5996	
1.3.3.4	Amaranthus retroflexus		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5987	
1.3.3.4	Brassica juncea		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5987	
1.3.3.4	Chenopodium album		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5987	
1.3.3.4	Digitaria sanguinalis		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5987	
1.3.3.4	Echinochloa crus-galli		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5987	
1.3.3.4	Eclipta prostrata		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5987	
1.3.3.4	Homo sapiens		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5987	
1.3.3.4	Setaria viridis		2-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5987	
1.3.3.4	Amaranthus retroflexus		2-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5986	
1.3.3.4	Brassica juncea		2-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5986	
1.3.3.4	Chenopodium album		2-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5986	
1.3.3.4	Digitaria sanguinalis		2-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5986	
1.3.3.4	Echinochloa crus-galli		2-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5986	
1.3.3.4	Eclipta prostrata		2-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5986	
1.3.3.4	Homo sapiens		2-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5986	
1.3.3.4	Setaria viridis		2-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5986	
1.3.3.4	Amaranthus retroflexus		2-[4-chloro-2-fluoro-5-(propan-2-yloxy)phenyl]-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5988	
1.3.3.4	Brassica juncea		2-[4-chloro-2-fluoro-5-(propan-2-yloxy)phenyl]-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5988	
1.3.3.4	Chenopodium album		2-[4-chloro-2-fluoro-5-(propan-2-yloxy)phenyl]-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5988	
1.3.3.4	Digitaria sanguinalis		2-[4-chloro-2-fluoro-5-(propan-2-yloxy)phenyl]-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5988	
1.3.3.4	Echinochloa crus-galli		2-[4-chloro-2-fluoro-5-(propan-2-yloxy)phenyl]-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5988	
1.3.3.4	Eclipta prostrata		2-[4-chloro-2-fluoro-5-(propan-2-yloxy)phenyl]-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5988	
1.3.3.4	Homo sapiens		2-[4-chloro-2-fluoro-5-(propan-2-yloxy)phenyl]-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5988	
1.3.3.4	Setaria viridis		2-[4-chloro-2-fluoro-5-(propan-2-yloxy)phenyl]-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	5988	
1.3.3.4	Amaranthus retroflexus		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9544	
1.3.3.4	Brassica juncea		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9544	
1.3.3.4	Chenopodium album		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9544	
1.3.3.4	Digitaria sanguinalis		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9544	
1.3.3.4	Echinochloa crus-galli		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9544	
1.3.3.4	Setaria viridis		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-1H-isoindole-1,3(2H)-dione	687248	9544	
1.3.3.4	Amaranthus retroflexus		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9548	
1.3.3.4	Brassica juncea		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9548	
1.3.3.4	Chenopodium album		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9548	
1.3.3.4	Digitaria sanguinalis		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9548	
1.3.3.4	Echinochloa crus-galli		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9548	
1.3.3.4	Setaria viridis		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	687248	9548	
1.3.3.4	Amaranthus retroflexus		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9500	
1.3.3.4	Brassica juncea		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9500	
1.3.3.4	Chenopodium album		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9500	
1.3.3.4	Digitaria sanguinalis		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9500	
1.3.3.4	Echinochloa crus-galli		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9500	
1.3.3.4	Setaria viridis		2-[4-chloro-3-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	687248	9500	
1.3.3.4	Amaranthus retroflexus		2-[4-chloro-5-(cyclopentyloxy)-2-fluorophenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5982	
1.3.3.4	Brassica juncea		2-[4-chloro-5-(cyclopentyloxy)-2-fluorophenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5982	
1.3.3.4	Chenopodium album		2-[4-chloro-5-(cyclopentyloxy)-2-fluorophenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5982	
1.3.3.4	Digitaria sanguinalis		2-[4-chloro-5-(cyclopentyloxy)-2-fluorophenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5982	
1.3.3.4	Echinochloa crus-galli		2-[4-chloro-5-(cyclopentyloxy)-2-fluorophenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5982	
1.3.3.4	Eclipta prostrata		2-[4-chloro-5-(cyclopentyloxy)-2-fluorophenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5982	
1.3.3.4	Homo sapiens		2-[4-chloro-5-(cyclopentyloxy)-2-fluorophenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5982	
1.3.3.4	Setaria viridis		2-[4-chloro-5-(cyclopentyloxy)-2-fluorophenyl]-3-hydroxyoctahydro-1H-isoindol-1-one	711472	5982	
1.3.3.4	Zea mays		2-[4-fluoro-3-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)phenoxy]-N-prop-2-en-1-ylacetamide	698422	94189	
1.3.3.4	Zea mays		2-[4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)-2-[2-oxo-2-(prop-2-en-1-ylamino)ethoxy]phenoxy]-N-propylacetamide	698422	94190	
1.3.3.4	Nicotiana tabacum		2-[5-(4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl)-6-fluorobenzothiazol-2-ylthio]acetic acid	724557	62244	
1.3.3.4	Nicotiana tabacum		2-[5-(4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl)-6-fluorobenzothiazol-2-ylthio]propanoic acid	724557	62248	
1.3.3.4	Nicotiana tabacum		2-[6-chloro-5-(4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl)benzothiazol-2-ylthio]acetic acid	724557	62253	
1.3.3.4	Nicotiana tabacum		2-[6-chloro-5-(4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl)benzothiazol-2-ylthio]propanoic acid	724557	62257	
1.3.3.4	Amaranthus retroflexus		2-{4-chloro-2-fluoro-5-[(3-fluorobenzyl)oxy]phenyl}-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8184	
1.3.3.4	Brassica juncea		2-{4-chloro-2-fluoro-5-[(3-fluorobenzyl)oxy]phenyl}-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8184	
1.3.3.4	Chenopodium album		2-{4-chloro-2-fluoro-5-[(3-fluorobenzyl)oxy]phenyl}-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8184	
1.3.3.4	Digitaria sanguinalis		2-{4-chloro-2-fluoro-5-[(3-fluorobenzyl)oxy]phenyl}-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8184	
1.3.3.4	Echinochloa crus-galli		2-{4-chloro-2-fluoro-5-[(3-fluorobenzyl)oxy]phenyl}-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8184	
1.3.3.4	Eclipta prostrata		2-{4-chloro-2-fluoro-5-[(3-fluorobenzyl)oxy]phenyl}-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8184	
1.3.3.4	Setaria viridis		2-{4-chloro-2-fluoro-5-[(3-fluorobenzyl)oxy]phenyl}-3-hydroxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8184	
1.3.3.4	Amaranthus retroflexus		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8186	
1.3.3.4	Brassica juncea		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8186	
1.3.3.4	Chenopodium album		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8186	
1.3.3.4	Digitaria sanguinalis		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8186	
1.3.3.4	Echinochloa crus-galli		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8186	
1.3.3.4	Eclipta prostrata		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8186	
1.3.3.4	Setaria viridis		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-(prop-2-en-1-yloxy)-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8186	
1.3.3.4	Amaranthus retroflexus		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-ethoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8187	
1.3.3.4	Brassica juncea		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-ethoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8187	
1.3.3.4	Chenopodium album		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-ethoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8187	
1.3.3.4	Digitaria sanguinalis		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-ethoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8187	
1.3.3.4	Echinochloa crus-galli		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-ethoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8187	
1.3.3.4	Eclipta prostrata		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-ethoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8187	
1.3.3.4	Setaria viridis		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-ethoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8187	
1.3.3.4	Amaranthus retroflexus		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8185	
1.3.3.4	Brassica juncea		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8185	
1.3.3.4	Chenopodium album		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8185	
1.3.3.4	Digitaria sanguinalis		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8185	
1.3.3.4	Echinochloa crus-galli		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8185	
1.3.3.4	Eclipta prostrata		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8185	
1.3.3.4	Setaria viridis		2-{4-chloro-5-[(3-chlorobenzyl)oxy]-2-fluorophenyl}-3-methoxy-2,3,4,5,6,7-hexahydro-1H-isoindol-1-one	711472	8185	
1.3.3.4	Homo sapiens		3-(2-bromo-4-fluoro-5-nitrophenyl)-5-tert-butyl-1,3,4-oxadiazol-2(3H)-one	712221	100537	
1.3.3.4	Homo sapiens		3-(2-bromo-4-fluorophenyl)-5-tert-butyl-1,3,4-oxadiazol-2(3H)-one	712221	100534	
1.3.3.4	Homo sapiens		3-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-4-fluorophenyl)-1,1-diisopropylurea	696759	53066	
1.3.3.4	Homo sapiens		3-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)phenyl)-1,1-diisopropylurea	696759	53067	
1.3.3.4	Zea mays		3-(4-chloro-2-fluoro-5-hydroxyphenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26044	
1.3.3.4	Brassica rapa subsp. campestris		3-(4-chloro-2-fluoro-5-hydroxyphenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26044	
1.3.3.4	Myxococcus xanthus		3-(4-chloro-2-fluoro-5-hydroxyphenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26044	
1.3.3.4	Zea mays		3-(4-chloro-2-fluoro-5-methoxyphenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26045	
1.3.3.4	Brassica rapa subsp. campestris		3-(4-chloro-2-fluoro-5-methoxyphenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26045	
1.3.3.4	Myxococcus xanthus		3-(4-chloro-2-fluoro-5-methoxyphenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26045	
1.3.3.4	Brassica rapa subsp. campestris		3-(4-chloro-2-fluoro-5-propoxyphenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	51409	
1.3.3.4	Myxococcus xanthus		3-(4-chloro-2-fluoro-5-propoxyphenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	51409	
1.3.3.4	Brassica rapa subsp. campestris		3-(4-chloro-5-ethoxy-2-fluorophenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	51412	
1.3.3.4	Myxococcus xanthus		3-(4-chloro-5-ethoxy-2-fluorophenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	51412	
1.3.3.4	Homo sapiens		3-(5-amino-2,4-dichlorophenyl)-5-tert-butyl-1,3,4-oxadiazol-2(3H)-one	712221	100538	
1.3.3.4	Homo sapiens		3-(5-amino-2-bromo-4-fluorophenyl)-5-tert-butyl-1,3,4-oxadiazol-2(3H)-one	712221	100540	
1.3.3.4	Homo sapiens		3-(5-amino-4-chloro-2-fluorophenyl)-5-tert-butyl-1,3,4-oxadiazol-2(3H)-one	712221	100539	
1.3.3.4	Zea mays		3-(5-butoxy-4-chloro-2-fluorophenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26046	
1.3.3.4	Brassica rapa subsp. campestris		3-(5-butoxy-4-chloro-2-fluorophenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26046	
1.3.3.4	Myxococcus xanthus		3-(5-butoxy-4-chloro-2-fluorophenyl)-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26046	
1.3.3.4	Homo sapiens		3-(6-bromo-2-[(3-methylbut-2-en-1-yl)sulfanyl]-1,3-benzothiazol-5-yl)-5-tert-butyl-1,3,4-oxadiazol-2(3H)-one	712221		
1.3.3.4	Homo sapiens		3-chloro-N-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-4-fluorophenyl)-2,2-dimethylpropanamide	696759	53065	
1.3.3.4	Zea mays		3-[4-chloro-2-fluoro-5-(pentyloxy)phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26047	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-(pentyloxy)phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26047	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-(pentyloxy)phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26047	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-5,7-dimethyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	51410	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-5,7-dimethyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	51410	
1.3.3.4	Zea mays		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-6-prop-2-en-1-yl-3,6-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26053	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-6-prop-2-en-1-yl-3,6-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26053	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-6-prop-2-en-1-yl-3,6-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26053	
1.3.3.4	Zea mays		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26029	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26029	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26029	
1.3.3.4	Zea mays		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-7-prop-2-en-1-yl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26039	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-7-prop-2-en-1-yl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26039	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-(prop-2-en-1-yloxy)phenyl]-7-prop-2-en-1-yl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26039	
1.3.3.4	Zea mays		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-5,7-dimethyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26031	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-5,7-dimethyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26031	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-5,7-dimethyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26031	
1.3.3.4	Zea mays		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-6-prop-2-en-1-yl-3,6-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26052	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-6-prop-2-en-1-yl-3,6-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26052	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-6-prop-2-en-1-yl-3,6-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26052	
1.3.3.4	Zea mays		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26028	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26028	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26028	
1.3.3.4	Zea mays		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-7-methyl-5-(trifluoromethyl)-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26030	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-7-methyl-5-(trifluoromethyl)-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26030	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-7-methyl-5-(trifluoromethyl)-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26030	
1.3.3.4	Zea mays		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-7-prop-2-en-1-yl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26038	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-7-prop-2-en-1-yl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26038	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl]-7-prop-2-en-1-yl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26038	
1.3.3.4	Zea mays		3-[4-chloro-2-fluoro-5-[(2-methoxyethoxy)methoxy]phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26051	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-2-fluoro-5-[(2-methoxyethoxy)methoxy]phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26051	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-2-fluoro-5-[(2-methoxyethoxy)methoxy]phenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26051	
1.3.3.4	Zea mays		3-[4-chloro-5-(cyclohexyloxy)-2-fluorophenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	94191	
1.3.3.4	Zea mays		3-[4-chloro-5-[(2-chloroprop-2-en-1-yl)oxy]-2-fluorophenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26049	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-5-[(2-chloroprop-2-en-1-yl)oxy]-2-fluorophenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26049	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-5-[(2-chloroprop-2-en-1-yl)oxy]-2-fluorophenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26049	
1.3.3.4	Zea mays		3-[4-chloro-5-[(3-chloroprop-2-en-1-yl)oxy]-2-fluorophenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698422	26048	
1.3.3.4	Brassica rapa subsp. campestris		3-[4-chloro-5-[(3-chloroprop-2-en-1-yl)oxy]-2-fluorophenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	698439	26048	
1.3.3.4	Myxococcus xanthus		3-[4-chloro-5-[(3-chloroprop-2-en-1-yl)oxy]-2-fluorophenyl]-7-methyl-3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-one	699636	26048	
1.3.3.4	Nicotiana tabacum		3-[5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl]-6-fluorobenzothiazol-2-ylthio]propanoic acid	724557	62247	
1.3.3.4	Homo sapiens		3-[6-bromo-2-(prop-2-yn-1-ylsulfanyl)-1,3-benzothiazol-5-yl]-5-tert-butyl-1,3,4-oxadiazol-2(3H)-one	712221, 724554	27630	
1.3.3.4	Homo sapiens		3-[6-bromo-2-(prop-2-yn-1-ylsulfanyl)-1,3-benzothiazol-5-yl]-5-tert-butyl-1,3,4-thiadiazol-2(3H)-one	724554	62280	
1.3.3.4	Nicotiana tabacum		3-[6-chloro-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl]benzothiazol-2-ylthio]propanoic acid	724557	62256	
1.3.3.4	Nicotiana tabacum		4-bromo-3-(5'-carboxy-4'-chloro-2'-fluoro-phenyl)-1-methyl-5-trifluoromethyl-pyrazol	655341	79830	
1.3.3.4	Amaranthus retroflexus		4-chloro-phthalimide	711472	6002	
1.3.3.4	Brassica juncea		4-chloro-phthalimide	711472	6002	
1.3.3.4	Chenopodium album		4-chloro-phthalimide	711472	6002	
1.3.3.4	Digitaria sanguinalis		4-chloro-phthalimide	711472	6002	
1.3.3.4	Echinochloa crus-galli		4-chloro-phthalimide	711472	6002	
1.3.3.4	Eclipta prostrata		4-chloro-phthalimide	711472	6002	
1.3.3.4	Homo sapiens		4-chloro-phthalimide	711472	6002	
1.3.3.4	Setaria viridis		4-chloro-phthalimide	711472	6002	
1.3.3.4	Homo sapiens		4-fluoro-2-(7-fluoro-2-methyl-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)isoindoline-1,3-dione	696759	53053	
1.3.3.4	Homo sapiens		5-tert-butyl-3-(2,4-dichloro-5-nitrophenyl)-1,3,4-oxadiazol-2(3H)-one	712221	100535	
1.3.3.4	Homo sapiens		5-tert-butyl-3-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2(3H)-one	712221	100532	
1.3.3.4	Homo sapiens		5-tert-butyl-3-(2-[(3,3-dichloroprop-2-en-1-yl)sulfanyl]-6-fluoro-1,3-benzothiazol-5-yl)-1,3,4-oxadiazol-2(3H)-one	712221		
1.3.3.4	Homo sapiens		5-tert-butyl-3-(4-chloro-2-fluoro-5-nitrophenyl)-1,3,4-oxadiazol-2(3H)-one	712221	100536	
1.3.3.4	Homo sapiens		5-tert-butyl-3-(4-chloro-2-fluorophenyl)-1,3,4-oxadiazol-2(3H)-one	712221	100533	
1.3.3.4	Homo sapiens		5-tert-butyl-3-(6-chloro-2-[(3,3-dichloroprop-2-en-1-yl)sulfanyl]-1,3-benzothiazol-5-yl)-1,3,4-oxadiazol-2(3H)-one	712221		
1.3.3.4	Homo sapiens		5-tert-butyl-3-[6-chloro-2-(prop-2-en-1-ylsulfanyl)-1,3-benzothiazol-5-yl]-1,3,4-oxadiazol-2(3H)-one	712221	58533	
1.3.3.4	Homo sapiens		5-tert-butyl-3-[6-chloro-2-(prop-2-yn-1-ylsulfanyl)-1,3-benzothiazol-5-yl]-1,3,4-oxadiazol-2(3H)-one	712221, 724554	27628	
1.3.3.4	Homo sapiens		5-tert-butyl-3-[6-chloro-2-(prop-2-yn-1-ylsulfanyl)-1,3-benzothiazol-5-yl]-1,3,4-thiadiazol-2(3H)-one	724554	62274	
1.3.3.4	Homo sapiens		5-tert-butyl-3-[6-fluoro-2-(prop-2-en-1-ylsulfanyl)-1,3-benzothiazol-5-yl]-1,3,4-oxadiazol-2(3H)-one	712221	58535	
1.3.3.4	Homo sapiens		5-tert-butyl-3-[6-fluoro-2-(prop-2-yn-1-ylsulfanyl)-1,3-benzothiazol-5-yl]-1,3,4-oxadiazol-2(3H)-one	724554	103016	
1.3.3.4	Homo sapiens		5-tert-butyl-3-[6-fluoro-2-(prop-2-yn-1-ylsulfanyl)-1,3-benzothiazol-5-yl]-1,3,4-thiadiazol-2(3H)-one	724554	62267	
1.3.3.4	Nicotiana tabacum		5-[2-chloro-4-(trifluoromethyl)phenoxyl]-2-nitrobenzoic acid	655018	79827	transgenic YZI-1S cells show a 150fold greater resistance to the inhibitor compared to wild-type cells, inhibition of mitochondrial and chloroplastic isozymes
1.3.3.4	Nicotiana tabacum		acifluoren	655341	1604	light-dependent peroxidizing diphenyl ether herbicide
1.3.3.4	Nicotiana tabacum		acifluorfen	391009	1604	
1.3.3.4	Bacillus subtilis		acifluorfen	391011	1604	no inhibition at 0.1 mM
1.3.3.4	Homo sapiens		acifluorfen	391012	1604	competitive
1.3.3.4	Spinacia oleracea		acifluorfen	391014	1604	
1.3.3.4	Homo sapiens		acifluorfen	654874	1604	inhibition potency with recombinant wild-type and mutant enzymes, overview
1.3.3.4	Homo sapiens		acifluorfen	391004, 671294	1604	
1.3.3.4	Myxococcus xanthus		acifluorfen	674722	1604	is accommodated by the shape of the binding pocket and hold in place by electrostatic and aromatic interactions
1.3.3.4	Nicotiana tabacum		acifluorfen	676521	1604	necrotic leaf lesions visible within the first hours of light exposure
1.3.3.4	Myxococcus xanthus		acifluorfen	391005, 689348, 689352	1604	
1.3.3.4	Bacillus subtilis		acifluorfen	695527	1604	
1.3.3.4	Bacillus subtilis		acifluorfen	695546	1604	competitive inhibition with respect to protoporphyrinogen IX
1.3.3.4	Amaranthus tuberculatus		acifluorfen	711307	1604	; 
1.3.3.4	Bacillus subtilis		acifluorfen	712895	1604	a herbicide, binding structure, overview
1.3.3.4	Cucumis sativus		Acifluorfen-methyl	390996	4039	
1.3.3.4	Mus musculus		Acifluorfen-methyl	390997, 390999	4039	
1.3.3.4	Saccharomyces cerevisiae		Acifluorfen-methyl	390997, 390999	4039	
1.3.3.4	Solanum tuberosum		Acifluorfen-methyl	390997, 390999	4039	
1.3.3.4	Zea mays		Acifluorfen-methyl	390997, 390999	4039	
1.3.3.4	Saccharomyces cerevisiae		Acifluorfen-methyl	391001	4039	competitive
1.3.3.4	Bacillus subtilis		Acifluorfen-methyl	391011	4039	weak
1.3.3.4	Saccharomyces cerevisiae		arsenite	390982	332	slight inhibition
1.3.3.4	Hordeum vulgare		ascorbate	390998	88	
1.3.3.4	Pythium aphanidermatum		azafenidin	676391	9538	completely inhibits the in vitro mycelial growth
1.3.3.4	Pythium arrhenomanes		azafenidin	676391	9538	reduces Pythium arrhenomanes colonization of sugarcane, inhibits the in vitro mycelial growth
1.3.3.4	Pythium ultimum		azafenidin	676391	9538	completely inhibits the in vitro mycelial growth
1.3.3.4	Saccharum officinarum		azafenidin	676391	9538	applied to either leaves or steamed field soil is phytotoxic to plants
1.3.3.4	Mus musculus		bilirubin	390994, 390995	494	competitive
1.3.3.4	Bacillus subtilis		bilirubin	391011	494	competitive
1.3.3.4	Homo sapiens		bilirubin	654874	494	inhibition potency with recombinant wild-type and mutant enzymes, overview
1.3.3.4	Bacillus subtilis		Biliverdin	391011	1282	competitive
1.3.3.4	Homo sapiens		biliverdin IX hydrochloride	654874	79829	inhibition potency with recombinant wild-type and mutant enzymes, overview
1.3.3.4	Myxococcus xanthus		butafenacil	689348	90823	0.0001 mM
1.3.3.4	Myxococcus xanthus		carfentrazone	689348	90824	
1.3.3.4	Bacillus subtilis		carfentrazone-ethyl	672499	9540	22% less inhibition is found in T3 transgenic lines
1.3.3.4	Oryza sativa		carfentrazone-ethyl	672499	9540	0.01 mM inhibits growth of wild-type rice by 58%, but 22% less inhibition is found in T3 transgenic lines, photodynamic injury symptoms such as chlorosis and leaf rolling are obvious in wild-type, but not observed in transgenic lines
1.3.3.4	Myxococcus xanthus		carfentrazone-ethyl	689352	9540	
1.3.3.4	Amaranthus retroflexus		chlorphthalim	711472	111744	
1.3.3.4	Brassica juncea		chlorphthalim	711472	111744	
1.3.3.4	Chenopodium album		chlorphthalim	711472	111744	
1.3.3.4	Digitaria sanguinalis		chlorphthalim	711472	111744	
1.3.3.4	Echinochloa crus-galli		chlorphthalim	711472	111744	
1.3.3.4	Eclipta prostrata		chlorphthalim	711472	111744	
1.3.3.4	Setaria viridis		chlorphthalim	711472	111744	
1.3.3.4	Saccharomyces cerevisiae		Co2+	390982	21	inhibitory
1.3.3.4	Homo sapiens		cobalt-protoporphyrin	390986	24434	
1.3.3.4	Mus musculus		coenzyme Q0	390994	1753	above 0.03 mM
1.3.3.4	Saccharomyces cerevisiae		Cu2+	390982	28	inhibitory
1.3.3.4	Mus musculus		dicoumarol	390994	608	above 0.03 mM
1.3.3.4	Saccharomyces cerevisiae		diphenylene iodonium	391008	1212	competitive with respect to oxygen, strongly pH dependent, maximal at pH 8, inhibition by derivatives
1.3.3.4	Homo sapiens		diphenylene iodonium	391012	1212	50% inhibition at 0.1 mM
1.3.3.4	Zea mays		DTT	654442	42	inhibits activity of N-terminally processed-like enzyme form
1.3.3.4	Homo sapiens		ethyl ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		ethyl ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		ethyl ([6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Nicotiana tabacum		ethyl 1-[5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl]-6-fluoro benzothiazol-2-ylthio]acetate	724557	62242	
1.3.3.4	Nicotiana tabacum		ethyl 1-[5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl]-6-fluoro benzothiazol-2-ylthio]propanoate	724557	62243	
1.3.3.4	Nicotiana tabacum		ethyl 1-[6-bromo-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl] benzothiazol-2-ylthio]acetate	724557	62258	
1.3.3.4	Nicotiana tabacum		ethyl 1-[6-chloro-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl] benzothiazol-2-ylthio]acetate	724557	62255	
1.3.3.4	Nicotiana tabacum		ethyl 1-[6-chloro-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl] benzothiazol-2-ylthio]propanoate	724557	62254	
1.3.3.4	Homo sapiens		ethyl 2-((5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-2(3H)-yl)-6-fluorobenzothiazol-2-yl)sulfanyl)propanoate	712221	58536	with a broad spectrum of postemergence herbicidal activity
1.3.3.4	Homo sapiens		ethyl 2-(6-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-7-fluoro-2-methyl-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)-2-phenylacetate	696759	53059	
1.3.3.4	Homo sapiens		ethyl 2-(6-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-7-fluoro-2-methyl-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)acetate	696759	53056	
1.3.3.4	Homo sapiens		ethyl 2-(6-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-7-fluoro-2-methyl-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)propanoate	696759	53057	
1.3.3.4	Homo sapiens		ethyl 2-(6-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-7-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)butanoate	696759	53055	
1.3.3.4	Homo sapiens		ethyl 2-(6-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-7-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)propanoate	696759	53058	
1.3.3.4	Homo sapiens		ethyl 2-([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl)-2-methylpropanoate	712221		
1.3.3.4	Homo sapiens		ethyl 2-([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl)-2-methylpropanoate	712221		
1.3.3.4	Homo sapiens		ethyl 2-([6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl)propanoate	712221		
1.3.3.4	Amaranthus retroflexus		ethyl 2-chloro-3-[2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]propanoate	687248	9540	carfetrazone-ethyl
1.3.3.4	Brassica juncea		ethyl 2-chloro-3-[2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]propanoate	687248	9540	carfetrazone-ethyl
1.3.3.4	Chenopodium album		ethyl 2-chloro-3-[2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]propanoate	687248	9540	carfetrazone-ethyl
1.3.3.4	Digitaria sanguinalis		ethyl 2-chloro-3-[2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]propanoate	687248	9540	carfetrazone-ethyl
1.3.3.4	Echinochloa crus-galli		ethyl 2-chloro-3-[2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]propanoate	687248	9540	carfetrazone-ethyl
1.3.3.4	Setaria viridis		ethyl 2-chloro-3-[2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]propanoate	687248	9540	carfetrazone-ethyl
1.3.3.4	Amaranthus retroflexus		ethyl 2-[2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]propanoate	711472	5985	
1.3.3.4	Brassica juncea		ethyl 2-[2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]propanoate	711472	5985	
1.3.3.4	Chenopodium album		ethyl 2-[2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]propanoate	711472	5985	
1.3.3.4	Digitaria sanguinalis		ethyl 2-[2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]propanoate	711472	5985	
1.3.3.4	Echinochloa crus-galli		ethyl 2-[2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]propanoate	711472	5985	
1.3.3.4	Eclipta prostrata		ethyl 2-[2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]propanoate	711472	5985	
1.3.3.4	Homo sapiens		ethyl 2-[2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]propanoate	711472	5985	
1.3.3.4	Setaria viridis		ethyl 2-[2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]propanoate	711472	5985	
1.3.3.4	Amaranthus retroflexus		ethyl 2-[2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]propanoate	711472	5981	
1.3.3.4	Brassica juncea		ethyl 2-[2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]propanoate	711472	5981	
1.3.3.4	Chenopodium album		ethyl 2-[2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]propanoate	711472	5981	
1.3.3.4	Digitaria sanguinalis		ethyl 2-[2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]propanoate	711472	5981	
1.3.3.4	Echinochloa crus-galli		ethyl 2-[2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]propanoate	711472	5981	
1.3.3.4	Eclipta prostrata		ethyl 2-[2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]propanoate	711472	5981	
1.3.3.4	Homo sapiens		ethyl 2-[2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]propanoate	711472	5981	
1.3.3.4	Setaria viridis		ethyl 2-[2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]propanoate	711472	5981	
1.3.3.4	Homo sapiens		ethyl 3 ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl)propanoate	712221		
1.3.3.4	Homo sapiens		ethyl 3-([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl)butanoate	712221		
1.3.3.4	Homo sapiens		ethyl 3-([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl)propanoate	712221		
1.3.3.4	Homo sapiens		ethyl 3-([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl)propanoate	712221		
1.3.3.4	Homo sapiens		ethyl 3-([6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl)propanoate	712221		
1.3.3.4	Homo sapiens		ethyl 4-([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl)butanoate	712221		
1.3.3.4	Homo sapiens		ethyl 4-([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl)butanoate	712221		
1.3.3.4	Homo sapiens		ethyl 4-([6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl)butanoate	712221		
1.3.3.4	Amaranthus retroflexus		ethyl [2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]acetate	711472	5984	
1.3.3.4	Brassica juncea		ethyl [2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]acetate	711472	5984	
1.3.3.4	Chenopodium album		ethyl [2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]acetate	711472	5984	
1.3.3.4	Digitaria sanguinalis		ethyl [2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]acetate	711472	5984	
1.3.3.4	Echinochloa crus-galli		ethyl [2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]acetate	711472	5984	
1.3.3.4	Eclipta prostrata		ethyl [2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]acetate	711472	5984	
1.3.3.4	Homo sapiens		ethyl [2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]acetate	711472	5984	
1.3.3.4	Setaria viridis		ethyl [2-chloro-4-fluoro-5-(1-hydroxy-3-oxooctahydro-2H-isoindol-2-yl)phenoxy]acetate	711472	5984	
1.3.3.4	Amaranthus retroflexus		ethyl [2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]acetate	711472	5980	
1.3.3.4	Brassica juncea		ethyl [2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]acetate	711472	5980	
1.3.3.4	Chenopodium album		ethyl [2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]acetate	711472	5980	
1.3.3.4	Digitaria sanguinalis		ethyl [2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]acetate	711472	5980	
1.3.3.4	Echinochloa crus-galli		ethyl [2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]acetate	711472	5980	
1.3.3.4	Eclipta prostrata		ethyl [2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]acetate	711472	5980	
1.3.3.4	Homo sapiens		ethyl [2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]acetate	711472	5980	
1.3.3.4	Setaria viridis		ethyl [2-chloro-5-(1,3-dioxooctahydro-2H-isoindol-2-yl)-4-fluorophenoxy]acetate	711472	5980	
1.3.3.4	Homo sapiens		ethyl [[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	100542	
1.3.3.4	Homo sapiens		ethyl [[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	62262	
1.3.3.4	Pythium aphanidermatum		flumioxazin	676391	9316	85% inhibition of in vitro mycelial growth
1.3.3.4	Pythium arrhenomanes		flumioxazin	676391	9316	colonization of sugarcane is reduced by foliar application in field soil, inhibits the in vitro mycelial growth
1.3.3.4	Pythium ultimum		flumioxazin	676391	9316	62% inhibition of in vitro mycelial growth
1.3.3.4	Saccharum officinarum		flumioxazin	676391	9316	only minor necrosis of Pythium arrhenomanes-infested steamed field soil and field soil plants, reduces the root rot severity rating
1.3.3.4	Zea mays		flumioxazin	698422	9316	
1.3.3.4	Myxococcus xanthus		flumioxazin	699636	9316	
1.3.3.4	Mus musculus		FMN	390990	52	
1.3.3.4	Bos taurus		glutathione	390992	41	
1.3.3.4	Hordeum vulgare		glutathione	390998	41	
1.3.3.4	Saccharomyces cerevisiae		heme	390982	45	noncompetitive, reversible by dilution
1.3.3.4	Homo sapiens		heme	390986	45	0.001 mM cause 25% inhibition
1.3.3.4	Mus musculus		heme	390990	45	
1.3.3.4	Saccharomyces cerevisiae		Hemin	390982	45	noncompetitive, reversible by dilution
1.3.3.4	Bacillus subtilis		Hemin	391011	45	competitive
1.3.3.4	Myxococcus xanthus		imazapyr	689352	3009	
1.3.3.4	Rattus norvegicus		iodoacetamide	390981	63	
1.3.3.4	Saccharomyces cerevisiae		iodoacetamide	390981	63	
1.3.3.4	Saccharomyces cerevisiae		iodoacetamide	390982	63	slight inhibition
1.3.3.4	Desulfovibrio gigas		iodoacetamide	390988	63	
1.3.3.4	Bos taurus		iodoacetamide	390992	63	
1.3.3.4	Saccharomyces cerevisiae		iodoacetate	390982	87	slight inhibition
1.3.3.4	Amaranthus tuberculatus		lactofen	711307	58970	; 
1.3.3.4	Amaranthus tuberculatus		MC-15608	711307		; 
1.3.3.4	Mus musculus		menadione	390994	212	above 0.03 mM
1.3.3.4	Homo sapiens		metalloporphyrin	390986		Mn- and Co-protoporphyrin, weak inhibition by Cd-, Ni- and Fe-protoporphyrin, 5 min preincubation
1.3.3.4	Homo sapiens		methyl (2E)-4-([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl)but-2-enoate	712221		
1.3.3.4	Homo sapiens		methyl ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		methyl ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		methyl ([6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Nicotiana tabacum		methyl 1-[6-chloro-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl] benzothiazol-2-ylthio]acetate	724557	62253	
1.3.3.4	Homo sapiens		methyl 2-((5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-6-fluorobenzothiazol-2-yl)thio)acetate	725177	62282	
1.3.3.4	Homo sapiens		methyl 2-(6-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-7-fluoro-2-methyl-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)acetate	696759	53060	
1.3.3.4	Homo sapiens		methyl 2-(6-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-7-fluoro-2-methyl-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)propanoate	696759	53061	
1.3.3.4	Homo sapiens		methyl 2-(6-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-7-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)butanoate	696759	53062	
1.3.3.4	Amaranthus retroflexus		methyl 2-[3-methyl-(2-fluoro-4-chloro-5-ethyl-sulfonamidephenyl)-4,5-dihydro-5-oxo-1H-1,2,4-triazol-4-yl]methylenephenyl-2-(E)-methoxyiminoacetate	687248	9551	
1.3.3.4	Brassica juncea		methyl 2-[3-methyl-(2-fluoro-4-chloro-5-ethyl-sulfonamidephenyl)-4,5-dihydro-5-oxo-1H-1,2,4-triazol-4-yl]methylenephenyl-2-(E)-methoxyiminoacetate	687248	9551	
1.3.3.4	Chenopodium album		methyl 2-[3-methyl-(2-fluoro-4-chloro-5-ethyl-sulfonamidephenyl)-4,5-dihydro-5-oxo-1H-1,2,4-triazol-4-yl]methylenephenyl-2-(E)-methoxyiminoacetate	687248	9551	
1.3.3.4	Digitaria sanguinalis		methyl 2-[3-methyl-(2-fluoro-4-chloro-5-ethyl-sulfonamidephenyl)-4,5-dihydro-5-oxo-1H-1,2,4-triazol-4-yl]methylenephenyl-2-(E)-methoxyiminoacetate	687248	9551	
1.3.3.4	Echinochloa crus-galli		methyl 2-[3-methyl-(2-fluoro-4-chloro-5-ethyl-sulfonamidephenyl)-4,5-dihydro-5-oxo-1H-1,2,4-triazol-4-yl]methylenephenyl-2-(E)-methoxyiminoacetate	687248	9551	
1.3.3.4	Setaria viridis		methyl 2-[3-methyl-(2-fluoro-4-chloro-5-ethyl-sulfonamidephenyl)-4,5-dihydro-5-oxo-1H-1,2,4-triazol-4-yl]methylenephenyl-2-(E)-methoxyiminoacetate	687248	9551	
1.3.3.4	Nicotiana tabacum		methyl 2-[5-(4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl)-6-fluoro benzothiazol-2-ylthio]acetate	724557	62246	
1.3.3.4	Homo sapiens		methyl acifluorfen	654874	79828	inhibition potency with recombinant wild-type and mutant enzymes, overview
1.3.3.4	Amaranthus retroflexus		methyl [2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]amidosulfite	687248	9539	sulfentrazone
1.3.3.4	Brassica juncea		methyl [2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]amidosulfite	687248	9539	sulfentrazone
1.3.3.4	Chenopodium album		methyl [2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]amidosulfite	687248	9539	sulfentrazone
1.3.3.4	Digitaria sanguinalis		methyl [2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]amidosulfite	687248	9539	sulfentrazone
1.3.3.4	Echinochloa crus-galli		methyl [2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]amidosulfite	687248	9539	sulfentrazone
1.3.3.4	Setaria viridis		methyl [2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]phenyl]amidosulfite	687248	9539	sulfentrazone
1.3.3.4	Homo sapiens		methyl [[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	725177	62298	
1.3.3.4	Homo sapiens		methyl [[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	100541	
1.3.3.4	Homo sapiens		methyl [[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	62261	
1.3.3.4	Homo sapiens		methyl [[6-chloro-5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl]sulfanyl]acetate	725177	62296	
1.3.3.4	Homo sapiens		more	390981		
1.3.3.4	Rattus norvegicus		more	390981		inhibited by high salt concentrations
1.3.3.4	Saccharomyces cerevisiae		more	390981, 390982		inhibited by high salt concentrations
1.3.3.4	Mus musculus		more	390990		not inhibited by sulfhydryl reagents
1.3.3.4	Mus musculus		more	390997		inhibited by peroxidizing herbizides
1.3.3.4	Saccharomyces cerevisiae		more	390997		inhibited by peroxidizing herbizides
1.3.3.4	Solanum tuberosum		more	390997		inhibited by peroxidizing herbizides
1.3.3.4	Zea mays		more	390997		inhibited by peroxidizing herbizides
1.3.3.4	Saccharomyces cerevisiae		more	391001, 391006		inhibited by diphenylether herbicides
1.3.3.4	Homo sapiens		more	391012		inhibited by diphenylether herbicides; inhibited by tetrahydrophtalimide
1.3.3.4	Bacillus subtilis		more	391016		inhibited by diphenylether herbicides
1.3.3.4	Nicotiana tabacum		more	676521		antisense RNA expression inhibits the formation of PPOX I in transgenic plants
1.3.3.4	Bacillus subtilis		more	695527		Bacillus subtilis PPO is unique because of its resistance to inhibition by diphenylethers involving residue Y366 at a site adjacent to substrate and FAD cofactor, modeling and docking studies, overview
1.3.3.4	Homo sapiens		more	696759		bioactive conformation analysis of cyclic imides as protoporphyrinogen oxidase inhibitor by combining density functional theory-based conformation calculations, quantitative structureactivity relationship analysis, and molecular docking and dynamic simulations, detailed overview
1.3.3.4	Zea mays		more	698422		5(3)-amino-N-phenyl-1H-pyrazole-4-carboxamide derivative inhibitor synthesis and structure determination by NMR and single-crystal X-ray diffraction analysis, structure-activity relationships, overview. Herbicical activity of inhibitor compounds, overview
1.3.3.4	Brassica rapa subsp. campestris		more	698439		protoporphyrinogen oxidase inhibitor activities by quantitative structure-activity relationship analysis and molecular modelling, overview. Quantitative prediction of the herbicidal activities
1.3.3.4	Myxococcus xanthus		more	699636		molecular docking and 3D QSAR studies of protoporphyrinogen oxidase inhibitor 3H-pyrazolo[3,4-d][1,2,3]triazin-4-one derivatives using crystal structure PDB ID 2IVD, detailed overview
1.3.3.4	Amaranthus retroflexus		more	711472		design, syntheses and crystal structures of N-phenyl pyrrolidin-2-ones and N-phenyl-1H-pyrrol-2-ones as protoporphyrinogen oxidase inhibitors, quantitative structure-activity relationships, overview
1.3.3.4	Brassica juncea		more	711472		design, syntheses and crystal structures of N-phenyl pyrrolidin-2-ones and N-phenyl-1H-pyrrol-2-ones as protoporphyrinogen oxidase inhibitors, quantitative structure-activity relationships, overview
1.3.3.4	Chenopodium album		more	711472		design, syntheses and crystal structures of N-phenyl pyrrolidin-2-ones and N-phenyl-1H-pyrrol-2-ones as protoporphyrinogen oxidase inhibitors, quantitative structure-activity relationships, overview
1.3.3.4	Digitaria sanguinalis		more	711472		design, syntheses and crystal structures of N-phenyl pyrrolidin-2-ones and N-phenyl-1H-pyrrol-2-ones as protoporphyrinogen oxidase inhibitors, quantitative structure-activity relationships, overview
1.3.3.4	Echinochloa crus-galli		more	711472		design, syntheses and crystal structures of N-phenyl pyrrolidin-2-ones and N-phenyl-1H-pyrrol-2-ones as protoporphyrinogen oxidase inhibitors, quantitative structure-activity relationships, overview
1.3.3.4	Eclipta prostrata		more	711472		design, syntheses and crystal structures of N-phenyl pyrrolidin-2-ones and N-phenyl-1H-pyrrol-2-ones as protoporphyrinogen oxidase inhibitors, quantitative structure-activity relationships, overview
1.3.3.4	Homo sapiens		more	711472		design, syntheses and crystal structures of N-phenyl pyrrolidin-2-ones and N-phenyl-1H-pyrrol-2-ones as protoporphyrinogen oxidase inhibitors, quantitative structure-activity relationships, overview
1.3.3.4	Setaria viridis		more	711472		design, syntheses and crystal structures of N-phenyl pyrrolidin-2-ones and N-phenyl-1H-pyrrol-2-ones as protoporphyrinogen oxidase inhibitors, quantitative structure-activity relationships, overview
1.3.3.4	Homo sapiens		more	712221		design and synthesis of benzothiazole analogues of oxadiargyl, evaluation as enzyme inhibitors, quantitative structure-activity relationships, overview. Herbicidal potencies of inhibitors in several different plants, overview
1.3.3.4	Homo sapiens		more	724554		quantitative structure-activity relationships of 1,3,4-thiadiazol-2(3H)-ones and 1,3,4-oxadiazol-2(3H)-ones as human protoporphyrinogen oxidase inhibitors, 23 1,3,4-thiadiazol-2(3H)-ones bearing benzothiazole substructure are designed and synthesized, overview
1.3.3.4	Nicotiana tabacum		more	724557		design and synthesis of 1-(benzothiazol-5-yl)-1H-1,2,4-triazol-5-ones as protoporphyrinogen oxidase inhibitors, structure-activity relationships, computational simulations and binding free energy calculations, and herbicidal activities of the compounds against weeds, overview. The substituents, e.g. F, Cl, and Br, on position 2 affect the bioactive conformation of inhibitors. No inhibition by S-6-chloro-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl]benzothiazol-2-yl O-methyl carbonothioate and S-6-chloro-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl]benzothiazol-2-yl O-ethyl carbonothioate
1.3.3.4	Homo sapiens		more	725177		design and syntheses of N-(benzothiazol-5-yl)-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione and N-(benzothiazol-5-yl)isoindoline-1,3-dione as potent protoporphyrinogen oxidase inhibitors, herbicidal activities of the compounds, overview
1.3.3.4	Homo sapiens		more	726346		mechanism of substrate recognition and feedback inhibition of protoporphyrinogen oxidase, overview
1.3.3.4	Nicotiana tabacum		more	726346		mechanism of substrate recognition and feedback inhibition of protoporphyrinogen oxidase, overview
1.3.3.4	Homo sapiens		N'-(2,4-dichlorophenyl)-2,2-dimethylpropanehydrazide	712221	100529	
1.3.3.4	Homo sapiens		N'-(2-bromo-4-fluorophenyl)-2,2-dimethylpropanehydrazide	712221	100531	
1.3.3.4	Homo sapiens		N'-(4-chloro-2-fluorophenyl)-2,2-dimethylpropanehydrazide	712221	100530	
1.3.3.4	Homo sapiens		N-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-4-fluorophenylcarbamoyl)-3-(trifluoromethoxy)benzamide	696759	53072	
1.3.3.4	Homo sapiens		N-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-4-fluorophenylcarbamoyl)benzamide	696759	53071	
1.3.3.4	Homo sapiens		N-(2-chloro-5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)phenylcarbamoyl)benzamide	696759	53074	
1.3.3.4	Mus musculus		N-(4-chloro-2-fuoro-5-(propargyloxy)phenyl)-3,4,5,6-tetrahydrophthalimide	391003		S-23142, reversible, Kd: 0.41 nM
1.3.3.4	Chlamydomonas reinhardtii		N-(4-chloro-2-fuoro-5-(propargyloxy)phenyl)-3,4,5,6-tetrahydrophthalimide	391010		
1.3.3.4	Spinacia oleracea		N-(4-chloro-2-fuoro-5-(propargyloxy)phenyl)-3,4,5,6-tetrahydrophthalimide	391014, 391015		
1.3.3.4	Desulfovibrio gigas		N-ethylmaleimide	390988	46	
1.3.3.4	Mus musculus		N-ethylmaleimide	390990	46	no inhibition
1.3.3.4	Mus musculus		N-Methylprotoporphyrin	390990	4932	slight, 11% inhibition at 0.0001 mM
1.3.3.4	Bacillus subtilis		NaCl	654950	39	inhibits recombinant wild-type enzyme and mutant V311M
1.3.3.4	Hordeum vulgare		NAD(P)H	390998	5	
1.3.3.4	Zea mays		NADH	654442	3	inhibits activity of N-terminally processed-like enzyme form
1.3.3.4	Zea mays		NADPH	654442	5	inhibits activity of N-terminally processed-like enzyme form
1.3.3.4	Hordeum vulgare		o-phenanthroline	390998	58	in presence of glutathione
1.3.3.4	Amaranthus retroflexus		oxadiargyl	711472	111732	derived from chlorphthalim
1.3.3.4	Brassica juncea		oxadiargyl	711472	111732	derived from chlorphthalim
1.3.3.4	Chenopodium album		oxadiargyl	711472	111732	derived from chlorphthalim
1.3.3.4	Digitaria sanguinalis		oxadiargyl	711472	111732	derived from chlorphthalim
1.3.3.4	Echinochloa crus-galli		oxadiargyl	711472	111732	derived from chlorphthalim
1.3.3.4	Eclipta prostrata		oxadiargyl	711472	111732	derived from chlorphthalim
1.3.3.4	Homo sapiens		oxadiargyl	711472	111732	derived from chlorphthalim
1.3.3.4	Setaria viridis		oxadiargyl	711472	111732	derived from chlorphthalim
1.3.3.4	Homo sapiens		oxadiargyl	712221	111732	i.e. 3-[2,4-dichloro-5-(2-propynyloxy)phenyl]-5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-(3H)-one, an important PPO-inhibiting commercial herbicide
1.3.3.4	Myxococcus xanthus		oxadiazon	689348, 689352	4701	
1.3.3.4	Amaranthus retroflexus		oxadiazon	711472	4701	derived from chlorphthalim
1.3.3.4	Brassica juncea		oxadiazon	711472	4701	derived from chlorphthalim
1.3.3.4	Chenopodium album		oxadiazon	711472	4701	derived from chlorphthalim
1.3.3.4	Digitaria sanguinalis		oxadiazon	711472	4701	derived from chlorphthalim
1.3.3.4	Echinochloa crus-galli		oxadiazon	711472	4701	derived from chlorphthalim
1.3.3.4	Eclipta prostrata		oxadiazon	711472	4701	derived from chlorphthalim
1.3.3.4	Homo sapiens		oxadiazon	711472	4701	derived from chlorphthalim
1.3.3.4	Setaria viridis		oxadiazon	711472	4701	derived from chlorphthalim
1.3.3.4	Homo sapiens		oxadiazon	724554	4701	
1.3.3.4	Bacillus subtilis		oxyfluorfen	654950	5733	a diphenyl ether herbicide, competitive, the mutant V311M is slightly less sensitive to inhibition than the wild-type enzyme, inhibition kinetics
1.3.3.4	Bacillus subtilis		oxyfluorfen	672499	5733	26% less inhibition is found in T3 transgenic lines
1.3.3.4	Oryza sativa		oxyfluorfen	672499	5733	0.01 mM inhibits growth of wild-type rice by 70%, but 26% less inhibition is found in T3 transgenic lines, photodynamic injury symptoms such as chlorosis and leaf rolling are obvious in wild-type, but not observed in transgenic lines
1.3.3.4	Myxococcus xanthus		oxyfluorfen	676642	5733	increased herbicidal resistance resulting from dual expression of Myxococcus xanthus Protox in chloroplasts and mitochondria of transgenic rice
1.3.3.4	Oryza sativa		oxyfluorfen	676642	5733	wild-type is characterized by necrotic leaf lesions and increases in conductivity and malonyldialdehyde levels, whereas transgenic lines M4 and M7 do not show any change with up to 0.1 mM, transgenic plants suffer less oxidative stress, confirming increased herbicidal resistance results from dual expression of Myxococcus xanthus Protox in chloroplasts and mitochondria
1.3.3.4	Myxococcus xanthus		oxyfluorfen	689348, 689352	5733	
1.3.3.4	Myxococcus xanthus		oxyfuorfen	676307	5733	all wild-type and transgenic rice lines have a significant decrease in Protox activity, all transgenic rice lines expressing native Protox show enhanced resistance to oxyfluorfen as compared to nontransgenic rice
1.3.3.4	synthetic construct		oxyfuorfen	676307	5733	all wild-type and transgenic rice lines have a significant decrease in Protox activity, all transgenic rice lines expressing modified Protox show enhanced resistance to oxyfluorfen as compared to nontransgenic rice
1.3.3.4	Myxococcus xanthus		oxyXuorfen	676308	5733	transgenic rice lines TTS3 and TTS4 exhibit a reduced Protox activity, however, it is much greater than that of uninhibited Protox activity of wild type, seeds from all transgenic lines are able to germinate when treated with up to 0.5 mM, whereas seeds from the wild-type fail to germinate even when treated at levels as low as 0.001 mM, great accumulation of photodynamic protoporphyrin IX only in oxyfuorfen-treated wild-type plants, not in oxyfuorfen-treated TTS lines
1.3.3.4	Rattus norvegicus		p-hydroxymercuribenzoate	390981	92	more than 90% inhibition at 0.5 mM
1.3.3.4	Saccharomyces cerevisiae		p-hydroxymercuribenzoate	390981, 390982	92	
1.3.3.4	Myxococcus xanthus		paraquat	689352	302	
1.3.3.4	Amaranthus retroflexus		pentoxazone	711472	111737	derived from chlorphthalim
1.3.3.4	Brassica juncea		pentoxazone	711472	111737	derived from chlorphthalim
1.3.3.4	Chenopodium album		pentoxazone	711472	111737	derived from chlorphthalim
1.3.3.4	Digitaria sanguinalis		pentoxazone	711472	111737	derived from chlorphthalim
1.3.3.4	Echinochloa crus-galli		pentoxazone	711472	111737	derived from chlorphthalim
1.3.3.4	Eclipta prostrata		pentoxazone	711472	111737	derived from chlorphthalim
1.3.3.4	Homo sapiens		pentoxazone	711472	111737	derived from chlorphthalim
1.3.3.4	Setaria viridis		pentoxazone	711472	111737	derived from chlorphthalim
1.3.3.4	Homo sapiens		phenyl 2-[[5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]propanoate	725177	62284	
1.3.3.4	Homo sapiens		phenyl 2-[[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]propanoate	725177	62299	
1.3.3.4	Homo sapiens		phenyl 2-[[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl]-2-methylpropanoate	724554	103020	
1.3.3.4	Homo sapiens		phenyl 2-[[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl]propanoate	724554	103019	
1.3.3.4	Homo sapiens		phenyl 2-[[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]-2-methylpropanoate	724554	103013	
1.3.3.4	Homo sapiens		phenyl 2-[[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]propanoate	724554	103012	
1.3.3.4	Homo sapiens		phenyl 2-[[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl]-2-methylpropanoate	724554	62271	
1.3.3.4	Homo sapiens		phenyl 2-[[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl]propanoate	724554	62270	
1.3.3.4	Homo sapiens		phenyl 2-[[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]-2-methylpropanoate	724554	62263	
1.3.3.4	Homo sapiens		phenyl 2-[[6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl]-2-methylpropanoate	724554	103025	
1.3.3.4	Homo sapiens		phenyl 2-[[6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl]propanoate	724554	103024	
1.3.3.4	Homo sapiens		phenyl 2-[[6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl]-2-methylpropanoate	724554	62277	
1.3.3.4	Homo sapiens		phenyl 2-[[6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl]propanoate	724554	62276	
1.3.3.4	Homo sapiens		phenyl 2-[[6-chloro-5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl]sulfanyl]-2-methylpropanoate	725177	62293	
1.3.3.4	Homo sapiens		phenyl 2-[[6-chloro-5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl]sulfanyl]propanoate	725177	62292	
1.3.3.4	Homo sapiens		phenyl 2-[[6-chloro-5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl]sulfanyl]propanoate	725177	62303	
1.3.3.4	Homo sapiens		phenyl 3-[[5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]propanoate	725177	62288	
1.3.3.4	Homo sapiens		phenyl 3-[[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]propanoate	725177	62302	
1.3.3.4	Homo sapiens		phenyl 3-[[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl]propanoate	724554	103021	
1.3.3.4	Homo sapiens		phenyl 3-[[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl]propanoate	724554	62272	
1.3.3.4	Homo sapiens		phenyl 3-[[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]propanoate	724554	28445	
1.3.3.4	Homo sapiens		phenyl 3-[[6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl]propanoate	724554	103026	
1.3.3.4	Homo sapiens		phenyl 3-[[6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl]propanoate	724554	62278	
1.3.3.4	Homo sapiens		phenyl 3-[[6-chloro-5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl]sulfanyl]propanoate	725177	62294	
1.3.3.4	Homo sapiens		phenyl 3-[[6-chloro-5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl]sulfanyl]propanoate	725177	62304	
1.3.3.4	Homo sapiens		phenyl 4-[[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl]butanoate	724554	103022	
1.3.3.4	Homo sapiens		phenyl 4-[[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]butanoate	724554	103015	
1.3.3.4	Homo sapiens		phenyl 4-[[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl]butanoate	724554	62273	
1.3.3.4	Homo sapiens		phenyl 4-[[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]butanoate	724554	62266	
1.3.3.4	Homo sapiens		phenyl 4-[[6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl]butanoate	724554	103027	
1.3.3.4	Homo sapiens		phenyl 4-[[6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl]butanoate	724554	62279	
1.3.3.4	Homo sapiens		phenyl 4-[[6-chloro-5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl]sulfanyl]butanoate	725177	62295	
1.3.3.4	Homo sapiens		phenyl [[5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	725177	62283	
1.3.3.4	Homo sapiens		phenyl [[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	103018	
1.3.3.4	Homo sapiens		phenyl [[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	103014	
1.3.3.4	Homo sapiens		phenyl [[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	62269	
1.3.3.4	Homo sapiens		phenyl [[6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	103023	
1.3.3.4	Homo sapiens		phenyl [[6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	62275	
1.3.3.4	Homo sapiens		phenyl [[6-chloro-5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl]sulfanyl]acetate	725177	62291	
1.3.3.4	Mus musculus		phosphatidylcholine	34955	190	from egg and soybean
1.3.3.4	Homo sapiens		propan-2-yl ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		propan-2-yl ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		propan-2-yl ([6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		propan-2-yl [[5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	725177	62285	
1.3.3.4	Homo sapiens		propan-2-yl [[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	725177	62300	
1.3.3.4	Homo sapiens		propan-2-yl [[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	100544	
1.3.3.4	Homo sapiens		propan-2-yl [[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	62264	
1.3.3.4	Homo sapiens		propyl ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		propyl ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		propyl ([6-bromo-5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		propyl [[5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	725177	62287	
1.3.3.4	Homo sapiens		propyl [[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	725177	62301	
1.3.3.4	Homo sapiens		propyl [[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	100543	
1.3.3.4	Homo sapiens		propyl [[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	724554	62265	
1.3.3.4	Bos taurus		protoporphyrinogen-IX	390992	545	substrate inhibition above 0.05 mM
1.3.3.4	Homo sapiens		S-(5-(1,3-dioxo-4,5,6,7-tetrahydro-1H-isoindol-2(3H)-yl)-6-fluorobenzothiazol-2-yl) O-methyl carbonothioate	725177	62281	
1.3.3.4	Nicotiana tabacum		S-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl]-6-fluorobenzothiazol-2-yl O-ethyl carbonothioate	724557	62245	
1.3.3.4	Nicotiana tabacum		S-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl]-6-fluorobenzothiazol-2-yl O-methyl carbonothioate	724557	62244	
1.3.3.4	Nicotiana tabacum		S-6-chloro-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl]benzothiazol-2-yl O-ethyl carbonothioate	724557	103011	
1.3.3.4	Nicotiana tabacum		S-6-chloro-5-[4-difluoromethyl-3-methyl-5-oxo-4,5-dihydro-1,2,4-triazol-1-yl]benzothiazol-2-yl O-methyl carbonothioate	724557	103010	
1.3.3.4	Homo sapiens		S-[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl] O-phenyl carbonothioate	725177	62297	
1.3.3.4	Homo sapiens		S-[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl] O-ethyl carbonothioate	712221	58532	
1.3.3.4	Homo sapiens		S-[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl] O-phenyl carbonothioate	724554	103017	
1.3.3.4	Homo sapiens		S-[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl] O-ethyl carbonothioate	712221, 724554	27629	
1.3.3.4	Homo sapiens		S-[5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl] O-methyl carbonothioate	712221	58534	
1.3.3.4	Homo sapiens		S-[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl] O-phenyl carbonothioate	724554	62268	
1.3.3.4	Homo sapiens		S-[5-(5-tert-butyl-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl] O-ethyl carbonothioate	724554	62260	
1.3.3.4	Homo sapiens		S-[6-chloro-5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl] O-methyl carbonothioate	725177	62289	
1.3.3.4	Homo sapiens		S-[6-chloro-5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl] O-phenyl carbonothioate	725177	62290	
1.3.3.4	Pythium aphanidermatum		sulfentrazone	676391	3075	90% inhibition of in vitro mycelial growth, colonization of sugarcane is increased if applied to fiel soils
1.3.3.4	Pythium arrhenomanes		sulfentrazone	676391	3075	inhibits the in vitro mycelial growth, colonization of sugarcane is increased if applied to fiel soils
1.3.3.4	Pythium ultimum		sulfentrazone	676391	3075	99% inhibition of in vitro mycelial growth, colonization of sugarcane is increased if applied to field soils
1.3.3.4	Saccharum officinarum		sulfentrazone	676391	3075	only minor necrosis of Pythium arrhenomanes-infested steamed field soil and field soil plants
1.3.3.4	Amaranthus retroflexus		sulfentrazone	711472	3075	derived from chlorphthalim
1.3.3.4	Brassica juncea		sulfentrazone	711472	3075	derived from chlorphthalim
1.3.3.4	Chenopodium album		sulfentrazone	711472	3075	derived from chlorphthalim
1.3.3.4	Digitaria sanguinalis		sulfentrazone	711472	3075	derived from chlorphthalim
1.3.3.4	Echinochloa crus-galli		sulfentrazone	711472	3075	derived from chlorphthalim
1.3.3.4	Eclipta prostrata		sulfentrazone	711472	3075	derived from chlorphthalim
1.3.3.4	Homo sapiens		sulfentrazone	711472	3075	derived from chlorphthalim
1.3.3.4	Setaria viridis		sulfentrazone	711472	3075	derived from chlorphthalim
1.3.3.4	Homo sapiens		sulfentrazone	712221	3075	
1.3.3.4	Nicotiana tabacum		sulfentrazone	724557	3075	
1.3.3.4	Homo sapiens		tert-butyl ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-chloro-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		tert-butyl ([5-(5-tert-butyl-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl)acetate	712221		
1.3.3.4	Homo sapiens		tert-butyl [[5-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)-6-fluoro-1,3-benzothiazol-2-yl]sulfanyl]acetate	725177	62286	
1.3.3.4	Mus musculus		Ubiquinone-10	390994	3850	above 0.03 mM
1.3.3.4	Mus musculus		ubiquinone-6	390994	4097	above 0.03 mM
1.3.3.4	Zea mays		[2-chloro-4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)phenoxy]acetonitrile	698422	26050	
1.3.3.4	Brassica rapa subsp. campestris		[2-chloro-4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)phenoxy]acetonitrile	698439	26050	
1.3.3.4	Myxococcus xanthus		[2-chloro-4-fluoro-5-(7-methyl-4-oxo-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazin-3-yl)phenoxy]acetonitrile	699636	26050	
1.3.3.4	Mus musculus		[5-(t-butyl)-3-(2,4-dichloro-5-isopropoxyphenyl)-1,3,4-oxadiazol-2-one]	390997	4701	peroxidizing herbizides
1.3.3.4	Saccharomyces cerevisiae		[5-(t-butyl)-3-(2,4-dichloro-5-isopropoxyphenyl)-1,3,4-oxadiazol-2-one]	390997	4701	peroxidizing herbizides
1.3.3.4	Solanum tuberosum		[5-(t-butyl)-3-(2,4-dichloro-5-isopropoxyphenyl)-1,3,4-oxadiazol-2-one]	390997	4701	peroxidizing herbizides
1.3.3.4	Zea mays		[5-(t-butyl)-3-(2,4-dichloro-5-isopropoxyphenyl)-1,3,4-oxadiazol-2-one]	390997	4701	peroxidizing herbizides
2.7.9.2	Zea mays	more		721927		the DUF99-encoded protein catalyzes both the ADP-dependent inactivation and the Pi-dependent activation of phosphoenolpyruvate synthetase
2.7.9.2	Escherichia coli		2-oxoglutarate	645472, 645473	32	
2.7.9.2	Thermoproteus tenax		2-oxoglutarate	676065	32	strong inhibition at 1 mM
2.7.9.2	Escherichia coli		3-phosphoglyceraldehyde	645472	473	
2.7.9.2	Escherichia coli		3-phosphoglyceraldehyde	645473	473	weak
2.7.9.2	Escherichia coli		5'-adenylylmethylene diphosphonate	645469	3780	competitive to ATP
2.7.9.2	Escherichia coli		ADP	645472, 645473	8	
2.7.9.2	Thermoproteus tenax		ADP	676065	8	strong inhibition at 1 mM
2.7.9.2	Escherichia coli		ADP-glucose	645473	493	weak
2.7.9.2	Escherichia coli		AMP	645473	9	
2.7.9.2	Thermoproteus tenax		AMP	676065	9	strong inhibition at 1 mM
2.7.9.2	Escherichia coli		ATP	645468	7	excess of ATP inhibits at high concentrations of MgCl2 or MnCl2
2.7.9.2	Escherichia coli		Ca2+	645468	18	inhibits Mn2+-activated enzyme
2.7.9.2	Escherichia coli		F-	645470	158	
2.7.9.2	Escherichia coli		iodoacetate	645468	87	
2.7.9.2	Escherichia coli		malate	645473	246	
2.7.9.2	Escherichia coli		Mg2+	645468	25	divalent metal ion Mg2+ or Mn2+ required for forward reaction, inhibition at high concentrations of Mg2+ or Mn2+
2.7.9.2	Escherichia coli		Mn2+	645468	26	divalent metal ion Mg2+ or Mn2+ required for forward reaction, inhibition at high concentrations of Mg2+ or Mn2+
2.7.9.2	Escherichia coli		more	645470		no inhibition by arsenate
2.7.9.2	Pyrococcus furiosus		more	645478		not affected by Na+
2.7.9.2	Escherichia coli		oxalacetate	645472, 645473	53	
2.7.9.2	Escherichia coli		PCMB	645468	40	
2.7.9.2	Escherichia coli		phosphoenolpyruvate	645473	47	competitive to ATP
2.7.9.2	Escherichia coli		sulfhydryl reagents	645468	752	
6.3.4.13	Enterobacter aerogenes		ADP	1404	8	
6.3.4.13	Enterobacter aerogenes		EDTA	1404	223	
6.3.4.13	Enterobacter aerogenes		NaF	1404	209	
6.3.4.13	Enterobacter aerogenes		PCMB	1404	40	
5.3.1.24	Escherichia coli		1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	4611	747	product inhibition
5.3.1.24	Hansenula henricii		CoCl2	648883	347	0.001 mM, 20% inhibition
5.3.1.24	Hansenula henricii		CuSO4	648883	228	0.001 mM, 100% inhibition
5.3.1.24	Hansenula henricii		MnCl2	648883	262	0.001 mM, 45% inhibition
5.3.1.24	Escherichia coli		more	4611		not inhibited by indoleglycerol phosphate
5.3.1.24	Escherichia coli		more	638666		chemically synthesized N-(5-phospho-beta-D-ribosyl)anthranilate contains inhibitors, but not if it is generated by anthranilate phosphoribosyltransferase
5.3.1.24	Acinetobacter calcoaceticus		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	648872		
5.3.1.24	Bacillus subtilis		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	648872		
5.3.1.24	Brevibacterium flavum		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	648872		
5.3.1.24	Pseudomonas putida		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	648872		
5.3.1.24	Salmonella enterica subsp. enterica serovar Typhimurium		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	648872		
5.3.1.24	Serratia marcescens		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	648872		
5.3.1.24	Escherichia coli		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	4611, 648873		competitive inhibitor
5.3.1.24	Saccharomyces cerevisiae		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	4611, 648873		competitive inhibitor
5.3.1.24	Escherichia coli		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	648872, 648876		
5.3.1.24	Thermotoga maritima		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	648887		binds reversibly; competitive inhibitor
6.3.3.1	Escherichia coli		1-(5-phosphoribosyl)-5-aminoimidazole	1308	3629	
6.3.3.1	Escherichia coli		ADP	1308	8	
6.3.3.1	Saccharomyces cerevisiae		AMP	1316	9	competitive to ATP
6.3.3.1	Escherichia coli		fluorosulfonylbenzoyl adenosine	649909	5401	FSBA, time-dependent inactivation by covalent binding to Lys27
6.3.3.1	Escherichia coli		phosphate	1308	12	
6.3.2.6	Escherichia coli		adenosine 5'-(beta,gamma-imido)triphosphate	661204	2889	
6.3.2.6	Escherichia coli		IMP	661204	206	competitive with respect to 1-(5'-phosphoribosyl)-5-amino-4-carboxyimidazole
6.3.2.6	Escherichia coli		Maleate	661204	474	competitive with respect to L-Asp
6.3.2.6	Gallus gallus		PCMB	1263	40	
6.3.5.3	Gallus gallus		6-diazo-5-oxo-L-norleucine	1666	666	competitive analogue of Gln binds irreversibly at the Gln active site
6.3.5.3	Gallus gallus		6-diazo-5-oxo-L-norleucine	1665, 1667	666	
6.3.5.3	Gallus gallus		ADP	1667	8	
6.3.5.3	Gallus gallus		albizziin	1665	7122	
6.3.5.3	Gallus gallus		albizziin	1666	7122	competitive analogue of Gln binds irreversibly at the Gln active site
6.3.5.3	Gallus gallus		albizziin	1667	7122	presence of beta-5'-phosphoribosylformylglycinamide, ATP, and Mg2+ inhibits inactivation
6.3.5.3	Escherichia coli		albizziin	1670	7122	
6.3.5.3	Gallus gallus		beta-gamma-5'-Adenylyl methylene diphosphate	1667	2691	
6.3.5.3	Gallus gallus		Cyanate	1666, 1667	1039	
6.3.5.3	Mus musculus		Glu	1668	38	noncompetitive with respect to Gln, competitive with respect to ATP, uncompetitive with respect to 5'-phosphoribosylformylglycinamide
6.3.5.3	Escherichia coli		Glu	1670	38	
6.3.5.3	Gallus gallus		hydroxylamine	1666, 1667	80	
6.3.5.3	Gallus gallus		iodoacetamide	1665, 1666	63	
6.3.5.3	Gallus gallus		iodoacetamide	1667	63	rate of inactivation is 20-30times greater in the presence than in the absence of beta-5'-phosphoribosylformylglycinamide, ATP, and Mg2+
6.3.5.3	Gallus gallus		iodoacetate	1665, 1666	87	
6.3.5.3	Gallus gallus		iodoacetate	1667	87	rate of inactivation is 20-30times greater in the presence than in the absence of beta-5'-phosphoribosylformylglycinamide, ATP, and Mg2+
6.3.5.3	Gallus gallus		L-2-Amino-4-oxo-5-chloropentanoic acid	1667	4073	
6.3.5.3	Gallus gallus		Na+	1667	55	
6.3.5.3	Gallus gallus		O-diazoacetyl-L-Ser	1666	1381	i.e. L-azaserine, competitive analogue of Gln binds irreversibly at the Gln active site
6.3.5.3	Gallus gallus		O-diazoacetyl-L-Ser	1665, 1667	1381	
4.3.2.2	Leishmania donovani		2'-deoxy-AMP	1541	575	
4.3.2.2	Mus musculus		2'-deoxy-AMP	34457	575	competitive
4.3.2.2	Leishmania donovani		4-aminopyrazolo[3,4-d]pyrimidine ribose 5'-phosphate	1541	29967	
4.3.2.2	Plasmodium falciparum		5-aminoimidazole-4-carboxamide ribonucleoside	691116	4145	50% inhibition at 0.167 mM
4.3.2.2	Homo sapiens		5-aminoimidazole-4-carboxamide riboside 5'-monophosphate	693982	5013	i.e. ZMP or AICAR, product inhibition, accumulation in the brain of Lesch-Nyhan disease patients induces inhibition of mitochondrial oxidative phosphorylation and adenylosuccinate lyase activity, followed by dowregulation of ATP levels and multifocal cell death in the cerebellum
4.3.2.2	Leishmania donovani		8-Aza-AMP	1541	20136	
4.3.2.2	Bacillus subtilis		adenosine phosphonobutyric acid, 2'(3'),5'-diphosphate	695003	17373	i.e. APBADP, the non-cleavable substrate analogue acts as a competitive inhibitor with respect to either substrate. ASL binds up to 4 mol of APBADP per mole of enzyme tetramer, the enzyme exhibits negative cooperativity. Binding to enzyme mutants, overview
4.3.2.2	Homo sapiens		adenosine phosphonobutyric acid, 2'(3'),5'-diphosphate	695003	17373	i.e. APBADP, the non-cleavable substrate analogue acts as a competitive inhibitor with respect to either substrate. ASL binds up to 4 mol of APBADP per mole of enzyme tetramer, the enzyme exhibits positive cooperativity
4.3.2.2	Rattus norvegicus		adenyloethylphosphonate	34456	67045	
4.3.2.2	Rattus norvegicus		adenylophosphonobutyrate	34456		
4.3.2.2	Homo sapiens		adenylosuccinate 2',3'-acyclic (N,N-ethyl) diamine	34465	66157	weak
4.3.2.2	Homo sapiens		adenylosuccinate 2',3'-acyclic dialcohol	34465	30024	
4.3.2.2	Homo sapiens		adenylosuccinate 2',3'-acyclic dialdehyde	34465	30025	
4.3.2.2	Mus musculus		ADP	34457	8	weak, competitive
4.3.2.2	Saccharomyces cerevisiae		ammonium salt of N6-malonyl adenosine 5'-phosphate	34463	67066	noncompetitive inhibitor, irreversible
4.3.2.2	Leishmania donovani		AMP	1541	9	competitive
4.3.2.2	Artemia sp.		AMP	34451	9	competitive
4.3.2.2	Mus musculus		AMP	34457	9	
4.3.2.2	Homo sapiens		AMP	34461	9	
4.3.2.2	Plasmodium falciparum		AMP	691116	9	product inhibition competitive versus succinyladenosine monophosphate
4.3.2.2	Leishmania donovani		arabinosyl-AMP	1541	20202	
4.3.2.2	Mus musculus		arabinosyl-AMP	34457	20202	beta-D-arabinosyl-AMP, competitive
4.3.2.2	Mus musculus		ATP	34457	7	weak, competitive
4.3.2.2	Homo sapiens		CuSO4	730526	228	complete inhibition at 0.05 mM
4.3.2.2	Rattus norvegicus		DL-3-phosphonoalanine	34456	13648	
4.3.2.2	Leishmania donovani		EDTA	1541	223	above 15 mM
4.3.2.2	Rattus norvegicus		erythro-beta-fluoro-4-(N-succino)-5-aminoimidazole-4-carboxamide ribonucleotide	34449	66385	
4.3.2.2	Rattus norvegicus		erythro-beta-fluoroadenylosuccinate	34449	66386	
4.3.2.2	Rattus norvegicus		erythro-beta-fluoroaspartate	34449	66387	
4.3.2.2	Leishmania donovani		fumarate	1541	156	noncompetitive
4.3.2.2	Artemia sp.		fumarate	34451	156	noncompetitive
4.3.2.2	Homo sapiens		fumarate	34461	156	noncompetitive
4.3.2.2	Rattus norvegicus		I-	34449	422	100-200 mM
4.3.2.2	Bacillus subtilis		KBr	690934	1987	presence of increasing concentrations of KBr of 0.12.5 M disrupt electrostatic interactions leading to ASL dissociation and loss of catalytic activity
4.3.2.2	Artemia sp.		KCl	34451	74	stimulates up to maximum concentration of 80 mM, inhibition at higher concentration
4.3.2.2	Rattus norvegicus		L-Asp	34456	91	
4.3.2.2	Rattus norvegicus		mercaptopurinosuccinate	34456	20986	substrate inhibition
4.3.2.2	Mus musculus		Mg2+	34457	25	concentration of Mg2+ approaching that of EDTA
4.3.2.2	Leishmania donovani		MgCl2	1541	176	
4.3.2.2	Bacillus subtilis		more	664255		dithiothreitol increases inhibition of trans-4-hydroxy-2-nonenal; hydroxylamine reverses inhibition of trans-4-hydroxy-2-nonenal
4.3.2.2	Homo sapiens		more	664255		dithiothreitol increases inhibition of trans-4-hydroxy-2-nonenal; hydroxylamine reverses inhibition of trans-4-hydroxy-2-nonenal
4.3.2.2	Pyrobaculum aerophilum		more	664255		dithiothreitol increases inhibition of trans-4-hydroxy-2-nonenal; hydroxylamine reverses inhibition of trans-4-hydroxy-2-nonenal
4.3.2.2	Thermotoga maritima		more	664255		dithiothreitol increases inhibition of trans-4-hydroxy-2-nonenal; hydroxylamine reverses inhibition of trans-4-hydroxy-2-nonenal
4.3.2.2	Bacillus subtilis		more	690934		as hydrophobic interactions are weakened at 8&deg;C and 4&deg;C, the catalytic activity of ASL decreases strikingly and the enzyme dissociates to a mixture of monomer-dimer-trimer, with small amounts of tetramer
4.3.2.2	Saccharomyces cerevisiae		N-(5-amino-1-(beta-D-ribofuranosyl)imidazole-4-carbonyl)-L-threo-beta-methylaspartic acid 5'-phosphate	34467		
4.3.2.2	Rattus norvegicus		N6-(2-carboxyethyl)-AMP	34456	65127	i.e. adenylopropionate
4.3.2.2	Rattus norvegicus		N6-(D-1,2-dicarboxyethyl)-AMP	34456	65129	i.e. D-adenylosuccinate
4.3.2.2	Rattus norvegicus		N6-(D-1,2-dicarboxypropyl)-AMP	34456		i.e. adenyloglutarate
4.3.2.2	Rattus norvegicus		N6-(DL-1,2-dicarboxy-threo-2-hydroxyethyl)-AMP	34456	65130	i.e. adenylomalate
4.3.2.2	Rattus norvegicus		N6-(DL-1-carboxy-2-phosphonoethyl)AMP	34456	65131	i.e. adenylophosphonopropionate
4.3.2.2	Rattus norvegicus		N6-(L-1-carboxy-2-cyanoethyl)-AMP	34456	65132	i.e. adenylocyanopropionate
4.3.2.2	Rattus norvegicus		N6-(L-1-carboxy-2-methylsulfoxyethyl)-AMP	34456	65133	i.e. adenylomethylsulfoxypropionate
4.3.2.2	Saccharomyces cerevisiae		N6-(L-1-carboxy-2-nitroethyl)-AMP	1538	65134	competitive
4.3.2.2	Rattus norvegicus		N6-(L-1-carboxy-2-sulfinoethyl)-AMP	34456	65135	i.e. adenylosulfinopropionate
4.3.2.2	Rattus norvegicus		N6-(L-1-carboxy-2-sulfoethyl)-AMP	34456	66644	i.e. adenylosulfopropionate
4.3.2.2	Saccharomyces cerevisiae		nitroacrylate	1538	67206	0.02 mM, 70% inactivation
4.3.2.2	Rattus norvegicus		NO3-	34449	263	100-200 mM
4.3.2.2	Bacillus subtilis		nonenal	664255	1739	
4.3.2.2	Homo sapiens		nonenal	664255	1739	
4.3.2.2	Pyrobaculum aerophilum		nonenal	664255	1739	
4.3.2.2	Thermotoga maritima		nonenal	664255	1739	
4.3.2.2	Leishmania donovani		phosphate	1541	12	competitive
4.3.2.2	Rattus norvegicus		phosphopropionoadenosine	34456		
4.3.2.2	Rattus norvegicus		PO43-	34449	684	activates at low concentration, inhibits at high concentrations above 25 mM
4.3.2.2	Rattus norvegicus		SO42-	34449	148	activates at low concentrations, inhibits at concentrations above 25 mM
4.3.2.2	Rattus norvegicus		threo-beta-4-(N-succino)-5-aminoimidazole-4-carboxamide ribonucleotide	34449, 34450		
4.3.2.2	Rattus norvegicus		threo-beta-fluoroadenylosuccinate	34449, 34450	30464	
4.3.2.2	Bacillus subtilis		trans-4-hydroxy-2-nonenal	664255	1076	10-15 &micro;M, inhibitor reacts both with the free enzyme and the enzme substrate complex
4.3.2.2	Homo sapiens		trans-4-hydroxy-2-nonenal	664255	1076	10-15 &micro;M, inhibitor reacts both with the free enzyme and the enzme substrate complex
4.3.2.2	Pyrobaculum aerophilum		trans-4-hydroxy-2-nonenal	664255	1076	10-15 &micro;M, inhibitor reacts both with the free enzyme and the enzme substrate complex
4.3.2.2	Thermotoga maritima		trans-4-hydroxy-2-nonenal	664255	1076	10-15 &micro;M, inhibitor reacts both with the free enzyme and the enzme substrate complex
4.3.2.2	Saccharomyces cerevisiae		virazole 5'-phosphate	34467	3985	
2.5.1.19	Klebsiella pneumoniae	Br-		638181	285	stimulation at low concentrations, inhibition above 200 mM
2.5.1.19	Klebsiella pneumoniae	Cl-		638181	134	activation up to 100 mM, inhibition above
2.5.1.19	Sorghum bicolor	Cl-		638187	134	at about 100 mM
2.5.1.19	Klebsiella pneumoniae	F-		638181	158	stimulation
2.5.1.19	Sorghum bicolor	F-		638187	158	stimulation
2.5.1.19	Klebsiella pneumoniae	I-		638181	422	stimulation at low concentrations, inhibition above 100 mM
2.5.1.19	Klebsiella pneumoniae	NH4Cl		638181	282	stimulation, inhibition above 300 mM
2.5.1.19	Bacillus subtilis	NH4Cl		638199	282	maximal activation at 100 mM
2.5.1.19	Streptococcus pneumoniae	NH4Cl		638202	282	strong activation of forward reaction, effectiveness of activation in descending order: NH4Cl, Rb+, K+
2.5.1.19	Klebsiella pneumoniae	NO3-		638181	263	stimulation at low concentrations, inhibition above 15 mM
2.5.1.19	Sorghum bicolor	NO3-		638187	263	stimulation at low concentrations, inhibition above 15 mM
2.5.1.19	Sorghum bicolor	SO42-		638187	148	slight stimulation, inhibition above 50 mM
2.5.1.19	Agrobacterium sp.		(3R,4S,5R)-4-hydroxy-5-[(2R)-1-hydroxy-1-oxo-2-phosphono-propan-2-yl]oxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9610	RP-TI, (R)-phosphonate analogue of the (S)-tetrahedral reaction intermediate, competitive inhibitor of EPSPS forward reaction, 460fold decrease in potency compared to glyphosate-sensitive class I EPSPS from Escherichia coli
2.5.1.19	Escherichia coli		(3R,4S,5R)-4-hydroxy-5-[(2R)-1-hydroxy-1-oxo-2-phosphono-propan-2-yl]oxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9610	RP-TI, (R)-phosphonate analogue of the (S)-tetrahedral reaction intermediate, very potent competitive inhibitor of EPSPS forward reaction, binding induces substantial conformational change in enzymes backbone and active site (e.g., Glu341 and Arg124)
2.5.1.19	Staphylococcus aureus		(3R,4S,5R)-4-hydroxy-5-[(2R)-1-hydroxy-1-oxo-2-phosphono-propan-2-yl]oxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9610	RP-TI, (R)-phosphonate analogue of the (S)-tetrahedral reaction intermediate, competitive inhibitor of EPSPS forward reaction, 120-fold decrease in potency compared to glyphosate-sensitive class I EPSPS from Escherichia coli
2.5.1.19	Agrobacterium sp.		(3R,4S,5R)-4-hydroxy-5-[(2S)-1-hydroxy-1-oxo-2-phosphono-propan-2-yl]oxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9611	SP-TI, (S)-phosphonate analogue of the (S)-tetrahedral reaction intermediate, non-potent competitive inhibitor of EPSPS forward reaction
2.5.1.19	Escherichia coli		(3R,4S,5R)-4-hydroxy-5-[(2S)-1-hydroxy-1-oxo-2-phosphono-propan-2-yl]oxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9611	SP-TI, (S)-phosphonate analogue of the (S)-tetrahedral reaction intermediate, moderate competitive inhibitor of EPSPS forward reaction
2.5.1.19	Staphylococcus aureus		(3R,4S,5R)-4-hydroxy-5-[(2S)-1-hydroxy-1-oxo-2-phosphono-propan-2-yl]oxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9611	SP-TI, (S)-phosphonate analogue of the (S)-tetrahedral reaction intermediate, competitive inhibitor of EPSPS forward reaction
2.5.1.19	Escherichia coli		(3R,4S,5R)-5-((R)-1-carboxy-1-phosphono-ethoxy)-4-hydroxy-3-phosphonooxy-cyclohex-1-enecarboxylic acid	658112	9610	analogue of the tetrahedral reaction intermediate, competitive to both substrates, binding structure analysis, binding induces conformational changes to residues Arg124 and Glu341 within the active site, which results in structural alterations in the amino-terminal globular domain of the enzyme
2.5.1.19	Escherichia coli		(3R,4S,5R)-5-((S)-1-carboxy-1-phosphono-ethoxy)-4-hydroxy-3-phosphonooxy-cyclohex-1-enecarboxylic acid	658112	9611	analogue of the tetrahedral reaction intermediate, competitive to both substrates, binding structure analysis, binding induces no conformational changes
2.5.1.19	Agrobacterium sp.		(3R,4S,5R)-5-[(2R)-1,1-difluoro-3-hydroxy-3-oxo-2-phosphonooxy-propan-2-yl]oxy-4-hydroxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9609	2F-TI, (R)-difluoromethyl analogue of the (S)-tetrahedral reaction intermediate, competitive inhibitor of EPSPS forward reaction, 8fold decrease in potency compared to glyphosate-sensitive class I EPSPS from Escherichia coli
2.5.1.19	Escherichia coli		(3R,4S,5R)-5-[(2R)-1,1-difluoro-3-hydroxy-3-oxo-2-phosphonooxy-propan-2-yl]oxy-4-hydroxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9609	2F-TI, (R)-difluoromethyl analogue of the (S)-tetrahedral reaction intermediate, very potent competitive inhibitor of EPSPS forward reaction
2.5.1.19	Staphylococcus aureus		(3R,4S,5R)-5-[(2R)-1,1-difluoro-3-hydroxy-3-oxo-2-phosphonooxy-propan-2-yl]oxy-4-hydroxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9609	2F-TI, (R)-difluoromethyl analogue of the (S)-tetrahedral reaction intermediate, competitive inhibitor of EPSPS forward reaction, 4-fold decrease in potency compared to glyphosate-sensitive class I EPSPS from Escherichia coli
2.5.1.19	Escherichia coli		(Z)-3-fluorophosphoenolpyruvate	638176	2350	competitive vs. phosphoenolpyruvate at saturated shikimate 3-phosphate concentration and vice versa
2.5.1.19	Escherichia coli		3-Bromopyruvate	638179	1425	0.1 mM, approx. 80% inactivation after 5 min, maximum rate-constant: 0.31/min, substrates or a combination of shikimate 3-phosphat and glyphosate protect from inactivation, bromopyruvate modifies residues C408 and L411
2.5.1.19	Klebsiella pneumoniae		3-Bromopyruvate	638180	1425	1 mM, 50% inactivation after 3.4 min
2.5.1.19	Klebsiella pneumoniae		3-Bromopyruvate	638182	1425	glyphosate protects
2.5.1.19	Escherichia coli		5-Deoxy-shikimate 3-phosphate	638176	28992	competitive vs. shikimate 3-phosphate
2.5.1.19	Escherichia coli		5-enolpyruvylshikimate 3-phosphate	638175	1249	product inhibition
2.5.1.19	Klebsiella pneumoniae		5-enolpyruvylshikimate 3-phosphate	638181	1249	product inhibition
2.5.1.19	Klebsiella pneumoniae		Al3+	638181	229	10 mM, 37% inhibition
2.5.1.19	Sorghum bicolor		ammonium heptamolybdate	638187	13898	1.1 mM, 50% inhibition, no inhibition below 0.1 mM
2.5.1.19	Klebsiella pneumoniae		Br-	638181	285	inhibition above 200 mM, stimulation below
2.5.1.19	Sorghum bicolor		CaCl2	638187	193	above 100 mM
2.5.1.19	Escherichia coli		Carboxyallenyl phosphate	638176	67083	strong
2.5.1.19	Klebsiella pneumoniae		Cl-	638181	134	inhibition above 400 mM, stimulation below
2.5.1.19	Klebsiella pneumoniae		Co3+	638181	21	10 mM, 25% inhibition
2.5.1.19	Klebsiella pneumoniae		Cu2+	638181	28	10 mM, 90-95% inhibition
2.5.1.19	Sorghum bicolor		Cu2+	638187	28	5 mM, complete inhibition
2.5.1.19	Escherichia coli		diethyldicarbonate	638177	265	inactivation with a second-order rate constant of 220/M/min, subtstrates protect from inactivation, enzyme activity is recovered by treatment with hydroxylamine
2.5.1.19	Klebsiella pneumoniae		Fe2+	638181	23	10 mM, complete inhibition
2.5.1.19	Sorghum bicolor		Fe2+	638187	23	5 mM, 42% inhibition
2.5.1.19	Klebsiella pneumoniae		Fe3+	638181	66	10 mM, 60% inhibition
2.5.1.19	Sorghum bicolor		Fe3+	638187	66	5 mM, 68% inhibition
2.5.1.19	Escherichia coli		glyphosate	658298	633	competitive inhibition of the wild-type enzyme, mutant T42M is less sensitive
2.5.1.19	Salmonella enterica subsp. enterica serovar Typhimurium		glyphosate	658298	633	competitive inhibition of the wild-type enzyme, mutant T42M is less sensitive
2.5.1.19	Staphylococcus aureus		glyphosate	658759	633	slight inhibition, insensitivity is independent from cations, mechanism
2.5.1.19	Oryza sativa		glyphosate	682400	633	
2.5.1.19	Pseudomonas fluorescens		glyphosate	690523	633	N-phosphonomethylglycine
2.5.1.19	Agrobacterium sp.		glyphosate	690885	633	
2.5.1.19	Staphylococcus aureus		glyphosate	690885	633	
2.5.1.19	Mycobacterium tuberculosis		glyphosate	690976	633	Kd: 350 micromolar (pH 6.9, 25&deg;C), binding induces conformational change that leads to increase in alpha helix (40% to 57%) and decrease in beta-sheet (30% to 23%) content (revealed by circular dichroism spectroscopy) and prevents access of solvent to core molecule (revealed by hydrogen/deuterium exchange, peptic digestion and LC-ESI-MS)
2.5.1.19	Escherichia coli		glyphosate	691087	633	N-(phosphonomethyl)glycine, broad-spectrum herbicide
2.5.1.19	Pseudomonas stutzeri		glyphosate	691436	633	at 300 mM: no growth of Escherichia coli transformed with either EPSPS wild-type or mutant N130S
2.5.1.19	Bacteria		glyphosate	691936	633	3-phosphoshikimate binding is prerequisite for glyphosate binding
2.5.1.19	Bacteria		glyphosate	694557	633	competitor with phosphoenolpyruvate binding site, AroA(1398) transformation allows Escherichia coli DH5alpha and XL1 Blue colonies to grow on up to 200 mM glyphosate (non-transformed bacteria stop growing on 5 mM inhibitor), AroA(1398) integrated maize transgenic plant lines showed 54% survival upon glyphosate treatment compared to none of control plants
2.5.1.19	plant		glyphosate	694557	633	plants do not survive glyphosate spray treatment (1.78 l/ha of a 480 g AE/L formulation) in the field
2.5.1.19	Pseudomonas aeruginosa		glyphosate	694929	633	inhibits forward reaction only slightly at 0.2 mM but substantially at 20 mM
2.5.1.19	Escherichia coli		glyphosate	658112, 690885, 693010, 704646	633	
2.5.1.19	Ochrobactrum anthropi		glyphosate	721350	633	
2.5.1.19	Halothermothrix orenii		glyphosate	721379	633	
2.5.1.19	Pseudomonas fluorescens		glyphosate	723145	633	
2.5.1.19	Rahnella aquatilis		glyphosate	723574	633	
2.5.1.19	Bacillus cereus		glyphosate	723804	633	
2.5.1.19	Klebsiella pneumoniae		I-	638181	422	inhibition above 100 mM, stimulation below
2.5.1.19	Klebsiella pneumoniae		La3+	638181	1433	10 mM, complete inhibition
2.5.1.19	Sorghum bicolor		MgCl2	638187	176	above 100 mM
2.5.1.19	Klebsiella pneumoniae		Mn2+	638181	26	10 mM, 16% inhibition
2.5.1.19	Sorghum bicolor		Mn2+	638187	26	5 mM, 42% inhibition
2.5.1.19	Klebsiella pneumoniae		molybdate	638181	424	10 mM, complete inhibition
2.5.1.19	Escherichia coli		more	679818		insensitive to inhibition by glyphosate.
2.5.1.19	Pseudomonas aeruginosa		more	682499		resistant to glyphosate
2.5.1.19	Klebsiella pneumoniae		N-ethylmaleimide	638180	46	1 mM, 50% inactivation after approx. 3 min
2.5.1.19	Klebsiella pneumoniae		N-ethylmaleimide	638182	46	glyphosate protects
2.5.1.19	Escherichia coli		N-phosphonomethylglycine	638173	633	inhibition of enolpyruvate transfer, competitive vs. phosphoenolpyruvate
2.5.1.19	Klebsiella pneumoniae		N-phosphonomethylglycine	638173	633	
2.5.1.19	Neurospora crassa		N-phosphonomethylglycine	638173	633	
2.5.1.19	Escherichia coli		N-phosphonomethylglycine	638177	633	0.01 mM, 50% inhibition
2.5.1.19	Klebsiella pneumoniae		N-phosphonomethylglycine	638180	633	wild-type enzyme
2.5.1.19	Klebsiella pneumoniae		N-phosphonomethylglycine	638182	633	competitive vs. phosphoenolpyruvate, noncompetitive vs. shikimate 3-phosphate, 5-enolpyruvylshikimate 3-phosphate and phosphate, not inhibited by non-herbicidal analogues of glyphosate, e.g. aminomethylphosphonic acid, glyphosine, i.e. bis-N-(phosphonomethyl)glycine, or iminodiacetic acid; pH-dependent
2.5.1.19	Anabaena variabilis		N-phosphonomethylglycine	638183	633	3 mM, 50% inhibition, 25 mM, 90% inhibition; trivial name glyphosate, non-selective herbicide 'Round up', free acid or monoisopropylamine salt
2.5.1.19	Pisum sativum		N-phosphonomethylglycine	638173, 638184	633	
2.5.1.19	Lactuca sativa		N-phosphonomethylglycine	638185	633	
2.5.1.19	Pisum sativum		N-phosphonomethylglycine	638185	633	noncompetitive vs. phosphate, competitive vs. phosphoenolpyruvate, uncompetitive vs. shikimate 3-phosphate
2.5.1.19	Spinacia oleracea		N-phosphonomethylglycine	638185	633	
2.5.1.19	Triticum aestivum		N-phosphonomethylglycine	638185	633	
2.5.1.19	Zea mays		N-phosphonomethylglycine	638185	633	
2.5.1.19	Sorghum bicolor		N-phosphonomethylglycine	638187	633	
2.5.1.19	Nicotiana sylvestris		N-phosphonomethylglycine	638188	633	0.0183 mM, 50% inhibition, 0.5 mM 96% inhibition, competitive vs. phosphoenolpyruvate, uncompetitive vs. shikimate 3-phosphate at pH 7.0, mechanism; pH-dependent
2.5.1.19	Zea mays		N-phosphonomethylglycine	638198	633	0.006-0.008 mM, 50% inhibition, 1 mM, complete inhibition
2.5.1.19	Bacillus subtilis		N-phosphonomethylglycine	638199	633	0.25 mM, 50% inhibition of NH4Cl activated enzyme, 75 mM, 50% inhibition of nonactivated enzyme
2.5.1.19	Streptococcus pneumoniae		N-phosphonomethylglycine	638202	633	
2.5.1.19	Escherichia coli		N-phosphonomethylglycine	638207	633	mechanism of inhibition in atomic detail
2.5.1.19	Escherichia coli		N-phosphonomethylglycine	638175, 638176, 638178, 638179, 638200, 638203, 638209	633	
2.5.1.19	Eleusine indica		N-phosphonomethylglycine	638210	633	0.006 mM, 50% inhibition of glyphosate-sensitve strain, 0.03 mM, 50% inhibition of glyphosate-resistant strain
2.5.1.19	Salmonella enterica subsp. enterica serovar Typhimurium		N-phosphonomethylglycine	638173, 638203, 638210	633	
2.5.1.19	Klebsiella pneumoniae		NH4Cl	638181	282	inhibition above 300 mM, stimulation below
2.5.1.19	Klebsiella pneumoniae		NO3-	638181	263	inhibition above 150 mM, stimulation below
2.5.1.19	Klebsiella pneumoniae		Pb2+	638181	132	10 mM, 90-95% inhibition
2.5.1.19	Sorghum bicolor		Pb2+	638187	132	5 mM, 97% inhibition
2.5.1.19	Klebsiella pneumoniae		Phenylglyoxal	638180	258	2 mM, 50% inactivation after 32 min
2.5.1.19	Klebsiella pneumoniae		Phenylglyoxal	638182	258	glyphosate protects
2.5.1.19	Escherichia coli		phosphoenolpyruvate	638176	47	substrate inhibition
2.5.1.19	Klebsiella pneumoniae		phosphoenolpyruvate	638181	47	
2.5.1.19	Escherichia coli		pyruvate	638178	29	20 mM, 85% inactivation after 1 h in the presence of cyanoborhydride, no inactivation in the absence of cyanoborhydride, preincubation with 5-enolpyruvylshikimate or a combination of shikimate 3-phosphate and glyphosate prevents from inactivation
2.5.1.19	Petunia x hybrida		Reaction intermediate analogue	638186		
2.5.1.19	Klebsiella pneumoniae		shikimate 3-phosphate	638181	998	product inhibition
2.5.1.19	Petunia x hybrida		shikimate 3-phosphate-5-carboxymethyl-(2R)-phosphonate	638186	9610	competitive vs. 5-enolpyruvylshikimate-3-phosphate and phosphate
2.5.1.19	Petunia x hybrida		shikimate 3-phosphate-5-carboxymethyl-(2S)-phosphonate	638186	9611	competitive vs. 5-enolpyruvylshikimate-3-phosphate and phosphate
2.5.1.19	Sorghum bicolor		SO42-	638187	148	inhibition above 50 mM, slight stimulation below
2.5.1.19	Klebsiella pneumoniae		Zn2+	638181	19	10 mM, 90-95% inhibition
2.5.1.19	Sorghum bicolor		Zn2+	638187	19	5 mM, complete inhibition
4.1.1.65	Bos taurus	Cutsum		4776		maximal activity in presence of 0.1% cutsum
4.1.1.65	Clostridium butyricum	more		4781		optimal activity under anaerobic conditions
4.1.1.65	Escherichia coli	Nonionic detergents		4764		e.g. Triton X-100, absolute requirement
4.1.1.65	Saccharomyces cerevisiae	Pdr17		705619		the presence of a phosphatidylinositol transfer protein called Pdr17 is required for Psd2 function
4.1.1.65	Escherichia coli	pyruvate		4780	29	dependent on
4.1.1.65	Escherichia coli	pyruvate		4783	29	the small subunit contains a pyruvoyl prosthetic group
4.1.1.65	Escherichia coli	pyruvate		4785	29	the pyruvoyl residue is covalently bound to the amino terminus of one of the two nonidentical subunits
4.1.1.65	Escherichia coli	pyruvate		4790	29	dependent on; the pyruvate prosthetic group is in amide linkage to the amino terminus of the alpha-subunit. The prosthetic group is derived from Ser through a post-tranlational cleavage of a proenzyme
4.1.1.65	Bos taurus	sodium taurocholate		4776	1638	maximal activity in presence of 0.1% sodium taurocholate
4.1.1.65	Escherichia coli	Triton X-100		4767	57	
4.1.1.65	Rattus norvegicus	Triton X-100		4788	57	maximal activity, independent of phosphatidylserine concentration is expressed at Triton to phospholipid ratio of 5.6, inhibition at a molar ratio higher than 5.6
4.1.1.65	Plasmodium falciparum	Triton X-100		653276	57	enzyme activity depends on presence of Triton X-100, optimum concentration 0.052%
4.1.1.65	Rattus norvegicus		1,4-Dinitrophenol	4791	778	
4.1.1.65	Escherichia coli		4-Bromo-3-hydroxybenzyloxyamine	4769, 4775	20703	
4.1.1.65	Escherichia coli		Bile salt detergents	4773	6266	inactivation by dissociating the oligomeric enzyme
4.1.1.65	Clostridium butyricum		Cu2+	4781	28	
4.1.1.65	Escherichia coli		Cyanoborohydride	4769	13327	inactivation in presence of phosphatidylserine, no inactivation in absence of phosphatidylserine
4.1.1.65	Escherichia coli		Cyanoborohydride	4775	13327	
4.1.1.65	Mus musculus		cycloserine	4765	109176	
4.1.1.65	Mus musculus		D-penicillamine	4765	1979	
4.1.1.65	Mus musculus		deoxypyridoxine	4765	7167	reversion by pyridoxal phosphate
4.1.1.65	Escherichia coli		Hydrazines	4769	20408	phenylhydrazine
4.1.1.65	Escherichia coli		Hydrazines	4786	20408	in presence of an amine
4.1.1.65	Rattus norvegicus		hydroxylamine	4761	80	irreversible
4.1.1.65	Mus musculus		hydroxylamine	4765	80	
4.1.1.65	Escherichia coli		hydroxylamine	4769, 4775	80	
4.1.1.65	Bos taurus		hydroxylamine	4776	80	
4.1.1.65	Rattus norvegicus		hydroxylamine	4776	80	
4.1.1.65	Clostridium butyricum		hydroxylamine	4781	80	
4.1.1.65	Escherichia coli		hydroxylamine	4786	80	in presence of an amine
4.1.1.65	Escherichia coli		Ionic detergents	4764		e.g., Barlox-12, SDS
4.1.1.65	Clostridium butyricum		Ionic detergents	4781		e.g. SDS or cetyl trimethylammonium bromide, strong
4.1.1.65	Mus musculus		Isonicotinic acid hydrazide	4765	674	
4.1.1.65	Mus musculus		L-Penicillamine	4765	2386	
4.1.1.65	Homo sapiens		more	680942		DMSO has no discernable effect on product formation
4.1.1.65	Escherichia coli		N-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate	4773	7335	
4.1.1.65	Escherichia coli		NaBH4	4786	507	in presence of an amine
4.1.1.65	Escherichia coli		NaCNBH3	4786		in presence of an amine
4.1.1.65	Clostridium butyricum		NEM	4781	46	
4.1.1.65	Clostridium butyricum		Nonionic detergents	4781		e.g. Brij 35 or Tween 80, partial
4.1.1.65	Escherichia coli		O-Benzylhydroxylamine	4769	4499	
4.1.1.65	Bos taurus		p-hydroxymercuribenzoate	4776	92	
4.1.1.65	Clostridium butyricum		p-hydroxymercuribenzoate	4781	92	
4.1.1.65	Plasmodium knowlesi		phosphatidylinositol	727905	393	
4.1.1.65	Mus musculus		Thiosemicarbazide	4765	2487	
4.1.1.65	Tetrahymena pyriformis		Triton X-100	4766	57	effect is related to the molar ratio of triton to phospholipid
4.1.1.65	Rattus norvegicus		Triton X-100	4788	57	Triton X-100, maximal activity, independent of phosphatidylserine concentration is expressed at Triton to phospholipid ration of 5.6, inhibition at a molar ratio higher than 5.6
4.1.1.65	Escherichia coli		Zwitterionic detergents	4773		inactivation by dissociating the oligomeric enzyme
2.6.1.52	Bos taurus		2-Amino-4-phosphonobutyrate	640153	13355	
2.6.1.52	Bos taurus		2-oxoglutarate	640160	32	
2.6.1.52	Arabidopsis thaliana		L-cysteine	640159	70	
2.6.1.52	Spinacia oleracea		L-cysteine	640159	70	
2.6.1.52	Bos taurus		L-glutamate	640160	38	
2.6.1.52	Bos taurus		L-phosphoserine	640160	899	product inhibition
2.6.1.52	Entamoeba histolytica		O-acetylserine	675866	549	10 mM, 50% inhibition
2.6.1.52	Entamoeba histolytica		o-phospho-D-serine	675866	8524	10 mM, 70% inhibition
2.6.1.52	Entamoeba histolytica		O-phospho-L-threonine	675866	3403	10 mM, 65% inhibition
2.7.8.8	Escherichia coli	cardiolipin		643784	652	activates. The enzyme is completely desensitized by treatment for 5 min at 40&deg;C against the effect of cadiolipin without loss of activity
2.7.8.8	Escherichia coli	diphosphatidylglycerol		661745	652	membrane association and activity of PtdSer synthase is increased, studied with mixed micelles containing phosphatidylglycerol (one charge) or diphosphatidylglycerol (two charges), the two main anionic membrane lipids in Escherichia coli
2.7.8.8	Escherichia coli	more		643778		optimal activity is dependent on ionic strength, 0.3 or higher
2.7.8.8	Escherichia coli	more		643796		the enzyme reconstituted with lipid vesicles of various compositions exhibits practically no activity in the absence of a detergent and with the substrate CDP-diacylglycerol present only in the lipid vesicles. Inclusion of octylglucoside in the assay mixture increases the activity 20- to 1000fold, the degree of activation depends on the lipid composition of the vesicles. Inclusion of additional CDP-diacylglycerol in the assay mixture increases the activity 5- to 25-fold. When the fraction of phosphatidylglycerol is increased from 15 to 100 mol% in the vesicles the activity increases 10fold using the assay mixture containing octylglucoside. The highest activities are exhibited with the anionic lipids diphosphatidylglycerol and phosphatidic acid while phosphatidylinositol gives lower activity
2.7.8.8	Escherichia coli	more		661745		activity of phosphatidylserine synthase depends significantly on the nature and level of the lipids in the matrix, at which the enzyme is operating
2.7.8.8	Escherichia coli	phosphatidylethanolamine		643784	427	slightly activates. The enzyme is completely desensitized by treatment for 5 min at 40&deg;C against the effect of phosphatidylethanolamine without loss of activity
2.7.8.8	Escherichia coli	phosphatidylglycerol		661745	550	membrane association and activity of PtdSer synthase is increased, studied with mixed micelles containing phosphatidylglycerol (one charge) or diphosphatidylglycerol (two charges), the two main anionic membrane lipids in Escherichia coli
2.7.8.8	Escherichia coli	Triton X-100		643778	57	enzyme is dependent on a nonionic detergent such as Triton X-100
2.7.8.8	Escherichia coli	Triton X-100		643779	57	dependent on nonionic detergent, at 0.1 mM CDP-diacylglycerol optimal activity occurs at a Triton to substrate molar ratio of 8:1
2.7.8.8	Escherichia coli	Triton X-100		643782	57	increasing levels of Triton X-100 at low molecular ratios of Triton X-100 to CDP-diacylglycerol stimulate
2.7.8.8	Escherichia coli		Triton X-100	643782	57	inhibits activity as the molar ratio of Triton X-100 to CDP-diacylglycerol raises beyond the point of maximal activity
1.3.1.98	Staphylococcus epidermidis	FAD		286060	14	in presence of K+
1.3.1.98	Enterobacter cloacae	FAD		286063	14	11-25% stimulation
1.3.1.98	Mycobacterium tuberculosis		(4S)-1,2-bis(4-chlorophenyl)-5-[2-(2,4-difluorophenyl)-2-oxoethoxy]-4-methylpyrazolidin-3-one	723008	61581	
1.3.1.98	Candida albicans		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3,4-dichlorophenyl)amide	669810	11965	
1.3.1.98	Enterococcus faecalis		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3,4-dichlorophenyl)amide	669810	11965	
1.3.1.98	Escherichia coli		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3,4-dichlorophenyl)amide	669810	11965	
1.3.1.98	Staphylococcus aureus		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3,4-dichlorophenyl)amide	669810	11965	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3,4-dichlorophenyl)amide	669810	11965	
1.3.1.98	Candida albicans		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 4-tolylamide	669810	11964	
1.3.1.98	Enterococcus faecalis		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 4-tolylamide	669810	11964	
1.3.1.98	Escherichia coli		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 4-tolylamide	669810	11964	
1.3.1.98	Staphylococcus aureus		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 4-tolylamide	669810	11964	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 4-tolylamide	669810	11964	
1.3.1.98	Candida albicans		1,2-bis(3,4-dichlorophenyl)pyrazolidine-3,5-dione	669810	11937	
1.3.1.98	Enterococcus faecalis		1,2-bis(3,4-dichlorophenyl)pyrazolidine-3,5-dione	669810	11937	
1.3.1.98	Escherichia coli		1,2-bis(3,4-dichlorophenyl)pyrazolidine-3,5-dione	669810	11937	
1.3.1.98	Staphylococcus aureus		1,2-bis(3,4-dichlorophenyl)pyrazolidine-3,5-dione	669810	11937	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(3,4-dichlorophenyl)pyrazolidine-3,5-dione	669810	11937	
1.3.1.98	Candida albicans		1,2-bis(3-chlorophenyl)-3,5-dioxopyrazolidine-4-carboxylic acid (4-chlorophenyl)amide	669810	11962	
1.3.1.98	Enterococcus faecalis		1,2-bis(3-chlorophenyl)-3,5-dioxopyrazolidine-4-carboxylic acid (4-chlorophenyl)amide	669810	11962	
1.3.1.98	Escherichia coli		1,2-bis(3-chlorophenyl)-3,5-dioxopyrazolidine-4-carboxylic acid (4-chlorophenyl)amide	669810	11962	
1.3.1.98	Staphylococcus aureus		1,2-bis(3-chlorophenyl)-3,5-dioxopyrazolidine-4-carboxylic acid (4-chlorophenyl)amide	669810	11962	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(3-chlorophenyl)-3,5-dioxopyrazolidine-4-carboxylic acid (4-chlorophenyl)amide	669810	11962	
1.3.1.98	Candida albicans		1,2-bis(3-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11963	
1.3.1.98	Enterococcus faecalis		1,2-bis(3-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11963	
1.3.1.98	Escherichia coli		1,2-bis(3-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11963	
1.3.1.98	Staphylococcus aureus		1,2-bis(3-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11963	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(3-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11963	
1.3.1.98	Candida albicans		1,2-bis(3-chlorophenyl)pyrazolidine-3,5-dione	669810	11938	
1.3.1.98	Enterococcus faecalis		1,2-bis(3-chlorophenyl)pyrazolidine-3,5-dione	669810	11938	
1.3.1.98	Escherichia coli		1,2-bis(3-chlorophenyl)pyrazolidine-3,5-dione	669810	11938	
1.3.1.98	Staphylococcus aureus		1,2-bis(3-chlorophenyl)pyrazolidine-3,5-dione	669810	11938	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(3-chlorophenyl)pyrazolidine-3,5-dione	669810	11938	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-3,5-dioxo-N-phenylpyrazolidine-4-carboxamide	669810	11940	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-3,5-dioxo-N-phenylpyrazolidine-4-carboxamide	669810	11940	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-3,5-dioxo-N-phenylpyrazolidine-4-carboxamide	669810	11940	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-3,5-dioxo-N-phenylpyrazolidine-4-carboxamide	669810	11940	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-3,5-dioxo-N-phenylpyrazolidine-4-carboxamide	669810	11940	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4,4-bis(6-phenylhexyl)pyrazolidine-3,5-dione	723008	61586	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4,4-bis[2-(2,4-difluorophenyl)-2-oxoethyl]pyrazolidine-3,5-dione	723008	61579	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-(2,4-dichlorobenzyl)pyrazolidine-3,5-dione	723008	61589	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-(2-ethylbutyl)pyrazolidine-3,5-dione	723008	61597	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-(2-phenylethyl)pyrazolidine-3,5-dione	723008	28324	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-4-(3,4-dichlorobenzoyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11967	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-4-(3,4-dichlorobenzoyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11967	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-4-(3,4-dichlorobenzoyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11967	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-4-(3,4-dichlorobenzoyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11967	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-4-(3,4-dichlorobenzoyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11967	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-(3-methoxybenzyl)pyrazolidine-3,5-dione	723008	61585	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-(3-oxo-3-phenylpropyl)pyrazolidine-3,5-dione	723008	61584	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-(3-phenylpropyl)pyrazolidine-3,5-dione	723008	61594	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-(4-oxo-4-phenylbutyl)pyrazolidine-3,5-dione	723008	61580	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-(4-phenylbutyl)pyrazolidine-3,5-dione	723008	61599	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-(5-phenylpentyl)pyrazolidine-3,5-dione	723008	61593	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-(6-phenylhexyl)pyrazolidine-3,5-dione	723008	61598	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-4-cyclohexanecarbonyl-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11975	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-4-cyclohexanecarbonyl-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11975	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-4-cyclohexanecarbonyl-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11975	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-4-cyclohexanecarbonyl-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11975	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-4-cyclohexanecarbonyl-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11975	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-heptylpyrazolidine-3,5-dione	723008	61600	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-[2-(2,4-difluorophenyl)-2-oxoethyl]-4-methylpyrazolidine-3,5-dione	723008	61582	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-[2-(4-fluorophenyl)-2-oxoethyl]pyrazolidine-3,5-dione	723008	61583	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-[2-(diethylamino)ethyl]pyrazolidine-3,5-dione	723008	61603	
1.3.1.98	Mycobacterium tuberculosis		1,2-bis(4-chlorophenyl)-4-[3-(trifluoromethyl)benzyl]pyrazolidine-3,5-dione	723008	61587	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (1-naphthalen-2-ylethyl)amide	669810	11958	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (1-naphthalen-2-ylethyl)amide	669810	11958	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (1-naphthalen-2-ylethyl)amide	669810	11958	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (1-naphthalen-2-ylethyl)amide	669810	11958	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (1-naphthalen-2-ylethyl)amide	669810	11958	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (2-chlorophenyl)amide	669810	11945	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (2-chlorophenyl)amide	669810	11945	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (2-chlorophenyl)amide	669810	11945	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (2-chlorophenyl)amide	669810	11945	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (2-chlorophenyl)amide	669810	11945	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-chlorophenyl)amide	669810	11944	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-chlorophenyl)amide	669810	11944	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-chlorophenyl)amide	669810	11944	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-chlorophenyl)amide	669810	11944	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-chlorophenyl)amide	669810	11944	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-trifluoromethylphenyl)amide	669810	11942	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-trifluoromethylphenyl)amide	669810	11942	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-trifluoromethylphenyl)amide	669810	11942	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-trifluoromethylphenyl)amide	669810	11942	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-trifluoromethylphenyl)amide	669810	11942	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11941	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11941	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11941	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11941	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11941	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-cyanophenyl)amide	669810	11947	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-cyanophenyl)amide	669810	11947	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-cyanophenyl)amide	669810	11947	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-cyanophenyl)amide	669810	11947	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-cyanophenyl)amide	669810	11947	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-hydroxyphenyl)amide	669810	11951	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-hydroxyphenyl)amide	669810	11951	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-hydroxyphenyl)amide	669810	11951	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-hydroxyphenyl)amide	669810	11951	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-hydroxyphenyl)amide	669810	11951	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-methoxyphenyl)amide	669810	11946	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-methoxyphenyl)amide	669810	11946	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-methoxyphenyl)amide	669810	11946	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-methoxyphenyl)amide	669810	11946	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-methoxyphenyl)amide	669810	11946	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11943	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11943	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11943	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11943	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11943	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2,4-dichlorobenzylamide	669810	11954	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2,4-dichlorobenzylamide	669810	11954	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2,4-dichlorobenzylamide	669810	11954	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2,4-dichlorobenzylamide	669810	11954	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2,4-dichlorobenzylamide	669810	11954	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2-chlorobenzylamide	669810	11955	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2-chlorobenzylamide	669810	11955	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2-chlorobenzylamide	669810	11955	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2-chlorobenzylamide	669810	11955	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2-chlorobenzylamide	669810	11955	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 3,4-dichlorobenzylamide	669810	11953	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 3,4-dichlorobenzylamide	669810	11953	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 3,4-dichlorobenzylamide	669810	11953	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 3,4-dichlorobenzylamide	669810	11953	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 3,4-dichlorobenzylamide	669810	11953	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid cyclohexylamide	669810	11948	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid cyclohexylamide	669810	11948	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid cyclohexylamide	669810	11948	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid cyclohexylamide	669810	11948	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid cyclohexylamide	669810	11948	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenethylamide	669810	11956	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenethylamide	669810	11956	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenethylamide	669810	11956	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenethylamide	669810	11956	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenethylamide	669810	11956	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [1-(4-bromophenyl)ethyl]amide	669810	11957	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [1-(4-bromophenyl)ethyl]amide	669810	11957	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [1-(4-bromophenyl)ethyl]amide	669810	11957	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [1-(4-bromophenyl)ethyl]amide	669810	11957	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [1-(4-bromophenyl)ethyl]amide	669810	11957	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [4(3-(dimethylamino)propylcarbamoyl)-phenyl]amide	669810	11952	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [4(3-(dimethylamino)propylcarbamoyl)-phenyl]amide	669810	11952	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [4(3-(dimethylamino)propylcarbamoyl)-phenyl]amide	669810	11952	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [4(3-(dimethylamino)propylcarbamoyl)-phenyl]amide	669810	11952	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [4(3-(dimethylamino)propylcarbamoyl)-phenyl]amide	669810	11952	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-methoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11968	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-methoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11968	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-methoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11968	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-methoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11968	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-methoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11968	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11970	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11970	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11970	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11970	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11970	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethylbenzoyl)-1,2-dihydropyrazol-3-one	669810	11973	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethylbenzoyl)-1,2-dihydropyrazol-3-one	669810	11973	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethylbenzoyl)-1,2-dihydropyrazol-3-one	669810	11973	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethylbenzoyl)-1,2-dihydropyrazol-3-one	669810	11973	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethylbenzoyl)-1,2-dihydropyrazol-3-one	669810	11973	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(thiophene-2-carbonyl)-1,2-dihydropyrazol-3-one	669810	11972	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(thiophene-2-carbonyl)-1,2-dihydropyrazol-3-one	669810	11972	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(thiophene-2-carbonyl)-1,2-dihydropyrazol-3-one	669810	11972	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(thiophene-2-carbonyl)-1,2-dihydropyrazol-3-one	669810	11972	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(thiophene-2-carbonyl)-1,2-dihydropyrazol-3-one	669810	11972	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)-5-hydroxy-4-[2-(4-methoxyphenyl)acetyl]-1,2-dihydropyrazol-3-one	669810	11974	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)-5-hydroxy-4-[2-(4-methoxyphenyl)acetyl]-1,2-dihydropyrazol-3-one	669810	11974	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)-5-hydroxy-4-[2-(4-methoxyphenyl)acetyl]-1,2-dihydropyrazol-3-one	669810	11974	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)-5-hydroxy-4-[2-(4-methoxyphenyl)acetyl]-1,2-dihydropyrazol-3-one	669810	11974	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)-5-hydroxy-4-[2-(4-methoxyphenyl)acetyl]-1,2-dihydropyrazol-3-one	669810	11974	
1.3.1.98	Candida albicans		1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	669810	11936	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	669810	11936	
1.3.1.98	Escherichia coli		1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	669810	11936	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	669810	11936	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	669810	11936	
1.3.1.98	Candida albicans		1,2-bis(4-fluorophenyl)pyrazolidine-3,5-dione	669810	11939	
1.3.1.98	Enterococcus faecalis		1,2-bis(4-fluorophenyl)pyrazolidine-3,5-dione	669810	11939	
1.3.1.98	Escherichia coli		1,2-bis(4-fluorophenyl)pyrazolidine-3,5-dione	669810	11939	
1.3.1.98	Staphylococcus aureus		1,2-bis(4-fluorophenyl)pyrazolidine-3,5-dione	669810	11939	
1.3.1.98	Streptococcus pneumoniae		1,2-bis(4-fluorophenyl)pyrazolidine-3,5-dione	669810	11939	
1.3.1.98	Candida albicans		1,2-diphenylpyrazolidine-3,5-dione	669810	11935	slight inhibition
1.3.1.98	Enterococcus faecalis		1,2-diphenylpyrazolidine-3,5-dione	669810	11935	slight inhibition
1.3.1.98	Escherichia coli		1,2-diphenylpyrazolidine-3,5-dione	669810	11935	slight inhibition
1.3.1.98	Staphylococcus aureus		1,2-diphenylpyrazolidine-3,5-dione	669810	11935	slight inhibition
1.3.1.98	Streptococcus pneumoniae		1,2-diphenylpyrazolidine-3,5-dione	669810	11935	slight inhibition
1.3.1.98	Escherichia coli		3'-NADP+	286065	21450	noncompetitive with respect to NADPH
1.3.1.98	Escherichia coli		3-acetylpyridine adenine dinucleotide phosphate	286065	4537	oxidized form, competitive with respect to NADPH
1.3.1.98	Mycobacterium tuberculosis		4'-[[1,2-bis(4-chlorophenyl)-3,5-dioxopyrazolidin-4-yl]methyl]biphenyl-2-carbonitrile	723008	61590	
1.3.1.98	Mycobacterium tuberculosis		4,4-bis[2-(benzyloxy)ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	723008	61601	
1.3.1.98	Mycobacterium tuberculosis		4-(2-chlorobenzyl)-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	723008	61591	
1.3.1.98	Candida albicans		4-(4-butoxybenzoyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11969	
1.3.1.98	Enterococcus faecalis		4-(4-butoxybenzoyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11969	
1.3.1.98	Escherichia coli		4-(4-butoxybenzoyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11969	
1.3.1.98	Staphylococcus aureus		4-(4-butoxybenzoyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11969	
1.3.1.98	Streptococcus pneumoniae		4-(4-butoxybenzoyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11969	
1.3.1.98	Candida albicans		4-(4-chlorobenzoyl)1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11966	
1.3.1.98	Enterococcus faecalis		4-(4-chlorobenzoyl)1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11966	
1.3.1.98	Escherichia coli		4-(4-chlorobenzoyl)1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11966	
1.3.1.98	Staphylococcus aureus		4-(4-chlorobenzoyl)1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11966	
1.3.1.98	Streptococcus pneumoniae		4-(4-chlorobenzoyl)1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11966	
1.3.1.98	Candida albicans		4-(biphenylyl-4-carbonyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11971	
1.3.1.98	Enterococcus faecalis		4-(biphenylyl-4-carbonyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11971	
1.3.1.98	Escherichia coli		4-(biphenylyl-4-carbonyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11971	
1.3.1.98	Staphylococcus aureus		4-(biphenylyl-4-carbonyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11971	
1.3.1.98	Streptococcus pneumoniae		4-(biphenylyl-4-carbonyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11971	
1.3.1.98	Mycobacterium tuberculosis		4-benzyl-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	723008	61592	
1.3.1.98	Candida albicans		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid	669810	11950	
1.3.1.98	Enterococcus faecalis		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid	669810	11950	
1.3.1.98	Escherichia coli		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid	669810	11950	
1.3.1.98	Staphylococcus aureus		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid	669810	11950	
1.3.1.98	Streptococcus pneumoniae		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid	669810	11950	
1.3.1.98	Candida albicans		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid ethyl ester	669810	11949	
1.3.1.98	Enterococcus faecalis		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid ethyl ester	669810	11949	
1.3.1.98	Escherichia coli		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid ethyl ester	669810	11949	
1.3.1.98	Staphylococcus aureus		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid ethyl ester	669810	11949	
1.3.1.98	Streptococcus pneumoniae		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid ethyl ester	669810	11949	
1.3.1.98	Mycobacterium tuberculosis		4-[2-(benzyloxy)ethyl]-1,2-bis(4-chlorophenyl)-4-methylpyrazolidine-3,5-dione	723008	61595	
1.3.1.98	Mycobacterium tuberculosis		4-[2-(benzyloxy)ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	723008	61604	
1.3.1.98	Mycobacterium tuberculosis		4-[2-(benzylsulfanyl)ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	723008	61596	
1.3.1.98	Mycobacterium tuberculosis		4-[2-[benzyl(ethyl)amino]ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	723008	61602	
1.3.1.98	Mycobacterium tuberculosis		4-[3,5-bis(trifluoromethyl)benzyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	723008	61588	
1.3.1.98	Candida albicans		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-bromophenyl)amide	669810	11960	
1.3.1.98	Enterococcus faecalis		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-bromophenyl)amide	669810	11960	
1.3.1.98	Escherichia coli		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-bromophenyl)amide	669810	11960	
1.3.1.98	Staphylococcus aureus		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-bromophenyl)amide	669810	11960	
1.3.1.98	Streptococcus pneumoniae		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-bromophenyl)amide	669810	11960	
1.3.1.98	Candida albicans		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11959	
1.3.1.98	Enterococcus faecalis		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11959	
1.3.1.98	Escherichia coli		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11959	
1.3.1.98	Staphylococcus aureus		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11959	
1.3.1.98	Streptococcus pneumoniae		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11959	
1.3.1.98	Candida albicans		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenylamide	669810	11961	
1.3.1.98	Enterococcus faecalis		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenylamide	669810	11961	
1.3.1.98	Escherichia coli		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenylamide	669810	11961	
1.3.1.98	Staphylococcus aureus		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenylamide	669810	11961	
1.3.1.98	Streptococcus pneumoniae		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenylamide	669810	11961	
1.3.1.98	Escherichia coli		ADP	286065	8	at high concentration, competitive with respect to NADPH
1.3.1.98	Escherichia coli		ADP-ribose	286065	337	at high concentration, competitive with respect to NADPH
1.3.1.98	Mycobacterium tuberculosis		Ca2+	722410	18	complete inhibition at 10 mM
1.3.1.98	Enterobacter cloacae		Cs+	286064	478	
1.3.1.98	Mycobacterium tuberculosis		guanidine hydrochloride	722410	804	an exponential decrease in enzymatic activity from 100% to 20% is observed between 0 and 0.05 M, no activity is observed above 0.5 M
1.3.1.98	Streptococcus pneumoniae		Hg2+	286068	31	
1.3.1.98	Enterobacter cloacae		iodoacetamide	286063	63	
1.3.1.98	Escherichia coli		iodoacetate	286059	87	
1.3.1.98	Enterobacter cloacae		Li+	286064	142	slight, in presence of K+
1.3.1.98	Enterobacter cloacae		Mg2+	286064	25	markedly inhibits stimulatory effect of K+
1.3.1.98	Enterobacter cloacae		Mn2+	286064	26	markedly inhibits stimulatory effect of K+
1.3.1.98	Candida albicans		more	669810		maximal inhibition concentration, i.e. MIC, values, overview
1.3.1.98	Enterococcus faecalis		more	669810		maximal inhibition concentration, i.e. MIC, values, overview
1.3.1.98	Escherichia coli		more	669810		maximal inhibition concentration, i.e. MIC, values, overview
1.3.1.98	Staphylococcus aureus		more	669810		maximal inhibition concentration, i.e. MIC, values, overview
1.3.1.98	Streptococcus pneumoniae		more	669810		maximal inhibition concentration, i.e. MIC, values, overview
1.3.1.98	Escherichia coli		more	722831		not influenced by DMSO
1.3.1.98	Enterobacter cloacae		N-ethylmaleimide	286063	46	
1.3.1.98	Enterobacter cloacae		N-ethylmaleimide	286064	46	Na+ and K+ provide small but definite protection against inactivation by N-ethylmaleimide
1.3.1.98	Enterobacter cloacae		Na+	286064	55	slight, in presence of K+
1.3.1.98	Escherichia coli		NADP+	286065	6	noncompetitive with respect to NADPH
1.3.1.98	Escherichia coli		NADP+	722831	6	about 78% inhibition at 0.06 mM
1.3.1.98	Escherichia coli		NADPH	286065	5	substrate inhibition at pH 7.0, Ki: 1.6 mM
1.3.1.98	Escherichia coli		nicotinamide 1,N6-ethenoadenine dinucleotide phosphate	286065	11049	oxidized form, noncompetitive with respect to NADPH
1.3.1.98	Escherichia coli		nicotinamide hypoxanthine dinucleotide phosphate	286065	7467	oxidized form, noncompetitive with respect to NADPH
1.3.1.98	Escherichia coli		p-chloromercuribenzoate	286059	40	
1.3.1.98	Enterobacter cloacae		p-chloromercuribenzoate	286063	40	
1.3.1.98	Streptococcus pneumoniae		Pb2+	286068	132	
1.3.1.98	Escherichia coli		thio-NADP+	286065	1513	noncompetitive with respect to NADPH
1.3.1.98	Escherichia coli		thio-NADP+	722831	1513	about 80% inhibition at 0.06 mM
1.3.1.98	Escherichia coli		UDP	286065	24	at high concentration, noncompetitive with respect to NADPH
1.3.1.98	Escherichia coli		UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine	286065	4911	substrate inhibition at pH 6, Ki 0.01 mM with 0.15 mM NADPH, weaker at more basic pH
1.3.1.98	Mycobacterium tuberculosis		Urea	722410	110	no activity at 2.5 M
1.3.1.98	Escherichia coli		uridine diphospho-N-acetylglucosamine	286065	120	at very high concentration, noncompetitive with respect to NADPH
1.3.1.98	Escherichia coli		uridine diphospho-N-acetylmuramic acid	286065	70996	uncompetitive with respect to NADPH
2.5.1.72	Escherichia coli		1,10-phenanthroline	684659	58	inhibits reactivation of O2-inactivated enzyme
2.5.1.72	Escherichia coli		2,2'-dipyridyl	684659	317	inhibits reactivation of O2-inactivated enzyme
2.5.1.72	Escherichia coli		4,5-dithiohydroxyphthalic acid	721290		structural analogue of the 5-hydroxy-4,5-dihydropyridine-2,3-dicarboxylic acid intermediate. Compound coordinates to the enzyme [4Fe-4S] cluster through a differentiated iron site, thus leading to the inhibition of quinolate formation. Compound is inhibitory in vitro and in vivo
2.5.1.72	Escherichia coli		H2O2	684659	20	1 mM, inactivation
2.5.1.72	Escherichia coli		O2	684659	11	the activity of the enzyme within Escherichia coli is diminished by exposure of the cells to 4.2 atm O2, while the activity in extracts is rapidly decreased by 0.2 atm O2. Inactivation in extracts can be gradually reversed during anaerobic incubation, but is blocked by alpha, alpha'-dipyridyl or by 1,10-phenanthroline
2.5.1.72	Bacillus subtilis		O2	686712	11	complete loss of activity upon purification of enzyme in aerobic conditions or exposure to oxygen overnight
2.5.1.72	Escherichia coli		paraquat	684659	302	inactivation
2.5.1.78	Mycobacterium tuberculosis		(1R)-1,2-dideoxy-1-fluoro-1-(5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-D-ribo-hexitol	699718	49976	
2.5.1.78	Bacillus subtilis		(1S)-1,2-dideoxy-1-fluoro-1-(5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-D-ribo-hexitol	699718	17438	
2.5.1.78	Mycobacterium tuberculosis		(1S)-1,2-dideoxy-1-fluoro-1-(5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-D-ribo-hexitol	699718	17438	
2.5.1.78	Mycobacterium tuberculosis		(E)-3-hydroxy-4-(2-(5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-yl)vinyl)benzoic acid	699725	17978	
2.5.1.78	Schizosaccharomyces pombe		(E)-3-hydroxy-4-(2-(5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-yl)vinyl)benzoic acid	699725	17978	
2.5.1.78	Schizosaccharomyces pombe		(E)-4-(2-(5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-yl)vinyl)benzoate	699725	52199	
2.5.1.78	Mycobacterium tuberculosis		(E)-4-(2-(5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-yl)vinyl)benzoic acid	699725	52199	
2.5.1.78	Mycobacterium tuberculosis		(E)-5-nitro-6-(2-hydroxystyryl)pyrimidine-2,4(1H,3H)-dione	699725	17971	competitive
2.5.1.78	Schizosaccharomyces pombe		(E)-5-nitro-6-(2-hydroxystyryl)pyrimidine-2,4(1H,3H)-dione	699725	17971	competitive
2.5.1.78	Mycobacterium tuberculosis		(E)-5-nitro-6-(3-(pyridin-3-yl)vinyl)pyrimidine-2,4(1H,3H)-dione	699725	52206	
2.5.1.78	Mycobacterium tuberculosis		(E)-5-nitro-6-(3-nitrostyryl)pyrimidine-2,4(1H,3H)-dione	699725	17984	
2.5.1.78	Schizosaccharomyces pombe		(E)-5-nitro-6-(3-nitrostyryl)pyrimidine-2,4(1H,3H)-dione	699725	17984	
2.5.1.78	Mycobacterium tuberculosis		(E)-5-nitro-6-(4-bromostyryl)pyrimidine-2,4(1H,3H)-dione	699725	52201	
2.5.1.78	Mycobacterium tuberculosis		(E)-5-nitro-6-(4-nitrostyryl)pyrimidine-2,4(1H,3H)-dione	699725	17975	
2.5.1.78	Schizosaccharomyces pombe		(E)-5-nitro-6-(4-nitrostyryl)pyrimidine-2,4(1H,3H)-dione	699725	17975	
2.5.1.78	Mycobacterium tuberculosis		(E)-5-nitro-6-[2-(1H-pyrrol-2-yl)vinyl]pyrimidine-2,4(1H,3H)-dione	699725	17981	
2.5.1.78	Schizosaccharomyces pombe		(E)-5-nitro-6-[2-(1H-pyrrol-2-yl)vinyl]pyrimidine-2,4(1H,3H)-dione	699725	17981	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2,3,4-trimethoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52196	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2,3-dihydroxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17972	
2.5.1.78	Schizosaccharomyces pombe		(E)-6-(2,3-dihydroxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17972	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2,3-dimethoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17974	
2.5.1.78	Schizosaccharomyces pombe		(E)-6-(2,3-dimethoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17974	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2-(3H-indol-3-yl)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17983	
2.5.1.78	Schizosaccharomyces pombe		(E)-6-(2-(3H-indol-3-yl)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17983	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2-(naphthalen-2-yl)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17982	
2.5.1.78	Schizosaccharomyces pombe		(E)-6-(2-(naphthalen-2-yl)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17982	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2-fluoro-3-methoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17979	
2.5.1.78	Schizosaccharomyces pombe		(E)-6-(2-fluoro-3-methoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17979	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2-fluorostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52198	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2-hydroxy-3-nitrostyryl)-3-nitropyrimidine-2,4(1H,3H)-dione	699725	52204	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2-hydroxy-5-nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52203	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2-methoxy-5-nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17976	
2.5.1.78	Schizosaccharomyces pombe		(E)-6-(2-methoxy-5-nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17976	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2-methoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17973	
2.5.1.78	Schizosaccharomyces pombe		(E)-6-(2-methoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17973	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(2-nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52191	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(3,4,5-trimethoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52197	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(3,4-dimethoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52195	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(3-hydroxy-4-methoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52194	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(3-hydroxy-4-nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17977	
2.5.1.78	Schizosaccharomyces pombe		(E)-6-(3-hydroxy-4-nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	17977	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(3-hydroxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52192	competitive
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(4-chlorostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52202	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(4-fluorostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52200	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(4-hydroxy-3-nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52205	
2.5.1.78	Mycobacterium tuberculosis		(E)-6-(4-hydroxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione	699725	52193	
2.5.1.78	Schizosaccharomyces pombe		1,3,6,8-tetrahydroxynaphthyridine	699720	52207	
2.5.1.78	Mycobacterium tuberculosis		1,3,7-trihydro-9-D-ribityl-2,4,8-purinetrione	697864	7991	association constants and thermodynamic parameters of binding
2.5.1.78	Candida albicans		1,3,7-trihydro-9-D-ribityl-2,4,8-purinetrione	698735	7991	association constants and thermodynamic parameters of binding of different inhibitors to lumazine synthase
2.5.1.78	Bacillus subtilis		1-deoxy-1-(2,4,6,7-tetraoxo-1,3,4,5,6,7-hexahydropteridin-8(2H)-yl)-D-ribitol	699719	17497	
2.5.1.78	Mycobacterium tuberculosis		1-deoxy-1-(2,4,6,7-tetraoxo-1,3,4,5,6,7-hexahydropteridin-8(2H)-yl)-D-ribitol	699719	17497	
2.5.1.78	Bacillus subtilis		1-deoxy-1-(2,6,8-trioxo-1,2,3,6,7,8-hexahydro-9H-purin-9-yl)-D-ribitol	699717	7991	
2.5.1.78	Mycobacterium tuberculosis		1-deoxy-1-(2,6,8-trioxo-1,2,3,6,7,8-hexahydro-9H-purin-9-yl)-D-ribitol	699717	7991	
2.5.1.78	Bacillus subtilis		1-deoxy-1-[(2,6-dioxo-5-[[5-(phosphonooxy)pentanoyl]amino]-1,2,3,6-tetrahydropyrimidin-4-yl)amino]-D-ribitol	699717	16905	
2.5.1.78	Mycobacterium tuberculosis		1-deoxy-1-[2,4,6,7-tetraoxo-5-[4-(phosphonooxy)butyl]-1,3,4,5,6,7-hexahydropteridin-8(2H)-yl]-D-ribitol	699719	17985	
2.5.1.78	Mycobacterium tuberculosis		1-deoxy-1-[2,4,6,7-tetraoxo-5-[5-(phosphonooxy)pentyl]-1,3,4,5,6,7-hexahydropteridin-8(2H)-yl]-D-ribitol	699719	17986	
2.5.1.78	Bacillus subtilis		1-deoxy-1-[2,6,8-trioxo-7-[4-(phosphonooxy)butyl]-1,2,3,6,7,8-hexahydro-9H-purin-9-yl]-D-ribitol	699719	8055	
2.5.1.78	Mycobacterium tuberculosis		1-deoxy-1-[2,6,8-trioxo-7-[4-(phosphonooxy)butyl]-1,2,3,6,7,8-hexahydro-9H-purin-9-yl]-D-ribitol	699719	8055	
2.5.1.78	Bacillus subtilis		1-deoxy-1-[2,6,8-trioxo-7-[5-(phosphonooxy)pentyl]-1,2,3,6,7,8-hexahydro-9H-purin-9-yl]-D-ribitol	699717, 699719	5906	
2.5.1.78	Mycobacterium tuberculosis		1-deoxy-1-[2,6,8-trioxo-7-[5-(phosphonooxy)pentyl]-1,2,3,6,7,8-hexahydro-9H-purin-9-yl]-D-ribitol	699717, 699719	5906	
2.5.1.78	Bacillus subtilis		1-deoxy-1-[2,6,8-trioxo-7-[6-(phosphonooxy)hexyl]-1,2,3,6,7,8-hexahydro-9H-purin-9-yl]-D-ribitol	699717	12575	
2.5.1.78	Mycobacterium tuberculosis		1-deoxy-1-[2,6,8-trioxo-7-[6-(phosphonooxy)hexyl]-1,2,3,6,7,8-hexahydro-9H-purin-9-yl]-D-ribitol	699717	12575	
2.5.1.78	Bacillus subtilis		1-deoxy-1-[[2,6-dioxo-5-(4-phosphonobutyl)-1,2,3,6-tetrahydropyrimidin-4-yl]amino]-D-ribitol	699717	50345	
2.5.1.78	Bacillus subtilis		1-deoxy-1-[[2,6-dioxo-5-(5-phosphonopentyl)-1,2,3,6-tetrahydropyrimidin-4-yl]amino]-D-ribitol	699717	16906	
2.5.1.78	Bacillus subtilis		1-deoxy-1-[[2,6-dioxo-5-(6-phosphonohexyl)-1,2,3,6-tetrahydropyrimidin-4-yl]amino]-D-ribitol	699717	50346	
2.5.1.78	Bacillus subtilis		1-[(5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)(methyl)amino]-1-deoxy-D-ribitol hydrochloride	699718	12576	
2.5.1.78	Mycobacterium tuberculosis		1-[(5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)(methyl)amino]-1-deoxy-D-ribitol hydrochloride	699718	12576	
2.5.1.78	Bacillus subtilis		2,4-dioxo-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]-1,2,3,4-tetrahydropyrimidin-5-aminium chloride	688575	5180	inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Mycobacterium tuberculosis		2,4-dioxo-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]-1,2,3,4-tetrahydropyrimidin-5-aminium chloride	688575	5180	inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Schizosaccharomyces pombe		2,4-dioxo-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]-1,2,3,4-tetrahydropyrimidin-5-aminium chloride	688575	5180	inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Schizosaccharomyces pombe		2,5,8,11-tetraaza-5,11-dihydro-4,10-dihydroxyperylene-1,3,6,7,9,12-hexaone	699720	26279	
2.5.1.78	Mycobacterium tuberculosis		2-(2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)acetic acid	721826	61730	possible lead compound for inhibitor screening
2.5.1.78	Mycobacterium tuberculosis		3-(1,3,7,9-tetrahydro-9-D-ribityl-2,6,8-trioxopurin-7-yl)-1-propanol	699717	52209	
2.5.1.78	Bacillus subtilis		3-(1,3,7,9-tetrahydro-9-D-ribityl-2,6,8-trioxopurin-7-yl)propane 1-phosphate	699717	17987	
2.5.1.78	Mycobacterium tuberculosis		3-(1,3,7,9-tetrahydro-9-D-ribityl-2,6,8-trioxopurin-7-yl)propane 1-phosphate	699717	17987	
2.5.1.78	Mycobacterium tuberculosis		3-(1,3,7-trihydro-9-D-ribityl-2,6,8-purinetrion-7-yl)butane 1-phosphate	696207	10508	highly specific binding of the purinetrione inhibitor to the Mycobacterium tuberculosis enzyme with dissociation constants in micromolar range
2.5.1.78	Candida albicans		3-(1,3,7-trihydro-9-D-ribityl-2,6,8-purinetrione-7-yl)butane 1-phosphate	688576	8055	competitive
2.5.1.78	Magnaporthe grisea		3-(1,3,7-trihydro-9-D-ribityl-2,6,8-purinetrione-7-yl)butane 1-phosphate	688576	8055	competitive
2.5.1.78	Mycobacterium tuberculosis		3-(1,3,7-trihydro-9-D-ribityl-2,6,8-purinetrione-7-yl)butane 1-phosphate	688576	8055	competitive
2.5.1.78	Candida albicans		3-(1,3,7-trihydro-9-D-ribityl-2,6,8-purinetrione-7-yl)pentane 1-phosphate	688576	5906	competitive
2.5.1.78	Magnaporthe grisea		3-(1,3,7-trihydro-9-D-ribityl-2,6,8-purinetrione-7-yl)pentane 1-phosphate	688576	5906	competitive
2.5.1.78	Mycobacterium tuberculosis		3-(1,3,7-trihydro-9-D-ribityl-2,6,8-purinetrione-7-yl)pentane 1-phosphate	688576	5906	competitive
2.5.1.78	Mycobacterium tuberculosis		3-(1,3,7-trihydro-9-D-ribityl-2,6,8-purinetrione-7-yl)propane 1-phosphate	696207	94502	highly specific binding of the purinetrione inhibitor to the Mycobacterium tuberculosis enzyme with dissociation constants in micromolar range
2.5.1.78	Candida albicans		3-(1,3-dihydro-9-D-ribityl-2,4,8-purinetrione-7-yl)propane 1-phosphate	698735	94502	association constants and thermodynamic parameters of binding of different inhibitors to lumazine synthase
2.5.1.78	Aquifex aeolicus		3-(7-hydroxy-8-ribityllumazine-6-yl)propionic acid	699515		
2.5.1.78	Candida albicans		3-[4,6-dioxo-4,5,6,7-tetrahydro-1-D-ribityl-1H-pyrazolo[3,4-d]pyrimidin-3-yl]propyl 1-phosphate	688576	9502	competitive
2.5.1.78	Magnaporthe grisea		3-[4,6-dioxo-4,5,6,7-tetrahydro-1-D-ribityl-1H-pyrazolo[3,4-d]pyrimidin-3-yl]propyl 1-phosphate	688576	9502	mixed type inhibition
2.5.1.78	Mycobacterium tuberculosis		3-[4,6-dioxo-4,5,6,7-tetrahydro-1-D-ribityl-1H-pyrazolo[3,4-d]pyrimidin-3-yl]propyl 1-phosphate	688576	9502	competitive
2.5.1.78	Bacillus subtilis		4-(1,3,7,9-tetrahydro-9-D-ribityl-2,6,8-trioxopurin-7-yl)butane 1-phosphate	699717	17988	
2.5.1.78	Mycobacterium tuberculosis		4-(1,3,7,9-tetrahydro-9-D-ribityl-2,6,8-trioxopurin-7-yl)butane 1-phosphate	699717	17988	
2.5.1.78	Bacillus subtilis		4-(1,5,6,7-tetrahydro-6,7-dioxo-8-D-ribityllumazin-5-yl)butane 1-phosphate	699719	17985	
2.5.1.78	Mycobacterium tuberculosis		4-(1,5,6,7-tetrahydro-6,7-dioxo-8-D-ribityllumazin-5-yl)butane 1-phosphate	699719	17985	
2.5.1.78	Mycobacterium tuberculosis		4-(2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)butyl dihydrogen phosphate	721826	61731	mixed inhibition
2.5.1.78	Candida albicans		4-(6,7(5H,8H)-dioxo-8-D-ribityllumazine-5-yl)butane 1-phosphate	698735	17985	association constants and thermodynamic parameters of binding of different inhibitors to lumazine synthase
2.5.1.78	Mycobacterium tuberculosis		4-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)butyl dihydrogen phosphate	721826	94503	molecular modeling of binding to luminazine synthase. The main forces stabilizing the complex with the enzyme involve pi-pi stacking interactions with Trp27 and hydrogen bonding of the phosphates with Arg128, the backbone nitrogens of Gly85 and Gln86, and the side chain hydroxyl of Thr87
2.5.1.78	Candida albicans		4-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-yl)-butyl phosphate	698735	94503	association constants and thermodynamic parameters of binding of different inhibitors to lumazine synthase
2.5.1.78	Bacillus anthracis		4-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-yl)-n-butyl 1-phosphate	721152		competitive
2.5.1.78	Mycobacterium tuberculosis		4-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-yl)butyl 1-phosphate	697864	94503	association constants and thermodynamic parameters of binding
2.5.1.78	Bacillus subtilis		4-[2,4,7-trioxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,4,7,8-hexahydropteridin-6-yl]butanoic acid	637585	16844	uncompetitive, comparison with inhibition of Escherichia coli riboflavin synthase
2.5.1.78	Bacillus subtilis		4-[2,4,7-trioxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,4,7,8-hexahydropteridin-6-yl]butyl dihydrogen phosphate	637585	16845	competitive, comparison with inhibition of Escherichia coli riboflavin synthase
2.5.1.78	Bacillus subtilis		4-[2,4,7-trioxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,4,7,8-hexahydropteridin-6-yl]propyl dihydrogen phosphate	637585	16846	uncompetitive, comparison with inhibition of Escherichia coli riboflavin synthase
2.5.1.78	Candida albicans		4-[4,6-dioxo-4,5,6,7-tetrahydro1-D-ribityl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl]butyl 1-phosphate	688576	16851	competitive
2.5.1.78	Mycobacterium tuberculosis		4-[4,6-dioxo-4,5,6,7-tetrahydro1-D-ribityl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl]butyl 1-phosphate	688576	16851	competitive
2.5.1.78	Bacillus subtilis		5-(1,3,7,9-tetrahydro-9-D-ribityl-2,6,8-trioxopurin-7-yl)-1,1-difluoropentane 1-phosphonate	699717	17989	
2.5.1.78	Mycobacterium tuberculosis		5-(1,3,7,9-tetrahydro-9-D-ribityl-2,6,8-trioxopurin-7-yl)-1,1-difluoropentane 1-phosphonate	699717	17989	
2.5.1.78	Mycobacterium tuberculosis		5-(1,3,7-trihydro-9-d-ribityl-2,4,8-purinetrione-7-yl)1,1-difluoropentane-1-phosphate	697864	94504	association constants and thermodynamic parameters of binding
2.5.1.78	Mycobacterium tuberculosis		5-(1,3,7-trihydro-9-D-ribityl-2,4,8-purinetrione-7-yl)pentane1-phosphate	697864	5906	association constants and thermodynamic parameters of binding
2.5.1.78	Bacillus subtilis		5-(1,5,6,7-tetrahydro-6,7-dioxo-8-D-ribityllumazin-5-yl)pentane 1-phosphate	699719	17986	
2.5.1.78	Mycobacterium tuberculosis		5-(1,5,6,7-tetrahydro-6,7-dioxo-8-D-ribityllumazin-5-yl)pentane 1-phosphate	699719	17986	
2.5.1.78	Bacillus subtilis		5-(4-phosphonobutyryl)amino-6-D-ribitylaminouracil	637586	16866	comparison with inhibition of Escherichia coli riboflavin synthase
2.5.1.78	Bacillus subtilis		5-(5-phosphonopentyl)amino-6-D-ribitylaminouracil	637586	16906	comparison with inhibition of Escherichia coli riboflavin synthase
2.5.1.78	Bacillus subtilis		5-(5-phosphonoxyvaleryl)amino-6-D-ribitylaminouracil	637586	16905	mixed inhibition, comparison with inhibition of Escherichia coli riboflavin synthase
2.5.1.78	Bacillus anthracis		5-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-yl)-6-keton-hexyl 1-phosphate	721152		competitive
2.5.1.78	Bacillus anthracis		5-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-yl)-n-pentyl 1-phosphonate	721152		competitive
2.5.1.78	Aquifex aeolicus		5-(6-D-ribitylamino-2,4(1H,3H)pyrimidinedione-5-yl)-1-pentyl-phosphonic acid	699515	94501	
2.5.1.78	Bacillus subtilis		5-(hexyl 6-dihydrogen phosphate)-6-([(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino)pyrimidine-2,4(1H,3H)-dione	637585, 637586	6778	mixed inhibition, comparison with inhibition of Escherichia coli riboflavin synthase
2.5.1.78	Bacillus subtilis		5-(pentyl 6-dihydrogen phosphate)-6-([(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino)pyrimidine-2,4(1H,3H)-dione	637585	16906	mixed inhibition, comparison with inhibition of Escherichia coli riboflavin synthase
2.5.1.78	Bacillus subtilis		5-nitro-6-(D-ribitylamino)-2,4(1H,3H)-pyrimidinedione	699507	25619	
2.5.1.78	Schizosaccharomyces pombe		5-nitro-6-(D-ribitylamino)-2,4(1H,3H)-pyrimidinedione	697709, 699513	25619	
2.5.1.78	Brucella abortus		5-nitro-6-ribitylamino-2,4(1H,3H)-pyrimidinedione	688382	6439	crystallization data
2.5.1.78	Brucella melitensis		5-nitro-6-ribitylamino-2,4(1H,3H)-pyrimidinedione	688382	6439	crystallization data
2.5.1.78	Mesorhizobium loti		5-nitro-6-ribitylamino-2,4(1H,3H)-pyrimidinedione	688382	6439	crystallization data; crystallization data
2.5.1.78	Mycobacterium tuberculosis		5-nitro-6-styryluracil	699725	17980	
2.5.1.78	Schizosaccharomyces pombe		5-nitro-6-styryluracil	699725	17980	
2.5.1.78	Bacillus subtilis		5-nitro-6-[(D-ribityl)methyl]pyrimidine-2,4-dione	699718	52208	
2.5.1.78	Bacillus subtilis		5-nitro-6-[[(2R,3R,4R)-2,3,4,5 tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	688575	5183	inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Mycobacterium tuberculosis		5-nitro-6-[[(2R,3R,4R)-2,3,4,5 tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	688575	5183	inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Schizosaccharomyces pombe		5-nitro-6-[[(2R,3R,4R)-2,3,4,5 tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	688575	5183	inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Schizosaccharomyces pombe		5-nitroso-6-(D-ribitylamino)-2,4(1H,3H)-pyrimidinedione	697709	94505	
2.5.1.78	Aquifex aeolicus		5-nitroso-6-ribityl-amino-2,4(1H,3H)pyrimidinedione	699515	94500	
2.5.1.78	Candida albicans		5-[4,6-dioxo-4,5,6,7-tetrahydro-1-D-ribityl-1H-pyrazolo[3,4-d]pyrimidin-3-yl]pentyl 1-phosphate	688576	16907	competitive
2.5.1.78	Mycobacterium tuberculosis		5-[4,6-dioxo-4,5,6,7-tetrahydro-1-D-ribityl-1H-pyrazolo[3,4-d]pyrimidin-3-yl]pentyl 1-phosphate	688576	16907	competitive
2.5.1.78	Aquifex aeolicus		6,7-dioxo-5H-8-ribitylaminolumazine	699515	17497	
2.5.1.78	Mycobacterium tuberculosis		6-(1,3,7-trihydro-9-d-ribityl-2,4,8-purinetrione-7-yl)hexane 1-phosphate	697864	12575	association constants and thermodynamic parameters of binding
2.5.1.78	Schizosaccharomyces pombe		6-carboxyethyl-7-oxo-8-ribityllumazine	697709, 699513	52190	
2.5.1.78	Bacillus subtilis		6-methyl-7-methylidene-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-7,8-dihydropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione	637585	16903	mixed inhibition, comparison with inhibition of Escherichia coli riboflavin synthase
2.5.1.78	Bacillus subtilis		8-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]tetrahydropteridine-2,4,6,7(1H,3H)-tetrone	723033	19634	competitive
2.5.1.78	Mycobacterium tuberculosis		8-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]tetrahydropteridine-2,4,6,7(1H,3H)-tetrone	723033	19634	competitive
2.5.1.78	Bacillus subtilis		9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-7,9-dihydro-1H-purine-2,6,8(3H)-trione	637585	7991	comparison with inhibition of Escherichia coli riboflavin synthase
2.5.1.78	Bacillus subtilis		ethyl [(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)amino](oxo)acetate	723033	6019	competitive
2.5.1.78	Mycobacterium tuberculosis		ethyl [(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)amino](oxo)acetate	723033	6019	partial inhibition
2.5.1.78	Schizosaccharomyces pombe		ethyl [(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)amino](oxo)acetate	723033	6019	mixed type inhibition
2.5.1.78	Bacillus subtilis		more	637586		incorporation of an amide into 5-phosphonoalkyl-6-D-ribitylaminopyrimidinedione lumazine synthase inhibitors results in an unexpected reversal of selectivity for riboflavin synthase versus lumazine synthase
2.5.1.78	Bacillus subtilis		more	699717		certain purinetriones bearing phosphate side chains can inhibit both lumazine synthase as well as riboflavin synthase, and molecular modeling with 3-(1,3,7,9-tetrahydro-9-D-ribityl-2,6,8-trioxopurin-7-yl)propane 1-phosphate suggests possible binding modes to each enzyme. Antibiotics that would inhibit both lumazine synthase and riboflavin synthase would be less likely to suffer from the development of antibiotic resistance by the organisms that they are supposed to treat, since pathogenic microorganisms would have to simultaneously select for mutations in both enzymes in order to escape the cytotoxic effects of the antibiotics
2.5.1.78	Bacillus subtilis		more	699718		no inhibition: 5-amino-6-[(D-ribityl)methyl]pyrimidine-2,4-dione hydrochloride, 5-nitro-6-(N-methyl)ribitylpyrimidine-2,4-dione
2.5.1.78	Bacillus subtilis		N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dion-5-ylpropionamide	688578	7985	partial inhibition, inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Mycobacterium tuberculosis		N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dion-5-ylpropionamide	688578	7985	competitive, inhibition of both lumazine synthase and riboflavin synthase (EC 2.5.1.9)
2.5.1.78	Schizosaccharomyces pombe		N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dion-5-ylpropionamide	688578	7985	competitive, inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Bacillus subtilis		N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dione-5-ylisobutyramide	688578	7986	partial inhibition, inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Mycobacterium tuberculosis		N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dione-5-ylisobutyramide	688578	7986	partial inhibition, inhibition of both lumazine synthase and riboflavin synthase (EC 2.5.1.9)
2.5.1.78	Schizosaccharomyces pombe		N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dione-5-ylisobutyramide	688578	7986	competitive, inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Bacillus subtilis		N-[2,4-dioxo-6-(ribitylamino)-1,2,3,4-tetrahydropyrimidin-5-yl]oxalamic acid ethyl ester	688578	6019	competitive, inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Mycobacterium tuberculosis		N-[2,4-dioxo-6-(ribitylamino)-1,2,3,4-tetrahydropyrimidin-5-yl]oxalamic acid ethyl ester	688578	6019	partial inhibition, inhibition of both lumazine synthase and riboflavin synthase (EC 2.5.1.9)
2.5.1.78	Schizosaccharomyces pombe		N-[2,4-dioxo-6-(ribitylamino)-1,2,3,4-tetrahydropyrimidin-5-yl]oxalamic acid ethyl ester	688578	6019	mixed type inhibition, inhibition of both lumazine synthase and riboflavin synthase
2.5.1.78	Schizosaccharomyces pombe		riboflavin	697704	298	
2.5.1.9	Eremothecium gossypii	2,3-Dimercapto-1-propanol		637559	1854	enhances activity
2.5.1.9	Saccharomyces cerevisiae	2,3-Dimercapto-1-propanol		637559	1854	enhances activity
2.5.1.9	Eremothecium gossypii	2-mercaptoethanol		637559	59	enhances activity
2.5.1.9	Saccharomyces cerevisiae	2-mercaptoethanol		637559	59	enhances activity
2.5.1.9	Eremothecium ashbyi	diacetyl		637574	603	activates
2.5.1.9	Spinacia oleracea	more		637563		assay carried out under reducing condition to avoid side reactions and because of the lability of the enzyme in presence of O2
2.5.1.9	Geobacillus stearothermophilus	more		637575		no requirement for a cofactor
2.5.1.9	Eremothecium gossypii	N-acetylcysteine		637559	1771	enhances activity
2.5.1.9	Saccharomyces cerevisiae	N-acetylcysteine		637559	1771	enhances activity
2.5.1.9	Eremothecium gossypii	SO32-		637559	86	enhances activity
2.5.1.9	Bacillus subtilis	SO32-		637570	86	enhances activity; sodium sulfite
2.5.1.9	Saccharomyces cerevisiae	SO32-		637559, 637570	86	enhances activity
2.5.1.9	Escherichia coli		1-deoxy-1-[2,6,8-trioxo-7-[4-(phosphonooxy)butyl]-1,2,3,6,7,8-hexahydro-9H-purin-9-yl]-D-ribitol	723033	8055	competitive inhibition
2.5.1.9	Mycobacterium tuberculosis		1-deoxy-1-[2,6,8-trioxo-7-[4-(phosphonooxy)butyl]-1,2,3,6,7,8-hexahydro-9H-purin-9-yl]-D-ribitol	723033	8055	competitive inhibition
2.5.1.9	Escherichia coli		2,4-dioxo-6-[(3S,4S,5R)-3,4,5,6-tetrahydroxyhexyl]-1,2,3,4-tetrahydropyrimidin-5-aminium chloride	723033	61732	uncompetitive inhibition
2.5.1.9	Mycobacterium tuberculosis		2,4-dioxo-6-[(3S,4S,5R)-3,4,5,6-tetrahydroxyhexyl]-1,2,3,4-tetrahydropyrimidin-5-aminium chloride	723033	61732	uncompetitive inhibition
2.5.1.9	Escherichia coli		2,4-dioxo-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]-1,2,3,4-tetrahydropyrimidin-5-aminium chloride	688575	5180	
2.5.1.9	Mycobacterium tuberculosis		2,4-dioxo-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]-1,2,3,4-tetrahydropyrimidin-5-aminium chloride	688575	5180	
2.5.1.9	Saccharomyces cerevisiae		2-Amino-4,6-dihydroxy-8-D-ribityl-7-pteridinone	637561	63006	
2.5.1.9	Escherichia coli		2-chloro-N-(2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino)-1,2,3,4-tetrahydropyrimidin-5-yl)acetamide	723033		
2.5.1.9	Mycobacterium tuberculosis		2-chloro-N-(2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino)-1,2,3,4-tetrahydropyrimidin-5-yl)acetamide	723033		uncompetitive inhibition
2.5.1.9	Escherichia coli		2-chloro-N-(2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino)-1,2,3,4-tetrahydropyrimidin-5-yl)propanamide	723033		
2.5.1.9	Mycobacterium tuberculosis		2-chloro-N-(2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino)-1,2,3,4-tetrahydropyrimidin-5-yl)propanamide	723033		competitive inhibition
2.5.1.9	Escherichia coli		4-[2,4,7-trioxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,4,7,8-hexahydropteridin-6-yl]butanoic acid	637585	16844	comparison with inhibition of Bacillus subtilis lumazine synthase
2.5.1.9	Escherichia coli		4-[2,4,7-trioxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,4,7,8-hexahydropteridin-6-yl]butyl dihydrogen phosphate	637585	16845	comparison with inhibition of Bacillus subtilis lumazine synthase
2.5.1.9	Escherichia coli		4-[2,4,7-trioxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,4,7,8-hexahydropteridin-6-yl]propyl dihydrogen phosphate	637585	16846	competitive, comparison with inhibition of Bacillus subtilis lumazine synthase
2.5.1.9	Geobacillus stearothermophilus		5,5'-dithiobis(2-nitrobenzoate)	637575	196	
2.5.1.9	Saccharomyces cerevisiae		5,6,7,8-Tetrahydro-9-(1'-D-ribityl)isoalloxazine	637561	63564	
2.5.1.9	Escherichia coli		5-(4-phosphonobutyryl)amino-6-D-ribitylaminouracil	637586	16866	comparison with inhibition of Bacillus subtilis luminazine synthase/riboflavin synthase
2.5.1.9	Escherichia coli		5-(4-phosphonopentyryl)amino-6-D-ribitylaminouracil	637586	46826	comparison with inhibition of Bacillus subtilis luminazine synthase/riboflavin synthase
2.5.1.9	Escherichia coli		5-(5-phosphonoxyvaleryl)amino-6-D-ribitylaminouracil	637586	16905	mixed inhibition, comparison with inhibition of Bacillus subtilis luminazine synthase/riboflavin synthase
2.5.1.9	Escherichia coli		5-(hexyl 6-dihydrogen phosphate)-6-([(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino)pyrimidine-2,4(1H,3H)-dione	637585	6778	comparison with inhibition of Bacillus subtilis lumazine synthase
2.5.1.9	Escherichia coli		5-(hexyl 6-dihydrogen phosphate)-6-([(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino)pyrimidine-2,4(1H,3H)-dione	637586	6778	mixed inhibition, comparison with inhibition of Bacillus subtilis luminazine synthase/riboflavin synthase
2.5.1.9	Escherichia coli		5-(pentyl 6-dihydrogen phosphate)-6-([(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino)pyrimidine-2,4(1H,3H)-dione	637585	16906	comparison with inhibition of Bacillus subtilis lumazine synthase
2.5.1.9	Escherichia coli		5-amino-6-((2R,3R,4S)-2,3,4,5-tetrahydroxypentyloxy)-pyrimidine-2,4(1H,3H)-dione	723033		uncompetitive inhibition
2.5.1.9	Mycobacterium tuberculosis		5-amino-6-((2R,3R,4S)-2,3,4,5-tetrahydroxypentyloxy)-pyrimidine-2,4(1H,3H)-dione	723033		uncompetitive inhibition
2.5.1.9	Escherichia coli		5-amino-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	723033	19641	partial inhibition
2.5.1.9	Mycobacterium tuberculosis		5-amino-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	723033	19641	competitive inhibition
2.5.1.9	Escherichia coli		5-nitro-6-[(3S,4S,5R)-3,4,5,6-tetrahydroxyhexyl]pyrimidine-2,4(1H,3H)-dione	723033	19642	partial inhibition
2.5.1.9	Mycobacterium tuberculosis		5-nitro-6-[(3S,4S,5R)-3,4,5,6-tetrahydroxyhexyl]pyrimidine-2,4(1H,3H)-dione	723033	19642	competitive inhibition
2.5.1.9	Escherichia coli		5-nitro-6-[[(2R,3R,4R)-2,3,4,5 tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	688575	5183	
2.5.1.9	Mycobacterium tuberculosis		5-nitro-6-[[(2R,3R,4R)-2,3,4,5 tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	688575	5183	
2.5.1.9	Escherichia coli		5-nitro-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	723033	5183	partial inhibition
2.5.1.9	Mycobacterium tuberculosis		5-nitro-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	723033	5183	partial inhibition
2.5.1.9	Escherichia coli		5-nitro-6-[[(2S,3R,4R)-2,3,4,5-tetrahydroxypentyl]oxy]pyrimidine-2,4(1H,3H)-dione	723033	19640	competitive inhibition
2.5.1.9	Mycobacterium tuberculosis		5-nitro-6-[[(2S,3R,4R)-2,3,4,5-tetrahydroxypentyl]oxy]pyrimidine-2,4(1H,3H)-dione	723033	19640	partial inhibition
2.5.1.9	Escherichia coli		5-nitro-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]pyrimidine-2,4(1H,3H)-dione	723033	6439	mixed-type inhibition
2.5.1.9	Mycobacterium tuberculosis		5-nitro-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]pyrimidine-2,4(1H,3H)-dione	723033	6439	competitive inhibition
2.5.1.9	Saccharomyces cerevisiae		6,7-dihydroxy-8-ribityllumazine	637561	63668	
2.5.1.9	Saccharomyces cerevisiae		6,7-dimethyl-8-(1'-D-xylityl)lumazine	637561	63669	
2.5.1.9	Saccharomyces cerevisiae		6-Methyl-7-hydroxy-8-ribityllumazine	637561	10453	
2.5.1.9	Eremothecium ashbyi		6-Methyl-7-hydroxy-8-ribityllumazine	637565	10453	
2.5.1.9	Geobacillus stearothermophilus		6-Methyl-7-hydroxy-8-ribityllumazine	637575	10453	
2.5.1.9	Escherichia coli		6-methyl-7-methylidene-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-7,8-dihydropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione	637585	16903	competitive, comparison with inhibition of Bacillus subtilis lumazine synthase
2.5.1.9	Eremothecium ashbyi		7-hydroxy-6-(2-carboxyethyl)-8-(1-D-ribityl)lumazine	637565	33230	
2.5.1.9	Eremothecium ashbyi		7-hydroxy-6-(D-1,2-dihydroxyethyl)-8-(1-D-ribityl)lumazine	637565	33231	
2.5.1.9	Eremothecium ashbyi		7-Hydroxy-6-(L-1,2-dihydroxyethyl)-8-(1-D-ribityl)lumazine	637565	29051	i.e. photolumazine A
2.5.1.9	Eremothecium ashbyi		7-hydroxy-6-(p-hydroxyphenyl)-8-(1-D-ribityl)lumazine	637565		
2.5.1.9	Eremothecium ashbyi		7-Hydroxy-6-hydroxymethyl-8-(1-D-ribityl)lumazine	637565	29052	photolumazine B
2.5.1.9	Escherichia coli		7-hydroxy-7-methyl-8-((2S,3S,4R)-2,3,4,5-tetrahydroxypentyl)-7,8-dihydropteridin-2,4,6(1H,3H,5H)-trione	723033		
2.5.1.9	Mycobacterium tuberculosis		7-hydroxy-7-methyl-8-((2S,3S,4R)-2,3,4,5-tetrahydroxypentyl)-7,8-dihydropteridin-2,4,6(1H,3H,5H)-trione	723033		competitive inhibition
2.5.1.9	Eremothecium ashbyi		7-Hydroxy-8-(1-D-ribityl)lumazine	637565	29053	i.e. photolumazine
2.5.1.9	Escherichia coli		8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-5,8-dihydropteridine-2,4,6,7(1H,3H)-tetrone	723033	17497	competitive inhibition
2.5.1.9	Mycobacterium tuberculosis		8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-5,8-dihydropteridine-2,4,6,7(1H,3H)-tetrone	723033	17497	
2.5.1.9	Escherichia coli		9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-7,9-dihydro-1H-purine-2,6,8(3H)-trione	637585	7991	competitive, comparison with inhibition of Bacillus subtilis lumazine synthase
2.5.1.9	Escherichia coli		9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-7,9-dihydro-1H-purine-2,6,8(3H)-trione	723033	7991	competitive inhibition
2.5.1.9	Mycobacterium tuberculosis		9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-7,9-dihydro-1H-purine-2,6,8(3H)-trione	723033	7991	
2.5.1.9	Saccharomyces cerevisiae		Avidin	637563		moderately, no prevention by biotin
2.5.1.9	Geobacillus stearothermophilus		Ca2+	637575	18	
2.5.1.9	Spinacia oleracea		Cu2+	637563	28	
2.5.1.9	Geobacillus stearothermophilus		Cu2+	637575	28	
2.5.1.9	Escherichia coli		ethyl 2-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-ylamino)-2-oxoacetate	723033		uncompetitive inhibition
2.5.1.9	Mycobacterium tuberculosis		ethyl 2-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-ylamino)-2-oxoacetate	723033		uncompetitive inhibition
2.5.1.9	Escherichia coli		ethyl [(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)amino](oxo)acetate	723033	6019	mixed-type inhibition
2.5.1.9	Mycobacterium tuberculosis		ethyl [(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)amino](oxo)acetate	723033	6019	
2.5.1.9	Escherichia coli		ethyl [(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)amino](oxo)acetate	723033	61733	
2.5.1.9	Mycobacterium tuberculosis		ethyl [(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)amino](oxo)acetate	723033	61733	uncompetitive inhibition
2.5.1.9	Spinacia oleracea		Hg2+	637563	31	
2.5.1.9	Geobacillus stearothermophilus		Hg2+	637575	31	
2.5.1.9	Geobacillus stearothermophilus		iodoacetamide	637575	63	
2.5.1.9	Escherichia coli		methyl 2-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-ylamino)-2-oxoacetate	723033		uncompetitive inhibition
2.5.1.9	Mycobacterium tuberculosis		methyl 2-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-ylamino)-2-oxoacetate	723033		uncompetitive inhibition
2.5.1.9	Geobacillus stearothermophilus		Mg2+	637575	25	
2.5.1.9	Geobacillus stearothermophilus		Mn2+	637575	26	
2.5.1.9	Geobacillus stearothermophilus		more	637575		no effect by Ba2+, Co2+, EDTA
2.5.1.9	Escherichia coli		more	637586		incorporation of an amide into 5-phosphonoalkyl-6-D-ribitylaminopyrimidinedione lumazine synthase inhibitors results in an unexpected reversal of selectivity for riboflavin synthase versus lumazine synthase
2.5.1.9	Escherichia coli		N-(2,4-dioxo-6-((2R,3R,4R)-2,3,4,5-tetrahydroxypentylthio)-1,2,3,4-tetrahydropyrimidin-5-yl)methacrylamide	723033		
2.5.1.9	Mycobacterium tuberculosis		N-(2,4-dioxo-6-((2R,3R,4R)-2,3,4,5-tetrahydroxypentylthio)-1,2,3,4-tetrahydropyrimidin-5-yl)methacrylamide	723033		uncompetitive inhibition
2.5.1.9	Escherichia coli		N-(2,4-dioxo-6-((2R,3R,4R)-2,3,4,5-tetrahydroxypentylthio)-1,2,3,4-tetrahydropyrimidin-5-yl)propionamide	723033		
2.5.1.9	Mycobacterium tuberculosis		N-(2,4-dioxo-6-((2R,3R,4R)-2,3,4,5-tetrahydroxypentylthio)-1,2,3,4-tetrahydropyrimidin-5-yl)propionamide	723033		uncompetitive inhibition
2.5.1.9	Escherichia coli		N-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-yl)isobutyramide	723033		
2.5.1.9	Mycobacterium tuberculosis		N-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-yl)isobutyramide	723033		uncompetitive inhibition
2.5.1.9	Escherichia coli		N-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-yl)methacrylamide	723033		
2.5.1.9	Mycobacterium tuberculosis		N-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-yl)methacrylamide	723033		uncompetitive inhibition
2.5.1.9	Escherichia coli		N-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-yl)propionamide	723033		
2.5.1.9	Mycobacterium tuberculosis		N-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-yl)propionamide	723033		uncompetitive inhibition
2.5.1.9	Escherichia coli		N-(2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino)-1,2,3,4-tetrahydropyrimidin-5-yl)-3,3,3-trifluoropropanamide	723033		
2.5.1.9	Mycobacterium tuberculosis		N-(2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino)-1,2,3,4-tetrahydropyrimidin-5-yl)-3,3,3-trifluoropropanamide	723033		uncompetitive inhibition
2.5.1.9	Escherichia coli		N-(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methylpropanamide	723033	7986	uncompetitive inhibition
2.5.1.9	Mycobacterium tuberculosis		N-(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methylpropanamide	723033	7986	
2.5.1.9	Escherichia coli		N-(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)propanamide	723033	7985	uncompetitive inhibition
2.5.1.9	Mycobacterium tuberculosis		N-(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)propanamide	723033	7985	
2.5.1.9	Escherichia coli		N-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-methacrylamide	723033		
2.5.1.9	Mycobacterium tuberculosis		N-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-methacrylamide	723033		uncompetitive inhibition
2.5.1.9	Escherichia coli		N-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)propanamide	723033	61734	
2.5.1.9	Mycobacterium tuberculosis		N-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)propanamide	723033	61734	uncompetitive inhibition
2.5.1.9	Escherichia coli		N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dion-5-ylpropionamide	688578	7985	uncompetitive
2.5.1.9	Escherichia coli		N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dione-5-ylisobutyramide	688578	7986	uncompetitive
2.5.1.9	Escherichia coli		N-[2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino]-1,2,3,4-tetrahydropyrimidin-5-yl)methacrylamide	723033		
2.5.1.9	Mycobacterium tuberculosis		N-[2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino]-1,2,3,4-tetrahydropyrimidin-5-yl)methacrylamide	723033		partial inhibition
2.5.1.9	Escherichia coli		N-[2,4-dioxo-6-(ribitylamino)-1,2,3,4-tetrahydropyrimidin-5-yl]oxalamic acid ethyl ester	688578	6019	mixed type inhibition
2.5.1.9	Saccharomyces cerevisiae		p-chloromercuribenzenesulfonate	637561, 637563	1069	reversible by cysteine or 2-mercaptoethanol
2.5.1.9	Saccharomyces cerevisiae		p-chloromercuribenzoate	637563	40	
2.5.1.9	Spinacia oleracea		p-chloromercuribenzoate	637563	40	
2.5.1.9	Geobacillus stearothermophilus		p-chloromercuribenzoate	637575	40	
2.5.1.9	Saccharomyces cerevisiae		riboflavin	637561	298	product inhibition, Saccharomyces cerevisiae
2.5.1.9	Arabidopsis thaliana		riboflavin	658236	298	sigmoidal product inhibition
2.5.1.9	Geobacillus stearothermophilus		Zn2+	637575	19	
2.5.1.9	Escherichia coli		[3-(4-chlorophenyl)-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](m-tolyl)methanone	705302	9991	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Mycobacterium tuberculosis		[3-(4-chlorophenyl)-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](m-tolyl)methanone	705302	9991	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Escherichia coli		[3-(4-chlorophenyl)-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](o-tolyl)methanone	705302	12767	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Mycobacterium tuberculosis		[3-(4-chlorophenyl)-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](o-tolyl)methanone	705302	12767	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Escherichia coli		[3-(4-chlorophenyl)-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](p-tolyl)methanone	705302	12768	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Mycobacterium tuberculosis		[3-(4-chlorophenyl)-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](p-tolyl)methanone	705302	12768	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Escherichia coli		[5-(4-chlorophenyl)-5-hydroxy-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](m-tolyl)methanone	705302	9990	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Mycobacterium tuberculosis		[5-(4-chlorophenyl)-5-hydroxy-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](m-tolyl)methanone	705302	9990	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Escherichia coli		[5-(4-chlorophenyl)-5-hydroxy-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](o-tolyl)methanone	705302	9992	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Mycobacterium tuberculosis		[5-(4-chlorophenyl)-5-hydroxy-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](o-tolyl)methanone	705302	9992	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Escherichia coli		[5-(4-chlorophenyl)-5-hydroxy-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](p-tolyl)methanone	705302	9993	covalent hydrate of trifluoromethylated pyrazole
2.5.1.9	Mycobacterium tuberculosis		[5-(4-chlorophenyl)-5-hydroxy-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](p-tolyl)methanone	705302	9993	covalent hydrate of trifluoromethylated pyrazole
4.4.1.21	Edwardsiella tarda	D-glucose		694032	33	expression of LuxS is increased by 0.5% (w/v) D-glucose
4.4.1.21	Streptococcus pyogenes	more		691502		luxS expression is not regulated by autoinducer-2, modulation of luxS expression levels allows adjusting bacterial fitness in response to changing host conditions
4.4.1.21	Bacillus subtilis		(2S)-2-amino-4-[(2R,3R)-2,3-dihydroxy-3-N-hydroxycarbamoylpropylmercapto] butyric acid	678153	6760	
4.4.1.21	Vibrio harveyi		(2S)-2-amino-4-[(2R,3R)-2,3-dihydroxy-3-N-hydroxycarbamoylpropylmercapto] butyric acid	678153	6760	
4.4.1.21	Escherichia coli		(2S)-2-amino-4-[(2R,3R)-2,3-dihydroxy-3-N-hydroxycarbamoylpropylmercapto] butyric acid	681282	6760	
4.4.1.21	Bacillus subtilis		(2S)-2-amino-4-[(2R,3S)-2,3-dihydroxy-3-N-hydroxycarbamoylpropylmercapto] butyric acid	678153	6759	
4.4.1.21	Vibrio harveyi		(2S)-2-amino-4-[(2R,3S)-2,3-dihydroxy-3-N-hydroxycarbamoylpropylmercapto] butyric acid	678153	6759	
4.4.1.21	Escherichia coli		(2S)-2-amino-4-[(2R,3S)-2,3-dihydroxy-3-N-hydroxycarbamoylpropylmercapto] butyric acid	681282	6759	
4.4.1.21	Bacillus subtilis		(2S)-2-amino-6-(N-formyl-N-hydroxyamino)hexanoic acid	678153	40247	
4.4.1.21	Bacillus subtilis		D-erythronohydroxamic acid	678153	6761	
4.4.1.21	Vibrio harveyi		D-erythronohydroxamic acid	678153	6761	
4.4.1.21	Escherichia coli		D-erythronohydroxamic acid	681282	6761	
4.4.1.21	Bacillus subtilis		D-ribosylornithine	678153	45324	
4.4.1.21	Bacillus subtilis		methionine	678153	83	
4.4.1.21	Bacillus subtilis		more	682202		5,6,7,8,9-pentadeoxy-6-fluoro-D-ribo-dec-5(Z)-enofuranuronate a S-ribosylhomocysteine analogue and 5,6-dideoxy-6-fluoro-D-ribo-hex-5-enofuranose a S-ribosylhomocysteine analogue have no inhibitory activity
4.4.1.21	Bacillus subtilis		S-(1-amino-1,4-anhydro-1,5-dideoxy-D-ribitol-5-yl)-L-homocysteine	714473	59632	inhibition of Co(II)-substituted enzyme
4.4.1.21	Bacillus subtilis		S-(3,5-dideoxy-3-fluoro-1-O-methyl-D-xylofuranos-5-yl)-L-homocysteine	702662	54771	
4.4.1.21	Bacillus subtilis		S-(3,5-dideoxy-3-fluoro-D-xylofuranos-5-yl)-L-homocysteine	702662	54770	
4.4.1.21	Bacillus subtilis		S-(3,5-dideoxy-D-erythro-pentofuranos-5-yl)homocysteine	702662	54766	
4.4.1.21	Bacillus subtilis		S-(4-amino-4,5-dideoxy-alpha/beta-D-ribofuranos-5-yl)-L-homocysteine	714473	59634	inhibition of Co(II)-substituted enzyme. The hemiaminal may undergo ring opening to form an aldehyde which may undergo the aldose-ketose isomerization reaction to form a 2-ketone, which presumably binds to the LuxS active site with higher affinity than the original ribose analogue
4.4.1.21	Bacillus subtilis		S-(4-amino-4,5-dideoxy-D-ribono-1,4-lactam-5-yl)-L-homocysteine	714473	59633	inhibition of Co(II)-substituted enzyme
4.4.1.21	Bacillus subtilis		S-(5-deoxy-3-deoxy-3-bromo-D-xylofuranos-5-yl)-L-homocysteine	702662	9634	
4.4.1.21	Bacillus subtilis		S-(5-deoxy-3-deoxy-3-fluoro-D-xylofuranos-5-yl)-L-homocysteine	702662	17374	
4.4.1.21	Bacillus subtilis		S-(5-deoxy-3-O-methyl-D-ribofuranos-5-yl)homocysteine	702662	54768	
4.4.1.21	Bacillus subtilis		S-(5-deoxy-3-O-methyl-D-xylofuranos-5-yl)homocysteine	702662	54767	
4.4.1.21	Bacillus subtilis		S-(5-deoxy-D-xylofuranos-5-yl)-L-homocysteine	702662	54769	
4.4.1.21	Bacillus subtilis		S-[3-bromo-3,5-dideoxy-D-ribofuranos-5-yl]-L-homocysteine	692775	9634	
4.4.1.21	Escherichia coli		S-[3-bromo-3,5-dideoxy-D-ribofuranos-5-yl]-L-homocysteine	692775	9634	
4.4.1.21	Vibrio harveyi		S-[3-bromo-3,5-dideoxy-D-ribofuranos-5-yl]-L-homocysteine	692775	9634	
4.4.1.21	Bacillus subtilis		S-[3-fluoro-3,5-dideoxy-D-ribofuranos-5-yl]-L-homocysteine	692775	17374	
4.4.1.21	Escherichia coli		S-[3-fluoro-3,5-dideoxy-D-ribofuranos-5-yl]-L-homocysteine	692775	17374	
4.4.1.21	Vibrio harveyi		S-[3-fluoro-3,5-dideoxy-D-ribofuranos-5-yl]-L-homocysteine	692775	17374	
3.1.1.31	Homo sapiens		(NH4)2SO4	80873	334	0.06 M, 55% inhibition
3.1.1.31	Zymomonas mobilis		glucose-6-phosphate	80871	99	competitive
3.1.1.31	Plasmodium falciparum		glutathione	714104	41	PfGluPho is inhibited by S-glutathionylation
1.1.1.37	Mycobacterium phlei	2-mercaptoethanol		286635	59	
1.1.1.37	Corynebacterium glutamicum	citrate		656320	125	oxidation of malate to oxaloacetate
1.1.1.37	Mycobacterium phlei	cysteine		286635	70	
1.1.1.37	Anthocidaris crassispina	dithiothreitol		286652	42	
1.1.1.37	Mycobacterium phlei	glutathione		286635	41	
1.1.1.37	Corynebacterium glutamicum	Isocitrate		656320	242	oxidation of malate to oxaloacetate
1.1.1.37	Comamonas testosteroni	L-Malate		286630	180	
1.1.1.37	Sus scrofa	L-Malate		286629, 286630	180	
1.1.1.37	Escherichia coli	more		685734		Escherichia coli proteome response to a heatshock stress causes a 1.6-fold increase of malate dehydrogenase, even under the heat-shock condition, whereas the total number of soluble proteins decreases by about 5%
1.1.1.37	Malassezia pachydermatis	more		691578		highest MDH activity under aerobic conditions
1.1.1.37	Streptomyces coelicolor	more		711519		MDH is not affected by DTT or EDTA
1.1.1.37	Streptomyces aureofaciens	NaCl		286672	39	activation of the enzyme obtained by increasing the salt concentration to 3 M NaCl/l
1.1.1.37	Anthocidaris crassispina	Sodium phosphate		286652	2140	
1.1.1.37	Corynebacterium glutamicum		(NH4)2SO4	656320	334	reduction of oxaloacetate to malate and oxidation of malate to oxaloacetate
1.1.1.37	Sulfolobus acidocaldarius		(S)-malate	286660	180	product inhbition, 66% inhibition at 5 mM
1.1.1.37	Streptomyces coelicolor		(S)-malate	711519	180	substrate inhibition, 60% inhibition at 30 mM
1.1.1.37	Archaeoglobus fulgidus		(S)-malate	721445	180	product inhibitor
1.1.1.37	Zea mays		(S)-malate	723482	180	24.2% substrate inhibition at 20 mM
1.1.1.37	Homo sapiens		1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one	712850		i.e. differentiation-inducing factor DIF-1, a morphogen secreted from Dictyostelium discoideum, inhibits proliferation of several cancer cells via suppression of the Wnt/beta -catenin signaling pathway, specifically to mMDH and inhibits its activity, no binding of cytosolic MDH, overview
1.1.1.37	Sus scrofa		11-chloro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100454	65.3% inhibition at 0.010 mM
1.1.1.37	Methanospirillum hungatei		2',3'-Cyclic AMP	286639	733	
1.1.1.37	Sus scrofa		2,3-dimethoxy-6-oxo-5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine-9-carbonitrile	711909	100452	89.2% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		2,3-dimethoxy-9-(trifluoromethyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100445	97.7% inhibition at 0.010 mM
1.1.1.37	Arabidopsis thaliana		2,4-dichlorophenoxybutyric acid	689534	41910	
1.1.1.37	Sus scrofa		2-Hydroxy-5-nitrobenzyl bromide	286629	2674	
1.1.1.37	Homo sapiens		2-methoxy-1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one	712850		i.e. differentiation-inducing factor 2-MIDIF-1, a morphogen secreted from Dictyostelium discoideum, inhibits proliferation of several cancer cells via suppression of the Wnt/beta -catenin signaling pathway, binds specifically to mMDH and inhibits its activity, no binding of cytosolic MDH, overview
1.1.1.37	Sulfolobus acidocaldarius		2-oxoglutarate	286660	32	44% inhibition at 5 mM
1.1.1.37	Corynebacterium glutamicum		2-oxoglutarate	656320	32	reduction of oxaloacetate to malate and oxidation of malate to oxaloacetate
1.1.1.37	Haemophilus parasuis		3-Aminopyridine adenine dinucleotide	286671	10415	
1.1.1.37	Sus scrofa		3-methoxy-9-trifluormethyl-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100446	83.9% inhibition at 0.010 mM
1.1.1.37	Haemophilus parasuis		3-methylpyridine adenine dinucleotide	286671	31603	
1.1.1.37	Haemophilus parasuis		3-pyridylacetonitrile adenine dinucleotide	286671	69759	
1.1.1.37	Haemophilus parasuis		3-pyridylcarbinol adenine dinucleotide	286671	31613	
1.1.1.37	Zea mays		4-coumaric acid	723482	900	13.4% inhibition at 0.1 mM
1.1.1.37	Sus scrofa		4-methoxy-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100453	87.6% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		5-(3,4-dichlorobenzyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58373	
1.1.1.37	Sus scrofa		5-(4-methylbenzyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58372	
1.1.1.37	Sus scrofa		5-benzyl-9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58363	8.6% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		5-benzyl-9-chloro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58364	
1.1.1.37	Sus scrofa		5-benzyl-9-methoxy-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58368	
1.1.1.37	Sus scrofa		5-benzyl-9-methyl-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58367	
1.1.1.37	Sus scrofa		5-benzyl-9-tert-butyl-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58365	
1.1.1.37	Sus scrofa		5-benzyl-9-trifluoromethyl-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58366	
1.1.1.37	Sus scrofa		6-oxo-5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine-9-carbonitrile	711909	100440	91.3% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		6-oxo-5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine-9-carboxylic acid	711909	100442	98.7% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100436	78.7% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		8,10-dichloro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100455	28.7% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-(methylsulfinyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100444	96.2% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-(methylthio)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100443	76.6% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-(trifluoromethyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100439	88.3% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-bromo-12-(prop-2-en-1-yl)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100457	74.1% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-bromo-12-methyl-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100458	98.0% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-bromo-2,3-dimethoxy-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100447	56.3% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-bromo-2-methoxy-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100448	58.7% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-bromo-3-methoxy-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100449	15.0% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-bromo-4-hydroxy-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100451	25.9% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-bromo-4-methoxy-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100450	82.0% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-bromo-5-(3,4-dichlorobenzyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58371	
1.1.1.37	Sus scrofa		9-bromo-5-(4-methoxybenzyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58370	
1.1.1.37	Sus scrofa		9-bromo-5-(4-methylbenzyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58369	
1.1.1.37	Sus scrofa		9-bromo-5-methyl-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100456	81.9% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	4642	74.5% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-chloro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100437	73.4% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-fluoro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100438	46.2% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-methyl-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	100441	87.8% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	3442	54.2% inhibition at 0.010 mM
1.1.1.37	Sus scrofa		9-tert-butyl-5-(3,4-dichlorobenzyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one	711909	58374	
1.1.1.37	Methanospirillum hungatei		acetyl-CoA	286639	27	
1.1.1.37	Coccochloris peniocystis		acetyl-CoA	286664	27	
1.1.1.37	Haemophilus parasuis		adenosine	286671	116	
1.1.1.37	Haemophilus parasuis		adenosine 5'-diphosphoribose	286671	337	
1.1.1.37	Methanospirillum hungatei		ADP	286639	8	
1.1.1.37	Anthocidaris crassispina		ADP	286652	8	
1.1.1.37	Haemophilus parasuis		ADP	286671	8	
1.1.1.37	Sus scrofa		ADP	656883	8	competitive
1.1.1.37	Acinetobacter lwoffii		AgNO3	286631	307	
1.1.1.37	Methanospirillum hungatei		alpha-ketoglutarate	286639	32	end-product inhibition
1.1.1.37	Methanospirillum hungatei		alpha-ketoglutarate	286660	32	
1.1.1.37	Sulfolobus acidocaldarius		alpha-ketoglutarate	286660	32	
1.1.1.37	Haemophilus parasuis		AMP	286671	9	
1.1.1.37	Sus scrofa		AMP	656883	9	competitive
1.1.1.37	Taenia solium		arsenate	700562	222	uncompetitive inhibition
1.1.1.37	Methanospirillum hungatei		ATP	286639	7	
1.1.1.37	Aspergillus niger		ATP	286644	7	
1.1.1.37	Anthocidaris crassispina		ATP	286652	7	
1.1.1.37	Coccochloris peniocystis		ATP	286664	7	
1.1.1.37	Vigna radiata var. radiata		ATP	286664	7	
1.1.1.37	Haemophilus parasuis		ATP	286671	7	
1.1.1.37	Sus scrofa		ATP	656883	7	competitive
1.1.1.37	Zea mays		ATP	723482	7	43.7% inhibition at 5 mM
1.1.1.37	Flavobacterium frigidimaris		BaCl2	668012	968	1 mM, 24.9% inhibition
1.1.1.37	Sus scrofa		butyl 6-oxo-5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine-9-carboxylate	711909	58376	
1.1.1.37	Acinetobacter lwoffii		Ca2+	286631	18	
1.1.1.37	Bacillus subtilis		Ca2+	286635	18	
1.1.1.37	Rattus norvegicus		Ca2+	668125	18	decreases activity under normal and pathological conditions
1.1.1.37	Ceratonia siliqua		Ca2+	723710	18	
1.1.1.37	Flavobacterium frigidimaris		CaCl2	668012	193	1 mM, 29.1% inhibition
1.1.1.37	Sus scrofa		cAMP	656883	233	competitive
1.1.1.37	Coccochloris peniocystis		citrate	286664	125	
1.1.1.37	Corynebacterium glutamicum		citrate	656320	125	reduction of oxaloacetate to malate
1.1.1.37	Vulcanithermus mediatlanticus		citrate	667749	125	competitive with respect to oxaloacetate
1.1.1.37	Acinetobacter lwoffii		Co2+	286631	21	
1.1.1.37	Mycobacterium phlei		Co2+	286635	21	
1.1.1.37	Streptomyces coelicolor		Co2+	711519	21	36% inhibition at 2 mM
1.1.1.37	Coccochloris peniocystis		CoA	286664	10	
1.1.1.37	Flavobacterium frigidimaris		CoCl2	668012	347	1 mM, 39% inhibition
1.1.1.37	Mycobacterium phlei		Cu2+	286635	28	
1.1.1.37	Rattus norvegicus		Cu2+	668125	28	0.01-0.4 mM, activity from ischemic tissue decreases more significantly compared to the control
1.1.1.37	Zea mays		Cu2+	723482	28	25% inhibition at 0.1 mM
1.1.1.37	Flavobacterium frigidimaris		CuCl2	668012	295	1 mM, 89.8% inhibition
1.1.1.37	Bos taurus		D-fructose 1,6-diphosphate	286629	100	heart s-MDH, inhibits the binding of NADH
1.1.1.37	Bradyrhizobium japonicum		Dicarbonate	286655	20312	
1.1.1.37	Glycine max		Dicarbonate	286655	20312	
1.1.1.37	Thermus thermophilus		diethyldicarbonate	286640	265	
1.1.1.37	Streptomyces coelicolor		DMSO	711519	702	
1.1.1.37	Flavobacterium frigidimaris		EDTA	668012	223	1 mM, 52.2% inhibition
1.1.1.37	Sus scrofa		ethyl 6-oxo-5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine-9-carboxylate	711909	58362	
1.1.1.37	Rattus norvegicus		Fe2+	668125	23	
1.1.1.37	Streptomyces coelicolor		Fe2+	711519	23	complete inhibition at 2 mM
1.1.1.37	Zea mays		ferulic acid	723482	378	24.5% inhibition at 0.1 mM
1.1.1.37	Plasmodium falciparum		gossypol	655488	1358	IC50: 0.0115 mM
1.1.1.37	Sus scrofa		hexyl 6-oxo-5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine-9-carboxylate	711909	58378	
1.1.1.37	Mycobacterium phlei		Hg2+	286635	31	
1.1.1.37	Streptomyces avermitilis		Hg2+	723141	31	
1.1.1.37	Flavobacterium frigidimaris		HgCl2	668012	104	1 mM, complete inhibition
1.1.1.37	Flavobacterium frigidimaris		hydroxylamine	668012	80	1 mM, 57.1% inhibition
1.1.1.37	Dictyostelium discoideum		Hydroxymalonate	286646	3003	
1.1.1.37	Sus scrofa		Hydroxymalonate	286629, 286646	3003	
1.1.1.37	Haemophilus parasuis		Hydroxymalonate	286671	3003	
1.1.1.37	Glycine max		iodoacetamide	286655	63	
1.1.1.37	Mycobacterium phlei		iodoacetate	286635	87	
1.1.1.37	Flavobacterium frigidimaris		iodoacetate	668012	87	1 mM, 93.6% inhibition
1.1.1.37	Corynebacterium glutamicum		Isocitrate	656320	242	reduction of oxaloacetate to malate
1.1.1.37	Physarum polycephalum		L-Malate	286627	180	
1.1.1.37	Gallus sp.		L-Malate	286627, 286637, 286647	180	
1.1.1.37	Methanospirillum hungatei		L-Malate	286639, 286660	180	
1.1.1.37	Sulfolobus acidocaldarius		L-Malate	286660	180	product inhibition
1.1.1.37	Homo sapiens		L-Malate	286650, 286665	180	
1.1.1.37	Rattus norvegicus		L-Malate	286647, 286650, 286665	180	
1.1.1.37	Sus scrofa		L-Malate	286637, 286638, 286639, 286647, 286650, 286660, 286665	180	
1.1.1.37	Beggiatoa leptomitiformis		L-Malate	654915	180	inhibition constant: 3.65 mM
1.1.1.37	Sus scrofa		methyl 6-oxo-5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine-9-carboxylate	711909	58362	60.9% inhibition at 0.010 mM
1.1.1.37	Acinetobacter lwoffii		Mg2+	286631	25	
1.1.1.37	Bacillus subtilis		Mg2+	286635	25	
1.1.1.37	Mycobacterium phlei		Mg2+	286635	25	
1.1.1.37	Ceratonia siliqua		Mg2+	723710	25	
1.1.1.37	Flavobacterium frigidimaris		MgCl2	668012	176	1 mM,34.9% inhibition
1.1.1.37	Mycobacterium phlei		Mn2+	286635	26	
1.1.1.37	Vulcanithermus mediatlanticus		Mn2+	667749	26	2-40 mM
1.1.1.37	Streptomyces avermitilis		Mn2+	723141	26	
1.1.1.37	Flavobacterium frigidimaris		MnCl2	668012	262	1 mM, 28.6% inhibition
1.1.1.37	Sulfolobus acidocaldarius		more	286660		not inhibitory: AMP, ADP, ATP
1.1.1.37	Echinococcus granulosus		more	656753		unaffected by excess of L-malate
1.1.1.37	Clonorchis sinensis		more	689325		no substrate inhibition by L-malate up to 20 mM
1.1.1.37	Candida albicans		more	691578		strong decrease in MDH activity under aerobic conditions
1.1.1.37	Saccharomyces cerevisiae		more	691578		strong decrease in MDH activity under aerobic conditions
1.1.1.37	Streptomyces coelicolor		more	711519		MDH is not affected by DTT or EDTA
1.1.1.37	Sus scrofa		more	711909		development of 5-benzylpaullones and paullone-9-carboxylic acid alkyl esters as selective inhibitors of mMDH, overview
1.1.1.37	Homo sapiens		more	712850		differentiation-inducing factors DIF-3, i.e. 1-(3-chloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one, and 6-MIDIF-3, a 6-methoxy isomer of DIF-3, bind spefically to mMDH, but do not inhibit the enzyme activity, no binding of cytosolic MDH
1.1.1.37	Malus domestica		more	713301		cyMDH is sensitive to cold and salt stresses
1.1.1.37	Taenia solium		more	722201		not inhibitory: praziquantel and albendazole
1.1.1.37	Ceratonia siliqua		more	723710		no effect by NaCl
1.1.1.37	Anthocidaris crassispina		Na2SO3	286652	2592	
1.1.1.37	Phycomyces blakesleeanus		NAD+	286651	4	
1.1.1.37	Sulfolobus acidocaldarius		NAD+	286660	4	product inhbition, 29% inhibition at 5 mM, 42% inhibition at 10 mM; product inhibition
1.1.1.37	Haemophilus parasuis		NAD+	286671	4	
1.1.1.37	Acinetobacter lwoffii		NADH	286631	3	substrate inhibition
1.1.1.37	Sus scrofa		NADH	286638	3	product inhibition
1.1.1.37	Methanospirillum hungatei		NADH	286639	3	
1.1.1.37	Sus scrofa		NADH	286639	3	
1.1.1.37	Haemophilus parasuis		NADH	286671	3	product inhibition
1.1.1.37	Archaeoglobus fulgidus		NADH	721445	3	substrate inhibition
1.1.1.37	Sulfolobus acidocaldarius		NADP+	286660	6	product inhbition, 26% inhibition at 10 mM; product inhibition
1.1.1.37	Flavobacterium frigidimaris		NEM	668012	46	1 mM, complete inhibition
1.1.1.37	Mycobacterium phlei		Ni2+	286635	36	
1.1.1.37	Streptomyces avermitilis		Ni2+	723141	36	
1.1.1.37	Flavobacterium frigidimaris		NiCl2	668012	598	1 mM, 36.8% inhibition
1.1.1.37	Sus scrofa		octyl 6-oxo-5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine-9-carboxylate	711909	58379	
1.1.1.37	Drosophila virilis		oxaloacetate	286626, 286627	53	
1.1.1.37	Physarum polycephalum		oxaloacetate	286627	53	
1.1.1.37	Acinetobacter lwoffii		oxaloacetate	286631	53	substrate inhibition
1.1.1.37	Comamonas testosteroni		oxaloacetate	286630, 286640	53	
1.1.1.37	Aspergillus niger		oxaloacetate	286644	53	
1.1.1.37	Phycomyces blakesleeanus		oxaloacetate	286627, 286651	53	
1.1.1.37	Anthocidaris crassispina		oxaloacetate	286652	53	substrate inhibition
1.1.1.37	Sulfolobus acidocaldarius		oxaloacetate	286660	53	substrate inhibition; substrate inhibition, 29% inhibition at 5 mM
1.1.1.37	Thermus thermophilus		oxaloacetate	286640, 286660	53	substrate inhibition
1.1.1.37	Coccochloris peniocystis		oxaloacetate	286664	53	
1.1.1.37	Rattus norvegicus		oxaloacetate	286665	53	
1.1.1.37	Sus scrofa		oxaloacetate	286626, 286630, 286637, 286638, 286640, 286651, 286660, 286664, 286665	53	
1.1.1.37	Syntrophobacter fumaroxidans		oxaloacetate	286669	53	
1.1.1.37	Thermus thermophilus		oxaloacetate	286669	53	
1.1.1.37	Trichomonas gallinae		oxaloacetate	286670	53	
1.1.1.37	Trichomonas vaginalis		oxaloacetate	286670	53	
1.1.1.37	Tritrichomonas suis		oxaloacetate	286670	53	
1.1.1.37	Echinococcus granulosus		oxaloacetate	656753	53	above 0.025 mM
1.1.1.37	Mesembryanthemum crystallinum		oxaloacetate	656923	53	
1.1.1.37	Aptenia cordifolia		oxaloacetate	657090	53	substrate inhibition, pH-dependent
1.1.1.37	Vulcanithermus mediatlanticus		oxaloacetate	667749	53	
1.1.1.37	Clonorchis sinensis		oxaloacetate	689325	53	substrate inhibition at above 0.3 mM, 37% inhibition at 1 mM
1.1.1.37	Phytophthora infestans		oxaloacetate	700338	53	
1.1.1.37	Streptomyces coelicolor		oxaloacetate	711519	53	substrate inhibition, 50% inhibition at 6 mM
1.1.1.37	Archaeoglobus fulgidus		oxaloacetate	721445	53	substrate inhibition
1.1.1.37	Streptomyces avermitilis		oxaloacetate	723141	53	substrate inhibition
1.1.1.37	Zea mays		oxaloacetate	723482	53	27.4% substrate inhibition at 1 mM
1.1.1.37	Mycobacterium phlei		p-chloromercuribenzoate	286635	40	
1.1.1.37	Anthocidaris crassispina		p-Chloromercuriphenylsulfonate	286652	1069	
1.1.1.37	Sus scrofa		pentyl 6-oxo-5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine-9-carboxylate	711909	58377	
1.1.1.37	Glycine max		Phenylmethanesulfonylfluoride	286655	218	
1.1.1.37	Sus scrofa		propyl 6-oxo-5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine-9-carboxylate	711909	58375	
1.1.1.37	Haemophilus parasuis		pyridine adenine dinucleotide	286671	21660	
1.1.1.37	Flavobacterium frigidimaris		Semicarbazide	668012	322	1 mM, 61.3% inhibition
1.1.1.37	Corynebacterium glutamicum		succinate	656320	54	slight inhibition of reduction of oxaloacetate
1.1.1.37	Bos taurus		sulfite	286629	86	
1.1.1.37	Gallus sp.		sulfite	286629	86	
1.1.1.37	Sus scrofa		sulfite	286629	86	
1.1.1.37	Anthocidaris crassispina		sulfite	286652	86	
1.1.1.37	Dictyostelium discoideum		thyroxine	286646	1043	
1.1.1.37	Streptomyces coelicolor		Triton X-100	711519	57	
1.1.1.37	Pontonia pinnophylax		Urea	688101	110	enzyme activity and electrophoretic pattern of MDH and lactate dehydrogenase, EC 1.1.1.27, compared in relation to heat and urea inactivation, LDH is more sensitive than MDH, overview
1.1.1.37	Bacillus subtilis		Zn2+	286635	19	
1.1.1.37	Mycobacterium phlei		Zn2+	286635	19	
1.1.1.37	Anthocidaris crassispina		Zn2+	286652	19	
1.1.1.37	Beggiatoa leptomitiformis		Zn2+	654915	19	inhibition constant 1.7 mM
1.1.1.37	Vulcanithermus mediatlanticus		Zn2+	667749	19	0.05-0.5 mM
1.1.1.37	Streptomyces coelicolor		Zn2+	711519	19	73% inhibition at 2 mM
1.1.1.37	Streptomyces avermitilis		Zn2+	723141	19	
1.1.1.37	Zea mays		Zn2+	723482	19	25% inhibition at 1 mM
1.1.1.37	Flavobacterium frigidimaris		ZnCl2	668012	236	1 mM, 72.6% inhibition
2.5.1.48	Arabidopsis thaliana	L-threonine		666989	220	2 mM, increases the expression level of CGS
2.5.1.48	Helicobacter pylori		(1S,3aS,4R,6aR)-1,4-bis(1,3-benzodioxol-5-yl)hexahydropentalen-3a(1H)-ol	687456	25201	i.e. paulownin, NPLC604, noncompetitive, significant activity in the inhibition of Helicobacter pylori strain SS1 growth with MIC of 15 mg/ml
2.5.1.48	Helicobacter pylori		(1S,3aS,4S,6aS)-1,4-di(3,4,5-trimethoxy)-phenyloctahydropentalene	687456	25200	i.e. yangambin, NPLC605, noncompetitive, significant activity in the inhibition of Helicobacter pylori strain SS1 growth with MIC of 10 mg/ml
2.5.1.48	Triticum aestivum		(Z)-3-(2-phosphonethen-1-yl)pyridine-2-carboxylic acid	637448		Ki: 0.04 mM
2.5.1.48	Nicotiana tabacum		(Z)-3-(2-phosphonoethen-1-yl)pyridine-2-carboxylic acid	637454	33042	
2.5.1.48	Helicobacter pylori		2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione	687456	77473	i.e. alpha-lapachone, NPLC518, noncompetitive, significant activity in the inhibition of Helicobacter pylori strain SS1 growth with MIC of 2.6 mg/ml
2.5.1.48	Nicotiana tabacum		3-(phosphonomethyl)pyridine-2-carboxylic acid	637454	33138	
2.5.1.48	Lysinibacillus sphaericus		3-Methyl-2-benzothiazolinone hydrazone	637439	7080	
2.5.1.48	Triticum aestivum		4-(phosphonomethyl)pyridine-2-carboxylic acid	637448	13583	Ki: 0.045 mM
2.5.1.48	Nicotiana tabacum		4-(phosphonomethyl)pyridine-2-carboxylic acid	637454	13583	
2.5.1.48	Helicobacter pylori		6-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione	687456	108770	i.e. 9-hydroxy-alpha-lapachone, NPLC519, noncompetitive, significant activity in the inhibition of Helicobacter pylori strain SS1 growth with MIC of 2.5 mg/ml
2.5.1.48	Triticum aestivum		aminooxyacetic acid	637448	1037	
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		beta-mercaptopropionate	637429	2359	competitive inhibitor of gamma-replacement reaction
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		beta-mercaptopropionate	637430	2359	also a substrate for gamma-replacement reaction
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		chloromercuriphenylsulfonate	637429	1069	inhibition of gamma-elimination
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		cystathionine	637429	482	competitive, gamma-elimination
2.5.1.48	Lysinibacillus sphaericus		D-cycloserine	637439	689	
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		D-Cysteine	637429	1022	inhibition of gamma-elimination
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		dithiothreitol	637427	42	10% inhibition of beta-elimination from O-succinyl-L-serine
2.5.1.48	Triticum aestivum		DL-(E)-2-amino-5-phosphono-3-pentenoic acid	637448	13753	Ki: 0.0011 mM
2.5.1.48	Nicotiana tabacum		DL-(E)-2-amino-5-phosphono-3-pentenoic acid	637454	13753	
2.5.1.48	Nicotiana tabacum		DL-propargylglycine	637454	729	irreversible
2.5.1.48	Lysinibacillus sphaericus		hydroxylamine	637439	80	
2.5.1.48	Triticum aestivum		hydroxylamine	637448	80	
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		L-cysteine	637427	70	complete inhibition of gamma-elimination and beta-elimination
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		L-cysteine	637428	70	inhibition of beta-elimination
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		L-homocysteine	637427	260	partial inhibition of beta-elimination and gamma-elimination
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		L-homocysteine	637429	260	
2.5.1.48	Arabidopsis thaliana		L-methionine	666989	83	2 mM, decreases the expression level of CGS
2.5.1.48	Lysinibacillus sphaericus		more	637439		not inhibited by p-chloromercuribenzoate, iodoacetate, N-ethylmaleimide, 5,5'-dithiobis(2-nitrobenzoate), NaCN
2.5.1.48	Triticum aestivum		more	637448		no inhibition by 2-amino-1-hydroxycyclobutane-1-acetic acid
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		N-ethylmaleimide	637429	46	inhibition of gamma-elimination
2.5.1.48	Lysinibacillus sphaericus		phenylhydrazine	637439	333	
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		propargylglycine	637433	729	i.e. 2-amino-4-pentynoate
2.5.1.48	Lemna paucicostata		propargylglycine	637434	729	pseudo-first order inactivation kinetics
2.5.1.48	Salmonella enterica subsp. enterica serovar Typhimurium		propargylglycine	637445	729	
2.5.1.48	Triticum aestivum		propargylglycine	637448	729	
2.5.1.48	Spinacia oleracea		propargylglycine	637449	729	
2.5.1.48	Neurospora crassa		S-adenosyl-L-homocysteine	637426	34	
2.5.1.48	Neurospora crassa		S-adenosyl-L-methionine	637426	22	0.003 mM, 34% inhibition , 0.1 mM, 96% inhibition, physiological inhibitor
2.5.1.48	Triticum aestivum		S-adenosyl-L-methionine	637448	22	9.5 mM, 50% inhibition
2.5.1.48	Lysinibacillus sphaericus		Semicarbazide	637439	322	
2.3.1.117	Escherichia coli		2,6-dihydroxypimelic acid	486149	72385	0.54 mM, 66% inhibition
2.3.1.117	Escherichia coli		2-Hydroxytetrahydropyran-2,6-dicarboxylic acid	486149	29918	competitive inhibition
2.3.1.117	Escherichia coli		2-oxopimelic acid	486149	21889	5 mM, 57% inhibition
2.3.1.117	Escherichia coli		4-oxo-(2E,5E)-heptadien-1,7-dioic acid	486149	47680	0.5 mM, 32% inhibition
2.3.1.117	Escherichia coli		6-Aminocaproic acid	486149	1969	5 mM, 35% inhibition
2.3.1.117	Mycobacterium tuberculosis		acetate	705149	44	caused by inhibition of succinyl-CoA-binding or pH effect
2.3.1.117	Escherichia coli		CaCl2	486148	193	1 mM, 3% inhibition
2.3.1.117	Mycobacterium tuberculosis		Co2+	705149	21	partial inhibition
2.3.1.117	Escherichia coli		CoCl2	486148	347	1 mM, 95% inhibition
2.3.1.117	Escherichia coli		CuSO4	486148	228	1 mM, complete loss of activity
2.3.1.117	Escherichia coli		D-2-aminopimelate	486149	11128	competitive vs. L-2-aminopimelate and tetrahydropicolinate
2.3.1.117	Pseudomonas aeruginosa		D-2-aminopimelate	720852	11128	very weak competitive inhibition, L-2-aminopimelate and D-2-aminopimelate bind at the same site of the enzyme. Binding interaction analysis of the ligands in the enzyme active site suggests a misalignment of the amino group of D-2-aminopimelate for nucleophilic attack on the succinate moiety of the co-substrate succinyl-CoA as the structural basis of specificity and inhibition
2.3.1.117	Escherichia coli		D-2-hydroxypimelic acid	486149	72820	5 mM, 93% inhibition
2.3.1.117	Escherichia coli		DL-2-amino-5-thiapimelic acid	486149	72865	5 mM, 75% inhibition
2.3.1.117	Escherichia coli		L-2-hydroxypimelic acid	486149	72936	5 mM, 88% inhibition
2.3.1.117	Escherichia coli		MgCl2	486148	176	1 mM, 20% inhibition
2.3.1.117	Escherichia coli		MnCl2	486148	262	1 mM, 9% inhibition
2.3.1.117	Escherichia coli		more	486148		not inhibited by EDTA and Fe2+
2.3.1.117	Escherichia coli		N-ethylmaleimide	486148	46	16 mM, 42% inhibition
2.3.1.117	Escherichia coli		p-Chloromercuriphenylsulfonate	486148	1069	0.16 mM, 97% inhibition
2.3.1.117	Escherichia coli		pimelic acid	486149	8396	5 mM, 43% inhibition
2.3.1.117	Mycobacterium tuberculosis		Zn2+	705149	19	1 mM, complete loss of enzyme acitivity
2.3.1.117	Escherichia coli		ZnCl2	486148	236	1 mM, 88% inhibition
2.1.1.45	Bos taurus	(NH4)2SO4		485363	334	10 mM, relative activity 108%
2.1.1.45	Enterococcus faecalis	2,3-Dimercaptopropanol		485358	1854	absolute requirement for a thiol, synthetase shows greatly dimished activity in absence
2.1.1.45	Escherichia coli	2,3-Dimercaptopropanol		485358	1854	absolute requirement for a thiol, synthetase shows greatly dimished activity in absence
2.1.1.45	Homo sapiens	2,3-Dimercaptopropanol		485358	1854	absolute requirement for a thiol, synthetase shows greatly dimished activity in absence
2.1.1.45	Bos taurus	ATP		485363	7	0.1 mM, relative activity 102%
2.1.1.45	Mus musculus	beta-mercaptoethanol		485359, 485402	59	
2.1.1.45	Streptomyces aureofaciens	beta-mercaptoethanol		485402	59	essential for maximum activity
2.1.1.45	Streptomyces aureofaciens	dithioerythritol		485402	475	
2.1.1.45	Homo sapiens	dithiothreitol		485359	42	
2.1.1.45	Mus musculus	dithiothreitol		485359	42	thiols enhances enzyme activity
2.1.1.45	Sus scrofa	dithiothreitol		485362	42	maximal catalytic activity only in presence of sulfhydryl compounds
2.1.1.45	Homo sapiens	dithiothreitol		485381	42	enzyme activity is stimulated 2fold by 8-20 mM
2.1.1.45	Mus musculus	dithiothreitol		485402	42	
2.1.1.45	Streptomyces aureofaciens	dithiothreitol		485402	42	
2.1.1.45	Bacillus subtilis	dithiothreitol		485425	42	
2.1.1.45	Escherichia coli	dithiothreitol		485359, 485381, 485402, 485425	42	
2.1.1.45	Bos taurus	EDTA		485363	223	5.0 mM, relative activity 103%
2.1.1.45	Enterococcus faecalis	KCN		485358	149	
2.1.1.45	Escherichia coli	KCN		485358	149	
2.1.1.45	Homo sapiens	KCN		485358	149	
2.1.1.45	Escherichia coli		(+)tetrahydropteroylglutamate	485375	72260	
2.1.1.45	Escherichia coli		(2S)-2-[([4-[(2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)sulfanyl]phenyl]carbonyl)amino]pentanedioic acid	688294	8030	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
2.1.1.45	Homo sapiens		(2S)-2-[([4-[(2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)sulfanyl]phenyl]carbonyl)amino]pentanedioic acid	688294	8030	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on Escherichia coli and Toxoplasma gondii enzyme
2.1.1.45	Lactobacillus casei		(6R)-tetrahydropteroylglutamate	485370	72283	
2.1.1.45	Escherichia coli		(S)-2-(5(((1,2-dihydro-3-methyl-1-oxobenzo(f)quinazolin-9-yl)methyl)amino)1-oxo-2-isoindolinyl)glutaric acid	692639	12511	BW1843U89, U89, distorts the thymidylate synthase active site
2.1.1.45	Litopenaeus vannamei		(S)-2-(5(((1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9 yl)methyl)amino)1-oxo-2-isoindolinyl)glutaric acid	703308	12511	
2.1.1.45	Shrimp white spot syndrome virus		(S)-2-(5(((1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl)amino)1-oxo-2-isoindolinyl)glutaric acid	703308	12511	
2.1.1.45	Homo sapiens		(S)-2-(5-(((1,2-dihydro3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl)amino)-1-oxo-2-isoindolinyl)glutaric acid	485419	12511	BW1843U89
2.1.1.45	Acinetobacter baumannii		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Aeromonas hydrophila		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Ascaris suum		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Aspergillus clavatus		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Aspergillus fumigatus		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Aspergillus nidulans		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bacillus amyloliquefaciens		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bacillus anthracis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bacillus cereus		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bacillus licheniformis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bacillus weihenstephanensis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bacteroides fragilis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bacteroides thetaiotaomicron		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bartonella bacilliformis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bartonella henselae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bartonella quintana		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bordetella bronchiseptica		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bordetella parapertussis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Bordetella pertussis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Brucella abortus		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Brucella melitensis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Brucella suis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Burkholderia ambifaria		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Burkholderia dolosa		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Burkholderia mallei		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Burkholderia multivorans		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Burkholderia pseudomallei		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Burkholderia vietnamiensis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Candida albicans		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Candida glabrata		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Chaetomium globosum		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Chromobacterium violaceum		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Coccidioides immitis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Comamonas testosteroni		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Corynebacterium diphtheriae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Corynebacterium jeikeium		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Coxiella burnetii		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Cryptococcus neoformans		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Cryptosporidium hominis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Cryptosporidium parvum		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Debaryomyces hansenii		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Encephalitozoon cuniculi		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Enterobacter sp.		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Enterococcus faecalis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Enterococcus faecium		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Francisella tularensis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Fusobacterium nucleatum		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Haemophilus ducreyi		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Haemophilus influenzae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Human herpesvirus 1		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Legionella pneumophila		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Leishmania amazonensis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Leishmania braziliensis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Leishmania donovani		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Leishmania infantum		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Leishmania major		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Leishmania tropica		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Listeria monocytogenes		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Mycobacterium avium		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Mycobacterium bovis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Mycobacterium leprae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Mycobacterium tuberculosis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Mycobacterium ulcerans		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Mycoplasma genitalium		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Mycoplasma penetrans		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Mycoplasma pneumoniae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Neisseria gonorrhoeae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Neisseria meningitidis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Neosartorya fischeri		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Nocardia farcinica		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Novosphingobium aromaticivorans		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Pasteurella multocida		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Peptoclostridium difficile		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Plasmodium falciparum		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Plasmodium malariae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Plasmodium vivax		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Pneumocystis carinii		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Porphyromonas gingivalis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Propionibacterium acnes		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Pseudomonas aeruginosa		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Pseudomonas mendocina		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Salmonella enterica		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Salmonella enterica subsp. enterica serovar Paratyphi A		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Salmonella enterica subsp. enterica serovar Typhi		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Salmonella enterica subsp. enterica serovar Typhimurium		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Schistosoma japonicum		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Serratia proteamaculans		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Shewanella putrefaciens		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Shigella boydii		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Shigella dysenteriae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Shigella flexneri		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Shigella sonnei		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Staphylococcus aureus		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Staphylococcus epidermidis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Staphylococcus haemolyticus		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Staphylococcus saprophyticus		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Stenotrophomonas maltophilia		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Streptococcus agalactiae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Streptococcus mutans		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Streptococcus pneumoniae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Streptococcus pyogenes		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Streptococcus sanguinis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Toxoplasma gondii		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Trichinella spiralis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Trypanosoma brucei		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Trypanosoma cruzi		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Vibrio alginolyticus		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Vibrio cholerae		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Vibrio parahaemolyticus		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Vibrio vulnificus		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Yersinia bercovieri		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Yersinia enterocolitica		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Yersinia frederiksenii		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Yersinia intermedia		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Yersinia mollaretii		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Yersinia pestis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Yersinia pseudotuberculosis		1,1-bis-(4-hydroxyphenyl)-1H-naphtho[1,2-c]furan-3-one	703220	543	
2.1.1.45	Homo sapiens		1,3-propanediphosphonic acid	690892	25595	allosteric inhibitor of human thymidylate synthase; stabilizes an inactive conformer of loop 181-197. Mixed inhibitor of dUMP, uncompetitive inhibitor versus methylenetetrahydrofolate below 0.00025 mM, noncompetitive above 0.001 mM, respectively. 1,3-Propanediphosphonic acid shows positive cooperativity with antifolate inhibitor ZD9331. It leads to the formation of enzyme tetramers, but not of higher oligomers
2.1.1.45	Lactobacillus casei		1-(2'-deoxyribosyl)8-azapurin-2-one 5'-monophosphate	485385	72324	
2.1.1.45	Lactobacillus casei		1-(beta-D-2'-deoxyribofuranosyl)1,6-dihydro-8-azapurin-2(3H,6H)-one 5'-monophosphate	485385	72325	
2.1.1.45	Lactobacillus casei		1-(beta-D-2'-Deoxyribofuranosyl)8-azapurin-2-one 5'-monophosphate	485385	62664	
2.1.1.45	Mus musculus		1-(beta-D-2-deoxyribofuranosyl)-4-hydroxyamino-5-bromopyrimidin-2(1H)-one 5'-monophosphate	485427	21874	
2.1.1.45	Mus musculus		1-(beta-D-2-deoxyribofuranosyl)-4-hydroxyamino-5-chloropyrimidin-2(1H)-one 5'-monophosphate	485427	21875	
2.1.1.45	Mus musculus		1-(beta-D-2-deoxyribofuranosyl)-4-hydroxyamino-5-fluoropyrimidin-2(1H)-one 5'-monophosphate	485427	21876	
2.1.1.45	Mus musculus		1-(beta-D-2-deoxyribofuranosyl)-4-hydroxyamino-5-hydroxymethylpyrimidin-2(1H)-one 5'-monophosphate	485427	21877	
2.1.1.45	Mus musculus		1-(beta-D-2-deoxyribofuranosyl)-4-hydroxyamino-5-iodopyrimidin-2(1H)-one 5'-monophosphate	485427	21878	
2.1.1.45	Mus musculus		1-(beta-D-2-deoxyribofuranosyl)-4-hydroxyaminopyrimidin-2(1H)-one 5'-monophosphate	485427	21879	
2.1.1.45	Lactobacillus casei		1-ethyl-3-dimethylaminopropyl carbodiimide	485401	2269	
2.1.1.45	Lactobacillus casei		1-phenyl-3-(3-dimethylaminopropyl) carbodiimide	485401	72237	
2.1.1.45	Lactobacillus casei		1-phenyl-3-(3-trimethylaminopropyl) carbodiimide	485401	72238	
2.1.1.45	Mus musculus		10-formyl folic acid	485387	28621	
2.1.1.45	Mus musculus		10-formyl-5,8-dideazafolate	485382	1373	
2.1.1.45	Rattus norvegicus		10-formyldihydropteroylglutamate	485398	14308	
2.1.1.45	Rattus norvegicus		10-formyldihydropteroylheptaglutamate	485398		
2.1.1.45	Homo sapiens		10-formyldihydropteroylpentaglutamate	485398	32592	
2.1.1.45	Rattus norvegicus		10-formyltetrahydrofolate	485398	445	
2.1.1.45	Rattus norvegicus		10-Formyltetrahydrofolylheptaglutamate	485398	29881	
2.1.1.45	Rattus norvegicus		10-Formyltetrahydrofolylmonoglutamate	485398	29882	
2.1.1.45	Rattus norvegicus		10-formyltetrahydropteroylheptaglutamate	485398	72357	
2.1.1.45	Mus musculus		10-formyltetrahydropteroylmonoglutamate	485398	445	
2.1.1.45	Rattus norvegicus		10-formyltetrahydropteroylpolyglutamate	485398	32133	
2.1.1.45	Homo sapiens		10-methenyldihydropteroylpentaglutamate	485398		
2.1.1.45	Homo sapiens		10-methenyltetrahydropteroylheptaglutamate	485398		
2.1.1.45	Helicobacter pylori		10-methylfolate	720992		
2.1.1.45	Escherichia coli		10-propargyl-5,8-dideazafolate	688294	109179	PDDF
2.1.1.45	Homo sapiens		10-propargyl-5,8-dideazafolate	688294	109179	PDDF
2.1.1.45	Toxoplasma gondii		10-propargyl-5,8-dideazafolate	688294	109179	PDDF
2.1.1.45	Escherichia coli		10-propargyl-5,8-dideazafolate	692639	109179	PDDF, folate-like TS inhibitor
2.1.1.45	Escherichia coli		10-propargyl-5,8-dideazafolate	693567	109179	i.e. PDDF. Dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
2.1.1.45	Homo sapiens		10-propargyl-5,8-dideazafolate	693567	109179	i.e. PDDF. Dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on Escherichia coli and Toxoplasma gondii enzyme
2.1.1.45	Toxoplasma gondii		10-propargyl-5,8-dideazafolate	693567	109179	i.e. PDDF. Dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Escherichia coli enzyme
2.1.1.45	Litopenaeus vannamei		10-propargyl-5,8-dideazafolate	703308	109179	
2.1.1.45	Shrimp white spot syndrome virus		10-propargyl-5,8-dideazafolate	703308	109179	
2.1.1.45	Escherichia coli		10-propargyl-5,8-dideazafolate	485415, 705044	109179	
2.1.1.45	Homo sapiens		10-propargyl-5,8-dideazafolate	705044	109179	
2.1.1.45	Toxoplasma gondii		10-propargyl-5,8-dideazafolate	705044	109179	
2.1.1.45	Mycobacterium tuberculosis		1843U89	694812	25505	i.e. (2R)-2-(5-[[(1-hydroxy-3-methyl-5,10a-dihydrobenzo[f]quinazolin-9-yl)methyl]amino]-1-oxo-1,3-dihydro-2H-isoindol-2-yl)butanedioic acid, folate-based inhibitor
2.1.1.45	Escherichia coli		2',5-difluoro-ara-UMP	702544	54025	slow-binding (time-dependent) inhibitor
2.1.1.45	Escherichia coli		2'-deoxy-2',2'-difluorouridine 5'-dihydrogen	702544	54024	classic inhibitor (no time dependence of inhibition observed)
2.1.1.45	Trypanosoma brucei		2'-deoxy-5-fluorouridine 5'-phosphate	689059	640	
2.1.1.45	Rattus norvegicus		2'-deoxyuridine	485393	812	
2.1.1.45	Escherichia coli		2'-fluoro-ara-UMP	702544	54023	classic inhibitor (no time dependence of inhibition observed)
2.1.1.45	Streptococcus pneumoniae		2,4-diamino pteridine	485372	32538	
2.1.1.45	Streptococcus pneumoniae		2,4-diamino quinazoline antifolate	485372	28671	
2.1.1.45	Streptococcus pneumoniae		2-amino-4-hydroxyquinazoline	485372	16037	
2.1.1.45	Enterococcus faecalis		2-amino-4-hydroxyquinazoline folic acid	485375	14273	
2.1.1.45	Lactobacillus casei		2-amino-4-hydroxyquinazoline folic acid	485375	14273	
2.1.1.45	Mus musculus		2-amino-4-hydroxyquinazoline folic acid	485375	14273	
2.1.1.45	Streptococcus pneumoniae		2-amino-4-hydroxyquinazoline folic acid	485375	14273	
2.1.1.45	Escherichia coli		2-amino-5-[(2,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9960	
2.1.1.45	Homo sapiens		2-amino-5-[(2,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9960	
2.1.1.45	Toxoplasma gondii		2-amino-5-[(2,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9960	
2.1.1.45	Escherichia coli		2-amino-5-[(2-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9969	
2.1.1.45	Homo sapiens		2-amino-5-[(2-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9969	
2.1.1.45	Toxoplasma gondii		2-amino-5-[(2-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9969	
2.1.1.45	Escherichia coli		2-amino-5-[(3,4-dichlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one	693567	4266	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
2.1.1.45	Homo sapiens		2-amino-5-[(3,4-dichlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one	693567	4266	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on Escherichia coli and Toxoplasma gondii enzyme
2.1.1.45	Toxoplasma gondii		2-amino-5-[(3,4-dichlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one	693567	4266	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Escherichia coli enzyme
2.1.1.45	Escherichia coli		2-amino-5-[(3,4-dichlorophenyl)thio]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9961	
2.1.1.45	Homo sapiens		2-amino-5-[(3,4-dichlorophenyl)thio]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9961	
2.1.1.45	Toxoplasma gondii		2-amino-5-[(3,4-dichlorophenyl)thio]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9961	
2.1.1.45	Escherichia coli		2-amino-5-[(3,5-dichlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]-pyrimidin-4(3H)-one	705044	9962	
2.1.1.45	Homo sapiens		2-amino-5-[(3,5-dichlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]-pyrimidin-4(3H)-one	705044	9962	
2.1.1.45	Toxoplasma gondii		2-amino-5-[(3,5-dichlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]-pyrimidin-4(3H)-one	705044	9962	
2.1.1.45	Escherichia coli		2-amino-5-[(3,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9968	
2.1.1.45	Homo sapiens		2-amino-5-[(3,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9968	
2.1.1.45	Toxoplasma gondii		2-amino-5-[(3,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9968	
2.1.1.45	Escherichia coli		2-amino-5-[(3-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9967	
2.1.1.45	Homo sapiens		2-amino-5-[(3-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9967	
2.1.1.45	Toxoplasma gondii		2-amino-5-[(3-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9967	
2.1.1.45	Escherichia coli		2-amino-5-[(4-bromophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9966	
2.1.1.45	Homo sapiens		2-amino-5-[(4-bromophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9966	
2.1.1.45	Toxoplasma gondii		2-amino-5-[(4-bromophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9966	
2.1.1.45	Escherichia coli		2-amino-5-[(4-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	4306	
2.1.1.45	Homo sapiens		2-amino-5-[(4-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	4306	
2.1.1.45	Toxoplasma gondii		2-amino-5-[(4-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	4306	
2.1.1.45	Escherichia coli		2-amino-6-ethyl-5-(2-naphthylthio)thieno[2,3-d]pyrimidin-4(3H)-one	705044	9963	
2.1.1.45	Homo sapiens		2-amino-6-ethyl-5-(2-naphthylthio)thieno[2,3-d]pyrimidin-4(3H)-one	705044	9963	
2.1.1.45	Toxoplasma gondii		2-amino-6-ethyl-5-(2-naphthylthio)thieno[2,3-d]pyrimidin-4(3H)-one	705044	9963	
2.1.1.45	Escherichia coli		2-amino-6-ethyl-5-(phenylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	705044	4305	
2.1.1.45	Homo sapiens		2-amino-6-ethyl-5-(phenylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	705044	4305	
2.1.1.45	Toxoplasma gondii		2-amino-6-ethyl-5-(phenylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	705044	4305	
2.1.1.45	Escherichia coli		2-amino-6-ethyl-5-(pyridin-4-ylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	705044	9964	
2.1.1.45	Homo sapiens		2-amino-6-ethyl-5-(pyridin-4-ylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	705044	9964	
2.1.1.45	Toxoplasma gondii		2-amino-6-ethyl-5-(pyridin-4-ylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	705044	9964	
2.1.1.45	Escherichia coli		2-amino-6-ethyl-5-[(4-fluorophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	705044	9965	
2.1.1.45	Homo sapiens		2-amino-6-ethyl-5-[(4-fluorophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	705044	9965	
2.1.1.45	Toxoplasma gondii		2-amino-6-ethyl-5-[(4-fluorophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	705044	9965	
2.1.1.45	Escherichia coli		2-amino-6-ethyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	705044	4307	
2.1.1.45	Homo sapiens		2-amino-6-ethyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	705044	4307	
2.1.1.45	Toxoplasma gondii		2-amino-6-ethyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	705044	4307	
2.1.1.45	Escherichia coli		2-amino-6-methyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	693567	4267	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
2.1.1.45	Homo sapiens		2-amino-6-methyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	693567	4267	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on Escherichia coli and Toxoplasma gondii enzyme
2.1.1.45	Toxoplasma gondii		2-amino-6-methyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	693567	4267	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Escherichia coli enzyme
2.1.1.45	Escherichia coli		2-amino-6-methyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	693567	4268	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
2.1.1.45	Homo sapiens		2-amino-6-methyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	693567	4268	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on Escherichia coli and Toxoplasma gondii enzyme
2.1.1.45	Toxoplasma gondii		2-amino-6-methyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	693567	4268	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Escherichia coli enzyme
2.1.1.45	Lactobacillus casei		2-hydroxyethyl disulfide	485377	4349	
2.1.1.45	Crithidia fasciculata		2-mercaptoethanol	485374	59	
2.1.1.45	Strigomonas oncopelti		2-mercaptoethanol	485374	59	
2.1.1.45	Trypanosoma brucei		2-mercaptoethanol	485374	59	
2.1.1.45	Trypanosoma congolense		2-mercaptoethanol	485374	59	
2.1.1.45	Trypanosoma cruzi		2-mercaptoethanol	485374	59	
2.1.1.45	Trypanosoma lewisi		2-mercaptoethanol	485374	59	
2.1.1.45	Homo sapiens		3,3-bis(4-methoxyphenyl)-1H,3H-benzo[de]isochromen-1-one	695194	92058	induces apoptotic cell death in SK-MEL-2 and SK-MEL-28 melanoma cell lines, mediated by downregulation of Bcl-2 protein level and PARP cleavage, and independent of p53 and Bax. Pan-caspases inhibitor Z-VAD-FMK blocks the effect
2.1.1.45	Acinetobacter baumannii		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Aeromonas hydrophila		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Ascaris suum		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Aspergillus clavatus		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Aspergillus fumigatus		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Aspergillus nidulans		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bacillus amyloliquefaciens		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bacillus anthracis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bacillus cereus		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bacillus licheniformis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bacillus weihenstephanensis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bacteroides fragilis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bacteroides thetaiotaomicron		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bartonella bacilliformis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bartonella henselae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bartonella quintana		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bordetella bronchiseptica		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bordetella parapertussis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Bordetella pertussis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Brucella abortus		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Brucella melitensis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Brucella suis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Burkholderia ambifaria		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Burkholderia dolosa		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Burkholderia mallei		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Burkholderia multivorans		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Burkholderia pseudomallei		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Burkholderia vietnamiensis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Candida albicans		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Candida glabrata		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Chaetomium globosum		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Chromobacterium violaceum		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Coccidioides immitis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Comamonas testosteroni		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Corynebacterium diphtheriae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Corynebacterium jeikeium		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Coxiella burnetii		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Cryptococcus neoformans		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Cryptosporidium hominis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Cryptosporidium parvum		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Debaryomyces hansenii		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Encephalitozoon cuniculi		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Enterobacter sp.		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Enterococcus faecalis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Enterococcus faecium		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Francisella tularensis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Fusobacterium nucleatum		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Haemophilus ducreyi		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Haemophilus influenzae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Human herpesvirus 1		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Legionella pneumophila		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Leishmania amazonensis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Leishmania braziliensis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Leishmania donovani		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Leishmania infantum		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Leishmania major		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Leishmania tropica		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Listeria monocytogenes		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Mycobacterium avium		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Mycobacterium bovis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Mycobacterium leprae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Mycobacterium tuberculosis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Mycobacterium ulcerans		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Mycoplasma genitalium		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Mycoplasma penetrans		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Mycoplasma pneumoniae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Neisseria gonorrhoeae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Neisseria meningitidis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Neosartorya fischeri		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Nocardia farcinica		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Novosphingobium aromaticivorans		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Pasteurella multocida		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Peptoclostridium difficile		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Plasmodium falciparum		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Plasmodium malariae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Plasmodium vivax		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Pneumocystis carinii		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Porphyromonas gingivalis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Propionibacterium acnes		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Pseudomonas aeruginosa		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Pseudomonas mendocina		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Salmonella enterica		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Salmonella enterica subsp. enterica serovar Paratyphi A		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Salmonella enterica subsp. enterica serovar Typhi		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Salmonella enterica subsp. enterica serovar Typhimurium		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Schistosoma japonicum		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Serratia proteamaculans		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Shewanella putrefaciens		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Shigella boydii		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Shigella dysenteriae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Shigella flexneri		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Shigella sonnei		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Staphylococcus aureus		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Staphylococcus epidermidis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Staphylococcus haemolyticus		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Staphylococcus saprophyticus		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Stenotrophomonas maltophilia		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Streptococcus agalactiae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Streptococcus mutans		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Streptococcus pneumoniae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Streptococcus pyogenes		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Streptococcus sanguinis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Toxoplasma gondii		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Trichinella spiralis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Trypanosoma brucei		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Trypanosoma cruzi		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Vibrio alginolyticus		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Vibrio cholerae		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Vibrio parahaemolyticus		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Vibrio vulnificus		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Yersinia bercovieri		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Yersinia enterocolitica		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Yersinia frederiksenii		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Yersinia intermedia		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Yersinia mollaretii		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Yersinia pestis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Yersinia pseudotuberculosis		3,3-bis-(3-chloro-4-hydroxyphenyl)-1H,3H-[1,8-c,d]pyran-1-one	703220	540	
2.1.1.45	Lactobacillus casei		3-beta-D-ribofuranosylmaleimide	485375	72463	showdomycin
2.1.1.45	Lactobacillus casei		3-beta-D-ribofuranosylmaleimide 5'-phosphate	485375	72464	showdomycin 5'-phosphate
2.1.1.45	Escherichia coli		4-amino-N10-methylfolic acid	705044	213	
2.1.1.45	Homo sapiens		4-amino-N10-methylfolic acid	705044	213	
2.1.1.45	Toxoplasma gondii		4-amino-N10-methylfolic acid	705044	213	
2.1.1.45	Homo sapiens		5'-CGCGGTACGGACACCGCGCG-3'	692480		targets the TS mRNA translation start site TSS and increases the thymidylate synthase gene transcription in HeLa cell
2.1.1.45	Escherichia coli		5,10-methylenetetrahydrofolate	485397	336	
2.1.1.45	Lactobacillus casei		5,5'-dithiobis(2-nitrobenzoic acid)	485377	196	
2.1.1.45	Saccharomyces cerevisiae		5-bromo-2'-deoxyuridylic acid	485384	3659	
2.1.1.45	Mus musculus		5-bromo-N4-hydroxy-2'-deoxycytidine	485427	72544	
2.1.1.45	Mus musculus		5-bromoacetamido-5'-deoxythymidine	485391	21864	
2.1.1.45	Mus musculus		5-chloro-N4-hydroxy-2'-deoxycytidine	485427	72545	
2.1.1.45	Mus musculus		5-chloroacetamido-5'-deoxythymidine	485391	72244	
2.1.1.45	Mus musculus		5-fluoro-2'-deoxyuridine	694503	2364	comparison with inhibitory effect of FdUMP[10] and 5-fluorouraci
2.1.1.45	Enterococcus faecalis		5-fluoro-2'-deoxyuridine 5'-(p-aminophenyl phosphate)	485358	32651	
2.1.1.45	Lactobacillus casei		5-fluoro-2'-deoxyuridine 5'-(p-aminophenyl phosphate)	485379	32651	
2.1.1.45	Lactobacillus casei		5-fluoro-2'-deoxyuridine 5'-monophosphate	485378, 485405	640	
2.1.1.45	Mycobacterium tuberculosis		5-fluoro-2'-deoxyuridine 5'-monophosphate	694812	640	FdUMP
2.1.1.45	Helicobacter pylori		5-fluoro-2'-deoxyuridine monophosphate	720992		
2.1.1.45	Homo sapiens		5-fluoro-2'-deoxyuridine-5'-monophosphate	720965	640	
2.1.1.45	Acutodesmus obliquus		5-fluoro-2'-deoxyuridylic acid	392255	640	
2.1.1.45	Enterococcus faecalis		5-fluoro-2'-deoxyuridylic acid	485358	640	very strong inhibition, pseudo-noncompetitive
2.1.1.45	Enterobacteria phage T4		5-fluoro-2'-deoxyuridylic acid	485366, 485369	640	
2.1.1.45	Enterococcus faecalis		5-fluoro-2'-deoxyuridylic acid	485359, 485375, 485384	640	
2.1.1.45	Plasmodium berghei		5-fluoro-2'-deoxyuridylic acid	485389	640	
2.1.1.45	Daucus carota		5-fluoro-2'-deoxyuridylic acid	392255, 485394	640	
2.1.1.45	Streptomyces aureofaciens		5-fluoro-2'-deoxyuridylic acid	485402	640	
2.1.1.45	Angiostrongylus cantonensis		5-fluoro-2'-deoxyuridylic acid	485404	640	
2.1.1.45	Saccharomyces cerevisiae		5-fluoro-2'-deoxyuridylic acid	392255, 485384, 485393, 485402, 485404	640	
2.1.1.45	Plasmodium falciparum		5-fluoro-2'-deoxyuridylic acid	485404, 485413	640	
2.1.1.45	Bacillus subtilis		5-fluoro-2'-deoxyuridylic acid	485414	640	
2.1.1.45	Leishmania major		5-fluoro-2'-deoxyuridylic acid	392255, 485404, 485413, 485417	640	
2.1.1.45	Escherichia coli		5-fluoro-2'-deoxyuridylic acid	485358, 485359, 485369, 485375, 485383, 485397, 485402, 485413, 485417, 485419, 485423, 485430	640	
2.1.1.45	Homo sapiens		5-fluoro-2'-deoxyuridylic acid	485358, 485359, 485375, 485384, 485387, 485393, 485400, 485404, 485413, 485419, 485423, 485430	640	
2.1.1.45	Lactobacillus casei		5-fluoro-2'-deoxyuridylic acid	485359, 485366, 485369, 485375, 485377, 485378, 485379, 485383, 485384, 485385, 485387, 485393, 485397, 485400, 485411, 485419, 485423, 485430	640	
2.1.1.45	Mus musculus		5-fluoro-2'-deoxyuridylic acid	392255, 485359, 485369, 485375, 485383, 485384, 485387, 485393, 485400, 485402, 485404, 485413, 485427, 485430	640	
2.1.1.45	Rattus norvegicus		5-fluoro-2'-deoxyuridylic acid	485369, 485393, 485404, 485430	640	
2.1.1.45	Mus musculus		5-Fluoro-2-deoxyuridine	694503	2364	FUdR
2.1.1.45	Mus musculus		5-fluoro-dUMP	694503	640	
2.1.1.45	Mus musculus		5-fluoro-dUMP[10]	694503	25594	a 10-mer of 5-fluoro-dUMP, a suicide inhibitor of thymidylate synthase, designed to bypass resistance to 5-fluorouracil, acts as a pro-drug of 5-fluoro-dUMP
2.1.1.45	Homo sapiens		5-fluorodeoxyuridine	692480	2364	5-FUdR, TS-targeting chemotherapeutic agent
2.1.1.45	Homo sapiens		5-fluorodeoxyuridine	703391	2364	
2.1.1.45	Homo sapiens		5-fluorodeoxyuridine	703950	2364	forms an inhibitory, ternary covalent complex with the enzyme
2.1.1.45	Plasmodium falciparum		5-Fluoroorotate	485413	2276	
2.1.1.45	Plasmodium yoelii		5-Fluoroorotate	485413	2276	
2.1.1.45	Homo sapiens		5-fluoropyrimidine-2,4(1H,3H)-dione	702996	651	
2.1.1.45	Drosophila melanogaster		5-fluorouracil	485367	651	
2.1.1.45	Trypanosoma cruzi		5-fluorouracil	485374	651	
2.1.1.45	Crithidia fasciculata		5-fluorouracil	485374, 485413	651	
2.1.1.45	Plasmodium falciparum		5-fluorouracil	485413	651	
2.1.1.45	Escherichia coli		5-fluorouracil	485374, 485397, 485413, 485419, 485423	651	
2.1.1.45	Caenorhabditis elegans		5-fluorouracil	688987	651	
2.1.1.45	Homo sapiens		5-fluorouracil	691522	651	but a major mechanism of resistance to 5-fluorouracil is overexpression of thymidylate synthase
2.1.1.45	Homo sapiens		5-fluorouracil	692015	651	5-FU
2.1.1.45	Homo sapiens		5-fluorouracil	692480	651	5-FU, TS-targeting chemotherapeutic agent
2.1.1.45	Homo sapiens		5-fluorouracil	694481	651	WiDr cells: 0.005 mM inhibits growth to 22%, inhibition cannot be potentiated by leucovorin but is rescued by uridine, 0.025 mM inhibits growth to 10%, inhibition can be rescued badly by uridine to an value of 31%, SW-948 and HT-29 cells: 0.005 mM shows an antiproliferative activity that is not affected by leucovorine addition and can be rescued by uridine, 0.1 mM shows a complete inhibition that cannot be rescued by uridine
2.1.1.45	Mus musculus		5-fluorouracil	694481	651	0.001 mM inhibits growth to 13%, inhibition can be rescued by uridine, 0.005 mM inhibits growth completely, inhibition cannot be rescued by uridine
2.1.1.45	Homo sapiens		5-fluorouracil	694482	651	transfection with p53 induces resistance to 5-fluorouracil
2.1.1.45	Mus musculus		5-fluorouracil	694503	651	; comparison with inhibitory effect of FdUMP[10] and 5-fluoro-2'-deoxyuridine
2.1.1.45	Homo sapiens		5-fluorouracil	485395, 485413, 485419, 485423, 692158, 694120, 703950	651	
2.1.1.45	Homo sapiens		5-fluorouridine	485375	2106	
2.1.1.45	Escherichia coli		5-Formyl-2'-deoxyuridylic acid	485365, 485375	6103	
2.1.1.45	Homo sapiens		5-Formyl-2'-deoxyuridylic acid	485375	6103	
2.1.1.45	Lactobacillus casei		5-Formyl-2'-deoxyuridylic acid	485365, 485375	6103	
2.1.1.45	Mus musculus		5-haloacetamido-5'-deoxythymidine	485391	72552	
2.1.1.45	Homo sapiens		5-hydroseleno-2'-deoxyuridylic acid	485403	72553	
2.1.1.45	Homo sapiens		5-hydroxy-methyl-2'-deoxyuridine 5'-monophosphate	485428	72555	
2.1.1.45	Lactobacillus casei		5-iodo-2'-deoxyuridylic acid	485378	72557	
2.1.1.45	Mus musculus		5-iodoacetamido-5'-deoxythymidine	485391	72558	
2.1.1.45	Mus musculus		5-iodoacetamidomethyl-2'-deoxyuridine 5'-phosphate	485375	72559	
2.1.1.45	Escherichia coli		5-Mercapto-2'-deoxyuridylic acid	485375	7101	
2.1.1.45	Mus musculus		5-Mercapto-2'-deoxyuridylic acid	485375	7101	possesses antitumor activity against Ehrlich ascites cells
2.1.1.45	Homo sapiens		5-Mercapto-2'-deoxyuridylic acid	485375, 485415, 485428	7101	
2.1.1.45	Lactobacillus casei		5-Nitro-2'-deoxyuridine 5'-monophosphate	485378	29007	
2.1.1.45	Lactobacillus casei		5-nitro-2'-deoxyuridylic acid	485378, 485385	32660	
2.1.1.45	Lactobacillus casei		5-trifluoromethyl-2'-deoxyuridine 5'-monophosphate	485378	32661	
2.1.1.45	Homo sapiens		5-trifluoromethyl-2'-deoxyuridylic acid	485375	32662	
2.1.1.45	Homo sapiens		6-bromo-3,3-bis(3-chloro-4-hydroxyphenyl)-1H,3H-benzo[de]isochromen-1-one	695194	92113	induces apoptotic cell death in SK-MEL-2 and SK-MEL-28 melanoma cell lines, mediated by downregulation of Bcl-2 protein level and PARP cleavage, and independent of p53 and Bax. Pan-caspases inhibitor Z-VAD-FMK blocks the effect
2.1.1.45	Homo sapiens		6-chloro-3,3-bis(4-hydroxyphenyl)-1H,3H-benzo[de]isochromen-1-one	695194	92114	induces apoptotic cell death in SK-MEL-2 and SK-MEL-28 melanoma cell lines, mediated by downregulation of Bcl-2 protein level and PARP cleavage, and independent of p53 and Bax. Pan-caspases inhibitor Z-VAD-FMK blocks the effect
2.1.1.45	Helicobacter pylori		8-azapurinone deoxyribonucleoside 5'-phosphate	720992		
2.1.1.45	Angiostrongylus cantonensis		aminofolate	485404	21926	
2.1.1.45	Streptococcus pneumoniae		aminopterin	485372	769	
2.1.1.45	Crithidia fasciculata		aminopterin	485374	769	
2.1.1.45	Trypanosoma cruzi		aminopterin	485374	769	
2.1.1.45	Saccharomyces cerevisiae		aminopterin	485384	769	
2.1.1.45	Babesia gibsoni		antifolate	690467		inhibits activitiy of bifunctional DHFR-TS enzyme
2.1.1.45	Crithidia fasciculata		antrycide	485374	8797	
2.1.1.45	Strigomonas oncopelti		antrycide	485374	8797	
2.1.1.45	Trypanosoma brucei		antrycide	485374	8797	
2.1.1.45	Trypanosoma congolense		antrycide	485374	8797	
2.1.1.45	Trypanosoma cruzi		antrycide	485374	8797	
2.1.1.45	Trypanosoma lewisi		antrycide	485374	8797	
2.1.1.45	Acutodesmus obliquus		Arabinouridylate	392255	63963	
2.1.1.45	Bos taurus		ATP	485363	7	
2.1.1.45	Acinetobacter baumannii		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Aeromonas hydrophila		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Ascaris suum		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Aspergillus clavatus		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Aspergillus fumigatus		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Aspergillus nidulans		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bacillus amyloliquefaciens		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bacillus anthracis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bacillus cereus		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bacillus licheniformis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bacillus weihenstephanensis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bacteroides fragilis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bacteroides thetaiotaomicron		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bartonella bacilliformis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bartonella henselae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bartonella quintana		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bordetella bronchiseptica		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bordetella parapertussis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Bordetella pertussis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Brucella abortus		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Brucella melitensis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Brucella suis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Burkholderia ambifaria		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Burkholderia dolosa		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Burkholderia mallei		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Burkholderia multivorans		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Burkholderia pseudomallei		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Burkholderia vietnamiensis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Candida albicans		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Candida glabrata		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Chaetomium globosum		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Chromobacterium violaceum		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Coccidioides immitis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Comamonas testosteroni		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Corynebacterium diphtheriae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Corynebacterium jeikeium		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Coxiella burnetii		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Cryptococcus neoformans		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Cryptosporidium hominis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Cryptosporidium parvum		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Debaryomyces hansenii		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Encephalitozoon cuniculi		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Enterobacter sp.		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Enterococcus faecalis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Enterococcus faecium		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Francisella tularensis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Fusobacterium nucleatum		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Haemophilus ducreyi		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Haemophilus influenzae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Human herpesvirus 1		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Legionella pneumophila		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Leishmania amazonensis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Leishmania braziliensis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Leishmania donovani		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Leishmania infantum		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Leishmania major		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Leishmania tropica		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Listeria monocytogenes		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Mycobacterium avium		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Mycobacterium bovis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Mycobacterium leprae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Mycobacterium tuberculosis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Mycobacterium ulcerans		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Mycoplasma genitalium		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Mycoplasma penetrans		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Mycoplasma pneumoniae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Neisseria gonorrhoeae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Neisseria meningitidis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Neosartorya fischeri		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Nocardia farcinica		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Novosphingobium aromaticivorans		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Pasteurella multocida		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Peptoclostridium difficile		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Plasmodium falciparum		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Plasmodium malariae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Plasmodium vivax		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Pneumocystis carinii		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Porphyromonas gingivalis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Propionibacterium acnes		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Pseudomonas aeruginosa		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Pseudomonas mendocina		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Salmonella enterica		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Salmonella enterica subsp. enterica serovar Paratyphi A		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Salmonella enterica subsp. enterica serovar Typhi		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Salmonella enterica subsp. enterica serovar Typhimurium		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Schistosoma japonicum		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Serratia proteamaculans		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Shewanella putrefaciens		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Shigella boydii		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Shigella dysenteriae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Shigella flexneri		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Shigella sonnei		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Staphylococcus aureus		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Staphylococcus epidermidis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Staphylococcus haemolyticus		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Staphylococcus saprophyticus		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Stenotrophomonas maltophilia		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Streptococcus agalactiae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Streptococcus mutans		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Streptococcus pneumoniae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Streptococcus pyogenes		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Streptococcus sanguinis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Toxoplasma gondii		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Trichinella spiralis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Trypanosoma brucei		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Trypanosoma cruzi		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Vibrio alginolyticus		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Vibrio cholerae		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Vibrio parahaemolyticus		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Vibrio vulnificus		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Yersinia bercovieri		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Yersinia enterocolitica		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Yersinia frederiksenii		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Yersinia intermedia		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Yersinia mollaretii		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Yersinia pestis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Yersinia pseudotuberculosis		benzyloxycarbonylamino-N,O-didansyl-L-tyrosine	703220	542	
2.1.1.45	Homo sapiens		BGC 9331	691614	48221	treatment results in concentration-dependent increase in thymidine uptake in FR-positive epidermoid KB cells and in increase of membrane-associated equilibrative nucleoside transporter type 1 levels. Tumor [18F]-fluorothymidine accumulation in KB xenografts increases by more than 2fold with maximal levels at 1 to 4 hours and 4 to 24 hours after drug treatment. Quantitiative changes in tumor [18F]-fluorothymidine uptake are associated with increased tumor dUrd levels. BGC 9331 induces accumulation of [18F]-fluorothymidine uptake in the intestine
2.1.1.45	Homo sapiens		BGC 945	691614	48820	alpha-folate receptor targeted antifolate TS inhibitor; cyclopenta[g]quinazoline-based inhibitor. Treatment results in concentration-dependent increase in thymidine uptake in FR-positive epidermoid KB cells and in increase of membrane-associated equilibrative nucleoside transporter type 1 levels. Tumor [18F]-fluorothymidine accumulation in KB xenografts increases by more than 2fold with maximal levels at 1 to 4 hours and 4 to 24 hours after drug treatment. Quantitiative changes in tumor [18F]-fluorothymidine uptake are associated with increased tumor dUrd levels
2.1.1.45	Mus musculus		bromo-2'-deoxyuridine	485427	32721	
2.1.1.45	Homo sapiens		bromodeoxyuridine	485375	2363	
2.1.1.45	Homo sapiens		capecitabine	692015	25475	prodrug of 5-fluorouracil
2.1.1.45	Pneumocystis carinii		CB3717	485420	21678	
2.1.1.45	Mus musculus		chloro-2'-deoxyuridine	485427	32726	
2.1.1.45	Escherichia coli		Chloroacetamide	485357	7150	
2.1.1.45	Saccharomyces cerevisiae		Cibacron blue	485384	861	
2.1.1.45	Lactobacillus casei		cyanide	485377	112	
2.1.1.45	Homo sapiens		cytosine arabinoside	485375	1495	
2.1.1.45	Mus musculus		D1694	485413	2263	
2.1.1.45	Plasmodium falciparum		D1694	485413	2263	
2.1.1.45	Mus musculus		D1694 pentaglutamate	485413	14293	
2.1.1.45	Plasmodium falciparum		D1694 pentaglutamate	485413	14293	
2.1.1.45	Streptococcus pneumoniae		deaza-aminopterin	485372	32736	
2.1.1.45	Escherichia coli		diglutamate	485375	5463	
2.1.1.45	Enterococcus faecalis		dihydrofolate	485358	173	
2.1.1.45	Angiostrongylus cantonensis		dihydrofolate	485404	173	
2.1.1.45	Escherichia coli		dihydrofolate	485358, 485415	173	
2.1.1.45	Lactobacillus casei		dihydropteroylglutamate	485376	173	
2.1.1.45	Lactobacillus casei		dihydropteroylhexaglutamate	485370	21796	
2.1.1.45	Homo sapiens		dihydropteroylpentaglutamate	485398	21680	
2.1.1.45	Lactobacillus casei		dihydropteroyltriglutamate	485370	72850	
2.1.1.45	Crithidia fasciculata		dimidium	485374	8803	
2.1.1.45	Strigomonas oncopelti		dimidium	485374	8803	
2.1.1.45	Trypanosoma brucei		dimidium	485374	8803	
2.1.1.45	Trypanosoma congolense		dimidium	485374	8803	
2.1.1.45	Trypanosoma cruzi		dimidium	485374	8803	
2.1.1.45	Trypanosoma lewisi		dimidium	485374	8803	
2.1.1.45	Mus musculus		dithiophosphate	485430	32741	
2.1.1.45	Bos taurus		dTMP	485363	518	
2.1.1.45	Enterococcus faecalis		dTMP	485358, 485363	518	
2.1.1.45	Gallus gallus		dTMP	485363	518	
2.1.1.45	Saccharomyces cerevisiae		dTMP	485384	518	
2.1.1.45	Rattus norvegicus		dTMP	485393	518	
2.1.1.45	Crithidia fasciculata		ethidium	485374	5630	
2.1.1.45	Strigomonas oncopelti		ethidium	485374	5630	
2.1.1.45	Trypanosoma brucei		ethidium	485374	5630	
2.1.1.45	Trypanosoma congolense		ethidium	485374	5630	
2.1.1.45	Trypanosoma cruzi		ethidium	485374	5630	
2.1.1.45	Trypanosoma lewisi		ethidium	485374	5630	
2.1.1.45	Homo sapiens		ethyl methanesulfonate	485419	32747	
2.1.1.45	Escherichia coli		ethylene glycol	485431	1064	
2.1.1.45	Mus musculus		FdUMP[10]	694503	25594	multimer of 5-fluoro-2'-deoxyuridine 5'-monophosphate, inhibits cell growth with greater potency than 5-fluorouracil and 5-fluoro-2'-deoxyuridine
2.1.1.45	Mus musculus		FdUSSO3	485430		
2.1.1.45	Drosophila melanogaster		fluorodeoxyuridine monophosphate	485367		
2.1.1.45	Mus musculus		fluorodeoxyuridine monophosphate	485430		
2.1.1.45	Homo sapiens		fluoroorotic acid	485375	2276	
2.1.1.45	Escherichia coli		folic acid oligoglutamate	485371		
2.1.1.45	Homo sapiens		gefitinib	694120	11782	inhibits the expression of the transcription factor E2F-1, resulting in a down-regulation of thymidylate synthase at the mRNA and protein level; inhibits the expression of the transcription factor E2F-1, resulting in the down-regulation of thymidylate synthase at the mRNA and protein levels
2.1.1.45	Escherichia coli		glutamate	485375	38	
2.1.1.45	Lactobacillus casei		glyceraldehyde 3-phosphate	485399	473	
2.1.1.45	Escherichia coli		glycerol	485431	129	
2.1.1.45	Homo sapiens		GW1843U89	694482	12511	
2.1.1.45	Mus musculus		GW1843U89	694503	12511	direct folate-based inhibitor
2.1.1.45	Mycobacterium tuberculosis		GW1843U89	694812	12511	
2.1.1.45	Lactobacillus casei		H2O2	485377	20	
2.1.1.45	Mus musculus		hydroxymethyl-2'-deoxyuridine	485427	32771	
2.1.1.45	Acutodesmus obliquus		Hydroxyurea	392255	673	supresses thymidilate synthase in growing algae, but no effect on purified enzyme
2.1.1.45	Mus musculus		iodo-2'-deoxyuridine	485427	5403	
2.1.1.45	Lactobacillus casei		iodoacetamide	485375, 485377	63	
2.1.1.45	Escherichia coli		iodoacetate	485357	87	
2.1.1.45	Homo sapiens		Iododeoxyuridine	485375	5403	
2.1.1.45	Plasmodium berghei		KCl	485389	74	
2.1.1.45	Streptococcus pneumoniae		methasquin	485372	21823	
2.1.1.45	Streptococcus pneumoniae		methopterin	485372	213	
2.1.1.45	Escherichia coli		methopterin	485365, 485372, 485376	213	
2.1.1.45	Homo sapiens		methopterin	485376, 485393	213	
2.1.1.45	Rattus norvegicus		methopterin	485393	213	
2.1.1.45	Acutodesmus obliquus		methotrexate	392255	213	
2.1.1.45	Drosophila melanogaster		methotrexate	485367	213	
2.1.1.45	Enterobacteria phage T2		methotrexate	485388	213	
2.1.1.45	Enterobacteria phage T4		methotrexate	485388	213	
2.1.1.45	Plasmodium berghei		methotrexate	485389	213	
2.1.1.45	Angiostrongylus cantonensis		methotrexate	485404	213	
2.1.1.45	Saccharomyces cerevisiae		methotrexate	392255, 485384, 485404	213	
2.1.1.45	Escherichia coli		methotrexate	705044, 711474	213	
2.1.1.45	Homo sapiens		methotrexate	485358, 485376, 485384, 485389, 485404, 705044, 711474	213	
2.1.1.45	Toxoplasma gondii		methotrexate	705044, 711474	213	
2.1.1.45	Crithidia fasciculata		Mg2+	485374	25	
2.1.1.45	Strigomonas oncopelti		Mg2+	485374	25	
2.1.1.45	Trypanosoma brucei		Mg2+	485374	25	
2.1.1.45	Trypanosoma congolense		Mg2+	485374	25	
2.1.1.45	Trypanosoma cruzi		Mg2+	485374	25	
2.1.1.45	Trypanosoma lewisi		Mg2+	485374	25	
2.1.1.45	Homo sapiens		more	694481		5FU-LV, combination of 5-fluorouracil and leucovorin
2.1.1.45	Mus musculus		more	694481		combination of 5-FU and leucovorin, enhances the inhibition of thymidylate synthase, 0.001 mM inhibits growth to only 1%, inhibition can be rescued by uridine to an almost normal value of 83%
2.1.1.45	Mus musculus		more	694503		combination of leucovorin and 5-fluorouracil 5FU-LV, IC50 0.00016 (FM3A/0 cell)
2.1.1.45	Acinetobacter baumannii		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Aeromonas hydrophila		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Ascaris suum		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Aspergillus clavatus		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Aspergillus fumigatus		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Aspergillus nidulans		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bacillus amyloliquefaciens		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bacillus anthracis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bacillus cereus		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bacillus licheniformis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bacillus weihenstephanensis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bacteroides fragilis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bacteroides thetaiotaomicron		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bartonella bacilliformis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bartonella henselae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bartonella quintana		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bordetella bronchiseptica		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bordetella parapertussis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Bordetella pertussis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Brucella abortus		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Brucella melitensis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Brucella suis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Burkholderia ambifaria		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Burkholderia dolosa		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Burkholderia mallei		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Burkholderia multivorans		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Burkholderia pseudomallei		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Burkholderia vietnamiensis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Candida albicans		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Candida glabrata		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Chaetomium globosum		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Chromobacterium violaceum		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Coccidioides immitis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Comamonas testosteroni		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Corynebacterium diphtheriae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Corynebacterium jeikeium		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Coxiella burnetii		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Cryptococcus neoformans		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Cryptosporidium hominis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Cryptosporidium parvum		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Debaryomyces hansenii		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Encephalitozoon cuniculi		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Enterobacter sp.		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Enterococcus faecalis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Enterococcus faecium		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Francisella tularensis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Fusobacterium nucleatum		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Haemophilus ducreyi		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Haemophilus influenzae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Human herpesvirus 1		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Legionella pneumophila		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Leishmania amazonensis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Leishmania braziliensis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Leishmania donovani		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Leishmania infantum		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Leishmania major		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Leishmania tropica		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Listeria monocytogenes		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Mycobacterium avium		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Mycobacterium bovis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Mycobacterium leprae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Mycobacterium tuberculosis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Mycobacterium ulcerans		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Mycoplasma genitalium		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Mycoplasma penetrans		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Mycoplasma pneumoniae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Neisseria gonorrhoeae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Neisseria meningitidis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Neosartorya fischeri		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Nocardia farcinica		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Novosphingobium aromaticivorans		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Pasteurella multocida		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Peptoclostridium difficile		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Plasmodium falciparum		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Plasmodium malariae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Plasmodium vivax		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Pneumocystis carinii		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Porphyromonas gingivalis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Propionibacterium acnes		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Pseudomonas aeruginosa		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Pseudomonas mendocina		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Salmonella enterica		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Salmonella enterica subsp. enterica serovar Paratyphi A		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Salmonella enterica subsp. enterica serovar Typhi		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Salmonella enterica subsp. enterica serovar Typhimurium		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Schistosoma japonicum		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Serratia proteamaculans		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Shewanella putrefaciens		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Shigella boydii		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Shigella dysenteriae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Shigella flexneri		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Shigella sonnei		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Staphylococcus aureus		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Staphylococcus epidermidis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Staphylococcus haemolyticus		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Staphylococcus saprophyticus		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Stenotrophomonas maltophilia		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Streptococcus agalactiae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Streptococcus mutans		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Streptococcus pneumoniae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Streptococcus pyogenes		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Streptococcus sanguinis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Toxoplasma gondii		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Trichinella spiralis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Trypanosoma brucei		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Trypanosoma cruzi		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Vibrio alginolyticus		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Vibrio cholerae		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Vibrio parahaemolyticus		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Vibrio vulnificus		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Yersinia bercovieri		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Yersinia enterocolitica		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Yersinia frederiksenii		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Yersinia intermedia		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Yersinia mollaretii		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Yersinia pestis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Yersinia pseudotuberculosis		N,O-didansyl-L-tyrosine	703220	541	
2.1.1.45	Escherichia coli		N-(4-((2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo(3,2-d)pyrimidin-5-yl)methyl)benzoyl)-L-glutamic acid	688294	9594	
2.1.1.45	Homo sapiens		N-(4-((2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo(3,2-d)pyrimidin-5-yl)methyl)benzoyl)-L-glutamic acid	688294	9594	
2.1.1.45	Toxoplasma gondii		N-(4-((2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo(3,2-d)pyrimidin-5-yl)methyl)benzoyl)-L-glutamic acid	688294	9594	
2.1.1.45	Homo sapiens		N-(4-((2-amino-6-methyl-4-oxo-3,4-dihydrothieno(2,3-d)pyrimidin-5-yl)sulfanyl)benzoyl)-L-glutamic acid	693567	4269	
2.1.1.45	Escherichia coli		N-(4-((2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-5-yl)thio)benzoyl)-L-glutamic acid	688294	8030	
2.1.1.45	Toxoplasma gondii		N-(4-((2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-5-yl)thio)benzoyl)-L-glutamic acid	688294	8030	
2.1.1.45	Homo sapiens		N-(4-((2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-5-yl)thio)benzoyl)-L-glutamic acid	688294, 693567	8030	
2.1.1.45	Homo sapiens		N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamyl-gamma-glutamyl-gamma-glutamylglutamic acid	702155	9950	
2.1.1.45	Homo sapiens		N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamylglutamic acid	702155	9949	
2.1.1.45	Homo sapiens		N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)glutamic acid	702155	213	
2.1.1.45	Homo sapiens		N-([5-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2,3-dihydrothiophen-2-yl]carbonyl)-4-methylideneglutamic acid	702155	5263	
2.1.1.45	Escherichia coli		N-ethylmaleimide	485357	46	
2.1.1.45	Lactobacillus casei		N-ethylmaleimide	485377	46	
2.1.1.45	Escherichia coli		N-[4-[(2,4-diamino-5-methyl-furo[2,3-d]pyrimidin-6-yl)thio]-benzoyl]-L-glutamic acid	711474	6941	
2.1.1.45	Homo sapiens		N-[4-[(2,4-diamino-5-methyl-furo[2,3-d]pyrimidin-6-yl)thio]-benzoyl]-L-glutamic acid	711474	6941	
2.1.1.45	Toxoplasma gondii		N-[4-[(2,4-diamino-5-methyl-furo[2,3-d]pyrimidin-6-yl)thio]-benzoyl]-L-glutamic acid	711474	6941	
2.1.1.45	Escherichia coli		N-[4-[(2-amino-6-ethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)thio]benzoyl]-L-glutamic acid	705044	9985	
2.1.1.45	Homo sapiens		N-[4-[(2-amino-6-ethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)thio]benzoyl]-L-glutamic acid	705044	9985	
2.1.1.45	Toxoplasma gondii		N-[4-[(2-amino-6-ethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)thio]benzoyl]-L-glutamic acid	705044	9985	
2.1.1.45	Escherichia coli		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl]benzoyl]-L-glutamic acid	688294	9594	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Escherichia coli enzyme; dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
2.1.1.45	Homo sapiens		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl]benzoyl]-L-glutamic acid	688294	9594	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on Escherichia coli and Toxoplasma gondii enzyme
2.1.1.45	Escherichia coli		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl]-L-glutamic acid	693567	4269	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
2.1.1.45	Homo sapiens		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl]-L-glutamic acid	693567	4269	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on Escherichia coli and Toxoplasma gondii enzyme
2.1.1.45	Toxoplasma gondii		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl]-L-glutamic acid	693567	4269	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Escherichia coli enzyme
2.1.1.45	Escherichia coli		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl]-L-glutamic acid	705044	4269	potent inhibitor of thymidylate synthase
2.1.1.45	Homo sapiens		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl]-L-glutamic acid	705044	4269	potent inhibitor of thymidylate synthase
2.1.1.45	Toxoplasma gondii		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl]-L-glutamic acid	705044	4269	potent inhibitor of thymidylate synthase
2.1.1.45	Homo sapiens		N-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5264	
2.1.1.45	Homo sapiens		N-[4-[2-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5266	
2.1.1.45	Homo sapiens		N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2-fluorobenzoyl]-4-methylideneglutamic acid	702155	5265	
2.1.1.45	Homo sapiens		N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5928	
2.1.1.45	Homo sapiens		N-[4-[2-(2-amino-4-methylquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid	702155	5262	
2.1.1.45	Rattus norvegicus		N10-formyltetrahydrofolate	485398	2297	
2.1.1.45	Mus musculus		N4-hydroxy-2'-deoxycytidine	485427	73201	
2.1.1.45	Mus musculus		N4-hydroxy-5-methyl-2'-deoxycytidine	485427	73202	
2.1.1.45	Escherichia coli		N5-formiminotetrahydropteroyltriglutamate	485371	29830	
2.1.1.45	Escherichia coli		N5-formyltetrahydropteroyloligoglutamate	485371, 485375	32842	
2.1.1.45	Plasmodium berghei		NaCl	485389	39	
2.1.1.45	Homo sapiens		nolatrexed	694482	5883	transfection with p53 induces resistance to nolatrexed
2.1.1.45	Mus musculus		nolatrexed	694503	5883	
2.1.1.45	Enterobacteria phage T4		novobiocin	694135	1313	coumarin antibiotic produced by Streptomyces nivens, at 10 mM concentration the self-splicing of primary transcripts is inhibited by about 5%, at 40 mM concentration the splicing rate is inhibited by about 50%. The splicing inhibition is strongly dependent on Mg2+
2.1.1.45	Helicobacter pylori		o-propargyl-5,8-dideazafolate	720992		
2.1.1.45	Homo sapiens		OSI-7904L	691589	12511	a liposomal thymidylate synthase inhibitor, a liposomal formulation of OSI-7904 (S)-2-(5-((1,2-dihydro-3-methyl-1-oxobenzo(f)quinazolin-9-yl)methyl)amino-1-oxo-2-isoindolynl)-glutaric acid, administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma; treatment of patients with advanced colorectal carcinoma, in combination with oxaliplatin. At the highest dose level of OSI-7904L 9 mg/m2, oxaliplatin 130 mg/m2, one of nine patients experienced dose-limiting toxicity of grade 3 oral mucositis with cycle 1 and five further patients required dose reductions. The toxicity profile of stomatitis, diarrhea, nausea, fatigue, sensory neuropathy and skin rash was consistent with that expected for a thymidylate synthase inhibitor/oxaliplatin combination regimen. High interpatient variability with no detectable interaction between OSI-7904L and oxaliplatin
2.1.1.45	Lactobacillus casei		p-chloromercuribenzoate	485359, 485377	40	
2.1.1.45	Trypanosoma brucei		pemetrexed	689059	873	
2.1.1.45	Homo sapiens		pemetrexed	692480	873	TS-targeting chemotherapeutic agent
2.1.1.45	Escherichia coli		pemetrexed	693567	873	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
2.1.1.45	Homo sapiens		pemetrexed	693567	873	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on Escherichia coli and Toxoplasma gondii enzyme
2.1.1.45	Toxoplasma gondii		pemetrexed	693567	873	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Escherichia coli enzyme
2.1.1.45	Homo sapiens		pemetrexed	694482	873	transfection with p53 induces resistance to pemetrexed
2.1.1.45	Mus musculus		pemetrexed	694503	873	direct folate-based inhibitor; inhibitory to cell growth even in cell lacking thymidylate synthase activity
2.1.1.45	Escherichia coli		pemetrexed	688294, 705044, 711474	873	
2.1.1.45	Homo sapiens		pemetrexed	688294, 705044, 711474	873	
2.1.1.45	Toxoplasma gondii		pemetrexed	688294, 705044, 711474	873	
2.1.1.45	Crithidia fasciculata		Pentamidine	485374	1634	
2.1.1.45	Strigomonas oncopelti		Pentamidine	485374	1634	
2.1.1.45	Trypanosoma brucei		Pentamidine	485374	1634	
2.1.1.45	Trypanosoma congolense		Pentamidine	485374	1634	
2.1.1.45	Trypanosoma cruzi		Pentamidine	485374	1634	
2.1.1.45	Trypanosoma lewisi		Pentamidine	485374	1634	
2.1.1.45	Lactobacillus casei		Phenylglyoxal	485409	258	
2.1.1.45	Escherichia coli		piritrexim	705044	3911	
2.1.1.45	Homo sapiens		piritrexim	705044	3911	
2.1.1.45	Toxoplasma gondii		piritrexim	705044	3911	
2.1.1.45	Escherichia coli		plevitrexed	705044	9958	
2.1.1.45	Homo sapiens		plevitrexed	705044	9958	
2.1.1.45	Toxoplasma gondii		plevitrexed	705044	9958	
2.1.1.45	Rattus norvegicus		Procion blue	485393	21970	
2.1.1.45	Homo sapiens		propylene diphosphonate	720995		mixed competitive-noncompetitive inhibitor with respect to dUMP
2.1.1.45	Crithidia fasciculata		prothidium	485374	8818	
2.1.1.45	Strigomonas oncopelti		prothidium	485374	8818	
2.1.1.45	Trypanosoma brucei		prothidium	485374	8818	
2.1.1.45	Trypanosoma congolense		prothidium	485374	8818	
2.1.1.45	Trypanosoma cruzi		prothidium	485374	8818	
2.1.1.45	Trypanosoma lewisi		prothidium	485374	8818	
2.1.1.45	Homo sapiens		pteroyldiglutamate	485395	10663	
2.1.1.45	Homo sapiens		Pteroylheptaglutamate	485395	8464	
2.1.1.45	Escherichia coli		pteroylhexaglutamate	485375	8819	
2.1.1.45	Lactobacillus casei		pteroylhexaglutamate	485370, 485375	8819	
2.1.1.45	Homo sapiens		pteroylhexaglutamate	485395	8819	
2.1.1.45	Homo sapiens		pteroylmonoglutamate	485376, 485395	1001	
2.1.1.45	Homo sapiens		pteroylpentaglutamate	485395	3172	
2.1.1.45	Lactobacillus casei		pteroylpolyglutamate	485370	11110	
2.1.1.45	Homo sapiens		pteroylpolyglutamate	485395	11110	
2.1.1.45	Homo sapiens		pteroyltetraglutamate	485395	13711	
2.1.1.45	Homo sapiens		Pteroyltriglutamate	485395	4091	
2.1.1.45	Lactobacillus casei		pyridoxal 5'-phosphate	485396	30	
2.1.1.45	Streptococcus pneumoniae		quinaspar	485372	32873	
2.1.1.45	Enterobacteria phage T2		Quinazoline	485388	5504	
2.1.1.45	Enterobacteria phage T4		Quinazoline	485388	5504	
2.1.1.45	Lactobacillus casei		Quinazoline	485388	5504	
2.1.1.45	Trypanosoma brucei		raltitrexed	689059	2263	
2.1.1.45	Homo sapiens		raltitrexed	692016	2263	RTX, a folate analog that is a specific inhibitor of TS; treatment can stimulate accurate recombination events in human cells. Gene conversions not associated with crossovers are specifically enhanced severalfold. Recombination events provoked by a double-strand break are not impacted by treatment with raltitrexed, nor is error-prone double-strand break repair via nonhomologous end-joining
2.1.1.45	Homo sapiens		raltitrexed	692480	2263	TS-targeting chemotherapeutic agent
2.1.1.45	Homo sapiens		raltitrexed	694482	2263	transfection with p53 induces resistance to raltitrexed
2.1.1.45	Mus musculus		raltitrexed	694503	2263	direct folate-based inhibitor
2.1.1.45	Escherichia coli		raltitrexed	705044, 711474	2263	
2.1.1.45	Homo sapiens		raltitrexed	692015, 703391, 705044, 711474	2263	
2.1.1.45	Toxoplasma gondii		raltitrexed	705044, 711474	2263	
2.1.1.45	Streptococcus pneumoniae		SK 28,757	485372	32033	
2.1.1.45	Streptococcus pneumoniae		SK 28,758	485372	32032	
2.1.1.45	Streptococcus pneumoniae		SK 28,815	485372		
2.1.1.45	Crithidia fasciculata		suramin	485374	568	
2.1.1.45	Strigomonas oncopelti		suramin	485374	568	
2.1.1.45	Trypanosoma brucei		suramin	485374	568	
2.1.1.45	Trypanosoma congolense		suramin	485374	568	
2.1.1.45	Trypanosoma cruzi		suramin	485374	568	
2.1.1.45	Trypanosoma lewisi		suramin	485374	568	
2.1.1.45	Escherichia coli		tetrahydrohomofolate	485375	73309	
2.1.1.45	Bos taurus		tetrahydromethotrexate	485373, 485383	5672	
2.1.1.45	Escherichia coli		tetrahydromethotrexate	485373, 485383	5672	
2.1.1.45	Lactobacillus casei		tetrahydromethotrexate	485379, 485383	5672	
2.1.1.45	Mus musculus		tetrahydromethotrexate	485373, 485383	5672	
2.1.1.45	Mus musculus		thiophosphate	485430	4095	
2.1.1.45	Enterococcus faecalis		thymidine phosphate	485358	1952	product inhibition
2.1.1.45	Enterococcus faecalis		thymidine phosphate	485363	1952	
2.1.1.45	Saccharomyces cerevisiae		thymidine phosphate	485384	1952	
2.1.1.45	Angiostrongylus cantonensis		thymidine phosphate	485404	1952	
2.1.1.45	Bos taurus		thymidine phosphate	485363, 485404	1952	
2.1.1.45	Escherichia coli		thymidine phosphate	485358, 485363, 485415	1952	
2.1.1.45	Mus musculus		thymidine phosphate	485363, 485404, 485415, 485427	1952	
2.1.1.45	Homo sapiens		Thymitaq	485419	5883	
2.1.1.45	Homo sapiens		TomudexR	485419, 485430	21980	
2.1.1.45	Rattus norvegicus		TomudexR	485430	21980	
2.1.1.45	Mus musculus		trifluoromethyldeoxyuridine 5'-monophosphate	485359	21983	
2.1.1.45	Enterobacteria phage T4		trifluoromethyldeoxyuridine 5'-monophosphate	485366	21983	
2.1.1.45	Drosophila melanogaster		trifluoromethyldeoxyuridine 5'-monophosphate	485367	21983	
2.1.1.45	Trypanosoma cruzi		trimethoprim	485374	418	
2.1.1.45	Angiostrongylus cantonensis		trimethoprim	485404	418	
2.1.1.45	Crithidia fasciculata		trimethoprim	485374, 485404	418	
2.1.1.45	Escherichia coli		trimethoprim	705044, 711474	418	
2.1.1.45	Homo sapiens		trimethoprim	705044, 711474	418	
2.1.1.45	Toxoplasma gondii		trimethoprim	705044, 711474	418	
2.1.1.45	Escherichia coli		trimetrexate	705044, 711474	2328	
2.1.1.45	Homo sapiens		trimetrexate	705044, 711474	2328	
2.1.1.45	Toxoplasma gondii		trimetrexate	705044, 711474	2328	
2.1.1.45	Rattus norvegicus		UDP-glucuronate	485393	200	
2.1.1.45	Plasmodium berghei		Urea	485389	110	
2.1.1.45	Mus musculus		vanoxonin-vanadium	485390	73346	
2.1.1.45	Homo sapiens		ZD1694	720995	2263	
2.1.1.45	Homo sapiens		ZD9331	690892	48221	antifolate inhibitor, shows positive cooperativity with 1,3-propanediphosphonic acid
2.7.4.16	Escherichia coli		ADP	642545	8	product inhibition
2.7.4.16	Escherichia coli		AMP	642545	9	
2.7.4.16	Escherichia coli		Cs+	642545	478	antagonizes stimulation by K+
2.7.4.16	Escherichia coli		diphosphate	642545	13	
2.7.4.16	Escherichia coli		EDTA	642545	223	
2.7.4.16	Escherichia coli		Li+	642545	142	antagonizes stimulation by K+
2.7.4.16	Escherichia coli		more	642545		no inhibition by phosphate, KCN, iodoacetic acid, arsenate or arsenite
2.7.4.16	Escherichia coli		N-ethylmaleimide	642545	46	
2.7.4.16	Escherichia coli		Na+	642545	55	antagonizes stimulation by K+
2.7.4.16	Escherichia coli		NaF	642545	209	weak
2.7.4.16	Escherichia coli		Oxythiamine	642545	3831	
2.7.4.16	Escherichia coli		PCMB	642545	40	2-mercaptoethanol reverses
2.7.4.16	Escherichia coli		pyrithiamine	642545	3841	
2.7.4.16	Escherichia coli		Pyrithiamine phosphate	642545	65398	
2.7.4.16	Escherichia coli		thiamine	642545	522	
4.1.1.31	Zea mays	1,2-Epoxypropylphosphonic acid		4331	65815	
4.1.1.31	Escherichia coli	2-mercaptoethanol		4286	59	activates
4.1.1.31	Thermosynechococcus vulcanus	3-phosphoglycerate		656978	174	slight stimulation
4.1.1.31	Cicer arietinum	3-Phosphoglyceric acid		4301	174	activates
4.1.1.31	Coccochloris peniocystis	3-Phosphoglyceric acid		4307	174	
4.1.1.31	Triticum aestivum	6-benzylaminopurine		671401	4447	natural cytokinin BAP
4.1.1.31	Starkeya novella	acetoacetyl-CoA		4337	167	activates
4.1.1.31	Bradyrhizobium japonicum	acetyl-CoA		714787	27	allosteric activator, PPC activity in extracts decreases by more than 75% in assays lacking acetyl-CoA
4.1.1.31	Cicer arietinum	alpha-glycerophosphate		4301	352	activates
4.1.1.31	Starkeya novella	Butyryl-CoA		4337	235	activates
4.1.1.31	Ricinus communis	D-fructose 6-phosphate		656117	82	2 mM, 1.2fold increase of activity of PEPC2 at pH 7.3, activity of PEPC2 at pH 8 is nearly identical to activity without glucose 6-phosphate
4.1.1.31	Citrus sinensis	D-fructose 6-phosphate		716631	82	
4.1.1.31	Ricinus communis	D-glucose 1-phosphate		656117	386	2 mM, 1.2fold increase of activity of PEPC2 at pH 7.3, activity of PEPC2 at pH 8 is nearly identical to activity without glucose 6-phosphate
4.1.1.31	Ricinus communis	D-glucose 6-phosphate		656117	99	2 mM, 1.2fold increase of activity of PEPC2 at pH 7.3, activity of PEPC2 at pH 8 is nearly identical to activity without glucose 6-phosphate; 2 mM, 2fold increase of activity of PEPC1 at pH 7.3, 1.18fold increase in activity of PEPC1 at pH 8
4.1.1.31	Cucumis sativus	D-glucose 6-phosphate		656395	99	allosteric activator
4.1.1.31	Zea mays	D-glucose 6-phosphate		657356	99	activates
4.1.1.31	Amaranthus hypochondriacus	D-glucose 6-phosphate		681618	99	dry heat, dark, 25&deg;C: 253% activation, 45&deg;C: 347% activation/dry heat, light, 25&deg;C: 400% activation, 45&deg;C: 856% activation/wet heat, dark, 25&deg;C: 258% activation, 45&deg;C: 400% activation/wet heat, light, 25&deg;C: 456% activation, 45&deg;C: 908% activation
4.1.1.31	Hydrilla verticillata	D-glucose 6-phosphate		682339	99	
4.1.1.31	Alternanthera ficoidea	D-glucose 6-phosphate		682463	99	
4.1.1.31	Alternanthera pungens	D-glucose 6-phosphate		682463	99	
4.1.1.31	Alternanthera sessilis	D-glucose 6-phosphate		682463	99	
4.1.1.31	Arabidopsis thaliana	D-glucose 6-phosphate		701501	99	
4.1.1.31	Oryza sativa	D-glucose 6-phosphate		706563	99	1.17fold activation of isoform Osppc4 at pH 7.3, 2.51fold activation of isoform Osppc2a at pH 7.3
4.1.1.31	Amaranthus hypochondriacus	D-glucose 6-phosphate		715758	99	
4.1.1.31	Citrus sinensis	D-glucose 6-phosphate		716631	99	
4.1.1.31	Chlamydomonas reinhardtii	dihydroxyacetone phosphate		4316	241	activates
4.1.1.31	Monoraphidium minutum	dihydroxyacetone phosphate		4317	241	isoenzyme PEPC2 is inactivated 6fold by 2.0 mM, 52% activation by isoenzyme PEPC2
4.1.1.31	Glycine max	dihydroxyacetone phosphate		4318	241	activates at pH 7 in absence of glycerol, but has no effect under other assay conditions
4.1.1.31	Thiobacillus thioparus	Dioxane		4289	2121	stimulates
4.1.1.31	Rhodopseudomonas sp.	Dioxane		4340	2121	
4.1.1.31	Rhodopseudomonas sp.	ethanol		4340	65	activates
4.1.1.31	Flaveria trinervia	ethylene glycol		728350	1064	
4.1.1.31	Zea mays	fructose 1,6-bisphosphate		4294	100	weak activation
4.1.1.31	Cicer arietinum	fructose 1,6-bisphosphate		4301	100	activates
4.1.1.31	Methanothermus sociabilis	fructose 1,6-bisphosphate		4315	100	no effect
4.1.1.31	Thermosynechococcus vulcanus	fructose 1,6-diphosphate		656978	100	activates
4.1.1.31	Bryophyllum fedtschenkoi	fructose 6-phosphate		4295	82	activates at pH 7.8
4.1.1.31	Glycine max	fructose 6-phosphate		4318	82	activates at pH 7 in absence of glycerol, but has no effect under other assay conditions
4.1.1.31	Ricinus communis	fructose 6-phosphate		656117	82	2 mM, 2fold increase of activity of PEPC1 at pH 7.3, 1.27fold increase in activity of PEPC1 at pH 8
4.1.1.31	Escherichia coli	fructose diphosphate		4286	100	activates
4.1.1.31	Vicia faba	fusicoccin		657094	11697	rapid activation, reduces sensitivity towards the feedback-inhibitor malate
4.1.1.31	Bryophyllum fedtschenkoi	galactose 6-phosphate		4295	1862	activates at pH 7.8
4.1.1.31	Thermosynechococcus vulcanus	Gln		656978	96	slight stimulation
4.1.1.31	Thermosynechococcus vulcanus	Glu		656978	38	slight stimulation
4.1.1.31	Zea mays	glucose 1-phosphate		4294	386	weak activation
4.1.1.31	Bryophyllum fedtschenkoi	glucose 1-phosphate		4295	386	activates at pH 7.8
4.1.1.31	Glycine max	glucose 1-phosphate		4318	386	activates at pH 7 in absence of glycerol, but has no effect under other assay conditions
4.1.1.31	Ricinus communis	glucose 1-phosphate		656117	386	2 mM, 1.64fold increase of activity of PEPC1 at pH 7.3, 1.07fold increase in activity of PEPC1 at pH 8
4.1.1.31	Thermosynechococcus vulcanus	glucose 1-phosphate		656978	386	slight stimulation
4.1.1.31	Zea mays	glucose 6-phosphate		4294	99	significant activation
4.1.1.31	Umbilicus rupestris	glucose 6-phosphate		4296	99	maximal activation at 2 mM
4.1.1.31	Commelina communis	glucose 6-phosphate		4300	99	
4.1.1.31	Cicer arietinum	glucose 6-phosphate		4301	99	activates
4.1.1.31	Amaranthus viridis	glucose 6-phosphate		4305	99	
4.1.1.31	Embryophyta	glucose 6-phosphate		4308	99	C4 plants and CAM plants
4.1.1.31	Methanothermus sociabilis	glucose 6-phosphate		4315	99	no effect
4.1.1.31	Glycine max	glucose 6-phosphate		4318	99	activates at pH 7 in absence of glycerol, but has no effect under other assay conditions
4.1.1.31	Vicia faba	glucose 6-phosphate		4320	99	activates
4.1.1.31	Amaranthus hypochondriacus	glucose 6-phosphate		4323	99	desensitization by bicarbonate
4.1.1.31	Persea americana	glucose 6-phosphate		4326	99	stimulates
4.1.1.31	Brassica rapa subsp. campestris	glucose 6-phosphate		4332	99	
4.1.1.31	Flaveria pringlei	glucose 6-phosphate		4338	99	
4.1.1.31	Flaveria trinervia	glucose 6-phosphate		4338	99	
4.1.1.31	Brassica napus	glucose 6-phosphate		655409	99	activates
4.1.1.31	Thermosynechococcus vulcanus	glucose 6-phosphate		656978	99	slight stimulation
4.1.1.31	Zea mays	glucose 6-phosphate		662338	99	activates wild-type enzyme
4.1.1.31	Zea mays	glucose 6-phosphate		4325, 663033	99	
4.1.1.31	Ricinus communis	glucose 6-phosphate		663146	99	activates PEPC1
4.1.1.31	Chlamydomonas reinhardtii	glutamine		4316	96	activates
4.1.1.31	Monoraphidium minutum	glutamine		4317	96	isoenzyme PEPC1 is inactivated more than 4fold by 2 mM, 8% activation of isoenzyme PEPC2
4.1.1.31	Zea mays	Gly		4294	68	significant activation
4.1.1.31	Zea mays	Gly		4325, 4339	68	
4.1.1.31	Zea mays	glycerol		4325	129	activates
4.1.1.31	Ricinus communis	glycerol 3-phosphate		656117	352	2 mM, 1.2fold increase of activity of PEPC2 at pH 7.3, activity of PEPC2 at pH 8 is nearly identical to activity without glucose 6-phosphate; 2 mM, 1.83fold increase of activity of PEPC1 at pH 7.3, 1.16fold increase in activity of PEPC1 at pH 8
4.1.1.31	Zea mays	glycine		662338	68	allosteric activator
4.1.1.31	Zea mays	glycine		663033	68	
4.1.1.31	Escherichia coli	GTP		4286	35	activates
4.1.1.31	Starkeya novella	Heptanoyl-CoA		4337	2984	activates
4.1.1.31	Starkeya novella	Hexanoyl-CoA		4337	330	activates
4.1.1.31	Zea mays	His		4325	296	stimulates
4.1.1.31	Flaveria trinervia	L-glucose 6-phosphate		728350		
4.1.1.31	Hakea prostrata	L-glucose 6-phosphate		728519		5.1fold stimulation of activity at 5 mM
4.1.1.31	Ricinus communis	malate		656117	246	2 mM, 1.2fold increase of activity of PEPC2 at pH 7.3, activity of PEPC2 at pH 8 is nearly identical to activity without glucose 6-phosphate
4.1.1.31	Bryophyllum fedtschenkoi	malonate		4295	328	inhibits at pH 7.8, increases activity at pH 5.8
4.1.1.31	Triticum aestivum	more		671401		the results presented indicate that both the natural cytokinin BAP and synthetic preparations exhibiting cytokinin activity (TDZ, kartolin-2, and kartolin-4) attenuate the suppression PEPK activities in wheat seedlings and mature plant leaves, associated with water deficiency
4.1.1.31	Clostridium perfringens	more		716881		not activated by D-glucose 6-phosphate
4.1.1.31	Triticum aestivum	N-isopropoxycarbonyl-4-chlorophenylcarbamoyl-ethanolamine		671401	88580	synthetic preparation exhibiting cytokinin activity: kartolin-4
4.1.1.31	Triticum aestivum	O-isopropyl-N-2-hydroxyethylcarbamate		671401	88579	synthetic preparation exhibiting cytokinin activity: kartolin-2
4.1.1.31	Amaranthus hypochondriacus	phosphate		681618	12	dry heat, dark, 25&deg;C: 222% activation, 45&deg;C: 275% activation/dry heat, light, 25&deg;C: 321% activation, 45&deg;C: 636% activation/wet heat, dark, 25&deg;C: 225% activation, 45&deg;C: 315% activation/wet heat, light, 25&deg;C: 368% activation, 45&deg;C: 687% activation
4.1.1.31	Zea mays	phosphoenolpyruvate		654812	47	free, allosteric activator
4.1.1.31	Bryophyllum fedtschenkoi	Polyethylene glycol		4292	2061	required for maximal activity
4.1.1.31	Acetobacter aceti	propionyl-CoA		4293	297	absolute requirement for acetyl-CoA or propionyl-CoA
4.1.1.31	Starkeya novella	propionyl-CoA		4337	297	activates
4.1.1.31	Coccochloris peniocystis	pyruvate		4307	29	activates
4.1.1.31	Starkeya novella	succinyl-CoA		4337	198	activates
4.1.1.31	Triticum aestivum	thidiazuron		671401	7476	synthetic preparation exhibiting cytokinin activity: TDZ
4.1.1.31	Starkeya novella	valeryl-CoA		4337	1555	activates
4.1.1.31	Flaveria pringlei		(+)-catechin	727533	1795	
4.1.1.31	Flaveria trinervia		(+)-catechin	727533	1795	
4.1.1.31	Amaranthus hypochondriacus		(S)-malate	656404	180	
4.1.1.31	Flaveria trinervia		2-(4-methoxyphenyl)-3-phenyl-quinoxaline	727533		
4.1.1.31	Acetobacter aceti		2-oxoglutarate	4293	32	
4.1.1.31	Amaranthus viridis		2-oxoglutarate	4305	32	
4.1.1.31	Coccochloris peniocystis		2-oxoglutarate	4307	32	
4.1.1.31	Chlamydomonas reinhardtii		2-oxoglutarate	4316	32	
4.1.1.31	Monoraphidium minutum		2-oxoglutarate	4317	32	isoenzyme PEPC1 is more sensitive to inhibition than isoenzyme PEPC2
4.1.1.31	Glycine max		2-oxoglutarate	4318	32	potent inhibitor at pH 7 in absence of glycerol, but its effectiveness is decreased by raising the pH to 8 and/or by adding glycerol
4.1.1.31	Lupinus luteus		2-oxoglutarate	4319	32	inhibition of enzyme form PEPC I and PEPC II, no inhibition of enzyme form PEPC III
4.1.1.31	Glycine max		2-phosphoglycerate	4318	606	
4.1.1.31	Plasmodium falciparum		3,3-dichloro-2-(dihydroxyphosphinoylmethyl) propenoate	728643		micromolar inhibitor
4.1.1.31	Escherichia coli		3-Mercaptopropionate	4311	2359	
4.1.1.31	Glycine max		3-phosphoglycerate	4318	174	
4.1.1.31	Plasmodium berghei		ADP	4285	8	
4.1.1.31	Zea mays		ADP	4294	8	competitive
4.1.1.31	Umbilicus rupestris		ADP	4296	8	
4.1.1.31	Thermus sp.		ADP	4330	8	
4.1.1.31	Rhodopseudomonas sp.		ADP	4340	8	
4.1.1.31	Methanothermobacter thermautotrophicus		ADP	662013	8	10mM, 57% inhibition in presence of 5 mM Mg2+, 46% inhibition in presence of 15 mM Mg2+
4.1.1.31	Flaveria pringlei		AG 1433	727533		i.e. 2-(3,4-dihydroxyphenyl)-6,7-dimethylquinoxaline
4.1.1.31	Flaveria trinervia		AG 1433	727533		i.e. 2-(3,4-dihydroxyphenyl)-6,7-dimethylquinoxaline
4.1.1.31	Hyphomicrobium methylovorum		Ag+	4341	71	
4.1.1.31	Coccochloris peniocystis		alpha-Hydroxy-2-pyridylmethanesulfonate	4307	66173	
4.1.1.31	Thermosynechococcus vulcanus		alpha-ketoglutarate	656978	32	10 mM, 9% inhibition
4.1.1.31	Medicago sativa		AMP	4298	9	slight
4.1.1.31	Methanothermobacter thermautotrophicus		AMP	662013	9	10mM, 16% inhibition in presence of 5 mM Mg2+, 12% inhibition in presence of 15 mM Mg2+
4.1.1.31	Plasmodium berghei		Asp	4285	91	
4.1.1.31	Thiobacillus thioparus		Asp	4289	91	L-Asp, competitive
4.1.1.31	Acetobacter aceti		Asp	4293	91	
4.1.1.31	Zea mays		Asp	4294	91	
4.1.1.31	Umbilicus rupestris		Asp	4296	91	
4.1.1.31	Amaranthus viridis		Asp	4305	91	
4.1.1.31	Embryophyta		Asp	4308	91	
4.1.1.31	Chlamydomonas reinhardtii		Asp	4316	91	
4.1.1.31	Monoraphidium minutum		Asp	4317	91	isoenzyme PEPC1 is more sensitive to inhibition than isoenzyme PEPC2
4.1.1.31	Glycine max		Asp	4318	91	potent inhibitor at pH 7 in absence of glycerol, but its effectiveness is decreased by raising the pH to 8 and/or by adding glycerol
4.1.1.31	Lupinus luteus		Asp	4319	91	at pH 7.2, weak competitive inhibition for enzyme form PEPC I, strong competitive inhibition for enzyme form PEPC II and enzyme form PEPC III
4.1.1.31	Thermus sp.		Asp	4330	91	
4.1.1.31	Rhodopseudomonas sp.		Asp	4340	91	
4.1.1.31	Hyphomicrobium methylovorum		Asp	4341	91	
4.1.1.31	Escherichia coli		Asp	4308, 4311, 657356	91	
4.1.1.31	Zea mays		aspartate	663033	91	
4.1.1.31	Ricinus communis		aspartate	663146	91	IC50 of phospho-PEPC1: 0.35 mM, IC50 of dephospho-PEPC1: 0.32 mM; IC50 of phospho-PEPC2: 2.6 mM, IC50 of dephospho-PEPC2: 4.5 mM, enzyme form PEPC2
4.1.1.31	Corynebacterium glutamicum		aspartate	726746	91	the enzyme loses about 95% activity when the aspartate concentration is more than 2 mM
4.1.1.31	Plasmodium berghei		ATP	4285	7	
4.1.1.31	Zea mays		ATP	4294	7	competitive
4.1.1.31	Umbilicus rupestris		ATP	4296	7	
4.1.1.31	Cicer arietinum		ATP	4301	7	
4.1.1.31	Coccochloris peniocystis		ATP	4307	7	
4.1.1.31	Thermus sp.		ATP	4330	7	
4.1.1.31	Brassica rapa subsp. campestris		ATP	4332	7	
4.1.1.31	Rhodopseudomonas sp.		ATP	4340	7	
4.1.1.31	Hyphomicrobium methylovorum		ATP	4341	7	
4.1.1.31	Ricinus communis		ATP	656117	7	2 mM, 65% decreases of activity of PEPC1 at pH 7.3, 13% decrease in activity of PEPC2 at pH 8
4.1.1.31	Thermosynechococcus vulcanus		ATP	656978	7	5.0 mM, 57% inhibition
4.1.1.31	Methanothermobacter thermautotrophicus		ATP	662013	7	10mM, 92% inhibition in presence of 5 mM Mg2+, 65% inhibition in presence of 15 mM Mg2+
4.1.1.31	Amaranthus viridis		baicalein	4342	838	
4.1.1.31	Amaranthus viridis		Baicalin	4342	2603	
4.1.1.31	Medicago sativa		Ca2+	4298	18	substitution of 20 mM CaCl2 for 20 mM MgCl2 results in 90-100% inhibition
4.1.1.31	Cicer arietinum		Ca2+	4301	18	5 mM, in presence of 5 mM Mg2+, 83% inhibition
4.1.1.31	Brassica rapa subsp. campestris		Cd2+	4332	48	5 mM, in presence of 5 mM Mg2+
4.1.1.31	Molinema dessetae		Cd2+	4336	48	
4.1.1.31	Hyphomicrobium methylovorum		Cd2+	4341	48	
4.1.1.31	Plasmodium berghei		Chloroquine	4285	1087	
4.1.1.31	Plasmodium berghei		citrate	4285	125	
4.1.1.31	Acetobacter aceti		citrate	4293	125	
4.1.1.31	Zea mays		citrate	4294	125	
4.1.1.31	Umbilicus rupestris		citrate	4296	125	
4.1.1.31	Coccochloris peniocystis		citrate	4307	125	
4.1.1.31	Escherichia coli		citrate	4311	125	
4.1.1.31	Euglena gracilis		citrate	4314	125	
4.1.1.31	Glycine max		citrate	4318	125	potent inhibitor at pH 7 in absence of glycerol, but its effectiveness is decreased by raising the pH to 8 and/or by adding glycerol
4.1.1.31	Hyphomicrobium methylovorum		citrate	4341	125	
4.1.1.31	Citrus sinensis		citrate	716631	125	strong inhibition
4.1.1.31	Zea mays		Cl-	4294	134	
4.1.1.31	Acetobacter aceti		Co2+	4293	21	maximal activity at 1 mM Co2+, strong decrease of activity above 4 mM
4.1.1.31	Brassica rapa subsp. campestris		Co2+	4332	21	5 mM, in presence of 5 mM Mg2+
4.1.1.31	Cicer arietinum		CTP	4301	56	
4.1.1.31	Molinema dessetae		Cu2+	4336	28	
4.1.1.31	Hyphomicrobium methylovorum		Cu2+	4341	28	
4.1.1.31	Escherichia coli		Cys	4311	70	
4.1.1.31	Thermosynechococcus vulcanus		D-fructose	656978	111	10 mM, 19% inhibition
4.1.1.31	Thermosynechococcus vulcanus		D-Fructose 1-phosphate	656978	544	10 mM, 26% inhibition
4.1.1.31	Thermosynechococcus vulcanus		D-fructose 2,6-diphosphate	656978	573	0.3 mM, 35% inhibition
4.1.1.31	Ricinus communis		D-fructose 6-phosphate	704531	82	99% residual activity at 2 mM
4.1.1.31	Ricinus communis		D-glucose 1-phosphate	704531	386	95% residual activity at 2 mM
4.1.1.31	Ricinus communis		D-glucose 6-phosphate	704531	99	93% residual activity at 2 mM
4.1.1.31	Spinacia oleracea		D-Phospholactate	4288	56262	
4.1.1.31	Embryophyta		diethyl dicarbonate	4308	265	causes dissociation of the enzyme into dimers and monomers
4.1.1.31	Brassica napus		DL-isocitrate	655409	242	
4.1.1.31	Plasmodium berghei		EDTA	4285	223	
4.1.1.31	Flaveria pringlei		epigallocatechin gallate	727533	936	
4.1.1.31	Flaveria trinervia		epigallocatechin gallate	727533	936	
4.1.1.31	Molinema dessetae		Fe2+	4336	23	
4.1.1.31	Hyphomicrobium methylovorum		Fe2+	4341	23	
4.1.1.31	Amaranthus viridis		fisetin	4342	955	
4.1.1.31	Thermus sp.		fructose 1,6-diphosphate	4330	100	
4.1.1.31	Acetobacter aceti		fumarate	4293	156	
4.1.1.31	Escherichia coli		fumarate	4311	156	
4.1.1.31	Thermosynechococcus vulcanus		fumarate	656978	156	10 mM, 31% inhibition
4.1.1.31	Plasmodium berghei		GDP	4285	49	
4.1.1.31	Acetobacter aceti		Glu	4293	38	
4.1.1.31	Amaranthus viridis		Glu	4305	38	
4.1.1.31	Chlamydomonas reinhardtii		Glu	4316	38	
4.1.1.31	Monoraphidium minutum		Glu	4317	38	isoenzyme PEPC1 is more sensitive to inhibition than isoenzyme PEPC2
4.1.1.31	Glycine max		Glu	4318	38	potent inhibitor at pH 7 in absence of glycerol, but its effectiveness is decreased by raising the pH to 8 and/or by adding glycerol
4.1.1.31	Lupinus luteus		Glu	4319	38	inhibition of enzyme form PEPC I and PEPC II, no inhibition of enzyme form PEPC III
4.1.1.31	Thermus sp.		glucose 6-phosphate	4330	99	
4.1.1.31	Ricinus communis		glutamate	663146	38	IC50 of phospho-PEPC1: 2.1 mM, IC50 of dephospho-PEPC1: 2.2 mM; IC50 of phospho-PEPC2: 4.1 mM, IC50 of dephospho-PEPC2: 7.0 mM, enzyme form PEPC2
4.1.1.31	Hyphomicrobium methylovorum		glycerate	4341	1287	
4.1.1.31	Ricinus communis		glycerol 3-phosphate	704531	352	98% residual activity at 2 mM
4.1.1.31	Hyphomicrobium methylovorum		glyoxylate	4341	95	
4.1.1.31	Plasmodium berghei		GTP	4285	35	
4.1.1.31	Cicer arietinum		GTP	4301	35	
4.1.1.31	Thermus sp.		GTP	4330	35	
4.1.1.31	Rhodopseudomonas sp.		GTP	4340	35	
4.1.1.31	Methanothermobacter thermautotrophicus		GTP	662013	35	10mM, 58% inhibition in presence of 5 mM Mg2+, 15% inhibition in presence of 15 mM Mg2+
4.1.1.31	Thermus sp.		guanidine hydrochloride	4330	804	
4.1.1.31	Brassica rapa subsp. campestris		Hg2+	4332	31	5 mM, in presence of 5 mM Mg2+
4.1.1.31	Coccochloris peniocystis		Isocitrate	4307	242	
4.1.1.31	Amaranthus viridis		kaempferol	4342	341	
4.1.1.31	Methanothermobacter thermautotrophicus		KCl	662013	74	0.05-1.0 M, 60% inhibition at 0.25 M, 27% inhibition at 0.1 M
4.1.1.31	Brassica napus		L-Asp	655409	91	
4.1.1.31	Ricinus communis		L-Asp	656117	91	2 mM, 95% decreases of activity of PEPC1 at pH 7.3, 49% decrease in activity of PEPC2 at pH 8
4.1.1.31	Thermosynechococcus vulcanus		L-Asp	656978	91	more sensitive to inhibition by Asp at pH 9.0 than at pH 7.0
4.1.1.31	Oryza sativa		L-Asp	706563	91	
4.1.1.31	Clostridium perfringens		L-Asp	716881	91	L-Asp competitively inhibits the enzyme with respect to the substrate, Mg2+-phosphoenolpyruvate
4.1.1.31	Methanothermobacter thermautotrophicus		L-aspartate	662013	91	10 mM, 41% inhibition in presence of 5 mM Mg2+ or 15 mM Mg2+
4.1.1.31	Arabidopsis thaliana		L-aspartate	701501	91	
4.1.1.31	Ricinus communis		L-aspartate	704531	91	98% residual activity at 2 mM
4.1.1.31	Ricinus communis		L-aspartate	714092	91	
4.1.1.31	Sulfolobus acidocaldarius		L-aspartate	725031	91	4 mM, complete inhibition
4.1.1.31	Sulfolobus solfataricus		L-aspartate	725236	91	allosteric inhibitor
4.1.1.31	Brassica napus		L-Glu	655409	38	
4.1.1.31	Ricinus communis		L-Glu	656117	38	2 mM, 96% decreases of activity of PEPC1 at pH 7.3, 22% decrease in activity of PEPC2 at pH 8
4.1.1.31	Oryza sativa		L-Glu	706563	38	
4.1.1.31	Spinacia oleracea		L-lactate	4288	338	
4.1.1.31	Brassica napus		L-Malate	655409	180	
4.1.1.31	Annona cherimola		L-Malate	656941	180	IC50: 3.84 mM for enzyme from mesocarop, stored in air, 5.95 mM for enzyme from mesocarop stored in 20% CO2, 2.01 mM for enzyme from peel stored in air
4.1.1.31	Sorghum bicolor		L-Malate	657092	180	the inhibition by 0.16 mM L-malate, pH 7.3, decreases from 70 to 30%, along with a consistent increase in IC50 from 0.075 mM to 0.22 mM after 5 days of germination
4.1.1.31	Zea mays		L-Malate	662338	180	inhibits wild-type enzyme
4.1.1.31	Fagus sylvatica		L-Malate	682146	180	
4.1.1.31	Bienertia sinuspersici		L-Malate	682409	180	
4.1.1.31	Haloxylon persicum		L-Malate	682409	180	
4.1.1.31	Suaeda aralocaspica		L-Malate	682409	180	
4.1.1.31	Suaeda eltonica		L-Malate	682409	180	
4.1.1.31	Suaeda linifolia		L-Malate	682409	180	
4.1.1.31	Xylosalsola richteri		L-Malate	682409	180	
4.1.1.31	Arabidopsis thaliana		L-Malate	701501, 703706	180	
4.1.1.31	Ricinus communis		L-Malate	704531	180	84% residual activity at 2 mM
4.1.1.31	Oryza sativa		L-Malate	706563	180	
4.1.1.31	Ricinus communis		L-Malate	714092	180	
4.1.1.31	Amaranthus hypochondriacus		L-Malate	656910, 715758	180	
4.1.1.31	Amaranthus edulis		L-Malate	716474	180	
4.1.1.31	Citrus sinensis		L-Malate	716631	180	weak inhibition at physiological pH values
4.1.1.31	Sulfolobus acidocaldarius		L-Malate	725031	180	10 mM, 48% inhibition
4.1.1.31	Sulfolobus solfataricus		L-Malate	725236	180	allosteric inhibitor
4.1.1.31	Spinacia oleracea		L-Phospholactate	4288	9863	
4.1.1.31	Sorghum bicolor		lyso-phosphatidic acid	706331	848	addition of 0.05 mM phosphatidic acid decreases PEPC activity to approximately 45% of the control activity
4.1.1.31	Zea mays		lyso-phosphatidic acid	706331	848	addition of 0.05 mM phosphatidic acid decreases PEPC activity to approximately 45% of the control activity
4.1.1.31	Thiobacillus thioparus		malate	4289	246	competitive; L-malate
4.1.1.31	Bryophyllum fedtschenkoi		malate	4292, 4295	246	
4.1.1.31	Umbilicus rupestris		malate	4296	246	L-malate
4.1.1.31	Medicago sativa		malate	4298	246	
4.1.1.31	Commelina communis		malate	4300	246	
4.1.1.31	Cicer arietinum		malate	4301	246	
4.1.1.31	Amaranthus viridis		malate	4305	246	
4.1.1.31	Bryophyllum fedtschenkoi		malate	4306	246	the day form of the enzyme is 10times more sensitive than the night form of the enzyme
4.1.1.31	Embryophyta		malate	4308	246	L-malate
4.1.1.31	Escherichia coli		malate	4308, 4311	246	
4.1.1.31	Coleataenia prionitis		malate	4313	246	
4.1.1.31	Panicum milioides		malate	4313	246	
4.1.1.31	Steinchisma laxum		malate	4313	246	
4.1.1.31	Glycine max		malate	4318	246	potent inhibitor at pH 7 in absence of glycerol, but its effectiveness is decreased by raising the pH to 8 and/or by adding glycerol
4.1.1.31	Lupinus luteus		malate	4319	246	competitive inhibitor of enzyme form PEPC I and enzyme form PEPC III, mixed-type inhibitor for enzyme form PEPC II
4.1.1.31	Vicia faba		malate	4299, 4320	246	
4.1.1.31	Zea mays		malate	4322	246	reduction of the inhibitory effect by ethylene glycol and bicarbonate
4.1.1.31	Amaranthus hypochondriacus		malate	4323	246	desensitization by bicarbonate
4.1.1.31	Zea mays		malate	4324	246	the phosphorylated enzyme is less sensitive to malate
4.1.1.31	Thermus sp.		malate	4330	246	
4.1.1.31	Brassica rapa subsp. campestris		malate	4332	246	
4.1.1.31	Hyphomicrobium methylovorum		malate	4341	246	
4.1.1.31	Ricinus communis		malate	656117	246	2 mM, 96% decreases of activity of PEPC1 at pH 7.3, 59% decrease in activity of PEPC1 at pH 8
4.1.1.31	Cucumis sativus		malate	656395	246	1 mM
4.1.1.31	Amaranthus hypochondriacus		malate	656404	246	
4.1.1.31	Portulaca oleracea		malate	656909	246	
4.1.1.31	Pinus halepensis		malate	656925	246	
4.1.1.31	Vicia faba		malate	657094	246	feedback inhibitor
4.1.1.31	Digitaria sanguinalis		malate	663028	246	IC50: 8 mM for PEPC activity in situ, 1.5 mM for PEPC activity in vitro
4.1.1.31	Zea mays		malate	4294, 4325, 4335, 4339, 663033	246	
4.1.1.31	Ricinus communis		malate	663146	246	IC50 of phospho-PEPC1: 0.075 mM, IC50 of dephospho-PEPC1: 0.029 mM; IC50 of phospho-PEPC2: 0.57 mM, IC50 of dephospho-PEPC2: 1.47 mM, enzyme form PEPC2
4.1.1.31	Brachiaria hybrid cultivar		malate	681610	246	
4.1.1.31	Amaranthus hypochondriacus		malate	681618	246	dry heat, dark, 25&deg;C: 96% inhibition, 45&deg;C: 84% inhibition/dry heat, light, 25&deg;C: 59% inhibition, 45&deg;C: 31.2% inhibition/wet heat, dark, 25&deg;C: 94%, 45&deg;C: 76% inhibition /wet heat, light, 25&deg;C: 46% inhibition, 45&deg;C: 17% inhibition
4.1.1.31	Hydrilla verticillata		malate	682339	246	
4.1.1.31	Ananas comosus		malate	682446	246	
4.1.1.31	Kalanchoe daigremontiana		malate	682446	246	
4.1.1.31	Kalanchoe pinnata		malate	682446	246	
4.1.1.31	Arabidopsis thaliana		malate	714099	246	
4.1.1.31	Beta vulgaris		malate	714099	246	
4.1.1.31	Brassica napus		malate	714099	246	
4.1.1.31	Chlamydomonas reinhardtii		malate	4316, 714099	246	
4.1.1.31	Citrus sinensis		malate	714099	246	
4.1.1.31	Glycine max		malate	714099	246	
4.1.1.31	Helianthus annuus		malate	714099	246	
4.1.1.31	Hordeum vulgare		malate	714099	246	
4.1.1.31	Lotus japonicus		malate	714099	246	
4.1.1.31	Lupinus albus		malate	714099	246	
4.1.1.31	Musa cavendishii		malate	714099	246	
4.1.1.31	Nicotiana tabacum		malate	714099	246	
4.1.1.31	Oryza sativa		malate	714099	246	
4.1.1.31	Ricinus communis		malate	714099	246	
4.1.1.31	Solanum lycopersicum		malate	714099	246	
4.1.1.31	Solanum tuberosum		malate	714099	246	
4.1.1.31	Triticum aestivum		malate	714099	246	
4.1.1.31	Flaveria pringlei		malate	4338, 728348	246	
4.1.1.31	Flaveria trinervia		malate	4338, 728348	246	
4.1.1.31	Hakea prostrata		malate	728519	246	
4.1.1.31	Coccochloris peniocystis		Maleate	4307	474	
4.1.1.31	Escherichia coli		Maleate	4311	474	
4.1.1.31	Bryophyllum fedtschenkoi		malonate	4295	328	inhibits at pH 7.8, increases activity at pH 5.8
4.1.1.31	Coccochloris peniocystis		malonate	4307	328	
4.1.1.31	Clostridium perfringens		malonate	716881	328	weak inhibitor
4.1.1.31	Spinacia oleracea		methyl phosphate	4288	4875	
4.1.1.31	Zea mays		Mg-(1,2-epoxypropylphosphonic acid) complex	4331		
4.1.1.31	Zea mays		Mg2+	654812	25	free, non-competitive. Substrate inhibition by Mg-phosphoenolpyruvate is caused by inhibition by high Mg2+ and ionic strength
4.1.1.31	Monoraphidium minutum		microcystin-LR	653470	3874	PEPC2
4.1.1.31	Acetobacter aceti		Mn2+	4293	26	maximal activity at 0.5 mM Mn2+, strong decrease of activity above 2 mM
4.1.1.31	Medicago sativa		Mn2+	4298	26	substitution of 20 mM MnCl2 for 20 mM MgCl2 results in 90-100% inhibition
4.1.1.31	Cicer arietinum		Mn2+	4301	26	5 mM, in presence of 5 mM Mg2+, 72% inhibition
4.1.1.31	Thermosynechococcus vulcanus		more	663185		the enzyme is almost insensitive to feedback inhibition at neutral pH
4.1.1.31	Arabidopsis thaliana		more	706331		not inhibited by phosphatidic acid, phosphatidylinositol, phosphatidylinositol 4-phosphate, lyso-phosphatidic acid, phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine
4.1.1.31	Sorghum bicolor		more	706331		phosphatidylcholine and phosphatidylethanolamine have no effect on enzyme activity
4.1.1.31	Zea mays		more	706331		phosphatidylcholine and phosphatidylethanolamine have no effect on enzyme activity
4.1.1.31	Citrus sinensis		more	716631		the enzyme is poorly affected by L-Glu and L-Asp
4.1.1.31	Flaveria pringlei		more	727533		not inhibited by 2-(4-methoxyphenyl)-3-phenyl-quinoxaline
4.1.1.31	Amaranthus viridis		morin	4342	868	
4.1.1.31	Amaranthus viridis		myricetin	4342	403	
4.1.1.31	Vicia faba		NaCl	4312	39	200 mM, 50% inhibition
4.1.1.31	Methanothermobacter thermautotrophicus		NaCl	662013	39	0.05-1.0 M, 60% inhibition at 0.25 M, 27% inhibition at 0.1 M
4.1.1.31	Monoraphidium minutum		NaF	653470	209	PEPC2
4.1.1.31	Escherichia coli		NEM	4286	46	
4.1.1.31	Brassica rapa subsp. campestris		Ni2+	4332	36	weak
4.1.1.31	Hyphomicrobium methylovorum		Ni2+	4341	36	
4.1.1.31	Spinacia oleracea		oxalate	4288	166	
4.1.1.31	Plasmodium berghei		oxaloacetate	4285	53	
4.1.1.31	Cicer arietinum		oxaloacetate	4301	53	
4.1.1.31	Amaranthus viridis		oxaloacetate	4305	53	
4.1.1.31	Coccochloris peniocystis		oxaloacetate	4307	53	
4.1.1.31	Zea mays		oxaloacetate	4325	53	
4.1.1.31	Brassica rapa subsp. campestris		oxaloacetate	4332	53	
4.1.1.31	Acetobacter aceti		p-hydroxymercuribenzoate	4293	92	glutathione protects
4.1.1.31	Acetobacter aceti		PCMB	4293	40	glutathione protects
4.1.1.31	Embryophyta		PCMB	4308	40	causes dissociation of the enzyme into dimers and monomers
4.1.1.31	Hyphomicrobium methylovorum		PCMB	4341	40	
4.1.1.31	Thiobacillus thioparus		phosphate	4289	12	orthophosphate is noncompetitive with phosphoenolpyruvate
4.1.1.31	Bryophyllum fedtschenkoi		phosphate	4292	12	
4.1.1.31	Coccochloris peniocystis		phosphate	4307	12	
4.1.1.31	Glycine max		phosphate	4318	12	activates at pH 7 in absence of glycerol, inhibits under other assay conditions
4.1.1.31	Thermus sp.		phosphate	4330	12	
4.1.1.31	Sorghum bicolor		phosphatidic acid	706331	408	addition of 0.05 mM phosphatidic acid decreases PEPC activity to approximately 40% of the control activity. Inclusion of D-glucose 6-phosphate or L-malate do not change the effect of phosphatidic acid on PEPC, preincubation of the enzyme with 5 mM phosphoenolpyruvate prior to the addition of phosphatidic acid did not prevent inactivation either. The incubation of phosphatidic acid-inactivated PEPC with protein kinase A does not restore PEPC activity
4.1.1.31	Zea mays		phosphatidic acid	706331	408	addition of 0.05 mM phosphatidic acid decreases PEPC activity to approximately 40% of the control activity. Inclusion of D-glucose 6-phosphate or L-malate do not change the effect of phosphatidic acid on PEPC, preincubation of the enzyme with 5 mM phosphoenolpyruvate prior to the addition of phosphatidic acid did not prevent inactivation either. The incubation of phosphatidic acid-inactivated PEPC with protein kinase A does not restore PEPC activity
4.1.1.31	Sorghum bicolor		phosphatidylinositol	706331	393	addition of 0.05 mM phosphatidic acid decreases PEPC activity to approximately 40% of the control activity
4.1.1.31	Zea mays		phosphatidylinositol	706331	393	addition of 0.05 mM phosphatidic acid decreases PEPC activity to approximately 40% of the control activity
4.1.1.31	Sorghum bicolor		phosphatidylinositol 4-phosphate	706331	1707	addition of 0.05 mM phosphatidic acid decreases PEPC activity to approximately 50% of the control activity
4.1.1.31	Zea mays		phosphatidylinositol 4-phosphate	706331	1707	addition of 0.05 mM phosphatidic acid decreases PEPC activity to approximately 50% of the control activity
4.1.1.31	Sorghum bicolor		phosphatidylserine	706331	358	addition of 0.05 mM phosphatidic acid decreases PEPC activity to approximately 80% of the control activity
4.1.1.31	Zea mays		phosphatidylserine	706331	358	addition of 0.05 mM phosphatidic acid decreases PEPC activity to approximately 80% of the control activity
4.1.1.31	Spinacia oleracea		phosphite	4288	943	
4.1.1.31	Vicia faba		phosphoenolpyruvate	4299	47	above 1 mM
4.1.1.31	Spinacia oleracea		Phosphoglycolate	4288	997	
4.1.1.31	Coccochloris peniocystis		Picolinic acid	4307	3360	
4.1.1.31	Zea mays		pyruvate	4294	29	
4.1.1.31	Lupinus luteus		pyruvate	4319	29	inhibition of enzyme form PEPC I and PEPC II, no inhibition of enzyme form PEPC III
4.1.1.31	Annona cherimola		pyruvate	656941	29	
4.1.1.31	Amaranthus viridis		quercetin	4342	131	
4.1.1.31	Brassica napus		quercetin	655409	131	
4.1.1.31	Amaranthus viridis		quercitrin	4342	1437	
4.1.1.31	Coccochloris peniocystis		quinolinic acid	4307	1319	
4.1.1.31	Amaranthus viridis		rutin	4342	832	
4.1.1.31	Brassica napus		rutin	655409	832	
4.1.1.31	Coccochloris peniocystis		SO42-	4307	148	
4.1.1.31	Acetobacter aceti		succinate	4293	54	
4.1.1.31	Escherichia coli		succinate	4311	54	
4.1.1.31	Euglena gracilis		succinate	4314	54	
4.1.1.31	Hyphomicrobium methylovorum		succinate	4341	54	
4.1.1.31	Zea mays subsp. mays		sulfite	713687	86	
4.1.1.31	Escherichia coli		Tartrate	4311	614	
4.1.1.31	Cicer arietinum		UTP	4301	61	
4.1.1.31	Medicago sativa		Zn2+	4298	19	substitution of 20 mM ZnCl2 for 20 mM MgCl2 results in 90-100% inhibition
4.1.1.31	Brassica rapa subsp. campestris		Zn2+	4332	19	5 mM, in presence of 5 mM Mg2+
4.1.1.31	Molinema dessetae		Zn2+	4336	19	
4.1.1.31	Hyphomicrobium methylovorum		Zn2+	4341	19	
5.3.1.1	Bos taurus	9-methyl-beta-carbolinium ion		662960	82372	1 mM, stimulates
5.3.1.1	Methanococcus maripaludis	dithiothreitol		727725	42	required
5.3.1.1	Gallus gallus	phosphite		727027	943	
5.3.1.1	Trypanosoma brucei subsp. brucei	phosphite		714259, 727027, 727662	943	
5.3.1.1	Trypanosoma cruzi		(1Z,2Z)-N,N'-dihydroxy-4-methylcyclohexa-3,5-diene-1,2-diimine	714899	59388	
5.3.1.1	Trypanosoma cruzi		(2E)-2-[(4-methyl-5-oxido-1,2,5-oxadiazol-3-yl)methylidene]hydrazinecarbothioamide	714899	59384	
5.3.1.1	Trypanosoma cruzi		(2E)-2-[(5-nitrofuran-2-yl)methylidene]hydrazinecarbothioamide	714899	59381	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		(2E)-2-[2-[(3-oxido-2,1,3-benzoxadiazol-5-yl)methoxy]benzylidene]-N-(prop-2-en-1-yl)hydrazinecarbothioamide	714899	59376	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		(2E)-N-(naphthalen-2-yl)-2-[(2E)-3-(5-nitrofuran-2-yl)prop-2-en-1-ylidene]hydrazinecarboxamide	714899	59380	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		(2E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(5-nitrofuran-2-yl)methylidene]hydrazinecarboxamide	714899	59372	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		(4-methyl-1,2,3-thiadiazol-5-yl)methanol	714899	101236	29% inhibition at 0.4 mM
5.3.1.1	Homo sapiens		1,2,4-thiadiazole	714899	113213	59% inhibition at 0.1 mM
5.3.1.1	Trypanosoma cruzi		1,2,4-thiadiazole	714899	113213	
5.3.1.1	Trypanosoma cruzi		1,2,6-thiadiazine	714899	113273	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		1,3,4-oxathiazole	714899	113275	
5.3.1.1	Saccharomyces cerevisiae		1-Chloro-3-hydroxyacetone	2560	37197	
5.3.1.1	Leishmania mexicana		2,2'-methylenebis(1,3-benzothiazole)	678178	24222	irreversible inactivation
5.3.1.1	Trypanosoma brucei		2,2'-methylenebis(1,3-benzothiazole)	678178	24222	irreversible inactivation
5.3.1.1	Trypanosoma cruzi		2,2'-methylenebis(1,3-benzothiazole)	678178	24222	40% inactivation at 0.05 mM, irreversible
5.3.1.1	Saccharomyces cerevisiae		2,4-Dinitrofluorobenzene	2560	2186	no inhibition
5.3.1.1	Oryctolagus cuniculus		2,4-Dinitrofluorobenzene	2561	2186	
5.3.1.1	Trypanosoma cruzi		2,6-dibenzyl-4-[(5-nitrothiophen-2-yl)methylidene]-1,2,6-thiadiazinane-3,5-dione 1,1-dioxide	714899	59373	irreversible inhibitor
5.3.1.1	Bos taurus		2,9-dimethyl-beta-carbolinium ion	662960	82328	
5.3.1.1	Leishmania mexicana		2-(N-formyl-N-hydroxy)-aminoethyl phosphonate	651108	35568	
5.3.1.1	Giardia intestinalis		2-carboxyethyl methanethiosulfonate	694062	92771	modifies four Cys per subunit of dimeric protein and induces 97% of inactivation. Inactivation does not affect secondary structure nor induce dimer dissociation. Cys modification decreases thermal stability of the enzyme
5.3.1.1	Pyrococcus woesei		2-carboxyethylphosphonic acid	649096	14716	
5.3.1.1	Bos taurus		2-methyl-beta-carbolinium ion	662960	82327	
5.3.1.1	Trypanosoma cruzi		2-phenyl-4H-chromen-4-one	714899	1213	
5.3.1.1	Pisum sativum		2-phosphoglycerate	2565	606	
5.3.1.1	Escherichia coli		2-Phosphoglycolate	2586	997	
5.3.1.1	Moritella marina		2-Phosphoglycolate	2586	997	
5.3.1.1	Gallus gallus		2-Phosphoglycolate	661085	997	
5.3.1.1	Giardia intestinalis		2-Phosphoglycolate	663355	997	
5.3.1.1	Saccharomyces cerevisiae		2-Phosphoglycolate	678722	997	strong, competitive. Inhibition results in a large decrease in the unfolding rate constant of the protein. 2-phosphoglycolate shows similar binding affinities in the transition states for the rate-limiting steps of the forward and backward reactions, implicating that both transition states resemble each other in the active site architecture
5.3.1.1	Trypanosoma brucei		2-Phosphoglycolate	650149, 678177, 690232	997	
5.3.1.1	Saccharomyces cerevisiae		2-Phosphoglycolate	714198	997	competitive inhibition
5.3.1.1	Gallus gallus		2-Phosphoglycolate	727027	997	competitive inhibition
5.3.1.1	Trypanosoma brucei subsp. brucei		2-Phosphoglycolate	727027	997	competitive inhibition
5.3.1.1	Pyrococcus woesei		2-phosphoglycolic acid	649096	997	
5.3.1.1	Trypanosoma cruzi		2-[(1E)-2-nitroprop-1-en-1-yl]thiophene	714899	59386	
5.3.1.1	Trypanosoma cruzi		2-[(3-aminophenyl)disulfanyl]aniline	714899	101234	
5.3.1.1	Trypanosoma cruzi		3,5-diphenyl-1,2,4-thiadiazole	714899	59383	74% inhibition at 0.4 mM
5.3.1.1	Trypanosoma cruzi		3-(2-benzothiazolylthio)-1-propanesulfonic acid	662625	82326	binds to the dimer interface of the enzyme and thereby abolishes its function with a high level of selectivity
5.3.1.1	Trypanosoma cruzi		3-(4-methylphenyl)-5-[(4-methylphenyl)sulfonyl]-1,2,4-thiadiazole	714899	59379	
5.3.1.1	Trypanosoma cruzi		3-nitrobiphenyl-4-amine	714899	59389	
5.3.1.1	Sulfolobus solfataricus		3-phospho-D-glycerate	724980	181	
5.3.1.1	Pisum sativum		3-phosphoglycerate	2565	174	
5.3.1.1	Plasmodium falciparum		3-phosphoglycerate	701474	174	binding at the active site with the dimer-interface site showing strong electrostatic anchoring of the phosphate group involving the Arg98 and Lys112 residues of TIM, comparisons of binding structures at the interface, overview
5.3.1.1	Trypanosoma brucei		4,4'-Dithiopyridine	728551	4618	
5.3.1.1	Trypanosoma cruzi		4,4'-Dithiopyridine	728551	4618	
5.3.1.1	Trypanosoma cruzi		4-(4-nitrobenzylidene)-2,6-bis(2-phenylethyl)-1,2,6-thiadiazinane-3,5-dione 1,1-dioxide	714899	59377	irreversible inhibitor, 85% inhibition at 0.4 mM
5.3.1.1	Trypanosoma cruzi		4-[(5-nitrofuran-2-yl)methylidene]-4H-1,2,6-thiadiazine-3,5-diamine 1,1-dioxide	714899	59370	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		4-[(5-nitrothiophen-2-yl)methylidene]-2,6-bis(2-phenylethyl)-1,2,6-thiadiazinane-3,5-dione 1,1-dioxide	714899	59382	irreversible inhibitor
5.3.1.1	Giardia intestinalis		5,5'-dithio-bis(2-nitrobenzoic acid)	694062	196	derivatizes four of the five Cys per subunit of dimeric protein, resulting in inactivation and dissociation of the dimer to stable monomers
5.3.1.1	Rhipicephalus microplus		5,5'-dithio-bis(2-nitrobenzoic acid)	715181	196	about 50% inhibition at about 0.05 mM
5.3.1.1	Saccharomyces cerevisiae		5,5'-dithiobis(2-nitrobenzoate)	2560	196	no inhibition
5.3.1.1	Oryctolagus cuniculus		5,5'-dithiobis(2-nitrobenzoate)	2561	196	
5.3.1.1	Trypanosoma brucei		5,5'-dithiobis(2-nitrobenzoate)	728551	196	
5.3.1.1	Trypanosoma cruzi		5,5'-dithiobis(2-nitrobenzoate)	728551	196	
5.3.1.1	Trypanosoma cruzi		5-[(1E)-2-nitroprop-1-en-1-yl]-1,3-benzodioxole	714899	59387	
5.3.1.1	Leishmania mexicana		6,6'-bi-1,3-benzothiazole-2,2'-diamine	678178	16039	irreversible inactivation. Not inhibitory on human, yeast, chicken, Plasmodium falciparum, and Entamoeba histolytica enzyme
5.3.1.1	Trypanosoma brucei		6,6'-bi-1,3-benzothiazole-2,2'-diamine	678178	16039	irreversible inactivation. Not inhibitory on human, yeast, chicken, Plasmodium falciparum, and Entamoeba histolytica enzyme
5.3.1.1	Trypanosoma cruzi		6,6'-bi-1,3-benzothiazole-2,2'-diamine	678178	16039	91% inactivation at 0.05 mM, irreversible. Not inhibitory on human, yeast, chicken, Plasmodium falciparum, and Entamoeba histolytica enzyme
5.3.1.1	Trypanosoma cruzi		6,6'-bi-1,3-benzothiazole-2,2'-diamine	714899	16039	
5.3.1.1	Pisum sativum		6-phosphogluconate	2565	327	5 mM, 9% inhibition
5.3.1.1	Trypanosoma cruzi		6-[(E)-2-(5-nitrothiophen-2-yl)ethenyl]-2,1,3-benzoxadiazole 1-oxide	714899	59371	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		6-[(E)-2-[(4-fluorophenyl)sulfanyl]ethenyl]-2,1,3-benzoxadiazole 1-oxide	714899	59375	irreversible inhibitor
5.3.1.1	Trypanosoma cruzi		8-bromo-5,10-dioxidophenazin-2-yl chloroacetate	714899	59390	50% inhibition at 0.4 mM
5.3.1.1	Saccharomyces cerevisiae		Acetylphosphate	2560	305	competitive
5.3.1.1	Oryctolagus cuniculus		Acetylphosphate	2561	305	
5.3.1.1	Gallus gallus		arsenate	661085	222	
5.3.1.1	Gallus gallus		arsenate	727027	222	competitive inhibition
5.3.1.1	Trypanosoma brucei subsp. brucei		arsenate	727027	222	competitive inhibition
5.3.1.1	Saccharomyces cerevisiae		AsO2-	2560	4824	competitive
5.3.1.1	Oryctolagus cuniculus		AsO2-	2561	4824	
5.3.1.1	Homo sapiens		AsO43-	2562	222	competitive
5.3.1.1	Secale cereale		AsO43-	2570	222	
5.3.1.1	Trypanosoma brucei		AsO43-	2573, 678177, 690232	222	
5.3.1.1	Homo sapiens		ATP	2562	7	
5.3.1.1	Pisum sativum		ATP	2565	7	5 mM, 39% inhibition
5.3.1.1	Bos taurus		ATP	662960	7	
5.3.1.1	Lolium multiflorum		Atrazine	704137	844	a herbicide which interferes with photosynthesis
5.3.1.1	Bartonella henselae		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Caenorhabditis elegans		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Entamoeba histolytica		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Escherichia coli		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Gallus gallus		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Geobacillus stearothermophilus		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Giardia intestinalis		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Helicobacter pylori		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Homo sapiens		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Leishmania mexicana		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Methanocaldococcus jannaschii		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Moritella marina		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Mycobacterium tuberculosis		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Oryctolagus cuniculus		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Plasmodium falciparum		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Pyrococcus woesei		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Saccharomyces cerevisiae		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Tenebrio molitor		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Thermoproteus tenax		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Thermotoga maritima		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Trypanosoma brucei brucei		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Trypanosoma cruzi		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
5.3.1.1	Trypanosoma cruzi		butylbrevifolin carboxylate	702595	54797	
5.3.1.1	Homo sapiens		Chloroacetol phosphate	2562	64226	
5.3.1.1	Pisum sativum		citrate	2565	125	25 mM, 9% inhibition
5.3.1.1	Canis lupus familiaris		cyclo(Gly-Pro-Phe-Val-Phe-PSI[CS-NH]Phe)	2576	13626	no inhibition
5.3.1.1	Escherichia coli		cyclo(Gly-Pro-Phe-Val-Phe-PSI[CS-NH]Phe)	2576	13626	no inhibition
5.3.1.1	Oryctolagus cuniculus		cyclo(Gly-Pro-Phe-Val-Phe-PSI[CS-NH]Phe)	2576	13626	no inhibition
5.3.1.1	Trypanosoma sp.		cyclo(Gly-Pro-Phe-Val-Phe-PSI[CS-NH]Phe)	2576	13626	
5.3.1.1	Canis lupus familiaris		cyclo[Trp-Phe-D-Pro-Phe-Phe-Lys(benzyloxycarbonyl)-]	2582	13627	no inhibition
5.3.1.1	Escherichia coli		cyclo[Trp-Phe-D-Pro-Phe-Phe-Lys(benzyloxycarbonyl)-]	2582	13627	no inhibition
5.3.1.1	Oryctolagus cuniculus		cyclo[Trp-Phe-D-Pro-Phe-Phe-Lys(benzyloxycarbonyl)-]	2582	13627	no inhibition
5.3.1.1	Trypanosoma brucei		cyclo[Trp-Phe-D-Pro-Phe-Phe-Lys(benzyloxycarbonyl)-]	2582	13627	
5.3.1.1	Trypanosoma brucei		cyclo[Trp-Tyr(OSO3Na)-D-Phe-Thr(OSO3Na)-Lys(benzyloxycarbonyl)-]	2582	66283	noncompetitive, reversible
5.3.1.1	Saccharomyces cerevisiae		D-alpha-glycerophosphate	2560	3866	competitive
5.3.1.1	Oryctolagus cuniculus		D-alpha-glycerophosphate	2561	3866	
5.3.1.1	Homo sapiens		D-alpha-glycerophosphate	2562	3866	competitive
5.3.1.1	Oryctolagus cuniculus		D-alpha-glycerophosphate	2563	3866	competitive
5.3.1.1	Oryctolagus cuniculus		D-erythrose 4-phosphate	2561	416	
5.3.1.1	Bartonella henselae		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Caenorhabditis elegans		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Entamoeba histolytica		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Escherichia coli		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Gallus gallus		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Geobacillus stearothermophilus		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Giardia intestinalis		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Helicobacter pylori		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Homo sapiens		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Leishmania mexicana		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Methanocaldococcus jannaschii		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Moritella marina		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Mycobacterium tuberculosis		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Oryctolagus cuniculus		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Plasmodium falciparum		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Pyrococcus woesei		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Saccharomyces cerevisiae		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Tenebrio molitor		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Thermoproteus tenax		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Thermotoga maritima		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Trypanosoma brucei brucei		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Trypanosoma cruzi		DL-glycidol phosphate	714686	109182	suicide inhibitor
5.3.1.1	Trypanosoma cruzi		ethyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,2,4-thiadiazole-5-carboxylate	714899	59378	
5.3.1.1	Trypanosoma cruzi		ethyl 3-phenyl-1,2,4-thiadiazole-5-carboxylate	714899	59374	
5.3.1.1	Trypanosoma cruzi		ethylbrevifolin carboxylate	702595	54796	
5.3.1.1	Lolium multiflorum		fluorodifen	704137	6444	a herbicide which interferes with photosynthesis
5.3.1.1	Pisum sativum		fructose 1,6-diphosphate	2565	100	5 mM, 69% inhibition
5.3.1.1	Pisum sativum		fructose 6-phosphate	2565	82	5 mM, 44% inhibition
5.3.1.1	Pisum sativum		glucose 1-phosphate	2565	386	5 mM, 10% inhibition
5.3.1.1	Pisum sativum		glucose 6-phosphate	2565	99	5 mM, 25% inhibition
5.3.1.1	Tenebrio molitor		glycerol 1-phosphate	704030	352	
5.3.1.1	Lolium multiflorum		GSSG	704137	283	oxidized glutathione is a strong inhibitor of the enzyme at low concentrations
5.3.1.1	Chlamydomonas reinhardtii		H2O2	728349	20	the inhibition of the enzyme is negligible when incubated with 0.1 mM H2O2, whereas a 10% inhibition is observed with 1 mM H2O2
5.3.1.1	Oryctolagus cuniculus		iodoacetamide	2561	63	
5.3.1.1	Saccharomyces cerevisiae		iodoacetate	2560	87	no inhibition
5.3.1.1	Oryctolagus cuniculus		iodoacetate	2561	87	
5.3.1.1	Secale cereale		iodoacetate	2570	87	
5.3.1.1	Plasmodium falciparum		KFGNGSYTGEVS	651284	77391	peptide that corresponds to loop 3 of the triosephosphate isomerase, residues 68-79. Efficient inhibitor with the activity falling to about 45% at 1000fold molar excess of the peptide in case of the wild-type enzyme. In the case of either of the mutants, Y74C and Y74G, even at 100fold molar excess of the peptide, only 30% activity can be obtained
5.3.1.1	Plasmodium falciparum		KYGNGSCTGEVS	651284	77392	peptide that is an analog of the peptide that corresponds to loop 3 of the protein, residues 68-79, with the replacement Y74C and F69Y. Inhibits the activity of the mutant enzymes Y74C and Y74G, with about 40% activity remaining in the presence of 1000fold molar excess of the peptide
5.3.1.1	Staphylococcus aureus		mannobiose	705563	1502	
5.3.1.1	Staphylococcus aureus		Mannopentaose	705563	3571	
5.3.1.1	Staphylococcus aureus		Mannotetraose	705563	4439	
5.3.1.1	Staphylococcus aureus		Mannotriose	705563	2993	docking simulation
5.3.1.1	Trypanosoma brucei		methyl methanethiosulfonate	2578	1724	derivatizes Cys14 to a methyl sulfide
5.3.1.1	Gallus gallus		methyl methanethiosulfonate	2584	1724	no inhibition
5.3.1.1	Oryctolagus cuniculus		methyl methanethiosulfonate	2584	1724	
5.3.1.1	Saccharomyces cerevisiae		methyl methanethiosulfonate	2584	1724	no inhibition
5.3.1.1	Schizosaccharomyces pombe		methyl methanethiosulfonate	2584	1724	
5.3.1.1	Leishmania mexicana		methyl methanethiosulfonate	2587	1724	the sensitivity of enzyme from Trypanosoma cruzi is about 40times higher than that of Trypanosoma brucei and 200times higher than that of Leishmania mexicana
5.3.1.1	Trypanosoma brucei		methyl methanethiosulfonate	2587	1724	the sensitivity of enzyme from Trypanosoma cruzi is about 40times higher than that of Trypanosoma brucei and 200times higher than that of Leishmania mexicana
5.3.1.1	Trypanosoma cruzi		methyl methanethiosulfonate	2587	1724	the sensitivity of enzyme from Trypanosoma cruzi is about 40times higher than that of Trypanosoma brucei and 200times higher than that of Leishmania mexicana
5.3.1.1	Giardia intestinalis		methyl methanethiosulfonate	694062	1724	derivatizes three of the five Cys per subunit of dimeric protein and induces 50% of inactivation. Inactivation does not affect secondary structure nor induce dimer dissociation. Cys modification decreases thermal stability of the enzyme
5.3.1.1	Rhipicephalus microplus		methyl methanethiosulfonate	715181	1724	about 50% inhibition at about 0.05 mM
5.3.1.1	Trypanosoma cruzi		methylbrevifolin carboxylate	702595	54795	molecular docking simulations and enzyme binding structure, and inhibition kinetics, overview
5.3.1.1	Entamoeba histolytica		methylmethane thiosulfonate	652896	1724	0.6 mM, 2 h, complete loss of activity, dissociates the dimeric enzyme inducing formation of a compact monomeric state
5.3.1.1	Trypanosoma brucei		methylmethane thiosulfonate	682787	1724	modification at C15 in the dimer interface, inducing abolition of catalysis and structural changes. Susceptibility of Trypanosoma cruzi enzyme to modification of C15 is nearly 100fold higher than susceptibility of C15 of Trypanosoma brucei
5.3.1.1	Trypanosoma cruzi		methylmethane thiosulfonate	682787	1724	modification at C15 in the dimer interface, inducing abolition of catalysis and structural changes. Susceptibility of Trypanosoma cruzi enzyme to modification of C15 is nearly 100fold higher than susceptibility of C15 of Trypanosoma brucei
5.3.1.1	Leishmania donovani		methylmethane thiosulfonate	727428	1724	induces 75% enzyme inactivation within 15 min at 0.25 mM concentration
5.3.1.1	Trypanosoma brucei		methylmethane thiosulfonate	728551	1724	60% residual activity at 0.1 mM
5.3.1.1	Trypanosoma cruzi		methylmethane thiosulfonate	728551	1724	almost complete inhibition at 0.1 mM
5.3.1.1	Plasmodium falciparum		more	651284		ANWKCNGTLE, the peptide that corresponds to loop 1 of triosephosphate isomerase, residues 9-18, shows only negligible inhibition of wild-type enzyme and mutant enzymes Y74G and Y74C, with a fall in the enzymatic activity by only about 20% at 1000fold molar excess of the peptide
5.3.1.1	Homo sapiens		more	693299		in drug-resistant SGC7901 cells induced by vincristine sulfate, triosephosphate isomerase is downregulated.The sensitivity of TPI-SGC7901/VCR cells to adriamycin, vincristine, 5-fluorouracil and cis-dichlorodiamine platinum, as well as the accumulation and retention to adriamycin, are significantly increased when compared to their control cell lines
5.3.1.1	Trypanosoma cruzi		more	702595		brevifolin carboxylate derivatives isolated from Geranium bellum selectively inactivate the enzyme partially, no inhibition by methyl tri-O-methylbrevifolin carboxylate
5.3.1.1	Staphylococcus aureus		more	705563		stronger inhibition by alpha-(1,3)-mannooligosaccharides than with triose, binding constants, overview
5.3.1.1	Mus musculus		more	705903		recombinant expression of Tau in CHO-K1 cells leads to increased protection of TPI against oxidative damage, but also to decreased enzyme activity, with unaltered TPI expression levels
5.3.1.1	Homo sapiens		more	706845		TPI phosphorylation by cyclin A/Cdk2 kinase leads to reduced TPI activity, prevented by treatment with olomoucine, a specific inhibitor of Cdk2
5.3.1.1	Homo sapiens		more	714899		not inhibited by 1,2,6-thiadiazine, phenazine 5,9-dioxide, and 1,3,4-oxathiazole
5.3.1.1	Trypanosoma brucei		N-ethylmaleimide	728551	46	
5.3.1.1	Trypanosoma cruzi		N-ethylmaleimide	728551	46	
5.3.1.1	Trypanosoma cruzi		N-[(2-oxido-4-phenyl-1,2,5-oxadiazol-3-yl)methyl]naphthalen-1-amine	714899	59385	72% inhibition at 0.4 mM
5.3.1.1	Trypanosoma cruzi		N-[(4-methyl-5-oxido-1,2,5-oxadiazol-3-yl)methyl]naphthalen-1-amine	714899	101235	41% inhibition at 0.4 mM
5.3.1.1	Oryctolagus cuniculus		NEM	2561	46	
5.3.1.1	Oryctolagus cuniculus		o-Iodosobenzoate	2561	1554	
5.3.1.1	Oryctolagus cuniculus		p-benzoquinone	2561	270	
5.3.1.1	Secale cereale		p-hydroxymercuribenzoate	2570	92	
5.3.1.1	Trypanosoma brucei		p-hydroxymercuribenzoate	2573	92	
5.3.1.1	Saccharomyces cerevisiae		PCMB	2560	40	no inhibition
5.3.1.1	Oryctolagus cuniculus		PCMB	2561	40	
5.3.1.1	Trypanosoma cruzi		phenazine 5,9-dioxide	714899	113274	84% inhibition at 0.4 mM
5.3.1.1	Saccharomyces cerevisiae		phosphate	2560	12	competitive
5.3.1.1	Oryctolagus cuniculus		phosphate	2561	12	
5.3.1.1	Trypanosoma brucei		phosphate	2573	12	
5.3.1.1	Helicobacter pylori		phosphate	682773	12	competitive, occupies the substrate binding pocket
5.3.1.1	Saccharomyces cerevisiae		phosphoenolpyruvate	2560	47	competitive
5.3.1.1	Oryctolagus cuniculus		phosphoenolpyruvate	2561	47	
5.3.1.1	Pisum sativum		phosphoenolpyruvate	2565	47	
5.3.1.1	Trypanosoma brucei		phosphoenolpyruvate	2573	47	
5.3.1.1	Sulfolobus solfataricus		phosphoenolpyruvate	724980	47	
5.3.1.1	Saccharomyces cerevisiae		Phosphoglycolate	2560	997	competitive
5.3.1.1	Oryctolagus cuniculus		Phosphoglycolate	2561	997	
5.3.1.1	Homo sapiens		Phosphoglycolate	2562	997	competitive
5.3.1.1	Oryctolagus cuniculus		Phosphoglycolate	2563	997	and its corresponding hydroxamate; competitive
5.3.1.1	Homo sapiens		Phosphoglycolate	2567	997	
5.3.1.1	Trypanosoma brucei		Phosphoglycolate	2573	997	2-phosphoglycolate
5.3.1.1	Saccharomyces cerevisiae		Phosphoglycolate	2575	997	
5.3.1.1	Geobacillus stearothermophilus		Phosphoglycolate	2590	997	2-phosphoglycolate
5.3.1.1	Homo sapiens		Phosphoglycolate	2591	997	2-phosphoglycolate
5.3.1.1	Oryctolagus cuniculus		phosphoglycoloaldoxime	661343	37744	
5.3.1.1	Oryctolagus cuniculus		phosphoglycolohydrazide	661343	9123	
5.3.1.1	Saccharomyces cerevisiae		Phosphoglycolohydroxamate	2575	7234	
5.3.1.1	Oryctolagus cuniculus		Phosphoglycolohydroxamate	661343	7234	
5.3.1.1	Leishmania mexicana		Phosphoglycolohydroxamate	706663	7234	the reaction-intermediate analogue binds to the active site with two hydrogen-bonding interactions between PGH and the Glu167 side-chain oxygen atoms
5.3.1.1	Escherichia coli		S-Phenyl-p-toluenethiosulfonate	2584	10773	no inhibition
5.3.1.1	Gallus gallus		S-Phenyl-p-toluenethiosulfonate	2584	10773	
5.3.1.1	Oryctolagus cuniculus		S-Phenyl-p-toluenethiosulfonate	2584	10773	
5.3.1.1	Saccharomyces cerevisiae		S-Phenyl-p-toluenethiosulfonate	2584	10773	no inhibition
5.3.1.1	Schizosaccharomyces pombe		S-Phenyl-p-toluenethiosulfonate	2584	10773	
5.3.1.1	Secale cereale		SO42-	2570	148	CuSO4
5.3.1.1	Trypanosoma brucei		SO42-	2573	148	
5.3.1.1	Pisum sativum		succinate	2565	54	5 mM, 9% inhibition
5.3.1.1	Trypanosoma brucei		suramin	2573	568	
5.3.1.1	Oryctolagus cuniculus		[3-amino-3-(hydroxyimino)propyl]phosphonic acid	661343	37546	
2.3.1.19	Clostridium acetobutylicum		ADP	486470	8	
2.3.1.19	Clostridium acetobutylicum		AMP	486470	9	
2.3.1.19	Clostridium acetobutylicum		ATP	486470	7	
2.3.1.19	Clostridium acetobutylicum		NADP+	486470	6	
2.3.1.19	Clostridium acetobutylicum		NADPH	486470	5	
6.3.2.13	Mycobacterium tuberculosis		1-methyl-2-[(4Z)-tetradec-4-en-1-yl]quinolin-4(1H)-one	715309	27993	inhibitory to enzyme and growth inhibitor of Mycobacterium tuberculosis and rapid-growing mycobacteria
6.3.2.13	Mycobacterium tuberculosis		1-methyl-2-[(5Z)-tetradec-5-en-1-yl]quinolin-4(1H)-one	715309	27994	inhibitory to enzyme and growth inhibitor of Mycobacterium tuberculosis and rapid-growing mycobacteria
6.3.2.13	Mycobacterium tuberculosis		2-[(1E)-dec-1-en-1-yl]-1-methylquinolin-4(1H)-one	715309	27995	inhibitory to enzyme and growth inhibitor of Mycobacterium tuberculosis and rapid-growing mycobacteria
6.3.2.13	Mycobacterium tuberculosis		2-[(1E)-dodec-1-en-1-yl]-1-methylquinolin-4(1H)-one	715309	27996	inhibitory to enzyme and growth inhibitor of Mycobacterium tuberculosis and rapid-growing mycobacteria
6.3.2.13	Mycobacterium tuberculosis		2-[(1E)-tridec-1-en-1-yl]-1-methylquinolin-4(1H)-one	715309	27997	inhibitory to enzyme and growth inhibitor of Mycobacterium tuberculosis and rapid-growing mycobacteria
6.3.2.13	Escherichia coli		Butylamine	651110	1044	500 mM, 88% inhibition
6.3.2.13	Escherichia coli		Butyrate	651110	385	500 mM, 44% inhibition
6.3.2.13	Escherichia coli		ethylamine	651110	565	500 mM, 73% inhibition
6.3.2.13	Escherichia coli		methylamine	651110	279	500 mM, 80% inhibition
6.3.2.13	Escherichia coli		more	1039		
6.3.2.13	Pseudomonas aeruginosa		MurEP1	702135		time-dependent inhibition
6.3.2.13	Escherichia coli		MurNAc(alpha-methyl)-L-Ala-D-Glu	1027	66565	
6.3.2.13	Escherichia coli		MurNAc(beta-methyl)-L-Ala-D-Glu	1027	66566	
6.3.2.13	Staphylococcus aureus		N-([(2S)-2-[(2-naphthylsulfonyl)amino]propyl]-sulfonyl)-D-glutamic acid	677175	41746	60% residual activity at 1 mM
6.3.2.13	Staphylococcus aureus		N-([(2S)-2-[([1,1'-biphenyl]-4-yl-sulfonyl)amino]-propyl]sulfonyl)-D-glutamic acid	677175	41755	12% residual activity at 1 mM
6.3.2.13	Staphylococcus aureus		N-[((2S)-2-[[(E)-3-(1,3-benzodioxol-5-yl)-2-propenoyl]amino]propyl)sulfonyl]-D-glutamic acid	677175	41748	64% residual activity at 1 mM
6.3.2.13	Staphylococcus aureus		N-[[(2S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]sulfonyl]-D-glutamic acid	677175	41744	41% residual activity at 1 mM
6.3.2.13	Staphylococcus aureus		N-[[(2S)-2-([2-[2-(acetylamino)phenoxy]acetyl]-amino)propyl]sulfonyl]-D-glutamic acid	677175	41747	56% residual activity at 1 mM
6.3.2.13	Staphylococcus aureus		N-[[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-ethyl]sulfonyl]-D-glutamic acid	677175	41745	1 mM
6.3.2.13	Escherichia coli		Nalpha-Propionyl-L-Ala-2-amino-6-phosphonohexanoate	1036	66650	
6.3.2.13	Escherichia coli		Nalpha-Propionyl-L-Ala-3-phosphonoacetamido-Ala	1036	66651	
6.3.2.13	Escherichia coli		Nalpha-Propionyl-L-Ala-buthionine sulfoximine	1036	66652	
6.3.2.13	Escherichia coli		P1-MurNAc-L-Ala-D-Glu	1027	28612	
6.3.2.13	Escherichia coli		Propionyl-L-Ala-D-Glu(CH2Cl)-OH	1037	66718	
6.3.2.13	Escherichia coli		Propionyl-L-Ala-xi-2-amino-4-phosphonobutanoate	1037	66719	
6.3.2.13	Escherichia coli		Propylamine	651110	1072	500 mM, 87% inhibition
6.3.2.13	Bacillus cereus		UDP-MurNAc-L-Ala-D-Glu	1031	2405	above 0.4 mM
2.5.1.7	Enterobacter cloacae	dithiothreitol		637603	42	included in the assay reaction mixture
2.5.1.7	Escherichia coli	dithiothreitol		637606	42	included in the assay reaction mixture
2.5.1.7	Enterobacter cloacae	thiol groups		637587, 637589	752	required for activity
2.5.1.7	Escherichia coli		(E)-3-fluorophosphoenolpyruvate	637596	11148	pseudosubstrate, formation of a tetrahedral intermediate in the reaction pathway, investigation of chirality of the intermediate stereospecifically formed at the active site in D2O
2.5.1.7	Escherichia coli		(E)-3-fluorophosphoenolpyruvate	637597	11148	formation of 2 reaction intermediates: a covalent phosphofluorolactyl-enzyme adduct and a free phosphofluorolactyl-UDP-GlcNAc tetrahedral adduct; inactivation; kinetics
2.5.1.7	Enterobacter cloacae		(S)-2-[2-(naphthalene-1-sulfonylamino)-5-(naphthalene-1-sulfonyloxy)-benzoylamino]-pentanedioic acid	659457	80691	competitive with UDP-N-acetylglucosamine
2.5.1.7	Enterobacter cloacae		(S)-2-[2-(naphthalene-1-sulfonylamino)-5-(naphthalene-1-sulfonyloxy)-benzoylamino]-succinic acid	659457	80690	
2.5.1.7	Escherichia coli		(Z)-3-fluorophosphoenolpyruvate	637596	2350	pseudosubstrate, formation of a tetrahedral intermediate in the reaction pathway, investigation of chirality of the intermediate stereospecifically formed at the active site in D2O
2.5.1.7	Escherichia coli		(Z)-3-fluorophosphoenolpyruvate	637597	2350	formation of 2 reaction intermediates: a covalent phosphofluorolactyl-enzyme adduct and a free phosphofluorolactyl-UDP-GlcNAc tetrahedral adduct; inactivation; kinetics
2.5.1.7	Escherichia coli		(Z)-3-fluorophosphoenolpyruvate	637598	2350	kinetics, mutant C115D; wild-type and mutant C115D, competitive against phosphoenolpyruvate
2.5.1.7	Enterobacter cloacae		1-tuliposide A	721372	111808	potent inhibitor
2.5.1.7	Escherichia coli		1-tuliposide A	721372	111808	potent inhibitor
2.5.1.7	Mycobacterium tuberculosis		1-tuliposide A	721372	111808	potent inhibitor
2.5.1.7	Pseudomonas aeruginosa		1-tuliposide A	721372	111808	potent inhibitor
2.5.1.7	Staphylococcus aureus		1-tuliposide A	721372	111808	potent inhibitor
2.5.1.7	Streptococcus pneumoniae		1-tuliposide A	721372	111808	potent inhibitor
2.5.1.7	Enterobacter cloacae		1-tuliposide B	721372	111809	potent inhibitor
2.5.1.7	Escherichia coli		1-tuliposide B	721372	111809	potent inhibitor
2.5.1.7	Mycobacterium tuberculosis		1-tuliposide B	721372	111809	potent inhibitor
2.5.1.7	Pseudomonas aeruginosa		1-tuliposide B	721372	111809	potent inhibitor
2.5.1.7	Staphylococcus aureus		1-tuliposide B	721372	111809	potent inhibitor
2.5.1.7	Streptococcus pneumoniae		1-tuliposide B	721372	111809	potent inhibitor
2.5.1.7	Escherichia coli		2-(4-methylpiperazin-1-yl)-3,4-dihydronaphthalen-1(2H)-one	685595	16867	
2.5.1.7	Staphylococcus aureus		2-(4-methylpiperazin-1-yl)-3,4-dihydronaphthalen-1(2H)-one	685595	16867	
2.5.1.7	Enterobacter cloacae		2-oxo-1,3-benzoxathiol-5-yl (3-chlorophenyl)carbamate	721372	5350	
2.5.1.7	Mycobacterium tuberculosis		2-oxo-1,3-benzoxathiol-5-yl (3-chlorophenyl)carbamate	721372	5350	
2.5.1.7	Pseudomonas aeruginosa		2-oxo-1,3-benzoxathiol-5-yl (3-chlorophenyl)carbamate	721372	5350	
2.5.1.7	Streptococcus pneumoniae		2-oxo-1,3-benzoxathiol-5-yl (3-chlorophenyl)carbamate	721372	5350	
2.5.1.7	Escherichia coli		2-oxo-1,3-benzoxathiol-5-yl (3-chlorophenyl)carbamate	721372, 722469	5350	
2.5.1.7	Staphylococcus aureus		2-oxo-1,3-benzoxathiol-5-yl (3-chlorophenyl)carbamate	721372, 722469	5350	
2.5.1.7	Escherichia coli		2-oxo-1,3-benzoxathiol-5-yl methylcarbamate	722469	19635	
2.5.1.7	Staphylococcus aureus		2-oxo-1,3-benzoxathiol-5-yl methylcarbamate	722469	19635	
2.5.1.7	Escherichia coli		2-oxo-1,3-benzoxathiol-5-yl pyridine-4-carboxylate	722469	19636	
2.5.1.7	Staphylococcus aureus		2-oxo-1,3-benzoxathiol-5-yl pyridine-4-carboxylate	722469	19636	
2.5.1.7	Escherichia coli		2-oxo-1,3-benzoxathiol-6-yl 4-nitrobenzenesulfonate	722469	19638	
2.5.1.7	Staphylococcus aureus		2-oxo-1,3-benzoxathiol-6-yl 4-nitrobenzenesulfonate	722469	19638	
2.5.1.7	Enterobacter cloacae		2-oxo-1,3-benzoxathiol-6-yl benzenesulfonate	721372	5353	
2.5.1.7	Mycobacterium tuberculosis		2-oxo-1,3-benzoxathiol-6-yl benzenesulfonate	721372	5353	
2.5.1.7	Pseudomonas aeruginosa		2-oxo-1,3-benzoxathiol-6-yl benzenesulfonate	721372	5353	
2.5.1.7	Streptococcus pneumoniae		2-oxo-1,3-benzoxathiol-6-yl benzenesulfonate	721372	5353	
2.5.1.7	Escherichia coli		2-oxo-1,3-benzoxathiol-6-yl benzenesulfonate	721372, 722469	5353	
2.5.1.7	Staphylococcus aureus		2-oxo-1,3-benzoxathiol-6-yl benzenesulfonate	721372, 722469	5353	
2.5.1.7	Enterobacter cloacae		2-oxo-1,3-benzoxathiol-6-yl methanesulfonate	721372	5352	
2.5.1.7	Mycobacterium tuberculosis		2-oxo-1,3-benzoxathiol-6-yl methanesulfonate	721372	5352	
2.5.1.7	Pseudomonas aeruginosa		2-oxo-1,3-benzoxathiol-6-yl methanesulfonate	721372	5352	
2.5.1.7	Streptococcus pneumoniae		2-oxo-1,3-benzoxathiol-6-yl methanesulfonate	721372	5352	
2.5.1.7	Escherichia coli		2-oxo-1,3-benzoxathiol-6-yl methanesulfonate	721372, 722469	5352	
2.5.1.7	Staphylococcus aureus		2-oxo-1,3-benzoxathiol-6-yl methanesulfonate	721372, 722469	5352	
2.5.1.7	Escherichia coli		2-oxo-1,3-benzoxathiol-6-yl sulfamate	722469	10287	
2.5.1.7	Staphylococcus aureus		2-oxo-1,3-benzoxathiol-6-yl sulfamate	722469	10287	
2.5.1.7	Escherichia coli		2-[4-(2-hydroxyethyl)piperazin-1-yl]-3,4-dihydronaphthalen-1(2H)-one	685595	16839	
2.5.1.7	Staphylococcus aureus		2-[4-(2-hydroxyethyl)piperazin-1-yl]-3,4-dihydronaphthalen-1(2H)-one	685595	16839	
2.5.1.7	Escherichia coli		2-[4-(2-hydroxyethyl)piperazin-1-yl]-6,7-dimethoxy-3,4-dihydronaphthalen-1(2H)-one	685595	16834	
2.5.1.7	Staphylococcus aureus		2-[4-(2-hydroxyethyl)piperazin-1-yl]-6,7-dimethoxy-3,4-dihydronaphthalen-1(2H)-one	685595	16834	
2.5.1.7	Enterobacter cloacae		3-Bromopyruvate	637594	1425	irreversible, inhibitory effect is increased by UDP-GlcNAc
2.5.1.7	Enterobacter cloacae		4,7-dichloro-5-hydroxy-1,3-benzoxathiol-2-one	721372	5351	
2.5.1.7	Mycobacterium tuberculosis		4,7-dichloro-5-hydroxy-1,3-benzoxathiol-2-one	721372	5351	
2.5.1.7	Pseudomonas aeruginosa		4,7-dichloro-5-hydroxy-1,3-benzoxathiol-2-one	721372	5351	
2.5.1.7	Streptococcus pneumoniae		4,7-dichloro-5-hydroxy-1,3-benzoxathiol-2-one	721372	5351	
2.5.1.7	Escherichia coli		4,7-dichloro-5-hydroxy-1,3-benzoxathiol-2-one	721372, 722469	5351	
2.5.1.7	Staphylococcus aureus		4,7-dichloro-5-hydroxy-1,3-benzoxathiol-2-one	721372, 722469	5351	
2.5.1.7	Staphylococcus epidermidis		5,5'-dithiobis(2-nitrobenzoic acid)	637591	196	complete inhibition at 0.01 M; i.e. DTNB
2.5.1.7	Escherichia coli		5,7-dibromo-6-hydroxy-1,3-benzoxathiol-2-one	722469	19639	
2.5.1.7	Staphylococcus aureus		5,7-dibromo-6-hydroxy-1,3-benzoxathiol-2-one	722469	19639	
2.5.1.7	Enterobacter cloacae		5-(prop-2-en-1-yloxy)-1,3-benzoxathiol-2-one	721372	5349	
2.5.1.7	Mycobacterium tuberculosis		5-(prop-2-en-1-yloxy)-1,3-benzoxathiol-2-one	721372	5349	
2.5.1.7	Pseudomonas aeruginosa		5-(prop-2-en-1-yloxy)-1,3-benzoxathiol-2-one	721372	5349	
2.5.1.7	Streptococcus pneumoniae		5-(prop-2-en-1-yloxy)-1,3-benzoxathiol-2-one	721372	5349	
2.5.1.7	Escherichia coli		5-(prop-2-en-1-yloxy)-1,3-benzoxathiol-2-one	721372, 722469	5349	
2.5.1.7	Staphylococcus aureus		5-(prop-2-en-1-yloxy)-1,3-benzoxathiol-2-one	721372, 722469	5349	
2.5.1.7	Enterobacter cloacae		5-bromo-2-oxo-1,3-benzoxathiol-6-yl phenyl carbonate	721372	10289	
2.5.1.7	Escherichia coli		5-bromo-2-oxo-1,3-benzoxathiol-6-yl phenyl carbonate	721372	10289	
2.5.1.7	Mycobacterium tuberculosis		5-bromo-2-oxo-1,3-benzoxathiol-6-yl phenyl carbonate	721372	10289	
2.5.1.7	Pseudomonas aeruginosa		5-bromo-2-oxo-1,3-benzoxathiol-6-yl phenyl carbonate	721372	10289	
2.5.1.7	Staphylococcus aureus		5-bromo-2-oxo-1,3-benzoxathiol-6-yl phenyl carbonate	721372	10289	
2.5.1.7	Streptococcus pneumoniae		5-bromo-2-oxo-1,3-benzoxathiol-6-yl phenyl carbonate	721372	10289	
2.5.1.7	Enterobacter cloacae		5-hydroxy-1,3-benzoxathiol-2-one	721372	10288	
2.5.1.7	Escherichia coli		5-hydroxy-1,3-benzoxathiol-2-one	721372	10288	
2.5.1.7	Mycobacterium tuberculosis		5-hydroxy-1,3-benzoxathiol-2-one	721372	10288	
2.5.1.7	Pseudomonas aeruginosa		5-hydroxy-1,3-benzoxathiol-2-one	721372	10288	
2.5.1.7	Staphylococcus aureus		5-hydroxy-1,3-benzoxathiol-2-one	721372	10288	
2.5.1.7	Streptococcus pneumoniae		5-hydroxy-1,3-benzoxathiol-2-one	721372	10288	
2.5.1.7	Escherichia coli		5-hydroxy-7-(3-methylphenyl)-1,3-benzoxathiol-2-one	722469	28327	
2.5.1.7	Staphylococcus aureus		5-hydroxy-7-(3-methylphenyl)-1,3-benzoxathiol-2-one	722469	28327	slight inhibition at 0.12 mM
2.5.1.7	Enterobacter cloacae		5-hydroxy-7-(4-methoxyphenyl)-1,3-benzoxathiol-2-one	721372	6020	
2.5.1.7	Mycobacterium tuberculosis		5-hydroxy-7-(4-methoxyphenyl)-1,3-benzoxathiol-2-one	721372	6020	
2.5.1.7	Pseudomonas aeruginosa		5-hydroxy-7-(4-methoxyphenyl)-1,3-benzoxathiol-2-one	721372	6020	
2.5.1.7	Staphylococcus aureus		5-hydroxy-7-(4-methoxyphenyl)-1,3-benzoxathiol-2-one	721372	6020	
2.5.1.7	Streptococcus pneumoniae		5-hydroxy-7-(4-methoxyphenyl)-1,3-benzoxathiol-2-one	721372	6020	
2.5.1.7	Escherichia coli		5-hydroxy-7-(4-methoxyphenyl)-1,3-benzoxathiol-2-one	721372, 722469	6020	
2.5.1.7	Staphylococcus aureus		5-hydroxy-7-(4-methoxyphenyl)-1,3-benzoxathiol-2-one	722469	6020	slight inhibition at 0.12 mM
2.5.1.7	Escherichia coli		5-hydroxybenzo[d][1,3]oxathiol-2-one	722469		
2.5.1.7	Staphylococcus aureus		5-hydroxybenzo[d][1,3]oxathiol-2-one	722469		
2.5.1.7	Enterobacter cloacae		5-hydroxynaphtho[1,2-d][1,3]oxathiol-2-one	721372	5354	
2.5.1.7	Mycobacterium tuberculosis		5-hydroxynaphtho[1,2-d][1,3]oxathiol-2-one	721372	5354	
2.5.1.7	Pseudomonas aeruginosa		5-hydroxynaphtho[1,2-d][1,3]oxathiol-2-one	721372	5354	
2.5.1.7	Streptococcus pneumoniae		5-hydroxynaphtho[1,2-d][1,3]oxathiol-2-one	721372	5354	
2.5.1.7	Escherichia coli		5-hydroxynaphtho[1,2-d][1,3]oxathiol-2-one	721372, 722469	5354	
2.5.1.7	Staphylococcus aureus		5-hydroxynaphtho[1,2-d][1,3]oxathiol-2-one	721372, 722469	5354	
2.5.1.7	Escherichia coli		5-hydroxynaphtho[2,1-d][1,3]oxathiol-2-one	722469	19637	
2.5.1.7	Staphylococcus aureus		5-hydroxynaphtho[2,1-d][1,3]oxathiol-2-one	722469	19637	
2.5.1.7	Escherichia coli		5-methoxy-1,3-benzoxathiole	722469	28328	
2.5.1.7	Staphylococcus aureus		5-methoxy-1,3-benzoxathiole	722469	28328	slight inhibition at 0.12 mM
2.5.1.7	Escherichia coli		5-methoxybenzo[d][1,3]oxathiol-2-one	722469		
2.5.1.7	Staphylococcus aureus		5-methoxybenzo[d][1,3]oxathiol-2-one	722469		
2.5.1.7	Escherichia coli		6,7-dimethoxy-2-[4-(2-phenylethyl)piperazin-1-yl]-3,4-dihydronaphthalen-1(2H)-one	685595	16912	
2.5.1.7	Staphylococcus aureus		6,7-dimethoxy-2-[4-(2-phenylethyl)piperazin-1-yl]-3,4-dihydronaphthalen-1(2H)-one	685595	16912	
2.5.1.7	Escherichia coli		7-(4-fluorophenyl)-5-hydroxy-1,3-benzoxathiol-2-one	722469	28326	
2.5.1.7	Staphylococcus aureus		7-(4-fluorophenyl)-5-hydroxy-1,3-benzoxathiol-2-one	722469	28326	slight inhibition at 0.12 mM
2.5.1.7	Enterobacter cloacae		Ca2+	637587	18	weak
2.5.1.7	Escherichia coli		cnicin	688290	46837	sesquiterpene lactone. The enzyme catalyzes the formation of a covalent adduct between cnicin and substrate UDP-N-acetylglucosamine via an anti-Michael 1,3-addition of UDP-N-acetylglucosamine to an alpha,beta-unsaturated carbonyl function in cnicin thus forming a noncovalent suicide inhibitor
2.5.1.7	Enterobacter cloacae		cnicine	721372	111805	
2.5.1.7	Escherichia coli		cnicine	721372	111805	
2.5.1.7	Mycobacterium tuberculosis		cnicine	721372	111805	
2.5.1.7	Pseudomonas aeruginosa		cnicine	721372	111805	
2.5.1.7	Staphylococcus aureus		cnicine	721372	111805	
2.5.1.7	Streptococcus pneumoniae		cnicine	721372	111805	
2.5.1.7	Escherichia coli		Co2+	706916	21	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
2.5.1.7	Escherichia coli		Cu2+	706916	28	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
2.5.1.7	Pseudomonas aeruginosa		Cu2+	706916	28	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
2.5.1.7	Enterobacter cloacae		cynaropicrin	721372	111806	
2.5.1.7	Escherichia coli		cynaropicrin	721372	111806	
2.5.1.7	Mycobacterium tuberculosis		cynaropicrin	721372	111806	
2.5.1.7	Pseudomonas aeruginosa		cynaropicrin	721372	111806	
2.5.1.7	Staphylococcus aureus		cynaropicrin	721372	111806	
2.5.1.7	Streptococcus pneumoniae		cynaropicrin	721372	111806	
2.5.1.7	Enterobacter cloacae		diarylmethane	721372		
2.5.1.7	Escherichia coli		diarylmethane	721372		
2.5.1.7	Mycobacterium tuberculosis		diarylmethane	721372		
2.5.1.7	Pseudomonas aeruginosa		diarylmethane	721372		
2.5.1.7	Staphylococcus aureus		diarylmethane	721372		
2.5.1.7	Streptococcus pneumoniae		diarylmethane	721372		
2.5.1.7	Haemophilus influenzae		ebselen	705091	1837	inhibitor covalently modifies the cysteine residue near the active site-loop of MurA, modification changes the open conformation of MurA to a more closed configuration, when compound is incubated for 30 min with dithiothreitol, its inhibitory activity against Haemophilus influenzae MurA is completely eliminated
2.5.1.7	Enterobacter cloacae		ebselen	721372	1837	
2.5.1.7	Escherichia coli		ebselen	721372	1837	
2.5.1.7	Mycobacterium tuberculosis		ebselen	721372	1837	
2.5.1.7	Pseudomonas aeruginosa		ebselen	721372	1837	
2.5.1.7	Staphylococcus aureus		ebselen	721372	1837	
2.5.1.7	Streptococcus pneumoniae		ebselen	721372	1837	
2.5.1.7	Escherichia coli		Fe2+	706916	23	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
2.5.1.7	Pseudomonas aeruginosa		Fe2+	706916	23	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
2.5.1.7	Enterobacter cloacae		fosfomycin	637594	872	irreversible, active site SH-group is involved
2.5.1.7	Enterobacter cloacae		fosfomycin	637598	872	alkylates Cys115
2.5.1.7	Escherichia coli		fosfomycin	637598	872	alkylates Cys115; competitive against phosphoenolpyruvate; inhibits the wild-type, mutant C155D is completely resistant; t1/2 for inactivation of the wild-type enzyme: 6 s
2.5.1.7	Escherichia coli		fosfomycin	637599	872	binds covalently to Cys115
2.5.1.7	Enterobacter cloacae		fosfomycin	637605	872	binds covalently to Cys115
2.5.1.7	Escherichia coli		fosfomycin	637606	872	binding study by isothermal titration calorimetry; binds covalently to Cys115
2.5.1.7	Chlamydia trachomatis		fosfomycin	637609	872	resistant to fosfomycin inhibition due to exchange of cysteine for aspartate in the active site
2.5.1.7	Enterobacter cloacae		fosfomycin	658639	872	irreversible, alkylation of C115
2.5.1.7	Enterobacter cloacae		fosfomycin	674498	872	0.01 mM
2.5.1.7	Enterobacter cloacae		fosfomycin	675082	872	selectively inhibited by fosfomycin, which forms a covalent bond to the sulfhydryl group of the catalytically relevant Cys115 residue
2.5.1.7	Escherichia coli		fosfomycin	675082	872	selectively inhibited by fosfomycin, which forms a covalent bond to the sulfhydryl group of the catalytically relevant Cys115 residue
2.5.1.7	Bacillus anthracis		fosfomycin	684494	872	
2.5.1.7	Escherichia coli		fosfomycin	702267	872	enolpyruvyl UDP-GlcNAc synthase is an antimicrobial target that is inhibited by the antibiotic fosfomycin
2.5.1.7	Haemophilus influenzae		fosfomycin	705091	872	
2.5.1.7	Staphylococcus aureus		fosfomycin	705785	872	despite low level expression during normal growth, murZ expression is strongly induced up to 6fold following exposure to inhibitors of peptidoglycan biosynthesis, minimum inhibitory concentration is 4 mg/ml; the naturally occurring antibiotic, which is an analogue of phosphoenolpyruvate, irreversibly inhibits the majority of MurA enzymes, fosfomycin minimum inhibitory concentration is 8 mg/ml, peptidoglycan content is reduced by approximately 25% following inactivation of murA
2.5.1.7	Pseudomonas aeruginosa		fosfomycin	706916	872	
2.5.1.7	Aliivibrio fischeri		fosfomycin	721232	872	
2.5.1.7	Enterobacter cloacae		fosfomycin	721372	872	irreversible inhibitor
2.5.1.7	Escherichia coli		fosfomycin	721372	872	irreversible inhibitor
2.5.1.7	Mycobacterium tuberculosis		fosfomycin	721372	872	irreversible inhibitor
2.5.1.7	Pseudomonas aeruginosa		fosfomycin	721372	872	irreversible inhibitor
2.5.1.7	Staphylococcus aureus		fosfomycin	721372	872	irreversible inhibitor
2.5.1.7	Streptococcus pneumoniae		fosfomycin	721372	872	irreversible inhibitor
2.5.1.7	uncultured bacterium		fosfomycin	721910	872	
2.5.1.7	Haemophilus influenzae		fosfomycin	721958	872	more than 90% inhibition at 0.2 mM
2.5.1.7	Mycobacterium tuberculosis		fosfomycin	722423	872	
2.5.1.7	Escherichia coli		fosfomycin	685595, 706916, 722469	872	
2.5.1.7	Staphylococcus aureus		fosfomycin	685595, 722469	872	
2.5.1.7	Enterobacter cloacae		fosfomycin	637602, 637603, 722746	872	
2.5.1.7	Enterobacter cloacae		HESFWYLPHHQSY	721372	111804	competitive inhibition
2.5.1.7	Escherichia coli		HESFWYLPHHQSY	721372	111804	competitive inhibition
2.5.1.7	Mycobacterium tuberculosis		HESFWYLPHHQSY	721372	111804	competitive inhibition
2.5.1.7	Pseudomonas aeruginosa		HESFWYLPHHQSY	721372	111804	competitive inhibition
2.5.1.7	Staphylococcus aureus		HESFWYLPHHQSY	721372	111804	competitive inhibition
2.5.1.7	Streptococcus pneumoniae		HESFWYLPHHQSY	721372	111804	competitive inhibition
2.5.1.7	Enterobacter cloacae		Hg2+	637587	31	weak
2.5.1.7	Enterobacter cloacae		imidazole	721372	390	
2.5.1.7	Escherichia coli		imidazole	721372	390	
2.5.1.7	Mycobacterium tuberculosis		imidazole	721372	390	
2.5.1.7	Pseudomonas aeruginosa		imidazole	721372	390	
2.5.1.7	Staphylococcus aureus		imidazole	721372	390	
2.5.1.7	Streptococcus pneumoniae		imidazole	721372	390	
2.5.1.7	Enterobacter cloacae		iodoacetamide	637605	63	inhibition by alkylation of the active site Cys155, pH-dependent, no alkylation below pH 7.0, maximum alkylation at pH 9.0
2.5.1.7	Enterobacter cloacae		iodoacetate	637587	87	
2.5.1.7	Escherichia coli		MnCl2	706916	262	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
2.5.1.7	Pseudomonas aeruginosa		MnCl2	706916	262	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
2.5.1.7	Escherichia coli		more	637590		no inhibition by UDP-galactose
2.5.1.7	Enterobacter cloacae		more	637594		no inhibition by pyruvate and fluoropyruvate
2.5.1.7	Enterobacter cloacae		more	659457		inhibitors derived from 5-sulfonoxy-anthranilic acid obstruct the transition from the open and unliganded to the closed UDP-N-acetylglucosamine liganded form
2.5.1.7	Enterobacter cloacae		N-ethylmaleimide	637587	46	
2.5.1.7	Staphylococcus epidermidis		N-ethylmaleimide	637591	46	complete inhibition at 0.2 M
2.5.1.7	Enterobacter cloacae		p-chloromercuribenzoate	637587	40	
2.5.1.7	Pseudomonas aeruginosa		PEP 1354 peptide	676301		competitive inhibitor
2.5.1.7	Escherichia coli		PGE-553828	637606		competitive against UDP-GlcNAc; inhibition mechanism, kinetics
2.5.1.7	Enterobacter cloacae		phosphoenol-2-ketovalerate	637594		
2.5.1.7	Escherichia coli		phosphonomycin	637590		i.e. L-cis-2-epoxypropylphosphonic acid; inhibitor binding site is distinct from active site; irreversible inactivation, requires the presence of UDP-GlcNAc
2.5.1.7	Escherichia coli		phosphonomycin	637593		irreversible inactivation, requires the presence of UDP-GlcNAc
2.5.1.7	Enterobacter cloacae		pyrazolopyrimidine	721372	111802	reversible inhibitor
2.5.1.7	Escherichia coli		pyrazolopyrimidine	721372	111802	reversible inhibitor
2.5.1.7	Mycobacterium tuberculosis		pyrazolopyrimidine	721372	111802	reversible inhibitor
2.5.1.7	Pseudomonas aeruginosa		pyrazolopyrimidine	721372	111802	reversible inhibitor
2.5.1.7	Staphylococcus aureus		pyrazolopyrimidine	721372	111802	reversible inhibitor
2.5.1.7	Streptococcus pneumoniae		pyrazolopyrimidine	721372	111802	reversible inhibitor
2.5.1.7	Enterobacter cloacae		RWJ-110192	721372	111763	reversible inhibitor
2.5.1.7	Escherichia coli		RWJ-110192	721372	111763	reversible inhibitor
2.5.1.7	Mycobacterium tuberculosis		RWJ-110192	721372	111763	reversible inhibitor
2.5.1.7	Pseudomonas aeruginosa		RWJ-110192	721372	111763	reversible inhibitor
2.5.1.7	Staphylococcus aureus		RWJ-110192	721372	111763	reversible inhibitor
2.5.1.7	Streptococcus pneumoniae		RWJ-110192	721372	111763	reversible inhibitor
2.5.1.7	Mycobacterium tuberculosis		RWJ-110192	722423	111763	
2.5.1.7	Enterobacter cloacae		RWJ-140998	721372	111764	irreversible inhibitor
2.5.1.7	Escherichia coli		RWJ-140998	721372	111764	irreversible inhibitor
2.5.1.7	Mycobacterium tuberculosis		RWJ-140998	721372	111764	irreversible inhibitor
2.5.1.7	Pseudomonas aeruginosa		RWJ-140998	721372	111764	irreversible inhibitor
2.5.1.7	Staphylococcus aureus		RWJ-140998	721372	111764	irreversible inhibitor
2.5.1.7	Streptococcus pneumoniae		RWJ-140998	721372	111764	irreversible inhibitor
2.5.1.7	Mycobacterium tuberculosis		RWJ-140998	722423	111764	
2.5.1.7	Enterobacter cloacae		RWJ-3981	721372	14279	irreversible inhibitor
2.5.1.7	Escherichia coli		RWJ-3981	721372	14279	irreversible inhibitor
2.5.1.7	Mycobacterium tuberculosis		RWJ-3981	721372	14279	irreversible inhibitor
2.5.1.7	Pseudomonas aeruginosa		RWJ-3981	721372	14279	irreversible inhibitor
2.5.1.7	Staphylococcus aureus		RWJ-3981	721372	14279	irreversible inhibitor
2.5.1.7	Streptococcus pneumoniae		RWJ-3981	721372	14279	irreversible inhibitor
2.5.1.7	Mycobacterium tuberculosis		RWJ-3981	722423	14279	
2.5.1.7	Enterobacter cloacae		T6361	721372	111765	competitive inhibition
2.5.1.7	Escherichia coli		T6361	721372	111765	competitive inhibition
2.5.1.7	Mycobacterium tuberculosis		T6361	721372	111765	competitive inhibition
2.5.1.7	Pseudomonas aeruginosa		T6361	721372	111765	competitive inhibition
2.5.1.7	Staphylococcus aureus		T6361	721372	111765	competitive inhibition
2.5.1.7	Streptococcus pneumoniae		T6361	721372	111765	competitive inhibition
2.5.1.7	Mycobacterium tuberculosis		T6361	722423	111765	
2.5.1.7	Enterobacter cloacae		T6362	659457	5763	
2.5.1.7	Enterobacter cloacae		T6362	721372	5763	competitive inhibition
2.5.1.7	Escherichia coli		T6362	721372	5763	competitive inhibition
2.5.1.7	Mycobacterium tuberculosis		T6362	721372	5763	competitive inhibition
2.5.1.7	Pseudomonas aeruginosa		T6362	721372	5763	competitive inhibition
2.5.1.7	Staphylococcus aureus		T6362	721372	5763	competitive inhibition
2.5.1.7	Streptococcus pneumoniae		T6362	721372	5763	competitive inhibition
2.5.1.7	Mycobacterium tuberculosis		T6362	722423	5763	
2.5.1.7	Mycobacterium tuberculosis		T6362-I	722423		
2.5.1.7	Enterobacter cloacae		terreic acid	721372	111803	irreversible inhibitor
2.5.1.7	Escherichia coli		terreic acid	721372	111803	irreversible inhibitor
2.5.1.7	Mycobacterium tuberculosis		terreic acid	721372	111803	irreversible inhibitor
2.5.1.7	Pseudomonas aeruginosa		terreic acid	721372	111803	irreversible inhibitor
2.5.1.7	Staphylococcus aureus		terreic acid	721372	111803	irreversible inhibitor
2.5.1.7	Streptococcus pneumoniae		terreic acid	721372	111803	irreversible inhibitor
2.5.1.7	Haemophilus influenzae		thimerosal	705091	1997	inhibitor covalently modifies the cysteine residue near the active site-loop of MurA, modification changes the open conformation of MurA to a more closed configuration, when compound is incubated for 30 min with dithiothreitol, its inhibitory activity against Haemophilus influenzae MurA is completely eliminated
2.5.1.7	Enterobacter cloacae		thimerosal	721372	1997	
2.5.1.7	Escherichia coli		thimerosal	721372	1997	
2.5.1.7	Mycobacterium tuberculosis		thimerosal	721372	1997	
2.5.1.7	Pseudomonas aeruginosa		thimerosal	721372	1997	
2.5.1.7	Staphylococcus aureus		thimerosal	721372	1997	
2.5.1.7	Streptococcus pneumoniae		thimerosal	721372	1997	
2.5.1.7	Haemophilus influenzae		thiram	705091	4706	inhibitor covalently modifies the cysteine residue near the active site-loop of MurA, modification changes the open conformation of MurA to a more closed configuration, when compound is incubated for 30 min with dithiothreitol, its inhibitory activity against Haemophilus influenzae MurA is completely eliminated
2.5.1.7	Enterobacter cloacae		thiram	721372	4706	
2.5.1.7	Escherichia coli		thiram	721372	4706	
2.5.1.7	Mycobacterium tuberculosis		thiram	721372	4706	
2.5.1.7	Pseudomonas aeruginosa		thiram	721372	4706	
2.5.1.7	Staphylococcus aureus		thiram	721372	4706	
2.5.1.7	Streptococcus pneumoniae		thiram	721372	4706	
2.5.1.7	Enterobacter cloacae		Trypsin	637602		wild-type and mutant C115S, no protection via individually binding of substrates or inhibitor fosfomycin, but via binding of both, the 2 substrates and inhibitor fosfomycin
2.5.1.7	Enterobacter cloacae		tulipaline A	721372	61531	
2.5.1.7	Escherichia coli		tulipaline A	721372	61531	
2.5.1.7	Mycobacterium tuberculosis		tulipaline A	721372	61531	
2.5.1.7	Pseudomonas aeruginosa		tulipaline A	721372	61531	
2.5.1.7	Staphylococcus aureus		tulipaline A	721372	61531	
2.5.1.7	Streptococcus pneumoniae		tulipaline A	721372	61531	
2.5.1.7	Enterobacter cloacae		tulipaline B	721372	111807	
2.5.1.7	Escherichia coli		tulipaline B	721372	111807	
2.5.1.7	Mycobacterium tuberculosis		tulipaline B	721372	111807	
2.5.1.7	Pseudomonas aeruginosa		tulipaline B	721372	111807	
2.5.1.7	Staphylococcus aureus		tulipaline B	721372	111807	
2.5.1.7	Streptococcus pneumoniae		tulipaline B	721372	111807	
2.5.1.7	Escherichia coli		UDP-N-acetylmuramic acid	637590	1441	weak
2.5.1.7	Staphylococcus epidermidis		UDP-N-acetylmuramic acid	637591	1441	
2.5.1.7	Escherichia coli		UDP-N-acetylmuramic acid	658113	1441	competitive with phosphate
2.5.1.7	Escherichia coli		UDP-N-acetylmuramic acid	702267	1441	
2.5.1.7	Escherichia coli		UDP-N-acetylmuramic acid-L-Ala	637590	3004	weak
2.5.1.7	Escherichia coli		UDP-N-acetylmuramic acid-L-Ala-D-Glu	637590	2727	weak
2.5.1.7	Staphylococcus epidermidis		UDP-N-acetylmuramic acid-L-Ala-D-Glu	637591	2727	no inhibition
2.5.1.7	Enterobacter cloacae		UDP-N-acetylmuramyl-L-Ala-D-Glu-meso-alpha,epsilon-diaminopimelic acid	637588	13548	inhibitor binding site is distinct from active site
2.5.1.7	Bacillus cereus		UDP-N-acetylmuramyl-L-Ala-D-Glu-meso-alpha,epsilon-diaminopimelic acid	637590	13548	
2.5.1.7	Escherichia coli		UDP-N-acetylmuramyl-L-Ala-D-Glu-meso-alpha,epsilon-diaminopimelic acid	637590	13548	above 1 mM
2.5.1.7	Enterobacter cloacae		uridine diphospho-N-acetylmuramyl-L-Ala-D-gamma-Glu-meso-alpha,epsilon-diaminopimelic-acid-D-Ala-D-Ala	637588	8627	inhibitor binding site is distinct from active site
2.5.1.7	Bacillus cereus		uridine diphospho-N-acetylmuramyl-L-Ala-D-gamma-Glu-meso-alpha,epsilon-diaminopimelic-acid-D-Ala-D-Ala	637590	8627	
2.5.1.7	Escherichia coli		uridine diphospho-N-acetylmuramyl-L-Ala-D-gamma-Glu-meso-alpha,epsilon-diaminopimelic-acid-D-Ala-D-Ala	637590	8627	above 1 mM
2.5.1.7	Escherichia coli		Zn2+	706916	19	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
2.5.1.7	Pseudomonas aeruginosa		Zn2+	706916	19	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
2.7.7.23	Neurospora crassa	2-mercaptoethanol		643061	59	slight stimulation
2.7.7.23	Giardia intestinalis	D-Glucosamine 6-phosphate		643071	417	allosteric, 0.003 mM, 5fold increase of activity, reversible by dialysis
2.7.7.23	Saccharomyces cerevisiae	dithioerythritol		643059	475	highly stimulating
2.7.7.23	Neurospora crassa	dithioerythritol		643061	475	highly stimulating
2.7.7.23	Saccharomyces cerevisiae	dithiothreitol		643059, 643060	42	highly stimulating
2.7.7.23	Neurospora crassa	dithiothreitol		643061	42	highly stimulating
2.7.7.23	Neurospora crassa	glutathione		643061	41	slight stimulation
2.7.7.23	Neurospora crassa		1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]dihydropyrimidine-2,4(1H,3H)-dione	643062	33190	
2.7.7.23	Saccharomyces cerevisiae		1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]dihydropyrimidine-2,4(1H,3H)-dione	643062	33190	
2.7.7.23	Haemophilus influenzae		4-chloro-N-(3-methoxypropyl)-N-[1-(2-phenylethyl)piperidin-3-yl]benzamide	706622	53113	a 1.9 A resolution crystal structure of this synthetic small-molecule inhibitor of GlmU is presented. The determined crystal structure indicates that the inhibitor occupies an allosteric site adjacent to the GlcNAc-1-P substrate-binding region, thus, preventing structural rearrangements that are required for the enzymatic reaction
2.7.7.23	Haemophilus influenzae		4-chloro-N-[1-[2-(2-fluorophenyl)ethyl]piperidin-3-yl]-N-(3-methoxypropyl)benzamide	706622	53115	
2.7.7.23	Haemophilus influenzae		4-chloro-N-[1-[2-(3-fluorophenyl)ethyl]piperidin-3-yl]-N-(3-methoxypropyl)benzamide	706622	53116	
2.7.7.23	Haemophilus influenzae		4-chloro-N-[1-[2-(4-fluorophenyl)ethyl]piperidin-3-yl]-N-(3-methoxypropyl)benzamide	706622	53117	
2.7.7.23	Haemophilus influenzae		4-fluoro-N-(3-methoxypropyl)-N-[1-(2-phenylethyl)piperidin-3-yl]benzamide	706622	53114	
2.7.7.23	Neurospora crassa		5-Hydroxyuridine	643062	13237	
2.7.7.23	Saccharomyces cerevisiae		5-Hydroxyuridine	643062	13237	
2.7.7.23	Ovis aries		diphosphate	643057	13	slight inhibition above 8 mM
2.7.7.23	Saccharomyces cerevisiae		diphosphate	643060	13	above 75 mM
2.7.7.23	Arabidopsis thaliana		diphosphate	721526	13	0.5 mM, 56% reduction in activity
2.7.7.23	Ovis aries		EDTA	643057	223	not reversible by addition of Mg2+
2.7.7.23	Arabidopsis thaliana		EDTA	721526	223	5 mM, 11% residual activity
2.7.7.23	Bos taurus		fluoride	643058	158	inhibits Mg2+ but not Mn2+ activated enzyme
2.7.7.23	Saccharomyces cerevisiae		fluoride	643059	158	slight inhibition
2.7.7.23	Arabidopsis thaliana		hydromycin	721526		0.5 mg/ml, 36% reduction in activity
2.7.7.23	Xanthomonas oryzae pv. oryzae		luteolin	719411	364	minimal inhibitory concentration for growth of Xanthomonas oryzae pv. oryzae, 186 microg/ml
2.7.7.23	Saccharomyces cerevisiae		Mercuric chloride	643059	3822	
2.7.7.23	Saccharomyces cerevisiae		Mercuric chloride	643060	3822	complete inactivation with 0.5 mM at 30&deg;C, 45 min, reversible by addition of 1 mM dithiothreitol
2.7.7.23	Xanthomonas oryzae pv. oryzae		N'-[(4-chloro-3,5-dimethylphenoxy)acetyl]-2,4-dihydroxybenzohydrazide	719411	19667	minimal inhibitory concentration for growth of Xanthomonas oryzae pv. oryzae, 420 microg/ml
2.7.7.23	Xanthomonas oryzae pv. oryzae		N'1,N'6-bis[2-(naphthalen-2-yloxy)acetyl]hexanedihydrazide	719411	19668	minimal inhibitory concentration for growth of Xanthomonas oryzae pv. oryzae, 302 microg/ml
2.7.7.23	Saccharomyces cerevisiae		N-ethylmaleimide	643059	46	
2.7.7.23	Moniliophthora perniciosa		N-[(2R,3R,4R,6R)-2-(2,3-dihydroxy-5-nitrophenoxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]acetamide	722022	102551	most active inhibitor among compounds tested, forms a hydrogen bonding network with residues Arg116, Gly381, Arg383 and Lys408, with the distance ranging from 2.9 A to and 3.14 A. The hydrophobic interaction is observed with the aromatic ring of Tyr382 with a distance of 3.85 A. The aromatic ring of the inhibitor also interacts with the Lys123 through a pi-cation interaction, with a distance of 3.99 A
2.7.7.23	Ovis aries		p-chloromercuribenzoate	643057	40	completely reversible with cysteine
2.7.7.23	Saccharomyces cerevisiae		p-chloromercuribenzoate	643059	40	
2.7.7.23	Neurospora crassa		pseudouridine	643062	4898	
2.7.7.23	Saccharomyces cerevisiae		pseudouridine	643062	4898	
2.7.7.23	Arabidopsis thaliana		streptomycin	721526	1731	0.5 mg/ml, 74% reduction in activity
2.7.7.23	Escherichia coli		UDP-N-acetyl-D-glucosamine	288685	120	slight product inhibition in reverse reaction
2.7.7.23	Giardia intestinalis		UMP	643067	127	inhibits catabolic reaction
2.7.7.23	Neurospora crassa		uridine	643062	227	
2.7.7.23	Saccharomyces cerevisiae		uridine	643062	227	competitive with diphosphate, noncompetitive with UDP-N-acetyl-D-glucosamine, activity could be restored by dialysis
2.4.1.227	Escherichia coli	Ca2+		488971	18	
2.4.1.227	Escherichia coli	cardiolipin		703764	652	the activity of MurG is increased in the presence of cardiolipin
2.4.1.227	Escherichia coli	dimethyl sulfoxide		488978	702	
2.4.1.227	Escherichia coli	DMSO		703764	702	high concentration (35%) of dimethylsulfoxide is necessary for maximal enzyme activity
2.4.1.227	Escherichia coli	Mg2+		488971, 488973, 488974, 488976, 488978	25	
2.4.1.227	Peptoclostridium difficile		(1R,3R,3aS,6aR)-1-{[2-({[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl] methyl}amino)-2-oxoethyl]carbamoyl}-3-(2-methoxyphenyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrol-2-ium	723086	102399	
2.4.1.227	Escherichia coli		(1R,3S,3aR,6aS)-3-((S)-1,2-dihydroxyethyl)-N-(2-((((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)amino)-2-oxoethyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxamide	721824	102379	
2.4.1.227	Escherichia coli		(1R,3S,3aR,6aS)-3-(2,3-dimethoxyphenyl)-N-[2-({[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}amino)-2-oxoethyl]-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxamide	721824	102378	
2.4.1.227	Escherichia coli		(1R,3S,3aR,6aS)-N-[2-({[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}amino)-2-oxoethyl]-1-methyl-4,6-dioxo-3,5-diphenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxamide	721824	102376	
2.4.1.227	Escherichia coli		(1R,3S,3aR,6aS)-N-[2-({[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}amino)-2-oxoethyl]-3-(2-methoxyphenyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxamide	721824	102377	
2.4.1.227	Escherichia coli		(1R,3S,3aR,6aS)-N-[2-({[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}amino)-2-oxoethyl]-3-(2-methoxyphenyl)-2-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxamide	721824	102387	
2.4.1.227	Escherichia coli		(2S)-N-{[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}-1-{[(1R,3S,3aR,6aS)-3-(2-methoxyphenyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrol-1-yl]carbonyl}pyrrolidine-2-carboxamide	721824		
2.4.1.227	Escherichia coli		(2S)-N-{[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}-1-{[(1R,3S,3aR,6aS)-5-ethyl-3-(2-methoxyphenyl)-1-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrol-1-yl]carbonyl}pyrrolidine-2-carboxamide	721824	102390	
2.4.1.227	Peptoclostridium difficile		(4R,4aR,5aS,6R,12aS)-4-(dimethylamino)-1,5,10,12,12a-pentahydroxy-6-methyl-3,11-dioxo-3,4,4a,5,5a,6,11,12a- octahydrotetracene-2-carboxamide	723086	102393	
2.4.1.227	Peptoclostridium difficile		({2-[3-(4-methoxybenzyl)-6-(methoxycarbonyl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-2-oxoethyl}sulfanyl)acetic acid	723086	102394	
2.4.1.227	Peptoclostridium difficile		2-(carboxyethynyl)-3,4-dihydroxybenzoic acid	723086	102395	
2.4.1.227	Peptoclostridium difficile		2-(phosphonooxy)butanoic acid	723086	102397	
2.4.1.227	Peptoclostridium difficile		4-{[(1S,11aS)-5,11-dioxo-7-phenyl-2,3,5,10,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-1-yl]amino}-4-oxobutanoic acid	723086	102398	
2.4.1.227	Escherichia coli		5'-({[(2R,3R,3aR,6aR)-3-carboxy-2-(2,3-dihydroxypropyl)-6a-methyl-4,6-dioxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824	102383	
2.4.1.227	Escherichia coli		5'-({[(2S,3R,3aR,6aR)-3-carboxy-2-(2-methoxyphenyl)-6a-methyl-4,6-dioxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824	102382	
2.4.1.227	Escherichia coli		5'-({[(2S,3R,3aS,6aR)-3-carboxy-2-(2,3-dimethoxyphenyl)-6a-methyl-4,6-dioxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824		
2.4.1.227	Escherichia coli		5'-({[(2S,3R,3aS,6aR)-3-carboxy-2-(2-methoxyphenyl)-6a-methyl-4,6-dioxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824	102385	
2.4.1.227	Escherichia coli		5'-({[(2S,3R,3aS,6aR)-3-carboxy-2-(3,4-dimethoxyphenyl)-6a-methyl-4,6-dioxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824	102386	
2.4.1.227	Escherichia coli		5'-({[(2S,3R,3aS,6aR)-3-carboxy-6a-methyl-4,6-dioxo-2-phenylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824	102384	
2.4.1.227	Peptoclostridium difficile		5'-deoxy-5'-[(N-{[(2R,3R,4R,5R)-3-(methoxycarbonyl)-5-(2-methoxyphenyl)-2,4-dimethylpyrrolidinium-2-yl]carbonyl}glycyl) amino]uridine	723086	102400	
2.4.1.227	Escherichia coli		5'-O-(3-{[(1R,3S,3aR,6aS)-3-(2-methoxyphenyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrol-1-yl]methoxy}-3-oxopropanoyl)uridine	721824	102391	
2.4.1.227	Escherichia coli		5'-O-(4-{[(1R,3S,3aR,6aS)-3-(2-methoxyphenyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrol-1-yl]methoxy}-4-oxobutanoyl)uridine	721824	102392	
2.4.1.227	Escherichia coli		5'-[(1-{[(2R,3R,4R,5S)-3,4-bis(methoxycarbonyl)-5-(2-methoxyphenyl)-2-methylpyrrolidin-2-yl]carbonyl}-L-prolyl)amino]-5'-deoxyuridine	721824	102389	
2.4.1.227	Escherichia coli		5'-[(1-{[(2R,3S,4R,5S)-3,4-bis(methoxycarbonyl)-5-(2-methoxyphenyl)-2-methylpyrrolidin-2-yl]carbonyl}-L-prolyl)amino]-5'-deoxyuridine	721824	102388	
2.4.1.227	Escherichia coli		5'-{[(3S,4R,5S)-3,4-bis(methoxycarbonyl)-5-(2-methoxyphenyl)-2-methyl-D-prolylglycyl]amino}-5'-deoxyuridine	721824	102381	
2.4.1.227	Escherichia coli		5'-{[(3S5'-{[(3S,4R,5S)-3,4-bis(methoxycarbonyl)-2-methyl-5-phenyl-D-prolylglycyl]amino}-5'-deoxyuridine,4R,5S)-3,4-bis(methoxycarbonyl)-2-methyl-5-phenyl-D-prolylglycyl]amino}-5'-deoxyuridine	721824	102380	
2.4.1.227	Escherichia coli		cephalosporin C	657559	398	50% inhibition at 0.014 mg/ml
2.4.1.227	Escherichia coli		EDTA	488971	223	
2.4.1.227	Escherichia coli		methanol	488978	78	
2.4.1.227	Escherichia coli		Moenomycin	658448	2590	50% inhibition at 0.0106 mM
2.4.1.227	Escherichia coli		more	703764		not inhibited by UMP, nor any other nucleotide diphosphate, UDP-N-acetylgalactosamine fails to show inhibitory activity even at millimolar concentrations
2.4.1.227	Escherichia coli		more	721824		a transition state mimic is designed for MurG, containing a functionalised proline, linked through the alpha-carboxylic acid, via a spacer, to a uridine nucleoside. A set of 15 functionalised prolines are synthesised, using a convergent dipolar cycloaddition reaction, which are coupled via either a glycine, proline, sarcosine, or diester linkage to the 5'-position of uridine. The library of 18 final compounds are tested as inhibitors of Escherichia coli glycosyltransferase MurG, overview
2.4.1.227	Peptoclostridium difficile		more	723086		inhibitor binding mode, molecular modeling, overview
2.4.1.227	Peptoclostridium difficile		N-({6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl}sulfonyl)-D-glutamic acid	723086	102396	
2.4.1.227	Escherichia coli		N-p-chlorobiphenyl-vancomycin	658448	80653	50% inhibition at 0.00125 mM
2.4.1.227	Escherichia coli		NG-p-chlorobiphenyl-vancomycin	658448	80652	50% inhibition at 0.0214 mM
2.4.1.227	Escherichia coli		Ni2+	488971	36	
2.4.1.227	Escherichia coli		nisin	657559	13919	50% inhibition at 0.016 mg/ml
2.4.1.227	Escherichia coli		ramoplanin	488972, 703764	21972	
2.4.1.227	Escherichia coli		ramoplanin	721824	21972	90% inhibition at 0.02 mM
2.4.1.227	Escherichia coli		trifluoroethanol	488978	7477	
2.4.1.227	Escherichia coli		tunicamycin	488972	1243	
2.4.1.227	Escherichia coli		tunicamycin	657559	1243	50% inhibition at 0.0003 mg/ml
2.4.1.227	Escherichia coli		UDP	488976	24	competitive inhibitor of UDP-GlcNAc donor, noncompetitive inhibitor of lipid I acceptor analogue
2.4.1.227	Escherichia coli		UDP	703764	24	
2.4.1.227	Escherichia coli		Vancomycin	657559	1560	50% inhibition at 0.009 mg/ml
2.4.1.227	Escherichia coli		Vancomycin	658448	1560	50% inhibition at 0.0157 mM
2.4.1.227	Escherichia coli		Zn2+	488971	19	
2.4.1.227	Peptoclostridium difficile		[1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl]bis(phosphonic acid)	723086	2629	
6.3.2.9	Escherichia coli		(2R)-2-[((3-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl)carbonyl)amino]pentanedioic acid	714905	59230	
6.3.2.9	Escherichia coli		(2R)-2-[((4-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl)carbonyl)amino]pentanedioic acid	714905	59228	
6.3.2.9	Escherichia coli		(2R)-2-[[(7-(2-ethoxy-2-oxoethoxy)naphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705031	54913	NMR and molecular dynamics analysis
6.3.2.9	Escherichia coli		(2R)-2-[[(7-(3-phenylpropoxy)naphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705031	54912	NMR and molecular dynamics analysis
6.3.2.9	Escherichia coli		(2R)-2-[[(7-(4-cyanobenzyloxy)naphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705031	18427	NMR and molecular dynamics analysis
6.3.2.9	Escherichia coli		(2R)-2-[[(7-(4-cyanobenzyloxy)naphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705227	18427	calculation of binding free energies. Main driving force for binding are non-polar van der Waals-interactions
6.3.2.9	Escherichia coli		(2R)-2-[[(7-benzyloxynaphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705227	54915	calculation of binding free energies. Main driving force for binding are non-polar van der Waals-interactions
6.3.2.9	Escherichia coli		(2R)-2-[[(7-butoxynaphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705031	54911	NMR and molecular dynamics analysis
6.3.2.9	Escherichia coli		(2R)-2-[[(7-pentoxynaphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705227	54914	calculation of binding free energies. Main driving force for binding are non-polar van der Waals-interactions
6.3.2.9	Escherichia coli		(2S)-2-[((4-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl)carbonyl)amino]pentanedioic acid	714905	59229	
6.3.2.9	Escherichia coli		(R,Z)-2-(3-((1-carboxy-N-(4-((4-oxo-2-thioxothiazolidin-5-ylidene)-methyl)phenyl)formamido)methyl)benzamido)pentanedioic acid	715866	59233	
6.3.2.9	Escherichia coli		(R,Z)-2-(3-((2-carboxy-N-(4-((4-oxo-2-thioxothiazolidin-5-ylidene)-methyl)phenyl)acetamido)methyl)benzamido)pentanedioic acid	715866	59234	in addition, weak activity against Gram-positive Staphylococcus aureus and Enterococcus faecalis
6.3.2.9	Escherichia coli		(R,Z)-2-(3-((3-carboxy-N-(4-((4-oxo-2-thioxothiazolidin-5-ylidene)-methyl)phenyl)propanamido)methyl)benzamido)pentanedioic acid	715866	59235	in addition, weak activity against Gram-positive Staphylococcus aureus and Enterococcus faecalis
6.3.2.9	Escherichia coli		(R,Z)-2-(3-((4-((2,4-dioxothiazolidin-5-ylidene)methyl)phenylamino)methyl)benzamido)pentanedioic acid	715847	59236	
6.3.2.9	Escherichia coli		(R,Z)-2-(3-((4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)phenylamino)methyl)benzamido)pentanedioic acid	715847	112424	
6.3.2.9	Escherichia coli		1-Phospho-N-acetylmuramoyl-L-Ala-D-Glu	1293	28612	
6.3.2.9	Escherichia coli		2,3,4,5-tetrabromo-6-(3,6-dihydroxy-9H-xanthen-9-yl)benzoic acid	702636	54909	inhibitor identified by structure-based virtual screening
6.3.2.9	Escherichia coli		2,4,6-Trinitrobenzenesulfonic acid	1302	2353	
6.3.2.9	Escherichia coli		2-((4-[(2S)-butan-2-ylamino]-6-(ethylamino)-1,3,5-triazin-2-yl)sulfanyl)-N-(2-chlorophenyl)acetamide	715974	59224	0.5 mM, 50% inhibition. Inhibitory to both MurC and MurD, ECs 6.3.2.8 and 6.3.2.9, respectively
6.3.2.9	Escherichia coli		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 2-nitrobenzenesulfonate	694288	49650	71% inhibition at 0.05 mM
6.3.2.9	Escherichia coli		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 3-nitrobenzenesulfonate	694288	49651	70% inhibition at 0.05 mM
6.3.2.9	Escherichia coli		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 4-nitrobenzenesulfonate	694288	25766	
6.3.2.9	Escherichia coli		2-([2-(naphthalen-2-ylsulfonyl)hydrazono]methyl)phenyl 2-(benzo[d][1,3]dioxol-5-yl)acetate	694288	49657	49% inhibition at 0.10 mM
6.3.2.9	Escherichia coli		2-bromo-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	25767	
6.3.2.9	Escherichia coli		2-[([6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl]sulfonyl)amino]-5-hydroxybenzoic acid	714902	27999	
6.3.2.9	Escherichia coli		2-[([6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl]sulfonyl)amino]benzene-1,4-dicarboxylic acid	714902	28000	
6.3.2.9	Escherichia coli		3-([[(5-amino-1,3,4-thiadiazol-2-yl)sulfanyl]acetyl]amino)-4-methylbenzoic acid	704728	54910	
6.3.2.9	Escherichia coli		3-bromo-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	17392	
6.3.2.9	Escherichia coli		4-([(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl)-6-(naphthalen-2-ylmethyl)-1,3,5-triazin-2-amine	715974	59226	0.5 mM, 33% inhibition. Inhibitory to both MurC and MurD, ECs 6.3.2.8 and 6.3.2.9, respectively
6.3.2.9	Escherichia coli		4-cyano-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	49654	78% inhibition at 0.05 mM
6.3.2.9	Escherichia coli		4-[([6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl]sulfonyl)amino]benzene-1,3-dicarboxylic acid	714902	28001	
6.3.2.9	Escherichia coli		4-[([6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl]sulfonyl)amino]cyclohexane-1,3-dicarboxylic acid	714902	27998	
6.3.2.9	Escherichia coli		6-([(1,1-dioxidotetrahydrothiophen-3-yl)sulfanyl]methyl)-N-(2-phenylethyl)-1,3,5-triazine-2,4-diamine	715974	59225	0.25 mM, 11% inhibition. Inhibitory to both MurC and MurD, ECs 6.3.2.8 and 6.3.2.9, respectively
6.3.2.9	Escherichia coli		6-[(1-methyl-1H-imidazol-2-yl)sulfanyl]-N,N'-diphenyl-1,3,5-triazine-2,4-diamine	715974	59227	0.5 mM, 30% inhibition. Inhibitory to both MurC and MurD, ECs 6.3.2.8 and 6.3.2.9, respectively
6.3.2.9	Escherichia coli		benzylidene rhodanines	694288		possess MurC inhibitory activity in the low micromolar range
6.3.2.9	Escherichia coli		beta,gamma-methyleneadenosine 5'-triphosphate	704728	2691	nonhydrolyzable ATP analogue
6.3.2.9	Escherichia coli		CPAHWPHPC	692904	49658	i.e. peptide MD-C7C_1, inhibits MurD
6.3.2.9	Escherichia coli		CSAWSNKFC	692904	49659	i.e. peptide MD-C7C_2, inhibits MurD
6.3.2.9	Escherichia coli		D-2-Aminoadipic acid	1293	29249	
6.3.2.9	Escherichia coli		D-Asp	1293	517	weak
6.3.2.9	Escherichia coli		D-erythro-3-Methylglutamic acid	1300	29262	
6.3.2.9	Escherichia coli		D-erythro-4-Methylglutamic acid	1300	29263	
6.3.2.9	Escherichia coli		D-Gln	1293	1586	weak
6.3.2.9	Escherichia coli		D-Pyroglutamic acid	1293	20102	
6.3.2.9	Escherichia coli		dihydrouridine 5'-diphosphate-N-acetylmuramoyl-L-Ala-D-Glu	1293	30158	
6.3.2.9	Escherichia coli		DL-2-Amino-4-phosphonobutyric acid	1293	13355	
6.3.2.9	Escherichia coli		DL-2-aminopimelic acid	1293	20331	
6.3.2.9	Escherichia coli		DL-homocysteic acid	1300	5454	
6.3.2.9	Pseudomonas aeruginosa		HLPTSSLFDTTG	676300	41878	
6.3.2.9	Escherichia coli		HSSWYIQHFPPL	692904	49660	i.e. peptide MD-12, inhibits MurD
6.3.2.9	Escherichia coli		L-Glu	1293	38	
6.3.2.9	Lysinibacillus sphaericus		L-Glu	985	38	50 mM, product inhibition
6.3.2.9	Lysinibacillus sphaericus		Mg2+	985	25	
6.3.2.9	Lysinibacillus sphaericus		Mn2+	985	26	weak
6.3.2.9	Escherichia coli		more	650571		synthesis and evaluation of a series of transition-state analog inhibitors
6.3.2.9	Escherichia coli		more	692904		design of peptidomimetic lead compounds with the ultimate objective of small molecule chemotherapeutic development, affinity selection by immobilized MurD with addition of ATP in an attempt to achieve conformationally homogenous population of target enzymes, overview. No inhibition by peptide MD-C7C_3, i.e. CQSSPHMSC
6.3.2.9	Escherichia coli		more	694288		design and synthesis of N-benzylidenesulfonohydrazide inhibitors of MurC as antibacterial agents
6.3.2.9	Leptospira interrogans		more	715722		generation of MurD 3D models using crystal structures of PDB entries 1EEH and 2JFF as templates in Modeller9v7 and generation of an in-house library of 1,496 MurD inhibitor analogs. Virtual screening of the best-ranked compounds with pharmacokinetics property prediction has provided 17 MurD inhibitors for developing anti-leptospirosis drug targeting peptidoglycan biosynthesis pathway
6.3.2.9	Escherichia coli		N'-((2-[(2-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	25765	
6.3.2.9	Escherichia coli		N'-((2-[(3-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	49643	70% inhibition at 0.05 mM
6.3.2.9	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)(2-fluorophenyl)methanesulfonohydrazide	694288	49648	39% inhibition at 0.10 mM
6.3.2.9	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)(phenyl)methanesulfonohydrazide	694288	49647	58% inhibition at 0.10 mM
6.3.2.9	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	25764	
6.3.2.9	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-2-nitrobenzenesulfonohydrazide	694288	49645	86% inhibition at 0.10 mM
6.3.2.9	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-3-nitrobenzenesulfonohydrazide	694288	49646	74% inhibition at 0.10 mM
6.3.2.9	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)[4-(trifluoromethyl)phenyl]methanesulfonohydrazide	694288	49649	57% inhibition at 0.10 mM
6.3.2.9	Escherichia coli		N'-((3-[(3-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	49644	61% inhibition at 0.05 mM
6.3.2.9	Escherichia coli		N-(2-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-3,5-dinitrobenzamide	694288	49656	
6.3.2.9	Escherichia coli		N-(2-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-4-nitrobenzamide	694288	25769	
6.3.2.9	Escherichia coli		N-(3-[[(carboxyacetyl)[4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl]amino]methyl]benzoyl)-D-glutamic acid	715866	59232	
6.3.2.9	Escherichia coli		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-2-naphthamide	694288	25768	19% inhibition at 0.01 mM
6.3.2.9	Escherichia coli		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-2-nitrobenzamide	694288	17391	
6.3.2.9	Escherichia coli		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-3,5-dinitrobenzamide	694288	49653	78% inhibition at 0.10 mM
6.3.2.9	Escherichia coli		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-4-nitrobenzamide	694288	49655	81% inhibition at 0.05 mM
6.3.2.9	Escherichia coli		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	49652	56% inhibition at 0.10 mM
6.3.2.9	Escherichia coli		N-(6-butoxy-naphthalene-2-sulfonyl)-D-glutamic acid	675446	12117	competitive versus D-Glu, non-competitive versus ATP and UDP-N-acetylmuramoyl-L-Ala
6.3.2.9	Escherichia coli		N-(6-butoxy-naphthalene-2-sulfonyl)-L-glutamic acid	675446	16139	competitive versus D-Glu, non-competitive versus UDP-N-acetylmuramoyl-L-Ala
6.3.2.9	Escherichia coli		N-([(2S)-2-[(2-naphthylsulfonyl)amino]propyl]-sulfonyl)-D-glutamic acid	677175	41746	1 mM, 75% residual activity
6.3.2.9	Escherichia coli		N-([(2S)-2-[([1,1'-biphenyl]-4-yl-sulfonyl)amino]-propyl]sulfonyl)-D-glutamic acid	677175	41755	1 mM, 70% residual activity
6.3.2.9	Escherichia coli		N-[((2S)-2-[[(E)-3-(1,3-benzodioxol-5-yl)-2-propenoyl]amino]propyl)sulfonyl]-D-glutamic acid	677175	41748	1 mM, 80% residual activity
6.3.2.9	Escherichia coli		N-[2-fluoro-5-[([4-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl]amino)methyl]benzoyl]-D-glutamic acid	715866	59231	
6.3.2.9	Escherichia coli		N-[[(2S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]sulfonyl]-D-glutamic acid	677175	41744	1 mM, 74% residual activity
6.3.2.9	Escherichia coli		N-[[(2S)-2-([2-[2-(acetylamino)phenoxy]acetyl]-amino)propyl]sulfonyl]-D-glutamic acid	677175	41747	1 mM, 93% residual activity
6.3.2.9	Escherichia coli		N-[[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-ethyl]sulfonyl]-D-glutamic acid	677175	41745	1 mM, 77% residual activity
6.3.2.9	Escherichia coli		Phosphinate	1302	13488	an analogue of UDP-N-acetylmuramoyl-dipeptide, the N-acetylmuramoyl moiety being replaced by a hexanoyl chain and the peptide bond between L-Ala and D-Glu by a tetrahedral phosphinate bond
6.3.2.9	Escherichia coli		potassium phosphate	1305	1140	highly dependent on, optimal concentration: 11-16 mM, inhibition above 20 mM, phosphate ion is responsible for inhibition
6.3.2.9	Pseudomonas aeruginosa		RPTHSPI	676300	24351	peptides are synthesized from consensus sequences to evaluate their inhibitory potential against the essential MurD enzyme. The C-7-C mers MurDp1 (RPTHSPI) gives a decrease of MurD ATPase activity with a significant IC50 value of 4 mM. The 12 mers MurDp2 (HLPTSSLFDTTG) inhibits MurD with an IC50 value of 15 mM indicating a weak inhibition. Both peptides show a correlation between an increase in concentration versus an increase in inhibition values
6.3.2.9	Escherichia coli		UDP-N-acetylmuramoyl-L-Ala-D-Glu	1276, 1293	2727	
6.3.2.9	Escherichia coli		[1-[(6-Uridinediphospho)hexanamido]ethyl](2,4-dicarboxybutyl)phosphinate pentasodium salt	1303	62596	good inhibitor, closely resembles the tetrahedral intermediate that is presumed to form the ligation reaction
6.3.2.8	Staphylococcus aureus	2-mercaptoethanol		1280	59	maximal concentration 2.5 mM; stimulates
6.3.2.8	Bacillus subtilis	2-mercaptoethanol		1282	59	stimulates
6.3.2.8	Chlamydia trachomatis	ammonium sulfate		651729	334	20% stimulation at concentrations above 25mM
6.3.2.8	Bacillus subtilis	Cys		1282	70	stimulates
6.3.2.8	Bacillus subtilis	dithiothreitol		1282	42	stimulates
6.3.2.8	Bacillus subtilis	glutathione		1282	41	stimulates
6.3.2.8	Escherichia coli		(5Z)-5-([2-[(4-chlorobenzyl)sulfanyl]-5-nitrophenyl]methylidene)-2-thioxo-1,3-thiazolidin-4-one	694288	47717	
6.3.2.8	Escherichia coli		(5Z)-5-([4-[(E)-2-phenylethenyl]phenyl]methylidene)-2-thioxo-1,3-thiazolidin-4-one	694288	47718	
6.3.2.8	Escherichia coli		1H-indazole-3-carbohydrazide	691815	49641	
6.3.2.8	Escherichia coli		2-((4-[(2S)-butan-2-ylamino]-6-(ethylamino)-1,3,5-triazin-2-yl)sulfanyl)-N-(2-chlorophenyl)acetamide	715974	59224	0.5 mM, 26% inhibition
6.3.2.8	Escherichia coli		2-(4-{[(E)-2-(1H-indazol-3-ylcarbonyl)hydrazono]methyl} phenoxy) acetic acid	691815	92895	complete inhibition at 0.5 mM
6.3.2.8	Escherichia coli		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 2-nitrobenzenesulfonate	694288	49650	55% inhibition at 0.05 mM
6.3.2.8	Escherichia coli		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 3-nitrobenzenesulfonate	694288	49651	65% inhibition at 0.05 mM
6.3.2.8	Escherichia coli		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 4-nitrobenzenesulfonate	694288	25766	75% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		2-([2-(naphthalen-2-ylsulfonyl)hydrazono]methyl)phenyl 2-(benzo[d][1,3]dioxol-5-yl)acetate	694288	49657	57% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		2-bromo-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	25767	41% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		2-phenyl-1,3-thiazole-5-carbohydrazide	691815	92886	
6.3.2.8	Escherichia coli		2-phenyl-N'-[(E)-(2,3,4-trihydroxyphenyl)methylidene]-1,3-thiazole-5-carbohydrazide	691815	49642	18% inhibition at 0.25 mM
6.3.2.8	Escherichia coli		2-[4-({(E)-2-[(4-methyl-1,3-thiazol-5-yl)carbonyl]hydrazono} methyl)phenoxy]acetic acid	691815	92907	complete inhibition at 0.5 mM
6.3.2.8	Escherichia coli		3,3,3-Trifluoro-DL-Ala	1286, 1288	8342	
6.3.2.8	Escherichia coli		3,3-Difluoro-L-Ala	1286, 1288	28796	
6.3.2.8	Escherichia coli		3-bromo-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	17392	
6.3.2.8	Escherichia coli		3-chloro-L-Ala	1277, 1286, 1287, 1288, 1289	1230	
6.3.2.8	Escherichia coli		3-Cyano-L-Ala	1277, 1286, 1287, 1288, 1289	2822	
6.3.2.8	Escherichia coli		3-Fluoro-L-Ala	1286, 1287, 1288	20017	
6.3.2.8	Escherichia coli		4-([(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl)-6-(naphthalen-2-ylmethyl)-1,3,5-triazin-2-amine	715974	59226	0.5 mM, 30% inhibition
6.3.2.8	Escherichia coli		4-({(E)-2-[(4-methyl-1,3-thiazol-5-yl)carbonyl]hydrazono} methyl)benzoic acid	691815	92906	94% inhibition at 0.5 mM
6.3.2.8	Escherichia coli		4-cyano-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	49654	91% inhibition at 0.05 mM
6.3.2.8	Escherichia coli		4-methyl-1,3-thiazole-5-carbohydrazide	691815	92885	
6.3.2.8	Escherichia coli		4-methyl-N'-[(E)-(2,3,4-trihydroxyphenyl)methylidene]-1,3-thiazole-5-carbohydrazide	691815	92901	26% inhibition at 0.5 mM
6.3.2.8	Escherichia coli		4-methyl-N'-[(E)-(2-phenyl-1,3-thiazol-4-yl)methylidene]-1,3-thiazole-5-carbohydrazide	691815	92909	complete inhibition at 0.5 mM
6.3.2.8	Escherichia coli		4-{[(E)-2-(1H-indazol-3-ylcarbonyl)hydrazono]methyl}benzoic acid	691815	92894	complete inhibition at 0.5 mM
6.3.2.8	Escherichia coli		5-methyl-N-([4-(5-phenyl-1-benzofuran-2-yl)phenyl]sulfonyl)thiophene-2-carboxamide	661276	15398	IC50 2.3 microM
6.3.2.8	Escherichia coli		6-([(1,1-dioxidotetrahydrothiophen-3-yl)sulfanyl]methyl)-N-(2-phenylethyl)-1,3,5-triazine-2,4-diamine	715974	59225	0.25 mM, 32% inhibition
6.3.2.8	Escherichia coli		6-[(1-methyl-1H-imidazol-2-yl)sulfanyl]-N,N'-diphenyl-1,3,5-triazine-2,4-diamine	715974	59227	0.5 mM, 36% inhibition
6.3.2.8	Escherichia coli		ADP	662701	8	
6.3.2.8	Staphylococcus aureus		Ba2+	1280	105	inhibits activation by Mn2+
6.3.2.8	Escherichia coli		benzohydrazide	691815	16899	
6.3.2.8	Escherichia coli		benzylidene rhodanines	694288		possess MurC inhibitory activity in the low micromolar range
6.3.2.8	Escherichia coli		beta-gamma-methyleneadenosine 5'-triphosphate	662701	2691	
6.3.2.8	Staphylococcus aureus		Ca2+	1280	18	inhibits activation by Mn2+
6.3.2.8	Bacillus subtilis		Ca2+	1282	18	
6.3.2.8	Staphylococcus aureus		Cd2+	1280	48	inhibits activation by Mn2+
6.3.2.8	Staphylococcus aureus		Co2+	1280	21	inhibits activation by Mn2+
6.3.2.8	Bacillus subtilis		Cu2+	1282	28	
6.3.2.8	Staphylococcus aureus		Fe2+	1280	23	inhibits activation by Mn2+
6.3.2.8	Escherichia coli		feglymycin	727302	108742	isolated from Streptomyces sp. DSM 11171, 13-mer peptide, noncompetitive inhibition, the inhibition is fully reversible after dilution
6.3.2.8	Staphylococcus aureus		feglymycin	727302	108742	isolated from Streptomyces sp. DSM 11171, 13-mer peptide, noncompetitive inhibition, the inhibition is fully reversible after dilution
6.3.2.8	Bacillus cereus		Gly	1282	68	
6.3.2.8	Bacillus subtilis		Gly	1282	68	
6.3.2.8	Escherichia coli		Gly	1286, 1289	68	
6.3.2.8	Staphylococcus aureus		Hg2+	1280	31	inhibits activation by Mn2+
6.3.2.8	Escherichia coli		KCl	1289	74	inhibition above 100 mM
6.3.2.8	Escherichia coli		L-2-aminobutyrate	1286, 1288	1112	
6.3.2.8	Staphylococcus aureus		L-Ala-L-1-aminoethylphosphinic acid	1278	64720	i.e. alaphosphin
6.3.2.8	Escherichia coli		L-Allylglycine	1288	14152	weak
6.3.2.8	Escherichia coli		L-Cys	1286, 1288	70	weak
6.3.2.8	Escherichia coli		L-lactate	1286	338	
6.3.2.8	Escherichia coli		L-Propargylglycine	1286, 1288	729	
6.3.2.8	Bacillus subtilis		L-Ser	1282	89	inhibits reaction with Gly + N-acetylmuramate + ATP
6.3.2.8	Escherichia coli		L-Ser	1286, 1289	89	
6.3.2.8	Escherichia coli		L-Vinylglycine	1286, 1288	1625	
6.3.2.8	Escherichia coli		methyl4-({(E)-2-[(4-methyl-1,3-thiazol-5-yl)carbonyl]hydrazono}methyl)benzoate	691815	92905	95% inhibition at 0.5 mM
6.3.2.8	Escherichia coli		methyl4-{[(E)-2-(1H-indazol-3-ylcarbonyl)hydrazono]methyl} benzoate	691815	92893	complete inhibition at 0.5 mM
6.3.2.8	Staphylococcus aureus		Mg2+	1280	25	inhibits activation by Mn2+
6.3.2.8	Escherichia coli		more	650555		synthesis and evaluation of a series of transition-state analog inhibitors
6.3.2.8	Escherichia coli		more	691815		inhibitor design and synthesis, mass spectrometric analysis, ligand molecular docking calculations, inhibitory potency, MIC values lay above 0.128 mg/ml, overview
6.3.2.8	Escherichia coli		more	694288		design and synthesis of N-benzylidenesulfonohydrazide inhibitors of MurC as antibacterial agents
6.3.2.8	Escherichia coli		N'-((2-[(2-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	25765	30% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		N'-((2-[(3-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	49643	36% inhibition at 0.05 mM
6.3.2.8	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)(2-fluorophenyl)methanesulfonohydrazide	694288	49648	59% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)(phenyl)methanesulfonohydrazide	694288	49647	complete inhibition at 0.10 mM
6.3.2.8	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	25764	36% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-2-nitrobenzenesulfonohydrazide	694288	49645	95% inhibition at 0.01 mM
6.3.2.8	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-3-nitrobenzenesulfonohydrazide	694288	49646	
6.3.2.8	Escherichia coli		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)[4-(trifluoromethyl)phenyl]methanesulfonohydrazide	694288	49649	
6.3.2.8	Escherichia coli		N'-((3-[(3-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	49644	58% inhibition at 0.05 mM
6.3.2.8	Escherichia coli		N'-[(E)-(2,3,4-trihydroxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92887	42% inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N'-[(E)-(2,3,4-trihydroxyphenyl)methylidene]benzohydrazide	691815	92910	64% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		N'-[(E)-(2,4-dihydroxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92888	74% inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N'-[(E)-(2-hydroxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92892	complete inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N'-[(E)-(2-phenyl-1,3-thiazol-4-yl)methylidene]-1H-indazole-3-carbohydrazide	691815	92899	78% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		N'-[(E)-(2-phenyl-1,3-thiazol-4-yl)methylidene]benzohydrazide	691815	92917	70% inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N'-[(E)-(3,4-dihydroxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92889	36% inhibition at 0.5 mM
6.3.2.8	Escherichia coli		N'-[(E)-(3,4-dihydroxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide	691815	92902	95% inhibition at 0.5 mM
6.3.2.8	Escherichia coli		N'-[(E)-(3,4-dihydroxyphenyl)methylidene]benzohydrazide	691815	92912	complete inhibition at 0.5 mM
6.3.2.8	Escherichia coli		N'-[(E)-(3,4-dimethoxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92891	complete inhibition at 0.5 mM
6.3.2.8	Escherichia coli		N'-[(E)-(3,4-dimethoxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide	691815	92903	complete inhibition at 0.5 mM
6.3.2.8	Escherichia coli		N'-[(E)-(3,4-dimethoxyphenyl)methylidene]benzohydrazide	691815	92914	97% inhibition at 0.5 mM
6.3.2.8	Escherichia coli		N'-[(E)-(3,5-dichloro-2-hydroxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide	691815	92904	43% inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N'-[(E)-(3-hydroxy-4-methoxyphenyl)methylidene] benzohydrazide	691815	92913	92% inhibition at 0.5 mM
6.3.2.8	Escherichia coli		N'-[(E)-(3-hydroxy-4-methoxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92890	67% inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N'-[(E)-(4-cyanophenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92898	complete inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N'-[(E)-(4-cyanophenyl)methylidene]benzohydrazide	691815	92916	complete inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N'-[(E)-(4-nitrophenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92897	91% inhibition at 0.5 mM
6.3.2.8	Escherichia coli		N'-[(E)-1H-indol-3-ylmethylidene]-1H-indazole-3-carbohydrazide	691815	92900	complete inhibition at 010 mM
6.3.2.8	Escherichia coli		N'-[(E)-1H-indol-3-ylmethylidene]benzohydrazide	691815	92918	93% inhibition at 0.5 mM
6.3.2.8	Escherichia coli		N'-{(E)-[4-(dimethylamino)phenyl]methylidene}-1H-indazole-3-carbohydrazide	691815	92896	95% inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N'-{(E)-[4-(dimethylamino)phenyl]methylidene}-4-methyl-1,3-thiazole-5-carbohydrazide	691815	92908	97% inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N'-{(E)-[4-(dimethylamino)phenyl]methylidene}benzohydrazide	691815	92915	complete inhibition at 0.25 mM
6.3.2.8	Escherichia coli		N-(2-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-3,5-dinitrobenzamide	694288	49656	51% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		N-(2-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-4-nitrobenzamide	694288	25769	
6.3.2.8	Escherichia coli		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-2-naphthamide	694288	25768	
6.3.2.8	Escherichia coli		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-2-nitrobenzamide	694288	17391	
6.3.2.8	Escherichia coli		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-3,5-dinitrobenzamide	694288	49653	72% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-4-nitrobenzamide	694288	49655	71% inhibition at 0.05 mM
6.3.2.8	Escherichia coli		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	49652	97% inhibition at 0.10 mM
6.3.2.8	Escherichia coli		N-Methyl-L-Ala	1286	5492	weak
6.3.2.8	Escherichia coli		N-[(E)-(2,4-dihydroxyphenyl)methylidene]benzohydrazide	691815	92911	complete inhibition at 0.5 mM
6.3.2.8	Escherichia coli		NaCl	1289	39	inhibition above 100 mM
6.3.2.8	Bacillus subtilis		NEM	1282	46	
6.3.2.8	Escherichia coli		NEM	1287	46	partial protection by ATP
6.3.2.8	Staphylococcus aureus		Ni2+	1280	36	inhibits activation by Mn2+
6.3.2.8	Bacillus subtilis		Ni2+	1282	36	
6.3.2.8	Escherichia coli		p-hydroxymercuribenzoate	1287	92	partial protection by ATP
6.3.2.8	Bacillus subtilis		PCMB	1282	40	
6.3.2.8	Escherichia coli		potassium phosphate	1288	1140	no effect up to 20 mM, significant decrease of activity at higher concentrations
6.3.2.8	Escherichia coli		UDP-2-(acetylamino)-4-O-[[(2-carboxypropyl)(hydroxy)phosphoryl]methyl]-2-deoxy-alpha-D-glucopyranose	662701	82348	
6.3.2.8	Escherichia coli		UDP-N-acetylmuramoyl-L-Ala	1289	3004	
6.3.2.8	Staphylococcus aureus		Zn2+	1280	19	inhibits activation by Mn2+
6.3.2.8	Bacillus subtilis		Zn2+	1282	19	
1.3.5.2	Plasmodium falciparum	more		712147		activity of the bc1 complex is essential for providing oxidized ubiqinone to DHODH for the formation of pyrimidines
1.3.5.2	Candida albicans	oxygen		673547	11	seems to promote very low DHODH activity
1.3.5.2	Plasmodium falciparum		(2,3-difluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(2,5-difluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(2,6-difluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(2-chloro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(2-fluoro-4-methyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Homo sapiens		(2E)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide	654974	79571	50% inhibition at 0.000435 mM
1.3.5.2	Homo sapiens		(2Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[4-(trifluoromethyl)phenyl]prop-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		(2Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[4-(trifluoromethyl)phenyl]prop-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Homo sapiens		(2Z)-2-cyano-N-(2',3-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		(2Z)-2-cyano-N-(2',3-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Homo sapiens		(2Z)-2-cyano-N-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		(2Z)-2-cyano-N-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Homo sapiens		(2Z)-2-cyano-N-(2,3'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		(2Z)-2-cyano-N-(2,3'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Homo sapiens		(2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		(2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Homo sapiens		(2Z)-N-(2'-chlorobiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		(2Z)-N-(2'-chlorobiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Homo sapiens		(2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		(2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Homo sapiens		(2Z)-N-(biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		(2Z)-N-(biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Homo sapiens		(2Z)-N-[2'-chloro-3-(trifluoromethyl)biphenyl-4-yl]-2-cyano-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		(2Z)-N-[2'-chloro-3-(trifluoromethyl)biphenyl-4-yl]-2-cyano-3-hydroxybut-2-enamide	699460		inhibitor based on the active metabolite of the anti-inflammatory drug leflunomide. Comparison of inhibitory effect and binding to human and Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		(3,4-difluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(3,4-dimethyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(3,5-bis-trifluoromethyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(3,5-difluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(3-chloro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(3-fluoro-4-methyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(3-fluoro-4-trifluoromethyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(3-fluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(4-benzyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(4-bromo-3-trifluoromethyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(4-bromo-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(4-chloro-3-trifluoromethyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(4-chloro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(4-difluoromethoxy-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(4-fluoro-3-methyl-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(4-fluoro-phenyl)-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(4-methoxy-phenyl)(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2,3,4,5,6-pentafluorophenyl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2,3,4-trifluoro-phenyl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2,3,5,6-tetrafluoro-phenyl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2,4,5-trifluoro-phenyl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2,4,6-trifluoro-phenyl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2-trifluoromethyl-phenyl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(3-trifluoromethyl-phenyl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(4-methyl-3-trifluoromethylphenyl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(4-nitro-phenyl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(4-trifluoromethoxy-phenyl)-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(4-trifluoromethyl-phenyl)-amine	712682		DSM74
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-m-tolyl-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-naphthalen-2-yl-amine	712682		DSM1, a potent triazolopyrimidine-based inhibitor of PfDHODH that shows greater than 4000fold selectivity for the malarial enzyme when compared to human DHODH
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-o-tolyl-amine	712682		
1.3.5.2	Plasmodium falciparum		(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-p-tolyl-amine	712682		
1.3.5.2	Bos taurus		(R)-dihydroorotate	391224	62580	
1.3.5.2	Rattus norvegicus		1,10-phenanthroline	391221	58	
1.3.5.2	Plasmodium falciparum		1-(1-naphthyl)-3-[2-(trifluoromethyl)phenyl]urea	656285	36323	50% inhibition at 0.0004 mM, wild type, 0.00034 mM, mutant R265A, above 0.2, mutant H185A
1.3.5.2	Plasmodium falciparum		1-(2-methoxyphenyl)-3-(1-naphthyl)urea	656285	19095	50% inhibition at 0.00023 mM, wild type, 0.00024 mM, mutant R265A, 0.140, mutant H185A
1.3.5.2	Homo sapiens		1-(2-methoxyphenyl)-3-naphthalen-1-ylurea	712147	19095	
1.3.5.2	Plasmodium falciparum		1-(2-methoxyphenyl)-3-naphthalen-1-ylurea	712147	19095	
1.3.5.2	Plasmodium falciparum		1-(4-chlorophenyl)-3-quinolin-8-ylurea	656285	36324	50% inhibition at 0.00078 mM, wild type, 0.002 mM, mutant R265A, above 0.4, mutant H185A
1.3.5.2	Toxoplasma gondii		1-hydroxy-2-dodecyl-4(1)quinolone	725920		competitive with regard to decylubiquinone, uncompetitive with regard to dihydroorotate
1.3.5.2	Homo sapiens		2-(4'-tert-butyl-2-chloro-biphenyl-4-ylcarbamoyl)-cyclopent-1-enecarboxylic acid	654974	79569	50% inhibition at 0.000080 mM
1.3.5.2	Plasmodium falciparum		2-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamino)-benzonitrile	712682		
1.3.5.2	Homo sapiens		2-([[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79555	50% inhibition at 0.000007 mM
1.3.5.2	Homo sapiens		2-([[2-chloro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79564	50% inhibition at 0.000020 mM
1.3.5.2	Homo sapiens		2-([[2-chloro-4'-(dimethylamino)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79559	50% inhibition at 0.00005 mM
1.3.5.2	Homo sapiens		2-([[3'-(trifluoromethoxy)-3-(trifluoromethyl)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79568	50% inhibition at 0.000840 mM
1.3.5.2	Homo sapiens		2-([[3,5-difluoro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79553	50% inhibition at 0.000033 mM
1.3.5.2	Homo sapiens		2-([[3-chloro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79566	50% inhibition at 0.000290 mM
1.3.5.2	Homo sapiens		2-([[3-cyano-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79567	50% inhibition at 0.000370 mM
1.3.5.2	Homo sapiens		2-([[3-fluoro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79545	50% inhibition at 0.00028 mM
1.3.5.2	Homo sapiens		2-([[3-fluoro-4'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79546	50% inhibition at 0.00570 mM
1.3.5.2	Homo sapiens		2-([[3-methyl-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79565	50% inhibition at 0.000150 mM
1.3.5.2	Homo sapiens		2-([[3-nitro-3'-(trifluoromethoxy)biphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79572	50% inhibition at 0.000390 mM
1.3.5.2	Homo sapiens		2-([[4'-(dimethylamino)-3,5-difluorobiphenyl-4-yl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79552	50% inhibition at 0.00061 mM
1.3.5.2	Homo sapiens		2-([[4-(1-naphthyl)-2-(trifluoromethyl)phenyl]amino]carbonyl)cyclopent-1-ene-1-carboxylic acid	654974	79570	50% inhibition at 0.000180 mM
1.3.5.2	Homo sapiens		2-cyano-3-(9-ethyl-9H-carbazol-3-ylamino)acrylic acid ethyl ester	675315	9317	IC50: 0.491 mM
1.3.5.2	Plasmodium falciparum		2-cyano-3-(9-ethyl-9H-carbazol-3-ylamino)acrylic acid ethyl ester	675315	9317	IC50: 0.00044 mM
1.3.5.2	Homo sapiens		2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(cyano)phenyl]-propenamide	656088	36338	50% inhibition at 0.0.00035 mM, N-terminally truncated protein
1.3.5.2	Plasmodium falciparum		2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(cyano)phenyl]-propenamide	656088	36338	50% inhibition at 0.712 mM, N-terminally truncated protein
1.3.5.2	Homo sapiens		2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(nitro)phenyl]-propenamide	656088	23044	50% inhibition at 0.00025 mM, N-terminally truncated protein
1.3.5.2	Plasmodium falciparum		2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(nitro)phenyl]-propenamide	656088	23044	50% inhibition at 0.543 mM, N-terminally truncated protein
1.3.5.2	Homo sapiens		2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(trifluoromethyl)phenyl]-propenamide	656088	36337	50% inhibition at 0.00019 mM, N-terminally truncated protein
1.3.5.2	Plasmodium falciparum		2-cyano-3-cyclopropyl-3-hydroxy-N-[4'-(trifluoromethyl)phenyl]-propenamide	656088	36337	50% inhibition at 1.08 mM, N-terminally truncated protein
1.3.5.2	Toxoplasma gondii		2-cyano-3-hydroxy-N-(2',3,3'-trichlorobiphenyl-4-yl)but-2-enamide	725919		
1.3.5.2	Toxoplasma gondii		2-hydroxyethylidene-cyano acetic acid 4-trifluoromethyl anilide	725919	6405	A177-1726, active derivative of human inhibitor leflunomide
1.3.5.2	Homo sapiens		2-hydroxyethylidene-cyanoacetic acid 4-trifluoromethyl anilide	390923	6405	anti-proliferative effect of A77 1726 is mediated by inhibition of enzyme
1.3.5.2	Homo sapiens		2-hydroxyethylidene-cyanoacetic acid 4-trifluoromethyl anilide	390926	6405	inbibits by interference with the transfer of electrons from flavin to quinone
1.3.5.2	Homo sapiens		2-hydroxyethylidene-cyanoacetic acid 4-trifluoromethyl anilide	391233, 391241	6405	A77 1726, active metabolite of leflumonide
1.3.5.2	Homo sapiens		2-hydroxyethylidene-cyanoacetic acid 4-trifluoromethyl anilide	391246	6405	noncompetitive versus ubiquinone, uncompetitive versus dihydroorotate, study of kinetics
1.3.5.2	Plasmodium falciparum		2-methyl-3-nitro-N-[3-(trifluoromethyl)phenyl]benzamide	656285	36322	50% inhibition at 0.00008 mM, wild type, 0.00037 mM, mutant R265A, 0.120, mutant H185A
1.3.5.2	Plasmodium falciparum		2-methyl-N-1-naphthyl-3-nitrobenzamide	656285	36320	50% inhibition at 0.00008 mM, wild type, 0.00048 mM, mutant R265A, 0.180, mutant H185A
1.3.5.2	Homo sapiens		2-[(2,5-dichlorophenyl)sulfanyl]-5-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	725670	19800	compound has therapeutically relevant activity against human enzyme
1.3.5.2	Plasmodium falciparum		2-[(2,5-dichlorophenyl)sulfanyl]-5-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	725670	19800	no specific inhibition of Plasmodium enzyme, good inhibitor of human enzyme
1.3.5.2	Homo sapiens		2-[(2,5-dichlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	725670	19799	compound has therapeutically relevant activity against human enzyme
1.3.5.2	Plasmodium falciparum		2-[(2,5-dichlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	725670	19799	no specific inhibition of Plasmodium enzyme, good inhibitor of human enzyme
1.3.5.2	Homo sapiens		2-[(3,4-dichlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	725670	19798	compound is less active with human enzyme but good inhibitor of Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		2-[(3,4-dichlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	725670	19798	
1.3.5.2	Homo sapiens		2-[(4-chlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	725670	19797	compound is less active with human enzyme but good inhibitor of Plasmodium falciparum enzyme
1.3.5.2	Plasmodium falciparum		2-[(4-chlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	725670	19797	
1.3.5.2	Homo sapiens		2-[(biphenyl-4-ylamino)carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79544	50% inhibition at 0.00041 mM
1.3.5.2	Homo sapiens		2-[(E)-2-(2-methylphenyl)ethenyl]quinolin-4-ol	712147	19097	
1.3.5.2	Plasmodium falciparum		2-[(E)-2-(2-methylphenyl)ethenyl]quinolin-4-ol	712147	19097	
1.3.5.2	Homo sapiens		2-[[(2',3,5-trifluorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79551	50% inhibition at 0.000045 mM
1.3.5.2	Homo sapiens		2-[[(2'-chloro-3,5-difluorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79554	50% inhibition at 0.000018 mM
1.3.5.2	Homo sapiens		2-[[(2'-chlorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79562	50% inhibition at 0.000225 mM
1.3.5.2	Homo sapiens		2-[[(2,3,5,6-tetrafluoro-2'-methoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79833	50% inhibition at 0.000008 mM
1.3.5.2	Homo sapiens		2-[[(3'-ethoxy-3,5-difluorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79563	50% inhibition at 0.000017 mM
1.3.5.2	Homo sapiens		2-[[(3,3'-dimethoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79561	50% inhibition at 0.000170 mM
1.3.5.2	Homo sapiens		2-[[(3,5-difluoro-2',4'-dimethoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79550	50% inhibition at 0.000090 mM
1.3.5.2	Homo sapiens		2-[[(3,5-difluoro-2'-methoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79549	50% inhibition at 0.000042 mM
1.3.5.2	Homo sapiens		2-[[(3-chloro-2'-methoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79556	50% inhibition at 0.000310 mM
1.3.5.2	Homo sapiens		2-[[(3-chloro-4'-methoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79557	50% inhibition at 0.00840 mM
1.3.5.2	Homo sapiens		2-[[(3-fluoro-3'-hydroxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974		50% inhibition at 0.000610 mM
1.3.5.2	Homo sapiens		2-[[(3-fluoro-4'-methoxybiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79547	50% inhibition at 0.00170 mM
1.3.5.2	Homo sapiens		2-[[(4'-bromo-2-chlorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79558	50% inhibition at 0.000070 mM
1.3.5.2	Homo sapiens		2-[[(4'-bromo-3-chlorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79560	50% inhibition at 0.002900 mM
1.3.5.2	Homo sapiens		2-[[(4'-bromo-3-fluorobiphenyl-4-yl)amino]carbonyl]cyclopent-1-ene-1-carboxylic acid	654974	79548	50% inhibition at 0.000735 mM
1.3.5.2	Lactococcus lactis		3,4-dihydroxybenzoate	685158	593	
1.3.5.2	Lactococcus lactis		3,5-Dihydroxybenzoate	685158	4022	
1.3.5.2	Homo sapiens		3-hydroxy-2-(3,3-dichloroallyl)-1,4-naphthoquinone	656088	15012	50% inhibition at 0.000065 mM, i. e. dichloroallyl lawsone, N-terminally truncated protein
1.3.5.2	Plasmodium falciparum		3-hydroxy-2-(3,3-dichloroallyl)-1,4-naphthoquinone	656088	15012	50% inhibition at 0.220 mM, i. e. dichloroallyl lawsone, N-terminally truncated protein
1.3.5.2	Plasmodium falciparum		4-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamino)-2-trifluoromethylbenzonitrile	712682		
1.3.5.2	Plasmodium berghei		4-pentyl-1,3,4,10-tetrahydroacridin-9(2H)-one	698855	5242	
1.3.5.2	Plasmodium vivax		4-pentyl-1,3,4,10-tetrahydroacridin-9(2H)-one	698855	5242	
1.3.5.2	Homo sapiens		4-pentyl-1,3,4,10-tetrahydroacridin-9(2H)-one	712147	5242	
1.3.5.2	Plasmodium falciparum		4-pentyl-1,3,4,10-tetrahydroacridin-9(2H)-one	698855, 712147	5242	
1.3.5.2	Plasmodium falciparum		4-[(5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]-2-(trifluoromethyl)benzonitrile	711913	100635	
1.3.5.2	Homo sapiens		5,6-dimethyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	27719	
1.3.5.2	Plasmodium falciparum		5,6-dimethyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	27719	
1.3.5.2	Homo sapiens		5-(1H-benzimidazol-1-yl)-N-propylthiophene-2-carboxamide	712147	19101	
1.3.5.2	Plasmodium falciparum		5-(1H-benzimidazol-1-yl)-N-propylthiophene-2-carboxamide	712147	19101	
1.3.5.2	Homo sapiens		5-(1H-indol-1-yl)-N-propylthiophene-2-carboxamide	712147	19100	
1.3.5.2	Plasmodium falciparum		5-(1H-indol-1-yl)-N-propylthiophene-2-carboxamide	712147	19100	
1.3.5.2	Homo sapiens		5-(2-methyl-1H-benzimidazol-1-yl)-N-propylthiophene-2-carboxamide	712147	19102	
1.3.5.2	Plasmodium falciparum		5-(2-methyl-1H-benzimidazol-1-yl)-N-propylthiophene-2-carboxamide	712147	19102	
1.3.5.2	Plasmodium berghei		5-(2-methyl-1H-indol-1-yl)-N-propylthiophene-2-carboxamide	698855	5243	
1.3.5.2	Plasmodium vivax		5-(2-methyl-1H-indol-1-yl)-N-propylthiophene-2-carboxamide	698855	5243	
1.3.5.2	Homo sapiens		5-(2-methyl-1H-indol-1-yl)-N-propylthiophene-2-carboxamide	712147	5243	
1.3.5.2	Plasmodium falciparum		5-(2-methyl-1H-indol-1-yl)-N-propylthiophene-2-carboxamide	698855, 712147	5243	
1.3.5.2	Homo sapiens		5-(4-methylpiperazin-1-yl)-N-propylthiophene-2-carboxamide	712147	19104	
1.3.5.2	Plasmodium falciparum		5-(4-methylpiperazin-1-yl)-N-propylthiophene-2-carboxamide	712147	19104	
1.3.5.2	Homo sapiens		5-(piperidin-1-yl)-N-propylthiophene-2-carboxamide	712147	19105	
1.3.5.2	Plasmodium falciparum		5-(piperidin-1-yl)-N-propylthiophene-2-carboxamide	712147	19105	
1.3.5.2	Plasmodium falciparum		5-aminoorotate	390929	5618	
1.3.5.2	Plasmodium falciparum		5-bromoorotate	390929	5620	
1.3.5.2	Homo sapiens		5-ethyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	27721	
1.3.5.2	Plasmodium falciparum		5-ethyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	27721	
1.3.5.2	Plasmodium falciparum		5-Fluoroorotate	390929	2276	
1.3.5.2	Plasmodium falciparum		5-iodoorotate	390929	6376	
1.3.5.2	Homo sapiens		5-methoxy-2-[(4-phenoxyphenyl)amino]benzoic acid	696289	46198	
1.3.5.2	Homo sapiens		5-methyl-7-(naphthalen-2-yloxy)[1,2,4]triazolo[1,5-a]pyrimidine	712147	27718	
1.3.5.2	Plasmodium falciparum		5-methyl-7-(naphthalen-2-yloxy)[1,2,4]triazolo[1,5-a]pyrimidine	712147	27718	
1.3.5.2	Homo sapiens		5-methyl-7-(naphthalen-2-ylsulfanyl)[1,2,4]triazolo[1,5-a]pyrimidine	712147	27717	
1.3.5.2	Plasmodium falciparum		5-methyl-7-(naphthalen-2-ylsulfanyl)[1,2,4]triazolo[1,5-a]pyrimidine	712147	27717	
1.3.5.2	Plasmodium falciparum		5-methyl-N-(2,3,4-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100625	
1.3.5.2	Plasmodium falciparum		5-methyl-N-(2,4,5-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100626	
1.3.5.2	Plasmodium falciparum		5-methyl-N-(3-methylphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100614	
1.3.5.2	Plasmodium falciparum		5-methyl-N-(4-methylphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100617	
1.3.5.2	Plasmodium falciparum		5-methyl-N-(4-nitrophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100621	
1.3.5.2	Plasmodium falciparum		5-methyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	698938	5907	i.e. DSM1
1.3.5.2	Homo sapiens		5-methyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	5907	
1.3.5.2	Plasmodium falciparum		5-methyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	5907	
1.3.5.2	Plasmodium falciparum		5-methyl-N-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100615	
1.3.5.2	Plasmodium falciparum		5-methyl-N-[4-(trifluoromethoxy)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100619	
1.3.5.2	Plasmodium falciparum		5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine	698938	5245	i.e. DSM74
1.3.5.2	Homo sapiens		5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	5245	
1.3.5.2	Plasmodium falciparum		5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913, 712147	5245	
1.3.5.2	Plasmodium falciparum		5-methyl-N-[4-methyl-3-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100633	
1.3.5.2	Plasmodium falciparum		5-Methylorotate	390929	4373	
1.3.5.2	Bos taurus		5-Methylorotate	391224	4373	
1.3.5.2	Homo sapiens		6-chloro-2-(2'-fluorobiphenyl-4-yl)quinoline-4-carboxylic acid	696289		
1.3.5.2	Homo sapiens		6-methyl-N-phenyl-3aH-inden-4-amine	712147	27716	
1.3.5.2	Plasmodium falciparum		6-methyl-N-phenyl-3aH-inden-4-amine	712147	27716	
1.3.5.2	Homo sapiens		A77 1726	390924	4552	malononitrilamide, 50% inhibition at 18-773 nM
1.3.5.2	Mus musculus		A77 1726	390924	4552	malononitrilamide, 50% inhibition at 18-773 nM
1.3.5.2	Rattus norvegicus		A77 1726	390924	4552	malononitrilamide, 50% inhibition at 18-773 nM
1.3.5.2	Homo sapiens		A77 1726	390926	4552	
1.3.5.2	Rattus norvegicus		A77 1726	390926	4552	
1.3.5.2	Mus musculus		A77 1726	697767	4552	active metabolite of the anti-rheumatic drug leflunomide
1.3.5.2	Drosophila melanogaster		A77-1726	655723	4552	50% inhibition at 0.00045 mM, wild-type, 0.00033 mM, DELTA2-21 mutant, 0.00031 mM, DELTA22-37 mutant, 0.00036 mM, DELTA2-37 mutant
1.3.5.2	Mus musculus		A77-1726	690005	4552	
1.3.5.2	Plasmodium falciparum		atovaquone	390929	5653	
1.3.5.2	Homo sapiens		atovaquone	391242	5653	competitive to quinone
1.3.5.2	Rattus norvegicus		atovaquone	391242	5653	competitive to quinone
1.3.5.2	Rattus norvegicus		atovaquone	657301	5653	50% inhibition at 0.000698 mM, wild-type enzyme, 0.000904 mM, DELTA1-29 mutant
1.3.5.2	Enterococcus faecalis		Barbituric acid	390930	3788	competitive to dihydroorotate, dead-end inhibitor
1.3.5.2	Bos taurus		Barbituric acid	391226	3788	
1.3.5.2	Plasmodium falciparum		benzoquinones	390929		ubiquinone-0 and decylubiquinone
1.3.5.2	Plasmodium falciparum		biphenyl-4-yl-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine	712682		
1.3.5.2	Drosophila melanogaster		brequinar	655723	23077	50% inhibition at 0.567 mM, wild-type, 0.528 mM, DELTA2-21 mutant, 0.615 mM, DELTA22-37 mutant, 0.662 mM, DELTA2-37 mutant
1.3.5.2	Rattus norvegicus		brequinar	657301	23077	50% inhibition at 0.000367 mM, wild-type enzyme, 0.000127 mM, DELTA1-29 mutant
1.3.5.2	Homo sapiens		brequinar	684555	23077	sensitive to brequinar at a 0.01 mM concentration
1.3.5.2	Homo sapiens		brequinar sodium	390921	2623	tight binding, most potent inhibitor, mutant H26A is insensitive, wild-type and other mutants are inhibited by 50% at concentrations between 6 and 10 nM
1.3.5.2	Homo sapiens		brequinar sodium	390922	2623	potent, noncompetitive inhibitor
1.3.5.2	Homo sapiens		brequinar sodium	390924	2623	50% inhibition at 6-127 nM
1.3.5.2	Mus musculus		brequinar sodium	390924	2623	50% inhibition at 6-127 nM
1.3.5.2	Rattus norvegicus		brequinar sodium	390924	2623	50% inhibition at 6-127 nM
1.3.5.2	Bos taurus		brequinar sodium	390925	2623	complete activity termination in all tissues at 0.01 mM
1.3.5.2	Cavia porcellus		brequinar sodium	390925	2623	complete activity termination in all tissues at 0.01 mM
1.3.5.2	Homo sapiens		brequinar sodium	390925	2623	complete activity termination in all tissues at 0.01 mM
1.3.5.2	Mus musculus		brequinar sodium	390925	2623	complete activity termination in all tissues at 0.01 mM
1.3.5.2	Rattus norvegicus		brequinar sodium	390925	2623	complete activity termination in all tissues at 0.01 mM
1.3.5.2	Sus scrofa		brequinar sodium	390925	2623	complete activity termination in all tissues at 0.01 mM
1.3.5.2	Homo sapiens		brequinar sodium	390926	2623	; inbibits by interference with the transfer of electrons from flavin to quinone
1.3.5.2	Rattus norvegicus		brequinar sodium	390926	2623	
1.3.5.2	Homo sapiens		brequinar sodium	391246	2623	competitive versus ubiquinone, uncompetitive versus dihydroorotate, study of kinetics
1.3.5.2	Candida albicans		brequinar sodium	673547	2623	1 mM reduces the activity by more than 50% of the full-length enzyme
1.3.5.2	Plasmodium falciparum		chloronaphthoquinone	390929	63058	
1.3.5.2	Bos taurus		cis-5-methyldihydroorotate	391224	66277	
1.3.5.2	Escherichia coli		deoxycholate	391227	369	
1.3.5.2	Drosophila melanogaster		dichloroallyl lawsone	655723	15012	50% inhibition at 0.00051 mM, wild-type, 0.00031 mM, DELTA2-21 mutant, 0.00020 mM, DELTA22-37 mutant, 0.00021 mM, DELTA2-37 mutant
1.3.5.2	Homo sapiens		dichloroallyl-lawsone	391242	15012	competitive to quinone
1.3.5.2	Rattus norvegicus		dichloroallyl-lawsone	391242	15012	competitive to quinone
1.3.5.2	Plasmodium falciparum		diethyl [(1H-benzimidazol-5-ylamino)methylidene]propanedioate	675315	84478	
1.3.5.2	Plasmodium falciparum		diethyl [(1H-indazol-5-ylamino)methylidene]propanedioate	675315	84475	
1.3.5.2	Plasmodium falciparum		diethyl [(5a,9a-dihydrodibenzo[b,d]thiophen-2-ylamino)methylidene]propanedioate	675315	84474	
1.3.5.2	Plasmodium falciparum		diethyl [(biphenyl-3-ylamino)methylidene]propanedioate	675315	84482	
1.3.5.2	Plasmodium falciparum		diethyl [(biphenyl-4-ylamino)methylidene]propanedioate	675315	84480	
1.3.5.2	Homo sapiens		diethyl [(dibenzo[b,d]thiophen-2-ylamino)methylidene]propanedioate	712147	16798	
1.3.5.2	Plasmodium falciparum		diethyl [(dibenzo[b,d]thiophen-2-ylamino)methylidene]propanedioate	712147	16798	
1.3.5.2	Plasmodium falciparum		diethyl {[(2-methylphenyl)amino]methylidene}propanedioate	675315	84477	
1.3.5.2	Plasmodium falciparum		diethyl {[(4-methylphenyl)amino]methylidene}propanedioate	675315	84476	
1.3.5.2	Homo sapiens		diethyldicarbonate	390921	265	histidine-selective covalent modifier
1.3.5.2	Homo sapiens		diethyldicarbonate	390922	265	histidine-selective covalent modifier; histidine-selective modifying agent, dose-dependent
1.3.5.2	Escherichia coli		Dodecyl sulfate	391227	10561	
1.3.5.2	Plasmodium falciparum		ethyl (2Z)-3-(biphenyl-3-ylamino)-2-cyanoprop-2-enoate	675315	84481	
1.3.5.2	Plasmodium falciparum		ethyl (2Z)-3-(biphenyl-4-ylamino)-2-cyanoprop-2-enoate	675315	84479	
1.3.5.2	Plasmodium berghei		ethyl 4-(4-ethoxybenzyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate	698855	5244	
1.3.5.2	Plasmodium vivax		ethyl 4-(4-ethoxybenzyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate	698855	5244	
1.3.5.2	Homo sapiens		ethyl 4-(4-ethoxybenzyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate	712147	5244	
1.3.5.2	Plasmodium falciparum		ethyl 4-(4-ethoxybenzyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate	698855, 712147	5244	
1.3.5.2	Neurospora crassa		fatty acids	391223	663	noncompetitive with respect to ubiquinone
1.3.5.2	Escherichia coli		fatty acids	391227	663	
1.3.5.2	Plasmodium berghei		Genz-667348	712475	10153	
1.3.5.2	Plasmodium falciparum		Genz-667348	712475	10153	
1.3.5.2	Plasmodium vivax		Genz-667348	712475	10153	
1.3.5.2	Plasmodium berghei		Genz-668857	712475	10154	
1.3.5.2	Plasmodium falciparum		Genz-668857	712475	10154	
1.3.5.2	Plasmodium vivax		Genz-668857	712475	10154	
1.3.5.2	Plasmodium berghei		Genz-669178	712475	10155	
1.3.5.2	Plasmodium falciparum		Genz-669178	712475	10155	
1.3.5.2	Plasmodium vivax		Genz-669178	712475	10155	
1.3.5.2	Enterococcus faecalis		H2O2	390930	20	byproduct, tends to inactivate enzyme
1.3.5.2	Plasmodium falciparum		Lapachol	390929	4872	
1.3.5.2	Homo sapiens		Lapachol	391242	4872	
1.3.5.2	Rattus norvegicus		Lapachol	391242	4872	
1.3.5.2	Plasmodium falciparum		Lawsone	390929	1855	
1.3.5.2	Homo sapiens		Lawsone	391242	1855	
1.3.5.2	Rattus norvegicus		Lawsone	391242	1855	
1.3.5.2	Homo sapiens		leflunomide	390921, 390926	5659	
1.3.5.2	Plasmodium falciparum		menadione	390929	212	
1.3.5.2	Homo sapiens		MNA 279	390924	21827	malononitrilamide, 50% inhibition at 22-715 nM
1.3.5.2	Mus musculus		MNA 279	390924	21827	malononitrilamide, 50% inhibition at 22-715 nM
1.3.5.2	Rattus norvegicus		MNA 279	390924	21827	malononitrilamide, 50% inhibition at 22-715 nM
1.3.5.2	Homo sapiens		MNA 715	390924	21828	malononitrilamide, 50% inhibition at 41-109 nM
1.3.5.2	Mus musculus		MNA 715	390924	21828	malononitrilamide, 50% inhibition at 41-109 nM
1.3.5.2	Rattus norvegicus		MNA 715	390924	21828	malononitrilamide, 50% inhibition at 41-109 nM
1.3.5.2	Rattus norvegicus		more	391221		not: bathophenathroline, sulfonate, ethylendiaminetetraacetate, cyanide, azide
1.3.5.2	Homo sapiens		more	391242		kinetics of inhibition
1.3.5.2	Rattus norvegicus		more	391242		kinetics of inhibition
1.3.5.2	Homo sapiens		more	675294		competitive nature of small molecule inhibitors toward the putative ubiquinone binding site
1.3.5.2	Homo sapiens		more	675315		DHODH-specific inhibitors with low nanomolar binding affinities bind in the N-terminal hydrophobic channel of dihydroorotate dehydrogenase, the presumed site of ubiquinone binding during oxidation of dihydroorotate to orotate
1.3.5.2	Plasmodium falciparum		more	675315		DHODH-specific inhibitors with low nanomolar binding affinities bind in the N-terminal hydrophobic channel of dihydroorotate dehydrogenase, the presumed site of ubiquinone binding during oxidation of dihydroorotate to orotate
1.3.5.2	Plasmodium falciparum		more	711913		development and evaluation of triazolopyrimidine-based DHODH inhibitors, overview. Detailed quantitative structure-activity relationship study and molecular docking studies, the 2-methyltriazolopyrimidine ring interacts with some polar and some nonpolar amino acids whereas the substituted phenyl ring binds with a hydrophobic pocket of the enzyme formed by some nonpolar amino acid residues, overview
1.3.5.2	Homo sapiens		more	712147		screening for potent inhibitors of PfDHODH and effect on the human enzyme, overview. The compiunds show strong selectivity for the malarial enzyme over that from the human host, inhibition mechanism, overview
1.3.5.2	Plasmodium falciparum		more	712147		screening for potent inhibitors of PfDHODH that show strong selectivity for the malarial enzyme over that from the human host. Lead optimization of a triazolopyrimidine-based series, inhibition mechanism, overview
1.3.5.2	Plasmodium berghei		more	712475		drug screening and identification of a series of N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides with low nanomolar in vitro potency against DHODH, selective for the parasite enzymes over human DHODH, tolerability in the mouse, overview
1.3.5.2	Plasmodium falciparum		more	712475		drug screening and identifictaion of a series of N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides with low nanomolarin vitro potency against DHODH, selective for the parasite enzymes over human DHODH, tolerability in the mouse, overview
1.3.5.2	Plasmodium vivax		more	712475		drug screening and identification of a series of N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides with low nanomolar in vitro potency against DHODH, selective for the parasite enzymes over human DHODH, tolerability in the mouse, overview
1.3.5.2	Plasmodium falciparum		more	712682		identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice, overview
1.3.5.2	Toxoplasma gondii		more	725919		not inhibitory: brequinar, atovaquone, N-(3,5-difluoro-4-(trifluoromethyl)phenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
1.3.5.2	Plasmodium falciparum		N-(2,3-difluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100624	
1.3.5.2	Plasmodium falciparum		N-(2,4-dichlorophenyl)-2-naphthamide	656285	19096	50% inhibition at 0.00005 mM, wild type, 0.00008 mM, mutant R265A, above 0.05, mutant H185A
1.3.5.2	Homo sapiens		N-(2,4-dichlorophenyl)naphthalene-2-carboxamide	712147	19096	
1.3.5.2	Plasmodium falciparum		N-(2,4-dichlorophenyl)naphthalene-2-carboxamide	712147	19096	
1.3.5.2	Homo sapiens		N-(2-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	27723	
1.3.5.2	Plasmodium falciparum		N-(2-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	27723	
1.3.5.2	Plasmodium falciparum		N-(2-fluoro-4-methylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100627	
1.3.5.2	Plasmodium falciparum		N-(2-fluorophenyl)-2-naphthamide	656285	79543	50% inhibition at 0.00047 mM, wild type, 0.00030 mM, mutant R265A, 0.21, mutant H185A
1.3.5.2	Homo sapiens		N-(2-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	27722	
1.3.5.2	Plasmodium falciparum		N-(2-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	27722	
1.3.5.2	Plasmodium falciparum		N-(3,4-dichlorophenyl)-2-methyl-3-nitrobenzamide	656285	36321	50% inhibition at 0.00008 mM, wild type, 0.0028 mM, mutant R265A, 0.06, mutant H185A
1.3.5.2	Plasmodium falciparum		N-(3,4-difluorophenyl)-2-methyl-3-nitrobenzamide	656285	36319	50% inhibition at 0.00026 mM, wild type, 0.00082 mM, mutant R265A, 0.25, mutant H185A
1.3.5.2	Plasmodium falciparum		N-(3,4-difluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100628	
1.3.5.2	Plasmodium falciparum		N-(3,4-dimethylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100634	
1.3.5.2	Plasmodium falciparum		N-(3,5-dichloro-phenyl)-2-methyl-3-nitro-benzamide	696249	8064	
1.3.5.2	Plasmodium falciparum		N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide	656285	8064	50% inhibition at 0.00002 mM, wild type, 0.0004 mM, mutant R265A, 0.13, mutant H185A
1.3.5.2	Homo sapiens		N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide	712147	8064	
1.3.5.2	Plasmodium falciparum		N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide	712147	8064	
1.3.5.2	Plasmodium falciparum		N-(3,5-difluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100629	
1.3.5.2	Plasmodium falciparum		N-(3-bromophenyl)-2-methyl-3-nitrobenzamide	656285	36317	50% inhibition at 0.00006 mM, wild type, 0.0012 mM, mutant R265A, 0.140, mutant H185A
1.3.5.2	Toxoplasma gondii		N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide	725919		
1.3.5.2	Plasmodium falciparum		N-(3-chloro-4-fluorophenyl)-2-methyl-3-nitrobenzamide	656285	36318	50% inhibition at 0.0001 mM, wild type, 0.0005 mM, mutant R265A, 0.13, mutant H185A
1.3.5.2	Homo sapiens		N-(3-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	12923	
1.3.5.2	Plasmodium falciparum		N-(3-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913, 712147	12923	
1.3.5.2	Plasmodium falciparum		N-(3-fluoro-4-methylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100636	
1.3.5.2	Homo sapiens		N-(3-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	12922	
1.3.5.2	Plasmodium falciparum		N-(3-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913, 712147	12922	
1.3.5.2	Plasmodium falciparum		N-(4-benzylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100623	
1.3.5.2	Plasmodium falciparum		N-(4-bromo-2-methylphenyl)-2-naphthamide	656285	36316	50% inhibition at 0.00005 mM, wild type, 0.00005 mM, mutant R265A, 0.57, mutant H185A
1.3.5.2	Homo sapiens		N-(4-bromophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	19099	
1.3.5.2	Plasmodium falciparum		N-(4-bromophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913, 712147	19099	
1.3.5.2	Plasmodium falciparum		N-(4-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100616	
1.3.5.2	Plasmodium falciparum		N-(4-fluoro-3-methylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100630	
1.3.5.2	Homo sapiens		N-(4-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	19098	
1.3.5.2	Plasmodium falciparum		N-(4-fluorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913, 712147	19098	
1.3.5.2	Plasmodium falciparum		N-(4-methoxyphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100618	
1.3.5.2	Mus musculus		N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide	690005	5659	Leflunomide
1.3.5.2	Homo sapiens		N-(anthracen-2-yl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	12595	
1.3.5.2	Plasmodium falciparum		N-(anthracen-2-yl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	12595	
1.3.5.2	Homo sapiens		N-(anthracen-2-yl)-N,5-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	27720	
1.3.5.2	Plasmodium falciparum		N-(anthracen-2-yl)-N,5-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	27720	
1.3.5.2	Plasmodium falciparum		N-(biphenyl-4-yl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100622	
1.3.5.2	Plasmodium falciparum		N-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	698938	12595	i.e. DSM2
1.3.5.2	Plasmodium berghei		N-cyclopropyl-5-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)thiophene-2-carboxamide	698855		
1.3.5.2	Plasmodium falciparum		N-cyclopropyl-5-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)thiophene-2-carboxamide	698855		
1.3.5.2	Plasmodium vivax		N-cyclopropyl-5-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)thiophene-2-carboxamide	698855		
1.3.5.2	Homo sapiens		N-propyl-5-(1H-pyrazol-1-yl)thiophene-2-carboxamide	712147	19103	
1.3.5.2	Plasmodium falciparum		N-propyl-5-(1H-pyrazol-1-yl)thiophene-2-carboxamide	712147	19103	
1.3.5.2	Homo sapiens		N-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	712147	12921	
1.3.5.2	Plasmodium falciparum		N-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913, 712147	12921	
1.3.5.2	Plasmodium falciparum		N-[4-(difluoromethoxy)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100620	
1.3.5.2	Plasmodium falciparum		N-[4-bromo-3-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100632	
1.3.5.2	Plasmodium falciparum		N-[4-chloro-3-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	711913	100631	
1.3.5.2	Escherichia coli		Orotate	390918	373	competitive to dihydroorotate
1.3.5.2	Cavia porcellus		Orotate	390925	373	
1.3.5.2	Mus musculus		Orotate	390925	373	
1.3.5.2	Rattus norvegicus		Orotate	390925	373	
1.3.5.2	Sus scrofa		Orotate	390925	373	
1.3.5.2	Plasmodium falciparum		Orotate	390929	373	also inhibitors: 5-substituted orotates; competitive to dihydroorotate; strong competitive inhibitor
1.3.5.2	Enterococcus faecalis		Orotate	390930	373	
1.3.5.2	Neurospora crassa		Orotate	391223	373	
1.3.5.2	Bos taurus		Orotate	391224	373	competitive to dihydroorotate
1.3.5.2	Bos taurus		Orotate	390925, 391226	373	
1.3.5.2	Escherichia coli		Orotate	391227	373	
1.3.5.2	Trypanosoma cruzi		oxonate	696221	4167	crystallization data
1.3.5.2	Homo sapiens		redoxal	390924	5664	50% inhibition at 45-88 nM
1.3.5.2	Mus musculus		redoxal	390924	5664	50% inhibition at 45-88 nM
1.3.5.2	Rattus norvegicus		redoxal	390924	5664	50% inhibition at 45-88 nM
1.3.5.2	Drosophila melanogaster		redoxal	655723	5664	50% inhibition at 0.029 mM, wild-type, 0.057 mM, DELTA2-21 mutant, 0.040 mM, DELTA22-37 mutant, 0.056 mM, DELTA2-37 mutant
1.3.5.2	Homo sapiens		redoxal	656088	5664	50% inhibition at 0.000013 mM, N-terminally truncated protein
1.3.5.2	Plasmodium falciparum		redoxal	656088	5664	50% inhibition at 0.071 mM, N-terminally truncated protein
1.3.5.2	Candida albicans		redoxal	673547	5664	0.5 mM exhibit an inhibitory effect of more than 50% on full-length DHODH and N-terminally truncated DHODH compared with the noninhibited reaction
1.3.5.2	Plasmodium falciparum		rhodamine 123	390929	4993	mitochondrial inhibitor
1.3.5.2	Homo sapiens		teriflunomide	712071	4552	a redox-silent coenzyme Q antagonist of DHODH
1.3.5.2	Rattus norvegicus		Thenoyltrifluoroacetone	391221	3760	
1.3.5.2	Bos taurus		Thenoyltrifluoroacetone	391224	3760	
1.3.5.2	Bos taurus		toltrazuril	390925	8782	50% inhibition at 0.1 mM
1.3.5.2	Cavia porcellus		toltrazuril	390925	8782	50% inhibition at 0.1 mM
1.3.5.2	Homo sapiens		toltrazuril	390925	8782	50% inhibition at 0.1 mM
1.3.5.2	Mus musculus		toltrazuril	390925	8782	50% inhibition at 0.1 mM
1.3.5.2	Rattus norvegicus		toltrazuril	390925	8782	50% inhibition at 0.1 mM
1.3.5.2	Sus scrofa		toltrazuril	390925	8782	50% inhibition at 0.1 mM
1.3.5.2	Mus musculus		[2-fluoro-2',5'-dimethyl-4'-[6-(3-methyl-2-butenyloxy)pyridin-3-yl]biphenyl-4-yl]-(3-methyl-2-butenyl)amine	697767	17932	i.e. S-2678, suppresses immunoglobulin production in mouse B cells in vitro, with little or no inhibition of cell proliferation, probably through inhibitionof class switch recombination in the immunoglobulin heavy chain loci in B cells. In vivo antibody production induced by systemic immunization with ovalbumin is dramatically suppressed by oral administration of S-2678, without any toxicological signs. S-2678 does not affect T-cell activation in vitro, and cytokine production induced by intravenous anti-CD3 antibody in mice. S-2678 does not affect host defense in a mouse model of Candida infection, whereas leflunomide severely impaires it
2.5.1.31	Lactobacillus plantarum	capric acid		637484	1286	enhancement factor: 0.04 in absence of Triton X-100, 1.0 in presence of 0.1% Triton X-100
2.5.1.31	Lactobacillus plantarum	cardiolipin		637475	652	Lactobacillus plantarum, Escherichia coli, and bovine cardiolipin. Good activator in absence of detergent
2.5.1.31	Micrococcus luteus	cardiolipin		637475	652	weak stimulation
2.5.1.31	Micrococcus luteus	cardiolipin		637476	652	marked effect in activating lipid-depleted enzyme
2.5.1.31	Micrococcus luteus	cardiolipin		637481	652	poor activator
2.5.1.31	Lactobacillus plantarum	cardiolipin		637483	652	activates
2.5.1.31	Lactobacillus plantarum	cardiolipin		637484	652	from bovine, enhancement factor: 0.8 in absence of Triton X-100, 0.1 in presence of 0.1% Triton X-100
2.5.1.31	Lactobacillus plantarum	cetyl sulfate		637475	33301	half-maximal activation at 0.04 mM
2.5.1.31	Lactobacillus plantarum	cetyl sulfate		637484	33301	activates
2.5.1.31	Bacillus subtilis	deoxycholate		637475	369	weak stimulation
2.5.1.31	Lactobacillus plantarum	deoxycholate		637475	369	half-maximal activation at 0.33 mM
2.5.1.31	Micrococcus luteus	deoxycholate		637475	369	weak stimulation
2.5.1.31	Lactobacillus plantarum	deoxycholate		637480	369	maximal stimulation at 0.2% v/v or 4.8 mM
2.5.1.31	Micrococcus luteus	deoxycholate		637481	369	poor activator
2.5.1.31	Lactobacillus plantarum	deoxycholate		637484	369	activates
2.5.1.31	Lactobacillus plantarum	dipalmitoylphosphatidic acid		637484	19875	enhancement factor: 0.2 in absence of Triton X-100, 1.2 in presence of 0.1% Triton X-100
2.5.1.31	Lactobacillus plantarum	Dodecyl sulfate		637475	10561	half-maximal activation at 0.075 mM
2.5.1.31	Lactobacillus plantarum	Dodecyl sulfate		637484	10561	activates
2.5.1.31	Lactobacillus plantarum	lauric acid		637484	711	enhancement factor: 0.1 in absence of Triton X-100, 2.3 in presence of 0.1% Triton X-100
2.5.1.31	Bacillus subtilis	lecithin		637475	190	weak stimulation
2.5.1.31	Micrococcus luteus	lecithin		637475	190	from egg, stimulates
2.5.1.31	Micrococcus luteus	lecithin		637481	190	14fold stimulation at 2 mM; from egg, stimulates
2.5.1.31	Micrococcus luteus	lysophosphatidylglycerol		637476	7208	weak effect in activating lipid-depleted enzyme
2.5.1.31	Micrococcus luteus	more		637481		enzyme is inactive in absence of added effectors
2.5.1.31	Lactobacillus plantarum	myristic acid		637483	691	activates
2.5.1.31	Lactobacillus plantarum	myristic acid		637484	691	activates; enhancement factor: 0.2 in absence of Triton X-100, 2.1 in presence of 0.1% Triton X-100
2.5.1.31	Lactobacillus plantarum	oleic acid		637475	320	good activator in absence of detergent
2.5.1.31	Lactobacillus plantarum	oleic acid		637484	320	enhancement factor: 0.9 in absence of Triton X-100, 1.3 in presence of 0.1% Triton X-100
2.5.1.31	Lactobacillus plantarum	palmitic acid		637484	431	enhancement factor: 0.8 in absence of Triton X-100, 1.4 in presence of 0.1% Triton X-100
2.5.1.31	Lactobacillus plantarum	phosphatidic acid		637475	408	from egg, good activator in absence of detergent
2.5.1.31	Lactobacillus plantarum	phosphatidic acid		637484	408	enhancement factor: 0.8 in absence of Triton X-100, 1.0 in presence of 0.1% Triton X-100; from egg, good activator in absence of detergent
2.5.1.31	Micrococcus luteus	phosphatidylglycerol		637476	550	marked effect in activating lipid-depleted enzyme
2.5.1.31	Lactobacillus plantarum	phosphatidylserine		637484	358	enhancement factor: 0.05 in absence of Triton X-100, 0.4 in presence of 0.1% Triton X-100
2.5.1.31	Micrococcus luteus	Phospholipid		637481	528	phospholipid extract from Micrococcus luteus stimulates
2.5.1.31	Escherichia coli	Phospholipid		637485	528	
2.5.1.31	Bacillus subtilis	Polyamines		637474		stimulate in presence of Mg2+
2.5.1.31	Bacillus subtilis	putrescine		637474	144	stimulates
2.5.1.31	Lactobacillus plantarum	stearic acid		637484	663	enhancement factor: 0.07 in absence of Triton X-100, 0.8 in presence of 0.1% Triton X-100
2.5.1.31	Lactobacillus plantarum	trans,trans,trans-geranylgeranyl diphosphate		637483	205	stimulates activity with farnesyl diphosphate as substrate
2.5.1.31	Lactobacillus plantarum	trans,trans-farnesyl diphosphate		637483	76	stimulates activity with farnesyl diphosphate as substrate
2.5.1.31	Escherichia coli	Triton		637485	57	0.01 microM of UPPs with 5 microM of (2E,6E)-farnesyl diphosphate and 50 microM of isopentenyl diphosphate, 0.5 mM MgCl2, and 50 mM KCl in Hepes buffer (pH 7.5) is 190fold less active (0.013 s-1) for the IPP consumption in the absence of Triton; the UPPs steady-state kcat value in the presence of 0.1% Triton is 190fold larger than in the absence of Triton
2.5.1.31	Bacillus subtilis	Triton X-100		637474	57	
2.5.1.31	Bacillus subtilis	Triton X-100		637475	57	strong stimulation
2.5.1.31	Lactobacillus plantarum	Triton X-100		637475	57	half-maximal activation at 3.4 mM
2.5.1.31	Micrococcus luteus	Triton X-100		637476	57	marked decrease of activity when a small amount of detergent is added, activity gradually increases as further detergent is added, being fully restored when the concentration reaches 2%
2.5.1.31	Lactobacillus plantarum	Triton X-100		637477	57	activates; requirement for Triton X-series detergents
2.5.1.31	Micrococcus luteus	Triton X-100		637475, 637481	57	stimulates
2.5.1.31	Escherichia coli	Triton X-100		637482	57	no activity in absence; no activity in the activation by Triton X-100 is almost saturated at a concentration of 0.02%
2.5.1.31	Lactobacillus plantarum	Triton X-100		637480, 637483	57	activates
2.5.1.31	Escherichia coli	Triton X-100		659232	57	1.5% v/v, 2 molecules are bound in the active site tunnel of the beta-subunit, binding structure
2.5.1.31	Escherichia coli	Triton X-100		673055	57	
2.5.1.31	Micrococcus luteus	Triton X-100		673055	57	
2.5.1.31	Lactobacillus plantarum	Triton X-102		637477		stimulates
2.5.1.31	Lactobacillus plantarum	Triton X-114		637477	3847	stimulates
2.5.1.31	Lactobacillus plantarum	Triton X-45		637477		stimulates
2.5.1.31	Bacillus subtilis	Tween 80		637474	428	stimulates
2.5.1.31	Bacillus subtilis	Tween 80		637475	428	strong stimulation
2.5.1.31	Escherichia coli		(2E,6E)-farnesyl thiodiphosphate	637494	3950	(2E,6E)-farnesyl diphosphate analogue
2.5.1.31	Streptococcus pneumoniae		(2E,6E)-farnesyl thiodiphosphate	707529	3950	substrate analogue
2.5.1.31	Bacillus subtilis		(2E,6E,10E)-4-methylfarnesyl diphosphate	708500	56258	competitive inhibitor against (2Z,6E,10E)-geranylgeranyl diphosphate
2.5.1.31	Bacillus subtilis		(2Z,6E,10E)-4-methyl-geranylgeranyl diphosphate	708500	27276	allylic substrate homologue, competitive inhibitor against the allylic primer. It also acts as a strong noncompetitive inhibitor against isopentenyl diphosphate
2.5.1.31	Streptococcus pneumoniae		(4aS,8aS)-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro[1,6]naphthyridine-3-carboxylic acid (4-piperidin-1-ylphenyl)amide	707529	98811	
2.5.1.31	Bacillus subtilis		(E)-3-methyl-3-pentenyl diphosphate	708500	18608	reactive as substrate and competitive inhibition profile
2.5.1.31	Escherichia coli		(E,E)-[1-3H]-(2-diazo-3-trifluoropropionyloxy)geranyl diphosphate	708911	98810	
2.5.1.31	Escherichia coli		(S)-farnesyl thiodiphosphate	708864	3950	an extremely poor substrate for UPPs
2.5.1.31	Lactobacillus plantarum		1,2-Cyclohexanedione	637473	1706	; 
2.5.1.31	Lactobacillus plantarum		1,2-Cyclohexanedione	637475	1706	
2.5.1.31	Micrococcus luteus		3-desmethyl (2Z,6E,10E)-geranylgeranyl diphosphate	685691	25185	mixed inhibition with farnesyl diphosphate, competitive inhibition with reaction intermediate (2Z,6E,10E)-geranylgeranyl diphosphate
2.5.1.31	Micrococcus luteus		3-desmethyl farnesyl diphosphate	685691	12387	competitive with farnesyl diphosphate, mixed inhibition with reaction intermediate (2Z,6E,10E)-geranylgeranyl diphosphate; competitive with farnesyl diphosphate, mixed inhibition with reaction intermediate (Z,E,E)-geranylgeranyl diphosphate
2.5.1.31	Micrococcus luteus		3-desmethyl Z-geranylgeranyl diphosphate	685691	25185	mixed inhibition with farnesyl diphosphate, competitive inhibition with reaction intermediate (Z,E,E)-geranylgeranyl diphosphate
2.5.1.31	Escherichia coli		3-[5-(5,6-dihydrobenzimidazo[1,2-c]quinazolin-6-yl)-2,5-dihydrofuran-2-yl]benzenesulfonamide	699031	5179	barely inhibits UPPS of Escherichia coli; i.e. HTS04781. contrary to Helicobacter pylori, HTS04781 is almost not inhibitory in Escherichia coli
2.5.1.31	Helicobacter pylori		3-[5-(5,6-dihydrobenzimidazo[1,2-c]quinazolin-6-yl)-2,5-dihydrofuran-2-yl]benzenesulfonamide	699031	5179	; i.e. HTS04781, crystallization data. The sulfonamide group forms H-bonds with Gly16 and Arg26 and the N atom in the tetracyclic ring is hydrogen bound to the main chain of Met12. Extensive hydrophobic interactions are found between the tetracyclic ring with the surrounding residues including Met12, His30, Gly33 and Val34
2.5.1.31	Escherichia coli		3-[5-(5,6-dihydrobenzimidazo[1,2-c]quinazolin-6-yl)-2,5-dihydrofuran-2-yl]benzenesulfonamide	704720	5179	barely inhibits UPPS of Escherichia coli
2.5.1.31	Helicobacter pylori		3-[5-(5,6-dihydrobenzimidazo[1,2-c]quinazolin-6-yl)-2,5-dihydrofuran-2-yl]benzenesulfonamide	704720	5179	
2.5.1.31	Streptococcus pneumoniae		5-benzyl-4-hydroxy-5-methyl-2-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid (4-cyclohexylphenyl)amide	707529	56259	
2.5.1.31	Escherichia coli		7-(2,6-dimethyl-8-diphospho-2,6-octadienyloxy)-8-methyl-4-trifluoromethyl-chromen-2-one geranyl diphosphate	708864	109273	competitive inhibitor, substrate analogue prepared and utilized to study ligand interactions
2.5.1.31	Escherichia coli		BPH-629	676880	24312	potent inhibitor
2.5.1.31	Escherichia coli		BPH-629	721794	24312	bindiing structure in enzyme chain B, overview
2.5.1.31	Lactobacillus plantarum		Butanedione	637473	603	; 
2.5.1.31	Lactobacillus plantarum		Butanedione	637475	603	
2.5.1.31	Streptococcus pneumoniae		dihydropyridin-2-one	721794		
2.5.1.31	Lactobacillus plantarum		EDTA	637477	223	
2.5.1.31	Micrococcus luteus		EDTA	637491	223	
2.5.1.31	Escherichia coli		farnesyl thiodiphosphate	659476, 721275	3950	
2.5.1.31	Lactobacillus plantarum		iodoacetate	637475	87	
2.5.1.31	Streptococcus pneumoniae		isopentyl thiodiphosphate	707529	98812	substrate analogue
2.5.1.31	Escherichia coli		Mg2+	659476	25	inhibitory at high concentrations of e.g. 50 mM; inhibitory at high concentrations of e.g. 50 mM
2.5.1.31	Lactobacillus plantarum		more	637475, 637477		no inhibition by phosphate
2.5.1.31	Escherichia coli		more	657857		farnesol (1 mM) lacking the diphosphate does not inhibit the UPPS reaction; no inhibition by farnesol
2.5.1.31	Helicobacter pylori		more	699031		virtual screening of inhibitors from a library of 58635 compounds performed
2.5.1.31	Streptococcus pneumoniae		more	707529		tetramic acids are selective and potent inhibitors of UPPS
2.5.1.31	Bacillus subtilis		more	708500		Z-isomer ZHIPP, (Z)-3-methyl-3-pentenyl diphosphate, which is not accepted as substrate by the enzyme, exhibited no inhibition on the synthase reaction
2.5.1.31	Escherichia coli		N,N'-bis(6-chloro-1,3-benzothiazol-2-yl)methanedisulfonamide	699031	4255	; i.e. BTB06061
2.5.1.31	Helicobacter pylori		N,N'-bis(6-chloro-1,3-benzothiazol-2-yl)methanedisulfonamide	699031	4255	; i.e. BTB06061, crystallization data. The sulfur atom in the thiazole ring of BTB06061 may form H-bonds with Asn15 and His30 while the SO2 group is hydrogen bound with Met12. The aromatic rings of BTB06061 form hydrophobic interactions with the surrounding hydrophobic residues, including Val34, Leu37, Ala56 and Tyr79
2.5.1.31	Escherichia coli		N,N'-bis(6-chloro-1,3-benzothiazol-2-yl)methanedisulfonamide	704720	4255	barely inhibits UPPS of Escherichia coli
2.5.1.31	Helicobacter pylori		N,N'-bis(6-chloro-1,3-benzothiazol-2-yl)methanedisulfonamide	704720	4255	
2.5.1.31	Bacillus subtilis		NH4+	637474	50	20 mM, 20% inhibition
2.5.1.31	Lactobacillus plantarum		Phenylglyoxal	637473	258	; 
2.5.1.31	Lactobacillus plantarum		Phenylglyoxal	637475	258	
2.5.1.31	Escherichia coli		S-farnesyl thiodiphosphate	637494	3950	
2.5.1.31	Micrococcus luteus		SO42-	637492	148	competitive inhibitor with respect to (2E,6E)-farnesyl diphosphate; competitive inhibitor with respect to farnesyl diphosphate
2.5.1.31	Penicillium brasilianum		spirohexaline	722468	61714	
2.5.1.31	Micrococcus luteus		tetramic acid	721794		the crystal structure is used for modelling with bound inhibitor tetramic acid
2.5.1.31	Streptococcus pneumoniae		tetramic acid	721794		binding structure, overview
2.5.1.31	Streptococcus pneumoniae		tetronic acid	721794		
2.5.1.31	Micrococcus luteus		Triton X-100	637476	57	marked decrease of activity when a small amount of detergent is added, activity gradually increases as further detergent is added, being fully restored when the concentration reaches 2%
2.5.1.31	Lactobacillus plantarum		Triton X-100	637480	57	inhibition at concentration above 1%
2.5.1.31	Escherichia coli		Triton X-100	721794	57	C55 is retained in the active site for further elongation, whereas the kcat is increased by 190fold under steady-state condition by 0.1% Triton X-100
2.5.1.31	Penicillium brasilianum		viridicatumtoxin	722468	61715	
2.3.1.30	Escherichia coli DH5[alpha]		2-amino-9-(naphthalen-2-yl)-9H-purin-6-ol	704098	51414	0.05 microg/microl showing 38% inhibition in the presence of 0.10 mM acetyl-CoA, binding to active site
2.3.1.30	Entamoeba histolytica		2-amino-9-naphthalen-2-yl-9H-purin-6-ol	704098	51414	
2.3.1.30	Escherichia coli DH5[alpha]		3-oxo-2-phenyl-3,5-dihydro-2H-pyrazolo[3,4-d]thieno[2,3-b]pyridine-7-carboxylate	704098	17687	most potent inhibitor, 0.05 microg/microl showing 50% inhibition in the presence of 0.10 mM acetyl-CoA, binding to active site, increasing Km, decreasing Vmax
2.3.1.30	Entamoeba histolytica		3-oxo-2-phenyl-3,5-dihydro-2H-pyrazolo[3,4-d]thieno[2,3-b]pyridine-7-carboxylic acid	704098	17687	
2.3.1.30	Escherichia coli DH5[alpha]		4,10-dihydroxy-1,7-phenanthroline-3,9-dicarboxylate	704098	51413	0.05 microg/microl showing 24% inhibition in the presence of 0.10 mM acetyl-CoA, binding to active site
2.3.1.30	Entamoeba histolytica		4,10-dihydroxy-1,7-phenanthroline-3,9-dicarboxylic acid	704098	51413	
2.3.1.30	Escherichia coli		ATP	657835	7	mixed non-competitive with respect to serine
2.3.1.30	Paracoccus denitrificans		CoA	34691	10	weak
2.3.1.30	Phaseolus vulgaris		CoA	486753	10	
2.3.1.30	Citrullus lanatus subsp. vulgaris		CoA	486762	10	
2.3.1.30	Escherichia coli		CoA	486778	10	
2.3.1.30	Escherichia coli		cysteine	657835	70	competitive versus acetyl-CoA, mixed non-competitive with respect to serine
2.3.1.30	Escherichia coli		cysteine	659391	70	competitive, binds at the serine substrate site, negatively regulates its own synthesis
2.3.1.30	Arabidopsis thaliana		cysteine	706161	70	feedback inhibition; feedback inhibition
2.3.1.30	Entamoeba histolytica		cysteine	719916	70	competitive inhibitor of Ser
2.3.1.30	Paracoccus denitrificans		D-Cysteine	34691	1022	
2.3.1.30	Phaseolus vulgaris		D-Cysteine	486753	1022	
2.3.1.30	Trypanosoma cruzi		D-Cysteine	486773	1022	no inhibition
2.3.1.30	Thermus thermophilus HB8		EDTA	659095	223	1.0 mM, complete inhibition
2.3.1.30	Trypanosoma cruzi		glutathione	486773	41	weak, allosteric inhibition
2.3.1.30	Salmonella enterica subsp. enterica serovar Typhimurium		glycine	486761	68	competitive against L-serine, noncompetitive against acetyl-CoA
2.3.1.30	Escherichia coli		glycine	486778	68	competitive against L-serine, noncompetitive against acetyl-CoA
2.3.1.30	Haemophilus influenzae		glycine	657672	68	competitive versus L-serine, uncompetitive versus acetyl-CoA
2.3.1.30	Escherichia coli		glycine	657835	68	mixed non-competitive inhibitor of propionyl transfer to serine with respect to propionyl-CoA
2.3.1.30	Paracoccus denitrificans		hydroxylamine	34691	80	
2.3.1.30	Phaseolus vulgaris		hydroxylamine	486753	80	
2.3.1.30	Paracoccus denitrificans		iodoacetamide	34691	63	
2.3.1.30	Paracoccus denitrificans		KCN	34691	149	
2.3.1.30	Escherichia coli		L-alanine	486778	97	noncompetitive against acetyl-CoA
2.3.1.30	Escherichia coli		L-Cys	676935	70	
2.3.1.30	Escherichia coli		L-cysteic acid	486752	2703	
2.3.1.30	Paracoccus denitrificans		L-cysteine	34691	70	
2.3.1.30	Phaseolus vulgaris		L-cysteine	486753	70	
2.3.1.30	Salmonella enterica subsp. enterica serovar Typhimurium		L-cysteine	486752, 486756	70	
2.3.1.30	Citrullus lanatus subsp. vulgaris		L-cysteine	486762	70	allosteric inhibition
2.3.1.30	Cyanidioschyzon merolae		L-cysteine	486767	70	
2.3.1.30	Arabidopsis thaliana		L-cysteine	486768	70	
2.3.1.30	Citrullus lanatus subsp. vulgaris		L-cysteine	486768	70	recombinant wild-type and mutants, not mutant M280I, inhibitor binding motif
2.3.1.30	Spinacia oleracea		L-cysteine	486772	70	
2.3.1.30	Trypanosoma cruzi		L-cysteine	486773	70	allosteric inhibition
2.3.1.30	Allium tuberosum		L-cysteine	486775	70	feed-back inhibition; weak
2.3.1.30	Arabidopsis thaliana		L-cysteine	486765, 486775	70	feed-back inhibition of cytosolic isozyme SAT-c, not of mitochondrial and plastidic isozymes SAT-m and SAT-p
2.3.1.30	Citrullus lanatus subsp. vulgaris		L-cysteine	486775	70	feed-back inhibition
2.3.1.30	Spinacia oleracea		L-cysteine	486775	70	feed-back inhibition
2.3.1.30	Escherichia coli		L-cysteine	486752, 486756, 486757, 486777	70	
2.3.1.30	Haemophilus influenzae		L-cysteine	657672	70	dead-end inhibitor, competitive against botn substrates in both reaction directions
2.3.1.30	Allium cepa		L-cysteine	660107	70	IC50: 0.0031 mM
2.3.1.30	Arabidopsis thaliana		L-cysteine	660253	70	feedback inhibition, isoform Serat3,1, noncompetitive versus L-serine, competitive versus acetyl-CoA
2.3.1.30	Pisum sativum		L-cysteine	660267	70	under physiological conditions L-cysteine specifically inhibits chloroplast enzyme activity, which is linked to the sulfate assimilation network. This metabolic feedback control does not apply to the enzyme activity located in cytosol
2.3.1.30	Glycine max		L-cysteine	660305	70	competitive in response to acetyl-CoA, noncompetitive in presence of L-Ser
2.3.1.30	Entamoeba histolytica		L-cysteine	705594	70	0.03 mM, 0.5 mM, and 1 mM, strong inhibition, 5-500 microM L-cysteine in the presence of 0.5 mM L-serine inhibits the enzyme remarkably, much less but still significantly in the presence of 3 mM L-serine, 90% inhibition by 0.3 mM L-cysteine with 3 mM L-serine (as found in throphozoite culture), acetyl-CoA concentration influences the inhibitory efficiency as well; 0.5 mM inhibits by 75.3%, no inhibition with 0.03 mM, 1 mM not determined, 20% inhibition by 0.3 mM L-cysteine with 3 mM L-serine (as found in throphozoite culture); 1 mM, weak inhibition, no inhibition by 0.3 mM L-cysteine with 3 mM L-serine (as found in throphozoite culture) or at other L-cysteine concentrations from 10-1000 micoM in the presence of 3 mM L-serine
2.3.1.30	Trypanosoma cruzi		L-cystine	486773	923	allosteric inhibition
2.3.1.30	Paracoccus denitrificans		L-homocysteine	34691	260	weak
2.3.1.30	Phaseolus vulgaris		L-homocysteine	486753	260	weak
2.3.1.30	Trypanosoma cruzi		L-homocysteine	486773	260	weak
2.3.1.30	Paracoccus denitrificans		L-homoserine	34691	294	weak
2.3.1.30	Trypanosoma cruzi		L-homoserine	486773	294	weak
2.3.1.30	Paracoccus denitrificans		L-methionine	34691	83	
2.3.1.30	Phaseolus vulgaris		L-methionine	486753	83	weak
2.3.1.30	Glycine max		L-Ser	660305	89	
2.3.1.30	Escherichia coli		L-serine	486752	89	above 3 mM, weak
2.3.1.30	Salmonella enterica subsp. enterica serovar Typhimurium		L-serine	486752	89	
2.3.1.30	Salmonella enterica subsp. enterica serovar Typhimurium		L-serine	486761	89	product inhibition, competitive against CoA and noncompetitive against O-acetyl-L-serine
2.3.1.30	Haemophilus influenzae		L-serine	657672	89	product inhibition is noncompetitive with respect to O-acetyl-L-serine and CoA
2.3.1.30	Citrullus lanatus subsp. vulgaris		more	486762		beta-(pyrazol-1-yl)-L-alanine has no inhibitory effect
2.3.1.30	Escherichia coli		more	486778		no inhibition by N-acetylserine
2.3.1.30	Arabidopsis thaliana		more	660253		isoform Serat3,1 is insensitive to feedback inhibition by L-Cys
2.3.1.30	Mus musculus		more	704098		no growth inhibition of mouse cell culture with 4,10-dihydroxy-1,7-phenanthroline-3,9-dicarboxylic acid, 2-amino-9-naphthalen-2-yl-9H-purin-6-ol, or 3-oxo-2-phenyl-3,5-dihydro-2H-pyrazolo[3,4-d]thieno[2,3-b]pyridine-7-carboxylic acid in a MTT assay
2.3.1.30	Entamoeba histolytica		more	705594		no inhibition by 0.03 mM L-cystine, 0.5 mM D-cysteine, DL-homocysteine, DL-homoserine, and oxidized glutathione (reduced glutathione not determined); no inhibition with 0.03 and 0.5 mM L-cystine, 0.5 mM D-cysteine, DL-homocysteine, DL-homoserine, and N-acetyl-L-serine; no inhibition with 0.03 mM L-cystine, 0.5 mM D-cysteine, DL-homocysteine, DL-homoserine, N-acetyl-L-serine, and oxidized glutathione
2.3.1.30	Escherichia coli		N-acetyl-L-cysteine	486752	1771	
2.3.1.30	Trypanosoma cruzi		N-acetyl-L-cysteine	486773	1771	weak
2.3.1.30	Entamoeba histolytica		N-acetyl-L-cysteine	705594	1771	1 mM weak inhibition; 1 mM, weak inhibition; 1 mM, weak inhibition
2.3.1.30	Entamoeba histolytica		N-acetyl-L-serine	705594	26858	0.5 mM, weak inhibition
2.3.1.30	Paracoccus denitrificans		N-ethylmaleimide	34691	46	
2.3.1.30	Salmonella enterica subsp. enterica serovar Typhimurium		O-acetyl-L-serine	486761	549	product inhibition, competitive against acetyl-CoA and noncompetitive against O-acetyl-L-serine
2.3.1.30	Haemophilus influenzae		O-acetyl-L-serine	657672	549	product inhibition is noncompetitive against acetyl-CoA and uncompetitive against L-serine
2.3.1.30	Entamoeba histolytica		oxidized glutathione	705594	283	0.5 mM, weak inhibition
2.3.1.30	Paracoccus denitrificans		p-chloromercuribenzoate	34691	40	
2.3.1.30	Phaseolus vulgaris		p-chloromercuribenzoate	486753	40	
2.3.1.30	Entamoeba histolytica		reduced glutathione	705594	41	0.5 mM weak inhibition; 0.5 mM, weak inhibition
2.3.1.30	Salmonella enterica subsp. enterica serovar Typhimurium		S-methyl-L-cysteine	486761	724	competitive against O-acetyl-L-serine, noncompetitive against CoA
2.3.1.30	Haemophilus influenzae		S-methyl-L-cysteine	657672	724	competitive versus O-acetyl-L-serine and competitive versus CoA
3.5.1.108	Escherichia coli	Bovine serum albumin		695538		addition of bovine serum albumin slightly increases activity
3.5.1.108	Pseudomonas aeruginosa		(2R)-N-hydroxy-3-naphthalen-2-yl-2-[(naphthalen-2-ylsulfonyl)amino]propanamide	701103	94792	potent inhibitor, shows antibacterial activity against a wide range of Gram-negative pathogens, binding mode
3.5.1.108	Escherichia coli		(3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)methanethiol	699421	51516	
3.5.1.108	Aquifex aeolicus		(3R,5R)-3-hydroxy-5-(2-(hydroxyamino)-2-oxoethyl)-2-(hydroxymethyl)tetrahydro-2H-pyran-4-yl tetradecanoate	696206	17688	substrate-analog LpxC inhibitor, possesses little or no antibacterial activity, because it probably cannot penetrate the Gram-negative cell envelope
3.5.1.108	Escherichia coli		(3R,5R)-3-hydroxy-5-(2-(hydroxyamino)-2-oxoethyl)-2-(hydroxymethyl)tetrahydro-2H-pyran-4-yl tetradecanoate	696206	17688	substrate-analog LpxC inhibitor, possesses little or no antibacterial activity, because it probably cannot penetrate the Gram-negative cell envelope
3.5.1.108	Escherichia coli		(4R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide	695538	17656	i.e L-161,240
3.5.1.108	Escherichia coli		(4R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide	695629	17656	the inhibitor is active against a Pseudomonas aeruginosa construct in which the endogenous lpxC gene is inactivated and in which LpxC activity is supplied by the lpxC gene from Escherichia coli. An Escherichia coli construct in which growth is dependent on the Pseudomonas aeruginosa lpxC gene is resistant to the compound
3.5.1.108	Escherichia coli		(4R)-N-hydroxy-2-(4-methoxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide	695538	26024	i.e. L-159,692
3.5.1.108	Escherichia coli		(4R)-N-hydroxy-2-tricyclo[3.3.1.1-3,7]dec-1-yl-4,5-dihydro-1,3-oxazole-4-carboxamide	698451	94239	1 microg/ml, high inhibitory activity
3.5.1.108	Pseudomonas aeruginosa		(R)-(hydroxyamino)((R)-2-(4-methoxy-3-propyl-5-(trifluoromethoxy)phenyl)-4,5-dihydrothiazol-4-yl)methanol	697251	51545	
3.5.1.108	Pseudomonas aeruginosa		(R)-2-(1-butyl-1H-indazol-3-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	697251	51542	
3.5.1.108	Escherichia coli		(R)-2-(2-bromophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94217	1 microg/ml, nearly complete loss of activity
3.5.1.108	Pseudomonas aeruginosa		(R)-2-(2-butyl-2H-indazol-3-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	697251	51543	
3.5.1.108	Escherichia coli		(R)-2-(3,4-dichlorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94230	1 microg/ml, exellet biological activity
3.5.1.108	Escherichia coli		(R)-2-(3,4-difluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94228	1 microg/ml, exellet biological activity
3.5.1.108	Escherichia coli		(R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	17656	1 microg/ml
3.5.1.108	Escherichia coli		(R)-2-(3,5-dichlorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94227	1 microg/ml, moderate activity
3.5.1.108	Escherichia coli		(R)-2-(3,5-difluoro-4-methoxyphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	51530	1 microg/ml, good activity
3.5.1.108	Escherichia coli		(R)-2-(3,5-difluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	51532	1 microg/ml, moderate activity
3.5.1.108	Escherichia coli		(R)-2-(3,5-dimethoxyphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94211	1 microg/ml, 67% inhibition
3.5.1.108	Escherichia coli		(R)-2-(3-(dichloromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94224	1 microg/ml
3.5.1.108	Escherichia coli		(R)-2-(3-bromo-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94231	1 microg/ml, exellet biological activity
3.5.1.108	Escherichia coli		(R)-2-(3-chloro-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94229	1 microg/ml, exellet biological activity
3.5.1.108	Escherichia coli		(R)-2-(3-cyanophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94223	1 microg/ml
3.5.1.108	Pseudomonas aeruginosa		(R)-2-(3-ethoxy-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	697251	51541	
3.5.1.108	Escherichia coli		(R)-2-(3-fluoro-4-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94226	1 microg/ml, slight lower inhibitory activity than (R)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide
3.5.1.108	Escherichia coli		(R)-2-(3-fluoro-5-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94232	1 microg/ml, good activity
3.5.1.108	Pseudomonas aeruginosa		(R)-2-(4-(3-fluorobenzyloxy)-3-(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	697251	51538	
3.5.1.108	Pseudomonas aeruginosa		(R)-2-(4-(allyloxy)-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	697251	51536	
3.5.1.108	Pseudomonas aeruginosa		(R)-2-(4-(dimethylamino)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	697251	51539	
3.5.1.108	Escherichia coli		(R)-2-(4-(hexyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	51531	1 microg/ml, 86% inhibition
3.5.1.108	Escherichia coli		(R)-2-(4-(hydroxycarbamoyl)-4,5-dihydrooxazol-2-yl)benzyl benzoate	698451	94216	1 microg/ml, nearly complete loss of activity
3.5.1.108	Escherichia coli		(R)-2-(4-bromophenylsulfonamido)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxypropanamide	695628	51495	
3.5.1.108	Escherichia coli		(R)-2-(4-chloro-3-nitrophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94221	1 microg/ml
3.5.1.108	Pseudomonas aeruginosa		(R)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	697251	26073	
3.5.1.108	Escherichia coli		(R)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	26073	1 microg/ml, most potent compound
3.5.1.108	Pseudomonas aeruginosa		(R)-2-(4-fluoro-3-methylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	697251	51535	
3.5.1.108	Escherichia coli		(R)-2-(4-fluoro-3-nitrophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94219	1 microg/ml
3.5.1.108	Escherichia coli		(R)-2-(4-tert-butylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94214	1 microg/ml, 58% inhibition
3.5.1.108	Escherichia coli		(R)-2-(biphenyl-4-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94213	1 microg/ml, 69% inhibition
3.5.1.108	Escherichia coli		(R)-2-decyl-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94238	1 microg/ml, high inhibitory activity
3.5.1.108	Aquifex aeolicus		(R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide	696206	4281	
3.5.1.108	Escherichia coli		(R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide	695628, 696206, 696322, 700934	4281	
3.5.1.108	Rhizobium leguminosarum		(R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide	700934	4281	
3.5.1.108	Pseudomonas aeruginosa		(R)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-2-isopropyl-4-oxobutanamide	699138	51518	
3.5.1.108	Pseudomonas aeruginosa		(R)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-2-methyl-4-oxobutanamide	699138	51526	
3.5.1.108	Escherichia coli		(R)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine	699421	51509	
3.5.1.108	Pseudomonas aeruginosa		(R)-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-1H-indazole-3-carboxamide	697251	51537	
3.5.1.108	Pseudomonas aeruginosa		(R)-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-4-methoxy-3-propyl-5-(trifluoromethoxy)benzamide	697251	51544	
3.5.1.108	Pseudomonas aeruginosa		(R)-N-hydroxy-2-(1H-indazol-3-yl)-4,5-dihydrooxazole-4-carboxamide	697251	51540	
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(2,3,5-trifluoro-4-methoxyphenyl)-4,5-dihydrooxazole-4-carboxamide	698451	52749	1 microg/ml, good activity
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(2-methylprop-1-enyl)-4,5-dihydrooxazole-4-carboxamide	698451	94233	1 microg/ml, moderate activity
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(3,4,5-triethoxyphenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94212	1 microg/ml, 72% inhibition
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94225	1 microg/ml, exellet inhibitory activity
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(3-methoxyphenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94210	1 microg/ml, 44% inhibition
3.5.1.108	Pseudomonas aeruginosa		(R)-N-hydroxy-2-(4-((3-nitrophenoxy)methyl)phenyl)-4,5-dihydrooxazole-4-carboxamide	697251	51534	
3.5.1.108	Pseudomonas aeruginosa		(R)-N-hydroxy-2-(4-(3-nitrobenzyloxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	697251	51547	
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(4-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	698451	9760	1 microg/ml
3.5.1.108	Pseudomonas aeruginosa		(R)-N-hydroxy-2-(4-hydroxyphenyl)-4,5-dihydrooxazole-4-carboxamide	697251	51548	
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(4-methoxy-3,5-dimethylphenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94215	1 microg/ml, 71% inhibition
3.5.1.108	Pseudomonas aeruginosa		(R)-N-hydroxy-2-(4-methoxy-3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	697251	51546	
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(4-methoxy-3-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94220	1 microg/ml
3.5.1.108	Pseudomonas aeruginosa		(R)-N-hydroxy-2-(4-methoxy-3-propyl-5-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	697251	51533	
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(4-methoxyphenyl)-4,5-dihydrooxazole-4-carboxamide	698451	26024	1 microg/ml
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(4-methyl-3-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94222	1 microg/ml
3.5.1.108	Escherichia coli		(R)-N-hydroxy-2-(4-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94218	1 microg/ml
3.5.1.108	Pseudomonas aeruginosa		(R)-N-hydroxy-2-p-tolyl-4,5-dihydrothiazole-4-carboxamide	697251	51549	
3.5.1.108	Escherichia coli		(R,E)-2-(2-chlorostyryl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94237	1 microg/ml, moderate activity
3.5.1.108	Escherichia coli		(R,E)-N-hydroxy-2-(3-(trifluoromethyl)styryl)-4,5-dihydrooxazole-4-carboxamide	698451	94236	1 microg/ml, moderate activity
3.5.1.108	Escherichia coli		(R,E)-N-hydroxy-2-(4-nitrostyryl)-4,5-dihydrooxazole-4-carboxamide	698451	94235	1 microg/ml, moderate activity
3.5.1.108	Escherichia coli		(R,E)-N-hydroxy-2-styryl-4,5-dihydrooxazole-4-carboxamide	698451	94234	1 microg/ml, moderate activity
3.5.1.108	Pseudomonas aeruginosa		(S)-3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-4,5-dihydroisoxazole-5-carboxamide	699138	51522	
3.5.1.108	Pseudomonas aeruginosa		(S)-3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-5-methyl-4,5-dihydroisoxazole-5-carboxamide	699138	51519	
3.5.1.108	Escherichia coli		(S)-3-(4-methoxyphenyl)-4,5-dihydro-isoxazole-5-carboxylic acid hydroxyamide	699421	51510	
3.5.1.108	Pseudomonas aeruginosa		(S)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-2-methyl-4-oxobutanamide	699138	51525	
3.5.1.108	Aquifex aeolicus		(S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine	696206	3986	
3.5.1.108	Escherichia coli		(S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine	696206	3986	phenyloxazoline hydroxamic acid, competitive inhibitor in Escherichia coli, not active as an antibiotic against Aquifex aeolicus, Pseudomonas aeruginosa and other clinically important pathogens
3.5.1.108	Escherichia coli		(S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine	695628, 696322, 700934	3986	
3.5.1.108	Rhizobium leguminosarum		(S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine	700934	3986	
3.5.1.108	Aquifex aeolicus		1,5-anhydro-2-C-(carboxymethyl-N-hydroxyamide)-2-deoxy-3-O-myristoyl-D-glucitol	696204	52748	synthesis of the 13C-labeled substrate-analogue inhibitor, and the subsequent refinement of the solution structure of the LpxC-inhibitor complex using residual dipolar couplings. Structural basis for the design of more potent LpxC inhibitors. The best LpxC inhibitors should contain: (1) a zinc-chelating group situated between two hydrophobic molecular moieties and (2) a negatively charged group or polar group capable of forming salt bridges or hydrogen bonds with the basic patch. For the hydrophobic fragment to fit within the hydrophobic passage, a linear chemical group without branches is preferable and the total length from the hydroxamate group (which presumably binds Zn2+) to the terminal end of the linear fragment should be less than 15 A. Any hydrophobic group with a length beyond 15 A might require flexibility to fit the curved surface extending the hydrophobic passage, where the terminal methyl and the last two methylene groups of the 1,5-anhydro-2-C-(carboxymethyl-N-hydroxyamide)-2-deoxy-3-O-myristoyl-D-glucitol acyl chain are located
3.5.1.108	Aquifex aeolicus		1,5-anhydro-2-C-(carboxymethyl-N-hydroxyamide)-2-deoxy-3-O-myristoyl-D-glucitol	700371	52748	the solution structure of LpxC in complex with the substrate-analog inhibitor 1,5-anhydro-2-C-(carboxymethyl-N-hydroxyamide)-2-deoxy-3-O-myristoyl-D-glucitol, reveals a novel alpha/beta fold, a unique zinc-binding motif and a hydrophobic passage that captures the acyl chain of the inhibitor
3.5.1.108	Aquifex aeolicus		1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-3-O-tetradecanoyl-D-glucitol	696211	52748	the X-ray crystal structure of LpxC complexed with TU-514 allows for a detailed examination of the coordination geometry of the catalytic zinc ion and other enzyme-inhibitor interactions in the active site. The hydroxamate group of TU-514 forms a bidentate chelate complex with the zinc ion and makes hydrogen bond interactions with conserved active site residues E78, H265, and T191. The inhibitor C-4 hydroxyl group makes direct hydrogen bond interactions with E197 and H58. Finally, the C-3 myristate moiety of the inhibitor binds in the hydrophobic tunnel of the active site
3.5.1.108	Escherichia coli		2,3-dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime	696322	51552	weak inhibitor
3.5.1.108	Escherichia coli		2,4-dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime	696322	51551	
3.5.1.108	Pseudomonas aeruginosa		2-(1-butyl-1H-indazol-3-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9770	
3.5.1.108	Pseudomonas aeruginosa		2-(2-butyl-2H-indazol-3-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9771	
3.5.1.108	Pseudomonas aeruginosa		2-(3,4-bis(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	699138	52745	
3.5.1.108	Pseudomonas aeruginosa		2-(3-(3-(cyclopentyloxy)-4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)-N-hydroxyacetamide	699138	51520	
3.5.1.108	Pseudomonas aeruginosa		2-(3-allyl-5-fluoro-4-methoxy-2-methylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12604	
3.5.1.108	Pseudomonas aeruginosa		2-(3-bromo-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12605	
3.5.1.108	Pseudomonas aeruginosa		2-(3-bromo-5-fluoro-4-methoxyphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12603	
3.5.1.108	Pseudomonas aeruginosa		2-(3-chloro-4-(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12598	
3.5.1.108	Pseudomonas aeruginosa		2-(3-chloro-5-fluoro-1H-indol-2-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12611	
3.5.1.108	Pseudomonas aeruginosa		2-(3-ethoxy-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	9766	
3.5.1.108	Pseudomonas aeruginosa		2-(3-fluoro-4-(2-(trifluoromethyl)benzyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	699420	51499	
3.5.1.108	Pseudomonas aeruginosa		2-(3-fluoro-4-(3-(trifluoromethyl)benzyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699420	26063	
3.5.1.108	Pseudomonas aeruginosa		2-(3-fluoro-4-(3-methylbenzyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	699138	51517	
3.5.1.108	Pseudomonas aeruginosa		2-(3-fluoro-5-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12606	
3.5.1.108	Pseudomonas aeruginosa		2-(4-(3-fluorobenzyloxy)-3-(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12596	
3.5.1.108	Pseudomonas aeruginosa		2-(4-(allyloxy)-3-(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	699420	51496	
3.5.1.108	Pseudomonas aeruginosa		2-(4-(allyloxy)-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12607	
3.5.1.108	Pseudomonas aeruginosa		2-(4-(allyloxy)-3-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	699420	51498	
3.5.1.108	Pseudomonas aeruginosa		2-(4-(but-3-enyloxy)-3-(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12597	
3.5.1.108	Pseudomonas aeruginosa		2-(4-(but-3-enyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9762	
3.5.1.108	Pseudomonas aeruginosa		2-(4-(but-3-enyloxy)phenyl)-N-hydroxy-4,5-dihydrothiazole-4-carboxamide	696606, 696607, 699138, 699420	9775	
3.5.1.108	Pseudomonas aeruginosa		2-(4-(dimethylamino)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9768	
3.5.1.108	Pseudomonas aeruginosa		2-(4-(heptyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699420	26062	
3.5.1.108	Pseudomonas aeruginosa		2-(4-acetamidophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699420	26064	
3.5.1.108	Pseudomonas aeruginosa		2-(4-acetylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12610	
3.5.1.108	Pseudomonas aeruginosa		2-(4-bromophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	699420	51501	
3.5.1.108	Pseudomonas aeruginosa		2-(4-butylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9761	
3.5.1.108	Pseudomonas aeruginosa		2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12601	
3.5.1.108	Pseudomonas aeruginosa		2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-5,6-dihydro-4H-1,3-oxazine-4-carboxamide	699420	51505	
3.5.1.108	Pseudomonas aeruginosa		2-(4-fluoro-3-methylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12602	
3.5.1.108	Pseudomonas aeruginosa		2-(4-fluoro-3-propylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9765	
3.5.1.108	Pseudomonas aeruginosa		2-(4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9764	
3.5.1.108	Pseudomonas aeruginosa		2-(4-fluorophenyl)-N-hydroxy-4,5-dihydrothiazole-4-carboxamide	699420	51507	
3.5.1.108	Pseudomonas aeruginosa		2-(5-fluoro-1H-indol-2-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	699420	51503	
3.5.1.108	Pseudomonas aeruginosa		2-(5-fluoro-1H-indol-2-yl)-N-hydroxy-5,6-dihydro-4H-1,3-oxazine-4-carboxamide	699420	51506	
3.5.1.108	Escherichia coli		2-mercapto-1-[3-(4-methoxyphenyl)-4,5-dihydro-isoxazol-5-yl]ethanone	699421	51512	racemate
3.5.1.108	Escherichia coli		2-thioacetyl-1-[3-(4-methoxyphenyl)-4,5-dihydro-isoxazol-5-yl]ethanone	699421	51511	racemate
3.5.1.108	Escherichia coli		2-[[4-(diethylamino)-2-hydroxyphenyl]carbonyl]benzoic acid	719053	19209	compound shows good activity against Escherichia coli and Pseudomonas aeruginosa
3.5.1.108	Escherichia coli		3,4,5-trihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime	696322	51553	weak inhibitor, contains a 5 position hydroxyl and exhibits greatly reduced inhibitory potency
3.5.1.108	Rhizobium leguminosarum		3,4-dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime	696322	51550	50 microM, 49% inhibition
3.5.1.108	Pseudomonas aeruginosa		3-(3-(cyclopentyloxy)-4-methoxyphenyl)-4,5-dihydroisoxazole-5-carboxamide	699138	51524	
3.5.1.108	Pseudomonas aeruginosa		3-(3-(cyclopentyloxy)-4-methoxyphenyl)-4,5-dihydroisoxazole-5-carboxylic acid	699138	51521	
3.5.1.108	Pseudomonas aeruginosa		3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-4,5-dihydroisoxazole-5-carboxamide	699138	52746	
3.5.1.108	Pseudomonas aeruginosa		3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-5-methyl-4,5-dihydroisoxazole-5-carboxamide	699138	52747	
3.5.1.108	Pseudomonas aeruginosa		3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-5-propyl-4,5-dihydroisoxazole-5-carboxamide	699138	51527	
3.5.1.108	Pseudomonas aeruginosa		3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-N-methyl-4,5-dihydroisoxazole-5-carboxamide	699138	51529	
3.5.1.108	Escherichia coli		3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl(methyl)phosphinic acid	699421	51515	
3.5.1.108	Pseudomonas aeruginosa		3-ethoxy-4-fluoro-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)benzamide	696606, 699420	26069	
3.5.1.108	Pseudomonas aeruginosa		4-(3-(cyclopentyloxy)-4-methoxyphenyl)-4-oxobutanoic acid	699138	51528	
3.5.1.108	Pseudomonas aeruginosa		4-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-4-oxobutanamide	699138	51523	
3.5.1.108	Pseudomonas aeruginosa		4-(allyloxy)-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-3-(trifluoromethoxy)benzamide	696606, 699138, 699420	12612	
3.5.1.108	Pseudomonas aeruginosa		4-(but-3-enyloxy)-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)benzamide	696606, 696607, 699138, 699420	9772	
3.5.1.108	Pseudomonas aeruginosa		4-fluoro-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)benzamide	696606, 699420	26068	
3.5.1.108	Escherichia coli		5'-O-[(E)-(2,3,4-trihydroxybenzylidene)amino]uridine	696322	18016	50 microM, 80% inhibition, pH-dependent, two-step, covalent inhibitor. 2,3,4-trihydroxybenzaldehyde O-((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime represents a new class of LpxC inhibitors that exploit the uridine binding site to form a covalent complex. While not antibiotic, it may provide a new scaffold for extension of existing LpxC-inhibiting antibiotics to target the UDP binding pocket
3.5.1.108	Helicobacter pylori		5'-O-[(E)-(2,3,4-trihydroxybenzylidene)amino]uridine	696322	18016	50 microM, 21% inhibition, pH-dependent, two-step, covalent inhibitor. 2,3,4-trihydroxybenzaldehyde O-((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime represents a new class of LpxC inhibitors that exploit the uridine binding site to form a covalent complex. While not antibiotic, it may provide a new scaffold for extension of existing LpxC-inhibiting antibiotics to target the UDP binding pocket
3.5.1.108	Escherichia coli		5'-O-[(E)-(3,4-dihydroxybenzylidene)amino]uridine	696322	51550	50 microM, 60% inhibition, inhibitor as potent as (E)-2,3,4-trihydroxybenzaldehyde O-((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime
3.5.1.108	Helicobacter pylori		5'-O-[(E)-(3,4-dihydroxybenzylidene)amino]uridine	696322	51550	50 microM, 41% inhibition
3.5.1.108	Aquifex aeolicus		Ciprofloxacin	696206	932	
3.5.1.108	Escherichia coli		Ciprofloxacin	696206	932	
3.5.1.108	Escherichia coli		dipicolinic acid	696193	1090	0.02 mM, complete inhibition
3.5.1.108	Escherichia coli		EDTA	695538	223	5 mM, complete loss of activity
3.5.1.108	Escherichia coli		EDTA	696193	223	t1/2: 4 min at 0.005 mM EDTA at 1 &deg;C
3.5.1.108	Pseudomonas aeruginosa		EDTA	698550	223	0.002 mM, complete inactivation, reactivated by the addition of excess heavy metal
3.5.1.108	Escherichia coli		more	695628		(R)-2-(4-bromophenylsulfonamido)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxypropanamide and (R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide show predominantly gram-negative activities, with activities against members of the Enterobacteriaceae, Serratia marcescens, Morganella morganii, Moraxella catarrhalis, Haemophilus influenzae, and Burkholderia cepacia. Neither compound showed activity against Pseudomonas aeruginosa; however, against a leaky Pseudomonas aeruginosa strain, some activity is seen with (R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide. (R)-2-(4-bromophenylsulfonamido)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxypropanamide and (R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide have little or no activity against the gram-positive bacteria tested
3.5.1.108	Pseudomonas aeruginosa		more	695629		(4R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide is active against a Pseudomonas aeruginosa construct in which the endogenous lpxC gene is inactivated and in which LpxC activity is supplied by the lpxC gene from Escherichia coli. An Escherichia coli construct in which growth is dependent on the Pseudomonas aeruginosa lpxC gene is resistant to the compound
3.5.1.108	Escherichia coli		more	696193		incubation of 10 nM LpxC in buffer without bovine serum albumin for 30 min completely inactivates the enzyme. When this enzyme is diluted further (4fold) into buffer containing 1 mg/ml bovine serum albumin, 100% of the activity is restored when assayed after a 2 h incubation. High concentrations of LpxC in the assays can eliminate the requirement of bovine serum albumin
3.5.1.108	Aquifex aeolicus		more	696206		(S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine, phenyloxazoline hydroxamic acid, competitive inhibitor in Escherichia coli, not active as an antibiotic against Aquifex aeolicus, Pseudomonas aeruginosa and other clinically important pathogens
3.5.1.108	Escherichia coli		more	696209		the affinity of LpxC for both product and fatty acids is significantly influenced by changes in the number and identity of metal ions bound to the LpxC active site. Therefore, interactions with these metal ions are critical for molecular recognition of ligands by LpxC and may mimic similar contacts with active site inhibitors. These data indicate that the potency of LpxC inhibitors in vitro can be altered by assay conditions used in screening and/or development of LpxC inhibitors and that the metal ion status of LpxC in vivo will likely influence the effectiveness of LpxC inhibitors as antibiotics
3.5.1.108	Escherichia coli		more	696322		dithiothreitol, glutathione and the C207A mutant prevent the formation of a covalent complex by (E)-2,3,4-trihydroxybenzaldehyde O-((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime; no inhibitory effect by 2,4-dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime, 3,4-dimethoxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime, and 2,3,4-trimethoxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime
3.5.1.108	Escherichia coli		more	699038		mass spectrometry-based screening is a valuable high-throughput screening tool for detecting inhibitors of enzymatic targets involving difficult to detect reactions
3.5.1.108	Escherichia coli		more	699139		study the potentially important structural differences in active sites of both proteins responsible for making the inhibitors selective for Escherichia coli as compared to Pseudomonas aeruginosa LpxC, homology models of the LpxC of both organisms are developed and validated on the basis of a 3D profile and PROCHECK. Subsequently, a molecular electrostatic potential (MEP)-based surface and cavity-depth analysis is performed. Finally, a cross-docking analysis of reported inhibitors is performed to reveal selective binding modes. These studies identify differences between the two active sites and have implications for designing effective strategies to identify LpxC inhibitors that can be developed as novel broad-spectrum antibacterial drugs
3.5.1.108	Pseudomonas aeruginosa		more	699139		study the potentially important structural differences in active sites of both proteins responsible for making the inhibitors selective for Escherichia coli as compared to Pseudomonas aeruginosa LpxC, homology models of the LpxC of both organisms are developed and validated on the basis of a 3D profile and PROCHECK. Subsequently, a molecular electrostatic potential (MEP)-based surface and cavity-depth analysis is performed. Finally, a cross-docking analysis of reported inhibitors is performed to reveal selective binding modes. These studies identify differences between the two active sites and have implications for designing effective strategies to identify LpxC inhibitors that can be developed as novel broad-spectrum antibacterial drugs
3.5.1.108	Aquifex aeolicus		more	700934		(S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine and (R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide do not inhibit Aquifex aeolicus LpxC
3.5.1.108	Rhizobium leguminosarum		more	700934		no evidence of time-dependent inhibition is observed in assays with either the wild-type or mutants
3.5.1.108	Escherichia coli		N'-formyl-3-(4-methoxyphenyl)-4,5-dihydroisoxazole-5-carbohydrazide	699421	51513	
3.5.1.108	Escherichia coli		N-(((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)-2-((Z)-2,3,4-trihydroxybenzylideneaminooxy)acetamide	696322	51554	
3.5.1.108	Aquifex aeolicus		N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide	696206	3987	N-aroyl-L-threonine hydroxamic acid, antibiotic activity comparable to ciprofloxacin, slow, tight-binding LpxC inhibitor
3.5.1.108	Escherichia coli		N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide	696206	3987	N-aroyl-L-threonine hydroxamic acid, antibiotic activity comparable to ciprofloxacin, slow, tight-binding LpxC inhibitor
3.5.1.108	Escherichia coli		N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide	696322	3987	
3.5.1.108	Aquifex aeolicus		N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide	700934	3987	as effectively as ciprofloxacin or tobramycin
3.5.1.108	Escherichia coli		N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide	700934	3987	as effectively as ciprofloxacin or tobramycin
3.5.1.108	Rhizobium leguminosarum		N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide	700934	3987	wild-type is insensitive to N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide
3.5.1.108	Pseudomonas aeruginosa		N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-1H-indazole-3-carboxamide	696606, 696607, 699138, 699420	9773	
3.5.1.108	Pseudomonas aeruginosa		N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-4-(trifluoromethoxy)benzamide	696606, 699420	26070	
3.5.1.108	Pseudomonas aeruginosa		N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-4-methoxy-3-propyl-5-(trifluoromethoxy)benzamide	696606, 699420	26071	
3.5.1.108	Pseudomonas aeruginosa		N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-4-methylbenzamide	696606, 699420	26067	
3.5.1.108	Escherichia coli		N-ethylmaleimide	696180	46	1 mM, complete inhibition
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)-4,5-dihydrooxazole-4-carboxamide	696606, 699420	26066	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(1H-indazol-3-yl)-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9769	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(2-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	696606, 699420	26061	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9759	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(3-(trifluoromethyl)phenyl)-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9767	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(3-propyl-4,5-bis(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	699138	26357	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4'-propylbiphenyl-4-yl)-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9763	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-((3-nitrophenoxy)methyl)phenyl)-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12600	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-(3-methylbut-2-enyloxy)-3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	699420	51497	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-(3-nitrobenzyloxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12599	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9760	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-(trifluoromethoxy)phenyl)-4,5-dihydrothiazole-4-carboxamide	699420	51508	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12608	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-hydroxyphenyl)-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699420	17689	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-iodophenyl)-4,5-dihydrooxazole-4-carboxamide	699420	51502	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-methoxy-3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	696606, 699420	26060	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-methoxy-3-propyl-5-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699420	26059	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-methoxy-3-propyl-5-(trifluoromethoxy)phenyl)-4,5-dihydrothiazole-4-carboxamide	696606, 696607, 699420	17690	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(4-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide	699420	51500	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydrooxazole-4-carboxamide	696606, 699420	26065	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydrothiazole-4-carboxamide	696606, 699420	26072	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydrooxazole-4-carboxamide	696606, 699138, 699420	12609	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-p-tolyl-4,5-dihydrooxazole-4-carboxamide	696606, 696607, 699138, 699420	9758	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-p-tolyl-4,5-dihydrothiazole-4-carboxamide	696606, 696607, 699138, 699420	9774	
3.5.1.108	Pseudomonas aeruginosa		N-hydroxy-2-p-tolyl-5,6-dihydro-4H-1,3-oxazine-4-carboxamide	699420	51504	
3.5.1.108	Escherichia coli		N-[3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperazine-1-carboxamide	719053	60753	compound shows good activity against Escherichia coli and Pseudomonas aeruginosa
3.5.1.108	Escherichia coli		N-[3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(phenylethynyl)benzamide	719053	60750	compound shows good activity against Escherichia coli and Pseudomonas aeruginosa
3.5.1.108	Escherichia coli		N-[3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperidine-1-carboxamide	719053	60751	compound shows good activity against Escherichia coli and Pseudomonas aeruginosa
3.5.1.108	Escherichia coli		N-[3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperazine-1-carboxamide	719053	60752	compound shows good activity against Escherichia coli and Pseudomonas aeruginosa
3.5.1.108	Aquifex aeolicus		tobramycin	696206	731	
3.5.1.108	Escherichia coli		tobramycin	696206	731	
3.5.1.108	Escherichia coli		Zn2+	695538	19	0.1 mM, about 65% loss of activity
3.5.1.108	Escherichia coli		Zn2+	696193	19	
3.5.1.108	Aquifex aeolicus		Zn2+	696198	19	
3.5.1.108	Escherichia coli		[3-(4-methoxyphenyl)-4,5-dihydro-isoxazol-5-yl]phosphonic acid	699421	51514	
4.2.1.75	Euglena gracilis	more		5875		no bound cofactor
4.2.1.75	Rattus norvegicus	more		5880		no bound cofactor
4.2.1.75	Rattus norvegicus	more		5878, 5889		reduced pteroylpolyglutamate factor associated with enzyme, may function as cofactor
4.2.1.75	Escherichia coli		5,5'-dithiobis(2-nitrobenzoate)	5888	196	
4.2.1.75	Euglena gracilis		Butane-2,3-dione	5875	603	20% residual activity after 45 min at 40 mM
4.2.1.75	Bacillus subtilis		Butane-2,3-dione	5887	603	
4.2.1.75	Homo sapiens		Cd2+	5876	48	
4.2.1.75	Rattus norvegicus		Cd2+	5877	48	
4.2.1.75	Mus musculus		Coproporphyrins	5881		
4.2.1.75	Homo sapiens		Cu2+	5876	28	
4.2.1.75	Rattus norvegicus		Cu2+	5877	28	
4.2.1.75	Euglena gracilis		diethyl dicarbonate	5875	265	10% residual activity after 5 min at 0.41 mM
4.2.1.75	Bacillus subtilis		diethyl dicarbonate	5887	265	
4.2.1.75	Escherichia coli		diethyl dicarbonate	5888	265	
4.2.1.75	Homo sapiens		Hg2+	5876	31	
4.2.1.75	Rattus norvegicus		Hg2+	5877	31	
4.2.1.75	Homo sapiens		hydroxylamine	5883	80	
4.2.1.75	Escherichia coli		iodoacetamide	5888	63	
4.2.1.75	Escherichia coli		iodoacetic acid	5888	87	
4.2.1.75	Euglena gracilis		Macrocyclic spiro-lactam derivatives	5890, 5891		
4.2.1.75	Homo sapiens		N-ethylmaleimide	5883	46	
4.2.1.75	Escherichia coli		N-ethylmaleimide	5888	46	
4.2.1.75	Euglena gracilis		NaN3	5875	211	25-30% residual activity with 1.0 mM
4.2.1.75	Bacillus subtilis		NaN3	5887	211	60% residual activity with 5.0 mM
4.2.1.75	Homo sapiens		NH4+	5883	50	
4.2.1.75	Homo sapiens		p-chloromercuribenzoate	5876	40	
4.2.1.75	Escherichia coli		p-chloromercuribenzoate	5888	40	
4.2.1.75	Homo sapiens		p-hydroxymercuribenzoate	5883	92	
4.2.1.75	Rattus norvegicus		PbCl2	5877	2059	
4.2.1.75	Euglena gracilis		Phenylglyoxal	5875	258	50% residual activity after 1 min at 0.3 mM
4.2.1.75	Bacillus subtilis		Phenylglyoxal	5887	258	
4.2.1.75	Euglena gracilis		pyridoxal 5'-phosphate	5875	30	
4.2.1.75	Rattus norvegicus		pyridoxal 5'-phosphate	5880	30	
4.2.1.75	Bacillus subtilis		pyridoxal 5'-phosphate	5887	30	Pyridoxal 5'-phosphate and subsequent treatment with NaBH4
4.2.1.75	Homo sapiens		sulphydryl reagents	5883	752	
4.2.1.75	Euglena gracilis		uroporphyrinogen III	5875	1736	product inhibition
4.2.1.75	Mus musculus		uroporphyrinogen III	5881	1736	product inhibition
4.2.1.75	Mus musculus		Uroporphyrins	5881	67244	
4.2.1.75	Homo sapiens		Zn2+	5876	19	
4.2.1.75	Rattus norvegicus		Zn2+	5877	19	
